<SEC-DOCUMENT>0001628908-22-000098.txt : 20220803
<SEC-HEADER>0001628908-22-000098.hdr.sgml : 20220803
<ACCEPTANCE-DATETIME>20220803160324
ACCESSION NUMBER:		0001628908-22-000098
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		124
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220803
DATE AS OF CHANGE:		20220803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		221132473

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>evh-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:a212dad2-7296-44b7-8af9-e12f408b43ae,g:23ff20ea-0869-45df-9d88-aeb2d6e74df5,d:1ec4d9b5233f4aa5a7f5353c408fadd2--><html xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:evh="http://www.evolenthealth.com/20220630" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80L2ZyYWc6YWRjYTJhMjY0NmE2NGVjZDg4MThiMDQ1ZDMzNDRiNDcvdGFibGU6YjU5ZDIzYjgxMjBmNDA4N2JhNmU3NGIyOTY0NWIyMTMvdGFibGVyYW5nZTpiNTlkMjNiODEyMGY0MDg3YmE2ZTc0YjI5NjQ1YjIxM18xLTEtMS0xLTUwMjk5_8862be39-4299-49d5-a5b9-cd6ca84dbcdf">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80L2ZyYWc6YWRjYTJhMjY0NmE2NGVjZDg4MThiMDQ1ZDMzNDRiNDcvdGFibGU6YjU5ZDIzYjgxMjBmNDA4N2JhNmU3NGIyOTY0NWIyMTMvdGFibGVyYW5nZTpiNTlkMjNiODEyMGY0MDg3YmE2ZTc0YjI5NjQ1YjIxM18yLTEtMS0xLTUwMjk5_fa52cf5a-b2f6-4bd8-88e5-12141ff3563e">false</ix:nonNumeric><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80L2ZyYWc6YWRjYTJhMjY0NmE2NGVjZDg4MThiMDQ1ZDMzNDRiNDcvdGFibGU6YjU5ZDIzYjgxMjBmNDA4N2JhNmU3NGIyOTY0NWIyMTMvdGFibGVyYW5nZTpiNTlkMjNiODEyMGY0MDg3YmE2ZTc0YjI5NjQ1YjIxM18zLTEtMS0xLTUwMjk5_e3ae108f-2608-4747-8c39-9d9051c3e7e3">2022</ix:nonNumeric><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80L2ZyYWc6YWRjYTJhMjY0NmE2NGVjZDg4MThiMDQ1ZDMzNDRiNDcvdGFibGU6YjU5ZDIzYjgxMjBmNDA4N2JhNmU3NGIyOTY0NWIyMTMvdGFibGVyYW5nZTpiNTlkMjNiODEyMGY0MDg3YmE2ZTc0YjI5NjQ1YjIxM180LTEtMS0xLTUwMjk5_656aab5e-f79a-42bb-a8f3-aaa20592db5b">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80L2ZyYWc6YWRjYTJhMjY0NmE2NGVjZDg4MThiMDQ1ZDMzNDRiNDcvdGFibGU6YjU5ZDIzYjgxMjBmNDA4N2JhNmU3NGIyOTY0NWIyMTMvdGFibGVyYW5nZTpiNTlkMjNiODEyMGY0MDg3YmE2ZTc0YjI5NjQ1YjIxM181LTEtMS0xLTUwMjk5_22ff95c8-fd35-4e22-a4b2-5d6d2ecaab10">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i4911134f45a64c4ca8b04e812b37c8e9_D20210101-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNS0wLTEtMS01MDI5OQ_25776320-c78c-4049-999b-e8ec8d6418cf">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i6f80fd138cee4ef2abfdef7ff9b68ef6_I20220630" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81OC9mcmFnOjE3N2FlZmY5YjYwZjQwNTM4NzQyZTdmMmY1YzFjMTIxL3RhYmxlOjJhMWRlMTEwNGE4YzQyOTBhMTc1ZDNmYmZkNzRmNDJmL3RhYmxlcmFuZ2U6MmExZGUxMTA0YThjNDI5MGExNzVkM2ZiZmQ3NGY0MmZfMi0xLTEtMS01MDI5OQ_4cfafc32-eab8-470e-9c70-7450adc9de99">6</ix:nonNumeric><ix:nonNumeric contextRef="i9a64da34af914c9daa54dedee5a5cd92_I20220630" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81OC9mcmFnOjE3N2FlZmY5YjYwZjQwNTM4NzQyZTdmMmY1YzFjMTIxL3RhYmxlOjJhMWRlMTEwNGE4YzQyOTBhMTc1ZDNmYmZkNzRmNDJmL3RhYmxlcmFuZ2U6MmExZGUxMTA0YThjNDI5MGExNzVkM2ZiZmQ3NGY0MmZfMy0xLTEtMS01MDI5OQ_a7edf994-3a40-4ae2-b13c-550584869711">12</ix:nonNumeric><ix:nonNumeric contextRef="i132fb5a493164122bbdcd92d3b2833eb_I20220630" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81OC9mcmFnOjE3N2FlZmY5YjYwZjQwNTM4NzQyZTdmMmY1YzFjMTIxL3RhYmxlOjJhMWRlMTEwNGE4YzQyOTBhMTc1ZDNmYmZkNzRmNDJmL3RhYmxlcmFuZ2U6MmExZGUxMTA0YThjNDI5MGExNzVkM2ZiZmQ3NGY0MmZfNC0xLTEtMS01MDI5OQ_e1510c02-654e-4289-829d-12be02938b71">12</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i0f5f7300b0d042e0a3bd9a21c41816ba_D20200801-20200831" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83My9mcmFnOjE4ZGQwNWFhZDlkZjQzOTdiYjYyMzlmZDczMzQ3OWM4L3RleHRyZWdpb246MThkZDA1YWFkOWRmNDM5N2JiNjIzOWZkNzMzNDc5YzhfNQ_af625767-125e-4889-a364-a1dfd2456d6a">.0548667</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i804fa23f02a940218c7286e946780122_D20181001-20181031" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83My9mcmFnOjE4ZGQwNWFhZDlkZjQzOTdiYjYyMzlmZDczMzQ3OWM4L3RleHRyZWdpb246MThkZDA1YWFkOWRmNDM5N2JiNjIzOWZkNzMzNDc5YzhfMjE1_38cf07d4-bd06-4f2a-975b-caf47a954acb">.0299135</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e86b1305605495eb71612e57efef826_I20220729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i6ea08b719de041fc860ca2321a09f2b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8946244240e648d0a726ae8260273c82_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib26e65edf5734cb5a6a97189f7553074_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icedd565fde88475e9cb04f61cf5d0594_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia57e8ce997404651a93ef7beb639c1fc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12f3a63417094173a2013d8e4651e2e0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4eecfcec6264b2fb00d016b793a019b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd40945fb1484885837f7eecfa567b33_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i857e987b97514fad8244212f054173d6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e5e1239271498cbccbaa25d09f5b81_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia37f68ad663840209db72f32dcc9dfdc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i351ea9834113446b96f0ad47bfeced58_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i516e6c58c8cb48b1b164c617bc7de6db_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7370f70d6fa74976a5e9c877a75a03a4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i958225ec182147f59a33c03bebe13eef_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9600a3d7bfdd4cf2815bf9a7f3593ec9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab17026c20264a4c8395c9212169b9ba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e70344e764b4b3eadeaeb6935ee38ec_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed22694590747a1bd2bf4c01a9a662d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i942e52ba18744355b76f7bfdb9cc3cea_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1386eedb115480fa7ca578380d21b98_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8f5739ceffa4cb4899666cc1243c638_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b61856fe974331a02b815438214cb5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3116ce9873b14871adcc379848660cb6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c7070523c2a4ac0a2bfd9ae3b7d3917_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7acd46ba77bf4a96a952527d6ff359fd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib89434c9149543b4bf183e45ab6d2cf8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f315c260fa84b9f8d0fc3b0633fcce4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae9ab04f40cb4c6bad7fa0fa0fad903f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23bc8d4fc78f4724b0d9d7084e7cf0a8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3102f93190494ddfbe3bef856a36e4ee_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8df42535fdba44a8a1627241486db72e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89706c80b2d7431b8baf438482e6530c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef1ba80206c47a796768e04faddc954_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d886f333c9c4fd6a9e342ad9244c5cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2007122f7a6c433aaea325edfea7445c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia13c29e1eae04177baea5d09b310b513_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4911134f45a64c4ca8b04e812b37c8e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id32760879e474657bbcb44bcfd8b4cbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e24955768747af87552990e9881d89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94fd6d6b927d418abe899d5a671e0e19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782b0724932e45c1b2ed8ea424d579e1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id74b0636d9fe405398d1c373024c9a01_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf10f4217fba4210b4c5f9862e155922_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64151525a8774f5e8e11c91ec179e8ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e2ac7d92b6447f2848e96bc058402a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6081395d9faa4fdcab6aed9df74e298b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7edb2b3056d4a5688f8e8aaafb90eef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie633b270dd0c4bbc8043c2a1e40d609c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic30a5e30d65042cc8f8a3f395110a09a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5d6c1e91bd04b9d96ff15934542fb4a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cd9533bbf4643e5aeaa123dabd40c39_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bdd7eadd3304d3a9a793b4224c5ecee_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i159494a380f0403f9294af2487029a51_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i843b60b3c07d4c0f966b1c7efd11f445_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e9c59f6393b4a8faa1337db8d4243fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f49366fb4ea4c75a9085b9b029857ac_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4458c03c2b504669b6dc29624dbd3320_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d346c5c8ea64d16b5d1df5450434600_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id592466e76c249e8b646509e71afaf92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4de7d7c7a1b34a538212057e51b487b2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0fd83c25925422897d5d200f710ee27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e843b7962284872a802350d9f9601e8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07da018892914858a3261ae1eb51a8be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="reportingunit"><xbrli:measure>evh:reportingUnit</xbrli:measure></xbrli:unit><xbrli:context id="i422269ae7dc54ddf975203be2bc9ec3f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4ee5d15f6c48e98699e31b2e8899a7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b656d6a747c43c0807ef9a72b117fe5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18f73ba368e43578c5dc017d9986091_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8920304c21f34d2e8d814f99e02bb672_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f2470a268e4d5593d8214f2752ddb2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id10401febbb0459b90ba3a22611bb8d1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="source"><xbrli:measure>evh:source</xbrli:measure></xbrli:unit><xbrli:context id="i1576668fe0314dd3b3b3ec454798b582_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8072fe070714d70b4c7d5054c1d19bd_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ecfc57dd454ea480838c4fc5252936_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie80fd38d9d5b4ab2bc9f658f6aadf4a0_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id53f2482994740c4afac4ded4824ffa5_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i477230494f1041fd9804ec69666a9459_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica9021ecacd5411b9522695f0968fd6e_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i569f17d92bfa4d41a92b3f6f73066652_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff1070f5f0bf442684f5ebf0e562d035_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b5a5d27c5cd45318130592162ae2979_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cfda0e9098c4c609e2cc6cf7786ab7f_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i155bf891da8c4ffd8ff2e7f58e3b77cb_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75dc927515b3477cb3c9aeebb4a7a7d0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30adaf2d743e41079b7a12ac72d1fc61_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ef29e9326024b2192d9ecc9a670b854_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e64363b84144ffdac3dc9bb780e39a8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide9111e594364928b4f284bff447dc08_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e532127d5f44dcaa0a6d0b870251c4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18910942b2e485ea30def8e9cefca28_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i908235d4f83442cfa2a22b2a90120a12_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id190777694a14c8296979c0037b1333a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b23e58105b4c5f9f250d293d1bbf58_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b903bf1e5f4a638b29eeb71fe6c6b4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d5d6d44adc4e43990ce92c4c44933a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1702427992f426b85f07248e2895331_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib280f91a402940c69f0c3e5cc12d4d56_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0b2ccb4486a4651913ac8302c5c0ec4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18dabb68c8274ea0a5201f8219bce96d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb66e4294e54785b37e073174f3db3c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60f215dd151c4adb9f5d581b6725305d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d31d53daf04bb8b14968d7533e3c30_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa385ea46e294eeabd2ab99940f8e291_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66dd2b3d936841cea2ea68298ff824f5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1117684efa42b1a391ffcc826e14e1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf1aec104e64ca9ab855423a51a4a6c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if40f448b1aee435882087e7f40e19f83_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i861b85e9482e4845a118116261fe251b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i031024ab0cda4f04a32cb998ae9efc29_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie94a3b4a3c854650a274a22df3bb7e4b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic519d1466dfe43928dcfe5d77bdee3ae_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i404e9ab7124f42c99765abd6b37736c1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36ffca71bef413bab9a1cae99ccecfa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie208d4a1cb3e4377a6d2ee9c2549f37c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia71fe81096cc402e8ae97e15131a0756_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b091472e7f14e738060f39d3bb11f9e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7def236e69944f2bfd7976a1f32c4f4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84587f740e7e43fb93a344871522bc54_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i313903f297d04e91ba3039b43d058117_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice247f5d11034730aa4a605431fb5369_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f80fd138cee4ef2abfdef7ff9b68ef6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a64da34af914c9daa54dedee5a5cd92_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i132fb5a493164122bbdcd92d3b2833eb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55fd2849c11d40aa8dac15390f64e184_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e9cc56ffee4613adb9a6ab56554271_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3532becac70546b4bcc03b106edda27c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3ce003447674e2abab64b23eeba11a1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c9dc97776a4d2ab2a8a979cad50e02_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff2de2ac36d149c7b524f3b5582f9909_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bcd88cb096e4aeab56740f6386ffe14_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeb135f182f34812b3000c1ef3bc7bba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b532269dce647ae8ba0e135b9f58fd9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i872c6081b968491a9d538c7086489d91_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26704ded411543a5924bf706b6248305_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f98d9fd601a4df297a857523d498b81_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a3c0b9b3254cfc9d6d4301e6079769_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd3ac7207dd485b866d1ecf9d8370e4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb1b05b4923144d994dffe62ce8c0056_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia32e4243b72b414dbf63a7b58e4444cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i461ebb8b4b4143dfb77186edf095976d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ccca889cbf4b0c9a6c45d4e2792d4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaade151a67ae47c98d6ef7473bc42db4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3a47a1bfe944f4bbffaee6cdd3b92ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief715b13c4fc48beb1cac256135e9d7f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb1738f7f0924690b9cc702596588af5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ff1f6df23841edbf927ca013625866_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7055b6f3699b4fc89fec4593a36e0cf2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5282067d6cfa41b8b9bc8d0fd65c75a1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic460399d0bce4695b06b3c4950e6867b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7732b8c39c44818a62b633ed2eec750_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c7ba00b2dca4b97bd4add7fef4ab781_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9098a44763454939966aead2b01058a5_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aa8d21a22a84ccabb1b42d66a503b1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i744902b106114f94aaf10f93f79da793_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31ec6c709d854ece8b361ce8b9f623c6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf7021225a1d4ebe992272c6b7a424f3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ab714214aec4c62895368e7b5d77d47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb91a25096ac488099c2f68651d8104a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id929ac4578254f3a8ac5a00ef4adae72_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47bf34c04d3d4427a895561238e93dfb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7ca912d3a02465795eea96c1e250e26_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e4ef4f58a5044038cbe7d46e8dfea60_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i960826d299ae4c44bc47f074ce02ed28_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cb0816a5da441f6960846569f93e09e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c75751fbbd54a6eae8d08e6b4ab94a2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2d81d730eae4c75b3cb95f6789994b0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2706c4da523140c79cd5bc0fc5dd4e18_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13f3c31fcc184de09194d8a0f21020a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i525fe873d3c2406f95c7b1e8fe7f01a1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if49cfadd37a2439693bcaef2ca7aea4e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96994f66670d402b9792042ce4aa991c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90169973e5d44809bbd3c5d4c63ea01d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a84937692640da928c5aff561db4f2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7f5959c88534df58f8cc98840f9d9c6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50f6763c502f4844b08ec38b15b78eb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40c2436f586643c299cf6643b5e47526_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic284e67a71b64b93b2d5099b8216ad4f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59a87beef6454e0cacb2bf3bac49aa68_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c1e999ffea0466ea3a2914cd626dbde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d41b951fcf5438d958a6230f14dd8c2_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaedce6468a3e4e8ca15a5333813a91c5_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79aed8a5f7344a37b2a701ae05c1b842_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c24e626673740bfbc5c482a85f9be03_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f45a85ad1d44d3b1bba8c3ef692bb0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id96a059c175048b68ce735b693389c60_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide775581b0c2448ba46085d3508e93e6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5bfcb0c398a4d1ba18c1a7084e71a4d_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id342da7701a44166b2290441fd002835_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic42188622755410b90efa5d41026374a_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7530c57faa32498ca2794192fcf4a689_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice3c432af1ef4dc0a423e7d7b0e84b24_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idffc7ad1a4654adf98f1038cfa6da4be_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6be98831456946c8b796aa596a41a463_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2420da3a7fa34500b18bdcbdb21aba50_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e82484500e428e8076ddebadf195b8_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5631b43e9caf49eeb64e4768bdfb4735_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ca31f441294fd2bd58db5233a8cc5f_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5870d3d480b24bfb8fce0c75a91af736_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0f03be090e54e69ab5736238c33be28_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93205c45ea8547a98bc7ff1c11408e54_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e280a759a5741be8b52ce88da866568_I20181022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b03deaf81e94b908e898c240f288f46_I20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b019d63dd4e49a68deed79176b07e2d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc2482dd4334134b1fadb0256b066b3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62205ea298424eb981ea4ca7c04b1743_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aa4d8786f5243df8cf17673c36d708d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56b4489e137445769dd2d5c0552d9a73_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d77309eeff741329a3b33008063d50d_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5ae38a0018f4e7a9d7dcd73631d6bd7_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0901a44b29f424c9815549f850adf16_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4df19daedef45a6b93e44ce65f0f0e7_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3584d11db2f3491898d24a547ffcbb7a_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7648a33bd59947509a7713b0d44e5483_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c63bf821d6e48e2ab3a8136ab3612ae_D20211201-20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i427a803b22b943cbb1135ad1eb47ec78_I20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6ccdc5191c44efea9d1d9edc7499e87_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica61ba8f679544528ab9c464177763cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44077d7155334c2a88271bade68c730c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9d50749331f4a3db9bce7b2180496cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcf121a6589f44c98a0e5e8344398edb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33bdb53de4cf4bf4acf5c9415254f853_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199532edebf94240832d93a367225b5e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i287a359f1cb24979b1d38fe6e75caa46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f5f7300b0d042e0a3bd9a21c41816ba_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i804fa23f02a940218c7286e946780122_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddc1d80def48423e86b4d3005ffe55ed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff1d7b85971f4121968757b59f6d1b6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6ed29b7f1b44cf89f0a291dd12cf6d2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0198a0ff5cce4a9b91c42f736cd3a452_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2dde99085614be3a48c4e542d462eac_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">evh:ShareholderClassActionComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice2334023a474418a26edc96b4914f57_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f5855d88434c3285d8d998872119e6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b48f947d8c0471a835cbc7da3f1cf01_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97331e99ea5547e0b35d6859a1d13dd0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i858366f085d4485eb18d0f7cc216d020_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CenterForMedicareAndMedicaidServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea8512b30824967af5d24f3c9c780b0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:BrightHealthManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f081253ccd6415999b9700a0d052cc4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4369d3b9e5314c63bacd3f01a5ccb6b1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f3674d843144031a1c5d85f7415f252_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffcd008fc3494897b3c4b55545b1ecf2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id09252d541af4f6480d509935a97ae1c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59876efdc3d43669106ec8d543d109a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f5b407f5d74c80b132051dcf12fe42_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4697f31a51524c06a29c429847fa3a82_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7549a5bc04b3412f8b50fb05b19fe749_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:BlueCrossAndBlueShieldOfNorthCarolinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8618f6dc2f0455a9e812da51a84fc9f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafda5615eab24ad0adebb2033f75ea7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38cfdd80181d48dc95c448a5bd762e1c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92f67640b93b448585be7724489ed0b2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31cae587563b4dfaba6a55698e21f99a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0fe093ce52b4d0081c2f7e51b68a9fa_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a4e8a319824f4b96b6989839081ca3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d54b939218e47729004114229359446_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5f918cd7826430298dbf550d4b035ad_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if231d8338180440882ba220f0ce751c6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide8b1a427528491e95fa193e43b94d38_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcfcf1b04d4841ccbb92d2a7320961fe_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2901a75f3a247c5ac744dd557ba51f0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24857afd029946ad953d32e472b7bcbc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd7310dc91f4778877cc439a686f2ce_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie134ed611c47418485ab07b86a56f78d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2447e2f271ab4cd5b596bc7f50ab65ce_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i964b6c8302364f4fa39a31e5fe8af1a4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a6bfcf39da045688459cbd536822b1d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bfb82287c064822b44c47e618455986_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia74da95131c94444b02cb9706d3d7af2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f9d2b1aa2e48d89223c9302b8b413b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida2bfbe459a7424eb6baf496ceffcbc0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9002002234e467d88e03554eac894c8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b58614dca7f4fbeb927b1354f4e9b79_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa8508ca389418f81bf326a680bd658_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7783015b2ae54c6e9b2422c563ab6deb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b51644e7c048c88aea7ed7a62c9f77_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc87bed7f2074590b61ec2fb0cc0f0f8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f97a58aa80547029649a0cf3a2a5dd7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic329299275fa4a088f919d8e59845bff_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76cc4f8c28014238a98362c8d2ef9224_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92729353701e4160afc71576b5f23a25_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib699196b28014c31a00d19bb66ee014a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10c9925c2945438f916183ef76ede0c0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84dbc81371174a2aaee8be24c4769d0e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i527e4616505d460da52a06d5e9031339_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id03a4fc06028452a8a6a2c80df8c07cf_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7deec1f9d05a4e7b8276434ce19b2f18_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f9702c58070468c9b2a1580cb0175db_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ea4f0986d4c4a1e9f1370d4957fd642_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ee8a89e489b4af9ac0113c9d93ce86e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb490ebfa4014df7bbc4f1b2f06baaaa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54dd4caef2f344379688eaef3449c98e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94ebbd62d39b4c6e878b3190d03982a1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8f2eb0ac1624558acdb53e52c269e19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bd208a32416460385f7876f38b23d85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if038fb24676c4fbe8fcd625e0c03f2e4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if35ad6a7d0874e9989f37adcab1d604c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic72c81faddfb4d16898248ad47a599c1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic59c227acd8640a480a066d3194993ca_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f1f46b4a5da4b88ab1161c697899756_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901fed8a465841a2a7d4e3c79e3b289f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e8394722604655b91f21d472ddc55f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f4d51ef9aa4ab4a4f13f3a70a0afb2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a0e0359a3b54f88ac3fba23ecf413ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67639f87145d4008acf2702010dc086c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9af5aa7ede47a29b2eff96c883a5f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idad3e10b3ea8472d88039d89be09d82a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d10e11febe742e388c4185b0dfb5f67_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20f895ec0c394fb7a1b6962e0c4d6c9c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1d611e598104338b6853034734ea3e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65efdf8b544f497a9ccb4054da27c745_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i117805e609ff46d0921c81fc5e9621b3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ddb18e6282b4f94a145adbb9bf20767_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieea3e0212f024a4cb925e63dc3d63669_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f2571b77c148eba97976fcd4e2bcf2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6a6977963ca49b586c2fcf93713da7b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7607171276ef40a8b48df3ab23ab716e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8255e04a5a48e69c16aa566c4151bc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fac99680e9547b89140b689b06a4952_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47e7ef4ce9c44edb84ead5d40559f606_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib07e032acadb4ab4aeff1fa0375c42f0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e2e5a89677e4a3694479947d5a435a8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7295fdf6eb154c00992c57534af23daa_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5adf3c79b7f64f2aa0af3af80b0553b1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0464c31a82d4d04b71913910715453f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d215ef7e89344058608e5d4f9363124_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f163348ee8540d09c2f6ee2944703fc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e3a1495b5e04e5b850b1f4ce62855aa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1caf080cfaca42c29144aff3c13b93b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4a298cd056483f927ffa2a3469d4ee_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2548e4d1f3694bce8967d2081c947aac_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b3b51310ab149b399238bbc8da2f487_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f99af9f1bbe4f909c3d4ea820bf365b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67189557a7ea47dfa0d97556d16c7c5a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>evh:segment</xbrli:measure></xbrli:unit><xbrli:context id="i29d5e516649a4eb1bd68a4ae83bd5e16_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i420c2960b8964c268e95e8eda2a47790_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f83964678a340d8a8a7893bffb76713_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ad7b61e97de4695ab5cc762df1bab8d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c4cc0b519ac4301afbf3a86f9d1a16f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5fd05553c104209a219f91c15de897b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e90bde16c38406cb0456caf29ecea2a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1fd13e0887f4184bc87321d513724b5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ace05961a24c8aad395abf32e9e34e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia437c1047b404319a8f7f650e06e4e90_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8546f2bf902a41be9774135aea47d11d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09d7524a42e2444db7f04130d8c7e586_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c79847ac9a6406dbd571e7e8285c8ab_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie88d244c079c44a6a96afafc4dd811c7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc490f2a102c40368f57f3b421851b0d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5fb402086e24b79a85a9f5d622bf485_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d9d012a2bb4aea8bee56c1bbb1747d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea87c5d05fc147deb58c839bf401c1ee_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i371114cbc06e4f95811ba2a6fec0c8b1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7734adf1b5e6413988815cac05b34700_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i748aee67f29648e5bcea7fa5140a470e_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie583be11220d441c9171d7d8b813691e_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ac2d191e26480fa87349b7a8290bde_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b9cc6fdb0d444239ea5b97cef38f068_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244a3a3fba544622b797356979f8025f_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>evh:day</xbrli:measure></xbrli:unit><xbrli:context id="i47af930ce9a049169a33fecd6da9992c_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2065d4ade06445edb3d844c8ae917420_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i151d150fd9d24075af69e985884cae3a_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5ea489e80dc4ac28fa3620d03b1c6d0_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0379117a2c6c4cab9b19860640687c97_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMS0xLTEtNTAyOTk_c73fb9ae-1251-4539-9157-05f9e988f6bd id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMS0xLTEtNTAyOTk_6e579c51-776c-481d-b0d7-7151719b7e28 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMy0xLTEtNTAyOTk_78b7293f-57e3-44f6-9cd6-cab6a1c2b4dc id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMy0xLTEtNTAyOTk_e331c0b9-e116-4212-87f0-3fbd284d7232 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMS0xLTEtNTAyOTk_c3daba8c-5415-4626-a6f0-894377885a08 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0xLTEtMS01MDI5OQ_6ff647ab-fc7f-4b9f-8ba2-6da66d240d2d id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0xLTEtMS01MDI5OQ_97a656e4-10e5-42a1-b495-b5cdd1969fea id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0zLTEtMS01MDI5OQ_70fe2f65-5e3f-42d1-9054-6bf2243f19a2 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMy0xLTEtNTAyOTk_9d97e8d6-10c5-497f-8469-fdd1ffdcf538 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMy0xLTEtNTAyOTk_21824ee8-66f2-4feb-81be-27e21a353033 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0zLTEtMS01MDI5OQ_e9cfb95b-d053-4a12-b35e-ceeda4fe4188 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMS0xLTEtNTAyOTk_e7fa3d27-9397-4ab1-bd1a-cfa9c7e74f93" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MjM2NA_d0078107-c79a-4908-a96b-fcb12333a564 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTAyOTk_cc81acb2-9163-4391-91dc-f0317c70e013 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTAyOTk_6dccf1fb-174b-4581-aaea-f9ea25f1d932 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTA2NTk_d0078107-c79a-4908-a96b-fcb12333a564 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTA2NTk_49497634-fa51-4fa0-8ab4-f53f91f2fa50 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MDI5OQ_cc81acb2-9163-4391-91dc-f0317c70e013 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MDI5OQ_6dccf1fb-174b-4581-aaea-f9ea25f1d932 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MjM2NA_49497634-fa51-4fa0-8ab4-f53f91f2fa50" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMS0xLTEtNTAyOTk_4c1972bb-dfd5-4f56-9c73-e15c8c00e245 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMS0xLTEtNTAyOTk_ee292a9f-87ae-4203-bf77-93525b8dfbc2 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMy0xLTEtNTAyOTk_5c760221-6054-44a2-b77c-2d92546fb78d id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMy0xLTEtNTAyOTk_c7a5e83c-5f21-49c0-b45f-eebb0c4d690d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RleHRyZWdpb246MzJlOTdlODQ4YmVmNDkzMjg4ZWRlY2QzODFiMGE4ZWRfNTcx_567b7399-c20a-4925-8240-cbdd77cce4ce" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDI5OQ_69277f2f-30d6-41c3-bcac-5fb7817d7d63 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDU4OA_1a89fd1b-74de-463e-a1e5-2355d32025e7 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDYwNA_d025d75a-23ed-4fd9-803c-6e9eda31fa44 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDYwNA_1988702f-171f-41b1-85e9-cb63feec4a20 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDI5OQ_3d2a993f-44b2-4115-aa5e-34b7dcf52020 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDI5OQ_17b92439-90b9-43f1-91f1-6f1c765fb21a id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDI5OQ_85fe62ba-44a3-4785-b828-b469eeda2fdb id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDU4OA_55975170-d5a0-4043-94f4-be240ba735b5 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDI5OQ_5c9aeeb5-648f-4616-8c31-69a18c6f0408 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDI5OQ_93cc4c54-276c-44e8-94c1-f48e1cb760c6 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDU5Ng_ac682693-add5-4a42-9252-82d4e320ee74 id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDU5Ng_911a2c47-3850-4275-81ec-10373623a70c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></div></td></tr></table></div><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMzA5_797818c7-6ca6-446d-9018-a9553ed9c6ea">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMzEw_f544d7ae-7519-4fc2-8cf4-d8e6bb67b02a">S</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMDY_1811a45f-1a9c-4a75-ae0e-16c4ec66f0d8">June&#160;30, 2022</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span><br/></span></div><div style="padding-left:18pt;padding-right:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMTU_6151c599-0ff9-417d-ad64-30b80f1523ed">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:38.25pt;padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18zOTc_1569134e-f370-45fb-9b04-c2545cb095ce">001-37415</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y180Mjc_cdde3680-387f-4017-9420-8b142886b71e">Evolent Health, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:479.25pt"><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8wLTEtMS0xLTUwMjk5_4481b247-0cf9-4661-ac60-21d55a3f1d8a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8wLTktMS0xLTUwMjk5_92182389-7f59-4ae3-90f4-c770a10500bc">32-0454912</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8zLTEtMS0xLTUwMjk5_70c0c14d-03e2-4622-84ca-da8f45549347">800 N. Glebe Road</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8zLTMtMS0xLTUwMjk5_3fe698fd-6220-42a2-9f19-656dd18505e2">Suite 500</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8zLTUtMS0xLTUwMjk5_98864a75-fc6f-4a21-938a-daba404ee64c">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8zLTctMS0xLTUwMjk5_47ee2ad7-170a-42d7-8c19-d9b93e6b33ae">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8zLTktMS0xLTUwMjk5_a291f1d1-0765-4439-93ac-d0e571f40423">22203</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;           </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y181MzU_368ebc49-e508-4f7f-8342-77097fb0241a">571</ix:nonNumeric>) <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y181Mzk_6a4b5a0c-5bc0-4b77-ba4d-e24dfbf8b0a6">389-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:256.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:190.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6ODUxNmU5YWYzMTE4NGQyZTk1MTY1NGJlODlhZjRjMTkvdGFibGVyYW5nZTo4NTE2ZTlhZjMxMTg0ZDJlOTUxNjU0YmU4OWFmNGMxOV8xLTAtMS0xLTUwMjk5_9fabd2d6-edca-4b1b-9b1a-b0f5948ea5c6">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6ODUxNmU5YWYzMTE4NGQyZTk1MTY1NGJlODlhZjRjMTkvdGFibGVyYW5nZTo4NTE2ZTlhZjMxMTg0ZDJlOTUxNjU0YmU4OWFmNGMxOV8xLTEtMS0xLTUwMjk5_b0b27f08-de16-40de-b1c8-e559e56241d5">EVH</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6ODUxNmU5YWYzMTE4NGQyZTk1MTY1NGJlODlhZjRjMTkvdGFibGVyYW5nZTo4NTE2ZTlhZjMxMTg0ZDJlOTUxNjU0YmU4OWFmNGMxOV8xLTItMS0xLTUwMjk5_776a0372-f41b-4227-96c3-a5ff3642b9cf">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18xMDQw_ee2c4cd5-4362-4ce2-ae06-9eef995a6b4d">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18xMzYy_1077a9a7-9fde-49d6-acee-2cded992f891">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No  &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18xNzI5_6192de5d-13f0-4664-a06c-a2be672071b3">Large accelerated filer</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  Accelerated filer  &#9744;  Non-accelerated filer &#9744;  Smaller reporting company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18xODEw_8443a7e0-b608-4a11-b32c-91f283cd825e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMzEx_1555c6f6-8be2-4fa2-8263-6e90d9a94319">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMjE1_dd300a93-2951-4038-b866-bd8816017fa0">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No&#160; </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of July&#160;29, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i7e86b1305605495eb71612e57efef826_I20220729" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMjQ2_e2c84f0b-f41d-4d50-97a3-ec8da7f13222">91,669,520</ix:nonFraction> shares of the registrant&#8217;s Class A common stock outstanding.</span></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_19">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_22">1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_22">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_112">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_112">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_112">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_136">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_136">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_136">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_139">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_139">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_139">52</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_142">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_145">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_145">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_145">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_208">1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_208">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_148">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_151">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_151">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_151">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_154">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_154">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_154">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_157">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_157">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_157">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_160">5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_160">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_160">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_163">6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_163">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_163">55</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_169">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ec4d9b5233f4aa5a7f5353c408fadd2_169">56</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Explanatory Note</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Quarterly Report on Form 10-Q, unless the context otherwise requires, &#8220;Evolent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Evolent Health, Inc. and its consolidated subsidiaries. Evolent Health LLC, a subsidiary of Evolent Health, Inc. through which we conduct our operations, has owned all of our operating assets and substantially all of our business since inception. Evolent Health, Inc. is a holding company and its principal asset is all of the Class A common units of Evolent Health LLC.</span></div><div><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_16"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this report and in other written or oral statements made by us or on our behalf are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;aim,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;shall,&#8221; &#8220;may,&#8221; &#8220;might&#8221; and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to grow our impact significantly throughout this year and beyond, future actions, trends in our businesses, prospective services, new partner additions/expansions, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements.&#160;Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the significant portion of revenue we derive from our largest partners, and the potential loss, non-renewal, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">evolution in the market for value-based care;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertainty in the health care regulatory framework, including the potential impact of policy changes;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to offer new and innovative products and services;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to completed and future acquisitions, investments, alliances and joint ventures, including our acquisition of the Implantable Provider Group, Inc., which could divert management resources, result in unanticipated costs or dilute our stockholders;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial benefits we expect to receive as a result of the sale of certain assets of Passport may not be realized;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the growth and success of our partners, which is difficult to predict and is subject to factors outside of our control, including governmental funding reductions and other policy changes, enrollment numbers for our partners&#8217; plans, premium pricing reductions, selection bias in at-risk membership and the ability to control and, if necessary, reduce health care costs;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to maintain profitability for our total cost of care and New Century Health&#8217;s performance-based contracts and products, including capitation and risk-bearing contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions and the impact thereof on the economy resulting from the COVID-19 pandemic and other public health emergencies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to recover the significant upfront costs in our partner relationships;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract new partners and successfully capture new growth opportunities;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the increasing number of risk-sharing arrangements we enter into with our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to estimate the size of our target markets;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain and enhance our reputation and brand recognition;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consolidation in the health care industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competition which could limit our ability to maintain or expand market share within our industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to governmental payer audits and actions, including whistleblower claims;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to partner with providers due to exclusivity provisions in our contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to our offshore operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of additional goodwill and intangible asset impairments on our results of operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve profitability in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of litigation, including the ongoing class action lawsuit;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">data loss or corruption due to failures or errors in our systems and service disruptions at our data centers;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adequate protection of our intellectual property, including trademarks;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any alleged infringement, misappropriation or violation of third-party proprietary rights;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our use of &#8220;open source&#8221; software;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third parties and licensed technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to use, disclose, de-identify or license data and to integrate third-party technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third-party vendors to host and maintain our technology platform;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to utilize benefits under the tax receivables agreement described herein;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of agreements between us and certain of our pre-IPO investors;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the conditional conversion features of the 2024 and 2025 convertible notes, which, if triggered, could require us to settle the 2024 or 2025 convertible notes in cash;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential volatility of our Class A common stock price;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our second amended and restated certificate of incorporation and third amended and restated by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of certain of our investors to compete with us without restrictions;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our second amended and restated certificate of incorporation which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intention not to pay cash dividends on our Class A common stock.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements.  Our Annual Report on Form 10-K for the year ended December 31, 2021 (the "2021 Form 10-K") and other documents filed with the SEC include additional factors that could affect our businesses and financial performance. Moreover, we operate in a rapidly changing and competitive environment.  New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_19"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Financial Statements</span></div><div><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_25"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands, except share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:521.25pt"><tr><td style="width:1.0pt"></td><td style="width:325.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMy0xLTEtMS01MDI5OQ_257cf865-391e-4043-9b36-f068243da4c1">193,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMy0zLTEtMS01MDI5OQ_8a209f91-566b-4e45-8cbc-b961da12592f">266,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNC0xLTEtMS01MDI5OQ_4db3b800-b304-4ebf-9e78-35845657e03a">74,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNC0zLTEtMS01MDI5OQ_1e026770-9260-43b6-88c1-61419cd06108">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0xLTEtMS01MDI5OQ_97a656e4-10e5-42a1-b495-b5cdd1969fea">118,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0zLTEtMS01MDI5OQ_e9cfb95b-d053-4a12-b35e-ceeda4fe4188">130,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0xLTEtMS01MDI5OQ_6ff647ab-fc7f-4b9f-8ba2-6da66d240d2d">37,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0zLTEtMS01MDI5OQ_70fe2f65-5e3f-42d1-9054-6bf2243f19a2">51,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNy0xLTEtMS01MDI5OQ_2df252fd-6d6a-496a-ab4b-17fe160bd0a9">423,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNy0zLTEtMS01MDI5OQ_a8da48fd-60f4-43e7-afb2-624b2abc24a7">523,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfOC0xLTEtMS01MDI5OQ_0dbf653c-ddb1-4f8d-be6b-f565e1031919">12,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfOC0zLTEtMS01MDI5OQ_54c99049-77b0-4c3b-b4b1-0ba9de2569a0">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfOS0xLTEtMS01MDI5OQ_8f11685d-70d2-4d05-a50f-2137a504b1ee">3,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfOS0zLTEtMS01MDI5OQ_ba235c1b-37bf-43f9-9d3e-bf71a01972a3">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTAtMS0xLTEtNTAyOTk_a765f80b-00a8-450e-bbbc-b595f1463daf">92,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTAtMy0xLTEtNTAyOTk_3d0858b5-cc42-440b-9e73-ab8e6ddeed33">81,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTEtMS0xLTEtNTAyOTk_f467cc1f-ae9a-4b9e-9bee-606b5991864a">50,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTEtMy0xLTEtNTAyOTk_a20213be-0873-4e6a-98f8-49bf5162620d">50,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMS0xLTEtNTAyOTk_c73fb9ae-1251-4539-9157-05f9e988f6bd">6,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMy0xLTEtNTAyOTk_21824ee8-66f2-4feb-81be-27e21a353033">6,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTMtMS0xLTEtNTAyOTk_864734d8-96c1-4015-98f8-01f18c513317">22,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTMtMy0xLTEtNTAyOTk_0c55e7bb-a19c-4173-a7e0-75a8c8eeaced">32,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTQtMS0xLTEtNTAyOTk_40297c6d-5e6a-4f0d-a399-36f35ea609d2">264,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTQtMy0xLTEtNTAyOTk_d8a093e6-504c-4664-91b0-59fb78ef52cd">279,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTUtMS0xLTEtNTAyOTk_e7c9085d-d297-4f99-9863-c329e4aff7cc">426,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTUtMy0xLTEtNTAyOTk_b554a331-d7de-4ad1-bb95-9a634fa31504">426,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTYtMS0xLTEtNTAyOTk_5308bfb9-dd25-40a8-9ad2-e06cdb0edc9c">1,303,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTYtMy0xLTEtNTAyOTk_a0ab5e04-06e2-4e5d-aeee-f83b3d271071">1,419,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMS0xLTEtNTAyOTk_6e579c51-776c-481d-b0d7-7151719b7e28">96,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMy0xLTEtNTAyOTk_78b7293f-57e3-44f6-9cd6-cab6a1c2b4dc">96,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMS0xLTEtNTAyOTk_e7fa3d27-9397-4ab1-bd1a-cfa9c7e74f93">75,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMy0xLTEtNTAyOTk_9d97e8d6-10c5-497f-8469-fdd1ffdcf538">107,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjItMS0xLTEtNTAyOTk_d234d571-8f12-4cae-a841-abb837fb13f7">6,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjItMy0xLTEtNTAyOTk_6a798a83-167b-43b8-8065-e0927f754963">7,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjMtMS0xLTEtNTAyOTk_98876eb6-3a81-4f5d-8cc2-f86a5fe9641f">29,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjMtMy0xLTEtNTAyOTk_60ba112c-8583-4256-bc94-8db5a619a9ab">51,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjQtMS0xLTEtNTAyOTk_c0e9cb99-7f79-4b40-a1a7-ab858e8928b6">8,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjQtMy0xLTEtNTAyOTk_587e8b9c-8af0-4760-883e-6f6420e7d883">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance - based arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMS0xLTEtNTAyOTk_c3daba8c-5415-4626-a6f0-894377885a08">125,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMy0xLTEtNTAyOTk_e331c0b9-e116-4212-87f0-3fbd284d7232">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjYtMS0xLTEtNTAyOTk_ba35d818-669b-42ee-baf6-a56d2eb0a7ad">342,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjYtMy0xLTEtNTAyOTk_59b6d178-b4ae-47f4-a664-33234139759f">445,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjctMS0xLTEtNTAyOTk_7f40fb0e-3277-4f28-bf9b-f226c6e5aa96">283,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjctMy0xLTEtNTAyOTk_f2428e19-1a4d-48e6-a144-670ccc60a640">215,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjgtMS0xLTEtNTAyOTk_6ba11d65-60de-4a56-9d12-549b78449b6d">4,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjgtMy0xLTEtNTAyOTk_d6b52c54-dede-4053-bb92-b298ed773f1a">5,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjktMS0xLTEtNTAyOTk_1d42115f-e8e7-4cf3-a15c-25b86fb1455e">58,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjktMy0xLTEtNTAyOTk_3e47d3da-29cf-4a09-81ef-ce0a5e566a4c">57,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzAtMS0xLTEtNTAyOTk_28ca91a0-5a86-4239-9639-ce1cc1e44479">1,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzAtMy0xLTEtNTAyOTk_1e656525-1a00-493e-9129-5525612684e7">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzEtMS0xLTEtNTAyOTk_8908cf92-2372-4f4a-89e6-bda02f7702b5">690,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzEtMy0xLTEtNTAyOTk_06d54094-dd6e-4eff-8fbc-a42ba0e2e0cb">725,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and Contingencies (See Note 11)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzItMS0xLTEtNTAyOTk_b921ca0c-8fe7-4068-b178-28563263a24a"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzItMy0xLTEtNTAyOTk_fb0adae7-b96a-4c42-9163-677bbd636ec4"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl8yNw_2810b51b-d34e-498c-b8ad-72b43ad32ab7"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl8yNw_9594887c-ea6d-46eb-b3b9-818cd4874d3f">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl80MQ_755ba1ab-9569-45cc-90ed-6f0e8af068c6"><ix:nonFraction unitRef="shares" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl80MQ_ccf1aa20-88c1-4c83-a323-e8962676730a">750,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl82Mw_dba124ee-ce63-4ca4-bfb1-50762df3e78d">91,657,480</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl83MA_cb352c43-a751-477f-a142-3943215b1ebb">90,758,318</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMS0xLTEtNTAyOTk_00edb1a8-ca9e-4584-aa54-df0bcf806c82">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMy0xLTEtNTAyOTk_8581b91a-a573-49d3-aa71-afd1b9884084">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzUtMS0xLTEtNTAyOTk_8ba1e87c-1633-4e84-b93f-b046a2914d60">1,231,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzUtMy0xLTEtNTAyOTk_13cc6e8f-df8b-48cc-a014-a2504e8afc0d">1,340,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzYtMS0xLTEtNTAyOTk_d42c4fdf-ba18-4586-a6a6-a6bb2eb2e9fe">782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzYtMy0xLTEtNTAyOTk_b3f5d975-aa7e-4bc8-90c9-30e4bebb546a">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzctMS0xLTEtNTAyOTk_2c23e8ee-c169-4229-9b18-30070666b1c7">596,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzctMy0xLTEtNTAyOTk_46f7f167-56e7-4afa-bddd-ac3d983958d0">626,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzgtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjo5YTExMDA2ZTVmMTU0MWU0OWJmMzc3ODVhOTZhOGQyZV8yOQ_4e491049-c092-4e35-8ce9-96d37fd89348"><ix:nonFraction unitRef="shares" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzgtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjo5YTExMDA2ZTVmMTU0MWU0OWJmMzc3ODVhOTZhOGQyZV8yOQ_a3688d61-5f89-421a-b979-de276187d549">1,537,582</ix:nonFraction></ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzgtMS0xLTEtNTAyOTk_88ae886e-1ee3-46e9-ad75-f834b5095457">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzgtMy0xLTEtNTAyOTk_06a5319c-e3b5-4b89-a748-ce30e0463644">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzktMS0xLTEtNTAyOTk_fead2357-c9d3-456b-84c8-8d17bd9c9df5">613,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzktMy0xLTEtNTAyOTk_7600c7ef-8ae7-452a-94b3-bd9a0fb01bf2">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNDAtMS0xLTEtNTAyOTk_54034b4c-44ea-42af-9ea8-21ee794de2a7">1,303,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNDAtMy0xLTEtNTAyOTk_5c07109a-96b6-465d-b375-3066e0029256">1,419,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 18 for amounts attributable to related parties included in these line items.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_28"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/>(unaudited, in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:543.00pt"><tr><td style="width:1.0pt"></td><td style="width:271.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDU4OA_1a89fd1b-74de-463e-a1e5-2355d32025e7">319,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDU4OA_55975170-d5a0-4043-94f4-be240ba735b5">222,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDI5OQ_69277f2f-30d6-41c3-bcac-5fb7817d7d63">616,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDI5OQ_5c9aeeb5-648f-4616-8c31-69a18c6f0408">437,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDU5Ng_911a2c47-3850-4275-81ec-10373623a70c">249,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDU5Ng_ac682693-add5-4a42-9252-82d4e320ee74">172,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDI5OQ_93cc4c54-276c-44e8-94c1-f48e1cb760c6">469,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDI5OQ_17b92439-90b9-43f1-91f1-6f1c765fb21a">329,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDYwNA_1988702f-171f-41b1-85e9-cb63feec4a20">58,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDYwNA_d025d75a-23ed-4fd9-803c-6e9eda31fa44">42,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDI5OQ_85fe62ba-44a3-4785-b828-b469eeda2fdb">117,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDI5OQ_3d2a993f-44b2-4115-aa5e-34b7dcf52020">101,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNy0xLTEtMS01MDYxMg_5c713e1a-c784-452b-acab-e5b0f704c2c5">15,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNy0zLTEtMS01MDYxMg_3101ed74-ad8d-4d16-ac51-76e7408e6c2f">14,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNy0xLTEtMS01MDI5OQ_52e315e2-656c-42d1-aacc-94e8d380fd2c">30,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNy0zLTEtMS01MDI5OQ_9c6ffd64-b875-4f41-90ee-55d30d9b84c4">30,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOC0xLTEtMS01MDYyNg_dfd1b9dd-c74b-4997-9d87-4bd9351cb536">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOC0zLTEtMS01MDYyNg_3b632233-5b57-4064-bfc4-f1ce1d4d477d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOC0xLTEtMS01MDI5OQ_c1463bce-a319-4ea3-b3ec-13369b701ccf">6,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOC0zLTEtMS01MDI5OQ_105ec464-12e2-4b3c-9646-ec8a7b0713e9">594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOS0xLTEtMS01MDYyNg_5919e52d-5a7d-445f-861e-c80e40312873">324,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOS0zLTEtMS01MDYyNg_404677b9-f539-45b7-8906-878e86103fa2">229,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOS0xLTEtMS01MDI5OQ_6b436524-dded-49eb-9d71-ea1ae728f88b">624,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOS0zLTEtMS01MDI5OQ_dc3f9ff3-cff0-4733-bde4-2dc4acb9bab1">460,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTAtMS0xLTEtNTA2MjY_3737c224-db1e-40e8-88d8-afc201a1f116">4,633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTAtMy0xLTEtNTA2MjY_9aa88232-b0c8-487b-8eae-8766e5a09721">7,671</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTAtMS0xLTEtNTAyOTk_5476f0a7-c612-47b9-8e50-e6c6394ac08e">7,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTAtMy0xLTEtNTAyOTk_8377b28b-0d80-4412-9c67-544a4620b045">23,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTEtMS0xLTEtNTA2MjY_2c7fd4da-bb62-4abb-9676-bf6e03061de5">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTEtMy0xLTEtNTA2MjY_23ee9933-4c04-496e-a5d9-6cd6b251c3c7">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTEtMS0xLTEtNTAyOTk_9ed4b197-f83e-4d92-815e-3fddd284bbf2">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTEtMy0xLTEtNTAyOTk_ba8765c7-73f2-4c51-80d6-973e9450a72d">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTItMS0xLTEtNTA2MjY_980c785f-3c41-445c-9809-39e58c413668">2,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTItMy0xLTEtNTA2MjY_fcf6ddc2-3420-41b6-b3e7-a6f62801ae05">6,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTItMS0xLTEtNTAyOTk_0c3d52c5-b7b9-45e7-ae6c-7dd6f31caff6">4,389</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTItMy0xLTEtNTAyOTk_cf922404-940b-48da-a63c-5d9cdb64ecdb">12,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTMtMS0xLTEtNTA2NDI_532371ed-7292-4af5-ae85-9c28fe14e188">1,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTMtMy0xLTEtNTA2NDI_5ec83cf9-83bd-4f28-987d-d201d39bb46a">4,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTMtMS0xLTEtNTAyOTk_772b0223-f248-4dc7-bec8-9ab864cb5e86">2,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTMtMy0xLTEtNTAyOTk_b90eeedf-4ce1-4b9e-8ffc-18b86469d786">12,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTQtMS0xLTEtNTA2NDU_03c07e02-43c6-4193-8b95-3e190d93b902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTQtMy0xLTEtNTA2NDU_77370f4d-6558-4f84-b464-c5f346fbe0d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTQtMS0xLTEtNTAyOTk_782732ca-5fd7-4949-9e86-9e7784ddf433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTQtMy0xLTEtNTAyOTk_03542c00-12a9-4f83-9e99-6be2e2961e88">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTUtMS0xLTEtNTA2NTI_16e509cc-2957-4694-a8e5-64279889b5da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTUtMy0xLTEtNTA2NTI_91b002f7-d609-4d25-81e3-f9e412ba0c97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTUtMS0xLTEtNTAyOTk_01c84cac-8963-423d-9e0c-1ceab438eceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTUtMy0xLTEtNTAyOTk_e389997c-a3ea-4761-919c-6ba84a13025d">19,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTYtMS0xLTEtNTA2NTk_fa5a6863-e9bb-4760-9beb-d8a33fa683d8">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTYtMy0xLTEtNTA2NTk_67a69309-78e4-4be9-841f-71d42cc87f2b">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTYtMS0xLTEtNTAyOTk_8826c335-8f5b-4d7b-b309-49e5690f89a8">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTYtMy0xLTEtNTAyOTk_36af74ce-94bc-4b9d-bd08-b0ff72a9482c">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTctMS0xLTEtNTA2NTk_e1f3b69f-8226-4286-99a1-4dc4058edce9">4,309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTctMy0xLTEtNTA2NTk_56a93eea-e83b-4c7b-bf54-116344c83827">9,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTctMS0xLTEtNTAyOTk_9ab025a3-64f7-4c6c-be6d-e2cce74bdf9e">8,457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTctMy0xLTEtNTAyOTk_3e27395a-19ec-4acc-88c6-46d08052012e">19,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTgtMS0xLTEtNTA2NTk_8d340b63-743d-434e-8e93-8df1799945e3">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTgtMy0xLTEtNTA2NTk_5dbe7074-7c67-4b7e-9c9b-b65ba52940e0">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTgtMS0xLTEtNTAyOTk_b72a5cad-2452-4dd8-abe8-65aa57c75350">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTgtMy0xLTEtNTAyOTk_61d67c4d-693e-451e-9f70-9d4c0bff4545">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTktMS0xLTEtNTA2NTk_a18efcc0-26c1-40a8-b285-2b77595deb95">4,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTktMy0xLTEtNTA2NTk_05e6ff98-613b-42b7-8fdf-21017a50b82a">9,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTktMS0xLTEtNTAyOTk_cf7ba85f-9d70-4564-b248-3c5ab3abd91b">9,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTktMy0xLTEtNTAyOTk_745240e1-c2fb-40f2-945e-f63634659172">20,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTA2NTk_d0078107-c79a-4908-a96b-fcb12333a564">463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTA2NTk_49497634-fa51-4fa0-8ab4-f53f91f2fa50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTAyOTk_6dccf1fb-174b-4581-aaea-f9ea25f1d932">463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTAyOTk_cc81acb2-9163-4391-91dc-f0317c70e013">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMS0xLTEtNTA2NTk_10ac028c-89f7-4af7-80f9-34ab4e32e9e2"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMS0xLTEtNTA2NTk_7948e45f-8d96-4ea4-b9c6-3b20feeee5b6">4,588</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMy0xLTEtNTA2NTk_1acd41b6-42ce-45ae-a4a1-03d19643a650"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMy0xLTEtNTA2NTk_c3862b2a-4d72-496d-b7e0-f334b76efc7c">9,107</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMS0xLTEtNTAyOTk_9de7c05c-8ff5-49a7-a0fa-6adbc9eca954"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMS0xLTEtNTAyOTk_a1e5913a-80c9-4d4e-98e9-37b9a429f74c">9,938</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMy0xLTEtNTAyOTk_8901d8b4-bc5c-47d0-9431-64b6adc94066"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMy0xLTEtNTAyOTk_bb195bd1-d582-459e-9876-c28c963d1c05">18,914</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMS0xLTEtNTA2ODI_485f8172-519d-4db8-9aed-4799287e8186"><ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMS0xLTEtNTA2ODI_8355fdd5-4e49-42e8-b447-5bc60b22d565">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMy0xLTEtNTA2ODI_22b63fdb-447c-4f0e-b062-dbd3ef19cd8c"><ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMy0xLTEtNTA2ODI_8ae57cde-39cb-45ea-ad89-116a1790131c">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMS0xLTEtNTAyOTk_9b9629f2-0d83-4975-9977-6ff59dfc6aef"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMS0xLTEtNTAyOTk_b6000604-7750-4e79-8f0f-7b737cda8fa1">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMy0xLTEtNTAyOTk_51986ab2-8998-4136-9236-ccd91dd19900"><ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMy0xLTEtNTAyOTk_f8c42eff-43de-49fb-b7c3-b43d543b531c">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMS0xLTEtNTA2ODI_e3b9ea4d-4e41-4467-a709-f0c6a630b4b6"><ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMS0xLTEtNTA2ODI_fd21a903-cf8b-49f1-b98d-4603eda45280">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMy0xLTEtNTA2ODI_3398dcf7-71be-4a2d-b3cb-f96294615a1e"><ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMy0xLTEtNTA2ODI_d1ce6784-6ad2-4ace-9d6f-deae258379e5">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMS0xLTEtNTAyOTk_5dc7a43d-578a-4be3-9269-b52f17c8b3a6"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMS0xLTEtNTAyOTk_85c081d6-9eaf-4668-84ea-a67c89dc82b2">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMy0xLTEtNTAyOTk_0ca56ccf-fb13-4418-9dec-67e6074c8574"><ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMy0xLTEtNTAyOTk_798eff45-60b2-455d-9c7a-9af99196bae1">0.02</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMS0xLTEtNTA2ODU_7a65e334-57d7-4878-bdfd-5c1b9c4f9bd2"><ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMS0xLTEtNTA2ODU_9453d8a9-eec7-4306-8c88-ff964bce8b6d">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMy0xLTEtNTA2ODU_688690ff-b6c4-4da6-aba8-506911ebf495"><ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMy0xLTEtNTA2ODU_7343f8c5-ee6a-465a-a801-3e37c33ac703">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMS0xLTEtNTAyOTk_12962f70-5c62-4b02-b9f2-da79d80cb9af"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMS0xLTEtNTAyOTk_5ecc3bd6-602a-47da-86bc-b7111a531ad5">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMy0xLTEtNTAyOTk_bb9b3f1b-30af-4b1e-83c8-4a8ea9925c0e"><ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMy0xLTEtNTAyOTk_e7620d26-5d56-482b-8cb1-d67e65ce2e29">0.22</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMS0xLTEtNTA2OTA_197cea3b-b8e6-4dc6-bb04-e2517ebc3bf5"><ix:nonFraction unitRef="shares" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMS0xLTEtNTA2OTA_f73b6be8-0559-4edc-a4ec-525d36a2cf68">90,071</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMy0xLTEtNTA2OTA_04b21dc9-bcb1-47cb-9b38-2bccddcc1c8a"><ix:nonFraction unitRef="shares" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMy0xLTEtNTA2OTA_20a29989-6086-40ab-a7c3-24bd2e418e4f">85,448</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMS0xLTEtNTAyOTk_53b5f9ce-d970-4657-94a1-c315b1e69321"><ix:nonFraction unitRef="shares" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMS0xLTEtNTAyOTk_5e57e7cf-9f3a-4611-9f09-ef7b143f6d62">89,792</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMy0xLTEtNTAyOTk_0f412b0b-9466-4a0f-942d-631e68f121a5"><ix:nonFraction unitRef="shares" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMy0xLTEtNTAyOTk_c8a5bad9-5fe3-4e34-be45-f8eb414f8265">85,056</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzMtMS0xLTEtNTA2OTk_1e5e317d-316e-41b7-b3a7-6efde24349f6">4,588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzMtMy0xLTEtNTA2OTk_ab4fd6df-8d30-4850-8d5c-14c389ce453b">9,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzMtMS0xLTEtNTAyOTk_c17de08c-762f-4592-b2b8-5d2de5745318">9,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzMtMy0xLTEtNTAyOTk_c91f547c-35fa-457f-ad85-65633176dcc5">18,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes, related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzUtMS0xLTEtNTA2OTk_4beb9a28-a99f-4ec1-a7a6-5904f2bc4cf9">288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzUtMy0xLTEtNTA2OTk_23dd3e26-269e-4af8-a6cd-3caa786676c6">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzUtMS0xLTEtNTAyOTk_a4a6b480-ab86-47b3-9202-0a749293f228">420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzUtMy0xLTEtNTAyOTk_30ae1654-9676-4ed8-95f3-028b3000ff0f">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzYtMS0xLTEtNTA2OTk_d9f4e596-20f1-42f7-b07e-21339b9b4185">4,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzYtMy0xLTEtNTA2OTk_79593568-552a-4ac3-9f91-76fac1c36488">9,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzYtMS0xLTEtNTAyOTk_e1844cdd-bc33-46d8-bba2-2d56f72b56d1">10,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzYtMy0xLTEtNTAyOTk_d05752be-3de3-4168-9886-0fc16fb9c090">19,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</ix:footnote></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes $(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfNDk0NzgwMjMyNTQ4Mg_26b2f69f-de74-4a2c-889b-a19ac36d8193"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfNDk0NzgwMjMyNTQ4Mg_4aca174c-29b5-4e14-b905-9f48320d20fd">0.5</ix:nonFraction></ix:nonFraction>)&#160;million loss on disposal for the three and six months ended June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-5" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMjY5_ac040d59-83f7-4884-9009-ebda27bd6d7b">1.9</ix:nonFraction>&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021, respectively</ix:footnote>.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.230%"><tr><td style="width:1.0%"></td><td style="width:34.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.570%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib26e65edf5734cb5a6a97189f7553074_I20220331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy0xLTEtMS01MDg4Mg_d4470500-8caa-4638-aed1-a4a554bff758">91,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib26e65edf5734cb5a6a97189f7553074_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy0zLTEtMS01MDg4Mg_fe3c7532-30d0-4874-92d8-127b228d8355">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icedd565fde88475e9cb04f61cf5d0594_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy01LTEtMS01MDg4Mg_80c2c396-3af2-4d17-a09f-fe9df61f7257">1,224,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia57e8ce997404651a93ef7beb639c1fc_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy03LTEtMS01MDg4Mg_c5a9d5da-5160-4015-a5e3-3fea8631201d">494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f3a63417094173a2013d8e4651e2e0_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy05LTEtMS01MDg4Mg_a4e9f891-daf8-4e09-86ad-5663f1d64c04">592,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4eecfcec6264b2fb00d016b793a019b_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy0xMS0xLTEtNTA4ODI_630eac24-bced-4a99-ac58-427248325c78">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd40945fb1484885837f7eecfa567b33_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy0xMy0xLTEtNTA4ODI_1d22d74c-e595-4355-a393-2a7c0ac9e1de">611,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e987b97514fad8244212f054173d6_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfNS01LTEtMS01MDg0Mg_b3a86978-748e-4c16-ba27-6948e3907a13">7,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfNS0xMy0xLTEtNTA4NDI_ade69419-b3c3-4f16-95eb-c4b998ebf5a4">7,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84e5e1239271498cbccbaa25d09f5b81_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfNy0xLTEtMS01MDg1NA_df1f6faa-8339-4c7d-bfdf-923fb85e755c">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i857e987b97514fad8244212f054173d6_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfNy01LTEtMS01MDg1NA_61ba373b-57b4-4b96-8424-6de1b0ff4cca">256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfNy0xMy0xLTEtNTA4NTQ_bfd6ffa0-0f76-415f-8252-bd676ae46e80">256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia37f68ad663840209db72f32dcc9dfdc_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfOC03LTEtMS01MDg1NA_7693d2f0-06ed-4f1b-b60b-9b9aad03655c">288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfOC0xMy0xLTEtNTA4NTQ_14fe8306-fa39-4488-8050-621ac77e8d5f">288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i351ea9834113446b96f0ad47bfeced58_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfOS05LTEtMS01MDg1NA_d67c3fac-2af5-4a82-adf6-87ffda4365ea">4,588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfOS0xMy0xLTEtNTA4NTQ_62daf232-9ed0-4130-928c-72dfc58e1d3d">4,588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i516e6c58c8cb48b1b164c617bc7de6db_I20220630" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtMS0xLTEtNTA4NjE_1f9a6017-4a15-4304-9f50-a66c4f17139d">91,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516e6c58c8cb48b1b164c617bc7de6db_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtMy0xLTEtNTA4NjE_1c92f17a-ae86-476a-9709-aa9116137ea4">916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7370f70d6fa74976a5e9c877a75a03a4_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtNS0xLTEtNTA4NjE_697772f0-cf66-4459-8315-a9d57d5f5bee">1,231,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958225ec182147f59a33c03bebe13eef_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtNy0xLTEtNTA4NjE_6c30d472-7d6a-491e-b166-848506134441">782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9600a3d7bfdd4cf2815bf9a7f3593ec9_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtOS0xLTEtNTA4NjE_82bfa22d-0a6b-4f10-963f-3d302e444fad">596,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab17026c20264a4c8395c9212169b9ba_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtMTEtMS0xLTUwODYx_ac906651-c90e-4e1c-8e41-6227a8b7cd28">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtMTMtMS0xLTUwODYx_38b1fa55-aa86-4029-ad3c-0bfd3c845a37">613,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e70344e764b4b3eadeaeb6935ee38ec_I20210331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctMS0xLTEtNTUwMzQ_1e87b200-4303-42d9-b362-9359db812d5a">86,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e70344e764b4b3eadeaeb6935ee38ec_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctMy0xLTEtNTUwMzQ_58f94fe6-8272-4156-898f-db14cbb7eaaa">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed22694590747a1bd2bf4c01a9a662d_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctNS0xLTEtNTUwMzQ_7ac4f26b-1d7d-4c08-a362-2bd5c6bc1bf7">1,236,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i942e52ba18744355b76f7bfdb9cc3cea_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctNy0xLTEtNTUwMzQ_d7984057-d67c-4253-bfe9-932c23e3dd8f">309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1386eedb115480fa7ca578380d21b98_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctOS0xLTEtNTUwMzQ_0f029346-861e-4274-95c1-416bbcdffb96">598,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f5739ceffa4cb4899666cc1243c638_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctMTEtMS0xLTU1MDM0_005c91c4-d967-4c2e-ab10-f625aa14d77a">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b61856fe974331a02b815438214cb5_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctMTMtMS0xLTU1MDM0_23437b80-e91a-4efe-b7d2-fa2876eaf892">617,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3116ce9873b14871adcc379848660cb6_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTktNS0xLTEtNTUwMzA_c58e7d79-f5b5-4d93-9ea9-2aa9e2baef9e">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTktMTMtMS0xLTU1MDMw_0b5f4252-660d-4935-9b4f-64870e24fccd">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c7070523c2a4ac0a2bfd9ae3b7d3917_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjAtMS0xLTEtNTUwMzA_49c5763e-c2ef-41a3-90f0-cacb3bafdec7">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7070523c2a4ac0a2bfd9ae3b7d3917_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjAtMy0xLTEtNTUwMzA_ecc5425c-0dde-4c00-a6bc-87dbbde0fc3c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3116ce9873b14871adcc379848660cb6_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjAtNS0xLTEtNTUwMzA_cceffc6d-c46c-48b0-b812-2c330d07d42a">2,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjAtMTMtMS0xLTU1MDMw_65d578bc-eb86-4277-807c-e216d05294ce">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c7070523c2a4ac0a2bfd9ae3b7d3917_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjEtMS0xLTEtNTUwMzA_d1031a0a-ea13-4f99-9847-934974d7b57c">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7070523c2a4ac0a2bfd9ae3b7d3917_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjEtMy0xLTEtNTUwMzA_ba204dd2-fcf4-42ed-9ad3-93b9b2dc3398">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3116ce9873b14871adcc379848660cb6_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjEtNS0xLTEtNTUwMzA_1f1e5195-512c-4fe4-8cec-3f886a252fad">455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjEtMTMtMS0xLTU1MDMw_03832aa6-a353-4eee-9c9f-b429451f81d3">454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7acd46ba77bf4a96a952527d6ff359fd_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjItNy0xLTEtNTUwMzA_220e3718-413f-428b-b5cb-be0ccbd21a2e">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjItMTMtMS0xLTU1MDMw_8343dfca-ee96-49e9-b03c-4892808b74c5">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib89434c9149543b4bf183e45ab6d2cf8_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjMtOS0xLTEtNTUwMzA_d9acc697-68af-4f90-ae3f-0f4fa0fe589e">9,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjMtMTMtMS0xLTU1MDMw_dcde5fa3-a587-46fc-9a28-b5358798db88">9,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f315c260fa84b9f8d0fc3b0633fcce4_I20210630" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtMS0xLTEtNTUwMzI_5f6632f6-ccf1-4e12-a262-1e13cdb071a0">87,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f315c260fa84b9f8d0fc3b0633fcce4_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtMy0xLTEtNTUwMzI_c4b66098-7357-4d63-ac03-2fcf8a590a5d">872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae9ab04f40cb4c6bad7fa0fa0fad903f_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtNS0xLTEtNTUwMzI_5753a1d2-04fd-4a7b-b542-75ef3dcfe0b7">1,242,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23bc8d4fc78f4724b0d9d7084e7cf0a8_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtNy0xLTEtNTUwMzI_3d45729d-da13-49bf-9217-ab5046194c56">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3102f93190494ddfbe3bef856a36e4ee_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtOS0xLTEtNTUwMzI_1017b131-d9e3-4e22-8232-86086a99eb57">608,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8df42535fdba44a8a1627241486db72e_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtMTEtMS0xLTU1MDMy_29324f5e-094f-4a44-a614-5073ee776260">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtMTMtMS0xLTU1MDMy_e76a9785-a819-4794-9ed1-7119814a1d26">614,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:727.50pt"><tr><td style="width:1.0pt"></td><td style="width:256.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:108.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:82.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:39.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:79.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89706c80b2d7431b8baf438482e6530c_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy0xLTEtMS01MDI5OQ_33009161-3f1e-4269-84ca-f54fef065bba">90,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89706c80b2d7431b8baf438482e6530c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy0zLTEtMS01MDI5OQ_446005f6-8d32-4756-a417-ee0ee34d3ca4">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef1ba80206c47a796768e04faddc954_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy01LTEtMS01MDI5OQ_749870e5-d06a-4c63-a346-a4103594a361">1,340,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d886f333c9c4fd6a9e342ad9244c5cf_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy03LTEtMS01MDI5OQ_ef5d9100-c1c1-426f-8d87-32b75fb76e30">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2007122f7a6c433aaea325edfea7445c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy05LTEtMS01MDI5OQ_80e48c15-8dc7-4b3b-9cdb-8408ca09bb2e">626,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia13c29e1eae04177baea5d09b310b513_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy0xMS0xLTEtNTAyOTk_f857e4e6-bbca-4f6b-b472-c184e39d7b4d">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy0xMy0xLTEtNTAyOTk_a61850a2-02dd-4df8-adff-57dbf3c9ddb6">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNS0wLTEtMS01MDI5OQ_25776320-c78c-4049-999b-e8ec8d6418cf">Cumulative-effect adjustment from adoption of ASC 2020-06</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id32760879e474657bbcb44bcfd8b4cbe_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNS01LTEtMS01MDI5OQ_ace91666-b82e-4d2e-80ed-3dfab68fe016">106,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e24955768747af87552990e9881d89_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNS05LTEtMS01MDI5OQ_84cb9a5f-1f4a-4815-8c15-cd9605e95f33">39,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94fd6d6b927d418abe899d5a671e0e19_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNS0xMy0xLTEtNTAyOTk_803f98d0-90c0-43fa-931e-43971dad1ca2">66,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782b0724932e45c1b2ed8ea424d579e1_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNi01LTEtMS01MDI5OQ_4c94ab64-7faa-4100-af5c-7fe24598e545">12,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNi0xMy0xLTEtNTAyOTk_8378ca5c-283b-4529-bd01-313f886e53de">12,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNy0xLTEtMS01MDI5OQ_4df3d447-aaa0-4a12-876a-1475d1c4ba76">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782b0724932e45c1b2ed8ea424d579e1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNy01LTEtMS01MDI5OQ_3b5d389f-bef0-4259-b3ff-005504e8ff4c">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNy0xMy0xLTEtNTAyOTk_97b8ef29-f0b1-4573-98b8-0949870e46f4">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOC0xLTEtMS01MDI5OQ_91b7f838-b64c-42d8-a78a-813ea4666c68">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOC0zLTEtMS01MDI5OQ_e5c19012-8070-4db6-9758-7888f1ed6412">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782b0724932e45c1b2ed8ea424d579e1_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOC01LTEtMS01MDI5OQ_4d79283a-a02d-48f0-8a89-10734dc5f474">5,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOC0xMy0xLTEtNTAyOTk_587ef4cc-8b8c-4f12-b7c3-97552f4125c0">5,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leveraged stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOS0xLTEtMS01MDI5OQ_2a353431-5ac3-467d-bafb-c193ad60379d">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOS0zLTEtMS01MDI5OQ_31c9a787-82fb-46d6-9091-aedc2fa58e07">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782b0724932e45c1b2ed8ea424d579e1_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOS01LTEtMS01MDI5OQ_90fc2a4b-8489-4457-8c35-ddd5b7b45a18">11,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOS0xMy0xLTEtNTAyOTk_1a59470a-2310-42c2-850b-99f4604fcde2">11,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id74b0636d9fe405398d1c373024c9a01_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTAtNy0xLTEtNTAyOTk_287636c3-9ba4-4e82-9e9c-9e763425f2d2">420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTAtMTMtMS0xLTUwMjk5_fab28264-dd3d-4905-ad52-f6da5de4c6ae">420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf10f4217fba4210b4c5f9862e155922_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTEtOS0xLTEtNTAyOTk_153fac5e-f5c6-4a4e-8b3c-c715a3d7fa40">9,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTEtMTMtMS0xLTUwMjk5_7c58e681-0d84-4998-8296-1ab87130fa77">9,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i516e6c58c8cb48b1b164c617bc7de6db_I20220630" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtMS0xLTEtNTAyOTk_5fe751ae-4f26-4e73-826d-c9367bf0dc9d">91,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516e6c58c8cb48b1b164c617bc7de6db_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtMy0xLTEtNTAyOTk_72d633fb-a622-4e99-9973-1ca4cfe2afa3">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7370f70d6fa74976a5e9c877a75a03a4_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtNS0xLTEtNTAyOTk_5c933256-160b-442b-a6e6-755a2f61bd52">1,231,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958225ec182147f59a33c03bebe13eef_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtNy0xLTEtNTAyOTk_97c18b7d-14e5-4a30-8b6d-7986e14745c7">782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9600a3d7bfdd4cf2815bf9a7f3593ec9_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtOS0xLTEtNTAyOTk_7652d852-ca6a-46e4-b58d-a1e8c471eb58">596,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab17026c20264a4c8395c9212169b9ba_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtMTEtMS0xLTUwMjk5_12d56e05-615e-48b1-ba10-b0a46a2d4d19">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtMTMtMS0xLTUwMjk5_963a57bd-e735-44bb-845f-9aa71d3c8e2f">613,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64151525a8774f5e8e11c91ec179e8ba_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktMS0xLTEtNTAyOTk_53cb7d8f-09d5-439c-b1f7-96fa3ffc2844">85,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64151525a8774f5e8e11c91ec179e8ba_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktMy0xLTEtNTAyOTk_de1f82bc-95a1-40e2-bd1a-162813b1ff88">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2ac7d92b6447f2848e96bc058402a1_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktNS0xLTEtNTAyOTk_d1199f6f-89bc-4e13-abcd-13721c620138">1,229,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6081395d9faa4fdcab6aed9df74e298b_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktNy0xLTEtNTAyOTk_bfe5c215-d940-4dc8-be19-6cf1ec45475b">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7edb2b3056d4a5688f8e8aaafb90eef_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktOS0xLTEtNTAyOTk_0d95d286-c8ae-4948-82d4-c6d879b9361b">589,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie633b270dd0c4bbc8043c2a1e40d609c_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktMTEtMS0xLTUwMjk5_5866dddf-7ba9-4749-87c5-467339a0e2b5">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktMTMtMS0xLTUwMjk5_65722719-ca30-487c-8399-553571eedc47">619,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d6c1e91bd04b9d96ff15934542fb4a_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjEtNS0xLTEtNTAyOTk_bd77061f-ad55-480b-a85c-6ffd7dac4d02">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjEtMTMtMS0xLTUwMjk5_eefaf38d-a8d1-457f-b404-7b3bdff7f4ed">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8cd9533bbf4643e5aeaa123dabd40c39_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjItMS0xLTEtNTAyOTk_89fcc068-b88d-4c21-8143-840aed8dc94e">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd9533bbf4643e5aeaa123dabd40c39_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjItMy0xLTEtNTAyOTk_2e4d052b-cdcc-4e56-a72a-bdf410a98fdc">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d6c1e91bd04b9d96ff15934542fb4a_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjItNS0xLTEtNTAyOTk_3f79ea8b-3861-48c6-833b-909c9e7d9363">9,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjItMTMtMS0xLTUwMjk5_09e04f82-e784-4976-b02f-f9fa827fe5f8">9,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8cd9533bbf4643e5aeaa123dabd40c39_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjMtMS0xLTEtNTAyOTk_cb5a29c1-e9ef-4ebe-9bc6-f5a8520fea5c">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd9533bbf4643e5aeaa123dabd40c39_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjMtMy0xLTEtNTAyOTk_efb47f51-6a77-4d8a-bf22-37ead165a8f2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d6c1e91bd04b9d96ff15934542fb4a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjMtNS0xLTEtNTAyOTk_6c65ba99-5361-4f97-acf6-6323f5f7e3f6">3,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjMtMTMtMS0xLTUwMjk5_ad67c719-2017-4b67-91bd-65d33ddf4c04">3,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bdd7eadd3304d3a9a793b4224c5ecee_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjQtNy0xLTEtNTAyOTk_c7076e28-9465-4da9-a392-70dc19e28175">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjQtMTMtMS0xLTUwMjk5_732e8477-45ed-4565-ac7c-2102a7b2d1da">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i159494a380f0403f9294af2487029a51_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjUtOS0xLTEtNTAyOTk_acc6c3e8-25fb-455f-ad6a-75576ae59d8c">18,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjUtMTMtMS0xLTUwMjk5_b0b0f058-26f3-4766-90ec-e6fdfe052737">18,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f315c260fa84b9f8d0fc3b0633fcce4_I20210630" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctMS0xLTEtNTAyOTk_cd570ee4-fca5-43e2-976b-4bd4573f7116">87,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f315c260fa84b9f8d0fc3b0633fcce4_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctMy0xLTEtNTAyOTk_50d92437-06d9-49f5-a292-e68d43b4b317">872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae9ab04f40cb4c6bad7fa0fa0fad903f_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctNS0xLTEtNTAyOTk_e4f9bdc4-46cc-4ab5-b35b-c484a3c3d212">1,242,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23bc8d4fc78f4724b0d9d7084e7cf0a8_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctNy0xLTEtNTAyOTk_bf9bb97d-1bca-4b33-8ef9-d78bc4205cb3">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3102f93190494ddfbe3bef856a36e4ee_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctOS0xLTEtNTAyOTk_10f2bd9e-d439-4291-9298-fb478a1c4895">608,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8df42535fdba44a8a1627241486db72e_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctMTEtMS0xLTUwMjk5_79b1eb54-5a17-4f50-9c90-a38e10b082fe">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctMTMtMS0xLTUwMjk5_5180b351-3a26-4b6c-9a1d-ff7388ab01d2">614,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"></td><td style="width:326.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Used In Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMy0xLTEtMS01MDI5OQ_0d31846e-6838-491c-b5ee-deefcfdc5dde">9,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMy0zLTEtMS01MDI5OQ_49bb9004-d9bb-407e-a332-62c2031e850f">18,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNS0xLTEtMS01MDI5OQ_0616ad72-cf9a-42aa-bcff-ed8020f47d77">6,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNS0zLTEtMS01MDI5OQ_c4d5ffbd-719f-4d7d-a377-408aa735677d">594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNi0xLTEtMS01MDI5OQ_b7ffd419-e5d4-4eca-b205-a227008167c3">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNi0zLTEtMS01MDI5OQ_6fbc6da1-eacf-46b6-adcb-d491afe48288">1,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNy0xLTEtMS01MDI5OQ_e6b7bdf5-e75f-43ba-8827-22ab5920b89e">2,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNy0zLTEtMS01MDI5OQ_ea90a76c-b6d0-4e8b-9756-4bf912169c4f">12,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfOS0xLTEtMS01MDI5OQ_f865967d-9294-43ad-81e3-fb6a57cbc4a3">30,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfOS0zLTEtMS01MDI5OQ_5e822b09-b2cc-4c2b-8c0a-70ccded79044">30,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTAtMS0xLTEtNTAyOTk_275ae5b5-75ed-408d-960d-c67bc5b2652a">12,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTAtMy0xLTEtNTAyOTk_9ba09b01-16f7-4e79-b9c7-51ebf63474fe">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTEtMS0xLTEtNTAyOTk_b5a5916d-0331-4306-8290-8d54109aab6a">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTEtMy0xLTEtNTAyOTk_1c220b03-9430-4089-adf2-dd5e21be4e36">268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTItMS0xLTEtNTAyOTk_63f56c4b-3674-4218-81e5-9b8f82bb57ec">13,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTItMy0xLTEtNTAyOTk_5e1f7bc8-564a-4098-be37-87a269af8f9b">8,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTMtMS0xLTEtNTAyOTk_fe3575cb-4e2c-4685-8c80-f63a4140fffd">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTMtMy0xLTEtNTAyOTk_4eb8a794-1970-4575-a050-66286c1db34f">8,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTQtMS0xLTEtNTAyOTk_a86b68b3-b3db-4fa4-a113-6a4e3f20d7b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTQtMy0xLTEtNTAyOTk_dcd119a1-4363-4c96-98aa-11d845918781">22,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTUtMS0xLTEtNTAyOTk_05ee1a85-43bd-49ca-a72e-6e9810dbf97d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTUtMy0xLTEtNTAyOTk_85d67e64-508e-4fcc-a99e-35b7914db2a8">19,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current operating cash inflows (outflows), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTYtMS0xLTEtNTAyOTk_7def0408-5205-4c25-919c-dbd91ae87d7b">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTYtMy0xLTEtNTAyOTk_d862cfe6-73d3-4afd-a1a8-94a0c2e15ab2">729</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and contract assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTgtMS0xLTEtNTAyOTk_eb479991-c102-4ed5-9c01-f40aa8d10dd0">13,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTgtMy0xLTEtNTAyOTk_7aa3b9c8-b443-4abb-b789-03c2fbc8255f">120,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current and non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTktMS0xLTEtNTAyOTk_7508d309-c250-4b0b-ac92-ddb367068b47">8,453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTktMy0xLTEtNTAyOTk_b5e4538a-e8ce-4a40-980e-14a852ebd2f6">3,439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjAtMS0xLTEtNTAyOTk_ed0fdbcc-0def-448f-ace4-4dcd02b0b1a3">3,284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjAtMy0xLTEtNTAyOTk_44315dd7-586a-4596-9b04-47fcf0bdb212">3,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjEtMS0xLTEtNTAyOTk_bacd4f9a-792a-4787-b28d-c2e19f3d048c">823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjEtMy0xLTEtNTAyOTk_da8466f4-3924-4523-9058-cd7aa96607f6">9,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjItMS0xLTEtNTAyOTk_de91b2d0-3d3e-4582-9c28-3d4a1cfe6540">24,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjItMy0xLTEtNTAyOTk_078b65f6-9148-4e32-8d1f-5391fd891755">17,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjMtMS0xLTEtNTAyOTk_43d305f7-bc5d-4a87-a8f7-1234f31cd0d4">22,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjMtMy0xLTEtNTAyOTk_8c8ae354-0113-4058-b71c-dc71dba20654">21,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjQtMS0xLTEtNTAyOTk_44b0ffa1-d054-4cbe-acad-652595b9f46d">3,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjQtMy0xLTEtNTAyOTk_92a31164-ae85-4b54-86b0-03d463354dde">2,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjUtMS0xLTEtNTAyOTk_c94bf264-c8af-4276-8723-abaf0ad41651">45,334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjUtMy0xLTEtNTAyOTk_ad1ee920-f9b9-4dab-bf21-bbe9989abff6">62,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use operating assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjYtMS0xLTEtNTAyOTk_1f922677-8cb5-4753-92f4-fb7c48066fd2">669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjYtMy0xLTEtNTAyOTk_5b357ea9-df58-4942-8545-56fcde6f543f">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjctMS0xLTEtNTAyOTk_e5d79869-abd9-4f37-90cc-0ef96fcb81cf">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjctMy0xLTEtNTAyOTk_7fbcc143-2df5-4100-8116-4123c3639435">2,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjgtMS0xLTEtNTAyOTk_c25b822e-2704-4f15-ab5d-84904b4d9843">858</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjgtMy0xLTEtNTAyOTk_32f48674-37bc-4f12-a1dd-442675f18883">1,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjktMS0xLTEtNTAyOTk_c8b02452-ca62-431d-ae25-6298ac7c7752">43,778</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjktMy0xLTEtNTAyOTk_a2f1c233-c806-4532-a4ae-2ba5fce52053">72,410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for asset acquisitions and business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzEtMS0xLTEtNTAyOTk_211f04d9-55f4-45dc-9f5f-d2189157fb7b">9,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzEtMy0xLTEtNTAyOTk_69f4a28a-3692-43a6-b343-9661fca600a8">1,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from transfer of membership and release of Passport escrow</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzItMS0xLTEtNTAyOTk_00514beb-09f2-479a-930c-f6a19cf29aee">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzItMy0xLTEtNTAyOTk_0f9858f8-68a4-4788-abd0-710a6ba63d5d">42,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of non-strategic assets and divestiture of discontinued operations, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzMtMS0xLTEtNTAyOTk_e4707b95-c1d1-4457-9eeb-4b907da53c79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzMtMy0xLTEtNTAyOTk_df7a5d79-a824-46d7-babb-e27d96c060dd">3,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzQtMS0xLTEtNTAyOTk_934c134a-a520-499d-9511-6b2e972bd059">4,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzQtMy0xLTEtNTAyOTk_384ce7b6-494b-4b7d-9007-60ccaa03da0c">9,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzUtMS0xLTEtNTAyOTk_b38d640c-3d6d-406e-b193-1b8e7a132dc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzUtMy0xLTEtNTAyOTk_1edd232b-7aaa-47e3-98b1-51558a975a7d">2,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities and sales of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzYtMS0xLTEtNTAyOTk_e86c0d10-d726-4d5e-86c8-0b010ef38f00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzYtMy0xLTEtNTAyOTk_e48402eb-d8e9-4900-af35-bad48e32d69e">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in internal-use software and purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzctMS0xLTEtNTAyOTk_8e106202-eae2-4640-b611-620f83111afe">17,744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzctMy0xLTEtNTAyOTk_c13ad71f-3ded-40b8-b7e8-a13c48857e40">11,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzgtMS0xLTEtNTAyOTk_224185a6-bcda-45f2-8bf8-0da809a37f63">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzgtMy0xLTEtNTAyOTk_f058e148-8fad-4686-b484-ad900bcb93d2">40,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Used In Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in working capital balances related to claims processing on behalf of partners</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDAtMS0xLTEtNTAyOTk_45e31173-8f56-40e0-bc59-2fadfafe1311">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDAtMy0xLTEtNTAyOTk_078d936a-93f8-4968-9e43-ccb804cb0e2c">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of Credit Agreement including settlement of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDEtMS0xLTEtNTAyOTk_d43ee110-b3af-4631-bb4c-e553ec94a4b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDEtMy0xLTEtNTAyOTk_f8f1c253-985c-4c1b-8ea7-d22292e4218b">98,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDItMS0xLTEtNTAyOTk_019f93a7-f89e-4987-8573-52e021468440">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDItMy0xLTEtNTAyOTk_8c72e293-7f81-4156-9e86-908f3597da0b">9,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to Sponsors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDMtMS0xLTEtNTAyOTk_b7121078-3e30-46c4-983a-fc0518405e54">14,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDMtMy0xLTEtNTAyOTk_c007d16a-5d01-4801-af2e-194d0964233c">1,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes withheld and paid for vesting of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDQtMS0xLTEtNTAyOTk_53d8d912-554e-4287-aa32-c8f5d08f4d74">16,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDQtMy0xLTEtNTAyOTk_7573b2f8-a373-4bb4-81d7-41266e04671b">3,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDUtMS0xLTEtNTAyOTk_7cb6acf4-e9ea-4f5a-a3b3-dddbaaa2ae9b">30,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDUtMy0xLTEtNTAyOTk_714f23d6-869b-4281-abc6-066ba8eceb49">91,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"></td><td style="width:326.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDYtMS0xLTEtNTAyOTk_23f6e388-9a5e-4e3e-854e-bca4988a30a4">375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDYtMy0xLTEtNTAyOTk_b0de145a-d570-4631-87a9-471128009776">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDctMS0xLTEtNTAyOTk_f722eaba-86fa-4b5e-af96-ce6d3256facd">74,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDctMy0xLTEtNTAyOTk_d176db04-af64-4471-a447-cf0554f43eb5">123,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of beginning-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMS0xLTEtNTAyOTk_4c1972bb-dfd5-4f56-9c73-e15c8c00e245">354,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMy0xLTEtNTAyOTk_c7a5e83c-5f21-49c0-b45f-eebb0c4d690d">361,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of end-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMS0xLTEtNTAyOTk_ee292a9f-87ae-4203-bf77-93525b8dfbc2">280,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMy0xLTEtNTAyOTk_5c760221-6054-44a2-b77c-2d92546fb78d">238,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RleHRyZWdpb246MzJlOTdlODQ4YmVmNDkzMjg4ZWRlY2QzODFiMGE4ZWRfNTcx_567b7399-c20a-4925-8240-cbdd77cce4ce" footnoteRole="http://www.xbrl.org/2003/role/footnote">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80MC9mcmFnOmE4MDQzZDEyYWIyOTQzZWM4ZmJjYzI0ZDI2ZjUzNjg2L3RleHRyZWdpb246YTgwNDNkMTJhYjI5NDNlYzhmYmNjMjRkMjZmNTM2ODZfMTA3Mg_6e261e55-a548-483a-9c82-24deaae23f92" continuedAt="iadb491e8e39241be855f343f98e4913a" escape="true">Organization </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iadb491e8e39241be855f343f98e4913a" continuedAt="i4bc209d183ba4ae59c9a754168681502"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred losses from operations. As of June&#160;30, 2022, the Company had unrestricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80MC9mcmFnOmE4MDQzZDEyYWIyOTQzZWM4ZmJjYzI0ZDI2ZjUzNjg2L3RleHRyZWdpb246YTgwNDNkMTJhYjI5NDNlYzhmYmNjMjRkMjZmNTM2ODZfNTMw_76ef3a60-9910-43b3-8573-9880acb864d3">193.1</ix:nonFraction> million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4bc209d183ba4ae59c9a754168681502">Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NjU_8727b1fd-75ee-4ee9-b596-ccbd337fd770" continuedAt="i5d920bbd724241aaad0dd1330ffe7e91" escape="true">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i5d920bbd724241aaad0dd1330ffe7e91" continuedAt="ibd08ccf2e0954b5d8ab9f1d1a8d87227"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU2MDU_8bc88c1f-7b16-40ea-9e6c-20d4cd3cb51b" continuedAt="i4e33233af25c491b93dda31a7fa988ca" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4e33233af25c491b93dda31a7fa988ca">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2021 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NzQ_b8fb7432-c46e-43e4-ad0a-151c370d1034" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1ODE_e5f74ecc-0585-45f0-abdf-6f6c0227ee72" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ibd08ccf2e0954b5d8ab9f1d1a8d87227" continuedAt="ide0bdfd085de42ac84f05b36ec128fcf"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NDg_d72d5c70-c496-45ba-ace0-35a44b90af9b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NTU_9a4145a4-6ba9-4956-a746-2c252dbeccd3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843b60b3c07d4c0f966b1c7efd11f445_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMS0xLTEtMS01MDI5OQ_77a2d1d3-a162-4b63-9351-487e055ef7ab">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9c59f6393b4a8faa1337db8d4243fe_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMS0zLTEtMS01MDI5OQ_6ef6817c-f3df-4104-b903-358db4bc152f">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f49366fb4ea4c75a9085b9b029857ac_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMi0xLTEtMS01MDI5OQ_d847e3b0-a6c6-4af0-a4b8-2977430a444e">11,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4458c03c2b504669b6dc29624dbd3320_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMi0zLTEtMS01MDI5OQ_ed6e910a-d895-460a-8108-168195bb1465">11,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d346c5c8ea64d16b5d1df5450434600_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMy0xLTEtMS01MDI5OQ_2569057c-ef4f-43db-aafb-20a32e62681c">73,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id592466e76c249e8b646509e71afaf92_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMy0zLTEtMS01MDI5OQ_aa553893-7da2-4b4d-a917-d3cb46da6d26">73,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de7d7c7a1b34a538212057e51b487b2_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNC0xLTEtMS01MDI5OQ_c5c6637c-841e-417d-ab2a-a5870c51d8a7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0fd83c25925422897d5d200f710ee27_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNC0zLTEtMS01MDI5OQ_54dc06d6-98c8-4b98-a8a5-047563ef311c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNS0xLTEtMS01MDI5OQ_cd54b2e6-ff8d-45ff-9cde-21b329dec269">87,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNS0zLTEtMS01MDI5OQ_b85b6a67-1442-466a-85cf-045c00dd1943">88,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNy0xLTEtMS01MDI5OQ_94296386-06ac-4467-a120-5f898a50e98d">74,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNy0zLTEtMS01MDI5OQ_70137a8e-1bf5-4214-b6f5-9d3141a2c99a">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfOC0xLTEtMS01MDI5OQ_81e012ef-2fc9-4281-99d2-d8df316b3875">74,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfOC0zLTEtMS01MDI5OQ_7710e9ab-7327-4995-b9ff-a96ee7f71865">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMTAtMS0xLTEtNTAyOTk_0a5884dc-4bac-4dbe-9c78-225e402b2ee5">12,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMTAtMy0xLTEtNTAyOTk_e9c55d68-7982-4a9d-81bc-4607bd2185ea">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMTEtMS0xLTEtNTAyOTk_9536aaed-f635-4609-8448-bf3dd646891b">12,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMTEtMy0xLTEtNTAyOTk_5740ea09-aca2-40c7-8df4-835386667688">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of June&#160;30, 2022 and December 31, 2021, approximately $<ix:nonFraction unitRef="usd" contextRef="i2e843b7962284872a802350d9f9601e8_I20220630" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMzcyNw_b359c421-2bdb-4a8f-8e42-0998fa3cf35b">11.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i07da018892914858a3261ae1eb51a8be_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMzczNA_0f0cfb57-9875-4891-bd3b-ddc236cebc15">11.7</ix:nonFraction> million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NTY_1496d3e2-189f-4268-ab36-e247333897f4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfMi0xLTEtMS01MDI5OQ_26e2c71d-fbad-4c1c-a25a-86093ea074da">193,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" name="evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfMi0zLTEtMS01MDI5OQ_5e53758b-986d-4dfb-8129-6b92e9eaa053">207,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfMy0xLTEtMS01MDI5OQ_ebfd92d1-a1db-4bd7-bcb3-62e9d663eeaa">87,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfMy0zLTEtMS01MDI5OQ_1af4146b-7d16-4452-b119-c1db5f544552">31,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfNS0xLTEtMS01MDI5OQ_b2397693-30ea-4514-a416-094de6f8d868">280,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfNS0zLTEtMS01MDI5OQ_102b2586-8ec2-4fd7-83ae-57c963e153bd">238,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.</span></div></ix:nonNumeric></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1ODM_fa78ed75-da12-4230-aa63-bad14a44b730" continuedAt="if32c3717f907434987107ecb33117ed9" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ide0bdfd085de42ac84f05b36ec128fcf" continuedAt="id707e721774b459b994fbdd6c8898d96"><ix:continuation id="if32c3717f907434987107ecb33117ed9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1ODk_1235490d-85b4-48ce-a51e-06ecca5294ab" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has <ix:nonFraction unitRef="reportingunit" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfNzU0NQ_2a083814-e743-4acb-b535-3b7579c233f0">three</ix:nonFraction> reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NDY_b4b9f2b0-c340-4df2-97ca-2a1c0a294a1d" continuedAt="ie61087ff6dd24fb787cdd63b8df56a65" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NjQ_14ebba4c-3c5b-44ec-b798-5a51f222b8ce" continuedAt="i6bb861754d7f4230af5cbe4156eff1c1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:438.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i422269ae7dc54ddf975203be2bc9ec3f_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMC0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOmQwZDU2YmE0ZjMwODQ2NzI4ZTM3OTA3ZmQwNDBiNjg5XzQ_ca7c7ffd-f726-444b-b521-550a721c3fb6">10</ix:nonNumeric> - <ix:nonNumeric contextRef="icd4ee5d15f6c48e98699e31b2e8899a7_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMC0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOmQwZDU2YmE0ZjMwODQ2NzI4ZTM3OTA3ZmQwNDBiNjg5Xzk_92ab8efa-bd0f-48bc-a98f-27c24edd71eb">20</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b656d6a747c43c0807ef9a72b117fe5_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMS0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOmZjYjc5ZGNiMmJkYjQ5OWViOTk4MDIzMDc1ZDk5ZTFmXzQ_032e8976-bafb-4681-8cc8-9073759ea27b">10</ix:nonNumeric> - <ix:nonNumeric contextRef="ic18f73ba368e43578c5dc017d9986091_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMS0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOmZjYjc5ZGNiMmJkYjQ5OWViOTk4MDIzMDc1ZDk5ZTFmXzk_b20a1180-0743-4914-bf76-7b981943aa4e">25</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8920304c21f34d2e8d814f99e02bb672_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMi0xLTEtMS01MDI5OQ_42ba26b0-c360-4f43-80d9-434691a31802">5</ix:nonNumeric> years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie2f2470a268e4d5593d8214f2752ddb2_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMy0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOjAxYTJmMmYzZDEyMzQ1OTM4MmNiODM3NWEyNzI2ZTgzXzQ_d9b5be9e-5758-429f-93fa-5f85ca6ea9ad">3</ix:nonNumeric> - <ix:nonNumeric contextRef="id10401febbb0459b90ba3a22611bb8d1_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMy0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOjAxYTJmMmYzZDEyMzQ1OTM4MmNiODM3NWEyNzI2ZTgzXzk_fe29e43d-2086-4ecf-95ac-4873ba249102">5</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie61087ff6dd24fb787cdd63b8df56a65">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value.</ix:continuation> See Note 9 for additional discussion regarding our intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1Nzg_96c66de8-c6f7-403c-a82e-dca35a00cb17" continuedAt="i84834a95240645838ee6337e4626d952" escape="true">Research and Development Costs</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i84834a95240645838ee6337e4626d952">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and was $<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTA5OTUxMTY0MzYzNg_16d656a0-f376-4eb8-82ce-bb22546904cb">3.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTA5OTUxMTY0MzY0NA_26e88782-14b3-480c-a09e-992b6d8ee566">7.9</ix:nonFraction>&#160;million for the three and six months ended June 30, 2022, respectively.</ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:LiabilityReserveEstimatePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1ODU_01703d8c-47a1-4745-935c-62935dd0f952" continuedAt="i9a6cb02936d34839ab2f7d31ded2f10c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id707e721774b459b994fbdd6c8898d96" continuedAt="ic3adcfd7dd0241ba9c6d8629e9c07404"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9a6cb02936d34839ab2f7d31ded2f10c" continuedAt="icb34757a4b0741189c888e2be3eed758">uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icb34757a4b0741189c888e2be3eed758">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.</ix:continuation> See Note 21 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="evh:RightOfOffsetPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NzI_92e7e424-7114-4d85-a87b-77d554b2a22c" continuedAt="i9c859c38676a430784cffc3b5c961d60" escape="true">Right of Offset</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9c859c38676a430784cffc3b5c961d60">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.</ix:continuation> As of June&#160;30, 2022 and December&#160;31, 2021, approximately <ix:nonFraction unitRef="number" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTIyNDc_4da2515f-80cc-4095-89a5-ad28d33c2aee">64</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTIyNTQ_d9f05bf9-0112-4a0a-b6ae-6cc2b790af46">42</ix:nonFraction>% of gross accounts receivable was netted against claims payable in lieu of cash receipt. Furthermore, as of June&#160;30, 2022, approximately <ix:nonFraction unitRef="number" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTIzODI_e8d0afeb-b0c7-4222-adcd-b27269740aca">13</ix:nonFraction>% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU2MDg_72f8b4ae-cf8e-4ac7-afb7-4f77833b1851" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1OTI_57cc079f-66d3-47bd-a229-bd281427d409" continuedAt="ib6a1a9f6adb54fb492606346ad439ca5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from <ix:nonFraction unitRef="source" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="INF" name="evh:NumberOfSourcesOfRevenue" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMzI5ODUzNDg5OTMwNA_7a9f0e95-2321-4c10-b4ee-6caaca6f5a69">two</ix:nonFraction> sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic3adcfd7dd0241ba9c6d8629e9c07404">See Note 6 for further discussion of our policies related to revenue recognition.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_46"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMzE3Mw_a8fd881e-fae7-4f89-b9be-6d4758e80bc0" continuedAt="i75981325105549ac9b87f1e438f27941" escape="true">Recently Issued Accounting Standards</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i75981325105549ac9b87f1e438f27941"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMzE3OA_6c04e994-1919-4d22-9a0a-75dc3afad4d5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $<ix:nonFraction unitRef="usd" contextRef="i1576668fe0314dd3b3b3ec454798b582_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMjIxMQ_7bed4fb8-e0bb-4b46-8e09-51d1ceeea1c8">39.8</ix:nonFraction>&#160;million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="if8072fe070714d70b4c7d5054c1d19bd_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMjI1Mw_3c286d43-2065-4374-9241-ff42973f66e7">106.2</ix:nonFraction>&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $<ix:nonFraction unitRef="usd" contextRef="ib3ecfc57dd454ea480838c4fc5252936_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMjMyNA_80f043f1-6fc7-4320-8c8d-a5e14cc166d8">25.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie80fd38d9d5b4ab2bc9f658f6aadf4a0_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMjMzMQ_2b4ee06c-37a1-4730-a8c7-0497bd2c3f9b">41.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_49"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMzQ2MA_2a3abdb2-5ee6-4981-8939-b14a6811d08a" continuedAt="ibadc24c236e4428caf7eaf073d730340" escape="true">Transactions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ibadc24c236e4428caf7eaf073d730340" continuedAt="ibd7492b3eec545c68c7d93d469e57bf9"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vital Decisions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company completed its acquisition of Vital Decisions, including <ix:nonFraction unitRef="number" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMTU2_14184e4f-ab50-4f5b-8851-a85a7de28e1b">100</ix:nonFraction>% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total merger consideration, net of cash on hand and certain closing adjustments, was $<ix:nonFraction unitRef="usd" contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfNzE3_2adda0b2-56b5-4a2e-af21-2a551296d0df">117.7</ix:nonFraction> million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $<ix:nonFraction unitRef="usd" contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfODU2_f033ee28-ec60-4bc2-8792-54735126a34a">46.5</ix:nonFraction> million of cash consideration, <ix:nonFraction unitRef="shares" contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfODgy_885bc26a-ac3a-4e4d-8cdb-b9b0e658b975">1.8</ix:nonFraction>&#160;million shares of Class A common stock, fair valued at $<ix:nonFraction unitRef="usd" contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfOTMy_ee7ddb2e-7392-4680-b6e7-8961e74ec672">56.6</ix:nonFraction> million as of October 1, 2021, and an earn-out of up to $<ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfOTgz_1c0a89d7-8f74-4665-b938-ade9e297b74f">45.0</ix:nonFraction>&#160;million, fair valued at $<ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMTAwMg_97a6e55d-d452-4ade-990b-6611a6011b25">14.6</ix:nonFraction> million as of October 1, 2021. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMzQ2Nw_e1e848f5-a8aa-4747-ba01-65dc1c2bbc5c" continuedAt="i2476a554a5be4feda6b039921096ade6" escape="true"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMzQ2OA_b57e9d84-d12c-47ab-b565-5dcb19027045" continuedAt="if8229001f2744af9a3188f080b68d435" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMS0xLTEtMS01MDI5OQ_034b296c-c424-4197-839f-0900b947e239">46,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMi0xLTEtMS01MDI5OQ_fc52d11a-a708-4167-b82f-728d8d949290">56,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMy0xLTEtMS01MDI5OQ_f73e4d72-4155-46fd-8203-e6ba6e259d81">14,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfNC0xLTEtMS01MDI5OQ_a1fa3b4f-4bec-4a63-a995-b751ae92b79f">117,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibd7492b3eec545c68c7d93d469e57bf9"><div><ix:continuation id="i2476a554a5be4feda6b039921096ade6"><ix:continuation id="if8229001f2744af9a3188f080b68d435"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfNy0xLTEtMS01MDI5OQ_c8f5a5a6-f53b-4b72-afe8-dfadabad4357">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfOC0xLTEtMS01MDI5OQ_16aad94d-8782-413d-8fc6-905ac1c5f836">3,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfOS0xLTEtMS01MDI5OQ_023f912b-55bd-4d3b-a669-558bc0e2678d">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTAtMS0xLTEtNTAyOTk_3cf22b80-8b16-47a0-b304-585f8577ace1">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTEtMS0xLTEtNTAyOTk_4e1339cd-e544-4a39-a2a0-5bf09346981d">7,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9021ecacd5411b9522695f0968fd6e_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTQtMS0xLTEtNTAyOTk_c5089e4f-4d79-488b-9d8d-98d56b53a510">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569f17d92bfa4d41a92b3f6f73066652_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTUtMS0xLTEtNTAyOTk_2b2a5f04-8f66-40de-8dde-f0e2540de9ae">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1070f5f0bf442684f5ebf0e562d035_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTYtMS0xLTEtNTAyOTk_b6e98dc3-90bb-4df5-a915-5de97d997863">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTctMS0xLTEtNTAyOTk_31067b81-35f3-4eb1-a801-9121f23882f4">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjAtMS0xLTEtNTAyOTk_8911ee7a-bafa-49a2-acb1-df3a1a2bafa9">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjEtMS0xLTEtNTAyOTk_216944c4-b66a-4ebc-9532-47c208f4f391">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjItMS0xLTEtNTAyOTk_c9cf79ab-4941-4fb8-a1c5-48aa59e4d947">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjMtMS0xLTEtNTAyOTk_c2736c5d-4e07-4787-b97f-d9bf7d54df98">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjQtMS0xLTEtNTAyOTk_285fb174-ae40-4de8-907a-a63c05aacdea">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjUtMS0xLTEtNTAyOTk_e5e71da6-bab1-4a57-9257-f8b56c6ecb9c">2,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjYtMS0xLTEtNTAyOTk_bc128300-ed3c-4828-b029-ec7639d951bc">6,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjgtMS0xLTEtNTAyOTk_bee281f9-237f-47c1-8321-881a2659049f">77,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjktMS0xLTEtNTAyOTk_330e6fa2-0126-463a-bac3-668bfafcb848">117,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of <ix:nonNumeric contextRef="i9b5a5d27c5cd45318130592162ae2979_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMTY2OA_5c039e61-ce9e-4cfc-8994-ba671b0ad782">13</ix:nonNumeric> years, <ix:nonNumeric contextRef="i5cfda0e9098c4c609e2cc6cf7786ab7f_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMTY3Mg_99c5579e-1fed-4aac-bea1-d25ec6522c06">5</ix:nonNumeric> years, and <ix:nonNumeric contextRef="i155bf891da8c4ffd8ff2e7f58e3b77cb_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMTY4MA_6026ddf1-09fa-4017-9fa1-87fce823eb66">15</ix:nonNumeric> years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $<ix:nonFraction unitRef="usd" contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMzE0Ng_1d59b020-7033-4bc5-95ef-ef671632a5c9">69.6</ix:nonFraction>&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments will be finalized by the end of the third quarter of 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RleHRyZWdpb246ZDFkNGE3OWIxMjQ2NDAxYWFhZDg4MDViYzRhM2Y2MzNfMjI5NA_a0acbb99-e0dc-4dcb-95b4-f8327d1ea319" continuedAt="i21e6613aca144f2aa880ad677762766d" escape="true">Discontinued Operations</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i21e6613aca144f2aa880ad677762766d" continuedAt="i3da335cd8401444cacf8b3ce1d96211b">On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.</ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3da335cd8401444cacf8b3ce1d96211b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RleHRyZWdpb246ZDFkNGE3OWIxMjQ2NDAxYWFhZDg4MDViYzRhM2Y2MzNfMjI5NQ_3c0d069a-7e32-4822-a83f-87cd576123f2" continuedAt="ic49c8a8aee8a47f4af3183badb2b2b11" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six <br/>Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75dc927515b3477cb3c9aeebb4a7a7d0_D20210401-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMi0xLTEtMS01OTQ3MQ_45cd1822-d5d4-491c-9df1-f1892d58b7b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30adaf2d743e41079b7a12ac72d1fc61_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMS0xLTEtMS01MDI5OQ_b65253c0-d4a0-4789-bb20-f0c5c3b48e95">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef29e9326024b2192d9ecc9a670b854_D20210401-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMy0xLTEtMS01OTQ3MQ_828fa1df-4a59-4a40-b621-7962e89057f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e64363b84144ffdac3dc9bb780e39a8_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMi0xLTEtMS01MDI5OQ_298ad10c-dfb7-41b4-bd4d-94829902f1d7">44,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfNC0xLTEtMS01OTQ3MQ_c6abd930-0021-48a8-be66-7e5f30a43e5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMy0xLTEtMS01MDI5OQ_9c2cdedd-5be7-4f7f-8496-875ee66840ee">44,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfNy0xLTEtMS01OTQ3MQ_39c44844-6d0e-4fed-8b6c-e5d91a5e6503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfNi0xLTEtMS01MDI5OQ_8fce3ef5-2369-42b7-8b8e-f2dc5738e7a3">5,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfOC0xLTEtMS01OTQ3MQ_ab86c846-4e7d-46bd-9e54-f420675fa4aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfNy0xLTEtMS01MDI5OQ_5be3e68e-b75b-467c-abb6-903646658095">33,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfOS0xLTEtMS01OTQ3MQ_12898778-fbbd-4750-879c-6379bb47f744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfOC0xLTEtMS01MDI5OQ_7e4278ff-8177-44dd-98a1-1f604b88e7e7">5,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTAtMS0xLTEtNTk0NzE_fc281a29-3490-4166-b31c-25df1c23830e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfOS0xLTEtMS01MDI5OQ_ca66b475-1fe2-4a8d-9eed-7e3132620a75">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTEtMS0xLTEtNTk0NzE_81324f3a-17f7-4c38-afe2-116997dd16d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTAtMS0xLTEtNTAyOTk_dc96dbfd-dad4-4835-b16d-1647fd13c7de">45,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTItMS0xLTEtNTk0NzE_4bce9602-4fbd-44c2-8f30-7ca077f1bb35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTEtMS0xLTEtNTAyOTk_45cd59be-5e1f-4109-92a3-9f9f3351efdd">930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTMtMS0xLTEtNTk0NzE_c02f5d56-1415-4284-8271-d57245395aed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTItMS0xLTEtNTAyOTk_820ac5c3-5da5-4b9a-96f1-647439848343">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTQtMS0xLTEtNTk0NzE_670ac8fc-dbf9-4f99-b38a-7ebabeb0b558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTMtMS0xLTEtNTAyOTk_c7d8ebdf-8a6e-4ace-8dbe-07a621faa222">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTUtMS0xLTEtNTk0NzE_314520a2-20a2-454b-8990-9d5026463da2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTQtMS0xLTEtNTAyOTk_f9d9845d-d21a-4ef6-b01e-a4155fe404ed">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTYtMS0xLTEtNTk0NzE_c4208258-9498-4f38-b6da-f963b556da5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTUtMS0xLTEtNTAyOTk_0ef73340-c99a-4203-88c9-ac8792cc7673">847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTctMS0xLTEtNTk0NzE_3e9c5c38-5e60-4635-924a-57652f36847e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTYtMS0xLTEtNTAyOTk_4abb07f7-a4bb-4e56-8112-1ce6fa0ffef1">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTgtMS0xLTEtNTk0NzE_91868229-3f1d-4087-892c-fe33e51dd37f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTctMS0xLTEtNTAyOTk_13f06d27-a927-415b-bbbb-ed700447d17a">521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $<ix:nonFraction unitRef="usd" contextRef="id3e532127d5f44dcaa0a6d0b870251c4_D20210101-20210630" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RleHRyZWdpb246ZDFkNGE3OWIxMjQ2NDAxYWFhZDg4MDViYzRhM2Y2MzNfMTY4OQ_3bfb2ab0-bc46-4fb4-8afb-057547abd3ef">2.8</ix:nonFraction>&#160;million for the six months ended June 30, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $<ix:nonFraction unitRef="usd" contextRef="id3e532127d5f44dcaa0a6d0b870251c4_D20210101-20210630" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RleHRyZWdpb246ZDFkNGE3OWIxMjQ2NDAxYWFhZDg4MDViYzRhM2Y2MzNfMjA2Mg_efadc642-ffc5-4235-9a37-f566d4969cc1">1.1</ix:nonFraction> million for the six months ended June 30, 2021.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. <ix:continuation id="ic49c8a8aee8a47f4af3183badb2b2b11" continuedAt="icc14949e5f3b4ec8b6538b14dea93c7d">Cash flows related to the True Health business during the six months ended June 30, 2021:</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="icc14949e5f3b4ec8b6538b14dea93c7d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:89.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjJhZDAzMDk5NGZmZDQ0MGQ5OTdmMDc2N2U5ZGVjZmMzL3RhYmxlcmFuZ2U6MmFkMDMwOTk0ZmZkNDQwZDk5N2YwNzY3ZTlkZWNmYzNfMC0xLTEtMS01MDI5OQ_4f57e49d-145d-42dc-a49c-afbedaecc547">5,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjJhZDAzMDk5NGZmZDQ0MGQ5OTdmMDc2N2U5ZGVjZmMzL3RhYmxlcmFuZ2U6MmFkMDMwOTk0ZmZkNDQwZDk5N2YwNzY3ZTlkZWNmYzNfMS0xLTEtMS01MDI5OQ_66088199-3083-41de-9474-27ceaed8192c">2,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTAyNzk_56794889-a5d3-4da3-80a6-73770508a18e" continuedAt="icfba6c82cb9a4056a85a31f4408d27fb" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib6a1a9f6adb54fb492606346ad439ca5" continuedAt="ia0e112039f004ccd905ce232862b7021"><ix:continuation id="icfba6c82cb9a4056a85a31f4408d27fb" continuedAt="i1c2f1866a6c64e26b4256e7ec4217350"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1c2f1866a6c64e26b4256e7ec4217350" continuedAt="ia0410e4e313d4c4eaa479ca8027dee9d"><ix:continuation id="ia0e112039f004ccd905ce232862b7021"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTAyODE_b2f774d3-1da7-4725-be41-7da251675e7a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:114.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic18910942b2e485ea30def8e9cefca28_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy0xLTEtMS01MTMzOA_0e921b07-533c-4a03-90e9-fde26b5f5eda">55,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908235d4f83442cfa2a22b2a90120a12_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy0zLTEtMS01MTMzMQ_860639ee-b80b-4b54-a360-4c8c452205c5">52,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id190777694a14c8296979c0037b1333a_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy01LTEtMS01MTM0NQ_415a8d29-55aa-4996-9557-490e4801073b">86,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b23e58105b4c5f9f250d293d1bbf58_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy03LTEtMS01MTM0NQ_3b586dc8-3e70-4a76-a684-92b7f8e1eeb7">53,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b903bf1e5f4a638b29eeb71fe6c6b4_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy0xLTEtMS01MDI5OQ_8a463f7e-3261-4cae-a422-7406391740ed">122,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d5d6d44adc4e43990ce92c4c44933a_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy0zLTEtMS01MDI5OQ_704cdb7e-95d9-48ac-aec0-e4c312e59655">112,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1702427992f426b85f07248e2895331_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy01LTEtMS01MDI5OQ_e8450e27-c7f5-4434-84d1-df5ac77c56cb">156,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib280f91a402940c69f0c3e5cc12d4d56_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy03LTEtMS01MDI5OQ_94276e72-9b09-46ed-8479-ee9b839a4972">96,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0b2ccb4486a4651913ac8302c5c0ec4_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC0xLTEtMS01MTMzOA_5c4e6ffb-837a-4c67-88a0-ec8424ea581c">9,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18dabb68c8274ea0a5201f8219bce96d_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC0zLTEtMS01MTMzMQ_e5c47f33-0cd8-4ce7-9889-d5f87a591ecd">6,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb66e4294e54785b37e073174f3db3c_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC01LTEtMS01MTM0NQ_215c7c39-7e43-4911-9554-84c7ba2b51ac">101,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f215dd151c4adb9f5d581b6725305d_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC03LTEtMS01MTM0NQ_da42413a-0a3b-4e79-91ba-62eb41e6f1e0">90,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d31d53daf04bb8b14968d7533e3c30_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC0xLTEtMS01MDI5OQ_7447d135-1fcb-4004-81ee-1914fc1afec7">14,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa385ea46e294eeabd2ab99940f8e291_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC0zLTEtMS01MDI5OQ_2e45e240-6dd0-44c1-85be-b3920e91c2a0">14,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66dd2b3d936841cea2ea68298ff824f5_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC01LTEtMS01MDI5OQ_b44648a2-9afa-4b7d-bc25-8c671e1f0f7d">193,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1117684efa42b1a391ffcc826e14e1_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC03LTEtMS01MDI5OQ_355af165-06bd-4428-9f75-e50181d58298">176,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf1aec104e64ca9ab855423a51a4a6c_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS0xLTEtMS01MTMzOA_1cbe6eb6-cc90-4ce5-91e2-1c3e1188449c">27,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if40f448b1aee435882087e7f40e19f83_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS0zLTEtMS01MTMzMQ_a738b3e0-82a6-4ca5-81de-a90bd616153d">16,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b85e9482e4845a118116261fe251b_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS01LTEtMS01MTM0NQ_d0ac8eda-976f-44cd-a2fc-f87f73fe4183">39,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031024ab0cda4f04a32cb998ae9efc29_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS03LTEtMS01MTM0NQ_d7a5f9b2-d1d2-4ad9-a911-aea5331e505a">2,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94a3b4a3c854650a274a22df3bb7e4b_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS0xLTEtMS01MDI5OQ_96821df7-cc48-40fa-8071-fbb690b76e85">62,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic519d1466dfe43928dcfe5d77bdee3ae_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS0zLTEtMS01MDI5OQ_0a2c6ff3-c77b-471f-8019-5c858dcd9ebd">32,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i404e9ab7124f42c99765abd6b37736c1_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS01LTEtMS01MDI5OQ_c07ac4f0-27a8-4e09-8610-89f80101f97b">67,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36ffca71bef413bab9a1cae99ccecfa_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS03LTEtMS01MDI5OQ_6f2286a7-5ef5-4198-bd90-ee6b6f33af62">3,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie208d4a1cb3e4377a6d2ee9c2549f37c_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi0xLTEtMS01MTMzOA_03023f56-2e99-41bc-8ed8-095a724311d8">92,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71fe81096cc402e8ae97e15131a0756_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi0zLTEtMS01MTMzMQ_99223873-0817-4ff9-9b0b-4535792a32a6">74,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b091472e7f14e738060f39d3bb11f9e_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi01LTEtMS01MTM0NQ_2b86e47f-8803-46ae-bd74-bf41f9c297f9">227,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7def236e69944f2bfd7976a1f32c4f4_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi03LTEtMS01MTM0NQ_029232f2-a7d3-40b9-b9db-7a309be66c76">147,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi0xLTEtMS01MDI5OQ_e5e93daa-ad93-4b97-80b2-94387e20c544">199,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi0zLTEtMS01MDI5OQ_ef94aa82-5484-4dbf-baa9-0daef1815784">159,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi01LTEtMS01MDI5OQ_1e589af3-a07d-4a6f-9add-616efc2c058d">417,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi03LTEtMS01MDI5OQ_53f20758-badb-4e97-bd26-5e1c61524d4f">277,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $<ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfNTE2Ng_397ea223-c91d-4e0e-9946-964c100aca88">139.6</ix:nonFraction> million of transaction price to performance obligations that are unsatisfied as of June&#160;30, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately <ix:nonFraction unitRef="number" contextRef="i6f80fd138cee4ef2abfdef7ff9b68ef6_I20220630" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfNTc4NQ_81be2e03-8453-4818-b773-4ed399ee07ae">28</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i9a64da34af914c9daa54dedee5a5cd92_I20220630" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfNTc4OQ_a686bc87-c6cf-438e-802a-186b871770d0">60</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i132fb5a493164122bbdcd92d3b2833eb_I20220630" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfNTc5Ng_31cd4351-cc1b-4331-a06f-91ac3f4c0d77">82</ix:nonFraction>% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia0410e4e313d4c4eaa479ca8027dee9d" continuedAt="id664a60152b84337b8933250e61c8de2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTAyODQ_c30d3308-fac6-4423-a3d5-bb30e2d5ee46" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June&#160;30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMS0xLTEtMS01MDI5OQ_fd1a2446-daa3-4519-bd3f-307c72555e95">116,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMS0zLTEtMS01MDI5OQ_43c30ee0-d591-44b5-90ff-4b935a0286d8">129,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMi0xLTEtMS01MDI5OQ_a9d6705d-ad6a-41c6-aa17-49ab02280913">5,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMi0zLTEtMS01MDI5OQ_b5efa413-914a-4fd5-bd86-406d465f9618">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMy0xLTEtMS01MDI5OQ_de9a68ad-7f7d-4a7e-951b-4a02b9aed844">8,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMy0zLTEtMS01MDI5OQ_de2668d7-5741-472d-abe1-48c5f2757566">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfNC0xLTEtMS01MDI5OQ_a81a2bd4-04bd-404d-ad56-5c28d4fc7c25">3,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfNC0zLTEtMS01MDI5OQ_ce80376d-c832-49d9-b574-6bb08a592228">4,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the six months ended June 30, 2022 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjBlYWRkYzYxOGU0ZjQ0ZTBhMzE2ODhkNGZmN2E5N2M4L3RhYmxlcmFuZ2U6MGVhZGRjNjE4ZTRmNDRlMGEzMTY4OGQ0ZmY3YTk3YzhfMS0xLTEtMS01MDI5OQ_e21c7b6b-7e91-4ad0-be9e-037a9b3da67d">16,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjBlYWRkYzYxOGU0ZjQ0ZTBhMzE2ODhkNGZmN2E5N2M4L3RhYmxlcmFuZ2U6MGVhZGRjNjE4ZTRmNDRlMGEzMTY4OGQ0ZmY3YTk3YzhfMi0xLTEtMS01MDI5OQ_6f6ab731-53c7-465d-a91a-5622e9873e0c">10,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjBlYWRkYzYxOGU0ZjQ0ZTBhMzE2ODhkNGZmN2E5N2M4L3RhYmxlcmFuZ2U6MGVhZGRjNjE4ZTRmNDRlMGEzMTY4OGQ0ZmY3YTk3YzhfMy0xLTEtMS01MDI5OQ_8e9d46a3-127e-4974-807c-70db5a7ba9fa">6,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjBlYWRkYzYxOGU0ZjQ0ZTBhMzE2ODhkNGZmN2E5N2M4L3RhYmxlcmFuZ2U6MGVhZGRjNjE4ZTRmNDRlMGEzMTY4OGQ0ZmY3YTk3YzhfNC0xLTEtMS01MDI5OQ_d3e6fed3-7339-4202-a062-4d9101445ada">12,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTA5OTUxMTYzODM4Mw_8e12d0dc-3917-4d01-ba11-fb69120a5ef7">19.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfNzk5OA_3b0969d3-0799-4e35-a368-ac91f03c938f">46.1</ix:nonFraction>&#160;million for the three and six months ended June 30, 2022, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of June&#160;30, 2022 and December 31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i55fd2849c11d40aa8dac15390f64e184_I20220630" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfODY1MQ_c8cfb0fb-cfb3-49e5-aec9-05bfcece158e">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i91e9cc56ffee4613adb9a6ab56554271_I20211231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfODY1OA_dc989eea-1c6e-4683-90c4-669328fe6591">5.2</ix:nonFraction> million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of $<ix:nonFraction unitRef="usd" contextRef="i3532becac70546b4bcc03b106edda27c_D20220401-20220630" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTA5OTUxMTYzODE2Ng_a124930f-90eb-4cd0-a0fb-7579d30c06af">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia3ce003447674e2abab64b23eeba11a1_D20220101-20220630" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfODg3Mw_32529eb1-77ff-43fc-a175-aabca36f095d">1.7</ix:nonFraction> million for the three and six months ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i84c9dc97776a4d2ab2a8a979cad50e02_D20210401-20210630" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTA5OTUxMTYzODIyNQ_5e8aea5a-155c-44b5-921a-035d45259ff8">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff2de2ac36d149c7b524f3b5582f9909_D20210101-20210630" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfODg4MA_c365f00c-7779-49f4-9627-7d90588041c6">1.0</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our platform and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of June&#160;30, 2022 and December 31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i4bcd88cb096e4aeab56740f6386ffe14_I20220630" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfOTYzNg_1ff77e3f-763e-4dc0-ade2-6ca25666f6e4">18.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieeb135f182f34812b3000c1ef3bc7bba_I20211231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfOTY0Mw_d8cc4f48-7cea-4dcf-874b-9c2f164c42f4">27.4</ix:nonFraction> million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id664a60152b84337b8933250e61c8de2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for certain customers of $<ix:nonFraction unitRef="usd" contextRef="i4b532269dce647ae8ba0e135b9f58fd9_D20220401-20220630" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTA5OTUxMTYzODM1MA_11b9502b-9caa-40ef-a67a-634f231b2f12">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i872c6081b968491a9d538c7086489d91_D20220101-20220630" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfOTk0MQ_88b829e6-6e9a-4983-9e58-400b9a689735">11.5</ix:nonFraction> million for the three and six months ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i26704ded411543a5924bf706b6248305_D20210401-20210630" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTA5OTUxMTYzODM2MA_af64872e-8034-4d35-a3f2-b6055f75404c">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4f98d9fd601a4df297a857523d498b81_D20210101-20210630" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfOTk0OA_44a1b43d-3e97-4e25-b270-859433342089">7.3</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or <ix:nonNumeric contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" name="us-gaap:CapitalizedContractCostAmortizationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTAxNjY_6729c73e-8e0c-4908-8ce1-c20c93f9b269">five years</ix:nonNumeric>. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:CreditLossFinancialInstrumentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjk0Nw_c05e8764-ae89-4bae-bd29-02b3b1f31ed0" continuedAt="id1bd8f02985149b981291f4e059efd76" escape="true">Credit Losses </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id1bd8f02985149b981291f4e059efd76"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic and current inflationary pressures on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the three and six months ended June 30, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three and six months ended June 30, 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;June&#160;30, 2022,&#160;<ix:nonFraction unitRef="number" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjMwMA_acef2ccc-0c22-4507-a6a5-2e24fbed4246">90</ix:nonFraction>% were current, <ix:nonFraction unitRef="number" contextRef="i98a3c0b9b3254cfc9d6d4301e6079769_I20220630" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjMxNw_16ef6d0a-0653-454d-a482-e16e16f61ac2">6</ix:nonFraction>%&#160;were past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="icfd3ac7207dd485b866d1ecf9d8370e4_I20220630" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjM1OA_9a0d165a-ee26-401d-9701-ea88953a588d">8</ix:nonFraction>% past due less than 120 days and at December 31, 2021, <ix:nonFraction unitRef="number" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjQxNQ_946ff4eb-103e-4f79-bac1-a719ee72f71e">90</ix:nonFraction>% was current, <ix:nonFraction unitRef="number" contextRef="idb1b05b4923144d994dffe62ce8c0056_I20211231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjQzMQ_c4ff14c5-6748-4d19-9e83-c2af5a2b67a0">2</ix:nonFraction>% was past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="ia32e4243b72b414dbf63a7b58e4444cc_I20211231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjQ3MQ_acf1ba1a-1dcc-43a8-adf4-d35f3b65be0e">3</ix:nonFraction>% past due less than 120 days. As of&#160;June&#160;30, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$<ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjU5MA_befa5ef9-9c40-47ad-a04c-237b7656f344">127.7</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjU5Nw_843cbfbb-b1c3-410e-b869-891ccff7cb1a">171.5</ix:nonFraction>&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$<ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjczMA_68b74b2c-ccac-4981-8304-0bdcdb81235d">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjczNw_9a5a0504-220c-4f40-9a26-be136583bbfa">3.4</ix:nonFraction> million, respectively. <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjk0OA_26fc3e3c-54f7-4514-bcb4-26f5b21b0b55" continuedAt="i6f67e4c4f4e048abb6c4f357ce6bdd99" escape="true">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="i6f67e4c4f4e048abb6c4f357ce6bdd99"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfMi0xLTEtMS01MDI5OQ_002097b5-999b-497b-a668-8bf7bcc94a68">3,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfMi0zLTEtMS01MDI5OQ_6187b9e6-9f88-4fa4-8d79-a7733f366531">7,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfMy0xLTEtMS01MDI5OQ_ed9c7809-0b5e-484a-89ca-6547a1a1d06c">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfMy0zLTEtMS01MDI5OQ_6677f52c-6f0a-4cb3-8d4c-b4cd875e4cbb">611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfNC0xLTEtMS01MDI5OQ_451eb4ea-ef4f-486f-9879-c6b5233404e1">3,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfNC0zLTEtMS01MDI5OQ_c090c5af-8a1b-4c55-91f6-7ea253986a13">7,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNTc0_c45577e0-e6bb-4803-9673-c5b7bd47460f" continuedAt="i4a29460e93ef4d61b3a2883ec4652afd" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4a29460e93ef4d61b3a2883ec4652afd" continuedAt="i05077bad6ff64a7b8986e4917ab4ddb6"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNTgx_475703d0-9424-4775-8777-e771b4f7dd75" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461ebb8b4b4143dfb77186edf095976d_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMS0xLTEtMS01MDI5OQ_0add18d9-6d56-4ab1-ae4e-838b670affad">26,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ccca889cbf4b0c9a6c45d4e2792d4d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMS0zLTEtMS01MDI5OQ_0cf3697c-ff2b-451b-90ef-5dd8a8fe6731">21,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaade151a67ae47c98d6ef7473bc42db4_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMi0xLTEtMS01MDI5OQ_b02033a7-39dc-4d63-8968-8b3cf2d02a47">4,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a47a1bfe944f4bbffaee6cdd3b92ae_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMi0zLTEtMS01MDI5OQ_9efdebd0-0231-4454-b561-f4a472b004fb">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief715b13c4fc48beb1cac256135e9d7f_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMy0xLTEtMS01MDI5OQ_3ae89587-a20c-42b5-a775-da731381b7ac">173,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1738f7f0924690b9cc702596588af5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMy0zLTEtMS01MDI5OQ_4db770b2-167c-4013-92fa-a997bfc7d15f">159,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ff1f6df23841edbf927ca013625866_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNC0xLTEtMS01MDI5OQ_6418dca6-b067-495e-8efa-936c490f7296">23,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7055b6f3699b4fc89fec4593a36e0cf2_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNC0zLTEtMS01MDI5OQ_f733d4a0-beab-48c6-bb48-92a178c14a40">15,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNS0xLTEtMS01MDI5OQ_1627a6d8-d5d3-48ab-9914-94ba74f6c9d5">226,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNS0zLTEtMS01MDI5OQ_6f2c0cdd-ae1c-448b-a1ee-ab73f5b2503f">200,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNi0xLTEtMS01MDI5OQ_9f4aa87e-406a-4b11-b59d-bbcf486240c2">134,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNi0zLTEtMS01MDI5OQ_beb930d2-c2b0-4fdf-8526-a97ece7983dc">119,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNy0xLTEtMS01MDI5OQ_79571184-464e-4c66-a364-5c63d472ff1f">92,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNy0zLTEtMS01MDI5OQ_3e46c095-adfe-49a2-94ab-b2ad0d449950">81,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i05077bad6ff64a7b8986e4917ab4ddb6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $<ix:nonFraction unitRef="usd" contextRef="i5282067d6cfa41b8b9bc8d0fd65c75a1_D20220401-20220630" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODM2MQ_0a5e3eb2-519d-4a6d-ab06-315a383fe436">7.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic460399d0bce4695b06b3c4950e6867b_D20220101-20220630" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTM5_25fa1f09-3e2d-4f0f-b01b-6c5682496a73">13.5</ix:nonFraction> million for the three and six months ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ic7732b8c39c44818a62b633ed2eec750_D20210401-20210630" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODQwMg_8399c8d2-2a5f-4ac6-8818-c1f81a198fb6">5.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7c7ba00b2dca4b97bd4add7fef4ab781_D20210101-20210630" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTQ2_eec1545b-3047-4f86-a3d6-0cde0004077a">11.1</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="ief715b13c4fc48beb1cac256135e9d7f_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMjk5_7d7833e4-da31-46a0-865a-f171df0b65e7">71.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifb1738f7f0924690b9cc702596588af5_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMzA2_01ede2f6-6d06-408c-adea-ef51a80ffe18">71.2</ix:nonFraction> million as of June&#160;30, 2022 and December 31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODQ2Mw_716a5824-93b0-4651-9a36-92ec9f42a391">7.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNDE2_2949bb7f-c4be-422e-867b-37dee559c4e4">15.4</ix:nonFraction> million for the three and six months ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODUxMA_10684483-f722-4557-808b-243a8e2eaff1">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNDIz_ea6612db-fd2d-46d8-bae7-98cf5396b2b7">15.4</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, of which amortization expense related to capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODUzNA_00deeb75-7204-4a3a-b123-2f580808bf27">6.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNTUy_16af232b-9744-432c-9d78-e791d766976a">13.2</ix:nonFraction> million for the three and six months ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODU3OA_775fb0ec-13a0-45b5-aead-dce9f3632964">6.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNTU2_cded9389-f491-450f-aa08-91bfe06b3566">13.3</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMzAwNA_960caf2e-fb52-45a8-a2b9-83fedb06975c" continuedAt="i7672ab87a20c48e5b41ba511dd6b0b8f" escape="true">Goodwill and Intangible Assets, Net</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i7672ab87a20c48e5b41ba511dd6b0b8f" continuedAt="idc2320ce5c2a4eb0a60d620b52b458bc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="reportingunit" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMzE3_73a82c91-b976-4797-bd22-47bf61112e93">three</ix:nonFraction> reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three and six months ended June 30, 2022</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will perform our annual impairment test on October 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our <ix:nonFraction unitRef="reportingunit" contextRef="i9098a44763454939966aead2b01058a5_D20211001-20211031" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMTg4NA_a55a5939-59a7-4028-95f9-1eafc940bb3f">three</ix:nonFraction> reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMjk4Ng_a2288e06-4c4c-40ab-b2f6-99ae3ca86e60" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa8d21a22a84ccabb1b42d66a503b1c_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMS0xLTEtMS01MDI5OQ_8376e427-b452-4977-8f70-1a2e76c7f16c">214,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744902b106114f94aaf10f93f79da793_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMS0zLTEtMS01MDI5OQ_151d4233-fb2b-420a-9526-94c08fcfe3ad">211,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMS01LTEtMS01MDI5OQ_c27bf560-4a53-41af-ad83-882ec2e55437">426,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMi0xLTEtMS01MDI5OQ_c2a1358d-51c7-497b-91ad-b7ab7f41038f">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMi0zLTEtMS01MDI5OQ_a05e2574-e9e1-435f-b3b4-5bcb7120697d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMi01LTEtMS01MDI5OQ_206f07a3-8dae-4f6c-a29e-f86f3bb64585">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31ec6c709d854ece8b361ce8b9f623c6_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMy0xLTEtMS01MDI5OQ_6ca244e3-5b5a-42ef-88d0-41a95750e8d3">214,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7021225a1d4ebe992272c6b7a424f3_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMy0zLTEtMS01MDI5OQ_a913f906-a404-415f-bd39-e2a1acab9792">211,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMy01LTEtMS01MDI5OQ_743aa318-d362-47d0-8810-6cef5b4b34e4">426,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab714214aec4c62895368e7b5d77d47_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNS0xLTEtMS01MDI5OQ_ea550e1d-64f2-4c8a-affb-6ed5cba45eeb">214,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb91a25096ac488099c2f68651d8104a_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNS0zLTEtMS01MDI5OQ_086adbee-54b5-4691-93b8-962e4607e417">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNS01LTEtMS01MDI5OQ_bb557bda-6d9c-44f1-82b4-db0e366aa68e">349,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNi0xLTEtMS01MDI5OQ_7ac98e2e-1b0a-4fdd-aec2-919a17446c43">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNi0zLTEtMS01MDI5OQ_772e9866-945a-4e17-96aa-53035a14f81b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNi01LTEtMS01MDI5OQ_bed1e879-769b-430b-82ca-1838299fee10">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id929ac4578254f3a8ac5a00ef4adae72_I20210630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNy0xLTEtMS01MDI5OQ_d653955e-c589-4012-907b-8311749befdf">214,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47bf34c04d3d4427a895561238e93dfb_I20210630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNy0zLTEtMS01MDI5OQ_dd3cf781-91fa-4120-b1cd-a0cc8ff1cff3">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNy01LTEtMS01MDI5OQ_a7ac74f3-c084-4080-86ce-35da79ff4bf2">349,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $<ix:nonFraction unitRef="usd" contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMjI0OQ_4d2aaafc-374f-4370-b046-9c89ca11d624"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMjI0OQ_c721de2a-3ca4-4382-8277-1546b3944ec4">575.5</ix:nonFraction></ix:nonFraction> million as of both December 31, 2021 and 2020.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="idc2320ce5c2a4eb0a60d620b52b458bc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6bb861754d7f4230af5cbe4156eff1c1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2022 and December&#160;31, 2021  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7ca912d3a02465795eea96c1e250e26_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi0xLTEtMS01MDI5OQ_066ac9bf-5fcf-46ec-8ed9-5d11fc88ef7d">11.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e4ef4f58a5044038cbe7d46e8dfea60_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi0zLTEtMS01MDI5OQ_812c8057-a008-45e6-971c-755bd3b229b7">25,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e4ef4f58a5044038cbe7d46e8dfea60_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi01LTEtMS01MDI5OQ_c34d5961-579a-414f-aa90-dfdcf412adb7">8,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e4ef4f58a5044038cbe7d46e8dfea60_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi03LTEtMS01MDI5OQ_e13ab8cc-d183-49b8-a9ee-e6ff442f2246">17,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i960826d299ae4c44bc47f074ce02ed28_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi05LTEtMS01MDI5OQ_4a33b541-f6b6-411b-8327-606bc6fde5ea">12.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb0816a5da441f6960846569f93e09e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi0xMS0xLTEtNTAyOTk_4c7d6533-f921-464a-a469-6a66a60e4564">25,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb0816a5da441f6960846569f93e09e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi0xMy0xLTEtNTAyOTk_7bb095f7-3c0e-4039-b205-3299154bcda6">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb0816a5da441f6960846569f93e09e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi0xNS0xLTEtNTAyOTk_83bede3a-094c-4225-af2b-6e4b96888645">18,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c75751fbbd54a6eae8d08e6b4ab94a2_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy0xLTEtMS01MDI5OQ_aed8b8f7-9b9f-4758-887a-383a814011df">14.4</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d81d730eae4c75b3cb95f6789994b0_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy0zLTEtMS01MDI5OQ_6c9cc81e-a672-4f6f-ae1d-4f8f058d8b74">311,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d81d730eae4c75b3cb95f6789994b0_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy01LTEtMS01MDI5OQ_363f26b2-8094-48fe-be9f-f8d38e379c8f">81,125</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d81d730eae4c75b3cb95f6789994b0_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy03LTEtMS01MDI5OQ_ed3a827c-c9ae-4017-944c-652c44f6d1e3">229,894</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2706c4da523140c79cd5bc0fc5dd4e18_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy05LTEtMS01MDI5OQ_6184d7d9-bdc2-451b-8d73-c5258f583bd2">14.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f3c31fcc184de09194d8a0f21020a7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy0xMS0xLTEtNTAyOTk_49f06dc7-005e-4a85-bd85-8e5434b9c2fb">311,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f3c31fcc184de09194d8a0f21020a7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy0xMy0xLTEtNTAyOTk_79bef51f-948a-41f2-93fb-2508a6aa0e25">72,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f3c31fcc184de09194d8a0f21020a7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy0xNS0xLTEtNTAyOTk_e7bbda43-4031-4997-9e47-50e8139d98d9">238,322</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8920304c21f34d2e8d814f99e02bb672_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC0xLTEtMS01MDI5OQ_e113dc43-9fce-41fe-af29-07253f0a3d14">1.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525fe873d3c2406f95c7b1e8fe7f01a1_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC0zLTEtMS01MDI5OQ_ee5de95a-7942-438a-81b2-c67365d9dc34">87,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525fe873d3c2406f95c7b1e8fe7f01a1_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC01LTEtMS01MDI5OQ_573250c8-27ac-4e47-8fe5-1be9dfa7c0ec">77,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525fe873d3c2406f95c7b1e8fe7f01a1_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC03LTEtMS01MDI5OQ_5228d8bd-33fe-48d3-a7b6-b6a4efaa2388">10,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if49cfadd37a2439693bcaef2ca7aea4e_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC05LTEtMS01MDI5OQ_6b2c2679-f831-4a0f-97eb-e8ff65cf92cd">2.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96994f66670d402b9792042ce4aa991c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC0xMS0xLTEtNTAyOTk_4f454de8-6f73-473a-86f9-c31e28760830">87,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96994f66670d402b9792042ce4aa991c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC0xMy0xLTEtNTAyOTk_ade27291-9297-419d-9613-311004febfba">73,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96994f66670d402b9792042ce4aa991c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC0xNS0xLTEtNTAyOTk_2f32924a-1c9b-442f-ad19-ad31ca07fa2d">14,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90169973e5d44809bbd3c5d4c63ea01d_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS0xLTEtMS01MDI5OQ_54d6dabf-f264-40f3-9566-23a2650a5521">0.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a84937692640da928c5aff561db4f2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS0zLTEtMS01MDI5OQ_903d840b-3d8d-45e6-ac5a-e5d6a0573c78">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a84937692640da928c5aff561db4f2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS01LTEtMS01MDI5OQ_d297f94b-a3cb-46a5-9462-ccce6ad8d28a">1,050</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a84937692640da928c5aff561db4f2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS03LTEtMS01MDI5OQ_73b334ff-e5eb-4c54-812c-5bd3dbdf4e48">168</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7f5959c88534df58f8cc98840f9d9c6_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS05LTEtMS01MDI5OQ_1c3cc5f2-3d4e-4443-b860-f489a25c8f8f">1.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f6763c502f4844b08ec38b15b78eb9_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS0xMS0xLTEtNTAyOTk_c9b997fa-3d9b-4465-9a57-bba2ddff5fad">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f6763c502f4844b08ec38b15b78eb9_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS0xMy0xLTEtNTAyOTk_ae072d4f-4537-4a9b-b0fe-46e81394b1f2">950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f6763c502f4844b08ec38b15b78eb9_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS0xNS0xLTEtNTAyOTk_3c66c71e-b3a2-4bcf-9ee3-d22bb82337bc">268</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i40c2436f586643c299cf6643b5e47526_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi0xLTEtMS01MDI5OQ_044881f8-111b-4001-973a-15a7e532565a">1.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic284e67a71b64b93b2d5099b8216ad4f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi0zLTEtMS01MDI5OQ_167afee1-3819-43a9-8ff4-82add9957b54">16,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic284e67a71b64b93b2d5099b8216ad4f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi01LTEtMS01MDI5OQ_01a37912-438e-42a4-a9e9-f1dece8f527b">9,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic284e67a71b64b93b2d5099b8216ad4f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi03LTEtMS01MDI5OQ_499448ca-e950-4a08-8304-c2faff4014c2">6,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i59a87beef6454e0cacb2bf3bac49aa68_D20220101-20220331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi05LTEtMS01MDI5OQ_3657fcb7-1451-43c0-93c7-d658ddd2dba7">2.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1e999ffea0466ea3a2914cd626dbde_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi0xMS0xLTEtNTAyOTk_80902006-23d8-442d-a95d-797ffb9a0f58">16,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1e999ffea0466ea3a2914cd626dbde_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi0xMy0xLTEtNTAyOTk_a63c4432-f99d-4e4b-8451-fef96ecf078c">7,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1e999ffea0466ea3a2914cd626dbde_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi0xNS0xLTEtNTAyOTk_d2468bc6-183c-4db3-937c-9ad001fc75d5">8,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy0zLTEtMS01MDI5OQ_c0aaf03c-18ed-458f-b0d1-2689cca6d87b">442,195</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy01LTEtMS01MDI5OQ_0b4f3bb3-84bc-4b42-a12f-004cd8b77123">177,349</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy03LTEtMS01MDI5OQ_676d63d5-7f48-47e4-b8f1-4501e7264831">264,846</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy0xMS0xLTEtNTAyOTk_6dcaf487-7303-4c52-b8d6-2d093b1a3e33">442,376</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy0xMy0xLTEtNTAyOTk_122a8bba-db3e-4983-ae0c-c332c93a88ed">162,592</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy0xNS0xLTEtNTAyOTk_a4c38de4-4212-4e13-97cf-5018bf9fa851">279,784</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMTA5OTUxMTYzMDc5NA_27900192-f584-424f-8aee-f33b01df72de">7.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMjUxOQ_42b53ade-84ea-4836-9533-c8d030578d1c">14.8</ix:nonFraction> million for the three and six months ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMTA5OTUxMTYzMDk2Nw_9cd63e23-fac8-4e89-9cea-107fc8a52d86">7.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMTA5OTUxMTYzMDk3NQ_18a9cec4-8743-49e5-bbb6-e6b9b0577944">14.7</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMzAwMQ_19249b87-a362-4e1d-998f-0ea3dd9d95a7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of June&#160;30, 2022, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:478.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfMC0xLTEtMS01MDI5OQ_ff0acb31-895d-4bf5-8baa-cb2fa422244c">14,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfMS0xLTEtMS01MDI5OQ_c6fc689d-49ae-4e5a-8fa7-168366f7fb02">26,760</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfMi0xLTEtMS01MDI5OQ_6de46033-6de9-4568-830e-d6960700cf2e">20,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfMy0xLTEtMS01MDI5OQ_8ea47b8b-7834-4cad-8f7c-e10fc265fdd3">19,330</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfNC0xLTEtMS01MDI5OQ_4426e164-e54e-4477-86c7-9fb257896cc9">19,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfNS0xLTEtMS01MDI5OQ_27cf4bb6-a768-4f47-8b3a-04ceec4a6ce2">164,353</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfNi0xLTEtMS01MDI5OQ_ed9e89dc-1975-4cdf-ae2f-a0d1e12575a9">264,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the three and six months ended June 30, 2022, that would require an impairment test for our intangible assets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_70"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTc2Njg_aa991f5c-fe30-4d36-931e-804bd1ec9d46" continuedAt="ice6ae56c3a054547897bfb9b1e6fa6d6" escape="true">Long-term Debt</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ice6ae56c3a054547897bfb9b1e6fa6d6" continuedAt="icf696bc535de4807bc02bf3d54f1bebc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzg_16704000-60c2-4891-8793-8527b08afc7e">117.1</ix:nonFraction>&#160;million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTE1_9c9b83ad-16fc-45be-9a42-a65bf711f032">3.50</ix:nonFraction>% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $<ix:nonFraction unitRef="usd" contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzMz_ce818c93-24da-4c33-93bb-4ff4ad4906c1">84.2</ix:nonFraction> million aggregate principal amount of 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="iaedce6468a3e4e8ca15a5333813a91c5_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDAx_1990d906-8007-4551-9fbf-84fe27d4163b">84.2</ix:nonFraction> million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDkw_57fe795c-7b56-4c56-acbf-386373688dbb">2.5</ix:nonFraction>&#160;million, and issued $<ix:nonFraction unitRef="usd" contextRef="i79aed8a5f7344a37b2a701ae05c1b842_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTA1_f35b09b0-bf97-40d4-8ea9-b336f658e315">32.8</ix:nonFraction> million aggregate principal amount of New Notes for cash at par. We incurred $<ix:nonFraction unitRef="usd" contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTg1_1bc71ee6-6ba5-4a04-861f-589bb78d99b4">3.0</ix:nonFraction>&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to <ix:nonFraction unitRef="number" contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA1Nw_9784383e-27b6-46a7-9574-c035b153e9c7">3.50</ix:nonFraction>% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i8c24e626673740bfbc5c482a85f9be03_D20220401-20220630" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM2NQ_ade12412-d368-45e4-ad16-dc8998f0e03a"><ix:nonFraction unitRef="usd" contextRef="i51f45a85ad1d44d3b1bba8c3ef692bb0_D20210401-20210630" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM2NQ_b37b0fba-60f1-443d-bdc8-341b466c4982">1.0</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id96a059c175048b68ce735b693389c60_D20220101-20220630" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM3Mg_c24c455f-9363-49cd-b0ee-df197a540d32"><ix:nonFraction unitRef="usd" contextRef="ide775581b0c2448ba46085d3508e93e6_D20210101-20210630" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM3Mg_fea75f84-caf5-4c29-b8a4-4f827bb990c0">2.0</ix:nonFraction></ix:nonFraction> million for both the three and six months ended June 30, 2022 and 2021, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icf696bc535de4807bc02bf3d54f1bebc" continuedAt="i68c5e065bb8a4b99b41e75e01f847913"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTc5MA_3373af80-56b4-4853-b56e-982fd22d5604">18.23</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTkwNg_93e3c5cc-0b75-4ab7-b40f-bc00c6bd99b8">6.4</ix:nonFraction>&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMjgyMQ_a0186a97-6ff3-409b-a4b7-5713ca293145">78.9</ix:nonFraction>&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="if5bfcb0c398a4d1ba18c1a7084e71a4d_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMjk3MA_539611f4-0ec7-4eab-9bb4-1503e4c3f9a6">38.1</ix:nonFraction>&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzA2NQ_eba92773-d41b-46a9-be95-cbe4c38d2e92">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id342da7701a44166b2290441fd002835_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzA3Mg_132d5956-e760-4e71-a4e3-eccd533582cb">1.3</ix:nonFraction>&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="if5bfcb0c398a4d1ba18c1a7084e71a4d_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzIwNA_3d11818a-8e07-4b0f-802b-5df119a4aab4">38.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzIwOA_eda95e84-9533-440d-be68-4d830464e76f">1.7</ix:nonFraction>&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $<ix:nonFraction unitRef="usd" contextRef="ic42188622755410b90efa5d41026374a_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzg4Nw_6617a960-10e3-4492-bfdc-f299052e78e9">38.1</ix:nonFraction>&#160;million decrease in additional paid-in capital and a $<ix:nonFraction unitRef="usd" contextRef="i7530c57faa32498ca2794192fcf4a689_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzkzNQ_ec454c8b-a8d3-42ea-ba32-9a870f43a697">1.3</ix:nonFraction>&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $<ix:nonFraction unitRef="usd" contextRef="ice3c432af1ef4dc0a423e7d7b0e84b24_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDA3Ng_217fbaca-fb9b-47d9-952d-115f0d5641e5">11.7</ix:nonFraction>&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="ib3ecfc57dd454ea480838c4fc5252936_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDM1OA_80f043f1-6fc7-4320-8c8d-a5e14cc166d8">25.1</ix:nonFraction>&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i8c24e626673740bfbc5c482a85f9be03_D20220401-20220630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NTYzMQ_b7af28cf-3c45-485f-bfcd-e76711318156">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id96a059c175048b68ce735b693389c60_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDc2MQ_d4528e87-3a31-495e-9f31-063c5054a5fb">0.4</ix:nonFraction> million for the three and six months ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i51f45a85ad1d44d3b1bba8c3ef692bb0_D20210401-20210630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NTc4NQ_cb6a6355-656c-463f-82e7-0847534ae2e5">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ide775581b0c2448ba46085d3508e93e6_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDc2OA_658cceef-121b-47d1-8f91-8a8eba46aad4">3.9</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTAyOA_b9cd3517-fe3d-436b-9f4e-2e01da1b86df">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTQ0OQ_fcfff1f9-cbf0-4a31-8772-12a743cdba66">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTUwNA_2100a368-0c5a-47db-915a-920a63c7d426">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTU2MA_ccb7841c-5ffe-4e81-8940-68aaa86a0661">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTc5OA_4467319f-2708-41ea-b124-12b1244db431">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;2019 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="idffc7ad1a4654adf98f1038cfa6da4be_I20191230" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNjQ3Mw_a96b0b8a-b606-47be-b132-f8b05c36a8d7">75.0</ix:nonFraction> million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i6be98831456946c8b796aa596a41a463_I20191230" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNjYwNQ_97c89d65-3ebc-448c-bfd7-d334714dca20">50.0</ix:nonFraction> million (the &#8220;DDTL Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's 2019 Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i68c5e065bb8a4b99b41e75e01f847913" continuedAt="i0ff8f78846d64e34b7d694a4019c191f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $<ix:nonFraction unitRef="usd" contextRef="i2420da3a7fa34500b18bdcbdb21aba50_D20210108-20210108" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzY4OA_40129228-b4ea-4180-b4eb-e54c70937177">98.6</ix:nonFraction>&#160;million, which included $<ix:nonFraction unitRef="usd" contextRef="i2420da3a7fa34500b18bdcbdb21aba50_D20210108-20210108" decimals="-5" name="evh:PaymentsOfMakeWholePremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzcwNw_7f92d10a-8c2a-4d40-8751-d1b94478aa7b">9.7</ix:nonFraction>&#160;million for the make-whole premium as well as $<ix:nonFraction unitRef="usd" contextRef="i2420da3a7fa34500b18bdcbdb21aba50_D20210108-20210108" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzc0OA_103456b2-de29-4c81-96c2-6dfdc1962078">0.2</ix:nonFraction>&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $<ix:nonFraction unitRef="usd" contextRef="i00e82484500e428e8076ddebadf195b8_D20210108-20210108" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzg2MQ_051327d6-2321-428f-9383-4bb6c24285e2">19.2</ix:nonFraction>&#160;million, representing the remaining unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i00e82484500e428e8076ddebadf195b8_D20210108-20210108" decimals="-5" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzkyNw_1ecf1c69-2426-4054-93f4-4ee073cdc50a">9.5</ix:nonFraction>&#160;million, the make-whole premium and $<ix:nonFraction unitRef="usd" contextRef="i00e82484500e428e8076ddebadf195b8_D20210108-20210108" decimals="-3" name="us-gaap:LegalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzk1OA_59126934-8ab1-444e-90f3-afb72f25ec15">35</ix:nonFraction>&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the 2019 Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of <ix:nonFraction unitRef="shares" contextRef="i5631b43e9caf49eeb64e4768bdfb4735_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightUnissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODE4NA_2ec8e5e7-632f-47c8-a33f-7540a81b3020">1,513,786</ix:nonFraction> shares of Class A common stock at a per share purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i5631b43e9caf49eeb64e4768bdfb4735_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODI1Nw_c62dd7a7-ed8a-4304-a56f-9804455fe872">8.05</ix:nonFraction>. The holders could exercise the warrants at any time until <ix:nonNumeric contextRef="ib6ca31f441294fd2bd58db5233a8cc5f_D20191230-20191230" name="evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODMxOQ_fec09ea3-ab88-4047-9a51-c8991dfe366d">thirty days</ix:nonNumeric> after the maturity of the 2019 Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the 2019 Credit Agreement for $<ix:nonFraction unitRef="usd" contextRef="i5870d3d480b24bfb8fce0c75a91af736_D20210108-20210108" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODc0NQ_5746c03b-33aa-435d-a3c0-948253b31b4e">13.7</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $<ix:nonFraction unitRef="usd" contextRef="id0f03be090e54e69ab5736238c33be28_I20181031" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODc5OA_541a0a16-7974-4222-9deb-28a43e1140c3">172.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="id0f03be090e54e69ab5736238c33be28_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODgzNQ_adef235c-e468-4703-8a36-69b11a7ba575">1.50</ix:nonFraction>% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTEwMw_62c8130d-356b-4227-8485-c014607ac587">166.6</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="i93205c45ea8547a98bc7ff1c11408e54_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTExOQ_cd1e0663-59f9-47fe-b66e-fbdc14cc3fbe">5.9</ix:nonFraction> million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $<ix:nonFraction unitRef="usd" contextRef="i4e280a759a5741be8b52ce88da866568_I20181022" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTIyMA_3030b8d3-d631-451d-b7bb-1da630adfe16">150.0</ix:nonFraction> million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $<ix:nonFraction unitRef="usd" contextRef="i3b03deaf81e94b908e898c240f288f46_I20181024" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTM0OA_2e43ea8c-a1e8-4c1d-8c65-5ec9d7fd2056">22.5</ix:nonFraction> million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;<ix:nonFraction unitRef="number" contextRef="id0f03be090e54e69ab5736238c33be28_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTY4OA_adef235c-e468-4703-8a36-69b11a7ba575">1.50</ix:nonFraction>%&#160;per annum. The Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i0b019d63dd4e49a68deed79176b07e2d_D20220101-20220630" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NTgxNQ_7b60c468-16ba-44d8-92ce-ed4d6db7f21f"><ix:nonFraction unitRef="usd" contextRef="i2bc2482dd4334134b1fadb0256b066b3_D20220401-20220630" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NTgxNQ_d5a6b2da-33a1-4b4e-8ddd-73b9d873a8c7">0.7</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i62205ea298424eb981ea4ca7c04b1743_D20210101-20210630" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTc0Mw_429b1c1f-9641-431b-9a6f-8d21eb5d1be6"><ix:nonFraction unitRef="usd" contextRef="i5aa4d8786f5243df8cf17673c36d708d_D20210401-20210630" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTc0Mw_4681c4a6-0405-4e79-b69d-be383ae96d8f">1.3</ix:nonFraction></ix:nonFraction> million for both the three and six months ended June 30, 2022 and 2021 respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="id0f03be090e54e69ab5736238c33be28_I20181031" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA2NzE_8ec59867-ec30-4daa-b02b-bf5689cd2836">33.43</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA3ODc_301fffb0-2af1-4b3c-8a42-a51e0ee7fb6c">5.2</ix:nonFraction> million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="id0f03be090e54e69ab5736238c33be28_I20181031" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTE2OTU_e24a7644-d1f1-48b6-8d2e-d4989ac95837">100.7</ix:nonFraction> million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i56b4489e137445769dd2d5c0552d9a73_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTE4NDQ_96715669-1e6e-4264-8bb1-06e2ea73c5ee">71.8</ix:nonFraction> million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="id0f03be090e54e69ab5736238c33be28_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTIwNTU_f1e9c7c1-6751-43f2-8e07-9fdca6bc46fb">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6d77309eeff741329a3b33008063d50d_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTIwNjI_1ca6b55c-ad33-4c92-ac0f-79a86117d1bc">2.5</ix:nonFraction> million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="i56b4489e137445769dd2d5c0552d9a73_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTIxOTM_96715669-1e6e-4264-8bb1-06e2ea73c5ee">71.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id0f03be090e54e69ab5736238c33be28_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTIxOTc_f1e9c7c1-6751-43f2-8e07-9fdca6bc46fb">3.4</ix:nonFraction> million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $<ix:nonFraction unitRef="usd" contextRef="id5ae38a0018f4e7a9d7dcd73631d6bd7_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTI5MjM_57e8d822-eced-40a8-98fc-58fd4017a049">71.8</ix:nonFraction>&#160;million </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0ff8f78846d64e34b7d694a4019c191f" continuedAt="ib958224612014bf28caae58454a959f9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease in additional paid-in capital and a $<ix:nonFraction unitRef="usd" contextRef="if0901a44b29f424c9815549f850adf16_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTI5NzE_cd68ca0c-92b3-409b-92ca-d80c761b05a5">2.5</ix:nonFraction>&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="ie4df19daedef45a6b93e44ce65f0f0e7_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTMxMTE_d5215c07-c661-4c27-9c1b-9dd7e55bfd26">28.1</ix:nonFraction>&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="ie80fd38d9d5b4ab2bc9f658f6aadf4a0_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTMzOTM_2b4ee06c-37a1-4730-a8c7-0497bd2c3f9b">41.3</ix:nonFraction>&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i2bc2482dd4334134b1fadb0256b066b3_D20220401-20220630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NjAwNw_cad3bf85-51ad-4288-950c-8e2658c5e95c">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0b019d63dd4e49a68deed79176b07e2d_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM3OTY_96972f50-bb95-4d14-a4dd-370583a7db9f">0.6</ix:nonFraction> million for the three and six months ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i5aa4d8786f5243df8cf17673c36d708d_D20210401-20210630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NjE1Ng_3bf8f6f9-56dc-4769-a002-7d8067fa96e7">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i62205ea298424eb981ea4ca7c04b1743_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM4MDM_078704ec-c93a-4ba2-8e93-418b2777e020">4.8</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTQwOTg_6aeef0c0-928f-4fb1-aa8e-25d486085f6d">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTQ0OTc_dbebc0d3-4153-483a-9447-82cdf9d98329">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTQ1NTI_643d9447-2b8d-4031-9671-c558b4700c73">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTQ2MDg_0060c7af-f6f1-486d-9fad-f51a24709d49">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTQ4NDY_1e4dca08-e74d-409e-b218-86312a3901f7">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i3584d11db2f3491898d24a547ffcbb7a_I20161231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTUwMTQ_a0bc8a9e-445c-4d7e-9543-79232bfa750f">125.0</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i3584d11db2f3491898d24a547ffcbb7a_I20161231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTUwNTE_00e62cdd-1646-484e-b4fb-be0b2a3a09d2">2.00</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7648a33bd59947509a7713b0d44e5483_D20161201-20161231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTUyNzQ_84069fb8-64d5-4165-9e4f-036c2ca0fbe3">120.4</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="i3584d11db2f3491898d24a547ffcbb7a_I20161231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTUyOTA_af8eb51b-4840-42be-91b6-1184e0832395">4.6</ix:nonFraction> million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTU3MDg_7ac3d723-f3ec-47c5-ab53-30910d27aa3d">84.2</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="iaedce6468a3e4e8ca15a5333813a91c5_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTU3NzI_4e36100d-818c-415b-ba73-37f05e3fb417">84.2</ix:nonFraction>&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTU5MDU_d1a47f63-7c87-4c18-9693-2bc1574d2a51">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTYwNDk_25a5411f-6193-4b24-8ce1-304178c18258">4.8</ix:nonFraction>&#160;million, including an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTYwOTI_fa8eee6b-6bc8-4827-8f0c-8e5213193f94">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $<ix:nonFraction unitRef="usd" contextRef="iaedce6468a3e4e8ca15a5333813a91c5_D20200801-20200831" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTYxNjU_b033f28f-a1ba-4be6-bca8-3b4284424b21">14.0</ix:nonFraction>&#160;million of the 2021 Notes with $<ix:nonFraction unitRef="usd" contextRef="iaedce6468a3e4e8ca15a5333813a91c5_D20200801-20200831" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTYxOTE_c12c9dfa-8e22-48a9-b3a5-258191617cc0">13.9</ix:nonFraction>&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i9c63bf821d6e48e2ab3a8136ab3612ae_D20211201-20211201" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTYzNjU_68b90b77-cf89-463e-9d00-777a29b3d040">26.7</ix:nonFraction>&#160;million were settled, at the option of the holders, by converting $<ix:nonFraction unitRef="usd" contextRef="i9c63bf821d6e48e2ab3a8136ab3612ae_D20211201-20211201" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTY0MjY_f42156e4-c1a7-4b6e-9ca5-34321191a6af">26.3</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $<ix:nonFraction unitRef="usd" contextRef="i9c63bf821d6e48e2ab3a8136ab3612ae_D20211201-20211201" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTY1MDk_e32b792b-3b5b-441d-a08e-6a122fab8f24">0.4</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $<ix:nonFraction unitRef="usd" contextRef="i427a803b22b943cbb1135ad1eb47ec78_I20211201" decimals="-5" name="evh:DebtConversionOriginalDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTY2NjQ_6a7430b7-3750-42d6-90d4-7ecad25a5549">28.5</ix:nonFraction>&#160;million resulting in a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="i9c63bf821d6e48e2ab3a8136ab3612ae_D20211201-20211201" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTY3MTM_9d774b74-032c-47a2-8054-8a518fdde09a">2.2</ix:nonFraction>&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2021.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib958224612014bf28caae58454a959f9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of June&#160;30, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTc2NjY_73d9c39b-7c6f-4bc3-a19c-226eb1d129b7" continuedAt="idddad0ddbf3046d1947a60792fb4db82" escape="true">The following table summarizes the carrying value of the long-term convertible debt as of June&#160;30, 2022 and December 31, 2021 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="idddad0ddbf3046d1947a60792fb4db82"><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ccdc5191c44efea9d1d9edc7499e87_I20220630" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMi0xLTEtMS01MDI5OQ_db048660-f9c1-4f46-ac2f-616194aa3284">114,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica61ba8f679544528ab9c464177763cc_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMi0zLTEtMS01MDI5OQ_2f411648-5180-4ffc-9c92-a50401234393">89,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ccdc5191c44efea9d1d9edc7499e87_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMy0xLTEtMS01MDI5OQ_da88eb53-a71f-4839-a905-a7062e8402c2">2,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica61ba8f679544528ab9c464177763cc_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMy0zLTEtMS01MDI5OQ_93b88cd4-d005-4f06-afda-d6167aeead51">27,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ccdc5191c44efea9d1d9edc7499e87_I20220630" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNC0xLTEtMS01MDI5OQ_6a2bcf97-e622-46d6-b9b5-4f2196e874ec">117,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica61ba8f679544528ab9c464177763cc_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNC0zLTEtMS01MDI5OQ_d820ab63-a406-4220-9218-5a3984d0911c">117,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id96a059c175048b68ce735b693389c60_D20220101-20220630" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNS0xLTEtMS01MDI5OQ_97542fe5-a272-41cb-8f7e-e78e18a54832">2.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide775581b0c2448ba46085d3508e93e6_D20210101-20210630" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNS0zLTEtMS01MDI5OQ_00de7656-205e-40c4-8bfc-ea901ec1ac4d">2.9</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44077d7155334c2a88271bade68c730c_I20220630" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNi0xLTEtMS01MDI5OQ_2f964849-47ee-42b6-8adc-6f72a75a6948">197,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d50749331f4a3db9bce7b2180496cb_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNi0zLTEtMS01MDI5OQ_b5996abb-a2ea-4d51-8df3-e3a811560410">195,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf121a6589f44c98a0e5e8344398edb_I20220630" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfOS0xLTEtMS01MDI5OQ_7091a7bf-0f57-4566-857e-5e94d8620a9a">168,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33bdb53de4cf4bf4acf5c9415254f853_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfOS0zLTEtMS01MDI5OQ_2bbfb471-3570-4751-a2d1-1621a60da062">126,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf121a6589f44c98a0e5e8344398edb_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTAtMS0xLTEtNTAyOTk_bd02cdf2-e625-4743-84dd-f49e438415ee">4,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33bdb53de4cf4bf4acf5c9415254f853_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTAtMy0xLTEtNTAyOTk_5c2457ef-dff2-4078-aa9b-826d4694aac5">46,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf121a6589f44c98a0e5e8344398edb_I20220630" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTEtMS0xLTEtNTAyOTk_6a676b11-1420-46d1-a4b8-dad21119f394">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33bdb53de4cf4bf4acf5c9415254f853_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTEtMy0xLTEtNTAyOTk_3500a043-e2e2-42c6-9a1c-e1c06885af57">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0b019d63dd4e49a68deed79176b07e2d_D20220101-20220630" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTItMS0xLTEtNTAyOTk_a7c176f5-a999-4228-b71c-a0809569fabd">3.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i62205ea298424eb981ea4ca7c04b1743_D20210101-20210630" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTItMy0xLTEtNTAyOTk_0c723f4e-a499-4706-90c6-1c640e1ce6bb">3.8</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199532edebf94240832d93a367225b5e_I20220630" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTMtMS0xLTEtNTAyOTk_7d616610-05b0-42ec-8157-ed5bd72746c0">195,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i287a359f1cb24979b1d38fe6e75caa46_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTMtMy0xLTEtNTAyOTk_5d96b6d1-0e24-4185-96dd-de0516b8473f">177,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTI0ODE_aa8eceb1-f6a0-499a-a6d0-12264a5b5b77" continuedAt="i6a4c3b77d31e4839b9651bebe676f74b" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6a4c3b77d31e4839b9651bebe676f74b" continuedAt="i8390935e1cc4496790627f332cf943ae"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $<ix:nonFraction unitRef="usd" contextRef="iddc1d80def48423e86b4d3005ffe55ed_I20220630" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTc1_40241eed-0fed-4a3f-a48e-96df1c2b3d06">13.8</ix:nonFraction>&#160;million and&#160;$<ix:nonFraction unitRef="usd" contextRef="iff1d7b85971f4121968757b59f6d1b6a_I20211231" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTgy_16d93401-f6c1-4b4a-a163-8ae253584d3c">15.4</ix:nonFraction> million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $<ix:nonFraction unitRef="usd" contextRef="id6ed29b7f1b44cf89f0a291dd12cf6d2_I20220630" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMzAx_e5e18fee-bf81-4bf0-9b35-06afaa91fad6">13.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0198a0ff5cce4a9b91c42f736cd3a452_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMzA4_746ac397-c627-453c-8361-fe3e37b7871a">15.4</ix:nonFraction> million, respectively, in restricted cash and restricted investments as collateral as of June&#160;30, 2022 and December&#160;31, 2021. The letters of credit have current expiration dates between June 2022 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8390935e1cc4496790627f332cf943ae" continuedAt="if5ce11031a0c4fb8902036895af60258"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three and six months ended June 30, 2022, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of June&#160;30, 2022, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:EffectsOfReinsuranceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTI0ODM_e9239ee3-6679-4ed8-834b-72de5eb96fa0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:438.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:AssumedPremiumsWritten" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfMi0xLTEtMS01MDI5OQ_92075583-2a87-408e-b229-dc2ad7c9360b">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:AssumedPremiumsWritten" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfMi0zLTEtMS01MDI5OQ_1c35aae5-8a8a-465f-b39b-d2ffdf7b79d4">17,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfMy0xLTEtMS01MDI5OQ_262dea3f-90cb-4565-b31c-2313b8fd51de">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfMy0zLTEtMS01MDI5OQ_70cfc2bc-c093-4702-818e-b639f52ec868">16,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNC0xLTEtMS01MDI5OQ_db626a08-7e1f-4a1c-b390-ab1f34c1c8a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNC0zLTEtMS01MDI5OQ_19475a01-45d8-4435-a0ee-4508e5c1cf39">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNS0xLTEtMS01MDI5OQ_550ea1c3-f43d-4e79-8d43-dd33bf3e79cb">151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNS0zLTEtMS01MDI5OQ_493acc7c-88c4-42db-9227-fddaf6193044">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNi0xLTEtMS01MDI5OQ_4910fa69-712b-4d4c-acd8-4ab1bfebb9c7">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNi0zLTEtMS01MDI5OQ_1128b5bf-fd67-4a4a-bd18-b4dab82781ae">4,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNy0xLTEtMS01MDI5OQ_6d5f4f42-a0e5-4573-b530-484bc7c6edc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNy0zLTEtMS01MDI5OQ_3e3896a5-fad3-4273-9a73-cda48b5c6733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:ProceedsRepaymentsForReinsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfOC0xLTEtMS01MDI5OQ_a0c41602-9428-4e5e-b8fd-4ba3e7bc4e4d">328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="evh:ProceedsRepaymentsForReinsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfOC0zLTEtMS01MDI5OQ_a34acd02-3d62-41bb-8664-ee7028ab87e4">7,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable (receivable) for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfOS0xLTEtMS01MDI5OQ_0f8a5226-5654-478f-8e45-f3ba54799252">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" sign="-" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfOS0zLTEtMS01MDI5OQ_d6d4ee4e-cef1-4776-993a-a3f9568c7340">3,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if5ce11031a0c4fb8902036895af60258" continuedAt="i0ade908bf5b94e9da3285ca3464efc11"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#8217;s customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="INF" name="evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfNjcyMA_f4349757-d744-494d-82a7-d01d19e96f5b">85</ix:nonFraction>% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#8217;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, was filed on December 2, 2021. On July 13, 2022, the parties to the class action executed a term sheet for settlement of the litigation, subject to documentation of the settlement and approval of the court after notice to class members. On August 2, 2022, the lead plaintiff in the case filed an unopposed motion seeking preliminary approval of the settlement and related exhibits, including draft notice to class members and a proposed final order. The settlement stipulation is subject to preliminary and final approval by the court. If the settlement is approved, we expect that the agreed-upon settlement payment of $<ix:nonFraction unitRef="usd" contextRef="ic2dde99085614be3a48c4e542d462eac_D20220801-20220801" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMzI5ODUzNDg5OTM0MA_8e95190a-aca9-4745-8ade-564173f13c5c">23.5</ix:nonFraction>&#160;million will be funded entirely by applicable directors&#8217; and officers&#8217; liability insurance. As such, we do not expect to incur a significant net loss or cash outflow as a result of the settlement of this matter.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lincolnshire Police Pension Fund, derivatively on behalf o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. (&#8220;Derivative Action&#8221;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs have not yet responded to the motion to dismiss and there is not currently a briefing schedule on file with the Delaware Chancery Court. Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of June&#160;30, 2022, approximately <ix:nonFraction unitRef="number" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="3" name="evh:CashFDICInsuredAmountPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTA4MTg_8d9c57f8-3487-422b-80ba-f1219bd01111">98.6</ix:nonFraction>% of our $<ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTA4Mjg_fbcbf0b8-388f-4a22-9b53-604dff6c3844">280.4</ix:nonFraction> million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately <ix:nonFraction unitRef="number" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="3" name="evh:CashHeldInInternationalBanksPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTA5Nzk_e483c861-838c-4a71-bfd7-85f3572f63fc">0.9</ix:nonFraction>% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0ade908bf5b94e9da3285ca3464efc11" continuedAt="ic6b632535ec14503ac3a117b7e10081d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTI0ODg_699549ea-e4a7-4b1a-a89d-35d88a8aadda" continuedAt="ice03db096353408ca22191c80831979d" escape="true">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable, as of June&#160;30, 2022 and December&#160;31, 2021:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ice03db096353408ca22191c80831979d" continuedAt="ib19b328f49334f2ca875bc2c01cbe3c7"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice2334023a474418a26edc96b4914f57_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfMS0xLTEtMS02MDYwMQ_3256cb43-1558-4212-84ab-6edaa74621dd">24.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74f5855d88434c3285d8d998872119e6_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfMS0zLTEtMS01MDI5OQ_a1fa8971-653f-44ce-9a9b-c29755b81e4a">46.4</ix:nonFraction>%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b48f947d8c0471a835cbc7da3f1cf01_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfMy0xLTEtMS01MDI5OQ_3024de64-892d-4426-805d-0277cc460ed2">10.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97331e99ea5547e0b35d6859a1d13dd0_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfMy0zLTEtMS01MDI5OQ_8f865b28-5adc-4a77-bd45-e154e9619d25">10.4</ix:nonFraction>%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Centers for Medicare and Medicaid Services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i858366f085d4485eb18d0f7cc216d020_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfNC0xLTEtMS02MDYzMQ_6dfb8f4b-08c5-49da-a334-83017bd9beaf">12.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idea8512b30824967af5d24f3c9c780b0_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfNS0xLTEtMS02MDY0NQ_1b7836e3-d271-477a-8f96-a56b62b9142c">11.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib19b328f49334f2ca875bc2c01cbe3c7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and six months ended June 30, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f081253ccd6415999b9700a0d052cc4_D20220401-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMi0xLTEtMS01MjIxMQ_7ddb623b-0312-46b7-a160-1d6e48df17f8">24.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4369d3b9e5314c63bacd3f01a5ccb6b1_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMi0zLTEtMS01MjIyMw_1c02afdc-9354-422b-8044-16f52161a9db">29.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f3674d843144031a1c5d85f7415f252_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMi0xLTEtMS01MDI5OQ_45ea8a89-a4cb-4334-8b62-89fe59e41a38">24.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iffcd008fc3494897b3c4b55545b1ecf2_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMi0zLTEtMS01MDI5OQ_2bdc5e27-6c73-4170-82e6-b48cff6886b6">29.2</ix:nonFraction>%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id09252d541af4f6480d509935a97ae1c_D20220401-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMy0xLTEtMS01MjIwNA_461137ae-e35a-4d59-be04-bafceb0bb465">11.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie59876efdc3d43669106ec8d543d109a_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMy0zLTEtMS01MjIzMA_b1f60908-82af-4fa2-a77b-5f26b5990f13">14.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3f5b407f5d74c80b132051dcf12fe42_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMy0xLTEtMS01MDI5OQ_6cbcce7f-ac90-4382-9eb1-19e9fd14d4db">11.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4697f31a51524c06a29c429847fa3a82_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMy0zLTEtMS01MDI5OQ_455c6a74-b3f9-458c-836c-b235b1344c4c">14.5</ix:nonFraction>%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross and Blue Shield of North Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7549a5bc04b3412f8b50fb05b19fe749_D20220401-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfNC0xLTEtMS02MDY4Ng_7170b7fc-1225-4b81-8667-9fbdf9b4dc37">10.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic6b632535ec14503ac3a117b7e10081d">We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</ix:continuation>&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMzI1OA_5506dc9b-b4de-4be4-94c5-cc4ecb8a1123" continuedAt="i4cab629eb6034f209e60cb68d2a32083" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4cab629eb6034f209e60cb68d2a32083" continuedAt="i6665f41005a24a04971f8d6f2d74d518"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6665f41005a24a04971f8d6f2d74d518"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $<ix:nonFraction unitRef="usd" contextRef="ia8618f6dc2f0455a9e812da51a84fc9f_I20220630" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMjY2Mw_6815632c-b998-4229-bd61-6902ec032434">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iafda5615eab24ad0adebb2033f75ea7e_I20211231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMjY3MA_a4571d37-f353-4828-80cc-5f884b1098d2">3.8</ix:nonFraction> million in letters of credit as of June&#160;30, 2022 and December&#160;31, 2021. As of June&#160;30, 2022 and December&#160;31, 2021, the Company held $<ix:nonFraction unitRef="usd" contextRef="ia8618f6dc2f0455a9e812da51a84fc9f_I20220630" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMjc0NQ_24d6efa5-09b4-4817-8ac5-66014951f11f">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iafda5615eab24ad0adebb2033f75ea7e_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMjc1Mg_881862de-53fe-415a-a33b-181331d17ccb">3.8</ix:nonFraction> million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMzI1OQ_15c9a326-8123-4b3a-9db9-38955aecda14" continuedAt="i9037465248dc4770bebf857e545fef31" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of June&#160;30, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:237.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i38cfdd80181d48dc95c448a5bd762e1c_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMS0yLTEtMS01MDI5OQ_7b93de75-cccd-4f0c-9888-f2cf4be522f8">9.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38cfdd80181d48dc95c448a5bd762e1c_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMS00LTEtMS01MDI5OQ_c4b5c2db-f73f-45f5-bef5-92416f19b55f">34,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38cfdd80181d48dc95c448a5bd762e1c_I20220630" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMS02LTEtMS01MDI5OQ_d9ac58e1-f1ed-47e6-bd4d-06f8f7a2f20a">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i92f67640b93b448585be7724489ed0b2_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMi0yLTEtMS01MDI5OQ_8f881b82-8a80-474d-903d-bd941e9d8725">8.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f67640b93b448585be7724489ed0b2_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMi00LTEtMS01MDI5OQ_20c5fe85-5a42-4d41-8576-ca331d662b82">39,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f67640b93b448585be7724489ed0b2_I20220630" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMi02LTEtMS01MDI5OQ_79ebc47a-b2b5-41d1-97d6-c250891be0d3">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i31cae587563b4dfaba6a55698e21f99a_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMy0yLTEtMS01MDI5OQ_d34fa53b-f9e0-4a06-931b-e1856f39f651">3.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31cae587563b4dfaba6a55698e21f99a_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMy00LTEtMS01MDI5OQ_36e32c5a-a95d-42fe-b16d-c8be9d9b4bce">1,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31cae587563b4dfaba6a55698e21f99a_I20220630" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMy02LTEtMS01MDI5OQ_7c9f5c1c-5b72-4860-a6e3-63fe7af65d3e">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib0fe093ce52b4d0081c2f7e51b68a9fa_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNC0yLTEtMS01MDI5OQ_78e81237-99be-4cca-b017-455a95f3d373">1.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0fe093ce52b4d0081c2f7e51b68a9fa_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNC00LTEtMS01MDI5OQ_af3a1963-190f-42e8-b6ea-8b7abfc807d9">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0fe093ce52b4d0081c2f7e51b68a9fa_I20220630" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNC02LTEtMS01MDI5OQ_042e6105-a2a5-409d-bec3-d147ff6dd5f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i11a4e8a319824f4b96b6989839081ca3_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNS0yLTEtMS01MDI5OQ_c06a4e24-3c58-44ec-90db-65941b6381e1">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a4e8a319824f4b96b6989839081ca3_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNS00LTEtMS01MDI5OQ_708d0655-8b48-46c6-9a7d-a8b8ccb450da">4,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a4e8a319824f4b96b6989839081ca3_I20220630" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNS02LTEtMS01MDI5OQ_eee84acc-b007-436d-89e3-3ae1daf8b653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMzI2MA_cb0eece2-2a1d-415b-b667-ea10c59330b6" continuedAt="i03c0b582c3524f23b031c38ea45da269" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMi0xLTEtMS01NTA2Mw_6da37c2f-e4a0-4fe7-8283-3f236209e0a1">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMi0zLTEtMS01NTA2Mw_20ea69a1-a709-4c97-8315-5b8c7f650016">2,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMi0xLTEtMS01MDI5OQ_74a94c39-ef4f-4778-8d62-3668f3004b45">4,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMi0zLTEtMS01MDI5OQ_1a667879-61b4-4d8b-8b5d-ac9f3dfff4cf">7,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMy0xLTEtMS01MjMxOA_b4390cef-198c-4414-8fd9-8e9412c4ebe2">1,171</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMy0zLTEtMS01MjMxOA_f35dfb6b-0be2-4ec6-afa5-9f70dfc172db">1,192</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMy0xLTEtMS01MDI5OQ_48d0aad1-b33a-4131-9dbb-ac6a7200af61">2,497</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMy0zLTEtMS01MDI5OQ_c809d175-af1b-4d83-b177-bc902b56e6e2">2,513</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfNC0xLTEtMS01MjMyNQ_fa1bc73a-6c1d-41f1-a2e7-6ecf8df6a94a">3,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfNC0zLTEtMS01MjMyNQ_7c617870-4d85-4984-970a-bee1b221ca74">3,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfNC0xLTEtMS01MDI5OQ_28e642c2-7b35-4327-8b37-303987eaea64">7,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfNC0zLTEtMS01MDI5OQ_06635693-2214-4961-960c-6cd98c2525b9">9,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i9037465248dc4770bebf857e545fef31"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of June&#160;30, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfMS0xLTEtMS01MDI5OQ_c9df44b3-e885-44a4-99ec-2d40680532fe">5,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfMi0xLTEtMS01MDI5OQ_5628c277-396b-4cac-a0de-cbe536925524">10,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfMy0xLTEtMS01MDI5OQ_f3fdc0a2-b1d8-4204-85d1-95a08506d450">10,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfNC0xLTEtMS01MDI5OQ_53425112-f930-4769-8c19-3652edaf2d9e">9,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfNS0xLTEtMS01MDI5OQ_54576b71-b8b6-4de5-bfb5-e0e2c2a4190f">8,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfNi0xLTEtMS01MDI5OQ_0219e976-de22-4df1-8aad-364c4845bf97">40,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfNy0xLTEtMS01MDI5OQ_f5e82dc2-9f85-4fa0-9f1d-63bd2fc29aa4">84,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfOS0xLTEtMS01MDI5OQ_8546f344-8389-4ae5-989a-d8e3b6c878a0">19,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfMTAtMS0xLTEtNTAyOTk_d6ebe903-de48-4bde-be6b-340ba4f4a2ac">64,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i03c0b582c3524f23b031c38ea45da269"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjFmZGQ4YWFmZDM3YjRkYTk5MTdlNzc1MzAyNTdlNmM0L3RhYmxlcmFuZ2U6MWZkZDhhYWZkMzdiNGRhOTkxN2U3NzUzMDI1N2U2YzRfMS0xLTEtMS01MDI5OQ_b0ab76f7-baf7-4a73-a7e0-d555c7d6c2c1">6.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjFmZGQ4YWFmZDM3YjRkYTk5MTdlNzc1MzAyNTdlNmM0L3RhYmxlcmFuZ2U6MWZkZDhhYWZkMzdiNGRhOTkxN2U3NzUzMDI1N2U2YzRfMi0xLTEtMS01MDI5OQ_88f87696-d450-4c9e-ab62-a77165572c6e">8.3</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_82"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RleHRyZWdpb246NmQ3M2M4YjhlNWRhNDk2YWI2YjA5NGRlYTIwNThjNDZfMzUz_b8f464c1-f2c1-4110-8ca1-6e7484c3d4a6" continuedAt="i5d5d15c4034448e09f70ea46fd46a62d" escape="true">Loss Per Common Share</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i5d5d15c4034448e09f70ea46fd46a62d"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RleHRyZWdpb246NmQ3M2M4YjhlNWRhNDk2YWI2YjA5NGRlYTIwNThjNDZfMzQx_784d649a-9313-4ef4-b4ed-9bd49dec4dfe" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:288.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMi0xLTEtMS01MjM2MA_a18efcc0-26c1-40a8-b285-2b77595deb95">4,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMi0zLTEtMS01MjM2MA_05e6ff98-613b-42b7-8fdf-21017a50b82a">9,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMi0xLTEtMS01MDI5OQ_cf7ba85f-9d70-4564-b248-3c5ab3abd91b">9,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMi0zLTEtMS01MDI5OQ_745240e1-c2fb-40f2-945e-f63634659172">20,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MjM2NA_d0078107-c79a-4908-a96b-fcb12333a564">463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MjM2NA_49497634-fa51-4fa0-8ab4-f53f91f2fa50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MDI5OQ_6dccf1fb-174b-4581-aaea-f9ea25f1d932">463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MDI5OQ_cc81acb2-9163-4391-91dc-f0317c70e013">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0xLTEtMS01NTUwMA_62c30aa7-8701-44e4-83c9-125ef9fa625c"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0xLTEtMS01NTUwMA_789cea32-0a2c-4472-9d4b-1e221a42e408">4,588</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0zLTEtMS01NTUxMA_b528ba5c-0d8d-46fd-9353-9a6c4e1285ae"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0zLTEtMS01NTUxMA_c5cc5564-fc76-4665-9de2-9bc53d8b19a2">9,107</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0xLTEtMS01MDI5OQ_071b4d2e-7213-4176-9794-ad2849a45adb"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0xLTEtMS01MDI5OQ_277edb41-089a-4d99-955a-9992f6a848f4">9,938</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0zLTEtMS01MDI5OQ_464827c9-5ea2-4be7-93f2-215a05027e61"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0zLTEtMS01MDI5OQ_694cb801-830b-4ea4-9bd5-c6e422cf548d">18,914</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0xLTEtMS01MjM2OQ_41f5d268-1f8d-4c2d-a385-c9e08c0f72c8"><ix:nonFraction unitRef="shares" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0xLTEtMS01MjM2OQ_6ad0f78d-e413-4159-b6f8-0aaf7e5ff8a7">90,071</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0zLTEtMS01MjM2OQ_5ead25c1-071b-4036-a56f-97db9ea68cae"><ix:nonFraction unitRef="shares" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0zLTEtMS01MjM2OQ_85e6bbd0-5212-4a6e-9468-303c4f000d65">85,448</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0xLTEtMS01MDI5OQ_53b5f9ce-d970-4657-94a1-c315b1e69321"><ix:nonFraction unitRef="shares" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0xLTEtMS01MDI5OQ_5e57e7cf-9f3a-4611-9f09-ef7b143f6d62">89,792</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0zLTEtMS01MDI5OQ_0f412b0b-9466-4a0f-942d-631e68f121a5"><ix:nonFraction unitRef="shares" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0zLTEtMS01MDI5OQ_c8a5bad9-5fe3-4e34-be45-f8eb414f8265">85,056</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMS0xLTEtNTIzNzI_485f8172-519d-4db8-9aed-4799287e8186"><ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMS0xLTEtNTIzNzI_8355fdd5-4e49-42e8-b447-5bc60b22d565">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMy0xLTEtNTIzNzI_22b63fdb-447c-4f0e-b062-dbd3ef19cd8c"><ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMy0xLTEtNTIzNzI_8ae57cde-39cb-45ea-ad89-116a1790131c">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMS0xLTEtNTAyOTk_9b9629f2-0d83-4975-9977-6ff59dfc6aef"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMS0xLTEtNTAyOTk_b6000604-7750-4e79-8f0f-7b737cda8fa1">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMy0xLTEtNTAyOTk_51986ab2-8998-4136-9236-ccd91dd19900"><ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMy0xLTEtNTAyOTk_f8c42eff-43de-49fb-b7c3-b43d543b531c">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMS0xLTEtNTIzNzI_e3b9ea4d-4e41-4467-a709-f0c6a630b4b6"><ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMS0xLTEtNTIzNzI_fd21a903-cf8b-49f1-b98d-4603eda45280">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMy0xLTEtNTIzNzI_3398dcf7-71be-4a2d-b3cb-f96294615a1e"><ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMy0xLTEtNTIzNzI_d1ce6784-6ad2-4ace-9d6f-deae258379e5">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMS0xLTEtNTAyOTk_5dc7a43d-578a-4be3-9269-b52f17c8b3a6"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMS0xLTEtNTAyOTk_85c081d6-9eaf-4668-84ea-a67c89dc82b2">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMy0xLTEtNTAyOTk_0ca56ccf-fb13-4418-9dec-67e6074c8574"><ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMy0xLTEtNTAyOTk_798eff45-60b2-455d-9c7a-9af99196bae1">0.02</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMS0xLTEtNTIzNzU_7a65e334-57d7-4878-bdfd-5c1b9c4f9bd2"><ix:nonFraction unitRef="usdPerShare" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMS0xLTEtNTIzNzU_9453d8a9-eec7-4306-8c88-ff964bce8b6d">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMy0xLTEtNTIzNzU_688690ff-b6c4-4da6-aba8-506911ebf495"><ix:nonFraction unitRef="usdPerShare" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMy0xLTEtNTIzNzU_7343f8c5-ee6a-465a-a801-3e37c33ac703">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMS0xLTEtNTAyOTk_12962f70-5c62-4b02-b9f2-da79d80cb9af"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMS0xLTEtNTAyOTk_5ecc3bd6-602a-47da-86bc-b7111a531ad5">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMy0xLTEtNTAyOTk_bb9b3f1b-30af-4b1e-83c8-4a8ea9925c0e"><ix:nonFraction unitRef="usdPerShare" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMy0xLTEtNTAyOTk_e7620d26-5d56-482b-8cb1-d67e65ce2e29">0.22</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RleHRyZWdpb246NmQ3M2M4YjhlNWRhNDk2YWI2YjA5NGRlYTIwNThjNDZfMzUy_5faf268a-7c68-4f00-966f-cea95e11a670" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:288.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d54b939218e47729004114229359446_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMi0xLTEtMS01MjQxMA_2dabee9c-e0f5-4b26-a6de-83747cfb607e">1,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5f918cd7826430298dbf550d4b035ad_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMi0zLTEtMS01MjQxMA_0e9acac9-c4b2-4cab-b850-5e4282bd65fd">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if231d8338180440882ba220f0ce751c6_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMi0xLTEtMS01MDI5OQ_9b85dbe4-2154-472a-ab7c-32c22ce24876">1,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide8b1a427528491e95fa193e43b94d38_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMi0zLTEtMS01MDI5OQ_6fb0a5a9-184c-45a5-9fd0-828d894fc5a0">1,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcfcf1b04d4841ccbb92d2a7320961fe_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMy0xLTEtMS01MjQxMA_bb1ab702-3514-439b-8f45-d355d7bdd023">1,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2901a75f3a247c5ac744dd557ba51f0_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMy0zLTEtMS01MjQxMA_d3e3c5ae-f2e5-4cfa-9f5c-443782fa2af7">1,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24857afd029946ad953d32e472b7bcbc_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMy0xLTEtMS01MDI5OQ_0f661c6f-cf5c-4565-b9b1-08ddd19de9aa">1,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabd7310dc91f4778877cc439a686f2ce_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMy0zLTEtMS01MDI5OQ_32883b3a-6010-4ac7-b3c0-271eff82f5b1">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie134ed611c47418485ab07b86a56f78d_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNC0xLTEtMS01MjQxMA_c9926779-1afc-44de-87e2-b3a56307315d">11,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2447e2f271ab4cd5b596bc7f50ab65ce_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNC0zLTEtMS01MjQxMA_7713cd86-2bfb-41c2-8b70-5c930753c53b">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i964b6c8302364f4fa39a31e5fe8af1a4_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNC0xLTEtMS01MDI5OQ_ee17b5ef-488d-43a0-995f-c04d74b0f4ca">11,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a6bfcf39da045688459cbd536822b1d_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNC0zLTEtMS01MDI5OQ_5b65f08e-305c-4482-a812-73a9c6eaba1b">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNS0xLTEtMS01MjQxMA_69f5208a-daaf-4367-9f54-cb1747655511">15,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNS0zLTEtMS01MjQxMA_0617110b-3c7f-4ff4-8085-3ac2c8a00f78">16,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNS0xLTEtMS01MDI5OQ_8a68eb72-48e6-4c4e-9e46-bc8cbb9365fc">15,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNS0zLTEtMS01MDI5OQ_bf367c17-777f-4cfa-9806-d7f733980085">16,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMzI3_4c87cdd0-264b-4853-9eb0-6cc02bee7dd4" continuedAt="i99244e5e6fc141b4abea344df8202a63" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i99244e5e6fc141b4abea344df8202a63" continuedAt="i450ce13103354b6b9c59338a0014db14"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMzI4_3a1c1299-9fd6-4528-9f75-feb0ab9a3a65" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:288.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bfb82287c064822b44c47e618455986_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMy0xLTEtMS01MjQ4MA_4714b577-8837-4932-8906-94d79f06a7cb">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia74da95131c94444b02cb9706d3d7af2_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMy0zLTEtMS01MjQ4MA_226885c0-6daf-4e8a-b830-ce27d0608e33">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f9d2b1aa2e48d89223c9302b8b413b_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMy0xLTEtMS01MDI5OQ_774de994-7d8c-4371-bda8-3889f62be397">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida2bfbe459a7424eb6baf496ceffcbc0_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMy0zLTEtMS01MDI5OQ_bd9dbc31-987c-4dc1-a79f-15c896db84b6">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9002002234e467d88e03554eac894c8_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNC0xLTEtMS01MjQ4Nw_9c101c09-9c50-45cf-9ba1-ba69c80dd47d">4,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b58614dca7f4fbeb927b1354f4e9b79_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNC0zLTEtMS01MjQ4Nw_94ba84f7-49f5-45d5-b7aa-e5b5f8e72e6d">2,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa8508ca389418f81bf326a680bd658_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNC0xLTEtMS01MDI5OQ_27f0cfd9-c9c1-4d9b-bd59-af6ea5854cce">7,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7783015b2ae54c6e9b2422c563ab6deb_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNC0zLTEtMS01MDI5OQ_10c552da-b74f-47aa-b0d0-b64a3f61ee70">4,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b51644e7c048c88aea7ed7a62c9f77_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNS0xLTEtMS01MjQ5NA_efde0a3c-3c5d-41d0-b3c0-9c38ad5c07c0">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc87bed7f2074590b61ec2fb0cc0f0f8_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNS0zLTEtMS01MjQ5NA_907a7bc5-075b-409e-9bda-c6406174028f">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f97a58aa80547029649a0cf3a2a5dd7_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNS0xLTEtMS01MDI5OQ_30f52eec-0517-4dd9-9fc4-e968d1000e64">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic329299275fa4a088f919d8e59845bff_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNS0zLTEtMS01MDI5OQ_920dd2b3-115e-4666-be2c-1f41367f7e85">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76cc4f8c28014238a98362c8d2ef9224_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNi0xLTEtMS01MjQ5NA_d6f1afb5-76ba-4b40-b42f-cb2fd2ce8689">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92729353701e4160afc71576b5f23a25_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNi0zLTEtMS01MjQ5NA_ea814209-f17a-4978-8ff8-1f3b95085087">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib699196b28014c31a00d19bb66ee014a_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNi0xLTEtMS01MDI5OQ_2951ae6a-81bf-4f69-88df-64d0942571c9">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c9925c2945438f916183ef76ede0c0_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNi0zLTEtMS01MDI5OQ_091528b3-4284-4208-ba62-016e68c13844">980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNy0xLTEtMS01MjQ5NA_d1a21991-36b6-429b-861c-6fec5f569261">7,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNy0zLTEtMS01MjQ5NA_292aaed7-87dc-4f12-a9ce-206d6bb74350">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNy0xLTEtMS01MDI5OQ_a2fcc096-ea70-4bd3-9d03-5f95ba401bc2">12,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNy0zLTEtMS01MDI5OQ_53a0913e-3ac3-4413-8e55-988a9f4e7984">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84dbc81371174a2aaee8be24c4769d0e_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTAtMS0xLTEtNTI1MTQ_8c15fb8d-e542-4053-8033-0f072b9fa238">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i527e4616505d460da52a06d5e9031339_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTAtMy0xLTEtNTI1MTQ_0c85a7b2-7cdf-406b-80c5-a7ba7261f359">892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03a4fc06028452a8a6a2c80df8c07cf_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTAtMS0xLTEtNTAyOTk_924b242b-1eeb-4c0e-94a3-dd00b7da141d">1,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7deec1f9d05a4e7b8276434ce19b2f18_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTAtMy0xLTEtNTAyOTk_9e47a40a-7381-490b-898a-f46830463490">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f9702c58070468c9b2a1580cb0175db_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTEtMS0xLTEtNTI1MTQ_ad87f13c-b325-4b77-8a86-f125e5184453">5,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea4f0986d4c4a1e9f1370d4957fd642_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTEtMy0xLTEtNTI1MTQ_90327d2e-9409-4d0a-93ab-2ebed5bb58ef">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee8a89e489b4af9ac0113c9d93ce86e_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTEtMS0xLTEtNTAyOTk_f4b8741a-089b-4eba-9ae8-13ae894e9164">10,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb490ebfa4014df7bbc4f1b2f06baaaa_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTEtMy0xLTEtNTAyOTk_71faaa18-108a-4787-8ed0-9148e0ad7ea0">5,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTItMS0xLTEtNTI1MTQ_58a044a2-cd9c-4390-882d-38e9607fd7de">7,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTItMy0xLTEtNTI1MTQ_7faee790-5976-4ac4-b561-d696d8bcc933">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTItMS0xLTEtNTAyOTk_e3f2d5a7-be51-4fd9-969d-600bc53576e0">12,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTItMy0xLTEtNTAyOTk_53a0913e-3ac3-4413-8e55-988a9f4e7984">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i450ce13103354b6b9c59338a0014db14"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMTcx_5653bfdb-6f08-4975-a34b-03a72cb473ce"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMTcx_76340ec6-1181-43b5-a948-697f22fc4731"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMTcx_aefb7822-eedc-4be1-8a77-ac11d1578026"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMTcx_e711f07f-8d1d-43da-b64a-f0d9dce6277c">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> stock-based compensation was capitalized as software development costs for the three and six months ended June 30, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMzI5_9d037c75-101b-44c6-86e3-148ae4479810" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9002002234e467d88e03554eac894c8_D20220401-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMi0xLTEtMS01MjU1Mw_d861ffb4-c8da-4cf3-92f3-d608194ad069">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b58614dca7f4fbeb927b1354f4e9b79_D20210401-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMi0zLTEtMS01MjU1Mw_c7157cf8-60e6-41d7-9c25-e67e8a685a38">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfa8508ca389418f81bf326a680bd658_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMi0xLTEtMS01MDI5OQ_1fbe8668-8b65-49b8-9c1d-6bfe89962b58">980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7783015b2ae54c6e9b2422c563ab6deb_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMi0zLTEtMS01MDI5OQ_5102f2c3-979e-48a0-b53e-a0dd6387f277">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76cc4f8c28014238a98362c8d2ef9224_D20220401-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMy0xLTEtMS01MjU1Mw_709965ea-b926-4391-bde7-860c1b8633c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92729353701e4160afc71576b5f23a25_D20210401-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMy0zLTEtMS01MjU1Mw_83330cca-2052-4add-ab59-a4a24930e0a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib699196b28014c31a00d19bb66ee014a_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMy0xLTEtMS01MDI5OQ_0a53b2fb-80dd-4726-b183-afa459bd8ae2">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10c9925c2945438f916183ef76ede0c0_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMy0zLTEtMS01MDI5OQ_4a9e56ea-90e1-4fee-901e-b60af2747abc">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_88"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMTQ1MQ_d64a17fc-a73c-4116-a7e1-d6912752cdf4" continuedAt="if9f75a11bcd44aefa2bd8a0ea730bdac" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if9f75a11bcd44aefa2bd8a0ea730bdac"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax expense (benefit) of $(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzI5ODUzNDg4NTA4MA_4568e746-c951-4938-8a61-e01299b2a366">0.2</ix:nonFraction>)&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzI5ODUzNDg4NTExMg_7a9d8baa-88fe-4510-9f09-c9be265aa90f">1.0</ix:nonFraction>&#160;million and was recognized for the three and six months ended June 30, 2022, respectively, which resulted in effective tax rates of <ix:nonFraction unitRef="number" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMTA5OTUxMTYyOTMwNg_47eef0b7-3356-4dfc-9574-70d4392b0251">3.9</ix:nonFraction>% and (<ix:nonFraction unitRef="number" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzAx_6017eedd-00b8-4c35-a318-153e2d9e8fad">11.4</ix:nonFraction>)%, respectively. An income tax expense (benefit) of $<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzI5ODUzNDg4NTE0NA_0ebe6251-27ee-48e8-9d69-92357cab867c">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzI5ODUzNDg4NTE3OA_14491221-2384-4460-a539-b15ced70fe11">0.7</ix:nonFraction>&#160;million was recognized for the three and six months ended June 30, 2021, respectively, which resulted in effective tax rates of (<ix:nonFraction unitRef="number" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMTA5OTUxMTYyOTM1OQ_93e7dea4-deea-4324-981f-8e87f39e8878">1.0</ix:nonFraction>)% and (<ix:nonFraction unitRef="number" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzA4_a92066bf-e04b-474d-b3ed-39b63bc582b7">3.6</ix:nonFraction>)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax expense recorded during the three and six months ended June 30, 2022 and 2021 primarily relates to foreign taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, the Company had unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfNjMx_d8071612-9320-478e-b1d8-3ca36da01af3">0.6</ix:nonFraction> million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of June&#160;30, 2022, there are no changes to the unrecognized tax benefits. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="INF" name="evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMTE1Ng_97de1f39-c86d-413c-b7b0-c77d3ffb1cc7">85</ix:nonFraction>% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above for discussion of our TRA.</span></div></ix:continuation><div><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_91"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMjE3NQ_10e9a463-2628-4a3f-8e72-5ed64d1c5b5c" continuedAt="ifc13f0e4de684bd5be72b84b11c5bea0" escape="true">Investments in Equity Method Investees</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ifc13f0e4de684bd5be72b84b11c5bea0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;June&#160;30, 2022 and December&#160;31, 2021, the Company&#8217;s economic interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="i54dd4caef2f344379688eaef3449c98e_I20220630" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTI0NA_25c5796d-684c-4de5-a056-2f403036f96f">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i94ebbd62d39b4c6e878b3190d03982a1_I20220630" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTI1MQ_68db7c2c-d175-4473-aaf8-800cf5fdd325">38</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if8f2eb0ac1624558acdb53e52c269e19_I20211231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTI1OA_0ffbc92e-0565-4456-8103-0ce7eadccb08">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5bd208a32416460385f7876f38b23d85_I20211231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTI2NQ_7e849bfd-c3d4-4027-bc9e-7439148f76bf">39</ix:nonFraction>%, respectively, and voting interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="if8f2eb0ac1624558acdb53e52c269e19_I20211231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTM1Mg_029f661c-0d6a-499b-a676-26f559fd89c9"><ix:nonFraction unitRef="number" contextRef="i54dd4caef2f344379688eaef3449c98e_I20220630" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTM1Mg_6cffbb82-4b12-481b-9029-6f72164f0086">25</ix:nonFraction></ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5bd208a32416460385f7876f38b23d85_I20211231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTM1OQ_7382521e-9a0c-48f8-b81d-c84a1bcd4e5f"><ix:nonFraction unitRef="number" contextRef="i94ebbd62d39b4c6e878b3190d03982a1_I20220630" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTM1OQ_e61b7dcc-10b5-4e0c-a587-1e8fd0b6074d">40</ix:nonFraction></ix:nonFraction>%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTA5OTUxMTYyOTk1Nw_a537e0a3-ad58-4f40-98b8-d2ccb911534c">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTgwMQ_0d6c8305-759d-482d-942c-7f5f5b12303c">2.5</ix:nonFraction> million for the three and six months ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTA5OTUxMTYzMDAzOQ_84ea3918-a85b-4449-8464-99047c804e99">4.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTgwOA_0503f1e6-2ffe-40b6-a4cd-1527e7c3ab80">12.7</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $<ix:nonFraction unitRef="usd" contextRef="if038fb24676c4fbe8fcd625e0c03f2e4_D20220401-20220630" decimals="-5" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTA5OTUxMTYzMDA3Mg_89905dbc-5578-4ce6-a6b7-5dca3b90f1ab">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if35ad6a7d0874e9989f37adcab1d604c_D20220101-20220630" decimals="-5" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMjExMw_8fb500da-aee2-4f56-98a7-67b3d7c03bb8">7.5</ix:nonFraction> million for the three and six months ended June 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ic72c81faddfb4d16898248ad47a599c1_D20210401-20210630" decimals="-5" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTA5OTUxMTYzMDE1Ng_d78e8b26-20e9-4c05-b7de-a10c77983e4a">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic59c227acd8640a480a066d3194993ca_D20210101-20210630" decimals="-5" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMjEyMA_c029466d-4414-406d-8675-0c3a4fd6c7e9">8.6</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_94"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17. <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RleHRyZWdpb246YmI5ZmRiYjk5OWQ2NDk4MWJiMzAxYjNhMDYxOWE2MzFfNDk2MQ_529b6c45-0e97-4aa2-b154-a0186d35001f" continuedAt="i61f1ec7d6f8449298fee20c1af94bca8" escape="true"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RleHRyZWdpb246YmI5ZmRiYjk5OWQ2NDk4MWJiMzAxYjNhMDYxOWE2MzFfNDk4Nw_d6890209-3dbe-4024-94c5-dc9ec1cadeeb" continuedAt="ia6b18016f3e14c5f98df07e78da2d519" escape="true">Fair Value Measurement</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i61f1ec7d6f8449298fee20c1af94bca8" continuedAt="i9c15e11415cc47cebc9d9468470cfc54"><ix:continuation id="ia6b18016f3e14c5f98df07e78da2d519" continuedAt="id6717bbf32f648b9b7c564c1b697a8b0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RleHRyZWdpb246YmI5ZmRiYjk5OWQ2NDk4MWJiMzAxYjNhMDYxOWE2MzFfNDk3NA_abf65e9c-26d2-4f4d-ae98-3cb454d359f5" continuedAt="ia67759a1195a4d088446294936a30d8d" escape="true">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:continuation id="ia67759a1195a4d088446294936a30d8d" continuedAt="i522514f32ef94a5e9c4a9216c9046127"> </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i522514f32ef94a5e9c4a9216c9046127"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f1f46b4a5da4b88ab1161c697899756_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfMy0xLTEtMS01MDI5OQ_25073793-9804-41e0-a663-e7499909f162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901fed8a465841a2a7d4e3c79e3b289f_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfMy0zLTEtMS01MDI5OQ_0f0cae6a-256d-42b6-ac14-153922f7f594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e8394722604655b91f21d472ddc55f_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfMy01LTEtMS01MDI5OQ_7749cf44-6dda-4bd7-8963-cab7e3f4dea1">33,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f4d51ef9aa4ab4a4f13f3a70a0afb2_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfMy03LTEtMS01MDI5OQ_70b7ab7a-c2dd-4506-9206-888f8c0716c2">33,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f1f46b4a5da4b88ab1161c697899756_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfNC0xLTEtMS01MDI5OQ_1d099d8b-2a48-4ded-bef0-70f150ac6c82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901fed8a465841a2a7d4e3c79e3b289f_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfNC0zLTEtMS01MDI5OQ_bf9bb33f-1989-41c6-b3e0-945d735f0da2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e8394722604655b91f21d472ddc55f_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfNC01LTEtMS01MDI5OQ_cced9446-14e2-452c-835b-5ce3596b43cb">33,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f4d51ef9aa4ab4a4f13f3a70a0afb2_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfNC03LTEtMS01MDI5OQ_387a17af-c3ba-4e87-9add-de4b0d30f2df">33,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a0e0359a3b54f88ac3fba23ecf413ab_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfMy0xLTEtMS01MDI5OQ_779d7751-3b68-4694-9c32-176bdbf500e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67639f87145d4008acf2702010dc086c_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfMy0zLTEtMS01MDI5OQ_70d99907-7619-4233-afbb-ba4e2b037b6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9af5aa7ede47a29b2eff96c883a5f1_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfMy01LTEtMS01MDI5OQ_dcea9835-f054-438e-962e-0591892e66fb">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad3e10b3ea8472d88039d89be09d82a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfMy03LTEtMS01MDI5OQ_d63cd124-23c3-44fd-a5ff-15f8a4a1bb29">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a0e0359a3b54f88ac3fba23ecf413ab_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfNC0xLTEtMS01MDI5OQ_3cf5023c-643b-43d0-af8d-0af43bb4a6f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67639f87145d4008acf2702010dc086c_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfNC0zLTEtMS01MDI5OQ_d141cd69-2232-47ad-800c-750bfe68f015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9af5aa7ede47a29b2eff96c883a5f1_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfNC01LTEtMS01MDI5OQ_47c91c1a-7384-4cd0-bb8d-15f7b6e3dcce">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad3e10b3ea8472d88039d89be09d82a_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfNC03LTEtMS01MDI5OQ_5a8c2133-028f-496a-a8fd-aa87dadfd278">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.</span></div></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three and six months ended June 30, 2022 and 2021, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the acquisition of Vital Decisions includes a provision for additional equity consideration contingent upon the Company obtaining certain annualized performance metrics during the three months ending December 31, 2022. The fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Vital Decisions contingent consideration are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9c15e11415cc47cebc9d9468470cfc54"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RleHRyZWdpb246YmI5ZmRiYjk5OWQ2NDk4MWJiMzAxYjNhMDYxOWE2MzFfNDk2Mw_f559e370-0b55-4016-a69a-f810bd0bc658" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfMi0xLTEtMS01MDI5OQ_fc0124fc-050b-431a-80e6-b0a1f962536d">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfMi0zLTEtMS01MDI5OQ_a831a988-2b85-49b2-b2fe-fe5bdb7dbac4">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfMy0xLTEtMS01MDI5OQ_efaebbb6-927c-48d5-86dc-9d3cc33a0a9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfMy0zLTEtMS01MDI5OQ_6e9bfd71-8219-4e10-8cda-e514eadc5c6e">13,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfNC0xLTEtMS01MDI5OQ_53ded41a-27a9-468e-82c2-12b24916e377">4,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfNC0zLTEtMS01MDI5OQ_a74de3a3-f418-4114-a87a-4229074d2401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfNS0xLTEtMS01MDI5OQ_2b76242f-9b63-4d59-9910-a5e2443418cf">33,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfNS0zLTEtMS01MDI5OQ_41d35dec-753f-4ae8-af39-4f76eef32a06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RleHRyZWdpb246YmI5ZmRiYjk5OWQ2NDk4MWJiMzAxYjNhMDYxOWE2MzFfNDk3MA_9a23fd91-1839-47ef-b07f-2eb7ef072afc" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e8394722604655b91f21d472ddc55f_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjk1M2I5Y2ZkMzg2ZDQyODVhZmY2MWEwMWIyZmU2MzU3L3RhYmxlcmFuZ2U6OTUzYjljZmQzODZkNDI4NWFmZjYxYTAxYjJmZTYzNTdfMy0xLTEtMS01MDI5OQ_38291e34-9a98-4879-9fff-692c52910dae">33,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d10e11febe742e388c4185b0dfb5f67_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjk1M2I5Y2ZkMzg2ZDQyODVhZmY2MWEwMWIyZmU2MzU3L3RhYmxlcmFuZ2U6OTUzYjljZmQzODZkNDI4NWFmZjYxYTAxYjJmZTYzNTdfMy03LTEtMS01MDI5OQ_45bc3e15-ca8b-4519-86c3-18973f143cc3">36,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20f895ec0c394fb7a1b6962e0c4d6c9c_I20220630" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjk1M2I5Y2ZkMzg2ZDQyODVhZmY2MWEwMWIyZmU2MzU3L3RhYmxlcmFuZ2U6OTUzYjljZmQzODZkNDI4NWFmZjYxYTAxYjJmZTYzNTdfNC03LTEtMS01MDI5OQ_53512e12-c743-4cdf-97f8-73eb868684c5">10.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9af5aa7ede47a29b2eff96c883a5f1_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOmJiODdmYTM1OTAwZTQxZTdiMWIzNDFjMWZkMGNhYWVkL3RhYmxlcmFuZ2U6YmI4N2ZhMzU5MDBlNDFlN2IxYjM0MWMxZmQwY2FhZWRfMy0xLTEtMS01MDI5OQ_e46701f9-1504-44dc-86be-232fef0b55bb">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d611e598104338b6853034734ea3e6_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOmJiODdmYTM1OTAwZTQxZTdiMWIzNDFjMWZkMGNhYWVkL3RhYmxlcmFuZ2U6YmI4N2ZhMzU5MDBlNDFlN2IxYjM0MWMxZmQwY2FhZWRfMy03LTEtMS01MDI5OQ_26cf04b7-466e-4569-b35d-a556a1b48dae">30,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65efdf8b544f497a9ccb4054da27c745_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOmJiODdmYTM1OTAwZTQxZTdiMWIzNDFjMWZkMGNhYWVkL3RhYmxlcmFuZ2U6YmI4N2ZhMzU5MDBlNDFlN2IxYjM0MWMxZmQwY2FhZWRfNC03LTEtMS01MDI5OQ_81512f05-803f-4b69-bdc0-12f130caad4e">6.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="id6717bbf32f648b9b7c564c1b697a8b0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18. <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RleHRyZWdpb246MmRhMTlmZDhmZDg1NDYwYTgwZThjMTY0NjNjNjFiYjJfMTIwMw_ff1075c3-d07e-4acd-99d9-6f612c2b3962" continuedAt="i5c88d4d255ff48bf9f5da32d95aacfae" escape="true">Related Parties </ix:nonNumeric><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5c88d4d255ff48bf9f5da32d95aacfae" continuedAt="ic9db1413558f43d0a34fc54140955904"> </ix:continuation></span></div><ix:continuation id="ic9db1413558f43d0a34fc54140955904" continuedAt="id410dd22d9304f80b9e2b2eaba37f901"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="id410dd22d9304f80b9e2b2eaba37f901"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RleHRyZWdpb246MmRhMTlmZDhmZDg1NDYwYTgwZThjMTY0NjNjNjFiYjJfMTIwNQ_d3682534-9100-47fb-81f0-468c699fdff3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfMi0xLTEtMS01MDI5OQ_664d0093-0a87-4535-966c-cf6d60f7bd81">4,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfMi0zLTEtMS01MDI5OQ_345136cd-f81e-41d9-a580-d1b694e83a59">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfMy0xLTEtMS01MDI5OQ_573143f3-6e82-49ae-954a-123bc836d4ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfMy0zLTEtMS01MDI5OQ_95f42056-2655-4c6d-b1c3-906fb4022a78">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfNC0xLTEtMS01MDI5OQ_7d530405-4540-4c8a-821b-741c8dbc262d">5,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfNC0zLTEtMS01MDI5OQ_b6f3c1cc-3efd-4b5d-8e4e-6edf61b6a462">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfNy0xLTEtMS01MDI5OQ_afb286bc-e5c3-4366-ab1e-fda062fc1fa4">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfNy0zLTEtMS01MDI5OQ_fb28f054-3be8-441b-a610-4076aa5dccda">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfOC0xLTEtMS01MDI5OQ_3ddb5718-97f2-4704-aa6d-418fddc0a59b">972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfOC0zLTEtMS01MDI5OQ_712fb992-0695-421d-a69e-a9a597f3a53a">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfOS0xLTEtMS01MDI5OQ_28ddabf6-01e1-4643-b5ee-ca1f3e8775a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfOS0zLTEtMS01MDI5OQ_90f8d58c-4a42-47ea-b10c-a0e9d8f6ceb4">734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea3e0212f024a4cb925e63dc3d63669_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfMi0xLTEtMS01MjkwNA_bfc2ead3-63f5-49aa-94ce-2770de7f59ee">42,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f2571b77c148eba97976fcd4e2bcf2_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfMi0zLTEtMS01MjkwNA_e1f62b24-9e74-4645-a216-b5f32bf720b7">10,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a6977963ca49b586c2fcf93713da7b_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfMi0xLTEtMS01MDI5OQ_2b223fed-000a-4e52-b23a-21b1af07bb2f">74,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7607171276ef40a8b48df3ab23ab716e_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfMi0zLTEtMS01MDI5OQ_9deb5958-e36f-43e9-a334-7e1a2e6e32c9">25,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8255e04a5a48e69c16aa566c4151bc_D20220401-20220630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNS0xLTEtMS01MjkxMg_1a6f2eba-f6fb-414e-b1ed-41e64411cd2c">36,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fac99680e9547b89140b689b06a4952_D20210401-20210630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNS0zLTEtMS01MjkxMg_52a9d51a-fff3-4723-89b1-530e520e8af9">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e7ef4ce9c44edb84ead5d40559f606_D20220101-20220630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNS0xLTEtMS01MDI5OQ_7ae79548-897e-4cd2-839b-8b9d8f7735c0">63,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib07e032acadb4ab4aeff1fa0375c42f0_D20210101-20210630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNS0zLTEtMS01MDI5OQ_31e04fe2-be59-413f-947b-2c75708ceb4f">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2e5a89677e4a3694479947d5a435a8_D20220401-20220630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNi0xLTEtMS01MjkxMg_2560f4e2-d5bc-4695-8eb0-51a69294d256">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7295fdf6eb154c00992c57534af23daa_D20210401-20210630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNi0zLTEtMS01MjkxMg_e9a8c4ee-30bd-49c5-9f8d-82067b026d39">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adf3c79b7f64f2aa0af3af80b0553b1_D20220101-20220630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNi0xLTEtMS01MDI5OQ_5939fc19-75c3-4aa1-bbe0-44703288b3a7">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0464c31a82d4d04b71913910715453f_D20210101-20210630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNi0zLTEtMS01MDI5OQ_9dc25e64-bd19-4973-afcb-3160acc5c159">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19. <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90ZXh0cmVnaW9uOjRhNTE4YzAxMzY0NDQwNDlhZTc2OTQxNjZjYWM2M2ZjXzE0NjQ_7ac306aa-b076-491d-9185-4d8d79dd4b56" continuedAt="iad97e1844ce84bcba8e12b8e641032a7" escape="true">Repositioning and Other Changes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iad97e1844ce84bcba8e12b8e641032a7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90ZXh0cmVnaW9uOjRhNTE4YzAxMzY0NDQwNDlhZTc2OTQxNjZjYWM2M2ZjXzE0NjU_c38c5884-d9d7-4322-8df3-adb38c61219c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Costs Incurred through December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d215ef7e89344058608e5d4f9363124_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzEtMS0xLTEtNTAyOTk_d707bd56-0b90-4555-bb92-c1025b9937bd">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f163348ee8540d09c2f6ee2944703fc_D20210401-20210630" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzEtMy0xLTEtNTI5NDQ_1f3c159d-a688-4e53-8d85-49f884bf44e4">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e3a1495b5e04e5b850b1f4ce62855aa_D20210101-20210630" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzEtMy0xLTEtNTAyOTk_b3eede6e-7766-4e14-883b-11103e61d846">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1caf080cfaca42c29144aff3c13b93b6_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzItMS0xLTEtNTAyOTk_d6dc5ef1-9b01-4f91-b7c3-c2e1052063b2">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4a298cd056483f927ffa2a3469d4ee_D20210401-20210630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzItMy0xLTEtNTI5NDQ_92169361-78fa-44d6-a6e3-ae46e396c7d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2548e4d1f3694bce8967d2081c947aac_D20210101-20210630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzItMy0xLTEtNTAyOTk_5eb32a9e-e04f-4bba-a507-892ffb897ab2">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3b51310ab149b399238bbc8da2f487_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzMtMS0xLTEtNTAyOTk_eac7494c-9891-4d41-a747-c6888ddb1ed9">5,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f99af9f1bbe4f909c3d4ea820bf365b_D20210401-20210630" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzMtMy0xLTEtNTI5NDQ_34d15161-cde9-4cdb-a999-72ad47b3330f">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67189557a7ea47dfa0d97556d16c7c5a_D20210101-20210630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzMtMy0xLTEtNTAyOTk_fe9e0a82-3b3b-416d-9cfe-76ade5f9a6ee">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzQtMS0xLTEtNTAyOTk_8a6e2576-67c1-4565-b216-8102a27ec6ca">8,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzQtMy0xLTEtNTI5NDQ_c3cc0a60-1b5a-4d5d-878e-0bb32b2b2919">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzQtMy0xLTEtNTAyOTk_28520f8d-afea-4bc1-af91-2dc020bbb843">6,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 20. <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzI5NjY_074b5994-ac19-47b0-a870-f95c6087fe63" continuedAt="ibd73b8eaf8a14433a9fa4b38f8e5b554" escape="true">Segment Reporting</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibd73b8eaf8a14433a9fa4b38f8e5b554" continuedAt="i7d7c202eae7d43eea0112a88eaa96805">We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into <ix:nonFraction unitRef="segment" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzI0Mg_ea8ff5c0-1fc6-4886-888a-affa345b570f">two</ix:nonFraction> reportable segments as follows:</ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i7d7c202eae7d43eea0112a88eaa96805" continuedAt="id633a158fcad4c7a818d45394f2f7aa5"><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, provision for income taxes, depreciation and amortization expenses, adjusted to exclude gain on transfer of membership, loss on repayment of debt, net, gain from equity method investees, changes in fair value of contingent consideration, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain from discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzI5NjI_d1066ebf-bd41-4171-8142-7d501c5f9a2d" continuedAt="ic9964e07d0b040158fe89799322c3b01" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d5e516649a4eb1bd68a4ae83bd5e16_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtMS0xLTEtNTI5NTE_9efc4d84-5498-4996-bf75-3d69ad8dab7a">92,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i420c2960b8964c268e95e8eda2a47790_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtMy0xLTEtNTI5NTE_088bcd24-1b06-4b94-981d-d000541ff06d">227,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f83964678a340d8a8a7893bffb76713_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtNS0xLTEtNTI5NTE_55863b14-3a78-4916-8158-bec29bb63965">460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad7b61e97de4695ab5cc762df1bab8d_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtNy0xLTEtNTI5NTE_ad764486-a775-46ee-b618-4cc237f33dc0">319,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4cc0b519ac4301afbf3a86f9d1a16f_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtOS0xLTEtNTI5NTE_1fc23232-56bb-4863-9893-018b8551029b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtMTEtMS0xLTUyOTUx_99a26b99-75b4-46d1-af72-214a7ed3ceb0">319,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5fd05553c104209a219f91c15de897b_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtMS0xLTEtNTI5NTE_0c50224a-da2b-4115-be42-209104d4986f">75,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e90bde16c38406cb0456caf29ecea2a_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtMy0xLTEtNTI5NTE_b809e6dc-a227-4fb5-8ecb-bf810b7d39d0">147,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1fd13e0887f4184bc87321d513724b5_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtNS0xLTEtNTI5NTE_d5558f61-051b-47d6-bffc-b8c821cefe9b">460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ace05961a24c8aad395abf32e9e34e_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtNy0xLTEtNTI5NTE_29a24886-298a-4731-89ea-37a0852041d0">222,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia437c1047b404319a8f7f650e06e4e90_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtOS0xLTEtNTI5NTE_952135f7-eeef-43df-8857-d14e0b6afd3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtMTEtMS0xLTUyOTUx_3e2ca088-e538-46e3-b59e-ab3b69044f08">222,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d5e516649a4eb1bd68a4ae83bd5e16_D20220401-20220630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEwLTEtMS0xLTUyOTUx_8febdcbf-ca08-45fe-afbf-e15d0ad865ff">15,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i420c2960b8964c268e95e8eda2a47790_D20220401-20220630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEwLTMtMS0xLTUyOTUx_a48400dc-2f00-43ee-aff9-aac720bfa4a8">13,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad7b61e97de4695ab5cc762df1bab8d_D20220401-20220630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEwLTUtMS0xLTUyOTUx_2d987c30-98c5-44f2-b47f-ee4bda19675f">28,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4cc0b519ac4301afbf3a86f9d1a16f_D20220401-20220630" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEwLTctMS0xLTUyOTUx_9fd9c01e-3e6b-492f-8769-edf45abdb44a">6,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEwLTktMS0xLTUyOTUx_a4096d23-a26a-4399-898e-12323b9c9d9c">21,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5fd05553c104209a219f91c15de897b_D20210401-20210630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEzLTEtMS0xLTUyOTUx_eda7b58a-8688-4de4-a41a-34682781e957">6,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e90bde16c38406cb0456caf29ecea2a_D20210401-20210630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEzLTMtMS0xLTUyOTUx_5ba4a561-8507-464b-b383-58df7ef8aa66">13,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ace05961a24c8aad395abf32e9e34e_D20210401-20210630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEzLTUtMS0xLTUyOTUx_05b678f6-e645-43b8-9e5f-66be286923ee">20,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia437c1047b404319a8f7f650e06e4e90_D20210401-20210630" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEzLTctMS0xLTUyOTUx_2b4c03a4-e3fc-4097-b896-1ca9b2ba3bdd">6,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEzLTktMS0xLTUyOTUx_be0e5b47-b08d-4a29-8870-7153f4d941e1">13,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8546f2bf902a41be9774135aea47d11d_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtMS0xLTEtNTAyOTk_3d96b1da-420f-461d-8384-779e76e9f484">200,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09d7524a42e2444db7f04130d8c7e586_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtMy0xLTEtNTAyOTk_c7d435ea-fab1-4a2d-b9ab-b7d874845804">417,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c79847ac9a6406dbd571e7e8285c8ab_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtNS0xLTEtNTAyOTk_5691460b-bc2c-439e-993c-98c0a5310b0c">920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88d244c079c44a6a96afafc4dd811c7_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtNy0xLTEtNTAyOTk_0897a6e7-9ba3-448b-993f-abd496eb9e96">616,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc490f2a102c40368f57f3b421851b0d_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtOS0xLTEtNTAyOTk_bd0e378b-7846-423e-a0d3-d411bb8bad27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtMTEtMS0xLTUwMjk5_2fbfe452-05ee-4c08-82b9-41febb8afe13">616,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fb402086e24b79a85a9f5d622bf485_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtMS0xLTEtNTAyOTk_2604bcb6-c17d-4a54-9e1c-86c363b4408b">160,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d9d012a2bb4aea8bee56c1bbb1747d_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtMy0xLTEtNTAyOTk_cc0cf26c-c9fe-4012-9e87-c3104f2dc382">277,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea87c5d05fc147deb58c839bf401c1ee_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtNS0xLTEtNTAyOTk_be621d1e-9ba5-4e31-b91a-0c243425899e">898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371114cbc06e4f95811ba2a6fec0c8b1_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtNy0xLTEtNTAyOTk_6a332264-9e1e-4a28-91f4-65444268be42">437,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7734adf1b5e6413988815cac05b34700_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtOS0xLTEtNTAyOTk_7f8889b6-0f51-4d90-a754-40e4f3d3eab9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtMTEtMS0xLTUwMjk5_a0d9bd8c-8222-4ab2-982b-d629dbc8043b">437,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id633a158fcad4c7a818d45394f2f7aa5"><ix:continuation id="ic9964e07d0b040158fe89799322c3b01"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8546f2bf902a41be9774135aea47d11d_D20220101-20220630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEwLTEtMS0xLTUwMjk5_16c5d46e-428b-4e73-9a94-8267f771bd6e">23,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09d7524a42e2444db7f04130d8c7e586_D20220101-20220630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEwLTMtMS0xLTUwMjk5_3c02fed6-8f01-4110-95ed-b47ed9099e01">35,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88d244c079c44a6a96afafc4dd811c7_D20220101-20220630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEwLTUtMS0xLTUwMjk5_50c8ca54-5495-4642-b18b-95dd668c4b2d">59,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc490f2a102c40368f57f3b421851b0d_D20220101-20220630" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEwLTctMS0xLTUwMjk5_680393ed-3445-4f00-b98a-fcbbc8830688">13,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEwLTktMS0xLTUwMjk5_4320ab89-85af-4a1e-8e1a-4712d03cfb84">45,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fb402086e24b79a85a9f5d622bf485_D20210101-20210630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEzLTEtMS0xLTUwMjk5_06aedd4c-052f-460c-8be4-44e2d96f17ed">12,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d9d012a2bb4aea8bee56c1bbb1747d_D20210101-20210630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEzLTMtMS0xLTUwMjk5_436a96b1-5290-4a2a-b465-c6a4c7967954">29,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371114cbc06e4f95811ba2a6fec0c8b1_D20210101-20210630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEzLTUtMS0xLTUwMjk5_522e913b-e882-4089-926b-3d3044d9fe79">42,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7734adf1b5e6413988815cac05b34700_D20210101-20210630" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEzLTctMS0xLTUwMjk5_f7fff6e6-e223-4522-ab11-e4a1eb31d701">13,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEzLTktMS0xLTUwMjk5_2fdca9bf-61a5-4147-af25-4b89f22f52c5">28,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzI5NjQ_bb5b32d9-3412-459a-a73a-fc09e9a59c4a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzItMS0xLTEtNTMyMzk_cc213c14-3485-4229-9627-772858bfc410">4,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzItMy0xLTEtNTMyMzk_2e5a2638-28b7-4be9-bc89-849549bbd62f">9,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzItMS0xLTEtNTAyOTk_35c29167-bfc8-431f-bc19-c021b9e5b3af">9,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzItMy0xLTEtNTAyOTk_67c6aeb8-8768-492a-9be9-1099e3470074">18,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzQtMS0xLTEtNTMyMzE_2c7fd4da-bb62-4abb-9676-bf6e03061de5">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzQtMy0xLTEtNTMyMzE_7b510061-fa90-4fb2-820a-c4476c72997d">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzQtMS0xLTEtNTAyOTk_9ed4b197-f83e-4d92-815e-3fddd284bbf2">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzQtMy0xLTEtNTAyOTk_998de72e-3c0e-4f7d-b16e-3de00f34c7f5">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzUtMS0xLTEtNTMyMzQ_980c785f-3c41-445c-9809-39e58c413668">2,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzUtMy0xLTEtNTMyMzQ_5026a581-73b2-4241-855f-42be1cae8d0f">6,274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzUtMS0xLTEtNTAyOTk_0c3d52c5-b7b9-45e7-ae6c-7dd6f31caff6">4,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzUtMy0xLTEtNTAyOTk_401ee9f4-268f-4d3a-8c26-8fe27b390a55">12,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzYtMS0xLTEtNTMyMzk_66dd00e9-c04f-453c-95bc-22432f9a75f8">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzYtMy0xLTEtNTMyMzk_7dd863b1-f5ca-44ce-bd61-52ed55a927b0">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzYtMS0xLTEtNTAyOTk_11c29d80-a1c8-45ea-b0cb-1a5b678a0b27">1,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzYtMy0xLTEtNTAyOTk_63bb37ef-d4f8-488b-bbc7-7507776a72e0">702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzctMS0xLTEtNTMyMzk_0715d8c0-e7ba-4997-aa52-09573ea189ee">15,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzctMy0xLTEtNTMyMzk_5a3fe96e-b7eb-4ef7-aec6-04003ac98363">14,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzctMS0xLTEtNTAyOTk_7057ea20-56d8-4bf0-a52b-5caac8aae476">30,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzctMy0xLTEtNTAyOTk_af4b36cb-861c-4abf-87ff-4f03ba71f03f">30,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzgtMS0xLTEtNTMyMzk_3ecc4a78-5768-4e5e-816b-21e3be1e78db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzgtMy0xLTEtNTMyMzk_427f193e-ecb5-4d44-9892-db3a842c6a53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzgtMS0xLTEtNTAyOTk_1cd5fd02-bbbe-41c4-8831-3e3f4bdea02d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzgtMy0xLTEtNTAyOTk_88fb5ad4-66d9-4259-b11e-0dfcfe101bcd">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzktMS0xLTEtNTMzMDA_fc041e4c-30b9-4996-8a3d-b8358cc94cfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzktMy0xLTEtNTMzMDA_9d0bd75b-408f-4b3c-8ccb-9216f002ceeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzktMS0xLTEtNTAyOTk_a54e5c91-07b7-409d-8b3e-9f16475d7d64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzktMy0xLTEtNTAyOTk_35fcb3b2-7cba-43c6-bb2a-efcb8d3fe9c5">19,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEwLTEtMS0xLTUzMzM3_2902be53-35ef-48e4-8bc9-4f8875ecb8cb">1,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEwLTMtMS0xLTUzMzM3_29a0ffc1-0f7a-4e23-a4fe-2883bb139a85">4,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEwLTEtMS0xLTUwMjk5_01ffc85d-0b83-496b-8982-45c609240fed">2,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEwLTMtMS0xLTUwMjk5_d6e4c085-c84a-45a2-8a48-8eafcfc03ffc">12,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzExLTEtMS0xLTUzMzQw_9eb1296c-520e-41ee-9edf-9ee7b6a5522b">800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzExLTMtMS0xLTUzMzQw_5fe0f31e-f718-482e-90bf-f91947e14334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzExLTEtMS0xLTUwMjk5_502c4160-241f-488e-b645-70172553b590">6,878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzExLTMtMS0xLTUwMjk5_b1609b05-9078-461b-be8e-b672e74b7a15">594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEyLTEtMS0xLTUzMzQw_e3ff43bc-1cb8-4632-a14f-a6870cb0bb5d">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEyLTMtMS0xLTUzMzQw_3835ff58-94e7-4018-ad0c-6e0b96383133">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEyLTEtMS0xLTUwMjk5_d6d08bd6-be7b-4906-8d40-43287dba1e9b">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEyLTMtMS0xLTUwMjk5_dc7f8f85-3401-43eb-91de-d20545bf982a">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEzLTEtMS0xLTUzMzQ3_8c581b50-ecaa-4d94-b788-93b791dcb713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEzLTMtMS0xLTUzMzQ3_f0282e9f-1bbc-4acc-8953-f1e44371f63a">663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEzLTEtMS0xLTUwMjk5_e32898b3-c64b-4a9e-ae87-10c5f3035c60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEzLTMtMS0xLTUwMjk5_7a4bcc22-d1b0-41e7-b778-afbea9073451">6,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE0LTEtMS0xLTUzMzQ3_da1826a5-e533-41fb-b401-abbfcd67ab15">7,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE0LTMtMS0xLTUzMzQ3_fe18f363-5800-4f31-b309-c2c6c0242af6">3,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE0LTEtMS0xLTUwMjk5_e81e5e6b-e627-4104-9676-cda3cb4c03e8">12,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE0LTMtMS0xLTUwMjk5_21f7146b-4e8d-4498-b5b8-08532aa6188f">7,359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE1LTEtMS0xLTUzMzQ3_e76ab99e-8f94-4f80-b333-2d962bb09b88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE1LTMtMS0xLTUzMzQ3_a9bd5e72-837d-4ad9-9a34-39311353b147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE1LTEtMS0xLTUwMjk5_67407af9-1b7d-4f9f-9ef6-1a3bf7f00e02">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE1LTMtMS0xLTUwMjk5_0a88f02e-ec2f-4013-bf18-aee079b2059c">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE2LTEtMS0xLTUzMzUy_5bc923af-9d8b-40bc-a814-ae91c917d4ba">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE2LTMtMS0xLTUzMzUy_44cd82d5-8167-4538-b3d1-683eec37010a">196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE2LTEtMS0xLTUwMjk5_132f0ca6-60dd-4acc-8dc2-0490e6bb611c">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE2LTMtMS0xLTUwMjk5_c15810be-18a4-4169-aa96-543654d3e20d">323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE3LTEtMS0xLTUzMzUy_ba597674-1e3d-4581-b90f-a8daa7480398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE3LTMtMS0xLTUzMzUy_037092ba-2735-4dd6-b99b-5a5cd1a7a697">1,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE3LTEtMS0xLTUwMjk5_a5c15502-8868-4b1b-886a-4e4386ebf414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE3LTMtMS0xLTUwMjk5_aa55592e-b88d-41a6-8b82-4ba6f56ed09b">6,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE4LTEtMS0xLTUzMzUy_ca6205d2-bd99-4248-b6ae-887ad513bc39">3,421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="evh:TransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE4LTMtMS0xLTUzMzUy_20d106e9-8abd-4782-854e-20acafb9a5b5">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE4LTEtMS0xLTUwMjk5_c65e4f87-13cd-4898-85aa-48c652da2084">3,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE4LTMtMS0xLTUwMjk5_dc73c194-1265-4cf5-8a65-41a4059c5068">2,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE5LTEtMS0xLTUzMzUy_1c1e0b3c-dbce-4509-964c-393e4c99508b">463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE5LTMtMS0xLTUzMzUy_679384c5-e3b3-404a-9eec-e971bd848e0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE5LTEtMS0xLTUwMjk5_23c4e756-3cd3-4239-a254-98f322b773e7">463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE5LTMtMS0xLTUwMjk5_31efc605-826b-4d74-9af9-2247336a237d">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzIwLTEtMS0xLTUzMjU5_bef75670-3ca8-4436-a25e-df532532d044">21,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzIwLTMtMS0xLTUzMjU5_d5376237-36de-465d-a314-3ccb414cce00">13,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzIwLTEtMS0xLTUwMjk5_d57d8e3f-d3bb-48e3-a135-80add91acf9f">45,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzIwLTMtMS0xLTUwMjk5_291b3509-71a1-45d1-93e1-c30a7ae4b1a8">28,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $(<ix:nonFraction unitRef="usd" contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzQ5NDc4MDIzMjc5OTE_26b2f69f-de74-4a2c-889b-a19ac36d8193"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzQ5NDc4MDIzMjc5OTE_4aca174c-29b5-4e14-b905-9f48320d20fd">0.5</ix:nonFraction></ix:nonFraction>)&#160;million loss on disposal of discontinued operations for the three and six months ended June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-5" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzI3NTQ_ac040d59-83f7-4884-9009-ebda27bd6d7b">1.9</ix:nonFraction>&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021, respectively.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_106"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 21. <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:InsuranceDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90ZXh0cmVnaW9uOjc5ZTg5ZjZhYzYxYzRjZWZiNjJmNGRmMGNjYjgxNGNlXzQ2MjU_a1d698b3-cd50-4547-bb6c-63c7440d341a" continuedAt="i66e97cd17d1647f5bdf71b2c15ef85bd" escape="true">Reserve for Claims and Performance-Based Arrangements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i66e97cd17d1647f5bdf71b2c15ef85bd" continuedAt="i133ad41102d949f5bf9beef0be91f854"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i133ad41102d949f5bf9beef0be91f854"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90ZXh0cmVnaW9uOjc5ZTg5ZjZhYzYxYzRjZWZiNjJmNGRmMGNjYjgxNGNlXzQ2Mjc_5c403cf5-27af-4bb8-b813-93f880fc6e82" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:226.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa8d21a22a84ccabb1b42d66a503b1c_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtMS0xLTEtNTAyOTk_90a62be0-8b88-4706-9d3d-022fb6866e32">25,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744902b106114f94aaf10f93f79da793_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtMy0xLTEtNTAyOTk_572cb2e2-e9b5-4695-87a4-b2dad2e0af96">145,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtNS0xLTEtNTAyOTk_800cafb5-cb7f-4887-abbe-1f6996b244ea">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab714214aec4c62895368e7b5d77d47_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtNy0xLTEtNTAyOTk_32ef35ac-4a75-46c9-b789-60c98c6a6af9">56,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb91a25096ac488099c2f68651d8104a_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtOS0xLTEtNTAyOTk_5d63823e-1fdd-4956-aa3a-cd2222024782">122,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtMTEtMS0xLTUwMjk5_3211d48d-8a34-4f3e-8890-403dcc29ad66">178,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtMS0xLTEtNTAyOTk_02aa8c8e-5a2b-491b-99b1-c83e8ce41144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtMy0xLTEtNTAyOTk_6317709c-ff6a-495c-bd70-692819b787a6">246,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtNS0xLTEtNTAyOTk_d92ea550-cec2-4f10-a24e-7c8275a46677">246,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtNy0xLTEtNTAyOTk_ce67632c-208f-446a-9ee9-bdaa4dfd3b32">8,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtOS0xLTEtNTAyOTk_ca043789-fe0e-4819-a447-f9500547d70f">219,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtMTEtMS0xLTUwMjk5_5e50ef38-4949-4f8d-8168-2a4324b2a38c">228,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtMS0xLTEtNTAyOTk_7eb1c7c5-7ffc-4f1f-9f05-636991190612">10,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtMy0xLTEtNTAyOTk_fc788ab4-8f46-4007-9d24-1f9aa938c631">32,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtNS0xLTEtNTAyOTk_e325d42d-0e0e-44ae-9c5a-f318791324bb">22,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtNy0xLTEtNTAyOTk_8cf6749c-991d-40ab-8177-554f94ea1af2">6,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtOS0xLTEtNTAyOTk_3d4a8ec0-eadf-4fc8-b1b2-0328619b89e7">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtMTEtMS0xLTUwMjk5_bd1c2178-59a9-44cb-9f71-5e7161f7b63d">6,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtMS0xLTEtNTAyOTk_3a5741e3-e1bc-428b-a076-5b412be5d071">1,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtMy0xLTEtNTAyOTk_815da677-4de7-4ef5-852c-6a3a07444646">202,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtNS0xLTEtNTAyOTk_51a93bfc-3b9b-47e9-a5a6-c13efbe24211">201,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtNy0xLTEtNTAyOTk_b2bc7a08-f80f-4cc2-ae50-002e4ce3ada8">20,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtOS0xLTEtNTAyOTk_08d3f6a3-c569-4c48-8343-61fb9eb7ff68">73,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtMTEtMS0xLTUwMjk5_68d662e4-0e61-4cf3-af36-275d217cc483">94,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktMS0xLTEtNTAyOTk_d516ee40-4e7b-445b-a86d-3bde0caabd24">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktMy0xLTEtNTAyOTk_37839752-a333-484f-9106-8947df78c23b">100,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktNS0xLTEtNTAyOTk_90b850a0-91b4-46d4-97f7-7ea1ca868132">101,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktNy0xLTEtNTAyOTk_87acf920-bace-4ec5-86f1-62cf80b84b8e">20,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktOS0xLTEtNTAyOTk_e415d08d-252e-4b84-870e-f35ba87fbdca">71,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktMTEtMS0xLTUwMjk5_27dad9ba-f824-449d-945c-741d9210d9d0">92,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTEtMS0xLTUwMjk5_7a4719f1-f208-488f-9f40-d823a4908f8b">9,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTMtMS0xLTUwMjk5_c6f21202-d92d-47e2-9e5a-aff20dcb065b">23,774</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTUtMS0xLTUwMjk5_8293c40d-319d-4d07-99f6-3984b07538b7">33,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTctMS0xLTUwMjk5_7bcc252e-4b16-474f-87be-fddbc4449c32">26,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTktMS0xLTUwMjk5_c8086e80-189e-4af5-96b9-5d5a53a612c2">74,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTExLTEtMS01MDI5OQ_1b1482e3-e163-4071-ad1b-28b0b82085a2">48,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on reserves for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTEtMS0xLTUwMjk5_e7a2e5b4-f444-4462-93ae-d9aa1e9f8195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTMtMS0xLTUwMjk5_13fb9760-bde2-4bbc-b9ba-949157a6e101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTUtMS0xLTUwMjk5_341730e4-f96f-4188-86ed-127b62a54014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTctMS0xLTUwMjk5_83c008fd-e9dc-4394-92e7-be2421c6d8e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTktMS0xLTUwMjk5_de14749c-c2f5-4c13-addd-c06135efcae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTExLTEtMS01MDI5OQ_374b6177-2427-4b02-a011-45e4726d7950">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31ec6c709d854ece8b361ce8b9f623c6_I20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTEtMS0xLTUwMjk5_55bf0af2-6556-41d3-8ee6-0a737a62679b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7021225a1d4ebe992272c6b7a424f3_I20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTMtMS0xLTUwMjk5_32cf63d5-d633-4616-a018-d91fa9c2713c">12,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTUtMS0xLTUwMjk5_025cb042-2489-4f33-ac44-f4ebc4ecda37">12,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id929ac4578254f3a8ac5a00ef4adae72_I20210630" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTctMS0xLTUwMjk5_25bc5c02-6267-4911-ae4d-b932beec99dd">3,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47bf34c04d3d4427a895561238e93dfb_I20210630" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTktMS0xLTUwMjk5_bd581c09-08c0-488e-89b8-693b486ae594">7,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTExLTEtMS01MDI5OQ_c8a58054-36a9-40d2-bd41-9ed4da22acf4">11,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31ec6c709d854ece8b361ce8b9f623c6_I20220630" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTEtMS0xLTUwMjk5_94583ad5-b329-49e2-a215-c86f9ff8c40c">16,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7021225a1d4ebe992272c6b7a424f3_I20220630" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTMtMS0xLTUwMjk5_4f440c04-4cba-4f8e-bc30-115d6b6aef1e">109,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTUtMS0xLTUwMjk5_9e1997c5-8d51-4faa-89c2-2ae1d2217893">125,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id929ac4578254f3a8ac5a00ef4adae72_I20210630" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTctMS0xLTUwMjk5_e2eb7c74-e189-4531-ae60-71b43b9dcf6b">33,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47bf34c04d3d4427a895561238e93dfb_I20210630" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTktMS0xLTUwMjk5_5b4d5c61-cb4a-4c2d-8ec0-11ffc90f0f04">204,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTExLTEtMS01MDI5OQ_74a5e3b0-1d9f-421f-baa7-28c01285cd5f">238,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_109"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 22.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90ZXh0cmVnaW9uOmQyMDViODgzZjRkYTQxYTE4ZDM3Y2JhNjVhN2I4YTdjXzEyOQ_51cf746e-bcdc-49be-aa48-0d830f8af7d0" continuedAt="i6bd1e0487d6441619d4e04f757fb35a5" escape="true">Supplemental Cash Flow Information </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6bd1e0487d6441619d4e04f757fb35a5"><ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90ZXh0cmVnaW9uOmQyMDViODgzZjRkYTQxYTE4ZDM3Y2JhNjVhN2I4YTdjXzEzNA_ba53b09b-e755-45fc-bcfd-21e3b7fd8d57" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzMtMS0xLTEtNTAyOTk_0d463669-6025-47ca-b28c-6b59dcc736b1">1,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzMtMy0xLTEtNTAyOTk_08a99189-6f4a-4b95-a39d-fc91164baabb">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzUtMS0xLTEtNTAyOTk_c0e86b98-ccc2-4774-b784-b9884afdd742">7,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzUtMy0xLTEtNTAyOTk_91a8818d-5931-4119-8c42-fcecae50e1b8">6,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" decimals="-3" sign="-" name="evh:RightOfUseAssetAcquiredAndDisposedOf" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzYtMS0xLTEtNTAyOTk_5567e95a-17a8-4c51-b75e-90d8286adb1a">4,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630" decimals="-3" name="evh:RightOfUseAssetAcquiredAndDisposedOf" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzYtMy0xLTEtNTAyOTk_f8f888d7-9198-4389-805f-1695db18fa87">2,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_256"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 23.  <ix:nonNumeric contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzUz_b8ab9334-4198-44aa-8e62-13b31dba9cd2" continuedAt="i8ebf2b1ed01440fcada3b7a67d282fc8" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8ebf2b1ed01440fcada3b7a67d282fc8" continuedAt="i588687b7c1c34cb69795c7cc47de1ad8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of  IPG</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company, Evolent Health LLC, and Endzone Merger Sub, Inc, entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with TPG Growth Iceman Parent, Inc., and TPG Growth V Iceman, L.P. to acquire Implantable Provider Group, Inc. (&#8220;IPG&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i748aee67f29648e5bcea7fa5140a470e_D20220801-20220801" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQ5NDc4MDIzMzYwOTY_47aad6d6-eb26-453f-8827-6c3e333eab88">250.0</ix:nonFraction> million in cash and $<ix:nonFraction unitRef="usd" contextRef="i748aee67f29648e5bcea7fa5140a470e_D20220801-20220801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQ5NDc4MDIzMzYxMTg_087413c0-2fae-4444-a8cf-56c49a786153">125.0</ix:nonFraction>&#160;million in Class A Common Stock of the Company, together with a potential earnout of up to $<ix:nonFraction unitRef="usd" contextRef="i748aee67f29648e5bcea7fa5140a470e_D20220801-20220801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ4OTIxMjQ_b157682f-c1f6-42d8-87fd-834c3dae9eb0">87.0</ix:nonFraction>&#160;million  payable in in cash and shares of Class A Common Stock of the Company in 2023. On August 1, 2022, the transactions contemplated by the Merger Agreement were consummated and the Company issued <ix:nonFraction unitRef="shares" contextRef="ie583be11220d441c9171d7d8b813691e_D20220801-20220801" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ4OTQ0Nzg_5a9a0f6f-ae9e-4391-b109-5f695d5b1bfa">3.7</ix:nonFraction>&#160;million shares of Class A Common Stock in connection therewith. IPG will report into Evolent&#8217;s specialty care management offering, New Century Health, and will be consolidated into the Company&#8217;s Clinical Solutions segment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ares Secured Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022 (the &#8220;Closing Date&#8221;), the Company entered into a Credit Agreement, by and among the Company, Evolent Health LLC (&#8220;Evolent&#8221;), Endzone Merger Sub, Inc. (&#8220;Endzone&#8221; or &#8220;Initial Borrower&#8221;), which upon consummation of the transactions contemplated by the Merger Agreement will be merged with and into TPG Growth Iceman Parent, Inc., Implantable Provider Group, Inc. (&#8220;Implantable&#8221;, collectively with Evolent, Endzone and TPG Growth Iceman Parent, the &#8220;Borrowers&#8221; and each a &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, Ares Capital Corporation, as administrative agent, and ACF Finco I LP, as collateral agent and as revolver agent (the &#8220;2022 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrowers in the form of (i) an initial term loan in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i26ac2d191e26480fa87349b7a8290bde_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ4OTIxMzk_ba610eab-06b3-4d8d-bb7d-5d224fe56aef">175.0</ix:nonFraction>&#160;million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a revolving credit facility in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i0b9cc6fdb0d444239ea5b97cef38f068_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDc3OTQ_ac346b14-8db5-44e8-9494-920a3c78b7b4">50.0</ix:nonFraction>&#160;million, to be determined by reference to the lesser of $<ix:nonFraction unitRef="usd" contextRef="i0b9cc6fdb0d444239ea5b97cef38f068_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDc4MjM_ac346b14-8db5-44e8-9494-920a3c78b7b4">50.0</ix:nonFraction>&#160;million, to be determined by reference to the lesser of $<ix:nonFraction unitRef="usd" contextRef="i0b9cc6fdb0d444239ea5b97cef38f068_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ5MjEyMzY_534a2546-dcb4-49f7-a074-a201236f7ac8">50.0</ix:nonFraction>&#160;million and a borrowing base (the &#8220;Revolving Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;2022 Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the Initial Term Loan Facility on August 1, 2022 (the &#8220;Initial Term Loan&#8221;), and also borrowed $<ix:nonFraction unitRef="usd" contextRef="i244a3a3fba544622b797356979f8025f_D20220801-20220801" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ5MjEyNTE_c01588a2-46d3-42e1-b80d-677c1e2be780">50.0</ix:nonFraction>&#160;million under the Revolving Facility on the Closing Date. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2022 Credit Agreement, on August 1, 2022, the Company entered into a Security Agreement, by and among the Company, the Borrowers, the other guarantors and the collateral agent for the benefit of the secured parties and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The proceeds of the Initial Term Loan may be used to fund ongoing working capital needs and other growth capital expenditure investments, and to finance the transactions contemplated by the Merger Agreement and fund fees and expenses incurred in connection therewith. The proceeds of the Revolving Facility may be used to finance the transactions contemplated by the Merger Agreement and to pay fees and expenses incurred in connection therewith on the Closing Date and thereafter to fund acquisitions, ongoing working capital needs and other growth capital investments and to pay fees and expenses in connection therewith.  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Initial Term Loan and loans under the Revolving Facility will mature on the date that is the earliest of (a) August 1, 2027, (b) the date on which all amounts outstanding under the 2022 Credit Agreement have been declared or have automatically become due and payable under the terms of the 2022 Credit Agreement and (c) the date that is ninety-one (<ix:nonFraction unitRef="day" contextRef="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ5MjE0ODE_10328e97-ed3e-4a65-928c-ed23f66685ea">91</ix:nonFraction>) days prior to the maturity date of any Junior Debt (as defined in the 2022 Credit Agreement) unless certain liquidity conditions are satisfied.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest and Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The interest rate for each loan under the 2022 Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the 2022 Credit Agreement) plus <ix:nonFraction unitRef="number" contextRef="i47af930ce9a049169a33fecd6da9992c_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDc4Mzg_49cbac04-b86d-4492-b13a-7b64cfab70a5">5.50</ix:nonFraction>%, or the base rate plus <ix:nonFraction unitRef="number" contextRef="i2065d4ade06445edb3d844c8ae917420_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3MDU_8d9c3259-5a62-4955-ae88-2e7a923cf760">4.50</ix:nonFraction>% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus <ix:nonFraction unitRef="number" contextRef="i151d150fd9d24075af69e985884cae3a_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDc5MTE_c9039cfc-e6ce-4d1b-af98-11ed44802559">3.50</ix:nonFraction>%, or the </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i588687b7c1c34cb69795c7cc47de1ad8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">base rate plus <ix:nonFraction unitRef="number" contextRef="id5ea489e80dc4ac28fa3620d03b1c6d0_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ5MjE0NzQ_b7174475-b5c7-484b-8d5c-0052442c94a3">2.50</ix:nonFraction>%. A commitment fee of (a) <ix:nonFraction unitRef="number" contextRef="i0379117a2c6c4cab9b19860640687c97_D20220801-20220801" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3MTI_7270dbb6-6732-4be0-845c-8ecc6d0112e1">2.00</ix:nonFraction>% per annum of the aggregate amount of the commitments in respect of the Term Loan Facility as of the Closing Date and (b) <ix:nonFraction unitRef="number" contextRef="i244a3a3fba544622b797356979f8025f_D20220801-20220801" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3MjM_49af092f-1e9c-461a-bf4a-855a21e5b1b2">2.00</ix:nonFraction>% of the aggregate amount of the commitments in respect of the Revolving Facility as of the Closing Date is payable by the Borrowers quarterly in arrears.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepayment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts outstanding under the Credit Facility may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) <ix:nonFraction unitRef="number" contextRef="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3MzE_3679774c-631f-491f-b05c-db8aa48f52c7">3.00</ix:nonFraction>% of the principal amount so prepaid after the Closing Date but prior to the first anniversary of the Closing Date; (2) <ix:nonFraction unitRef="number" contextRef="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3Mzk_e441107d-1b1d-4beb-af36-777c66d378b4">2.00</ix:nonFraction>% of the principal amount so prepaid after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date; (3) <ix:nonFraction unitRef="number" contextRef="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3NDc_2787fc96-f919-4cb0-8ffb-bf2037ce4912">1.00</ix:nonFraction>% of the principal amount so prepaid after the second anniversary of the Closing Date but prior to the third anniversary of the Closing Date; and (4) <ix:nonFraction unitRef="number" contextRef="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3NTU_d7f0219a-36a3-4e62-84d6-2ee496c3074d">0.00</ix:nonFraction>% of the principal amount so prepaid on or after the third anniversary of the Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees and Collateral.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The 2022 Credit Facilities are guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain exceptions. The 2022 Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain exceptions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenants and Other Provisions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The 2022 Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum liquidity test commencing upon closing of the 2022 Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending September 30, 2022. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the 2022 Credit Facilities.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_112"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand the Company&#8217;s financial condition and results of operations. The MD&amp;A is provided as a supplement to, and should be read in conjunction with our consolidated financial statements and the accompanying notes to consolidated financial statements presented in &#8220;Part I &#8211; Item 1. Financial Statements&#8221; of this Form 10-Q; our 2021 Form 10-K, including the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;; and our current reports on Form 8-K filed in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_115"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_118"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a market leader in the new era of value-based care, in which the delivery of health care is increasingly funded by at-risk payment models.  We provide integrated solutions to both health care providers, including independent physicians and health systems, as well as payers, including health plans and other risk-bearing organizations, with a common end: to improve health care quality and outcomes while reducing cost. We consider value-based care to be the necessary convergence of health care payment and delivery. We believe the pace of this convergence is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and managed Medicaid, and innovation in data and technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were an early innovator in value-based care, founded in 2011 by members of our management team, UPMC, an integrated delivery system based in Pittsburgh, Pennsylvania, and The Advisory Board Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our operations and allocate resources across two reportable segments: Evolent Health Services and Clinical Solutions. The Company&#8217;s EHS segment provides an integrated administrative and clinical platform for health plan administration and population health management. Our Clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for Specialty Care Management in Oncology and Cardiology and holistic Total Cost of Care improvement. Our economic opportunity in the Clinical Solutions segment, which we believe to be significant, is largely based on (a) the total amount of medical expenses under management, and (b) the amount of savings we are able to generate relative to a benchmark or target. These partnerships, which we refer to as performance-based arrangements, include both capitation and shared savings arrangements. We also generate Clinical Solutions revenue by providing our technology and services platform on a fee basis. We go to market for our Specialty Care Management under the brand name New Century Health, and for our Total Cost of Care solution under the brand name Evolent Care Partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue is recognized in the United States and substantially all of our long-lived assets are located in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred operating losses since our inception, in part because we have invested heavily in resources to support our growth. We intend to invest aggressively in the success of our partners, expand our geographic footprint and further develop our capabilities. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health&#8217;s Response to COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the services we provide and market dynamics in our end markets and with our significant customers, to date the COVID-19 pandemic has not materially impacted our financial condition, the results of operations, or our outlook. As of June&#160;30, 2022, we had cash and cash equivalents of $193.1 million and as of the date the financial statements were available to be issued, we believe our current cash balance is sufficient to meet our liquidity needs for the next twelve months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has also affected global access to capital and caused significant volatility in financial markets. In addition, we have and are experiencing varying levels of inflation resulting in part from higher labor costs. Significant deterioration of the U.S. and global economies or rapid increases in inflation could have an adverse impact on our future liquidity needs. Although the impact </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the COVID-19 pandemic on our business has not been severe to date, the long-term impact of the pandemic on medical costs (including in oncology and cardiology), our partners and the global economy is uncertain and will depend on various factors, including the scope, severity and duration of the pandemic, including resurgence of COVID-19 cases due to more contagious variants such as Omicron and the effectiveness of vaccines. A prolonged economic downturn or recession resulting from the pandemic could adversely affect many of our partners which could, in turn, adversely impact our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent&#8217;s focus throughout this pandemic has been the health and safety of its employees and their families, as well as ensuring that we continue to furnish uninterrupted high-quality service to our partners. Evolent has deployed a multi-faceted response to COVID-19, overseen by its Emergency Preparedness Team, led by the General Counsel, Chief Compliance Officer and Chief Talent Officer, that focuses on maintaining its workforce in a manner that does not disrupt service delivery or operations. Evolent is closely monitoring and overseeing any issues of noncompliance or deficiencies with client operational service level agreements and continuing to review contractual business requirements in light of state and federal mandates, emergency laws and orders, and available financial support opportunities.  Evolent is also mindful of the impact COVID-19 has on its vendors and subcontractors and we will continue to work with them regarding our collective obligations to Evolent&#8217;s customers. We require a COVID-19 Business Continuity Attestation from subcontractors and vendors, confirming that operational and financial obligations will be met and aiming to ensure that privacy and security risks or incidents can be mitigated and disclosed in a timely manner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent has instituted a voluntary return to the office. Fully vaccinated employees and those who have provided an approved religious or medical exemption are permitted to return to the Company&#8217;s offices in-person.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Impact of COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In evaluating the impact of COVID-19 on our business, we considered, among other factors, the nature of the services we provide, end market trends and outlook and customer-specific trends. In addition, we focused on possible changes in membership and medical utilization trends. Based on our analysis, we do not believe that our overall membership has been significantly impacted by the pandemic to date.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">With regards to medical utilization trends, in particular in our two largest specialties oncology and cardiology, while forecasting future impact is challenging, our analysis suggests that utilization during the six months ended June 30, 2022 (as measured by authorizations per thousand members) is similar to what it was before the pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our two most significant service offerings in terms of revenue are specialty care management and administrative simplification services.&#160;Because both of these services offerings provide critical services to our clients and their members and have relatively long lead times to implement such services, we currently do not anticipate any material near-term disruption to the relevant contracts as a result of the pandemic. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Inflation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We experience pricing pressures in the form of competitive prices in addition to rising costs for certain inflation-sensitive operating expenses such as labor, employee benefits and facility leases. We do not believe these impacts were material to our revenues or net income during the six months ended June 30, 2022. However, significant sustained inflation driven by the macroeconomic environment or other factors could negatively impact our margins, profitability and results of operations in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross and Blue Shield of North Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has undertaken several transactions, some of which may impact year-to-year comparisons. The following is a discussion of certain of those transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of  IPG</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company, Evolent Health LLC, and Endzone Merger Sub, Inc, entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with TPG Growth Iceman Parent, Inc., and TPG Growth V Iceman, L.P. to acquire Implantable Provider Group, Inc. (&#8220;IPG&#8221;) for $250.0 million in cash and $125.0&#160;million in Class A Common Stock of the Company, together with a potential earnout of up to $87.0&#160;million  payable in in cash and shares of Class A Common Stock of the Company in 2023.  On August 1, 2022, the transactions contemplated by the Merger Agreement were consummated and the Company issued 3.7 million shares of Class A Common Stock in connection therewith.   IPG will report into Evolent&#8217;s specialty care management offering, New Century Health, and will be consolidated into the Company&#8217;s Clinical Solutions segment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ares Secured Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 1, 2022 (the &#8220;Closing Date&#8221;), the Company entered into a Credit Agreement, by and among the Company, Evolent Health LLC (&#8220;Evolent&#8221;), Endzone Merger Sub, Inc. (&#8220;Endzone&#8221; or &#8220;Initial Borrower&#8221;), which upon consummation of the transactions contemplated by the Merger Agreement will be merged with and into TPG Growth Iceman Parent, Inc., Implantable Provider Group, Inc. (&#8220;Implantable&#8221;, collectively with Evolent, Endzone and TPG Growth Iceman Parent, the &#8220;Borrowers&#8221; and each a &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, Ares Capital Corporation, as administrative agent, and ACF Finco I LP, as collateral agent and as revolver agent (the &#8220;2022 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrowers in the form of (i) an initial term loan in the aggregate principal amount of $175.0&#160;million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million and a borrowing base (the &#8220;Revolving Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;2022 Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the Initial Term Loan Facility on August 1, 2022 (the &#8220;Initial Term Loan&#8221;), and also borrowed $50.0 million under the Revolving Facility on the Closing Date. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the 2022 Credit Agreement, on August 1, 2022, the Company entered into a Security Agreement, by and among the Company, the Borrowers, the other guarantors and the collateral agent for the benefit of the secured parties and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Proceeds.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The proceeds of the Initial Term Loan may be used to fund ongoing working capital needs and other growth capital expenditure investments, and to finance the transactions contemplated by the Merger Agreement and fund fees and expenses incurred in connection therewith. The proceeds of the Revolving Facility may be used to finance the transactions contemplated by the Merger Agreement and to pay fees and expenses incurred in connection therewith on the Closing Date and thereafter to fund acquisitions, ongoing working capital needs and other growth capital investments and to pay fees and expenses in connection therewith.  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Maturity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Initial Term Loan and loans under the Revolving Facility will mature on the date that is the earliest of (a) August 1, 2027, (b) the date on which all amounts outstanding under the 2022 Credit Agreement have been declared or have automatically become due and payable under the terms of the 2022 Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the 2022 Credit Agreement) unless certain liquidity conditions are satisfied.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Interest and Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The interest rate for each loan under the 2022 Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the 2022 Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the base rate plus 2.50%. A commitment fee of (a) 2.00% per annum of the aggregate amount of the commitments in respect of the Term Loan Facility as of the Closing Date and (b) 2.00% of the aggregate amount of the commitments in respect of the Revolving Facility as of the Closing Date is payable by the Borrowers quarterly in arrears.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Prepayment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Amounts outstanding under the Credit Facility may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 3.00% of the principal amount so prepaid after the Closing Date but prior to the first anniversary of the Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the Closing Date but prior to the third anniversary of the Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Guarantees and Collateral.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The 2022 Credit Facilities are guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain exceptions. The 2022 Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain exceptions.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Covenants and Other Provisions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The 2022 Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum liquidity test commencing upon closing of the 2022 Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending September 30, 2022. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the 2022 Credit Facilities.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_124"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A included in our 2021 Form 10-K contains a detailed discussion of our critical accounting policies and estimates. There have been no material changes to our critical accounting policies and estimates since our 2021 Form 10-K. See &#8220;Item 1. Financial Statements - Note 2&#8221; in this Form 10-Q for a summary of our significant accounting policies and see &#8220;Item 1. Financial Statements - Note 3&#8221; in this Form 10-Q for information regarding the Company&#8217;s adoption of new accounting standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2021 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price plus the fair value of any non-controlling interests in the acquiree over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. The Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. Qualitative factors include macroeconomic, industry and market considerations, overall financial performance, industry, legal and other relevant events and factors affecting the reporting unit. Additionally, as part of this assessment, we may perform a quantitative analysis to support the qualitative factors above by applying sensitivities to assumptions and inputs used in measuring a reporting unit&#8217;s fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). We use discounted cash flow analyses and market multiple analyses in order to estimate reporting unit fair values. Discounted cash flow analyses rely on significant judgement and assumptions about expected future cash flows, weighted-average cost of capital, discount rates, expected long-term growth rates and operating margins. These assumptions are based on estimates of future revenue and earnings after considering such factors as general economic and market conditions which drive key assumptions of revenue growth rates, operating margins, capital expenditures and working capital requirements. The weighted average cost of capital is based on market-based factors/inputs but also considers the specific risk characteristics of the reporting unit&#8217;s cash flow forecast. A significant change to these estimates and assumptions could cause the estimated fair values of our reporting units and intangible assets to decline and increase the risk of an impairment charge to earnings. Intangible assets with finite lives are assessed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest fair value of our single reporting unit was below the carrying value. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the six months ended June 30, 2022</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We will perform our annual impairment test on October 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard on January 1, 2022 however, it did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method as of January 1, 2022, with adjustments which reduced additional paid-in capital by $106.2&#160;million and increased retained earnings by $39.8&#160;million and increased the net carrying amount of the 2024 Notes and 2025 Notes by $25.1&#160;million and $41.3&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_127"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company and its principal asset is all of the Class&#160;A common units in Evolent Health LLC, which has owned all of our operating assets and substantially all of our business since inception. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Components of our Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (exclusive of depreciation and amortization)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through performance-based arrangements.  Subsequent to the consolidation of EVH Passport on September 1, 2020, our cost of revenue includes the consolidated impact of the run out of EVH Passport&#8217;s operations, consisting principally of updates to EVH Passport&#8217;s claims reserve based on actual claims payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses consist of the amortization of intangible assets associated with the step up in fair value of Evolent Health LLC&#8217;s assets and liabilities for the Offering Reorganization, amortization of intangible assets recorded as part of our various business combinations and asset acquisitions and depreciation of property and equipment, including the amortization of capitalized software.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lives on Platform and PMPM Fees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health Services Lives on Platform are calculated by summing members on our value-based care and comprehensive health plan administrative platform. Clinical Solutions Lives on Platform are calculated by summing the Clinical Solutions Lives on Platform in our Performance suite and New Century Health Technology and Services suite Lives on Platform. Clinical Solutions Lives on Platform in our Performance suite are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts not under ASO arrangements. New Century Health Technology and Services suite Lives on Platform are calculated by summing members covered for oncology specialty care services, members covered for cardiology specialty care services and members covered for advance care planning services for contracts under ASO arrangements. Members covered for more than one category are counted in each category. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health Services average per member per month (&#8220;PMPM&#8221;) fee is defined as platform and operations revenue pertaining to the Evolent Health Services segment during the period reported divided by the average of the beginning and ending Evolent Health Services segment membership during the period reported divided by the number of months in the period. Clinical Solutions Performance suite Average PMPM fee is defined as platform and operations services revenue pertaining to our Clinical Solutions Performance suite during the period reported divided by the average of the beginning and ending Clinical Solutions Performance suite membership during the period reported divided by the number of months in the period. New Century Health Technology and Services suite Average PMPM fee is defined as platform and operations revenue pertaining to the New Century Health Technology and Services suite during the period reported divided by the average of the beginning and ending New Century Heath Technology and Services Suite membership during the period reported divided by the number of months in the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses lives on platform and PMPM fees because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc. Consolidated Results</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:114.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands, except percentages)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.1%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.3%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.4%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,257.9)%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229,728&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,844&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624,427&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,683&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.5%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,633)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,671)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,431)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,616)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.5%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue as a % of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses as a % of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Results for the Three Months Ended June 30, 2022 to 2021 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $97.9 million, or 44.1%, to $319.9 million for the three months ended June 30, 2022, as compared to 2021. This increase is primarily due to the addition of new partners and expansion with  existing partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,603&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from our Evolent Health Services segment increased by $17.5&#160;million for the three months ended June 30, 2022, as compared to 2021 due to expansion of services with existing customers. Revenue from our Clinical Solutions segment increased by $80.4&#160;million for three months ended June 30, 2022 as compared to 2021 due to new partner additions as well as expansion into new markets within current New Century Health Technology and Services Suite partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s lives on platform as of June&#160;30, 2022 and 2021 and PMPM fees for the three months ended June 30, 2022 and 2021 (Lives on Platform in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lives on Platform</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average PMPM Fees</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolent Health Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance suite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Century Health Technology and Services suite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We had 48 and 41 operating partners as of June&#160;30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total cost of revenue by segment (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.361%"><tr><td style="width:1.0%"></td><td style="width:25.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,595&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,457&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased by $77.6 million, or 45.1%, to $249.7 million for the three months ended June 30, 2022, as compared to 2021. Cost of revenue increased by approximately $57.5 million due to higher claims activity in our Clinical Solutions and Evolent Health Services segments, $12.9 million due to higher personnel costs due to increased headcount and expected benefits accruals to employees and $7.3 million in higher professional fees primarily due to costs incurred for contracts that went live during the quarter and third-party service fees for existing customers. Approximately $1.2 million and $0.9 million of total personnel costs was attributable to stock-based compensation expense for the three months ended June 30, 2022 and 2021, respectively. Cost of revenue represented 78.0% and 77.5% of total revenue for the three months ended June 30, 2022 and 2021, respectively. Our cost of revenue increased as a percentage of our total revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to decrease as a percentage of total revenue over the longer-term subject to the composition of our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total selling, general and administrative by segment (amounts in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,034&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,344&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,955&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased by $16.3 million, or 38.1%, to $59.0 million for the three months ended June 30, 2022, as compared to 2021. The increase is driven primarily by higher personnel fees due to increased headcount and expected benefits accruals to employees of $8.3 million and higher stock compensation of $3.1 million offset, in part by lower professional fees from the Repositioning Plan and shareholder advisory services of $2.9 million and the termination of certain leases of $0.3 million. Approximately $5.9 million and $2.8 million of total personnel costs were attributable to stock-based compensation expense for the three months ended June 30, 2022 and 2021, respectively. Acquisition and severance costs accounted for approximately $3.4 million and $0.1 million of total selling, general and administrative expenses for the three months ended June 30, 2022 and 2021, respectively. Selling, general and administrative expenses represented 18.4% and 19.2% of total revenue for the three months ended June 30, 2022, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as compared to 2021, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives completed in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses increased $0.2 million, or 1.3%, to $15.1 million for the three months ended June 30, 2022, as compared to 2021. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded a loss on change in fair value of contingent consideration of&#160;$0.8 million&#160;for the three months ended June 30, 2022 related to contingent consideration incurred as a result of the acquisition of Vital Decisions in October 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Results for the Six Months Ended June 30, 2022 to 2021 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $179.9 million, or 41.1%, to $617.0 million for the six months ended June 30, 2022, as compared to 2021. This increase is primarily due to the addition of new partners and expansion with existing partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,967&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from our Evolent Health Services segment increased by $39.5 million for the six months ended June 30, 2022, as compared to 2021 due to expansion of services with existing customers. Revenue from our Clinical Solutions segment increased by $140.4 million for the six months ended June 30, 2022 as compared to 2021 due to new partner additions as well as expansion into new markets within current New Century Health Technology and Services Suite partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents the Company&#8217;s lives on platform as of June&#160;30, 2022 and 2021 and PMPM fees for the six months ended June 30, 2022 and 2021 (Lives on Platform in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lives on Platform</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average PMPM Fees</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,095</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance suite</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,539</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Century Health Technology and Services suite</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,299</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We had 48 and 41 operating partners as of June&#160;30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total cost of revenue by segment for the six months ended June 30, 2022, as compared to 2021 (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.361%"><tr><td style="width:1.0%"></td><td style="width:25.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,703&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,945&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased by $139.5 million, or 42.3%, to $469.4 million for the six months ended June 30, 2022, as compared to 2021. Cost of revenue increased by approximately $96.0 million due to higher claims activity in our Clinical Solutions and Evolent Health Services segments, $21.2 million due to higher personnel costs due to increased headcount and expected benefits accruals to employees and $17.1 million in higher professional fees primarily due to costs incurred for contracts that went live during the quarter and third-party service fees for existing customers. Approximately $2.0 million and $1.5 million of total personnel costs was attributable to stock-based compensation expense for the six months ended June 30, 2022 and 2021, respectively. Cost of revenue represented 76.1% and 75.5% of total revenue for the six months ended June 30, 2022 and 2021, respectively. Our cost of revenue increased as a percentage of our total revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to decrease as a percentage of total revenue over the longer-term subject to the composition of our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total selling, general and administrative by segment for the six months ended June 30, 2022, as compared to 2021 (amounts in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,887&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased by $16.6 million, or 16.4%, to $117.9 million for the six months ended June 30, 2022, as compared to 2021. The increase is driven primarily by higher personnel fees due to increased headcount and expected benefits accruals to employees of $16.6 million and higher stock compensation of $4.5 million offset, in part by lower professional fees from the Repositioning Plan and shareholder advisory services of $10.3 million and the termination of certain leases of $2.8 million. Approximately $10.4 million and $5.9 million of total personnel costs were attributable to stock-based compensation expense for the six months ended June 30, 2022 and 2021, respectively. Acquisition and severance costs accounted for approximately $3.9&#160;million and $2.1&#160;million of total selling, general and administrative expenses for the six months ended June 30, 2022 and 2021, respectively. Selling, general and administrative expenses represented 19.1% and 23.2% of total revenue for the six months ended June 30, 2022, as compared to 2021, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives completed in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses decreased $0.1 million, or 0.4%, to $30.2 million for the six months ended June 30, 2022, as compared to 2021. The decrease was due primarily to lower amortization on existing technology of $1.7 million, offset in part by higher amortization from ongoing customer relationships of $1.3 million. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded a (gain) loss on change in fair value of contingent consideration of&#160;$6.9 million&#160;for the six months ended June 30, 2022 related to the liabilities acquired as a result of the acquisition of Vital Decisions in October 2021 and&#160;$(0.6) million for the six months ended June 30, 2021 related to liabilities incurred from entering into our warrant agreements that were settled in January 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Non-Operating Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our interest expense is primarily attributable to our 2021 Notes, 2024 Notes, 2025 Notes and 2019 Credit Agreement with Ares Capital Corporation. We recorded interest expense (including amortization of deferred financing costs) of approximately $2.1 million and $4.4 million for the three and six months ended June 30, 2022, respectively, and $6.3 million and $12.6 million for the three and six months ended June 30, 2021, respectively. The decrease in interest expense during the three and six months ended June 30, 2022 compared to 2021 is driven primarily by the adoption of ASU 2020-06 combined with the termination of the 2019 Credit Agreement in January 2021. See &#8220;Part I - Item 1.  Financial Statements - Note 10&#8221; in this Form 10-Q for the information related to interest expense.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain from Equity Method Investees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated its proportional share of the investees&#8217; earnings and losses each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $2.0 million and $2.5 million for the three and six months ended June 30, 2022, respectively, and $4.9 million and $12.7 million for the three and six months ended June 30, 2021, respectively. The change in gain from equity method investees for the three and six months ended June 30, 2022 compared to 2021 is driven primarily by the sale of our Florida equity investee&#8217;s membership during the three months ended March 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain from Transfer of Membership</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2021, EVH Passport received a cash payment from Molina in the amount of $23.0 million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The foregoing amount represents 50% of the payment that EVH Passport is eligible to receive based on the number of such enrollees. The remaining 50% was received in the first quarter of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Repayment of Debt</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for (Benefit) Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax (benefit) provision of $(0.2) million and $1.0 million and was recognized for the three and six months ended June 30, 2022, respectively, which resulted in effective tax rates of 3.9% and (11.4)%, respectively. An income tax expense of $0.1 million and $0.7 million for the three and six months ended June 30, 2021, respectively, which resulted in effective tax rates of (1.0)% and (3.6)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income (Loss) from Discontinued Operations, Net of Tax</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2021, the Company determined that True Health met the held for sale criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements. The True Health Closing occurred on March 31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in the loss from discontinued operations in the consolidated statements of operations for the six months ended June 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the six months ended June 30, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the six months ended June 30, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_130"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVIEW OF CONSOLIDATED FINANCIAL CONDITION</span></div><div style="text-align:center"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_133"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred operating losses and net cash outflows from operations. The Company incurred operating losses of $7.4 million and $23.6 million for the six months ended June 30, 2022 and 2021, respectively. Net cash and restricted cash used in operating activities was $43.8 million and $72.4 million for the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company had $193.1 million of cash and cash equivalents and $87.4 million in restricted cash and restricted investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months. Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities and the timing and extent of our spending to support our investment efforts and expansion into other markets. We may also seek to invest in, or acquire complementary businesses, applications or technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary of cash flows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands) has been derived from our financial statements included in &#8220;Part I - Item 1.  Financial Statements - Consolidated Statements of Cash Flows:&#8221;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,778)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $43.8 million for the six months ended June 30, 2022 were primarily due to our net loss of $9.9 million, non-cash items including depreciation and amortization expenses of $30.2 million, stock-based compensation expense of $12.4 million, amortization of contract cost assets of $13.2 million and change in fair value of contingent consideration of $6.9 million. Our operating cash outflows were affected by the timing of our customer and vendor payments driven by increases in </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounts receivables and prepaid expenses and other assets and reductions in reserves for claims, performance-based arrangements and accrued compensation and employee benefits and accrued liabilities contributed approximately $88.0 million to our cash outflows. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $72.4 million for the six months ended June 30, 2021 were primarily due to our net loss of $18.9 million, a loss on the repayment and termination of our Credit Agreement of $19.2 million, a gain on the disposal of assets of $1.9 million, gain on the transfer of memberships of $23.0 million and non cash items including depreciation and amortization expenses of $30.3 million and stock-based compensation expense of $7.4 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts receivables and contract cost assets and reductions in accrued liabilities and accrued compensation and employee benefits contributed approximately $163.3 million to our cash outflows. Those cash outflows were offset, in part by increased reserves for claims and performance-based arrangements of approximately $62.6 million.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by investing activities of $0.3 million in the six months ended June 30, 2022 were primarily attributable to $23.0 million from the transfer of membership and release of Passport escrow and $4.2 million from returns from our equity method investments offset, in part by $17.7 million of investments in internal-use software and purchases of property and equipment and a $9.0 million paid for our acquisition of IPG.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by investing activities of $40.4 million in the six months ended June 30, 2021 were primarily attributable to cash flows of $43.0 million from the transfer of membership and release of Passport escrow and returns of investment on equity method investments of $9.4 million offset, in part by $11.5 million from investments in internal-use software and purchases of property and equipment and $3.0 million of purchases of investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $30.7 million in the six months ended June 30, 2022 were primarily related to $16.5 million from taxes withheld for restricted stock unit vesting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $91.1 million in the six months ended June 30, 2021 were primarily related to the repayment and termination of our Credit Agreement and settlement of our outstanding warrant agreements with Ares Capital Corporation of $98.4 million, offset, in part by a $2.4 million decrease in net working capital balances held on behalf of our partners for claims processing services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows from Discontinued Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the six months ended June 30, 2021 were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the amount of cash and cash equivalents on hand and cash flows from operations will be adequate for us to execute our business strategy and meet anticipated requirements for lease obligations, capital expenditures working capital and debt service for 2022. Our estimated contractual obligations (in thousands) as of June&#160;30, 2022, were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:268.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023-2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025-2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases for facilities </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations related to vendor contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt interest and termination payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt principal repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,181&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,281&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,565&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounts Receivable, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. During the six months ended June 30, 2022, accounts receivable, net, increased due primarily to the timing of cash receipts from existing customers combined with modest receivables from new customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments of $87.4 million is carried at cost and includes cash held on behalf of other entities for pharmacy and claims management services of $73.6 million, collateral for letters of credit required as security deposits for facility leases of $2.3 million, amounts held with financial institutions for risk-sharing arrangements of $11.5 million as of June&#160;30, 2022. See &#8220;Part I - Item 1. Financial Statements - Note 2&#8221; for further details of the Company&#8217;s restricted cash balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uses of Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal uses of cash are in the operation and expansion of our business. The Company does not anticipate paying a cash dividend on our Class A common stock in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_136"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company had cash and cash equivalents and restricted cash and restricted investments of $280.4 million, which consisted of bank deposits with FDIC participating banks of $276.4 million, bank deposits in international banks of $2.5 million and investments in money market funds of $1.5 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in interest rates affect the interest earned on our cash and cash equivalents (including restricted cash). Our investments (including restricted investments) are classified as held-to-maturity and therefore are not subject to interest rate risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had $289.6 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates. Refer to the discussion in &#8220;Part I - Item 1.  Financial Statements - Note 10&#8221; for additional information on our long-term debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2018, we have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the U.S. dollar, primarily the Indian Rupee. In general, we are a net payor of currencies other than the U.S. dollar. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may, in the future, negatively affect our operating results as expressed in U.S. dollars. At this time, we have not entered into, but in the future, we may enter into, derivatives or other financial instruments in an attempt to hedge our foreign currency exchange risk. It is difficult to predict the effect hedging activities would have on our results of operations. We recognized a foreign currency translation losses of $0.3 million and $0.4 million for the three and six months ended June 30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_139"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. The Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of June&#160;30, 2022, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended June&#160;30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inherent Limitations of Internal Controls</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_142"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion of legal proceedings included within &#8220;Part I &#8211; Item 1. Financial Statements and Supplementary Data - Note 11 - Commitments and Contingencies - Litigation Matters&#8221; is incorporated by reference into this Item 1.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_148"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant business risks are described in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;2021 Form 10-K&#8221;). These risk factors are supplemented for the item described below. The risks and uncertainties we describe are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business or operations. Any adverse effect on our business, financial condition or operating results could result in a decline in the value of our securities and the loss of all or part of your investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Increasing inflationary pressures and consumer costs may have a negative effect on our margins, profitability and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The broader U.S. economy has experienced higher than expected inflationary pressures during the first six months of 2022 related to continued supply chain disruptions, labor shortages and geopolitical instability. Increasing inflationary pressures may have a negative effect on our profit margins and earnings due to associated costs increases. Additionally, we face an increasingly competitive labor market due to sustained labor shortages in part from the COVID-19 pandemic and are subject to inflationary pressures on employee wages and salaries which may increase labor costs. Failure to retain highly skilled employees due to wage inflation could have a material adverse impact on our business, results of operations or financial condition. See the risk factor captioned &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we lose key members of our management team or employees or are unable to attract and retain the employees we need, our compensation costs will increase and our business and operating results will be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; in our 2021 Form 10-K. While we are unable to predict the direction of the economy or if inflation will increase or revert to normal levels, if the current inflationary trends continue for a sustained period of time, our margins, profitability and results of operations could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restrictive covenants in our 2022 Credit Agreement may interfere with our ability to access the revolving credit facility under the 2022 Credit Agreement, or to obtain new financing or to engage in other business activities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 Credit Agreement imposes significant operating and financial restrictions on us. These restrictions limit our ability and/or the ability of certain of our subsidiaries to, among other things:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incur or guarantee additional debt;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incur certain liens;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">merge or consolidate;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">transfer or sell assets;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">make certain investments;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">pay dividends and make other distributions on, or redeem or repurchase, capital stock; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">enter into transactions with affiliates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are required to comply with certain financial covenants consisting of a minimum liquidity test, and, commencing on the last day of the fiscal quarter ending September 30, 2022, a total secured leverage test. As a result of these restrictions, we will be limited as to how we conduct our business and we may be unable to raise additional debt or equity financing to compete effectively or to take advantage of new business opportunities. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot assure you that the Company will be able to maintain compliance with these covenants in the future and, if it fails to do so, that it will be able to obtain waivers from the lenders and/or amend the covenants. The Company&#8217;s failure to comply </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the restrictive covenants described above as well as the terms of any future indebtedness could result in an event of default, which, if not cured or waived, could result in it being required to repay these borrowings before their due date and the lenders would be entitled to foreclose on collateral. If the Company is forced to refinance these borrowings on less favorable terms or cannot refinance these borrowings, our results of operations and financial condition could be adversely affected.  In addition, we may be unable to access future borrowings under our revolving facility if we are unable to satisfy the applicable conditions precedent.  </span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_157"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_160"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_163"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.  Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_166"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">Asset Purchase Agreement, dated May 28, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Evolent Health, Inc. and Justify Holdings, Inc., filed as Exhibit 2.4 to the Company&#8217;s Report on Form 10-Q filed with the SEC on August 9, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">First Amendment to Asset Purchase Agreement, dated as of December 30, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Justify Holdings, Inc., and Evolent Health, Inc., filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K with the SEC on December 31, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:47pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">Purchase Agreement and Plan of Merger, dated August 2, 2021, by and among Evolent Health, Inc., Evolent Health LLC, EV Thunder Merger Sub, LLC, WindRose Health Investors III, L.P., Vital Decisions Acquisition, LLC and WindRose Health Investors, LLC, as the representative,  filed as Exhibit 2.1 to the Company&#8217;s report on Form 8-K filed with the SEC on August 4, 2021 and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex24.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex24.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex24.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex24.htm">Agreement and Plan of Merger, dated August 1, 2022, by and among Evolent Health, Inc., Evolent Health LLC, Endzone Merger Sub, Inc, TPG Growth Iceman Parent, Inc. and the Sellers&#8217; </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex24.htm">R</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex24.htm">epresentative.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex41.htm">Registration Rights Agreement, dated August 1, 2022, by and between Evolent Health, Inc., TPG Growth V Iceman, L.P.,  and the individuals in Schedule I of the agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex101.htm">10.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex101.htm">Credit Agreement, by and among Evolent Health, Inc., Evolent Health LLC, certain subsidiaries of Evolent Health, Inc, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex101.htm"> and ACF Finco I LP, as</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex101.htm"> revolving agent and collateral agent, dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex101.htm"> as of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex101.htm"> August 1, 2022.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex102.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex102.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex102.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex102.htm">Security Agreement, by and among Evolent Health, Inc., Evolent Health LLC, the other guarantors and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex102.htm">ACF Finco I LP, as</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex102.htm"> collateral agent for the benefit of the secured parties, dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex102.htm"> as of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex102.htm"> August 1, 2022.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">3*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">Guarantee Agreement, by Evolent Health, Inc. and each of the other guarantors in favor of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">Ares Capital </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">Corporation, as administrative age</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">nt for the lenders</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm"> and A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">CF Finco I LP, as collateral agent for the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">lenders</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm"> dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q2form10qex103.htm">August 1, 2022.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a63022exhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a63022exhibit311.htm">Certification of the Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a63022exhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a63022exhibit312.htm">Certification of the Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a63022exhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a63022exhibit321.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a63022exhibit322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a63022exhibit322.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q, formatted as Inline XBRL</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">* The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule or exhibit upon the request of the SEC in accordance with Item 601(b)(2) of Regulation S-K. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i1ec4d9b5233f4aa5a7f5353c408fadd2_169"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:249.00pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registrant</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Johnson</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Johnson</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Aammaad Shams</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aammaad Shams</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Accounting Officer and Controller</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated:  August&#160;3, 2022 </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.4
<SEQUENCE>2
<FILENAME>a2022q2form10qex24.htm
<DESCRIPTION>EX-2.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i649a3a409a124fa4b643ff6500d07394_6554"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 2.4</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AGREEMENT AND PLAN OF MERGER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BY AND AMONG</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> EVOLENT HEALTH, INC.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EVOLENT HEALTH, LLC,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ENDZONE MERGER SUB, INC.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TPG GROWTH ICEMAN PARENT, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE SELLERS&#8217; REPRESENTATIVE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DATED AS OF JUNE 24, 2022</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i649a3a409a124fa4b643ff6500d07394_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TABLE OF CONTENTS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LIST OF EXHIBITS AND SCHEDULES</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3</font></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AGREEMENT AND PLAN OF MERGER</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_22" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 1 DEFINITIONS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_25" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DEFINITIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_28" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CROSS REFERENCES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 2 THE MERGER</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_40" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE MERGER</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_43" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 19pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE CLOSING AND THE EFFECTIVE TIME</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_46" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 19pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EFFECT OF THE MERGER</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 19pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ORGANIZATIONAL DOCUMENTS OF THE SURVIVING CORPORATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_52" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 19pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DIRECTORS AND OFFICERS OF THE SURVIVING CORPORATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_55" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 19pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EFFECT OF THE MERGER ON THE COMPANY STOCK, STOCK OPTIONS AND MERGER SUB</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_58" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 19pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MECHANISM OF PAYMENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_85" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">23</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 19pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NO FURTHER OWNERSHIP RIGHTS IN THE COMPANY STOCK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_121" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 19pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.9</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">REPAID INDEBTEDNESS&#59; COMPANY TRANSACTION EXPENSES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_124" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 19pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CLOSING ADJUSTMENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 19pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.11</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DISSENTING STOCK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_157" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 19pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.12</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EARNOUT CONSIDERATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_166" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 3 CONDITIONS TO CLOSING</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_7003" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONDITIONS TO THE OBLIGATIONS OF THE COMPANY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_7008" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONDITIONS TO EVOLENT ENTITIES&#8217; OBLIGATIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_205" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">32</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 4 COVENANTS PRIOR TO CLOSING</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_256" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">34</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AFFIRMATIVE COVENANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_259" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">34</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NEGATIVE COVENANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_271" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">35</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">REASONABLE BEST EFFORTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_274" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">35</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.4</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXCLUSIVITY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_277" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">35</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">REGULATORY APPROVAL</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_280" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.6</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONSENTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_292" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">37</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.7</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">REPRESENTATION AND WARRANTY INSURANCE POLICY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_295" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">37</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.8</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FINANCING COOPERATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_298" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">38</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.9</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FINANCING EFFORTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_310" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">41</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.10</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WRITTEN CONSENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_319" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.11</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">REGISTRATION OF SHARES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_322" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.12</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PRE-CLOSING FINANCIAL STATEMENTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_325" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">43</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 5 REPRESENTATIONS AND WARRANTIES REGARDING</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;THE COMPANY GROUP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_337" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ORGANIZATION AND POWER&#59; SUBSIDIARIES AND INVESTMENTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_340" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">44</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AUTHORIZATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_349" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">44</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CAPITALIZATION.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_352" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">44</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.4</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ABSENCE OF CONFLICTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_364" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FINANCIAL STATEMENTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_367" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.6</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ABSENCE OF CERTAIN DEVELOPMENTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_382" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">47</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.7</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">REAL PROPERTY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_448" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.8</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ASSETS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_457" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.9</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONTRACTS AND COMMITMENTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_460" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">50</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.10</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">INTELLECTUAL PROPERTY RIGHTS AND PRIVACY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_538" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.11</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GOVERNMENTAL LICENSES AND PERMITS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_613" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">58</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.12</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LITIGATION&#59; PROCEEDINGS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_616" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">59</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.13</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COMPLIANCE WITH LAWS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_619" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">59</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.14</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ENVIRONMENTAL MATTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_643" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.15</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EMPLOYEES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_646" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.16</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EMPLOYEE BENEFIT PLANS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_661" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">62</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.17</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TAX MATTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_697" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">65</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.18</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BROKERAGE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_757" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">67</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.19</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AFFILIATE TRANSACTIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_760" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">67</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.20</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">INSURANCE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_763" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">67</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.21</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">UNDISCLOSED LIABILITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_766" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">68</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.22</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BOOKS AND RECORDS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_769" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">68</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.23</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ANTI-CORRUPTION AND INTERNATIONAL RISK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_772" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">68</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.24</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUSTOMERS, SURGICAL CENTERS, AND SUPPLIERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_796" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">69</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.25</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DISCLAIMER</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_799" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">69</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.26</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 RELIEF</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_802" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">70</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 6 REPRESENTATIONS AND WARRANTIES OF EVOLENT</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ENTITIES AND MERGER SUB</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_805" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">70</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ORGANIZATION AND POWER&#59; OWNERSHIP OF MERGER SUB&#59; NO PRIOR ACTIVITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_808" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">71</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AUTHORIZATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_811" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">71</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CAPITALIZATION OF PURCHASER</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_814" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">71</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.4</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NO VIOLATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_817" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">72</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.5</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LITIGATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_820" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">72</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.6</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">INVESTMENT INTENT&#59; RESTRICTED SECURITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_829" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">72</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.7</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BROKERAGE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_832" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">73</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.8</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DUE DILIGENCE REVIEW</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_835" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">73</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.9</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FINANCING</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_838" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">73</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.10</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SOLVENCY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_847" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">74</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.11</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECURITIES LAWS MATTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_850" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">75</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.12</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ANTI-CORRUPTION AND INTERNATIONAL RISK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_868" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">76</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 7 TERMINATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_892" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">77</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TERMINATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_895" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">77</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EFFECT OF TERMINATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_919" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">78</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 8 ADDITIONAL AGREEMENTS&#59; COVENANTS AFTER CLOSING</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_934" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">79</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MUTUAL ASSISTANCE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_937" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">80</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PRESS RELEASE AND ANNOUNCEMENTS&#59; CONFIDENTIALITY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_940" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">80</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXPENSES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_943" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">80</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FURTHER TRANSFERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_946" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">81</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.5</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TRANSFER TAXES&#59; RECORDING CHARGES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_949" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">81</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SELLERS&#8217; REPRESENTATIVE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_952" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">81</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DIRECTORS AND OFFICERS INSURANCE&#59; EMPLOYEE MATTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_973" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">83</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.8</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TAX MATTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_988" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">86</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.9</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXCLUDED AETNA RECEIVABLES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1036" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">90</a></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 9 MISCELLANEOUS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1042" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">91</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NON-SURVIVAL OF REPRESENTATIONS AND WARRANTIES&#59; EXCLUSIVE REMEDY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1045" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">91</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.2</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMENDMENT AND WAIVER</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1057" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">92</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTICES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1060" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">92</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.4</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ASSIGNMENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1063" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">93</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.5</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SEVERABILITY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1066" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">93</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.6</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NO STRICT CONSTRUCTION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1069" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">93</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.7</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CAPTIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1072" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">94</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.8</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NO THIRD-PARTY BENEFICIARIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1075" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">94</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.9</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SPECIFIC PERFORMANCE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1078" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">94</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.10</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GUARANTY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1081" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">95</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.11</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COMPLETE AGREEMENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1084" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">95</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.12</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COUNTERPARTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1087" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">95</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.13</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GOVERNING LAW AND JURISDICTION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1090" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">95</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.14</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WAIVER OF JURY TRIAL</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1093" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">95</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.15</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NON-RECOURSE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1096" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">96</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.16</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CERTAIN LENDER MATTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i649a3a409a124fa4b643ff6500d07394_1099" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">96</a></font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii</font></div></div></div><div id="i649a3a409a124fa4b643ff6500d07394_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AGREEMENT AND PLAN OF MERGER</font></div><div style="margin-bottom:0.18pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS AGREEMENT AND PLAN OF MERGER (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of June 24, 2022, by and among Evolent Health, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Evolent Health LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and together with Parent, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Evolent Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Endzone Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Purchaser (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Merger Sub</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), TPG Growth Iceman Parent, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and TPG Growth V Iceman, L.P., solely in its capacity as the Sellers&#8217; Representative (as defined below).  Capitalized terms used in this Agreement and not otherwise defined shall have the respective meanings given to such terms in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the board of directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), subject to the terms and conditions set forth herein, has (i) declared the advisability of this Agreement and approved and adopted this Agreement, and (ii) resolved to recommend approval and adoption of this Agreement by all of the Company Stockholders entitled to approve and adopt this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the board of directors of Merger Sub has (i) declared the advisability of this Agreement and (ii) approved and adopted this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the board of directors of Parent, Parent, in its capacity as the sole member and managing member of Purchaser, and Purchaser, in its capacity as the sole stockholder of Merger Sub, have (i) declared the advisability of this Agreement and (ii) approved and adopted this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company Board and the board of directors of Merger Sub have each approved the merger of Merger Sub with and into the Company, with the Company as the surviving corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Surviving Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), upon the terms and subject to the conditions set forth in this Agreement and the applicable provisions of the Delaware General Corporation Law (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), whereby each issued and outstanding share of Company Stock (other than the Company Stock to be canceled pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Dissenting Stock (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) shall be converted into the right to receive a portion of the Final Merger Cash Consideration (as defined herein), Share Consideration and, if applicable, Earnout Consideration, upon the terms and subject to the conditions set forth herein and based upon the applicable liquidation preferences and other rights, preferences and privileges of such class of the Company Stock as set forth in the Company Charter and Bylaws&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, within twenty-four (24) hours of the execution and delivery of this Agreement, the Company anticipates delivering to Purchaser a written consent executed by the holders of a majority of the outstanding shares of Company Stock, approving this Agreement, the Merger and the other transactions contemplated hereby in accordance with Section 251 of the DGCL (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Written Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, concurrently with the execution and delivery of this Agreement, certain Company Stockholders have executed and delivered Support Agreements in favor of the Evolent Entities, each of which is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Support Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company, Merger Sub and Evolent Entities desire to make certain representations, warranties, covenants and agreements in connection with the Merger, and also to prescribe various conditions to the Merger, as set forth in, and subject to the provisions of, this Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div id="i649a3a409a124fa4b643ff6500d07394_25"></div><div style="padding-left:126pt;padding-right:126pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE I</font></div><div style="padding-left:252pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:126pt;padding-right:126pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DEFINITIONS</font></div><div id="i649a3a409a124fa4b643ff6500d07394_28"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As used in this Agreement, the following terms have the meanings set forth below.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting Principles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means GAAP as in effect as of the Closing Date, using and applying the same accounting principles, practices, methodologies and procedures used by the Company in the preparation of the Audited Financial Statements in respect of the period ended December 31, 2021&#59; provided, that if such accounting principles, practices, methodologies and procedures are inconsistent with GAAP in effect as of the Closing Date, then GAAP shall control.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accredited Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an &#8220;accredited investor&#8221; as defined and determined pursuant to Rule 501(a) of Regulation D promulgated under the Securities Act.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accredited Investor Questionnaire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a questionnaire used to determine the status of Sellers as either Accredited Investors or Non-Accredited Investors in form and substance reasonably satisfactory to Parent and the Company. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued Income Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an amount, which shall not be less than zero in the aggregate, equal to the sum of (1) the unpaid Income Tax liabilities (whether or not yet due and owing) of each member of the Company Group for all taxable periods (or portions thereof in the case of a Straddle Period, calculated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) beginning on or after January 1, 2021 and ending on or before the Closing Date (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (which amount shall be reflected as a positive number), and (2) the overpayment (if any) of Income Taxes of the Company Group for Applicable Periods (which amount shall be reflected as a negative number), separately calculated for (a) each applicable taxing jurisdiction in which the Company Group filed Tax Returns for Income Taxes in the last Tax period for which such Tax Returns were required to be filed prior to the date hereof and (b) each jurisdiction in which the Company Group commenced activities and became subject to Income Tax on or after January 1, 2021 and prior to the Closing Date&#59; provided, that, for purposes of calculating Accrued Income Taxes, (i) all Transaction Tax Deductions shall be taken into account to the extent &#8220;more likely </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">than not&#8221; (or higher level of confidence) deductible in the Pre-Closing Tax Period and applying the seventy percent safe-harbor election under Revenue Procedure 2011-29 to any &#8220;success based fees,&#8221; (ii) any Income Taxes attributable to transactions outside the ordinary course of business on the Closing Date after the time of the Closing shall be excluded&#59; (iii) (A) any financing or refinancing arrangements entered into at any time by or at the direction of Purchaser or any of its Affiliates or (B) any other transactions entered into by or at the direction of Purchaser or any of its Affiliates in connection with the transactions contemplated hereby shall not be taken into account&#59; (iv) any and all accruals or reserves established or required to be established under GAAP methodologies that require the accrual for contingent Income Taxes or with respect to uncertain Tax positions shall be excluded&#59; (v) the net present value of any and all Tax liabilities under Section 965 of the Code (including in connection with any election under Section 965 of the Code, the Treasury regulations thereunder and other similar provisions of law) shall be included&#59; (vi) all deferred Tax assets and deferred Tax liabilities established for GAAP purposes shall be excluded, (vii) an amount equal to $150,000 shall be included&#59; and (viii) such liability for Income Taxes shall be calculated in accordance with the past practice (including reporting positions, jurisdictions, elections and accounting methods) of the Company Group in preparing Tax Returns for Income Taxes except to the extent a change to such past practice is required by a change in Law after the date hereof.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any action, order, writ, injunction, demand, claim, charge, complaint, grievance, demand, notice of violation, suit, litigation, proceeding, arbitration, mediation, audit, inquiry, dispute, criminal prosecution, citation, summons, subpoena or investigation of any nature by or before any Governmental Authority, whether civil, criminal, administrative, judicial, investigative, regulatory or otherwise, whether at law or in equity, whether formal or informal, whether public or private.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustment Escrow Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means cash in the amount of $3,000,000.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustment Escrow Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Adjustment Escrow Amount deposited into escrow pursuant to the Escrow Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of any particular Person means any other Person controlling, controlled by or under common control with such particular Person.  For purposes of this definition, the term &#8220;control&#8221; (including the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliated Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an affiliated group as defined in Section&#160;1504 of the Code (or any analogous combined, consolidated or unitary group defined under state, local or foreign Income Tax law) of which any member of the Company Group is or has been a member.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Aggregate Initial Cash Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) the Cash Consideration, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (ii) the aggregate amount of Estimated Cash as of the Measurement Time on the Business Day prior to the Closing Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (iii) the aggregate amount of Estimated Indebtedness, measured immediately prior to the Closing (provided however that Taxes included in the definition of Indebtedness shall be calculated as of the end of the day on the Closing Date taking into account the transactions contemplated hereby), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (iv) the aggregate amount of Estimated Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Transaction Expenses (to the extent not paid by the Company Group by the Measurement Time immediately prior to the Closing), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (v) the Adjustment Escrow Amount, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (vi) the Sellers&#8217; Representative Expense Fund, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (vii) the amount, if any, by which Estimated Working Capital as of the Measurement Time on the day prior to the Closing Date, as determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, is less than the Target Working Capital (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Downward Closing Working Capital Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (viii) the amount, if any, by which Estimated Working Capital as of the close of business on the day prior to the Closing Date, as determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, is greater than the Target Working Capital (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Upward Closing Working Capital Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) the U.S. Foreign Corrupt Practices Act of 1977 (as amended from time to time), (ii) the United Kingdom Bribery Act, (iii) anti-bribery legislation promulgated by the European Union and implemented by its member states, (iv) legislation adopted in furtherance of the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transaction, and (v) other anti-bribery and anti-corruption laws, regulations or ordinances applicable to the Business and its Subsidiaries and their respective operations from time to time.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Money Laundering Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means anti-money laundering-related Laws, regulations, and codes of practice applicable to the Business and the Company and its Subsidiaries and their operations from time to time, including without limitation (i) the EU Anti-Money Laundering Directives and any Laws, decrees, administrative orders, circulars, or instructions implementing or interpreting the same, and (ii) the applicable financial recordkeeping and reporting requirements of the U.S. Currency and Foreign Transaction Reporting Act of 1970, as amended from time to time.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Borrowed Money Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person at any date, without duplication&#58; (i)&#160;all obligations of such Person for borrowed money (excluding any trade payables, accounts payable, and any other current liabilities)&#59; and (ii)&#160;any accrued interest and fees related to any of the foregoing.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the business of the Company Group as currently conducted or is contemplated being conducted on the date hereof or the Closing Date.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any day other than a Saturday or Sunday or any other day on which commercial banks in San Francisco, California or New York, New York are authorized or required by law to close.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CARES Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Coronavirus Aid, Relief, and Economic Security Act (Pub. L. 116-136) and any administrative or other guidance published with respect thereto by any Governmental Authority, or any other Law or executive order or memo intended to address the consequences of COVID-19, including, but not limited to, the Consolidated Appropriations Act, 2021.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the aggregate amount of all cash and cash equivalents (including marketable securities, liquid instruments, petty cash, deposits in transit to the extent there has been a reduction of receivables on account therefor, the amount of any received and uncleared checks, wires or drafts, and taking into account the amount of any issued but uncleared checks, wires or drafts, recorded in accordance with GAAP, with the exception that to the extent GAAP </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">requires any amounts of overdrafts to be recorded as a liability, such amounts shall be reflected as Cash)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that &#8220;Cash&#8221; shall not include any Restricted Cash.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means $250,000,000&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that upon written notice by Sellers&#8217; Representative to Purchaser prior to Closing, the Cash Consideration may be increased in the sole discretion of the Evolent Entities.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Internal Revenue Code of 1986, as amended from time to time, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commitment Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the executed debt financing commitment letter, dated as of the date hereof, between Purchaser and Ares Capital Management LLC, including all exhibits, attachments, appendices and schedules thereto as of the date hereof, as amended, restated, amended and restated, supplemented or replaced in compliance with this Agreement (including following a Financing Failure Event), pursuant to which, subject to the terms and conditions thereof, the financial institutions party thereto have agreed to provide or cause to be provided the debt financing set forth therein for the purposes of financing the transactions contemplated hereby. For purposes of this Agreement, the term &#8220;Commitment Letter&#8221; shall be deemed to include any commitment letter (or similar agreement) with respect to any Alternative Financing arranged in compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (and any Commitment Letter remaining in effect at the time in question).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Charter and Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Company&#8217;s certificate of incorporation and bylaws, each as amended and restated from time to time and as currently in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Fundamental Reps</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means those representations and warranties contained in the first and second sentences of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Organization), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Authorization), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Capitalization) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Brokerage).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Company and each of its Subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Optionholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Person that holds any Stock Options.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all of the issued and outstanding Class A Common Stock and Class B Common Stock of the Company, par value $0.001 per share.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Person that holds any Company Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Stock Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the 2021 TPG Growth Iceman Parent, Inc. Stock Plan, as amended and restated from time to time and as currently in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the aggregate amount, without duplication, of all fees and expenses incurred by, or on behalf of, or to be paid by, the Company Group, the Sellers, and the Sellers&#8217; Representative in connection with the negotiation and execution of this Agreement and the consummation of the transactions contemplated hereby and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any similar transactions with other potential buyers, in each case, to the extent not paid prior to the Closing Date, including&#58; (i) all fees (including brokerage fees, commissions and finders fees) and expenses for services rendered by third party brokers, bankers, attorneys, accountants or other representatives, (ii) the amount of any change-in-control payments, transaction bonuses, retention payments, severance or other similar payments payable by any of the Company Group to any current or former director, manager, officer, employee or individual independent contractor from or incurred in connection with this Agreement or the transactions contemplated hereby, excluding any &#8220;double trigger payments&#8221; or other severance or termination payments that become payable in whole or in part by actions taken by the Company Group post-Closing or at the direction of Parent or Purchaser, and the employer portion of payroll, social security, unemployment or similar Taxes arising therefrom, (iii) all unpaid fees and expenses due and payable by the Company Group under any advisory, management services or similar agreement between any member of the Company Group and any Company Stockholder or any of their Affiliates, and (iv) all fees and expenses incurred in connection with the hosting of the IPG data room by Box.  Notwithstanding the foregoing, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; will exclude all amounts, costs, fees, expenses and payment obligations to the extent included in Indebtedness or Working Capital.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any written or oral legally binding contract, agreement, instrument, commitment or undertaking of any nature (including leases, subleases, licenses, mortgages, notes, guarantees, sublicenses, subcontracts, letters of intent and purchase orders).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Court Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any judgment, decision, consent decree, injunction, ruling or order of any Governmental Authority that is expressly by its terms binding on any Person or its property. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the novel coronavirus, SARS-CoV-2 or COVID-19 (and all related strains and sequences), including any intensification, resurgence or any evolutions or mutations thereof, or related or associated epidemics, pandemics, disease outbreaks or public health emergencies.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any quarantine, &#8220;shelter in place,&#8221; &#8220;stay at home,&#8221; workforce reduction, social distancing, shut down, closure, sequester or any other Law, Court Order, directive, guidelines or recommendations by any Governmental Authority in connection with or in response to COVID-19, including, but not limited to, the CARES Act.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Debt Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the debt financing contemplated by the Commitment Letter.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Distribution Waterfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; is defined in, and shall be calculated in accordance with, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Distribution Waterfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, which shall be updated as necessary and delivered, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, by the Company prior to the Closing.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Earnout Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an aggregate amount of up to $87,000,000, which will be payable by the Evolent Entities in cash and Parent Shares (valued based on the volume weighted average closing price of such Parent Shares on the New York Stock Exchange for the ten (10) trading days ending on the last trading day immediately prior to the payment of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Earnout Consideration), if at all, in accordance with the terms set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, however, that up to $31,071,000 of the Earnout Consideration will be based upon the achievement of certain metrics of the Company Group and satisfaction of conditions in the second half of 2022 and will be payable up to 100% in Parent Shares&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, further, that up to $87,000,000 of the Earnout Consideration (less any Earnout Consideration previously paid) will be based upon the achievement of certain metrics of the Company Group and satisfaction of conditions in the first three quarters of 2023 and will be payable in Parent Shares and cash, as described further in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (provided, however, that the first $30,000,000 (less any Earnout Consideration paid in cash in the second half of 2022) of Earnout Consideration payable with respect to the first three (3) quarters of 2023 will be paid, if at all, in cash).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any plan, contract, program, policy, agreement, or arrangement, whether or not reduced to writing, and whether or not subject to ERISA, that is (a) a welfare plan within the meaning of Section 3(1) of ERISA, (b) a pension plan within the meaning of Section 3(2) of ERISA, (c) a stock bonus, stock purchase, stock option, restricted stock, stock appreciation right, profits interest, phantom equity, or similar equity or equity-based plan, contract, program, policy, agreement or arrangement, or (d) an employment, individual independent contractor, severance, termination pay, deferred-compensation, retirement, profit-sharing, welfare-benefit, paid time-off, bonus, incentive, commission, retention, change-of-control, material fringe-benefit or other compensation or benefit plan, contract, program, policy, agreement, or arrangement, in each case, (i) that is maintained sponsored, contributed to (or required to be contributed to) or entered into by the Company Group for the benefit of any current or former director, officer, employee or individual independent contractor of the Company Group, or the beneficiaries or dependents of any such individual or (ii) under which the Company Group has any Liability, including through any ERISA Affiliate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Enterprise Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means $375,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means all applicable federal, state, local and foreign statutes, regulations, and ordinances concerning pollution or protection of the environment, as the foregoing are enacted and in effect, on the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Employee Retirement Income Security Act of 1974, as amended from time to time, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Escrow Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means U.S. Bank, National Association.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Escrow Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the escrow agreement by and among Purchaser, the Sellers&#8217; Representative and the Escrow Agent in a form reasonably acceptable to Purchaser and the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended from time to time, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Aetna Receivables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the amount of any account receivables of the Company that are outstanding from Aetna Networks Services LLC or Aetna Health </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Management, LLC  as of Closing Date which were billed at least 45 days prior to Closing Date and were initially denied payment by Aetna Networks Services LLC or Aetna Health Management, LLC, as applicable. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that certain Credit Agreement, dated as of March 19, 2021, between the Company, TPG Growth Iceman Intermediate, Inc., Citizens Bank, N.A. as administrative agent and as collateral agent, and the Lenders party thereto, as amended, restated, amended and restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Export Control Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the EC Regulation 428&#47;2009 and the implementing laws and regulations of the EU member states&#59; the U.S. Export Administration Act, U.S. Export Administration Regulations, U.S. Arms Export Control Act, U.S. International Traffic in Arms Regulations, and their respective implementing rules and regulations&#59; the U.K. Export Control Act 2002 (as amended and extended by the Export Control Order 2008) and its implementing rules and regulations&#59; and other similar export control laws or restrictions applicable to the Company and its Subsidiaries and their respective operations from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Federal Health Care Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means as provided in 42 U.S.C. &#167;1320a-7b(f), as amended from time to time, including Medicare, Medicaid, TRICARE, CHAMPVA, and state health care programs (as defined therein).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Merger Cash Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an amount equal to the sum of (i) the Aggregate Initial Cash Consideration, (ii) any payments required to be made to the Company Stockholders, and to the Company for the benefit of the Company Optionholders pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">or Section 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (iii) the Adjustment Escrow Amount (less any payments required to be made to Purchaser or one of its subsidiaries pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) and (iv) any amount of the Sellers&#8217; Representative Expense Fund (less any amounts used by the Sellers&#8217; Representative) distributed pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Failure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any of the following (a) any commitments under the Commitment Letter or any definitive agreement with respect to the Debt Financing expiring or being terminated, (b) for any reason all or any portion of the Debt Financing becomes unavailable, such that the remaining available portion thereof is less than the Required Amounts, on the terms and conditions set forth in the Commitment Letter (including any market flex provisions therein or in any Fee Letter), (c) a breach, termination, default or repudiation by any Financing Source of such obligations to fund the commitments under the Commitment Letter or any definitive agreement with respect to the Debt Financing to the extent that the remaining funded portion thereof is less than the Required Amounts, or (d) any party to a Commitment Letter (or any definitive agreement with respect to the Debt Financing) or any Affiliate or agent of such Person shall allege (in writing) that any of the events set forth in clauses (a) through (c) has occurred.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Notice Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any of the following&#58; (a) any Financing Failure Event, (b) the Evolent Entities obtain actual knowledge of any material breach, termination, default or repudiation by any Evolent Entity or, to the knowledge of Purchaser, any other party thereto, under the Commitment Letter or any definitive agreement related to the Debt </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Financing, (c) receipt by any Evolent Entity, Merger Sub or any of their respective Affiliates or Representatives of any written notice or other written communication from any Financing Source, any lender or any other Person with respect to any actual, threatened or alleged breach, default, termination or repudiation by any party to the Commitment Letter or any definitive agreement related to the Debt Financing of any provision of the Commitment Letter or any definitive agreement related to the Debt Financing, or (d) the good faith belief by any Evolent Entity or Merger Sub that it will not be able to obtain the Debt Financing in an amount sufficient to pay the Required Amounts and on the terms, in the manner or from the sources contemplated by the Commitment Letter for any other reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Sources</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Persons that have committed or at any time commit to provide or otherwise have entered or at any time enter into agreements in connection with the Debt Financing in connection with the transactions contemplated by this Agreement, including the parties named in the Commitment Letter and any joinder agreements thereto together with their Affiliates and their Affiliates&#8217; respective controlling persons,, officers, directors, general or limited partners, members, managers, advisors, agents, employees and representatives, and the respective successors and assigns of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Fraud</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an act, committed with intent to deceive or mislead a party to this Agreement, and to induce it to enter into this Agreement, that involves (a) a false representation or warranty of material fact in connection with the transactions contemplated by this Agreement&#59; (b) actual knowledge by the party making such representation or warranty that such representation or warranty is false&#59; (c) an intention to induce the Person to whom such representation or warranty is made to act or refrain from acting in reliance upon it&#59; (d) causing that Person, in justifiable reliance upon such false representation or warranty and with ignorance to the falsity of such representation or warranty, to take or refrain from taking action&#59; and (e) causing such Person to suffer damage by reason of such reliance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means United States generally accepted accounting principles, in effect as of the date hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any government, governmental agency, department, bureau, office, commission, authority, or instrumentality, or its designee, or court of competent jurisdiction, or any subdivision thereof, or any mediator, arbitrator or arbitral body, in each case whether foreign, federal, state, or local.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all permits, licenses, franchises, orders, registrations, certificates, consents, approvals and other authorizations obtained from or issued by any Governmental Authority, including, without limitation, those listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any hazardous or toxic materials, substances or wastes, including toxic chemicals, petroleum products or byproducts, friable asbestos and polychlorinated biphenyls.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Health Care Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Laws pertaining to health care regulatory matters applicable to the Company Group, including, but not limited to&#58; (a) the Federal Health Care </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Program Anti-Kickback Statute, 42 U.S.C. &#167; 1320a-7b(b)&#59; (b) the Federal physician self-referral law, 42 U.S.C. &#167; 1395nn&#59; (c) the False Claims Act, 31 U.S.C. &#167;&#167; 3729-3733 (as amended from time to time)&#59; (d) the Program Fraud Civil Remedies Act, 31 U.S.C. &#167;&#167; 3801-3812&#59; (e) the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; 1320a-7a and 1320a-7b&#59; (f) the Exclusion Laws, 42 U.S.C. &#167; 1320a-7&#59; (g) HIPAA&#59; (h) any state and local Laws regulating the privacy or security of personally identifiable health care data, in each case as amended from time to time&#59; (i) the Medicare statute, Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167; 1395-1395lll, and the Medicaid statute, Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; 1396-1396w-5 (the Medicaid statute)&#59; (j) any Laws concerning the splitting of health care professional fees&#59; (k) any state health care professional licensure Laws&#59; (l) any Laws relating to billing or claims for reimbursement for health care services, including Laws related to patient charges, timely repayment of overpayments and submissions to any payor&#59; (m) all Laws related to the storage, dispensing, administering, transportation, and maintenance of controlled substances, pharmaceuticals, drugs or devices, including, the Federal Controlled Substances Act, 21 U.S.C. &#167; 801 et seq., the Food, Drug and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq., the Prescription Drug Marketing Act of 1987, and the Drug Supply Chain Security Act of 2013&#59; (n) all Laws relating to the provision of, or billing or payment for health care items or services&#59; and (o) all Laws relating to utilization review, payors, third-party administrators, preferred provider networks, warranties, discounts, rebates, licensing, kickbacks, claims, processing, risk-bearing organizations and insurers.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HIPAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Health Insurance Portability and Accountability Act of 1996, the Health Information Technology for Economic and Clinical Health Act (Title XIII of the American Recovery and Reinvestment Act of 2009), and as otherwise may be amended from time to time, and any and all implementing regulations, as in effect from time to time, including, but not limited to, the Privacy Standards (45 C.F.R. Parts 160 and 164, Subparts A and E), the Electronic Transactions Standards (45 C.F.R. Parts 160 and 162), the Security Standards (45 C.F.R. Parts 160 and 164, Subparts A and C), and the Notification in the Case of Breach of Unsecured Protected Health Information Standards (45 CFR Part 164, Subpart D).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HSR Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended from time to time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Income Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any net income Tax, or any franchise, margin or similar Tax (however denominated) incurred in lieu of a Tax on net income.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person at any date, without duplication&#58; (i) all obligations of such Person for borrowed money&#59; (ii) all obligations of such Person in respect of letters of credit, surety bonds, performance bonds, bankers&#8217; acceptances, or similar obligations to the extent drawn upon&#59; (iii) any monetary obligations of such Person evidenced by any note, bond, debenture or other debt security&#59; (iv) any monetary obligations of a Person secured by a Lien against the assets of such Person other than Permitted Liens, other than trade payables entered into in the ordinary course of business, (v) all interest rate swaps, collars, caps and similar hedging obligations&#59; (vi) the deferred purchase price of property or services in respect of which the Company Group is liable, contingently or otherwise (including &#8220;earn-outs&#8221; and &#8220;seller notes&#8221; payable with respect to the acquisition of any business, assets or securities and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any related broker fees) assuming the maximum amount thereof&#59; (vii) all indebtedness created or arising under any conditional sale or other title retention agreement with respect to property acquired by a Person (even though the rights and remedies of such Person or lender under such agreement in the default are limited to repossession or sale of such property)&#59; (viii) all obligations of the Company Group as lessee under leases that have been or should be, in accordance with GAAP, recorded as capital leases or financing leases on the balance sheet&#59; (ix) any obligations for declared but unpaid dividends or other obligations owed to the Company Stockholders or Company Optionholders&#59; (x) unpaid severance or other termination-related payments or benefits arising as a result of the termination of any employment or individual service relationship with the Company prior to the Closing, together with the employer-portion of any payroll, social security, unemployment or similar Taxes arising therefrom&#59; (xi) all Liabilities with respect to accrued but unpaid bonus and commission payments, together with the employer portion of any payroll, social security, unemployment or similar Taxes arising therefrom&#59; (xii) the amount of Accrued Income Taxes, (xii) obligations for deferred payroll Taxes under the CARES Act&#59; (xiii) liabilities for earned but unpaid 401(k), deferred compensation, profit sharing, matching contribution or claim, premium or other costs associated with an Employee Plan&#59; (xiv) liabilities related to any underfunded liability under any Employee Plan that is a nonqualified deferred compensation plan, defined benefit pension plan, or retiree health or welfare plan that is sponsored or maintained by such Person&#59; (xv) any guarantees or other direct or indirect liability of such Person (including the incurrence of a Lien) with respect to any of the foregoing obligations in clauses (i) through (xiv) of any other Person&#59; and (xvi) any accrued interest and fees (including prepayment penalties, premiums, breakage costs, fees and other costs and expenses associated with repayment) related to any of the foregoing. Notwithstanding the foregoing, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; will exclude all amounts, costs, fees, expenses and payment obligations to the extent included in Company Transaction Expenses or Working Capital.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i)&#160;in the case of an individual, the actual knowledge of such individual without independent investigation, (ii) in the case of the Company, the actual knowledge of Vince Coppola, Sherwin Krug, Amy Schornick, and Brian Holt, in each case without independent investigation, (iii)&#160;in the case of any other Person that is not an individual, the actual knowledge of the chief executive officer and chief financial officer (or persons serving in similar capacities) of such Person, in each case without independent investigation and (iv) in the case of the Purchaser, the actual knowledge of Seth Blackley, John Johnson and Jonathan Weinberg, in each case without independent investigation&#59; provided that the inclusion of Mr. Weinberg shall not require disclosure that would operate to waive any legal privilege afforded to information known to (or work product of or held by) Mr. Weinberg in his role as General Counsel to the Evolent Entities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, all foreign, federal, state, local or municipal laws, statutes, ordinances, directives, regulations, and rules, and all orders, writs, injunctions, awards, judgments and decrees (and any regulations promulgated thereunder), and other legislative measures or decisions having the force of law, treaties, conventions and other agreements between states, or between states and supranational bodies, rules of common law, and equity and all civil or other codes, applicable to the assets, properties and business of the applicable Person.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Leased Real Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all of the right, title and interest of the Company Group under all written leases, subleases, licenses, concessions and other agreements (written or oral) other than bailment arrangements, pursuant to which the Company Group holds a leasehold or sub-leasehold estate in, or is granted the right to use or occupy, any land, buildings, improvements, fixtures or other interest in real property which is used in the operation of the Business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all debts, liabilities, commitments and obligations, whether accrued or fixed, absolute or contingent, matured or unmatured, determined or determinable, liquidated or unliquidated, asserted or unasserted, known or unknown, whenever or however arising, including those arising under any Law or any Action or order of a Governmental Authority and those arising under any Contract, regardless of whether such debt, liability, commitment or obligation would be required to be reflected on a balance sheet prepared in accordance with GAAP or disclosed in the notes thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any mortgage, pledge, security interest, encumbrance, equitable or ownership interest, lien, license, option, right of first offer or first refusal, restriction, restrictive covenant, easement, charge or claim or any other similar interest or encumbrance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the amount of any losses, claims, demands, obligations, deficiencies, assessments, judgments, penalties, Taxes, costs, liabilities, damages or expenses (including reasonable legal fees and costs of investigation).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any event, circumstance, change, occurrence or effect (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that, individually or in the aggregate, has had, or would be reasonably expected to have, a material and adverse effect upon the assets, liabilities, financial condition or operating results of the Company Group, taken as a whole&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, none of the following (either alone or in combination with any other Event) shall be deemed to constitute, and none of the following shall be taken into account in determining whether there has been, a Material Adverse Effect&#58; any adverse Event, to the extent arising from or relating to (i) general business, industry or economic conditions, including such conditions related to the Business, (ii) any failure by one or more members of the Company Group to meet its financial projections, estimates or budgets (but not excluding, for the avoidance of doubt, any and all underlying causes of such failure), (iii) national or international political or social conditions, including the engagement by the United States or any other country or group in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack upon the United States or any other country, or any of their respective territories, possessions, or diplomatic or consular offices or upon any military installation, equipment or personnel of the United States or any other country or group,  or any cyber terrorism, or the conflict between the Russian Federation and Ukraine including the impact of any sanctions or embargos related thereto and any involvement of member states of the North Atlantic Treaty Organization and any effects thereof, (iv)&#160;changes in GAAP after the date hereof, (v)&#160;changes in law, rules, regulations, orders, or other binding directives issued by any Governmental Authority, in each case after the date hereof, (vi)&#160; the taking of any action required by this Agreement and the other agreements contemplated hereby, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that this clause (vi) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall not diminish the effect of, and shall be disregarded for purposes of, the representations and warranties contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the covenants contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (vii) changes affecting capital market conditions in the United States or any other country, (viii) any &#8220;act of God,&#8221; including, but not limited to, weather, natural disasters and earthquakes, (ix)&#160; the public announcement of the execution of this Agreement or the transactions contemplated hereunder (including, to the extent arising from such announcement, any cancellation of or delays in customer purchases or orders, any reduction in sales, any disruption in supplier, distributor, partner or similar relationships or (x) the termination or threatened termination of any agreements set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (excluding, for the avoidance of doubt, any such actions caused directly or indirectly by a breach of the representations contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), in the case of clauses (i), (iii), (v), (vii), and (viii), except to the extent such event has a disproportionate effect on the Company Group as compared to other participants in the Company Group&#8217;s industry.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Measurement Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean 11&#58;59 pm ET on the Business Day immediately prior to the Closing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Accredited Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Seller who is not an Accredited Investor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">NYSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the New York Stock Exchange.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parent Public Disclosure Record</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all reports, schedules, forms, registration statements, statements and other documents (including exhibits and other information incorporated therein) furnished or filed by or on behalf of Parent on EDGAR in the period starting four (4) years prior the date hereof and ending on the second Business Day prior to the date hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parent Share Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the volume weighted average closing price of such Parent Shares on the New York Stock Exchange for the ten (10) trading days ending on the last trading day immediately prior to the Closing Date. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parent Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; mean shares of Class A Common Stock of Parent, par value $0.01 per share.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all Federal Health Care Program and all other health care service plans, health maintenance organizations, health insurers and&#47;or other private, commercial, or governmental third-party payors.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i)&#160;cashiers&#8217;, landlords&#8217;, mechanics&#8217;, materialmens&#8217;, carriers&#8217;, workmens&#8217;, repairmens&#8217;, contractors&#8217; and warehousemens&#8217; Liens arising or incurred in the ordinary course of business and for amounts which are not delinquent or are being contested in good faith by appropriate proceedings and for which appropriate reserves have been established in accordance with GAAP, (ii)&#160;easements, covenants, conditions, rights-of-way, restrictions and other similar charges and encumbrances of record and other title defects not interfering materially with the ordinary conduct of the Business or detracting materially from the use, occupancy, value or marketability of title of the assets subject thereto, (iii) statutory Liens for current Taxes not yet due and payable or Liens for Taxes the validity of which are being </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">contested in good faith by appropriate proceedings by the Company Group and for which appropriate reserves have been established in accordance with GAAP, (iv) purchase money Liens securing rental payments under capital lease or finance lease arrangements, (v) zoning, building codes or other land use Laws regulating the use or occupancy of the Leased Real Property or the activities conducted thereon which are imposed by any Governmental Authority having jurisdiction over such Leased Real Property which are not violated by the current use or occupancy of such Leased Real Property or the operation of the Business, (vi) non-exclusive licenses of Intellectual Property Rights granted to a customer or service provider in the ordinary course of business in connection with the provision or receipt by the Company Group of products and services, (vii) Liens granted to any lender at the Closing in connection with any financing by the Evolent Entities of the transactions contemplated hereby and (viii) any other Liens set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;1.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated association, corporation, limited liability company, entity or governmental entity (whether federal, state, county, city or otherwise and including, without limitation, any instrumentality, division, agency or department thereof).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pre-Closing Tax Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any taxable period (or portion thereof) ending on or prior to the Closing Date.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Rights Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Registration Rights Agreement to be entered into by Parent and TPG Growth V Iceman, L.P. and each other Seller that wishes to receive registration rights with respect to Parent Shares received by such Seller, at the Closing in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Required Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) the Financial Statements, (ii) the unaudited consolidated balance sheet of the Company Group as of March 31, 2022 and the related unaudited consolidated statements of operations, stockholders&#8217; equity and cash flows for the three-month period then ended and (iii) the unaudited consolidated balance sheet of the Company Group and related unaudited consolidated statements of operations, stockholders&#8217; equity and cash flows for each fiscal quarter ending after March 31, 2022 and at least forty-five (45) days prior to the Closing Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Cash which is not freely usable by the Company Group because it is subject to restrictions or limitations on use or distribution by Law, by Contract, or otherwise, including amounts restricted associated with contractual arrangements.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any country or geographic region that has been the subject of comprehensive Sanctions, within the last three (3) years, which currently includes, without limitation&#58; Belarus, Cuba, Iran, North Korea, Russia, Sudan, Syria, and the Crimea, Donetsk, and Luhansk regions of Ukraine, as well as the following countries subject to targeted sectoral sanctions&#58; Belarus and Russia. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Person that (a) appears on one or more Restricted Party List, (b) is a resident in, located in, or organized under the laws of a Restricted Country, or (c) is majority-owned or controlled by any of the foregoing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Party Lists</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; include the list of sanctioned entities maintained by the United Nations&#59; the Specially Designated Nationals and Blocked Persons List, the Foreign Sanctions Evaders List and the Sectoral Sanctions Identifications List, all administered by the Office of Foreign Assets Control&#59; the U.S. Denied Persons List, the U.S. Entity List, and the U.S. Unverified List, all administered by the U.S. Department of Commerce&#59; the consolidated list of Persons, Groups and Entities Subject to E.U. Financial Sanctions, as implemented by the E.U. Common Foreign &#38; Security Policy&#59; and similar lists of restricted parties maintained by other Governmental Authorities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means those trade, economic and financial sanctions Laws, regulations, embargoes, and restrictive measures (in each case having the force of law) administered, enacted or enforced from time to time by (a) the United States (including without limitation the Department of Treasury, Office of Foreign Assets Control), (b) the European Union and enforced by its member states, (c) the United Nations, (d) Her Majesty&#8217;s Treasury, or (e) other similar governmental bodies with regulatory authority over the Company and its Subsidiaries and their respective operations from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the disclosure schedules to this Agreement delivered by the Company and the Sellers concurrently herewith.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities Act of 1933, as amended from time to time, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sellers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Company Stockholders and the Company Optionholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Share Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the number of Parent Shares equal to the quotient of (i) the Share Consideration Amount </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">divided by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (ii) the Parent Share Price.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Share Consideration Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Enterprise Value </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Cash Consideration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any option that is exercisable for shares of Company Stock and that was granted under any Company Stock Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, any partnership, limited liability company, corporation or other business entity of which (i) if a corporation, a majority of the total voting power of shares of capital stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (ii) if a partnership, limited liability company or other business entity, a majority of the partnership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a combination thereof. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Target Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;1.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all foreign, federal, state or local income, gross receipts, franchise, estimated, alternative minimum, add-on minimum, sales, gain, use, transfer, real property gains, registration, value added, excise, natural resources, assessment under Section 4980H of the Code, severance, stamp, occupation, premium, windfall profit, environmental, customs, duties, real property, personal property, capital stock, social security, unemployment, disability, payroll, license, profits, escheat, abandoned, or unclaimed property obligation, employment, employee, withholding or other taxes of any kind, including any interest, penalties or additions thereto, in each case, whether disputed or not.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Benefit Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any payment to be made to Sellers under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Contest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; is defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(e)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Return</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any return, declaration, report, claim for refund, information return or other document (including any related or supporting schedule, statement or information) filed or required to be filed in connection with the determination, assessment or collection of any Tax of any party or the administration of any laws, regulations or administrative requirements relating to any Tax, and including any amendment thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Tax Deductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Income Tax deductions, losses, or credits that are deductible in a Pre-Closing Tax Period of the Company Group, determined at a &#8220;more likely than not&#8221; (or greater) level of comfort, and that relate to or arise from (a) the payment of Company Transaction Expenses, (b) the payments in respect of Options pursuant to or contemplated by this Agreement or any other compensation payable as a result of the transactions contemplated by this Agreement, and (c) the employer portion of payroll, social security, unemployment or similar Taxes arising from the payments described in clause (b), and (d) any other payments attributable to the transactions contemplated by this Agreement that are economically borne by Sellers. Transaction Tax Deductions shall include any net operating loss of the Company Group to the extent attributable to the foregoing deductions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Tax Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any actual reduction in Income Taxes of Parent, Purchaser, the Company Group or any of their Subsidiaries paid to a Governmental Authority with respect to any taxable year beginning on or before the date that is twenty-four (24) months following the Closing Date as a result of the Transaction Tax Deductions, determined on a with and without basis and in accordance with the same principles provided for in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">WARN Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Worker Adjustment Retraining and Notification Act of 1988, as amended from time to time, and the rules and regulations promulgated thereunder, or any similar foreign, state or local law, regulation or ordinance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#160;(i) current assets, less (ii) current liabilities, each excluding Cash, Restricted Cash,&#160;deferred tax asset and liabilities, Indebtedness, unpaid Company Transaction Expenses, Excluded Aetna Receivables, prepaid expenses, interest </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">receivables and operating lease liabilities, each component determined in accordance with the Accounting Principles as illustrated on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For the avoidance of doubt, Working Capital shall not include any purchase accounting or other adjustment arising out of the consummation of the transactions contemplated by this Agreement or any previous transaction.&#160;</font></div><div id="i649a3a409a124fa4b643ff6500d07394_37"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Cross-References</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of the following terms shall have the meaning specified in the Section of this Agreement set forth opposite such term&#58;</font></div><div style="padding-left:37.62pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.134%"><tr><td style="width:1.0%"></td><td style="width:70.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">280G Approval</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7(d)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accounting Arbitrator</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(c)(ii)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Actual Cash</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(b)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Actual Company Transaction Expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(b)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Actual Indebtedness</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(b)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Actual Working Capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(b)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Adjusted Aggregate Initial Cash Consideration</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(d)(i)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Antitrust Law</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5(b)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable Percentage</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(c)(iii)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Business Associate Agreements</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.13(g)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certificate of Merger</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Closing</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Closing Date</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Closing Statement</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company Board</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company IP Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.10(a)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company Related Persons</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2(c)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company Software</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.10(b)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidentiality Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Continuing Employees</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7(c)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Contracting Parties</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D&#38;O Beneficiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D&#38;O Claim</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7(a)</font></div></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:37.62pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.134%"><tr><td style="width:1.0%"></td><td style="width:70.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D&#38;O Insurance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dispute Notice</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(c)(ii)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dissenting Stock</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.11(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DGCL</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Downward Closing Working Capital Adjustment</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective Time</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Pension Plans</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.16(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Plans</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.16(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Welfare Plans</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.16(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Estimated Cash</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Estimated Company Transaction Expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Estimated Indebtedness</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Estimated Working Capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Events</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Evolent Entities</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fee Letters</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.7(b)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Final Cash</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(c)(i)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Final Company Transaction Expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(c)(i)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Final Indebtedness</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(c)(i)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Final Working Capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10(c)(i)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financial Statements</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Information Security Reviews</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.10(l)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Insurance Cap</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Insurance Policies</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Latest Balance Sheet</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Letter of Transmittal</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liability Cap</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Malicious Code</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.10(a)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Material Customer</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.9(a)(xii)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Material Supplier</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.9(a)(xiii)</font></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:37.62pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.134%"><tr><td style="width:1.0%"></td><td style="width:70.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Merger</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Merger Sub</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Multiemployer Plan</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.16(b)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Plans</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7(c)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nonparty Affiliates</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Optionholder Cash Consideration</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6(d)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Optionholder Cash Payment</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7(b)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Optionholder Consideration</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6(d)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Optionholder Earnout Consideration</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6(d)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Optionholder Share Consideration</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6(d)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other Plans</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.16(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Outbound IP Contracts</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.9(a)(ix)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Parent</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payoff Letters</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Privacy Laws</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.10(a)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prospectus Supplement</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Purchaser</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Purchaser Disclosure Schedule</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Purchaser Entities</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Purchaser Financial Statements</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.13</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Purchaser Prepared Returns</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.8(b)(ii)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Purchaser Related Persons</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2(c)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recourse Exceptions</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regulatory Filings</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.13(g)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Repaid Indebtedness</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Representation and Warranty Policy</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Representatives</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Required Amounts</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.9(a)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SEC Filings</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.12(e)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 280G</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7(d)</font></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:37.62pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.134%"><tr><td style="width:1.0%"></td><td style="width:70.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 280G Payments</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7(d)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller Termination Fee Expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2(c)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sellers&#8217; Counsel</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6(f)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sellers&#8217; Representative</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sellers&#8217; Representative Expense Fund</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6(e)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Solvent</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Straddle Period</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.8(a)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stockholder Cash Consideration</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6(a)(i)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stockholder Cash Payment</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7(a)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stockholder Consideration</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6(a)(i)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stockholder Earnout Consideration</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6(a)(i)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stockholder Share Consideration</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Surviving Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Termination Date</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1(d)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Termination Fee</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2(b)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trademarks</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.10(a)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upward Closing Working Capital Adjustment</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VDR</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Written Consent</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recitals</font></td></tr></table></div><div style="padding-left:37.62pt"><font><br></font></div><div id="i649a3a409a124fa4b643ff6500d07394_40"></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 2</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">THE MERGER</font></div><div id="i649a3a409a124fa4b643ff6500d07394_43"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">The Merger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At the Effective Time and subject to and upon the terms and conditions of this Agreement and the applicable provisions of the DGCL and the Company Charter and Bylaws, Merger Sub shall be merged with and into the Company, the separate corporate existence of Merger Sub shall cease, and the Company shall continue as the Surviving Corporation and as a wholly-owned Subsidiary of Purchaser (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Merger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div id="i649a3a409a124fa4b643ff6500d07394_46"></div><div style="margin-bottom:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">The Closing and the Effective Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The closing of the transactions contemplated by this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall take place at the offices of Ropes &#38; Gray LLP, 3 Embarcadero Center, San Francisco California, commencing at 10&#58;00 a.m. local time on the second Business Day following the satisfaction or waiver of all conditions of the parties to consummate the transactions contemplated by this Agreement (other than the conditions with respect to actions the respective parties will take at the Closing itself, but subject to the satisfaction of such conditions at the Closing), or at such other place or on such other date as is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">mutually agreeable to Purchaser and the Sellers&#8217; Representative&#59; provided, however, that in no event shall Evolent Entities be obligated to consummate the Closing prior to August 1, 2022.  The date of the Closing is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;  On the Closing Date, and upon the terms and subject to the conditions of this Agreement, the parties shall cause the Merger to be consummated by filing the Certificate of Merger (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate of Merger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, with the Secretary of State of the State of Delaware, as required by, and executed in accordance with, the applicable provisions of the DGCL (the time of such filing with the Secretary of State of the State of Delaware, or such later time as may be agreed upon in writing by Purchaser and the Company and specified in the Certificate of Merger, shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div id="i649a3a409a124fa4b643ff6500d07394_49"></div><div style="margin-bottom:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Effect of the Merger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At the Effective Time, the effect of the Merger shall be as provided in the applicable provisions of the DGCL. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, except as otherwise agreed to pursuant to the terms of this Agreement, all of the property, rights, privileges, powers and franchises of the Company and Merger Sub shall vest in the Surviving Corporation, and all debts, liabilities and duties of the Company and Merger Sub shall become the debts, liabilities and duties of the Surviving Corporation.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_52"></div><div style="margin-bottom:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Organizational Documents of the Surviving Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At the Effective Time, by virtue of the Merger and without any action on the part of Merger Sub or the Company, the certificate of incorporation and the bylaws of the Surviving Corporation shall be the certificate of incorporation and bylaws of Merger Sub, as in effect immediately prior to the Effective Time until duly amended as provided therein or by applicable Laws.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_55"></div><div style="margin-bottom:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Directors and Officers of the Surviving Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The directors and officers of Merger Sub immediately prior to the Effective Time shall become the directors and officers of the Surviving Corporation immediately after the Effective Time, each to hold such office in accordance with the provisions of the certificate of incorporation and bylaws of the Surviving Corporation.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_58"></div><div style="margin-bottom:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Effect of the Merger on the Company Stock, Stock Options and Merger Sub.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Effect on the Company Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At the Effective Time, by virtue of the Merger and without any action on the part of Merger Sub, the Company or the Company Stockholders, each class, series and subclass of Company Stock (other than Dissenting Stock) issued and outstanding immediately prior to the Effective Time, upon the terms and subject to the conditions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and elsewhere in this Agreement, will be cancelled and extinguished and be converted automatically into the right to receive that portion of the Final Merger Cash Consideration and Share Consideration pursuant to the Distribution Waterfall and shall no longer be outstanding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each class, series and subclass of Company Stock (other than Dissenting Stock) that is issued and outstanding immediately prior to the Effective Time shall be converted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">into the right to receive a portion of the Final Merger Cash Consideration (the &#8220;Stockholder Cash Consideration&#8221;), Share Consideration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholder Share Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Earnout Consideration, if any (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholder Earnout Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, together with the Stockholder Cash Consideration and Stockholder Share Consideration, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholder Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in accordance with the Distribution Waterfall.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each share of Dissenting Stock shall be converted into the right to receive payment from the Surviving Corporation with respect thereto in accordance with Section 2.11.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For purposes of calculating the amount to be paid to each Company Stockholder (other than holders of Dissenting Stock) at the Effective Time, the amounts described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be calculated assuming that the Final Merger Cash Consideration is equal to the Aggregate Initial Cash Consideration, and shall be adjusted following the Closing as set forth herein.  The amount to be paid to each Company Stockholder for each class, series and subclass of Company Stock (other than Dissenting Stock) held shall be rounded down to the nearest whole cent. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All classes, series and subclasses of Company Stock, when cancelled, extinguished, and converted pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, shall no longer be outstanding and shall automatically be cancelled and retired, and each former holder thereof shall cease to have any rights with respect thereto, except the right to receive the consideration provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Conversion of Merger Sub&#8217;s Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At and as of the Effective Time, each share of Merger Sub&#8217;s capital stock shall be converted into one share of Surviving Corporation&#8217;s capital stock.  Each certificate of Merger Sub evidencing ownership of any such capital stock shall automatically be deemed to evidence ownership of such interests of the Surviving Corporation.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Cancellation of Treasury Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any Company Stock that is owned by the Company and not issued and outstanding as of the Effective Time shall be automatically cancelled and shall cease to exist and no consideration shall be delivered in exchange therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At the Closing, each Stock Option outstanding as of immediately prior to the Closing will, by virtue of the Closing and without further action on the part of the holder thereof, be cancelled and each such outstanding Stock Option will be converted into the right to receive, subject to the conditions set forth herein, a portion of the Final Merger Cash Consideration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Optionholder Cash Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Share Consideration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Optionholder Share Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Earnout Consideration, if any (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Optionholder Earnout Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, and together with the Optionholder Cash Consideration, and Optionholder Share Consideration, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Optionholder Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in each case as calculated and as set forth on the Distribution Waterfall.  The Optionholder Cash Consideration shall be promptly paid to each Company Optionholder by the Company in accordance with and subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as applicable, promptly following the Closing for amounts payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and promptly following the date any such amounts become payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (and in any case by the next normal payroll date of the Company following </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the date such portion of the Optionholder Cash Consideration becomes payable pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) through the Company&#8217;s payroll systems (other than with respect to the Optionholder Consideration in respect of non-employee service providers). The Optionholder Consideration shall be paid  to such Company Optionholder following receipt by the Company of a duly executed Option Cancellation Agreement, in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and the Company shall be entitled to deduct and withhold from the consideration otherwise payable or deliverable to any Company Optionholder pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> such amounts as it is required to deduct and withhold with respect to the making of such payment under any provision of federal, state, local or foreign tax law. Any amounts required to be withheld with respect to the Optionholder Share Consideration shall reduce the amount of Optionholder Cash Consideration that would otherwise be payable to the Optionholder. If the Company so withholds such amounts, such amounts shall be treated for all purposes of this Agreement as having been paid to the Company Optionholders in respect of which the Company made such deduction and withholding.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_85"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Mechanism of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">At the Effective Time,  Purchaser or Merger Sub shall deliver, or Purchaser or Merger Sub shall otherwise take all steps necessary to cause to be delivered, by wire transfer of immediately available funds (x) the aggregate Stockholder Cash Payments (as determined as of the Effective Time) to&#160;the Company Stockholders, for exchange in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and (y) the aggregate Optionholder Cash Payments (as determined as of the Effective Time) to the Company, solely for the benefit of the Company Optionholders, for exchange in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company shall deliver the Optionholder Cash Payments to the Company Optionholders pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7(b), 2.7(c) and 2.7(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Promptly following the date hereof, the Evolent Entities and the Company will deliver a letter of transmittal (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Letter of Transmittal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to each Company Stockholder, for use in effecting delivery of shares of Company Stock. To the extent that a Company Stockholder (other than a holder of Dissenting Stock) delivers a duly executed and completed Letter of Transmittal to the Purchaser at least two (2) Business Days prior to the Closing, the Purchaser shall pay to such Company Stockholder at the Closing, such Company&#8217;s Stockholder&#8217;s portion of the Stockholder Cash Consideration as set forth for such Company Stockholder in the Distribution Waterfall (together with any cash payable to such Company Stockholder in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholder Cash Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) which amounts shall be paid or caused to be paid by the Evolent Entities by wire transfer in accordance with the instructions provided by such Company Stockholder at least two (2) Business Days prior to Closing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Following the date hereof, each Company Optionholder shall deliver to Purchaser a duly executed and completed Option Cancellation Agreement no later than three (3) Business Days prior to Closing. To the extent that a Company Optionholder delivers a duly executed Option Cancellation Agreement to the Company at least three (3) Business Days prior to Closing, the Company shall pay to such Company Optionholder at the Closing cash in an amount equal to such Company Optionholders portion of the Optionholder Cash Consideration </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">as set forth for such Company Optionholder in the Distribution Waterfall (together with any cash payable to such Company Optionholder in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Optionholder Cash Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which amounts shall be paid promptly following the Closing (and in any case by the next normal payroll date of the Company following the Closing Date) through the Company&#8217;s payroll systems (other than with respect to any Optionholder Cash Payment in respect of non-employee service providers, which payments shall be delivered to such non-employee service providers by wire transfer of immediately available funds). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Following the Closing, (x) upon delivery by a Company Stockholder (other than a holder of Dissenting Stock) to the Purchaser of a duly completed and executed Letter of Transmittal, such Company Stockholder shall be entitled to receive, as soon as practicable but in no event later than five (5) Business Days after such delivery, such Company Stockholder&#8217;s Stockholder Cash Payment, which amounts shall be paid by wire transfer in accordance with the instructions provided by such Company Stockholder and (y) upon delivery by a Company Optionholder to the Company and Purchaser of a duly executed Option Cancellation Agreement, such Company Optionholder shall be entitled to receive payment of such Company Optionholder&#8217;s Optionholder Cash Payment promptly (and in any case by the next normal payroll date of the Company following such delivery) through the Company&#8217;s payroll systems (other than with respect to Optionholder Cash Payment in respect of non-employee service providers, which payments shall be delivered to such non-employee service providers by wire transfer of immediately available funds).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">To the extent that a Company Stockholder (other than a holder of Dissenting Stock) or Company Optionholder delivers a duly executed Letter of Transmittal or Option Cancellation Agreement, as applicable, and Accredited Investor Questionnaire to the Evolent Entities at least two (2) Business Days prior to Closing and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Evolent Entities shall deliver to such Company Stockholder or Company Optionholder, and such Company Stockholder or Company Optionholder shall be entitled to receive, at or promptly following the Closing, evidence of the issuance by Parent&#8217;s transfer agent, in the form of book entry shares or in the alternative shares in certificated form representing such Company Stockholder&#8217;s Stockholder Share Consideration or such Company Optionholder&#8217;s Optionholder Share Consideration.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Following the Closing, upon delivery by a Company Stockholder (other than a holder of Dissenting Stock) or Company Optionholder of a duly executed Letter of Transmittal or Option Cancellation Agreement, as applicable, and Accredited Investor Questionnaire to the Evolent Entities, the Evolent Entities shall, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, deliver to such Company Stockholder or Company Optionholder, and such Company Stockholder or Company Optionholder shall be entitled to receive, as soon as practicable but in no event later than five (5) Business Days after such delivery, evidence of the issuance by Parent&#8217;s transfer agent, in the form of book entry shares or in the alternative shares in certificated form representing such Company Stockholder&#8217;s Stockholder Share Consideration or such Company Optionholder&#8217;s Optionholder Share Consideration.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The issuance of any Parent Shares to any Seller hereunder shall be expressly conditioned upon such Seller providing written evidence reasonably satisfactory to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Evolent Entities that such Seller is an Accredited Investor (including by delivery of an Accredited Investor Questionnaire completed in a manner satisfactory to the Evolent Entities). If any Seller is not an Accredited Investor, Purchaser and the Company shall (in lieu of issuing Parent Shares to such Seller) provide for the payment of cash as means to compensate such Non-Accredited Investors in such amounts as would have otherwise been paid in respect of such Shares determined by multiplying (x) the Parent Share Price by (y) the Parent Shares such Non-Accredited Investor would otherwise be entitled to receive pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Neither of the Evolent Entities nor the Surviving Corporation shall be liable to any Person in respect of any cash delivered to a public official pursuant to any applicable abandoned property, escheat or similar law.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">No fractional Parent Shares shall be issued in the Merger.&#160; All fractional Parent Shares that any Seller would be entitled to receive shall be aggregated and calculations shall be rounded to three decimal places.&#160; In lieu of any such fractional shares, each Seller otherwise entitled to a fractional interest in a Parent Share shall be entitled to receive a cash payment in lieu thereof (rounded to the nearest cent), which payment shall be determined by multiplying (x) the Parent Share Price by (y) the fractional interest in a Parent Share such holder would otherwise be entitled to receive pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160; As soon as practicable after determination of the amount of cash, if any, to be paid to any Seller in lieu of any fractional Parent Shares, the Purchaser shall make available such amounts, without interest, to the Sellers entitled to receive such cash.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">No Seller may assign or transfer any right to receive Parent Shares pursuant to this Agreement without the prior written consent of Parent (which may be withheld in Parent&#8217;s sole discretion), other than (i)&#160;on death by will or intestacy, (ii)&#160;pursuant to a court order, (iii)&#160;by operation of Law (including a consolidation or merger), (iv)&#160;to or for the benefit of any spouse, children, parents, uncles, aunts, siblings, grandchildren (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved Relatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or to a trust established solely for the benefit of such Seller and&#47;or his, her or its Approved Relatives or (v)&#160;without consideration, in connection with the dissolution, liquidation or termination of any corporation, limited liability company or other entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding any other provision of this Agreement, each of the Company, the Surviving Corporation, the Evolent Entities, Merger Sub and any other applicable withholding agent shall be entitled to deduct and withhold from the consideration otherwise payable to any Seller, or otherwise pursuant to this Agreement such amounts as may be required to be deducted or withheld with respect to the making of such payment under the Code, or any applicable provision of state, local or foreign Tax law.  To the extent that amounts are so deducted or withheld and paid over to the appropriate taxing authority by the Company, the Surviving Corporation, the Evolent Entities, Merger Sub or any other applicable withholding agent, such amounts shall be treated for all purposes of this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid.  The parties agree to use commercially reasonable efforts to take any action as may be necessary to mitigate, reduce or eliminate any Tax that could be imposed under applicable Law with respect to the transactions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">contemplated pursuant to this Agreement other than with respect to any compensatory payments to employees and other individual service providers and other than with respect to any withholding required as a result of the failure to timely deliver the affidavit described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2(h)(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of this Agreement.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_121"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Further Ownership Rights in the Company Stock or Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The portion of the Final Merger Cash Consideration and Share Consideration paid in respect of the exchange of Company Stock in accordance with the terms hereof shall be deemed to be in full satisfaction of all rights pertaining to such Company Stock, and, upon the Effective Time, there shall be no further registration of transfers on the records of the Surviving Corporation of Company Stock which were outstanding immediately prior to the Effective Time.  No holder of Options, nor any other participant in the Company Stock Plan shall, from and after the Closing, have any right thereunder to acquire any securities of the Company or to receive any payment or benefit with respect to any award previously granted under the Company Stock Plan and the Company Stock Plan shall be terminated effective upon the Closing.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_124"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Repaid Indebtedness&#59; Company Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It is contemplated by the parties that, upon the Closing, all Borrowed Money Indebtedness of the Company Group as of the Closing Date, including, without limitation, under the Existing Credit Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Repaid Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will be fully repaid and that Purchaser shall make or cause to be made such repayment on behalf of the Company Group out of cash proceeds otherwise payable to Sellers on the Closing Date.  In order to facilitate such repayment, prior to the Closing, the Company shall obtain and deliver to the Purchaser customary payoff letters for all Repaid Indebtedness of the Company Group, which payoff letters shall acknowledge the aggregate principal amount and all accrued but unpaid interest constituting the Repaid Indebtedness and include customary lien release and termination provisions (contingent solely upon receipt of the applicable payoff amounts set forth therein) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payoff Letters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  In addition, it is contemplated by the parties hereto that, upon the Closing, all of the Company Transaction Expenses (to the extent not paid by the Company Group prior to the Closing) will be fully paid, and that such payment will be funded by Purchaser or one of its Subsidiaries out of cash proceeds otherwise payable to Sellers.  Subject to the satisfaction of the Company Group&#8217;s conditions, covenants and obligations to be satisfied prior to the Closing, in connection with the Closing, Purchaser shall make payment of the Company Transaction Expenses on the Closing Date in order to discharge the amounts payable thereunder&#59; provided, however, that the foregoing shall not apply to Taxes included in Company Transaction Expenses, which shall be paid by the applicable member of the Company Group when due. In addition, it is contemplated by the parties hereto that, upon the Closing, Purchaser shall pay or cause to be paid the Sellers&#8217; Representative Expense Fund to the Sellers&#8217; Representative to be held in trust to cover and reimburse the fees and expenses incurred by the Sellers&#8217; Representative for its obligations in connection with this Agreement and the transactions contemplated herein.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_127"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Closing Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Determination of Closing Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No later than three (3) Business Days prior to the Closing, the Company shall provide the Evolent Entities with a statement (the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Closing Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) setting forth its good faith estimate of Working Capital as of the Measurement Time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), a good faith estimate of the aggregate amount of all Cash of the Company Group as of the Measurement Time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), a good faith estimate of the aggregate amount of all Indebtedness of the Company Group as of immediately prior to the Closing (other than with respect to Taxes included in Indebtedness, which shall be calculated as of the end of the day on the Closing Date) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), a good faith estimate of the aggregate amount of all Company Transaction Expenses of the Company Group as of immediately prior to the Closing (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Company Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the amount by which the Aggregate Initial Cash Consideration is to be adjusted on account thereof. In addition, the Estimated Closing Statement will set forth the Excluded Aetna Receivables.  The Estimated Closing Statement and the determinations contained therein shall be prepared in accordance with this Agreement, the Accounting Principles and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Sellers&#8217; Representative and the Company shall (i) provide the Evolent Entities and their Representatives with reasonable access during normal business hours to the books, records (including work papers, schedules, memoranda and other documents), supporting data, facilities and employees of the Company for purposes of their review of the Closing Statement, and (ii)&#160;reasonably cooperate with the Evolent Entities and their Representatives in connection with such review, including providing on a timely basis all other information reasonably necessary or useful in connection with the review of the Estimated Closing Statement as is requested by the Purchaser or its Representatives.  Notwithstanding anything to the contrary in this Agreement, between the Measurement Time and the Closing,&#160;the Sellers shall not, and Sellers shall not cause any member of the Company Group to, take any action (or omit to take any action) (including, for the avoidance of doubt, payment of any dividends, satisfaction of any Indebtedness, or payment of any Company Transaction Expenses) with the effect of modifying Estimated Cash, Estimated Indebtedness, Estimated Working Capital or Estimated Company Transaction Expenses (in each case as if such amounts were measured as of immediately prior to the Closing rather than as of the Measurement Time) in order to increase the Aggregate Initial Cash Consideration payable to the Sellers. If any such payments are made between the Measurement Time and the Closing which are not captured as a deduction to Aggregate Initial Cash Consideration through either a liability in Net Working Capital, Transaction Expenses or Indebtedness, Available Cash shall be reduced by the value of such payment.  For the avoidance of doubt, and without duplication, if any payments are made between the Measurement Time and the end of the day on the Closing Date which reduce the value of Accrued Income Taxes, Available Cash shall be reduced by the value of such payment.  The calculations of Actual Working Capital and Actual Cash delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be based upon the draft Closing Statement delivered pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> after the Company&#8217;s good faith consideration of the reasonable comments of the Purchaser thereon.  The Company shall also deliver to the Evolent Entities, together with the Closing Statement, the updated Distribution Waterfall reflecting amounts to be paid in accordance with this Agreement to each Company Stockholder and Company Optionholder at the Closing. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Determination of Post-Closing Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No later than seventy-five (75) days following the Closing, Purchaser shall deliver to the Sellers&#8217; Representative the calculation of the actual Working Capital as of the Measurement Time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Actual Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (prepared in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;1.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) and a calculation of the actual Cash of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Company Group as of the Measurement Time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Actual Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), a calculation of the actual aggregate amount of all Indebtedness of the Company Group as of immediately prior to the Closing (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Actual Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and a calculation of the actual aggregate amount of all Company Transaction Expenses of the Company Group as of immediately prior to the Closing (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Actual Company Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) calculated in a manner consistent with the Accounting Principles, the definitions and other applicable provisions of this Agreement. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Disputed Final Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No later than thirty (30) days following the delivery by Purchaser of the calculation of Actual Working Capital, Actual Cash, Actual Indebtedness and Actual Company Transaction Expenses, the Sellers&#8217; Representative shall notify Purchaser in writing whether it accepts or disputes the accuracy of the calculation of Actual Working Capital, Actual Cash, Actual Indebtedness and Actual Company Transaction Expenses.  During such thirty (30) day period, the Sellers&#8217; Representative and its agents shall be provided with such access to the financial books and records of the Purchaser and the Company Group as well as any relevant work papers as it may reasonably request to enable it to evaluate the Actual Working Capital, Actual Cash, Actual Indebtedness and Actual Company Transaction Expenses.  If the Sellers&#8217; Representative accepts the calculation of Actual Working Capital, Actual Cash, Actual Indebtedness and Actual Company Transaction Expenses determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, or if the Sellers&#8217; Representative fails within such thirty (30) day period to notify Purchaser of any dispute with respect thereto, then the calculation of Actual Working Capital determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; the calculation of Actual Cash determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; the calculation of Actual Indebtedness determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and the calculation of Actual Company Transaction Expenses determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Company Transaction Expenses&#8221; which, in each case, shall be deemed final and conclusive and binding. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;If the Sellers&#8217; Representative disputes the accuracy of the calculation of Actual Working Capital, Actual Cash, Actual Indebtedness or Actual Company Transaction Expenses, the Sellers&#8217; Representative shall provide written notice to Purchaser no later than thirty (30) days following the delivery by Purchaser to the Sellers&#8217; Representative of the calculation of Actual Working Capital, Actual Cash, Actual Indebtedness and Actual Company Transaction Expenses (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dispute Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), setting forth those items that the Sellers&#8217; Representative disputes.  During the thirty (30) day period following delivery of a Dispute Notice, Purchaser and the Sellers&#8217; Representative shall negotiate in good faith with a view to resolving their disagreements over the disputed items.  During such thirty (30) day period and until the final determination of Actual Working Capital, Actual Cash, Actual Indebtedness and&#47;or Actual Company Transaction Expenses in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.10(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as the case may be, (as so determined, or as determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> above, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Company Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; respectively), the Sellers&#8217; Representative and its agents shall be provided with such access to the financial books and records of the Purchaser and the Company Group as it may reasonably request.  If the parties resolve their differences over the disputed items in accordance with the foregoing procedure, Final Working Capital, Final Cash, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Final Indebtedness and Final Company Transaction Expenses shall be the amounts agreed upon by them.  If the parties fail to resolve their differences over the disputed items within such thirty (30) day period, then Purchaser and the Sellers&#8217; Representative shall forthwith jointly request that an independent national accounting firm, to be mutually agreed to at the time (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting Arbitrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) make a binding determination as to the disputed items in accordance with this Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;The Accounting Arbitrator will under the terms of its engagement have no more than thirty (30) days from the date of referral and no more than ten (10) Business Days from the final submission of information and testimony by Purchaser and the Sellers&#8217; Representative within which to render its written decision with respect to the disputed items (and only with respect to any unresolved disputed items set forth in the Dispute Notice) and the final calculation of Actual Working Capital, Actual Cash, Actual Indebtedness and Actual Company Transaction Expenses shall be based solely on the resolution of such disputed items.  The Accounting Arbitrator shall review such submissions and base its determination solely on such submissions.  In resolving any disputed item, the Accounting Arbitrator may not assign a value to any item greater than the maximum value for such item claimed by either party or less than the minimum value for such item claimed by either party.  The decision of the Accounting Arbitrator shall be deemed final and binding upon the parties and enforceable by any court of competent jurisdiction and the Accounting Arbitrator&#8217;s final calculation of Actual Working Capital shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Working Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; the Accounting Arbitrator&#8217;s final calculation of Actual Cash shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Cash,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; the Accounting Arbitrator&#8217;s final calculation of Actual Indebtedness shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and the Accounting Arbitrator&#8217;s final calculation of Actual Company Transaction Expenses shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Company Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.&#8221; The fees and expenses of the Accounting Arbitrator shall be allocated to be paid by Purchaser, on the one hand, and the Sellers&#8217; Representative (on behalf of the Sellers, severally and not jointly, in proportion to the applicable percentage set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;2.11(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)), on the other, based upon the percentage that the portion of the contested amount not awarded to each party bears to the amount actually contested by such party, as determined by the Accounting Arbitrator.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Payment following Calculation of Final Working Capital, Final Cash, Final Indebtedness, and Final Company Transaction Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Following the final determination of Final Working Capital, Final Cash, Final Indebtedness and Final Company Transaction Expenses, the Aggregate Initial Cash Consideration shall be recalculated by substituting the Final Working Capital for the Estimated Working Capital in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Final Cash for the Estimated Cash in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Final Indebtedness for the Estimated Indebtedness in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Final Company Transaction Expenses for the Estimated Company Transaction Expenses in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adjusted Aggregate Initial Cash Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and if (after taking into account any Upward Closing Working Capital Adjustment or Downward Closing Working Capital Adjustment at the Closing) (A) the Adjusted Aggregate Initial Cash Consideration is greater than the Aggregate Initial Cash Consideration on the Closing Date, then such difference shall be paid or caused to be paid by Purchaser to the Company Stockholders in accordance with such Person&#8217;s Applicable Percentage and to the Surviving Corporation (for the benefit of the Company Optionholders in accordance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with such Person&#8217;s Applicable Percentage) (provided that such amount to be paid or caused to be paid by Purchaser pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not exceed the amount of the Adjustment Escrow Fund)&#59; or (B) the Aggregate Initial Cash Consideration on the Closing Date is greater than the Adjusted Aggregate Initial Cash Consideration, then the Purchaser and the Sellers&#8217; Representative shall deliver joint written instructions to the Escrow Agent directing the Escrow Agent to release such difference from the Adjustment Escrow Fund to Purchaser or one of its subsidiaries (provided that such amount paid to the Purchaser or one of its subsidiaries pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not exceed the amount of the Adjustment Escrow Fund) and to release any remaining funds, after payment of any adjustment to Purchaser or one of its subsidiaries, to the Company Stockholders in accordance with such Person&#8217;s Applicable Percentage and to the Surviving Corporation (for the benefit of the Company Optionholders in accordance with such Person&#8217;s Applicable Percentage). In the event that (i) the full amount (if any) by which the Aggregate Initial Cash Consideration on the Closing Date exceeds the Adjusted Aggregate Initial Cash Consideration is greater than the Adjustment Escrow Fund, Purchaser shall have no recourse against the Sellers&#8217; Representative, the Sellers or any other Person beyond the amount of the Adjustment Escrow Fund, and (ii) the full amount (if any) by which the Adjusted Aggregate Initial Cash Consideration is greater than the Aggregate Initial Cash Consideration is greater the amount of the Adjustment Escrow Fund, the Sellers&#8217; Representative and the Sellers shall have no recourse against the Purchaser or the Surviving Corporation or any other Person beyond the amount of the Adjustment Escrow Fund.  </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;All payments pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be made by wire transfer of immediately available funds to an account designated in advance by the Sellers&#8217; Representative, the Company or Purchaser, as applicable, and all such payments and releases from the Adjustment Escrow Fund, as applicable, shall be made on or prior to the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Business Day following&#58; (A) the thirty (30) day period following Purchaser&#8217;s delivery of the calculation of the Actual Working Capital and Actual Cash pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> if the Sellers&#8217; Representative does not timely dispute either of such amounts pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; (B) the date of the Sellers&#8217; Representative&#8217;s and Purchaser&#8217;s mutual determination of Final Working Capital, Final Indebtedness, Final Transaction Expenses and Final Cash in the event the Sellers&#8217; Representative timely disputes either of such amounts pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Sellers&#8217; Representative&#8217;s and Purchaser&#8217;s differences are resolved without the engagement of an Accounting Arbitrator pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; and (C) the date of the Accounting Arbitrator&#8217;s determination of Final Working Capital, Final Indebtedness, Final Transaction Expenses and&#47;or Final Cash pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in the event the Sellers&#8217; Representative timely disputes either of such amounts pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Sellers&#8217; Representative and Purchaser are unable to resolve their differences pursuant to Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2.10(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All payments pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be treated as adjustments to the purchase price for Tax purposes, unless otherwise required by Law.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_157"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Dissenting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Notwithstanding any provision of this Agreement to the contrary, shares of Company Stock that are outstanding immediately prior to the Effective Time and that are held by Company Stockholders who shall have not voted in favor of the Merger and who shall have demanded properly in writing appraisal for such shares in accordance with Section 262 of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DGCL (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dissenting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall not be converted into, or represent the right to receive, any portion of the Aggregate Initial Cash Consideration or Final Merger Cash Consideration, Share Consideration and Earnout Consideration payable pursuant to the terms of this Agreement.  Such holders of Company Stock shall be entitled to receive payment of the appraised value of such shares of Company Stock held by them in accordance with the provisions of such Section 262, except that all Dissenting Stock held by the holders of Company Stock who shall have failed to perfect or who effectively shall have withdrawn or lost their rights to appraisal of such shares under such Section 262 shall thereupon have the rights provided in Section 262.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company shall give (i)&#160;Purchaser and the Sellers&#8217; Representative prompt written notice of any demands for appraisal received by the Company, withdrawals of such demands, and any other instruments served pursuant to the DGCL and received by the Company and (ii)&#160;Purchaser the opportunity to direct all negotiations and proceedings with respect to demands for appraisal under the DGCL.  The Company shall not, except with the prior written consent of Purchaser, make any payment with respect to any demands for appraisal or offer to settle or settle any such demands.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_166"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Earnout Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company Stockholders and Company Optionholders shall be eligible to receive the Shareholder Earnout Consideration and the Optionholder Earnout Consideration, respectively, if any, as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto. Notwithstanding the foregoing, any portion of the Earnout Consideration otherwise issuable to a Company Stockholder or Company Optionholder who is not an Accredited Investor may be in the form of cash as opposed to Parent Shares. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_7003"></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 3</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CONDITIONS TO CLOSING</font></div><div id="i649a3a409a124fa4b643ff6500d07394_7008"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Conditions to the Obligations of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The obligations of the Company to consummate the transactions contemplated by this Agreement are subject to the satisfaction of the following conditions on or before the Closing Date&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">each of the representations and warranties set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be true and correct as if the Closing Date were substituted for the date of this Agreement throughout such representations and warranties (except that such representations and warranties that are made as of a specific date need only be true and correct as of such date), except where the failure of any such representations and warranties to be true and correct has not had, individually or in the aggregate, a material adverse effect on the ability of the Evolent Entities or Merger Sub to consummate the transactions contemplated hereby&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Evolent Entities and Merger Sub shall have performed in all material respects all the covenants and agreements required to be performed by each of them under this Agreement prior to the Closing&#59;  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any applicable waiting period under the HSR Act relating to the transactions contemplated by this Agreement shall have expired or been terminated&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">no law or order shall have been enacted or entered into after the date hereof that would prohibit the consummation of the Merger&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Escrow Agreement shall have been duly executed by Purchaser and the Escrow Agent&#59; </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Purchaser shall have delivered to the Sellers&#8217; Representative each of the following&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a certificate from an officer of each of the Evolent Entities and Merger Sub in the form set forth as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> attached hereto, dated as of the Closing Date, stating that the applicable preconditions specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 3.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> have been satisfied&#59; </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;certified copies of the resolutions duly adopted by the board of directors (or equivalent governing bodies) of each of the Evolent Entities and Merger Sub authorizing the execution, delivery and performance of this Agreement, the other agreements contemplated hereby, and the consummation of all transactions contemplated hereby and thereby&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the Registration Rights Agreement duly executed by Purchaser&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;a Purchase Price Adjustment Agreement substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Price Adjustment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) duly executed by Purchaser.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any condition specified in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> may be waived by the Sellers&#8217; Representative on behalf of the Sellers and the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, however, that no such waiver will be effective against the Sellers or the Company unless it is set forth in a writing executed by the Sellers&#8217; Representative.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_205"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Conditions to Evolent Entities&#8217; Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The obligation of the Evolent Entities and Merger Sub to consummate the transactions contemplated by this Agreement is subject to the satisfaction of the following conditions on or before the Closing Date&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">(i) the representations and warranties set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (other than Company Fundamental Reps and those representations and warranties that address matters as of particular dates) shall be true and correct as of the date of this Agreement and as of the Closing Date as though then made, (ii) the representations and warranties set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that address matters as of particular dates (other than the Company Fundamental Reps) shall be true and correct as of such dates, except in the case of clauses (i) and (ii) above where the failure of such representations and warranties to be so true and correct have not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect (without giving effect to materiality, Material Adverse Effect or similar phrases in such representations and warranties), and (iii) the Company Fundamental Reps shall be true and correct in all but de minimis respects as of the date of this Agreement and as of the Closing Date as though then made&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Company shall have performed in all material respects all of the covenants and agreements required to be performed by it under this Agreement prior to the Closing&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">there shall not have occurred any facts, events, changes, developments or effects which, individually or in the aggregate, has constituted or would reasonably expected to constitute a Material Adverse Effect&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">any applicable waiting period under the HSR Act relating to the transactions contemplated by this Agreement shall have expired or been terminated&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">no law or order shall have been enacted or entered into after the date hereof that would prohibit the consummation of the Merger&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the Escrow Agreement shall have been duly executed by the Sellers&#8217; Representative and the Escrow Agent&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The agreements set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.2(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have been terminated without any further liability to the Company or its Subsidiaries&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the following shall have been delivered to the Evolent Entities&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a certificate from an officer of the Company in the form set forth as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> attached hereto, dated as of the Closing Date, stating that the applicable preconditions specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 3.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> have been satisfied&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;certified copies of the resolutions duly adopted by the Company Board authorizing the execution, delivery and performance of this Agreement, the other agreements contemplated hereby, and the consummation of all transactions contemplated hereby and thereby&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;a duly completed and executed affidavit, issued pursuant to Sections 1.897-2(h) and 1.1445-2(c) of the Treasury Regulations, certifying under penalties of perjury that the shares of Company Stock are not United States real property interests within the meaning of Section 897(c) of the Code, together with an accompanying notice to the IRS, in each case, in a form reasonably acceptable to Purchaser and the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Form of FIRPTA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), provided that Purchaser&#8217;s only remedy for failing to deliver the affidavit required under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2(h)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be to withhold such amounts as are required by law to be withheld&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;the Written Consents&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;written letters of resignation from each of the current members of the board of directors of each member of the Company Group (only in their capacities as directors), in each case effective at the Effective Time&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;the Registration Rights Agreement duly executed by TPG Growth V Iceman, L.P. and each other Seller that wishes receive registration rights with respect to Purchaser Shares received by such Seller&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;the Purchase Price Adjustment Agreement duly executed by TPG Growth V Iceman, L.P. and each other Seller receiving Purchaser Shares&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Company shall have delivered the Payoff Letters to the Evolent Entities not later than two (2) days prior to the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any condition specified in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> may be waived by Purchaser, on behalf of the Evolent Entities and Merger Sub&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, however, that no such waiver shall be effective unless it is set forth in a writing executed by Purchaser.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_256"></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 4</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COVENANTS PRIOR TO CLOSING</font></div><div id="i649a3a409a124fa4b643ff6500d07394_259"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Affirmative Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  From the date hereof and prior to the earlier to occur of the Closing Date and the date that this Agreement is terminated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, except as otherwise provided herein or as required by law, the Company shall and shall cause each other member of the Company Group to&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">use its reasonable best efforts to conduct the Business in the ordinary course of business and as is consistent in all material respects with past custom and practice, and the Company shall (and shall cause the Company Group to) use reasonable best efforts to preserve substantially intact its present business organization and its existing relationships with the Company Group's customers and suppliers&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the parties agree that the Company shall not make or be required to make payments of estimated Taxes for its taxable year beginning on January 1, 2022&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">cooperate reasonably with Purchaser in Purchaser&#8217;s investigation of the Business and its properties, to permit Purchaser and its authorized representatives, at the sole cost of Purchaser, to (i)&#160;have reasonable access to its premises, books and records, during normal business hours and with reasonable prior written notice, (ii)&#160;visit and visually inspect any of its properties during normal business hours and with reasonable prior written notice, and (iii)&#160;discuss its affairs, finances and accounts with its key employees identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;4.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Purchaser shall coordinate all contact with any of the key employees through the Sellers&#8217; Representative or its designee&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, notwithstanding anything to the contrary in this Agreement, none of the Sellers or the Company shall be required to disclose any information if such disclosure would, in the sole discretion of the Sellers&#8217; Representative, (A) result in the waiver of any attorney-client or other legal privilege or (B) contravene any applicable Laws or regulations, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Sellers or the Company, as applicable, shall give the Purchaser reasonable notice of such decision and attempt to avoid such failure to disclose to the extent possible under applicable Law or in a manner to retain legal or other privilege&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">use commercially reasonable efforts to incorporate any suggestions from Evolent into any contemplated agreements between the Company (or its Subsidiaries) and Vizient (or its applicable affiliates including Sg-2, LLC).</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary contained herein, nothing herein shall prevent the Company or the Business from taking any action, including the establishment of any policy, procedure or protocol, in response to COVID-19 or any COVID-19 Measures, and such action </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall not be deemed to violate or breach this Agreement in any way, be deemed to constitute an action taken outside of the ordinary course of business or serve as a basis for Purchaser to terminate this Agreement or assert that any of the conditions to the Closing contained herein have not been satisfied, provided the actions taken by the Company and&#47;or the Business were the result of reasonable best efforts to respond to COVID-19 or any COVID-19 Measures and provided further that the Sellers, the Company and&#47;or the Business, as applicable, give the Purchaser reasonable notice of such action, and, except for actions required to comply with COVID-19 Measures, Purchaser provides consent to such action in writing (such consent not to be unreasonably conditioned, withheld, or delayed).</font></div><div id="i649a3a409a124fa4b643ff6500d07394_271"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Negative Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  From the date hereof and prior to the earlier to occur of the Closing Date and the date that this Agreement is terminated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, except as otherwise required in this Agreement, as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;4.2,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as required by law or with the prior written consent of Purchaser, which shall not be unreasonably withheld, conditioned or delayed, the Company shall not and shall cause each other member of the Company Group not to, take any of the actions listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. It being acknowledged and provided that the Company may determine it needs to take measures or will sustain impacts on its business as a result of COVID-19, and nothing herein shall prevent the Company from taking, following the provision of reasonable notice to Purchaser and, except for actions required to comply with COVID-19 Measures, receipt of consent of the Purchaser (such consent not to be unreasonably conditioned, withheld, or delayed) all reasonable measures it deems fit in order to preserve its Business as a result thereof, nor shall any impact sustained by the Company Group be deemed as a breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_274"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Reasonable Best Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each such party shall, on or prior to the Closing, use its reasonable best efforts to fulfill or obtain the fulfillment of the conditions precedent to the consummation of the transactions contemplated hereby, including the execution and delivery of any documents, certificates, instruments or other papers that are reasonably required for the consummation of the transactions contemplated hereby.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_277"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Between the date hereof and the earlier of the Closing and the termination of this Agreement in accordance with its terms, the Company shall not, nor shall it permit its respective directors, officers, shareholders, employees, affiliates, agents, attorneys, or investment bankers (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to, directly or indirectly, solicit or initiate, encourage, negotiate, or accept or enter into the submission of, or proposals or offers relating to, any acquisition, recapitalization, liquidation, business combination, dissolution, or similar transaction involving all or any material portion of the Company, its subsidiaries or their respective assets or to seek financing to consummate any such transaction (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Competing Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  In addition, the Company shall, and shall cause its respective Representatives to, immediately cease any and all discussions and negotiations with third parties with respect to a Competing Transaction. If, between the date hereof and the earlier of the Closing and the termination of this Agreement in accordance with its terms, any third party makes an unsolicited bid or expression of interest with respect to a Competing Transaction or otherwise requests confidential information with regard to the Company or any of its Subsidiaries in connection with a Competing Transaction, the Company shall promptly notify or cause its applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Representatives to notify Purchaser of such bid, expression of interest, or request, and promptly notify such third party in writing that the Company is subject to an exclusivity agreement with respect to the sale of the Company that prohibits it from considering the bid, expression of interest, or request for information.  </font></div><div id="i649a3a409a124fa4b643ff6500d07394_280"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Without limiting the generality of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Subject to the terms and conditions of this Agreement, each party shall, and shall cause its Affiliates to, use its reasonable best efforts to (i) file a Notification and Report Form pursuant to the HSR Act with respect to the transactions contemplated hereby as soon as reasonably practicable following the date hereof, but no later than June 29, 2022&#59; and (ii) supply as promptly as practicable any additional information and documentary material that may be requested or required pursuant to any Antitrust Law, including the HSR Act. Purchaser shall pay all filing fees required under the HSR Act or any other Antitrust Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In connection with the efforts referenced in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to obtain all requisite approvals and authorizations for the transactions contemplated by this Agreement under the HSR Act, any other competition or antitrust related legal or regulatory requirements of foreign jurisdiction, commissions or governing bodies (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Antitrust Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or any state law, each of the parties shall use reasonable best efforts to (i) cooperate with each other in connection with any filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private party&#59; (ii) keep the other parties informed in all material respects of any material communication received by such party from, or given by such party to, any Governmental Authority and of any material communication received or given in connection with any proceeding by a private party, in each case, regarding any of the transactions contemplated hereby&#59; and (iii) to the extent permitted by law, permit the other party to review any material communication given to it by, and consult with each other in advance of any meeting or conference with, any Governmental Authority, including in connection with any proceeding by a private party.  The foregoing obligations in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be subject to the Confidentiality Agreement and any attorney-client, work product or other privilege.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Without limiting the generality of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, if any objections are asserted with respect to the transactions contemplated hereby under any Antitrust Law or if any suit is instituted or threatened by any Governmental Authority or any private party challenging any of the transactions contemplated hereby as violative of any Antitrust Law or if a filing pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is reasonably likely to be rejected or conditioned by a Governmental Authority, then each of the parties shall use reasonable best efforts to resolve such objections or challenges as such Governmental Authority or private party may have to such transactions, including to vacate, lift, reverse or overturn any order, whether temporary, preliminary or permanent, so as to permit consummation of the transactions contemplated by this Agreement as soon as practicable and in any event on or prior to the Termination Date.   Without limiting the generality of the foregoing, Purchaser shall promptly take and use reasonable best efforts to diligently pursue all actions necessary to eliminate any concerns on the part of, or to satisfy any conditions imposed by, any Governmental Authority with jurisdiction over the enforcement of any applicable Law, including any Antitrust Law, regarding the legality of Purchaser&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">acquisition of all or any portion of the Company Stock. Without limiting the foregoing, Purchaser shall not be required to take (and Purchaser&#8217;s &#8220;best efforts&#8221; shall expressly not include the taking of) any of the following actions&#58; (A) selling, licensing or otherwise disposing of, or holding separate and agreeing to sell, license or otherwise dispose of (i) any entities, assets or facilities of any member of the Company Group after the Closing or (ii) any entity, facility or asset of Purchaser or its Affiliates before or after the Closing, (B) terminating, amending or assigning existing relationships and contractual rights and obligations (other than terminations that would result in a breach of a contractual obligation to a third party) and (C)&#160;amending, assigning or terminating existing licenses or other agreements (other than terminations that would result in a breach of a license or such other agreement with a third party) and entering into such new licenses or other agreements.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_292"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Purchaser acknowledges that certain consents to the transactions contemplated by this Agreement may be required from parties to contracts or other agreements to which the Company Group is a party and that such consents have not been obtained and may not be obtained. Subject to the terms and conditions set forth in this Agreement, including compliance with the covenants set forth herein, including the last sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Purchaser agrees that the Sellers and the Company Group shall not have any liability whatsoever (absent Fraud) to Purchaser (and Purchaser shall not be entitled to assert any claims) arising out of or relating to the failure to obtain any consents that may have been or may be required in connection with the transactions contemplated by this Agreement or because of the default, acceleration or termination of or loss of right under any such contract or other agreement as a result thereof. The Purchaser further agrees that, subject to the terms and conditions of this Agreement, including compliance with the covenants set forth herein, including the last sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no representation, warranty, covenant or Agreement of the Sellers or any member of the Company Group contained herein shall be breached or deemed breached and no condition of the Purchaser shall be deemed not to be satisfied as a result of the failure to obtain any consent or as a result of any such default, acceleration or termination or loss of right or any action commenced or threatened by or on behalf of any Person arising out of or relating to the failure to obtain any consent or any such default, acceleration or termination or loss of right. As promptly as practicable after the date hereof, each member of the Company Group shall use reasonable efforts to obtain all consents of, and provide all notices to, third parties required or otherwise advisable pursuant to the terms of the applicable contracts in connection with the transactions contemplated hereby including those set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_295"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Representation and Warranty Insurance Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In connection with the Closing, the Evolent Entities may obtain and pay for, and the Company shall, and shall cause each of its Subsidiaries to, reasonably cooperate with the Evolent Entities prior to the Closing in order to obtain a purchaser-side representations and warranties insurance policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representation and Warranty Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to provide coverage for the Evolent Entities with respect to Losses suffered or incurred with respect to breaches of or inaccuracies in the representations and warranties set forth in Article 5.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">37</font></div></div></div><div id="i649a3a409a124fa4b643ff6500d07394_298"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Financing Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">From the date hereof until the earlier to occur of the Closing Date and the date that this Agreement is terminated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company shall use reasonable best efforts to, and shall use reasonable best efforts to cause its Subsidiaries and its and their respective officers, employees, advisors and other representatives to, at Purchaser&#8217;s sole cost and expense and at Purchaser&#8217;s reasonable request, cooperate with the Evolent Entities in connection with the arrangement of the Debt Financing, including the use of reasonable best efforts in respect of (i) participating in, on reasonable advance notice and at reasonable locations, a reasonable number of virtual or telephonic meetings, due diligence sessions, and other presentations to, and with, Financing Sources (including direct contact between the senior management and other representatives of the Company Group, on the one hand, and the actual and potential Financing Sources, on the other hand) and sessions with ratings agencies, in each case, to the extent customary in connection with financings of the type contemplated by the Commitment Letter, (ii) assisting with the preparation of customary materials for rating agency presentations, lender and investor presentations, business projections, bank information memoranda, prospectuses and similar documents required in connection with the Debt Financing and other customary marketing and syndication materials required in connection with the Debt Financing (and identifying any portion of the information set forth in any of the foregoing that would constitute material nonpublic information if the Company or any parent company of the Company were a public reporting company) (it being understood that (a) none of the Company, its Subsidiaries or any Seller shall be responsible in any manner for information related to the Debt Financing that may be included in any pro forma financial statements and (b) without limiting the obligations to assist set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Evolent Entities and Merger Sub shall be solely responsible for the preparation of such pro forma financial statements), (iii) furnishing the Evolent Entities with the Required Information and such other financial information regarding the Company and its Subsidiaries as may be reasonably requested in writing by the Evolent Entities in connection with the Debt Financing, (iv) delivering customary authorization letters with respect to any bank information memoranda to the extent contemplated by the Commitment Letter (which authorization letters shall be in form and substance satisfactory to the Company (it being agreed that the Evolent Entities shall furnish such letters to the Company and provide the Company with a reasonable opportunity to review and comment with respect thereto)), (v) assisting in the preparation of, and executing and delivering, as applicable, definitive financing documents (including guarantee and collateral documents and customary closing certificates with respect to the Debt Financing) as may be required by the Debt Financing and any related schedules, annexes and exhibits thereto (including by providing information in the possession of, or reasonably ascertainable by, the Company in connection therewith), (vi) assisting with the pledging of, and granting of Liens on, collateral for the Debt Financing, including by delivering notices of prepayment within the time periods required by the relevant agreements governing Indebtedness of the Company Group and obtaining customary payoff letters, lien terminations and instruments of discharge, and give any other necessary notices, to allow for the payoff, discharge and termination in full of existing Liens of the Company Group (to the extent not contemplated under this Agreement to survive the consummation of the Closing), (vii) ensuring that the Financing Sources benefit from existing lending relations (if any) of the Company, (viii) providing the Evolent Entities, Merger Sub and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Financing Sources, at least four (4) Business Days prior to the Closing Date, all documentation and other information required by regulatory authorities under applicable &#8220;know your customer&#8221; and anti-money laundering rules and regulations, including the PATRIOT Act, in each case to the extent reasonably requested in writing by the Evolent Entities at least nine (9) Business Days prior to the Closing Date, (ix) reasonably cooperating in satisfying the conditions precedent set forth in the Commitment Letter to the extent satisfaction of any such condition reasonably requires the cooperation of, or is within the control of, the Company Group and (x) taking corporate actions reasonably necessary to permit the consummation of the Debt Financing, in each case with respect to foregoing, subject to the limitations contained in this Agreement (including Section 4.8(b) below). The Company and its Subsidiaries consent to the customary and reasonable use of the Company&#8217;s logos solely in connection with any Debt Financing&#59; provided, that such logos are used solely in a manner that is not intended, or reasonably likely, to harm or disparage the Company or any of its Subsidiaries or the reputation or goodwill of the Company or any of its Subsidiaries. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding anything in this Agreement to the contrary, (i) none of the Company or any of its Subsidiaries or any of their respective directors, officers, employees, advisors, representatives or agents shall be required to execute or enter into any certificate, instrument, agreement or other document in connection with the Debt Financing which will be effective prior to the Closing, except for customary authorization letters in any marketing materials for the Debt Financing, to the extent contemplated by the Commitment Letter (which authorization letters shall be in form and substance satisfactory to the Company (it being agreed that the Evolent Entities shall furnish such letters to the Company and provide the Company with a reasonable opportunity to review and comment with respect thereto)), (ii) nothing herein shall require cooperation or other actions or efforts on the part of the Company or any of its Subsidiaries or any of their respective directors, officers, employees, advisors, representatives or agents in connection with the Debt Financing to the extent it (A) would interfere unreasonably with the business or operations of the Company or any of its Subsidiaries, (B) would or would reasonably be expected to cause any condition to the Closing set forth in this Agreement not to be satisfied or (C) would or would reasonably be expected cause any breach of this Agreement or any violation of Law or material Contract, (iii) neither the Company nor any of its Subsidiaries nor any of their respective directors, officers, employees, advisors, representatives or agents shall be required to, or be required to commit to, (1) take any action that is not contingent upon the Closing or enter into execute any agreement or document (other than customary authorization letters to the extent contemplated by the Commitment Letter (which authorization letters shall be in form and substance satisfactory to the Company (it being agreed that the Evolent Entities shall furnish such letters to the Company and provide the Company with a reasonable opportunity to review and comment with respect thereto))) unless the effectiveness thereof shall be conditioned upon, or become operative upon or after, the occurrence of the Closing, (2) take any action that would, or would reasonably be expected to, result in any officer, director, employee, agent or other representative of the Company or any of its Subsidiaries incurring any personal liability with respect to any matters relating to the Debt Financing, (3) deliver or cause the delivery of (A) any certificate necessary for the Debt Financing that will be effective prior to Closing or (B) any legal opinions, (4) deliver or cause the delivery of any pro forma financial information or any other financial information not readily available to the Company (other than the Required </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information), (5) pay any commitment or other similar fee in connection with the Debt Financing prior to the Closing, (6) waive or amend any terms of this Agreement or any other material Contract to which the Company or its Subsidiaries is party, (7) provide access to or disclose information where the Company determines that such access or disclosure would or would reasonably be expected to jeopardize the attorney-client privilege or contravene any Law or material Contract, or take any action that will conflict with or violate the organizational documents of Company or any of its Subsidiaries or any legal requirements or result in the contravention of, or would reasonably be expected to result in a violation or breach of, or default under, any Law or material Contract, provided that the Company Group shall use reasonable best efforts to provide such information in a manner that would not jeopardize the attorney client privilege or result in such contravention, breach or violation, or (8) adopt resolutions or take similar action approving the Debt Financing effective prior to the Closing (or otherwise approve the agreements, documents or instruments pursuant to which the Debt Financing is made, except for customary authorization letters in any marketing materials for the Debt Financing to the extent contemplated by the Commitment Letter (which authorization letters shall be in form and substance satisfactory to the Company (it being agreed that the Evolent Entities shall furnish such letters to the Company and provide the Company with a reasonable opportunity to review and comment with respect thereto))) (it being agreed that directors and officers of Subsidiaries of the Company may sign resolutions or consents that do not become effective until the Closing solely to the extent that they will remain directors and&#47;or officers after giving effect to the Closing). All non-public or other confidential information provided by the Company or its Subsidiaries pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be kept confidential in accordance with the Confidentiality Agreement, except that Purchaser and Merger Sub shall be permitted to disclose such information to any Financing Sources or potential Financing Sources and other financial institutions and investors that may become parties to the Debt Financing (and, in each case, to their respective counsel and auditors) as permitted pursuant to the Confidentiality Agreement. None of the Company or any of its Subsidiaries shall be required to bear any cost or expense, pay any commitment or other similar fee, make any other payment, incur any other liability or provide or agree to provide any indemnity, in each case, in connection with the Debt Financing prior to the Closing. Purchaser shall reimburse the Company, its Subsidiaries and the Sellers and their respective Representatives for any reasonable and documented out of pocket fees and expenses incurred pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (other than with respect to the Company&#8217;s obligations to deliver the Required Information and, for the avoidance of doubt, compensation of its and its Subsidiaries&#8217; employees) and shall indemnify and hold harmless the Company, its Subsidiaries and the Sellers and their respective Representatives from and against any and all liabilities, losses, damages, claims, costs, expenses, interest, awards, judgments, and penalties incurred or suffered by them in connection with any actions taken pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Evolent Entities shall not have any obligation to indemnify and hold harmless any such party or Person to the extent that any such damages suffered or incurred arose from (x) historical information provided by or on behalf of the Company or its Affiliates or (y) the willful misconduct, gross negligence, fraud or intentional misrepresentation of, the Company or any of its Subsidiaries or its or their respective Representatives.  Notwithstanding the foregoing, it is understood and agreed by the Evolent Entities that receipt of third-party financing is not a condition to the obligation of such Persons to consummate the Closing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Notwithstanding anything to the contrary herein, a breach by the Company of its obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not constitute a breach of this Agreement or a breach for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or a failure of the conditions precedent set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">unless (i) Purchaser provides reasonably prompt written notice of the alleged breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, specifying in reasonable detail specific steps to cure such alleged breach in a manner consistent with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and provides the Company with a reasonable period of time to cure such breach, (ii) such breach constitutes a material breach of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and has not been cured within the applicable period specified by Purchaser and (iii) such breach directly results in, and is the primary cause of, the Debt Financing not being available to Purchaser.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_310"></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Financing Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Evolent Entities shall use reasonable best efforts to take, and shall cause their Affiliates and Representatives to take, or cause to be taken, all reasonable actions and to do, or cause to be done, all things reasonably necessary or advisable to arrange and obtain the Debt Financing at Closing on the terms and conditions described in the Commitment Letter, including using reasonable best efforts (i) to maintain in effect the Commitment Letter until the consummation of the Closing and the other transactions contemplated hereby and to comply with their obligations, including the satisfaction at or prior to the Closing of all conditions to the funding of the Debt Financing under the Commitment Letter, (ii) to negotiate and enter into definitive agreements with respect to the Debt Financing on the terms and conditions consistent with those set forth in the Commitment Letter (including any &#8220;market flex&#8221; provisions therein or in any Fee Letter), and (iii) to consummate the Debt Financing at or prior to or, concurrently with, the Closing. The Evolent Entities shall not without the written consent of the Company, not to be unreasonably withheld, conditioned or delayed, consent to or cause (a) any amendment or modification to, or any waiver of any provision under, the Commitment Letter if such amendment, modification or waiver (i) imposes new or additional conditions, or otherwise expands any of the conditions, to the receipt of the Debt Financing in a manner that would reasonably be expected to delay or prevent the Closing, or (ii) reduces the aggregate amount of the Debt Financing committed to be funded at Closing below the Required Amounts or (iii) permits or effects any assignment, release or termination of the Commitment Letter or of the obligations of any counterparty thereto (provided, that nothing herein shall foreclose the Financing Sources party to the Commitment Letter from making assignments to their respective Affiliates in accordance with the terms hereof), (b) any other amendment, modification to, or any waiver of any provision under, the Commitment Letter that would reasonably be expected to adversely affect the ability of the Evolent Entities to consummate the transactions contemplated by this Agreement prior to the Termination Date (provided, that, so long as any such event is not otherwise prohibited by this sentence, (x) the Evolent Entities may replace or amend the Commitment Letter to add lenders, lead arrangers, bookrunners, syndication agents or similar entities that have not executed the Commitment Letter as of the date hereof, in each case to the extent contemplated by the Commitment Letter and (y) the exercise of any unredacted &#8220;flex&#8221; provisions in any Fee Letter will not be deemed an amendment, modification or waiver under the Commitment Letter under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), (c) any other amendment, modification to, or any waiver of any provision under, the Commitment Letter that would reasonably be expected to (i) make the funding of any portion of the Debt Financing (or satisfaction of the conditions to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">obtaining any portion of the Debt Financing) less likely to occur, (ii) adversely impact the ability of the Evolent Entities to enforce its rights against the other parties to the Commitment Letter or the definitive agreements with respect thereto in any material respect, or (iii) delay or prevent the funding of any portion of the Debt Financing at the Closing, or (d) any early termination of the Commitment Letter unless it is replaced with a new commitment that, were it structured as an amendment to the existing Commitment Letter, would satisfy the requirements of this Section (the foregoing clauses (a) through (d), collectively, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adverse Effect on Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Evolent Entities shall, upon reasonable request of the Company, keep the Company informed on a reasonably current basis and in reasonable detail of the status of its efforts to obtain and finalize the Debt Financing.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Evolent Entities shall promptly (and, in any event, within two (2) Business Days) notify the Company in writing of the occurrence of any Financing Notice Event. Without limiting its other obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, if a Financing Failure Event occurs, the Evolent Entities shall (i) use reasonable best efforts to, as promptly as practicable following the occurrence of such Financing Failure Event, take, and cause their Affiliates and Representatives to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary or advisable (in each case, on a reasonable best efforts basis) to obtain alternative debt financing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Alternative Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in any amount necessary to replace any unavailable portions of the Debt Financing from the same or other sources and which do not include terms and conditions to the consummation of such Alternative Financing that are materially less favorable (taken as a whole) to the Evolent Entities than the terms and conditions set forth in the Commitment Letter (including the &#8220;flex&#8221; provisions of any Fee Letters), and (ii) promptly provide the Company with a true and complete copy of a new financing commitment in respect of such Alternative Financing&#59; provided, however, that in no event shall any such Alternative Financing, without the prior written consent of the Company (not to be unreasonably withheld, conditioned or delayed), have an Adverse Effect on Financing. Upon any permitted amendment, supplement, modification or replacement of the Commitment Letter (including with respect to any Alternative Financing) in accordance with clause (a) or (b) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the term &#8220;Commitment Letter&#8221; shall mean the Commitment Letter as so amended, supplemented, modified or replaced, and references to &#8220;Debt Financing&#8221; shall include the financing contemplated by the Commitment Letter as so amended, supplemented, modified or replaced.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_319"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Written Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Promptly, and in any event within twenty-four (24) hours, following the execution of this Agreement, the Company shall, upon consideration of the recommendation of the board of directors of the Company, solicit and use its reasonable best efforts to obtain the Written Consent.  Upon obtaining the Written Consent, the Company shall promptly send a copy of such Written Consent to all Company Stockholders entitled to receive such copy under the organizational documents of the Company and applicable law. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_322"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Registration of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Parent agrees to prepare and file with the SEC, at its discretion, either (a) a Registration Statement on Form S-3ASR (or a Registration Statement on Form S-3 if it is no longer eligible to file a Registration Statement on Form S-3ASR) or (b) a prospectus supplement pursuant to Rule 424(b)(7) under the Securities Act (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) relating to Parent&#8217;s Registration Statement on Form S-3ASR, in either such case covering the resale of the Share Consideration pursuant to the Registration Rights Agreement. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall use its commercially reasonable efforts to ensure that all Accredited Investor Questionnaires to be delivered in connection with such Registration Rights Agreement are delivered to Parent at least three (3) Business Days prior to the Closing.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_325"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Pre-Closing Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Until the Closing Date, the Company shall deliver to Purchaser within thirty (30) days after the end of each month a copy of the unaudited monthly consolidated financial statements of the Company Group as of the end of such month and for the fiscal period then ended prepared in a manner and containing information consistent with the preparation of the monthly unaudited Financial Statements. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Following the date hereof and until the earlier to occur of the Closing Date and the date that this Agreement is terminated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company shall use commercially reasonable efforts to ensure that on the later of August 12, 2022 or 12 days after the Closing, the Company shall deliver to Purchaser in an Excel format, the unaudited consolidated monthly balance sheets of the Company Group and the related unaudited consolidated monthly statements of operations for each month beginning January 2022 to June 30 2022, each prepared in accordance with GAAP as it applies to a public business entity (except that such balance sheet and related statements of operations are subject to normal year-end adjustments and reclassifications (which are not materially individually or in the aggregate) and lacks footnote disclosure and other presentation items).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Following the date hereof and until the earlier to occur of the Closing Date and the date that this Agreement is terminated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company shall use commercially reasonably efforts to ensure that on the later of August 12, 2022 or 12 days after the Closing, the Company shall deliver to Purchaser in Excel format, the unaudited consolidated monthly balance sheets of the Company Group and the related unaudited consolidated monthly statements of operations for each month beginning January 2021 to December 31, 2021, each prepared in accordance with GAAP as it applies to a public business entity (except that such balance sheet and related statements of operations are subject to normal year-end adjustments and reclassifications (which are not material individually or in the aggregate) and lacks footnote disclosure and other presentation items). </font></div><div id="i649a3a409a124fa4b643ff6500d07394_6708"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Promptly following the date hereof, the Company shall deliver each of the notices set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div id="i649a3a409a124fa4b643ff6500d07394_337"></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 5</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES REGARDING THE COMPANY GROUP</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As a material inducement to the Evolent Entities and Merger Sub to enter into this Agreement, the Company hereby represents and warrants to the Evolent Entities and Merger Sub as of the date hereof and as of the Closing as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">43</font></div></div></div><div id="i649a3a409a124fa4b643ff6500d07394_340"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Organization and Power&#59; Subsidiaries and Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Each member of the Company Group is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization.  Each member of the Company Group has all requisite corporate power and authority to execute and deliver this Agreement and the other agreements contemplated hereby and to perform its obligations hereunder and thereunder.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> no member of the Company Group owns or controls (directly or indirectly) any stock, partnership interest, joint venture interest, equity participation or other security or interest in any other Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each member of the Company Group is duly licensed or qualified to do business as a foreign entity and is in good standing in each jurisdiction listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, which jurisdictions constitute all of the jurisdictions in which the ownership, operation, or lease of properties or the conduct of the Business requires such member of the Company Group to be so qualified, except to the extent the failure to be so licensed or qualified would not have a Material Adverse Effect.  Each member of the Company Group has all requisite corporate power and authority to own, lease and operate the properties currently owned by it and to carry on its business as now conducted.  The organizational documents of each member of the Company Group, accurate and complete copies of which have previously been furnished to Purchaser, reflect all amendments thereto, and are correct and complete in all respects.  No member of the Company Group is in breach or default of any material obligation under its organizational documents.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_349"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The execution, delivery and performance by the Company Group of this Agreement, the other agreements contemplated hereby to which it is a party and each of the transactions contemplated hereby or thereby have been duly and validly authorized by the members of the Company Group, as the case may be, and no other act or proceeding on the part of any member of the Company Group, their respective governing bodies or stockholders is necessary to authorize the execution, delivery or performance by the Company Group of this Agreement or any other agreement contemplated hereby to which it is a party or the consummation of any of the transactions contemplated hereby or thereby other than the Written Consent.  This Agreement has been duly executed and delivered by the Company, and, assuming the due execution and delivery of this Agreement and the other agreements contemplated hereby by the other parties hereto and thereto, this Agreement constitutes, and the other agreements contemplated hereby to which it is a party upon execution and delivery by the members of the Company Group, as applicable, will each constitute, a valid and binding obligation of such member of the Company Group, enforceable against such Person in accordance with its terms, except as such enforceability may be limited by (a) applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors&#8217; rights generally, and (b) applicable equitable principles (whether considered in a proceeding at law or in equity). </font></div><div id="i649a3a409a124fa4b643ff6500d07394_352"></div><div style="margin-bottom:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Capitalization.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Schedule&#160;5.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> accurately sets forth the authorized and outstanding equity interests of the Company and the name, number, class and series (if applicable) of equity </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">interests held by each holder thereof.  All of the issued and outstanding equity of the Company, and the Stock Options, have been duly authorized and validly issued, are fully paid and nonassessable, free and clear of all Liens (except for Liens under applicable securities laws or Liens under any stock option award agreement), and were offered, issued, sold and delivered in compliance with all applicable Law and regulations governing the issuance of securities and were not issued in violation of (or subject to) any preemptive rights, rights of first refusal or similar rights.  Except for this Agreement and as may be set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, there are no outstanding or authorized options, warrants, rights, contracts, pledges, calls, puts, rights to subscribe, conversion rights, preemptive or other agreements or commitments to which the Company is a party or which is binding upon the Company providing for the issuance, disposition or acquisition of any of its equity or any rights or interests exercisable therefor. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth, as of the date of this Agreement, a true, correct and complete list of each outstanding Stock Option, including, in each case to the extent applicable, the holder thereof, the date of grant, the number of shares Company Stock issuable thereunder on the grant date, and the exercise price with respect thereto. Each Stock Option was granted in material compliance with all applicable Laws and, with respect to the Stock Options, the terms and conditions of the Company Stock Plan. Except as may be set forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, there are no voting agreements or other contracts, agreements, commitments, arrangements, instruments or rights of any kind of nature outstanding or in effect with respect to the equity interests of the Company or which restrict the transfer of the equity interests of the Company.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, there are no outstanding or authorized equity appreciation, phantom stock or similar rights with respect to the Company.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Each of the Company&#8217;s Subsidiaries is wholly-owned, directly or indirectly, by the Company.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> accurately sets forth (i) the name of each member of the Company Group (other than the Company), (ii) the jurisdiction of its formation or organization and (iii) the name and number of equity interests held by each Person holding equity interests thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The information set forth on the Distribution Waterfall is and will be at Closing true and correct (subject to the assumptions set forth therein (including all amounts and estimates)). No Person will be entitled to receive any payment or consideration as a result of the Merger or the other transactions contemplated by this Agreement or any other agreement entered into in connection with this Agreement, other than the Persons and in the amounts shown in the Distribution Waterfall.  The allocation of Final Merger Cash Consideration and Share Consideration among the Sellers in the manner contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Distribution Waterfall is consistent with, and determined in accordance with, the applicable provisions of the Company Charter and Bylaws.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_364"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Absence of Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the execution, delivery and performance by the Company of this Agreement and the other agreements contemplated hereby to which it is a party and the consummation of each of the transactions contemplated hereby or thereby will not (a) violate, result in any breach of, constitute a default under, result in the termination or acceleration of, create in any party the right to accelerate, terminate, modify or cancel, or require any notice under (i) the Company Charter and Bylaws, any other organizational documents of any member of the Company Group or (ii), any contract set forth on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(or required to be set forth on) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, except where such violation, conflict, breach, default, acceleration, termination, modification, cancellation, or failure to give notice is not material to the Company Group, taken as a whole&#59; (b) require any authorization, consent, approval, exemption or notice to any Governmental Authority under the provisions of any law, statute, rule, regulation, judgment, order or decree (except for the filing and recordation of the Certificate of Merger as required by the DGCL and any such actions required by the HSR Act or any other Antitrust Law), except where such failure to give notice, file, or to obtain such authorization, consent, approval or exemption would not be material to the Company Group, taken as a whole&#59; (c)&#160;violate, conflict with, contravene or give any Person the right to exercise any remedy or obtain any relief under, any Court Order or Laws applicable to the members of the Company Group or Governmental Licenses, or (d)&#160;result in the creation of any Lien (other than a Permitted Lien) upon any of the properties or assets of any member of the Company Group.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_367"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> contains the following financial statements (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the unaudited consolidated balance sheet of the Company Group as of April 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Latest Balance Sheet</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the related unaudited consolidated statements of operations for the four-month period then ended&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the unaudited consolidated balance sheet of the Company Group as of December 31, 2021 and the related unaudited consolidated statements of operations for the annual period then ended&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the audited consolidated balance sheets of the Company Group as of December 31, 2020 and 2019 and the related consolidated statements of operations, stockholders&#8217; equity and cash flows for the annual periods then ended&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the audited consolidated balance sheet of the Company Group as of December 31, 2021 and the related consolidated statements of operations, stockholders&#8217; equity and cash flows for the period from March 2021, to December 31, 2021.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as set forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each of the foregoing Financial Statements is derived from and in accordance with the Company Group&#8217;s books and records and is accurate and complete in all respects and presents fairly in all material respects the consolidated financial condition, results of operations and changes in cash flows of the Company Group throughout the periods covered thereby, and such Financial Statements have been prepared in accordance with GAAP (with the latest audited financial statements being prepared in accordance with GAAP) consistently applied throughout the periods indicated (except that the Latest Balance Sheet and the related unaudited consolidated statements of operations and cash flows are subject to normal year-end adjustments and reclassifications (which are not material individually or in the aggregate) and lacks footnote disclosure and other presentation items).  The Company Group maintains a standard system of accounting established and administered in accordance with GAAP. No member of the Company Group has any liabilities in respect of Indebtedness except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For each item of Indebtedness, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> correctly sets forth the debtor, the Contract governing the Indebtedness, the principal amount of the Indebtedness as the date of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement, the creditor, the maturity date, and the collateral, if any, securing the Indebtedness (and all Contracts governing all related Liens).  All accounts and notes receivable reflected on the Latest Balance Sheet and all accounts and notes receivable arising subsequent to the Latest Balance Sheet Date and on or prior to the Closing Date that will be reflected in the Final Working Capital, or Final Cash (as applicable), have arisen or will arise in the ordinary course of business, represent or will represent legal, valid, binding and enforceable obligations owed to an member of the Company Group and subject only to consistently recorded reserves for bad debts set forth on the Latest Balance Sheet have been, or will be, collected or are, or will be, collectible in the aggregate recorded amounts thereof in accordance with their terms and will not be subject to any contests, claims, counterclaims or setoffs. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_382"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Absence of Certain Developments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, since December 31, 2021, the Company Group as a whole has operated in the ordinary course of business and has not&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">suffered a Material Adverse Effect&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">sold, leased, assigned, licensed or transferred any of its assets or portion thereof in any single transaction or series of related transactions having a fair market value in excess of $50,000 in the aggregate (other than in the ordinary course of business and sales of obsolete assets or assets with no book value) or mortgaged, pledged or subjected them to any additional Lien, except for Permitted Liens&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">made any capital expenditures or commitments therefor in excess of $500,000 in the aggregate, other than, other than in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">suffered any extraordinary casualty loss, except for any such casualty loss covered by insurance&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">created, incurred, assumed or guaranteed any Indebtedness either involving more than $250,000 in the aggregate or outside the ordinary course of business, except, in any case, for borrowings under the Existing Credit Agreement necessary to meet ordinary working capital requirements&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">amended or authorized the amendment of its certificate of incorporation or bylaws (or equivalent governing documents)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">made any material change in its accounting methods or practices or financial reporting principles, except in so far as was required in order to comply with a change in GAAP&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">declared, set aside or paid any dividends on or made any other distributions (whether in cash, equity interests or property) in respect of any Company Stock or split, combined or reclassified any Company Stock&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">issued, sold, delivered (whether through the issuance or granting of options, warrants, commitments, subscriptions, rights to purchase or otherwise), any shares of any class of Company Stock or any other any equity interests or equity equivalents (including any options or appreciation rights) or purchased, redeemed or otherwise acquired any of its Company Stock&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">adopted a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization (other than this Agreement)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">assumed, guaranteed, endorsed or otherwise became liable or responsible, whether directly, contingently or otherwise, for the obligations of any other Person&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">made any loans, advances or capital contributions to or investments in any other Person, except for normal extensions of credit to customers in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt"> entered into, amended, waived any rights under, renewed, or terminated any Contract listed, or that would be required to be listed, on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, or failed to exercise any rights of renewal under any Contract listed or that would be required to be listed, on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">sold, assigned, transferred, leased, licensed, encumbered, abandoned or permitted to lapse any of its material Intellectual Property Rights, except for non-exclusive licenses granted to customers, distributors, suppliers, or service providers in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">hired, engaged or terminated any current or former director, officer, employee or individual independent contractor with annual base compensation in excess of $150,000, or entered into, adopted, materially amended or terminated any Employee Plan, or materially increased the compensation or benefits payable to any current or former director, officer, employee, or individual independent contractor&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">incurred any Liability to its directors, officers or stockholders (other than Liabilities to pay compensation or benefits in connection with services rendered in the ordinary course of business)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">entered into any transactions with any Seller (or any Affiliate of any Seller) or any Affiliate of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">initiated, threatened or settled any litigation or action before or by any Governmental Authority involving any member of the Company Group or any of their current or former employees or independent contractors&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.36pt">(i) made, changed, or revoked any material Tax election, (ii) made any material change in its Tax accounting methods, (iii) settled or compromised any audit, dispute, proceeding, or investigation in respect of any material Tax claim or assessment, (iv) consented to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any extension or waiver of the limitation period applicable to any material Tax claim or assessment, (v) filed any amended Tax Return relating to material Taxes, or (vi) entered into any contractual obligation in respect of material Taxes with any Governmental Authority&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">acquired by merging or consolidating with, or by purchasing a substantial portion of the assets of, any Person or division thereof (other than inventory) or otherwise acquired or licensed any assets or properties (other than inventory or Intellectual Property Rights in the ordinary course of business) that were material to the Company Group taken as a whole&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">committed or agreed to do any of the foregoing (other than negotiations and agreements with Purchaser and its representatives regarding the transactions contemplated by this Agreement).</font></div><div id="i649a3a409a124fa4b643ff6500d07394_448"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Real Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Leased Real Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth the address of each Leased Real Property facility of the Company Group.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, with respect to each of the leases for such Leased Real Property facility&#58; (i) such lease is in all material respects legal, valid, binding and enforceable against the member of the Company Group which is party to such lease, and is in full force and effect subject to proper execution of such lease by the other parties thereto and has not been modified&#59; (ii) the transactions contemplated hereby do not require the consent of any other party to such lease and will not result in a breach of or default under such lease&#59; and (iii) no member of the Company Group, and, to the Company&#8217;s Knowledge, no other party, is in material breach or material default under any such lease, nor has an event occurred or does a circumstance exist which, with the delivery of notice, passage of time or both, would constitute such a breach or default or permit the termination, modification or acceleration of rent under such lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Real Property Used in the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Leased Real Property identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> comprises all of the material real property used in the operation of the Business or leased by any member of the Company Group.  No member of the Company Group has a fee interest in any real property.  The Company Group has a leasehold interest in each parcel of Leased Property, subject to proper authorization and execution of the lease with respect to each parcel of Leased Property by the other party thereto and the application of any bankruptcy or other creditor&#8217;s rights laws, free and clear of all Liens (except for Permitted Liens), and except as disclosed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no member of the Company Group has assigned or sublet its interest in any Leased Real Property facility or parcel. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_457"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  One or more members of the Company Group owns good and valid title, free and clear of all Liens, other than Permitted Liens, to all of the tangible and intangible personal property and assets shown on or accounted for in the Latest Balance Sheet.  All of the tangible assets (whether owned or leased) of the Company Group are in good condition and repair (ordinary wear and tear excepted) and collectively constitute all of the tangible properties, rights, interests and other tangible assets used in or necessary to enable the Company Group to conduct its Business as now conducted.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div></div></div><div id="i649a3a409a124fa4b643ff6500d07394_460"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Contracts and Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Schedule&#160;5.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth a true and complete list of the following Contracts (other than purchase orders and invoices entered into in the ordinary course of Business) to which any member of the Company Group is a party and which are in effect as of the date hereof (together with any Contracts or other commitments entered into pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> which would be a Contract if entered into on the date hereof)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Contracts which provide for the sale of products or services by any member of the Company Group that contemplates or involves the payment or delivery of cash or other consideration to the Company in an amount or having a value in excess of $250,000, other than purchase orders for sale of inventory in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Contracts which involve commitments to make capital expenditures or which provide for the purchase of goods or services by any member of the Company Group from any one Person that contemplates or involves the payment or delivery of cash or other consideration by the Company in an amount or having a value in excess of $250,000&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Contracts (A) evidencing the Indebtedness of the Company Group, (B) relating to the creation of any security interest or Lien in the Company Group&#8217;s assets (other than Permitted Liens) or (C) relating to any guaranty by any member of the Company Group of any Indebtedness or other obligation in respect of borrowed money&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Contracts with any director, officer, employee or individual independent contractor of any member of the Company Group that provide for compensation in any calendar year in excess of $100,000 and that are not immediately terminable by the applicable Company Group member without cost, advance notice or Liability&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;collective bargaining agreements or Contracts with any labor union, works council, or other similar employee representative group (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Union</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) respecting employees of the Company Group&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;settlement Contracts with respect to any action before or by any Governmental Authority pursuant to which the Company Group is subject to any outstanding material monetary or other obligations as of the date of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;Contracts which provides for indemnification of any employee, officer or director of the Company Group&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;all licenses, sublicenses, and other Contracts pursuant to which a member of the Company Group is granted a license or rights under (including, without limitation, any covenant not to sue, co-existence agreement, or similar agreements), receives an assignment of rights in, or is otherwise authorized to use or exploit any Intellectual Property Rights of any Person (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Licensed IP Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), but excluding (i) licenses for off-the-shelf, &#8220;shrink wrap&#8221; and other similar generally commercially available software that (A) is generally available to similarly-situated Persons as the Company Group on general commercial terms, and (B) involves </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">license, maintenance, support and other fees less than $30,000 per year in the aggregate, and (ii) agreements with current and former employees, individual consultants, and individual independent contractors of the Company Group entered into on the Company Group&#8217;s applicable form(s) of agreement in the ordinary course of business, copies of which form(s) of agreement have been provided to Purchaser&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;all licenses, sublicenses, and other Contracts pursuant to which any Person is granted a license or rights under (including, without limitation, any covenant not to sue, co-existence agreement, or similar agreements), receives an assignment of rights in, or is otherwise authorized to use or exploit any Company-Owned IP Rights, but excluding non-exclusive licenses to customers, resellers, and distributors entered into in the ordinary course of business (such Contracts listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.9(a)(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Outbound IP Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;Contracts with any Governmental Authority other than sale orders for the sale of inventory in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;Contracts relating to the marketing, sale, advertising or promotion of its products or services involving consideration in excess of $250,000&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;Contracts with the Company Group&#8217;s top seven (7) Payor customers based on revenue attributable to such customers during the 2021 fiscal year (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Customer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiii)&#160;&#160;&#160;&#160;Contracts with the largest fifteen (15) ambulatory surgery centers or other health care facility pursuant to which the Company Group provides management services and&#47;or billing services by dollar value of services provide by the Company Group for fiscal year 2021 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Managed Surgical Centers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiv)&#160;&#160;&#160;&#160;any supply or services Contracts with the Company Group&#8217;s top ten (10) vendors or suppliers based on amounts purchased from such vendors or suppliers during the 2021 fiscal year (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Supplier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xv)&#160;&#160;&#160;&#160;other than Contracts with Managed Surgical Centers, any agreement with any health care professional (other than an employment agreement)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xvi)&#160;&#160;&#160;&#160;Contracts imposing any restriction on the right or ability of any member of the Company Group to (A) engage or participate in any line of business, (B) market or geographic area (C) compete with or hire any other Person or solicit any customer, vendor, employee or other service provider&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xvii)&#160;&#160;&#160;&#160;Contract granting most favored nation pricing, exclusive sales, distribution, marketing or other exclusive rights, rights of refusal, rights of first negotiation or similar rights and&#47;or terms to any Person, or any Contract otherwise limiting the right of the Company or any Subsidiary to sell, distribute or manufacture any products or services, or to purchase or otherwise obtain any software, components, parts, subassemblies or services&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xviii)&#160;&#160;&#160;&#160;Contracts with respect to any partnership, joint venture, strategic alliance or any sharing of revenues, profits, losses, costs or liabilities or similar arrangement&#59;</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xix)&#160;&#160;&#160;&#160;Contracts between members of the Company Group or otherwise required to be set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xx)&#160;&#160;&#160;&#160;Contracts pursuant to which any member of the Company Group is a lessor or a lessee of any property, personal or real, or holds or operates any tangible personal property owned by another Person, except for any leases of personal property under which the aggregate annual rent or lease payments do not exceed $150,000&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xxi)&#160;&#160;&#160;&#160;Contracts relating to the acquisition or disposition of any material business, stock or assets that has obligations that are still in effect or under which any member of the Company Group has any Liability or remaining obligations, including with respect to an &#8220;earn out&#8221;, contingent purchase price, or similar contingent payment obligation, or any indemnification obligation&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xxii)&#160;&#160;&#160;&#160;any amendment, supplement or modification (whether written, or to the Knowledge of the Company, oral) in respect of any of the foregoing and any Contract or commitment to enter into any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as disclosed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; (i) to the Knowledge of the Company, no Contract set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> has been breached in any material respect or canceled or terminated by the other party which has not been duly cured or reinstated&#59; (ii) no Contract set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> has been breached or violated by any member of the Company Group which has not been duly cured or reinstated&#59; (iii) no member of the Company Group is in receipt of any written claim or, to the Knowledge of the Company, other notice or communication of default or intent to cancel, amend or terminate under any such Contract&#59; and (iv) each Contract listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is valid, binding and enforceable against the Company or one or more members of the Company Group, as applicable, except as such enforceability may be limited by (A) applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors&#8217; rights generally, and (B) applicable equitable principles (whether considered in a proceeding at law or in equity).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">With respect to the Company&#8217;s largest one hundred (100) ambulatory surgery centers or other health care facilities pursuant to which the Company Group provides management services and&#47;or billing services by dollar value of services provide by the Company Group for fiscal year 2021 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Top Surgical Centers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (i) the name of each Top Surgical Center is set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (ii) to the Knowledge of the Company, no Contract with any Top Surgical Center has been breached in any material respect or canceled or terminated by the other party which has not been duly cured or reinstated&#59; (ii) no Contract with any Top Surgical Center has been breached or violated by any member of the Company Group which has not been duly cured or reinstated&#59; (iii) no member of the Company Group is in receipt of any written claim or, to the Knowledge of the Company, other notice or communication of default or intent to cancel, amend or terminate under any Contract with any Top Surgical Center and (iv) each Contract with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Top Surgical Center is valid, binding and enforceable against the Company or one or more members of the Company Group, as applicable, except (A) as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors&#8217; rights generally, and applicable equitable principles (whether considered in a proceeding at law or in equity) or (B) to the extent that the breach, default, termination or invalidity of Contracts with the Top Surgical Centers, are not or would not be expected to be material to the Company Group taken as a whole.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_538"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Intellectual Property Rights and Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">As used in this Agreement, the following terms shall have the meanings indicated below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company-Owned IP Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Intellectual Property Rights owned or purported to be owned by any member of the Company Group, including all Company Registered IP Rights and Company Software.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company IP Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Intellectual Property Rights used in the conduct of the Business, including all Company-Owned IP Rights and Licensed IP Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Registered IP Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means United States, international and foreign&#58; (a) patents and patent applications (including provisional applications), (b) registered trademarks, applications to register trademarks, intent-to-use applications, or other registrations or applications related to trademarks, (c) registered Internet domain names, and (d) registered copyrights and applications for copyright registration, in each case registered or filed in the name of, or owned or purported to be owned by any member of the Company Group.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Source Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the software source code of any Software embodying any Company-Owned IP Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;Handling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the receipt, access, acquisition, collection, compilation, use, storage, processing, transmission, safeguarding, security, disposal, destruction, disclosure, sale or distribution of information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all worldwide rights, title and interests in and to all intellectual property rights of every kind and nature, however denominated, including&#58; (a) patents and utility models and applications therefor and all reissues, divisions, re-examinations, renewals, extensions, provisionals, continuations and continuations-in-part thereof&#59; (b)&#160;trade secrets, confidential information, and proprietary information&#59; (c)&#160;copyrights, copyrights registrations, mask works, and applications therefor, and all other rights corresponding thereto throughout the world&#59; (d)&#160;industrial designs&#59; (e)&#160;trademarks, trade names, logos, service marks, brands, and trade dress (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), any registrations or applications therefor, and related goodwill and activities associated therewith&#59; (f)&#160;all rights in databases and data collections and all other proprietary rights in Software and technology&#59; (g) domain names and social media accounts and handles&#59; (h) rights of privacy and publicity, and moral rights&#59; (i)&#160; all other intellectual property and proprietary rights&#59; and (j) any and all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">registrations, applications, recordings, licenses, common-law rights, statutory rights, administrative rights and contractual rights relating to any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Malicious Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any virus, Trojan horse, worm, or other software routines or hardware components designed to permit unauthorized access, disable, erase, or otherwise harm Software, hardware or data.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Open Source Software</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any software subject to any license meeting the Open Source Definition (as promulgated by the Open Source Initiative) or the Free Software Definition (as promulgated by the Free Software Foundation), or any substantially similar license, including but not limited to any license approved by the Open Source Initiative, or any Creative Commons License, or software distributed under a license that requires disclosure of source code or requires derivative works based on such software to be made publicly available under the same license.  For the avoidance of doubt, Open Source Software includes, without limitation, software subject to &#8220;copyleft&#8221; licenses.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any information that (i) relates to an individual Person and (A) is subject to Handling obligations under applicable Law or Contract, or (B) is subject to a requirement, under applicable Law or Contract, that any Person be notified if such information is lost, misused, wrongly accessed, wrongly acquired or compromised, (ii) alone or in combination with other information, is capable of identifying a specific individual Person, or (iii) constitutes any health or other sensitive information of an individual Person.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all applicable Laws, other than HIPAA, concerning the Handling of Personal Information or other individually identifiable information including, without limitation, state data breach notification Laws, state health information protection Laws, state social security number protection Laws, the Federal Trade Commission Act, U.S. federal and state Law, in particular the California Consumer Privacy Act of 2018 and its regulations, the Telephone Consumer Protection Act, the Controlling the Assault of Non-Solicited Pornography And Marketing Act of 2003, the New York SHIELD Act, the Payment Card Industry Data Security Standard, issued by the Payment Card Industry Security Standards Council, as may be revised from time to time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">PCI-DSS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Americans with Disabilities Act (ADA), and all other state Laws concerning privacy and consumer protection.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Software</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means computer software programs, operating systems and databases, including object code, source code, firmware and embedded versions thereof and documentation related thereto.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">System</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Systems</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Software, hardware, networks, databases, electronics, platforms, servers, interfaces, applications, websites and related information technology systems and services used or held for use by any Company Group member, including any outsourced systems and services, that are owned or used by any Company Group member.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Schedule&#160;5.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth a complete and accurate list of all Company Registered IP Rights, including for each item, (i) the jurisdictions in which it has been issued or registered or in which any application for such issuance and registration has been filed or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">jurisdictions in which any other filing or recordation has been made, (ii) the recorded owner(s), (iii) the application number and application date, (iv) the registration number and registration date, and (v) the status of such Company Registered IP Rights (i.e., whether issued, registered, or applied for).  Each item of Company Registered IP Rights is subsisting and valid and enforceable (or in the case of applications, applied for), and all registration, maintenance and renewal fees currently due in connection with such Company Registered IP Rights have been paid.   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> also sets forth a complete and accurate list of&#58; (A) each item of material proprietary Software owned or purported to be owned by a member of the Company Group (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Software</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (B) all material unregistered Trademarks.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company Group, collectively, exclusively owns worldwide rights, titles and interests in and to all Company-Owned IP Rights, free and clear of any Liens (other than Permitted Liens and licenses granted in the Outbound IP Contracts), and is the owner of record of all Company Registered IP Rights.  No Company-Owned IP Rights are subject to any outstanding Court Order, and there is no pending or, to the Company&#8217;s Knowledge, threatened Action challenging the ownership, validity, use and legality, scope of right or enforceability of any Company-Owned IP Rights.  The Company Group owns, or is duly licensed under or otherwise authorized to use, all Company IP Rights, free and clear of any Liens, other than Permitted Liens, and without any infringement, misappropriation or violation of the Intellectual Property Rights of any Person.  The Company Group will continue to own or have after the Closing valid rights or licenses as are sufficient to use all of the Company IP Rights to the same extent as prior to the Closing.  The Company IP Rights constitute all the Intellectual Property Rights currently used in or necessary for the conduct of the business of each Company Group as of the date of this Agreement. The consummation of the transactions contemplated by this Agreement (i) will not result in the loss or impairment of the Company Group&#8217;s rights in any Company-Owned IP Rights and (ii) will not result in the breach of, or create on behalf of any third party, the right to terminate or modify any agreement as to which any member of the Company Group is a party and pursuant to which such member is authorized or licensed to use any Licensed IP Rights.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Each member of the Company Group has taken commercially reasonable measures and maintained commercially reasonable practices to protect and preserve the security and confidentiality of all material confidential information and trade secrets owned by such member of the Company Group and all third-party confidential information or trade secrets in the possession or control of such member of the Company Group.  The Company Group has required all employees and other Persons with access to the confidential information and trade secrets of a member of the Company Group to execute enforceable Contracts requiring them to maintain the confidentiality of such confidential information and trade secrets and use such information only for the benefit of the Company Group.  To the Knowledge of the Company, no material confidential information or trade secret of a member of the Company Group has entered the public domain.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.10(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company Group has secured, by present assignment to a member of the Company Group pursuant to an enforceable written Contract or by operation of Law, from all current and former consultants, advisors, independent contractors and employees who independently or jointly contributed to or participated in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">conception, reduction to practice, creation or development of any portions of Company-Owned IP, exclusive ownership of, all of such consultant&#8217;s, advisor&#8217;s, independent contractor&#8217;s or employee&#8217;s rights, titles and interests in and to such Intellectual Property Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.10(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to the Knowledge of the Company, there is currently no, and in the past four (4) years there has not been any unauthorized use, unauthorized disclosure, interference, infringement, violation, dilution or misappropriation of any Company-Owned IP Rights by any Person. Except as set forth on Schedule 5.10(f), no member of the Company Group has (i) brought any Action for or given any notice alleging interference, infringement, violation, dilution, or misappropriation of any Company-Owned IP Rights, nor (ii) issued any written communication inviting any Person to take a license, ownership interest, release, covenant not to sue, or similar right with respect to the Company-Owned IP Rights that such member of the Company Group believes is being infringed or violated by such Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.10(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company Group, the Company Group&#8217;s operation of its business, and the use of any products or services of the Company Group have not in the past four (4) years interfered with, misappropriated, infringed, diluted, or violated any Intellectual Property Rights of any Person in any material respect, and do not interfere with, misappropriate, infringe, dilute, or violate any Intellectual Property Rights of any Person in any material respect.  No member of the Company Group has received any charge, complaint, claim, demand or notice from any Person in the past four (4) years alleging any such interference, misappropriation, infringement, dilution, or violation of Intellectual Property Rights (including any invitation to license or a request or demand to refrain from using any Intellectual Property Rights of any Person in connection with the conduct of the Company Group&#8217;s business or use of the Company Group&#8217;s products or services.  No member of the Company Group is or has been party to any Action in the past four (4) years alleging such interference, misappropriation, infringement, dilution, or violation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company Group, collectively, (i) lawfully owns, leases, licenses, or otherwise has a valid and adequate right to use via Contract all Systems that are used in the operations of the Business, which are reasonably sufficient for the immediate needs of the Company Group, including as to capacity, scalability, and ability to process current and anticipated peak volumes in a timely manner, and (ii) will continue to have such rights immediately after the Closing.  In the past four (4) years, there has been no failure or other material substandard performance of any System, in each case which has caused a material disruption to any Company Group member. The Company Group maintains commercially reasonable security, back-up, disaster recovery and business continuity plans, procedures and facilities and acts in compliance therewith in all material respects, and the Company Group has taken commercially reasonable steps to test such plans and procedures on a periodic basis and such plans and procedures have proven effective in all material respects. No Company Group member has been subjected to an audit of any kind in connection with any license or other Contract pursuant to which the Company Group member holds rights to any third-party Software, nor has received any notice of intent to conduct any such audit.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Schedule 5.10(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> lists all Open Source Software contained in the Company Software and describes (i) the applicable software name and version number, and (ii) the license under which such code was obtained.  Except as disclosed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.10(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, none of the Company-Owned IP Rights or any product or service of a member of the Company Group constitutes, contains or is dependent on any Open Source Software. Each member of the Company Group is in compliance, in all material respects, with the terms and conditions of all Contracts relating to Open Source Software used by such member of the Company Group in any manner, including attribution and notice obligations.  No member of the Company Group has incorporated, distributed or combined Open Source Software into or with any Software of the Company Group or Company-Owned IP Rights, or otherwise used Open Source Software, in such a manner that (i) would require any such Software or Company-Owned IP Rights to be disclosed, delivered, distributed, licensed or otherwise made available in source code form, (ii) limit a Company Group member&#8217;s freedom to seek full compensation in connection with the marketing, licensing or distribution of any of the material products or services of the Business, (iii) allow a third party to decompile, disassemble or otherwise reverse engineer or re-license any such Software or Company-Owned IP Rights, or (iv) grant any patent license, non-assertion covenant, or other rights under any such Software or Company-Owned IP Rights.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">No member of the Company Group has disclosed, delivered or licensed to any Person or agreed or obligated itself to disclose, deliver or license to any Person, or permitted the disclosure or delivery to any escrow agent or other Person of, any Company Source Code or trade secret that is part of the Systems, product or services of the Company Group, other than disclosures to employees, contractors and consultants involved in the development of Company Software products and subject to written agreements requiring such employees, contractors, and consultants to maintain the confidentiality of such Company Source Code.  No event has occurred, none of the Company-Owned IP Rights are or have been used in a manner, and no circumstance or condition exists, that (with or without notice or lapse of time, or both) will, or would reasonably be expected to, result in the disclosure, delivery, distribution or license of any Company Source Code, other than disclosures to employees and consultants involved in the development of Company Software products and subject to written agreements requiring such employees, contractors, and consultants to maintain the confidentiality of such Company Source Code.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company Group possesses and maintains a complete and accurate copy of all Company Source Code and other documentation and materials necessary to assemble, compile, link, modify, maintain, support and operate the Company Software in all material respects. The Company Software&#58; (i) conforms in all material respects with all current specifications established by the Company Group&#59; (ii) is operative for its intended purpose free of any material defects or deficiencies&#59; and (iii) has been maintained by the Company Group. There is no Malicious Code in any of the Company Software or the Systems owned by the Company Group.</font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">The Company Group&#8217;s Handling of Personal Information is and for the past four (4) years has been in compliance, in all material respects, with all Privacy Laws and Contracts (including privacy policies, data subject consents and terms of use) applicable to any Company Group member or to which any Company Group member is bound (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Data Security </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). In the past four (4) years, the Company Group has maintained and complied, in all material respects, with written policies and procedures regarding data security and privacy, which policies are consistent in all material respects with all applicable Privacy Laws, and has maintained administrative, technical and physical safeguards designed to protect the confidentiality, privacy and security of all Personal Information collected by or on behalf of the Company Group that are reasonable and, in any event, in material compliance with all Data Security Requirements. The Company Group has not been involved in any legal proceeding, received any written complaint or notification from any Person or been subject to any investigation by a Governmental Authority, in each case involving a breach or alleged breach of or noncompliance with any Data Security Requirements. In the past four (4) years&#58; (i) no breach, security incident or violation of any Data Security Requirements in relation to Personal Information has occurred or is threatened&#59; and (ii) no circumstance has arisen in which applicable Privacy Laws would require the Company Group to notify any Governmental Authority of any breach, security incident or unauthorized or illegal disclosure or use of Personal Information. The Company Group has the right in accordance with the Data Security Requirements to Handle Personal Information for the purpose such information is and has been Handled by the Company Group. Neither the execution, delivery or performance of this Agreement, nor the consummation of any of the transactions contemplated by this Agreement, will violate any applicable Data Security Requirements. Upon execution of this Agreement, the Company Group shall have the right to use and process any Personal Information collected, processed or used by them before the signature date of this Agreement in order to be able to conduct the ordinary course of Business, to the same extent as immediately prior to such execution. Each member of the Company Group has entered into commercially reasonable arrangements to the extent required by applicable Privacy Laws with vendors, service providers and other Persons whose relationship with such Company Group involves the Handling of Personal Information. Each member of the Company Group has (i) regularly conducted vulnerability testing, risk assessments, and external audits of, and tracks security incidents related to, Systems and conducted all security management processes required by Privacy Laws and&#47;or HIPAA (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Information Security Reviews</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (ii) timely corrected any material exceptions or vulnerabilities identified in such Information Security Reviews, and (iii) installed generally available software security patches and other fixes to identified technical information security vulnerabilities in accordance with industry standards. The Company Group provides its workforce members with periodic training on privacy and data security matters in material compliance with Privacy Laws.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_613"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Governmental Licenses and Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> contains a complete and accurate listing of all material Governmental Licenses used by the Company Group in the conduct of the Business. All such Governmental Licenses are in full force and effect.  Except as indicated on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, one or more members of the Company Group  owns or possesses all right, title and interest in and to all of the Governmental Licenses that are necessary to own and operate the Business.  Each member of the Company Group is in compliance in all material respects with the terms and conditions of such Governmental Licenses and has been for the six (6) prior years in compliance in all material respects with the terms and requirements of its Governmental Licenses, and no suspension, cancellation, termination, modification, revocation, forfeiture, or nonrenewal of any such Governmental License is pending or, to the Company&#8217;s Knowledge, threatened.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></div></div><div id="i649a3a409a124fa4b643ff6500d07394_616"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Litigation&#59; Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (a) as of the date hereof, there are no Actions pending or, to the Company&#8217;s Knowledge, threatened against any member of the Company Group, or any of their respective assets or the Business, and, to the Knowledge of the Company, no facts or circumstances exist that could reasonably be expected to result in any such Actions pending or threatened against any member of the Company Group, or any of their respective assets or the Business, (b) no member of the Company Group is subject to any currently effective material Court Order of any Governmental Authority and (c) in the past four (4) years, (i) there have been no material lawsuits or other proceedings brought by any Governmental Authority against any member of the Company Group and (ii) no member of the Company Group has entered into any material settlement with, or become subject to any material Court Order of, any Governmental Authority. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_619"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company Group is, and for the past four (4) years has been, in compliance in all material respects with all applicable Laws, including all applicable Health Care Laws, and, to the Knowledge of the Company, no facts or circumstances exist that could reasonably be expected to result in a member of the Company Group being out of compliance in any material respect with any applicable Laws, including any applicable Health Care Law.  For the past four (4) years, no notice has been received by the Company Group alleging a material violation of, material liability for, or regarding an investigation or audit related to, any Law, including any Health Care Law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No member of the Company Group is currently or for the last four (4) years, has been, with respect to any Governmental Authority&#58; (i) party to any consent decree, judgment, corrective action plan, corporate integrity agreement, deferred prosecution agreement, order, settlement, or similar undertaking that (A) requires the payment of money by the Company Group to any Government Authority, (B) requires any recoupment of money from the Company Group by any Governmental Authority, or (C) prohibits any activity currently conducted by the Company Group&#59; or (ii) subject to any actual settlement agreement, corporate integrity agreement or certification of compliance agreement with any Governmental Authority.  To the Company&#8217;s Knowledge, no member of the Company Group is a defendant or named party in any unsealed qui tam&#47;False Claims Act litigation. No member of the Company Group has been charged with, convicted of or entered a plea of guilty or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to any criminal or civil offense relating to the delivery of any item or service under a Federal Health Care Program or any other violation of Health Care Laws. For the last four (4) years, to the Knowledge of the Company, no Person with which a member of the Company Group has a contract has been the subject of an audit, investigation, recoupment, demand, judgment, settlement agreement, corporate integrity agreement, unsealed qui tam&#47;False Claims Act litigation, or similar action or review by any Governmental Authority as the result of or related to the relationship between that Person and such member of the Company Group, or any such charges, bills or records submitted which reflect the financial or managerial relationship between such Person and the Company Group, or the charges made by the Company Group to such Person.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">For the last four (4) years, the Company Group has not received written notice from any customer, Managed Surgical Center, or device manufacturer alleging the Company&#8217;s noncompliance with applicable Health Care Laws or contractual requirements. No Member of the Company Group is subject to any audit or review nor, to the Company&#8217;s Knowledge, is any audit or review threatened against a member of the Company Group by any Payor or Governmental Authority arising from the obligations of the Company Group under its contractual obligations to a Managed Surgical Center, except for audits or reviews conducted in the ordinary course of business. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company Group does not submit claims to or on behalf of, and is not reimbursed by, directly or indirectly, any Federal Health Care Program. For the last four (4) years, the Company Group has not presented, or caused to be presented, a claim to any Payor for payment or reimbursement that (i) was not materially in compliance with Payor requirements or Health Care Laws&#59; (ii) was for an item or service that was known or should have been known to not have been provided as claimed&#59; or (iii) was knowingly false or fraudulent.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Neither the Company Group nor any of its directors, officers, employees, nor, to the Knowledge of the Company, any of its contractors or agents is currently, has been, or is threatened to be&#58; (i) debarred, excluded, precluded or suspended from participating in any Governmental Health Program&#59; (ii) listed on the System for Award Management Excluded Parties List System or the U.S. Department of Health and Human Services&#8217; Office of Inspector General List of Excluded Individuals&#47;Entities&#59; (iii) designated a Specially Designated National or Blocked Person by the Office of Foreign Asset Control of the U.S. Department of Treasury&#59; or (iv) subjected to any other debarment, exclusion, or sanction list or database.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Neither the Company Group, nor any of its directors, officers, employees, nor, to the Knowledge of the Company, any of its contractors or agents, have, directly or indirectly, made or offered to make, or solicited or received, any contribution, gift, bribe, rebate, payoff, influence payment, kickback or inducement to any Person, or entered into any similar financial arrangement, regardless of form, in each case, in material violation of any applicable Health Care Law or to obtain or maintain favorable treatment in securing business in violation of any Health Care Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company Group (i) is, and for the past four (4) years, has been, in compliance in all material respects with HIPAA&#59; (ii) has not experienced a &#8220;Breach&#8221; of &#8220;Unsecured Protected Health Information,&#8221; as such terms are defined at 45 C.F.R. &#167; 164.402&#59; (iii) has in place with each Covered Entity or Business Associate (as such terms are defined in HIPAA) on whose behalf a member of the Company Group creates, receives, maintains, or transmits Protected Health Information a business associate agreement that complies with the requirements of HIPAA, and is and has for the last four (4) years been in material compliance with the terms of all such &#8220;Business Associate&#8221; and &#8220;Subcontractor Business Associate&#8221; agreements (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business Associate Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; (iv) has not received written notice from any Governmental Authority, nor, to the Company&#8217;s Knowledge, has any such written notice, claim, or action been filed or commenced against any member of the Company Group to the effect that any member of the Company Group is not in compliance with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HIPAA&#59; and (v) has not received written notice of any investigation by or complaint to the Office for Civil Rights with respect to HIPAA compliance by any member of the Company Group.  Each member of the Company Group has adopted, and for the past four (4) years has been in compliance with, written privacy and security compliance policies and procedures in compliance with HIPAA. Each member of the Company Group has the right, pursuant to its Business Associate Agreements and its written privacy and security compliance policies, to use and disclose Protected Health Information for all purposes such information is being and has been used and disclosed.  </font></div><div id="i649a3a409a124fa4b643ff6500d07394_643"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Environmental Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each member of the Company Group is, and at all times during the past four (4) years has been, in compliance in all material respects with all Environmental Laws.  No member of the Company Group has at any time during the past four (4) years received any written notice regarding any material violation of, or any material liability under, any Environmental Law with respect to the operations, properties or facilities of the Company Group.  No member of the Company Group has released any Hazardous Materials in material violation of any Environmental Laws and in a manner which could give or could reasonably be expected to give rise to any material liabilities pursuant to Environmental Laws.  </font></div><div id="i649a3a409a124fa4b643ff6500d07394_646"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">At all times during the past four (4) years each member of the Company Group has complied in all material respects with all applicable Laws relating to the employment of labor, including but not limited to Laws relating to discrimination, harassment, retaliation, terms and conditions of employment, worker classification (including the proper classification of workers as independent contractors and consultants and as exempt and non-exempt), wages, hours, termination of employment, occupational safety and health (including any applicable guidance published by any Governmental Authority related to the COVID-19 pandemic), leaves of absence, employee privacy, data privacy, and employment practices, including the Immigration Reform and Control Act, and has not engaged in any material unfair labor practice.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (i) there are no Actions pending or, to the Company&#8217;s Knowledge, threatened against any member of the Company Group or any of their officers, directors or employees (in their capacity as such) before any Governmental Authority concerning alleged employment discrimination, violation of any Law relating to employment, any Contract relating to employment or labor, or any other matters relating to the employment of labor, and, to the Company&#8217;s Knowledge, there are no facts and circumstances that could give rise to any such Action, (ii) during the past four (4) years there has not been, nor to the Company&#8217;s Knowledge, has there been any threat of, any Union organization activities or attempts, work stoppages, strikes, lockouts, picketing, slowdowns, petition seeking recognition of a bargaining representative filed with any labor relations board or other Governmental Authority, unfair labor practice complaint or grievance, or other similar labor activity or labor dispute affecting any member of the Company Group, (iii) no member of the Company Group is a party, or otherwise subject, to any collective bargaining agreement or other Contract with a Union, and no such contract is being negotiated by any member of the Company Group, and (iv) no employee of any member of the Company Group (in their capacity as such) is a member of any Union with respect to their employment by the Company Group.  During the past four (4) years, no member </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the Company Group has implemented any employee layoffs, plant closing or terminations that constituted a &#8220;Mass Layoff&#8221; or &#8220;Plant Closing&#8221; within the meaning of the WARN Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as would not result in a material Liability to the Company Group, for the past four (4) years, each member of the Company Group has withheld all amounts required by Law or by agreement to be withheld from the wages, salaries and other payments to employees, and is not liable for any arrears of wages, compensation, Taxes, penalties or other sums for failure to comply with any of the foregoing.  Except as would not result in a material Liability to the Company Group, for the past four (4) years, each member of the Company Group has paid to all directors, officers, employees and individual independent contractors all wages, salaries, commissions, bonuses, and other compensation due for any services performed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">True and complete information as to the name or employee identification number, current job title and base annual compensation for all current employees of each member of the Company Group has been provided to Purchaser. To the Company&#8217;s Knowledge, no current executive, key employee or group of employees of any member of the Company Group has given notice to any member of the Company Group that any such employee intends to terminate his, her or their employment with any member of the Company Group within the twelve (12) months immediately following the date hereof.  No employee of any member of the Company Group (i) is employed under a non-immigrant work visa or other work authorization that is limited in duration, or (ii) to the Company&#8217;s Knowledge,</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">has been the subject of any sexual harassment, sexual assault, or sexual discrimination allegations during his or her tenure at the Company Group.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt"> Since January 1, 2021, no member of the Company Group has instituted any reductions in force or layoffs affecting ten (10) or more of its employees, placed ten (10) or more of its employees on unpaid leave or furlough, or materially reduced the hours or weekly pay of ten (10) or more of its employees.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_661"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Schedule&#160;5.16(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth a list of each material Employee Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.16(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  (and separately identified as such on such schedule), no member of the Company Group or any ERISA Affiliate participates in or contributes to, or has in the past four (4) years participated in or been required to contribute to, or has any Liability  with respect to (i) any &#8220;multiemployer plan&#8221; (as defined in Section 3(37) of ERISA) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Multiemployer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (ii) any &#8220;multiple employer plan&#8221; described in Section 413 of the Code, (iii) any plan subject to Title IV of ERISA, (iv) any plan subject to the minimum funding standards of Section 412 of the Code or Section 302 of ERISA, or (v) any &#8220;multiple employer welfare arrangement&#8221; as defined in Section 3(40) of ERISA.  Without limitation of the foregoing, no member of the Company Group has incurred or could reasonably be expected to incur any Liability under Title IV of ERISA with respect to any employee benefit plan which any ERISA Affiliate participates in, contributes to, or is required to contribute or has participated in, contributed to, or been required to contribute to at any time in the past four (4) years.  The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Person, trade or business that, together with any member of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company Group, would be treated as a &#8220;single employer&#8221; within the meaning of Section 4001(b)(1) of ERISA or 414(b), (c), (m) or (o) of the Code.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as required under applicable Law, (i) no member of the Company Group nor any ERISA Affiliate maintains or has any Liability to contribute to any Employee Plan which provides, and (ii) no member of the Company Group nor any ERISA Affiliate otherwise has any obligation to provide or has any Liability with respect to, post-termination or post-retirement health, life insurance or other welfare benefits to current or former directors, officers, employees, or individual independent contractors, their spouses, dependents or beneficiaries, other than health benefits required to be provided under Code Section 4980B or similar Laws, for which the covered Person pays the full premium cost of coverage.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">There are no pending or, to the Company&#8217;s Knowledge, threatened Actions (other than routine claims for benefits) with respect to any Employee Plan or any trusts which are associated with such Employee Plan, and to the Company&#8217;s Knowledge, there are no facts that would reasonably be expected to give rise to any such Action, and none of the Employee Plans are under audit or investigation by the Internal Revenue Service, the Department of Labor or other applicable Governmental Authorities. No member of the Company Group nor any ERISA Affiliate has filed or been required to file with the IRS a Form 8928 in order to self-report any health plan violations which are subject to material excise Taxes under applicable provisions of the Code, and, to the Company&#8217;s Knowledge, there are no facts or circumstances that would reasonably be expected to result in any member of the Company Group being required by the Code to file any such Form 8928.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">With respect to each Employee Plan that is a &#8220;group health plan&#8221; within the meaning of Section 5000(b)(1) of the Code, each member of the Company Group and their ERISA Affiliates have maintained and administered each such plan in all material respects in compliance with the Patient Protection and Affordable Care Act of 2010, as amended, and the regulations issued thereunder, and has complied in all material respects with the applicable reporting requirements under Sections 6055 and 6056 of the Code&#59; to the Company&#8217;s Knowledge, there exists no basis upon which any member of the Company Group or any ERISA Affiliate reasonably would be expected to be subject to any material penalties or material assessable payments under Section 4980B or Section 4980H of the Code, nor to the Company&#8217;s Knowledge has any of the member of the Company Group or their ERISA Affiliates received any correspondence from the IRS or other agencies indicating that such penalties are or may be due.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.16(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> each Employee Plan has been established, maintained, funded and administered in all material respects in accordance with its terms and all applicable Laws.  Each Employee Plan intended to be qualified under Section 401(a) of the Code and each trust intended to qualify under Section 501(a) of the Code has obtained from the IRS a favorable determination notification, advisory and&#47;or opinion letter upon which it can rely, as to its qualified and tax-exempt status (or the qualified and tax-exempt status of the master or prototype form on which it is established) and, to the Company&#8217;s Knowledge, no fact or circumstance exists that would reasonably be expected to adversely affect the qualified status of any such Employee Plan or trust.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No &#8220;Prohibited Transaction,&#8221; within the meaning of Section 4975 of the Code or Sections 406 or 407 of ERISA and not otherwise exempt under Section 408 of ERISA, has occurred with respect to any Employee Plan that would result in material Liability to the Company Group.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.16(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the execution of this Agreement and the consummation of the transactions contemplated by this Agreement (alone or together with any other event which, standing alone, would not by itself trigger such entitlement or acceleration) will not (i) entitle any Person to any payment, vesting, distribution, or increase in compensation or benefits under or with respect to any Employee Plan, (ii) otherwise trigger any acceleration (of vesting or payment of benefits or compensation or otherwise) or (iii) result in any breach or violation of, or default under, any Employee Plan. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Each Employee Plan that is a &#8220;nonqualified deferred compensation plan&#8221; subject to Section 409A of the Code has been operated and maintained in compliance with Section 409A of the Code and the regulations and guidance provided thereunder in all material respects.  No member of the Company Group has any Liability or obligation to pay or reimburse any Taxes, or related penalties or interest, that may be incurred pursuant to Code Section 4999 or Code Section 409A.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">The Company has made available the following documents to Purchaser with respect to each material Employee Plan as applicable&#58; (1) correct and complete copies of the current plan documents (including all amendments thereto and form of award agreements thereunder) (or, with respect to any unwritten plan, a summary of the material terms thereof) and current related trust documents including any insurance contracts or other funding arrangements and amendments thereto, (2)&#160; the most recent summary plan description together with the summary or summaries of material modifications thereto, if any, (3) the most recent Internal Revenue Service (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) determination, opinion, notification and advisory letters, (4) the three most recent annual reports (Form Series 5500 and all schedules and financial statements attached thereto), (5) any material notices, letters, or non-routine correspondence with any Governmental Authority relating to such Employee Plan from the last  four (4) years, (6) the actuarial reports and annual nondiscrimination testing results for the three (3) most recently completed plan years&#59; and (7) any material filings pertaining to corrective actions taken with respect to any Employee Plan under the Internal Revenue Service&#8217;s Voluntary Correction Program or the Department of Labor&#8217;s Delinquent Filer Voluntary Compliance Program or the Voluntary Fiduciary Correction Program. No member of the Company Group has any express commitment to create any employee benefit plan, program or arrangement or to modify, amend or terminate any Employee Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No member of the Company Group nor, to the Company&#8217;s Knowledge, any ERISA Affiliate, has used the services of workers provided by third-party contract labor suppliers, temporary employees, &#8220;leased employees&#8221; within the meaning of Section 414(n) of the Code or individuals who have provided services as independent contractors in a manner that would reasonably be expected to result in the disqualification of any Employee Plan or the assessment of material penalties or material excise taxes with respect to any Employee Plan by the Internal Revenue Service, the Department of Labor or any other Governmental Authorities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></div></div></div><div id="i649a3a409a124fa4b643ff6500d07394_697"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.17(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each member of the Company Group has timely filed with the appropriate Governmental Authority all Tax Returns required to be filed by it. All such Tax Returns are true, accurate, and complete in all material respects and have been prepared in compliance in all material respects with all applicable Laws and regulations.  All Taxes of each member of the Company Group due and payable (whether or not shown as payable on any Tax Return) have been timely paid in full to the appropriate Governmental Authority in the manner required by Law.  The Company Group has made available to Purchaser copies of all federal income Tax Returns filed with respect to the Company Group for taxable periods ending on or after December 31, 2015, and all examination reports, and statements of deficiencies assessed against or agreed to by any member of the Company Group with respect to such taxable periods.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.17(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;no member of the Company Group has consented to or is subject to any extension of time in which any Tax may be assessed or collected by any taxing authority, which extension is in effect as of the date hereof&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;no member of the Company Group has requested or been granted an extension of the time for filing any Tax Return to a date later than the Closing Date other than automatic extensions taken in accordance with past practice&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;there is no action, suit, taxing authority proceeding or audit now in progress or pending against or with respect to the Company Group with respect to any Tax or Tax Return, and, to the Company&#8217;s Knowledge, no such action, suit, taxing authority proceeding or audit is threatened&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;no member of the Company Group has been a member of an Affiliated Group (other than a group of which the Company is or was the parent)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;no member of the Company Group is a party to or bound by any Tax indemnity agreement, Tax allocation agreement or Tax sharing agreement, or similar agreement, except to the extent such agreement was entered into in the ordinary course of business and not primarily related to Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">No member of the Company Group has requested or entered into closing agreements, private letter rulings, technical advice memoranda or similar agreements or rulings relating to any material Taxes, in each case, that will have continuing effect after the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No member of the Company Group has executed any power of attorney with respect to any Tax, other than powers of attorney that are no longer in force.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">There are no Liens upon any of the assets or properties of any member of the Company Group other than liens for Taxes not yet due and payable.  No claim has ever been </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">made by any Governmental Authority in a jurisdiction where a member of the Company Group does not file Tax Returns that such member of the Company Group is or may be subject to taxation by that jurisdiction.  Each member of the Company Group is and has at all times been resident for Tax purposes in its country of incorporation or formation and is not and has not at any time been a resident in any other country for any Tax purpose (including any arrangement for the avoidance of double taxation).  No member of the Company Group is or has been subject to Tax in any country other than the country of its incorporation or formation by virtue of having a branch, permanent establishment, place of control or management or fixed place of business in that jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">No member of the Company Group has participated in, nor are any of them currently participating in, a &#8220;Listed Transaction&#8221; within the meaning of Section&#160;6707A(c) of the Code or Treasury Regulation Section&#160;1.6011-4(b), a &#8220;reportable transaction&#8221; as defined under Section 6706A(c)(1) of the Code and Treasury Regulations Section 1.6011-4(b), or any transaction requiring disclosure under a corresponding or similar provision of state, local or foreign law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No member of the Company Group has any liability for the Taxes of any Person (other than another member of the Company Group) under Section&#160;1.1502-6 of the Treasury Regulations (or any similar provision of state, local or foreign law) as a transferee or successor, by contract or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No member of the Company Group will be required to include in income, or exclude any item of deduction from, Taxable income for any Taxable period (or portion thereof) ending after the Closing Date as a result of any (i)&#160;change in (or use of an improper) method of accounting for a Taxable period ending on or prior to the Closing Date pursuant to Section 481(a) of the Code (or any predecessor provision) or any similar provision of state, local or foreign Tax law, (ii) &#8220;closing agreement&#8221; described in Section&#160;7121 of the Code (or any corresponding or similar provision of state, local or foreign Tax law), (iii)&#160;intercompany transactions or any excess loss account described in Treasury Regulations under Section&#160;1502 of the Code (or any corresponding or similar provision of state, local or foreign Tax law), (iv)&#160;installment sale or open transaction disposition made on or prior to the Closing Date, or (v) prepaid amounts received before the Closing Date outside the ordinary course of business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">There is no application pending with any Governmental Authority requesting permission for any changes in the Company&#8217;s or any Subsidiary&#8217;s accounting methods for Tax purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">No member of the Company Group has constituted either a &#8220;distributing corporation&#8221; or a &#8220;controlled corporation&#8221; in a distribution of stock purported or intended to qualify in whole or in part for Tax-free treatment under Sections&#160;355 or 361 of the Code.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Each member of the Company Group has complied (and until the Closing will comply) with all applicable legal requirements relating to the payment, reporting and withholding of Taxes (including withholding of Taxes pursuant to Sections&#160;1441, 1442, 1445 and 1446 of the Code or similar provisions under any state, local or foreign law), has, within the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">time and in the manner prescribed by law, deducted and withheld from any amounts paid or owing to any employee, agent, independent contractor, creditor, Stockholder or other third party, and paid over to the proper governmental authorities (or is properly holding for such timely payment) all amounts required to be so withheld and paid over under all applicable legal requirements, including federal and state Income Taxes, Federal Insurance Contribution Act, Medicare, Federal Unemployment Tax Act, relevant state income and employment Tax withholding laws, and has timely filed all withholding Tax Returns and complied with related recordkeeping requirements, for all periods through and including the Closing Date.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">No member of the Company Group has any liability for Taxes arising from Section 965 of the Code.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">No member of the Company Group has made any election to defer any payroll Taxes under the CARES Act or Notice 2020-65.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Schedule 5.17(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> lists the entity classification of each member of the Company Group for U.S. federal income tax purposes.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_757"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Brokerage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as disclosed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, there are no claims for brokerage commissions, finder&#8217;s fees or similar compensation in connection with the transactions contemplated by this Agreement based on any arrangement or agreement made by any member of the Company Group, and the Company Group will not have any obligations with respect to any investment bank, finder, or broker after the Closing.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_760"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Affiliate Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except for (a) advances to employees, officers and directors for expenses incurred in the ordinary course of business consistent with past custom and practice, (b) equity, option or employment agreements with any employee, officer or consultant of any member of the Company Group, (c) any benefits under any Employee Plan, (d) any inter-company agreements solely among the Company and&#47;or any of its Subsidiaries and (e) those Contracts disclosed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no officer, director, stockholder or Affiliate of the Company is a party to any material contract, commitment or transaction with any member of the Company Group or has any material interest in any material property used by any member of the Company Group.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_763"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth a complete and correct list of each insurance policy to which any member of the Company Group is a party, a named insured or otherwise the beneficiary of coverage (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  All of such Insurance Policies are legal, valid, binding and enforceable and in full force and effect, and none of the Company nor any of the Company&#8217;s Subsidiaries is in material breach or default with respect to its obligations under such Insurance Policies.  There are currently no material claims pending against the Company or any of its Subsidiaries which are covered under any Insurance Policies and no material pending claims have been denied are subject to an insurer&#8217;s reservation of rights. All premiums due and payable with respect to the Insurance Policies have been paid.  The Company has provided to the Purchaser accurate and complete copies of all the material Insurance Policies and surety bonds </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(including copies of all written amendments, supplements, waivers of rights and other modifications).</font></div><div id="i649a3a409a124fa4b643ff6500d07394_766"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Undisclosed Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company Group has no Liabilities of the type that would be required to be disclosed or reserved against a balance sheet prepared in accordance with GAAP, other than (a) those set forth in the Latest Balance Sheet, (b) those incurred in the conduct of the Company Group&#8217;s business since the Latest Balance Sheet date in the ordinary course of business and consistent with past practices (but excluding, for the avoidance of doubt, any Liabilities incurred due to violation of a Law or breach of a Contract), (c) those incurred by the Company Group in connection with this Agreement, and (d) the Liabilities set forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_769"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The books, records and accounts of the Company Group are in all material respects true, complete and correct.  The minute books of the Company Group made available to Purchaser accurately and adequately reflect in all material respects all action previously taken by the holders of the Company Stockholders and the board of directors or other governing body (including all committees) of each member of the Company Group.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth the names and locations of all banks, trust companies, savings and loan associations and other financial institutions at which the members of the Company Group maintain accounts of any nature and the names of all Persons authorized to draw thereon or make withdrawals therefrom.  </font></div><div id="i649a3a409a124fa4b643ff6500d07394_772"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Anti-Corruption and International Risk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the last four (4) years, neither the members of the Company Group nor any of their directors, officers, or employees, nor, to the Company&#8217;s Knowledge, any of their agents has, directly or indirectly, given or agreed to give any rebate, gift, or similar benefit to any supplier, customer, governmental employee or other Person who was, is, or may be in a position to help or hinder the Company Group (or assist in connection with any actual or proposed transaction by the Company Group) in violation of the Anti-Corruption Laws.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">During the last four (4) years, neither the members of the Company Group, nor any director, officer, or employee, nor, to the Company&#8217;s Knowledge, any agent, distributor, consultant, affiliate, or any person acting on behalf of the members of the Company Group, has taken any action, either directly or indirectly, in a violation of the Anti-Corruption Laws, including making, offering, authorizing, or promising any payment, contribution, gift, entertainment, bribe, rebate, kickback, or any other thing of value, regardless of form or amount, to any (i) foreign or domestic government official or employee, (ii) employee of a foreign or domestic government-owned entity, (iii) foreign or domestic political party official or organization to obtain a competitive advance to receive favorable treatment in obtaining or retaining a business, or to compensate for favorable treatment already secured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the last four (4) years, neither the members of the Company Group nor, to the Company&#8217;s Knowledge, any director, officer, employee, agent, distributor, consultant, Affiliate, or other Person acting on behalf of the Company Group, has been the subject of any investigations, reviews, audits, or inquiry by any Governmental Authority alleging noncompliance with any applicable Law.  During the last four (4) years, each member of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company Group and its directors, officers, and employees, and, to the Company&#8217;s Knowledge, its consultants and agents has at all times fully complied with, and are currently in full compliance with, the Anti-Corruption Laws.  No member of the Company Group, nor, to the Company&#8217;s Knowledge, any director, officer, employee, agent, distributor, consultant, Affiliate, or other Person acting on behalf of the members of the Company Group, is, or has been, under administrative, civil, or criminal investigation, indictment, information, suspension, debarment, or audit (other than a routine contract audit) by any party, in connection with alleged or possible violations of the Anti-Corruption Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No director, officer, employee, agent, or other Person acting on behalf of or for the benefit of the Company Group, and, to the Company&#8217;s Knowledge, none of the Company Group&#8217;s Affiliates or any representatives of any such Affiliate is a Restricted Party nor has engaged in, nor is it now engaged in, any dealings or transactions with or for the benefit of any Restricted Party, nor has otherwise violated Sanctions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">None of the members of the Company Group has violated, nor are in violation of, any Anti-Money Laundering Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">The members of the Company Group have obtained export licenses and permissions as required by, and otherwise have operated, and are presently in compliance with the Export Control Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The members of the Company Group have established and continue to maintain reasonable internal controls and procedures designed to prevent their officers, employees, contractors, sub-contractors, service providers, agents and intermediaries from undertaking any activity, practice, or conduct relating to the business of the Business and its Subsidiaries that would constitute an offense under the Anti-Corruption Laws, Anti-Money Laundering Laws, Export Control Laws, or Sanctions.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_796"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Customers, Surgical Centers, and Suppliers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth a complete and accurate list of the Material Customers, Managed Surgical Centers, and Material Suppliers.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, since January 1, 2021, no Material Customer, Managed Surgical Centers, or Material Supplier of any member of the Company Group has had any dispute with any member of the Company Group, made or threatened to make an indemnification claim against any member of the Company Group, cancelled, terminated or otherwise materially altered (including any material reduction in the rate or amount of sales or purchases or material increase in the prices charged or paid, as the case may be) or notified any member of the Company Group of any intention to do any of the foregoing or otherwise threatened in writing to cancel, terminate or materially alter (including any material reduction in the rate or amount of sales or purchases or material increase in the prices charged or paid as the case may be) its relationship with any member of the Company Group.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_799"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as expressly set forth in this Agreement under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the certificates delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and any Letters of Transmittal, Option Cancellation Agreements, and Accredited Investor Questionnaires delivered in connection with this Agreement, none of the Sellers or any member of the Company Group makes any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">69</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">representation or warranty, express or implied, at law or in equity with respect to the Company Group and any such other representations or warranties are hereby expressly disclaimed, including any implied representation or warranty as to condition, merchantability, suitability or fitness for a particular purpose.  Notwithstanding anything to the contrary, (a)&#160;none of the Sellers or any member of the Company Group shall be deemed to make to Purchaser any representation or warranty with respect to the Company Group other than as expressly made by such Person in this Agreement under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the certificates delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and any Letters of Transmittal, Option Cancellation Agreements, and Accredited Investor Questionnaires delivered in connection with this Agreement, and (b)&#160;Except as expressly set forth in this Agreement under Article 5 and the certificates delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, none of the Sellers or any member of the Company Group make any representation or warranty to Purchaser with respect to (i)&#160;any projections, estimates or budgets heretofore delivered to or made available to Purchaser or its counsel, accountants or advisors of future revenues, expenses or expenditures or future results of operations of the Company Group or any member thereof, or (ii) except as expressly covered by a representation and warranty contained in this this Agreement under Article 5 and the certificates delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, any other information or documents (financial or otherwise) made available to Purchaser or its counsel, accountants or advisors with respect to any Seller or any member of the Company Group.  Purchaser hereby acknowledges and agrees to such disclaimer and that, except to the extent specifically set forth in this this Agreement under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the certificates delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Purchaser is acquiring the Company Stock on an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">as is, where is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; basis.  Notwithstanding anything set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or otherwise set forth in this Agreement, Purchaser retains all of its rights and remedies with respect to claims based on Fraud with respect to the representations and warranties of the Company in connection with Article 5 and the certificates delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_802"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">COVID-19 Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no member of the Company Group has obtained any material financial aid or other assistance or relief under, any federal, state or local programs adopted in response to COVID-19, including the CARES Act, the Enhancement Act, the Federal Reserve Main Street Lending Program and any similar non-US law or program.  With respect to any assistance or relief set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company Group has complied in all material respects with the requirements of the applicable program.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_805"></div><div style="margin-bottom:12pt;margin-top:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 6</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF EVOLENT ENTITIES AND MERGER SUB</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except (a) as disclosed in the Parent Public Disclosure Record (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that this section (a) shall not apply to statements (excluding factual statements) that are contained under the captions &#8220;Risk Factors&#8221; or &#8220;Forward-Looking Statements,&#8221; or any other disclosures in the Parent Public Disclosure Record which are similarly cautionary, predictive or forward looking in nature), and (b) as set forth in the disclosure schedule delivered by Purchaser to the Company and dated as of the date of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),as an inducement to the Company to enter into this Agreement, the Evolent Entities and Merger Sub represent and warrant as of the date hereof as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></div></div></div><div id="i649a3a409a124fa4b643ff6500d07394_808"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Organization and Power&#59; Ownership of Merger Sub&#59; No Prior Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of the Evolent Entities and Merger Sub is a corporation or limited liability company duly organized, validly existing and in good standing under the laws of the State of Delaware.  Purchaser and Merger Sub have all requisite corporate or limited liability company power and authority to execute and deliver this Agreement and the other agreements contemplated hereby and to perform their respective obligations hereunder and thereunder.  Parent owns directly or indirectly 100% of the issued and outstanding membership interests of Purchaser, and Purchaser owns directly or indirectly 100% of the issued and outstanding stock of Merger Sub.  Merger Sub was formed solely for the purpose of engaging in the transactions contemplated by this Agreement.  Except for obligations or liabilities incurred in connection with its formation and the transactions contemplated by this Agreement, Merger Sub has not and will not have incurred, directly or indirectly, through any Subsidiary or Affiliate, any obligations or liabilities or engaged in any business activities of any type or kind whatsoever or entered into any agreements or arrangements with any Person. Purchaser is in good standing in the state or country of its incorporation (in so far as that concept is recognized in the relevant jurisdiction) and has all requisite power and authority to own, lease and operate its properties and assets and to carry on its business as now being conducted, and is duly qualified to do business and is in good standing as a foreign corporation (in so far as that concept is recognized in the relevant jurisdiction) in each jurisdiction in which the character of the properties it owns, operates or leases or the nature of its activities makes such qualification necessary, except for such failures to be so qualified or in good standing that, individually or in the aggregate, would not have a material adverse effect on Parent&#8217;s or Purchaser&#8217;s ability to consummate the transactions contemplated hereby.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_811"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The execution, delivery and performance by the Evolent Entities and Merger Sub of this Agreement, the other agreements contemplated hereby to which Parent, Purchaser or Merger Sub, as applicable, is a party and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by all requisite corporate action and no other corporate act or proceeding on the part of Parent, Purchaser or Merger Sub, or their respective board of directors (or equivalent governing body) or stockholders or members, as applicable, is necessary to authorize the execution, delivery or performance of this Agreement or the other agreements contemplated hereby to which Parent, Purchaser or Merger Sub, as applicable, is a party and the consummation of the transactions contemplated hereby or thereby.  This Agreement has been duly executed and delivered by Parent, Purchaser and Merger Sub and, assuming the due execution and delivery of this Agreement and the other agreements contemplated hereby by the other parties hereto and thereto, this Agreement constitutes, and the other agreements contemplated hereby to which Parent, Purchaser or Merger Sub, as applicable, is a party upon execution and delivery by Parent, Purchaser and Merger Sub will each constitute, a valid and binding obligation of Purchaser and Merger Sub, enforceable in accordance with their terms, except as such enforceability may be limited by (a) applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors&#8217; rights generally, and (b) applicable equitable principles (whether considered in a proceeding at law or in equity).</font></div><div id="i649a3a409a124fa4b643ff6500d07394_814"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Capitalization of Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As of May 23, 2022, the authorized capital of Purchaser consists of 750,000,000 Parent Shares and 100,000,000 shares of Class B common </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">stock, par value $0.01 per share. All of the issued and outstanding ordinary shares of Purchaser have been duly authorized and validly issued and are fully paid and nonassessable.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_817"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Violation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;6.4,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the execution, delivery and performance by Parent, Purchaser and Merger Sub of this Agreement and the other agreements contemplated hereby to which Parent, Purchaser or Merger Sub, as applicable, is a party and the consummation of each of the transactions contemplated hereby or thereby will not (a)&#160;violate, conflict with, result in any material breach of, constitute a material default under, result in the termination or acceleration of, create in any party the right to accelerate, terminate, modify or cancel, or require any notice under either of its articles of incorporation or bylaws (or equivalent governing documents) or, to Purchaser&#8217;s Knowledge, any material Contract, material agreement, material arrangement, material indenture, material mortgage, material loan agreement, material lease, material sublease, material license, material sublicense, material franchise, material permit, material obligation or material instrument to which Parent, Purchaser or Merger Sub is a party or by which it is bound or affected, except in each case as would otherwise not reasonably be expected to have a material adverse effect on Parent&#8217;s or Purchaser&#8217;s ability to consummate the transactions contemplated hereby&#59; or (b)&#160;require any authorization, consent, approval, exemption or notice to any Governmental Authority under the provisions of any law, statute, rule, regulation, judgment, order or decree (except for (a) the filing and recordation of the Certificate of Merger as required by the DGCL and any such actions required by the HSR Act or any other applicable Law, and (b) any filings, notices, permits, authorizations, registrations, consents or approvals of which the failure to make or obtain would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on Parent&#8217;s or Purchaser&#8217;s ability to consummate the transactions contemplated hereby).</font></div><div id="i649a3a409a124fa4b643ff6500d07394_820"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">As of the date of this Agreement, there are no actions, suits, proceedings, orders or investigations pending or, to Purchaser&#8217;s Knowledge, threatened against or affecting Purchaser or Merger Sub, at law or in equity, or before or by any Governmental Authority, which would adversely affect Parent&#8217;s, Purchaser&#8217;s or Merger Sub&#8217;s performance under this Agreement, the other agreements contemplated hereby or the consummation of the transactions contemplated hereby or thereby.</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No Evolent Entity is subject to any currently effective material Court Order of any Governmental Authority that may have the effect of preventing, delaying, making illegal or otherwise interfering with Parent&#8217;s, Purchaser&#8217;s or Merger Sub&#8217;s performance under this Agreement, the other agreements contemplated hereby or the consummation of the transactions contemplated hereby or thereby. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_829"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Investment Intent&#59; Restricted Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Purchaser is directly or indirectly acquiring the Company Stock solely for Purchaser&#8217;s own account, for investment purposes only, and not with a view to, or with any present intention of, reselling or otherwise distributing the Company Stock or dividing its participation herein with others.  Purchaser understands and acknowledges that (a) none of the Company Stock have been registered or qualified under the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Securities Act, or under any securities laws of any state of the United States or other jurisdiction, in reliance upon specific exemptions thereunder for transactions not involving any public offering&#59; (b) all of the Company Stock constitute &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">restricted securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as defined in Rule 144 under the Securities Act&#59; (c) none of the Company Stock is traded or tradable on any securities exchange or over-the-counter&#59; and (d) none of the Company Stock may be sold, transferred or otherwise disposed of unless a registration statement under the Securities Act with respect to such Company Stock and qualification in accordance with any applicable state securities laws becomes effective or unless such registration and qualification is inapplicable, or an exemption therefrom is available.  Purchaser will not transfer or otherwise dispose any of the Company Stock acquired directly or indirectly hereunder or any interest therein in any manner that may cause any Company Stockholder to be in violation of the Securities Act or any applicable state securities laws.  Purchaser is an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">accredited investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as defined in Rule 501(a) of the Securities Act. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_832"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Brokerage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  There are no claims for brokerage commissions, finder&#8217;s fees or similar compensation in connection with the transactions contemplated by this Agreement based on any arrangement or agreement made or alleged to have been made by or on behalf of Purchaser or Merger Sub (or their respective officers, directors, employees or agents), except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Purchaser Disclosure Schedule.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_835"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Due Diligence Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of Purchaser and Merger Sub acknowledges that&#58; (a) it has completed to its satisfaction its own due diligence review with respect to the Company Group and it is entering into the transactions contemplated by this Agreement based on such investigation and, except for the specific representations and warranties made by the Company in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, it is not relying upon any representation or warranty of any member of the Company Group or any Affiliate thereof or any equityholder, officer, director, employee, agent or advisor, or any of them, nor upon the accuracy of any record, projection or statement made available or given to Purchaser or Merger Sub in the performance of such investigation, (b) it has had access to its full satisfaction to the Company Group and their respective books and records, Contracts, agreements and documents (including Tax Returns and related documents), and employees, agents and representatives, and (c) it has had such opportunity to seek accounting, legal, tax or other advice or information in connection with its entry into this Agreement and the other documents referred to herein relating to the consummation of the transactions contemplated hereby and thereby as it has seen fit. Notwithstanding anything to the contrary in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or otherwise set forth in this Agreement, Purchaser retains all of its right and remedies with respect to claims based on fraud. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_838"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The aggregate proceeds of the Debt Financing contemplated by the Commitment Letter to be funded on the Closing Date (together with cash on hand of the Evolent Entities) are sufficient for the Evolent Entities to pay in full the Aggregate Initial Cash Consideration and the fees and expenses incurred by the Evolent Entities or Merger Sub and all other amounts payable in cash pursuant to this Agreement and the other documents contemplated hereby or otherwise necessary to consummate all the transactions contemplated hereby and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">thereby, in each case, to the extent such amounts are due and payable on the Closing Date (such amounts, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Required Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)..</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Evolent Entities have delivered to the Company (i) a true, complete and correct copy of the Commitment Letter as in effect on the date hereof, and (ii) a true, complete and correct copy of any fee letter entered into in connection with the Commitment Letter (including all exhibits, attachments, appendices and schedules thereto as of the date hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Fee Letters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that the fees and similar economic terms, including any economic flex provisions (none of which could affect the conditionality, enforceability, timing, availability, termination or aggregate principal amount of the Debt Financing) in a copy of any Fee Letter may be redacted in a customary manner.  The Commitment Letter has not been amended, waived, supplemented or modified and the obligations and commitments contained such Commitment Letter have not been withdrawn, terminated or rescinded, and no such amendment, waiver, supplement, modification, withdrawal, termination or rescindment is pending. The Commitment Letter is in full force and effect as of the date hereof and constitutes a legal, valid and binding obligation of Parent and, to Purchaser&#8217;s Knowledge, each other party thereto, enforceable against such party in accordance with its terms, except, in each case, as such enforcement may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization or moratorium Laws, other similar Laws affecting creditors&#8217; rights and general principles of equity affecting the availability of specific performance and other equitable remedies. The Evolent Entities have fully paid any and all commitment fees or other fees in connection with the Commitment Letter and the Fee Letters that are payable on or prior to the date hereof, if any.   There are no side letters or other Contracts or arrangements related to the Debt Financing other than as expressly set forth in the Commitment Letter furnished to the Company pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The Commitment Letter is not subject to any conditions or other similar contingencies (including pursuant to any &#8220;flex&#8221; provisions in the related fee letter or otherwise) other than as expressly set forth therein and not redacted in the version provided to the Company.  Assuming the conditions set forth in Article 3 are satisfied at Closing, Parent has no reason to believe that any of the conditions to the Debt Financing will not be satisfied or the full amount of the Debt Financing will not be available to Evolent Entities on the Closing Date, and Parent is not aware of the existence of any fact or event as of the date hereof that would be reasonably expected to cause such conditions to the Financing not to be satisfied or the full amount of the Debt Financing not be available and the Closing not to occur.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_847"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Closing, and after giving effect to all of the transactions contemplated by this Agreement (including the Debt Financing) assuming the satisfaction or waiver of conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> at Closing, the accuracy of the representations and warranties of the Company Group in this Agreement, without giving effect to any materiality or &#8220;Material Adverse Effect&#8221; qualifications therein, and that any estimates or projections of the Company provided to Purchaser by or on behalf of the Company on or prior to the date hereof were prepared in good faith based on assumptions that were reasonable when made, each member of the Company Group, on a consolidated basis, will be Solvent.  For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Solvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that, with respect to any Person and as of any date of determination, (a) the amount of the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">present fair saleable value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of the assets of such Person, will, as of such date, exceed the amount of all &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">liabilities of such Person, contingent or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">otherwise,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as of such date, as such quoted terms are generally determined in accordance with applicable federal laws governing determinations of the insolvency of debtors, (b) the present fair saleable value of the assets of such Person will, as of such date, be greater than the amount that will be required to pay the liability of such Person on its indebtedness as its indebtedness becomes absolute and matured, (c) such Person will not have, as of such date, an unreasonably small amount of capital with which to conduct its business and (d) such Person will be able to pay its indebtedness as it matures.  For purposes of the foregoing definition only, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a liability in connection with another Person&#8217;s (x) right to payment, whether or not such a right is reduced to judgment, liquidated, unliquidated, fixed, contingent, matured, unmatured, disputed, undisputed, legal, equitable, secured or unsecured or (y) right to any equitable remedy for breach of performance if such breach gives rise to a right of payment, whether or not such right to an equitable remedy is reduced to judgment, fixed, contingent, matured, unmatured, disputed, undisputed, secured or unsecured.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_850"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Securities Laws Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Parent Shares are registered pursuant to Section 12(b) of the Exchange Act and no securities commission or similar regulatory authority has issued any order preventing or suspending trading of any securities of Parent, and Parent is in compliance in all material respects with applicable requirements under the Exchange Act and the Securities Act.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Parent is in compliance in all material respects with the requirements of the NYSE for continued listing of the Parent Shares thereon. Parent has not taken any action designed to terminate, or likely to have the effect of terminating, the registration of the Parent Shares under the Exchange Act or the listing of such shares on the NYSE.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Trading in Parent Shares on the NYSE is not currently halted or suspended. No delisting, suspension of trading or cease trading order with respect to the Parent Shares is pending or, to the knowledge of Purchaser, threatened. To the knowledge of Parent, as of the date of this Agreement, no inquiry, review or investigation (formal or informal) of Parent by any securities commission or similar regulatory authority under the Exchange Act or the Securities Act or by the NYSE is in effect or ongoing or expected to be implemented or undertaken.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For the past four (4) years,  Parent has timely filed all forms, reports, statements and documents, including financial statements and management&#8217;s discussion and analysis required to be filed by Parent under the Exchange Act or the Securities Act, as the case may be and the rules and policies of the NYSE (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The documents in the Parent Public Disclosure Record, as at the respective dates filed, were in compliance in all material respects with the Exchange Act, the Securities Act and, where applicable, the rules and policies of the NYSE.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">None of the documents in the Parent Public Disclosure Record, as of their respective dates (and, if amended or superseded by a filing prior to the date hereof, then on the date of such filing), contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">75</font></div></div></div><div id="i649a3a409a124fa4b643ff6500d07394_868"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Anti-Corruption and International Risk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the last four (4) years, neither Evolent Entity, nor any of their directors, officers, or employees, nor, to the Purchaser&#8217;s Knowledge, any of their agents has, directly or indirectly, given or agreed to give any rebate, gift, or similar benefit to any supplier, customer, governmental employee or other Person who was, is, or may be in a position to help or hinder the Evolent Entities (or assist in connection with any actual or proposed transaction by the Evolent Entities) in violation of the Anti-Corruption Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">During the last four (4) years, neither Evolent Entity, nor any director, officer, or employee, nor, to the Purchaser&#8217;s Knowledge, any agent, distributor, consultant, affiliate, or any person acting on behalf of the Purchaser Entities, has taken any action, either directly or indirectly, in a violation of the Anti-Corruption Laws, including making, offering, authorizing, or promising any payment, contribution, gift, entertainment, bribe, rebate, kickback, or any other thing of value, regardless of form or amount, to any (i) foreign or domestic government official or employee, (ii) employee of a foreign or domestic government-owned entity, (iii) foreign or domestic political party official or organization to obtain a competitive advance to receive favorable treatment in obtaining or retaining a business, or to compensate for favorable treatment already secured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the last four (4) years, the Evolent Entities and their directors, officers, and employees, and, to the Purchaser&#8217;s Knowledge, their consultants and agents have at all times fully complied with, and are currently in full compliance with, the Anti-Corruption Laws.  Neither Evolent Entity nor, to the Purchaser&#8217;s Knowledge, any director, officer, employee, agent, distributor, consultant, Affiliate, or other Person acting on behalf of the members of the Evolent Entities, are, or have been, under administrative, civil, or criminal investigation, indictment, information, suspension, debarment, or audit (other than a routine contract audit) by any party, in connection with alleged or possible violations of the Anti-Corruption Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No director, officer, employee, agent, or other Person acting on behalf of or for the benefit of the Evolent Entities, and, to the Purchaser&#8217;s Knowledge, none of the Evolent Entities&#8217; Affiliates or any representatives of any such Affiliate is a Restricted Party nor has engaged in, nor is it now engaged in, any dealings or transactions with or for the benefit of any Restricted Party, nor has otherwise violated Sanctions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">No Evolent Entity has violated, nor are in violation of, any Anti-Money Laundering Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">The Evolent Entities have obtained export licenses and permissions as required by, and otherwise have operated, and are presently in compliance with the Export Control Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Evolent Entities have established and continue to maintain reasonable internal controls and procedures designed to prevent their officers, employees, contractors, sub-contractors, service providers, agents and intermediaries from undertaking any activity, practice, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or conduct relating to the business of the Purchaser Entities that would constitute an offense under the Anti-Corruption Laws, Anti-Money Laundering Laws, Export Control Laws, or Sanctions. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_892"></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><br><br>TERMINATION</font></div><div id="i649a3a409a124fa4b643ff6500d07394_895"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be terminated at any time prior to the Closing only as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">by mutual written consent of Purchaser and Merger Sub, on the one hand, and the Sellers&#8217; Representative, on behalf of the Company, on the other hand&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">by Purchaser and Merger Sub providing written notice to the Sellers&#8217; Representative if there has been a breach of the representations and warranties or covenants and agreements by the Company set forth in this Agreement, which would result in the failure of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 3.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to be satisfied (but not waived) (so long as Purchaser and Merger Sub have provided the Sellers&#8217; Representative with written notice of such breach and the breach has continued without cure until the earliest to occur of (i) ten (10) Business Days following the date of such notice of breach and (ii) the Termination Date)&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">by the Sellers&#8217; Representative, on behalf of the Company, providing written notice to Purchaser and Merger Sub if there has been a material and willful breach of the representations and warranties or covenants and agreements by Evolent Entities or Merger Sub set forth in this Agreement, which would result in the failure of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 3.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to be satisfied (but not waived) (so long as the Sellers&#8217; Representative has provided Purchaser and Merger Sub with written notice of such breach and the breach has continued without cure until the earliest to occur of (i) twenty (20) Business Days following the date of such notice of breach and (ii) the Termination Date)&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">by either Purchaser and Merger Sub, on the one hand, or the Sellers&#8217; Representative, on behalf of the Company, on the other hand, if the transactions contemplated hereby have not been consummated by December 31, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that a party shall not be entitled to terminate this Agreement pursuant to this subsection&#160;(d) if&#160;that party&#8217;s breach of this Agreement has prevented the consummation of the transactions contemplated hereby at or prior to such time&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Upon written notice from the Purchaser to the Company, if the Company has not delivered the Written Consent within twenty-four (24) hours of the date hereof in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Upon written notice by either Purchaser to the Sellers&#8217; Representative, on the one hand, or the Sellers&#8217; Representative on behalf of the Company, on the other hand, if following the date of this Agreement, any Governmental Authority issues, enacts, promulgates or enforces any Law (that is final and non-appealable and that has not been vacated, withdrawn, or overturned) restraining, enjoining, or otherwise prohibiting the transactions contemplated hereby&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided that no party hereto may terminate this Agreement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> if such party is in breach of this Agreement and such breach has been the cause of or has resulted in such action by a Governmental Authority&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">by the Sellers&#8217; Representative, on behalf of the Company, if (i) all the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> have been satisfied or waived (other than conditions that by their terms or nature are to be satisfied at the Closing, but subject to such conditions being capable of satisfaction at the Closing), (ii) the date that the Closing is required to have occurred in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> has passed, (iii) the Company has irrevocably confirmed by written notice to Parent that all the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> have been satisfied (other than conditions that by their terms or nature are to be satisfied at the Closing, but subject to such conditions being capable of satisfaction at the Closing) or that it is willing to waive any such unsatisfied conditions if the Closing is consummated and that each the Company is ready, willing and able to consummate the Closing and (iv) the Evolent Entities do not consummate the Closing within five (5) Business Days following delivery of such notice.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_919"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In the event of termination of this Agreement as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, this Agreement shall forthwith become void and there shall be no liability or obligation hereunder on the part of any party hereto (other than pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the second sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Press Releases and Announcements&#59; Confidentiality), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Expenses), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> which shall survive any such termination), except for intentional or willful breaches of this Agreement by any such party prior to the time of such termination.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event that this Agreement is validly terminated (i) by the Sellers&#8217; Representative pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or (ii) by either Purchaser and Merger Sub or the Sellers&#8217; Representative pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and at such time the Sellers&#8217; Representative could have terminated this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, then Purchaser shall pay, or cause to be paid, to the Sellers&#8217; Representative (for the benefit the Company and the Sellers) or another designee thereof an amount in cash by wire transfer of immediately available funds equal to $30,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Termination Fee shall be paid within two (2) Business Days of the date of such termination.  In no event shall Purchaser be required to pay the Termination Fee on more than one occasion at the same or at different times and the occurrence of different events.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Notwithstanding anything to the contrary herein, the exclusive remedies of Sellers, the Company Group, Sellers&#8217; Representative, and their respective Affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Related Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) against the Evolent Entities, Merger Sub and any of their respective former, current or future direct or indirect Affiliates, Representatives, controlling Persons, members, general or limited partners, other equityholders, successors or assignees (or any former, current or future direct or indirect Affiliates, Representatives, controlling persons, members, general or limited partners, other equityholders, successors or assignees of any of the foregoing) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Related Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in respect of this Agreement shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the following&#58; (i) specific performance prior to the termination of this Agreement pursuant to, and only to the extent expressly permitted by, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or (ii) the termination of this Agreement in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and to collect, if applicable, the Termination Fee pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If Purchaser fails to pay the Termination Fee when due and payable pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and, in order to obtain such payment, the Company or the Sellers&#8217; Representative commences an action, suit or proceeding that results in a final, non-appealable judgment against Purchaser for the Termination Fee, then Purchaser shall pay to the Sellers&#8217; Representative (for the benefit the Company and the Sellers) or another designee thereof, in addition to the Termination Fee, any reasonable documented out-of-pocket fees, costs and expenses (including reasonable legal fees) incurred by the Company or the Sellers&#8217; Representative in connection with any such action, suit or proceeding (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Seller Termination Fee Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Payment of the Termination Fee, if due and payable pursuant to this Agreement, and the Seller Termination Fee Expenses, to the extent applicable, shall be the sole and exclusive monetary remedy in the event of a termination of this Agreement and none of the Purchaser Related Persons shall have any further liability or obligation relating to or arising out of this Agreement, any agreements, instruments, and documents contemplated hereby or executed in connection herewith or the transactions contemplated hereby or thereby (including the failure to consummate the Closing). Without limiting the foregoing, no Company Related Person shall seek or obtain, nor shall it permit any of its Affiliates or Representatives or any other Person on its or their behalf to seek or obtain, nor shall any Person be entitled to seek or obtain, any recovery or award or any damages of any kind (including damages for the loss of the benefit of the bargain, opportunity cost, loss of premium, time value of money or otherwise, or any consequential, special, expectancy, indirect or punitive damages) other than Sellers&#8217; right to obtain the Termination Fee if and when payable hereunder, and the Company Related Persons shall not be entitled to commence or pursue any action against the Purchaser Related Persons or any of the Financing Sources arising out of or in connection with this Agreement, any agreements, instruments, certificates and documents contemplated hereby or executed in connection herewith, or the transactions contemplated hereby or thereby (including the failure to consummate the transactions contemplated hereby), other than litigation against the Evolent Entities and Merger Sub to enforce the payment of the Termination Fee pursuant to this Agreement or specific performance pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary herein, in no event shall Evolent Entities and Merger Sub be obligated to pay the Termination Fee on more than one occasion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For the avoidance of doubt, the Company and the Sellers&#8217; Representative shall be entitled to pursue both a grant of specific performance under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the payment of the Termination Fee under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, but under no circumstances shall the Company and the Sellers&#8217; Representative be permitted or entitled to receive both a grant of specific performance under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to cause the Evolent Entities to effect the Closing and the payment of the Termination Fee under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_934"></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><br><br>ADDITIONAL AGREEMENTS&#59; COVENANTS AFTER CLOSING</font></div><div id="i649a3a409a124fa4b643ff6500d07394_937"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Mutual Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of the parties hereto agrees that they will mutually cooperate in the expeditious filing of all notices, reports and other filings with any Governmental Authority required to be submitted jointly by any of the parties hereto in connection with the execution and delivery of this Agreement, the other agreements contemplated hereby and the consummation of the transactions contemplated hereby or thereby.  Subsequent to the Closing, each of the parties hereto, at their own cost, will reasonably assist each other (including by the retention of records and the provision of access to relevant records) in the preparation of their respective Tax Returns and the filing and execution of Tax elections, if required, as well as in the defense of any audits or litigation that may ensue as a result of the filing thereof, to the extent that such assistance is reasonably requested.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_940"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Press Release and Announcements&#59; Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless required by law (in which case each of Purchaser and the Sellers&#8217; Representative shall, to the fullest extent permitted by law, consult with the other party prior to any such disclosure as to the form and content of such disclosure), from and after the date hereof, through and including the Closing Date, no press releases, announcements to the employees, customers or suppliers of the Business or other releases of information related to this Agreement or the transactions contemplated hereby will be issued or released without the consent of both Purchaser and the Sellers&#8217; Representative or otherwise as set forth in the communications plan agreed to by Purchaser and Sellers&#8217; Representative prior to the date hereof. Purchaser acknowledges that following the date hereof, regardless of whether this Agreement is terminated, that certain confidentiality agreement by and between the Company and Purchaser, dated as of January 18, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), shall remain in full force and effect in accordance with its terms. Notwithstanding the foregoing, a press release of the Parent with respect to this Agreement and the transactions contemplated hereby will be issued by Parent promptly following the execution and delivery of this Agreement and promptly following Closing (the content of which press release is subject to the reasonable advanced approval of the Company prior to external disclosure) and Parent will file with the SEC a Current Report on Form 8-K promptly following the date hereof, which will include a copy of this Agreement (provided that, at Parent&#8217;s discretion, a copy may be filed with its Quarterly Report or Form 10-Q, and a Current Report on Form 8-K, promptly following the Closing). For the avoidance of doubt, the parties hereto acknowledge and agree that the Sellers&#8217; Representative and its Affiliates (except for the Company and its Subsidiaries) may provide (a) general information about the subject matter of this Agreement and the Company and its Subsidiaries (including its and their performance) in connection with the Sellers Representative's or its Affiliates' fund raising, marketing, informational or reporting activities, and (b) information about this Agreement, including the economic terms hereof, and the Company and its Subsidiaries in connection with ordinary course communications with the Seller Representatives' or its Affiliates' partners (including limited partners). </font></div><div id="i649a3a409a124fa4b643ff6500d07394_943"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise set forth in this Agreement, each of the parties hereto shall be solely responsible for and shall bear all of its own costs and expenses incident to its obligations under and in respect of this Agreement and the transactions contemplated hereby, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">including, but not limited to, any such costs and expenses incurred by any party hereto in connection with the negotiation, preparation and performance of and compliance with the terms of this Agreement (including the fees and expenses of legal counsel, accountants, investment bankers or other representatives and consultants), regardless of whether the transactions contemplated hereby are consummated&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Purchaser shall be solely responsible for all filing fees under the HSR Act (or any other Antitrust Law) and other governmental approvals and all costs associated with obtaining any third party consents in connection with the transactions contemplated by this Agreement. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_946"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Further Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of the parties hereto shall, and shall cause its Affiliates to, execute and deliver such further instruments and take such additional action as any other party hereto may reasonably request to effect or consummate the transactions contemplated hereby</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each such party shall, on or prior to the Closing, use its reasonable best efforts to fulfill or obtain the fulfillment of the conditions precedent to the consummation of the transactions contemplated hereby, including the execution and delivery of any documents, certificates, instruments or other papers that are reasonably required for the consummation of the transactions contemplated hereby.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_949"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Transfer Taxes&#59; Recording Charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary herein, all transfer, documentary, sales, use, stamp, registration and other such Taxes, and all conveyance fees, recording charges and other fees and charges (including any penalties and interest) incurred in connection with consummation of the transactions contemplated by this Agreement shall be paid or caused to be paid by Purchaser when due, and Purchaser will, at its own expense, file all necessary Tax Returns and other documentation with respect to all such Taxes, fees and charges, and, if required by applicable Law, the Sellers will, and will cause their Affiliates to, join in the execution of any such Tax Returns and other documentation.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_952"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Sellers&#8217; Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Sellers, by approving the principal terms of the Merger (including by executing the Written Consent), Letter of Transmittal and&#47;or Option Cancellation Agreement hereby constitute and appoint TPG Growth V Iceman, L.P. as the Sellers&#8217; Representative.  For purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sellers&#8217; Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the representative, true and lawful agent, proxy and attorney in fact of the Sellers for all purposes of this Agreement and the Escrow Agreement, with full power and authority on such Seller&#8217;s behalf (i)&#160;to consummate the transactions contemplated herein, (ii)&#160;to pay such Seller&#8217;s expenses (whether incurred on or after the date hereof) incurred in connection with the negotiation and performance of this Agreement, (iii) to receive, give receipt and disburse (or cause to be disbursed) any funds received hereunder on behalf of or to such Seller and each other Seller and to holdback from disbursement any such funds to the extent it reasonably determines may be necessary, (iv) to execute and deliver any certificates representing the Company Stock and execution of such further instruments as Purchaser shall reasonably request, (v)&#160;to execute and deliver on behalf of such Seller all documents contemplated herein and any amendment or waiver hereto, (vi)&#160;to take all other actions to be taken by or on behalf of such Seller in connection herewith, (vii) to negotiate, settle, compromise and otherwise handle all disputes under this Agreement, including without limitation, disputes regarding Estimated Working Capital and any adjustment pursuant to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (viii)&#160;to waive any condition to the obligation of the Sellers to consummate the transactions contemplated herein, (ix) to give and receive notices on behalf of the Sellers and (x) to do each and every act and exercise any and all rights which such Seller is, or the Sellers collectively are, permitted or required to do or exercise under this Agreement.  The Sellers, by approving the principal terms of the Merger and&#47;or accepting the consideration payable to them hereunder, irrevocably grant unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing necessary or desirable to be done in connection with the transactions contemplated by this Agreement, as fully to all intents and purposes as the Sellers might or could do in person.  Each of the Sellers agrees that such agency and proxy are coupled with an interest, are therefore irrevocable without the consent of the Sellers&#8217; Representative and shall survive the death, incapacity or bankruptcy of any Seller.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">All decisions, actions, consents and instructions of the Sellers&#8217; Representative shall be final and binding upon all the Sellers and no Seller shall have any right to object, dissent, protest or otherwise contest the same, except for fraud, bad faith or willful misconduct. Neither the Sellers&#8217; Representative nor any agent employed by Sellers&#8217; Representative shall incur any liability to any Seller relating to the performance of its duties hereunder except for actions or omissions constituting fraud, bad faith or willful misconduct.  The Sellers&#8217; Representative shall not have by reason of this Agreement a fiduciary relationship in respect of any Seller, except in respect of amounts actually received on behalf of such Seller.  The Sellers&#8217; Representative shall not be required to make any inquiry concerning either the performance or observance of any of the terms, provisions or conditions of this Agreement.  The Evolent Entities and Merger Sub may conclusively rely upon, without independent verification or investigation, all decisions made by, and all written notices and deliveries of, the Sellers&#8217; Representative in connection with this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Sellers shall cooperate with the Sellers&#8217; Representative and any accountants, attorneys or other agents whom the Sellers&#8217; Representative may retain to assist in carrying out Sellers&#8217; Representative&#8217;s duties hereunder.  The Sellers shall reimburse the Sellers&#8217; Representative for all costs and expenses, including professional fees, incurred.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event that the Sellers&#8217; Representative becomes unable to perform the Sellers&#8217; Representative&#8217;s responsibilities or resigns from such position, the Company Stockholders holding, prior to the Closing, a majority of the Company Stock shall select another representative to fill such vacancy and such substituted representative shall (i) be deemed to be the Sellers&#8217; Representative for all purposes of this Agreement and (ii) exercise the rights and powers of, and be entitled to the indemnity, reimbursement and other benefits of, the Sellers&#8217; Representative.  </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">At the Effective Time, the Purchaser shall deliver or cause to be delivered to the Sellers&#8217; Representative an amount in cash equal to $500,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sellers&#8217; Representative Expense Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to be held in trust to cover and reimburse the fees and expenses incurred by the Sellers&#8217; Representative for its obligations in connection with this Agreement and the transactions contemplated herein.  Any balance of the Sellers&#8217; Representative Expense Fund not incurred for such purposes shall be returned to the Sellers in accordance with their respective Applicable Percentage.  For all Tax purposes, the Sellers&#8217; Representative Expense Fund shall be treated as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">having been received and voluntarily set aside by the Sellers at the time of Closing, after any withholding required by applicable Law, and for the avoidance of doubt any Taxes required to be withheld in respect of the Sellers&#8217; Representative Expense Fund that is treated as having been paid to an Optionholder at Closing shall, notwithstanding any other provision of this Agreement, be withheld from the portion of the Optionholder Consideration paid to the applicable Optionholder.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">It is acknowledged by each of the parties hereto that the Company Group and the Sellers&#8217; Representative (and its Affiliates) have retained Ropes &#38; Gray LLP (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sellers&#8217; Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to act as their counsel in connection with the transactions contemplated hereby and that Sellers&#8217; Counsel has not acted as counsel for any other Person in connection with the transactions contemplated hereby and that no other party or Person has the status of a client of the Sellers&#8217; Counsel for conflict of interest or any other purposes as a result thereof.  Purchaser and the Company hereby agree that, in the event that a dispute arises between Purchaser, the Company or any of their respective Affiliates and Sellers&#8217; Representative or any of its Affiliates, Sellers&#8217; Counsel may represent Sellers&#8217; Representative or any of its Affiliates in such dispute even though the interests of Sellers&#8217; Representative or any of its Affiliates may be directly adverse to Purchaser, any member of the Company Group or any of their respective Affiliates and even though Sellers&#8217; Counsel may have represented a member of the Company Group in a matter substantially related to such dispute, and Purchaser, the Company and their respective Affiliates hereby waive, on behalf of themselves and each of their Affiliates, any conflict of interest in connection with such representation by Sellers&#8217; Counsel.  Each of Purchaser and the Company further agrees that, as to all pre-Closing communications among Sellers&#8217; Counsel, any member of the Company Group, and any Seller that relate in any way to the transactions contemplated by this Agreement, the attorney-client privilege, the expectation of client confidence and all other rights to any evidentiary privilege belong to Sellers&#8217; Representative and its Affiliates, as applicable, and may be controlled by Sellers&#8217; Representative and its Affiliates and shall not pass to or be claimed by Purchaser, the Company Group or any of their respective Affiliates.  Purchaser and the Company agree to take, and to cause their respective Affiliates to take, all steps necessary to implement the intent of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.6(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_973"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Directors and Officers Insurance&#59; Employee Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">At or prior to the Closing, the Company shall purchase for the benefit of any Person who is on the date hereof, or who becomes prior to the Closing Date, an officer, director or manager of any member of the Company Group (each such Person, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">D&#38;O Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), officers&#8217; and directors&#8217; liability insurance coverage (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">D&#38;O Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) with respect to all losses, claims, damages, liabilities, costs and expenses (including attorney&#8217;s fees and expenses), judgments, fines, losses, and amounts paid in settlement in connection with any actual or threatened action, suit, claim, proceeding or investigation (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">D&#38;O Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the extent that any such D&#38;O Claim is based on, or arises out of, (i) the fact that such D&#38;O Beneficiary is or was a manager, director or officer of any member of the Company Group at any time prior to the Closing Date or is or was serving at the request of any member of the Company Group as a manager, director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust or other enterprise at any time prior to the Closing Date, or (ii) this Agreement or any of the transactions contemplated hereby or thereby (but </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">83</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">excluding any claim made by the Purchaser or the Company Group in connection with this Agreement or any of the transactions contemplated hereby or thereby) in each case to the extent that any such D&#38;O Claim pertains to any matter or fact arising, existing, or occurring prior to or at the Closing Date, regardless of whether such D&#38;O Claim is asserted or claimed prior to, at or after the Closing Date, which coverage will be substantially similar to the existing D&#38;O Insurance of the Company Group, a copy of which has been made available to Purchaser&#8217;s counsel, including, without limitation, (x) an overall coverage amount not less than the overall coverage amount under the existing D&#38;O Insurance of the Company Group and (y) coverage for liability under the Securities Act and the Exchange Act in an amount not less than the coverage amounts for such liabilities under the existing D&#38;O Insurance of the Company Group&#59; provided, however, that if such policy is not available at a cost equal to or less than three hundred percent (300%) of the annual premiums paid as of the date hereof under the existing D&#38;O Insurance (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then the Company Group shall be required to obtain as much coverage as is possible under substantially similar policies for such annual premiums as do not exceed the Insurance Cap.  The cost of such D&#38;O Insurance shall be borne by Purchaser.  For a period of six (6) years after the Closing, Purchaser shall not, and shall not permit any member of the Company Group (including the Surviving Corporation) to, amend, repeal or modify (in a manner adverse to the beneficiary thereof) any provision in such Person&#8217;s certificates of incorporation, bylaws, limited liability company agreement or comparable governing documents relating to the exculpation or indemnification of, or advancement of expenses to, any officers, directors or managers, it being the intent of the parties hereto that the officers, directors and managers of the Company Group on the date hereof shall continue to be entitled to such exculpation, indemnification and advancement to the full extent of the law.   The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are intended to be for the benefit of, and enforceable by, each D&#38;O Beneficiary and such Person&#8217;s estate, heirs and representatives, and are in addition to, and not in substitution for, any other rights to indemnification or contribution that any such Person may have pursuant to law, the organizational documents of any member of the Company Group, contract or otherwise.  </font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Purchaser and Company hereby acknowledge that the D&#38;O Beneficiaries has or may have certain rights to indemnification, advancement of expenses and&#47;or insurance provided by the Sellers&#8217; Representative or its Affiliates. The Purchaser and Company hereby unconditionally and irrevocably waive, relinquish and release, and covenant and agree not to exercise (and to cause each of their Subsidiaries and Affiliates not to exercise), any rights that the Company Group may now have or hereafter acquire against any of the Sellers&#8217; Representative or its Affiliates or any D&#38;O Beneficiary that arise from or relate to the existence, payment, performance or enforcement of their obligations under this Agreement or under any other indemnification agreement (whether pursuant to contract or organizational documents) with any person or entity, including, without limitation, any right of subrogation (whether pursuant to contract or common law), reimbursement, exoneration, contribution or indemnification, or to be held harmless, and any right to participate in any claim or remedy of any D&#38;O Beneficiary against the Sellers&#8217; Representative or its Affiliates, whether or not such claim, remedy or right arises in equity or under contract, statute or common law, including, without limitation, the right to take or receive from the Sellers&#8217; Representative or its Affiliates, directly or indirectly, in cash or other property or by set-off or in any other manner, payment or security on account of such claim, remedy or right.  The Company hereby acknowledge hereby agree that it is the indemnitor of first resort under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, its obligations to any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">84</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D&#38;O Beneficiary under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to provide a indemnification are primary and any obligation of the Sellers&#8217; Representative or its Affiliates to provide indemnification for the same expenses, liabilities, judgments, fines, penalties, costs and amounts paid in settlement incurred by such D&#38;O Beneficiary are secondary). The rights of the D&#38;O Beneficiaries under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be in addition to any rights such D&#38;O Beneficiaries may have under the organizational documents of any member of the Company Group or under any applicable Contracts or Laws, and nothing in this Agreement is intended to, shall be construed as or shall release or impair any rights to directors&#8217; and officers&#8217; insurance claims under any policy that is or has been in existence with respect to any member of the  Company Group for any of its managers, officers or other employees (it being understood and agreed that the indemnification provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is not prior to or in substitution of any such claims under such policies).</font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Purchaser shall, or shall cause the Company Group to, provide to all of the employees of the Company Group as of the Closing who continue employment with the Company Group, Purchaser or any of its Affiliates immediately after the Closing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), for a period ending on the earlier of the one-year anniversary of the Closing Date and the date the Continuing Employee terminates employment with the Company Group, Purchaser or any of their Affiliates, an hourly wage or base salary, as applicable, commission and other periodic cash incentive opportunities (excluding change-in-control, transaction, and retention bonus opportunities) and employee benefits (excluding equity compensation and defined benefit pension benefits) that are substantially comparable (in the case of benefits, as determined in the aggregate) to those provided by the Company Group to the applicable Continuing Employee as of the Closing (subject to any applicable vesting schedule for employee contributions under the New Plans).  Purchaser further agrees that, from and after the Closing Date, Purchaser shall and shall cause each member of the Company Group and any subsidiary of Purchaser to grant each Continuing Employee credit for such Continuing Employee&#8217;s service with any member of the Company Group prior to the Closing Date for eligibility and vesting purposes and for purposes of determining the amount of paid time off and severance (but not for any other benefit accrual purposes under any defined benefit pension plan, retiree health plan or incentive equity or other long-term incentive compensation plan) under any benefit or compensation plan, program, agreement or arrangement that may be established or maintained by Purchaser or a member of the Company Group or any of its or their Subsidiaries on or after the Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">New Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the same extent that such service was recognized by any member of the Company Group under an Employee Plan as of the Closing (except to the extent such credit would result in duplication of benefits.  In addition, Purchaser shall use commercially reasonable efforts, including, to the extent necessary, obtaining the consent of any applicable insurer, to (x) cause to be waived all pre-existing condition exclusion and actively-at-work requirements and similar limitations, eligibility waiting periods and evidence of insurability requirements under any New Plans to the extent waived or satisfied by the applicable Continuing Employee under any Employee Plan as of the Closing Date and (y) cause any deductible, co-insurance and out-of-pocket covered expenses paid on or before the Closing Date by the applicable Continuing Employee (or covered dependent thereof) of any member of the Company Group to be taken into account for purposes of satisfying applicable deductible, coinsurance and maximum out-of-pocket provisions after the Closing Date under any applicable New Plan in the year of initial participation. Purchaser agrees that Purchaser and the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">85</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company Group will be solely responsible for any obligations arising under Section 4980B of the Code with respect to all &#8220;M&#38;A qualified beneficiaries&#8221; as defined in Treasury Regulation Section 54.4980B-9. Nothing contained herein, express or implied, is intended to (i) create any third-party beneficiary or other rights in any current or former employee, director, officer or independent contractor of any member of the Company Group to enforce the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (ii) confer upon any employee of any member of the Company Group any right to employment or continued employment for any period, or any term or condition of employment or continued receipt of any specific employee benefit, in each case with or from any member of the Company Group, the Purchaser or their respective Affiliates, (iii) shall constitute a termination, adoption, amendment to or any other modification of any New Plan or Employee Plan or (iv) (subject to compliance with the other provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) limit in any way the right of any member of the Company Group, Purchaser, or their respective Affiliates to amend or terminate any New Plan or Employee Plan at any time.  Upon written request of Purchaser at least ten (10) days prior to the Closing Date, the Company Group shall (or shall cause the applicable plan sponsor to), at least one Business Day prior to the Closing Date, adopt written resolutions (or take other necessary and appropriate action(s)) to terminate any Employee Plan designated by the Purchaser, including any Employee Plan that is intended to qualify under Section 401(a) of the Code with a cash or deferred arrangement described in Section 401(k) of the Code. In addition, Purchaser shall take any and all actions as may be required to permit each Continuing Employee to make rollover contributions of &#8220;eligible rollover distributions&#8221; (within the meaning of Section 401(a)(31) of the Code, including plan loans) to a qualified retirement plan sponsored by Purchaser or any of its Affiliates that includes a cash or deferred arrangement under Section 401(k) of the Code, effective as of the date of eligibility, in an amount equal to any eligible rollover distribution made to such Continuing Employee from any such Company Plan that is a cash or deferred arrangement described in Section 401(k) of the Code that is required to be terminated pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company will, or will cause the applicable Subsidiary to, take all necessary actions to solicit stockholder approval (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">280G Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (in accordance with the requirements of Section 280G(b) of the Code and the regulations thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 280G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)) of any payments or benefits paid or payable by the Company Group that would, absent stockholder approval, reasonably be expected to be parachute payments within the meaning of Section 280G (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 280G Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Prior to soliciting such 280G Approval, the Company (or the applicable Subsidiary) will use reasonable best efforts to obtain waivers from any disqualified individuals (within the meaning of Section 280G) providing that, unless such payments and benefits to such individuals are approved by the stockholders in the manner required under Section 280G, no such payments and benefits will be paid or provided.  No later than four (4) Business Days prior to the Closing Date, the Company will notify the Evolent Entities whether or not the 280G Approval was obtained with respect to any Section 280G Payments that were subject to such stockholder vote.  To the extent 280G Approval is sought, the Company shall provide to the Evolent Entities at least five (5) Business Days prior to the distribution of the waivers, copies of all documents prepared by the Company in connection with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.7(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (including calculations) for the Evolent Entities&#8217; review and shall consider in good faith for incorporation all of the Evolent Entities&#8217; comments.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_988"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">86</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Straddle Periods&#59; Certain Purchaser Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the extent it is necessary for purposes of this Agreement to determine the amount of any Tax items attributable to any taxable period that includes (but does not end on) the Closing Date (a &#8220;Straddle Period&#8221;) that is allocable to a Pre-Closing Tax Period, the Taxes for the Pre-Closing Tax Period shall, for Taxes other than Taxes based upon or related to income, gains, receipts, sales or payroll or other transaction-based Taxes (including withholding Taxes), be deemed to be the amount of such Tax for the entire Straddle Period multiplied by a fraction the numerator of which is the number of days in the Pre-Closing Tax Period and the denominator of which is the number of days in the entire Straddle Period, and in the case of any Tax based upon or related to income, gains, receipts, sales or payroll or other transaction-based Taxes (including withholding Taxes) be deemed equal to the amount which would be payable if the relevant Straddle Period ended at the end of the day on the Closing Date (and for such purpose, the taxable period of any partnership or other pass-through entity, in which any member of the Company Group holds a beneficial interest shall be deemed to terminate at such time).  Notwithstanding the foregoing, exemptions, allowances or deductions that are calculated on an annual basis, such as the deduction for depreciation, shall be apportioned on a daily basis and Taxes that are computed on a periodic basis, such as property Taxes, shall also be apportioned on a daily basis.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The calculation of the Aggregate Initial Cash Consideration and the Adjusted Aggregate Initial Cash Consideration, as finally determined, shall not take into account any change in the Tax liability of the Company Group from any of the following actions of the Purchaser (and its Subsidiaries and Affiliates, including the Company Group) after the Closing except to the extent such action was required by a change in Law after the date hereof&#58; (a) the filing, amendment or other modification of any Tax Return with respect to a Pre-Closing Tax Period or Straddle Period, (b) the extension or waiver of any statute of limitations or other period for the assessment of any Tax or deficiency with respect to a Pre-Closing Tax Period or Straddle Period, (c) the initiation of any voluntary contact with a Governmental Body (including entering into any voluntary disclosure agreement or similar process) with respect to any Pre-Closing Tax Period or Straddle Period, or (d) the adoption, making or changing of any Tax election or accounting method or practice with respect to, or that has retroactive effect to, any Pre-Closing Tax Period or Straddle Period.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Tax Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The Company Group, at its sole cost and expense, shall prepare and timely file, or shall cause to be prepared and timely filed, all Tax Returns in respect of the Company Group (or any member thereof) that are required to be filed (taking into account applicable extensions validly obtained) on or before the Closing Date. Such Tax Returns shall be prepared by treating items on such Tax Returns in a manner consistent with the past practices of the Company Group, as applicable, with respect to such items, except as required by applicable Law.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Purchaser, at its sole cost and expense, shall cause the Company Group to prepare and timely file all Tax Returns of the Company Group due after the Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Prepared Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and timely pay the Taxes due in connection with any Purchaser </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">87</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prepared Return&#59; provided, that for the avoidance of doubt, Purchaser&#8217;s obligation to pay such Taxes shall not affect the calculation of the Aggregate Initial Cash Consideration and the Adjusted Aggregate Initial Cash Consideration, as finally determined. To the extent that a Purchaser Prepared Return relates to Income Taxes for a Pre-Closing Tax Period or a Straddle Period and otherwise could have an effect on the Tax Benefit Payment (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reviewed Income Tax Return</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), such Tax Return shall be prepared in accordance with the past practices of the Company Group. At least thirty (30) days prior to the due date (taking into account extensions validly obtained) of any Reviewed Income Tax Return, Purchaser shall provide a draft of such Tax Return to the Sellers&#8217; Representative and shall permit the Sellers&#8217; Representative to review and comment thereon. Sellers&#8217; Representative and Purchaser will cooperate in good faith to resolve any dispute regarding the Sellers&#8217; Representative&#8217;s comments to any Reviewed Income Tax Return&#59; provided, however, if for any reason, Sellers&#8217; Representative and Purchaser are unable to promptly resolve any such dispute, then such dispute shall be promptly resolved by the Accounting Arbitrator in accordance with the principles set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (provided that the fees and expenses of the Accounting Arbiter shall be borne one half (1&#47;2) by each of Purchaser, on the one hand, and the Sellers&#8217; Representative (on behalf of the Sellers, severally and not jointly, in proportion to the Applicable Percentage, on the other. The decision of the Accounting Arbiter shall be final and binding upon the Parties. If the due date (giving effect to any valid extensions properly obtained) for filing any such Reviewed Income Tax Return that is the subject of a dispute is prior to the date that such dispute is resolved by the Accounting Arbiter, then Purchaser shall be entitled to cause the Company Group to file such Tax Return reflecting its position and, if necessary, the Company Group shall thereafter promptly file an amendment to such Reviewed Income Tax Return to conform such Tax Return to the decision of the Accounting Arbiter.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;To the maximum extent permitted by Law, all Transaction Tax Deductions shall be reported in Pre-Closing Tax Periods (and otherwise treated as attributable to Pre-Closing Tax Periods), or, in the case of a Straddle Period, allocated to the portion of such Straddle Period ending on the Closing Date in accordance with Section 8.8(a).  Seventy percent (70%) of any success-based fees shall be deducted in accordance with Internal Revenue Service Rev. Proc. 2011-29, 2011-18 I.R.B. 746.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Purchaser and the Sellers&#8217; Representative shall cooperate fully, as and to the extent reasonably requested, in connection with (i) the filing of Tax Returns, (ii) any audit, litigation or other proceeding with respect to Taxes and Tax Returns, in each case with respect to a Pre-Closing Tax Period or Straddle Period.  Such cooperation shall include the retention, and (upon the other party&#8217;s request) the provision, of records and information which are reasonably relevant to any such audit, litigation or other proceeding and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the party requesting assistance shall pay the reasonable out-of-pocket expenses incurred by the party providing such assistance&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no party shall be required to provide assistance at times or in amounts that would interfere unreasonably with the business and operations of such party.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Tax Refunds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All refunds of Income Taxes of the Company and its Subsidiaries (or Tax credits received in lieu thereof) that are attributable to any overpayments of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">88</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Taxes (i) for the taxable year beginning on January 1, 2021, and (ii) the taxable year beginning on January 1, 2022, that are received by Purchaser, the Surviving Corporation or a Subsidiary or any of their Affiliates following the Closing shall be for the account of the Sellers, and the full amount of such refunds shall be paid to the Sellers&#8217; Representative (for distribution to the Sellers) within fifteen (15) Business Days after receipt thereof (or in the case of such Tax credits, the filing of a Tax Return electing to receive such Tax credit) by wire transfer of immediately available funds, except to the extent such refund or credit was previously taken into account in Accrued Income Taxes as finally determined. The Surviving Corporation shall, and shall cause its Subsidiaries to apply for all Tax refunds to which Sellers may be entitled pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as reasonably requested by the Sellers&#8217; Representative, including by timely filing or causing to be timely filed all forms reasonably and timely requested by the Sellers&#8217; Representative and all Reviewed Income Tax Returns, and shall, to the extent it would cause a refund of Taxes for the Company or a Subsidiary for a Pre-Closing Tax Period, carry back all net operating losses or other Tax attributes attributable to a Pre-Closing Tax Period to the fullest extent permitted by applicable Law.  Notwithstanding the foregoing, any payment to be made to an Optionholder under this Section 8.8(d) shall be made through the payroll system of the Surviving Corporation or applicable Subsidiary thereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Certain Tax Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement to the contrary, neither Purchaser nor any of their Affiliates (including, after the Closing, the Surviving Corporation and its Subsidiaries) shall, unless required by applicable Law or requested by the Seller Representative pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.06(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or otherwise consented to in writing by the Seller Representative (such consent to not be unreasonably withheld, conditioned or delayed), (A) amend any Tax Return of the Company and its Subsidiaries filed on or prior to the Closing Date or any Reviewed Income Tax Return, (B) enter into or pursue any voluntary disclosure agreement or voluntary disclosure program or similar program with a Governmental Authority or file any ruling or request with a Governmental Authority, in each case with respect to the Company and its Subsidiaries for a Pre-Closing Tax Period, or (C) file or change any Tax election with respect to the Company and its Subsidiaries that has a retroactive effect to a Pre-Closing Tax Period, in each case if such action otherwise could reasonably be expected to have an effect on any payment to be made to the Sellers under this Agreement (including under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or the Tax Benefit Payment).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;If, after the Closing, Purchaser or any of their Affiliates (including, after the Closing, the Surviving Corporation or a Subsidiary) receives notice of any audit, other administrative proceeding or inquiry or judicial proceeding involving Taxes (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Contest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) imposed in whole or in part for a Pre-Closing Tax Period and that could affect the amount of any payment to be made to the Sellers under this Agreement (including under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof), then within twenty (20) days after receipt of such notice, Purchaser (A) shall notify the Sellers&#8217; Representative of such Tax Contest, (B) shall keep the Sellers&#8217; Representative reasonably informed of all material developments with respect to such Tax Contest, (C) shall afford Sellers&#8217; Representative the opportunity to comment on any material submission to the applicable Governmental Authority in the course of such Tax Contest, which comments Purchaser shall consider in good faith, (D) shall permit the Sellers&#8217; Representative to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">89</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">elect to participate, at the Sellers&#8217; Representative&#8217;s sole cost and expense, in the defense of such Tax Contest, and (E) shall consult in good faith with Sellers&#8217; Representative prior to settling any such Tax Contest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Closing of Tax Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The parties hereto shall, to the extent permitted or required under applicable Law, treat the Closing Date as the last day of the taxable period of the Company and its Subsidiaries for all Tax purposes, and Purchaser shall cause the members of the Company Group that are treated as domestic corporations to join Purchaser&#8217;s &#34;consolidated group&#34; (as defined in Treasury Regulation Section 1.1502-1(h)) effective on the day after the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Transaction Tax Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. To the extent that Purchaser, the Company, any of their Subsidiaries or other Affiliates realizes any Transaction Tax Benefit (other than a Transaction Tax Benefit to the extent actually taken into account in calculating Initial Cash Consideration and the Adjusted Aggregate Initial Cash Consideration, as finally determined), the amount of such Transaction Tax Benefit shall be for the benefit of Sellers. To the extent that any of Purchaser, the Company, any Subsidiary of the Company or any of their Affiliates realizes a Transaction Tax Benefit that, pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, is for the benefit of the Sellers, Purchaser shall within ten (10) days of the filing of the Tax Return reflecting such Transaction Tax Benefit (or to the extent in the form of a refund, receiving the refund from the applicable Governmental Authority), pay to the Sellers&#8217; Representative for distribution to the Sellers the amount of such Transaction Tax Benefit. </font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Escrow Funds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The parties hereto agree that, for federal and all applicable state and local Income Tax reporting purposes, (i) Purchaser or one of its Subsidiaries will be the owner of the Adjustment Escrow Fund and all income earned thereon shall, as of the end of each of Purchaser&#8217;s taxable years be reported as having been earned by Purchaser or one of its Subsidiaries, whether or not such income was disbursed during such calendar year and (ii) the right of Sellers to distributions from the Adjustment Escrow Fund and to receive the Earnout Consideration shall be treated as deferred contingent purchase price eligible for installment sale treatment under Section 453 of the Code and any corresponding provision of state or local law.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1036"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Excluded Aetna Receivables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All Excluded Aetna Receivables that are received by Purchaser, the Surviving Corporation or a Subsidiary or any of their Affiliates following the Closing and prior to the first anniversary of the Closing Date shall be for the account of the Sellers, and the full amount of such refunds shall be paid to the Sellers&#8217; Representative (for distribution to the Sellers) within fifteen (15) Business Days after receipt thereof by wire transfer of immediately available funds. Notwithstanding the foregoing, any payment to be made to an Optionholder under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be made through the payroll system of the Surviving Corporation or applicable Subsidiary thereof.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1039"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">   Notwithstanding anything in the Agreement to the contrary, Purchaser shall have no obligation to make any payment pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that would result in aggregate payments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">90</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> being in excess of $16,600,000, or to make any payment pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(d</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> after the date that is the three-year anniversary of the Closing Date.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1042"></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 9</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">MISCELLANEOUS</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1045"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Non-Survival of Representations and Warranties&#59; Exclusive Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except for claims of Fraud or representations or warranties of Purchaser, its Affiliates, and their respective Subsidiaries under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, none of the representations, warranties, covenants and agreements of the parties in this Agreement or in any instrument delivered by the parties pursuant to this Agreement shall survive the Effective Time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not limit any covenant or agreement of the parties which by its terms contemplates performance after the Effective Time, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No Seller shall bear any liability with respect to Losses incurred or suffered by Purchaser or any of its Affiliates as a result of a breach of or inaccuracy in any of the representations and warranties set forth in this Agreement, other than in the event of Fraud.  Purchaser acknowledges and agrees that from and after the Closing, in the absence of Fraud, the Representation and Warranty Policy is Purchaser&#8217;s sole and exclusive remedy with respect to any and all claims relating to the representations and warranties made under this Agreement.  In furtherance of the foregoing, Purchaser, on behalf of itself and its Affiliates, waives, from and after the Closing, to the fullest extent permitted under applicable Law, any and all rights, claims and causes of action it may have against any Seller or its Affiliates relating to the operation of the Company and its Subsidiaries or their respective businesses or relating to the subject matter of this Agreement and the Schedules attached hereto and the transactions contemplated hereby and thereby, whether arising under or based upon any federal, state, local or foreign statute, law, ordinance, rule or regulation or otherwise (including any right, whether arising at law or in equity, to seek indemnification, contribution, cost recovery, damages, or any other recourse or remedy, including as may arise under common law), except for claims and causes of action based on Fraud or claims arising under any covenant or agreement of the parties or their Affiliates or Sellers which by its terms contemplates performance of such covenant or agreement after the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Evolent Entities shall not bear any liability with respect to Losses incurred or suffered by any Seller or any of their Affiliates as a result of a breach of or inaccuracy in any of the representations and warranties set forth in this Agreement, other than in the event of Fraud. In furtherance of the foregoing, Sellers, on behalf of themselves and their Affiliates, waive, from and after the Closing, to the fullest extent permitted under applicable Law, any and all rights, claims and causes of action they may have against the Evolent Entities  or their Affiliates relating to the operation of the Company and its Subsidiaries or their respective businesses or relating to the subject matter of this Agreement and the Schedules attached hereto and the transactions contemplated hereby and thereby, whether arising under or based upon any federal, state, local or foreign statute, law, ordinance, rules or regulation or otherwise (including any rights, whether arising at law or in equity, to seek indemnification, contribution, cost </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">91</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">recovery, damages, or any other recourse or remedy, including as may arise under common law), except for claims and causes of action based on Fraud or claims arising under any covenant or agreement of the parties or their Affiliates which by its terms contemplates performance of such covenant or agreement after the Closing.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1057"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below, this Agreement may not be amended, altered or modified except by a written instrument executed by Purchaser and the Sellers&#8217; Representative (on behalf of the Sellers, and prior to the Closing, the Company).  No course of dealing between or among any Persons having any interest in this Agreement will be deemed effective to modify, amend or discharge any part of this Agreement or any rights or obligations of any Person under or by reason of this Agreement.  No waiver of any of the provisions of this Agreement shall be deemed or shall constitute, a waiver of any other provisions, whether or not similar, nor shall any waiver constitute a continuing waiver, and no extension of time granted by any party hereto for the performance of any obligation or act by any other party hereto shall be deemed to be an extension of time for any other obligation or act hereunder.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1060"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All notices, demands and other communications to be given or delivered to Purchaser, the Company, or any Seller under or by reason of the provisions of this Agreement will be in writing and will be deemed to have been given (i) when delivered if personally delivered, (ii) one (1) Business Day after being sent by reputable overnight courier, or (iii) when transmitted if delivered by facsimile or electronic mail (transmission confirmed), in each case to the addresses indicated below (unless another address is so specified in writing)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">If to any Seller, the Sellers&#8217; Representative or prior to the Closing, to the Company, then to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TPG Growth V Iceman, L.P.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">301 Commerce Street</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Suite 3300</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forth Worth, TX 76102</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Office of General Counsel</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c&#47;o Matthew Delja</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; officeofgeneralcounsel&#64;tpg.com</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CC&#58; mdelja&#64;tpg.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>with copies, which shall not constitute notice, to&#58;<br><br>Implantable Provider Group, Inc.</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2300 Lakeview Parkway</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Suite 500</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alpharetta, GA 30009</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;&#160;&#160;&#160;&#160;Vince Coppola</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Facsimile No.&#58; (866) 753-0194</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; vcoppola&#64;ipg.com </font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">92</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ropes &#38; Gray, LLP<br>Three Embarcadero Center<br>San Francisco, CA 94111-4006 <br>Telephone&#58; (415) 315-2319<br>Email&#58; jason.freedman&#64;ropesgray.com&#59; elizabeth.gallucci&#64;ropesgray.com<br>Attention&#58; Jason S. Freedman and Elizabeth Gallucci</font></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">If to Evolent Entities or Merger Sub, or after the Closing, to the Company, then to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;<br><br></font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Evolent Health, Inc.</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">800 N. Glebe Road, Suite 500</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arlington, Virginia 22203</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Jonathan Weinberg, General Counsel</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; jweinberg&#64;evolenthealth.com<br><br>with copies, which shall not constitute notice, to&#58;<br><br></font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bass, Berry &#38; Sims PLC</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">150 Third Ave. South, Suite 2800</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, Tennessee 37201</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Angela Humphreys</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; ahumphreys&#64;bassberry.com</font></div><div style="margin-bottom:0.12pt;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div><div id="i649a3a409a124fa4b643ff6500d07394_1063"></div><div style="margin-bottom:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of each of the parties hereto and their respective successors and permitted assigns.  Neither this Agreement nor any rights, benefits or obligations set forth herein may be assigned by any of the parties hereto without the prior written consent of Purchaser and the Sellers&#8217; Representative, any attempted assignment without such prior written consent shall be void. Notwithstanding anything to the contrary contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Evolent Entities may collaterally assign their rights under this Agreement to any of the Financing Sources pursuant to the terms of the Debt Financing solely for purposes of creating a security interest herein. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_1066"></div><div style="margin-bottom:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.  </font></div><div id="i649a3a409a124fa4b643ff6500d07394_1069"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and the parties intend that no rule of strict construction will be applied against any Person.  The use of the word &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; in this Agreement or in any of the agreements contemplated hereby shall be by way </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">93</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of example rather than by limitation.  Unless the context otherwise requires, any reference to a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be deemed to refer to a section of this Agreement, exhibit to this Agreement or a schedule to this Agreement, as applicable.  The words &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">hereof,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">herein</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">hereunder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and words of similar import referring to this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement.  Any references to &#8220;employee&#8221; or &#8220;employees&#8221; of the Company include any employee or employees supplied to the Company by any professional employer organization.  For purposes of this Agreement, any document or item will only be deemed &#8220;delivered&#8221;, &#8220;provided&#8221; or &#8220;made available&#8221; (or any word or phrase of similar import) to Purchaser within the meaning of this Agreement if such document or item is included in the electronic data room hosted on behalf of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">VDR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) two (2) Business Days prior to the Closing Date.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1072"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Captions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The captions used in this Agreement are for convenience of reference only and do not constitute a part of this Agreement and shall not be deemed to limit, characterize or in any way affect any provision of this Agreement, and all provisions of this Agreement shall be enforced and construed as if no caption had been used in this Agreement.  </font></div><div id="i649a3a409a124fa4b643ff6500d07394_1075"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise expressly set forth in this Agreement (including as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> above and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below), nothing herein expressed or implied is intended or shall be construed to confer upon or give to any Person, other than the parties hereto and their respective permitted successors and assigns, any rights or remedies under or by reason of this Agreement, such third parties specifically including employees or creditors of the Company Group.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1078"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of the parties hereto acknowledges that the rights of each party to consummate the transactions contemplated hereby are unique and recognize and affirm that in the event of a breach of this Agreement by any party, money damages would be inadequate and the non-breaching party would have no adequate remedy at law.  Accordingly, the parties agree that such non-breaching party shall have the right, in addition to any other rights and remedies existing in their favor at law or in equity, to enforce their rights and the other party&#8217;s obligations hereunder not only by an action or actions for damages but also by an action or actions for specific performance, injunctive and&#47;or other equitable relief (without posting of bond or other security). Notwithstanding the foregoing, it is expressly agreed that the Sellers&#8217; Representative and the Company will be entitled to specific performance of the Evolent Entities to consummate the Transactions only in the event that (i) all conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> have been satisfied or waived (other than those that by their terms or nature are to be satisfied at the Closing (provided such conditions are capable of being satisfied)), (ii) the amounts committed to be funded in connection with the Debt Financing have been funded or will be funded at the Closing, in each case, in accordance with the Commitment Letters, (iii) the Company and Sellers&#8217; Representative has irrevocably confirmed in writing to the Evolent Entities that all of conditions to Closing set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> have been satisfied or waived (other than those that by their terms or nature are to be satisfied at the Closing (provided such conditions are capable of being satisfied)), that the Company and Sellers&#8217; Representative stand ready, willing and able to consummate the Closing and that if specific performance is granted, then the Company will take all actions required to be taken by it to cause the Closing to occur </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">94</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and (iv) the Evolent Entities and Merger Sub fail to consummate the Closing on or prior to the date on which the Closing should have occurred pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For the avoidance of doubt, under no circumstance shall the Company and Sellers&#8217; Representative be permitted or entitled to receive both a grant of specific performance pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and payment of the Termination Fee pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1081"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Guaranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Parent, intending to be legally bound, hereby absolutely, irrevocably and unconditionally guarantees to the Company and the Sellers&#8217; Representative  the due and punctual performance and discharge of all of the payment obligations of Purchaser under this Agreement, including any obligations set forth in (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.8(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (solely to the extent relating to the financing cooperation reimbursement and indemnification obligations thereunder), (iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (with respect to the Termination Fee and any related costs and expenses payable by Purchaser) and (iv) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, if, as and when those obligations become payable.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1084"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Complete Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This document and the documents referred to herein contain the complete agreement between the parties and supersede any prior understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1087"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in one or more counterparts, any one of which may be by portable document format (.pdf) or facsimile, and all of which taken together shall constitute one and the same instrument.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1090"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Governing Law and Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement, any Agreements contemplated hereby or thereby, the transactions contemplated hereby, the negotiation of any of the foregoing or the relationship of the parties hereto under or in connection with any of the foregoing (in each case, whether sounding in contract, tort or statute, and whether in law or in equity), and all issues and questions concerning the construction, validity, interpretation and enforceability of this Agreement and any of the Schedules hereto, shall be governed by and construed in accordance with the domestic laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.  To the extent permitted by law, each of the parties hereto hereby irrevocably submits to the jurisdiction of any state court sitting in the State of Delaware or United States federal court sitting in Wilmington, Delaware, over any suit, action or other proceeding brought by any party arising out of or relating to this Agreement, and each of the parties hereto hereby irrevocably agrees that all claims with respect to any such suit, action or other proceeding shall be heard and determined in such courts.  In the event of any litigation regarding or arising from this Agreement, the prevailing party shall be entitled to recover from the non-prevailing party its reasonable expenses, attorneys&#8217; fees and costs incurred therein or in enforcement or collection of any judgment or award rendered therein. </font></div><div id="i649a3a409a124fa4b643ff6500d07394_1093"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">95</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1096"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Non-Recourse</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except for (i) claims based on Fraud, (ii) to the extent otherwise set forth in the Confidentiality Agreement, or (iii) claims under any document, instrument or certificate expressly referenced under this Agreement and&#47;or entered into in connection with this Agreement and the transactions contemplated hereby and thereby to the extent in accordance with the terms of such Agreement (clauses (i) through (iii) of this paragraph, together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Recourse Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), all claims, obligations, liabilities, or causes of action (whether in contract or in tort, in law or in equity, or granted by statute) that may be based upon, in respect of, arise under, out or by reason of, be connected with, or relate in any manner to this Agreement, or the negotiation, execution, or performance of this Agreement (including any representation or warranty made in, in connection with, or as an inducement to, this Agreement), may be made only against (and such representations and warranties are those solely of) the Persons that are expressly identified as parties in the preamble to this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Contracting Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  No Person who is not a Contracting Party, including any past, present or future director, officer, employee, incorporator, member, partner, manager, stockholder, Affiliate, agent, attorney, representative or assignee of, and any financial advisor or lender to, any Contracting Party, or any past, present or future director, officer, employee, incorporator, member, partner, manager, stockholder, Affiliate, agent, attorney, representative or assignee of, and any financial advisor or lender to, any of the foregoing (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nonparty Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) nor any Financing Source, shall have any liability (whether in contract or in tort, in law or in equity, or granted by statute) for any claims, causes of action, obligations, or liabilities arising under, out of, in connection with, or related in any manner to this Agreement or based on, in respect of, or by reason of this Agreement or its negotiation, execution, performance, breach or termination (other than as set forth in the Confidentiality Agreement), and, to the maximum extent permitted by Law, each Contracting Party hereby knowingly and irrevocably waives and releases all such liabilities, claims, causes of action, and obligations against any such Nonparty Affiliates and Financing Sources&#59; provided that the foregoing shall not limit liability of any Nonparty Affiliate for any Recourse Exception.</font></div><div id="i649a3a409a124fa4b643ff6500d07394_1099"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">Certain Lender Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The parties hereby agree that (a) no Financing Source shall have any liability (whether in contract or in tort, in law or in equity, or granted by statute, or otherwise) for any claims, causes of action, obligations or losses arising under, out of, in connection with or related in any manner to this Agreement or based on, in respect of or by reason of this Agreement or its negotiation, execution, performance or breach, or termination, including without limitation any liability in respect of any Termination Fee&#59; and any and all such liability, claims, causes of action, obligations and losses are hereby knowingly and irrevocably waived, disclaimed, and released in full (provided that nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall limit the liability or obligations of the Financing Sources under the Commitment Letter (and any fee letter entered into in connection therewith) or the definitive documentation for the Debt Financing), (b) any claim, suit, action or proceeding of any kind or description (whether at law, in equity, in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">96</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">contract, in tort or otherwise) involving any Financing Source arising out of or relating to the transactions contemplated pursuant to this Agreement, the Debt Financing, the Commitment Letter (and any fee letter entered into in connection therewith) or the performance of services thereunder shall be subject to the exclusive jurisdiction of a state or federal court sitting in the Borough of Manhattan in the City and State of New York, and no party hereto will bring, permit any of their respective Affiliates to bring, or support anyone else in bringing, any such claim, suit, action or proceeding in any other court, (c) the waiver of rights to trial by jury set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> applies to any such claim, suit, action or proceeding, (d) the Commitment Letter (and any fee letter entered into in connection therewith) will be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York (other than as expressly set forth in the Commitment Letter) without reference to principles of conflicts or choices of laws, (e) only Purchaser (including its permitted successors and assigns under the Commitment Letter) and the other parties to the Commitment Letter at their own direction shall be permitted to bring any claim against a Financing Source for failing to satisfy any obligation to fund the Debt Financing including pursuant to the terms of the Commitment Letter, (f) no amendment or waiver of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 7.2(c), 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that is adverse to the Financing Sources shall be effective without the prior written consent of the Financing Sources party to the Commitment Letter and (g) the Financing Sources are express and intended third party beneficiaries of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 7.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, which Section 9.16 shall, with respect to the matters referenced in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> only, supersede any provision of this Agreement to the contrary.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">*     *      *      *     *</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">97</font></div></div></div><div id="i649a3a409a124fa4b643ff6500d07394_1102"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above-written.</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PARENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC. </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Seth Blackley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Seth Blackley </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;   Chief  Executive Officer</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PURCHASER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, LLC</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Seth Blackley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Seth Blackley</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;   Chief Executive Officer</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">MERGER SUB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ENDZONE MERGER SUB, INC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">_&#47;s&#47; Jonathan Weinberg </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">________________</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;   Secretary</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i649a3a409a124fa4b643ff6500d07394_1147"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above-written.</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COMPANY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TPG GROWTH ICEMAN PARENT, INC.</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Sherwin Krug</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">__________________</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;  Sherwin Krug</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;    Chief Financial Officer</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SELLERS&#8217; REPRESENTATIVE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TPG GROWTH V ICEMAN, L.P.</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; TPG Growth V SPV GP, LLC</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its general partner</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Ken Murphy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">___________________</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Ken Murphy</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58; Chief Operating Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>a2022q2form10qex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5868e673a3484a51be436ae675e6a25a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 4.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Execution Version</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">REGISTRATION RIGHTS AGREEMENT</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Registration Rights Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), is dated as of August 1, 2022, by and between Evolent Health, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), TPG Growth V Iceman, L.P., a Delaware limited partnership (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">TPG Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the individuals set forth on Schedule I hereto (together with the TPG Holder, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company, Evolent Health LLC, a Delaware limited liability company, Endzone Merger Sub, Inc., a Delaware corporation and TPG Growth Iceman Parent, Inc., a Delaware corporation are parties to that certain Agreement and Plan of Merger, dated June 24, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Merger Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;&#59; capitalized terms used herein but not otherwise defined shall have the meanings set forth in the Merger Agreement)&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, in connection with the consummation of the transaction contemplated by the Merger Agreement, the parties desire to enter into this Agreement to grant certain registration rights to the Holders as set forth in this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW THEREFORE, in consideration of the premises and the mutual promises herein made, and in consideration of the representations, warranties and covenants herein contained, the parties agree as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Registration Rights.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.34pt">For purposes of this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Shelf Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Registration Statement of the Company filed with the SEC on Form S-3 prior to Closing for an offering to be made on a continuous basis pursuant to Rule 415 under the 1933 Act and which will cover the resale of the Parent Shares, or another registration statement of the Company filed with the SEC that replaces such registration statement. The Company will use its reasonable best efforts (i) to maintain the effectiveness of a Shelf Registration Statement in accordance with the terms hereof and (ii) upon the request of the TPG Holder, which shall be made no earlier than five (5) Business Days following the date hereof, to file such amendments, including post-effective amendments, and prospectus supplements as may be necessary to provide for the resale of the Parent Shares by such Holder from time to time (but subject to the terms of the Purchase Price Adjustment Agreement), and pursuant to any method or combination of methods legally available to, and reasonably requested by, the TPG Holder, and shall include a plan of distribution that provides each applicable Holder with a reasonably appropriate opportunity to sell the Parent Shares pursuant to such Shelf Registration Statement. The Company shall use its reasonable best efforts to prepare and file with the SEC such amendments, including post-effective amendments and supplements as may be necessary to keep such Shelf Registration Statement effective and in compliance with the provisions of the 1933 Act until the earlier of (a) the first anniversary of the date of this Agreement and (b) such time as the Holder no longer owns any Parent Shares. Notwithstanding the foregoing, the Holders agree to sell any Parent Shares pursuant to Rule 144 of the 1933 Act if, at the time of such proposed sale, resale under Rule 144 of the 1933 Act is available without any limitations. Holders will provide any necessary assistance and information as may be reasonably requested by the Company in order for the Company to comply with its obligations under this Section 1. The Company will pay all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">costs and expenses of the Company (which shall not include, for the avoidance of doubt, any underwriting discounts or commissions or other expenses of the Holders) in connection with such Shelf Registration Statement as well as any amendments or supplements thereto. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19pt">If the continued use of the Shelf Registration Statement at any time would require the Company to make an Adverse Disclosure or if in the good faith judgment of the Board of Directors of the Company the use of the Shelf Registration Statement as set forth herein would be materially detrimental to the Company and the Board of Directors concludes, as a result, that it is in the best interests of the Company to suspend use of the Shelf Registration Statement, the Company may, upon giving prompt written notice of such action to each Holder, suspend use of the Shelf Registration Statement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Shelf Suspension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Company shall not be permitted to exercise a Shelf Suspension (i)&#160;more than twice during any 12-month period, or (ii)&#160;for a period exceeding 60 days in the aggregate during any 12-month period. In the case of a Shelf Suspension, the Holders agree to suspend use of the applicable prospectus and in connection with any sale or purchase of, or offer to sell or purchase, Parent Shares, upon receipt of the notice referred to above. The Company shall immediately notify each Holder in writing upon the termination of any Shelf Suspension, and upon such termination, promptly amend or supplement any prospectus, if necessary, so, it does not contain any untrue statement or omission and furnish to such Holder such numbers of copies of the prospectus as so amended or supplemented as such Holder may reasonably request. Notwithstanding the provisions of this Section 1(b), the Company may not postpone the filing or effectiveness of, or suspend use of, the Shelf Registration Statement past the date upon which the applicable Adverse Disclosure is disclosed to the public or ceases to be material. During a Shelf Suspension, the Company shall be prohibited from filing a registration statement for its own account or for the account of any other Holder or holder of its securities.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adverse Disclosure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means public disclosure of material non-public information that, in the good faith judgment of the Board of Directors of the Company, after consultation with outside legal counsel to the Company&#58; (i)&#160;would be required to be made in any registration statement filed with the SEC by the Company so that such registration statement, from and after its effective date, does not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading&#59; (ii)&#160;would not be required to be made at such time but for the filing, effectiveness or continued use of such registration statement&#59; and (iii)&#160;the Company has a&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">bona</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">fide</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;business purpose for not disclosing publicly.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19pt">At any time during which the Company has an effective Shelf Registration Statement with respect to Parent Shares and until the earlier of (i) the first anniversary of the date of this Agreement and (ii) such time as the Holder no longer owns any Parent Shares, by notice to the Company specifying the intended method or methods of disposition of such Registrable Securities, as soon as reasonably practicable (taking into account any required notice period under the Existing RRA) following the written request of the TPG Holder (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Shelf Takedown Request</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that the Company effect an underwritten public offering of all or a portion of such Registrable Securities (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Shelf Takedown</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company shall amend or supplement the Shelf Registration Statement for such purpose in a manner consistent with the Holder&#8217;s intended distribution&#59; provided, however, in no event shall the Company be required to undertake more than three (3) Shelf Takedowns with respect to the Parent Shares. All determinations as to whether to complete any Shelf Takedown and as to the timing, manner, price and other terms of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any Shelf Takedown contemplated by this Section 1C shall be determined by the TPG Holder, and the Company shall use its reasonable best efforts to cause any such offering to occur as promptly as practicable, consistent with the intended plan of distribution. In such event, the TPG Holder shall have the right to designate the lead managing underwriter and each other managing underwriter to administer the offering, subject to the Company&#8217;s approval (not to be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing, (x) in an auction style block trade process, the TPG Holder will have the right to choose the underwriter, consistent with its right above to determine the terms of any Shelf Takedown for any underwritten offering to be effected as an overnight or bought deal or block trade and (y) the Holders agree to sell any Parent Shares pursuant to Rule 144 of the 1933 Act if, at the time of such proposed sale, resale under Rule 144 of the 1933 Act is available without any limitations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">1D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;padding-left:18.34pt;text-decoration:underline">Company Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">. The Company will use commercially reasonable efforts to effect the registration of the Parent Shares in accordance with the terms hereof, and pursuant thereto the Company will, as expeditiously as possible&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;padding-left:27pt">enter into and perform such customary agreements (including, as applicable, underwriting agreements in customary form), in form and substance reasonably satisfactory to the Company, and take all such other actions as the Holders or the underwriters, if any, reasonably request in order to expedite or facilitate the disposition of such Parent Shares (including, without limitation, making available the executive officers of the Company and participating in virtual  &#8220;road shows,&#8221; investor presentations, marketing events and other selling efforts)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;padding-left:27pt">in the case of any underwritten offering, use its reasonable best efforts to obtain, and deliver to the underwriter(s), in the manner and to the extent provided for in the applicable underwriting agreement, one or more cold comfort letters from the Company&#8217;s independent public accountants in customary form and covering such matters of the type customarily covered by cold comfort letters&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;padding-left:27pt">use its reasonable best efforts to provide (i) a legal opinion of the Company&#8217;s outside counsel dated the date of the Prospectus addressed to the Company addressing the validity of the Parent Shares being offered thereby, (ii) on the date that such Parent Shares are delivered to the underwriters for sale in connection with a Shelf Takedown, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the closing date of the applicable sale, (a) one or more legal opinions of the Company&#8217;s outside counsel, dated such date, in form and substance as customarily given to underwriters in an underwritten public offering or, if requested and customary, in the case of a non-underwritten offering, to the broker, placement agent or other agent of the Holder assisting in the sale of the Parent Shares, in form and substance as customarily given to a broker, placement agent or other agent in such non-underwritten offering, and (b) in  an underwritten public offering, one or more &#8220;negative assurances letters&#8221; of the Company&#8217;s outside counsel, dated such date, in form and substance as is customarily given to underwriters in the underwritten public offering, addressed to the underwriters and (iii) customary certificates executed by authorized officers of the Company as may be reasonably requested by each Holder or any underwriter of such Parent Shares&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt">promptly notify each selling Holder and the managing underwriter or underwriters, if any, when the Company becomes aware of the happening of any event as a result of which the Shelf Registration Statement or the Prospectus contains any untrue statement of a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">material fact or omits to state a material fact necessary to make the statements therein (in the case of such prospectus or any preliminary prospectus, in light of the circumstances under which they were made) not misleading, when any issuer free writing prospectus includes information that may conflict with the information contained in the Shelf Registration Statement, or, if for any other reason it shall be necessary during such time period to amend or supplement such Shelf Registration Statement or Prospectus in order to comply with the 1933 Act and, as promptly as reasonably practicable thereafter, prepare and file with the SEC, and furnish without charge to the selling Holders and the managing underwriter or underwriters, if any, an amendment or supplement to such Shelf Registration Statement or Prospectus, which shall correct such misstatement or omission or effect such compliance.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:43.2pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Each Holder agrees that, as promptly as possible after receipt of any notice from the Company of the happening of any event of the kind described in Section&#160;1D.4, such Holder will forthwith discontinue disposition of Parent Shares pursuant to the Shelf Registration Statement until such Holder&#8217;s receipt of the copies of the supplemented or amended Prospectus contemplated by Section&#160;1D.4, or until such Holder is advised in writing by the Company that the use of the Prospectus may be resumed, and has received copies of any additional or supplemental filings that are incorporated by reference in the Prospectus, or any amendments or supplements thereto, and if so directed by the Company, such Holder shall deliver to the Company (at the Company&#8217;s expense) all copies, other than permanent file copies then in such Holder&#8217;s possession, of the Prospectus covering such Parent Shares current at the time of receipt of such notice. In the event the Company shall give any such notice, the period during which the Shelf Registration Statement is required to be maintained effective shall be extended by the number of days during the period from and including the date of the giving of such notice to and including the date when each seller of Parent Shares covered by the Shelf Registration Statement either receives the copies of the supplemented or amended Prospectus contemplated by Section&#160;1D.4 or is advised in writing by the Company that the use of the Prospectus may be resumed.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:43.2pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">During the period beginning on the date hereof and ending at 12&#58;01 a.m. on August 4, 2022, no Holder shall (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any Share Consideration, or (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the Share Consideration, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of any Share Consideration, in cash or otherwise. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.67pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Indemnification by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Company will indemnify and hold harmless each Holder and their respective Affiliates, and their respective directors, officers, trustees, members, partners, managers, employees, investment advisers and agents, and each other Person, if any, who controls such Holder within the meaning of the 1933 Act, against any and all losses, claims, damages, liabilities and expenses (including, without limitation, any reasonable attorneys&#8217; fees and expenses incurred in connection with defending or investigating any such action or claim) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), joint or several, to which they may become subject under the 1933 Act or otherwise, insofar as such Losses (or actions in respect thereof) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">arise out of or are based upon (i) any untrue or alleged untrue statement of any material fact contained in any Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof, (ii) any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements in any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof, in light of the circumstances under which they were made not misleading or (iii) any violation or alleged violation by the Company or any of its subsidiaries of any federal, state, foreign or common law rule or regulation applicable to the Company or any of its subsidiaries and relating to action or inaction in connection with any such registration, disclosure document or other document or report, except, in each case, to the extent that any such Losses arise out of or are based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with Holder Information (as defined below). In no event shall the Company be liable for fees and expenses of more than one counsel separate from its own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ndemnification by Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Holder agrees to indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors, officers, employees, stockholders and each person who controls the Company (within the meaning of the 1933 Act) against any Losses resulting from any untrue statement of a material fact or any omission of a material fact required to be stated in any Registration Statement or Prospectus or preliminary Prospectus or amendment or supplement thereto or necessary to make the statements therein not misleading, to the extent, but only to the extent that such untrue statement or omission is contained in any information furnished in writing by such Holder, relating to such Holder, to the Company specifically for inclusion in such Registration Statement or Prospectus or amendment or supplement thereto (&#8220;Holder Information&#8221;). In no event shall the liability of such Holder be greater in amount than the dollar amount of the proceeds (net of all expense paid by such Holder in connection with any claim relating to this Section 1E and the amount of any damages such has otherwise been required to pay by reason of such untrue statement or omission) received by such Holder upon the sale of the Parent Shares included in such Registration Statement giving rise to such indemnification obligation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Conduct of Indemnification Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party&#59; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person)&#59; and provided, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which shall not be unreasonably withheld or conditioned, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If for any reason the indemnification provided for in the preceding paragraphs 1E.1 and 1E.2 is unavailable to an indemnified party or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant equitable considerations. No person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the 1933 Act shall be entitled to contribution from any person not guilty of such fraudulent misrepresentation. In no event shall the contribution obligation of a Holder be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such holder in connection with any claim relating to this Section 1E and the amount of any damages such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Parent Shares giving rise to such contribution obligation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.34pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19pt;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be amended only upon the written consent of all of the parties hereto.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.34pt;text-decoration:underline">Counterparts&#59; Facsimile and Email</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed simultaneously in two or more counterparts (each of which may be transmitted via facsimile or email), any one of which need not contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.67pt;text-decoration:underline">Descriptive Headings&#59; Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Section headings used in this Agreement are for convenience only and are not to affect the construction of, or to be taken into consideration in interpreting, such agreement. The use of the word &#8220;including&#8221; or any variation or derivative thereof in this Agreement is by way of example rather than by limitation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:20.33pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any rules, principles or provisions of choice of law or conflict of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.34pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. EACH PARTY TO THIS AGREEMENT HEREBY WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, TRIAL BY JURY IN ANY LITIGATION IN ANY COURT WITH RESPECT TO, IN CONNECTION WITH, OR ARISING OUT OF THIS AGREEMENT OR THE VALIDITY, PROTECTION, INTERPRETATION, COLLECTION OR ENFORCEMENT THEREOF.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.34pt;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:23.01pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. This Agreement and the other documents referred to herein contain the entire agreement between the parties hereto and supersede any prior understandings, agreements or representations by or between the parties hereto, written or oral, which may have related to the subject matter hereof in any way.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.34pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. This Agreement will terminate on the earlier of (i) the first anniversary of the date of this Agreement and (ii) such time as the Holder no longer owns any Parent Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.34pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">1933 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the Securities Act of 1933.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">1934 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the Securities Exchange Act of 1934.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Existing RRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the Registration Rights Agreement by and among Evolent Health, Inc. and certain stockholders, dated as of June 4, 2015.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; have the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Holder Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 1E.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Merger Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meanings set forth in the recitals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 1(E).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Parent Shares covered by such Registration Statement and by all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus, and (ii) any &#8220;free writing prospectus&#8221; as defined in Rule 405 under the 1933 Act.</font></div><div style="margin-bottom:7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">registered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; refer to a registration made by preparing and filing a Registration Statement or similar document in compliance with the 1933 Act, and the declaration or ordering of effectiveness of such Registration Statement or document.</font></div><div style="margin-bottom:7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any registration statement of the Company under the 1933 Act that covers the resale of any of the Parent Shares pursuant to the provisions of this Agreement, amendments and supplements to such Registration Statement, including post-effective amendments, all exhibits and all material incorporated by reference in such Registration Statement.</font></div><div style="margin-bottom:7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Shelf Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 1A.</font></div><div style="margin-bottom:7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Shelf Suspension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 1B.</font></div><div style="margin-bottom:7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">TPG Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*  *  *  *  *</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i5868e673a3484a51be436ae675e6a25a_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVOLENT HEALTH, INC.<br><br><br>By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;<br>      Title&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Registration Rights Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:225pt;padding-right:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TPG GROWTH V ICEMAN, L.P.<br><br><br>By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;<br>      Title&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Registration Rights Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:72pt;text-indent:243.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________</font></div><div style="text-indent:243.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vince Coppola</font></div><div style="text-indent:243.35pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Registration Rights Agreement&#93;</font></div></div></div><div id="i5868e673a3484a51be436ae675e6a25a_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-right:72pt;text-indent:243.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________</font></div><div style="text-indent:243.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neepa Patel</font></div><div style="text-indent:243.35pt"><font><br></font></div><div style="text-indent:243.35pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Registration Rights Agreement&#93;</font></div></div></div><div id="i5868e673a3484a51be436ae675e6a25a_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-right:72pt;text-indent:243.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________</font></div><div style="text-indent:243.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Brian Holt</font></div><div style="text-indent:243.35pt"><font><br></font></div><div style="text-indent:243.35pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Registration Rights Agreement&#93;</font></div></div></div><div id="i5868e673a3484a51be436ae675e6a25a_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-right:72pt;text-indent:243.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________</font></div><div style="text-indent:243.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amy Schornick</font></div><div style="text-indent:243.35pt"><font><br></font></div><div style="text-indent:243.35pt"><font><br></font></div><div style="margin-top:6pt;text-indent:243.35pt"><font><br></font></div><div style="margin-top:6pt;text-indent:243.35pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Registration Rights Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-right:72pt;text-indent:243.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________</font></div><div style="text-indent:243.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Kerry Perry</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Registration Rights Agreement&#93;</font></div></div></div><div id="i5868e673a3484a51be436ae675e6a25a_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vince Coppola</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neepa Patel</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Brian Holt</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amy Schornick</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Kerry Perry</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.268%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>a2022q2form10qex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iaa36735c66cb43c599ee5c9251d15861_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">EXECUTION VERSION</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CREDIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by and among</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EVOLENT HEALTH LLC,<br>as Administrative Borrower,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ENDZONE MERGER SUB, INC.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Initial Borrower</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which upon consummation of the TPG Acquisition will be merged with and into</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TPG GROWTH ICEMAN PARENT, INC.,</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as TPG and, upon consummation of the TPG Acquisition, as the survivor thereof, as a Borrower,</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IMPLANTABLE PROVIDER GROUP, INC., </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as a Borrower</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EVOLENT HEALTH, INC., </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Parent</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain Subsidiaries thereof, as Guarantors,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Lenders  <br>from Time to Time Party Hereto,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARES CAPITAL CORPORATION,<br>as Administrative Agent,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ACF FINCO I LP, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Collateral Agent,</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ACF FINCO I LP, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Revolving Agent,</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:84pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated as of August 1, 2022<br>___________________________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_4"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Article I&#160;&#160;&#160;&#160;Definitions&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">2</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 1.01&#160;&#160;&#160;&#160;Defined Terms&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">2</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 1.02&#160;&#160;&#160;&#160;Other Interpretive Provisions&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_226" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">48</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 1.03&#160;&#160;&#160;&#160;Accounting Terms and Determination&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_226" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">48</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 1.04&#160;&#160;&#160;&#160;Rounding&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_229" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">48</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 1.05&#160;&#160;&#160;&#160;References to Agreements, Laws, etc&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_232" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">48</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 1.06&#160;&#160;&#160;&#160;Times of Day&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_235" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">49</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 1.07&#160;&#160;&#160;&#160;Timing of Payment of Performance&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_238" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">50</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 1.08&#160;&#160;&#160;&#160;Corporate Terminology&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_241" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">50</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 1.09&#160;&#160;&#160;&#160;UCC Definitions&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_244" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">50</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 1.10&#160;&#160;&#160;&#160;Divisions&#59; Series&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_247" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">50</a></font></div><div style="margin-bottom:6pt;padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 1.11&#160;&#160;&#160;&#160;Rates&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_250" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">50</a></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Article II&#160;&#160;&#160;&#160;Amount and Terms of Credit Facilities&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_253" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">51</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.01&#160;&#160;&#160;&#160;Loans&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_256" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">51</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.02&#160;&#160;&#160;&#160;Borrowing Procedures and Settlements&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_298" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">52</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.03&#160;&#160;&#160;&#160;Notice of Borrowing&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_349" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">57</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.04&#160;&#160;&#160;&#160;Disbursement of Term Loans&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_352" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">57</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.05&#160;&#160;&#160;&#160;Payment of Loans&#59; Evidence of Debt&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_364" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">58</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.06&#160;&#160;&#160;&#160;Conversions and Continuations&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_379" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">59</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.07&#160;&#160;&#160;&#160;Pro Rata Borrowings&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_385" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">59</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.08&#160;&#160;&#160;&#160;Interest&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_388" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">59</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.09&#160;&#160;&#160;&#160;&#91;Reserved&#93;&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_427" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">61</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.10&#160;&#160;&#160;&#160;Increased Costs, Illegality, etc&#160;&#160;&#160;&#160; </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_430" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">61</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)  If any Change in Law shall&#58;&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_433" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">61</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.11&#160;&#160;&#160;&#160;Compensation&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_445" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">62</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.12&#160;&#160;&#160;&#160;Change of Lending Office&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_448" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">63</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.13&#160;&#160;&#160;&#160;Notice of Certain Costs&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_451" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">63</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.14&#160;&#160;&#160;&#160;Bank Accounts and Collections&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_454" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">63</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.15&#160;&#160;&#160;&#160;Defaulting Lenders&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_478" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">65</a></font></div><div style="margin-bottom:6pt;padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 2.16&#160;&#160;&#160;&#160;Benchmark Replacement Setting&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_496" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">66</a></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Article III&#160;&#160;&#160;&#160;&#91;RESERVED&#93;&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_514" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">66</a></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Article IV&#160;&#160;&#160;&#160;Fees and Commitment Terminations and Reductions&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_517" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">67</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 4.01&#160;&#160;&#160;&#160;Fees&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_520" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">67</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 4.02&#160;&#160;&#160;&#160;Mandatory Termination of Commitments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_529" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">68</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 4.03&#160;&#160;&#160;&#160;Reduction of Commitments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_538" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">68</a></font></div><div style="margin-bottom:6pt;padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 4.04&#160;&#160;&#160;&#160;Prepayment Premium&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_541" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">68</a></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Article V&#160;&#160;&#160;&#160;Payments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_553" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">69</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 5.01&#160;&#160;&#160;&#160;Voluntary Prepayments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_556" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">69</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 5.02&#160;&#160;&#160;&#160;Mandatory Prepayments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_577" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">70</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 5.03&#160;&#160;&#160;&#160;Payment of Obligations&#59; Method and Place of Payment&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_655" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">73</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;i</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 5.04&#160;&#160;&#160;&#160;Net Payments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_664" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">74</a></font></div><div style="margin-bottom:6pt;padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Section 5.05&#160;&#160;&#160;&#160;Computations of Interest and Fees&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_700" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">77</a></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Article VI&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_703" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">77</a></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Conditions Precedent&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_706" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">77</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 6.01&#160;&#160;&#160;&#160;Conditions Precedent to Initial Credit Extension&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_709" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">77</a></font></div><div style="margin-bottom:6pt;padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 6.02&#160;&#160;&#160;&#160;Conditions Precedent to all Credit Extensions after the Closing Date&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_820" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">80</a></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Article VII&#160;&#160;&#160;&#160;Representations, Warranties and Agreements&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_832" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">81</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.01&#160;&#160;&#160;&#160;Corporate Status&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_835" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">81</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.02&#160;&#160;&#160;&#160;Corporate Power and Authority&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_838" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">81</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.03&#160;&#160;&#160;&#160;No Violation&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_841" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">82</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.04&#160;&#160;&#160;&#160;Litigation, Labor Controversies, etc&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_844" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">82</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.05&#160;&#160;&#160;&#160;Use of Proceeds&#59; Regulations U and X&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_847" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">82</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.06&#160;&#160;&#160;&#160;Approvals, Consents, etc&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_850" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">82</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.07&#160;&#160;&#160;&#160;Investment Company Act&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_853" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">83</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.08&#160;&#160;&#160;&#160;Full Disclosure&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_856" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">83</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.09&#160;&#160;&#160;&#160;Financial Condition&#59; No Material Adverse Effect&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_865" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">83</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.10&#160;&#160;&#160;&#160;Tax Returns and Payments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_877" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">84</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.11&#160;&#160;&#160;&#160;Compliance with ERISA&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_880" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">84</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.12&#160;&#160;&#160;&#160;Capitalization and Subsidiaries&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_883" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">85</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.13&#160;&#160;&#160;&#160;Intellectual Property&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_886" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">85</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.14&#160;&#160;&#160;&#160;Environmental&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_889" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">85</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.15&#160;&#160;&#160;&#160;Ownership of Properties&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_904" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">85</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.16&#160;&#160;&#160;&#160;No Default&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_907" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">86</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.17&#160;&#160;&#160;&#160;Solvency&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_910" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">86</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.18&#160;&#160;&#160;&#160;Licensed Insurance Entities&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_913" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">87</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.19&#160;&#160;&#160;&#160;Compliance with Laws&#59; Authorizations&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_919" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">87</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.20&#160;&#160;&#160;&#160;Contractual or Other Restrictions&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_922" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">87</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.21&#160;&#160;&#160;&#160;Transaction Documents&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_925" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">87</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.22&#160;&#160;&#160;&#160;Collective Bargaining Agreements&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_928" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">87</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.23&#160;&#160;&#160;&#160;Insurance&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_931" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">88</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.24&#160;&#160;&#160;&#160;Evidence of Other Indebtedness&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_934" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">88</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.25&#160;&#160;&#160;&#160;&#91;Reserved&#93;&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_937" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">88</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.26&#160;&#160;&#160;&#160;Foreign Assets Control Regulations&#59; Anti-Money Laundering and Anti-Corruption Practices&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_940" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">88</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.27&#160;&#160;&#160;&#160;Patriot Act&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_943" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">89</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.28&#160;&#160;&#160;&#160;Holding Company&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_946" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">89</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.29&#160;&#160;&#160;&#160;Flood Insurance&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_949" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">89</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.30&#160;&#160;&#160;&#160;Location of Collateral&#59; Equipment List&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">89</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.31&#160;&#160;&#160;&#160;Health Care Matters&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_961" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">89</a></font></div><div style="margin-bottom:6pt;padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 7.32&#160;&#160;&#160;&#160;Eligible Accounts&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_994" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">92</a></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Article VIII&#160;&#160;&#160;&#160;Affirmative Covenants&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_997" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">92</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.01&#160;&#160;&#160;&#160;Financial Information, Reports, Notices and Information&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1000" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">92</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.02&#160;&#160;&#160;&#160;Books, Records and Inspections&#59; Field Exams&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1066" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">96</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.03&#160;&#160;&#160;&#160;Maintenance of Insurance&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1075" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">97</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.04&#160;&#160;&#160;&#160;Payment of Taxes&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1087" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">98</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.05&#160;&#160;&#160;&#160;Maintenance of Existence&#59; Compliance with Laws, etc&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1090" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">98</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.06&#160;&#160;&#160;&#160;Environmental Compliance&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1099" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">98</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.07&#160;&#160;&#160;&#160;ERISA&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1117" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">100</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.08&#160;&#160;&#160;&#160;Maintenance of Property and Assets&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1126" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">100</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.09&#160;&#160;&#160;&#160;End of Fiscal Years&#59; Fiscal Quarters&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1129" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">101</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.10&#160;&#160;&#160;&#160;Use of Proceeds&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1132" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">101</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.11&#160;&#160;&#160;&#160;Further Assurances&#59; Additional Guarantors and Grantors&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1135" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">101</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.12&#160;&#160;&#160;&#160;&#91;Reserved&#93;&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1156" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">103</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.13&#160;&#160;&#160;&#160;Compliance with Health Care Laws&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1159" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">103</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.14&#160;&#160;&#160;&#160;Intellectual Property&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1177" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">104</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.15&#160;&#160;&#160;&#160;Distributable Cash&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1186" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">104</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.16&#160;&#160;&#160;&#160;Post-Closing&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1189" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">104</a></font></div><div style="margin-bottom:6pt;padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 8.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Borrowing Base and Financial Statement Reportin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">g &#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1204" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">1</a><a href="#iaa36735c66cb43c599ee5c9251d15861_1204" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">0</a><a href="#iaa36735c66cb43c599ee5c9251d15861_1204" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">5</a></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Article IX&#160;&#160;&#160;&#160;Negative Covenants&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1228" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">106</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.01&#160;&#160;&#160;&#160;Limitation on Indebtedness&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1231" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">106</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.02&#160;&#160;&#160;&#160;Limitation on Liens&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1306" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">108</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.03&#160;&#160;&#160;&#160;Consolidation, Merger, etc&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1363" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">110</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.04&#160;&#160;&#160;&#160;Permitted Dispositions&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1366" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">111</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.05&#160;&#160;&#160;&#160;Investments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1426" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">112</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.06&#160;&#160;&#160;&#160;Restricted Payments, etc&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1513" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">115</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.07&#160;&#160;&#160;&#160;Modification of Certain Agreements&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1576" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">117</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.08&#160;&#160;&#160;&#160;Sale and Leaseback&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1579" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">118</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.09&#160;&#160;&#160;&#160;Transactions with Affiliates&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1582" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">118</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.10&#160;&#160;&#160;&#160;Restrictive Agreements, etc&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1585" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">118</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.11&#160;&#160;&#160;&#160;Hedging Transactions&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1597" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">119</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.12&#160;&#160;&#160;&#160;Changes in Business&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1600" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">119</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.13&#160;&#160;&#160;&#160;Financial Performance Covenant&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1603" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">119</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.14&#160;&#160;&#160;&#160;Disqualified Capital Stock&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1624" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">120</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.15&#160;&#160;&#160;&#160;&#91;Reserved&#93;&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1627" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">120</a></font></div><div style="margin-bottom:6pt;padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 9.16&#160;&#160;&#160;&#160;Holdings Covenant&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1630" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">120</a></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Article X&#160;&#160;&#160;&#160;Events of Default&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1669" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">122</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 10.01&#160;&#160;&#160;&#160;Listing of Events of Default&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1672" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">122</a></font></div><div style="margin-bottom:6pt;padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 10.02&#160;&#160;&#160;&#160;Remedies Upon Event of Default&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1732" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">125</a></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Article XI&#160;&#160;&#160;&#160;The Administrative Agent&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1735" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">126</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.01&#160;&#160;&#160;&#160;Appointment&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1738" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">126</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.02&#160;&#160;&#160;&#160;Delegation of Duties&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1741" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">126</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.03&#160;&#160;&#160;&#160;Exculpatory Provisions&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1744" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">126</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.04&#160;&#160;&#160;&#160;Reliance by Administrative Agent&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1747" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">127</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.05&#160;&#160;&#160;&#160;Notice of Default&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1750" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">127</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.06&#160;&#160;&#160;&#160;Nonreliance on Administrative Agent and Other Lenders&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1753" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">127</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.07&#160;&#160;&#160;&#160;Indemnification&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1756" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">128</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.08&#160;&#160;&#160;&#160;Agent in Its Individual Capacity&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1759" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">128</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.09&#160;&#160;&#160;&#160;Successor Agents&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1762" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">129</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.10&#160;&#160;&#160;&#160;Agents Generally&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1765" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">129</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.11&#160;&#160;&#160;&#160;Restrictions on Actions by Lenders&#59; Sharing of Payments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1768" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">129</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.12&#160;&#160;&#160;&#160;Agency for Perfection&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1777" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">130</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.13&#160;&#160;&#160;&#160;Authorization to File Proof of Claim&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1780" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">130</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.14&#160;&#160;&#160;&#160;Credit Bids&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1783" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">131</a></font></div><div style="margin-bottom:6pt;padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 11.15&#160;&#160;&#160;&#160;Binding Effect&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1786" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">131</a></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Article XII&#160;&#160;&#160;&#160;Miscellaneous&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1789" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">131</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.01&#160;&#160;&#160;&#160;Amendments and Waivers&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1792" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">131</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.02&#160;&#160;&#160;&#160;Notices and Other Communications&#59; Facsimile Copies&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1813" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">134</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.03&#160;&#160;&#160;&#160;No Waiver&#59; Cumulative Remedies&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1867" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">135</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.04&#160;&#160;&#160;&#160;Survival of Representations and Warranties&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1870" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">136</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.05&#160;&#160;&#160;&#160;Payment of Expenses&#59; Indemnification&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1873" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">136</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.06&#160;&#160;&#160;&#160;Successors and Assigns&#59; Participations and Assignments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1876" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">137</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.07&#160;&#160;&#160;&#160;Replacements of Lenders Under Certain Circumstances&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1903" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">142</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.08&#160;&#160;&#160;&#160;Securitization&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1912" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">143</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.09&#160;&#160;&#160;&#160;Adjustments&#59; Set-off&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1915" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">143</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.10&#160;&#160;&#160;&#160;Counterparts&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1921" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">144</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.11&#160;&#160;&#160;&#160;Severability&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1924" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">144</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.12&#160;&#160;&#160;&#160;Integration&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1927" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">144</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.13&#160;&#160;&#160;&#160;GOVERNING LAW&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1930" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">145</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.14&#160;&#160;&#160;&#160;Submission to Jurisdiction&#59; Waivers&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1933" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">145</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.15&#160;&#160;&#160;&#160;Acknowledgments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1954" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">146</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.16&#160;&#160;&#160;&#160;WAIVERS OF JURY TRIAL&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1966" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">146</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.17&#160;&#160;&#160;&#160;Confidentiality&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_1969" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">146</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.18&#160;&#160;&#160;&#160;Press Releases, etc&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2005" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">148</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.19&#160;&#160;&#160;&#160;Releases of Guarantees and Liens&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2008" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">148</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.20&#160;&#160;&#160;&#160;USA Patriot Act&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2017" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">149</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.21&#160;&#160;&#160;&#160;No Fiduciary Duty&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2020" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">149</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.22&#160;&#160;&#160;&#160;Authorized Officers&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2023" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">149</a></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.23&#160;&#160;&#160;&#160;Acknowledgement and Consent to Bail-In of EEA Financial Institutions&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2026" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">149</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.24&#160;&#160;&#160;&#160;Purchase Option&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2029" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">150</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.25&#160;&#160;&#160;&#160;All Obligations to Constitute Joint and Several Obligations&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2047" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">152</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.26&#160;&#160;&#160;&#160;Administrative Borrower&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2059" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">153</a></font></div><div style="padding-left:172.8pt;padding-right:36pt;text-indent:-136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 12.27&#160;&#160;&#160;&#160;Erroneous Payments&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2062" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">153</a></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">EXHIBITS</font></div><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2263" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A-1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Form of Assignment and Acceptance</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Exhibit B-1&#160;&#160;&#160;&#160;Form of Borrowing Base Certificate</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2269" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit C-1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Form of Compliance Certificate</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2311" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit N-1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Form of Notice of Borrowing<br></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2314" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit N-2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Form of Notice of Conversion or Continuation</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2446" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit R-1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;Form of Revolver Note <br></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"><a href="#iaa36735c66cb43c599ee5c9251d15861_2452" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit T-1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;Form of Term Loan Note<br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">v</font></div><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CREDIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS CREDIT AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, dated as of August 1, 2022, is among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Evolent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ENDZONE MERGER SUB, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Endzone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which upon consummation of the TPG Acquisition (as defined herein) will be merged with and into TPG GROWTH ICEMAN PARENT, INC., a Delaware corporation &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROVIDER GROUP, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Implantable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, collectively with Evolent, Endzone and TPG, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Subsidiaries signatory hereto as guarantors or hereafter designated as Guarantors pursuant to Section 8.11, the lenders from time to time party hereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARES CAPITAL CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Maryland corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Ares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited partnership (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ACF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as collateral agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and as revolver agent for the Revolving Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolver Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_13"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Borrowers have requested that the Lenders extend credit to the Borrowers in the form of (a) an initial term loan in the aggregate principal amount of $175,000,000 on the Closing Date to Initial Borrower (as defined herein)(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Term Loan Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (b) a revolving credit facility in the aggregate principal amount of up to $50,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which shall be fully funded to Initial Borrower on the Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Closing Date Revolver Draw</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (a) the proceeds of the Initial Term Loan Facility will be used (i) to finance the TPG Acquisition, (ii) to pay fees and expenses incurred in connection with the transactions contemplated hereby (including the TPG Acquisition), and (iii) to fund acquisitions, ongoing working capital needs and other growth capital expenditure investments (to the extent permitted hereunder) and (b) the proceeds of the Revolving Facility will be used (i) on the Closing Date, to finance the TPG Acquisition and to pay fees and expenses incurred in connection with the transactions contemplated hereby (including the TPG Acquisition) and (ii) thereafter to fund acquisitions, ongoing working capital needs, and other growth capital investments and to pay fees and expenses in connection with the foregoing.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_19"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the premises and the agreements, provisions and covenants herein contained, the parties hereto agree as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div id="iaa36735c66cb43c599ee5c9251d15861_22"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><br><br>Definitions</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_25"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As used herein, the following terms shall have the meanings specified in this Section 1.01, unless the context otherwise requires&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">2024 Convertible Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; shall mean Parent&#8217;s 3.50% Convertible Senior Notes due December 1, 2024 in favor of U.S. Bank National Association, as trustee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) and any refinancing and extension thereof to the extent such refinancing or extension complies with clause (y) of the definition of Additional Notes. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">2024 Convertible Notes Repurchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; shall mean Parent&#8217;s repurchase or redemption of all or any portion of the 2024 Convertible Notes, whether by tender offer, open-market purchases or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">2025 Convertible Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; shall mean Parent&#8217;s 1.50% Convertible Senior Notes due October 15, 2025, in favor of Trustee and any refinancing and extension thereof to the extent such refinancing or extension complies with clause (y) of the definition of Additional Notes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">2025 Convertible Notes Repurchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; shall mean Parent&#8217;s repurchase or redemption of all or any portion of the 2025 Convertible Notes, whether by tender offer, open-market purchases or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">ABR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; shall mean, for any day, a fluctuating rate of interest per annum (rounded upward, if necessary, to the next highest 1&#47;16 of 1%) equal to the highest of (a) the Prime Rate in effect on such day, (b) the Federal Funds Rate in effect on such day plus &#189; of one percentage point and (c) the Adjusted Term SOFR Rate with a tenor of one month (or any comparable Benchmark Replacement implemented pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 2.08(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">) (for the avoidance of doubt, in each case, not less than the Floor) plus two</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">percentage points.  Changes in the rate of interest on that portion of any Loans maintained as ABR Loans will take effect simultaneously with each change in the ABR.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">ABR Interest Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; shall have the meaning set forth in Section 2.08(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">ABR Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; shall mean each Loan bearing interest at ABR, as provided in Section 2.08(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">ACF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; shall have the meaning set forth in the recitals to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Acquisition Agreement Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means those representations and warranties made with respect to the Parent and its Subsidiaries in the Acquisition Agreement as are material to the interests of the Agents and the Lenders, but only to the extent that TPG Growth Iceman Parent, Inc. or TPG Growth Iceman Parent, Inc.&#8217;s Affiliates have the right (taking into account any applicable cure provisions) to terminate TPG Growth Iceman Parent, Inc.&#8217;s or TPG Growth Iceman Parent, Inc.&#8217;s Affiliates&#8217; obligations under the TPG Acquisition Agreement or the right not to consummate the TPG Acquisition (in each case, pursuant to the TPG Acquisition Agreement) as a result of a failure of such representations and warranties to be true and correct.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Additional Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean unsecured convertible senior notes issued by Parent after the Closing Date&#59; provided, that, (x) such Indebtedness shall not mature, amortize or be mandatorily redeemable (other than solely for Qualified Capital Stock), pursuant to a sinking fund obligation or otherwise (except as a result of a Change of Control or asset sale event so long as any rights of the holders thereof upon the occurrence of a Change of Control or asset sale event shall be subject to the prior repayment in full of the Loans and all other Obligations that are accrued and payable and the termination of the Commitments) earlier than the date that is ninety-one (91) days after the Maturity Date (as determined under clause (a) of the definition thereof), (y) the cash interest rate payable thereon does not exceed 4% per annum (it being agreed there shall be no maximum rate with respect to paid-in-kind interest payments or on the conversion price of such Additional Notes) and (z) no Credit Party (other than Parent) shall be an obligor under such unsecured convertible senior notes.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the preamble to this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Questionnaire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a questionnaire completed by each Lender, in a form approved by the Administrative Agent, in which such Lender, among other things, (a) designates one or more credit contacts to whom all syndicate-level information (which may contain material nonpublic information about the Credit Parties and their Related Parties or their respective securities) will be made available and who may receive such information in accordance with such Lender&#8217;s compliance procedures and Applicable Laws, including federal and state securities laws and (b) designates an address, facsimile number, electronic mail address and&#47;or telephone number for notices and communications with such Lender.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Adjusted Term SOFR Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, for purposes of any calculation, the rate per annum equal to (a) Term SOFR for such calculation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (b) the Term SOFR Adjustment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if Adjusted Term SOFR Rate as so determined shall ever be less than the Floor, then Adjusted Term SOFR Rate shall be deemed to be the Floor.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, any other Person that, directly or indirectly, through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, no Secured Party shall be an Affiliate of any Credit Party solely by reason of the provisions of the Credit Documents.  The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means either (a) the power to vote, or the beneficial ownership of, ten (10%) or more of the Voting Stock of such Person or (b) the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise.  The terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Controlling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; have meanings correlative thereto.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, the Administrative Agent, the Collateral Agent and the Revolving Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean this Credit Agreement, as the same may be amended, amended and restated, supplemented or otherwise modified from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any and all laws, rules or regulations relating to corruption or bribery, including, but not limited to, the FCPA and the U.K. Bribery Act 2010.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Anti-Money Laundering Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any and all laws, rules or regulations relating to money laundering or terrorism financing, including (a) 18 U.S.C. &#167;&#167; 1956 and 1957&#59; and (b) the Bank Secrecy Act, 31 U.S.C. &#167;&#167; 5311 et seq., as amended by the PATRIOT Act, and its implementing regulations.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Anti-Terrorism Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any laws relating to terrorism, trade sanctions programs and embargoes, import&#47;export licensing, money laundering or bribery, all as amended, supplemented or replaced from time to time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, the common law and any federal, state, local, foreign, multinational or international laws, statutes, codes, treaties, standards, rules and regulations, guidelines, ordinances, orders, judgments, writs, injunctions, decrees (including administrative or judicial precedents or authorities) and the interpretation or administration thereof by, and other determinations, directives, requirements or requests of, any Governmental Authority, in each case whether or not having the force of law and that are applicable to or binding upon such Person or any of its property or Products or to which such Person or any of its property or Products is subject.  For the avoidance of doubt, the term &#8220;Applicable Laws&#8221; shall include FATCA and any intergovernmental agreements with respect thereto between the United States and another jurisdiction.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Applicable Margin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (a) in the case of (i) an ABR Loan that is a Revolving Loan, 2.50% and (ii) a Term SOFR Loan that is a Revolving Loan, 3.50% and (b) in the case of a (i) an ABR Loan that is a Term Loan, 4.50% and (ii) a Term SOFR Loan that is a Term Loan, 5.50%. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Approved Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Person (other than a natural person) that is engaged in making, purchasing, holding or investing in bank loans and similar extensions of credit in the ordinary course and that is administered, advised or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers, advises or manages a Lender.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Ares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the recitals to this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Assignment and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an assignment and acceptance substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or such other form approved by the Administrative Agent.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Attributable Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, on any date, in respect of any Capitalized Lease of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Authorized Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Credit Party, the Chief Executive Officer, the Chief Financial Officer, secretary or any other senior financial officer (to the extent that such senior financial officer is designated as such in writing to the Administrative Agent by such Credit Party) of such Credit Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Available Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, at any date of determination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Available Amount Reference Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), an amount equal to the sum of (i) $20,000,000&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (ii) 50% of cumulative Excess Cash Flow </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (iii) the cumulative amount of net cash proceeds of issuances of Qualified Capital Stock received by Evolent after the Closing Date and prior to the Available Amount Reference Date, which net cash proceeds are not otherwise used for any other purpose, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (iv) Indebtedness and Disqualified Capital Stock of any Borrower or any Guarantor which have been exchanged or converted into Qualified Capital Stock of Evolent (or any direct or indirect parent thereof) after the Closing Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (v) the aggregate amount of Net Proceeds received by any Borrower in cash after the Closing Date from the sale, transfer or other disposition of any Investment to the extent not required to be used to prepay the Obligations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (vi) the aggregate amount of Declined Proceeds retained by the Borrowers (and not applied to repay or prepay any other Indebtedness) during the period from the Business Day immediately following the Closing Date through and including the Available Amount Reference Date, in each case of the amounts set forth in clause (i) through (vi) above, solely to the extent such amounts are not otherwise applied.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Availability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination, the aggregate amount that the Borrowers are entitled to borrow as Revolving Loans, in each case, under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (after giving effect to the then outstanding Revolver Usage).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Average Revolver Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any period, the sum of the aggregate amount of Revolver Usage for each calendar day in such period (calculated as of the end of each respective day) divided by the number of calendar days in such period.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Bail-In Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the exercise of any Write-Down and Conversion Powers by the applicable EEA Resolution Authority in respect of any liability of an EEA Financial Institution.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Bail-In Legislation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any EEA Member Country implementing Article 55 of Directive 2014&#47;59&#47;EU of the European Parliament and of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Federal Bankruptcy Reform Act of 1978.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Benchmark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, initially, the Term SOFR Reference Rate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if a Benchmark Transition Event has occurred with respect to the Term SOFR Reference Rate or the then-current Benchmark, then &#8220;Benchmark&#8221; means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to Section 2.16(a). </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Benchmark Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Benchmark Transition Event, the sum of&#58; (a) the alternate benchmark rate that has been selected by the Administrative Agent and the Administrative Borrower giving due consideration to (i) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement to the then-current Benchmark for U.S. dollar-denominated syndicated credit facilities at such time and (b) the related Benchmark Replacement Adjustment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, if such Benchmark Replacement as so determined </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">would be less than the Floor, such Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Credit Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Benchmark Replacement Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Administrative Agent and the Administrative Borrower giving due consideration to (a) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for U.S. dollar-denominated syndicated credit facilities at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Benchmark Replacement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a date and time determined by the Administrative Agent, which date shall be no later than&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;in the case of clause (a) or (b) of the definition of &#8220;Benchmark Transition Event,&#8221; the later of (i) the date of the public statement or publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide such Benchmark (or such component thereof)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;in the case of clause (c) of the definition of &#8220;Benchmark Transition Event,&#8221; the first date on which such Benchmark (or the published component used in the calculation thereof) has been determined and announced by the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non-representative&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such non-representativeness will be determined by reference to the most recent statement or publication referenced in such clause (c) and even if such Benchmark (or such component thereof) continues to be provided on such date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the avoidance of doubt, the &#8220;Benchmark Replacement Date&#8221; will be deemed to have occurred in the case of clause (a) or (b) with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current available tenors of such Benchmark (or the published component used in the calculation thereof).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Benchmark Transition Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of one or more of the following events with respect to the then-current Benchmark&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide such Benchmark (or such component thereof), permanently or indefinitely&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, at the time of such statement or publication, there is no successor administrator that will continue to provide such Benchmark (or such component thereof)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide such Benchmark (or such component thereof) permanently or indefinitely&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, at the time of such statement or publication, there is no successor administrator that will continue to provide such Benchmark (or such component thereof)&#59; or</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such Benchmark (or such component thereof) is not, or as of a specified future date will not be, representative.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the avoidance of doubt, a &#8220;Benchmark Transition Event&#8221; will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each such Benchmark (or the published component used in the calculation thereof).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Benchmark Transition Start Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, in the case of a Benchmark Transition Event, the earlier of (a) the applicable Benchmark Replacement Date and (b) if such Benchmark Transition Event is a public statement or publication of information of a prospective event, the 90th day prior to the expected date of such event as of such public statement or publication of information (or if the expected date of such prospective event is fewer than 90 days after such statement or publication, the date of such statement or publication).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Benchmark Unavailability Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, the period (if any) (a) beginning at the time that a Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Credit Document in accordance with Section 2.16 and (b) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Credit Document in accordance with Section 2.16.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Benefited Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 12.09.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Board of Governors of the Federal Reserve System of the United States (or any successor).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as to any Person, the board of directors (or comparable managers) of such Person, or any committee thereof duly authorized to act on behalf of the board of directors (or comparable managers).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, the Initial Borrower and, immediately following the consummation of the TPG Acquisition, any of TPG, Evolent or Implantable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Loans of the same Type and Class made, converted or continued on the same date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowing Base</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination (without duplication of any part thereof), the result of&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_28"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the sum of&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_31"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;(A) 80% of the amount of Eligible</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Billed Accounts attributable to the Evolent Health Services Business Segment, less (B) the amount, if any, of the Dilution Reserve, plus</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_34"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;(A) 80% of the amount of Eligible</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Billed Accounts attributable to the TPG Business Segment, less (B) the amount, if any, of the Dilution Reserve, plus</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_37"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;(A) 80% of the amount of Eligible</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Billed Accounts attributable to the Vital Business Segment, less (B) the amount, if any, of the Dilution Reserve, plus</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_40"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;50% of the amount of Eligible</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Billed Accounts attributable to the Clinical Solutions Business Segment, less (B) the amount, if any, of the Dilution Reserve, plus</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_43"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;(A) The lesser of (1) $15,000,000 and (2) 50% of the amount of Eligible Unbilled Accounts, less (B) the amount, if any, of the Dilution Reserve, minus</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_46"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;without duplication, the aggregate amount of all Reserves in effect at such time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowing Base Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a certificate in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 8.01(f).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any day excluding Saturday, Sunday, and any day which is a legal holiday under the laws of the State of New York or which is a day on which any Agent is, or is authorized to be, otherwise closed for transacting business with the public.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any and all shares, interests, participations, units or other equivalents (however designated) of capital stock of a corporation, membership interests in a limited liability company, partnership interests of a limited partnership, any and all equivalent ownership interests in a Person and any and all warrants, rights or options to purchase any of the foregoing.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Lease Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as applied to any Person, all obligations under Capitalized Leases of such Person or any of its Subsidiaries, in each case taken at the amount thereof accounted for as liabilities on the balance sheet (excluding the footnotes thereto) of such Person in accordance with GAAP. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Leases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as applied to any Person, all leases of property that have been or should be, in accordance with GAAP, recorded as capitalized leases on the balance sheet of such Person or any of its Subsidiaries, on a consolidated basis&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that for all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">purposes hereunder the amount of obligations under any Capitalized Lease shall be the amount thereof accounted for as a liability on the balance sheet (excluding the footnotes thereto) of such Person in accordance with GAAP&#59; provided, that, any lease classified as an operating lease on December 31, 2018 (assuming for purposes hereof that such lease was in existence on December 31, 2018)  shall continue to be treated as an operating lease regardless of its treatment under GAAP. For the avoidance of doubt, &#8220;Capitalized Leases&#8221; shall not include obligations or liabilities of any Person to pay rent or other amounts under any lease of (or other arrangement conveying the right to use) real or personal property, or a combination thereof, which obligations would be required to be classified and accounted for as an operating lease under GAAP as existing on December 31, 2018&#59; provided, that financial reporting obligations shall not be affected by this sentence.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cash Dominion Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the occurrence of an Event of Default&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, if such Event of Default is cured, waived or otherwise no longer exists, the Cash Dominion Event shall no longer be deemed to exist until such time as another Event of Default occurs&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, (A) a Cash Dominion Event may not be deemed to have ended under this definition on more than three (3) occasions in any period of three hundred sixty-five (365) consecutive days and (B) the expiration of any Cash Dominion Event in accordance with this definition shall not impair the commencement of any subsequent Cash Dominion Event.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_49"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;any direct obligation of (or unconditional guarantee by) the United States (or any agency or political subdivision thereof, to the extent such obligations are supported by the full faith and credit of the United States) maturing not more than one (1) year after the date of acquisition thereof&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_52"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;commercial paper maturing not more than one hundred eighty (180) days from the date of issue and issued by (i) a corporation (other than an Affiliate of any Credit Party) organized under the laws of any state of the United States or of the District of Columbia and, at the time of acquisition thereof, rated A-1 or higher by S&#38;P or P-1 or higher by Moody&#8217;s, or (ii) any Lender (or its holding company)&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_55"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;any certificate of deposit, time deposit or bankers&#8217; acceptance, maturing not more than one hundred eighty (180) days after its date of issuance, which is issued by either&#58; (i) a bank organized under the laws of the United States (or any state thereof) which has, at the time of acquisition thereof, (A)&#160;a credit rating of P2 or higher from Moody&#8217;s or A or higher from S&#38;P and (B)&#160;a combined capital and surplus greater than $500,000,000, or (ii) a Lender&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_58"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;any repurchase agreement having a term of thirty (30) days or less entered into with any Lender or any commercial banking institution satisfying, at the time of acquisition thereof, the criteria set forth in clause (c)(i) which (i) is secured by a fully perfected security interest in any obligation of the type described in clause (a), and (ii) has a market value at the time such repurchase agreement is entered into of not less than one hundred percent (100%) of the repurchase obligation of such Lender or commercial banking institution thereunder&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_61"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Cash Equivalents set forth on Schedule 9.05(g)&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_64"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;money market and mutual funds investing primarily in assets described in clauses (a) through (d) of this definition.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_67"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cash Management Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning specified therefor in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.14(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Casualty Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the damage, destruction or condemnation, as the case may be, of property of any Credit Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">CERCLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Comprehensive Environmental Response, Compensation and Liability Act of 1980.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an event or series of events by which&#58; (a) (1) any Person or group within the meaning of the Exchange Act and the rules of the SEC thereunder (other than each Borrower and its respective wholly-owned Subsidiaries and its affiliates and the employee benefit plans of each Borrower and its respective wholly-owned Subsidiaries) shall acquire ownership, directly or indirectly, beneficially or of record, of Capital Stock of the Parent representing more than fifty percent (50%) or, in the case of the Permitted Holders collectively, more than sixty percent (60%), of the aggregate ordinary voting power represented by the issued and outstanding Capital Stock of Parent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that a Person or group shall not be deemed a beneficial owner of, or to own beneficially, (x) any securities tendered pursuant to a tender or exchange offer made by or on behalf of such Person or group pursuant to a Schedule TO (or any successor form) until such tendered securities are accepted for purchase or exchange thereunder or (y) any securities to the extent such beneficial ownership (i) arises solely as a result of a revocable proxy delivered to such Person or group by a shareholder that is not, for the avoidance of doubt, a member of such &#8220;group&#8221; in response to a proxy or consent solicitation made pursuant to, and disclosed in accordance with, the applicable rules and regulations under the Exchange Act and (ii) is not also then reportable on Schedule 13D or Schedule 13G (or any successor schedule) under the Exchange Act&#59; and (2) any Person or group (within the meaning of the Exchange Act and the rules of the SEC thereunder) files or the Parent files, a Schedule TO or any schedule, form or report under the Exchange Act disclosing that such an event described in the immediately preceding clause (1) has occurred&#59; (b) the consummation of (A) any recapitalization, reclassification or change of the Class A common stock of the Parent (other than changes resulting from a subdivision or combination) as a result of which the Class A common stock of the Parent would be converted into, or exchanged for, stock, other securities, other property or assets&#59; (B) any share exchange, consolidation or merger of Parent pursuant to which the Class A common stock of Parent will be converted into cash, securities or other property or assets&#59; or (C) any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets of Parent and its Subsidiaries, taken as a whole, to any Person other than one of Parent&#8217;s Subsidiaries&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that a transaction described in clause (B) in which the holders of all classes of Parent&#8217;s Capital Stock immediately prior to such transaction hold, directly or indirectly, more than 50% of the voting power of all classes of Capital Stock of the continuing or surviving corporation or transferee or the parent thereof immediately after such transaction in substantially the same proportions as such holders held, directly or indirectly, immediately prior to such transaction shall not be a Change of Control pursuant to this clause (b)&#59; (c) the Class A common stock (or other common stock) of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Parent ceases to be listed or quoted on any of The New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or any of their respective successors)&#59; (d) Parent ceases to own one hundred percent (100%) of the issued and outstanding voting Capital Stock of Evolent&#59; (e) any Borrower ceases to own directly or indirectly one hundred percent (100%) of the issued and outstanding Capital Stock of each Guarantor (other than Parent), free and clear of all Liens, rights, options, warrants or other similar agreements or understandings, other than Liens in favor of Administrative Agent or non-consensual Permitted Liens arising by operation of applicable law&#59; or (f) a &#8220;Fundamental Change&#8221; (as defined in the Convertible Senior Notes) shall occur.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">mean the occurrence after the Closing Date of&#58;  (a) the adoption or effectiveness of any law, rule, regulation, judicial ruling, judgment or treaty, (b) any change in any law, rule, regulation, judicial ruling, judgment or treaty or in the administration, interpretation, implementation or application by any Governmental Authority of any law, rule, regulation, guideline or treaty, or (c) the making or issuance by any Governmental Authority of any request, rule, guideline or directive, whether or not having the force of law&#59; provided that notwithstanding anything in this Agreement to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii) all requests, rules, guidelines or directives concerning capital adequacy promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities shall, in each case, be deemed to be a &#8220;Change in Law,&#8221; regardless of the date enacted, adopted or issued.</font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Clinical Solutions Business Segment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the business of the following entities&#58; NCIS Holding, Inc., a Delaware corporation, NCH Management Systems, Inc., a California corporation, Evolent Care Partners Holding Company, Inc., a Delaware corporation, Evolent Care Partners of Texas, a Texas corporation, The Accountable Care Organization Ltd., a Michigan corporation, and Evolent Care Partners of North Carolina, Inc., a North Carolina corporation.</font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean August 1, 2022.</font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Closing Date Revolver Draw</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the recitals to this Agreement. </font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Internal Revenue Code of 1986, as amended from time to time, and the regulations promulgated and rulings issued thereunder.  Section references to the Code are to the Code, as in effect at the date of this Agreement, and any subsequent provisions of the Code, amendatory thereof, supplemental thereto or substituted therefor.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any assets of any Credit Party or other collateral upon which Administrative Agent has been granted a Lien in connection with this Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the preamble to this Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Security Agreement and each other document or agreement that creates or perfects any security interests granted by any of the Credit Parties to the Administrative Agent on behalf of the Secured Parties.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 11.14.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean all cash, checks, credit card slips or receipts, notes, instruments, and other items of payment (including insurance proceeds, proceeds of cash sales, rental proceeds and tax refunds) of the Credit Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any of the Initial Term Loan Commitment or Revolver Commitment.  The aggregate amount of the Commitments as of the Closing Date is $225,000,000, as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Person that is an operating company engaged in substantially similar business operations as the Borrowers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a certificate duly completed and executed by an Authorized Officer of the Administrative Borrower substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;C-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 12.17.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Connection Income Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Adjusted EBITDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, for a specified Test Period, an amount determined for Parent and its Subsidiaries on a consolidated basis equal to&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_70"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Consolidated Net Income,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_73"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;to the extent deducted in calculating Consolidated Net Income for such period (other than with respect to clause (b)(xiii) below), the sum of, without duplication, amounts for&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_76"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Consolidated Interest Expense (net of interest income)&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_79"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;(a) provisions for Taxes based on income and (b) any payments actually made pursuant to the TRA&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_82"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;total depreciation expense&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_85"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;total amortization expense&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_88"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;other non-cash charges reducing Consolidated Net Income (excluding any such non-cash item (x) to the extent that it represents an accrual or reserve for potential cash items in any future period or amortization of a prepaid cash item that was paid in a prior period or (y) relating to a write-down, write off or reserve with respect to receivables or inventory)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_91"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;losses, costs and expenses on asset sales, disposals or abandonments (other than (i) of current assets and (ii) asset sales, disposals or abandonments in the ordinary course of business)&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_94"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;fees and expenses incurred in connection with a Permitted Acquisition, other Investments permitted hereunder, Dispositions (other than in the ordinary course of business) permitted hereunder, Restricted Payments permitted hereunder or the refinancing or redemption of Indebtedness permitted hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, to the extent such transactions have not been consummated, such costs, fees and expenses (any such costs, fees and expenses, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Unconsummated Deal Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (x) shall not exceed $1,500,000 in any Test Period and (y) shall not exceed the aggregate amount of any adjustments made pursuant to this clause (b)(vii) during such period shall not exceed 25% of Consolidated Adjusted EBITDA (calculated together with clause (b)(xi) and clause (b)(xv)) for such period (calculated before giving effect to any such adjustments)&#59; provided that, the foregoing caps shall not include fees and expenses incurred prior to the Closing Date in connection with the transaction previously identified to the Administrative Agent as &#8220;Project Holiday&#8221;, so long as such amount does not exceed $3,500,000 in the aggregate&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_97"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;fees and expenses incurred in connection with the consummation of the Transactions on the Closing Date in an aggregate amount not to exceed $6,000,000, and to the extent disclosed to the Agents&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_100"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;non-cash adjustments pursuant to any management equity or equity-based plan or stock option plan or any other management or employee benefit plan or agreement or any stock subscription or stockholders agreement&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_103"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;(1) the effects of adjustments in the Parent&#8217;s and its Subsidiaries&#8217; consolidated financial statements pursuant to GAAP (including in the property and equipment, software, goodwill, intangible assets, deferred revenue and debt line items thereof) resulting from the application of recapitalization accounting or purchase accounting, as the case may be, in relation to the Transactions or any consummated acquisition or the amortization of any amounts thereof, (2) any non-cash losses, charges or adjustments resulting from the application of Accounting Standards Codification 606 and (3) earnout obligations and other similar contingent consideration&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_106"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;costs, fees and expenses relating to restructuring, severance, recruiting, retentions and relocations, signing and stay bonuses, payments made to employees or producers who are subject to non-compete agreements, and curtailments or modifications to pension and post-retirement employee benefits plans&#59; provided, that, the aggregate amount included in this clause (xi) during any Test Period shall not exceed 25% of Consolidated Adjusted EBITDA (calculated together with clause (b)(vii) (solely to the extent relating to Unconsummated Deal Expenses) and clause (b)(xv) for such period (calculated before giving effect to any such adjustments)&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_109"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;charges, losses or expenses to the extent paid for, reimbursed or indemnified by a Person other than Parent and its Subsidiaries or reimbursed through insurance by a Person other than Parent and its Subsidiaries, in each case to the extent such expenses are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">actually paid or refunded to Parent or any of its Subsidiaries (to the extent such payments or refunds are included in Consolidated Net Income)&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_112"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiii)&#160;&#160;&#160;&#160;proceeds received from business interruption insurance&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_115"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiv)&#160;&#160;&#160;&#160;to the extent included in Consolidated Net Income, losses attributable to non-controlling interests&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_118"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xv)&#160;&#160;&#160;&#160;extraordinary, unusual and non-recurring costs, expenses and losses in any Test Period&#59; provided, that, the aggregate amount included in this clause (xv) during any Test Period shall not exceed provided, that, the aggregate amount included in this clause (xv) during any Test Period shall not exceed 25% of Consolidated Adjusted EBITDA (calculated together with clause (b)(vii) (solely to the extent relating to Unconsummated Deal Expenses) and clause (b)(xi)) as of the end of the most recently ended Test Period as calculated before giving effect to the add-back in this clause (xv)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_121"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;to the extent included in calculating Consolidated Net Income for such period (other than with respect to clause (c)(iv)), the sum of, without duplication, amounts for&#58; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_124"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;other non-cash gains increasing Consolidated Net Income for such period (excluding any such non-cash item to the extent it represents the reversal of an accrual or reserve for a potential cash item in any prior period), </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_127"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;extraordinary, unusual and non-recurring gains and income&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_130"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;gains on asset sales, disposals or abandonments (other than (A) of current assets and (B) asset sales, disposals or abandonments in the ordinary course of business)&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_133"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;any software development costs to the extent capitalized during such period.  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided&#59; however, for purposes of determining the Total Secured Leverage Ratio, Consolidated Adjusted EBITDA shall be determined on a Pro Forma Basis.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Interest Expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, for any specified Test Period, for the Parent and its Subsidiaries, determined on a consolidated basis in accordance with GAAP, the sum of&#58;  (a) all interest in respect of Indebtedness (including, without limitation, the interest component of any payments in respect of Capitalized Lease Obligations) accrued or capitalized during such period (whether or not actually paid during such period) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (b) the net amount payable (or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the net amount receivable) in respect of Hedging Obligations relating to interest during such period (whether or not actually paid or received during such period).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Net Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, for any specified Test Period, the consolidated net income (or loss) of Parent and its Subsidiaries determined in accordance with GAAP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that there shall be excluded (i) the income (or loss) of any Person (other than </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">consolidated Subsidiaries of Parent) in which any Person (other than Parent or any of its consolidated Subsidiaries) has a joint ownership interest or that is accounted for by the equity method of accounting, except to the extent of the amount of dividends or other distributions actually paid to Parent or any of its consolidated Subsidiaries by such Person during such specified Test Period, (ii) the income (or loss) of any Person accrued prior to the date it becomes a consolidated Subsidiary of Parent or is merged into or consolidated with Parent or any of its consolidated Subsidiaries or such Person&#8217;s assets are acquired by Parent or any of its consolidated Subsidiaries, and (iii) the income of any consolidated Subsidiary of Parent (other than a Credit Party) to the extent that the declaration or payment of dividends or similar distributions by that consolidated Subsidiary of that income is not at the time permitted by operation of the terms of its charter or any agreement, instrument, judgment, decree, order, statute, rule, governmental regulation applicable to that consolidated Subsidiary or would require governmental (including regulatory) consent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, the income (or loss) of any consolidated Subsidiary of Parent (other than a Credit Party) shall not be excluded from this definition to the extent governmental (including regulatory) consent has been received for the declaration or payment of dividends or similar distributions by that consolidated Subsidiary of its income.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Secured Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">as of any date of determination, the outstanding principal amount of all Funded Debt that is secured, in whole or part, by a Lien on any asset of Parent or any of its Subsidiaries.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) the 2024 Convertible Notes, (ii) the 2025 Convertible Notes and (iii) any Additional Notes.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Contingent Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; shall mean, for any Person, any agreement, undertaking or arrangement by which such Person guarantees, endorses or otherwise becomes or is contingently liable upon (by direct or indirect agreement, contingent or otherwise, to provide funds for payment, to supply funds to, or otherwise to invest in, a debtor, or otherwise to assure a creditor against loss) the Indebtedness of any other Person (other than by endorsements of instruments in the course of collection), or guarantees the payment of dividends or other distributions upon the Capital Stock of any other Person.  The amount of any Person&#8217;s obligation under any Contingent Liability shall (subject to any limitation set forth therein) be deemed to be the outstanding principal amount of the debt, obligation or other liability guaranteed thereby.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the definition of &#8220;Affiliate.&#8221;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Controlling and Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the definition of &#8220;Affiliate.&#8221;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the 2024 Convertible Notes and&#47;or 2025 Convertible Notes.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean this Agreement, the Springing Control Agreements, the Fee Letter, the Guarantee Agreement, the Security Documents, the Intercompany Subordination Agreement, the Global Intercompany Note, any Notes issued by any Borrower hereunder, any intercreditor or subordination agreements in favor of the Administrative Agent with respect to this Agreement, and any other agreement entered into now, or in the future, by any Credit Party, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">on the one hand, and the Administrative Agent or Lender, on the other hand, in connection with this Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean and include the making (but not the conversion or continuation) of a Loan.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any of the Initial Term Loan Facility or Revolving Facility, as applicable, and, collectively, the Initial Term Loan Facility and Revolving Facility.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each Borrower, each of the Guarantors and each other Person that becomes a Credit Party hereafter pursuant to the execution of joinder documents.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cure Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 9.13(d).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cure Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 9.13(d).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Declined Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.02(k).  </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any event, act or condition that with notice or lapse of time, or both, would constitute an Event of Default.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 2.08(c).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Defaulting Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, subject to Section 2.15, any Lender that, as determined by the Administrative Agent, (a) has failed to (i) fund any portion of the Loans required to be funded by it hereunder for three (3) or more Business Days unless such Lender notifies the Administrative Agent and the Administrative Borrower in writing that such failure is the result of such Lender&#8217;s determination that one or more conditions precedent to funding (each of which conditions precedent, together with any applicable default, shall be specifically identified in such writing) has not been satisfied, or (ii) pay to the Administrative Agent, any other Lender any other amount required to be paid by it hereunder, (b) has notified the Administrative Borrower, or the Administrative Agent in writing that it does not intend to comply with its funding obligations or has made a public statement to that effect with respect to its funding obligations hereunder or under other agreements in which it commits to extend credit (unless such writing or public statement relates to such Lender&#8217;s obligation to fund a Loan hereunder and states that such position is based on such Lender&#8217;s determination that a condition precedent to funding (which condition precedent, together with any applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied), (c) has failed, within three (3) or more Business Days after written request by the Administrative Agent or the Administrative Borrower, to confirm in writing in a manner satisfactory to the Agents that it will comply with its prospective funding obligations hereunder (provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon receipt of such written confirmation by the Administrative Agent), or (d) has, or has a direct or indirect parent company that has, (i) become the subject of a bankruptcy or insolvency proceeding, (ii) had a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting in such capacity, (iii) taken any action in furtherance of, or indicated its consent to, approval of or acquiescence in any such proceeding or appointment or (iv) become the subject of a Bail-in Action&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender.  Any determination by the Administrative Agent that a Lender is a Defaulting Lender under any one or more of clauses (a) through (d) above shall be conclusive and binding absent manifest error.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Defaulting Lender Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) for the first 3 days from and after the date the relevant payment is due, the Prime Rate, and (b) thereafter, the interest rate then applicable to Loans as if the Prime Rate were applicable thereto. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Designated Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Deposit Account of each Borrower identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as a &#8220;Designated Account&#8221; (or such other Deposit Account of a Borrower located at Designated Account Bank that has been designated as such, in writing, by such Borrower to Collateral Agent).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Designated Account Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the depositary institution shown on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> which maintains the Designated Account of any Borrower (or such other bank that is located within the United States that has been designated as such, in writing, by a Borrower to Collateral Agent).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Dilution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination, a percentage, based upon the experience of the immediately prior twelve (12) months, that is the result of dividing the Dollar amount of (a) bad debt write-downs, discounts, advertising allowances, credits, or other dilutive items with respect to Credit Parties&#8217; Accounts during such period, by (b) the Credit Parties&#8217; billings with respect to Accounts during such period.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Dilution Reserve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination, a reserve that may be established by Revolver Agent in its Permitted Discretion, including, but not limited to, to address the results of any Field Exam performed by (or on behalf of) Revolver Agent, in an amount sufficient to reduce the advance rate against Eligible Billed Accounts and Eligible Unbilled Accounts by the number of full or partial percentage points by which Dilution is in excess of 5%.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, any sale, transfer, lease, contribution, division or other conveyance (including by way of merger) of, or the granting of options, warrants or other rights to, any of such Person&#8217;s or their respective Subsidiaries&#8217; assets (including receivables and Capital Stock of Subsidiaries) to any other Person in a single transaction or series of transactions.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Disqualified Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Capital Stock that, by its terms (or by the terms of any security or other Capital Stock into which it is convertible or for which it is exchangeable) or upon the happening of any event or condition, (a) matures or is mandatorily redeemable (other than solely for Qualified Capital Stock), pursuant to a sinking fund obligation or otherwise (except as a result of a Change of Control or asset sale so long as any rights of the holders thereof upon the occurrence of a Change of Control or asset sale event shall be subject to the prior repayment in full of the Loans and all other Obligations that are accrued and payable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and the termination of the Commitments), (b) is redeemable at the option of the holder thereof (other than solely for Qualified Capital Stock) (except as a result of a Change of Control or asset sale so long as any rights of the holders thereof upon the occurrence of a Change of Control or asset sale event shall be subject to the prior repayment in full of the Loans and all other Obligations that are accrued and payable and the termination of the Commitments), in whole or in part, (c) provides for the scheduled payment of dividends in cash or (d) is or becomes convertible into or exchangeable for Indebtedness or any other Capital Stock that would constitute Disqualified Capital Stock, in each case, prior to the date that is ninety-one (91) days after the Maturity Date (as determined under clause (a) of the definition thereof)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if such Capital Stock is issued pursuant to a plan for the benefit of employees of the Borrowers or their respective Subsidiaries or by any such plan to such employees, such Capital Stock shall not constitute Disqualified Capital Stock solely because it may be required to be repurchased by the Borrowers or their respective Subsidiaries in order to satisfy applicable statutory or regulatory obligations.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Disqualified Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any Person that is (a) designated by the Administrative Borrower, by written notice delivered to Administrative Agent on or prior to the Closing Date, as a (i) disqualified institution or (ii) Competitor or (b) clearly identifiable, solely on the basis of such Person&#8217;s name, as an Affiliate of any Person referred to in clause (a)(i) or (a)(ii) above&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, however, Disqualified Institutions shall (A) exclude any Person that the Administrative Borrower has designated as no longer being a Disqualified Institution by written notice delivered to the Administrative Agent from time to time, (B) exclude any bona fide debt fund, investment vehicle, regulated bank entity or unregulated lending entity (other than any person separately identified as a Disqualified Institution in accordance with clause (a)(ii) above or any Affiliate of a Person identified under clause (b) above) that is engaged in making, purchasing, holding or otherwise investing in commercial loans or similar extensions of credit in the ordinary course of business and (C) include (I) any Person that is added as a Competitor and (II) any Person that is clearly identifiable, solely on the basis of such Person&#8217;s name, as an Affiliate of any Person referred to in clause (C)(I), pursuant to a written supplement to the list of Competitors that are Disqualified Institutions, that is delivered by the Administrative Borrower after the date hereof to the Administrative Agent.  Such supplement shall become effective two (2) Business Days after the date that such written supplement is delivered to Administrative Agent, but which shall not apply retroactively to disqualify any Persons that have previously acquired an assignment or participation interest in the Loans and&#47;or Commitments as permitted herein.  Notwithstanding the foregoing, each Credit Party and the Lenders acknowledge and agree that the Administrative Agent shall not have any responsibility or obligation to determine whether any Lender or potential Lender is a Disqualified Institution and the Administrative Agent shall have no liability with respect to any assignment or participation made to a Disqualified Institution.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Distributable Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 10.01(m).  </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean dollars in lawful currency of the United States of America.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Domestic Holding Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a Domestic Subsidiary that has no material assets other than Capital Stock (or Capital Stock and indebtedness) of one or more Foreign Subsidiaries.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Domestic Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each Subsidiary of any Borrower that is organized under the Applicable Laws of the United States, any state thereof or the District of Columbia.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">EEA Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">EEA Member Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any of the member states of the European Union, Iceland, Liechtenstein and Norway.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">EEA Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any public administrative authority or any Person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Eligible Billed Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means those Accounts created by a Credit Party in the ordinary course of its business, that arise out of its rendition of services in the United States that have been acknowledged as accepted by the applicable Account Debtor, that comply with each of the representations and warranties respecting Eligible Billed Accounts made in the Credit Documents, and that are not excluded as ineligible by virtue of one or more of the excluding criteria set forth below&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such criteria may be revised from time to time by Revolver Agent in Revolver Agent&#8217;s Permitted Discretion including to address the results of any Field Exam performed by (or on behalf of) Revolver Agent from time to time after the Closing Date.  In determining the amount to be including, Eligible Billed Accounts shall be calculated net of customer deposits, unapplied cash, Taxes, discounts, credits and allowances.  Eligible Billed Accounts shall not include the following&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Accounts that the Account Debtor has failed to pay within 180 days of original invoice date and Accounts that are more than 90 days past due,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Accounts owed by an Account Debtor (or its Affiliates) where 50% or more of all Accounts owed by that Account Debtor (or its Affiliates) are deemed ineligible under clause (a) above,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Accounts with respect to which the Account Debtor is an Affiliate of a Borrower or an employee or agent of a Borrower or any Affiliate of a Borrower,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Accounts that are not payable in Dollars,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Accounts with respect to which the Account Debtor either (i) does not maintain its chief executive office in the United States, or (ii) is not organized under the laws of the United States or any state thereof, or (iii) is the government of any foreign country or sovereign state, or of any state, province, municipality, or other political subdivision thereof, or of any department, agency, public corporation, or other instrumentality thereof, unless (A) the Account is supported by an irrevocable letter of credit reasonably satisfactory to Revolver Agent (as to form, substance, and issuer or domestic confirming bank) that has been delivered to Collateral Agent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and is directly drawable by Revolver Agent, or (B) the Account is covered by credit insurance in form, substance, and amount, and by an insurer, reasonably satisfactory to Revolver Agent,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Accounts of a Credit Party with respect to which the Account Debtor is either (i) the United States or any department, agency, or instrumentality of the United States (exclusive, however, of Accounts with respect to which such Credit Party has complied, to the reasonable satisfaction of Revolver Agent, with the Assignment of Claims Act, 31 USC &#167;3727), or (ii) any state of the United States,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Accounts with respect to which the Account Debtor is a creditor of a Credit Party, has or has asserted a right of recoupment or setoff, or has disputed its obligation to pay all or any portion of the Account or has repaid only a portion of the Account, </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Accounts with respect to which the Account Debtor is an individual and not a corporate entity,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Accounts with respect to which the Account Debtor is subject to an Insolvency Proceeding, is not Solvent, has gone out of business, or as to which a Credit Party has received notice of an imminent Insolvency Proceeding or a material impairment of the financial condition of such Account Debtor,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;Accounts, the collection of which, Revolver Agent, in its Permitted Discretion following consultation with the Administrative Borrower, believes to be doubtful, including by reason of the Account Debtor&#8217;s financial condition,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Accounts that are not subject to a valid and perfected first priority Revolver Agent&#8217;s Lien,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Accounts with respect to which the services giving rise to such Account have not been performed and billed to the Account Debtor,</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;Accounts owned by a target acquired in connection with a Permitted Acquisition or any other Permitted Investment, until the completion of a customary due diligence investigation, which may include a field examination conducted by Revolver Agent, or the receipt of other information reasonably requested by Collateral Agent with respect to such target, in each case, reasonably satisfactory to Revolver Agent (which field examination may be conducted prior to the closing of such Permitted Acquisition or Permitted Investment),</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;&#91;reserved&#93;, </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;Accounts with respect to which the Account Debtor is a Sanctioned Person or Sanctioned Entity, &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;&#91;reserved&#93;,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;Accounts that are not a true and correct statement of bona fide indebtedness incurred in the amount of the Account for services rendered and accepted by the applicable Account Debtor, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;Accounts that have been redated, extended, compromised, settled or otherwise modified or discounted, except discounts or modifications that are granted by a Credit Party in the ordinary course of business and that are reflected in the calculation of the Borrowing Base, </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;the portion, if any, of any Account that includes a billing for interest, fees or late charges, or</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;Accounts which are otherwise unacceptable to Revolver Agent in its Permitted Discretion after consultation with the Administrative Borrower.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Eligible Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Eligible Billed Accounts and Eligible Unbilled Accounts.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Eligible Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.06(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Eligible Unbilled Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Accounts of a Credit Party (a) arising from the rendition of services in the United States that have been completed by the applicable Credit Party and that are evidenced by supporting documentation in form and substance satisfactory to Revolver Agent and (b) that qualify as Eligible Billed Accounts except that the invoice applicable to such Accounts has not been issued to the applicable Account Debtor&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that an Account shall cease to be an Eligible Unbilled Account upon the earlier of (i) the date the invoice applicable to such Account is issued to the applicable Account Debtor and (ii) one hundred eighty (180) days after the services giving rise to such Account have been completed by the applicable Credit Party.  In determining the amount to be included, Eligible Unbilled Accounts shall be calculated net of customer deposits and unapplied cash.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Endzone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the preamble to this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Environmental Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any and all administrative, regulatory, adjudicatory or judicial actions, suits, demands, demand letters, claims, liens, fines, penalties, requests for information, inquiries, notices of noncompliance or violation, investigations (other than internal reports prepared by the Credit Parties in the ordinary course of such Person&#8217;s business) or proceedings relating in any way to any Environmental Law, any Hazardous Material (including any exposure to any Hazardous Material), or any permit issued, or any approval given, under any such Environmental Law, including (i) by governmental or regulatory authorities for enforcement, cleanup, removal, response, remedial, investigation, monitoring or other actions or damages pursuant to any Environmental Law and (ii) by any Person seeking damages, contribution, indemnification, cost recovery, compensation or injunctive relief resulting from the presence, Release of, or threat of Release of, Hazardous Materials or arising from alleged injury or threat of injury to human health, public safety or the environment, pursuant to any Environmental Law.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Environmental Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any federal, state, foreign, regional, county or local statute, law, rule, regulation, ordinance and code now or hereafter in effect and, in each case, as amended, and any binding judicial or administrative interpretation thereof, including any binding judicial or administrative order, decree or judgment, relating to the protection of human health, safety or the environment or natural resources, including laws relating to the Release, threat of Release, manufacture, processing, distribution, use, presence, production, treatment, storage, disposal, transport, labeling or handling of, or exposure to, Hazardous Materials, including the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Federal Water Pollution Control Act, the Resource Conservation and Recovery Act, the Safe Drinking Water Act, the Toxic Substances Control Act, the Clean Air Act and CERCLA, and other similar state and local statutes and any regulations promulgated thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Employee Retirement Income Security Act of 1974, as amended from time to time, and the regulations promulgated thereunder.  Section references to ERISA are to ERISA as in effect at the date of this Agreement and any subsequent provisions of ERISA amendatory thereof, supplemental thereto or substituted therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each person (as defined in Section 3(9) of ERISA) that, together with any Credit Party or a Subsidiary thereof, is, or within the last six (6) years was, treated as a &#8220;single employer&#8221; within the meaning of Section 414(b), (c), (m) or (o) of the Code.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ERISA Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (a) the occurrence of any Reportable Event  with respect to a Plan, (b) any failure by any Plan to satisfy the minimum funding standard (within the meaning of Section 412 of the Code or Section 302 of ERISA) applicable to such Plan, in each case whether or not waived, (c) the filing pursuant to Section 412(c) of the Code or Section 302(c) of ERISA of an application for a waiver of the minimum funding standard with respect to any Plan, (d) a determination that any Plan is, or is reasonably expected to be, in &#8220;at-risk&#8221; status (as defined in Section 303 of ERISA or Section 430 of the Code), (e) the incurrence by any Credit Party or any ERISA Affiliate of any liability under Title IV of ERISA with respect to the non-standard termination of any Pension Plan, (f) the receipt by any Credit Party from the PBGC of any notice relating to an intention to terminate any Plan or Plans or to appoint a trustee to administer any Plan under Section 4042 of ERISA, (g) the incurrence by any Credit Party or any ERISA Affiliate of any liability with respect to its withdrawal or partial withdrawal from any Multiemployer Plan or (i) the receipt by any Credit Party or any ERISA Affiliate of any notice concerning the imposition of Withdrawal Liability on it or a determination that a Multiemployer Plan is, or is reasonably expected to be, insolvent, within the meaning of Title IV of ERISA or in &#8220;endangered&#8221; or &#8220;critical&#8221; status, within the meaning of Section 305 of ERISA.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Erroneous Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to it in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.27(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Erroneous Payment Deficiency Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to it in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.27(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Erroneous Payment Impacted Class</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to it in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.27(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Erroneous Payment Return Deficiency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to it in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.27(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">EU Bail-In Legislation Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Article X.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Evolent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the preamble to this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Evolent Health Services Business Segment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the business of Evolent and EH Holding Company, Inc., a Delaware corporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Excess Cash Flow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any fiscal period and with respect to Parent and its Subsidiaries determined on a consolidated basis in accordance with GAAP the result of&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Consolidated Adjusted EBITDA determined on a consolidated basis, for the twelve (12) fiscal month period most recently ended, minus</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the sum of, without duplication</font></div><div style="margin-bottom:6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the cash portion of interest on the Loans paid during such fiscal period,</font></div><div style="margin-bottom:6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the cash portion of income taxes paid during such period, and</font></div><div style="margin-bottom:6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;to the extent financed with internally generated cash, voluntary payments made in respect of the Term Loan during such period.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Excluded Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each deposit or securities accounts constituting (a) a zero balance account that sweeps on a daily basis into a deposit account subject to a Springing Control Agreement, (b) a deposit account used solely to fund payroll obligations, health benefit or employee benefit obligations, Tax obligations, escrow arrangements, trust accounts or holding third-party insurance funds or funds owned by (or held solely for the benefit of) Persons other than the Credit Parties or holding any funds to be used for the purpose of paying claims to satisfy statutory or regulatory requirements, (c) any other deposit or securities account so long as with respect to this clause (c), the aggregate amount on deposit in all such accounts does not exceed $1,000,000 at any one time (each account under this clause (c), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Monitored Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (d) a deposit account into which an Account Debtor makes payment under Medicare, Medicaid, TRICARE or any other health program operated by or financed in whole or in part by any foreign or domestic federal, state or local government so long as funds on deposit in such deposit account are transferred within two (2) Business Days to an account subject to a Springing Control Agreement or (e) a deposit account holding solely funds pledged as cash collateral to the extent permitted under Section 9.02(b) or Section 9.02(m). </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Excluded Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Subsidiary (1) for which guarantees at any time are prohibited or restricted by Applicable Laws (including financial assistance, fraudulent conveyance, preference, capitalization or any other Applicable Laws or regulations) (or contractually prohibited on the Closing Date (in the case of existing Subsidiaries) or on the date of acquisition or formation thereof (in the case of acquired or formed Subsidiaries), so long as such prohibition is not created in contemplation of such transaction) from guaranteeing the Obligations, or if guaranteeing the Obligations would require governmental (including regulatory) consent, non-disapproval, approval, filing, license or authorization (unless such consent, approval, license or authorization has been received), (2) not-for-profit subsidiaries, captive insurance companies and special purpose entities, (3) any non-wholly owned Subsidiary (x) in existence on the Closing Date or (y) to the extent a guaranty by such Subsidiary is prohibited by the terms of such person&#8217;s organizational or joint venture documents (to the extent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the prohibition is existing on the Closing Date or at the time any subsidiary is acquired, formed or established (and which prohibition is not created in contemplation of such transaction)), (4) any Subsidiary where the cost of providing a guarantee, taken as a whole, outweighs the benefit to the Lenders, as determined in the reasonable discretion of the Administrative Agent and Administrative Borrower, (5) any subsidiary to the extent a guarantee by such entity will result in material adverse tax or regulatory consequences, taken as a whole, to Parent and its Subsidiaries and (6) any Foreign Subsidiary, Domestic Holding Company and Licensed Insurance Entity (solely, in the case of any Licensed Insurance Entity, to the extent guaranteeing the Obligations would require governmental (including regulatory) consent, notification, non-disapproval, approval, filing, license or authorization or would otherwise be prohibited or restricted by Applicable Laws).  </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean with respect to the Administrative Agent, any Lender or any other recipient of any payment to be made by or on account of any Obligation of any Borrower hereunder, (a) income, franchise or similar Taxes imposed on (or measured by) its net income (i) by the United States of America, or by the jurisdiction under the laws of which such recipient is organized or in which its principal office is located or, in the case of any Lender, in which its applicable lending office is located or (ii) that are Other Connection Taxes, (b) any branch profits Taxes imposed by the United States of America or any similar tax imposed by any other jurisdiction in which a Borrower is located, (c) in the case of a Non-U.S. Lender, any withholding tax that is imposed on amounts payable to such Non-U.S. Lender pursuant to an Applicable Law in effect at the time such Non-U.S. Lender becomes a party to this Agreement (or designates a new lending office, unless such designation was at the request of the Administrative Borrower), except to the extent that such Non-U.S. Lender (or its assignor, if any) was entitled, at the time of designation of a new lending office (or assignment), to receive additional amounts from a Borrower with respect to such withholding tax pursuant to Section 5.04(a),  (d) Taxes imposed by reason of the failure of the Administrative Agent or such Lender to comply with its obligations under Section 5.04(b) and Section 5.04(c), or to the extent that such documentation fails to establish a complete exemption from applicable withholding Taxes, other than, in either case, due to a change in Applicable Laws after the Closing Date and (e) U.S. federal withholding Taxes imposed under FATCA.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Extraordinary Advances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning specified therefor in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Existing Earnouts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) the &#8220;Earnout Consideration&#8221; as defined under the TPG Acquisition Agreement, in an amount not to exceed $87,000,000, payable in Capital Stock and, absent the occurrence and continuance of any Event of Default, in cash and (ii) the &#8220;Earnout Consideration&#8221; as defined in that certain Purchase Agreement and Agreement and Plan of Merger, dated as of August 2, 2021 by and among Parent, Evolent, EV Thunder Merger Sub, LLC, Windrose Health Investors III, L.P., and Vital Decisions Acquisition, LLC, in an amount not to exceed $45,000,000, payable in Capital Stock and, absent the occurrence and continuance of any Event of Default, in cash.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">FATCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreement entered into pursuant to Section 1471(b)(1) of the Code </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities entered into in connection with the implementation of the foregoing.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Foreign Corrupt Practices Act of 1977, as amended from time to time, and the rules and regulations thereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Federal Funds Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, for any day, a fluctuating interest rate per annum equal to&#58; (a) the weighted average of the rates on overnight federal funds transactions with members of the Federal Reserve System, as published for such day (or, if such day is not a Business Day, for the next succeeding Business Day) by the Federal Reserve Bank of New&#160;York&#59; or (b) if such rate is not so published for any day which is a Business Day, the average of the quotations for such day on such transactions received by the Administrative Agent from three federal funds brokers of recognized standing selected by it.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Fee Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Fee Letter dated as of June 24, 2022 by and between the Evolent and Ares Capital Management LLC, and acknowledged by each Credit Party as of the Closing Date, as amended, restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean all amounts payable pursuant to, or referred to in, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or the Fee Letter.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Field Exam</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Financial Performance Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Fiscal Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each quarterly period corresponding to the Fiscal Year.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean any of the annual accounting periods of the Borrowers ending on December 31 of each year.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Flood Hazard Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the definition of the term &#8220;Flood Insurance Requirements.&#8221;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Flood Insurance Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, (i) the National Flood Insurance Act of 1968 as now or hereafter in effect or any successor statute thereto, (ii) the Flood Disaster Protection Act of 1973 as now or hereafter in effect or any successor statute thereto,&#160;(iii) the National Flood Insurance Reform Act of 1994 as now or hereafter in effect or any successor statute thereto,&#160;(iv) the&#160;Flood Insurance Reform Act of 2004 and (v) the Biggert &#8211;Waters Flood Insurance Reform Act of 2012, as now or hereafter in effect of any successor statute thereto, in each case,&#160;together with all statutory and regulatory provisions consolidating, amending, replacing, supplementing, implementing&#160; or interpreting any of the foregoing, as amended or modified from time to time.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Flood Insurance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) a completed &#8220;life of loan&#8221; Federal Emergency Management Standard Flood Hazard Determination as to whether such real property is in an area designated by the Federal Emergency Management Agency as having special flood or mud slide hazards (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Flood Hazard Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii) if such real property is a Flood Hazard Property, evidence as to (A) whether the community in which such real property, or as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">applicable, the leasehold interest of such Credit Party in such real property, is located is participating in the National Flood Insurance Program, (B) the applicable Credit Party&#8217;s written acknowledgment of receipt of written notification from the Administrative Agent (1) as to the fact that such real property is a Flood Hazard Property and (2) as to whether the community in which each such Flood Hazard Property is located is participating in the National Flood Insurance Program and (C) copies of flood insurance policies under the National Flood Insurance Program (or private insurance endorsed to cause such private insurance to be fully compliant with the federal law as regards private placement insurance applicable to the National Flood Insurance Program, with financially sound and reputable insurance companies not Affiliates of any Borrower) or a declaration page, application accompanied by proof of premium payment for such policies, or such other documentation as is satisfactory to the Agents and each Lender, with confirmation of such satisfaction of such Lender to be made in writing (which, for purposes of such confirmation, shall include email) and such confirmation shall not be unreasonably withheld or delayed, in each case, for the Parent and its Subsidiaries evidencing such flood insurance coverage in such amounts and with such deductibles as required by Flood Insurance Laws or as the Administrative Agent may request (but no less than required by applicable Flood Insurance Laws) and naming the Administrative Agent and its successors and&#47;or assigns as sole loss payee on behalf of the Lenders.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Floor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean 1.00%.  </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Foreign Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any plan, fund (including, without limitation, any superannuation fund) or other similar program established, contributed to (regardless of whether through direct contributions or through employee withholding) or maintained outside the United States by any Credit Party primarily for the benefit of employees of the Credit Parties residing outside the United States, which plan, fund or other similar program provides, or results in, retirement income, a deferral of income in contemplation of retirement or payments to be made upon termination of employment, and which plan is not subject to ERISA or the Code. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Foreign Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each Subsidiary of a Credit Party that is not a Domestic Subsidiary.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Funded Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any date of determination, all then outstanding Indebtedness of Parent and its Subsidiaries, on a consolidated basis, of the type described in clauses (a), (b) (excluding the amount of any undrawn or cash collateralized letters of credit), (d) and (f) of the defined term &#8220;Indebtedness.&#8221;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Funding Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the date on which a Borrowing occurs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean generally accepted accounting principles in the United States of America, as in effect from time to time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if the Administrative Borrower notifies the Administrative Agent that any Borrower requests an amendment to any provision hereof to eliminate the effect of any change occurring after the Closing Date in GAAP or in the application thereof on the operation of such provision (or if the Administrative Agent notifies the Administrative Borrower that the Required Lenders request an amendment to any provision hereof for such purpose), regardless of whether any such notice is given before or after such change in GAAP or in the application thereof, then the Administrative Agent, the Lenders and the Credit Parties shall negotiate in good faith to effect such amendment and such provision shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">be interpreted on the basis of GAAP as in effect and applied immediately before such change shall have become effective until such notice shall have been withdrawn or such provision amended in accordance herewith.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Global Intercompany Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Global Intercompany executed by the &#8220;Payors&#8221; listed on the signature pages thereto for the benefit of the &#8220;Payees&#8221; listed on the signature pages thereto.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the government of the United States, any foreign country or any multinational authority, or any state, commonwealth, protectorate or political subdivision thereof, and any entity, body or authority exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, including the PBGC and other quasi-governmental entities established to perform such functions.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Guarantee Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a Guarantee Agreement, executed and delivered by each Guarantor in favor of the Collateral Agent for the benefit of the Secured Parties, in form and substance satisfactory to the Agents.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Guarantee Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as to any Person, any Contingent Liability of such Person or other obligation of such Person guaranteeing or intended to guarantee any Indebtedness of any other Person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">primary obligor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in any manner, whether directly or indirectly, including any obligation of such Person, whether or not contingent, (a) to purchase any such Indebtedness or any property constituting direct or indirect security therefor, (b) to advance or supply funds (i) for the purchase or payment of any such Indebtedness or (ii) to maintain working capital or equity capital of the primary obligor or otherwise to maintain the net worth or solvency of the primary obligor, (c) to purchase property, securities or services primarily for the purpose of assuring the owner of any such Indebtedness of the ability of the primary obligor to make payment of such Indebtedness or (d) otherwise to assure or hold harmless the owner of such Indebtedness against loss in respect thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the term &#8220;Guarantee Obligations&#8221; shall not include endorsements of instruments for deposit or collection in the ordinary course of business or customary and reasonable indemnity obligations in effect on the Closing Date, entered into in connection with any acquisition or disposition of assets permitted under this Agreement (other than with respect to Indebtedness).  The amount of any Guarantee Obligation shall be deemed to be an amount equal to the stated or determinable amount of the Indebtedness in respect of which such Guarantee Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof (assuming such Person is required to perform thereunder) as determined by such Person in good faith.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Guarantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (a) Parent, (b) each Person that is a Domestic Subsidiary on the Closing Date, and (c) each Person that becomes a party to the Guarantee Agreement after the Closing Date pursuant to Section 8.11, in each case, other than any Excluded Subsidiary.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (a) any petroleum or petroleum products (except when used for refueling motor vehicles in commercially reasonable quantities that would not reasonably be expected to result in a Material Adverse Effect), radioactive materials, friable asbestos, urea formaldehyde foam insulation, transformers or other equipment that contain dielectric fluid containing regulated levels of polychlorinated biphenyls, and radon gas&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;any chemicals, materials or substances defined as or included in the definition of &#8220;hazardous substances,&#8221; &#8220;hazardous waste,&#8221; &#8220;hazardous materials,&#8221; &#8220;extremely hazardous waste,&#8221; &#8220;restricted hazardous waste,&#8221; &#8220;toxic substances,&#8221; &#8220;toxic pollutants,&#8221; &#8220;contaminants,&#8221; or &#8220;pollutants,&#8221; or words of similar import, under any Environmental Law&#59; and (c) any other chemical, material or substance, which is classified, prohibited, limited or regulated by, or forming the basis of liability under, any Environmental Law.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Health Care Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) any and all federal, state and local fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7(b)), the Stark Law (42 U.S.C. &#167; 1395nn), the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.), the administrative False Claims Law (42 U.S.C. &#167; 1320a-7b(a)), the Anti-Inducement Law (42 U.S.C. &#167; 1320a-7a(a)(5)), the exclusion laws (42 U.S.C. &#167; 1320a-7), the civil monetary penalty laws (42 U.S.C. &#167; 1320a-7a), the regulations promulgated pursuant to such statutes and any comparable state laws&#59; (ii) the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167; 1320d et seq.), and the regulations promulgated thereunder and any comparable state laws, (iii) Medicare (Title XVIII of the Social Security Act) and the regulations promulgated thereunder&#59; (iv) Medicaid (Title XIX of the Social Security Act) and the regulations promulgated thereunder&#59; (v) the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. No. 108-173) and the regulations promulgated thereunder&#59; (vi) quality, safety and accreditation standards and requirements of all applicable state laws or Governmental Authorities&#59; (vii) State and Federal Applicable Laws relating to the licensure, ownership or operation of a health care facility, health maintenance organization (HMO), Medicaid managed care organization (MCO), Medicare Advantage organization, provider service network (PSN) or insurance plan, including any assets used in connection therewith, (viii) Applicable Laws relating to the preparation, processing, evaluation or payment of claims, collection of accounts receivable, underwriting the cost of, or provision of management or administrative services in connection with, any and all of the foregoing, by any of Parent, its Subsidiaries or any Licensed Insurance Entity, including, but not limited to, laws and regulations relating to the administration of health  benefit policies, patient or program charges, recordkeeping, referrals, professional fee splitting, certificates of need, certificates of operations and authority, (ix) any and all federal or state laws regulating third-party administrators and pharmacy benefit managers, including those promulgated by state departments of insurance, and (x) any and all other applicable health care laws, rules, codes, statutes, ordinances, regulations, manual provisions, policies and administrative guidance, each of (i) through (x) as may be amended from time to time.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Hedge Termination Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, in respect of any one or more Hedging Obligations, after taking into account the effect of any legally enforceable netting agreement relating to such Hedging Obligations, (a)&#160;for any date on or after the date such Hedging Obligations have been closed out and termination value(s) determined in accordance therewith, such termination value(s) and (b)&#160;for any date prior to the date referenced in clause (a), the amount(s) determined as the mark-to-market value(s) for such Hedging Obligations, as determined based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Hedging Obligations (which may include any Lender or any Affiliate of a Lender).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Hedging Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, any and all obligations of such Person, whether absolute or contingent and howsoever and whensoever created, arising, evidenced or acquired under (a) any and all Hedging Transactions (b) any and all cancellations, buy backs, reversals, terminations or assignments of any Hedging Transactions and (c) any and all renewals, extensions and modifications of any Hedging Transactions and any and all substitutions for any Hedging Transactions.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Hedging Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of any Person shall mean (a) any transaction (including an agreement with respect to any such transaction) permitted under Section 9.11 now existing or hereafter entered into by such Person that is a rate swap transaction, swap option, basis swap, forward rate transaction, commodity swap, commodity option, equity or equity index swap or option, bond option, interest rate option, foreign exchange transaction, cap transaction, floor transaction, collar transaction, currency swap transaction, cross-currency rate swap transaction, currency option, spot transaction, credit protection transaction, credit swap, credit default swap, credit default option, total return swap, credit spread transaction, repurchase transaction, reverse repurchase transaction, buy&#47;sell-back transaction, securities lending transaction, or any other similar transaction (including any option with respect to any of these transactions) or any combination thereof, whether or not any such transaction is governed by or subject to any master agreement and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement or any other master agreement (any such master agreement, together with any related schedules, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Master Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), including any such obligations or liabilities under any Master Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">HIPAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Health Insurance Portability and Accountability Act of 1996, as the same may be amended, modified or supplemented from time to time, any successor statute thereto, any and all rules or regulations promulgated from time to time thereunder, and any comparable state laws.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Historical Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (a) audited consolidated financial statements of Parent for the Fiscal Years ended December 31, 2020 and December 31, 2021, (b) unaudited consolidated financial statements of Parent for the Fiscal Year to date period ended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March&#160;31, 2022 and (c) unaudited consolidated balance sheets and related statements of operations and cash flows of TPG Growth Iceman Parent, Inc. and its subsidiaries for each Fiscal Quarter ended after March 31, 2022 and at least forty-five (45) days prior to the Closing Date. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Holding Company Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;  shall mean any entity formed after the Closing Date and joined as a Guarantor under this Agreement pursuant to the terms of Section 8.11 for the sole purpose of holding the Capital Stock of any Licensed Insurance Entity or joint venture.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Implantable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the preamble to this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as to any Person at a particular time, without duplication, all of the following, whether or not included as indebtedness or liabilities in accordance with GAAP&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_136"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;all indebtedness of such Person for borrowed money and all indebtedness of such Person evidenced by bonds, debentures, notes, loan agreements or other similar instruments&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_139"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the maximum amount (after giving effect to any prior drawings or reductions which may have been reimbursed) available under all letters of credit (including standby and commercial), bankers&#8217; acceptances, bank guaranties, surety bonds, performance bonds and similar instruments issued or created by or for the account of such Person&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_142"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;the Hedge Termination Value of all Hedging Obligations of such Person&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_145"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;all obligations of such Person to pay the deferred purchase price of property or services, including earn-out obligations (including, but not limited to the Existing Earnout) (other than (i) trade accounts payable in the ordinary course of business and (ii) any earn-out obligation (including, but not limited to the Existing Earnout) until such obligation becomes a liability on the balance sheet of such Person in accordance with GAAP)&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_148"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;indebtedness (excluding prepaid interest thereon) secured by a Lien on property owned or being purchased by such Person (including indebtedness arising under conditional sales or other title retention agreements and mortgage, industrial revenue bond, industrial development bond and similar financings), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_151"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;all Attributable Indebtedness&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_154"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;all obligations of such Person in respect of Disqualified Capital Stock&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_157"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;all Guarantee Obligations of such Person in respect of any of the foregoing,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">, that Indebtedness shall not include (i) prepaid or deferred revenue arising in the ordinary course of business, (ii) purchase price holdbacks arising in the ordinary course of business in respect of a portion of the purchase price of an asset to satisfy warranties or other unperformed obligations of the seller of such asset, (iii) endorsements of checks or drafts arising in the ordinary course of business, (iv) trade accounts payable in the ordinary course of business, and (v) preferred Capital Stock to the extent not constituting Disqualified Capital Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The amount of any net Hedging Obligations on any date shall be deemed to be the Hedge Termination Value thereof as of such date.  The amount of Indebtedness of any Person for purposes of clause (e) above shall be deemed to be equal to the lesser of (x) the aggregate unpaid amount of such Indebtedness and (y) the fair market value of the property of such Person encumbered thereby as determined by such Person in good faith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Initial Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the preamble to this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Initial Term Loan Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; shall mean, (a) in the case of each Lender that is a Lender on the date hereof, the amount set forth opposite such Lender&#8217;s name on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 1.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> as such Lender&#8217;s &#8220;Initial Term Loan Commitment&#8221; and (b) in the case of any Lender that becomes a Lender after the date hereof, the amount specified as such Lender&#8217;s &#8220;Initial Term Loan Commitment&#8221; in the Assignment and Acceptance pursuant to which such Lender assumed all or a portion of the Initial Term Loan Commitment, in each case, as the same (x) shall be permanently reduced on the Closing Date upon the Initial Term Loan draw that such Lender funds and (y) may be changed from time to time pursuant to the terms hereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term Loan Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the recitals to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 2.01(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Insolvency Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any proceeding commenced by or against any Person under any provision of the Bankruptcy Code or under any other state or federal bankruptcy or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions, extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Security Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Intercompany Service Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean that certain Intercompany Service Agreement, dated as of January 31, 2018, by and between the Evolent and Evolent Health International Private Limited (formally known as Valence Health Solutions India Private Limited), as amended, restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Intercompany Subordination Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Intercompany Subordination Agreement dated as of the date hereof among the Credit Parties and the Administrative Agent.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, relative to any Person, (a) any loan, advance or extension of credit made by such Person to any other Person, including the purchase by such first Person of any bonds, notes, debentures or other debt securities of any such other Person, (b) Contingent Liabilities in favor of any other Person and (c) any Capital Stock or other investment held by such Person in any other Person.  The amount of any Investment at any time shall be the original principal or capital amount thereof less all returns of principal or equity thereon made on or before such time and shall, if made by the transfer or exchange of property other than cash, be deemed to have been made in an original principal or capital amount equal to the fair market value of such property at the time of such Investment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Junior Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any outstanding Indebtedness of the Parent or any of its Subsidiaries that is (i) secured by a lien that is junior to the lien securing the Obligations, (ii) unsecured or (iii) subordinated in right of payment to the Obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the preamble to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Letter of Direction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean that certain executed letter of direction from Administrative Borrower addressed to Administrative Agent, on behalf of itself and Lenders, directing the disbursement on the Closing Date of the proceeds of the Loans made on such date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Leverage Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.13(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Licensed Insurance Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Subsidiary of any Borrower listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.01(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to this Agreement, any other Subsidiary of any Borrower that operates as a licensed insurance company, is otherwise regulated by a Governmental Authority performing insurance regulatory functions or is a healthcare entity subject to regulatory capital requirements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any mortgage, pledge, security interest, hypothecation, assignment for collateral purposes, lien (statutory or other) or similar encumbrance, and any easement, right-of-way, license, restriction (including zoning restrictions), defect, exception or irregularity in title or similar charge or encumbrance (including any conditional sale or other title retention agreement or any lease in the nature thereof)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that in no event shall an operating lease entered into in the ordinary course of business or any precautionary UCC filings made pursuant thereto by an applicable lessor or lessee, be deemed to be a Lien.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any date of determination, Qualified Cash of the Credit Parties, net of any checks written by any Credit Party, plus Availability, in each case as of such date.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, individually, any Loan made by any Lender hereunder, and collectively, the Loans made by the Lenders hereunder. &#8220;Loan&#8221; shall include the Initial Term Loan and any Revolving Loan, Swingline Advance or Extraordinary Advance made (or to be made) hereunder.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Master Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the definition of the term &#8220;Hedging Transaction.&#8221;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a material adverse effect caused by a material adverse change in (a) the business, assets, properties, liabilities (actual or contingent), operations, financial condition or results of operations of the Parent and its Subsidiaries, taken as a whole, (b) the validity or enforceability of this Agreement or any of the other Credit Documents, (c) the Secured Parties&#8217; ability to enforce their rights or remedies hereunder or under any of the other Credit Documents, or (d) the ability of the Parent and its Subsidiaries, taken as a whole, to perform their payment and other material obligations under the Credit Documents to which they are parties.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Material Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean, as to any Person, (i) each contract or agreement to which such Person or any of its Subsidiaries is a party involving aggregate annual consideration payable to or by such Person or such Subsidiary of $15,000,000 or more, and (ii) all other contracts or agreements, the loss of which could reasonably be expected to result in a Material Adverse Effect.  A reasonably detailed description of each Material Contract is set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.01(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as of the Closing Date. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Material Real Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Real Property that has a fair market value in excess of $4,000,000, as reasonably determined by the Administrative Borrower based on information available to it&#59; provided that, in no event shall the real property located at Broadway and 18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Street in West Louisville, Kentucky constitute Material Real Property.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the date that is the earliest of (a) August 1, 2027, (b) the date on which the Commitments are voluntarily terminated pursuant to the terms hereof, (c) the date on which all amounts outstanding under this Agreement have been declared or have automatically become due and payable (whether by acceleration or otherwise) in accordance with the terms hereof, (d) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, clause (d) of this definition shall not apply if (x) Liquidity (A) at all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">times within the four (4) months prior to the maturity date of such Junior Debt and (B) immediately after giving effect to any such Junior Debt payment at maturity, exceeds the sum of (i) the principal amount of such maturing Junior Debt </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (ii) $67,200,000&#59; provided further that, clause (d) of this definition shall not apply in the event that the 2024 Convertible Notes and&#47;or 2025 Convertible Notes are converted to equity interests in accordance with the terms set forth in the applicable instrument prior to the date that is ninety-one (91) days prior to the maturity date of such Convertible Senior Note.  If such date is not a Business Day, the immediately succeeding Business Day.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Maturity Test Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Maximum Revolver Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means $50,000,000, decreased by the amount of reductions in the Revolver Commitments made in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Minimum Revolver Borrowing Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean $200,000.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Minimum Revolver Interest Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 2.08(a).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Monitored Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the definition of &#8220;Excluded Account&#8221;.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Moody&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Moody&#8217;s Investors Service, Inc. or any successor by merger or consolidation to its business.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Mortgage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a mortgage or a deed of trust, deed to secure debt, trust deed or other security document entered into by any applicable Credit Party and the Administrative Agent for the benefit of the Secured Parties in respect of any Real Property owned by such Credit Party, in such form as agreed between such Credit Party and the Administrative Agent, as amended, restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Mortgaged Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each parcel of Real Property and improvements thereto with respect to which a Mortgage is granted pursuant to Section 8.11(d).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Multiemployer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a &#8220;multiemployer plan&#8221; within the meaning of Section 3(37) of ERISA to which any Credit Party or any ERISA Affiliate makes, is making, is obligated, or within the last six (6) years has been obligated, to make contributions, or with respect to which any Credit Party has any liability, actual or contingent.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (a) in respect of a Disposition or Casualty Event, cash proceeds as and when received by the Person making a Disposition, as well as insurance proceeds and condemnation and similar awards received on account of a Casualty Event, net of&#58;  (i) in the event of a Disposition (w) the direct costs and expenses relating to such Disposition, (x) sales, use or other transaction Taxes actually paid, assessed or estimated by such Person (in good faith) to be payable in cash within the next twelve (12) months in connection with such proceeds </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if, after the expiration of the twelve (12) month period, the amount of estimated or assessed Taxes, if any, exceeded the Taxes actually paid in cash in respect of proceeds from such Disposition, the aggregate amount of such excess shall constitute Net Proceeds under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, be immediately applied to the prepayment of the Obligations in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (y) amounts required to be applied to pay principal, interest and prepayment premiums and penalties on Indebtedness (other than the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Obligations) secured by a Lien on the asset which is the subject of such Disposition and (z) with respect to a Disposition, any escrow or reserve for any indemnification payments (fixed or contingent) attributable to seller&#8217;s indemnities and representations and warranties to purchaser in respect of the applicable Disposition undertaken by any Credit Party or other liabilities in connection with such Disposition (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that upon release of any such escrow or reserve, the amount released shall be considered Net Proceeds) and (ii) in the event of a Casualty Event, (x) all money actually applied to repair or reconstruct the damaged property affected thereby or otherwise reinvested in replacement property in accordance with this Agreement, (y) all of the costs and expenses reasonably incurred in connection with the collection of such proceeds, award or other payments, and (z) any amounts retained by or paid to parties having superior rights to such proceeds, awards or other payments and (b) in respect of any incurrence of Indebtedness, cash proceeds, net of underwriting discounts and out-of-pocket costs and expenses paid or incurred in connection therewith in favor of any Person not an Affiliate of a Borrower in respect of any incurrence of Indebtedness, cash proceeds, net of underwriting discounts and reasonable out-of-pocket costs and expenses paid or incurred in connection therewith in favor of any Person not an Affiliate of a Borrower.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Non-Consenting Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 12.07(b).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Non-Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.04(a).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Non-U.S. Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 5.04(b).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as the context may require, a Revolver Note or a Term Loan Note.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Notice of Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 2.02(a).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Notice of Conversion or Continuation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 2.06.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean all Loans, advances, debts, liabilities, obligations, covenants and duties owing by any Credit Party to any Lender, Agent, or any other Person required to be indemnified hereunder, in each case, that arise under any Credit Document, whether or not for the payment of money, whether arising by reason of an extension of credit, loan, guaranty, indemnification or in any other manner, whether direct or indirect (including those acquired by assignment), absolute or contingent, due or to become due, now existing or hereafter arising and however acquired, including all fees, expenses and other amounts accruing during the pendency of any proceeding of the type described in Section 10.01(h), whether or not allowed in such proceeding.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 7.26.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Organization Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean&#58; (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction)&#59; (b) with respect to any limited liability company, the certificate or articles of formation or organization and operating agreement&#59; and (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and, if applicable, any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable Governmental Authority in the jurisdiction </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Connection Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any recipient, Taxes imposed as a result of a present or former connection between such recipient and the jurisdiction imposing such Tax (other than connections arising from such recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan, or sold or assigned an interest in any Loan).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any and all present or future stamp, court, documentary, intangible recording, filing or similar Taxes or any other excise or property Taxes, charges or similar levies (but excluding any Tax, charge or levy that constitutes an Excluded Tax) arising from any payment made hereunder or from the execution, delivery or enforcement of, from the receipt or perfection of a security interest under, or otherwise with respect to, this Agreement, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 12.07).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Overadvance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination, that the Revolver Usage is greater than any of the limitations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the recitals to this Agreement.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.06(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">12.06(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Patriot Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PBGC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Pension Benefit Guaranty Corporation established pursuant to Section 4002 of ERISA, or any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Pension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any single-employer plan, as defined in Section 4001(a)(15) of ERISA, and subject to Title IV of ERISA, Section 412 of the Code or Sections 302 or 303 of ERISA, that is or was within any of the preceding six plan years sponsored, maintained or contributed to (or to which there is or was an obligation to contribute) by any Credit Party or any ERISA Affiliate thereof, or respect of which any Credit Party or any ERISA Affiliate thereof otherwise has any obligation or liability, contingent or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a certificate in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit P-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, any permit, approval, clearance, authorization, enrollment, license, registration, certificate, concession, grant, franchise, variance or permission from, and any other contractual obligations with, any Governmental Authority, in each case, whether or not having the force of law and applicable to or binding upon such Person or any of its property or Products or to which such Person or any of its property or Products is subject.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Permitted Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any acquisition by a Credit Party or a Subsidiary of (i) all or substantially all of the assets of a target, which assets are located in the United States or (ii) one hundred percent (100%) of the Capital Stock of a target organized under the laws of any State in the United States or the District of Columbia, in each case, to the extent that each of the following conditions shall have been satisfied&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_160"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Parent and its Subsidiaries (including any new Subsidiary) shall execute and deliver the agreements, instruments and other documents required by Section 8.11&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, the Parent and its Subsidiaries may acquire Persons that do not become Credit Parties and assets that do not become Collateral after the Closing Date in an amount not to exceed a total consideration of $35,000,000&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_163"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;such acquisition shall not be hostile and shall have been approved by the board of directors (or other similar body) and&#47;or the stockholders or other equityholders of the target&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_166"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;no Event of Default shall then exist or would exist after giving effect thereto&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_169"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Parent and its Subsidiaries shall be in pro forma compliance with the covenants set forth in Section 9.12 and 9.13&#59;  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_172"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;the total consideration paid or payable for Permitted Acquisitions shall be funded solely with (x) net proceeds from an issuance of Qualified Capital Stock or cash on hand and from operations, (y) proceeds from the Revolving Facility and (z) net proceeds from the issuance of Additional Notes&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_175"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;the total consideration for the Acquisition set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.01(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not exceed $150,000,000 in the aggregate&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_178"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;the total consideration paid with respect to target Persons with pro forma Target Consolidated Adjusted EBITDA that is less than $0 shall not exceed $20,000,000 in the aggregate after the Closing Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">clause (g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not apply to the Acquisition set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.01(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_181"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing and the definition of Borrowing Base, no Accounts acquired in an Acquisition permitted hereunder shall be included in the Borrowing Base unless Revolver Agent, in its Permitted Discretion, determines that such Accounts conform to standards of eligibility established in accordance with this Agreement through completion of such audits, evaluations and appraisals thereof as Revolver Agent shall require (which appraisals, evaluations and audits shall be conducted at the expense of the Borrowers, jointly and severally, and in form, scope and substance acceptable to Revolver Agent in its Permitted Discretion).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_184"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Permitted Discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a determination made in the exercise of reasonable (from the perspective of a secured asset-based lender) business judgment.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_187"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Permitted Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean TPG Growth II Advisors, Inc., TPG Growth II BDH, L.P. and TPG Eagle Holdings L.P. and each of their Affiliates and any funds or partnerships </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">managed by any of them (but not including any portfolio companies or operating companies of any of the foregoing, notwithstanding the form of ownership of any such portfolio or operating companies), The Advisory Board Company and University of Pittsburgh Medical Center.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 9.02.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Permitted Refinancing Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Indebtedness issued or incurred (including by means of the extension or renewal of existing Indebtedness) to refinance, refund, extend, renew or replace existing Indebtedness of any Credit Party or any of its Subsidiaries permitted hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Refinanced Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the original principal amount of such refinancing, refunding, extending, renewing or replacing Indebtedness does not exceed the principal amount of such Refinanced Indebtedness </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the amount of any interest, premiums or penalties required to be paid thereon plus fees and expenses associated therewith.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any individual, partnership, joint venture, firm, corporation, limited liability company, association, trust or other enterprise or any Governmental Authority.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a Pension Plan or a Multiemployer Plan.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_190"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prepayment Premium</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the following amounts (expressed as a percentage of the principal amount of the Term Loans being prepaid or repaid or Revolver Commitments being reduced or terminated)&#58;</font></div><div style="padding-left:93pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.256%"><tr><td style="width:1.0%"></td><td style="width:49.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:0.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Time Period</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Prepayment Premium</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"><br></font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">After the Closing Date, but on or prior to the first anniversary of the Closing Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">3.0%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">After the first  anniversary, but on or prior to the second anniversary of the Closing Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">2.0%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">After the second anniversary, but prior to the third anniversary of the Closing Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.0%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">On or after the third anniversary of the Closing Date</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">0.0%</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prepayment Premium Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Primary Obligor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the definition of &#8220;Guarantee Obligations.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Prime Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a variable per annum rate, as of any date of determination, equal to the rate as of such date published in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as being the &#8220;Prime Rate&#8221; (or, if more than one rate is published as the Prime Rate, then the highest of such rates).  The Prime Rate will change as of the date of publication in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of a Prime Rate that is different from that published on the preceding Business Day.  In the event that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall, for any reason, fail or cease to publish the Prime Rate, the Administrative Agent shall choose a reasonably comparable index or source to use as the basis for the Prime Rate.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Privacy and Security Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 7.31(i).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any item or any service that is researched or developed, created, tested, packaged, labeled, distributed, manufactured, managed, performed, or otherwise used, offered, marketed, sold, or handled by or on behalf of the Credit Parties or any of their Subsidiaries, whether marketed or in development.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Pro Forma Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, for purposes of calculating the Total Secured Leverage Ratio&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_193"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Investments, acquisitions, mergers, consolidations and dispositions of any Subsidiary, line of business or division, that have been made by the specified Person or any of its Subsidiaries, or any Person or any of its Subsidiaries acquired by, merged or consolidated with the specified Person or any of its Subsidiaries, and including any related financing transactions and incurrences of Indebtedness, and including increases in ownership of Subsidiaries, during the applicable reference period or subsequent to such reference period and on or prior to the date of determination will be given pro forma effect, as if they had occurred on the first day of the applicable reference period&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_196"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any Person that is a Subsidiary on the date of determination will be deemed to have been a Subsidiary at all times during such reference period&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_199"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;any Person that is not a Subsidiary on the date of determination will be deemed not to have been a Subsidiary at any time during such reference period&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this definition, whenever pro forma effect is given to a transaction, the pro forma calculations shall be made in good faith by an Authorized Officer of the Administrative Borrower and shall be reasonably satisfactory to the Agents.  Any such pro forma calculation may include adjustments appropriate, in the good faith determination of the Administrative Borrower as set forth in an officers&#8217; certificate, to reflect operating expense reductions (but not revenue increases) expected to result from the applicable pro forma event if such adjustments are reasonably satisfactory to the Agents. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (a) with respect to the Initial Term Loan Commitment of any Lender at any time, a percentage, the numerator of which shall be the sum of such Lender&#8217;s unfunded Initial Term Loan Commitment, plus such Lender&#8217;s funded Initial Term Loans, and the denominator of which shall be the sum of the unused Initial Term Loan Commitments of all Lenders, plus all funded Initial Term Loans of all Lenders or (b) with respect to the Revolver  Commitment of any Lender at any time, a percentage, the numerator of be the sum of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Lender&#8217;s unfunded Revolver Commitment, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> such Lender&#8217;s funded Revolving Loan, and the denominator of which shall be the sum of the Revolver Commitment of all Lenders, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> all funded Revolving Loans of all Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Protective Advances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning specified therefor in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Purchase Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Purchase Option Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Purchase Option Trigger Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (a) an Event of Default has occurred and is continuing or (b) the Obligations have been accelerated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;10.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Qualified Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Capital Stock that is not Disqualified Capital Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Qualified Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any date of determination, the amount of unrestricted cash and Cash Equivalents of the Credit Parties that are in deposit accounts or in securities accounts, or any combination thereof, which deposit accounts and securities accounts are the subject of Springing Control Agreements and are maintained by a branch office of the applicable bank or securities intermediary located within the United States of America&#59; provided, that, for the first sixty (60) days (or such longer period as reasonably agreed to by the Administrative Agent) following the Closing Date there shall be no requirement that cash and Cash Equivalents of the Credit Parties be held in accounts subject to Springing Control Agreements in order for such cash and Cash Equivalents to be Qualified Cash.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Real Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, all right, title and interest of such Person (including, without limitation, any leasehold estate) in and to a parcel of real property owned, leased or operated by such Person together with, in each case, all improvements and appurtenant fixtures, equipment, personal property, easements and other property and rights incidental to the ownership, lease or operation thereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Refinanced Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the definition of &#8220;Permitted Refinancing Indebtedness.&#8221;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 12.06(b)(iv).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, activities that are subject to Health Care Laws.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Regulation D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Regulation D of the Board as from time to time in effect and any successor to all or a portion thereof establishing reserve requirements.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Regulation U</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Regulation U of the Board as from time to time in effect and any successor to all or a portion thereof establishing margin requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Regulation X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Regulation X of the Board as from time to time in effect and any successor to all or a portion thereof establishing margin requirements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Rejection Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any specified Person, such Person&#8217;s Affiliates and the directors, officers, employees, agents, trustees, advisors of such Person and any Person that possesses, directly or indirectly, the power to direct or cause the direction of the management or policies of such Person, whether through the ability to exercise voting power, by contract or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a &#8220;release,&#8221; as such term has the meaning set forth in CERCLA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Reportable Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an event described in Section 4043 of ERISA and the regulations thereunder (excluding any such event for which the notice requirement has been waived by the PBGC).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Required Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, at any date, Lenders having or holding a majority of the sum of (a) the outstanding principal amount of the Term Loans and (b) (i) the Revolver Commitment or (ii) if the Revolver Commitment has been terminated, the aggregate outstanding principal amount of the Revolving Loans&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Revolver Commitment of, and the portion of the outstanding principal amount of the Revolving Loans and the Term Loans held or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Required Revolving Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, at any date, Lenders having or holding a majority of (a) the Revolver Commitment or (b) if the Revolver Commitment has been terminated, the aggregate outstanding principal amount of the Revolving Loans&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Revolver Commitment of, and the portion of the outstanding principal amount of the Revolving  Loans held or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Revolving Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Required Term Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, at any date, the Lenders having or holding a majority of the outstanding principal amount of the Term Loans, any Defaulting Lender shall be excluded for purposes of making a determination of Required Term Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Restricted Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, (a) the declaration or payment of any dividend on, or the making of any payment or distribution on account of, or setting apart assets for a sinking or other analogous fund for the purchase, redemption, defeasance, retirement or other acquisition of, any class of Capital Stock of such Person or any warrants or options to purchase any such Capital Stock, whether now or hereafter outstanding, or the making of any other distribution in respect thereof, either directly or indirectly, whether in cash or property (it being understood, for the avoidance of doubt, that payments in the form of Capital Stock pursuant to an employee benefit plan shall not constitute Restricted Payments), (b) the payment or prepayment of principal of, or premium or interest or any other amount in respect of, any Indebtedness that is contractually subordinate to the Obligations unless such payment is permitted under the terms of the subordination agreement applicable thereto, (c) any payment in respect of earn-out obligations and (d) any payment or prepayment of principal of, or premium or interest in respect of the Convertible Senior Notes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolver Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to each Revolving Lender, its Revolver Commitment, and, with respect to all Revolving Lenders, their Revolver Commitments, in each case as such Dollar amounts are set forth beside such Revolving Lender&#8217;s name under the applicable heading on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or in the Assignment and Acceptance pursuant to which such Revolving Lender became a Revolving Lender hereunder, as such amounts may be reduced or increased from time to time pursuant to this Agreement and&#47;or assignments made in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolver Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the promissory note substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit R-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolver Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any date of determination, the amount of outstanding Revolving Loans (inclusive of Extraordinary Advances and Swingline Advances).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean ACF.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Agent&#8217;s Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Deposit Account of Revolver Agent identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (or such other Deposit Account of Revolver Agent that has been designated as such, in writing, by Revolver Agent to Administrative Borrower and the Lenders).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.06(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Creditors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.06(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, at any time, the aggregate amount of the Revolving Lenders&#8217; Revolver Commitments at such time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a Lender that has a Revolver Commitment, has an outstanding Revolving Loan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Loan Exposure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Revolving Lender, as of any date of determination (a) prior to the termination of the Revolver Commitments, the amount of such Lender&#8217;s Revolver Commitment, and (b) after the termination of the Revolver Commitments, the aggregate outstanding principal amount of the Revolving Loans (inclusive of Extraordinary Advances and Swingline Advances).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning specified therefor in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Revolving Loans shall include Extraordinary Advances and Swingline Advances, unless the context clearly requires otherwise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sanctioned Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (a) a country or a government of a country, (b) an agency of the government of a country, (c) an organization directly or indirectly controlled by a country or its government, (d) a Person resident in or determined to be resident in a country, in each case, that is subject to a country sanctions program administered and enforced by OFAC.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sanctioned Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a person named on the list of Specially Designated Nationals maintained by OFAC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall have the meaning set forth in Section 7.26.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Securities and Exchange Commission. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">S&#38;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Standard &#38; Poor&#8217;s Ratings Services or any successor by merger or consolidation to its business.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Secured Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, (a) the Lenders, (b) the Agents, (c) the beneficiaries of each indemnification obligation undertaken by any Credit Party under the Credit Documents and (d)&#160;any successors, endorsees, transferees and permitted assigns of each of the foregoing.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Securitization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 12.08.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a Security Agreement, by and among each Credit Party and the Collateral Agent for the benefit of the Secured Parties, in form and substance reasonably satisfactory to the Collateral Agent, as amended, restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Security Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, the Security Agreement, any Mortgage and each other security agreement or other instrument or document executed and delivered pursuant to Section 8.11 or pursuant to any of the Security Documents to secure any of the Obligations.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Settlement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Section 2.02(d)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Significant Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a Subsidiary of any Borrower that meets the definition of &#8220;significant subsidiary&#8221; in Article 1, Rule 1-02 of Regulation S-X under the Exchange Act.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a rate equal to the secured overnight financing rate as administered by the SOFR Administrator. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SOFR Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Solvency Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a solvency certificate dated as of the Closing Date, duly executed and delivered by an Authorized Officer of the Administrative Borrower to the Administrative Agent, in form and substance reasonably satisfactory to the Agents.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Solvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, at any date, that (a) the sum of such Person&#8217;s debt (including Contingent Liabilities) does not exceed the present fair saleable value of such Person&#8217;s present assets, (b) such Person&#8217;s capital is not unreasonably small in relation to its business as contemplated on such date, (c) such Person has not incurred and does not intend to incur debts including current obligations beyond its ability to pay such debts as they become due (whether at maturity or otherwise) and (d) such Person is &#8220;solvent&#8221; within the meaning given that term and similar terms under Applicable Laws relating to fraudulent transfers and conveyances.  For purposes of this definition, the amount of any Contingent Liability at any time shall be computed as the amount that, in light of all of the facts and circumstances existing at such time, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">represents the amount that can reasonably be expected to become an actual or matured liability (irrespective of whether such contingent liabilities meet the criteria for accrual under Statement of Financial Accounting Standard No. 5).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Specified Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Section 7.01(a), 7.02, 7.03(iii), 7.05, 7.07, 7.17, 7.26, and 7.27.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Springing Control Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Deposit Account that is subject to a Springing Control Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Springing Control Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an agreement in which a Credit Party, Collateral Agent, and Cash Management Bank maintaining the Deposit Account have agreed that the Cash Management Bank will comply with instructions originated by the Collateral Agent directing disposition of the funds in the Deposit Account without further consent by the Credit Party pursuant to terms reasonably satisfactory to the Collateral Agent and the Administrative Borrower.  Terms of the agreement shall provide control (within the meaning of Section 9-104 of the UCC) reasonably satisfactory to Collateral Agent.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Statutory Reserve Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, for any day as applied to any Term SOFR Loan, a fraction (expressed as a decimal), the numerator of which is the number one and the denominator of which is the number one minus the aggregate of the maximum reserve percentages that are in effect on that day (including any marginal, special, emergency or supplemental reserves), expressed as a decimal, as prescribed by the Board and to which the Administrative Agent is subject, for Eurocurrency funding (currently referred to as &#8220;Eurocurrency Liabilities&#8221; in Regulation D).  Such reserve percentages shall include those imposed pursuant to such Regulation D.  Term SOFR Loans shall be deemed to constitute Eurocurrency funding and to be subject to such reserve requirements without benefit of or credit for proration, exemptions or offsets that may be available from time to time to any Lender under such Regulation D or any comparable regulation.  The Statutory Reserve Rate shall be adjusted automatically on and as of the effective date of any change in any reserve percentage.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of any Person shall mean and include (a) any corporation more than fifty percent (50%) of whose Voting Stock having by the terms thereof power to elect a majority of the directors of such corporation (irrespective of whether or not at the time stock of any class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time owned by such Person, directly or indirectly, through Subsidiaries and (b) any partnership, association, joint venture or other entity in which such Person, directly or indirectly, through Subsidiaries, has more than a fifty percent (50%) voting equity interest at the time.  Unless otherwise expressly provided, all references herein to a &#8220;Subsidiary&#8221; shall mean a Subsidiary of a Credit Party.  Notwithstanding the foregoing, solely to the extent the Securities Exchange Commission has permitted the Parent to treat Justify Holdings, Inc. as being an unconsolidated entity, then for the purposes of the definition of &#8220;Consolidated Adjusted EBITDA,&#8221; &#8220;Consolidated Net Income,&#8221; &#8220;Consolidated Secured Debt,&#8221; &#8220;Funded Debt&#8221; and Section 8.01(a)-(c), Section 8.01(f) and Section 9.13 Justify Holdings, Inc. shall not be considered a &#8220;Subsidiary.&#8221;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Swingline Advance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;  has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Swingline Loan Limit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, at any time, the smaller of the following amounts&#58; (i) $10,000,000, (ii) the aggregate Revolver Commitment minus the Revolver Usage and (iii) the Borrowing Base, minus the amount of Revolving Loans outstanding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Target Consolidated Adjusted EBITDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, for any specified trailing 12 month period, an amount determined for any Person equal to (a) the consolidated net income (or deficit) of such Person in accordance with GAAP after eliminating all extraordinary nonrecurring items of income, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (b)&#160;without duplication and to the extent deducted in arriving at the consolidated net income of such Person, the sum of, without duplication, amounts for (i)&#160;total interest expense, (ii)&#160;provisions for Taxes based on income, (iii)&#160;total depreciation expense, (iv)&#160;total amortization expense, and (v)&#160;any other non-cash charges and expenses deducted in arriving at the consolidated net income of such Person (excluding any such non-cash item to the extent that it represents an accrual or reserve for potential cash items in any future period or amortization of an item that was paid in a prior period), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (c)&#160;without duplication and to the extent included in arriving at the consolidated net income of such Person, amounts for non-cash gains (excluding any such non-cash item to the extent it represents the reversal of an accrual or reserve for potential cash items in any prior period).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean all income, stamp or other taxes, duties, levies, imposts, charges, assessments, fees, deductions or withholdings, now or hereafter imposed, enacted, levied, collected, withheld or assessed by any Governmental Authority, and all interest, penalties, additions to tax or similar liabilities with respect thereto.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each Lender that holds an Initial Term Loan Commitment or a Term Loan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Initial Term Loan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term Creditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.06(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term Loan Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a promissory note substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;T-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term Loan Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.06(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;for any calculation with respect to a Term SOFR Loan, the Term SOFR Reference Rate for a tenor of ninety (90) days on the day (such day, the &#8220;Periodic Term SOFR Determination Day&#8221;) that is two (2) U.S. Government Securities Business Days prior to the first day of the applicable calendar quarter, as such rate is published by the Term SOFR Administrator&#59; provided, however, that (x) if as of 5&#58;00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Securities Business Days prior to such Periodic Term SOFR Determination Day and (y) with respect to any Borrowing of Term SOFR Loans on or before September 30, 2022, the Periodic Term SOFR Determination Day shall be July 28, 2022, and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;for any calculation with respect to an ABR Loan on any day, the Term SOFR Reference Rate for a tenor of ninety (90) days on the day (such day, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Base Rate Term SOFR Determination Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that is two (2) U.S. Government Securities Business Days prior to such day, as such rate is published by the Term SOFR Administrator&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, however, that if as of 5&#58;00 p.m. (New York City time) on any Base Rate Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such Base Rate Term SOFR Determination Day.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term SOFR Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a percentage equal to 0.15% per annum.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term SOFR Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Agents in their reasonable discretion).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term SOFR Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each Loan bearing interest at Adjusted Term SOFR Rate, as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.08(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Error! Reference source not found.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term SOFR Reference Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the forward-looking term rate based on SOFR.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Test Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, for any date of determination under this Agreement, the four (4) consecutive Fiscal Quarters of any Borrower most recently ended as of such date of determination.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Total Secured Leverage Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as of the last day of any Test Period, the ratio of (a) Consolidated Secured Debt as of such date to (b) Consolidated Adjusted EBITDA for such Test Period.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the recitals to this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the acquisition by Evolent of substantially all the assets of TPG Growth Iceman Parent, Inc. and each of its subsidiaries.   </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG Acquisition Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Agreement and Plan of Merger dated as of June 24, 2022, by and between Parent, Evolent, Endzone, TPG and TPG Growth V Iceman, L.P..</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG Business Segment&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the business of the TPG Entities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean TPG, TPG Growth Iceman Intermediate, Inc., a Delaware corporation, Implantable and Surgical Collections Group, Inc., a Delaware corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean that certain Income Tax Receivables Agreement, dated as of June 4, 2015, by and among Parent, Evolent, TPG Eagle Holdings, L.P., Ptolemy Capital, LLC, The Advisory Board Company, UPMC, TPG Growth II BDH, L.P., Premier Health Partners, Oxeon Partners, LLC and Medstar Health, Inc., as amended, restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each of the documents executed and&#47;or delivered in connection with the Transactions, including, without limitation, the Credit Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, the transactions contemplated by the Credit Documents, including the TPG Acquisition and the transactions contemplated by the TPG Acquisition Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Transactions Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 7.31(i).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Treasury Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean as of any prepayment date, shall mean the yield to maturity at the time of computation of United States Treasury Securities with a constant maturity (as compiled and published in the most recent Federal Reserve Statistical Release H.15 (519), which has become publicly available at least (2) two Business Days prior such prepayment (or, if such Statistical Release is no longer published, any publicly available source or similar market data) most nearly equal to the period from such prepayment date to the second anniversary of the Closing Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if the period from such prepayment date to the second anniversary of the Closing Date, the Treasury Rate shall be obtained by linear interpolation (calculated to the nearest one twelfth of a year) from the weekly average yields of United States Treasury Securities for which such yields are given.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the definition &#8220;2024 Convertible Notes.&#8221;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Type</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as to any Loan, its nature as an ABR Loan or Term SOFR Loan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Uniform Commercial Code as from time to time in effect in the State of New York.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Unadjusted Benchmark Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Unasserted Contingent Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning given to such term in the Security Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Unfunded Current Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of any Pension Plan shall mean the amount, if any, by which the present value of all accumulated benefit obligations under such Pension Plan as of the close of its most recent plan year, determined in accordance with FASB Accounting Standards Codification 715&#58; Compensation - Retirement Benefits, as in effect on the date hereof, exceeds the fair market value of the assets of such Pension Plan allocable to such accrued benefits.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Unused Line Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning specified therefor in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the United States of America.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">U.S. Government Securities Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Vital Business Segment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the business of MTS III Vital Decisions Blocker Corp., a Delaware corporation, Vital Decisions Acquisition LLC, a Delaware limited liability company, and Vital Decisions, LLC, a New Jersey limited liability company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Voting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, shares of such Person&#8217;s Capital Stock having the right to vote for the election of directors (or Persons acting in a comparable capacity) of such Person under ordinary circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Waterfall Trigger Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (w) an Event of Default under (i) Section 10.01(a) (payment default)&#59; (ii) Section 10.01(c) or (d) arising from the failure of any Borrower or any other Credit Party to observe or perform any obligation under any of Section 8.01(a) (liquidity certificate), 8.01(b) (delivery of quarterly financials) or 8.01(c) (annual financials) (solely to the extent such financial statements are not delivered to the Administrative Agent for delivery to each Lender within 30 days following the date such financial statements were required to be delivered pursuant to Section 8.01(a), Section 8.01(b) or Section 8.01(c), as applicable), Section 8.10 (use of proceeds) (solely as it relates to the use of proceeds of the Revolving Facility), Section 8.17 (Borrowing Base and Financial Statement Reporting), Section 9.01 (indebtedness), Section 9.02 (liens), Section 9.04 (dispositions), Section 9.05 (investments), Section 9.06 (restricted payments), or Section 9.12 (conduct of business)&#59; (iii) Section 10.01(f) (judgment default)&#59; (iv) Section 10.01(h) (insolvency proceedings, dissolution or liquidation)&#59; (v) Section 10.01(i) (liens)&#59; or (vi) Section 10.01(j) (change of control), (x) solely to the extent Required Lenders exercise rights under any Springing Control Agreement in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.14(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Cash Dominion Event, (y) solely to the extent that such amendment, modification or waiver is prohibited by Section 12.01(vi) without the consent of the Required Revolving Lenders, the amendment, modification or waiver of any of the provisions set forth in the immediately preceding clause (x) without the consent of the Required Revolving Lenders to such amendment, modification or waiver or (z) notice of any prepayment made pursuant to Section 5.02(a) from the Net Proceeds of any Disposition set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.01(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (it being understood that a Waterfall Trigger Event occurring pursuant to this clause (z) shall continue until such time the foregoing payment is completed). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Write-Down and Conversion Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_202"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 1.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Interpretive Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With reference to this Agreement and each other Credit Document, unless otherwise specified herein or in such other Credit Document&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_205"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The meanings of defined terms are equally applicable to the singular and plural forms of the defined terms.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_208"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The words &#8220;herein,&#8221; &#8220;hereto,&#8221; &#8220;hereof&#8221; and &#8220;hereunder&#8221; and words of similar import when used in any Credit Document shall refer to such Credit Document as a whole and not to any particular provision thereof.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_211"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Article, Section, Exhibit and Schedule references are to the Credit Document in which such reference appears.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_214"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The term &#8220;including&#8221; is by way of example and not limitation.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_217"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The term &#8220;documents&#8221; includes any and all instruments, documents, agreements, certificates, notices, reports, financial statements and other writings, however evidenced, whether in physical or electronic form.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_220"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;In the computation of periods of time from a specified date to a later specified date, the word &#8220;from&#8221; means &#8220;from and including&#8221;&#59; the words &#8220;to&#8221; and &#8220;until&#8221; each mean &#8220;to but excluding&#8221;&#59; and the word &#8220;through&#8221; means &#8220;to and including.&#8221;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_223"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Section headings herein and in the other Credit Documents are included for convenience of reference only and shall not affect the interpretation of this Agreement or any other Credit Document.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_226"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting Terms and Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with, GAAP, applied in a manner consistent with that used in preparing the Historical Financial Statements set forth in clause (a) of such definition, except as otherwise specifically prescribed herein. Notwithstanding any other provision contained herein, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to in Article IX shall be made, without giving effect to any election under  Accounting Standards Codification 825-10 or 470-20 (or any other Financial Accounting Standard having a similar result or effect) to value any Indebtedness or other liabilities of any Credit Party or any Subsidiary of any Credit Party at &#8220;fair value.&#8221; A breach of any Financial Performance Covenant shall be deemed to have occurred as of the last day of the relevant specified measurement period, regardless of when the financial statements reflecting such breach are delivered to the Administrative Agent.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_229"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rounding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any financial ratios required to be maintained or complied with by any Borrower pursuant to this Agreement (or required to be satisfied in order for a specific action to be permitted under this Agreement) shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest number).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_232"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">References to Agreements, Laws, etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Unless otherwise expressly provided herein, (a) references to Organization Documents, agreements (including the Credit Documents) and other Material Contracts shall be deemed to include all subsequent amendments, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">restatements, amendment and restatements, extensions, supplements and other modifications thereto, but only to the extent that such amendments, restatements, amendment and restatements, extensions, supplements and other modifications are permitted by any Credit Document&#59; and (b) references to any Applicable Law shall include all statutory and regulatory provisions consolidating, amending, replacing, supplementing or interpreting such Applicable Law.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_235"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.06&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Times of Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise specified, all references herein to times of day shall be references to Eastern time (daylight or standard, as applicable).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_238"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.07&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Timing of Payment of Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  When the payment of any obligation or the performance of any covenant, duty or obligation is stated to be due or performance required on a day which is not a Business Day, the date of such payment or performance shall extend to the immediately succeeding Business Day.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_241"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.08&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Terminology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any reference to officers, shareholders, stock, shares, directors, boards of directors, corporate authority, articles of incorporation, bylaws or any other such references to matters relating to a corporation made herein or in any other Credit Document with respect to a Person that is not a corporation shall mean and be references to the comparable terms used with respect to such Person.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_244"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.09&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">UCC Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  When used in this Agreement, the following terms have the same definitions as provided in Article 9 of the UCC, but for convenience in this Agreement the first letter of all such terms shall be capitalized&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accession,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Account,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Account Debtor,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Authenticate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (and all derivations thereof)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Certificate Of Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Chattel Paper,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Commercial Tort Claim,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Deposit Account,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Document,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Equipment,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">General Intangible,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Goods,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Health-Care-Insurance Receivable,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Instrument,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Inventory,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Investment Property,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Letter-Of-Credit Right,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Obligor,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (as specifically defined in Section 9-102(64) of the UCC)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Record,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Secondary Obligor,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Secured Party,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Software</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Supporting Obligation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_247"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Divisions&#59; Series</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For all purposes under the Credit Documents, if, in connection with any division or plan of division with respect to a limited liability company under Delaware law (or any comparable event under a different jurisdiction&#8217;s laws) or an allocation of assets to a series of a limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under Delaware law (or any comparable event under a different jurisdiction&#8217;s laws), (a) any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then such transaction shall constitute a &#8220;transfer&#8221; (as used in the definition of &#8220;Disposition&#8221; contained herein) from the original Person to the subsequent Person, and (b) any new Person comes into existence, such new Person shall be deemed to have been organized by the holders of its Capital Stock on the first date of its existence.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_250"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Administrative Agent does not warrant or accept responsibility for, and shall not have any liability with respect to (a) the continuation of, administration of, submission of, calculation of or any other matter related to the Prime Rate, the Term SOFR Reference Rate, Adjusted Term SOFR Rate or Term SOFR, or any component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">composition or characteristics of any such alternative, successor or replacement rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, the Prime Rate, the Term SOFR Reference Rate, Adjusted Term SOFR Rate, Term SOFR or any other Benchmark prior to its discontinuance or unavailability, or (b) the effect, implementation or composition of any Conforming Changes.  The Administrative Agent and its affiliates or other related entities may engage in transactions that affect the calculation of the Prime Rate, the Term SOFR Reference Rate, Term SOFR, Adjusted Term SOFR Rate, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to any Borrower.  The Administrative Agent may select information sources or services in its reasonable discretion to ascertain the Prime Rate, the Term SOFR Reference Rate, Term SOFR, Adjusted Term SOFR or any other Benchmark, in each case pursuant to the terms of this Agreement, and shall have no liability to any Borrower, any Lender or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_253"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><br>Amount and Terms of Credit Facilities</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_256"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_259"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to and upon the terms and conditions herein set forth&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_262"></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x) Each Term Lender having an Initial Term Loan Commitment agrees (severally, not jointly or jointly and severally) to make a term loan (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the Initial Borrower on the Closing Date in the amount of the Initial Term Loan Commitment of such Lender.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_265"></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(y) Each Revolving Lender agrees (severally, not jointly or jointly and severally) to make revolving loans (all such loans, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the Borrowers under a revolving credit facility in an amount at any one time outstanding (on an aggregate basis) not to exceed&#58; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_268"></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;on the Closing Date, an amount equal to the Maximum Revolver Amount, </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_271"></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;any time after the Closing Date, the lesser of&#58; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_274"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;an amount equal to such Revolving Lender&#8217;s Revolver Commitment, and </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_277"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;such Revolving Lender&#8217;s Pro Rata Share of an amount equal to the lesser of&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_280"></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;the amount equal to the Maximum Revolver Amount, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_283"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;the amount equal to the Borrowing Base as of such date (based upon the most recent Borrowing Base Certificate delivered by the Administrative Borrower to the Revolver Agent, as adjusted by the Revolving Agent for Reserves established by the Revolving Agent from time to time).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_286"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each of the Loans made pursuant to Section 2.01(a)(x) may, at the option of a Borrower, (i) be incurred and maintained as, and&#47;or converted into, ABR Loans or Term SOFR Loans&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that all such Term Loans made by each of the Lenders pursuant to the same Borrowing shall, unless otherwise specifically provided herein, consist entirely of Term Loans of the same Type and (ii) may be repaid or prepaid in accordance with the provisions hereof, but once repaid or prepaid may not be reborrowed.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_289"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Each Lender, may at its option, make any Term SOFR Loan by causing any domestic or foreign branch or Affiliate of such Lender to make such Term SOFR Loan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that (i) any exercise of such option shall not affect the obligation of any Borrower to repay such Term SOFR Loan and (ii) in exercising such option, such Lender shall use its reasonable efforts to minimize any increased costs to the Borrowers resulting therefrom.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_292"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Each of the Revolving Loans made pursuant to Section 2.01(a)(y) may be repaid and, subject to the terms and conditions of this Agreement, reborrowed at any time during the term of this Agreement.  The outstanding principal amount of the Revolving Loans, together with interest accrued and unpaid thereon, shall constitute Obligations and shall be due and payable on the Maturity Date or, if earlier, on the date on which they are declared due and payable pursuant to the terms of this Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_295"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Revolving Agent may at any time establish one or more reserves (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Reserves</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) under the Revolving Facility as the Revolving Agent may deem proper and appropriate in the Revolving Agent&#8217;s Permitted Discretion (including, without limitation, Reserves based on the results of any Field Exams, including relating to contingent liabilities of the Credit Parties under any Material Contract of such Credit Party).  A Reserve may reduce the Borrowing Base (by reduction of an advance rate set forth in the Borrowing Base or otherwise). For the avoidance of doubt, the Revolving Agent may in its Permitted Discretion (but the Revolving Agent shall have no obligation in any circumstance to) increase, reduce or release any Reserve that was previously established under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">clause (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_298"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Borrowing Procedures and Settlements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_301"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Procedure for Borrowing Revolving Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Borrowing of a Revolving Loan shall be made by a written request by an Authorized Officer pursuant to prior written notice in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit N-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or such other form approved by the Administrative Agent (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Notice of Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) delivered to Revolving Agent and received by Revolving Agent no later than 11&#58;00 a.m. one Business Day prior to the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Funding Date, specifying (i) the amount of such Borrowing (which such amount may not be less than the Minimum Revolver Borrowing Amount), and (ii) the requested Funding Date (which shall be a Business Day)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that Revolving Agent may, in its sole discretion, elect to accept as timely requests that are received later than 11&#58;00 a.m. on the applicable Business Day&#59; and, provided, further, that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Borrower shall promptly after delivery of such written request confirm Revolving Agent&#8217;s receipt thereof by phone or written confirmation.  With respect to each request for a Borrowing pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each Revolving Lender agrees that Revolving Agent may in Revolving Agent&#8217;s sole discretion, but Revolving Agent shall not be obligated to, make such requested Borrowing to Borrower on behalf of the Revolving Lenders as a Swingline Advance.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_304"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Making of Revolving Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_307"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;After receipt of a request for a Borrowing pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Revolving Agent at its option and in its discretion shall do either of the following&#58; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_310"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;in Revolving Agent&#8217;s sole discretion, advance the amount of the requested Borrowing to a Borrower disproportionately (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Swingline Advance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) out of Revolving Agent&#8217;s own funds on behalf of the Revolving Lenders in an aggregate amount not to exceed the Swingline Loan Limit, which advance shall be (i) on the Funding Date specified in the relevant Notice of Borrowing (which shall have been delivered no later than one (1) Business Day in advance of the requested Funding Date) and (ii) notwithstanding anything in the Notice of Borrowing to the contrary, an ABR Loan.  Revolving Agent shall make the proceeds of Swingline Advances available to a Borrower on the applicable Funding Date by transferring immediately available funds equal to such proceeds to the Designated Account.  All Swingline Advances made under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(b)(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be subject to Settlement in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below&#59; it being understood that all payments on any such Swingline Advances shall be payable solely to Revolving Agent solely for its own account until Settlement thereof shall have occurred.  For the avoidance of doubt, all Swingline Advances constitute Loans hereunder&#59; or </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_313"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(B)&#160;&#160;&#160;&#160;notify the Revolving Lenders by telephone, email, or other electronic form of transmission, of the requested Borrowing&#59; such notification to be sent by 1&#58;00 p.m. on the Business Day that is one (1) Business Day prior to the requested Funding Date.  If Revolving Agent has notified the Revolving Lenders of a requested Borrowing on the Business Day that is one (1) Business Day prior to the Funding Date, then each Revolving Lender shall make the amount of such Revolving Lender&#8217;s Pro Rata Share of the requested Borrowing available to Revolving Agent in immediately available funds, to Revolving Agent&#8217;s Account, not later than 10&#58;00 a.m. on the Business Day that is the requested Funding Date.  After Revolving Agent&#8217;s receipt of the proceeds of such Revolving Loans from the Revolving Lenders, Revolving Agent shall make the proceeds thereof available to a Borrower on the applicable Funding Date by transferring immediately available funds equal to such proceeds received by Agent to the Designated Account&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that, subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 2.02(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, no Revolving Lender shall have an obligation to make any Revolving Loan, if (1)&#160;one or more of the applicable conditions precedent set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> will not be satisfied on the requested Funding Date for the applicable Borrowing unless such condition has been waived, or (2)&#160;the requested Borrowing would exceed the Availability on such Funding Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_316"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;Unless Revolving Agent receives notice from a Revolving Lender prior to 9&#58;30 a.m. on the Business Day that is the requested Funding Date relative to a requested Borrowing as to which Revolving Agent has notified the Revolving Lenders of a requested Borrowing that such Revolving Lender will not make available as and when required hereunder to Revolving Agent for the account of a Borrower the amount of that Revolving Lender&#8217;s Pro Rata Share of the Borrowing, Revolving Agent may assume that each Revolving Lender has made or will make such amount available to Agent in immediately available funds on the Funding Date and Revolving Agent may (but shall not be so required), in reliance upon such assumption, make available to such Borrower a corresponding amount.  If, on the requested Funding Date, any Revolving Lender shall not have remitted the full amount that it is required to make available to Revolving Agent in immediately available funds and if Revolving Agent has made available to a Borrower such amount on the requested Funding Date, then such Revolving Lender shall make the amount of such Revolving Lender&#8217;s Pro Rata Share of the requested Borrowing available to Revolving Agent in immediately available funds, to Revolving Agent&#8217;s Account, no later than 10&#58;00 a.m. on the Business Day that is the first Business Day after the requested Funding Date (in which case, the interest accrued on such Lender&#8217;s portion of such Borrowing for the Funding Date shall be for Revolving Agent&#8217;s Account).  If any Revolving Lender shall not remit the full amount that it is required to make available to Revolving Agent in immediately available funds as and when required hereby and if Revolving Agent has made available to a Borrower such amount, then that Revolving Lender shall be obligated to immediately remit such amount to Revolving Agent, together with interest at the Defaulting Lender Rate for each day until the date on which such amount is so remitted.  A notice submitted by Revolving Agent to any Revolving Lender with respect to amounts owing under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;2.02(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> shall be conclusive, absent manifest error.  If the amount that a Revolving Lender is required to remit is made available to Revolving Agent, then such payment to Revolving Agent shall constitute such Revolving Lender&#8217;s Loan for all purposes of this Agreement.  If such amount is not made available to Revolving Agent on the Business Day following the Funding Date, Agent will notify the applicable Borrower of such failure to fund and, upon demand by Revolving Agent, such Borrower shall pay such amount to Revolving Agent for Revolving Agent&#8217;s Account, together with interest thereon for each day elapsed since the date of such Borrowing, at a rate per annum equal to the interest rate applicable ABR Loans at the time to the Revolving Loans composing such Borrowing.  If any Borrower and any Revolving Lender shall pay interest to the Revolving Agent for the same (or a portion of the same) period, the Revolving Agent shall promptly remit to such Borrower the amount of such interest paid by such Borrower for such period.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_319"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Protective Advances and Optional Overadvances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_322"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Any contrary provision of this Agreement or any other Credit Document notwithstanding, but subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(c)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, at any time Revolving Agent hereby is authorized by a Borrower and the Revolving Lenders, from time to time, in Revolving Agent&#8217;s sole discretion, to make Revolving Loans to, or for the benefit of, any Borrower, on behalf of the Revolving Lenders, that Revolving Agent, in its Permitted Discretion, deems necessary or desirable (1)&#160;to preserve or protect the Collateral, or any portion thereof, (2)&#160;to enhance the likelihood of repayment of the Obligations or (3) to pay any other amount chargeable to any Credit Party hereunder (the Revolving Loans described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Protective Advances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Notwithstanding the foregoing, no Protective Advance shall be made which would cause (A) the aggregate amount of all Protective Advances outstanding at any one time to exceed 10% of the Maximum Revolver Amount unless the Required Revolving </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Lenders otherwise agree or (B) the aggregate amount of Revolver Usage outstanding at any one time to exceed the Maximum Revolver Amount.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_325"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;Any contrary provision of this Agreement or any other Credit Document notwithstanding, but subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.02(c)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, the Revolving Lenders hereby authorize Revolving Agent, and Revolving Agent may, but is not obligated to, knowingly and intentionally, continue to make Revolving Loans to any Borrower notwithstanding that an Overadvance exists or would be created thereby, so long as (A) after giving effect to such Revolving Loans, the outstanding Revolver Usage does not exceed the Borrowing Base by more than 10% of the Maximum Revolver Amount (unless Required Revolving Lenders agree to a higher amount), and (B) after giving effect to such Revolving Loans, the outstanding Revolver Usage does not exceed the Maximum Revolver Amount.  In the event Revolving Agent obtains actual knowledge that an Overadvance exists, regardless of the amount of, or reason for, such excess, Revolving Agent shall notify the Revolving Lenders as soon as practicable and the Revolving Lenders with Revolver Commitments thereupon shall, together with Revolving Agent, jointly determine the terms of arrangements that shall be implemented with the Borrowers intended to eliminate the Overadvance within thirty (30) days.  In such circumstances, if any Revolving Lender with a Revolver Commitment objects to the proposed terms of reduction or repayment of any Overadvance, the terms of reduction or repayment thereof shall be implemented according to the determination of the Required Revolving Lenders.  The foregoing provisions are meant for the benefit of the Revolving Lenders and Revolving Agent and are not meant for the benefit of the Borrowers, which shall continue to be bound by the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Revolving Lender with a Revolver Commitment shall be obligated to make Revolving Loans in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> in, or settle Overadvances made by Revolving Agent with Revolving Agent as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.02(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, as applicable) for, the amount of such Revolving Lender&#8217;s Pro Rata Share of any unintentional Overadvances by Revolving Agent reported to such Revolving Lender, any intentional Overadvances made as permitted under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.02(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_328"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Each Protective Advance and each Overadvance (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Extraordinary Advance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be deemed to be a Revolving Loan hereunder.  Prior to Settlement with respect to Extraordinary Advances, all payments on the Extraordinary Advances made by Revolving Agent, including interest thereon, shall be payable to Revolving Agent solely for its own account.  The Extraordinary Advances shall be repayable on demand, secured by Revolving Agent&#8217;s Liens, constitute Obligations hereunder, and bear interest at the rate applicable from time to time to Revolving Loans.  The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are for the exclusive benefit of Revolving Agent and the Revolving Lenders and are not intended to benefit any Borrower (or any other Credit Party) in any way.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_331"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Notwithstanding anything contained in this Agreement or any other Credit Document to the contrary&#58; (A) no Extraordinary Advance may be made by Revolving Agent if such Extraordinary Advance would cause the aggregate principal amount of Extraordinary Advances outstanding to exceed an amount equal to 10% of the Maximum Revolver Amount&#59; and (B) to the extent that the making of any Extraordinary Advance causes the aggregate Revolver Usage to exceed the Maximum Revolver Amount, such portion of such Extraordinary Advance shall be for Revolving Agent&#8217;s sole and separate account and not for the account of any Revolving Lender and shall be entitled to priority in repayment in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_334"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It is agreed that each Revolving Lender&#8217;s funded portion of the Revolving Loans is intended by the Revolving Lenders to equal, at all times, such Revolving Lender&#8217;s Pro Rata Share of the outstanding Revolving Loans.  Such agreement notwithstanding, Revolving Agent and the Revolving Lenders agree (which agreement shall not be for the benefit of the Borrowers) that in order to facilitate the administration of this Agreement and the other Credit Documents, settlement among the Revolving Lenders as to the Revolving Loans (including the Swingline Advances and Extraordinary Advances) shall take place on a periodic basis in accordance with the following provisions&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_337"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;Revolving Agent shall request settlement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) with the Revolving Lenders on a weekly basis, or on a more frequent basis if so determined by Revolving Agent in its sole discretion (A) for itself, with respect to the outstanding Swingline Advances and Extraordinary Advances, and (B)&#160;with respect to Parent&#8217;s or their Subsidiaries&#8217; payments or other amounts received, as to each by notifying the Revolving Lenders by telecopy, telephone, or other similar form of transmission, of such requested Settlement, no later than 2&#58;00 p.m. on the Business Day immediately prior to the date of such requested Settlement (the date of such requested Settlement being the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Settlement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;).  Such notice of a Settlement Date shall include a summary statement of the amount of outstanding Revolving Loans (including Swingline Advances and Extraordinary Advances) for the period since the prior Settlement Date.  Subject to the terms and conditions contained herein)(including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">)&#58; (1)&#160;if the amount of the Revolving Loans (including Swingline Advances and Extraordinary Advances) made by a Revolving Lender that is not a Defaulting Lender exceeds such Revolving Lender&#8217;s Pro Rata Share of the Revolving Loans (including Swingline Advances and Extraordinary Advances) as of a Settlement Date, then Revolving Agent shall, by no later than 2&#58;00 p.m. on the Settlement Date, transfer in immediately available funds to a Deposit Account of such Revolving Lender (as such Revolving Lender may designate), an amount such that each such Revolving Lender shall, upon receipt of such amount, have as of the Settlement Date, its Pro Rata Share of the Revolving Loans (including Swingline Advances and Extraordinary Advances), and (2)&#160;if the amount of the Revolving Loans (including Swingline Advances and Extraordinary Advances) made by a Revolving Lender is less than such Revolving Lender&#8217;s Pro Rata Share of the Revolving Loans (including Swingline Advances and Extraordinary Advances) as of a Settlement Date, such Revolving Lender shall no later than 2&#58;00 p.m. on the Settlement Date transfer in immediately available funds to Revolving Agent&#8217;s Account, an amount such that each such Revolving Lender shall, upon transfer of such amount, have as of the Settlement Date, its Pro Rata Share of the Revolving Loans (including Swingline Advances and Extraordinary Advances).  Such amounts made available to Revolving Agent under clause (2) of the immediately preceding sentence shall be applied against the amounts of the applicable Swingline Advances or Extraordinary Advances and shall constitute Revolving Loans of such Revolving Lenders.  If any such amount is not made available to Revolving Agent by any Revolving Lender on the Settlement Date applicable thereto to the extent required by the terms hereof, Revolving Agent shall be entitled to recover for its account such amount on demand from such Revolving Lender together with interest thereon at the Defaulting Lender Rate.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_340"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;In determining whether a Revolving Lender&#8217;s balance of the Revolving Loans (including Swingline Advances and Extraordinary Advances) is less than, equal to, or greater than such Revolving Lender&#8217;s Pro Rata Share of the Revolving Loans (including Swingline Advances and Extraordinary Advances) as of a Settlement Date, Revolving Agent shall, as part of the relevant Settlement, apply to such balance the portion of payments actually </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">received in good funds by Revolving Agent with respect to principal, interest, fees payable by the Borrowers and allocable to the Revolving Lenders hereunder, and proceeds of Collateral.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_343"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Between Settlement Dates, Revolving Agent, to the extent Swingline Advances and&#47;or Extraordinary Advances for the account of Revolving Agent are outstanding, may apply any payments or other amounts received by Revolving Agent, that in accordance with the terms of this Agreement would be applied to the reduction of the Revolving Loans, to the Swingline Advances and&#47;or Extraordinary Advances.  During the period between Settlement Dates, Revolving Agent shall be entitled to all interest and fees at the applicable rate or rates payable under this Agreement on the daily amount of funds employed by Revolving Agent with respect to all Swingline Advances and Extraordinary Advances.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_346"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Anything in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to the contrary notwithstanding, in the event that a Revolving Lender is a Defaulting Lender, Revolving Agent shall be entitled to refrain from remitting settlement amounts to the Defaulting Lender and, instead, shall be entitled to elect to implement the provisions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_349"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Borrower shall give the Administrative Agent a Notice of Borrowing for Term Loans (i) prior to 1&#58;00 p.m. (New York time) at least three (3) Business Days&#8217; prior to each Borrowing of Term Loans, which are to be initially Term SOFR Loans and (ii) prior to 12&#58;00 noon (New York time) at least one (1) Business Day prior to the date of each Borrowing of Term Loans which are to be ABR Loans.  Except as otherwise expressly provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each Notice of Borrowing shall be irrevocable and shall specify (A) the aggregate principal amount of the Term Loans to be made, (B) the Funding Date (which shall be, in the case of Term Loans, the Closing Date), (C) whether the Term Loans shall consist of ABR Loans and&#47;or Term SOFR Loans and (D) Borrower&#8217;s wire instructions.  The Administrative Agent shall promptly give each Term Lender written notice  of each proposed Borrowing of Term Loans, of such Term Lender&#8217;s Pro Rata Share thereof and of the other matters covered by the related Notice of Borrowing.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_352"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disbursement of Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_355"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;No later than (i) 2&#58;00 p.m. (New York time), in the case of each Borrowing of Term Loans for which a Notice of Borrowing has been timely delivered in accordance with Section 2.03 (other than for Borrowings on the Closing Date), each Term Lender will make available its Pro Rata Share, if any, of the Borrowing requested to be made on such date in the manner provided below, and (ii) 5&#58;00 p.m. (New York time), in the case of the making of the Initial Term Loan, if the conditions set forth in Article VI to the effectiveness of this Agreement are met prior to 4&#58;00 p.m. (New York time) on the Closing Date, each Term Lender will make available its Pro Rata Share of the Initial Term Loan in the manner provided below.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_358"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Term Lender shall make available all amounts it is to fund to a Borrower, under any Borrowing of Term Loans, in immediately available funds to the Administrative Agent, and the Administrative Agent will make available to such Borrower, the aggregate of the amounts so made available in Dollars.  Unless the Administrative Agent shall have been notified in writing by any Term Lender prior to the date of any Borrowing of Term Loans that such Term Lender does not intend to make available to the Administrative Agent its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">portion of the Borrowing or Borrowings to be made on such date, the Administrative Agent may assume that such Term Lender has made such amount available to the Administrative Agent on such date of Borrowing, and the Administrative Agent, in reliance upon such assumption, may (in its sole discretion and without any obligation to do so) make available to such Borrower a corresponding amount.  If such corresponding amount is not in fact made available to the Administrative Agent by such Term Lender and the Administrative Agent has made available the same to the Borrower, the Administrative Agent shall be entitled to recover such corresponding amount from such Term Lender.  If such Term Lender does not pay such corresponding amount forthwith upon the Administrative Agent&#8217;s demand therefor, the Administrative Agent shall promptly notify the Administrative Borrower and the Borrowers, jointly and severally, shall promptly pay such corresponding amount to the Administrative Agent.  The Administrative Agent shall also be entitled to recover from such Term Lender or the Borrowers, as the case may be, interest on such corresponding amount in respect of each day from the date such corresponding amount was made available by the Administrative Agent to any Borrower, to the date such corresponding amount is recovered by the Administrative Agent, at a rate per annum equal to (i) if paid by such Lender, the Federal Funds Rate or (ii) if paid by any Borrower, the then-applicable rate of interest, calculated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, applicable to ABR Loans.  If such Borrower and such Term Lender shall pay interest to the Administrative Agent for the same (or a portion of the same) period, the Administrative Agent shall promptly remit to such Borrower the amount of such interest paid by such Borrower for such period.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_361"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be deemed to relieve any Lender from its obligation to fulfill its commitments hereunder or to prejudice any rights that the Borrowers may have against any Lender as a result of any default by such Lender hereunder (it being understood, however, that no Lender shall be responsible for the failure of any other Lender to fulfill its commitments hereunder).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_364"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Loans&#59; Evidence of Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_367"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Borrower, jointly and severally, agrees to pay to the Administrative Agent, for the benefit of the Lenders, on the Maturity Date, the aggregate amount of all outstanding Loans.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_370"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Lender shall maintain in accordance with its usual practice an account or accounts evidencing the Indebtedness of the Borrowers to the appropriate lending office of such Lender resulting from each Loan made by such lending office of such Lender from time to time, including the amounts of principal and interest payable and paid to such lending office of such Lender from time to time under this Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_373"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;Each Borrower agrees that from time to time on and after the Closing Date, upon the request to Administrative Agent by any Lender, at Borrowers&#8217; own expense, each Borrower will execute and deliver to such Lender a Note, evidencing the Loans made by, and payable to such Lender or registered assigns in a maximum principal amount equal to such Lender&#8217;s applicable Initial Term Loan Commitment or Revolver Commitment.  The Agents shall maintain the Register pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 12.06(b)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, and a subaccount for each Lender, in which Register and subaccounts (taken together) shall be recorded (i) the amount of each Loan </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">made hereunder and the Type of each Loan made, (ii) the amount of any principal or interest due and payable or to become due and payable from the Borrowers to each Lender hereunder and (iii) the amount of any sum received by the Administrative Agent from the Borrowers and each Lender&#8217;s share thereof.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_376"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(d)&#160;&#160;&#160;&#160;The entries made in the Register and accounts and subaccounts maintained pursuant to paragraphs (c) and (d) of this Section 2.05 shall, to the extent permitted by Applicable Law, be prima facie evidence of the existence and amounts of the obligations of the Borrowers therein recorded&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">, that the failure of any Lender or Administrative Agent to maintain such account, such Register or such subaccount, as applicable, or any error therein, shall not in any manner affect the obligation of the Borrowers to repay (with applicable interest) the Loans made to the Borrowers by such Lender in accordance with the terms of this Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_379"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 2.06&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Conversions and Continuations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  (a) The Borrowers shall have the option on any Business Day to convert all or a portion of the outstanding principal amount of Loans of one Type into a Borrowing or Borrowings of another Type&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that ABR Loans may not be converted into Term SOFR Loans if an Event of Default is in existence on the date of the proposed conversion and the Administrative Agent has, or the Required Lenders in respect of the Credit Facility that is the subject of such conversion have, determined in its or their sole discretion not to permit such conversion.  Each such conversion or continuation shall be effected by the Administrative Borrower by giving the Administrative Agent written notice prior to 1&#58;00 p.m. (New York time) at least three Business Days (or one (1) Business Day in the case of a conversion into ABR Loans) (and in either case on not more than five (5) Business Days) prior to such proposed conversion or continuation, in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit N-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> or such other form approved by the Administrative Agent (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Notice of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) specifying the Loans to be so converted or continued and the Type of Loans to be converted or continued.  The Administrative Agent shall give each Lender notice as promptly as practicable of any such proposed conversion or continuation affecting any of its Loans.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_382"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If any Event of Default is in existence at the time of any continuation of any Term SOFR Loans and the Administrative Agent determined in its or their sole discretion not to permit such continuation, such Term SOFR Loans shall be automatically converted into a Borrowing of ABR Loans.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_385"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 2.07&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Pro Rata Borrowings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Borrowing of the Initial Term Loan funded on the Closing Date under this Agreement shall be made by each Term Lender with an Initial Term Loan Commitment on the basis of its then-applicable Initial Term Loan Commitment.  Each Borrowing of Revolving Loans under this Agreement shall be made by each Revolving Lender with a Revolver Commitment on the basis of its then-applicable Revolver Commitment.  It is understood that no Lender shall be responsible for any default by any other Lender in its obligation to make Loans hereunder and that each Lender shall be obligated to make the Loans provided to be made by it hereunder, regardless of the failure of any other Lender to fulfill its commitments hereunder.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_388"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.08&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_391"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The unpaid principal amount of each ABR Loan shall bear interest from the date of the Borrowing thereof until repayment or prepayment thereof at a rate per annum that shall at all times be the Applicable Margin </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the ABR in effect from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_394"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(b)&#160;&#160;&#160;&#160;The unpaid principal amount of each Term SOFR Loan shall bear interest from the date of the Borrowing thereof until repayment or prepayment thereof at a rate per annum that shall at all times be the Applicable Margin in effect from time to time </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%"> the relevant Adjusted Term SOFR Rate.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_397"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(c)&#160;&#160;&#160;&#160;From and after the occurrence and during the continuance of any Event of Default, upon notice by the Administrative Agent to the Administrative Borrower (or automatically while any Event of Default under Section 10.01(a) or Section 10.01(h) exists), the Borrowers shall pay interest on the principal amount of all Loans and all other due and unpaid Obligations, to the extent permitted by Applicable Law, at the rate described in Section 2.08(a) or Section 2.08(b), as applicable, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%"> two (2) percentage points per annum (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;).  All such interest at the Default Rate shall be payable on demand of the Administrative Agent or the Required Lenders and in cash.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_400"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Interest on each Loan shall accrue from and including the date of any Borrowing to but excluding the date of any repayment thereof and shall be payable (i) in respect of each ABR Loan, quarterly in arrears on the first Business Day of each January, April, July and October, beginning with the Fiscal Quarter ending September 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ABR Interest Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (ii) in respect of each Term SOFR Loan, quarterly in arrears on the first Business Day of each January, April, July and October, commencing on September 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SOFR Interest Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (iii) in respect of each Loan, on any prepayment (on the amount prepaid), at maturity (whether by acceleration or otherwise) and, after such maturity, on demand.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_403"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;In connection with the use or administration of Term SOFR, the Administrative Agent will have the right to make Conforming Changes from time to time in consultation with the Administrative Borrower and, notwithstanding anything to the contrary herein or in any other Credit Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Credit Document.  The Administrative Agent will promptly notify the Administrative Borrower and the Lenders of the effectiveness of any Conforming Changes in connection with the use or administration of Term SOFR.   </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_406"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;On each of the ABR Interest Payment Date or SOFR Interest Payment Date, as applicable, the Borrowers, jointly and severally, shall pay all accrued and unpaid interest on the Loans by paying all such accrued interest in cash.  All accrued, but unpaid Interest shall be payable in cash on the Maturity Date.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_409"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;The Administrative Agent, upon determining the interest rate for any Borrowing of Term SOFR Loans, shall promptly notify the Administrative Borrower and the relevant Lenders thereof.  The Adjusted Term SOFR Rate for the Term SOFR Loans and ABR for the ABR Loans shall be determined on the first day of each January, April, July and October.  Each such determination shall, absent clearly demonstrable error, be final and conclusive and binding on all parties hereto.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_412"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement or any other Credit Document to the contrary, to the extent that the outstanding aggregate principal amount of the drawn Revolving Loans, is less than $20,000,000 on any date, the amount of interest payable on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">account of the Revolving Loans pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be equal to the amount of interest that would be payable had the outstanding principal amount of the Revolving Loans equaled $20,000,000 on such date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, to the extent the Revolver Commitment is reduced to an amount that is less than $20,000,000 (but greater than $0), then, to the extent that the outstanding principal amount of the Revolving Loans is less than $10,000,000 on any date, the amount of interest payable on account of the Revolving Loans pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be equal to the amount of interest that would be payable had the outstanding principal amount of the Revolving Loans equaled $10,000,000 on such date.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_427"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 2.09&#160;&#160;&#160;&#160;&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reserved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_430"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 2.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Increased Costs, Illegality, etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_433"></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)  If any Change in Law shall&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_436"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender (except any reserve requirement reflected in Adjusted Term SOFR Rate)&#59; or</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_439"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;subject any Lender to any Taxes (other than (A) Non-Excluded Taxes, (B) Taxes described in clauses (ii) through (iv) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its Loans, Commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto&#59; or</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_442"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;impose on any Lender any other condition, cost or expense (other than Taxes) affecting this Agreement or Loans made by such Lender or participation therein,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">and the result of any of the foregoing shall be to increase the cost to such Lender or any Lender of making or maintaining any Loan or of maintaining its obligation to make any such Loan, or to increase the cost to such Lender or any Lender of participating in, or to reduce the amount of any sum received or receivable by such Lender or any Lender hereunder (whether of principal, interest or any other amount) then, upon request of such Lender, the Administrative Borrower, within five (5) Business Days of demand therefor, will pay to such Lender, such additional amount or amounts as will compensate such, as the case may be, for such additional costs incurred or reduction suffered.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_415"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;At any time that any Term SOFR Loan is affected by the circumstances described in Section 2.10(a)(ii), the Administrative Borrower may either (A) if the affected Term SOFR Loan is then being made pursuant to a Borrowing, cancel said Borrowing by giving the Administrative Agent written notice thereof on the same date that the Administrative Borrower was notified by a Lender pursuant to Section 2.10(a)(ii) or (B) if the affected Term SOFR Loan is then outstanding, upon at least three (3) Business Days&#8217; notice to the Administrative Agent, require the affected Lender to convert each such Term SOFR Loan into an ABR Loan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if more than one Lender is so affected at any time, then all affected Lenders must be treated in the same manner pursuant to this Section 2.10(b)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if more than one Lender is affected at any time, then all affected Lenders must be treated in the same manner pursuant to this Section 2.10(b).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_418"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If, after the later of the date hereof, and that date such entity becomes a Lender hereunder, the adoption of any Applicable Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any Governmental Authority, central bank or comparable agency charged with the interpretation or administration thereof, or compliance by a Lender or its parent with any request or directive made or adopted after such date regarding capital adequacy (whether or not having the force of law) of any such authority, association, central bank or comparable agency, has the effect of reducing the rate of return on such Lender&#8217;s or its parent&#8217;s capital or assets as a consequence of such Lender&#8217;s commitments or obligations hereunder to a level below that which such Lender or its parent could have achieved but for such adoption, effectiveness, change or compliance (taking into consideration such Lender&#8217;s or its parent&#8217;s policies with respect to capital adequacy), then within five (5) days after written demand by such Lender (with a copy to the Administrative Agent), the Borrowers, jointly and severally, shall pay to such Lender such additional amount or amounts as will compensate such Lender or its parent for such reduction, it being understood and agreed, however, that a Lender shall not be entitled to such compensation as a result of such Lender&#8217;s compliance with, or pursuant to any request or directive to comply with, any such Applicable Law as in effect on the date hereof.  Each Lender (on its own behalf), upon determining in good faith that any additional amounts will be payable pursuant to this Section 2.10(c), will, as promptly as practicable upon ascertaining knowledge thereof, give written notice thereof to the Administrative Borrower, which notice shall set forth in reasonable detail the basis of the calculation of such additional amounts.  The failure to give any such notice, with respect to a particular event, within the time frame specified in Section 2.13, shall not release or diminish any of the Borrowers&#8217; obligation to pay additional amounts pursuant to this Section 2.10(c) for amounts accrued or incurred after the date of such notice with respect to such event.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_421"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;&#91;Reserved&#93;. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_424"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply to Taxes to the extent duplicative of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_445"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If (a) any payment of principal of a Term SOFR Loan is made by any Borrower to or for the account of a Lender other than on the last Business Day of a calendar quarter for such Term SOFR Loan as a result of a payment or conversion pursuant to Section 2.05, 2.06, 2.10 or 4.04, as a result of acceleration of the maturity of the Loans pursuant to Article X or for any other reason, (b) any Borrowing of Term SOFR Loans is not made as a result of a withdrawn Notice of Borrowing (except with respect to a revocation as provided in Section 2.10 or by reason of a Lender being a Defaulting Lender), (c) any ABR Loan is not converted into a Term SOFR Loan as a result of a withdrawn Notice of Conversion, (d) any Term SOFR Loan is not continued as a Term SOFR Loan as a result of a withdrawn Notice of Conversion or (e) any prepayment of principal of a Term SOFR Loan is not made as a result of a withdrawn notice of prepayment pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Borrowers shall, after receipt of a written request by such Lender (which request shall set forth in reasonable detail the basis for requesting such amount), pay to the Administrative Agent for the account of such Lender any amounts required to compensate such Lender for any additional losses, costs or expenses that such Lender may reasonably incur as a result of such payment, failure to convert, failure to continue, failure to prepay, reduction or failure to reduce, including any loss, cost or expense </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(excluding loss of anticipated profits) actually incurred by reason of the liquidation or reemployment of deposits or other funds acquired by such Lender to fund or maintain such Term SOFR Loan.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_448"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Lending Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Lender agrees that, upon the occurrence of any event giving rise to the operation of Section 2.10(a)(ii), 2.10(a)(iii), 2.10(b) or 5.04 with respect to such Lender, it will, if requested by the Administrative Borrower, use reasonable efforts (subject to overall policy considerations of such Lender) to designate another lending office for any Loans affected by such event&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such designation is made on such terms that such Lender and its lending office suffer no economic, legal or regulatory disadvantage, with the object of avoiding the consequence of the event giving rise to the operation of any such Section.  Nothing in this Section 2.12 shall affect or postpone any of the obligations of the Borrowers or the rights of any Lender provided in Section 2.10 or 5.04.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_451"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 2.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Notice of Certain Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Notwithstanding anything in this Agreement to the contrary, to the extent any notice required by Section 2.10, 2.11 or 5.04 is given by any Lender more than one hundred twenty (120) days after such Lender has knowledge (or should have had knowledge) of the occurrence of the event giving rise to the additional cost, reduction in amounts, loss, tax or other additional amounts described in such Sections, such Lender shall not be entitled to compensation under Section 2.10, 2.11 or 5.04, as the case may be, for any such amounts incurred or accruing prior to the giving of such notice to the Administrative Borrower.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_454"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 2.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bank Accounts and Collections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_457"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;The Credit Parties shall establish and maintain cash management services of a type and on terms reasonably satisfactory to the Collateral Agent at one or more banks reasonably satisfactory to Agent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Cash Management Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;).  Within sixty (60) days of the Closing Date (or such later date as Collateral Agent may reasonably agree in its sole discretion), each Credit Party will enter into a Springing Control Agreement with the applicable Cash Management Bank for each Deposit Account of Credit Parties (other than a Monitored Account or other Excluded Account).  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> sets forth a complete listing of Deposit Accounts for each Credit Party as of the Closing Date, including the identification of the Credit Party ownership, the name and address of the applicable Cash Management Bank, the account number, the purpose or usage of the account, and a designation of the account as a Springing Control Account, Excluded Account, or Monitored Account.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_460"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;Each Springing Control Agreement shall provide, among other things, that the applicable Cash Management Bank will comply with any instructions originated by Collateral Agent directing the disposition of the funds in the applicable Deposit Account subject to such Springing Control Agreement, without further consent by the applicable Credit Party.  With respect to each Springing Control Account, unless a Cash Dominion Event has occurred, the Collateral Agent will not elect to provide instructions to the applicable Cash Management Bank regarding the disposition of funds in such account.  Upon a Cash Dominion Event, the Required Lenders will maintain the right, in their sole discretion, to exercise rights provided for in each Springing Control Agreement, including requiring the applicable Cash Management Bank to forward funds in the applicable Deposit Account to the Collateral Agent to be applied in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 5.2(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#59; provided, that, prior to the exercise of such rights, at the sole election of Required Lenders, all amounts received in such Springing Control Account shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">sent on each Business Day by wire transfer or ACH payment to Collateral Agent for application at the end of each Business Day to the payment of the Obligations in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 5.02(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_463"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Collateral Agent shall credit to the payment of the Obligations any funds received by Collateral Agent for which Collateral Agent has received notice that such funds are collected and available to Collateral Agent (i) on the same day of Collateral Agent&#8217;s receipt of such notice if such notice is received by Collateral Agent on or before 2 p.m. on a Business Day, and (ii) on the Business Day immediately following Agent&#8217;s receipt of such notice if such notice is received by Collateral Agent after 2 p.m. on a Business Day, or if such notice is received by Collateral Agent on a day that is not a Business Day.  It is understood and agreed that the transfer and crediting of funds from a Springing Control Account may take up to two Business Days.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_466"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Each Credit Party will deposit or cause to be deposited, no later than the first Business Day after the date of receipt thereof, all proceeds in respect of any Collateral, all collections (of a nature susceptible to a deposit in a bank account) and all other amounts received by such Credit Party (including payments made by Account Debtors directly to such Credit Party and remittances on credit card sales) into a Deposit Account that is subject to a Springing Control Agreement (or to a lockbox, to the extent funds collected therefrom are deposited directly into a Deposit Account that is subject Springing Control Agreement).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_469"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;No Credit Party shall maintain or permit any of its Subsidiaries to maintain cash, Cash Equivalents, or other amounts in any Deposit Account (other than a Monitored Account or other Excluded Account, in the ordinary course of business), unless the Agent shall have received a Springing Control Agreement in respect of each such account.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_472"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Each Credit Party shall cause each Person processing or collecting any credit card payments or proceeds of receivables on behalf of the Credit Parties to deliver such payments or proceeds promptly, but not less frequently than each Business Day, into a Deposit Account that is subject to a Springing Control Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_475"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;If at any time, any Credit Party receives or otherwise has dominion and control of any proceeds or collections in contravention of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, such proceeds and collections shall (i) be held in trust by such Credit Party for benefit of the Collateral Agent, (ii) not be commingled with any of such Credit Party&#8217;s other funds or deposited in any account of such Credit Party,  and (iii) be deposited into the Revolving Agent&#8217;s Account or dealt with in such other fashion as such Credit Party may be instructed by the Collateral Agent, no later than the Business Day after receipt thereof.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_478"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Defaulting Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_481"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by Applicable Law&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_484"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Waivers and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  That Defaulting Lender&#8217;s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in Section 12.01.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_487"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reallocation of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any payment of principal, interest, fees or other amounts received by the Agents for the account of that Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Section 5.02(j) or Article X or otherwise, and including any amounts made available to any Agent by that Defaulting Lender pursuant to Section 12.09), shall be applied at such time or times as may be determined by the Agents as follows&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to Revolving Agent to the extent of any Swingline Advances and Extraordinary Advances that were made by Revolving Agent and that were required to be, but were not, paid by the Defaulting Lender,  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to the payment of any other amounts owing by that Defaulting Lender to the applicable Agent hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as the Administrative Borrower may request (so long as no Event of Default exists), to the funding of any Loan in respect of which that Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Agents&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, if so determined by the Agents and the Administrative Borrower, to be held in a noninterest bearing deposit account and released in order to satisfy such Defaulting Lender&#8217;s potential future funding with respect to Loans under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">fifth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to the payment of any amounts owing to the Lenders as a result of any judgment of a court of competent jurisdiction obtained by any Lender against that Defaulting Lender as a result of that Defaulting Lender&#8217;s breach of its obligations under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">sixth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, so long as no Event of Default exists, to the payment of any amounts owing to the Borrowers as a result of any judgment of a court of competent jurisdiction obtained by the Borrowers against that Defaulting Lender as a result of that Defaulting Lender&#8217;s breach of its obligations under this Agreement&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">seventh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to that Defaulting Lender or as otherwise directed by a court of competent jurisdiction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if such payment is a payment of the principal amount of any Loans in respect of which that Defaulting Lender has not fully funded its appropriate share.  Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender shall be deemed paid to and redirected by that Defaulting Lender, and each Lender irrevocably consents hereto.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_490"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Revolving Lender that is a Defaulting Lender shall not be entitled to receive any Unused Line Fees,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for any period during which that Revolving Lender is a Defaulting Lender (and the Borrowers shall not be required to pay any such fee that otherwise would have been required to have been paid to that Defaulting Lender).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_493"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Defaulting Lender Cure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  If the Administrative Borrower and each Agent agree in writing in their sole discretion that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein, that Lender will, to the extent applicable, purchase that portion of outstanding Loans of the other Lenders or take such other actions as the Agents may determine to be necessary to cause the Lenders to hold their respective Pro Rata Share of Loans, whereupon that Lender will cease to be a Defaulting Lender&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrowers while that Lender was a Defaulting Lender&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to a Lender that is not a Defaulting Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender&#8217;s having been a Defaulting Lender.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_496"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 2.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Benchmark Replacement Setting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_499"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary herein or in any other Credit Document, upon the occurrence of a Benchmark Transition Event, the Administrative Agent and the Administrative Borrower may amend this Agreement to replace the then-current Benchmark with a Benchmark Replacement.  Any such amendment with respect to a Benchmark Transition Event will become effective at 5&#58;00 p.m. (New York City time) on the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Business Day after the Administrative Agent has posted such proposed amendment to all affected Lenders and the Administrative Borrower so long as the Administrative Agent has not received, by such time, written notice of objection to such amendment from Lenders comprising the Required Lenders.  No replacement of a Benchmark with a Benchmark Replacement pursuant to this Section 2.16(a) will occur prior to the applicable Benchmark Transition Start Date.  No Hedge Agreement shall be deemed to be a &#8220;Credit Document&#8221; for purposes of this Section 2.16.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_502"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Replacement Conforming Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In connection with the use, administration, adoption or implementation of a Benchmark Replacement, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Credit Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Credit Document.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_505"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices&#59; Standards for Decisions and Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Administrative Agent will promptly notify the Administrative Borrower and the Lenders of (i) the implementation of any Benchmark Replacement and (ii) the effectiveness of any Conforming Changes in connection with the use, administration, adoption or implementation of a Benchmark Replacement.  The Administrative Agent will notify the Administrative Borrower of (x) the removal or reinstatement of any tenor of a Benchmark pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.16(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and (y) the commencement of any Benchmark Unavailability Period.  Any determination, decision or election that may be made by the Administrative Agent or, if applicable, any Lender (or group of Lenders) pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action or any selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Credit Document, except, in each case, as expressly required pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_508"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Unavailability of Tenor of Benchmark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Notwithstanding anything to the contrary herein or in any other Credit Document, at any time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current Benchmark is a term rate (including the Term SOFR Reference Rate) and either (A) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (B) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Administrative Agent may modify the tenor for any Benchmark settings (including, as applicable, the definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Term SOFR&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> at or after such time to remove and&#47;or replace such unavailable or non-representative tenor and (ii) if a tenor that was removed pursuant to clause (i) above either (A) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent may modify the tenor for all Benchmark settings (including, as applicable, the definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Term SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) at or after such time to reinstate such previously removed tenor.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_511"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Unavailability Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon the Administrative Borrower&#8217;s receipt of notice of the commencement of a Benchmark Unavailability Period, the Borrowers may revoke any pending request for a Borrowing of or conversion of Term SOFR Loans to be made, converted during any Benchmark Unavailability Period and, failing that, the Borrowers will be deemed to have converted any such request into a request for a Borrowing of or conversion to Prime Rate Loans.  During a Benchmark Unavailability Period or at any time that a tenor for the then-current Benchmark is not an available, the component of the Prime Rate based upon the then-current Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of the Prime Rate.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_514"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>&#91;RESERVED&#93;</font></div><div><font><br></font></div><div id="iaa36735c66cb43c599ee5c9251d15861_517"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>Fees and Commitment Terminations and Reductions</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_520"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_523"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Each Borrower, jointly and severally, agrees to pay to the Administrative Agent, all the Fees set forth in the Fee Letter.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_526"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Borrower, jointly and severally, agrees to pay to Revolving Agent, for the ratable account of the Revolving Lenders, an unused line fee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Unused Line Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in an amount equal to 0.50% times the result of (i) the aggregate amount of the Revolver Commitments, less (ii) the Average Revolver Usage during the immediately preceding month (or portion thereof), which Unused Line Fee shall be due and payable quarterly in arrears, on the first day of each calendar quarter from and after the Closing Date and on the date on which (X) the Obligations are paid in full in cash and (y) the Revolver Commitments are otherwise terminated in accordance with the terms hereof.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_529"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Termination of Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_532"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Initial Term Loan Commitment shall terminate at 5&#58;00 p.m. (New York time) on the Closing Date.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_535"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Revolving Commitment shall terminate at 2&#58;00 p.m. (New York time) on the Maturity Date.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_538"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reduction of Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Borrowers may reduce the Revolver Commitments, subject to payment of the Prepayment Premium, if applicable, in accordance with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to an amount (which may be zero) not less than the sum of (A) the Revolver Usage as of such date, plus (B) the principal amount of all Revolving Loans not yet made as to which a request has been given by a Borrower under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each such reduction shall be in an aggregate amount of $5,000,000 or any whole multiple of $1,000,000 in excess thereof (unless the Revolver Commitments are being reduced to zero and the amount of the Revolver Commitments in effect immediately prior to such reduction are less than $5,000,000), shall be made by providing not less than ten (10) Business Days prior written notice to Revolver Agent, and shall be irrevocable.  Once reduced, the Revolver Commitments may not be increased.  Each such reduction of the Revolver Commitments shall reduce the Revolver Commitments of each Revolving Lender proportionately in accordance with its ratable share thereof.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_541"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.04&#160;&#160;&#160;&#160;Prepayment Premium.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_544"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Upon (i) each mandatory prepayment of Term Loans made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, (ii) any voluntary prepayment of Term Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, (iii) any voluntary reduction or termination in Revolving Commitments and&#47;or (iv) any payment of the Loans and&#47;or reduction or termination of commitments resulting from any enforcement of remedies pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 10.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, including pursuant to acceleration thereunder (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Prepayment Premium Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), each Borrower, jointly and severally, shall pay to the Administrative Agent, for the ratable account of the Lenders according to their Pro Rata Share thereof, the Prepayment Premium applicable to the Term Loans so prepaid (or Revolving Commitments so reduced or terminated).  Notwithstanding the foregoing, the Prepayment Premium shall not be required to be paid with respect to (x) Revolver Commitment reductions of up to $10,000,000 in the aggregate during the term of this Agreement and (y) optional and mandatory prepayments of the Term Loans in an aggregate principal amount during the term of this Agreement that is less than the lesser of (x) $58,300,000 and (y) the Available Amount calculated as of the date of any such prepayment, with details of such calculation delivered to the Administrative Agent as certified by an Authorized Officer of the Administrative Borrower.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_547"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any Prepayment Premium payable in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be presumed to be equal to the liquidated damages sustained by Lenders as the result of the occurrence of the Prepayment Premium Event and the Credit Parties agree that it is reasonable under the circumstances currently existing.&#160; THE CREDIT PARTIES EXPRESSLY WAIVE, TO THE EXTENT PERMITTED BY APPLICABLE LAW, THE PROVISIONS OF ANY PRESENT OR FUTURE STATUTE OR LAW THAT PROHIBITS OR MAY PROHIBIT THE COLLECTION OF THE FOREGOING PREPAYMENT PREMIUM IN CONNECTION WITH ANY ACCELERATION.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_550"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Credit Parties expressly agree that&#58;&#160; (i) the Prepayment Premium is reasonable and is the product of an arm&#8217;s length transaction between sophisticated business people, ably represented by counsel&#59; (ii) the Prepayment Premium shall be payable notwithstanding the then prevailing market rates at the time payment is made&#59; (iii) there has been a course of conduct between the Lenders and the Credit Parties giving specific consideration in this transaction for such agreement to pay the Prepayment Premium&#59; (iv) the Credit Parties shall be estopped hereafter from claiming differently than as agreed to in this paragraph&#59; (v) their agreement to pay the Prepayment Premium is a material inducement to the Lenders to provide the Commitments and make the Term Loans, and (vi) the Prepayment Premium represents a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">good faith, reasonable estimate and calculation of the lost profits or damages of the Agents and Lenders and that it would be impractical and extremely difficult to ascertain the actual amount of damages to the Agents and Lenders or profits lost by the Agents and Lenders as a result of such Prepayment Premium Event.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_553"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><br><br>Payments</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_556"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 5.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Voluntary Prepayments</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_562"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to the terms and conditions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">4.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Borrowers shall have the right to prepay the Term Loans, in whole or in part, from time to time subject to payment of the Prepayment Premium. The Borrowers shall have the right to repay the Revolving Loans, in whole or in part, from time to time, without premium or penalty. Notwithstanding anything to the contrary herein, during the occurrence and continuance of a Waterfall Trigger Event, the Borrowers shall not make any voluntary prepayment of Term Loans without the consent of the Revolving Agent.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_565"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;When making a voluntary partial prepayment, the Administrative Borrower shall give the Administrative Agent written notice of (i) its intent to make such prepayment, (ii) the amount of such prepayment and (iii) in the case of Term SOFR Loans, the specific Borrowing(s) pursuant to which such prepayment will be made, no later than (A) in the case of Term SOFR Loans, 1&#58;00 p.m. (New York time) three (3) Business Days prior to, and (B) in the case of ABR Loans, 1&#58;00 p.m. (New York time) ) one (1) Business Day prior to the date of such prepayment, and such prepayment shall promptly be transmitted by the Administrative Agent to each of the relevant Lenders, as the case may be.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_568"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Each voluntary partial prepayment of any Loans shall be in a multiple of $500,000 and in aggregate principal amount of at least $100,000&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that no partial prepayment of Term SOFR Loans outstanding under a single Borrowing shall reduce the outstanding Term SOFR Loans outstanding under such Borrowing to an amount less than $500,000.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_571"></div><div style="margin-bottom:15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;With respect to each prepayment of Term Loans pursuant to this Section 5.01, the Borrowers may designate the Types of Loans that are to be prepaid and the specific Borrowing(s) pursuant to which made.  In the absence of a designation by the Borrowers as described in the preceding sentence, the Administrative Agent shall, subject to the above, make such designation in its reasonable discretion with a view, but no obligation, to minimize breakage costs owing under Section 2.11.  Each such prepayment shall be accompanied by all accrued interest on the Loans so prepaid, through the date of such prepayment.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_574"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Each prepayment in respect of any Term Loans pursuant to this Section 5.01 shall be applied ratably to Term Loans.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_577"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 5.02&#160;&#160;&#160;&#160;Mandatory Prepayments.  Upon three (3) Business Days prior written notice from Borrower to Administrative Agent and Revolver Agent, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">68</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_580"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Within five (5) Business Days of the receipt by any Credit Party of any Net Proceeds from any Disposition (other than a Disposition permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.04(s)),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Borrowers, jointly and severally, shall prepay the Loans in an amount equal to one hundred percent (100%) of the Net Proceeds from such Disposition in excess of $5,000,000 in any Fiscal Year (when combined with Net Proceeds from other Dispositions and Casualty Events received in such Fiscal Year), to be applied as set forth in Section 5.02(g)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, the Administrative Borrower may, at its option by notice in writing to the Administrative Agent, which such notice shall be received within thirty (30) days of the receipt of the Net Proceeds from such Disposition, within one hundred eighty (180) days after such event (or, if such Credit Party shall have entered into a binding commitment for the use of such Net Proceeds within such one hundred eighty (180) days, three hundred sixty (360) days after such event), instead reinvest such Net Proceeds in assets to be used in the business of the Borrowers so long as no Event of Default shall have occurred and be continuing at such time, in each case as certified by the Administrative Borrower in writing to the Administrative Agent.  Nothing in this Section 5.02(a) shall be construed to permit or waive any Default or Event of Default arising from any Disposition not permitted under the terms of this Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_583"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Within five (5) Business Days of the receipt by any Credit Party of any Net Proceeds from any Casualty Event, the Borrowers, jointly and severally, shall prepay the Loans in an amount equal to one hundred percent (100%) of such Net Proceeds in excess of $5,000,000 in any Fiscal Year (when combined with Net Proceeds from other Dispositions and Casualty Events received in such Fiscal Year), to be applied as set forth in Section 5.02(g)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that so long as no Event of Default shall have occurred and be continuing, the Administrative Borrower may, at its option by notice in writing to the Administrative Agent, which such notice shall be received within thirty (30) days of the receipt of the Net Proceeds from such Casualty Event, apply such Net Proceeds to the rebuilding or replacement of such damaged, destroyed or condemned assets or property, or otherwise reinvest such Net Proceeds in assets to be used in the business, so long as such Net Proceeds are in fact used to rebuild or replace the damaged, destroyed or condemned assets or property, or otherwise so reinvested, within one hundred eighty (180) days following the receipt of such Net Proceeds (or, if such Credit Party shall have entered into a binding commitment for the use of such Net Proceeds within such one hundred eighty (180) days, three hundred sixty (360) days after such event), with the amount of Net Proceeds unused after such period to be applied as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_586"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If, at any time, the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Revolver Usage on such date exceeds the lesser of (i) Revolver Commitment and (ii) the Borrowing Base, then the Borrowers, jointly and severally, shall immediately</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">prepay the Revolving Loans in an aggregate amount equal to the amount of such applicable excess.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_589"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Concurrently with the incurrence of any Indebtedness by any Credit Party (other than Indebtedness permitted under Section 9.01), the Borrowers, jointly and severally, shall prepay the Loans in an amount equal to one hundred percent (100%) of such Net Proceeds, to be applied as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be construed to permit or waive any Default or Event of Default arising from any incurrence of Indebtedness not permitted under the terms of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">69</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_592"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Substantially concurrently with any Change of Control, the Borrowers, jointly and severally, shall prepay the Loans in full, to be applied as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_595"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Immediately upon any acceleration of any Loans and&#47;or termination of commitments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Borrowers, jointly and severally, shall repay all the Loans and other Obligations, unless only a portion of Loans and other Obligations is so accelerated (in which case the portion so accelerated shall be so repaid).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_598"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.02(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, (A) amounts to be applied in connection with prepayments of the Loans pursuant to Sections 5.02(a), (b), (d) and (e) shall be applied,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to the prepayment of the Term Loans as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.02(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> until such Term Loans are repaid in full and, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to the outstanding principal amount of Protective Advances and Swingline Advances until paid in full, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to the outstanding principal amount of the Revolving Loans until paid in full, and, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to the prepayment of any other outstanding Obligations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that, during the occurrence and continuance of a Waterfall Trigger Event, such amounts shall be applied </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to the outstanding principal amount of Extraordinary Advances and Swingline Advances until paid in full and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to the outstanding principal amount of the Revolving Loans until paid in full, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to the prepayment of the Term Loans as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.02(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> until such Term Loans are repaid in full and, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to the prepayment of any other outstanding Obligation, (B) amounts to be applied in connection with prepayments of the Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.02(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall be applied, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to the outstanding principal amount of Extraordinary Advances and Swingline Advances until paid in full and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to the outstanding principal amount of the Revolving Loans until paid in full and (C) amounts to be applied in connection with repayments of the Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.02(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall be applied in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.02(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_601"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;Each prepayment of the Loans under Section 5.02 shall be accompanied by accrued interest to the date of such prepayment on the principal amount prepaid and the Prepayment Premium, as applicable.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_604"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Application to Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_607"></div><div style="margin-bottom:15pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;With respect to each prepayment of Term Loans elected by the Borrowers pursuant to Section 5.01 or required by (d), the Borrowers may designate the Types of Loans that are to be prepaid and the specific Borrowing(s) pursuant to which made.  In the absence of a designation by the Borrowers as described in the preceding sentence, the Administrative Agent shall, subject to the above, make such designation in its reasonable discretion with a view, but no obligation, to minimize breakage costs owing under Section 2.11. Subject to clause (g), each prepayment in respect of any Term Loans pursuant to this Section 5.02 shall be applied ratably to the outstanding Term Loans.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_610"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;With respect to each prepayment of Revolving Loans elected by the Borrowers pursuant to Section 5.01 or required by (d), the Borrowers may designate (i) the Types of Loans that are to be prepaid and the specific Borrowing(s) pursuant to which made and (ii) the Revolving Loans to be prepaid&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, subject to Section 2.15, each prepayment of any Loans made pursuant to a Borrowing shall be applied </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> among such Loans.  In the absence of a designation by the Borrowers as described in the preceding sentence, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Administrative Agent shall, subject to the above, make such designation in its reasonable discretion with a view, but no obligation, to minimize breakage costs owing under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_613"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Application of Collateral Proceeds and Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or any other provision of any Credit Document, (x) all payments (including, without limitation, prepayments) in respect of the Obligations after acceleration or a Waterfall Trigger Event and (y) all proceeds of Collateral and other payments received by any Agent pursuant to the exercise of remedies against the Collateral shall be applied as follows&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_616"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, ratably to pay any fees then due to the Agents under the Credit Documents and any costs or expense reimbursements of the Agents and any indemnities then due to the Agents under the Credit Documents, until paid in full,</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_619"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, ratably, to pay any fees, premiums (including any Prepayment Premiums), indemnities or expense reimbursements then due to any Revolving Lenders, until paid in full,</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_622"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, ratably, to pay interest due and payable in respect of any Swingline Advances and any Extraordinary Advances, until paid in full, </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_625"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, ratably, to pay principal on any Swingline Advances and any Extraordinary Advances, until paid in full,</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_628"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">fifth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, ratably, to pay interest due and payable in respect of any Revolving Loans, until paid in full, </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_631"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">sixth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to the ratable payment of all principal on the Revolving Loans until paid in full, </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_634"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">seventh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to the ratable payment of all other Revolving Credit Obligations then due and payable until paid in full</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_637"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">eighth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to pay any fees, premiums (including any Prepayment Premiums), indemnities or expense reimbursements then due of the Term Lenders until paid in full,</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_640"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ninth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, ratably to pay interest due in respect of the outstanding Term Loans until paid in full,</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_643"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">tenth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, ratably to pay the outstanding principal balance of the Term Loans until paid in full, </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_646"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">eleventh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to the pay any other Obligations due to any Agent or any Lender until paid in full, </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_649"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">seventh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to Borrowers or such other Person entitled thereto under Applicable Law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">71</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_652"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, each Lender may reject all or a portion of its Pro Rata Share of any mandatory prepayment (such declined amounts, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Declined Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of any class of Term Loans required to be made pursuant to clauses (a), (b), (c) or (d) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> by providing written notice (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Rejection Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the Administrative Agent and the Borrower no later than 1&#58;00 p.m. one (1) Business Day prior to the scheduled date of such prepayment (subject to extension by Administrative Agent in its sole discretion).  Each Rejection Notice from a Lender shall specify the principal amount of the mandatory prepayment of Term Loans to be rejected by such Lender. If a Lender fails to deliver a Rejection Notice to Administrative Agent within the time frame specified above or such Rejection Notice fails to specify the principal amount of the Term Loans to be rejected, any such failure will be deemed an acceptance of the total amount of such mandatory prepayment of such Term Loans. Any Declined Proceeds may be retained by the Borrowers.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_655"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 5.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment of Obligations&#59; Method and Place of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_658"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;The obligations of the Borrowers hereunder and under each other Credit Document are not subject to counterclaim, set-off, rights of rescission or any other defense.  Subject to Section 5.02, and except as otherwise specifically provided herein, all payments under this Agreement shall be made by the Borrowers, without set-off, rights of rescission, counterclaim or deduction of any kind, to the Administrative Agent for the ratable account of the Secured Parties entitled thereto, or, with respect to payments in connection with the Revolving Loans, to the Revolver Agent for the ratable account of the Revolving Lenders, as the case may be, not later than 2&#58;00 p.m. (New York time) on the date when due and shall be made in immediately available funds in Dollars to the applicable Agent at the location and&#47;or in the account specified by such Agent to the Administrative Borrower in writing for such purpose.  The applicable Agent will thereafter cause to be distributed on the same day (if payment was actually received by such Agent prior to 2&#58;00 p.m. (New York time), on such day) like funds relating to the payment of principal or interest or Fees ratably to the Secured Parties entitled thereto.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_661"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;For purposes of computing interest or fees, any payments under this Agreement that are made later than 2&#58;00 p.m. (New York time), shall be deemed to have been made on the next succeeding Business Day.  Whenever any payment to be made hereunder shall be stated to be due on a day that is not a Business Day, the due date thereof shall be extended to the next succeeding Business Day and, with respect to payments of principal, interest shall continue to accrue during such extension at the applicable rate in effect immediately prior to such extension.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_664"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 5.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Net Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_667"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to the following sentence, all payments made by or on behalf of any Borrower under this Agreement or any other Credit Document shall be made free and clear of, and without deduction or withholding for or on account of, any current or future Taxes (including Other Taxes) other than Excluded Taxes.  If any such non-excluded taxes, levies, imposts, duties, charges, fees, deductions or withholdings (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Non-Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) are required to be withheld from any amounts payable under this Agreement, the Borrowers shall increase the amounts payable to the Administrative Agent or such Lender to the extent necessary to yield to the Administrative Agent or such Lender (after payment of all Non-Excluded Taxes, including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any such Non-Excluded Taxes payable in respect of additional amounts paid pursuant to this Section 5.04(a)) interest or any such other amounts payable hereunder at the rates or in the amounts specified in this Agreement.  Whenever any Non-Excluded Taxes are payable by the Borrowers, as promptly as possible thereafter, the Borrowers shall send to the Administrative Agent for its own account or for the account of such Secured Party, as the case may be, a certified copy of an original official receipt (or other evidence acceptable to such Lender, acting reasonably) received by the Borrowers showing payment thereof.  If any Borrower fails to pay any Non-Excluded Taxes when due to the appropriate taxing authority or fails to remit to the Administrative Agent the required receipts or other required documentary evidence, the Borrowers shall indemnify the Administrative Agent and the Lenders for any incremental Taxes, interest, costs or penalties that may become payable by the Administrative Agent or any Lender as a result of any such failure.  In addition, the Borrowers, jointly and severally, shall pay any Other Taxes to the relevant Governmental Authority in accordance with Applicable Law.  The agreements in this Section 5.04(a) shall survive the termination of this Agreement and the payment of the Loans and all other amounts payable hereunder.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_670"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Lender that is not organized under the laws of the United States of America or any state thereof (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Non-U.S. Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_673"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;deliver to the Administrative Borrower and the Administrative Agent (2) two copies of either (A) in the case of Non-U.S. Lender claiming exemption from U.S. federal withholding tax under Section 871(h) or 881(c) of the Code with respect to payments of &#8220;portfolio interest,&#8221; United States Internal Revenue Service Form W-8BEN or W-8BEN-E (together with a certificate representing that such Non-U.S. Lender is not a bank for purposes of Section 881(c) of the Code, is not a 10-percent shareholder (within the meaning of Section 871(h)(3)(B) of the Code) of any Borrower and is not a controlled foreign corporation related to such Borrower (within the meaning of Section 864(d)(4) of the Code)),  (B) Internal Revenue Service Form W-8BEN, W-8BEN-E or Form W-8ECI, or (C) to the extent a Non-U.S. Lender is not the beneficial owner, executed originals of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, IRS Form W-8BEN-E, IRS Form W-9, the certificate described in (A) above, if applicable, and&#47;or other certification documents from each beneficial owner, as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if the Non-U.S. Lender is a partnership and one or more direct or indirect partners of such Non-U.S. Lender are claiming the portfolio interest exemption, such Non-U.S. Lender will provide the documents set forth in (A) above on behalf of each such direct and indirect partner, in each case, properly completed and duly executed by such Non-U.S. Lender claiming complete exemption from, or reduced rate of, U.S. federal withholding tax on payments by the Borrowers under this Agreement&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_676"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;deliver to the Administrative Borrower and the Administrative Agent two (2) further copies of any such form or certification (or any applicable successor form) promptly upon the obsolescence or invalidity of any form previously delivered by such Non-U.S. Lender&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_679"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;obtain such extensions of time for filing and complete such forms or certifications as may reasonably be requested by the Administrative Borrower or the Administrative Agent, unless in any such case any change in treaty, law or regulation has </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">occurred prior to the date on which any such delivery would otherwise be required that renders any such form inapplicable or would prevent such Lender from duly completing and delivering any such form with respect to it and such Lender so advises the Borrowers and the Administrative Agent, in which case such Lender shall not be required to provide any form under subparagraphs (i) or (ii) above.  Each Person that shall become a Participant pursuant to Section 12.06 or a Lender pursuant to Section 12.06 shall, upon the effectiveness of the related transfer, be required to provide all the forms and statements required pursuant to this Section 5.04(b) or Section 5.04(c), as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that in the case of a Participant such Participant shall furnish all such required forms and statements to the Lender from which the related participation shall have been purchased.  Notwithstanding any other provision of this paragraph, a Non-U.S. Lender shall not be required to deliver any form pursuant to this paragraph that such Non-U.S. Lender is not legally able to deliver.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_682"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Each Lender that is entitled to an exemption from or reduction of non-U.S. withholding tax under the law of the jurisdiction in which any Borrower is located, or any treaty to which such jurisdiction is a party, with respect to payments under this Agreement shall deliver to the Administrative Borrower (with a copy to the Administrative Agent), at the time or times prescribed by Applicable Law or reasonably requested by the Administrative Borrower, such properly completed and executed documentation prescribed by Applicable Law as will permit such payments to be made without withholding or at a reduced rate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such Lender is legally entitled to complete, execute and deliver such documentation and in such Lender&#8217;s reasonable judgment such completion, execution or submission would not materially prejudice the legal position of such Lender.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_685"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The Borrowers shall indemnify the Administrative Agent and each Lender within ten (10) days after written demand therefor, for the full amount of any Non-Excluded Taxes or Other Taxes paid by the Administrative Agent or such Lender, as the case may be, on or with respect to any payment by or on account of any obligation of the Borrowers hereunder (including Non-Excluded Taxes or Other Taxes imposed or asserted on or attributable to amounts payable under this Section) and any penalties, interest, additions to tax and reasonable expenses arising therefrom or with respect thereto, whether or not such Non-Excluded Taxes or Other Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to the amount of such payment or liability delivered to the Administrative Borrower by a Lender or by the Administrative Agent on its own behalf or on behalf of a Lender shall be conclusive absent manifest error.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_688"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;If a payment made to a Lender would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Administrative Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Administrative Borrower or the Administrative Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Administrative Borrower or the Administrative Agent as may be necessary for the Borrowers and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with such Lender&#8217;s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (e), &#8220;FATCA&#8221; shall include any amendments made to FATCA after the date of this Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_691"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;If any Lender or the Administrative Agent determines, in its sole discretion exercised in good faith, that it has received a refund of a Tax for which an additional payment has been made by the Borrowers pursuant to this Section 5.04 or Section 12.05 of this Agreement, then such Lender or the Administrative Agent, as the case may be, shall reimburse the Borrowers for such amount (but only to the extent of indemnity payments made, or additional amounts paid, by the Borrowers under this Section 5.04 and Section 12.05 with respect to the Tax giving rise to such refund), net of all out-of-pocket expenses of the Administrative Agent or such Lender (including any Taxes imposed on the receipt of such refund) and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Borrowers, upon the request of the Administrative Agent or such Lender, agrees to repay the amount paid over to the Borrowers (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> any penalties, interest or other charges imposed by the relevant Governmental Authority) to the Administrative Agent or such Lender in the event the Administrative Agent or such Lender is required to repay such refund to such Governmental Authority.  This paragraph shall not be construed to require the Administrative Agent or any Lender to make available its tax returns (or any other information relating to its taxes which it deems confidential) to the Borrowers or any other Person.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_694"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Any Lender claiming any additional amounts payable pursuant to this Section 5.04 shall use its reasonable efforts (consistent with its internal policies and requirements under Applicable Laws) to change the jurisdiction of its lending office if such a change would reduce any such additional amounts (or any similar amount that may thereafter accrue) and would not, in the reasonable determination of such Lender, be otherwise disadvantageous to such Lender.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_697"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Each party&#8217;s obligations under this Section 5.04 shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Loans and Commitments and the repayment, satisfaction or discharge of all obligations under any Credit Document.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_700"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 5.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Computations of Interest and Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All interest and fees shall be computed on the basis of the actual number of days (including the first day and the last day) occurring during the period for which such interest or fee is payable over a year comprised of (a) three hundred and sixty five (365) (or three hundred and sixty six (366) as appropriate) days in the case of ABR Loans and (b) three hundred and sixty (360) days in all other cases.  Payments due on a day that is not a Business Day shall (except as otherwise required by Section 2.09(c)) be made on the next succeeding Business Day and such extension of time shall be included in computing interest and fees in connection with that payment.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_703"></div><div style="margin-bottom:12pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">75</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE VI</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_706"></div><div style="margin-bottom:12pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><br>Conditions Precedent</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_709"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Conditions Precedent to Initial Credit Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The making of the initial Credit Extension is subject to the satisfaction (or waiver) of the following conditions precedent on or before the Closing Date&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_712"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Administrative Agent shall have received the following documents, duly executed by an Authorized Officer of each Credit Party and each other relevant party&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_715"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;this Agreement&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_718"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Fee Letter, as acknowledged by each Credit Party&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_721"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;a completed Borrowing Base Certificate dated as of July 29, 2022 (provided that, this clause (a)(iii) shall be a condition precedent only to the Credit Extension of the Closing Date Revolving Loans)&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_724"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;the  Intercompany Subordination Agreement&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_727"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;the Guarantee Agreement&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_730"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;the Security Agreement&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_733"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;each Note requested by any Lender&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_736"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;the Perfection Certificate&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_739"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;the Notice of Borrowing, reasonably satisfactory to the Administrative Agent for the Initial Term Loans and reasonably satisfactory to Revolving Agent for the Closing Date Revolver Draw&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_742"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)&#160;&#160;&#160;&#160;the Letter of Direction and flow of funds, reasonably satisfactory to the Agents&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_745"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xi)&#160;&#160;&#160;&#160;Trademark Security Agreement. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_748"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_751"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;To the extent required under the Security Documents, all Capital Stock of each Subsidiary (other than Excluded Subsidiaries) of each Credit Party shall have been pledged to the Administrative Agent.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_754"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;&#91;reserved&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">76</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_757"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;The Administrative Agent shall have received the results of a search of the UCC filings (or equivalent filings), in addition to tax Lien, judgment Lien, bankruptcy and litigation searches made with respect to each Credit Party, together with copies of the financing statements and other filings (or similar documents) disclosed by such searches, and accompanied by evidence satisfactory to the Collateral Agent that the Liens indicated in any such financing statement and other filings (or similar document) are Permitted Liens or have been released or will be released substantially simultaneously with the initial Credit Extensions hereunder.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_760"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iv)&#160;&#160;&#160;&#160;The Collateral Agent shall have received, in form and substance satisfactory to the Collateral Agent, the appropriate UCC (or equivalent) financing statements for filing in such office or offices as may be necessary or, in the opinion of the Collateral Agent, desirable, to perfect the Collateral Agent&#8217;s Liens in and to the Collateral.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Notwithstanding anything to the contrary herein, to the extent a perfected security interest in any Collateral (the security interest in respect of which cannot be perfected by means of the filing of a UCC financing statement, the making of a federal intellectual property filing or delivery of possession of capital stock or other certificated security of any applicable Credit Party) is not able to be provided on the Closing Date after the Borrowers&#8217; use of commercially reasonable efforts to do so, the perfection of such security interest in such Collateral will not constitute a condition precedent to the availability of the Initial Term Loans and Closing Date Revolving Loans on the Closing Date, but a security interest in such Collateral will be required to be perfected after the Closing Date pursuant to arrangements to be mutually agreed between the Borrowers and the Collateral Agent.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_763"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Opinions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Agents shall have received executed legal opinions of (i) King &#38; Spalding LLP, counsel to the Borrowers and the other Credit Parties, which opinion shall be addressed to the Agents and the Lenders and shall be in form and substance reasonably satisfactory to the Agents.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_766"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_769"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reserved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_772"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Officer&#8217;s Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrative Agent shall have received a certificate for each Credit Party, dated the Closing Date, duly executed and delivered by such Credit Party&#8217;s general counsel, secretary, other duly authorized officer, sole shareholder, managing member or general partner, as applicable, as to&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_775"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;resolutions of each such Person&#8217;s board of managers&#47;directors (or other managing body, in the case of a Person that is not a corporation) or shareholder(s) then in full force and effect expressly and specifically authorizing, to the extent relevant, all aspects of the Credit Documents and the other Transaction Documents applicable to such Person and the execution, delivery and performance of each Credit Document and each other Transaction Document, in each case, to be executed by such Person&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_778"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the incumbency and signatures of its certain of its Authorized Officers and any other of its officers, managing member or general partner, as applicable, authorized to act with respect to each Credit Document to be executed by such Person&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">77</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_781"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;each such Person&#8217;s Organization Documents, as amended, modified or supplemented as of Closing Date, with the certificate or articles of incorporation or formation certified by the appropriate officer or official body of the jurisdiction of organization of such Person&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_784"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;certificates of good standing with respect to each Credit Party from its relevant jurisdiction of incorporation or formation, each dated within a recent date prior to the Closing Date, such certificates to be issued by the appropriate officer or official body of the jurisdiction of organization of such Credit Party, which certificate shall indicate that such Credit Party is in good standing in such jurisdiction.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_787"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Solvency Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Administrative Agent shall have received a Solvency Certificate of the chief financial officer of the Administrative Borrower, on behalf of the Credit Parties, confirming the Solvency of the Credit Parties and their Subsidiaries after giving effect to the Transactions.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_790"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Agents shall have received (or in the case of clause (i) below, made available to the Administrative Agent through the materials filed with the SEC) the following documents and reports (each in form and substance reasonably satisfactory to the Agents)&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_793"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the Historical Financial Statements&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_796"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;a pro forma consolidated balance sheet of Parent, dated as of the last day of the most recently ended Fiscal Quarter for which financial statements were required to be filed with the SEC,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">prepared after giving effect to the Transactions as if the Transactions have occurred as of such date, which need not be prepared in compliance with Regulation S-X of the Securities Act of 1933, as amended, or include adjustments for purchase accounting.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_799"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Agents shall have received a certificate of insurance, in each case, as to the insurance required by Section 8.03, in form and substance reasonably satisfactory to the Agents.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_802"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Payment of Outstanding Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  (A)&#160;On the Closing Date, the Credit Parties and each of their respective Subsidiaries shall have no outstanding Indebtedness for borrowed money other than the Loans hereunder and the Indebtedness (if any) listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 7.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, and the Administrative Agent shall have received copies of all documentation and instruments evidencing the discharge of all such Indebtedness paid off in connection with the Transactions on the Closing Date, and (B) all Liens (other than Permitted Liens) securing payment of any such Indebtedness shall have been released and the Administrative Agent shall have received pay-off letters and all form UCC-3 termination statements and other instruments as may be reasonably requested by Administrative Agent in connection therewith. The terms, maturity and subordination of any indebtedness listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 7.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> shall be satisfactory to the Agents.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_805"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Since June 24, 2022, there has not occurred any facts, events, changes, developments or effects which, individually or in the aggregate has constituted or would reasonably be expected to constitute a Material Adverse Effect (as defined in the TPG Acquisition Agreement).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">78</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_808"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Fees and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of the Administrative Agent and each Lender shall have received, for its own respective account, (i) all fees and expenses due and payable to such Person under the Fee Letter and (ii) the reasonable fees, costs and expenses due and payable to such Person pursuant Sections 4.01 and 12.05 (including the reasonable and documented fees, disbursements and other charges of counsel) for which invoices have been presented at least two (2) Business Days prior to the Closing Date.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_811"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Patriot Act Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Administrative Agent shall have received, at least three (3) Business Days prior to the Closing Date, all documentation and other information required by banking regulatory authorities under applicable &#8220;know your customer&#8221; and Anti-Money Laundering Laws, rules and regulations, and any required Patriot Act compliance, the results of which are satisfactory to each Agent in its sole discretion, in each case, to the extent such information is requested at least five (5) Business Days prior to the Closing Date.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_814"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Representations and Acquisition Agreement Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Acquisition Agreement Representations and the Specified Representations shall be true and correct in all material respects, in each case, with the same effect as though such representations and warranties had been made on and as of the date of such Credit Extension (except where such representations and warranties expressly relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects as of such earlier date)&#59; provided, that any representation or warranty that is qualified as to &#8220;materiality,&#8221; &#8220;Material Adverse Effect&#8221; or similar language shall be true and correct in all respects on such respective dates.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_817"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">TPG Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The TPG Acquisition shall have been consummated or shall be consummated substantially concurrently with the initial Credit Extension hereunder in all material respects in accordance with the terms of the TPG Acquisition Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_820"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conditions Precedent to all Credit Extensions after the Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_823"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">No Default&#59; Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">.  The agreement of each Lender to make any Loan requested to be made by it on any date after the Closing Date is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">subject to the satisfaction of the condition precedent that at the time of each such Credit Extension and also after giving effect thereto&#58; (i) no Default or Event of Default shall have occurred and be continuing, (ii) all representations and warranties made by each Credit Party contained herein or in the other Credit Documents shall be true and correct in all material respects, in each case, with the same effect as though such representations and warranties had been made on and as of the date of such Credit Extension (except where such representations and warranties expressly relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects as of such earlier date)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">, that any representation or warranty that is qualified as to &#8220;materiality,&#8221; &#8220;Material Adverse Effect&#8221; or similar language shall be true and correct in all respects on such respective dates, and (iii) no injunction, writ, restraining order, or other order of any nature restricting or prohibiting, directly or indirectly, such Credit Extension shall have been issued and remain in force by any Governmental Authority against any Borrower, the Administrative Agent, any Lender.  The acceptance of the benefits of each Credit Extension shall constitute a representation and warranty by each Credit Party to each of the Lenders that all the applicable conditions specified above are satisfied as of that time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_826"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Prior to the making of each Loan, the Administrative Agent shall have received a Notice of Borrowing (in writing) meeting the requirements of Section 2.02(a) or Section 2.03, as applicable.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_829"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Borrowing Base Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Prior to the making of each Revolving Loan, the Revolving Agent shall have received a Borrowing Base Certificate no later than 11&#58;00 a.m. on the date of such request.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_832"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><br><br>Representations, Warranties and Agreements</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In order to induce the Lenders to enter into this Agreement, make the Loans as provided for herein, the Credit Parties make the following representations and warranties as of the Closing Date and as of the date of making of each Loan thereafter, all of which shall survive the execution and delivery of this Agreement&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_835"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Credit Party and each of their Subsidiaries (a) is a duly organized or formed and validly existing corporation, limited liability company or other registered entity in good standing under the laws of the jurisdiction of its organization and has the corporate or other organizational power and authority to own its property and assets and to transact the business in which it is engaged and (b) has duly qualified and is authorized to do business and is in good standing in all jurisdictions where it does business or owns assets, except where the failure to be so qualified, authorized or in good standing could not reasonably be expected to result in a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_838"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Power and Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Credit Party has the corporate or other organizational power and authority to execute, deliver and carry out the terms and provisions of the Credit Documents to which it is a party and has taken all necessary corporate or other organizational action to authorize the execution, delivery and performance of the Credit Documents to which it is a party.  Each Credit Party has duly executed and delivered the Credit Documents to which it is a party and such Credit Documents constitute the legal, valid and binding obligation of such Credit Party enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, moratorium, reorganization and other similar laws relating to or affecting creditors&#8217; rights generally and general principles of equity (whether considered in a proceeding in equity or law).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_841"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Violation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  None of (a) the execution, delivery and performance by any Credit Party of the Credit Documents to which it is a party and compliance with the terms and provisions thereof, (b) the consummation of the Transactions, or (c) the consummation of the other transactions contemplated hereby or thereby on the relevant dates therefor will (i) contravene in any material respect any applicable provision of any material Applicable Law of any Governmental Authority, (ii) result in any breach of any of the terms, covenants, conditions or provisions of, or constitute a default under, or result in the creation or imposition of (or the obligation to create or impose) any Lien upon any of the property or assets of any Credit Party (other than Permitted Liens and Liens created under the Credit Documents) pursuant to, (A) the terms of any material indenture, loan agreement, lease agreement, mortgage or deed of trust or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B) any other Material Contracts, in the case, of either clause (A) and (B) to which any Credit Party is a party or by which it or any of its property or assets is bound or (iii) violate any provision of the Organization Documents any Credit Party, except with respect to any conflict, breach or contravention or default (but not the creation of Liens other than Permitted Liens) referred to in clauses (ii)(A) or (ii)(B), to the extent that such conflict, breach, contravention or default could not reasonably be expected to have a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_844"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation, Labor Controversies, etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  There is no litigation, action, proceeding or labor controversy (including, without limitation, strikes, lockouts or slowdowns) against the Credit Parties or any of their respective Subsidiaries that is pending or, to the knowledge of any Credit Party, threatened in writing except as disclosed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and other matters that could not reasonably be expected to (x) have a Material Adverse Effect, or (y) result in monetary judgments or relief, individually or in the aggregate, in excess of $15,000,000 or (b) which purports to affect the legality, validity or enforceability of any Credit Document, any Transaction Document or the Transactions.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_847"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Proceeds&#59; Regulations U and X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The proceeds of the Loans are intended to be and shall be used solely for the purposes set forth in and permitted by Section 8.10.  No Credit Party is engaged in the business of extending credit for the purpose of purchasing or carrying margin stock, and no proceeds of any Credit Extension will be used to purchase or carry margin stock or otherwise for a purpose which violates, or would be inconsistent with Regulation&#160;U or Regulation X.  No Credit Party and no Subsidiary of any Credit Party owns any margin stock.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_850"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 7.06&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Approvals, Consents, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  No authorization or approval or other action by, and no notice to or filing with, any Governmental Authority or other Person, and no consent or approval under any contract or instrument (other than (a) those that have been duly obtained or made and which are in full force and effect, or if not obtained or made, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect, (b) the filing of UCC financing statements and other equivalent filings for foreign jurisdictions and (c) to the extent the Capital Stock of any Licensed Insurance Entity is subject to any Applicable Laws affecting any future rights or remedies of a Secured Party with respect to such Capital Stock) is required for the consummation of the Transactions or the due execution, delivery or performance by any Credit Party of any Credit Document to which it is a party, or for the due execution, delivery or performance of the other Credit Documents, in each case by any of the parties thereto.  There does not exist any judgment, order, injunction or other restraint issued or filed with respect to the transactions contemplated by the Credit Documents, the consummation of the Transactions, the making of any Credit Extension or the performance by the Credit Parties or any of their respective Subsidiaries of their Obligations under the Credit Documents.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_853"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 7.07&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Investment Company Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  No Credit Party is required to be registered, or will be required to be registered after giving effect to the Transactions and the transactions contemplated under the Credit Documents, as an &#8220;investment company&#8221; or a company &#8220;controlled&#8221; by an &#8220;investment company,&#8221; within the meaning of the Investment Company Act of 1940.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_856"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.08&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Full Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_859"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In connection with the execution of this Agreement and the Transactions, Credit Parties have disclosed to the Administrative Agent and the Lenders all agreements, instruments and corporate or other restrictions to which any Credit Party or any of its Subsidiaries is subject, and all other matters known to them, that, individually or in the aggregate, could reasonably be expected to have Material Adverse Effect.  None of the factual written information and data (taken as a whole) at any time furnished by any Credit Party, any of their respective Subsidiaries or any of their respective authorized representatives in writing to the Administrative Agent or any Lender (including all information contained in the representations and warranties, reports, exhibits or otherwise in the Credit Documents but excluding the Budget, any pro forma financial information or projections, which are subject to the requirements of clause (b) below) for purposes of or in connection with this Agreement contains any untrue statement of a material fact or omits to state any material fact necessary to make such information and data (taken as a whole) not materially misleading, in each case, at the time such information was provided in light of the circumstances under which such information or data was furnished.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_862"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Budget, pro forma financial information, Liquidity calculations and projections provided pursuant to this Agreement were prepared in good faith based upon assumptions believed by the Credit Parties to be reasonable at the time made in light of then current market conditions, it being recognized by the Administrative Agent and the Lenders that such projections as to future events are not to be viewed as facts, are subject to uncertainties and contingencies, and that actual results during the period or periods covered by any such projections are not guaranties of financial performance and may differ from the projected results and such differences may be material.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_865"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.09&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Condition&#59; No Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_868"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Historical Financial Statements present fairly in all material respects the financial position and results of operations of the Credit Parties at the respective dates of such information and for the respective periods covered thereby, subject in the case of unaudited financial information, to changes resulting from normal year end audit adjustments and to the absence of footnotes.  The Historical Financial Statements and all of the balance sheets, all statements of income and of cash flow and all other financial information furnished pursuant to Section 8.01 have been and will for all periods following the Closing Date be prepared in accordance with GAAP consistently applied.  All of the financial information furnished pursuant to Section 8.01 presents fairly in all material respects the financial position and results of operations of the Credit Parties at the respective dates of such information and for the respective periods covered thereby, subject in the case of unaudited financial information, to changes resulting from normal year end audit adjustments and to the absence of footnotes.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_871"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To the knowledge of any Credit Party, there are no material liabilities of any Credit Party of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise, and there is no existing condition, situation or set of circumstances which could reasonably be expected to result in any such liabilities, other than those liabilities provided for or disclosed in the most recently delivered financial statements pursuant to Section 8.01 or otherwise disclosed hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_874"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Since December 31, 2021, there has been no circumstance, event or occurrence, and no fact is known to the Credit Parties that has resulted in or could reasonably be expected to result in a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_877"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Returns and Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Credit Party has filed all applicable federal and state income Tax returns and all other material Tax returns, domestic and foreign, required to be filed by them and has paid all material Taxes and assessments payable by them that have become due, other than those not yet delinquent or being diligently contested in good faith by appropriate proceedings and by proper proceedings which stay the enforcement of any Lien as to which such Credit Party has maintained adequate reserves in accordance with GAAP.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_880"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect&#58;  (a) each Pension Plan is in compliance with ERISA, the Code and any Applicable Law&#59; (b) no ERISA Event has occurred (or is reasonably likely to occur)&#59; (c) each Pension Plan that is intended to qualify under Section 401(a) of the Code has received a favorable determination or opinion letter from the Internal Revenue Service, and nothing has occurred subsequent to the issuance of such determination letter which would reasonably be expected to prevent, or cause the loss of, such qualification&#59; (d) no failure by any Credit Party or any ERISA Affiliate to make any required contribution to a Multiemployer Plan when due has occurred&#59; (e) none of the Credit Parties or any ERISA Affiliate has incurred (or is reasonably expected to incur) any liability to or on account of a Plan pursuant to Section 409, 502(i), 502(l), 515, 4062, 4063, 4064, 4069, 4201 or 4204 of ERISA or Section 4971 or 4975 of the Code&#59; and (f) no Lien imposed under the Code or ERISA on the assets of any of the Credit Parties or any ERISA Affiliate exists (or is reasonably likely to exist).  Except as could not reasonably be expected to have a Material Adverse Effect, no employee welfare benefit plan within the meaning of &#167; 3(1) or &#167; 3(2)(B) of ERISA of any Credit Party provides benefit coverage subsequent to termination of employment except as required by Title I, Subtitle B, Part 6 of ERISA or applicable state insurance laws.  With respect to any Foreign Plan, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect&#58; (a) all employer and employee contributions required by applicable law or by the terms of such Foreign Plan have been made or, if applicable, accrued in accordance with normal accounting practices&#59; (b) the accrued benefit obligations of each Foreign Plan (based on those assumptions used to fund such Foreign Plan) with respect to all current and former participants do not exceed the assets of such Foreign Plan&#59; (c) each Foreign Plan that is required to be registered has been registered and has been maintained in good standing and applicable regulatory authorities&#59; and (d) each Foreign Plan is in compliance in all material respects with applicable law and regulations and with the terms of such Foreign Plan.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_883"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 7.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Capitalization and Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 7.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> as of the Closing Date, no Credit Party and no Subsidiary of any Credit Party (a) has any Subsidiaries or (b) is engaged in any joint venture or partnership with any other Person.  All of the issued and outstanding Capital Stock of each of the Credit Parties and their Subsidiaries is validly issued, fully paid and nonassessable, free and clear of all Liens, except those created under the Credit Documents.  All such securities were issued in compliance with all Applicable Laws concerning the issuance of securities.  Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 7.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, on the Closing Date there are no pre-emptive or other outstanding rights to purchase, options, warrants or similar rights or agreements (other than stock options granted to employees) pursuant to which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">83</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">any Credit Party may be required to issue, sell, repurchase or redeem any of its Capital Stock or any Capital Stock of its Subsidiaries.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_886"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Credit Party and each of its Subsidiaries owns, or possesses the right to use, all of the material trademarks, service marks, trade names, copyrights, patents, patent rights, licenses and other intellectual property rights that are reasonably necessary for the operation of their respective businesses.  To the knowledge of each Credit Party, the use of such material intellectual property does not infringe upon any intellectual property rights held by any other Person, except as could not reasonably be expected to have a Material Adverse Effect.  Except as specifically set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and as could not reasonably be expected to have a Material Adverse Effect, no claim or litigation regarding any of the foregoing is pending or, to the knowledge of such Credit Party threatened in writing.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_889"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Environmental</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_892"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;Except as would not reasonably be expected to result in a Material Adverse Effect&#58; (i) the Credit Parties and each of their respective Subsidiaries are in compliance with all material Environmental Laws in all jurisdictions in which the Credit Parties or such Subsidiary, as the case may be, are currently doing business (including obtaining, maintaining in full force and effect, and complying with all Permits required under Environmental Laws to operate the business of the Credit Parties and their respective Subsidiaries as currently conducted)&#59; (ii) none of the Credit Parties or any of their respective Subsidiaries is subject to any material Environmental Claim or any other material liability under any Environmental Law that is pending or, to the knowledge of such Credit Party, threatened in writing&#59; (iii) to the knowledge of the Credit Parties, there are no conditions relating to the formerly owned Real Property that could reasonably be expected to give rise to any material Environmental Claim against any of the Credit Parties or any of their Subsidiaries and (iv) no Lien in favor of any Governmental Authority securing, in whole or in part, material Environmental Claims has attached to any Real Property of any of the Credit Parties or any of their Subsidiaries.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_895"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;None of the Credit Parties or any of their respective Subsidiaries has treated, stored, transported, Released or disposed of Hazardous Materials at, from, on or under any currently or formerly owned Real Property, facility relating to its business, or, to the knowledge of any Credit Party, any other location, in each case, in a manner that could reasonably be expected to give rise to an Environmental Claim that could result in a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_898"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Each Credit Party has made available to the Administrative Agent copies of all existing material environmental assessment reports, assessments, reviews, audits, correspondence and other documents and data that have a material bearing on actual or potential Environmental Claims or compliance with Environmental Laws, in each case to the extent such reports, assessments, reviews, audits and documents and data are in their possession or reasonable control. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_901"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;This Section 7.14 contains the sole and exclusive representations and warranties of the Credit Parties with respect to matters arising under or relating to Environmental Laws, Environmental Claims, Hazardous Materials, Releases, or any other environmental, health or safety matters. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">84</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_904"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ownership of Properties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is a list of all of the Real Property owned or leased by any of the Credit Parties or their respective Subsidiaries as of the Closing Date, indicating, in each case, whether the respective property is owned or leased, the identity of the owner or lessor and the location of the respective property.  Each Credit Party owns (a)&#160;in the case of owned Real Property, good, indefeasible and marketable fee simple title to such Real Property, (b)&#160;in the case of owned personal property, good and valid title to such personal property and (c) in the case of leased Real Property or personal property, valid, subsisting, marketable, insurable and enforceable (except as may be limited by bankruptcy, insolvency, moratorium, fraudulent conveyance or other laws applicable to creditors&#8217; rights generally and by generally applicable equitable principles, whether considered in an action at law or in equity) leasehold interests (as the case may be) in such leased property, in each case, free and clear in each case of all Liens, except for Permitted Liens.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_907"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  None of the Credit Parties or any of their respective Subsidiaries is in default under or with respect to, or a party to, any Material Contract (copies of which have been received by the Administrative Agent) (other than any such Material Contract in respect of Indebtedness) that could, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.  Upon the effectiveness of this Agreement and the other Credit Documents, none of the Credit Parties or any of their respective Subsidiaries is in default under or with respect to any Material Contract in respect of Indebtedness the breach of which could reasonably be expected to have a Material Adverse Effect.  No Default has occurred and is continue or would result from the consummation of the transactions contemplated by this Agreement or any other Credit Document.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_910"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On the Closing Date after giving effect to the Transactions, Parent and its Subsidiaries, on a consolidated basis, are Solvent.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_913"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Insurance Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as set forth on Schedule 7.18 or as otherwise permitted under this Agreement, no Licensed Insurance Entity is (i) party to any credit agreement, loan agreement, indenture, guarantee, letter of credit, note, bond or other arrangement providing for or otherwise relating to any Indebtedness owed to any third party for borrowed money or any extension of credit (or commitment for any extension of credit), or (ii) subject to any Lien upon any property or assets of any kind (real or personal, tangible or intangible) of any such Licensed Insurance Entities (including its Capital Stock).  Notwithstanding anything in this Agreement to the contrary, the existence of restrictions or requirements under Applicable Laws with respect to Licensed Insurance Entities shall not be deemed to constitute a Lien or contravene any provision hereof, including this Section 7.18.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_919"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Laws&#59; Authorizations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Credit Party and each of its Subsidiaries (a) has complied and is complying with all Applicable Laws, (b) is in possession of and has all requisite Permits, governmental licenses, authorizations, consents and approvals required under Applicable Laws and (c) to the extent due and owing has fully paid all applicable user fees, to operate its business and relating to the Credit Party&#8217;s Products as currently conducted except, in each case, to the extent that failure to do so could not, in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">85</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_922"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Contractual or Other Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Other than the Credit Documents and to the extent permitted by Section 9.10, no Credit Party or any of its Subsidiaries, other than the Licensed Insurance Entities, is a party to any agreement or arrangement or subject to any Applicable Law that limits its ability to pay dividends to, or otherwise make Investments in or other payments to any Credit Party, that limits its ability to grant Liens in favor of the Administrative Agent or that otherwise limits its ability to perform the terms of the Credit Documents.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_925"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 7.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  All representations and warranties of (a)&#160;the Credit Parties (other than the TPG Entities) set forth in the Transaction Documents and (b)&#160;to the best knowledge of the Credit Parties, of each other Person, including, but not limited to, the TPG Parties (other than Lenders) party to the Transaction Documents, were true and correct in all material respects as of the time as of which such representations and warranties were made and shall be true and correct in all material respects as of the Closing Date as if such representations and warranties were made on and as of such date (unless such representation or warranty is given as of a specific date).  No default or event of default has occurred and is continuing under any Credit Document.  Each Credit Document is in full force and effect, enforceable against each of the Credit Parties thereto (except as may be limited by bankruptcy, insolvency, moratorium, fraudulent conveyance or other laws applicable to creditors&#8217; rights generally and by generally applicable equitable principles, whether considered in an action at law or in equity), the TPG Acquisition Agreement has not been amended or modified except as disclosed to the Administrative Agent on or prior to the Closing Date or otherwise in accordance with Section 9.07, and no waiver or consent has been granted under such document, except in accordance with Section 9.07.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_928"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Collective Bargaining Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Set forth on Schedule 7.22 is a list (including dates of expiration) of all collective bargaining or similar agreements between any Credit Party or any of its Subsidiaries and any labor union, labor organization or other bargaining agent, in respect of the employees of any Credit Party or any of its Subsidiaries as of the date hereof.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_931"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The properties of each Credit Party are insured with financially sound and reputable insurance companies which are not Affiliates of any Credit Party against loss and damage in such amounts, with such deductibles and covering such risks as are customarily carried by Persons of comparable size and of established reputation engaged in the same or similar businesses and owning similar properties in the general locations where such Credit Party operates, in each case as described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as in effect on the Closing Date.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_934"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Evidence of Other Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is a complete and correct list of each credit agreement, loan agreement, indenture, purchase agreement, guarantee, letter of credit or other arrangement providing for or otherwise relating to any Indebtedness or any extension of credit (or commitment for any extension of credit) to, any Credit Party outstanding on the Closing Date which will remain outstanding after the Closing Date (other than this Agreement and the other Credit Documents), and the aggregate principal or face amount outstanding in excess of $250,000, so long as the aggregate amount of all such Indebtedness does not exceed $1,000,000 under each such arrangement as of the Closing Date is correctly described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">86</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_937"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_940"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 7.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Foreign Assets Control Regulations&#59; Anti-Money Laundering and Anti-Corruption Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Each Credit Party and each Subsidiary of each Credit Party is (x) in compliance in all material respects with all U.S. economic sanctions laws, executive orders and implementing regulations (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) as promulgated by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), and (y) in compliance in all material respects with all applicable anti-money laundering and counter-terrorism financing provisions of the Bank Secrecy Act and all regulations issued pursuant to it.  No Credit Party and no Subsidiary or Affiliate of a Credit Party (i) is a Person designated by the U.S. government on the list of the Specially Designated Nationals and Blocked Persons (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">SDN List</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) with which a U.S. Person cannot deal with or otherwise engage in business transactions, (ii) is a Person who is otherwise the target of U.S. economic sanctions laws such that a U.S. Person cannot deal or otherwise engage in business transactions with such Person or (iii) is controlled by (including without limitation, by virtue of such Person being a director or owning voting shares or interests), or acts, directly or indirectly, for or on behalf of, any Person or entity on the SDN List or a foreign government that is the target of U.S. economic sanctions prohibitions such that the entry into, or performance under, this Agreement or any other Credit Document would be prohibited under U.S. law.  Each Credit Party and each Subsidiary of each Credit Party is in compliance in all material respects with all applicable Anti-Corruption Laws.  None of the Credit Parties or any Subsidiary thereof, nor to the knowledge of the Borrower, any director, officer, agent, employee, or other person acting on behalf of a Credit Party or any Subsidiary, has taken any action, directly or indirectly, that would result in a violation in any material respect of applicable Anti-Corruption Laws.  Each Credit Party and each Subsidiary of a Credit Party has instituted and will continue to maintain policies and procedures reasonably designed to promote compliance with Applicable Anti-Corruption laws.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_943"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.27&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Patriot Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Credit Parties, each of their Subsidiaries and each of their controlled Affiliates are in compliance in all material respects with (a) the Trading with the Enemy Act, and each of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B Chapter V, as amended) and any other enabling legislation or executive order relating thereto, (b) the Patriot Act and (c) other federal or state laws relating to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">know your customer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and Anti-Money Laundering Laws, rules and regulations.  No part of the proceeds of any Loan will be used directly or indirectly for any payments to any government official or employee, political party, official of a political party, candidate for political office or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_946"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.28&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holding Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of Parent and EH Holding Company, Inc. is a holding company and does not have any material liabilities (other than liabilities arising under the Credit Documents and Convertible Senior Notes), own any material assets (other than the Equity Interests of Borrower) or engage in any operations or business except as permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_949"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.29&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Flood Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Parent and its Subsidiaries maintain, if available, fully paid flood hazard insurance on all Real Property that is located in a special flood hazard area and that constitutes Collateral, on such terms and in such amounts as required by Flood Insurance Laws or as otherwise reasonably required by the Administrative Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">87</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_952"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.30&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Location of Collateral&#59; Equipment List</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 7.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> lists&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_955"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;all places at which Records relating to the Collateral, including, but not limited to, all Documents and Instruments relating to receivables and Inventory, are maintained by Borrower or by any other Person&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_958"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;subject to Section 9.15, all places where the Credit Parties&#8217; Collateral is located and whether the premises are owned or leased by Credit Parties or whether the premises are the premises of a warehouseman, bailee or other third party, and if owned by a third party, the name and address of such third party.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_961"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.31&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Health Care Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_964"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Health Care Laws&#59; Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Parent, each of its Subsidiaries and each Licensed Insurance Entity is and has for the last six (6) years been in compliance in all material respects with all Health Care Laws applicable to it, its products and its properties or other assets or its business or operation. Parent, each of its Subsidiaries and each Licensed Insurance Entity and, any Person acting on their behalf, has in effect all Permits, including, without limitation, all Permits necessary for it to own, lease or operate its properties and other assets and to carry on its business and operations, as presently conducted, except where the failure to have any such Permit would not be material to any of Parent, its Subsidiaries or the Licensed Insurance Entities. All such Permits are in full force and effect and there exists no default under, or material violation of, any such Permit and none of Parent, any of its Subsidiaries or any Licensed Insurance Entity has received notice of any current or proposed limitation, suspension, termination or revocation of any such Permit.  Except as set forth on Schedule 7.31, no action, demand, requirement or investigation by any Governmental Authority (excluding, for the avoidance of doubt, routine audits that occur in the ordinary course of business) and no material suit, action or proceeding by any other person, in each case with respect to any of Parent, any Subsidiary or any Licensed Insurance Entity is pending or, to the knowledge of such Person, threatened.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_967"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, all material reports, documents, claims, notices or approvals required to be filed, obtained, maintained or furnished pursuant to any Health Care Law to any Governmental Authority have been so filed, obtained, maintained or furnished, and all such material reports, documents, claims and notices were complete and correct in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_970"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  None of Parent, its Subsidiaries or any Licensed Insurance Entity has made an untrue statement of a material fact or fraudulent statement to any Governmental Authority, or, to the knowledge of any of Parent, its Subsidiaries or any Licensed Insurance Entity, (i) failed to disclose a material fact required to any Governmental Authority, or (ii) committed an act, or made a statement that, at the time such act occurred or such statement was made, would reasonably be expected to constitute a violation of any Health Care Law. None of Parent, its Subsidiaries or any Licensed Insurance Entity, officer, nor to the knowledge of any of Parent, its Subsidiaries or any Licensed Insurance Entity, any affiliate, employee or agent of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">88</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any of Parent, its Subsidiaries or any Licensed Insurance Entity, has made any untrue statement of a material fact regarding material claims incurred but not reported.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_973"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Each Licensed Insurance Entity has the requisite contract, license, enrollment, or other Permit to fulfill its obligations as (i) a Medicare Advantage organization in the Medicare program, (ii) a managed care organization in the respective Medicaid program in the state or states in which such Licensed Insurance Entity operates, (iii) a provider service network in the state or states in which such Licensed Insurance Entity operates, or (iv) as a health maintenance organization, managed care organization, or health insurance plan providing commercial health insurance in the state or states in which such Licensed Insurance Entity operates. Except as set forth on Schedule 7.31 there is no investigation, audit, claim, or other action pending, or to the knowledge of any of Parent, its Subsidiaries or any Licensed Insurance Entity, threatened which could reasonably be expected to result in a revocation, suspension, termination, probation, restriction or limitation, or non-renewal of the contract or other Permit necessary for a Licensed Insurance Entity to operate as a managed care organization under the Medicare program, the respective Medicaid program in the state or states in which such entity operates, or as a managed care organization providing commercial health insurance in the state or states in which such Licensed Insurance Entity operates.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_976"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accreditation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of Parent, its Subsidiaries and any Licensed Insurance Entity has received and maintains accreditation in good standing and without limitation or impairment by all applicable accrediting organizations, to the extent required by Applicable Laws.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_979"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to the knowledge of any Credit Party, there are no facts, circumstances or conditions that would reasonably be expected to form the basis for any material investigation, suit, claim, audit, action (legal or regulatory) or proceeding (legal or regulatory) by a Governmental Authority against or affecting any of Parent, its Subsidiaries or any Licensed Insurance Entity relating to any of the Health Care Laws. As of the Closing Date, none of Parent, its Subsidiaries or any Licensed Insurance Entity (1) is a party to a corporate integrity agreement, (2) has any reporting obligations pursuant to a settlement agreement, or (3) has any material reporting obligations pursuant to a plan of correction or other remedial measure entered into with any Governmental Authority in connection with any actual or alleged noncompliance with Health Care Laws.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_982"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Prohibited Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  During the past six (6) years, none of Parent, its Subsidiaries or any Licensed Insurance Entity has, directly or indirectly&#58; (1) given or agreed to give, or is aware that there has been made or that there is any illegal agreement to make, any illegal gift or gratuitous payment of any kind, nature or description (whether in money, property or services) to any past, present or potential patient, supplier, contractor, or any other person in material violation in any material respect of any Health Care Law&#59; (2) made or agreed to make, or is aware that there has been made or that there is any agreement to make, any contribution, payment or gift of funds or property to, or for the private use of, any governmental official, employee or agent where either the contribution, payment or gift or the purpose of such contribution, payment or gift is or was illegal in any material respect under the laws of any Governmental Authority having jurisdiction over such payment, contribution or gift&#59; (3) established or maintained any unrecorded fund or asset for any purpose or made any misleading, false or artificial entries on any of its books or records for any reason to the extent any such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">89</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">action would reasonably be expected to result in a Material Adverse Effect&#59; or (4) made, or agreed to make, or is aware that there has been made or that there is any agreement to make, any payment to any person with the intention or understanding that any part of such payment would be in material violation in any material respect of any Health Care Law.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_985"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  None of Parent, its Subsidiaries or any Licensed Insurance Entity is or, to the knowledge of any of Parent, its Subsidiaries or any Licensed Insurance Entity, has been threatened to be, (i) excluded from any federal health care program pursuant to 42 U.S.C. &#167; 1320a-7b and related regulations, (ii) &#8220;suspended&#8221; or &#8220;debarred&#8221; from selling products to the U. S. government or its agencies pursuant to the Federal Acquisition Regulation, relating to debarment and suspension applicable to federal government agencies generally (42 C.F.R. Subpart 9.4), or other Applicable Laws, or (iii) made a party to any other action by any Governmental Authority that may prohibit it from selling products to any governmental or other purchaser pursuant to any federal, state or local laws or regulations.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_988"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HIPAA Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the extent applicable to any of Parent, its Subsidiaries or any Licensed Insurance Entity and for so long as (1) any of Parent, its Subsidiaries or any Licensed Insurance Entity is a &#8220;covered entity&#8221; as defined in 45 C.F.R. &#167; 160.103, (2) any of Parent, its Subsidiaries or any Licensed Insurance Entity is a &#8220;business associate&#8221; as defined in 45 C.F.R. &#167; 160.103, (3) any of Parent, its Subsidiaries or any Licensed Insurance Entity is subject to or covered by the HIPAA Administrative Requirements codified at 45 C.F.R. Parts 160 &#38; 162 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Transactions Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and&#47;or the HIPAA Security and Privacy Requirements codified at 45 C.F.R. Parts 160 &#38; 164 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Privacy and Security Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and&#47;or (4) any of Parent, its Subsidiaries or any Licensed Insurance Entity sponsors any &#8220;group health plans&#8221; as defined in 45 C.F.R. &#167; 160.103, such Person has&#58; (i) developed and implemented appropriate safeguards to comply with HIPAA and (ii) is and has been for the past six (6) years in material compliance with HIPAA.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_991"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Integrity Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  None of Parent, its Subsidiaries or any Licensed Insurance entity, nor any officer, director, partner, agent, or managing employee of Parent, its Subsidiaries, or any Licensed Insurance Entity, is party to or bound by any individual integrity agreement, corporate integrity agreement, corporate compliance agreement, deferred prosecution agreement, or other formal or informal agreement with any Governmental Authority arising from actual or alleged noncompliance any Applicable Laws.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_994"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.32&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As to each Account that is identified by any Credit Party as an Eligible Account in a Borrowing Base Certificate submitted to Revolver Agent, such Account is (a) a bona fide existing payment obligation of the applicable Account Debtor created by the rendition of services to such Account Debtor in the ordinary course of a Credit Party&#8217;s business, (b) owed to a Credit Party without any known defenses, disputes, offsets, counterclaims, or rights of return or cancellation, and (c) not excluded as ineligible by virtue of one or more of the excluding criteria (other than any Revolver Agent-discretionary criteria) set forth in the definition of Eligible Accounts.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">90</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_997"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><br><br>Affirmative Covenants</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Credit Parties hereby covenant and agree that on the Closing Date and thereafter, until the Commitments have been terminated and the Loans and all other Obligations incurred hereunder (other than Unasserted Contingent Obligations) are paid in full in accordance with the terms of this Agreement&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1000"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Information, Reports, Notices and Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Credit Parties will furnish the Administrative Agent for further distribution to each Lender copies of the following financial statements, reports, notices and information </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that as to any information contained in materials filed with the SEC, Parent shall not be separately required to furnish such information under Sections 8.01(b) and (c) below)&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1003"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within thirty (30) days after the end of each month, a monthly Liquidity report based upon (and including) Parent&#8217;s and its Subsidiaries&#8217; account statements, together with a certification from an Authorized Officer of Parent, that Parent is in compliance with the minimum Liquidity requirement set forth in Section 9.13(b) in a form reasonably acceptable to Administrative Agent.  To the extent that any 2024 Convertible Notes or 2025 Convertible Notes are outstanding on the date that is four (4) months prior to the respective maturity date in such Convertible Senior Notes (each such date, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Maturity Test Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Borrower shall provide a Liquidity report on such Maturity Test Date, and thereafter on a weekly basis (or as frequently as may be requested by any Agent), demonstrating that the Maturity Date has not occurred.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1006"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Quarterly Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within forty-five (45) days after the end of each Fiscal Quarter of Parent and its Subsidiaries, (i) unaudited consolidated balance sheets of the Parent and its Subsidiaries as of the end of such Fiscal Quarter and (i) unaudited consolidated statements of income and cash flow of the Parent and its Subsidiaries for such Fiscal Quarter, including, in comparative form (both in Dollar and percentage terms) the figures for the corresponding Fiscal Quarter in, and year-to-date portion of, the immediately preceding Fiscal Year of Parent, certified as complete and correct by an Authorized Officer of the Administrative Borrower.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1009"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Annual Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Within ninety (90)&#160;days after the end of each Fiscal Year of Parent, copies of the consolidated balance sheets of Parent and its Subsidiaries, and the related consolidated statements of income and cash flows of Parent and its Subsidiaries for such Fiscal Year, setting forth in comparative form the figures for the immediately preceding Fiscal Year, such consolidated statements to be audited and certified accompanied by a report and unqualified opinion of Deloitte or another independent firm of certified public accountants of nationally recognized standing (or regionally recognized standing if reasonably acceptable to the Administrative Agent) (which report and opinion shall (x) state that such financial statements present fairly in all material respects the financial position for the periods indicated in conformity with GAAP applied on a basis consistent with prior years and (y) not be subject to any &#8220;going concern&#8221; or like qualifications or exceptions or any qualifications or exception as to the scope of the audit (other than as may be required as a result of (A) an actual </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">91</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">or prospective default or event of default with respect to any financial covenant (including the financial covenant set forth in Section 9.13) or (y) the impending maturity of any Indebtedness)).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1012"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Concurrently with the delivery of the financial information pursuant to clauses (b) and (c) above, a Compliance Certificate, executed by an Authorized Officer of the Administrative Borrower, (i) showing compliance with the Financial Performance Covenants and stating that no Default or Event of Default has occurred and is continuing (or, if a Default or an Event of Default has occurred, specifying the details of such Default or Event of Default and the actions taken or to be taken with respect thereto) and (ii) specifying any change in the identity of the Subsidiaries as at the end of such Fiscal Year or period, as the case may be, from the Subsidiaries identified to the Lenders on the Closing Date or the most recent Fiscal Quarter or period, as the case may be.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1015"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Entity Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the extent not delivered in accordance with clause (b) above, concurrently with the delivery of the financial information pursuant to clause (b) above, the Credit Parties shall deliver to the Administrative Agent statutory reporting provided in the ordinary course of business and consistent with past practices with respect to Justify Holdings, Inc. and quarterly summaries of operations provided to the respective board of directors (or equivalent governing body) of Justify Holdings, Inc..</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1018"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Within sixty (60) days after to the commencement of each Fiscal Year of Parent, commencing with its Fiscal Year 2023, the forecasted financial projections for the then current Fiscal Year (on a month-by-month basis), in each case (including projected consolidated balance sheet of Parent and its Subsidiaries as of the end of the following Fiscal Year, the related consolidated statements of projected cash flow, and projected income and a description or discussion of the underlying assumptions applicable thereto), in each case, as customarily prepared by management of the Credit Parties for their internal use consistent in scope with the financial statements provided pursuant to Section 8.01(b), setting forth (or offering a discussion of) the principal assumptions on which such projections are based (such projections, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1021"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Defaults</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  As soon as possible and in any event within five (5) Business Days after an Authorized Officer of the Administrative Borrower or any of its Subsidiaries obtains knowledge thereof, notice from an Authorized Officer of the Administrative Borrower of (i) the occurrence of any event that constitutes a Default or an Event of Default, which notice shall specify the nature thereof, the period of existence thereof and what action the applicable Credit Parties propose to take with respect thereto or (ii) the occurrence of a breach or nonperformance of, or any default under, any other Material Contracts of any Credit Party or any Subsidiary of a Credit Party, or any violation of, or noncompliance with any Applicable Laws (including Health Care Laws), in each case, which would reasonably be expected to result, either individually or in the aggregate, in a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1024"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Other Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  As soon as possible and in any event within five (5) Business Days after an Authorized Officer of the Administrative Borrower or any of its Subsidiaries obtains knowledge thereof, notice from an Authorized Officer of the Administrative Borrower of (i) the commencement of, or any material development in, any litigation, action, proceeding or labor controversy or proceeding affecting any Credit Party or any Subsidiary of any Credit Party or its respective property (A) in which the amount of damages claimed is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">92</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">$15,000,000 or more, (B) which would reasonably be expected to have a Material Adverse Effect, (C) which purports to affect the legality, validity or enforceability of any Credit Document, any other Transaction Document or (D) in which the relief sought is an injunction or other stay of the performance of this Agreement, any other Credit Document or any other document or instrument referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, or (ii) the occurrence of any development with respect to any litigation, action, proceeding or labor controversy described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 7.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that would reasonably be expected to result in a Material Adverse Effect, and, in each case, together with a statement of an Authorized Officer of the Administrative Borrower, which notice shall specify the nature thereof, and what actions the applicable Credit Parties propose to take with respect thereto, and, to the extent the Administrative Agent requests, copies of all documentation related thereto.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1027"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As soon as possible and in any event within five (5) Business Days after any Credit Party obtains knowledge of the occurrence of a breach or default or notice of termination by any party under, or material amendment entered into by any party to, any Transaction Document or any other document or instrument referred to in Section 9.07, a statement of an Authorized Officer of the Administrative Borrower setting forth details of such breach or default or notice of termination and the actions taken or to be taken with respect thereto and, if applicable, a copy of such amendment.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1030"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Management Letters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Promptly upon, and in any event within five (5) Business Days after, receipt thereof, copies of all &#8220;management letters&#8221; submitted to any Credit Party by the independent public accountants referred to in Section 8.01(c) in connection with each audit made by such accountants.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1033"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Casualty Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  With reasonable promptness, but in any event within five (5) days after any Credit Party obtains knowledge thereof, notice of any casualty or condemnation event with respect to a material portion of the Collateral.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1036"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Other Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  With reasonable promptness, such other information (financial or otherwise) as any Agent on its own behalf or on behalf of any Lender may reasonably request in writing from time to time, including with respect to any wind down process or release of statutory capital or other capital reserves&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that, notwithstanding anything herein to the contrary, none of the Parent nor any Subsidiary will be required to disclose or permit the inspection or discussion of, any document, information or other matter (i) in respect of which disclosure to any Agent or any Lender (or their respective contractors) is prohibited by law or any binding agreement (or would otherwise cause a breach or default thereunder) or (ii) that is subject to attorney-client or similar privilege or constitutes attorney work product.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1039"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within ten (10) Business days (or such longer prior as reasonably agreed to by the Administrative Agent) of the delivery of the financial statements provided for in Section 8.01(c), a report of a reputable insurance broker with respect to insurance policies maintained by the Credit Parties.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1042"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Convertible Senior Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No event later than five (5) days after delivery thereof, copies of all material statements, reports and notices made available to or from the Trustee with respect to any Convertible Senior Notes.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">93</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1045"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Health Care Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1048"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;In no event later than five (5) Business Days after delivery thereof, of any notice from any Governmental Authority of any investigation or audit, or pending or threatened proceedings relating to, any violation by Parent, any Subsidiary, or any Licensed Insurance Entity of any Applicable Laws, including or Health Care Laws, in each case, solely to the extent the same would reasonably be expected to result in a Material Adverse Effect.   </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1051"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;No later than five (5) Business Days after delivery thereof, the receipt of notice from any Governmental Authority threatening to limit, revoke, suspend or materially modify any Permit or contract held by any Licensed Insurance Entity that would reasonably be expected to result in a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1054"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Promptly notify, in the event that Parent, any Subsidiary, or any Licensed Insurance Entity experiences any (I) Breach of Unsecured Protected Health Information as &#8220;Breach,&#8221; &#8220;Unsecured Protected Health Information&#8221; and &#8220;Protected Health Information&#8221; are defined by HIPAA, or (II)  a Security Incident as &#34;Security Incident&#34; is defined by HIPAA, in each case which materially impacts the security or integrity of Parent, any Subsidiary, or any Licensed Insurance Entity.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1057"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;In no event later than five (5) Business Days after execution thereof, in the event that Parent, any Subsidiary, or any Licensed Insurance Entity becomes a party to or becomes bound by any corporate integrity agreement, corporate compliance agreement, deferred prosecution agreement, or other formal agreement with any Governmental Authority concerning compliance with Health Care Laws.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1060"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;Promptly, but in any event within three (3) days, notify the Administrative Agent if average daily Liquidity for the trailing seven (7) day period is less than $30,000,000.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1063"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Wind Down Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  With respect to Justify Holdings, Inc., promptly upon any material development relating to any wind down process, provide the Administrative Agent with a written notification setting forth the details of such material development, along with copies of any relevant documentation relating to such material development, including any notices or written communications from any Governmental Authority with respect to such material development.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, the obligations in clauses (b) and (c) of this Section 8.01 may be satisfied with respect to financial information of the Parent and the Subsidiaries by filing the Form 10-K, 10-Q or 8-K, as applicable, of the Parent with the Securities Exchange Commission.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Documents required to be delivered pursuant to clauses (b) and (c) of this Section 8.01 may be delivered electronically and if so delivered, shall be deemed to have been delivered on the earliest date on which (i) any Credit Party posts such documents, or provides a link thereto on Evolent&#8217;s website on the Internet and (ii) such financial statements and&#47;or other documents are posted on the Securities Exchange Commission&#8217;s website on the internet at www.sec.gov&#59; provided, that, (A) the Administrative Borrower shall, at the request of the Administrative Agent, continue to deliver copies (which delivery may be by electronic transmission) of such documents to the Administrative Agent and (B) the Administrative Borrower shall notify (which notification </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">94</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be by facsimile or electronic transmission) the Administrative Agent of the posting of any such documents on any website described in this paragraph. Each Lender shall be solely responsible for timely accessing posted documents or requesting delivery of paper copies of such documents from the Administrative Agent and maintaining its copies of such documents.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1066"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Books, Records and Inspections&#59; Field Exams</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1069"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;Parent will, and will cause each of its Subsidiaries to, maintain proper books of record and account, in which entries that are full, true and correct in all material respects and are in conformity with GAAP shall be made of all material financial transactions and matters involving the assets and business of the Credit Parties or such Subsidiary, as the case may be.  Parent will, and will cause each of its Subsidiaries to, permit representatives and independent contractors of any Agent to visit and inspect any of its properties (to the extent authorized pursuant to any leases for such properties), to examine its corporate, financial and operating records, and make copies thereof or abstracts therefrom (subject to applicable confidentiality agreements or undertakings and copyright laws), and to discuss its affairs, finances and accounts with its directors and officers (provided, that an authorized representative of the Credit Parties shall be allowed to be present and that any such inspection of properties shall not include any invasive or physically intrusive environmental sampling), all at the expense of the Credit Parties and (unless an Event of Default then exists) as often as such Agent may reasonably request, at reasonable times during normal business hours, upon reasonable advance notice to the Credit Parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that during any calendar year, absent the continuation of an Event of Default, reasonable expenses of a reasonable number of people in connection with only one (1) inspection by each Agent shall be at the Borrowers&#8217; expense and reimbursable under this Agreement.  Any information obtained by the Agents pursuant to this Section 8.02 may be shared with the Administrative Agent or any Lender upon the request of such Secured Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that, notwithstanding anything herein to the contrary, none of the Parent nor any Subsidiary will be required to disclose or permit the inspection or discussion of, any document, information or other matter (i) in respect of which disclosure to the Administrative Agent or any Lender (or their respective contractors) is prohibited by law or any binding agreement (or would otherwise cause a breach or default thereunder) or (ii) that is subject to attorney-client or similar privilege or constitutes attorney work product.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1072"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Credit Party will, and will permit each of its Subsidiaries to, permit representatives of Revolving Agent to conduct field examinations, appraisals and audits of Accounts (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Field Exams</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and other personal property of the Credit Parties and their Subsidiaries, which shall, be at such reasonable times during normal business hours and unless an Event of Default is continuing, upon reasonable advance notice to Parent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that for so long as no Event of Default shall have occurred and be continuing, Borrowers shall not be obligated to reimburse Revolving Agent for more than one (1) Field Exam in any twelve month period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that any additional Field Exams required by Revolving Agent in any given twelve month period shall be performed at the expense of Revolving Agent&#59; and, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if an Event of Default shall have occurred and be continuing, Revolving Agent may conduct additional Field Exams at Borrowers&#8217; expense.  For the avoidance of doubt, the reimbursement limitations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not apply to Field Exams conducted in connection with a Permitted Acquisition (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that unless agreed otherwise with the Administrative Borrower, there shall not be more than one such exam per Permitted Acquisition).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">95</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1075"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Maintenance of Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1078"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Parent will, and will cause each of its Subsidiaries to, at all times maintain in full force and effect, with insurance companies that Parent believes (in its reasonable business judgment) are financially sound and reputable at the time the relevant coverage is placed or renewed, insurance in at least such amounts and against at least such risks (and with such risk retentions) as are usually insured against in the same general area by companies engaged in businesses similar to those engaged in by the Credit Parties&#59; and will furnish to the Collateral Agent for further delivery to the Lenders, upon written request from the Collateral Agent, information presented in reasonable detail as to the insurance so carried, including (i) endorsements to (A) all casualty policies of the Credit Parties naming the Collateral Agent, on behalf of the Secured Parties, as loss payee and (B) all property policies of the Credit Parties naming the Collateral Agent, on behalf of the Secured Parties, as additional insured and (ii) legends providing that no cancellation, material reduction in amount or material change in insurance coverage thereof shall be effective until at least thirty (30) days after receipt by the Collateral Agent of written notice thereof.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1081"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Within thirty (30) days after the Closing Date, the Administrative Borrower shall have delivered to the Administrative Agent copies of each insurance policy (or binders in respect thereof).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1084"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Without limiting the foregoing, Parent will, and will cause each of its Subsidiaries to, (i) maintain, if available, fully paid flood hazard insurance on all owned or leased Real Property that is located in a special flood hazard area and that constitutes Collateral, on such terms and in such amounts as required by Flood Insurance Laws or as otherwise reasonably required by the Administrative Agent or any Lender, (ii) furnish to the Administrative Agent evidence of the renewal (and payment of renewal premiums therefor) of all such policies prior to the expiration or lapse thereof and (iii) furnish to the Administrative Agent prompt written notice of any redesignation of any such owned or leased improved Real Property into or out of a special flood hazard area.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1087"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Credit Parties will pay and discharge, and will cause each of their respective Subsidiaries to pay and discharge, all material Taxes payable by them that have become due, other than those not yet delinquent or being diligently contested in good faith and by proper proceedings, which stay the enforcement of any Lien as to which such Credit Party has maintained adequate reserves in accordance with GAAP.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1090"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Maintenance of Existence&#59; Compliance with Laws, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1093"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Credit Party will, and will cause its Subsidiaries to, (i) preserve and maintain in full force and effect its organizational existence and good standing under the laws of its jurisdiction of incorporation, organization or formation as applicable, except as permitted by Section 9.03 or Section 9.04 and (ii)&#160;preserve and maintain its good standing under the laws of each state or other jurisdiction where such Person is required to be so qualified, to do business as a foreign entity, except in the case of this clause (ii) where the failure to do so would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">96</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1096"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Credit Party shall, and shall cause each of its Subsidiaries to, comply with all Applicable Laws and Permits (including without limitation, all Registrations) of any Governmental Authority having jurisdiction over it, its business or its Products, except where such failures to comply would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. Without limiting the generality of the foregoing, each Credit Party and its Subsidiaries shall comply in all material respects with all Health Care Laws and their implementation by any applicable Governmental Authority and all lawful requests of any Governmental Authority applicable to its operations.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1099"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.06&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Environmental Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1102"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Credit Party will, and will cause its Subsidiaries to, use and operate all of its and their facilities and Real Property in compliance with all Environmental Laws, keep all necessary permits, approvals, certificates, licenses and other authorizations relating to environmental matters in effect and remain in compliance therewith, and handle all Hazardous Materials in compliance with all Environmental Laws, and keep its and their Real Property free of any Lien imposed by any Environmental Law, in each case, except where the failure to do so could not reasonably be expected to have a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1105"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Administrative Borrower will promptly give notice to the Administrative Agent upon any Credit Party or Subsidiary thereof becoming aware of&#58;  (i) any violation by any Credit Party or any of its Subsidiaries of any Environmental Law that could reasonably be expected to result in a Material Adverse Effect, (ii) any proceeding against or investigation of any Credit Party under any Environmental Law, including a written request for information or a written notice of violation or potential environmental liability from any Governmental Authority or any other Person, which could reasonably be expected to result in a Material Adverse Effect, (iii) the occurrence or discovery of a new Release or new threat of a Release (or discovery of any Release or threat of a Release previously undisclosed by any Credit Party to Administrative Agent) at, on, under or from any of the Real Property of any Credit Party or any facility or assets therein in excess of reportable or allowable standards or levels under any Environmental Law, or under circumstances, or in a manner or amount that could reasonably be expected to result in a Material Adverse Effect or (iv) any Environmental Claim arising or existing on or after the Closing Date which could reasonably be expected to result in a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1108"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In the event of a Release of any Hazardous Material on any Real Property of any Credit Party that could reasonably be expected to result in material liability on the part of any Credit Party under any Environmental Law, such Credit Party, upon discovery thereof, shall take all necessary steps to initiate and expeditiously complete all response, corrective and other action to mitigate and resolve any such violation or potential liability in accordance with and to the extent required of such Credit Party under Environmental Law, and shall keep the Administrative Agent informed on a regular basis of their actions and the results of such actions&#59; provided, however, that no Credit Party (or its respective Subsidiaries) shall be required to undertake any such response, corrective action or other action to the extent that its obligation to do so is being contested in good faith and by proper proceedings and appropriate reserves are being maintained with respect to such circumstances in accordance with GAAP.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">97</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1111"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Each Credit Party shall provide the Administrative Agent with copies of any material demand, request for information, notice, submittal, documentation or correspondence received or provided by any Credit Party or any of its Subsidiaries from or to any Governmental Authority or other Person under any Environmental Law to the extent the same would reasonably be expected to result in a Material Adverse Effect.  Such notice, submittal or documentation shall be provided to the Administrative Agent promptly and, in any event, within five (5) Business Days after such material is provided to any Governmental Authority or third party.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1114"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;At the reasonable written request of the Administrative Agent, the Borrowers shall obtain and provide, at their sole expense, an environmental site assessment (including, without limitation, the results of any groundwater or other testing, conducted at the Administrative Agent&#8217;s reasonable request) concerning any Real Property now or hereafter owned by any Credit Party or any of its Subsidiaries, conducted by an environmental consulting firm approved by the Administrative Agent indicating, to the reasonable satisfaction of the Administrative Agent, the likely presence or absence of Hazardous Materials and the potential cost of any required action in connection with any Hazardous Materials on, at, under or emanating from such Real Property&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such request may be made only if (i)&#160;there has occurred and is continuing an Event of Default, or (ii)&#160;circumstances exist that in the reasonable judgment of the Administrative Agent could be expected to result in a material violation of or material liability under any Environmental Law on the part of any Credit Party or its respective Subsidiaries&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, if the Borrowers fail to provide the same within ninety (90) days after such request was made, the Administrative Agent may but is under no obligation to conduct the same, and the Credit Parties shall grant and hereby do grant to the Administrative Agent and its agents access to such Real Property and specifically grants the Administrative Agent an irrevocable nonexclusive license, subject to the rights of tenants, to undertake such an assessment, all at the Borrowers&#8217; sole cost and expense.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1117"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 8.07&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">ERISA.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a) Promptly after any Credit Party or any Subsidiary of any Credit Party knows or has reason to know of the occurrence of any of the following events (including such events previously disclosed or exempt from disclosure hereunder, to the extent the liability therefor remains outstanding), the Borrowers will deliver to the Administrative Agent and each Lender a certificate of an Authorized Officer of the Administrative Borrower setting forth details as to such occurrence and the action, if any, that such Credit Party, such Subsidiary or such ERISA Affiliate is required or proposes to take, together with any notices (required, proposed or otherwise) given to or filed with or by such Credit Party, such Subsidiary, such ERISA Affiliate, the PBGC, a Plan participant (other than notices relating to an individual participant&#8217;s benefits) or the Plan administrator and all documentation with respect thereto&#58;  that a Reportable Event has occurred&#59; that a failure to satisfy the minimum funding standard of Section 412 of the Code or Section 302 of ERISA (whether or not waived in accordance with Section 412(c) of the Code or Section 302(c) of ERISA) has occurred (or is reasonably likely to occur) or an application is to be made to the Secretary of the Treasury for a waiver or modification of the minimum funding standard (including any required installment payments) or an extension of any amortization period under Section 412, 430 or 431 of the Code with respect to a Plan&#59; the failure to make a required contribution to any Plan if such failure is sufficient to give rise to a Lien under Section 303(k) or 4068 of ERISA or under Section 430(k) of the Code&#59; that a Pension Plan having an Unfunded Current Liability has been or is to be terminated, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">98</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">reorganized or partitioned under Title IV of ERISA (including the giving of written notice thereof)&#59; the taking of any action with respect to a Plan which would reasonably be expected to result in the requirement that any Credit Party furnish a bond or other security to the PBGC or such Plan&#59; that a proceeding has been instituted against a Credit Party, a Subsidiary thereof or an ERISA Affiliate pursuant to Section 515 of ERISA to collect a delinquent contribution to a Multiemployer Plan&#59; or that the PBGC has notified any Credit Party, any Subsidiary thereof or any ERISA Affiliate of its intention to appoint a trustee to administer any Plan&#59; or the occurrence of any event with respect to any Plan which could result in the incurrence by any Credit Party or any Subsidiary of any Credit Party of any material liability (including any contingent or secondary liability), fine or penalty.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1123"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Promptly following any request therefor, copies of any documents or notices described in Sections 101(f), 101(k) or 101(l) of ERISA that any Credit Party or any ERISA Affiliate may reasonably request with respect to any Plan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if any Credit Party or any ERISA Affiliate has not requested such documents or notices from the administrator or sponsor of the applicable Plan, the applicable Credit Party or the ERISA Affiliate(s) shall promptly make a request for such documents or notices from such administrator or sponsor and shall provide copies of such documents and notices promptly after receipt thereof.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1126"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 8.08&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Maintenance of Property and Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Each Credit Party will, and will cause its Subsidiaries to, maintain, preserve, protect and keep its tangible properties and assets in good repair, working order and condition (ordinary wear and tear and casualty excepted in the commercially reasonably business judgment of the Borrowers and subject to dispositions permitted pursuant to Section 9.04), and make necessary repairs, renewals and replacements thereof and will maintain and renew as necessary all licenses, permits and other clearances necessary to use and occupy such properties and assets, in each case, so that the business carried on by such Person may be properly conducted at all times, except where the failure to do so could not reasonably be expected to have a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1129"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">SECTION 8.09&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">End of Fiscal Years&#59; Fiscal Quarters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">.  The Credit Parties will, for financial reporting purposes, cause (a) each of their, and each of their Subsidiaries&#8217;, Fiscal Years to end on December 31 of each year and (b) each of their and each of their Subsidiaries&#8217;, Fiscal Quarters to end on dates consistent with such Fiscal Year-end&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">, that the Credit Parties may change their, and each of their respective Subsidiaries&#8217;, Fiscal Year-end (and change the end of the Fiscal Quarters in a corresponding manner) upon fifteen (15) days&#8217; prior written notice to the Administrative Agent.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1132"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 8.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  The proceeds of the Initial Term Loan shall be used to (i) to finance the TPG Acquisition, (ii) to pay fees and expenses incurred in connection with the transactions contemplated hereby (including the TPG Acquisition), and (iii) to fund acquisitions, ongoing working capital needs and other growth capital expenditure investments (to the extent permitted hereunder).  The proceeds of the Revolving Facility shall be used to (i) on the Closing Date, to finance the TPG Acquisition and to pay fees and expenses incurred in connection with the transactions contemplated hereby (including the TPG Acquisition) and (ii) thereafter to fund acquisitions, ongoing working capital needs, and other growth capital investments and to pay fees and expenses in connection with the foregoing.  The Credit Parties shall not use the proceeds of any Credit Extension made hereunder, or use or allow its respective directors, officers, employees and agents to use, the proceeds of any extension of credit (i) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">99</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">money, or anything else of value, to any Person in violation of any Anti-Corruption Laws, Anti-Terrorism Laws or Anti-Money Laundering Laws, (ii) for the purpose of funding, financing or facilitating any activities, business or transaction of or with any Person on the SDN List or (iii) in any manner that would result in the violation of any Sanctions applicable to any party.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1135"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Further Assurances&#59; Additional Guarantors and Grantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1138"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;The Credit Parties will and will cause their Subsidiaries (other than Excluded Subsidiaries) to execute any and all further documents, financing statements, agreements and instruments, and take all such further actions (including the filing and recording of financing statements, fixture filings, mortgages, deeds of trust (excluding leasehold deeds of trust) and other documents), which may be required under any Applicable Law, or which the Administrative Agent may reasonably request, in order to grant, preserve, protect and perfect the validity and priority of the security interests created or intended to be created by the Security Agreement, any Mortgage or any other Security Document, all at the sole cost and expense of the Borrowers.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1141"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;Subject to any applicable limitations set forth in the Guarantee Agreement and the Security Agreement, as applicable, the Credit Parties will promptly upon the formation or acquisition thereof (and in any event within thirty (30) days after the formation, division or acquisition thereof (or such later date as agreed by the Administrative Agent)) cause any direct or indirect Subsidiary formed or otherwise purchased or acquired after the Closing Date to execute (i) a supplement to the Guarantee Agreement in the form of Annex I to the Guarantee Agreement or a guarantee in form and substance reasonably satisfactory to the Agents, and (ii) a supplement to the Security Agreement in the form of Annex I to the Security Agreement or a security agreement in form and substance reasonably satisfactory to the Agents&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that no Excluded Subsidiary shall be required to execute the documentation described in clauses (i) and (ii) above for so long as it is an Excluded Subsidiary.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1144"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;Subject to any applicable limitations set forth in the Security Agreement and, in the case of the Licensed Insurance Entities, subject to Applicable Laws, the Credit Parties (i) will promptly upon the formation or acquisition thereof (and in any event within thirty (30) days after the formation or acquisition thereof (or such later date as agreed by the Administrative Agent)) pledge to the Administrative Agent for the benefit of the Secured Parties, all the Capital Stock of each Subsidiary (other than Excluded Subsidiaries) held by such Credit Party in each case, formed or otherwise purchased or acquired after the Closing Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that, with respect to any pledge of the Capital Stock of any Foreign Subsidiary or Domestic Holding Company, such pledge shall be limited to sixty five percent (65%) of the issued and outstanding Voting Stock and one hundred percent (100%) of the outstanding nonvoting Capital Stock of each Foreign Subsidiary and Domestic Holding Company, and (ii) will promptly deliver to the Administrative Agent any promissory notes executed after the Closing Date evidencing Indebtedness of any Credit Party or Subsidiary of any Credit Party that is owing to any other Credit Party or any other promissory notes executed after the Closing Date evidencing Indebtedness in excess of $4,000,000 owing to the Credit Parties.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1147"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;Subject to any applicable limitations set forth in any applicable Security Document, if any fee simple interest in Material Real Property is acquired by any Credit Party after the Closing Date, the Borrowers will notify the Administrative Agent and the Lenders thereof and will cause such assets to be subjected to a Lien securing the applicable Obligations </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">and will take, and cause the other Credit Parties to take, such actions as shall be necessary or reasonably requested by the Administrative Agent to grant and&#47;or perfect such Liens consistent with the applicable requirements of the Security Documents, including actions described in this Section 8.11(d), all at the sole cost and expense of the Borrowers within sixty (60) days after the acquisition of such Material Real Property (or such longer period as the Administrative Agent may agree).  Any Mortgage delivered to the Administrative Agent in accordance with the preceding sentence shall be accompanied by (A) a policy or policies (or unconditional binding commitment thereof) of title insurance issued by a nationally recognized title insurance company insuring the Lien of each Mortgage as a valid Lien (with the priority described therein) on the Mortgaged Property described therein, free of any other Liens except as expressly permitted by Section 9.02, together with such endorsements as the Administrative Agent may reasonably request and (B) if requested by the Administrative Agent, an opinion of local counsel to the applicable Credit Party(ies) in form and substance reasonably satisfactory to the Agents.  In addition to the obligations set forth in Section 8.03(a), the Credit Parties shall, in connection with the grant to the Administrative Agent for the benefit of the Secured Parties of any Mortgage with respect to any Real Property, (X) provide at least twenty (20) days&#8217; prior written notice to the Administrative Agent of the contemplated pledge of such Real Property as Collateral, (Y) the Borrowers shall provide each of the documents and determinations required by the Real Property Flood Insurance Requirements and (Z) notwithstanding anything to the contrary contained herein or in any other Credit Document, the Administrative Agent shall not enter into, accept or record (and no Credit Party shall be required to grant) any mortgage in respect of such Real Property until the Administrative Agent shall have received written confirmation (which shall, for purposes hereunder, include email) from each Lender that flood insurance compliance has been completed by such Lender with respect to such Real Property (such written confirmation not to be unreasonably withheld or delayed).&#160; Any increase, extension or renewal of this Agreement shall be subject to flood insurance due diligence and flood insurance compliance reasonably satisfactory to each Agent and each Lender.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1150"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, if the Administrative Borrower and the Administrative Agent determine that the cost of creating or perfecting any Lien on any property is excessive in relation to the practical benefits afforded to the Lenders thereby, then such property may be excluded from the Collateral for all purposes of the Credit Documents.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1153"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;For the avoidance of doubt, for all purposes under this Section 8.11, the formation and acquisition of a Person shall be deemed to include any formations and acquisitions by division&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that compliance with the requirements of this Section 8.11 shall not cure any Default or Event of Default for the occurrence of such division.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1156"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.12&#160;&#160;&#160;&#160;&#91;Reserved&#93;. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1159"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Health Care Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1162"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Without limiting or qualifying any other provision of this Agreement, Parent will comply, and will cause each other Credit Party, each Subsidiary and each Licensed Insurance Entity, to comply in all material respects, with all applicable Health Care Laws relating to the operation of such Person&#8217;s business.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">101</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1165"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Parent will maintain, and will cause each other Credit Party, each Subsidiary and each Licensed Insurance Entity, to maintain, all records required to be maintained by any Governmental Authority or otherwise required under any Health Care Law except where failure could not reasonably be expected to have a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1168"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Parent will, and will cause each other Credit Party, each Subsidiary and each Licensed Insurance Entity, to keep in full force and effect all material Permits required to operate such the business of Parent each other Credit Party, each Subsidiary, and each Licensed Insurance Entity under applicable Health Care Laws.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1171"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Parent will maintain, and will cause each other Credit Party, Subsidiary and Licensed Insurance Entity, to maintain on its behalf, a corporate compliance program that is reasonably designed to promote compliance with applicable Health Care Laws. Parent will permit and will cause such other Credit Parties, Subsidiaries and Licensed Insurance Entities to permit, Administrative Agent and&#47;or any of its outside consultants to review such corporate compliance program(s) from time to time.   </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1174"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Agreement, no Credit Party, Subsidiary, or Licensed Insurance Entity shall be required to furnish to Administrative Agent or Lender any protected health information or any patient related information, to the extent such disclosure to Administrative Agent or Lender is prohibited by Health Care Laws.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1177"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1180"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.04(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement, each Credit Party will (i) maintain its ownership of all Intellectual Property owned by such Credit Party, and shall not do any act knowingly or omit to do any act whereby any owned Intellectual Property may lapse, expire, become abandoned or cancelled, dedicated to the public, or unenforceable, or which would adversely affect the validity, grant, or enforceability of the security interest granted hereunder and (ii) take all reasonable steps in the United States Patent and Trademark Office and the United States Copyright Office and any other applicable Governmental Authority to pursue any application and maintain any registration of each trademark, patent, and copyright owned by such Credit Party, in each of (i) and (ii) except as could not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1183"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Credit Party will (i) maintain all licenses for third party Intellectual Property (including commercial software) licensed to such Credit Party and (ii) not violate any such licenses and not cause any such license to cease to be legal, valid, binding, enforceable and in full force and effect following the Closing Date, except for licenses that expire or are terminated in accordance with their terms and in the ordinary course of business (other than a termination resulting from a default or breach by the applicable Credit Party), in each of (i) and (ii), except as could not reasonably be expected to have a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1186"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 8.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Distributable Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  At least once in each Fiscal Year the Credit Parties shall evaluate (a) whether any Licensed Insurance Entity (or any Person that was previously a Licensed Insurance Entity) holds any cash or Cash Equivalents that were previously subject to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">102</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">risk-based capital requirements or other statutory capital reserve requirements under Applicable Laws or pursuant to the discretion of any Governmental Authority and (b) whether it is reasonably likely (in the reasonable business judgment of the Credit Parties) that the cash and Cash Equivalents described in clause (a) are no longer required to be restricted by such Applicable Laws or would be released with the consent of such Governmental Authority, as applicable, (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Subject</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;). To the extent that the Credit Parties determine in their reasonable business judgment during such evaluation period that any Subject Cash is likely to be permitted to be distributed to the Credit Parties, then the Credit Parties shall use commercially reasonable efforts to promptly cause such Subject Cash to be so distributed. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1189"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Post-Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary set forth in this Agreement and the Credit Documents&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1192"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Endorsements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within sixty (60) days after the date hereof (or such later date approved by Administrative Agent), the Borrowers shall deliver to the Agents, in form and substance reasonably satisfactory to the Agents, such insurance endorsements as required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1195"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Springing Control Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Within sixty (60) days after the date hereof (or such later date approved by Collateral Agent), the Borrowers shall deliver to the Collateral Agent all Springing Control Agreements required to be delivered under this Agreement, in each case in a form and substance reasonably satisfactory to the Collateral Agent and duly executed by the parties thereto.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1198"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Global Intercompany Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within thirty (30) days after the date hereof (or such later date approved by Collateral Agent), the Borrowers shall deliver to the Collateral Agent the Global Intercompany Note, together with an allonge related thereto indorsed in blank.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1201"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">NCIS Holdings Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within thirty (30) days after the date hereof (or such later date approved by Collateral Agent), the Borrowers shall deliver to the Collateral Agent that certain Note issued by NCIS Holdings, Inc. to Evolent, with a maturity date of October 2, 2025, together with an allonge related thereto indorsed in blank.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1204"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Borrowing Base and Financial Statement Reporting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Borrowers will deliver to Revolving Agent each of the financial statements, reports, projections or other items set forth below at the following times in form and substance satisfactory to Revolving Agent in its discretion&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1207"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Borrowing Base Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As soon as available, but in any event no later than thirty (30) days after the end of each fiscal month, calculated in respect of the immediately preceding month&#58; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1210"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;an executed Borrowing Base Certificate&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1213"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;a detailed aging of each Credit Party&#8217;s Accounts (each, based on and describing the respective invoice and due dates or terms of such invoice and delivered electronically in an acceptable format, if such Credit Party has implemented electronic reporting), along with a detailed calculation of those Accounts that are not Eligible Accounts&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">103</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1216"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;an Account roll-forward of each Credit Party&#8217;s Accounts, with supporting details supplied from sales journals, collection journals, credit registers and any other records, tied to the beginning and ending account receivable balances of each Credit Party&#8217;s general ledger (it being understood that such reporting will be consistent with the form provided prior to the Closing Date)&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1219"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;a summary aging (including the invoice or due date and, upon Revolving Agent&#8217;s request, with a detailed aging and aged by invoice or due date as so requested), by vendor, of each Credit Party&#8217;s accounts payable and any book overdraft (delivered electronically in an acceptable format, if such Credit Party has implemented electronic reporting) and a detailed aging, by vendor, of any held checks&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1222"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;a reconciliation of reported balances in the foregoing clauses (ii) and (iv) above to each Credit Party&#8217;s applicable general ledger account, and to its quarterly financial statements including any book reserves related to each category&#59; and </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1225"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Updated Borrowing Base Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within three (3) Business Days of the written request of Required Revolving Lenders (i) after the occurrence and during the continuance of an Event of Default or (ii) any time, the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Revolver Usage on such date exceeds the lesser of (i) Revolver Commitment and (ii) the Borrowing Base, an updated executed Borrowing Base Certificate reflecting changes in the Eligible Accounts availability since the last Borrowing Base Certificate. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1228"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><br><br>Negative Covenants</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Credit Party hereby covenants and agrees that on the Closing Date and thereafter, until the Commitments have been terminated and the Loans and all other Obligations incurred hereunder (other than Unasserted Contingent Obligations) are paid in full in accordance with the terms of this Agreement&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1231"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation on Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries or any Licensed Insurance Entity to, directly or indirectly, create, incur, issue, assume, guarantee, suffer to exist or otherwise become directly or indirectly liable, contingently or otherwise with respect to any Indebtedness, except for&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1234"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Indebtedness in respect of the Obligations&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1237"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Indebtedness existing as of the Closing Date (other than the Convertible Senior Notes) which is identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and which is not otherwise permitted by this Section 9.01, and, Permitted Refinancing Indebtedness thereof&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1240"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;unsecured Indebtedness (i) incurred in the ordinary course of business of such Credit Party and its Subsidiaries in respect of open accounts extended by suppliers on normal trade terms in connection with purchases of goods and services, which are not overdue for a period of more than ninety (90) days or, if overdue for more than ninety (90) days, as to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">104</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which a dispute exists and adequate reserves in conformity with GAAP have been established on the books of such Credit Party or Subsidiary and (ii) in respect of performance, surety or appeal bonds, bid bonds and similar obligations provided in the ordinary course of business, but excluding (in each case) Indebtedness incurred through the borrowing of money or Contingent Liabilities in respect thereof&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1243"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Indebtedness (i) evidencing the deferred purchase price of newly acquired property or incurred to finance the acquisition of equipment of such Credit Party and its Subsidiaries (pursuant to purchase money mortgages or otherwise, whether owed to the seller or a third party), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such Indebtedness is incurred within ninety (90) days after such acquisition of such equipment, and (ii) Capitalized Lease Obligations, and, with respect to each of clause (i) and (ii), Permitted Refinancing Indebtedness thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the aggregate amount of all Indebtedness outstanding pursuant to this clause (d) shall not at any time exceed $4,000,000&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1246"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;intercompany Indebtedness permitted pursuant to Section 9.05&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1249"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Contingent Liabilities of the Credit Parties and their Subsidiaries arising in the ordinary course of business with respect to surety and appeals bonds, bid bonds, performance bonds and other similar obligations&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1252"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Hedging Obligations not prohibited by Section 9.11&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1255"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;Indebtedness incurred in the ordinary course of business to finance insurance policy premiums&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1258"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Indebtedness incurred in the ordinary course of business in respect of netting services, overdraft protection, returned items, employee credit card programs and other similar services in connection with cash management and deposit accounts&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1261"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;2024 Convertible Senior Notes and any Additional Notes exchanged therefor&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1264"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;2025 Convertible Senior Notes and any Additional Notes exchanged therefor&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1267"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Additional Notes issued after the Closing Date&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1270"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;Letters of credit and reimbursement obligations in respect thereof in favor of suppliers, landlords and other counterparties at any one time outstanding not to exceed $50,000,000 in the aggregate after taking into account any outstanding letters of credit and similar reimbursement obligations scheduled pursuant to Section 9.01(b), and Permitted Refinancings thereof&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1273"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;Guarantee Obligations of any Credit Party and its Subsidiaries in respect of Indebtedness otherwise permitted hereunder or other obligations not prohibited hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if such Indebtedness is subordinated to the Obligations, such Guarantee Obligation shall be subordinated to the same extent&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">105</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1276"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)&#160;&#160;&#160;&#160;other unsecured Indebtedness not to exceed $5,000,000 at any time outstanding&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1279"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;the Existing Earnout&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1282"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;Indebtedness of the type set forth in Section 9.01(d) of a Person whose assets or Capital Stock are acquired by a Credit Party or any of its Subsidiaries in a Permitted Acquisition so long as (i) such Indebtedness was in existence prior to the date of such acquisition and was not incurred in connection with, or in contemplation of, such acquisition, (ii) no Credit Party (other than such Person so acquired in such acquisition or any other Person that such Person merges with or that acquires the assets of such Person in connection with such acquisition) shall have any liability or other obligation with respect to such Indebtedness, (iii) if such Indebtedness is secured, no Lien thereon shall extend to or cover any other assets other than the property or equipment acquired in such acquisition (other than the proceeds or products thereof, accessions or additions thereto and improvements thereon) or attach to any other property of any Credit Party and (iv) the aggregate outstanding principal amount of such Indebtedness does not exceed $5,000,000 at any time&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1285"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;Indebtedness consisting of promissory notes issued by any Credit Party or Subsidiary to former employees, officers, former officers, directors, and former directors (or any spouses, ex-spouses, beneficiaries, or estates of any of the foregoing) of any Credit Party or any Subsidiary issued to purchase or redeem Capital Stock of Parent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Redemption Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) issued in lieu of Restricted Payments permitted under Section 9.06(k)&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1288"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;Indebtedness (x) arising from the honoring by a bank or other financial institution of a check, draft or similar instrument inadvertently (except in the case of daylight overdrafts) drawn against insufficient funds in the ordinary course of business, (y) in respect of netting services, overdraft protection and other similar arrangements in connection with deposit or securities accounts in the ordinary course of business and (z) incurred in respect of credit cards, credit card processing services, debit cards, stored value cards, purchase cards (including so-called &#8220;procurement cards&#8221; or &#8220;P-cards&#8221;), or cash management services, in each case, incurred in the ordinary course of business&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1291"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;endorsement of negotiable instruments for deposit in the ordinary course of business&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1294"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(u)&#160;&#160;&#160;&#160;unsecured contingent liabilities arising with respect to customary indemnification provisions or deferred purchase price adjustments in connection with any Investment permitted hereunder or in connection with any asset sale or other dispositions permitted hereunder&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1297"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(v)&#160;&#160;&#160;&#160;Indebtedness in respect of (x) workers&#8217; compensation claims and self-insurance obligations (in each case other than for or constituting an obligation for money borrowed), including guarantees or obligations of Parent, the Borrowers and their respective Subsidiaries with respect to letters of credit supporting such workers&#8217; compensation claims and&#47;or self-insurance obligations and (y) bankers&#8217; acceptances, bank guarantees, letters of credit and bid, performance, surety bonds or similar instruments issued for the account of Parent, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">106</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Borrowers and their respective Subsidiaries in the ordinary course of business, including guarantees or obligations of any such Person with respect to bankers&#8217; acceptances and bid, performance or surety and appeals obligations&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1300"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(w)&#160;&#160;&#160;&#160;to the extent constituting Indebtedness, deferred compensation to employees, former employees, officers, former officers, directors, former directors, consultants (or any spouses, ex-spouses, or estates of any of the foregoing) incurred in the ordinary course of business or in connection with the Transactions, Permitted Acquisitions or other Investments permitted hereunder&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1303"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;unsecured earn-outs, seller notes, deferred purchase price obligations, holdbacks or similar obligations of any Credit Party, to the extent subordinated to the Obligations on terms and conditions reasonably satisfactory to the Agents.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1306"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation on Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries or any Licensed Insurance Entity to, directly or indirectly, create, incur, assume or suffer to exist any Lien upon any property or assets of any kind (real or personal, tangible or intangible) of any such Person (including its Capital Stock), whether now owned or hereafter acquired, except for the following (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1309"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Liens securing the Obligations&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1312"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(b)&#160;&#160;&#160;&#160;Liens existing as of the Closing Date and disclosed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Schedule 9.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%"> securing Indebtedness permitted under Section 9.01(b) (other than the Convertible Senior Notes) and any renewals or extensions thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">, that no such Lien shall (1) secure Indebtedness under any Convertible Senior Notes or (2) encumber any additional property and the principal amount of Indebtedness secured by such Lien shall not be increased (as such Indebtedness may be permanently reduced subsequent to the Closing Date), except to the extent permitted by Section 9.01(b)&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1315"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(c)&#160;&#160;&#160;&#160;Liens securing Capitalized Lease Liabilities and Liens securing Indebtedness of the type permitted under Section 9.01(d)(i)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">, that (i) the principal amount of the Indebtedness secured thereby does not exceed the cost of the applicable property at the time of such acquisition, replacement or construction and any fees, costs and expenses incurred in connection with the incurrence of such Indebtedness and (ii) such Lien secures only the assets that are the subject of the Indebtedness referred to in such clause and proceeds thereof&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1318"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Liens arising by operation of law in favor of carriers, warehousemen, mechanics, materialmen, suppliers, laborers and landlords and other similar Liens incurred in the ordinary course of business for amounts not overdue or being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been established on its books&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1321"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Liens incurred or deposits made in the ordinary course of business in connection with worker&#8217;s compensation, unemployment insurance or other forms of governmental insurance or benefits, or to secure performance of tenders, statutory obligations, bids, leases or other similar obligations (other than for borrowed money) entered into in the ordinary course of business or to secure obligations on surety, bid, appeal or performance bonds&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">107</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1324"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;judgment Liens not constituting an Event of Default under Section 10.01(f)&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1327"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;easements, rights-of-way, zoning restrictions, minor defects or irregularities in title and other similar encumbrances not interfering in any material respect with the value or use of the property to which such Lien is attached and other Liens on any Real Property subject to a Mortgage that are identified in any title insurance policy issued in favor of the Administrative Agent&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1330"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Liens for Taxes, assessments or other governmental charges or levies not yet due and payable or the non-payment of which is permitted by Section 7.10&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1333"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;Liens arising in the ordinary course of business by virtue of any contractual, statutory or common law provision relating to banker&#8217;s Liens, rights of set-off or similar rights and remedies covering deposit or securities accounts (including funds or other assets credited thereto) or other funds maintained with a depository institution or securities intermediary, so long as the applicable provisions of Section 8.12 have been complied with, in respect of such deposit accounts (other than Excluded Accounts)&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1336"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;Nonexclusive licenses, leases and sublicenses, and subleases granted by any Credit Party or any Subsidiary of a Credit Party or leases or subleases by any Credit Party or any Subsidiary of a Credit Party, in the ordinary course of its business and covering only the assets so licensed, sublicensed, leased or subleased&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1339"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Liens that are customary rights of set-off relating to the establishment of depository relations with banks not given in connection with the issuance of Indebtedness&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1342"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Liens arising from precautionary Uniform Commercial Code financing statements (or similar filings under other applicable law) regarding operating leases or consignment or bailee arrangements in the ordinary course of business&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1345"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;Cash collateral securing Indebtedness permitted under Section 9.01(m) in an amount not to exceed one hundred and ten percent (110%) of the amount of such Indebtedness&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1348"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)&#160;&#160;&#160;&#160;&#91;reserved&#93;&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1351"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;Liens in favor of the Borrowers or any other Credit Party securing intercompany Indebtedness permitted under the Credit Documents so long as any such Liens on the Collateral are subject to the Intercompany Subordination Agreement&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1354"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;statutory and common law landlords&#8217; liens under leases to which Parent or any of its Subsidiaries is a party&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1357"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;Liens of counterparties attaching solely to cash earnest money deposits made by Credit Parties or their Subsidiaries in connection with any letter of intent or purchase agreement entered into with respect to Permitted Acquisitions or capital expenditures permitted hereunder&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">108</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1360"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;other Liens securing Indebtedness or other obligations in an aggregate principal amount at the time of incurrence of any such Indebtedness or other obligations not exceeding $5,000,000. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1363"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">SECTION 9.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Consolidation, Merger, etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to, liquidate or dissolve, consolidate with, or merge into or with, any other Person or purchase or otherwise acquire all or substantially all of the assets of any Person (or any division thereof), except Permitted Acquisitions and other Investments permitted hereunder, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">, that (a) any Credit Party or Subsidiary of any Credit Party may liquidate or dissolve voluntarily into, and may merge with and into, any Borrower (so long as such Borrower is the surviving entity), (b) any Guarantor may liquidate or dissolve voluntarily into, and may merge with and into any Credit Party, (c) any Subsidiary that is not a Credit Party may liquidate or dissolve voluntarily into, and may merge with and into any other Subsidiary, (d) the assets or Capital Stock of any Credit Party may be purchased or otherwise acquired by any other Credit Party, (e) the assets or Capital Stock of any Subsidiary that is not a Credit Party may be purchased or otherwise acquired by any Borrower or any Subsidiary and (f) any Subsidiary of any Credit Party may file a certificate of division, adopt a plan of division or otherwise take any action to effectuate a division pursuant to Section 18-217 of the Delaware Limited Liability Company Act (or any analogous action taken pursuant to Applicable Law with respect to any corporation, limited liability company, partnership or other entity), so long as such surviving Person shall have complied with the requirements of Section 8.11 within the time periods set forth therein.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1366"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 9.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Permitted Dispositions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to, make a Disposition, or enter into any agreement to make a Disposition, of such Credit Party&#8217;s or such other Person&#8217;s assets (including receivables and Capital Stock of Subsidiaries) to any Person in one transaction or a series of transactions, unless such Disposition&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1369"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;is in the ordinary course of its business and is of surplus, used, obsolete or worn-out property or property no longer used or useful in its business&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1372"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;is a sale of Inventory in the ordinary course of business&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1375"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;is the leasing, subleasing or licensing, as lessor, of real or personal property no longer used or useful in such Person&#8217;s business or otherwise in the ordinary course of business&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1378"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;is a sale or disposition of equipment to the extent that such equipment is exchanged for credit against the purchase price of similar replacement equipment, or the proceeds of such Dispositions are reasonably promptly applied to the purchase price of similar replacement equipment, all in the ordinary course of business&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1381"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;is otherwise permitted by Section 9.02(j), 9.03, 9.05 (other than 9.05(l)) and 9.06 (other than 9.06(s))&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1384"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(f)&#160;&#160;&#160;&#160;is a Disposition of property by one Credit Party to another Credit Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">, that no Credit Party shall consummate a Disposition of the Capital Stock of a Licensed Insurance Entity to another Credit Party, unless such Credit Party is subject to and in compliance with Section 9.16&#59;   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">109</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1387"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;is a Disposition of property by a non-Credit Party to a Credit Party if the purchase price of said property is not higher than its fair market value&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1390"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;is a Disposition of property by a non-Credit Party to a non-Credit Party&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1393"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;is a Disposition of accounts receivable in connection with the collection or compromise thereof in the ordinary course of business or consistent with past practice (and not for financing purposes)&#59;  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1396"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;is the lapse or abandonment of Intellectual Property that is in the reasonable judgment of any Borrower or its Subsidiaries no longer commercially desirable to maintain or necessary or material for the conduct of the business of such Borrower or its Subsidiaries&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1399"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;&#91;reserved&#93;&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1402"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;so long as no Event of Default has occurred and is continuing, is a Disposition set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the purchase price of which is paid with not less than 75% of cash and the seller thereof receives not less than fair market value for such assets&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1405"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;is a Disposition of cash or Cash Equivalents&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1408"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)&#160;&#160;&#160;&#160;is a Disposition of assets acquired in connection with a Permitted Acquisition which is made to obtain the approval of an anti-trust authority&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1411"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)&#160;&#160;&#160;&#160;is a Disposition constituting a taking by condemnation or eminent domain or transfer in lieu thereof, or a Disposition consisting of or subsequent to a total loss or constructive total loss of property&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1414"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)&#160;&#160;&#160;&#160;is the surrender or waiver of contractual rights and settlement or waiver of contractual or litigation claims&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1417"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(q)&#160;&#160;&#160;&#160;is the unwinding of any Hedging Transaction pursuant to its terms&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1420"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(r)&#160;&#160;&#160;&#160;is, to the extent required by applicable law and with respect to any Subsidiary that is a Foreign Subsidiary, the sale or other disposition of a nominal amount of Capital Stock in any Subsidiary in order to qualify members of the board of directors or equivalent governing body of such Subsidiary&#59; or</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1423"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;so long as no Event of Default has occurred and is continuing, is a Disposition the purchase price of which is paid with not less than 75% of cash and the seller thereof receives not less than fair market value for such assets, not to exceed a value of $10,000,000 in the aggregate for all Credit Parties and their Subsidiaries in any Fiscal Year&#59; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, notwithstanding the foregoing, in no event shall any Credit Party, nor shall any Credit Party permit any of its Subsidiaries to, directly or indirectly, sell or otherwise dispose of any Capital Stock of any of its Subsidiaries, except (1) to qualify directors if required by Applicable Law or (2) pursuant to clause (e), (f), (g), (h), (k) or (l) above&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">110</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that notwithstanding the foregoing, in no event shall any Credit Party, nor shall any Credit Party permit any of its Subsidiaries to, directly or indirectly, sell or otherwise dispose of any Intellectual Property, except in accordance with (j) and (l) above. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1426"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to, purchase, make, incur, assume or permit to exist any Investment in any other Person, except&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1429"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Investments existing on the Closing Date and identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1432"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Investments in cash and Cash Equivalents&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1435"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Investments received in connection with the bankruptcy or reorganization of, or settlement of delinquent accounts and disputes with, customers and suppliers, in each case in the ordinary course of business&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1438"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Investments by way of contributions to capital or purchases of Capital Stock (i) outstanding as of the date hereof and (ii) hereafter (x) by any Credit Party in any other Credit Party and (y) by any Subsidiary that is not a Credit Party in any Subsidiary that is not a Credit Party&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1441"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Investments constituting (i)&#160;receivables arising, (ii)&#160;trade debt granted, or (iii)&#160;deposits made in connection with the purchase price of goods or services, in each case, in the ordinary course of business&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1444"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Investments consisting of any deferred portion of the sales price received by any Credit Party in connection with any Disposition permitted under Section 9.04&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1447"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Investments consisting of intercompany loans, other extensions of credit or other Investments (i) outstanding as of the date hereof and (ii) hereafter (x) by a Credit Party to any other Credit Party, (y) by a Subsidiary that is not a Credit Party to a Credit Party or another Subsidiary that is not a Credit Party or (z) by a Credit Party to any Subsidiary that is not a Credit Party or to any Licensed Insurance Entity, in each case so long as at the time of such Investment pursuant to this clause (z), (x) no Event of Default has occurred and is continuing and (y) either such Investment is scheduled on Schedule 9.05(g) or until the consummation of the Disposition set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.01(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the amount of such non-scheduled Investments shall be in the ordinary course of business consistent with past practice and not exceed $35,000,000 (which such amount shall be increased by 20% on each anniversary of the Closing Date) in the aggregate at any time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, any intercompany Indebtedness described above&#58; (1) shall be evidenced by one or more promissory notes in form and substance reasonably satisfactory to the Agents, duly executed and delivered in pledge to the Administrative Agent pursuant to the Security Documents, and shall not be forgiven or otherwise discharged for any consideration other than and to the extent of repayment in cash&#59; and (2) shall be subordinated to the Obligations pursuant to the subordination terms set forth therein&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1450"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;Permitted Acquisitions&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">111</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1453"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the maintenance of deposit accounts in the ordinary course of business so long as the applicable provisions of Section 8.12 have been complied with in respect of such deposit accounts&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1456"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;&#91;reserved&#93;&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1459"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;Investments in any Person to the extent such Investment represents the non-cash portion of the consideration received in a Disposition permitted pursuant to Section 9.04(i) or (m)&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1462"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(l)&#160;&#160;&#160;&#160;Investments consisting of (i) Indebtedness permitted by Section 9.01 (other than Section 9.01(e)), (ii) transactions permitted by Section 9.03, (iii) Dispositions permitted by Section 9.04 (other than Section 9.04(e)), (iv) Restricted Payments permitted by Section 9.06 (other than Section 9.06(s)) and (v) transactions permitted under Section 9.09 (other than Section 9.09(b)&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1465"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;the Credit Parties and their Subsidiaries  may (i) extend trade credit in the ordinary course of business and (ii) acquire and hold accounts receivables owing to any of them if created or acquired in the ordinary course of business and payable or dischargeable in accordance with customary terms&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1468"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)&#160;&#160;&#160;&#160;the Credit Parties and their Subsidiaries may endorse negotiable instruments held for collection in the ordinary course of business&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1471"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;to the extent constituting Investments, the Credit Parties and their Subsidiaries may make earnest money deposits made in connection with the acquisition of property or assets not prohibited hereunder&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1474"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(p)&#160;&#160;&#160;&#160;Investments consisting of extensions of credit in the nature of accounts receivable or notes receivable arising from the grant of trade credit in the ordinary course of business, and Investments received in satisfaction or partial satisfaction thereof in connection with the settlement of delinquent accounts in the ordinary course of business or from financially troubled account debtors to the extent reasonably necessary in order to prevent or limit loss&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1477"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;prepaid expenses or lease, utility and other similar deposits, in each case made in the ordinary course of business&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1480"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;promissory notes or other obligations of officers or other employees of such Credit Party or such Subsidiary acquired in connection with such officers&#8217; or employees&#8217; acquisition of Capital Stock in such Credit Party or such Subsidiary, so long as no cash is advanced by any Borrower or any of their respective Subsidiaries in connection with such Investment&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1483"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;Investments of any person that becomes a Subsidiary on or after the Closing Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that (i) such Investments exist at the time such person is acquired, (ii) such Investments are not made in anticipation or contemplation of such person becoming a Subsidiary, and (iii) such Investments are not directly or indirectly recourse to any Credit Party or any other Subsidiary or any of their respective assets, other than to the person that becomes a Subsidiary&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">112</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1486"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(t)&#160;&#160;&#160;&#160;so long as no Default or Event of Default has occurred and is continuing, Investments funded with equity proceeds of Qualified Capital or consideration paid in respect of the Capital Stock of Parent and contributed as Qualified Capital Stock to Evolent&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1489"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(u)&#160;&#160;&#160;&#160;the Transactions&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1492"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;&#91;reserved&#93;&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1495"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(w)&#160;&#160;&#160;&#160;&#91;reserved&#93;&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1498"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(x)&#160;&#160;&#160;&#160;Investments made in any Licensed Insurance Entity and Justify Holdings, Inc. to be used as statutory capital or for other capital reserves to the extent required by Applicable Laws or regulations or to the extent required by any Governmental Authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that, any Investments described in this clause (x) in an aggregate amount exceeding $4,000,000 at any time shall be evidenced by one or more promissory notes in form and substance reasonably satisfactory to the Agents (it being understood that any provisions required to be included in such note or notes under Applicable Law or as required by any applicable regulator or regulatory entity shall be satisfactory to the Agents), duly executed and delivered in pledge to the Administrative Agent pursuant to the Security Documents, and shall not be forgiven or otherwise discharged for any consideration other than and to the extent of repayment in cash&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1501"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(y)&#160;&#160;&#160;&#160;loans and other advances to officers, director and employees in an amount not to exceed $2,000,000 at any time&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1504"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(z)&#160;&#160;&#160;&#160;&#91;reserved&#93;&#59; and </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1507"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(aa)&#160;&#160;&#160;&#160;so long as no Event of Default has occurred and is continuing, additional Investments in an amount not to exceed $10,000,000 at any time. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1510"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">In addition, to the extent an Investment is permitted to be made by a Subsidiary directly in any Subsidiary or any other Person who is not a Credit Party (each such person, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Target Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) under any provision of this Section 9.05, such Investment may be made by advance, contribution or distribution by a Credit Party to a Subsidiary or Parent, which is further contemporaneously advanced or contributed to a Subsidiary for purposes of making the relevant Investment in the Target Person without such initial advance, contribution or distribution constituting an Investment (it being understood that such ultimate Investment in the Target Person must satisfy the requirements of, and shall count towards any thresholds in, a provision of this Section 9.05 as if made by the applicable Subsidiary directly to the Target Person).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1513"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 9.06&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Restricted Payments, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to, make any Restricted Payment, or make any deposit for any Restricted Payment, other than&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1516"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;payments by any Subsidiary of a Borrower to such Borrower or its direct parent (and, in the case of a Restricted Payment by a non-wholly owned Subsidiary, to a Borrower and any other Subsidiaries and to each other owner of Capital Stock of such Subsidiary based on their relative ownership interests of the relevant class of Capital Stock)&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">113</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1519"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Restricted Payments by any Credit Party or any of its Subsidiaries to pay dividends with respect to its Capital Stock payable solely in additional shares of its common stock (other than Disqualified Capital Stock)&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1522"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Restricted Payments by any Credit Party or any of its Subsidiaries to Parent to enable Parent to pay any applicable income or franchise Taxes then due and payable, to the extent such Taxes are attributable to the activities or income of the Borrowers and its Subsidiaries&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1525"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;regularly scheduled, nonaccelerated payments with respect to Indebtedness subordinated to the Obligations (including, without limitation, seller notes and earnout obligations) to the extent expressly permitted by the applicable subordination agreement or such other subordination terms with respect thereto&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1528"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;the 2024 Convertible Notes Repurchase on the maturity date (as set forth in the 2024 Convertible Notes)&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1531"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;redemptions, repurchases, retirements or other acquisitions of Capital Stock  (i) deemed to occur on the exercise of options by the delivery of Capital Stock in satisfaction of the exercise price of such options or (ii) in consideration of withholding or similar taxes payable by any future, present or former officer, employee, director, member of management, or consultant (or their respective estates, executors, administrators, heirs, family members, legatees, distributees, spouses, former spouses, domestic partners and former domestic partners), including deemed repurchases in connection with the exercise of stock options&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, any Restricted Payments made pursuant to this clause (f) are not be made in cash&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1534"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;conversion of the 2024 Convertible Notes and&#47;or the 2025 Convertible Notes into Qualified Capital Stock of Parent in accordance with the terms thereof&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1537"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;all mandatory or scheduled payments in respect of the Convertible Senior Notes&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1540"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;payment and&#47;or satisfaction of the Existing Earnouts (whether by way of cash payments or issuance of Capital Stock of the Parent)&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1543"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;the 2025 Convertible Notes Repurchase on the maturity date (as set forth in the 2025 Convertible Notes)&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1546"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(k)&#160;&#160;&#160;&#160;to the extent no Event of Default has occurred and is continuing at the time of such distribution (both before and after giving effect thereto), any Credit Party and any of its Subsidiaries may make distributions in an amount sufficient to make payments (with cash or Shareholder Redemption Notes) on account of the purchase, redemption, or other acquisition or retirement of any shares of the Capital Stock of a Credit Party or Subsidiary from former employees, officers, or directors of the Credit Parties and their Subsidiaries (or any spouses, ex-spouses, beneficiaries or estates of any of the foregoing) which may be in the form of forgiveness of Indebtedness, and Parent may make such payments (with cash or Shareholder Redemption Notes) on account of the purchase, redemption, or other acquisition or retirement of any shares of its Capital Stock, and, in each case, make distributions to satisfy any tax liabilities arising in connection with such transactions&#59; provided that the amount of such distributions and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">114</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">repurchases (including any such distributions or repurchases in the form of forgiveness of Indebtedness) may not exceed the sum of (x) $2,000,000 in any Fiscal Year plus (y) the amount of the cash proceeds of any permitted issuance of Qualified Capital Stock received by the Parent or Evolent for the purpose of making such payments and used solely for such purpose plus (z) key man life insurance proceeds received by the Parent, Borrowers or any of their respective Subsidiaries during such Fiscal Year&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1549"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;&#91;reserved&#93;&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1552"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(m)&#160;&#160;&#160;&#160;the making of any Restricted Payment within 60 days after the date of declaration thereof, if at the date of such declaration such Restricted Payment would have complied with another provision of this Section 9.06&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that the making of such Restricted Payment will reduce capacity for Restricted Payments pursuant to such other provision when so made&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1555"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)&#160;&#160;&#160;&#160;to the extent constituting Restricted Payments, the consummation of the Transactions&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1558"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(o)&#160;&#160;&#160;&#160;(i) the redemption, repurchase, retirement or other acquisition of any Capital Stock (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Retired Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) of Parent in exchange for, or out of the proceeds of, the substantially concurrent sale of, Capital Stock of Parent or contributions to the equity capital of Parent (other than any Disqualified Capital Stock) (collectively, including any such contributions, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Refunding Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) and (ii) the declaration and payment of dividends on the Retired Capital Stock out of the proceeds of the substantially concurrent sale of Refunding Capital Stock&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1561"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)&#160;&#160;&#160;&#160;the Parent and its Subsidiaries may make any payments required by the terms of the TRA&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1564"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(q)&#160;&#160;&#160;&#160;the Parent or any of the Subsidiaries may pay cash in lieu of fractional Capital Stock in connection with any dividend, split or combination thereof, any Permitted Acquisition or any exercise of warrants, options or other securities convertible into or exchangeable for Capital Stock&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1567"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;to the extent no Event of Default has occurred or is continuing and to the extent not prohibited by the applicable subordination provisions applicable thereto, the Parent and its Subsidiaries may pay earn-outs, seller notes, deferred purchase price obligations, holdbacks or similar obligations that were incurred pursuant to Section 9.01(x)&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1570"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(s)&#160;&#160;&#160;&#160;to the extent constituting Restricted Payments, the Borrowers and their respective Subsidiaries may enter into and consummate transactions permitted by Section 9.04 (other than Section 9.04(e)) and Section 9.05 (other than Section 9.05(l)). </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1573"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">To the extent that the Parent or its Subsidiaries are permitted to make any Restricted Payments pursuant to this Section 9.06, the same may be made as a loan or advance to the recipient thereof, and in such case the amount of such loan or advance so made shall reduce the amount of Restricted Payments that may be made by the Parent or its Subsidiaries in respect thereof.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1576"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 9.07&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Modification of Certain Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to, consent to any amendment, supplement, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">115</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">waiver or other modification of, or enter into any forbearance from exercising any rights with respect to the terms or provisions contained in (a) any of the Organization Documents if such amendment, modification or change would (i) require any mandatory redemption date of any Capital Stock, (ii) require any cash dividends or other payments in cash to be made earlier than the Maturity Date, (iii) in the case of a Credit Party, modify any name, jurisdiction of organization, organizational identification number or federal identification number unless at least five (5) Business Days prior written notice shall be given to the Administrative Agent (or such shorter period of time reasonably agreed to by the Administrative Agent) or (iv) otherwise be materially adverse to the interests of the Administrative Agent or the Lenders in any respect, (b) any document, agreement or instrument evidencing or governing any Indebtedness that has been contractually subordinated to the Obligations in right of payment or any Liens that have been contractually subordinated in priority to the Liens of the Administrative Agent, unless such amendment, supplement, waiver or other modification is permitted under the terms of the subordination agreement applicable thereto or (c) any Material Contract, except to the extent that such amendment, modification or change could not, individually or in the aggregate, reasonably be expected to be materially adverse to the interests of the Lender.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1579"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 9.08&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Sale and Leaseback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to, directly or indirectly, enter into any agreement or arrangement providing for the sale or transfer by it of any property (now owned or hereafter acquired) to a Person and the subsequent lease or rental of such property or other similar property from such Person.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1582"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 9.09&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Transactions with Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to, enter into or cause or permit to exist any arrangement, transaction or contract (including for the purchase, lease or exchange of property or the rendering of services) with any Affiliate except (a) on fair and reasonable terms no less favorable to such Credit Party or such Subsidiary than it could obtain in an arm&#8217;s-length transaction with a Person that is not an Affiliate, (b) any transaction expressly permitted under Section 9.03, Section 9.05(d), Section 9.05(g), Section 9.05(j), Section 9.05(r), Section 9.05(v), Section 9.05(w), Section 9.05(y) or Section 9.06, (c) customary fees to, and indemnifications of, directors, officers, consultants and employees of the Credit Parties and their respective Subsidiaries, (d) the payment of reasonable and customary compensation and indemnification arrangements and benefit plans (including, without limitation, health, disability and insurance plans) for officers and employees of the Credit Parties and their respective Subsidiaries in the ordinary course of business, (e) arrangements, transactions and contracts consented to by the Administrative Agent, (f) employment agreements and severance arrangements entered into by a Credit Party or any of the Subsidiaries in the ordinary course of business, (g) capital contributions by Parent or any of its Subsidiaries to any Subsidiary, to the extent otherwise permitted hereunder, (h) payments of loans (or cancellations of loans) to employees that are (A) approved by a majority of the board of directors (or other governing body) of the applicable Credit Party in good faith, (B) made in compliance with applicable law, and (C) otherwise permitted under this Agreement, (i) arrangements, transactions or contracts among the Credit Parties, their Subsidiaries, (j) the Transactions and performance of the Credit Parties and their Subsidiaries of their obligations under the TPG Acquisition Agreement, (k) the non-exclusive licensing of patents, trademarks, software, know-how, copyrights or other intellectual property rights in the ordinary course of business to permit the commercial exploitation of intellectual property rights, (l) payments to or from, and transactions with, joint ventures, in the ordinary course of business, in each case to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">116</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">extent otherwise permitted under Section 9.05 and (m) arrangements, transactions or contracts set forth on Schedule 9.09.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1585"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Agreements, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to, enter into any agreement (other than a Transaction Document) prohibiting&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1588"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the creation or assumption by any Credit Party of any Lien upon its properties, revenues or assets, whether now owned or hereafter acquired&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1591"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the ability of such Person to amend or otherwise modify any Credit Document&#59; or</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1594"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;the ability of such Person to make any dividends, directly or indirectly, to the Credit Parties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing prohibitions shall not apply to (i) customary restrictions of the type described in clause (a) above (which do not prohibit the Credit Parties from complying with or performing the terms of this Agreement and the other Credit Documents) which are contained in any agreement, (A) governing any Indebtedness permitted by Section 9.01(d) as to assets financed with the proceeds of such Indebtedness, (B) for the creation or assumption of any Lien on the sublet or assignment of any leasehold interest of any Credit Party or any of its Subsidiaries entered into in the ordinary course of business, (C) for the assignment of any contract entered into by any Credit Party or any of its Subsidiaries in the ordinary course of business or (D) for the transfer of any asset pending the close of the sale of such asset pursuant to a Disposition permitted under this Agreement, (ii) the agreements listed on Schedule 9.10, (iii) agreements in relation to the obligations set forth in Section 9.01(q) and (iv) any subordination agreement entered into by the Administrative Agent and any applicable counterparty as required hereunder&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1597"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Hedging Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to, enter into any Hedging Transaction, except (a) Hedging Transactions entered into to hedge or mitigate risks to which such Credit Party or such Subsidiary has actual exposure (other than those in respect of Capital Stock) and (b) Hedging Transactions entered into in order to effectively cap, collar or exchange interest rates (from fixed to floating rate, from one floating rate to another floating rate or otherwise) with respect to any interest-bearing liability or investment of such Credit Party or such Subsidiary.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1600"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Changes in Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to engage in any business other than the businesses the Credit Parties and their Subsidiaries are engaged in as of the date hereof and other businesses that are reasonably related, ancillary or incidental thereto or reasonable extensions thereof.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1603"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Performance Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Credit Parties will not permit&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1606"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Reserved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1609"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Minimum Liquidity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Liquidity to be less than $15,000,000 at any time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">117</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1612"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Total Secured Leverage Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Total Secured Leverage Ratio, as of the last day of each Fiscal Quarter for each Test Period (commencing with the Test Period ending on September 30, 2022) to be greater than 6&#58;00&#58;1.00.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1615"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cure Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1618"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in the event the Borrowers fail or reasonably believes they will fail to comply with the requirements of the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.13)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Leverage Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) until the expiration of the day that is ten (10) Business Days after the earlier to occur of (i) the date the Compliance Certificate calculating such covenants is actually delivered to the Administrative Agent and (ii) the date the Compliance Certificate calculating such covenants is required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.01(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Parent shall have the right to cure (and shall be deemed to have cured) any Event of Default resulting from such breach if Parent or any parent entity thereof issues Capital Stock (other than Disqualified Capital Stock), directly or indirectly, to the equity holders of Parent or any parent thereof for cash, or otherwise receives cash contributions to the capital of Parent, which is contributed contemporaneously to Evolent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cure Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in such amounts as are necessary to be in compliance with such Leverage Covenant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cure Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which Cure Amount shall be deemed to increase Consolidated Adjusted EBITDA for such period and shall be so calculated for any subsequent period that includes the Fiscal Quarter in respect of which the Cure Right was exercised.  In no event shall the Cure Amount be greater than the amount required for purposes of complying with the Leverage Covenant as set forth herein. The Cure Right may not be exercised more than two (2) times in any four (4) consecutive quarterly periods, and not more than five (5) times during the term of this Agreement. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1621"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;Upon the Administrative Agent&#8217;s receipt of the Cure Amount, the Leverage Covenant shall be recalculated and if the Credit Parties in compliance with the requirements of the Leverage Covenant, then the Credit Parties shall be deemed to have satisfied such Leverage Covenant as of the relevant date of determination with the same effect as though there had been no failure to comply therewith at such date, and the applicable breach or default of the Leverage Covenant that occurred shall be deemed cured for the purposes of this Agreement&#59; it being understood and agreed that, upon receipt by Administrative Agent of a timely irrevocable written notice from the Administrative Borrower stating that it intends to exercise the Cure Right hereunder and until the expiration of the ten (10) Business Day period referenced above, neither Administrative Agent nor any Lender shall exercise any remedies (including applying any Default Rate), or take any actions, against any Credit Party or any of its Subsidiaries or their respective assets or property as a result of any Event of Default arising solely due to the breach of the Leverage Covenant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that, subject to the foregoing, such Default or Event of Default shall be deemed existing for all other purposes of the Credit Documents. The resulting increase to Consolidated Adjusted EBITDA from the exercise of the Cure Right shall not result in any adjustment to Consolidated Adjusted EBITDA or any other financial definition for any purposes under this Agreement or any Credit Document, other than for purposes of calculating the applicable Leverage Covenant.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1624"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disqualified Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to, issue any Disqualified Capital Stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;118</font></div><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1627"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 9.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1630"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 9.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Holdings Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1633"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1636"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;Parent shall not own or acquire any assets (other than Capital Stock, cash and Cash Equivalents) or engage in any business or activity other than (i) the ownership of Capital Stock, and activities and assets incidental thereto, (ii) the maintenance of its corporate existence and activities incidental thereto and to its existence as a public company, including general and corporate overhead and the ability to incur fees, costs and expenses relating to such maintenance, (iii) activities required to comply with Applicable Laws, (iv) maintenance and administration of stock option and stock ownership plans and activities incidental thereto, (v) the receipt of Restricted Payments to the extent permitted by Section 9.06, (vi) concurrently with any issuance of Capital Stock, the redemption, purchase or retirement of any Capital Stock of Parent using the proceeds of, or conversion or exchange of any Capital Stock of, Parent for, such Capital Stock, (viii) the obtainment of, and the payment of any fees and expenses for, management, consulting, investment banking and advisory services to the extent otherwise permitted by this Agreement, (ix) compliance with its obligations under the Credit Documents or any Indebtedness or guarantees permitted under Section 9.16(a)(ii), (x) activities necessary or reasonably advisable for or incidental to the registration and listing of Parent&#8217;s common stock and the continued existence of Parent as a public company, (xi) any public offering of its common stock or any other issuance of its Capital Stock (including Qualified Capital Stock) (xii) the execution, delivery and performance of contracts in the ordinary course of business and consistent with past practice, (xiii) any transaction that Parent is expressly permitted to enter into or consummate under this Article IX, (xiv) providing indemnification and contribution to directors, officers, employees, members of management, and consultants, (xv) activities incidental to any of the foregoing activities.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1639"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Parent shall not create, incur, assume or permit to exist any Indebtedness except (i) Indebtedness created under the Credit Documents (or any Permitted Refinancing thereof), (ii) other unsecured Indebtedness permitted under Section 9.01, (iii) unsecured Guarantee Obligations of obligations of the Borrowers and their respective Subsidiaries to the extent not prohibited herein and (iv) liabilities imposed by law, including Tax liabilities, and other liabilities incidental to its existence and permitted business and activities.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1642"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Parent shall not create, incur, assume or permit to exist any Lien (other than Liens permitted by Sections 9.02(a), (f) and (h) or other non-consensual Permitted Liens arising by operation of applicable law) on any of the Voting Stock issued by Evolent to Parent.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1645"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EH Holding Company, Inc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1648"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;EH Holding Company, Inc. shall not own or acquire any assets (other than Capital Stock, cash and Cash Equivalents) or engage in any business or activity other than (i) the ownership of Capital Stock, and activities and assets incidental thereto, (ii) the maintenance of its corporate existence and activities incidental thereto, including general and corporate overhead, (iii) activities required to comply with Applicable Laws, (iv) maintenance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">119</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and administration of stock option and stock ownership plans and activities incidental thereto, (v) the receipt of Restricted Payments to the extent permitted by Section 9.06, (vi) concurrently with any issuance of Capital Stock, the redemption, purchase or retirement of any Capital Stock of Parent using the proceeds of, or conversion or exchange of any Capital Stock of, EH Holding Company, Inc. for, such Capital Stock, (viii) the obtainment of, and the payment of any fees and expenses for, management, consulting, investment banking and advisory services to the extent otherwise permitted by this Agreement, (ix) compliance with its obligations under the Credit Documents or any Indebtedness or guarantees permitted under Section 9.16(b)(ii), (x) any transaction that EH Holding Company, Inc. is expressly permitted to enter into or consummate under this Article IX and (xi) activities incidental to any of the foregoing activities.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1651"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;EH Holding Company, Inc. shall not create, incur, assume or permit to exist any Indebtedness except (i) Indebtedness created under the Credit Documents (or any Permitted Refinancing thereof) and (ii) liabilities imposed by law, including Tax liabilities, and other liabilities incidental to its existence.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1654"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;EH Holding Company, Inc. shall not create, incur, assume or permit to exist any Lien  on any Capital Stock of any Subsidiary or joint venture of EH Holding Company, Inc. to EH Holding Company, Inc.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1657"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Holding Company Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1660"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;No Holding Company Guarantor shall own or acquire any assets (other than Capital Stock, cash and Cash Equivalents) or engage in any business or activity other than (i) the ownership of Capital Stock, and activities and assets incidental thereto, (ii) the maintenance of its corporate existence and activities incidental thereto, including general and corporate overhead, (iii) activities required to comply with Applicable Laws, (iv) maintenance and administration of stock option and stock ownership plans and activities incidental thereto, (v) the receipt of Restricted Payments to the extent permitted by Section 9.06, (vi) concurrently with any issuance of Capital Stock, the redemption, purchase or retirement of any Capital Stock of Parent using the proceeds of, or conversion or exchange of any Capital Stock of, such Holding Company Guarantor for, such Capital Stock, (viii) the obtainment of, and the payment of any fees and expenses for, management, consulting, investment banking and advisory services to the extent otherwise permitted by this Agreement, (ix) compliance with its obligations under the Credit Documents or any Indebtedness or guarantees permitted under Section 9.16(c)(ii), (x) any transaction that Holding Company Guarantor is expressly permitted to enter into or consummate under this Article IX and (xi) activities incidental to any of the foregoing activities.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1663"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;No Holding Company Guarantor shall create, incur, assume or permit to exist any Indebtedness except (i) Indebtedness created under the Credit Documents (or any Permitted Refinancing thereof) and (ii) liabilities imposed by law, including Tax liabilities, and other liabilities incidental to its existence.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1666"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;No Holding Company Guarantor shall create, incur, assume or permit to exist any Lien  on any Capital Stock of any Subsidiary or joint venture of such Holding Company Guarantor to such Holding Company Guarantor.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">120</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1669"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><br><br>Events of Default</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1672"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Listing of Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the following events or occurrences described in this Section 10.01 shall constitute an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1675"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nonpayment of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Borrowers shall default in the payment of&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1678"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;any principal of any Loan when such amount is due&#59; or</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1681"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;any interest on any Loan when such amount is due and such default shall continue unremedied for a period of five (5) Business Days after such amount is due&#59; or</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1684"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any fee described in Article IV or any other monetary Obligation under the Credit Documents when such amount is due and such default shall continue unremedied for a period of five (5) Business Days after such amount is due.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1687"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Breach of Warranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any representation or warranty of any Credit Party made or deemed to be made in any Credit Document (including any certificates delivered pursuant to Article VI) which, by its terms, is subject to a materiality qualifier, is or shall be incorrect in any respect when made or deemed to have been made or any other representation or warranty of any Credit Party made or deemed to be made in any Credit Document (including any certificates delivered pursuant to Article VI) is or shall be incorrect in any material respect when made or deemed to have been made.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1690"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Non-Performance of Certain Covenants and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Any Credit Party shall default in the due performance or observance of any of its obligations under (i) Section 8.01(a) through (d), Section 8.01(f), Section 8.03, Section 8.05(a)(i) (solely with respect to the existence of the Parent and the Credit Parties), Section 8.10, Section 8.11(b), Section 8.11(c), Section 8.12, Section 8.15, Section 8.16, 8.17 or Article IX and (ii) Section 8.01(e) and such default under this subclause (ii) shall continue unremedied for a period of five (5) Business Days after the earlier of (x) any officer of any Credit Party shall first have actual knowledge thereof or (y) any Credit Party receives written notice from the Administrative Agent or the Required Lenders in respect thereof.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1693"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Performance of Other Covenants and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any Credit Party shall default in the due performance and observance of any covenant obligation contained in any Credit Document executed by it (other than as specified in Section 10.01(a), Section 10.01(b) or Section 10.01(c)), and such default shall continue unremedied for a period of thirty (30) Business Days after the earlier of (i) any officer of any Credit Party shall first have actual knowledge thereof or (ii) any Credit Party receives written notice from the Administrative Agent or the Required Lenders in respect thereof.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1696"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Default on Other Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  (i) A default shall occur in the payment of any amount when due (subject to any applicable grace period or cure period), whether by acceleration or otherwise, of any principal or stated amount of, or interest or fees on, any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;121</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indebtedness (other than the Obligations) of any Credit Party, or Subsidiary of any Credit Party having a principal or stated amount, individually or in the aggregate, in excess of $20,000,000, or a default shall occur in the performance or observance of any obligation or condition with respect to any such Indebtedness if the effect of such default is to accelerate the maturity of such Indebtedness or to permit the holder or holders of such Indebtedness, or any trustee or agent for such holders, to cause or declare such Indebtedness to become immediately due and payable or (iii) an &#8220;Event of Default&#8221; (as defined in the Convertible Senior Notes) shall have occurred and be continuing under the Convertible Senior Notes if the effect of such Event of Default is to permit the holder or holders of such Indebtedness, or any trustee or agent for such holders, to cause or declare such Indebtedness to become immediately due and payable or if, as a result of such Event of Default thereunder, the maturity of any Notes (as defined in the Convertible Senior Notes) thereunder has been accelerated, the Commitments (as defined therein) shall have been terminated or the noteholders otherwise shall cause such Notes to become due and payable (or require the conversion of such Convertible Senior Notes) in its entirety prior to its expressed maturity&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that clauses (i) and (ii) shall not apply to (x) Indebtedness which is convertible into Capital Stock and converts to Capital Stock in accordance with its terms and such conversion is not prohibited hereunder or (y) any breach or default that is waived (including in the form of amendment or forbearance) by the required holders of the applicable item of Indebtedness, in either case, prior to the acceleration of Loans pursuant to Section 10.02.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1699"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Judgments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any final judgment or order for the payment of money individually or in the aggregate in excess of $20,000,000 (exclusive of any amounts fully covered by insurance (less any applicable deductible) and as to which the insurer has been notified of the claim and has not disputed coverage) shall be rendered against any Credit Party or any of its Subsidiaries and such judgment shall not have been satisfied, vacated or discharged or stayed or bonded pending appeal within sixty (60)&#160;days after the entry thereof or enforcement proceedings shall have been commenced by any creditor upon such judgment or order.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1702"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  An ERISA Event occurs that has resulted or could reasonably be expected to result in a Material Adverse Effect.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1705"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy, Insolvency, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any Credit Party or any of its Significant Subsidiaries shall&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1708"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;become insolvent or generally fail to pay, or admit in writing its inability or unwillingness generally to pay, its debts as they become due&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1711"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;apply for, consent to, or acquiesce in the appointment of a trustee, receiver, sequestrator or other custodian for any substantial part of the assets or other property of any such Person, or make a general assignment for the benefit of creditors&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1714"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;in the absence of such application, consent or acquiesce to or permit or suffer to exist, the appointment of a trustee, receiver, sequestrator or other custodian for a substantial part of the property of any thereof, and such trustee, receiver, sequestrator or other custodian shall not be discharged within sixty (60)&#160;days&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that each Credit Party hereby expressly authorizes each Secured Party to appear in any court conducting any relevant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">122</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">proceeding during such sixty (60)-day period to preserve, protect and defend their rights under the Credit Documents&#59; </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1717"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iv)&#160;&#160;&#160;&#160;permit or suffer to exist the commencement of any bankruptcy, reorganization, debt arrangement or other case or proceeding under any bankruptcy or insolvency law or any dissolution, winding up or liquidation proceeding, in respect thereof, and, if any such case or proceeding is not commenced by such Person, such case or proceeding shall be consented to or acquiesced in by such Person, or shall result in the entry of an order for relief or shall remain for sixty (60)&#160;days undismissed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that each Credit Party hereby expressly authorizes each Secured Party to appear in any court conducting any such case or proceeding during such 60-day period to preserve, protect and defend their rights under the Credit Documents&#59; or</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1720"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;take any action authorizing, or in furtherance of, any of the foregoing.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1723"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Impairment of Security, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Any Credit Document or any Lien granted thereunder with respect to any material portion of the Collateral (except in accordance with its terms), in whole or in part, terminate, cease to be effective or cease to be the legally valid, binding and enforceable obligation of any Credit Party thereto, or any Credit Party or any other Person shall contest in writing such effectiveness, validity, binding nature or enforceability&#59; or, except as permitted under any Credit Document, any Lien on any material portion of the Collateral shall cease to be a perfected Lien (other than as a result of the Administrative Agent&#8217;s failure to take any action within its control).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1726"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any Change of Control shall occur.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1729"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Subordination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  The subordination provisions of any subordination agreement or any subordination provisions governing any subordinated Indebtedness shall for any reason be revoked or invalidated, or otherwise cease to be in full force and effect, or any Credit Party or any Affiliate of a Credit Party shall contest in writing the validity or enforceability thereof or deny in writing that it has any further liability or obligation thereunder, or the Obligations, for any reason shall not have the priority contemplated by such subordination provisions (other than as a result of the Administrative Agent&#8217;s failure to take any action within its control).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1732"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 10.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Remedies Upon Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  If any Event of Default shall occur for any reason, whether voluntary or involuntary, and be continuing, the Administrative Agent (i) may, and at the direction of the Required Revolving Lenders or Required Lenders, shall, by notice to the Administrative Borrower permanently reduce the Revolver Commitment in whole or in part, (ii) may, at the direction of the Required Lenders, declare all or any portion of the outstanding principal amount of the Loans and other Obligations to be due and payable and the Commitments (if not theretofore terminated) to be terminated, whereupon the full unpaid amount of such Loans and other Obligations which shall be so declared due and payable shall be and become immediately due and payable, without further notice, demand or presentment, and the Commitments shall terminate, (iii) may, and at the direction of the Required Lenders shall, set-off against any outstanding Obligations amounts held for the account of the Credit Parties as cash collateral or in the accounts of any Credit Party maintained by or with the any Agent, any Lender or their respective Affiliates and (iv) may, and at the direction of the Required Lenders shall, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">123</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">take any action or exercise on behalf of itself and the Lenders all rights and remedies available to it and the Lenders under the Credit Documents or applicable Law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that notwithstanding the foregoing, upon the occurrence of an Event of Default under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 10.01(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, all Commitments shall be automatically terminated and all Obligations shall automatically become due and payable. The Borrowers, jointly and severally, shall pay the Prepayment Premium upon any Term Loans so accelerated or any Commitments so reduced or terminated pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 10.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, if required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 4.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  The Lenders and the Administrative Agent shall have all other rights and remedies available at law or in equity or pursuant to any Credit Documents.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1735"></div><div style="margin-bottom:12pt;padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE XI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><br><br>The Administrative Agent</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1738"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 11.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. Each Lender (and, if applicable, each other Secured Party) hereby appoints Ares as its Administrative Agent under and for purposes of each Credit Document and hereby authorizes the Administrative Agent to act on behalf of such Lender (or, if applicable, each other Secured Party) under each Credit Document and, in the absence of other written instructions from the Lenders, pursuant to the terms of the Credit Documents received from time to time by the Administrative Agent, to exercise such powers hereunder and thereunder as are specifically delegated to or required of the Administrative Agent by the terms hereof and thereof, together with such powers as may be incidental thereto.  Each Lender (and, if applicable, each other Secured Party) hereby irrevocably designates and appoints the Administrative Agent as the agent of such Lender.  Notwithstanding any provision to the contrary elsewhere in this Agreement, the Administrative Agent shall not have any duties or responsibilities, except those expressly set forth herein, or any fiduciary relationship with any Lender or other Secured Party, and no implied covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or any other Credit Document or otherwise exist against the Administrative Agent.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1741"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 11.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Delegation of Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  The Administrative Agent may execute any of its duties under this Agreement and the other Credit Documents by or through agents or attorneys-in-fact and shall be entitled to advice of counsel concerning all matters pertaining to such duties.  The Administrative Agent shall not be responsible for the negligence or misconduct of any agents or attorneys-in-fact selected by it with reasonable care.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1744"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 11.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Exculpatory Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Neither the Administrative Agent nor any of its respective officers, directors, employees, agents, attorneys-in-fact or Affiliates shall be (a) liable for any action lawfully taken or omitted to be taken by it or such Person under or in connection with this Agreement or any other Credit Document (except to the extent that any of the foregoing are found by a final and nonappealable decision of a court of competent jurisdiction to have resulted from its or such Person&#8217;s own gross negligence or willful misconduct) or (b) responsible in any manner to any of the Lenders or any other Secured Party for any recitals, statements, representations or warranties made by any Credit Party or any officer thereof contained in this Agreement or any other Credit Document or in any certificate, report, statement or other document referred to or provided for in, or received by the Administrative Agent under or in connection with, this Agreement or any other Credit Document or for the value, validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Credit Document or for any failure of any Credit Party or other Person to perform its obligations hereunder or thereunder. The Administrative Agent shall not be required to take any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">124</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Credit Document or applicable law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any bankruptcy or insolvency law or other similar law or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any bankruptcy or insolvency law or other similar law.  The Administrative Agent shall not be under any obligation to any Lender to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or conditions of, this Agreement or any other Credit Document, or to inspect the properties, books or records of any Credit Party.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1747"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 11.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Reliance by Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Administrative Agent shall be entitled to rely, and shall be fully protected in relying, upon any instrument, writing, resolution, notice, consent, certificate, affidavit, letter, electronic mail, statement, order or other document or conversation believed by it to be genuine and correct and to have been signed, sent or made by the proper Person or Persons and upon advice and statements of legal counsel (including counsel to the Credit Parties), independent accountants and other experts selected by the Administrative Agent.  The Administrative Agent may deem and treat the payee of any note as the owner thereof for all purposes unless a written notice of assignment, negotiation or transfer thereof shall have been filed with the Administrative Agent.  The Administrative Agent shall be fully justified in failing or refusing to take any action under this Agreement or any other Credit Document unless it shall first receive such advice or concurrence of the Required Lenders (or, if so specified by this Agreement, all or other requisite Lenders) as it deems appropriate or it shall first be indemnified to its satisfaction by the Lenders against any and all liability and expense that may be incurred by it by reason of taking or continuing to take any such action.  The Administrative Agent shall in all cases be fully protected in acting, or in refraining from acting, under this Agreement and the other Credit Documents in accordance with a request of the Required Lenders (or, if so specified by this Agreement, all Lenders), and such request and any action taken or failure to act pursuant thereto shall be binding upon all the Lenders and all future holders of the Loans and all other Secured Parties.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1750"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 11.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Notice of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Administrative Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event of Default hereunder, except with respect to any Default or Event of Default in the payment of principal, interest and fees required to be paid to the Administrative Agent for the account of the Lenders unless the Administrative Agent has received notice from a Lender or the Borrowers referring to this Agreement, describing such Default or Event of Default and stating that such notice is a &#8220;notice of default.&#8221;  In the event that the Administrative Agent receives such a notice, the Administrative Agent shall give notice thereof to the Lenders.  The Administrative Agent shall take such action with respect to such Default or Event of Default as shall be reasonably directed by the Required Lenders (or, if so specified by this Agreement, all Lenders or any other instructing group of Lenders specified by this Agreement)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that unless and until the Administrative Agent shall have received such directions, the Administrative Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Default or Event of Default as the Administrative Agent shall deem advisable in the best interests of the Secured Parties.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">125</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1753"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 11.06&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Nonreliance on Administrative Agent and Other Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Lender (and, if applicable, each other Secured Party) expressly acknowledges that neither the Administrative Agent nor any of its respective officers, directors, employees, agents, attorneys-in-fact or Affiliates have made any representations or warranties to it and that no act by the Administrative Agent hereafter taken, including any review of the affairs of a Credit Party or any Affiliate of a Credit Party, shall be deemed to constitute any representation or warranty by the Administrative Agent to any Lender or any other Secured Party.  Each Lender (and, if applicable, each other Secured Party) represents to the Administrative Agent that it has, independently and without reliance upon the Administrative Agent or any other Lender or any other Secured Party, and based on such documents and information as it has deemed appropriate, made its own appraisal of an investigation into the business, operations, property, financial and other condition and creditworthiness of the Credit Parties and their Affiliates and made its own decision to make its Loans hereunder and enter into this Agreement. Each Lender (and, if applicable, each other Secured Party) also represents that it will, independently and without reliance upon the Administrative Agent or any other Lender or any other Secured Party, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit analysis, appraisals and decisions in taking or not taking action under this Agreement and the other Credit Documents, and to make such investigation as it deems necessary to inform itself as to the business, operations, property, financial and other condition and creditworthiness of the Credit Parties and their Affiliates.  Except for notices, reports and other documents expressly required to be furnished to the Lenders by the Administrative Agent hereunder, the Administrative Agent shall not have any duty or responsibility to provide any Lender or any other Secured Party with any credit or other information concerning the business, operations, property, condition (financial or otherwise), prospects or creditworthiness of any Credit Party or any Affiliate of a Credit Party that may come into the possession of the Administrative Agent or any of its officers, directors, employees, agents, attorneys-in-fact or Affiliates.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1756"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 11.07&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Lenders agree to indemnify the Administrative Agent in its capacity as such (to the extent not reimbursed by the Credit Parties and without limiting the obligation of the Credit Parties to do so), ratably according to their respective Total Credit Exposure in effect on the date on which indemnification is sought under this Section 11.07 (or, if indemnification is sought after the date upon which the Commitments shall have terminated and the Loans shall have been paid in full, ratably in accordance with such Total Credit Exposure immediately prior to such date), from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever that may at any time (whether before or after the payment of the Loans) be imposed on, incurred by or asserted against the Administrative Agent in any way relating to or arising out of, the Commitments, this Agreement, any of the other Credit Documents, any Specified Hedging Agreement or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by the Administrative Agent under or in connection with any of the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that no Lender shall be liable for the payment of any portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements that are found by a final and nonappealable decision of a court of competent jurisdiction to have resulted from the Administrative Agent&#8217;s gross negligence or willful misconduct.  The agreements in this Section 11.07 shall survive the payment of the Loans and all other amounts payable hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1759"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 11.08&#160;&#160;&#160;&#160;Agent in Its Individual Capacity.  The Administrative Agent and its Affiliates may make loans to, accept deposits from and generally engage in any kind of business with any Credit Party as though the Administrative Agent were not the Administrative Agent.  With respect to its Loans made or renewed by it, the Administrative Agent shall have the same rights and powers under this Agreement and the other Credit Documents as any Lender and may exercise the same as though it were not the Administrative Agent, and the terms &#8220;Lender,&#8221; &#8220;Lenders,&#8221; &#8220;Secured Party&#8221; and &#8220;Secured Parties&#8221; shall include the Administrative Agent in its individual capacity.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1762"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 11.09&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Successor Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  The Administrative Agent may resign as Administrative Agent, upon twenty (20) days&#8217; notice to the Lenders and the Administrative Borrower.  If the Administrative Agent shall resign as Administrative Agent under this Agreement and the other Credit Documents, then the Required Lenders (or with respect to the Revolving Agent, the Required Revolving Lenders) shall appoint from among the Lenders a successor agent, which successor agent shall (unless an Event of Default shall have occurred and be continuing) be subject to approval by the Administrative Borrower (which approval shall not be unreasonably withheld or delayed), whereupon such successor agent shall succeed to the rights (other than any rights to indemnity payments owed to the retiring Administrative Agent), powers and duties of the Administrative Agent, and the term &#8220;Administrative Agent&#8221; shall mean such successor agent effective upon such appointment and approval, and the former Administrative Agent&#8217;s rights (other than any rights to indemnity payments owed to the retiring Administrative Agent), powers and duties as Administrative Agent shall be terminated, without any other or further act or deed on the part of such former Agent or any of the parties to this Agreement or any holders of the Loans.  If no applicable successor agent has accepted appointment as Administrative Agent by the date that is twenty (20) days following such retiring Administrative Agent&#8217;s notice of resignation, such retiring Agent&#8217;s resignation shall nevertheless thereupon become effective (except that in the case of any Collateral held by the Administrative Agent for the benefit of the Secured Parties under any of the Credit Documents, the Administrative Agent will continue to hold such collateral security until such time as a successor Administrative Agent is appointed)  and the Lenders shall assume and perform all of the duties of the Administrative Agent hereunder until such time, if any, as the Required Lenders appoint a successor agent as provided for above.  After an Agent&#8217;s resignation as the Administrative Agent, the provisions of this Article XI shall inure to its benefit as to any actions taken or omitted to be taken by it while it was an Agent under this Agreement and the other Credit Documents.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1765"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 11.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Agents Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Except as expressly set forth herein, the Administrative Agent shall not have any duties or responsibilities hereunder in its capacity as such.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1768"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictions on Actions by Lenders&#59; Sharing of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1771"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;Each of the Lenders agrees that it shall not, without the express written consent of the Administrative Agent, and that it shall, to the extent it is lawfully entitled to do so, upon the written request of Administrative Agent, set-off against the Obligations, any amounts owing by such Lender to any Credit Party or any of their respective Subsidiaries or any deposit accounts of any Credit Party or any of their respective Subsidiaries now or hereafter maintained with such Lender.  Each of the Lenders further agrees that it shall not, unless specifically requested to do so in writing by Administrative Agent, take or cause to be taken any action, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;127</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">including, the commencement of any legal or equitable proceedings to enforce any Credit Document against any Credit Party or to foreclose any Lien on, or otherwise enforce any security interest in, any of the Collateral.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1774"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;Subject to Section 12.09, if, at any time or times any Lender shall receive (i) by payment, foreclosure, setoff, or otherwise, any proceeds of Collateral or any payments with respect to the Obligations, except for any such proceeds or payments received by such Lender from the Administrative Agent pursuant to the terms of this Agreement, or (ii) payments from the Administrative Agent in excess of such Lender&#8217;s pro rata share of all such distributions by the Administrative Agent, such Lender promptly shall (A) turn the same over to the Administrative Agent, in-kind, and with such endorsements as may be required to negotiate the same to the Administrative Agent, or in immediately available funds, as applicable, for the account of all of the Lenders and for application to the Obligations in accordance with the applicable provisions of this Agreement, or (B) purchase, without recourse or warranty, an undivided interest and participation in the Obligations owed to the other Lenders, so that such excess payment received shall be applied ratably as among the Lenders in accordance with their pro rata shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that to the extent that such excess payment received by the purchasing party is thereafter recovered from it, those purchases of participations shall be rescinded in whole or in part, as applicable, and the applicable portion of the purchase price paid therefor shall be returned to such purchasing party, but without interest except to the extent that such purchasing party is required to pay interest in connection with the recovery of the excess payment.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1777"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 11.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Agency for Perfection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Administrative Agent hereby appoints each other Secured Party as its agent (and each Secured Party hereby accepts such appointment) for the purpose of perfecting the Administrative Agent&#8217;s Liens in assets which, in accordance with Article 7 or Article 8, as applicable, of the Uniform Commercial Code of any applicable state can be perfected only by possession or control.  Should any Secured Party obtain possession or control of any such Collateral, such Secured Party shall notify Administrative Agent thereof, and, promptly upon Administrative Agent&#8217;s request therefor shall deliver possession or control of such Collateral to Administrative Agent or in accordance with Administrative Agent&#8217;s instructions.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1780"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 11.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Authorization to File Proof of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  In case of the pendency of any bankruptcy, insolvency or other similar proceeding with respect to any Credit Party, the Administrative Agent (irrespective of whether the principal of any Loan shall then be due and payable or whether the Administrative Agent shall have made any demand therefor) shall be entitled&#58; (i) to file and prove a claim in such proceeding for the full amount of the principal and interest owing and unpaid in respect of the Loans and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative Agent (including any claim for reimbursement under Section 12.05) allowed in such proceeding&#59; and (ii) to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same&#59; and any trustee, liquidator or another similar official in any such proceedings is hereby authorized by each Lender to make such payments to the Administrative Agent for the account of such Lender.  Nothing contained herein shall be deemed to authorize the Administrative Agent to consent to or accept or adopt on behalf of any Lender any plan of reorganization, arrangement, adjustment or composition affecting the obligations of the Credit Party hereunder or the rights of any Lender, or to authorize the Administrative Agent to vote in respect of the claim of any Lender in any such proceeding.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">128</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1783"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 11.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Credit Bids</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Each Credit Party and each Secured Party hereby irrevocably authorizes Administrative Agent, based upon the written instruction of the Required Lenders, to bid and purchase (either directly or through one (1) or more acquisition vehicles) all or any portion of the Collateral at any sale thereof conducted (i) by the Administrative Agent under the provisions of the Code, including pursuant to Sections 9-610 or 9-620 of the Code (ii) under the provisions of the Bankruptcy Code, including Section 363, 365 and&#47;or 1129 of the Bankruptcy Code or (iii)&#160;by the Administrative Agent (whether by judicial action or otherwise, including a foreclosure sale) in accordance with applicable law (clauses (i), (ii) an (iii), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Collateral Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;)&#59; and in connection with any Collateral Sale based upon the written instruction of Required Lenders, the Administrative Agent may accept noncash consideration, including debt and equity securities issued by such acquisition vehicle under the direction or control of the Administrative Agent and the Administrative Agent may offset all or any portion of the Obligations against the purchase price of such Collateral.  Each Secured Party hereby agrees that, except as otherwise provided in any Credit Documents, or with the written consent of the Administrative Agent and the Required Lenders, it will not take any enforcement action, accelerate obligations under any Credit Documents, or exercise any right that it might otherwise have under applicable law to credit bid at foreclosure sales, UCC sales or other similar dispositions of Collateral.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1786"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 11.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Each Secured Party, by accepting the benefits of the Credit Documents, agrees that (i) any action taken by the Administrative Agent or the Required Lenders (or, if expressly required hereby, a greater proportion of the Lenders) in accordance with the provisions of the Credit Documents, (ii) any action taken by the Administrative Agent in reliance upon the instructions of Required Lenders (or, where so required, such greater proportion) and (iii) the exercise by the Administrative Agent or the Required Lenders (or, where so required, such greater proportion) of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of the Secured Parties.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1789"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><br><br>Miscellaneous</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1792"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 12.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Amendments and Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Neither this Agreement nor any other Credit Document, nor any terms hereof or thereof, may be amended, supplemented or modified except in accordance with the provisions of this Section 12.01.  The Required Lenders may, or, with the consent of the Required Lenders or the Administrative Agent, as applicable, may, from time to time, (a) enter into with the relevant Credit Party or Credit Parties written amendments, supplements or modifications hereto and to the other Credit Documents for the purpose of adding any provisions to this Agreement or the other Credit Documents or changing in any manner the rights of the Lenders or the Credit Parties hereunder or thereunder or (b) waive, on such terms and conditions as the Required Lenders or the Administrative Agent, as the case may be, may specify in such instrument, any of the requirements of this Agreement or the other Credit Documents or any Default or Event of Default and its consequences&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that no such waiver, amendment, supplement or modification shall directly&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1795"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;(A) reduce or forgive any portion of any Loan or extend the final expiration date of any Lender&#8217;s Commitment or extend the final scheduled maturity date of any Loan or reduce the stated interest rate (it being understood that only the consent of the Required </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">129</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Lenders shall be necessary to waive any obligation of the Borrowers to pay interest at the Default Rate or amend Section 2.08(c)), or (B) reduce or forgive any portion or extend the date for the payment, of any interest or fee payable hereunder (other than as a result of waiving the applicability of any post-default increase in interest rates)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">or (C) amend or modify any provisions of Section 12.09(b) or any other provision that provides for the pro rata nature of disbursements by or payments to Lenders, in each case, without the written consent of each Lender directly and adversely affected thereby&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1798"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;(A) amend, modify or waive any provision of this Section 12.01 or consent to the assignment or transfer by any Credit Party of its rights and obligations under any Credit Document to which it is a party (except as permitted pursuant to Section 9.03), in each case, without the written consent of each Lender directly and adversely affected thereby or (B) amend, modify or waive, or reduce the percentages specified in the definition of the term (x) &#8220;Required Revolving Lenders&#8221; without the written consent of each Revolving Lender and (y) &#8220;Required Term Lenders&#8221; without the written consent of each Term Lender &#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1801"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;increase the aggregate amount of any Commitment of any Lender without the consent of such Lender&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1804"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;amend, modify or waive any provision of Article XI applicable to the Administrative Agent without the written consent of the Administrative Agent&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1807"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(v)&#160;&#160;&#160;&#160;release all or substantially all of the Guarantors under the Guarantee Agreement (except as expressly permitted by the Guarantee Agreement), or release all or substantially all of the Collateral under the Security Agreement and the Mortgages (except as expressly permitted thereby and in Section 12.19), in each case without the prior written consent of each Lender&#59; or</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1810"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(vi)&#160;&#160;&#160;&#160;amend, modify or waive (or have the effect of amending, modifying or waiving) Section 5.02(j) or the definition of Waterfall Trigger Event in any manner that adversely affects the Lenders without the consent of each Lender directly and adversely affected thereby.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Notwithstanding the foregoing or anything to the contrary herein&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;this Agreement may be amended (or amended and restated) with the written consent of the Required Lenders, the Administrative Agent, and the Borrowers (x) to add one or more additional credit facilities to this Agreement and to permit the extensions of credit from time to time outstanding thereunder and the accrued interest and fees in respect thereof to share ratably in the benefits of this Agreement and the other Credit Documents with the Loans and the accrued interest and fees in respect thereof and (y) to include appropriately the Lenders holding such credit facilities in any determination of the Required Lenders&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder, except that the Commitment of such Lender may not be increased or extended, and amounts payable to such Lender hereunder may not be permanently reduced without the consent of such Lender (other than reductions in fees and interest in which such reduction does not disproportionately affect such Lender)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">130</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii)&#160;&#160;&#160;&#160;schedules to this Agreement and the Security Agreement may be amended or supplemented with the consent of the Administrative Agent&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iv)&#160;&#160;&#160;&#160;this Agreement and any other Credit Document may be amended solely with the consent of the Administrative Agent and the Borrowers without the need to obtain the consent of any other Lender if such amendment is delivered in order to (x) correct or cure ambiguities, errors, omissions, defects, (y) effect administrative changes of a technical or immaterial nature or (z) correct or cure incorrect cross references or similar inaccuracies in this Agreement or the applicable Credit Document, in each case, with regards to clauses (x) through (z), the correction of which is not adverse to the interest of any Lender.  Guarantees, collateral documents, security documents, intercreditor agreements, and related documents executed in connection with this Agreement may be amended, modified, terminated or waived, and consent to any departure therefrom may be given, without the consent of any Lender if such amendment, modification, waiver or consent is given in order to cause such guarantee, collateral document, security document, intercreditor agreement or related document to be consistent with this Agreement and the other Credit Documents. Any such amendment shall become effective without any further consent of any other party to such Credit Document&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(v)&#160;&#160;&#160;&#160;(1) any amendment, modification, elimination, waiver, consent, termination, or release of, or with respect to, any provision of this Agreement or any other Credit Document that relates only to the relationship of the Lenders and the Agents among themselves, and that does not affect the rights or obligations of Parent or the Borrowers, shall not require consent by or the agreement of any Credit Party, (2) any amendment, waiver, modification, elimination, or consent of or with respect to any provision of this Agreement or any other Credit Document may be entered into without the consent of, or over the objection of, any Defaulting Lender and (3) any amendment contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.08(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> in connection with Conforming Changes or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> in connection with a Benchmark Transition Event shall be effective as contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.08(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, as applicable&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(vi)&#160;&#160;&#160;&#160;solely with the consent of the Required Revolving Lenders and the Required Lenders (and, to the extent involving the Swingline Advances, the Revolving Agent), any such agreement may amend, modify or waive any term relating solely to the Revolving Loans and the Swingline Advances&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that without limiting this clause (vi), no such amendment, modification, consent, waiver or elimination, without the consent of the Required Revolving Lenders (and, to the extent involving the Swingline Advances, the Revolving Agent), shall (A) amend or waive any provision of (including defined terms therein which pertain to Revolver Commitments) Section 2.01 (as it pertains to the Revolving Loans), 2.02 (as it pertains to the Revolving Loans and the Swingline Advances), 2.03 (as it pertains to the Revolving Loans), 2.04 (as it pertains to the Revolving Loans and the Swingline Advances), 2.05 (as it pertains to the Revolving Loans), 2.14, 4.01, 4.02 (as it pertains to the Revolving Loans), 4.03, 5.01 (as it pertains to the Revolving Loans), 2.08 (as it pertains to the Revolving Loans), 7.05 and 8.10 (in each case, as it pertains to the use of proceeds of Revolving Loans), 8.17, 11.14, 12.01 and 12.19 (in each case, as it pertains to amendments, waivers or modifications of the Administrative Agent&#8217;s or Revolving Agent&#8217;s rights to take action on behalf of the Revolving Lenders), Section 12.06(d) and Article X (in each case, as it pertains to the right of Required Revolving Lenders to terminate Revolver Commitments), (B) amend, modify or waive compliance with the conditions precedent to the obligations of any Revolving Lender or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">131</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Revolving Agent to make any Revolving Loan or Swingline Advance in Section 6.02, (C) amend modify or terminate any provision set forth in Section 6.02 or waive any Default or Event of Default for the sole purpose of satisfying the conditions precedent to the obligations of Revolving Lenders or the Revolving Agent to make any Revolving Loans or Swingline Advances in Section 6.02, (D) change the definition of &#8220;Change of Control&#8221; or waive (including, for the avoidance of doubt, by forbearance with respect to) any Default or Event of Default under or pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 10.01(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, (E) amend, waive or otherwise modify (or consent to any departure from including any waiver of a Default or Event of Default arising from a breach of) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and&#47;or the definition of Liquidity, Total Secured Leverage Ratio, Test Period, and&#47;or any other component definition used in any of the foregoing if the effect of any such amendment, waiver, modification or consent (together with each other amendment, waiver, consent or modification made in respect thereof without the consent of the Required Revolving Lenders) is to loosen (or have the effect of loosening) the covenant levels or any of them set forth in Section 9.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">by more than ten percent (10%) on a cumulative basis for any particular covenant level&#59; (F) amend, waive or otherwise modify (or consent to any departure from including any waiver of a Default or Event of Default arising from a breach of) any of (1) Sections 8.01(a), 8.01(b) or 8.01(c) (delivery of quarterly and annual financials), solely to the extent such financial statements are not delivered to the Administrative Agent for delivery to each Lender within 20 days following the date such financial statements were required to be delivered pursuant to Sections 8.01(a), 8.01(b) and 8.01(c) (2) Sections 9.02 (liens), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (investments), Section 9.01 (indebtedness), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.04 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(dispositions) or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (restricted payments), (3) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 10.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (payment), (4) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 10.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> arising from the failure of any Borrower or any other Credit Party to observe or perform its obligations under Section 9.12 (conduct of business)&#59; (5) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 10.01(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (insolvency proceedings, dissolution or liquidation)&#59; (6) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 10.01(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (judgment default)&#59; (7)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 10.01(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(liens) or (8) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 10.01(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (subordination)&#59; (G) amend, waive or otherwise modify any of the following definitions&#58; &#8220;Borrowing Base&#8221; (or any component definition used therein), &#8220;Borrowing Base Certificate&#8221;, &#8220;Minimum Revolver Interest Amount&#8221;, &#8220;Minimum Revolver Borrowing Amount&#8221;, &#8220;Notice of Borrowing&#8221;, &#8220;Cash Dominion Event&#8221;, &#8220;Collection Account&#8221;, &#8220;Excluded Account&#8221;, &#8220;Extraordinary Advance&#8221;, &#8220;Maximum Revolver Amount&#8221;, &#8220;Overadvance&#8221;, &#8220;Permitted Discretion&#8221;, &#8220;Reserves&#8221;, &#8220;Revolving Agent&#8217;s Account&#8221;, &#8220;Revolving Availability Period&#8221;, &#8220;Revolving Borrowing&#8221;, &#8220;Revolving Facility&#8221;, &#8220;Revolving Loan Exposure&#8221;, &#8220;Revolving Facility Commitment&#8221;, &#8220;Revolving Facility Exposure&#8221;, &#8220;Revolving Facility Maturity Date&#8221;, &#8220;Revolving Lender&#8221;, &#8220;Revolving Loans&#8221;, &#8220;Revolving Loan Account&#8221;, &#8220;Springing Controlled Account&#8221;, &#8220;Springing Control Agreement&#8221;, &#8220;Swingline Advance&#8221;, &#8220;Swingline Loan Limit&#8221;, &#8220;Waterfall Trigger Event&#8221;&#59; or (H) shorten the maturity or weighted average life to maturity of the Term Loans or require that any payment on the Term Loans be made earlier than the date originally scheduled for such payment.</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1813"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices and Other Communications&#59; Facsimile Copies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1816"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Unless otherwise expressly provided herein, all notices and other communications provided for hereunder or under any other Credit Document shall be in writing (including by electronic transmission).  All such written notices shall be mailed, e-mailed or delivered to the applicable address or electronic mail address, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">132</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1819"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;if to the Credit Parties, the Administrative Agent, to the address, electronic mail address or telephone number specified for such Person on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 12.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or to such other address, electronic mail address or telephone number as shall be designated by such party in a notice to the other parties&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1822"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;if to any other Lender, to the address, facsimile number, electronic mail address or telephone number specified in its Administrative Questionnaire or to such other address, facsimile number, electronic mail address or telephone number as shall be designated by such party in a notice to the Administrative Borrower, and the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">All such notices and other communications shall be deemed to be given or made upon the earlier to occur of&#58;  (i) actual receipt by the relevant party hereto and (ii) (A) if delivered by hand or by courier, when signed for by or on behalf of the relevant party hereto&#59; (B) if delivered by mail, three (3) Business Days after deposit in the mails, postage prepaid&#59; (C) if delivered by facsimile, when sent and receipt has been confirmed by telephone&#59; and (D) if delivered by electronic mail (which form of delivery is subject to the provisions of Section 12.02(c)), when delivered&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that notices and other communications to the Administrative Agent pursuant to Article II shall not be effective until actually received by such Person.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1861"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Effectiveness of Electronic Documents and Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Credit Documents may be transmitted and&#47;or signed by email or other electronic communication.  The effectiveness of any such documents and signatures shall have the same force and effect as manually signed originals and shall be binding on all Credit Parties, the Administrative Agent and the Lenders.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1864"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Reliance by the Administrative Agent and Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Administrative Agent and the Lenders shall be entitled to rely and act upon any notices purportedly given by or on behalf of any Credit Party even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice specified herein or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof.  All telephonic notices to the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1867"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 12.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">No Waiver&#59; Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  No failure to exercise and no delay in exercising, on the part of the Administrative Agent or any Lender, any right, remedy, power or privilege hereunder or under the other Credit Documents shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.  The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1870"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Survival of Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All representations and warranties made hereunder and in the other Credit Documents shall survive the execution and delivery of this Agreement and the making of the Loans hereunder.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1873"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 12.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Payment of Expenses&#59; Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Borrowers, severally and jointly, agrees, subject to any limitations set forth in the Fee Letter, (a) to pay or reimburse the Administrative Agent and the Lenders for all their reasonable and documented out-of-pocket costs and expenses incurred in connection with the development, preparation, negotiation and execution of, and any amendment, waiver, supplement or modification to, this Agreement and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">the other Credit Documents and any other documents prepared in connection herewith or therewith, and the consummation and administration of the transactions contemplated hereby and thereby, including the reasonable and documented fees, disbursements and other charges of one counsel (and, to the extent necessary, one local counsel in any relevant jurisdiction and, if reasonably required, one regulatory counsel) to the Administrative Agent, (b) to pay or reimburse (i) a single firm of counsel to the Administrative Agent, (ii) if reasonably necessary, one local counsel in each relevant jurisdiction (which may include special counsel acting in multiple jurisdictions) and (iii) solely in the case of an actual or perceived conflict of interest, one additional primary counsel and one additional counsel in each relevant jurisdiction (which may include a single special counsel acting in multiple jurisdictions) for each group of affected Lenders similarly situated taken as a whole, for all their reasonable and documented out-of-pocket costs and expenses incurred in connection with the enforcement or preservation of any rights under this Agreement, the other Credit Documents and any such other documents, and (c) to pay, indemnify and hold harmless each Lender and the Administrative Agent and their respective Related Parties from and against any and all other actual liabilities, obligations, losses, damages, penalties, actions, judgments, suits, and reasonable out-of-pocket costs, expenses or disbursements of any kind or nature whatsoever, including reasonable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">and documented</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">fees, disbursements and other charges of one counsel, arising as a result of the execution, delivery, enforcement, performance and administration of this Agreement, the other Credit Documents and any such other documents, including any of the foregoing relating to the violation of, noncompliance with or liability under, any Environmental Law on the part of any Credit Party or any of its Subsidiaries or any actual or alleged presence of Hazardous Materials as a result of the operations of each Credit Party or any of its Subsidiaries, including at any of their Real Property (all the foregoing in this clause (c), collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">indemnified liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the Credit Parties shall have no obligation hereunder to the Administrative Agent or any Lender nor any of their Related Parties with respect to indemnified liabilities arising from (i) the gross negligence or willful misconduct of the party to be indemnified or one of their Related Parties&#59; (ii) disputes among the Administrative Agent, the Lenders and&#47;or their transferees&#59; or (iii) diminution in value of any Real Property of any Credit Party resulting from the presence of Hazardous Materials existing at such Real Property on or before the Closing Date.  The agreements in this Section 12.05 shall survive repayment of the Loans and all other amounts payable hereunder and termination of this Agreement.  To the fullest extent permitted by Applicable Law, no Credit Party shall assert, and each Credit Party hereby waives, any claim against any Lender, the Administrative Agent and their respective Related Parties, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Credit Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or the use of the proceeds thereof.  No Lender, the Administrative Agent nor any of their respective Related Parties shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Credit Documents or the transactions contemplated hereby or thereby.  This Section 12.05 shall not apply to Taxes other than any Taxes that represent losses, claims, damages, etc., arising from a non-Tax claim.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1876"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.06&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successors and Assigns&#59; Participations and Assignments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">134</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1879"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that (i) except as set forth in Section 9.03, no Credit Party may assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of each Lender (and any attempted assignment or transfer by any Credit Party without such consent shall be null and void) and (ii) no Lender may assign or otherwise transfer its rights or obligations hereunder except in accordance with this Section 12.06.  Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants (to the extent provided in paragraph (c) of this Section 12.06) and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent, and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement.  Notwithstanding anything to the contrary herein, (a) any Lender shall be permitted to pledge or grant a security interest in all or any portion of such Lender&#8217;s rights hereunder including, but not limited to, any Loans (without the consent of, or notice to or any other action by, any other party hereto) to secure the obligations of such Lender or any of its Affiliates to any Person providing any loan, letter of credit or other extension of credit to or for the account of such Lender or any of its Affiliates and any agent, trustee or representative of such Person and (b) the Administrative Agent shall be permitted to pledge or grant a security interest in all or any portion of its respective rights hereunder or under the other Credit Documents, including, but not limited to, rights to payment (without the consent of, or notice to or any other action by, any other party hereto), to secure the obligations of the Administrative Agent or any of its Affiliates to any Person providing any loan, letter of credit or other extension of credit to or for the account of the Administrative Agent or any of its Affiliates and any agent, trustee or representative of such Person.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1882"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;Subject to the conditions set forth in paragraph (b)(ii) below, any Lender may assign to one or more assignees (other than to a Defaulting Lender or to any Borrower or to any of the Borrower&#8217;s Affiliates or Subsidiaries) (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Eligible Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitments and the Loans at the time owing to it) with the prior written consent (which consent in each case shall not be unreasonably withheld or delayed) of&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1885"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160;the Administrative Borrower&#59; provided, that (1) no consent of the Administrative Borrower shall be required for an assignment to a Lender, an Affiliate of a Lender, an Approved Fund or, if Default or an Event of Default pursuant to Section 10.01(a), 10.01(c) (solely with respect to a default under Section 9.13) or Section 10.01(h) has occurred and is continuing, any other assignee and (2) the Administrative Borrower shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within five (5) Business Days after having received notice thereof&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1888"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;the Administrative Agent&#59; provided, that no consent of the Administrative Agent shall be required for an assignment to a Lender, an Affiliate of a Lender or an Approved Fund.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Assignments shall be subject to the following additional conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">135</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;except in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund or an assignment of the entire remaining amount of the assigning Lender&#8217;s Commitments or Loans, the amount of the Commitments or Loans of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Acceptance with respect to such assignment is delivered to the Administrative Agent) shall not be less than $1,000,000, unless each of the Administrative Borrower and the Administrative Agent otherwise consents, which consent, in each case, shall not be unreasonably withheld or delayed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that no such consent of the Administrative Borrower shall be required if an Event of Default under Section 10.01(a), (c) (solely in respect of a breach of Section 8.01(a), (b), (c), (d) or (e), or Section 9.13) or Section 10.01(h) has occurred and is continuing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that contemporaneous assignments to a single assignee made by affiliated Lenders or related Approved Funds and contemporaneous assignments by a single assignor to affiliated Lenders or related Approved Funds shall be aggregated for purposes of meeting the minimum assignment amount requirements stated above&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender&#8217;s rights and obligations under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that this paragraph shall not be construed to prohibit the assignment of a proportionate part of all the assigning Lender&#8217;s rights and obligations in respect of Commitments or Loans&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)&#160;&#160;&#160;&#160;the parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Acceptance, together with a processing and recordation fee of $3,500&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that only one such fee shall be payable in connection with simultaneous assignments to two or more Approved Funds&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)&#160;&#160;&#160;&#160;the assignee, if it shall not be a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire and all &#8220;know your customer&#8221; documentation&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(E)&#160;&#160;&#160;&#160;No Lender may assign or otherwise transfer its rights or obligations hereunder to any of the Credit Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to such assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Administrative Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee (by its execution and delivery of the applicable Assignment and Acceptance to the Administrative Agent) and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent, or any Lender hereunder (and interest accrued thereon) and (y) acquire (and fund as appropriate) its full respective Pro Rata Share of all Loans.  Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">136</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii)&#160;&#160;&#160;&#160;Subject to acceptance and recording thereof pursuant to paragraph (b)(v) of this Section 12.06, from and after the recordation date of each Assignment and Acceptance in the Register, the assignee thereunder shall be a party hereto and, to the extent of the interest assigned by such Assignment and Acceptance, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Acceptance, be released from its obligations under this Agreement (and, in the case of an Assignment and Acceptance covering all of the assigning Lender&#8217;s rights and obligations under this Agreement, such Lender shall cease to be a party hereto but shall continue to be entitled to the benefits of Sections 2.10, 2.11, 5.03 and 12.05)&#59; provided, that except to the extent otherwise expressly agreed by the affected parties, no assignment by a Defaulting Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender&#8217;s having been a Defaulting Lender.  Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this Section 12.06 shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with paragraph (c) of this Section 12.06.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;The Administrative Agent, acting solely for this purpose as an agent of the Borrowers, shall maintain a copy of each Assignment and Acceptance delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amount of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;).  Further, the Register shall contain the name and address of the Administrative Agent and the lending office through which each such Person acts under this Agreement.  The entries in the Register shall be conclusive absent manifest error, and the Credit Parties, the Administrative Agent, and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary.  In addition, the Administrative Agent shall maintain on the Register information regarding the designation, and revocation of designation, of any Lender as a Defaulting Lender.  The Register, as in effect at the close of business on the preceding Business Day, shall be available for inspection by the Administrative Borrower, and any Lender, at any reasonable time and from time to time upon reasonable prior written notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;Upon its receipt of a duly completed Assignment and Acceptance executed by an assigning Lender and an assignee, the assignee&#8217;s completed Administrative Questionnaire (unless the assignee shall already be a Lender hereunder) and any written consent to such assignment required by paragraph (b)(i) of this Section 12.06, the Administrative Agent shall accept such Assignment and Acceptance and record the information contained therein in the Register.  No assignment shall be effective for purposes of this Agreement unless and until it has been recorded in the Register as provided in this paragraph.</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Disqualified Institutions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(A)&#160;&#160;&#160;&#160;No assignment or participation shall be made to any Person that was a Disqualified Institution as of the date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Trade Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) on which the assigning or transferring Lender entered into a binding agreement to sell and assign, or grant a participation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">137</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">in, all or a portion of its rights and obligations under this Agreement, as applicable, to such Person unless Administrative Agent and the Administrative Borrower (unless a Default or Event of Default under Section 10.01(a) or 10.01(h) has occurred and is continuing, in which case no consent from the Administrative Borrower is required) have consented in writing in their sole and absolute discretion to such assignment or participation, in which case such Person will not be considered a Disqualified Institution for the purpose of such assignment or participation.  For the avoidance of doubt, (x) no assignment or participation shall be retroactively invalidated pursuant to this Section 12.06(b)(vi) if the Trade Date therefor occurred prior to the assignee&#8217;s or participant&#8217;s becoming a Disqualified Institution (including as a result of the delivery of a notice pursuant to, and&#47;or the expiration of the notice period referred to in, the definition of &#8220;Disqualified Institution&#8221;), and (y) the execution by the Administrative Borrower or Agent of an Assignment and Acceptance with respect to such an assignment will not by itself result in such assignee no longer being considered a Disqualified Institution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;Administrative Agent and each assignor of a Loan or seller of a participation hereunder shall be entitled to rely conclusively on a representation of the assignee Lender or Participant in the relevant Assignment or participation agreement, as applicable, that such assignee or purchaser is not a Disqualified Institution.  The Administrative Agent shall have the right, and the Borrowers hereby expressly authorize Administrative Agent, to verbally disclose to any potential Lender or Participant whether not such Person is on the list of Disqualified Institutions provided by the Administrative Borrower and any updates thereto from time to time (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">DQ List</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Any assignment to a Disqualified Institution or grant or sale of participation to a Disqualified Institution in violation of this Section 12.06(b)(vi) shall not be void, but the other provisions of this Section 12.06 shall apply.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1891"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;Any Lender may, without the consent of the Borrowers, or the Administrative Agent, sell participations to one or more banks or other entities (other than a natural person, a Defaulting Lender or any Borrower or any of the Borrower&#8217;s Affiliates or Subsidiaries) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in all or a portion of such Lender&#8217;s rights and obligations under this Agreement (including all or a portion of its Commitments and the Loans owing to it)&#59; provided, that (A) such Lender&#8217;s obligations under this Agreement shall remain unchanged, (B)&#160;such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (C) the Borrowers, the Administrative Agent, and the other Lenders shall continue to deal solely and directly with such Lender in connection with such Lender&#8217;s rights and obligations under this Agreement.  Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement or any other Credit Document&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver described in clause (i) of the first proviso to Section 12.01.  Subject to paragraph (c)(ii) of this Section 12.06, each Borrower agrees that each Participant shall be entitled to the benefits of Sections 2.10, 2.11, and 5.04 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section 12.06.  To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 12.09(b) as though it were a Lender, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such Participant agrees to be subject to Section 12.09(a) as though it were a Lender.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">138</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1894"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;A Participant shall not be entitled to receive any greater payment under Section 2.10, 2.11 or 5.04 than the applicable Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the Borrowers&#8217; prior written consent.  A Participant shall not be entitled to the benefits of Section 5.04 unless the Borrowers are notified of the participation sold to such Participant and such Participant agrees, for the benefit of the Borrowers, to comply with Section 5.04(b) as though it were a Lender.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1897"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrowers, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant&#8217;s interest in the Lender&#8217;s obligations hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant&#8217;s interest in any commitments, loans, letters of credit or its other obligations under any Credit Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations.  The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.  For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall not have any responsibility for maintaining a Participant Register.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1900"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;Each Term Lender and, to the extent its claim arises in connection with a Term Loan, each other Indemnitee and holder of an Obligation of a Credit Party (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Term Creditors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) acknowledges and agrees that because of their differing rights in proceeds of the Collateral, the Obligations arising under or in respect of the Term Loans (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Term Loan Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) are fundamentally different from the obligations arising under or in respect of the Revolving Loans and the Revolver Commitments (and participations therein) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Revolving Credit Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) and must be separately classified in any plan of reorganization proposed or confirmed in any bankruptcy or insolvency proceeding involving any Borrower or any Guarantor as a debtor.  No Term Creditor shall seek in any such bankruptcy or insolvency proceeding to be treated as part of the same class of creditors as the Revolving Loans and&#47;or the Revolver Commitments (and participations therein), each other Indemnitee and holder of an Obligation of a Credit Party (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Revolving Creditors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) or shall oppose any pleading or motion by the Revolving Creditors for the Revolving Creditors and the Term Creditors to be treated as separate classes of creditors.  Notwithstanding the foregoing, and regardless of whether the Term Loan Obligations and the Revolving Credit Obligations are separately classified in any such plan of reorganization, the Term Creditors hereby acknowledge and agree that to the extent that the aggregate value of the Collateral exceeds the amount of the Revolving Credit Obligations, the Revolving Creditors shall be entitled to receive, in addition to amounts distributed to them in respect of principal, pre-petition interest and other claims, all amounts owing in respect of interest, and fees, costs and charges incurred subsequent to the commencement of the applicable bankruptcy or insolvency proceeding (regardless of whether such interest, and fees, costs and charges incurred subsequent to the commencement of the applicable bankruptcy or insolvency proceeding is allowed as part of the claims of the Revolving Creditors under Section&#160;506(b) of the Bankruptcy Code or otherwise) before any distribution (whether pursuant to a plan of reorganization or otherwise) is made in respect of any of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;139</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">claims held by the Term Creditors.  The Term Creditors hereby acknowledge and agree to hold in trust for the benefit of the Revolving Creditors and to turn over to the Revolving Creditors all distributions received or receivable by them in any bankruptcy or insolvency proceeding (whether pursuant to a plan of reorganization or otherwise) to the extent necessary to effectuate the intent of the preceding sentence, even if such turnover has the effect of reducing the claim or recovery of the Term Creditors.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1903"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.07&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Replacements of Lenders Under Certain Circumstances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1906"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;Any Borrower, at its sole cost and expense, shall be permitted to replace any Lender (or any Participant), other than an Affiliate of the Administrative Agent, that (i) requests reimbursement for amounts owing pursuant to Section 2.10, Section 2.11, Section 2.12 or Section 5.04, or (ii) is affected in the manner described in Section 2.10(a)(iii) and as a result thereof any of the actions described in such Section is required to be taken, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that (A) such replacement does not conflict with any Applicable Law, (B) no Default or Event of Default shall have occurred and be continuing at the time of such replacement, (C) the Borrowers, jointly and severally, shall repay (or the replacement bank or institution shall purchase, at par) all Loans and other amounts (other than any disputed amounts) pursuant to Section 2.10, Section 2.11, Section 2.12 or Section 5.04, as the case may be, owing to such replaced Lender prior to the date of replacement, (D) the replacement bank or institution, if not already a Lender, and the terms and conditions of such replacement, shall be reasonably satisfactory to each Agent, (E)&#160;the replaced Lender shall be obligated to make such replacement in accordance with the provisions of Section 12.06 (except that such replaced Lender shall not be obligated to pay any processing and recordation fee required pursuant thereto) and (F) any such replacement shall not be deemed to be a waiver of any rights that any Borrower, the Administrative Agent or any other Lender shall have against the replaced Lender.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1909"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;If any Lender (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Non-Consenting Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) has failed to consent to a proposed amendment, waiver, discharge or termination, which pursuant to the terms of Section 12.01 requires the consent of all of the Lenders affected or the Required Lenders and with respect to which the Required Lenders shall have granted their consent, then, provided that no Default or Event of Default then exists, any Borrower shall have the right (unless such Non-Consenting Lender grants such consent), at its own cost and expense, to replace such Non-Consenting Lender by requiring such Non-Consenting Lender to assign its Loans and Commitments to one or more assignees reasonably acceptable to the Administrative Agent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that&#58; (i) all Obligations of the Borrowers owing to such Non-Consenting Lender being replaced shall be paid in full to such Non-Consenting Lender concurrently with such assignment and (ii) the replacement Lender shall purchase the foregoing by paying to such Non-Consenting Lender a price equal to the principal amount thereof plus accrued and unpaid interest thereon.  In connection with any such assignment, the Borrowers, the Administrative Agent, such Non-Consenting Lender and the replacement Lender shall otherwise comply with Section 12.06 (except that such Non-Consenting Lender shall not be obligated to pay any processing and recordation fee required pursuant thereto).</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1912"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 12.08&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Securitization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Credit Parties hereby acknowledge that the Lenders and their Affiliates may securitize the Loans (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Securitization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) through the pledge of the Loans as collateral security for loans to the Lenders or their Affiliates or through the sale of the Loans or the issuance of direct or indirect interests in the Loans to their controlled Affiliates, which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">140</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">loans to the Lenders or their Affiliates or direct or indirect interests will be rated by Moody&#8217;s, S&#38;P or one or more other rating agencies.  The Credit Parties shall, to the extent commercially reasonable, cooperate with the Lenders and their Affiliates to effect any and all Securitizations.  Notwithstanding the foregoing, no such Securitization shall release the Lender party thereto from any of its obligations hereunder or substitute any pledgee, secured party or any other party to such Securitization for such Lender as a party hereto and no change in ownership of the Loans may be effected except pursuant to Section 12.06.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1915"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 12.09&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Adjustments&#59; Set-off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  (a) If any Lender (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Benefited Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) shall at any time receive any payment of all or part of its Loans, or interest thereon, or receive any collateral in respect thereof (whether voluntarily or involuntarily, by set-off, pursuant to events or proceedings of the nature referred to in Section 10.01(h) or otherwise), in a greater proportion than any such payment to or collateral received by any other Lender, if any, in respect of such other Lender&#8217;s Loans or interest thereon, such Benefited Lender shall (i) notify the Administrative Agent of such fact and (ii) purchase for cash from the other Lenders a participating interest in such portion of each such other Lender&#8217;s Loans, or shall provide such other Lenders with the benefits of any such collateral, or the proceeds thereof, as shall be necessary to cause such Benefited Lender to share the excess payment or benefits of such collateral or proceeds ratably with each of the Lenders&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">that (x) if all or any portion of such excess payment or benefits is thereafter recovered from such Benefited Lender, such purchase shall be rescinded, and the purchase price and benefits returned, to the extent of such recovery, but without interest and (y) the provisions of this Section shall not be construed to apply to (A) any payment made by or on behalf of the Borrowers pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the existence of a Defaulting Lender) or (B) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Loans to any assignee or participant (as to which the provisions of this Section shall apply).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Notwithstanding the foregoing, in the event that any Defaulting Lender shall exercise any such right of setoff, (1) all amounts so set-off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of Section 2.05(d) and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent and the Lenders, and (2) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of set-off.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Each Credit Party consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against such Credit Party rights of set-off and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of such Credit Party in the amount of such participation.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1918"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;After the occurrence and during the continuance of an Event of Default, to the extent consented to by Administrative Agent, in addition to any rights and remedies of the Lenders provided by law, each Lender shall have the right, without prior notice to any Borrower or any other Credit Party, any such notice being expressly waived by the Credit Parties to the extent permitted by Applicable Law, upon any amount becoming due and payable by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">141</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Borrowers hereunder (whether at the stated maturity, by acceleration or otherwise) to set-off and appropriate and apply against such amount any and all deposits (general or special, time or demand, provisional or final), in any currency, and any other credits, indebtedness or claims, in any currency, in each case, whether direct or indirect, absolute or contingent, matured or unmatured, at any time held or owing by such Lender or any branch or agency thereof to or for the credit or the account of the Borrowers, as the case may be.  Each Lender agrees promptly to notify the Administrative Borrower and the Administrative Agent after any such set-off and application made by such Lender&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that the failure to give such notice shall not affect the validity of such set-off and application.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1921"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 12.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  This Agreement and the other Credit Documents may be executed by one or more of the parties thereto on any number of separate counterparts (including by electronic transmission), and all of said counterparts taken together shall be deemed to constitute one and the same instrument.  A set of the copies of this Agreement signed by all the parties shall be lodged with the Administrative Borrower and the Administrative Agent.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1924"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 12.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.  Without limiting the foregoing provisions of this Section 12.11, if and to the extent that the enforceability of any provisions in this Agreement relating to Defaulting Lenders shall be limited by bankruptcy, insolvency, fraudulent conveyance, moratorium, reorganization and other similar laws relating to or affecting creditors&#8217; rights generally and general principles of equity (whether considered in a proceeding in equity or law), as determined in good faith by the Administrative Agent, then such provisions shall be deemed to be in effect only to the extent not so limited.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1927"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 12.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  This Agreement and the other Credit Documents represent the agreement of the Credit Parties, the Administrative Agent and the Lenders with respect to the subject matter hereof, and there are no promises, undertakings, representations or warranties by any party hereto or thereto relative to the subject matter hereof not expressly set forth or referred to herein or in the other Credit Documents.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1930"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 12.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">GOVERNING LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  THIS AGREEMENT, THE OTHER CREDIT DOCUMENTS (UNLESS EXPRESSLY PROVIDED OTHERWISE THEREIN) AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER AND THEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1933"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Submission to Jurisdiction&#59; Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each party hereto hereby irrevocably and unconditionally&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1936"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or in tort or otherwise, against the Administrative Agent, any Lender, or any Affiliate of the foregoing in any way relating to this Agreement or any other Credit Document or the transactions relating hereto or thereto, in any forum other than the courts of the State of New York sitting in New York County, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">142</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally submits to the jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by applicable law, in such federal court&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1939"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;consents that any such action or proceeding may be brought in such courts and waives any objection that it may now or hereafter have to the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1942"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or any substantially similar form of mail), postage prepaid, to the applicable party at its respective address set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 12.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or at such other address of which the Administrative Agent shall have been notified pursuant thereto&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1945"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit any right that the Administrative Agent or any Lender may otherwise have to bring any action or proceeding relating to this Agreement or any other Credit Document against any Borrower or any other Credit Party or their respective properties in the courts of any jurisdiction&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1948"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;waives, to the maximum extent not prohibited by law, all rights of rescission, set-off, counterclaims, and other defenses in connection with the repayment of the Obligations&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1951"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;waives, to the maximum extent not prohibited by law, any right it may have to claim or recover in any legal action or proceeding referred to in this Section 12.14 any special, exemplary, punitive or consequential damages.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1954"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acknowledgments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Credit Party hereby acknowledges that&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1957"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Credit Documents&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1960"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;neither the Administrative Agent nor any Lender has any fiduciary relationship with or duty to the Credit Parties arising out of or in connection with this Agreement or any of the other Credit Documents, and the relationship between the Administrative Agent and Lenders, on one hand, and the Credit Parties, on the other hand, in connection herewith or therewith is solely that of debtor and creditor&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1963"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;no joint venture is created hereby or by the other Credit Documents or otherwise exists by virtue of the transactions contemplated hereby among the Lenders or among the Credit Parties and the Lenders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">143</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_1966"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">WAIVERS OF JURY TRIAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  THE CREDIT PARTIES, THE ADMINISTRATIVE AGENT AND THE LENDERS HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVE TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER CREDIT DOCUMENT AND FOR ANY COUNTERCLAIM THEREIN.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1969"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 12.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  The Administrative Agent and Lender shall hold all Confidential Information confidential in accordance with its customary procedure for handling confidential information of this nature and (in the case of a Lender that is a bank) in accordance with safe and sound banking practices&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that Confidential Information may be disclosed by the Administrative Agent or Lender&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1972"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;as required by any governmental agency or representative thereof (including, without limitation, public disclosures by the Administrative Agent, Lender, or any of their Related Parties required by the SEC or any other governmental or regulatory authority)&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1975"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;pursuant to legal process&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1978"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;in connection with the enforcement of any rights or exercise of any remedies by the Administrative Agent or Lender under this Agreement or any other Credit Document or any action or proceeding relating to this Agreement or any other Credit Document&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1981"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;to the Administrative Agent&#8217;s or Lender&#8217;s attorneys, professional advisors, independent auditors or Affiliates,</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1984"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;in connection with&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1987"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the establishment of any special purpose funding vehicle with respect to the Loans,</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1990"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;any Securitization permitted under Section 12.08&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1993"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any prospective assignment of, or participation in, its rights and obligations pursuant to Section 12.06, to prospective assignees or Participants, as the case may be&#59;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1996"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iv)&#160;&#160;&#160;&#160;any Hedging Transaction entered into or proposed to be entered into in connection with the Loans made hereunder, to actual or proposed direct or indirect contractual counterparties&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_1999"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;any actual or proposed credit facility for loans, letters of credit or other extensions of credit to or for the account of the Administrative Agent or Lender or any of its Affiliates, to any Person providing or proposing to provide such loan, letter of credit or other extension of credit or any agent, trustee or representative of such Person&#59; or</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2002"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;with the consent of the Administrative Borrower&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that in the case of clause (e) hereof, the Person to whom Confidential Information is so disclosed is advised of and has been directed to comply with the provisions of this Section 12.17.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">144</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For purposes of this Section, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means all information received from a Credit Party or any Subsidiary, whether directly or from a Credit Party or a Subsidiary&#8217;s managers, officers, employees, attorneys, agents, or other advisors, relating to the Credit Parties or any Subsidiary or any of their respective businesses, other than any such information that is available to the Administrative Agent or any Secured Party on a nonconfidential basis prior to disclosure by or on behalf of such Credit Party or any Subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Notwithstanding the foregoing, (A) each of the Administrative Agent, the Lenders and any Affiliate thereof is hereby expressly permitted by the Credit Parties to refer to any Credit Party and any of their respective Subsidiaries in connection with any promotion or marketing undertaken by the Administrative Agent, Lender or Affiliate and, for such purpose, the Administrative Agent, Lender or Affiliate may utilize any trade name, trademark, logo or other distinctive symbol associated with such Credit Party or such Subsidiary or any of their businesses and (B) any information that is or becomes generally available to the public (other than as a result of prohibited disclosure by the Administrative Agent or Lender) shall not be subject to the provisions of this Section 12.17.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">EACH LENDER ACKNOWLEDGES THAT CONFIDENTIAL INFORMATION (AS DEFINED IN THIS SECTION 12.17) FURNISHED TO IT PURSUANT TO THIS AGREEMENT MAY INCLUDE MATERIAL NON-PUBLIC INFORMATION CONCERNING THE BORROWERS AND ITS RELATED PARTIES OR THEIR RESPECTIVE SECURITIES, AND CONFIRMS THAT IT HAS DEVELOPED COMPLIANCE PROCEDURES REGARDING THE USE OF MATERIAL NON-PUBLIC INFORMATION AND THAT IT WILL HANDLE SUCH MATERIAL NON-PUBLIC INFORMATION IN ACCORDANCE WITH THOSE PROCEDURES AND APPLICABLE LAW, INCLUDING FEDERAL AND STATE SECURITIES LAWS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ALL INFORMATION, INCLUDING WAIVERS AND AMENDMENTS, FURNISHED BY THE CREDIT PARTIES OR THE ADMINISTRATIVE AGENT PURSUANT TO, OR IN THE COURSE OF ADMINISTERING, THIS AGREEMENT WILL BE SYNDICATE-LEVEL INFORMATION, WHICH MAY CONTAIN MATERIAL NONPUBLIC INFORMATION ABOUT THE CREDIT PARTIES AND THEIR RELATED PARTIES OR THEIR RESPECTIVE SECURITIES.  ACCORDINGLY, EACH LENDER REPRESENTS TO THE CREDIT PARTIES AND THE ADMINISTRATIVE AGENT THAT IT HAS IDENTIFIED IN ITS ADMINISTRATIVE QUESTIONNAIRE A CREDIT CONTACT WHO MAY RECEIVE INFORMATION THAT MAY CONTAIN MATERIAL NONPUBLIC INFORMATION IN ACCORDANCE WITH ITS COMPLIANCE PROCEDURES AND APPLICABLE LAW.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2005"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 12.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Press Releases, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Credit Party will not, and will not permit any of its respective Subsidiaries, directly or indirectly, to publish any press release or other similar public disclosure or announcements (including any marketing materials) regarding this Agreement, the other Credit Documents, the Transaction Documents, or any of the Transactions, without the consent of the Administrative Agent, which consent shall not be unreasonably withheld.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">145</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2008"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 12.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Releases of Guarantees and Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  (a) Notwithstanding anything to the contrary contained herein or in any other Credit Document, the Administrative Agent is hereby irrevocably authorized and directed by each Secured Party (without requirement of notice to or consent of any Secured Party except as expressly required by Section 12.01) (x) to take any action requested by the Administrative Borrower having the effect of releasing any Collateral or guarantee obligations (i) to the extent necessary to permit consummation of any transaction not prohibited by any Credit Document or that has been consented to in accordance with Section 12.01 or (ii) under the circumstances described in paragraph (b) below and (y) enter into subordination or intercreditor agreements with respect to Indebtedness to the extent the Administrative Agent or the Collateral Agent is otherwise contemplated herein as being a party to such intercreditor or subordination agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2011"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;At such time as (i) the Loans and the other Obligations (other than Unasserted Contingent Obligations) shall have been paid in full and (ii) the Commitments have been terminated, the Collateral shall be automatically released from the Liens created by the Security Documents, and the Security Documents and all pledges and obligations (other than those expressly stated to survive such termination) of the Administrative Agent and each Credit Party under the Security Documents shall terminate, all without delivery of any instrument or performance of any act by any Person.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2014"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent&#8217;s authority to release its interest in particular types or items of property, or to release any guarantee obligations pursuant to this Section 12.19.  In each case as specified in this Section 12.19, the Administrative Agent will (and each Lender irrevocably authorizes and directs the Administrative Agent to), at the Administrative Borrower&#8217;s request and expense, (i) execute and deliver any termination statements, lien releases, discharges of security interests, and other similar discharge or release documents (and, if applicable, in recordable form) as are reasonably necessary to release, as of record, the Administrative Agent&#8217;s Liens and all notices of security interests and liens previously filed by the Administrative Agent and (ii) deliver all possessory collateral in the Administrative Agent&#8217;s possession, custody or control to the Administrative Borrower (or the Administrative Borrower&#8217;s designee), and (iii) execute and deliver to the applicable Credit Party such other documents as such Credit Party may reasonably request to evidence the release of such item of Collateral or obligation from the assignment, lien or security interest granted under the Security Documents, in each case in accordance with the terms of the Credit Documents and this Section 12.19.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2017"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 12.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">USA Patriot Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Each Lender hereby notifies each Credit Party that pursuant to the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Patriot Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), it is required to obtain, verify and record information that identifies the Credit Parties, which information includes the name and address of each Credit Party and other information that will allow such Lender to identify each Credit Party in accordance with the Patriot Act.  Each Credit Party agrees to provide all such information to the Lenders upon request by the Administrative Agent at any time, whether with respect to any Person who is a Credit Party on the Closing Date or who becomes a Credit Party thereafter.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2020"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 12.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">No Fiduciary Duty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Each Credit Party, on behalf of itself and its Subsidiaries, agrees that in connection with all aspects of the transactions contemplated hereby and any communications in connection therewith, the Credit Parties, their respective Subsidiaries </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">146</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">and Affiliates, on the one hand, and the Administrative Agent, the Lenders and their respective Affiliates, on the other hand, will have a business relationship that does not create, by implication or otherwise, any fiduciary duty on the part of the Administrative Agent, the Lenders or their respective Affiliates, and no such duty will be deemed to have arisen in connection with any such transactions or communications.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2023"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 12.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Authorized Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  The execution of any certificate requirement hereunder by an Authorized Officer shall be considered to have been done solely in such Authorized Officer&#8217;s capacity as an officer of the applicable Credit Party (and not individually).  Notwithstanding anything to the contrary set forth herein, the Secured Parties shall be entitled to rely and act on any certificate, notice or other document delivered by or on behalf of any Person purporting to be an Authorized Officer of a Credit Party and shall have no duty to inquire as to the actual incumbency or authority of such Person.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2026"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acknowledgement and Consent to Bail-In of EEA Financial Institutions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary in any Credit Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any EEA Financial Institution arising under any Credit Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of an EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by&#58; (a) the application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an EEA Financial Institution, and (b) the effects of any Bail-in Action on any such liability, including, if applicable&#58; (i) a reduction in full or in part or cancellation of any such liability, (ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such EEA Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Credit Document or (iii) the variation of the terms of such liability in connection with the exercise of the write-down and conversion powers of any EEA Resolution Authority.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2029"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2032"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Notice&#59; Purchase Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On one occasion exercised within 30 days of a Purchase Option Trigger Event, the Term Lenders shall have the option, but not the obligation, to (x) purchase from the Revolving Lenders all, but not less than all, of the Revolving Loans and other Revolving Credit Obligations owing to the Revolving Lenders and (y) assume all, but not less than all, of the then-existing Revolver Commitments. Such right shall be exercised by the applicable Term Lenders giving a written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Purchase Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the Administrative Agent (who shall in turn promptly deliver such notice to each Revolving Lender). A Purchase Notice once delivered shall be irrevocable. Each Term Lender shall have the right to purchase its pro rata share of the Revolving Credit Obligations and assume its pro rata share of the Revolver Commitments, and Term Lenders exercising such rights may exercise the rights of non-exercising Term Lenders, in each case on a pro rata basis as among exercising Term Lenders until such rights have been exercised as to all Revolving Credit Obligations and all Revolver Commitments (in any case, prior to issuance of the Purchase Notice).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">147</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2035"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Purchase Option Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. On the date specified in the Purchase Notice (which shall not be less than 3 Business Days nor more than 5 Business Days after delivery to Administrative Agent of the Purchase Notice) (such date the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Purchase Option Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), the Revolving Lenders shall sell to the exercising Term Lenders, and the exercising Term Lenders shall purchase from the Revolving Lenders, all, but not less than all, of the Revolving Credit Obligations, and the Revolving Lenders shall assign to the exercising Term Lenders, and the exercising Term Lenders shall assume from the Revolving Lenders all, but not less than all, of the then existing Revolver Commitments. Upon such closing, each selling Revolving Lender shall be released from all of its Revolver Commitments hereunder. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2038"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. The purchase, sale and assumption pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 12.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> shall be made by execution and delivery by the Administrative Agent, Revolving Lenders and exercising Term Lenders of an Assignment and Acceptance. Upon the date of such purchase and sale, (i) the exercising Term Lenders shall pay to the Administrative Agent for the Obligations with respect to the Revolving Loans and Swingline Advances owing to the Revolving Lenders and the Revolver Agent, including principal, interest accrued and unpaid thereon, and any fees accrued and unpaid thereon, to the extent earned or due and payable in accordance with the Credit Documents and irrespective of whether allowed or allowable in connection with any bankruptcy or insolvency proceeding, (ii) any contingent indemnification Obligations in respect of asserted indemnity claims payable to the Revolving Lenders or their respective Affiliates (which, in the case of contingent Obligations in respect thereof, shall be satisfied by providing the Administrative Agent cash collateral in an amount equal to 100% of such obligations&#59; it being agreed by the parties hereto that the Administrative Agent shall (A) be entitled to apply such cash collateral solely to satisfy such obligations owing to the selling Revolving Lenders and their respective Affiliates and (B) promptly return any unapplied portion of such cash collateral to the Collateral Agent for the benefit of the Term Lenders at such time as all such Obligations have been paid in full) and (iii) all expenses to the extent owing to the Revolving Lenders in accordance with the Credit Documents shall have been paid in full. Such purchase price and cash collateral shall be remitted by wire transfer of immediately available funds to the Collateral Agent in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 2.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, solely for the account of the selling Revolving Lenders and shall be immediately distributed to such selling Lenders in accordance with their respective ratable shares. Interest and fees shall be calculated to but excluding the Business Day on which such purchase and sale shall occur if the amounts so paid by the Term Lenders are received by the Administrative Agent prior to 2&#58;00 p.m. (New York time) and interest and fees shall be calculated to and including such Business Day if the amounts so paid by the Term Lenders are received by Administrative Agent later than 2&#58;00 p.m. (New York time).  If, within 12 months after the consummation of the purchase, sale and assumption made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 12.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, any Term Lender receives any Prepayment Premium solely and directly arising from the reduction or termination of Revolver Commitments in accordance with Section 4.04, then such Prepayment Premium shall be segregated and held in trust and promptly paid over to the Revolver Agent, for the benefit of the selling Revolver Lenders, in the same form as received, with any necessary endorsements. For the avoidance of doubt, the foregoing sentence shall not apply to any Prepayment Premium payable in respect of the Term Loans.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2041"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Nature of Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The purchase and sale pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 12.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> shall be expressly made without representation or warranty of any kind by the Revolving Lenders as to the Revolving Credit Obligations or otherwise and without recourse to the Revolving Lenders, except for representations and warranties as to the following made by each selling Lender </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">148</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">severally (and not jointly)&#58; (i) the amount of the Revolving Credit Obligations being purchased from such selling Lender (including as to the principal of and accrued and unpaid interest on such Revolving Credit Obligations, fees and expenses thereof), (ii) that such selling Lender owns the Revolving Credit Obligations held by it free and clear of any Liens created by it and (iii) such selling Lender has the full right and power to assign its Revolving Credit Obligations and such assignment has been duly authorized by all necessary corporate action by such selling Lender. Notwithstanding anything herein, each selling Revolving Lender shall retain all of their respective indemnification rights under the Credit Documents arising in respect of any act or omission that occurred on or before the date of such purchase and sale, and in furtherance of the foregoing, no amendment to such indemnification rights or their priority under any waterfall provision shall be amended, modified, waived or terminated without the consent of each affected selling Lender. In connection with any such exercise of the purchase option pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 12.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, the purchasing Term Lenders may amend the payment priority of all or any portion of the Revolving Loans and Revolver Commitments so purchased to remove the &#8220;super priority&#8221; provisions relating thereto and cause such purchased Revolving Loans and Revolver Commitments to be pari passu in right of payment with the Term Loans hereunder (it being understood that such purchased Revolving Loans and Revolver Commitments shall otherwise contain the same terms and provisions otherwise applicable to the existing Revolving Loans and Revolver Commitments). The Borrowers and the Lenders hereby agree that this Agreement may be amended without the consent of any Person to effect the foregoing changes.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2044"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For the avoidance of doubt, the purchase option of the Term Lenders described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> may be exercised by such Term Lenders&#8217; respective Affiliates who are Eligible Assignees hereunder.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2047"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">All Obligations to Constitute Joint and Several Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2050"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All Obligations shall constitute joint and several obligations of the Credit Parties and shall be secured by the Collateral Agent&#8217;s Lien, for the benefit of the Lenders, upon all of the Collateral, and by all other Liens heretofore, now or at any time hereafter granted by each Credit Party to the Collateral Agent, for the benefit of the Lenders, to the extent provided in the Credit Documents under which such Lien arises.  Each Credit Party expressly represents and acknowledges that it is part of a common enterprise with the other Credit Parties and that any financial accommodations by the Administrative Agent and the other members of the Lenders to any other Credit Party hereunder and under the other Loan Documents are and will be of direct and indirect interest, benefit and advantage to all Credit Parties.  Each Credit Party acknowledges that any notice or request given by any Credit Party (including the Administrative Borrower) to the Administrative Agent shall bind all Credit Parties, and that any notice given by the Administrative Agent or any other member of the Lenders to any Credit Party shall be effective with respect to all Credit Parties.  Each Credit Party acknowledges and agrees that each Credit Party shall be liable, on a joint and several basis, for all of the Loan and other Obligations, regardless of which Credit Party actually may have received the proceeds of any of the Loan or other extensions of credit or the amount of such Loan received or the manner in which the Administrative Agent or any other member of the Lenders accounts among the Credit Parties for such Loan or other extensions of credit on its books and records, and further acknowledges and agrees that the Loan and other extensions of credit to any Credit Party inure to the mutual benefit of all of the Credit Parties and that the Administrative Agent and the other members of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">149</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Lenders is relying on the joint and several liability of the Credit Parties in extending the Loan and other financial accommodations hereunder.  Each Credit Party shall be entitled to subrogation and contribution rights from and against the other Credit Party to the extent any Credit Party is required to pay to any member of the Lenders any amount in excess of the Loan advanced directly to, or other Obligations incurred directly by, such Credit Party or as otherwise available under Applicable Law&#59; provided, however, that such subrogation and contribution rights are and shall be subject to the terms and conditions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2053"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;In the event any Credit Party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Funding Credit Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) shall make any payment or payments under this Agreement or shall suffer any loss as a result of any realization upon any collateral granted by it to secure its obligations hereunder, such Funding Credit Party shall have the right to seek contribution payments from each other Credit Party (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Contributing Credit Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) to the extent permitted by Applicable Law.  Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 12.25(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> shall affect any Credit Party&#8217;s joint and several liability to the Lenders for the entire amount of its Obligations.  Each Credit Party covenants and agrees that (i) its right to receive any contribution hereunder from a Contributing Credit Party shall be subordinate and junior in right of payment to all obligations of the Credit Parties to the Lenders hereunder and (ii) it shall not exercise any such contribution rights unless and until the Obligations shall have been paid in full in cash.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2056"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;Nothing in this Section 12.25 shall affect any Credit Party&#8217;s joint and several liability to the Lenders for the entire amount of its Obligations.  Each Credit Party covenants and agrees that its right to receive any contribution hereunder from a contributing Credit Party shall be subordinate and junior in right of payment to all Obligations of the Borrower to the Lenders hereunder.  No Credit Party will exercise any rights that it may acquire by way of subrogation hereunder or under any other Loan Document or at law by any payment made hereunder or otherwise, nor shall any Credit Party seek or be entitled to seek any contribution or reimbursement from any other Credit Party in respect of payments made by such Credit Party hereunder or under any other Loan Document, until all amounts owing to the Lenders on account of the Obligations are paid in full in cash.  If any amounts shall be paid to any Credit Party on account of such subrogation or contribution rights at any time when all of the Obligations shall not have been paid in full, such amount shall be held by such Credit Party in trust for the Lenders segregated from other funds of such Credit Party, and shall, forthwith upon receipt by such Credit Party, be turned over to the Administrative Agent in the exact form received by such Credit Party (duly endorsed by such Credit Party to the Administrative Agent, if required), to be applied against the Obligations, whether matured or unmatured, as provided for herein.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2059"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 12.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Administrative Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Each Borrower hereby irrevocably appoints the Evolent as the borrowing agent and attorney-in-fact for all Borrower Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Administrative Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), which appointment shall remain in full force and effect unless and until the Administrative Agent shall have received prior written notice signed by each Borrower that such appointment has been revoked and that another Borrower has been appointed the Administrative Borrower.  Each Credit Party hereby irrevocably appoints and authorizes the Administrative Borrower (i) to provide the Administrative Agent with all notices with respect to the Loan obtained for the benefit of any Credit Party and all other notices and instructions under this Agreement and (ii) to take such action as the Administrative Borrower deems appropriate on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">150</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">its behalf to obtain the Loan and to exercise such other powers as are incidental thereto to carry out the purposes of this Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2062"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.27&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Erroneous Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2065"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;If the Administrative Agent notifies a Lender or Secured Party, or any Person who has received funds on behalf of a Lender or Secured Party (other than a Credit Party or any Subsidiary thereof) (any such Lender, Secured Party or other recipient, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Payment Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) that the Administrative Agent has determined in its sole discretion (whether or not after receipt of any notice under immediately succeeding clause (b)) that any funds received by such Payment Recipient from the Administrative Agent or any of its Affiliates were erroneously transmitted to, or otherwise erroneously or mistakenly received by, such Payment Recipient (whether or not known to such Lender, Secured Party or other Payment Recipient on its behalf)  (any such funds, whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise, individually and collectively, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Erroneous Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and demands the return of such Erroneous Payment (or a portion thereof), such Erroneous Payment shall at all times remain the property of the Agent, and such Lender or Secured Party shall (or, with respect to any Payment Recipient who received such funds on its behalf, shall cause such Payment Recipient to) promptly, but in no event later than one Business Day thereafter, return to the Administrative Agent the amount of any such Erroneous Payment (or portion thereof) as to which such a demand was made, in same day funds (in the currency so received), together with interest thereon in respect of each day from and including the date such Erroneous Payment (or portion thereof) was received by such Payment Recipient to the date such amount is repaid to the Administrative Agent in same day funds at the Defaulting Lender Rate. A notice of the Administrative Agent to any Payment Recipient under this clause (a) shall be conclusive, absent manifest error.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2068"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;Without limiting immediately preceding clause (a), each Payment Recipient hereby further agrees that if it receives a payment, prepayment or repayment (whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise) from the Administrative Agent (or any of its Affiliates) (x) that is in a different amount than, or on a different date from, that specified in a notice of payment, prepayment or repayment sent by the Agent (or any of its Affiliates) with respect to such payment, prepayment or repayment (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Payment Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), (y) that was not preceded or accompanied by a Payment Notice, or (z) that such Payment Recipient otherwise becomes aware was transmitted, or received, in error or by mistake (in whole or in part) in each case&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2071"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;an error may have been made (in the case of immediately preceding clauses (x) or (y)) or an error has been made (in the case of immediately preceding clause (z)) with respect to such payment, prepayment or repayment&#59; and</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2074"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;such Payment Recipient shall promptly (and, in all events, within one Business Day of its knowledge of such error) notify the Administrative Agent of its receipt of such payment, prepayment or repayment, the details thereof and that it is so notifying the Administrative pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 12.27(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2077"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;Each Lender or Secured Party hereby authorizes the Administrative Agent to set off, net and apply any and all amounts at any time owing to such Lender or Secured Party under </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">151</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">any Credit Document, or otherwise payable or distributable by the Administrative Agent to such Lender or Secured Party from any source, against any amount due to the Administrative Agent under immediately preceding clause (a) or under the indemnification provisions of this Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2080"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;In the event an Erroneous Payment (or portion thereof) is not recovered by the Administrative Agent for any reason, after demand therefor by the Administrative Agent in accordance with immediately preceding clause (a), from any Lender that has received such Erroneous Payment (or portion thereof) (or from any Payment Recipient who received such Erroneous Payment (or portion thereof) on its respective behalf)  (such unrecovered amount, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Erroneous Payment Return Deficiency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), upon the Administrative Agent&#8217;s request to such Lender at any time, (i) such Lender shall be deemed to have assigned its Loans (but not its Commitments) of the relevant class with respect to which such Erroneous Payment was made (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Erroneous Payment Impacted Class</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) in an amount equal to the Erroneous Payment Return Deficiency (such assignment of the Loans (but not Commitments) of the Erroneous Payment  Impacted Class, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Erroneous Payment Deficiency Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) at par plus any accrued and unpaid interest (with the assignment fee to be waived by the Administrative Agent in such instance), and is hereby (together with the Administrative Borrower) deemed to execute and deliver an Assignment and Acceptance with respect to such Erroneous Payment Deficiency Assignment, and such Lender shall deliver any Notes evidencing such Loans to the Administrative Borrower or the Administrative Agent, (ii) the Administrative Agent as the assignee Lender shall be deemed to acquire the Erroneous Payment Deficiency Assignment and (iii) upon such deemed acquisition, the Agent as the assignee Lender shall become a Lender or Issuing Bank, as applicable, hereunder with respect to such Erroneous Payment Deficiency Assignment and the assigning Lender shall cease to be a Lender, as applicable, hereunder with respect to such Erroneous Payment Deficiency Assignment, excluding, for the avoidance of doubt, its obligations under the indemnification provisions of this Agreement and its applicable Commitments which shall survive as to such assigning Lender. For the avoidance of doubt, no Erroneous Payment Deficiency Assignment will reduce the Commitments of any Lender and such Commitments shall remain available in accordance with the terms of this Agreement. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2083"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(e)&#160;&#160;&#160;&#160;The parties hereto agree that an Erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Obligations owed by any Borrower or any other Loan Party, except, in each case, to the extent such Erroneous Payment is, and solely with respect to the amount of such Erroneous Payment that is, comprised of funds received by the Administrative Agent from a Borrower, any other Credit Party or any Subsidiary thereof for the purpose of discharging any Obligation. </font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2086"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(f)&#160;&#160;&#160;&#160;To the extent permitted by applicable law, no Payment Recipient shall assert any right or claim to  an Erroneous Payment, and hereby waives, and is deemed to waive, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the return of any Erroneous Payment received, including without limitation waiver of any defense based on &#8220;discharge for value&#8221; or any similar doctrine.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2089"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(g)&#160;&#160;&#160;&#160;Each party&#8217;s obligations, agreements and waivers under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 12.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> shall survive the resignation or replacement of the Administrative Agent, any transfer of rights or obligations by, or the replacement of, a Lender, the termination of the Commitments and&#47;or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">152</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">repayment, satisfaction or discharge of all Obligations (or any portion thereof) under any Credit Document.</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGES FOLLOW&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">153</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2092"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, each of the parties hereto has caused a counterpart of this Agreement to be duly executed and delivered as of the date first above written.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">BORROWERS&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,<br>a Delaware limited liability company</font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IMPLANTABLE PROVIDE GROUP, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>a Delaware corporation </font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ENDZONE MERGER SUB, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,<br>a Delaware corporation </font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TPG GROWTH ICEMAN PARENT INC.,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">PARENT&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:36pt;padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">OTHER GUARANTORS&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EH HOLDING COMPANY, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT CARE PARTNERS HOLDING COMPANY, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:36pt;padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NCIS HOLDINGS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:36pt;padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NCH MANAGEMENT SYSTEMS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a California corporation</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:36pt;padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT CARE PARTNERS OF TEXAS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Texas corporation</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:36pt;padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MTS III VITAL DECISIONS BLOCKER CORP.,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VITAL DECISIONS ACQUISITION LLC,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company </font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VITAL DECISIONS LLC,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a New Jersey limited liability company</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE ACCOUNTABLE CARE ORGANIZATION LTD.,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Michigan limited company </font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT CARE PARTNERS OF NORTH CAROLINA, INC.,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a North Carolina corporation </font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SURGICAL COLLECTIONS GROUP, INC., </font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TPG GROWTH ICEMAN INTERMEDIATE, INC.,</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:3.45pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Jonathan Weinberg</font></div><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Secretary</font></div></td></tr><tr style="height:49pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"><div style="padding-left:3.45pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2095"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:36pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADMINISTRATIVE AGENT AND A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LENDER&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES CAPITAL MANAGEMENT LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,<br>a Delaware limited liability company</font></div><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Mitchell Goldstein&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Mitchell Goldstein<br>&#160;&#160;&#160;&#160;Title&#58; Authorized Signatory</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:36pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COLLATERAL AGENT AND A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LENDER&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,<br>a Delaware limited partnership</font></div><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Ryan T. Magee&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Ryan T. Magee<br>&#160;&#160;&#160;&#160;Title&#58; Authorized Signatory</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">REVOLVING AGENT&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,<br>a Delaware limited partnership</font></div><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Ryan T. Magee&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Ryan T. Magee<br>&#160;&#160;&#160;&#160;Title&#58; Authorized Signatory</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2098"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">LENDERS&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES CAPITAL CORPORATION<br></font></div><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES CAPITAL CORPORATION<br></font></div><div style="margin-bottom:36pt;padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2101"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">LENDERS&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES CAPITAL CORPORATION</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CION ARES DIVERSIFIED CREDIT FUND</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CADEX CREDIT FINANCING, LLC</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES CENTRE STREET PARTNERSHIP, L.P.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Centre Street GP, Inc., as general partner</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES JASPER FUND, L.P.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer&#58;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES JASPER FUND HOLDINGS, LLC</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, as servicer</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES ND CREDIT STRATEGIES FUND LLC</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its account manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES ND CSF HOLDINGS LLC</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, as servicer</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES SENIOR DIRECT LENDING MASTER FUND DESIGNATED ACTIVITY COMPANY</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES SENIOR DIRECT LENDING PARALLEL FUND (L), L.P.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES SENIOR DIRECT LENDING PARALLEL FUND (U), L.P.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES SDL HOLDINGS (U) INC.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SDL FINANCE 1 LP</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, as servicer</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SDL FINANCE 2 LP</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, as servicer</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES SENIOR DIRECT LENDING MASTER FUND II DESIGNATED ACTIVITY COMPANY</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares SDL II Capital Management LLC, its Manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES SENIOR DIRECT LENDING PARALLEL FUND (L) II, L.P.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares SDL II Capital Management LLC, its Manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES SENIOR DIRECT LENDING PARALLEL FUND (U) II, L.P.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares SDL II Capital Management LLC, its Manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SDL II FINANCE 1 LP</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares SDL II Capital Management LLC, its servicer</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SDL II FINANCE 2 LP</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares SDL II Capital Management LLC, its servicer</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES CREDIT INVESTMENT PARTNERSHIP II (A), L.P.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares SDL II Capital Management LLC, its Manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES SFERS CREDIT STRATEGIES FUND LLC</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES SFERS HOLDINGS LLC</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its servicer</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES COMMERCIAL FINANCE, L.P.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Commercial Finance Management LP, as manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Olek Szczupak&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Olek Szczupak<br>&#160;&#160;&#160;&#160;Title&#58; Authorized Signer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ACF FINCO I LP</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Olek Szczupak&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Olek Szczupak<br>&#160;&#160;&#160;&#160;Title&#58; Authorized Signer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES DIRECT FINANCE I LP</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADF I HOLDINGS LLC</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, as servicer</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AO MIDDLE MARKET CREDIT FINANCING L.P.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; AO Middle Market Credit Financing GP Ltd., its general partner</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; K. Patel&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; K. Patel<br>&#160;&#160;&#160;&#160;Title&#58; Director</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FEDERAL INSURANCE COMPANY</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NATIONWIDE LIFE INSURANCE COMPANY</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NATIONWIDE MUTUAL INSURANCE COMPANY</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BOWHEAD IMC LP</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AN CREDIT STRATEGIES FUND, L.P.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NORTH AMERICAN SPECIALTY INSURANCE COMPANY</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES DIVERSIFIED CREDIT STRATEGIES FUND (S), L.P.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Management LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Management LLC, its sub-advisor</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARES DIVERSIFIED CREDIT STRATEGIES FUND II (IM), L.P.</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ares Capital Management III LLC, its investment manager</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AJ MIDDLE MARKET CREDIT LP</font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:3.35pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Scott Lem<br>&#160;&#160;&#160;&#160;Title&#58; CAO, Treasurer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Credit Agreement</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2263"></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A-1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FORM OF ASSIGNMENT AND ACCEPTANCE</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; __________, 20&#91;__&#93;</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Reference is made to the Credit Agreement, dated as of August 1, 2022 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">EVOLENT HEALTH, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> EVOLENT HEALTH LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Evolent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">, ENDZONE MERGER SUB, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Endzone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Initial Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">which upon consummation of the TPG Acquisition (as defined in the Credit Agreement) will be merged with and into </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">TPG GROWTH ICEMAN PARENT, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">TPG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> IMPLANTABLE PROVIDER GROUP, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Implantable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;, collectively with Evolent, Endzone and TPG, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; and each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">the Subsidiaries signatory thereto as guarantors or thereafter designated as Guarantors pursuant to Section 8.11 of the Credit Agreement, the lenders from time to time party thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> ARES CAPITAL CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, a Maryland corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Ares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%"> ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, a Delaware limited partnership (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">ACF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), as collateral agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) and as revolver agent for the Revolving Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Revolver Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Unless otherwise defined herein, capitalized terms used herein and defined in the Credit Agreement shall have the meanings given to them in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">1.  The Assignor identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Assignor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) and the Assignee identified on Schedule l hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">2.  For an agreed consideration, the Assignor hereby irrevocably sells and assigns to the Assignee without recourse to the Assignor, and the Assignee hereby irrevocably purchases and assumes from the Assignor, without recourse to the Assignor, subject to and in accordance with the terms and conditions of the Credit Agreement, as of the Effective Date (as defined below), the interest described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule&#160;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Assigned Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) in and to the Assignor&#8217;s rights and obligations under the Credit Agreement and any other documents or instruments delivered pursuant thereto with respect to the Commitments (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Assigned Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) or Loans (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Assigned Facilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), as applicable, contained in the Credit Agreement as are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> hereto, in a principal amount for each such Assigned Commitments or Assigned Facilities, as applicable, as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule&#160;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">3.  The Assignor (x) represents and warrants that (i) it is the legal and beneficial owner of the Assigned Interest, (ii) the Assigned Interest is free and clear of any lien, encumbrance or other adverse claim and (iii) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Acceptance and to consummate the transactions contemplated hereby and (y)(i) makes no representation or warranty and assumes no responsibility with respect to any statements, warranties or representations made in or in connection with the Credit Agreement or with respect to the execution, legality, validity, </font></div><div style="height:66.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">Exhibit A-1 - 1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">enforceability, genuineness, sufficiency or value of the Credit Agreement, any other Credit Document or any other instrument or document furnished pursuant thereto, other than that the Assignor has not created any adverse claim upon the interest being assigned by it hereunder and that such interest is free and clear of any such adverse claim&#59; (ii) makes no representation or warranty and assumes no responsibility with respect to the financial condition of any Borrower, any Subsidiary or any other Loan Party or the performance or observance by any Borrower, any Subsidiary or any other Loan Party of any of their respective obligations under the Credit Agreement or any other Loan Document or any other instrument or document furnished pursuant hereto or thereto&#59; and (iii) attaches any promissory notes held by it evidencing the Assigned Facilities (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:110%">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) and (A) requests that the Administrative Agent or Revolver Agent, as applicable, upon request by the Assignee, exchange the attached Notes for a new Note or Notes payable to the Assignee and (B) if the Assignor has retained any interest in the Assigned Facilities, requests that the Administrative Agent or Revolver Agent, as applicable, exchange the attached Notes for a new Note or Notes payable to the Assignor, in each case in amounts which reflect the assignment being made hereby (and after giving effect to any other assignments which have become effective on the Effective Date (defined below)).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.  The Assignee (a)&#160;represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a Lender under the Credit Agreement and (ii) it meets all the requirements to be an assignee under Section 12.06(a) and (b) of the Credit Agreement (subject to such consents, if any, as may be required under Section 12.06(a) of the Credit Agreement)&#59; (b)&#160;confirms that (i) it has received a copy of the Credit Agreement, together with copies of the financial statements delivered pursuant to Section&#160;8.01 thereof and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Assignment and Acceptance, (ii) that it is sophisticated with respect to decisions to acquire assets of the type represented by the Assigned Interest and either it, or the Person exercising discretion in making its decision to acquire the Assigned Interest, is experienced in acquiring assets of such type&#59; and (iii) it has, independently and without reliance upon the Administrative Agent, Revolver Agent, or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Assignment and Assumption and to purchase the Assigned Interest&#59; (c)&#160;agrees that it will, independently and without reliance upon the Assignor, the Administrative Agent, Revolver Agent, or any other Lender and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit Agreement, the other Loan Documents or any other instrument or document furnished pursuant hereto or thereto&#59; (d)&#160;appoints and authorizes the Administrative Agent or Revolver Agent, as applicable, to take such action as agent on its behalf and to exercise such powers and discretion under the Credit Agreement, the other Loan Documents or any other instrument or document furnished pursuant hereto or thereto as are delegated to the Administrative Agent or Revolver Agent, as applicable, by the terms thereof, together with such powers as are incidental thereto&#59; and (e)&#160;agrees that it will be bound by the provisions of the Credit Agreement as a Lender thereunder, and to the extent of the Assigned Interest, and shall perform in accordance with its terms all the obligations which by the terms of the Credit Agreement are required to be performed by it as a Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.  The effective date of this Assignment and Acceptance shall be the Effective Date of Assignment described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Following the execution of this Assignment and Acceptance, it will be delivered to the Administrative Agent </font></div><div style="height:66.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">Exhibit A-1 - 2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and Revolver Agent for acceptance by it and recording by the Administrative Agent and Revolver Agent, pursuant to the Credit Agreement, effective as of the Effective Date (which shall not, unless otherwise agreed to by the Administrative Agent or Revolver Agent, as applicable, be earlier than five (5) Business Days after the date of such acceptance and recording by the Administrative Agent or Revolver Agent, as applicable).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.  Upon such acceptance and recording, from and after the Effective Date, the Administrative Agent or Revolver Agent, as applicable, shall make all payments in respect of the Assigned Interest (including payments of principal, interest, fees and other amounts) to the Assignor for amounts which have accrued to the Effective Date and to the Assignee for amounts which have accrued subsequent to the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.  From and after the Effective Date, (a) the Assignee shall be a party to the Credit Agreement and, to the extent provided in this Assignment and Acceptance, have the rights and obligations of a Lender thereunder and under the other Loan Documents and shall be bound by the provisions thereof and (b) the Assignor shall, to the extent provided in this Assignment and Acceptance, relinquish its rights and be released from its obligations under the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.  This Assignment and Acceptance shall be governed by and construed in accordance with the laws of the State of New York, without reference to conflicts of law provisions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have caused this Assignment and Acceptance to be executed as of the date first written above by their respective duly authorized officers on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font><br></font></div><div style="height:66.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">Exhibit A-1 - 3</font></div><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2266"></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Assignment and Acceptance</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Assignor&#58; &#91;_____&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Assignee&#58; &#91;_____&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective Date of Assignment&#58; &#91;_____&#93;, 20&#91;__&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assigned Interest </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Initial Term Loan Commitment&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Revolving Loan Commitment&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Initial Term Loan&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Revolving Term Loan&#93;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________________</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Principal Amount Assigned</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$__________</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Percentage of the applicable &#91;Assigned Commitment&#93; </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Assigned Loan&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____.______%</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Purchase Price for Assignment</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91;_____&#93; </font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;_____&#93;, as Assignor</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;_____&#93;, as Assignee </font></div></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; ____________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;  </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;  </font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; ________________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;  </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;  </font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assignee&#8217;s Address for Notices&#58; </font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">Exhibit A-1 - 4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Accepted and Consented to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;Consented To&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;ARES CAPITAL CORPORATION, <br>as Administrative Agent<br></font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">EVOLENT HEALTH LLC, <br>as Borrower<br><font style="font-size:7.8pt;position:relative;top:-4.2pt;vertical-align:baseline">1</font></font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; _________________________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; _________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; &#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Accepted and Consented to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;Consented To&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;ACF FINCO I LP, as Revolver Agent<br></font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">IMPLANTABLE PROVIDER GROUP, INC. as Borrower<br><font style="font-size:7.8pt;position:relative;top:-4.2pt;vertical-align:baseline">2</font></font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; _________________________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; _________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; &#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.717%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;Consented To&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">TPG GROWTH ICEMAN PARENT, INC. as Borrower<br><font style="font-size:7.8pt;position:relative;top:-4.2pt;vertical-align:baseline">3</font></font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; _________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To the extent required under the Credit Agreement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To the extent required under the Credit Agreement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To the extent required under the Credit Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">Exhibit A-1 - 5</font></div><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2269"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:110%;text-decoration:underline">EXHIBIT C-1</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%;text-decoration:underline">FORM OF COMPLIANCE CERTIFICATE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"><br><br>&#91;_______________&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#160;&#160;&#160;&#160;This certificate is delivered pursuant to Section 8.01(d) of the Credit Agreement, dated as of August 1, 2022 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;), among</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> EVOLENT HEALTH, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> EVOLENT HEALTH LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Evolent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%">, ENDZONE MERGER SUB, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Endzone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Initial Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">which upon consummation of the TPG Acquisition (as defined in the Credit Agreement) will be merged with and into </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%">TPG GROWTH ICEMAN PARENT, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%"> a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">TPG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> IMPLANTABLE PROVIDER GROUP, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Implantable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;, collectively with Evolent, Endzone and TPG, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221; and each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">each Subsidiary signatory thereto as guarantors or thereafter designated as Guarantors pursuant to Section 8.11 of the Credit Agreement, the lenders from time to time party thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> ARES CAPITAL CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">, a Maryland corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Ares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;), as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;), the Collateral Agent, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%">ACF FINCO I LP </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">as revolver agent for the Revolving Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Revolver Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;). Unless otherwise defined herein or the context otherwise requires, capitalized terms used herein and defined in the Credit Agreement shall have the meanings given to them in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">The Administrative Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">hereby certifies on behalf of the Credit Parties, that as of the date hereof &#91;no Default or Event of Default had occurred and is continuing&#93; &#91;a Default&#47;an Event of Default has occurred and is continuing and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Attachment 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%"> are the details specifying such Default or Event of Default and the action taken or to be taken with respect thereto&#93;.  The Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">hereby further certifies, on behalf of the Credit Parties, that as of &#91;_____&#93;, 20&#91;__&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:105%">Computation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8221;)&#58;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2272"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The financial statements delivered with this Certificate in accordance with Section 8.01 of the Credit Agreement have been prepared in accordance with GAAP, as applicable, and present fairly in all material respects the financial position and results of operations of the Credit Parties at the respective dates of such information and for the respective periods covered thereby, subject in the case of unaudited financial information, to changes resulting from normal year end audit adjustments and to the absence of footnotes.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2275"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">There are no material liabilities of any Credit Party of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise, and there is no existing condition, situation or set of circumstances which could reasonably be expected to result in any such liabilities, other than those liabilities provided for or disclosed in the financial statements delivered with this Certificate in accordance with Section 8.01 of the Credit Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2278"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The Liquidity is not less than $15,000,000 at any time.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2281"></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Total Secured Leverage Ratio on the last day of the Test Period ending on the Computation Date was ____ to 1.00, as computed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Attachment 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto. The Total Secured </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leverage Ratio for such period must not be greater than 6.00 &#58; 1.00 for such Test Period as pursuant to Section 9.13(c) of the Credit Agreement.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2284"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Attachment 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto contains the changes, if any, in the identity of the Subsidiaries from those identified to the Administrative Agent since &#91;the Closing Date&#93;</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2290"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#365f91;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#91;the date of the most recent Compliance Certificate delivered to the Administrative Agent&#93;.</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2293"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;Attachment 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto contains a written supplement, if any, substantially in the form of Schedules 5, as applicable, to the Security Agreement with respect to any additional assets and property acquired by any Credit Party in the form of an application for the issuance or registration of any Intellectual Property with the United States Patent and Trademark Office or the United States Copyright Office &#91;after the Closing Date&#93;</font><font style="color:#365f91;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#91;since the date of the most recent Compliance Certificate delivered to the Administrative Agent&#93;, in reasonable detail and each such written supplement shall be deemed to immediately and automatically amend such Schedule as then in effect.&#93;</font><font style="color:#365f91;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">6</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of page intentionally left blank&#93;</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To only be included for the first delivery of the Compliance Certificate only.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> To only be included for the first delivery of the Compliance Certificate only.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> To only be included for the first delivery of the Compliance Certificate only.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2296"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The foregoing information is true, complete and correct as of the Computation Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:225.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.371%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Administrative Borrower </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">By&#58; ___________________________________<br>&#160;&#160;&#160;&#160;Name&#58;<br>&#160;&#160;&#160;&#160;Title&#58;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:111%">&#91;Signature Page to Compliance Certificate&#93;</font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2299"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attachment 1<br>(to _&#47;_&#47;_<br>Compliance Certificate)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CONSOLIDATED ADJUSTED EBITDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-4.2pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As of _______ __, 20__ (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Computation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)<br>for the Test Period ending on the<br>Computation Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Computation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:83.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">I. Consolidated Adjusted EBITDA for the Computation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; an amount determined for the Borrower and its Subsidiaries on a consolidated basis equal to&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Net Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  the consolidated net income (or loss) of the Parent and its Subsidiaries determined in accordance with GAAP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">minus</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the income (or loss) of any Person (other than consolidated Subsidiaries of Parent) in which any Person (other than Parent or any of its consolidated Subsidiaries) has a joint ownership interest, or that is accounted for by the equity method of accounting, except to the extent of the amount of dividends or other distributions actually paid to Parent or any of its consolidated Subsidiaries by such Person during such specified period, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">minus</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the income (or loss) of any Person accrued prior to the date it becomes a consolidated Subsidiary of Parent or is merged into or consolidated with Parent or any of its consolidated Subsidiaries or such Person&#8217;s assets are acquired by Parent or any of its consolidated Subsidiaries, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr></table></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">All attachments to Compliance Certificate to be conformed with final Credit Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:83.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the income of any consolidated Subsidiary of Parent (other than a Credit Party) to the extent that the declaration or payment of dividends or similar distributions by that consolidated Subsidiary of that income is not at the time permitted by operation of the terms of its charter or any agreement, instrument, judgment, decree, order, statute, rule, governmental regulation applicable to that consolidated Subsidiary or would require governmental (including regulatory) consent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, the income (or loss) of any consolidated Subsidiary of Parent (other than a Credit Party) shall not be excluded from this definition to the extent governmental (including regulatory) consent has been received for the declaration or payment of dividends or similar distributions by that consolidated Subsidiary of its income&#8230;&#8230;&#8230;&#8230;..&#8230;&#8230;&#8230;&#8230;.&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;In each case to the extent deducted in calculating Consolidated Net Income for the Computation Period (other than with respect to clause (B)(13) below), the sum of, and without duplication, amounts for&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Interest Expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (net of interest income)&#58;  for the Borrower and its Subsidiaries, determined on a consolidated basis in accordance with GAAP, the sum of&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) all interest in respect of Indebtedness (including, without limitation, the interest component of any payments in respect of Capitalized Lease Obligations) accrued or capitalized during such period (whether or not actually paid during such period) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8230;&#8230; .</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) the net amount payable (or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the net amount receivable) in respect of Hedging Obligations relating to interest during such period (whether or not actually paid or received during such period)&#8230;&#8230;..</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$___________</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$___________</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2) Provisions for Taxes based on income and any payments made pursuant to the TRA&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.&#8230;&#8230;&#8230;&#8230;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3) Total depreciation expense&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;...&#8230;&#8230;&#8230;.&#8230;&#8230;&#8230;.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4) Total amortization expense&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:83.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5) Other non-cash charges reducing Consolidated Net Income (excluding any such non cash item (a) to the extent that it represents an accrual or reserve for potential cash items in any future period or amortization of a prepaid cash item that was paid in a prior period or (b) relating to a write-down, write off or reserve with respect to receivables or inventory)&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6) Losses, costs and expenses on asset sales, disposals or abandonments (other than (a) of current assets and (b) asset sales, disposals or abandonments in the ordinary course of business)&#8230; &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(7) Fees and expenses incurred in connection with a Permitted Acquisition, other Investments permitted under the Credit Agreement, Dispositions (other than in the ordinary course of business) permitted under the Credit Agreement, Restricted Payments permitted under the Credit Agreement or the refinancing or redemption of Indebtedness permitted under the Credit Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, to the extent such transactions have not been consummated, such Unconsummated Deal Expenses (a) shall not exceed $1,500,000 in any Test Period and (b) shall not exceed the aggregate amount of any adjustments made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> during such period shall not exceed 25% of Consolidated Adjusted EBITDA (calculated together with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for such period (calculated before giving effect to any such adjustments)&#59; provided that, the foregoing caps shall not include fees and expenses incurred prior to the Closing Date in connection with the transaction previously identified to the Administrative Agent as &#8220;Project Holiday&#8221;, so long as such amount does not exceed $3,500,000 in the aggregate&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.&#8230;&#8230;&#8230;&#8230;&#8230;.&#8230;&#8230;&#8230;&#8230;&#8230;.&#8230;&#8230;&#8230;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(8) Fees and expenses incurred in connection with the consummation of the Transactions on the Closing Date in an aggregate amount not to exceed     $6,000,000 and to the extent disclosed to the Agents&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(9) Non-cash adjustments pursuant to any management equity or equity-based plan or stock option plan or any other management or employee benefit plan or agreement or any stock subscription or stockholders agreement&#8230;&#8230;..</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10) (a) The effects of adjustments in the Parent&#8217;s and its Subsidiaries&#8217; consolidated financial statements pursuant to GAAP (including in the property and equipment, software, goodwill, intangible assets, deferred revenue and debt line items thereof) resulting from the application of recapitalization accounting or purchase accounting, as the case may be, in relation to the Transactions or any consummated acquisition or the amortization of any amounts thereof, (b) any non-cash losses, charges or adjustments resulting from the application of Accounting Standards Codification 606 and (c) earnout obligations and other similar contingent consideration&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:83.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(11) Costs, fees and expenses relating to restructuring, severance, recruiting, retentions and relocations, signing and stay bonuses, payments made to employees or producers who are subject to non-compete agreements, and curtailments or modifications to pension and post-retirement employee benefits plans&#59; provided, that, the aggregate amount included in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (B)(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> during any Test Period shall not exceed 25% of Consolidated Adjusted EBITDA (calculated together with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (solely to the extent relating to Unconsummated Deal Expenses) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the end of the most recently ended Test Period)&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(12) Charges, losses or expenses to the extent paid for, reimbursed or indemnified by a Person other than Parent and its Subsidiaries or reimbursed through insurance by a Person other than Parent and its Subsidiaries, in each case to the extent such expenses are actually paid or refunded to Parent or any of its Subsidiaries (to the extent such payments or refunds are included in Consolidated Net Income)&#8230;&#8230;&#8230;..&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(13) Proceeds received from business interruption insurance&#8230;&#8230;&#8230;..</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(14) To the extent included in Consolidated Net Income, losses attributable to non-controlling interests&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(15) Extraordinary, unusual and non-recurring costs, expenses and losses in any Test Period&#59; provided, that the aggregate amount included in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (B)(15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> during any Test Period shall not exceed, provided that, the aggregate amount included in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> during any Test Period shall not exceed 25% of Consolidated Adjusted EBITDA (calculated together with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (solely to the extent relating to Unconsummated Deal Expenses and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (11) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the end of the most recently ended Test Period &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(16) Sum of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (B)(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (B)(15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;In each case to the extent included in calculating Consolidated Net Income for the Computation Period, the sum of, without duplication, amounts for&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) Gains on asset sales, disposals or abandonments (other than of (a) current assets and (b) asset sales, disposals or abandonments in the ordinary course of business)&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2) Other non-cash gains increasing Consolidated Net Income for such period (excluding any such non-cash item to the extent it represents the reversal of an accrual or reserve for a potential cash item in any prior     period). &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:83.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3) Extraordinary, unusual and non-recurring gains and income&#8230;&#8230;.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4) Any software development costs to the extent capitalized during such period&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5) Sum of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (C)(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (C)(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;Consolidated Adjusted EBITDA for the Computation Period&#58;  The sum of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (B)(16)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> minus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (C)(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$___________</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2302"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attachment 2<br>(to _&#47;_&#47;_<br>Compliance Certificate)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%;text-decoration:underline">2</font></div><div style="padding-left:2.85pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.996%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18.2pt;padding-right:0.2pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Secured Debt outstanding on the last date of the Computation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:55.55pt;padding-right:0.2pt;text-indent:-19.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) The outstanding principal amount of all Funded Debt that is secured, in whole or party, by a Lien on any asset of Parent or any of its Subsidiaries &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.22pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18.2pt;padding-right:0.2pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Adjusted EBITDA for the Computation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:55.55pt;padding-right:0.2pt;text-indent:-19.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) The amount set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Attachment 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to this Compliance Certificate&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.22pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$___________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18.2pt;padding-right:0.2pt"><font><br></font></div><div style="padding-left:18.2pt;padding-right:0.2pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Total Secured Leverage Ratio on the last day of the Computation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  The ratio of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Item (A)(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to &#91;Item (B)(1)&#93;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div></td><td colspan="3" style="padding:2px 1.22pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">___ &#58; 1.00</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2305"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attachment 3<br>(to _&#47;_&#47;_<br>Compliance Certificate)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CHANGES IN IDENTITY OF THE SUBSIDIARIES</font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2308"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attachment 4<br>(to _&#47;_&#47;_<br>Compliance Certificate)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">UPDATES&#47;SUPPLEMENTS TO CERTAIN SCHEDULE 5 OF THE SECURITY AGREEMENT</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An updated Schedule 5 of the Security Agreement </font></div><div style="padding-left:2.85pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.996%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Attachment 5<br>(to _&#47;_&#47;_<br>Compliance Certificate)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DETAILS SPECIFYING DEFAULT OR EVENT OF DEFAULT<br>AND THE ACTION TAKEN OR TO BE TAKEN WITH RESPECT THERETO</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2311"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT N-1</font></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FORM OF NOTICE OF BORROWING</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ares Capital Corporation,</font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Administrative Agent</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2000 Avenue of the Stars, 12th Floor</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Los Angeles, CA 90067</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  agency&#64;aresmgmt.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br><br>Ladies and Gentlemen&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Notice of Borrowing is delivered to you as of &#91;__&#93;, 20&#91;__&#93; pursuant to Section 2.02(a) or 2.03(b) of the Credit Agreement, as applicable, dated as of August 1, 2022 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> EVOLENT HEALTH LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, ENDZONE MERGER SUB, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Endzone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which upon consummation of the TPG Acquisition (as defined in the Credit Agreement) will be merged with and into </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TPG GROWTH ICEMAN PARENT, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> IMPLANTABLE PROVIDER GROUP, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Implantable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, collectively with the Administrative Borrower, Endzone and TPG, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Subsidiaries signatory thereto as guarantors or thereafter designated as Guarantors pursuant to Section 8.11 of the Credit Agreement, the lenders from time to time party thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> ARES CAPITAL CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Maryland corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Ares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as administrative agent and collateral agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited partnership (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ACF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as collateral agent for the Lenders and as revolver agent for the Revolving Lenders. Unless otherwise defined herein, capitalized terms used herein and defined in the Credit Agreement shall have the meanings provided in the Credit Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;The Borrower signatory hereto hereby requests that on &#91;__&#93;, 20&#91;__&#93;, a &#91;Initial Term Loan&#93; &#91;Revolving Loan&#93; be made in the aggregate principal amount of ____________________ ($____________) as &#91;a&#93;&#91;an&#93; &#91;ABR Loan&#93; &#91;Term SOFR Loan&#93; to &#91;________&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  with interest payable quarterly in accordance with the Credit Agreement, with the proceeds of such Loan to be disbursed in accordance with Section 4 hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2) &#160;&#160;&#160;&#160;The Administrative Borrower hereby acknowledges that, pursuant to Section 6.02(a) of the Credit Agreement, the acceptance by the applicable Borrower for the benefit of the Credit Parties of the proceeds of the Loans requested hereby constitutes a representation and warranty by the Administrative Borrower, on behalf of each Credit Party, that, on the date of such Credit Extension (both immediately before and after giving effect thereto and to the application of the proceeds thereof) all the statements set forth in Section 6.01(g) or 6.02(a), as appliable, of the Credit Agreement are true and correct.  </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Insert applicable Borrower.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3) &#160;&#160;&#160;&#160;The Administrative Borrower agrees that if, prior to the time of the Borrowings requested hereby, any matter certified to herein by them will not be true and correct in all respects at the date of such Borrowings as if then made, they will immediately so notify the Administrative Agent.  Except to the extent, if any, that prior to the time of the Borrowings requested hereby, the Administrative Agent shall receive written notice to the contrary from the Administrative Borrower, each matter certified to herein shall be deemed to be certified as true and correct at the date of such Borrowings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4) &#160;&#160;&#160;&#160;Please wire transfer the proceeds of the Borrowings &#91;to the following account and financial institution&#93; &#91;for initial Notice of Borrowing&#59; in accordance with that certain Letter of Direction and Flow of Funds to be delivered to the Administrative Agent&#93;&#58; </font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Borrower&#58;  &#91;____________________&#93;</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bank Name&#58; &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bank Address&#58; &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Account Name&#58; &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Account No.&#58; &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ABA No.&#58; &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of page left intentionally blank.&#93;</font></div><div style="text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The undersigned Borrower has caused this Notice of Borrowing to be executed and delivered as of the date first written above.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;EVOLENT HEALTH LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font></div><div style="margin-bottom:6pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="margin-bottom:6pt;padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; ______________________________</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;______&#93;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;IMPLANTABLE PROVIDER GROUP, INC.,</font></div><div style="margin-bottom:6pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation </font></div><div style="margin-bottom:6pt;padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; ______________________________</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;______&#93;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;TPG GROWTH ICEMAN PARENT, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font></div><div style="margin-bottom:6pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="margin-bottom:6pt;padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; ______________________________</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2314"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT N-2</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FORM OF NOTICE OF CONVERSION </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ares Capital Corporation,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   as Administrative Agent</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2000 Avenue of the Stars, 12th Floor</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Los Angeles, CA 90067</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  agency&#64;aresmgmt.com</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ladies and Gentlemen&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Notice of Conversion is delivered to you as of &#91;____________&#93;, 20___ pursuant to Section 2.06 of the Credit Agreement, dated as of August 1, 2022 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> EVOLENT HEALTH LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, ENDZONE MERGER SUB, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Endzone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which upon consummation of the TPG Acquisition (as defined in the Credit Agreement) will be merged with and into </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TPG GROWTH ICEMAN PARENT, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> IMPLANTABLE PROVIDER GROUP, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Implantable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, collectively with the Administrative Borrower, Endzone and TPG, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), each of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Subsidiaries signatory thereto as guarantors or thereafter designated as Guarantors pursuant to Section 8.11 of the Credit Agreement, the lenders from time to time party thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> ARES CAPITAL CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Maryland corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Ares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited partnership (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ACF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as collateral agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and as revolver agent for the Revolving Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolver Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Unless otherwise defined herein or the context otherwise requires, capitalized terms used herein and defined in the Credit Agreement shall have the meanings given to them in the Credit Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrative Borrower hereby requests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that on ___________ __, 20___,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">5</font></div><div style="text-indent:0.18pt"><font><br></font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2317"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;$___________.00 of the currently outstanding principal amount of the &#91;Initial Term Loan&#93; &#91;Revolving Loan&#93; originally made on ___________ __, 20___ to &#91;________&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2320"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;all currently being maintained as &#91;ABR&#93;&#91;Term SOFR&#93; Loans,</font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2323"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;be converted into,</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.72pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Such request to be made prior to 1&#58;00 p.m. (New York time) at least three Business Days (or one Business Day in the case of a conversion into ABR Loans) (and in either case on not more than five Business Days) prior to the proposed conversion.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> Insert applicable Borrower.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.72pt"><font><br></font></div><div id="iaa36735c66cb43c599ee5c9251d15861_2326"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;&#91;ABR Loans&#93; &#91;Term SOFR&#93; Loans </font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.72pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except to the extent, if any, that prior to the time of the conversion requested hereby the Administrative Agent shall receive written notice to the contrary from the Administrative Borrower, each matter certified to herein shall be deemed to be certified as true and correct in all respects at the date of such conversion as if then made.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Administrative Borrower has caused this Notice of Conversion to be executed and delivered by its duly Authorized Officer this __ day of _________, 20__.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font></div><div style="margin-bottom:6pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="margin-bottom:6pt;padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2446"></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT R-1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FORM OF REVOLVER NOTE</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91;____________&#93;&#160;&#160;&#160;&#160;&#91;________ __&#93;, 20&#91;__&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FOR VALUE RECEIVED, the undersigned (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), hereby unconditionally promises to pay to &#91;_________________&#93;, a &#91;___________&#93; or its registered assigns (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in lawful money of the United States and in immediately available funds, the principal amount of (a)&#160;&#91;____________________&#93; DOLLARS ($&#91;________&#93;), or, if less, (b)&#160;the unpaid principal amount of the Revolver Loans of the Holder outstanding under the Credit Agreement (as defined below).  The principal amount of this Revolver Note (as amended, restated, amended and restated, supplemented or otherwise modified, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be paid in the amounts and on the dates specified in the Credit Agreement to the account designated by the Administrative Agent (as defined below). The Borrower further agrees to pay interest on the unpaid principal amount hereof from time to time outstanding at the rates and on the dates specified in the Credit Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Revolver Note (a)&#160;is one of the promissory notes referred to in the Credit Agreement, dated as of August 1, 2022 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> EVOLENT HEALTH LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Evolent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, ENDZONE MERGER SUB, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Endzone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which upon consummation of the TPG Acquisition (as defined in the Credit Agreement) will be merged with and into </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TPG GROWTH ICEMAN PARENT, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> IMPLANTABLE PROVIDER GROUP, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Implantable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, collectively with Evolent, Endzone and TPG, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the other Credit Parties from time to time party thereto, the lenders from time to time party thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> ARES CAPITAL CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Maryland corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Ares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited partnership (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ACF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as collateral agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and as revolver agent for the Revolving Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolver Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (b)&#160;is subject to the provisions of the Credit Agreement and (c)&#160;is subject to optional and mandatory prepayment in whole or in part as provided in the Credit Agreement.  This Revolver Note is secured and guaranteed as provided in the Credit Documents. Reference is hereby made to the Credit Documents for a description of the properties and assets in which a security interest has been granted, the nature and extent of the security and the guarantees, the terms and conditions upon which the security interests and each guarantee were granted and the rights of the Holder in respect thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon the occurrence of any one or more of the Events of Default, all principal and all accrued interest then remaining unpaid on this Revolver Note shall become, or may be declared to be, immediately due and payable, all as provided in the Credit Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit R-1 - 1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All parties now and hereafter liable with respect to this Revolver Note, whether maker, principal, surety, guarantor, endorser or otherwise, hereby waive presentment, demand, protest and all other notices of any kind.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise defined herein, capitalized terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN OR IN THE CREDIT AGREEMENT, THIS REVOLVER NOTE MAY NOT BE TRANSFERRED EXCEPT PURSUANT TO AND IN ACCORDANCE WITH THE REGISTRATION AND OTHER PROVISIONS OF SECTION&#160;12.06 OF THE CREDIT AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIS REVOLVER NOTE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW&#160;YORK. </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature page follows.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit R-1 - 2</font></div><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2449"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="padding-left:269.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:21.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,<br>a Delaware limited liability company</font></div></td></tr><tr style="height:27pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">By</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:39.1pt;padding-right:3.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:39.1pt;padding-right:3.1pt;text-indent:-36pt"><font><br></font></div></td></tr></table></div><div style="margin-bottom:24pt;text-align:right"><font><br></font></div><div style="padding-left:269.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:21.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IMPLANTABLE PROVIDER GROUP, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>a Delaware corporation</font></div></td></tr><tr style="height:27pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">By</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:39.1pt;padding-right:3.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:39.1pt;padding-right:3.1pt;text-indent:-36pt"><font><br></font></div></td></tr></table></div><div style="margin-bottom:24pt"><font><br></font></div><div style="padding-left:269.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:21.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TPG GROWTH ICEMAN PARENT, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>a Delaware corporation</font></div></td></tr><tr style="height:27pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">By</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:39.1pt;padding-right:3.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div></td></tr></table></div><div style="margin-bottom:24pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2452"></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT T-1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FORM OF TERM LOAN NOTE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91;____________&#93;&#160;&#160;&#160;&#160;&#91;________ __&#93;, 20&#91;__&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FOR VALUE RECEIVED, the undersigned (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), hereby unconditionally promises to pay to &#91;_________________&#93;, a &#91;___________&#93; or its registered assigns (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in lawful money of the United States and in immediately available funds, the principal amount of (a)&#160;&#91;____________________&#93; DOLLARS ($&#91;________&#93;), or, if less, (b)&#160;the unpaid principal amount of the Term Loans of the Holder outstanding under the Credit Agreement (as defined below).  The principal amount of this Term Loan Note (as amended, restated, amended and restated, supplemented or otherwise modified, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be paid in the amounts and on the dates specified in the Credit Agreement to the account designated by the Administrative Agent (as defined below). The Borrower further agrees to pay interest on the unpaid principal amount hereof from time to time outstanding at the rates and on the dates specified in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Term Note (a)&#160;is one of the promissory notes referred to in the Credit Agreement, dated as of August 1, 2022 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> EVOLENT HEALTH LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Evolent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, ENDZONE MERGER SUB, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Endzone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which upon consummation of the TPG Acquisition (as defined in the Credit Agreement) will be merged with and into </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TPG GROWTH ICEMAN PARENT, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> IMPLANTABLE PROVIDER GROUP, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Implantable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, collectively with Evolent, Endzone and TPG, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the other Credit Parties from time to time party thereto, the lenders from time to time party thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> ARES CAPITAL CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Maryland corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Ares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited partnership (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ACF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as collateral agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and as revolver agent for the Revolving Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolver Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),  (b)&#160;is subject to the provisions of the Credit Agreement and (c)&#160;is subject to optional and mandatory prepayment in whole or in part as provided in the Credit Agreement.  This Term Note is secured and guaranteed as provided in the Credit Documents. Reference is hereby made to the Credit Documents for a description of the properties and assets in which a security interest has been granted, the nature and extent of the security and the guarantees, the terms and conditions upon which the security interests and each guarantee were granted and the rights of the Holder in respect thereof.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon the occurrence of any one or more of the Events of Default, all principal and all accrued interest then remaining unpaid on this Term Note shall become, or may be declared to be, immediately due and payable, all as provided in the Credit Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit T-1 - 1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All parties now and hereafter liable with respect to this Term Note, whether maker, principal, surety, guarantor, endorser or otherwise, hereby waive presentment, demand, protest and all other notices of any kind.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise defined herein, capitalized terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN OR IN THE CREDIT AGREEMENT, THIS TERM NOTE MAY NOT BE TRANSFERRED EXCEPT PURSUANT TO AND IN ACCORDANCE WITH THE REGISTRATION AND OTHER PROVISIONS OF SECTION&#160;12.06 OF THE CREDIT AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS TERM NOTE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW&#160;YORK. </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature page follows.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit T-1 - 2</font></div><div><font><br></font></div></div></div><div id="iaa36735c66cb43c599ee5c9251d15861_2455"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="padding-left:269.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:21.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLENT HEALTH LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,<br>a Delaware limited liability company</font></div></td></tr><tr style="height:27pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">By</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:39.1pt;padding-right:3.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div></td></tr></table></div><div style="margin-bottom:24pt"><font><br></font></div><div style="padding-left:269.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:21.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IMPLANTABLE PROVIDER GROUP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>a Delaware corporation</font></div></td></tr><tr style="height:27pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">By</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:39.1pt;padding-right:3.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div></td></tr></table></div><div style="margin-bottom:24pt"><font><br></font></div><div style="padding-left:269.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:21.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TPG GROWTH ICEMAN PARENT, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>a Delaware corporation</font></div></td></tr><tr style="height:27pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">By</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:39.1pt;padding-right:3.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>a2022q2form10qex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i76b155cfa72c4ca9928458431bbb7d63_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="margin-bottom:3pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Execution Version</font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITY AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECURITY AGREEMENT, dated as of August 1, 2022, made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Grantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in favor of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) acting pursuant to this Agreement for the benefit of the Secured Parties (as defined in the Credit Agreement referred to below).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">W I T N E S S E T H&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, pursuant to the Credit Agreement, dated as of the date hereof (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> EVOLENT HEALTH LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Evolent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, ENDZONE MERGER SUB, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Endzone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which upon consummation of the TPG Acquisition (as defined in the Credit Agreement) will be merged with and into </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TPG GROWTH ICEMAN PARENT, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> IMPLANTABLE PROVIDER GROUP, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Implantable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, collectively with Evolent, Endzone and TPG, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the other Credit Parties from time to time party thereto, the lenders from time to time party thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> ARES CAPITAL CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Maryland corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Ares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Collateral Agent, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACF FINCO I LP </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">as revolver agent for the Revolving Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolver Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Lenders have severally agreed to make Loans to the Borrowers upon the terms and subject to the conditions set forth therein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, pursuant to the Guarantee Agreement, dated as of the date hereof (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, and together with any other such agreement at any time executed and delivered to the Collateral Agent by any other Guarantor, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Guarantee Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), delivered by the Guarantors party thereto in favor of Collateral Agent, such Guarantors have guaranteed the payment and performance of the each Borrower&#8217;s obligations and liabilities under the Credit Agreement as more fully set forth therein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, each of the Grantors is a member of an affiliated group of companies that includes each other&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, each Borrower and the other Grantors are engaged in related businesses, and each Grantor will derive substantial direct and indirect benefits from the making of the Loans and other financial accommodations under the Credit Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, it is a condition precedent to the obligation of the Lenders to make and continue making their respective Loans to the Borrowers under the Credit Agreement that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Grantors shall have executed and delivered this Agreement to the Collateral Agent for the benefit of the Secured Parties&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent, the Collateral Agent and the Lenders to enter into the Credit Agreement and to induce the Lenders to make and continue making their respective Loans to the Borrowers thereunder, each Grantor hereby agrees with the Collateral Agent, for the benefit of the Secured Parties, as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">DEFINED TERMS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  (a)  Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement, and the following terms which are defined in the UCC are used herein as so defined&#58; Account, Certificated Security, Chattel Paper, Commercial Tort Claim, Contract, Document, Equipment, Farm Product, General Intangible, Goods, Instrument, Inventory, Letter-of-Credit Right and Supporting Obligation.  All other terms used herein without definition which are not defined in the Credit Agreement shall have the definitions given therefor in the UCC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean this Security Agreement, as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Applicable Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (A) with respect to any Grantor that is a party hereto on the Closing Date, the Closing Date or (B) with respect to any Grantor that is not a party hereto on the Closing Date, the date on which an Assumption Agreement is executed and delivered by such Grantor.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Assumption Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 7.13.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section&#160;2.1.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any collateral account established by the Collateral Agent as provided in Sections&#160;5.1 or 5.4.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Copyrights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Grantor, (a) all copyrights arising under the laws of the United States, any other country or any political subdivision thereof, whether registered or unregistered and whether published or unpublished (including, without limitation, those listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as such schedule may be amended from time to time, all registrations and recordings thereof, and all applications in connection therewith, including, without limitation, all registrations, recordings and applications in the United States Copyright Office, and (b) the right to obtain all renewals thereof.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Copyright Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any written agreement naming any Grantor as licensor or licensee, granting any right under any Copyright, including, without limitation, the grant of rights to manufacture, distribute, exploit and sell materials derived from any Copyright.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">2</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Deposit Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall, with respect to any Grantor, have the meaning set forth in the UCC and, in any event, include, without limitation, any demand, time, savings, passbook or like account maintained with a depositary institution.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Domain Name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean all internet domain name registrations.  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Excluded Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 2.2.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Guarantor Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to each Guarantor, the unpaid &#8220;Obligations&#8221; (as defined under the Credit Agreement).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Guarantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, each Grantor other than a Borrower.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Grantor, collectively, all rights, priorities and privileges (including, without limitation, any IP Ancillary Rights) relating to intellectual property, now owned or hereafter acquired and owned by such Grantor, whether arising under United States, multinational or foreign laws or otherwise, including, without limitation, the Copyrights, the Patents, and the Trademarks.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Intercompany Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any promissory note evidencing loans made by any Grantor to any other Grantor or to any Subsidiary of any Grantor.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Investment Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Grantor, collectively, (a)&#160;all &#8220;investment property&#8221; as such term is defined in Section&#160;9-102(a)(49) of the UCC and (b)&#160;whether or not constituting &#8220;investment property&#8221; as so defined, all Pledged Notes and all Pledged Stock.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">IP Ancillary Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Intellectual Property, as applicable, all foreign counterparts to, and all divisionals, reversions, continuations, continuations-in-part, reissues, reexaminations, renewals and extensions of, such Intellectual Property, and, in each case, all rights to obtain any other IP Ancillary Right throughout the world.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">IP License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all contractual obligations (and any related IP Ancillary Rights), whether written or oral, granting any right, title and interest in or relating to any Intellectual Property.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Issuers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, each issuer of any Investment Property.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Grantor, (a) all letters patent of the United States, and any other jurisdiction, country or any political subdivision thereof, all foreign counterparts to, and all divisionals, reversions, continuations, continuations-in-part, reissues, reexaminations, renewals and extensions thereof and all goodwill associated therewith, including, without limitation, any of the foregoing referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as such schedule may be amended from time to time, (b) all applications for letters patent of the United States and any other jurisdiction, country or any political subdivision thereof, all foreign counterparts to, and all divisionals, reversions, continuations, continuations-in-part, reissues, reexaminations, renewals and extensions thereof, including, without limitation, any of the foregoing referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">3</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such schedule may be amended from time to time, and (c) all rights to obtain any foreign counterparts to, divisionals, reversions, continuations, continuations-in-part, reissues, reexaminations, renewals and extensions of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Pledged Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean all promissory notes listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as such schedule may be amended from time to time, all Intercompany Notes at any time issued to any Grantor and all other promissory notes issued to or held by any Grantor (other than promissory notes issued in connection with extensions of trade credit by any Grantor in the ordinary course of business).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Pledged Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the shares of Capital Stock listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as such schedule may be amended from time to time, together with any other shares, stock certificates, options, interests or rights of any nature whatsoever in respect of the Capital Stock of any Person that may be issued or granted to, or held by, any Grantor while this Agreement is in effect, in each case, except to the extent constituting Excluded Collateral.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean all &#8220;proceeds&#8221; as such term is defined in Section&#160;9-102(a)(64) of the UCC and, in any event, shall include, without limitation, all dividends or other income from the Investment Property, collections thereon or distributions or payments with respect thereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Receivable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any right to payment for goods sold or leased or for services rendered, whether or not such right is evidenced by an Instrument or Chattel Paper and whether or not it has been earned by performance (including, without limitation, any Account).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Secured Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (a) in the case of the Borrowers, the &#8220;Obligations&#8221; as defined in the Credit Agreement and (b) in the case of the Guarantors, the Guarantor Obligations.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the date on which (a) the Loans and the other Secured Obligations (other than Unasserted Contingent Obligations) shall have been paid in full in cash in accordance with the terms of the Credit Agreement and the other Credit Documents and (b) the Commitments have been terminated.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a party who is not a Credit Party or an Affiliate of any Credit Party.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Third Party IP License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.3.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; mean, with respect to any Grantor, all right, title and interest (and any related IP Ancillary Rights) arising under any Requirement of Law in or relating to proprietary, confidential and&#47;or non-public information, however documented, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">4</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">including but not limited to confidential ideas, know-how, concepts, methods, processes, formulae, reports, data, customer lists, mailing lists, business plans and all other trade secrets.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Grantor, (a) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers, and all goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, whether in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, or otherwise, and all common-law rights related thereto, including, without limitation, any of the foregoing referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as such schedule may be amended from time to time, and (b) the right to obtain all extensions or renewals thereof.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Uniform Commercial Code as in effect in the state of New York, as amended or modified from time to time.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Unasserted Contingent Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, at any time, Secured Obligations for taxes, costs, indemnifications, reimbursements, damages and other liabilities in respect of which no assertion of liability (whether oral or written) and no claim or demand for payment or indemnification (whether oral or written) has been made.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Definitional Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  (a)  The words &#8220;hereof&#8221;, &#8220;herein&#8221;, &#8220;hereto&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and Section and Schedule references are to this Agreement unless otherwise specified.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms.  Where the context requires, terms relating to the Collateral or any part thereof, when used in relation to a Grantor, shall refer to such Grantor&#8217;s Collateral or the relevant part thereof.</font></div><div style="margin-bottom:9pt;text-align:center;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9.36pt">GRANT OF SECURITY INTEREST</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18pt">Each Grantor hereby pledges and collaterally assigns to the Collateral Agent, and hereby grants to the Collateral Agent, for the benefit of the Secured Parties and their respective successors, indorsees, transferees and assigns, a security interest in all of the personal property listed below, whether now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time in the future may acquire any right, title or interest, wherever located (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), as collateral security for the prompt and complete payment in full in cash and performance when due (whether at the stated maturity, by acceleration or otherwise) of its Secured Obligations&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">all Accounts&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">all Chattel Paper&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all Contracts&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">5</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">all Deposit Accounts&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all Documents&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">all Equipment&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">all General Intangibles&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">all Instruments&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">all Intellectual Property&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">all Inventory&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">all Investment Property&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">all IP Licenses&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">all Letter-of-Credit Rights&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">all Domain Names&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">all Goods and other property not otherwise described above (except for any property specifically excluded from any clause in this section above, and any property specifically excluded from any defined term used in any clause of this section above)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">all income, royalties, proceeds and Liabilities at any time due or payable or asserted under or with respect to any Intellectual Property, including all rights to sue or recover at law or in equity for any past, present or future infringement, misappropriation, dilution or violation of any Intellectual Property&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">all books and records pertaining to the Collateral&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">all Commercial Tort Claims listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as such schedule may be amended from time to time, or described in any notice sent pursuant to Section 4.9&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.36pt">to the extent not otherwise included, all Proceeds, Supporting Obligations and products of any and all of the foregoing and all collateral security and guarantees given by any Person with respect to any of the foregoing&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">to the extent not covered by clauses (a) through (p) of this sentence, all other assets, personal property and rights of such Grantor, whether tangible or intangible&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, any Grantor&#8217;s rights under any agreement, including without limitation, such Grantor&#8217;s rights to claim a reversionary interest in any Intellectual Property pursuant to an underlying agreement. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">6</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.&#160;&#160;&#160;&#160;Notwithstanding the foregoing, &#8220;Collateral&#8221; shall not include, and the representations and covenants herein shall not apply to, the following (such items, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Excluded Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">more than 65% of the Voting Stock of each Foreign Subsidiary or Domestic Holding Company directly held by any Grantor if to do so would cause adverse tax consequences for any Grantor&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that immediately upon any amendment of the Code that would allow the pledge of a greater percentage of such Voting Stock without adverse tax consequences, &#8220;Collateral&#8221; shall include such greater percentage of Voting Stock of such Foreign Subsidiary from that time forward&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">any application for a trademark that would otherwise be deemed invalidated, cancelled or abandoned due to the grant of a Lien thereon unless and until such time as the grant of such Lien will not affect the validity of such trademark&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">any rights or interests in any lease, license, contract, or agreement, as such or the assets subject thereto if under the terms of such lease, license, contract, or agreement, or Applicable Law with respect thereto, the valid grant of a Lien therein or in such assets to Collateral Agent is prohibited and such prohibition has not been or is not waived or the consent of the other party to such lease, license, contract, or agreement has not been or is not otherwise obtained or under Applicable Law such prohibition cannot be waived&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the foregoing exclusions shall in no way be construed (i) to apply if any such prohibition would be rendered ineffective under the UCC (including Sections 9-406, 9-407 and 9-408 thereof) or other Applicable Law (including the United States bankruptcy code) or principles of equity, (ii) so as to limit, impair or otherwise affect the Collateral Agent&#8217;s unconditional continuing Liens upon any rights or interests of any Grantor in or to the Proceeds thereof (including proceeds from the sale, license, lease or other disposition thereof), including monies due or to become due under any such lease, license, contract, or agreement (including any Accounts or other Receivables) to the extent such Proceeds are not themselves Excluded Collateral, or (iii) to apply at such time as the condition causing such prohibition shall be remedied and, to the extent severable, &#8220;Collateral&#8221; shall include any portion of such lease, license, contract, agreement or assets subject thereto that does not result in such prohibition&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Capital Stock in any joint venture or Subsidiary that is not a wholly owned Subsidiary to the extent that granting a pledge of or a security interest in such Capital Stock under the Security Documents would not be permitted by the terms of such joint venture or such Subsidiary&#8217;s Organizational Documents&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">any United States intent-to-use trademark applications or intent-to-use service mark applications to the extent and for so long as the grant of a security interest therein would impair the validity or enforceability of, or render void or voidable or result in the cancellation of, a Credit Party&#8217;s right, title or interest therein or any trademark or service mark issued as a result of such application under applicable Federal law&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">assets in circumstances where the Administrative Agent and the Administrative Borrower reasonably agree that the cost of obtaining or perfecting a security </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">7</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">interest under the Credit Documents in such assets is excessive in relation to the benefit to the Secured Parties afforded thereby&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">any motor vehicles and any other assets subject to a certificate of title (other than proceeds thereof), to the extent a security interest in such motor vehicles or other assets cannot be perfected solely by filing a UCC financing statement&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">(i) any fee-owned Real Property that is not Material Real Property and (ii) any other Real Property in which the Grantors do not have a fee simple interest (and for the avoidance of doubt, the Credit Parties shall not be required to obtain landlord waivers, estoppels or collateral access letters for any Real Property)&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">margin stock and any Capital Stock of any Excluded Subsidiary&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">any lease, license or agreement or any property subject to a purchase money security interest, capital lease obligation or similar arrangement to the extent that a grant of a security interest therein would violate or invalidate such lease, license or agreement or purchase money, capital lease or similar arrangement or create a right of termination in favor of any other party thereto (other than a Grantor) after giving effect to the applicable anti-assignment provisions of the UCC and other applicable law&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">all Excluded Accounts&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">any property owed to or owned by any providers of an accountable care organization.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the avoidance of doubt, as of the Closing Date, no Grantor shall be required to enter into any pledge, security agreement, deed, charge agreement or similar agreement granting a security interest in any asset or property located outside of the United States or take any other action to create or perfect any security interest in such assets or property and no foreign intellectual property filings or searches shall be required.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt"> REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To induce the Collateral Agent and the Lenders to enter into the Credit Agreement and to induce the Lenders to make and continue to make their respective Loans to the Borrowers thereunder, each Grantor hereby represents and warrants to each Secured Party that&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Representations in Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the case of each Guarantor, all representations and warranties set forth in Article VII of the Credit Agreement which relate to or are contemplated to be made by any Credit Party are hereby incorporated herein by reference, are true and correct as of the date on which such representations and warranties are made or deemed made pursuant to the Credit Agreement, and each Secured Party shall be entitled to rely on each of them as if they were fully set forth herein.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Title&#59; No Other Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No financing statement or other public notice or record of a Lien with respect to all or any part of the Collateral is on file or of record in any public office, except such as have been filed in favor of the Collateral Agent, for the benefit of the Secured </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">8</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Parties, pursuant to this Agreement or as are expressly permitted by the terms of the Credit Agreement, including, without limitation, those made to create, evidence and&#47;or perfect Permitted Liens.  For the avoidance of doubt, it is understood and agreed that any Grantor may, in the ordinary course of its business, grant non-exclusive licenses to third parties to use Intellectual Property owned or developed by a Grantor. For purposes of this Agreement and the other Credit Documents, such licensing activity shall not constitute a &#8220;Lien&#8221; on such Intellectual Property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18pt;text-decoration:underline">Jurisdiction of Organization&#59; Chief Executive Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Grantor represents and warrants to the Secured Parties as of the Closing Date (other than with respect to clause (e) below) as follows&#58; (a) such Grantor&#8217;s exact legal name is that indicated on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and on the signature page hereof, (b) such Grantor is an organization of the type, and is organized in the jurisdiction, set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, (c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> accurately sets forth such Grantor&#8217;s organizational identification number or accurately states that such Grantor has none, (d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> accurately sets forth such Grantor&#8217;s place of business or, if more than one, its chief executive office, as well as the location of such Grantor&#8217;s books and records and such Grantor&#8217;s mailing address, if different, and (e) there has been no change in any of such information since the date of this Agreement except as has been previously disclosed to the Collateral Agent to the extent required by Section 4.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18pt;text-decoration:underline">Perfected Priority Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  As of the most recent Applicable Date, the security interests granted pursuant to this Agreement (i) upon completion of the filing of the Uniform Commercial Code financing statements (including fixture filings, as applicable) or other appropriate filings, recordings or registrations and other actions specified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and (ii) upon completion of the filing of an appropriate notice with the United States Patent and Trademark Office (which, in the case of all filings and other documents referred to on said Schedule, have been delivered to or prepared by the Collateral Agent in completed and duly executed form to the extent applicable), to the extent such actions described under the foregoing clauses (i) and (ii) are sufficient to perfect the Collateral under Article 9 of the UCC, will constitute legal and valid perfected security interests in all of the Collateral in favor of the Collateral Agent, for the benefit of the Secured Parties, as collateral security for the Secured Obligations, enforceable in accordance with the terms hereof against all creditors of each Grantor and any Persons purporting to purchase any Collateral from any Grantor, except as enforceability may be limited by the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors&#8217; rights generally, general equitable principles (whether considered in a proceeding in equity or at law),  and are prior to all other Liens on the Collateral except for Permitted Liens.  Such Uniform Commercial Code financing statements, filings in the United States Patent and Trademark Office and the United States Copyright Office, as applicable, or other appropriate filings, recordings or registrations prepared by the Collateral Agent based upon the information provided to the Collateral Agent for filing in each applicable governmental, municipal or other office specified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (as of the most recent Applicable Date), are all the filings, recordings and registrations that are necessary to establish a legal, valid and perfected security interest in favor of the Collateral Agent, for the benefit of the Secured Parties, in respect of all Collateral in which the security interest may be perfected by such filing, recording or registration in the United States, and no further or subsequent filing, refiling, recording, rerecording, registration or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">9</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">reregistration is necessary, except as provided under applicable law with respect to the filing of continuation statements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18pt;text-decoration:underline">Investment Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)  &#160;&#160;&#160;&#160;As of the most recent Applicable Date, as more fully set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule&#160;4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and subject to Section 2.2, the shares of Pledged Stock pledged by such Grantor hereunder constitute all the issued and outstanding shares of all classes of the Capital Stock of each Issuer owned by such Grantor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">All the shares of the Pledged Stock issued by any Subsidiary of any Grantor have been duly and validly issued and are fully paid and nonassessable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Each of the Pledged Notes constituting Collateral issued by any Subsidiary of any Grantor constitutes the legal, valid and binding obligation of the obligor with respect thereto, enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors&#8217; rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Such Grantor is the record and beneficial owner of, and has good and marketable title to, the Investment Property pledged by it hereunder, prior to all other Liens on such Collateral except for Permitted Liens.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">As of the Closing Date, all existing certificates representing Pledged Stock pledged by such Grantor hereunder (if such securities are certificated securities for purposes of Article 8 of the UCC), accompanied by instruments of transfer and undated stock powers endorsed in blank, have been delivered to the Collateral Agent in accordance with Section 4.5 and the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18pt;text-decoration:underline">Instruments, Promissory Notes and Chattel Paper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">No Indebtedness owed to any Grantor in excess of $4,000,000 is evidenced by one or more Instruments, promissory notes or Chattel Paper which has not been delivered, together with instruments of transfer with respect thereto endorsed in blank, to the Collateral Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Subject to the provisions set forth herein and in the Credit Agreement, all Indebtedness (i) by a Grantor to any other Grantor or (ii) by a Grantor to any Subsidiary of a Grantor that is not a Grantor in excess of $4,000,000 is evidenced by one or more Intercompany Notes, and such notes have been delivered, together with instruments of transfer with respect thereto endorsed in blank, to the Collateral Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18pt;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">As of the most recent Applicable Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule&#160;5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> lists all items of registered Intellectual Property and applications for registered Intellectual Property owned by such Grantor in its own name.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">10</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">As of the most recent Applicable Date, all registered Intellectual Property material to the business of such Grantor and described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule&#160;5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> is subsisting and unexpired and, to the knowledge of such Grantor, valid and enforceable, and no such registered Intellectual Property of such Grantor has been abandoned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">&#91;Reserved&#93;.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No holding, decision or judgment has been rendered by any Governmental Authority which would, in any respect, limit, cancel or question the validity of, or such Grantor&#8217;s rights in, any Intellectual Property material to the conduct of any Grantor&#8217;s business, other than as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as could not reasonably be expected to have a Material Adverse Effect, no action or proceeding is pending, or, to the knowledge of such Grantor, threatened, (i)&#160;seeking to limit, cancel or question the validity of any Intellectual Property material to the conduct of any Grantor&#8217;s business, or such Grantor&#8217;s ownership interest therein, or (ii)&#160;which, if adversely determined, is reasonably likely to have a Material Adverse Effect on any Intellectual Property material to the conduct of any Grantor&#8217;s business.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Commercial Tort Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">As of the most recent Applicable Date, no Grantor has rights in any Commercial Tort Claim for an amount in excess of $4,000,000 for all such claims, except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Upon the granting to Collateral Agent of a security interest in any Commercial Tort Claim pursuant to Section 4.9, such security interest will constitute a valid perfected security interest in favor of the Collateral Agent, for the benefit of the Secured Parties, as Collateral for the Secured Obligations, enforceable in accordance with the terms hereof against all creditors of such Grantor and any Persons purporting to purchase such Collateral from Grantor, which security interest shall be prior to all other Liens on such Collateral except for Permitted Liens.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Grantor hereby covenants and agrees with the Secured Parties that, from and after the date of this Agreement until the Termination Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covenants in Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Such Grantor shall (a) do each of the things set forth in the Credit Agreement that a Credit Party agrees and covenants to do and&#47;or, in the case of each Grantor that is a Subsidiary, that a Credit Party agrees and covenants to cause its Subsidiaries and&#47;or any Guarantor to do, and (b) not do each of the things set forth in the Credit Agreement that a Credit Party agrees and covenants not to do and&#47;or, in the case of each Grantor that is a Subsidiary, that a Credit Party agrees and covenants to cause its Subsidiaries and&#47;or any Guarantor not to do, in each case, fully as though such Grantor was a party thereto, and such agreements and covenants are incorporated herein by this reference, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">11</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Delivery of Instruments, Promissory Notes, Chattel Paper and Electronic Chattel Paper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Without limiting Section 4.5, if any amount in excess of $4,000,000 in the aggregate for all such Collateral, payable under or in connection with any Collateral shall be or become evidenced by an Instrument (other than checks received in the ordinary course of business), promissory note or tangible Chattel Paper, such Instrument, promissory note or tangible Chattel Paper shall promptly (and in any event no later than seven (7) Business Days, or such longer period as the Collateral Agent may agree in its sole discretion) be delivered to the Collateral Agent, together with such instruments of transfer with respect thereto endorsed in blank as the Collateral Agent may reasonably request, to be held for the benefit of the Secured Parties, as Collateral under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">  If any amount in excess of $4,000,000 in the aggregate payable under or in connection with any Collateral owned by such Grantor shall be or become evidenced by electronic chattel paper, such Grantor shall take all steps reasonably necessary to grant the Collateral Agent control of all such electronic chattel paper for the purposes of Section 9-105 of the UCC (or any similar section under any equivalent UCC) and all &#8220;transferable records&#8221; as defined in each of the Uniform Electronic Transactions Act and the Electronic Signatures in Global and National Commerce Act, promptly (and in any event no later than seven (7) Business Days, or such longer period as the Collateral Agent may agree in its sole discretion) after such Collateral is acquired or created.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">All Indebtedness with a principal amount in excess of $4,000,000 of such Grantor or any of its Subsidiaries that is owing to any other Grantor and that is evidenced by one or more Intercompany Notes shall promptly (and in any event no later than seven (7) Business Days, or such longer period as the Collateral Agent may agree in its sole discretion) be delivered to the Collateral Agent, together with such instruments of transfer with respect thereto endorsed in blank as the Collateral Agent may reasonably request, to be held for the benefit of the Secured Parties, as Collateral under this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Maintenance of Perfected Security Interest&#59; Further Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Such Grantor shall maintain the security interest created by this Agreement as a perfected security interest having at least the priority described in Section 3.4 and use commercially reasonable efforts to shall defend such security interest against the material claims and demands of all Persons whomsoever.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">At any time and from time to time, upon the written request of the Collateral Agent, and at the sole expense of such Grantor, such Grantor will promptly, and in any event no later than seven (7) Business Days, or such longer period as the Collateral Agent may agree in its sole discretion, duly execute and deliver, and have recorded, such further instruments and documents and take such further actions as the Collateral Agent may reasonably request for the purpose of obtaining or preserving the full benefits of this Agreement and of the rights and powers herein granted, including, without limitation, the filing of any financing or continuation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">12</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">statements under the UCC (or other similar laws) in effect in any jurisdiction with respect to the security interests created hereby.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Changes in Locations, Name, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Such Grantor shall provide notice within seven (7) Business Days (or such longer period as the Collateral Agent may agree in its sole discretion) to the Collateral Agent following taking the actions described under clauses (a) and (b) below&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">change the location of its chief executive office, sole place of business or location where it keeps its books and records from that referred to in Section&#160;3.3&#59; or</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">change its legal name, jurisdiction of organization, type of organization, identity or corporate structure.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investment Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If such Grantor shall be or become entitled to receive or shall receive any certificate in respect of any Pledged Stock (including, without limitation, any certificate representing a stock dividend or a distribution in connection with any reclassification, increase or reduction of capital or any certificate issued in connection with any reorganization of such Pledged Stock), option or rights in respect of any Pledged Stock, whether in addition to, in substitution of, as a conversion of, or in exchange for, any shares of the Pledged Stock, or otherwise in respect thereof, such Grantor shall accept the same as the agent of the Secured Parties, hold the same for the benefit of the Secured Parties and promptly (and in any event no later than seven (7) Business Days, or such longer period as the Collateral Agent may agree in its sole discretion) deliver the same forthwith to the Collateral Agent in the exact form received, duly endorsed by such Grantor to the Collateral Agent, if required, together with an undated stock transfer power covering such certificate duly executed in blank by such Grantor and otherwise in form and substance reasonably satisfactory to Collateral Agent, to be held by the Collateral Agent as additional Collateral for the Secured Obligations.  In case any distribution shall be made on or in respect of the Investment Property or any property shall be distributed upon or with respect to the Investment Property, the property so distributed shall be delivered to the Collateral Agent promptly (and in any event within seven (7) Business Days, or such longer period as the Collateral Agent may agree in its sole discretion) of its receipt, to be held by it as additional Collateral for the Secured Obligations.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Other than to the extent otherwise permitted under the Credit Agreement, such Grantor shall not grant &#8220;control&#8221; (within the meaning of such term under Article 9-106 of the UCC) over any Investment Property to any Person other than the Collateral Agent.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In the case of each Grantor which is an Issuer, such Issuer agrees that (i)&#160;it will be bound by the terms of this Agreement relating to the Investment Property issued by it and will comply with such terms insofar as such terms are applicable to it and (ii)&#160;the terms of Sections&#160;5.3(c) and 5.7 shall apply to it, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, with respect to all actions that may be required of it pursuant to Section&#160;5.3(c) with respect to the Investment Property issued by it.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No Grantor shall take any action to cause any membership interest, partnership interest, or other equity interest of any limited liability company, corporation or limited partnership owned or controlled by any Grantor comprising Collateral to be or become a &#8220;security&#8221; within the meaning of, or to be governed by, Article 8 of the UCC as in effect under </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">13</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the laws of the applicable jurisdiction and shall not cause or permit any such limited liability company, corporation or limited partnership to &#8220;opt in&#8221; or to take any other action seeking to establish any membership interest, partnership interest or other equity interest of such limited liability company or limited partnership comprising the Collateral as a &#8220;security&#8221; or to become certificated, in each case, without delivering all certificates (if any) evidencing such interest to the Collateral Agent in accordance with and as required by this Section 4.5 or, in the case of any uncertificated security, without taking such steps, to the extent requested by the Collateral Agent (following notice to the Collateral Agent of any such change, which shall be promptly provided by the Grantor), to provide the Collateral Agent with control (as defined in Article 8-106 of the UCC) of any such security.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  With respect to each item of Intellectual Property in the Collateral referenced below that is material to the conduct of any Grantor&#8217;s business&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">With respect to each such Trademark, material to such Grantor&#8217;s business, such Grantor (either itself or through licensees) will, in its reasonable business judgment, to the extent necessary or useful in the conduct of its business, (i)&#160;continue to use each such Trademark on each and every trademarked class of goods applicable to its then current lines of products and services as reflected in its current catalogs, brochures, price lists and other sales materials to the extent necessary to maintain such Trademark in full force and effect free from any reasonable claim of abandonment for non-use, (ii)&#160;maintain the quality of products and services offered under each such Trademark, (iii)&#160;reasonably use each such Trademark with the appropriate notice of registration and all other notices and legends required by Applicable Laws, and (iv)&#160;not (and not permit any licensee or sublicensee thereof to) do any act or knowingly omit to do any act whereby such Trademark is reasonably likely to become invalidated or materially impaired in any way.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Such Grantor (either itself or through licensees) will not, except as its reasonable business judgment otherwise dictates otherwise, do any act, or knowingly omit to do any act, whereby any such Patent material to such Grantor&#8217;s business is reasonably likely to become forfeited, abandoned or dedicated to the public.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Such Grantor (either itself or through licensees) (&#160;will not (and will not permit any licensee or sublicensee thereof to), except as its reasonable business judgment otherwise dictates otherwise, do any act or knowingly omit to do any act whereby any such Copyright material to such Grantor&#8217;s business is reasonably likely to become invalidated or otherwise impaired.  Such Grantor will not (either itself or through licensees), except as its reasonable business judgment otherwise dictates otherwise, do any act whereby any such Copyright material to such Grantor&#8217;s business may fall into the public domain (other than by expiration).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Such Grantor (either itself or through licensees) will not, except as its reasonable business judgment otherwise dictates otherwise, do any act that knowingly infringes the intellectual property rights of any other Person.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">14</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Such Grantor will in its reasonable business judgment, to the extent necessary or useful in the conduct of its business, take all reasonably necessary steps, including, without limitation, in any proceeding before the United&#160;States Patent and Trademark Office, the United&#160;States Copyright Office or any similar office or agency in any other country or any political subdivision thereof, to maintain and pursue each application (and to obtain the relevant registration) and to maintain each registration of such Intellectual Property material to such Grantor&#8217;s business, including, without limitation, paying of maintenance fees, filing of applications for renewal, affidavits of use and affidavits of incontestability.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Such Grantor shall, except as its reasonable business judgment otherwise dictates, take the actions reasonably necessary to protect the confidentiality of Trade Secrets material to such Grantor&#8217;s business and its rights therein.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Such Grantor shall notify the Collateral Agent reasonably promptly if it knows that any United States Patent, Trademark or Copyright, owned by such Grantor and that is material Intellectual Property, and is the subject of an application or registration, has or is reasonably likely to become abandoned, lost or dedicated to the public (except by expiration), or of any materially adverse and final determination (including the institution of, or any such materially adverse and final determination in, any proceeding in the United States Patent and Trademark Office or United States Copyright Office, as applicable, in connection with the prosecution of any application for issuance of a Patent or registration of a Trademark or Copyright) regarding such Grantor&#8217;s ownership of any such Patent, Trademark or Copyright, its right to register the same, or its right to keep and maintain the same.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Such Grantor agrees that, should it obtain an ownership or other interest in any Intellectual Property that constitutes Collateral after the Closing Date, (i) the provisions of this Agreement shall automatically apply thereto and (ii) any such Intellectual Property shall automatically become Intellectual Property subject to the terms and conditions of this Agreement, except, with respect to each (i) and (ii) above, if such interest in Intellectual Property is obtained under a license from a third party under which the grant of a security interest would not be permitted.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Whenever such Grantor, either by itself or through any agent, employee, licensee or designee, shall file an application for the issuance or registration of any Intellectual Property with the United&#160;States Patent and Trademark Office or the United&#160;States Copyright Office, such Grantor shall report such filing to the Collateral Agent together with the delivery of the compliance certificate as required by Section 8.01(d) of the Credit Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, upon receipt from the United States Copyright Office of notice of registration of any Copyright(s), such Grantor shall promptly (but no later than seven (7) Business Days following such receipt) notify Collateral Agent of such registration by delivering, or causing to be delivered to Collateral Agent, via overnight courier, electronic mail or telefacsimile at the addresses designated in the Credit Agreement, documentation sufficient for Collateral Agent to perfect Collateral Agent&#8217;s Liens on such Copyright(s).  Upon the reasonable request of the Collateral Agent, such Grantor shall execute and deliver promptly (and in any event within seven (7) Business Days, or such longer period as the Collateral Agent may agree in its sole discretion) in recordable form, any and all agreements, instruments, documents, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">15</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">papers as the Collateral Agent may request to evidence the Collateral Agent&#8217;s Lien on any issued Patent, registered Copyright or registered Trademark or any application therefor owned by such Grantor and the goodwill and general intangibles of such Grantor relating thereto or represented thereby.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commercial Tort Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If such Grantor shall obtain an interest in any Commercial Tort Claim for an amount in excess of $4,000,000 in the aggregate for all such claims, such Grantor shall promptly (and in any event within seven (7) Business Days, or such longer period as the Collateral Agent may agree in its sole discretion, after obtaining such Commercial Tort Claim) notify the Collateral Agent in writing, and upon the request of the Collateral Agent, promptly (and in any event within seven (7) Business Days, or such longer period as the Collateral Agent may agree in its sole discretion, after such request) amend </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and hereby authorizes the Collateral Agent to do such acts or things deemed reasonably necessary or desirable by the Collateral Agent to give the Collateral Agent a first priority (subject only to Permitted Liens) perfected security interest in any such Commercial Tort Claim.  Without limiting the foregoing, such Grantor agrees that the notice described in the first sentence of this Section 4.9 shall constitute the grant to Collateral Agent by such Grantor of a first priority (subject only to Permitted Liens) security interest in the Commercial Tort Claim described therein.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Letter-of-Credit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any Grantor is, now or at any time hereafter, a beneficiary under a letter of credit having a face amount of $6,000,000 or more for all such letters of credit, such Grantor shall promptly (but in any event within seven (7) Business Days, or such longer period as the  Collateral Agent may agree in its sole discretion) notify the Collateral Agent thereof and, at the request and option of the Collateral Agent, such Grantor shall promptly, pursuant to an agreement in form and substance reasonably satisfactory to the Collateral Agent, either (a) arrange for the issuer and any confirmer of such letter of credit to consent to an assignment to the Collateral Agent of the proceeds of the letter of credit, or (b) arrange for the Collateral Agent to become the transferee beneficiary of the letter of credit, with the Collateral Agent agreeing, in each case, that the proceeds of the letter of credit are to be applied as provided in the Credit Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">4.11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Further Assurances&#59; Pledge of Instruments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  At the sole expense of such Grantor and subject to Section 2.2 and the limitations set forth elsewhere herein, such Grantor shall promptly and duly execute and deliver any and all such further instruments and documents and take such further action as the Collateral Agent may reasonably request to obtain the full benefits of this Agreement and of the rights and powers herein granted, which shall in any case include, but shall not be limited to&#58; (a)&#160;using commercially reasonable efforts if reasonably required by the Collateral Agent to secure all consents and approvals necessary or appropriate for the grant of a security interest to the Collateral Agent in any Material Contract held by such Grantor or in which such Grantor has any right or Administrative not heretofore assigned, (b)&#160;authorizing the filing of and delivering and causing to be filed any financing or continuation statements under the UCC with respect to the security interests granted hereby, (c) filing or reasonably cooperating with the Collateral Agent in filing any forms or other documents required to be recorded with the United States Patent and Trademark Office, the United States Copyright Office, (d)&#160;at the Collateral Agent&#8217;s reasonable request, transferring such Grantor&#8217;s Collateral to the Collateral Agent&#8217;s possession (if a security interest in such Collateral can be perfected by possession under the UCC), (e) &#91;reserved&#93; and (f) upon the Collateral Agent&#8217;s reasonable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">16</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">request, executing and delivering or causing to be delivered written notice to insurers of the Collateral Agent&#8217;s security interest in, or claim in or under, any policy of insurance (including unearned premiums).  Such Grantor also hereby authorizes the Collateral Agent to file any such financing or continuation statement.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:9.36pt">  REMEDIAL PROVISIONS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">5.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Certain Matters Relating to Receivables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;padding-left:22.7pt">After the occurrence and during the continuance of an Event of Default, (i) the Collateral Agent shall have the right to make test verifications of the Receivables in any manner and through any medium that it reasonably considers advisable, and each Grantor shall furnish all such assistance and information as the Collateral Agent may require in connection with such test verifications, and (ii) upon the Collateral Agent&#8217;s request and at the expense of the relevant Grantor, such Grantor shall promptly cause independent public accountants or others satisfactory to the Collateral Agent to furnish to the Collateral Agent reports showing reconciliations, aging and test verifications of, and trial balances for, the Receivables.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;padding-left:22.02pt">The Collateral Agent hereby authorizes each Grantor to collect such Grantor&#8217;s Receivables, and the Collateral Agent may curtail or terminate said authorization at any time after the occurrence and during the continuance of an Event of Default.  If required by the Collateral Agent at any time after the occurrence and during the continuance of an Event of Default, any payments of Receivables, when collected by any Grantor, (i)&#160;shall be forthwith (and, in any event, within two (2) Business Days) deposited by such Grantor in the exact form received, duly endorsed by such Grantor to the Collateral Agent if required, in a Collateral Account maintained under the sole dominion and control of the Collateral Agent, subject to withdrawal by the Collateral Agent for the account of the Secured Parties only as provided in Section&#160;5.5, and (ii)&#160;until so turned over, shall be held by such Grantor for the benefit of the Secured Parties, segregated from other funds of such Grantor.  Each such deposit of Proceeds of Receivables shall be accompanied by a report identifying in reasonable detail the nature and source of the payments included in the deposit.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;padding-left:22.7pt">At the Collateral Agent&#8217;s reasonable request after the occurrence and during the continuance of an Event of Default, each Grantor shall promptly deliver to the Collateral Agent all original and other documents evidencing, and relating to, the agreements and transactions which gave rise to the Receivables, including, without limitation, all original orders, invoices and shipping receipts.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">5.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Communications with Obligors&#59; Grantors Remain Liable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;padding-left:22.7pt">The Collateral Agent in its own name, its designee&#8217;s, or in the name of the applicable Grantor may at any time after the occurrence and during the continuance of an Event of Default, or if the Collateral Agent believes, in good faith, that any information as to Receivables provided by such Grantor is incorrect in any material respects communicate with obligors under the Receivables and parties to the Contracts to verify with them to the Collateral Agent&#8217;s satisfaction the existence, amount and terms of any Receivables or Contracts.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;padding-left:22.02pt">Upon the request of the Collateral Agent at any time after the occurrence and during the continuance of an Event of Default, each Grantor shall promptly notify obligors of the Receivables and parties to the Contracts that the Receivables and the Contracts have been assigned to the Collateral Agent for the benefit of the Secured Parties and that payments in respect thereof shall be made directly to the Collateral Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">17</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Anything herein to the contrary notwithstanding, each Grantor shall remain liable under each of the Receivables and Contracts to observe and perform all the conditions and obligations to be observed and performed by it thereunder, all in accordance with the terms of any agreement giving rise thereto.  No Secured Party shall have any obligation or liability under any Receivable (or any agreement giving rise thereto) or Contract by reason of or arising out of this Agreement or the receipt by any Secured Party of any payment relating thereto, nor shall any Secured Party be obligated in any manner to perform any of the obligations of any Grantor under or pursuant to any Receivable (or any agreement giving rise thereto) or Contract, to make any payment, to make any inquiry as to the nature or the sufficiency of any payment received by it or as to the sufficiency of any performance by any party thereunder, to present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been assigned to it or to which it may be entitled at any time or times.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pledged Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Unless an Event of Default shall have occurred and be continuing and such Grantor shall have received prior written notice from the Collateral Agent of its intent to enforce its rights under Section 5.3(b), each Grantor shall be permitted to receive dividends and other distributions in respect of the Pledged Stock and all payments made in respect of the Pledged Notes, in each case paid in the normal course of business or otherwise as a result of the exercise of reasonable business judgment of the relevant Issuer, to the extent permitted by the Credit Agreement, and to exercise all voting and other rights with respect to the Investment Property&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that no vote shall be cast or other organizational right exercised or other action taken which would be inconsistent with or result in any violation of any provision of the Credit Agreement, this Agreement or any other Credit Document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">If an Event of Default shall have occurred and be continuing and the Collateral Agent shall give prior written notice of its intent to exercise such rights to the relevant Grantor or Grantors, (i)&#160;the Collateral Agent shall have the right to receive any and all dividends, payments or other Proceeds paid in respect of the Investment Property and make application thereof to the Secured Obligations in the order set forth in Section&#160;5.02(f) of the Credit Agreement, and (ii)&#160;any or all of the Investment Property shall be registered in the name of the Collateral Agent or its nominee, and the Collateral Agent or its nominee may exercise (1)&#160;all voting, corporate and other rights pertaining to such Investment Property at any meeting of shareholders of the relevant Issuer or Issuers or otherwise and (2)&#160;any and all rights of conversion, exchange and subscription and any other rights, privileges or options pertaining to such Investment Property as if it were the absolute owner thereof (including, without limitation, the right to exchange, at its discretion, any and all of the Investment Property upon the merger, consolidation, reorganization, recapitalization or other fundamental change in the corporate structure of any Issuer, or upon the exercise by any Grantor or the Collateral Agent of any right, privilege or option pertaining to such Investment Property, and in connection therewith, the right to deposit and deliver any and all of the Investment Property with any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as the Collateral Agent may determine), all without liability except to account for property actually received by it, but the Collateral Agent shall have no duty to any Grantor to exercise any such right, privilege or option and shall not be responsible for any failure to do so or delay in so doing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">18</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Each Grantor hereby authorizes and instructs each Issuer of any Investment Property pledged by such Grantor hereunder to (i)&#160;comply with any instruction received by it from the Collateral Agent in writing that (1)&#160;states that an Event of Default has occurred and is continuing and (2)&#160;is otherwise in accordance with the terms of this Agreement, without any other or further instructions from such Grantor, and each Grantor agrees that each Issuer shall be fully protected in so complying and shall have no duty or right to inquire as to the Collateral Agent&#8217;s authority to give such instruction, and (ii)&#160;when required hereby, pay any dividends or other payments with respect to the Investment Property directly to the Collateral Agent.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Proceeds to be Turned Over to Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to the rights of the Collateral Agent specified in Section&#160;5.1 with respect to payments of Receivables, if an Event of Default shall have occurred and be continuing and the Collateral Agent shall so notify the Grantor in question, such Grantor shall immediately comply with Section 8.12(b) of the Credit Agreement for benefit of the Collateral Agent, and all collections on such Receivables shall forthwith (and in any event within two (2) Business Days), upon receipt by such Grantor, be turned over to the Collateral Agent in the exact form received by such Grantor (duly endorsed by such Grantor to the Collateral Agent, if required).  All Proceeds received by the Collateral Agent hereunder shall be held by the Collateral Agent in a Collateral Account maintained under its sole dominion and control.  All Proceeds, while held by the Collateral Agent in a Collateral Account (or by such Grantor for the benefit of the Secured Parties), shall continue to be held as Collateral for all the Secured Obligations and shall not constitute payment thereof until applied as provided in Section&#160;5.5.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Application of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If an Event of Default shall have occurred and be continuing, at the Collateral Agent&#8217;s election, the Collateral Agent may, at any such time, apply all or any part of the Proceeds of Collateral, whether or not held in any Collateral Account, in payment of the Secured Obligations in the order set forth in Section 5.02(f) of the Credit Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">5.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">UCC and Other Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  If an Event of Default shall have occurred and be continuing, the Collateral Agent, on behalf of the Secured Parties, may exercise, in addition to all other rights and remedies granted to them in this Agreement and in any other instrument or agreement securing, evidencing or relating to the Secured Obligations, all rights and remedies of a secured party under the UCC or any other Applicable Law.  Without limiting the generality of the foregoing, the Collateral Agent, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below or as otherwise required herein) to or upon any Grantor or any other Person (all and each of which demands, defenses, advertisements and notices are hereby waived), may in such circumstances forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof, and&#47;or may forthwith sell, lease, assign, give option or options to purchase, or otherwise dispose of and deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker&#8217;s board or office of any Secured Party or elsewhere upon such commercially reasonable terms and conditions as it may deem advisable and at such prices as it may deem best, for cash or on credit, or for future delivery, without assumption of any credit risk.  Any Secured Party shall have the right upon any such public sale or sales, and, to the extent permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">19</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">or equity of redemption in any Grantor, which right or equity is hereby waived and released.  Each Grantor further agrees, at the Collateral Agent&#8217;s request, to assemble the Collateral and make it available to the Collateral Agent at places which the Collateral Agent shall reasonably select, whether at such Grantor&#8217;s premises or elsewhere.  The Collateral Agent shall apply the net proceeds of any action taken by it pursuant to this Section&#160;5.6, after deducting all reasonable costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of the Collateral or in any way relating to the Collateral or the rights of the Secured Parties hereunder, including, without limitation, reasonable attorneys&#8217; fees and disbursements, to the payment in whole or in part of the Secured Obligations in accordance with Section&#160;5.5, and only after such application and after the payment by the Collateral Agent of any other amount required by any provision of law, including, without limitation, Section&#160;9-615(a)(3) of the UCC, need the Collateral Agent account for the surplus, if any, to any Grantor.  Each Grantor hereby acknowledges that the Secured Obligations arose out of a commercial transaction, and agrees that if an Event of Default shall have occurred and be continuing, Collateral Agent shall have the right to an immediate writ of possession without notice of a hearing.  Collateral Agent shall have the right to the appointment of a receiver for the properties and assets of each Grantor, and each Grantor hereby consents to such rights and such appointment and hereby waives any objection such Grantor may have thereto or the right to have a bond or other security posted by Collateral Agent.  To the extent permitted by Applicable Law, each Grantor waives all claims, damages and demands it may acquire against any Secured Party arising out of the exercise by them of any rights hereunder.  If any notice of a proposed sale or other disposition of Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least ten (10) days before such sale or other disposition.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">5.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Sales of Pledged Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:22.7pt">Each Grantor recognizes that the Collateral Agent may be unable to effect a public sale of any or all the Pledged Stock, by reason of certain prohibitions contained in the Securities Act and applicable state securities laws or otherwise, and may be compelled to resort to one or more private sales thereof to a restricted group of purchasers which will be obliged to agree, among other things, to acquire such securities for their own account for investment and not with a view to the distribution or resale thereof.  Each Grantor acknowledges and agrees that any such private sale may result in prices and other terms less favorable than if such sale were a public sale and, notwithstanding such circumstances, agrees that selling collateral in a private sale as opposed to a public sale shall not be deemed to make such sale other than in a commercially reasonable manner.  The Collateral Agent shall be under no obligation to delay a sale of any of the Pledged Stock for the period of time necessary to permit the Issuer thereof to register such securities for public sale under the Securities Act, or under applicable state securities laws, even if such Issuer would agree to do so.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:22.02pt">Each Grantor agrees to use commercially reasonable efforts to promptly do or cause to be done all such other acts requested by the Collateral Agent as may be necessary to make such sale or sales of all or any portion of the Pledged Stock pursuant to this Section&#160;5.7 valid and binding and in compliance with any and all other Applicable Laws.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver&#59; Deficiency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Grantor shall remain liable for any deficiency if the proceeds of any sale or other disposition of the Collateral are insufficient to pay the Secured Obligations and the fees and disbursements of any attorneys employed by any Secured Party to collect such deficiency.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">20</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grant of License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the purpose of enabling the Collateral Agent to exercise the rights and remedies under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> at such time as the Collateral Agent shall be lawfully entitled to exercise such rights and remedies (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, convey, transfer or grant options to purchase any Collateral), and only during the continuance of an Event of Default, each Grantor hereby (a) grants to the Collateral Agent, for the benefit of the Collateral Agent and the other Secured Parties, an irrevocable (during the term of this Agreement), non-exclusive worldwide license (exercisable  only during the continuance of an Event of Default and without payment of royalty or other compensation to any Grantor) in Intellectual Property included in the Collateral, including in such license the right to use, license, sublicense or practice any such Intellectual Property or any Permit now owned or hereafter acquired by such Grantor, and wherever the same may be located, and including in such license access to all media in which any of the licensed items may be recorded or stored and to all Software and programs used for the compilation or printout thereof (provided that, with respect to Software and programs owned by a third party and licensed to such Grantor, such access is not prohibited under the applicable license agreement between such third party and such Grantor) and (b) irrevocably agrees that the Collateral Agent may (in its own name or with the name of Grantor) sell any of such Grantor&#8217;s Inventory directly to any person, including without limitation persons who have previously purchased such Grantor&#8217;s Inventory from such Grantor and in connection with any such sale or other enforcement of the Collateral Agent&#8217;s rights under this Security Agreement, may sell Inventory which bears any Trademark owned by or licensed to such Grantor and any Inventory that is covered by any Copyright owned by or licensed to such Grantor or any Inventory or Permit and the Collateral Agent may (but shall have no obligation to)  finish any work in process and affix any Trademark owned by or licensed to such Grantor and sell such Inventory as provided herein&#59; provided, however, that nothing in this Section 5.9 shall require a Grantor to grant any license that is prohibited by any rule of law, statute or regulation or is prohibited by, or constitutes a breach or default under or results in the termination of or gives rise to any right of acceleration, modification or cancellation under any contract, license, agreement, instrument or other document evidencing, giving rise to a right to use or therefore granted with respect to such property&#59; provided, further, that such licenses granted hereunder with respect to Trademarks shall be subject to the maintenance of quality standards with respect to the goods and services on which such Trademarks are used sufficient to preserve the validity of such Trademarks.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">  THE COLLATERAL AGENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Collateral Agent&#8217;s Appointment as Attorney-in-Fact, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Each Grantor hereby irrevocably appoints the Collateral Agent and any officer or agent thereof, with full power of substitution, as its true and lawful attorney-in-fact with full irrevocable power and authority in the place and stead of such Grantor and in the name of such Grantor or in its own name, for the purpose of carrying out the terms of this Agreement, to take any and all appropriate action and to execute any and all documents and instruments which may be necessary or desirable to accomplish the purposes of this Agreement, and, without limiting the generality of the foregoing, each Grantor hereby gives the Collateral Agent the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">21</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">power and right, on behalf of such Grantor, without notice to or assent by such Grantor, to do any or all of the following actions upon the occurrence and during the continuation of any Event of Default, in each case at the Collateral Agent&#8217;s sole option until the Termination Date&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">in the name of such Grantor or its own name, or otherwise, take possession of and endorse and collect any checks, drafts, notes, acceptances or other instruments for the payment of moneys due under any Receivable or Contract or with respect to any other Collateral and file any claim or take any other action or proceeding in any court of law or equity or otherwise deemed appropriate by the Collateral Agent for the purpose of collecting any and all such moneys due under any Receivable or Contract or with respect to any other Collateral whenever payable&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">to enforce all of such Grantor&#8217;s rights under and pursuant to all agreements with respect to the Collateral, all for the sole benefit of the Collateral Agent (for the benefit of the Secured Parties) as contemplated hereby and under the other Credit Documents and to enter into such other agreements as may be necessary or appropriate in the judgment of the Collateral Agent&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">in the case of any Intellectual Property that constitutes Collateral, execute and deliver, and have recorded, any and all agreements, instruments, documents and papers as the Collateral Agent may reasonably request to evidence the Secured Parties&#8217; security interest in such Intellectual Property and the goodwill and general intangibles of such Grantor relating thereto or represented thereby&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">pay or discharge taxes and Liens levied or placed on or threatened against the Collateral, effect any repairs to the Collateral and obtain any insurance called for by the terms of this Agreement and pay all or any part of the premiums therefor and the costs thereof, which amounts shall constitute Secured Obligations&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">execute, in connection with any sale provided for in Sections&#160;5.6 or 5.7, any endorsements, assignments or other instruments of conveyance or transfer with respect to the Collateral&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">(1)&#160;direct any party liable for any payment under any of the Collateral to make payment of any and all moneys due or to become due thereunder directly to the Collateral Agent or as the Collateral Agent shall direct&#59; (2)&#160;ask or demand for, collect, and receive payment of and receipt for, any and all moneys, claims and other amounts due or to become due at any time in respect of or arising out of any Collateral&#59; (3)&#160;sign and endorse any invoices, freight or express bills, bills of lading, storage or warehouse receipts, drafts against debtors, assignments, verifications, notices and other documents in connection with any of the Collateral&#59; (4)&#160;commence and prosecute any suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect the Collateral or any portion thereof and to enforce any other right in respect of any Collateral&#59; (5)&#160;defend any suit, action or proceeding brought against such Grantor with respect to any Collateral&#59; (6)&#160;settle, compromise or adjust any such suit, action or proceeding and, in connection therewith, give such discharges or releases as the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">22</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Collateral Agent may deem appropriate&#59; (7)&#160;assign any Copyright, Patent or Trademark that constitutes Collateral (along with the goodwill of the business to which any such Copyright, Patent or Trademark pertains), throughout the world for such term or terms, on such conditions, and in such manner, as the Collateral Agent shall in its sole discretion determine&#59; (8) perform any obligations of any Grantor under any Contract&#59; and (9)&#160;generally, sell, transfer, pledge and make any agreement with respect to or otherwise deal with any of the Collateral as fully and completely as though the Collateral Agent were the absolute owner thereof for all purposes, and do, at the Collateral Agent&#8217;s option and such Grantor&#8217;s expense, at any time, or from time to time, all acts and things which the Collateral Agent deems necessary to protect, preserve or realize upon the Collateral and the Secured Parties&#8217; security interests therein and to effect the intent of this Agreement, all as fully and effectively as such Grantor might do&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">to execute such other and further mortgages, pledges and assignments of the Collateral, and related instruments or agreements, as the Collateral Agent may reasonably require for the purpose of perfecting, protecting, maintaining or enforcing the security interests granted to the Collateral Agent (for the benefit of the Secured Parties) hereunder and under the other Credit Documents. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If any Grantor fails to perform or comply with any of its agreements contained herein or in any other Credit Document and an Event of Default is continuing, the Collateral Agent, at its option, but without any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The expenses of the Collateral Agent incurred in connection with actions undertaken as provided in this Section&#160;6.1, shall be payable by such Grantor to the Collateral Agent within ten (10) Business Days after written demand.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Each Grantor hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue hereof.  All powers, authorizations and agencies contained in this Agreement are coupled with an interest and are irrevocable until this Agreement is terminated and the security interests created hereby are released.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Duty of Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Collateral Agent&#8217;s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession, under Section&#160;9-207 of the UCC or otherwise, shall be to deal with it in the same manner as the Collateral Agent deals with similar property for its own account.  No Secured Party nor any of their respective officers, directors, employees or agents shall be liable for failure to demand, collect or realize upon any of the Collateral or for any delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or any other Person or to take any other action whatsoever with regard to the Collateral or any part thereof.  The powers conferred on the Secured Parties hereunder are solely to protect the Secured Parties&#8217; interests in the Collateral and shall not impose any duty upon any Secured Party to exercise any such powers.  The Secured Parties shall be accountable only for amounts that they actually receive as a result of the exercise of such powers, and neither they nor any of their officers, directors, employees or agents shall be responsible to any Grantor for any act or failure to act hereunder, except for their own gross negligence or willful misconduct.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">23</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Pursuant to any Applicable Law, each Grantor authorizes the Collateral Agent to file or record financing statements and other filing or recording documents or instruments with respect to the Collateral in such form and in such offices as the Collateral Agent determines appropriate to perfect the security interests of the Collateral Agent under this Agreement.  Each Grantor authorizes the Collateral Agent to use the collateral description &#8220;all personal property&#8221;, &#8220;all assets&#8221; or words of similar effect, regardless of whether any particular asset comprised in the Collateral falls within the scope of Article 9 of the UCC or the Uniform Commercial Code of any other applicable state, in any such financing statements.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authority of Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Grantor acknowledges that the rights and responsibilities of the Collateral Agent under this Agreement with respect to any action taken by the Collateral Agent or the exercise or non-exercise by the Collateral Agent of any option, voting right, request, judgment or other right or remedy provided for herein or resulting or arising out of this Agreement shall, as between the Secured Parties, be governed by the Credit Agreement and by such other agreements with respect thereto as may exist from time to time among them, but, as between the Collateral Agent and the Grantors, the Collateral Agent shall be conclusively presumed to be acting as agent for the Secured Parties with full and valid authority so to act or refrain from acting, and no Grantor shall be under any obligation, or entitlement, to make any inquiry respecting such authority.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">MISCELLANEOUS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Amendments in Writing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  None of the terms or provisions of this Agreement may be waived, amended, supplemented or otherwise modified except in accordance with Section&#160;12.01 of the Credit Agreement&#59; provided that the Schedules to this Agreement may be amended or supplemented by any Grantor at any time by delivering such amended or supplemented schedule to the Collateral Agent.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All notices, requests and demands to or upon the Collateral Agent or any Grantor hereunder shall be effected in the manner provided for in Section&#160;12.02 of the Credit Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">No Waiver by Course of Conduct&#59; Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Secured Party shall by any act (except by a written instrument pursuant to Section&#160;7.1), delay, indulgence, omission or otherwise be deemed to have waived any right or remedy hereunder or to have acquiesced in any Default or Event of Default.  No failure to exercise, nor any delay in exercising, on the part of any Secured Party, any right, power or privilege hereunder shall operate as a waiver thereof.  No single or partial exercise of any right, power or privilege hereunder shall preclude any other or further exercise thereof or the exercise of any other right, power or privilege.  A waiver by any Secured Party of any right or remedy hereunder on any one occasion shall not be construed as a bar to any right or remedy which such Secured Party would otherwise have on any future occasion.  The rights and remedies herein provided are cumulative, may be exercised singly or concurrently and are not exclusive of any other rights or remedies provided by law.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be binding upon the successors and assigns of each Grantor and shall inure to the benefit of the Collateral Agent and the other Secured Parties and their successors and assigns&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that no Grantor may assign, transfer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">24</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or delegate any of its rights or obligations under this Agreement without the prior written consent of the Collateral Agent.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Set-Off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Grantor hereby irrevocably authorizes the Collateral Agent and each Secured Party at any time and from time to time after the occurrence and during the continuance of an Event of Default, upon any amount becoming due and payable by such Grantor hereunder (whether at the stated maturity, by acceleration or otherwise), to set-off and appropriate and apply against such amount any and all deposits (general or special, time or demand, provisional or final), in any currency, and any other credits, indebtedness or claims, in any currency, in each case whether direct or indirect, absolute or contingent, matured or unmatured, at any time held or owing by such Secured Party to or for the credit or the account of such Grantor, or any part thereof in such amounts as the Collateral Agent or such Secured Party may elect, against and on account of the obligations and liabilities of such Grantor to the Collateral Agent or such Secured Party hereunder and claims of every nature and description of the Collateral Agent or such Secured Party against such Grantor, in any currency, whether arising hereunder, under the Credit Agreement, any other Credit Document or otherwise, as the Collateral Agent or such Secured Party may elect, whether or not any Secured Party has made any demand for payment and although such obligations, liabilities and claims may be contingent or unmatured.  Each Secured Party, or Collateral Agent on their behalf, shall notify such Grantor promptly of any such set-off and the application made by such Secured Party of the proceeds thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the failure to give such notice shall not affect the validity of such set-off and application.  The rights of each Secured Party under this Section 7.5 are in addition to other rights and remedies (including, without limitation, other rights of set-off) which such Secured Party may have and are subject to any applicable limitations set forth in the Credit Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy, PDF and&#47;or in any other electronic form), and all of said counterparts taken together shall be deemed to constitute one and the same instrument.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Section Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Section headings used in this Agreement are for convenience of reference only and are not to affect the construction hereof or be taken into consideration in the interpretation hereof.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the other Credit Documents represent the entire agreement of the Grantors and the Secured Parties with respect to the subject matter hereof and thereof, and there are no promises, undertakings, representations or warranties by any party hereto relative to the subject matter hereof and thereof not expressly set forth or referred to herein or in the other Credit Documents.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">25</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt;text-decoration:underline">GOVERNING LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.  THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW&#160;YORK.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Submission To Jurisdiction&#59; Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each party hereto hereby irrevocably and unconditionally&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">submits for itself and its property in any legal action or proceeding relating to this Agreement and the other Credit Documents to which it is a party, or for recognition and enforcement of any judgment in respect thereof, to the non-exclusive general jurisdiction of the courts of the State of New&#160;York sitting in New York County, the courts of the United&#160;States District Court for the Southern District of New&#160;York, and appellate courts from any thereof&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">consents that any such action or proceeding may be brought in such courts and waives any objection that it may now or hereafter have to the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court, and agrees not to plead or claim the same&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or any substantially similar form of mail), postage prepaid, to such party at the address provided for in Section&#160;7.2&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right to sue in any other jurisdiction&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">waives, to the maximum extent not prohibited by law, any right it may have to claim or recover in any legal action or proceeding referred to in this Section 7.11 any special, exemplary, punitive or consequential damages.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each party hereto hereby acknowledges that&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Credit Documents to which it is a party&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">no Secured Party has any fiduciary relationship with or duty to any Grantor arising out of or in connection with this Agreement or any of the other Credit Documents, and the relationship between the Grantors, on the one hand, and the Secured Parties, on the other hand, in connection herewith or therewith is solely that of debtor and creditor&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">no joint venture is created hereby or by the other Credit Documents or otherwise exists by virtue of the transactions contemplated hereby among the Secured Parties or among the Grantors and the Secured Parties.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Additional Grantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Subsidiary of any Credit Party that is required to become a party to this Agreement pursuant to Section&#160;8.11 of the Credit Agreement shall become a Grantor for all purposes of this Agreement upon execution and delivery by such Subsidiary of an Assumption Agreement in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annex&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Assumption Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">26</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Releases of Guarantees and Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Notwithstanding anything to the contrary contained herein or in any other Credit Document, the Collateral Agent is hereby irrevocably authorized by each Secured Party (without requirement of notice to or consent of any Secured Party except as expressly required by Section 12.01 of the Credit Agreement) to take any action requested by the Grantor having the effect of releasing any Collateral or guarantee obligations (i) to the extent necessary to permit consummation of any transaction not prohibited by any Credit Document or that has been consented to in accordance with Section 12.01 of the Credit Agreement, or (ii) under the circumstances described in paragraph (b) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">On the Termination Date, the Collateral shall be released from the Liens created by this Agreement and the other Security Documents, and this Agreement and the other Security Documents and all obligations (other than Unasserted Contingent Obligations) of the Collateral Agent and each Grantor under this Agreement and the other Security Documents shall terminate, all without delivery of any instrument or performance of any act by any Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In each case as specified in this Section 7.14, the Collateral Agent will (and each Lender irrevocably authorizes and directs the Collateral Agent to), at the Grantors&#8217; request and expense, (i) execute and deliver any termination statements, lien releases, discharges of security interests, and other similar discharge or release documents (and, if applicable, in recordable form) as are reasonably necessary to release, as of record, the Collateral Agent&#8217;s Liens and all notices of security interests and liens previously filed by the Collateral Agent and (ii) deliver all possessory collateral in the Collateral Agent&#8217;s possession, custody or control to the Administrative Borrower (or the Administrative Borrower&#8217;s designee), and (iii) execute and deliver to the applicable Credit Party such other documents as such Credit Party may reasonably request to evidence the release of such item of Collateral or obligation from the assignment, lien or security interest granted under the Security Documents, in each case in accordance with the terms of the Credit Documents and this Section 7.14.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">WAIVER OF JURY TRIAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.  EACH GRANTOR AND, BY ACCEPTANCE OF THE BENEFITS HEREOF, THE COLLATERAL AGENT AND EACH SECURED PARTY, HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER CREDIT DOCUMENT AND FOR ANY COUNTERCLAIM THEREIN.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page Follows.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">27</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i76b155cfa72c4ca9928458431bbb7d63_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, each of the undersigned has caused this Security Agreement to be duly executed and delivered as of the date first above written.</font></div><div style="margin-bottom:0.12pt;padding-left:243.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.620%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EVOLENT HEALTH, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EVOLENT HEALTH, LLC</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EH HOLDING COMPANY, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NCIS HOLDINGS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NCH MANAGEMENT SYSTEMS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Security Agreement&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:243.9pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:243.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.620%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EVOLENT CARE PARTNERS HOLDING COMPANY, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EVOLENT CARE PARTNERS OF TEXAS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">VITAL DECISIONS ACQUISITION LLC</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">VITAL DECISIONS LLC</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">THE ACCOUNTABLE CARE ORGANIZATION LTD.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div></td></tr></table></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:243.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.620%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EVOLENT CARE PARTNERS OF NORTH CAROLINA, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">MTS III VITAL DECISIONS BLOCKER CORP</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">TPG GROWTH ICEMAN PARENT, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ENDZONE MERGER SUB, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">TPG GROWTH ICEMAN INTERMEDIATE, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:243.9pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:243.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.620%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">IMPLANTABLE PROVIDER GROUP, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">SURGICAL COLLECTIONS GROUP, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Jonathan Weinberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Secretary</font></div></td></tr></table></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ACCEPTED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,<br>a Delaware limited partnership </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Ryan T. Magee&#160;&#160;&#160;&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Ryan T. Magee</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i76b155cfa72c4ca9928458431bbb7d63_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PLEDGED NOTES</font></div><div style="margin-bottom:0.12pt;padding-left:32.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.029%"><tr><td style="width:1.0%"></td><td style="width:30.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Name of Pledgor</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Name of Note Issuer</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Maturity<br>Date</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Evolent Health LLC</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NCIS Holdings, Inc.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$73.4M</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10&#47;1&#47;25</font></td></tr></table></div><div style="margin-bottom:24pt"><font><br></font></div><div style="margin-bottom:24pt"><font><br></font></div><div style="margin-bottom:24pt;text-align:right"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div></div><div id="i76b155cfa72c4ca9928458431bbb7d63_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:36pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LEGAL NAME&#59; JURISDICTION OF ORGANIZATION&#59; CHIEF EXECUTIVE OFFICE</font></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.993%"><tr><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.709%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Name of Grantor</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Organization</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Organizational Number</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Office</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5657253</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800 N. Glebe Rd., Suite 500<br>Arlington, VA 22203</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Limited liability company</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5021826</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800 N. Glebe Rd., Suite 500<br>Arlington, VA 22203</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Holding Company, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6514819</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800 N. Glebe Rd., Suite 500<br>Arlington, VA 22203</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NCIS Holdings, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4811737</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">675 Placentia Ave, Suite 300, Brea, CA 92821</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NCH Management Systems, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C2373483</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">675 Placentia Ave, Suite 300, Brea, CA 92821</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners Holding Company, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7650527</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800 N. Glebe Rd., Suite 500<br>Arlington, VA 22203</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners of Texas, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0803442698</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800 N. Glebe Rd., Suite 500<br>Arlington, VA 22203</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vital Decisions Acquisition LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Limited liability company</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5246730</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">379 Thornall Street, 3rd Floor, Edison, NJ 08837</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vital Decisions LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Limited liability company</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New Jersey</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0600110734</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">379 Thornall Street, 3rd Floor, Edison, NJ 08837</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Accountable Care Organization Ltd</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Michigan</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800764203</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800 N. Glebe Rd., Suite 500<br>Arlington, VA 22203</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.993%"><tr><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.709%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners of North Carolina, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">North Carolina</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2068344</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800 N. Glebe Rd., Suite 500<br>Arlington, VA 22203</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MTS III Vital Decisions Blocker Corp</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5251692</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800 N. Glebe Rd., Suite 500<br>Arlington, VA 22203</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TPG Growth Iceman Parent, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5306751</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">2300 Lakeview Parkway</font></div><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Suite 500</font></div><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alpharetta, GA 30009</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TPG Growth Iceman Intermediate, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5306923</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">2300 Lakeview Parkway</font></div><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Suite 500</font></div><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alpharetta, GA 30009</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Implantable Provider Group, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4790471</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">2300 Lakeview Parkway</font></div><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Suite 500</font></div><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alpharetta, GA 30009</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Surgical Collections Group, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6243507</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">2300 Lakeview Parkway</font></div><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Suite 500</font></div><div style="margin-bottom:6pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alpharetta, GA 30009</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Endzone Merger Sub, Inc.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporation</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6835330</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800 N. Glebe Rd., Suite 500, Arlington, VA 22203</font></td></tr></table></div><div style="margin-bottom:36pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:36pt;text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:36pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FILINGS AND OTHER ACTIONS<br>REQUIRED TO PERFECT SECURITY INTERESTS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">UCC Filings</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grantor</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdictions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Holding Company, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NCIS Holdings, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NCH Management Systems, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners Holding Company, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners of Texas, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vital Decisions Acquisition LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vital Decisions LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Accountable Care Organization Ltd.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Michigan</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners of North Carolina, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">North Carolina</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MTS III Vital Decisions Blocker Corp.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TPG Growth Iceman Parent, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TPG Growth Iceman Intermediate, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Implantable Provider Group, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Surgical Collections Group, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Endzone Merger Sub, Inc.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patent and Trademark Filings</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IP Security Agreements on IP listed on Schedule 5 hereto will be filed with USPTO.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">PLEDGED STOCK</font></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d0cece;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grantor</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(Pledgor)</font></div></td><td colspan="3" style="background-color:#d0cece;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issuer of Pledged Stock</font></td><td colspan="3" style="background-color:#d0cece;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Number of Shares&#47;Units</font></td><td colspan="3" style="background-color:#d0cece;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Class of Interests</font></td><td colspan="3" style="background-color:#d0cece;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Percentage of Class Owned</font></td><td colspan="3" style="background-color:#d0cece;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Percentage of Class Pledged</font></td><td colspan="3" style="background-color:#d0cece;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Certificate No(s).</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Units</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Holding Company, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NCIS Holdings, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NCIS Holdings, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NCH Management Systems, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners Holding Company, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners Holding Company, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners of Texas, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners Holding Company, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Accountable Care Organization Ltd</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners Holding Company, Inc.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Care Partners of North Carolina, Inc.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Assurance Solutions LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MTS III Vital Decisions Blocker Corp</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MTS III Vital Decisions Blocker Corp</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vital Decisions Acquisition LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vital Decisions Acquisition LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vital Decisions LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Evolent Health LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TPG Growth Iceman Parent, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TPG Growth Iceman Parent, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TPG Growth Iceman Intermediate, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TPG Growth Iceman Intermediate, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Implantable Provider Group, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Implantable Provider Group, Inc.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Surgical Collections Group, Inc.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr></table></div><div style="margin-bottom:36pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i76b155cfa72c4ca9928458431bbb7d63_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I.&#160;&#160;&#160;&#160;Copyrights and Copyright Licenses&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">None</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">II.&#160;&#160;&#160;&#160;Patents, Patent Applications and Patent Licenses&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">None</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">III.&#160;&#160;&#160;&#160;Trademarks, Trademark Applications and Trademark Licenses&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 23.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td><td colspan="3" style="background-color:#c0c0c0;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:44.95pt;padding-right:44.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:124%">MARK</font></div></td><td colspan="3" style="background-color:#c0c0c0;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 20.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COUNTRY</font></td><td colspan="3" style="background-color:#c0c0c0;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 2.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SERIAL NO.</font></td><td colspan="3" style="background-color:#c0c0c0;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:0.62pt;padding-right:0.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">REG DATE </font></div></td><td colspan="3" style="background-color:#c0c0c0;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:0.62pt;padding-right:0.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">REG. NO. </font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Evolent Health LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ABOVEHEALTH</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:16.57pt;padding-right:16.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%">75705146</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%">Dec 16, 2003</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%">2795110</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Evolent Health LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ACCELEHEALTH</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:16.57pt;padding-right:16.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">76593378</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Sep 20, 2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">2996693</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Evolent Health LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EVOLENT</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:16.57pt;padding-right:16.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">85444384</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Apr 23,2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4325213</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Evolent Health LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EVOLENT HEALTH</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:16.57pt;padding-right:16.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">86464635</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">Mar 8, 2016</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">4972079</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Evolent Health LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SHOP2MANAGE</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:16.57pt;padding-right:16.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">86623596</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Oct 25 2016</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">5069535</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Evolent Health LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">VISION</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:16.57pt;padding-right:16.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">86750084</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Dec 31, 2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">5950385</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Evolent Health LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">VMINE</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:16.57pt;padding-right:16.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">86750062</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Aug 20, 2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">5839929</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Evolent Health LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">VQUEST</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:16.57pt;padding-right:16.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">86750087</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Dec 17, 2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">5938234</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%">NCH Management Systems, Inc. (DBA New Century Health)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 11.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NEW CENTURY HEALTH</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%">USA</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%">85505343</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Apr 8, 2014</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4508817</font></div></td></tr></table></div><div style="height:87.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">NCH Management Systems, Inc. (DBA New Century Health)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NEW CENTURY HEALTH and design</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">85492236</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Apr 29, 2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4519879</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Vital Decisions, LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">VITAL DECISIONS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">77750195</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Dec 29, 2009</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">3731263</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Vital Decisions, LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MY Living Voice</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">90657422</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">N&#47;A</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">N&#47;A</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Vital Decisions, LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Living voice</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">86546894</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Apr 19, 2016</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4942693</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Vital Decisions, LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Express your values to Make Medical care Personal again</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">87006286</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Nov 29, 2016</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">5090641</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Vital Decisions, LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Advanced Care Alignment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">June 2, 2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">6071289</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Implantable Provider Group, Inc.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IPG and design</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">88470282</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">December 24, 2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">5944075</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Implantable Provider Group, Inc.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IPG</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">85690980</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">September 30, 2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4614271</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Implantable Provider Group, Inc.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IPG and design</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">September 30, 2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4614270</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Implantable Provider Group, Inc.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IPG DEVICE BENEFIT MANAGEMENT</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">September 9, 2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4599546</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Implantable Provider Group, Inc.</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IPG INTEGRATED SURGICAL SOLUTIONS</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">87713983</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">June 30, 2020</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">6088075</font></div></td></tr></table></div><div style="height:87.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Implantable Provider Group, Inc.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IPG PATHFINDER 360</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">85960626</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">January 21, 2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4470517</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.45pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Implantable Provider Group, Inc.</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MYSURGPRO</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">USA</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">88170423</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">January 14, 2020</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.67pt;padding-right:2.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">5962713</font></div></td></tr></table></div><div style="margin-bottom:24pt;text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COMMERCIAL TORT CLAIMS</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">None.</font></div><div style="height:87.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i76b155cfa72c4ca9928458431bbb7d63_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Annex I<br>to<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Security Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ASSUMPTION AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Assumption Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), dated as of ________________,&#160;20__, made by __________________, a ___________ corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Additional Grantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in favor of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) acting pursuant to this Assumption Agreement for the benefit of the Secured Parties (as defined in the Credit Agreement referred to below).  All capitalized terms not defined herein shall have the meaning ascribed to them in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, reference is made to that certain Credit Agreement, dated as of December 30, 2019 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited liability company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), its Subsidiaries signatory thereto as guarantors or hereafter designated as Guarantors pursuant to Section 8.11 of the Credit Agreement, the lenders from time to time party thereto (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Collateral Agent and the Administrative Agent&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, in connection with the Credit Agreement, the Credit Parties (other than the Additional Grantor) have entered into the Security Agreement, dated as of December 30, 2019 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in favor of the Collateral Agent, for the benefit of the Secured Parties&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Credit Agreement requires the Additional Grantor to become a party to the Security Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Additional Grantor has agreed to execute and deliver this Assumption Agreement in order to become a party to the Security Agreement&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, IT IS AGREED&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  By executing and delivering this Assumption Agreement, the Additional Grantor, as provided in Section&#160;7.13 of the Security Agreement, hereby becomes a party to the Security Agreement as a Grantor thereunder with the same force and effect as if originally named therein as a Grantor and, without limiting the generality of the foregoing, hereby (a) grants, pledges, collaterally assigns and transfers to the Collateral Agent, and hereby grants to the Collateral Agent, for the benefit of the Secured Parties and their </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">respective successors, indorsees, transferees and assigns, a security interest in the Collateral (as defined in the Security Agreement), as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration, mandatory prepayment or otherwise) of its Secured Obligations, and (b) expressly assumes all obligations and liabilities of a Grantor thereunder.  The information set forth in Annex&#160;1-A hereto is hereby added to the information set forth in Schedule&#91;s&#93; &#91;___&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to the Security Agreement.  The Additional Grantor hereby represents and warrants that, with respect to the Additional Grantor, each of the representations and warranties contained in Section 3 of the Security Agreement is true and correct on and as the date hereof (after giving effect to this Assumption Agreement) as if made on and as of such date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">GOVERNING LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.  THIS ASSUMPTION AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW&#160;YORK.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">No Novation or Release.  Nothing in this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Assumption Agreement shall be construed to release any other Grantor at any time party to the Security Agreement from its obligations and liabilities thereunder or otherwise affect any of such other Grantor&#8217;s obligations or liabilities under any Credit Document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned has caused this Assumption Agreement to be duly executed and delivered as of the date first above written.</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;ADDITIONAL GRANTOR&#93;,<br>a ______________________</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Refer to each Schedule which needs to be supplemented.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">Annex I - 2</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annex 1-A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;INSERT INFORMATION TO BE ADDED TO<br>THE APPLICABLE SECURITY AGREEMENT SCHEDULES&#93; </font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">Annex I - 3</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>6
<FILENAME>a2022q2form10qex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i70d302b3a680472685783a38b28d0718_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div><div style="margin-bottom:0.12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Execution Version</font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GUARANTEE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GUARANTEE AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), dated as of August 1, 2022, made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Guarantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in favor of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARES CAPITAL CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Maryland corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Ares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited partnership (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ACF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as collateral agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and as revolver agent for the Revolving Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolver Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, and together with the Administrative Agent and Collateral Agent, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">acting pursuant to this Guarantee for the benefit of the Secured Parties.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">W I T N E S E T H&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, pursuant to the Credit Agreement, dated as of the date hereof (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> EVOLENT HEALTH LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Evolent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, ENDZONE MERGER SUB, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Endzone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which upon consummation of the TPG Acquisition (as defined in the Credit Agreement) will be merged with and into </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TPG GROWTH ICEMAN PARENT, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> IMPLANTABLE PROVIDER GROUP, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Implantable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, collectively with Evolent, Endzone and TPG, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Subsidiaries signatory thereto as guarantors or hereafter designated as Guarantors pursuant to Section 8.11 of the Credit Agreement, the lenders from time to time party thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Agents,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Lenders have severally agreed to make Loans and other financial accommodations to the Borrowers upon the terms and subject to the conditions set forth therein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Borrowers are members of an affiliated group of companies and each Guarantor is either the direct parent or a Subsidiary of a Borrower&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the proceeds of the Loans and other financial accommodations under the Credit Agreement will be used as permitted thereunder&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Borrowers and the other Guarantors are engaged in related businesses, and each Guarantor will derive substantial direct and indirect benefits from the making of the Loans and other financial accommodations under the Credit Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, it is a condition precedent to the obligation of the Lenders to make and continue making their respective Loans and other financial accommodations to the Borrowers under the Credit Agreement that the Guarantors shall have executed and delivered this Guarantee to the Agents for the benefit of the Secured Parties&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of these premises and to induce the Lenders to make and continue making their respective Loans and other financial accommodations to the Borrowers under the Credit Agreement, each Guarantor hereby agrees with the Agents, for the benefit of the Secured Parties, as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">  DEFINITIONS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise defined herein, terms defined in the Credit Agreement or the Security Agreement and used herein shall have the meanings given to them in the Credit Agreement or the Security Agreement, as applicable.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Other Definitional Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  (a)&#160;The words &#8220;hereof,&#8221; &#8220;herein&#8221;, &#8220;hereto&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Guarantee shall refer to this Guarantee as a whole and not to any particular provision of this Guarantee, and Section and Schedule references are to this Guarantee unless otherwise specified.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">  GUARANTEE</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  (a)&#160;Each of the Guarantors hereby, jointly with the other Guarantors and severally, absolutely, unconditionally and irrevocably guarantees, as primary obligor and not merely as surety, to the Agents for the benefit of the Secured Parties and their respective successors, indorsees, transferees and assigns, the prompt and complete payment and performance by the Borrowers when due (whether at the stated maturity, by acceleration, mandatory prepayment or otherwise) of the Guaranteed Obligations.  For purposes hereof, &#8220;Guaranteed Obligations&#8221; means the unpaid &#8220;Obligations&#8221; (as defined under the Credit Agreement), including, without limitation, interest accruing at the then applicable rate provided in the Credit Agreement after the maturity thereof and interest accruing at the then applicable rate provided in the Credit Agreement after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or like proceeding, relating to any Borrower, whether or not a claim for post-filing or post-petition interest is allowed in such proceeding, whether direct or indirect, absolute or contingent, due or to become due, or now existing or hereafter incurred, which may arise under, out of, or in connection with, the Credit Agreement, the Security Agreement or any other Credit Document, in each case whether on account of principal, interest, reimbursement obligations, any prepayment premium, fees, indemnities, costs, expenses or otherwise (including, without limitation, all reasonable and documented fees and disbursements of counsel to the Agents or to the other Secured Parties that are required to be paid by the Borrowers pursuant to the terms of any of the foregoing agreements).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Anything herein or in any other Credit Document to the contrary notwithstanding, the maximum liability of each Guarantor hereunder and under the other Credit Documents shall in no event exceed the amount which can be guaranteed by such Guarantor under applicable federal and state laws, including, without limitation, those federal and state laws relating to the insolvency of debtors (after giving effect to the right of contribution established in Section 2.2 herein).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">2</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Each Guarantor agrees that the Guaranteed Obligations may at any time and from time to time exceed the amount of the liability of such Guarantor hereunder without impairing this Guarantee or affecting the rights and remedies of any Secured Party hereunder.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">This Guarantee shall remain in full force and effect until the Termination Date (as defined in the Security Agreement) occurs, notwithstanding that from time to time during the term of the Credit Agreement no Guaranteed Obligations may be outstanding.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">No payment made by any of the Borrowers, any of the Guarantors or any other Person or received or collected by any Secured Party from any of the Borrowers, any of the Guarantors or any other Person by virtue of any action or proceeding or any set-off or appropriation or application at any time or from time to time in reduction of or in payment of the Guaranteed Obligations shall be deemed to modify, reduce, release or otherwise affect the liability of any Guarantor hereunder which shall, notwithstanding any such payment (other than any payment made by such Guarantor in respect of the Guaranteed Obligations or any payment received or collected from such Guarantor in respect of the Guaranteed Obligations), remain liable for the Guaranteed Obligations up to the maximum liability of such Guarantor hereunder until the Termination Date occurs.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Right of Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Guarantor hereby agrees that to the extent that a Guarantor shall have paid more than its proportionate share of any payment made hereunder, such Guarantor shall be entitled to seek and receive contribution from and against any other Guarantor hereunder which has not paid its proportionate share of such payment.  Each Guarantor&#8217;s right of contribution shall be subject to the terms and conditions of Section&#160;2.3.  The provisions of this Section&#160;2.2 shall in no respect limit the obligations and liabilities of any Guarantor to the Secured Parties, and each Guarantor shall remain liable to the Secured Parties for the full amount guaranteed by such Guarantor hereunder.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">No Subrogation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any payment made by any Guarantor hereunder or any set-off or application of funds of any Guarantor by any Secured Party, no Guarantor shall be entitled to be subrogated to any of the rights of any Secured Party against any Borrower or any other Guarantor or any collateral security or guarantee or right of offset held by any Secured Party for the payment of the Guaranteed Obligations, nor shall any Guarantor seek or be entitled to seek any contribution or reimbursement from any Borrower or any other Guarantor in respect of payments made by such Guarantor hereunder, until the Termination Date occurs.  If any amount shall be paid to any Guarantor on account of such subrogation rights at any time prior to the Termination Date, such amount shall be held by such Guarantor for the benefit of Secured Parties, segregated from other funds of such Guarantor, and shall, forthwith upon receipt by such Guarantor, be turned over to the Collateral Agent in the exact form received by such Guarantor (duly indorsed by such Guarantor to the Collateral Agent, if required), to be applied against the Guaranteed Obligations, whether matured or unmatured, as the Agents may determine in accordance with Section 5.02(j) of the Credit Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Modification of the Guaranteed Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Guarantor shall remain obligated hereunder notwithstanding that, without any reservation of rights against any Guarantor and without notice to or further assent by any Guarantor, any demand for payment of any of the Guaranteed Obligations made by any Secured Party may be rescinded by such Secured Party and any of the Guaranteed Obligations continued, and the Guaranteed Obligations, or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">3</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">liability of any other Person upon or for any part thereof, or any collateral security or guarantee therefor or right of offset with respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended, modified, accelerated, compromised, waived, surrendered or released by any Secured Party, and the Credit Agreement and the other Credit Documents, and any other documents executed and delivered in connection therewith may be amended, modified, supplemented or terminated, in whole or in part, as the Agents (or the Required Lenders or all Lenders, as the case may be) may deem advisable from time to time, and any collateral security, guarantee or right of offset at any time held by any Secured Party for the payment of the Guaranteed Obligations may be sold, exchanged, waived, surrendered or released.  No Secured Party shall have any obligation to protect, secure, perfect or insure any Lien at any time held by it as security for the Guaranteed Obligations or for this Guarantee or any property subject thereto.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantee Absolute and Unconditional</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Guarantor waives to the fullest extent permitted by applicable law any and all notice of the creation, renewal, extension or accrual of any of the Guaranteed Obligations and notice of or proof of reliance by any Secured Party upon this Guarantee or acceptance of the guarantee contained in this Section 2.  The Guaranteed Obligations, and any of them, shall conclusively be deemed to have been created, contracted or incurred, or renewed, extended, amended or waived, in reliance upon this Guarantee and all dealings between any of the Borrowers and any of the Guarantors, on the one hand, and the Secured Parties, on the other hand, likewise shall be conclusively presumed to have been had or consummated in reliance upon this Guarantee.  Each Guarantor, to the fullest extent permitted by applicable law, waives diligence, presentment, protest, demand for payment and notice of default or nonpayment to or upon any of the Borrowers or any of the Guarantors with respect to the Guaranteed Obligations.  Each Guarantor waives, to the fullest extent permitted by law, any right such Guarantor may now have or hereafter acquire to revoke, rescind, terminate or limit (except as expressly provided herein) this Guarantee or any of its obligations hereunder.  Each Guarantor understands and agrees, to the fullest extent permitted by applicable law, that this Guarantee shall be construed as a continuing, absolute and unconditional guarantee of payment without regard to (a)&#160;the validity or enforceability of the Credit Agreement or any other Credit Document, any of the Guaranteed Obligations or any other collateral security therefor or guarantee or right of offset with respect thereto at any time or from time to time held by any Secured Party, (b)&#160;any defense, set-off or counterclaim (other than a defense of payment or performance) which may at any time be available to or be asserted by any Borrower or any other Person against any Secured Party, or (c)&#160;any other circumstance whatsoever (with or without notice to or knowledge of such Borrower or such Guarantor) which constitutes, or might be construed to constitute, an equitable or legal discharge of such Borrower with respect to any Guaranteed Obligations, or of such Guarantor under this Guarantee, in bankruptcy or in any other instance.  When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Guarantor, any Secured Party may, but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and remedies as it may have against any Borrower, any other Guarantor or any other Person or against any collateral security or guarantee for the Guaranteed Obligations or any right of offset with respect thereto, and any failure by any Secured Party to make any such demand, to pursue such other rights or remedies or to collect any payments from any Borrower, any other Guarantor or any other Person </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">4</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or to realize upon any such collateral security or guarantee or to exercise any such right of offset, or any release of any Borrower, any other Guarantor or any other Person or any such collateral security, guarantee or right of offset, shall not relieve any Guarantor of any obligation or liability hereunder, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of any Secured Party against any Guarantor.  For the purposes hereof, &#8220;demand&#8221; shall include the commencement and continuance of any legal proceedings.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reinstatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Guarantee shall continue to be effective, or be reinstated, as the case may be, if at any time payment, or any part thereof, of any of the Guaranteed Obligations is rescinded or must otherwise be restored or returned by any Secured Party upon the insolvency, bankruptcy, dissolution, liquidation or reorganization of any Borrower or any Guarantor, or upon or as a result of the appointment of a receiver, intervenor or conservator of, or trustee or similar officer for, any Borrower or any Guarantor or any substantial part of its property, or otherwise, all as though such payments had not been made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Guarantor hereby guarantees that payments hereunder will be paid to the Administrative Agent or Revolver Agent, as applicable, without set-off or counterclaim in Dollars at the location specified pursuant to the Credit Agreement.</font></div><div style="margin-bottom:12pt;padding-left:78.75pt;padding-right:78.75pt;text-align:center;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.86pt">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Guarantor hereby represents and warrants to the Agents and each other Secured Party that&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Representations in Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the case of each Guarantor, all representations and warranties set forth in Article VII of the Credit Agreement which relate to or are contemplated to be made by such Guarantor are hereby incorporated herein by reference, are true and correct as of the date on which such representations and warranties are made or deemed made pursuant to the Credit Agreement, and each Secured Party shall be entitled to rely on each of them as if they were fully set forth herein.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Other Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  (a)  Each Guarantor has knowledge of each other Credit Party&#8217;s financial condition and affairs and it has adequate means to obtain from each Credit Party, on an ongoing basis, information relating thereto and to such Credit Party&#8217;s ability to pay and perform the Guaranteed Obligations, and agrees to assume the responsibility for keeping, and to keep, so informed for so long as this Guarantee is in effect.  Each Guarantor acknowledges and agrees that the Secured Parties shall have no obligation to investigate the financial condition or affairs of any Credit Party for the benefit of such Guarantor nor to advise such Guarantor of any fact respecting, or any change in, the financial condition or affairs of any other Credit Party that might become known to any Secured Party at any time, whether or not such Secured Party knows or believes or has reason to know or believe that any such fact or change is unknown to such Guarantor, or might (or does) materially increase the risk of such Guarantor as guarantor, or might (or would) affect the willingness of such Guarantor to continue as a guarantor of the Guaranteed Obligations.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">It is in the best interests of each Guarantor to execute this Guarantee inasmuch as such Guarantor will derive substantial direct and indirect benefits from the Loans, other Credit Extensions and other financial accommodations made to the Borrowers by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">5</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Secured Parties pursuant to the Credit Documents, and each Guarantor agrees that the Secured Parties are relying on this representation in agreeing to make Loans, other Credit Extensions and other financial accommodations to the Borrowers.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">  COVENANTS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Guarantor covenants and agrees with the Secured Parties that, from and after the date of this Guarantee until the Termination Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covenants in Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Guarantor hereby agrees and covenants to (a) do each of the things set forth in the Credit Agreement that a Credit Party agrees and covenants to do and&#47;or, in the case of each Guarantor that is a Subsidiary, that a Credit Party agrees and covenants to cause its Subsidiaries and&#47;or any Guarantor to do, and (b) not do each of the things set forth in the Credit Agreement that a Credit Party agrees and covenants not to do and&#47;or, in the case of each Guarantor that is a Subsidiary, that a Credit Party agrees and covenants to cause its Subsidiaries and&#47;or any Guarantor not to do, in each case, fully as though such Guarantor was a party thereto, and such agreements and covenants are incorporated herein by this reference, mutatis mutandis.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">  MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Amendments in Writing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  None of the terms or provisions of this Guarantee may be waived, amended, supplemented or otherwise modified except in accordance with Section&#160;12.01 of the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All notices, requests and demands to or upon the Agents or any Guarantor hereunder shall be effected in the manner provided for in Section&#160;12.02 of the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">No Waiver by Course of Conduct&#59; Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Secured Party shall by any act (except by a written instrument pursuant to Section 5), delay, indulgence, omission or otherwise be deemed to have waived any right or remedy hereunder or to have acquiesced in any Default or Event of Default.  No failure to exercise, nor any delay in exercising, on the part of any Secured Party, any right, power or privilege hereunder shall operate as a waiver thereof.  No single or partial exercise of any right, power or privilege hereunder shall preclude any other or further exercise thereof or the exercise of any other right, power or privilege.  A waiver by any Secured Party of any right or remedy hereunder on any one occasion shall not be construed as a bar to any right or remedy which such Secured Party would otherwise have on any future occasion.  The rights and remedies herein provided are cumulative, may be exercised singly or concurrently and are not exclusive of any other rights or remedies provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Guarantee shall be binding upon the successors and assigns of each Guarantor and shall inure to the benefit of each Agent and the other Secured Parties and their successors and assigns&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that no Guarantor may assign, transfer or delegate any of its rights or obligations under this Guarantee without the prior written consent of the Administrative Agent and Revolving Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">6</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Set-Off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Guarantor hereby irrevocably authorizes the Administrative Agent, Revolver Agent and each Secured Party at any time and from time to time after the occurrence and during the continuance of an Event of Default, upon any amount becoming due and payable by such Guarantor hereunder (whether at the stated maturity, by acceleration or otherwise) to set-off and appropriate and apply against such amount any and all deposits (general or special, time or demand, provisional or final), in any currency, and any other credits, indebtedness or claims, in any currency, in each case whether direct or indirect, absolute or contingent, matured or unmatured, at any time held or owing by such Secured Party to or for the credit or the account of such Guarantor, or any part thereof in such amounts as Administrative Agent, Revolver Agent or such Secured Party may elect, against and on account of the obligations and liabilities of such Guarantor to Administrative Agent, Revolver Agent or such Secured Party, whether arising hereunder, under the Credit Agreement, or any other Credit Document to which such Guarantor is a party, as Administrative Agent, Revolver Agent or such Secured Party may elect, whether or not any Secured Party has made any demand for payment and although such obligations, liabilities and claims may be contingent or unmatured, in each case, for application in the order of priority set forth in the Credit Agreement. Each Secured Party, or Administrative Agent or Revolver Agent on their behalf, shall notify such Guarantor promptly of any such set-off and the application made by such Secured Party of the proceeds thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the failure to give such notice shall not affect the validity of such set-off and application.  The rights of each Secured Party under this Section are in addition to other rights and remedies (including, without limitation, other rights of set-off) which such Secured Party may have, and are subject to any applicable limitations set forth in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Guarantee may be executed by one or more of the parties to this Guarantee on any number of separate counterparts (including by telecopy, PDF and&#47;or other electronic form), and all of said counterparts taken together shall be deemed to constitute one and the same instrument.  Delivery of an executed counterpart to this Guarantee by facsimile transmission or by electronic mail in pdf format shall be as effective as delivery of a manually executed counterpart hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any provision of this Guarantee which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Section Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Section headings used in this Guarantee are for convenience of reference only and are not to affect the construction hereof or be taken into consideration in the interpretation hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Guarantee and the other Credit Documents represent the entire agreement of the Guarantors and the Secured Parties with respect to the subject matter hereof and thereof, and there are no promises, undertakings, representations or warranties by any party hereto relative to the subject matter hereof and thereof not expressly set forth or referred to herein or in the other Credit Documents.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">7</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All representations and warranties made by the Guarantors in this Guarantee and in the certificates or other instruments delivered in connection with or pursuant to this Guarantee shall be considered to have been relied upon by the other parties hereto and shall survive the execution and delivery of this Guarantee and the making of the Loans, regardless of any investigation made by any such other party or on its behalf and notwithstanding that any Agent or any Lender may have had notice or knowledge of any Default or Event of Default or incorrect representation or warranty at the time any credit is extended under the Credit Agreement, and shall continue in full force and effect as long as the principal of or any accrued interest on any Loan or any fee or any other amount payable under the Credit Agreement is outstanding and unpaid and so long as the Commitments have not expired or terminated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">GOVERNING LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  THIS GUARANTEE SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW&#160;YORK.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Submission To Jurisdiction&#59; Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each party hereto hereby irrevocably and unconditionally&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:22.7pt">agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or in tort or otherwise, against any Agent, any Lender, or any Affiliate of the foregoing in any way relating to this Guarantee or any other Credit Document or the transactions relating hereto or thereto, in any forum other than the courts of the State of New York sitting in New York County, and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally submits to the jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by applicable law, in such federal court&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:22.02pt">consents that any such action or proceeding may be brought in such courts and waives any objection that it may now or hereafter have to the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:22.7pt">agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or any substantially similar form of mail), postage prepaid, to such Guarantor at its address referred to in Section&#160;5.2 or at such other address of which the Administrative Agent or Revolver Agent, as applicable, shall have been previously notified in writing pursuant thereto&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:22.02pt">agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right to sue in any other jurisdiction&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:22.7pt">waives, to the maximum extent not prohibited by law, any right it may have to claim or recover in any legal action or proceeding referred to in this Section 5.12 any special, exemplary, punitive or consequential damages.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each party hereto hereby acknowledges that&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">8</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">it has been advised by counsel in the negotiation, execution and delivery of this Guarantee and the other Credit Documents to which it is a party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">no Secured Party has any fiduciary relationship with or duty to any Guarantor arising out of or in connection with this Guarantee or any of the other Credit Documents, and the relationship between the Guarantors, on the one hand, and the Secured Parties, on the other hand, in connection herewith or therewith is solely that of debtor and creditor&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">no joint venture is created hereby or by the other Credit Documents or otherwise exists by virtue of the transactions contemplated hereby among the Secured Parties or among the Guarantors and the Secured Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Guarantee is a continuing guarantee and shall remain in full force and effect until the Termination Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Additional Guarantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Subsidiary of any Credit Party that is required to become a party to this Guarantee pursuant to Section&#160;8.11 of the Credit Agreement and is not a signatory hereto shall become a Guarantor for all purposes of this Guarantee upon execution and delivery by such Subsidiary of an Assumption Agreement in the form of Annex&#160;I hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Releases of Guarantees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  (a)  Notwithstanding anything to the contrary contained herein or in any other Credit Document, the Administrative Agent and Revolver Agent are hereby irrevocably authorized and directed by each Secured Party (without requirement of notice to or consent of any Secured Party except as expressly required by Section 12.19 of the Credit Agreement) to take any action requested by any Guarantor having the effect of releasing any of its obligations hereunder (i) to the extent necessary to permit consummation of any transaction not prohibited by any Credit Document or that has been consented to in accordance with Section 12.01 of the Credit Agreement, or (ii) under the circumstances described in paragraph (b) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">On the Termination Date, this Guarantee and all obligations (other than those expressly stated to survive such termination) of the Administrative Agent and each Guarantor under this Guarantee shall automatically terminate, all without delivery of any instrument or performance of any act by any party or Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent&#8217;s authority to release any guarantee obligations pursuant to this Section 5.16.  In each case as specified in this Section 5.16, the Administrative Agent and Revolver Agent&#8217;s will (and each Lender irrevocably authorizes the Administrative Agent to), at the Credit Parties&#8217; expense, execute and deliver to the applicable Credit Party such documents as such Credit Party may reasonably request to evidence the release of such item guarantee obligation, in each case in accordance with the terms of the Credit Documents and this Section 5.16.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">WAIVER OF JURY TRIAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  EACH GUARANTOR AND, BY ACCEPTANCE OF THE BENEFITS HEREOF, THE AGENTS, AND EACH BENEFICIARY, HEREBY </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">9</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS GUARANTEE OR ANY OTHER CREDIT DOCUMENT AND FOR ANY COUNTERCLAIM THEREIN.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Marshaling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Agent nor any other Secured Party shall be required to marshal any present or future collateral security (including but not limited to the Collateral) for, or other assurances of payment of, the Guaranteed Obligations or any of them or to resort to such collateral security or other assurances of payment in any particular order, and all of the rights and remedies of the Secured Parties hereunder and of the Secured Parties in respect of such collateral security and other assurances of payment shall be cumulative and in addition to all other rights and remedies, however existing or arising.  To the extent that it lawfully may, each Guarantor hereby agrees that it will not invoke any law relating to the marshaling of collateral which might cause delay in or impede the enforcement of the Administrative Agent&#8217;s rights and remedies under this Guarantee or under any other instrument creating or evidencing any of the Guaranteed Obligations or under which any of the Guaranteed Obligations is outstanding or by which any of the Guaranteed Obligations is secured or payment thereof is otherwise assured, and, to the extent that it lawfully may, each Guarantor hereby irrevocably waives the benefits of all such laws.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page Follows.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">10</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i70d302b3a680472685783a38b28d0718_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, each of the undersigned has caused this Guarantee to be duly executed and delivered as of the date first above written.</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,<br>a Delaware corporation</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EH HOLDING COMPANY, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,<br>a Delaware corporation</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NCIS HOLDINGS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,<br>a Delaware corporation</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NCH MANAGEMENT SYSTEMS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,<br>a California corporation</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font><br></font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Guarantee Agreement&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT CARE PARTNERS HOLDING COMPANY, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,<br>a Delaware corporation</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT CARE PARTNERS OF TEXAS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,<br>a Texas corporation</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VITAL DECISIONS ACQUISITION LLC,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>a Delaware limited liability company</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VITAL DECISIONS LLC,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>a New Jersey limited liability company</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font><br></font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Guarantee Agreement&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:24pt;padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THE ACCOUNTABLE CARE ORGANIZATION LTD,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>a Michigan limited company</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT CARE PARTNERS OF NORTH CAROLINA, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,<br>a North Carolina corporation</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MTS III VITAL DECISIONS BLOCKER CORP,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>a Delaware corporation</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TPG GROWTH ICEMAN, INTERMEDIATE INC.,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Guarantee Agreement&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SURGICAL COLLECTIONS GROUP, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>a Delaware corporation</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Weinberg&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Jonathan Weinberg</font></div><div style="margin-bottom:42pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Secretary</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Guarantee Agreement&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ACCEPTED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARES CAPITAL CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,<br>as Administrative Agent</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Lem&#160;&#160;&#160;&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Scott Lem</font></div><div style="margin-bottom:42pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; CAO, Treasurer</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACF FINCO I LP,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>as Revolving Agent</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Ryan T. Magee&#160;&#160;&#160;&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Ryan T. Magee</font></div><div style="margin-bottom:42pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACF FINCO I LP,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>as Collateral Agent</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Ryan T. Magee&#160;&#160;&#160;&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Ryan T. Magee</font></div><div style="margin-bottom:42pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Guarantee Agreement&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i70d302b3a680472685783a38b28d0718_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Annex I<br> to<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantee Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ASSUMPTION AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Assumption Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), dated as of ________________,&#160;20__, made by ______________________________, a ______________ corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Additional Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in favor of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARES CAPITAL CORPORATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Maryland corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Ares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACF FINCO I LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware limited partnership (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ACF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as collateral agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and as revolver agent for the Revolving Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolver Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, and together with the Administrative Agent and Collateral Agent, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), acting pursuant to this Assumption Agreement for the benefit of the Secured Parties (as defined in the Credit Agreement referred to below).  All capitalized terms not defined herein shall have the meaning ascribed to them in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">W I T N E S E T H </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> EVOLENT HEALTH LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Evolent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, ENDZONE MERGER SUB, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Endzone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which upon consummation of the TPG Acquisition (as defined in the Credit Agreement) will be merged with and into </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TPG GROWTH ICEMAN PARENT, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TPG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> IMPLANTABLE PROVIDER GROUP, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Implantable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, collectively with Evolent, Endzone and TPG, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrowers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">each Subsidiary signatory thereto as guarantors or thereafter designated as Guarantors pursuant to Section 8.11 of the Credit Agreement, the lenders from time to time party thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and the Agents have entered into that certain Credit Agreement, dated as of August 1, 2022 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, in connection with the Credit Agreement, Parent and certain Subsidiaries of the Borrowers have entered into the Guarantee Agreement, dated as of August 1, 2022 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Guarantee Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in favor of the Agents for the benefit of the Secured Parties&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Credit Agreement requires the Additional Guarantor to become a party to the Guarantee Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Additional Guarantor has agreed to execute and deliver this Assumption Agreement in order to become a party to the Guarantee Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, IT IS AGREED&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Guarantee Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  By executing and delivering this Assumption Agreement, the Additional Guarantor, as provided in Section 5.15 of the Guarantee Agreement, hereby becomes a party to the Guarantee Agreement as a Guarantor thereunder with the same force and effect as if originally named therein as a Guarantor and, without limiting the generality of the foregoing, hereby (a) jointly with the other Guarantors and severally, absolutely, unconditionally and irrevocably guarantees, as primary obligor and note merely as surety, to the Agents, for the benefit of the Secured Parties and their respective successors, indorsees, transferees and assigns, the prompt and complete payment and performance by the Borrowers when due (whether at the stated maturity, by acceleration, mandatory prepayment or otherwise) of the Guaranteed Obligations, and (b) expressly assumes all obligations and liabilities of a Guarantor thereunder.  The Additional Guarantor hereby represents and warrants that, with respect to the Additional Guarantor, each of the representations and warranties contained in Section 3 of the Guarantee Agreement is true and correct in all material respects on and as the date hereof (after giving effect to this Assumption Agreement) as if made on and as of such date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">GOVERNING LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.  THIS ASSUMPTION AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW&#160;YORK WITHOUT REFERENCE TO CONFLICTS OF LAW PROVISIONS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">No Novation or Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in this Assumption Agreement shall be construed to release any other Guarantor at any time party to the Guarantee Agreement from its obligations and liabilities thereunder or otherwise affect any of such other Guarantor&#8217;s obligations or liabilities under any Credit Document.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned has caused this Assumption Agreement to be duly executed and delivered as of the date first above written.</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;ADDITIONAL GUARANTOR&#93;,<br>a <br><br><br>By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>&#160;&#160;&#160;&#160;Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>&#160;&#160;&#160;&#160;Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:24pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">Annex I - 2</font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>a63022exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i49333de4edfe40d986d30b762bf45910_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>a63022exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i69734b0d1b074e7a92054d27324d41e6_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>a63022exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i45d53d5523584f68a46285b9af4be686_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, Chief Executive Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2022 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>a63022exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib9af39a1f8ea415ba2f243bbe5c7e70f_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, Chief Financial Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2022 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>evh-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a212dad2-7296-44b7-8af9-e12f408b43ae,g:23ff20ea-0869-45df-9d88-aeb2d6e74df5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.evolenthealth.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.evolenthealth.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.evolenthealth.com/role/OrganizationDetails">
        <link:definition>2402401 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples">
        <link:definition>2103102 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
        <link:definition>2408404 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails">
        <link:definition>2409405 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandards" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards">
        <link:definition>2110103 - Disclosure - Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandardsDetails" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails">
        <link:definition>2411406 - Disclosure - Recently Issued Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Transactions" roleURI="http://www.evolenthealth.com/role/Transactions">
        <link:definition>2112104 - Disclosure - Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsTables" roleURI="http://www.evolenthealth.com/role/TransactionsTables">
        <link:definition>2313302 - Disclosure - Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsVitalDecisionsDetails" roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails">
        <link:definition>2414407 - Disclosure - Transactions - Vital Decisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations">
        <link:definition>2115105 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables">
        <link:definition>2316303 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofResultsofOperationsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails">
        <link:definition>2417408 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofCashFlowsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails">
        <link:definition>2418409 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.evolenthealth.com/role/RevenueRecognition">
        <link:definition>2119106 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables">
        <link:definition>2320304 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>2421410 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
        <link:definition>2422411 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
        <link:definition>2422411 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractBalancesDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails">
        <link:definition>2423412 - Disclosure - Revenue Recognition - Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractCostsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails">
        <link:definition>2424413 - Disclosure - Revenue Recognition - Contract Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLosses" roleURI="http://www.evolenthealth.com/role/CreditLosses">
        <link:definition>2125107 - Disclosure - Credit Losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesTables" roleURI="http://www.evolenthealth.com/role/CreditLossesTables">
        <link:definition>2326305 - Disclosure - Credit Losses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesAccountsReceivableNarrativeDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails">
        <link:definition>2427414 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails">
        <link:definition>2428415 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet">
        <link:definition>2129108 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables">
        <link:definition>2330306 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails">
        <link:definition>2431416 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNet" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet">
        <link:definition>2132109 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetTables" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables">
        <link:definition>2333307 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetImpairmentTestingDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails">
        <link:definition>2434417 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
        <link:definition>2435418 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
        <link:definition>2436419 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails">
        <link:definition>2437420 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://www.evolenthealth.com/role/LongtermDebt">
        <link:definition>2138110 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://www.evolenthealth.com/role/LongtermDebtTables">
        <link:definition>2339308 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2024NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails">
        <link:definition>2440421 - Disclosure - Long-term Debt - 2024 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtCreditAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails">
        <link:definition>2441422 - Disclosure - Long-term Debt - Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtWarrantAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails">
        <link:definition>2442423 - Disclosure - Long-term Debt - Warrant Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2025NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails">
        <link:definition>2443424 - Disclosure - Long-term Debt - 2025 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2021NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails">
        <link:definition>2444425 - Disclosure - Long-term Debt - 2021 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtConvertibleSeniorNotesCarryingValueDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
        <link:definition>2445426 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies">
        <link:definition>2146111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables">
        <link:definition>2347309 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2448427 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesReinsuranceAgreementsDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails">
        <link:definition>2449428 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesConcentrationRiskDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails">
        <link:definition>2450429 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.evolenthealth.com/role/Leases">
        <link:definition>2151112 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.evolenthealth.com/role/LeasesTables">
        <link:definition>2352310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails">
        <link:definition>2453430 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesPrimaryOfficeLeasesDetails" roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails">
        <link:definition>2454431 - Disclosure - Leases - Primary Office Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2455432 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails">
        <link:definition>2456433 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails_1" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1">
        <link:definition>2456433 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails">
        <link:definition>2457434 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.evolenthealth.com/role/LossPerCommonShare">
        <link:definition>2158113 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareTables" roleURI="http://www.evolenthealth.com/role/LossPerCommonShareTables">
        <link:definition>2359311 - Disclosure - Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareComputationofEarningsperShareDetails" roleURI="http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails">
        <link:definition>2460435 - Disclosure - Loss Per Common Share - Computation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>2461436 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.evolenthealth.com/role/StockbasedCompensation">
        <link:definition>2162114 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables">
        <link:definition>2363312 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockbasedCompensationExpenseDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>2464437 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails">
        <link:definition>2465438 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails">
        <link:definition>2466439 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.evolenthealth.com/role/IncomeTaxes">
        <link:definition>2167115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2468440 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvestees" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees">
        <link:definition>2169116 - Disclosure - Investments in Equity Method Investees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvesteesDetails" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails">
        <link:definition>2470441 - Disclosure - Investments in Equity Method Investees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.evolenthealth.com/role/FairValueMeasurement">
        <link:definition>2171117 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables">
        <link:definition>2372313 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
        <link:definition>2473442 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementChangesinContingentConsiderationandOtherDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails">
        <link:definition>2474443 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
        <link:definition>2475444 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.evolenthealth.com/role/RelatedParties">
        <link:definition>2176118 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesTables" roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables">
        <link:definition>2377314 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesAssetsandLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails">
        <link:definition>2478445 - Disclosure - Related Parties - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesRevenuesandExpensesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails">
        <link:definition>2479446 - Disclosure - Related Parties - Revenues and Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChanges" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges">
        <link:definition>2180119 - Disclosure - Repositioning and Other Changes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesTables" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables">
        <link:definition>2381315 - Disclosure - Repositioning and Other Changes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesDetails" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails">
        <link:definition>2482447 - Disclosure - Repositioning and Other Changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.evolenthealth.com/role/SegmentReporting">
        <link:definition>2183120 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.evolenthealth.com/role/SegmentReportingTables">
        <link:definition>2384316 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>2485448 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuefromSegmentstoConsolidatedDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
        <link:definition>2486449 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofAdjustedEBITDADetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails">
        <link:definition>2487450 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangements" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements">
        <link:definition>2188121 - Disclosure - Reserves for Claims and Performance-Based Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsTables" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables">
        <link:definition>2389317 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsDetails" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails">
        <link:definition>2490451 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation">
        <link:definition>2191122 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables">
        <link:definition>2392318 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>2493452 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.evolenthealth.com/role/SubsequentEvents">
        <link:definition>2194123 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails">
        <link:definition>2495453 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="evh_SharebasedCompensationIncludingOnetimeAdjustment" abstract="false" name="SharebasedCompensationIncludingOnetimeAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" abstract="false" name="IncomeLossfromEquityMethodInvestmentsServicesAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" abstract="false" name="PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IncreaseDecreaseInCapitalizedContractCostNet" abstract="false" name="IncreaseDecreaseInCapitalizedContractCostNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" abstract="false" name="PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CashHeldInInternationalBanksPercentage" abstract="false" name="CashHeldInInternationalBanksPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_NewNotesMember" abstract="true" name="NewNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_FinancingReceivablePercentNotPastDue" abstract="false" name="FinancingReceivablePercentNotPastDue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" abstract="true" name="MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_CashFDICInsuredAmountPercentage" abstract="false" name="CashFDICInsuredAmountPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodThreePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_EmployeeSeveranceAndTerminationBenefitsMember" abstract="true" name="EmployeeSeveranceAndTerminationBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EquityComponentOfLongTermDebtMember" abstract="true" name="EquityComponentOfLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodOnePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_GainOnTransferOfMembership" abstract="false" name="GainOnTransferOfMembership" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" abstract="false" name="PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" abstract="false" name="ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_PlatformsAndOperationsServicesMember" abstract="true" name="PlatformsAndOperationsServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_FloridaBlueMedicareIncMember" abstract="true" name="FloridaBlueMedicareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" abstract="false" name="TaxReceivablesAgreementPercentofTaxSavingstobePaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DebtIssuanceCostsNetDebtComponent" abstract="false" name="DebtIssuanceCostsNetDebtComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EquityMethodInvestmentVotingInterestPercentage" abstract="false" name="EquityMethodInvestmentVotingInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_VitalDecisionsMember" abstract="true" name="VitalDecisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TrueHealthMember" abstract="true" name="TrueHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CenterForMedicareAndMedicaidServicesMember" abstract="true" name="CenterForMedicareAndMedicaidServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtConversionOriginalDebtFairValue" abstract="false" name="DebtConversionOriginalDebtFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_BlueCrossAndBlueShieldOfNorthCarolinaMember" abstract="true" name="BlueCrossAndBlueShieldOfNorthCarolinaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightofUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" abstract="true" name="RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationClaimsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CookCountyHealthAndHospitalsSystemMember" abstract="true" name="CookCountyHealthAndHospitalsSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodFourPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" abstract="false" name="PaymentsForProceedsFromClaimsProcessingFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RightOfOffsetPolicyPolicyTextBlock" abstract="false" name="RightOfOffsetPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="evh_ShareholderAdvisoryServices" abstract="false" name="ShareholderAdvisoryServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2025Member" abstract="true" name="SeniorConvertibleNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TransactionCosts" abstract="false" name="TransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward" abstract="true" name="AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_NumberOfSourcesOfRevenue" abstract="false" name="NumberOfSourcesOfRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" abstract="false" name="CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RestrictedCashforBenefitManagementServicesMember" abstract="true" name="RestrictedCashforBenefitManagementServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" abstract="false" name="IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ClinicalSolutionsSegmentMember" abstract="true" name="ClinicalSolutionsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ServicesAgreementsMember" abstract="true" name="ServicesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PaymentsOfMakeWholePremium" abstract="false" name="PaymentsOfMakeWholePremium" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SeniorCreditFacilitiesMember" abstract="true" name="SeniorCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_WeightedAverageCommonSharesOutstandingAbstract" abstract="true" name="WeightedAverageCommonSharesOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DeferredFinancingFeesMember" abstract="true" name="DeferredFinancingFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ShareholderClassActionComplaintMember" abstract="true" name="ShareholderClassActionComplaintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" abstract="false" name="CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_LeveragedStockUnitsLSUsMember" abstract="true" name="LeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_A2022CreditFacilitiesMember" abstract="true" name="A2022CreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" abstract="false" name="DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_CommercialAndOtherCustomersMember" abstract="true" name="CommercialAndOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_MedicareCustomersMember" abstract="true" name="MedicareCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" abstract="false" name="ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ContractFulfillmentCostsMember" abstract="true" name="ContractFulfillmentCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" abstract="false" name="TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_RightOfUseAssetAcquiredAndDisposedOf" abstract="false" name="RightOfUseAssetAcquiredAndDisposedOf" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FInancialAssetLessThan120DaysPastDueMember" abstract="true" name="FInancialAssetLessThan120DaysPastDueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" abstract="false" name="DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2024Member" abstract="true" name="SeniorConvertibleNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BonusesAndCommissionsMember" abstract="true" name="BonusesAndCommissionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_FInancialAssetLessThan60DaysMember" abstract="true" name="FInancialAssetLessThan60DaysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" abstract="false" name="LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_InitialTermLoanFacilityMember" abstract="true" name="InitialTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_GainLossOnDispositionOfAssetsOperatingActivities" abstract="false" name="GainLossOnDispositionOfAssetsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ImplantableProviderGroupIncMember" abstract="true" name="ImplantableProviderGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ProfessionalServicesRestructuringMember" abstract="true" name="ProfessionalServicesRestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RestrictedCashforOtherContractualCommitmentsMember" abstract="true" name="RestrictedCashforOtherContractualCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" abstract="false" name="AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ProceedsFromMaturityOfInvestments" abstract="false" name="ProceedsFromMaturityOfInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DelayedDrawTermLoanFacilityMember" abstract="true" name="DelayedDrawTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CollateralwithFinancialInstitutionsMember" abstract="true" name="CollateralwithFinancialInstitutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" abstract="true" name="RestrictedCashforLettersofCreditforFacilityLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ProceedsRepaymentsForReinsurance" abstract="false" name="ProceedsRepaymentsForReinsurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MolinaHealthcareMember" abstract="true" name="MolinaHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BelowMarketLeasesMember" abstract="true" name="BelowMarketLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PremiumsRevenueMember" abstract="true" name="PremiumsRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ConvertibleSeniorNotesdue2021Member" abstract="true" name="ConvertibleSeniorNotesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" abstract="false" name="IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" abstract="false" name="AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MedicaidCustomersMember" abstract="true" name="MedicaidCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" abstract="false" name="CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BrightHealthManagementIncMember" abstract="true" name="BrightHealthManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EvolentHealthServicesSegmentMember" abstract="true" name="EvolentHealthServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_EquityMethodInvestmentEconomicInterestPercentage" abstract="false" name="EquityMethodInvestmentEconomicInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PerformanceBasedRestrictedStockUnitsPSUsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>evh-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a212dad2-7296-44b7-8af9-e12f408b43ae,g:23ff20ea-0869-45df-9d88-aeb2d6e74df5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ba2a3c22-4220-43be-bc02-f79d70a6a77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b9d67776-a81b-43f1-ad21-ac2f386286d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba2a3c22-4220-43be-bc02-f79d70a6a77f" xlink:to="loc_us-gaap_AccountsPayableCurrent_b9d67776-a81b-43f1-ad21-ac2f386286d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8e849eaa-bb8d-437d-94dc-6f48b4e3c70c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba2a3c22-4220-43be-bc02-f79d70a6a77f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8e849eaa-bb8d-437d-94dc-6f48b4e3c70c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_afe33ed3-1bc2-43c8-a695-eefa31c607fe" xlink:href="evh-20220630.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba2a3c22-4220-43be-bc02-f79d70a6a77f" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_afe33ed3-1bc2-43c8-a695-eefa31c607fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c1037e35-d952-4c8c-8ea4-41730d452a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba2a3c22-4220-43be-bc02-f79d70a6a77f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c1037e35-d952-4c8c-8ea4-41730d452a5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c8786dfe-42fb-4170-9e31-02232aee410a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba2a3c22-4220-43be-bc02-f79d70a6a77f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c8786dfe-42fb-4170-9e31-02232aee410a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a75e296a-1cb3-4056-8841-1700d8d09a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba2a3c22-4220-43be-bc02-f79d70a6a77f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a75e296a-1cb3-4056-8841-1700d8d09a2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_42e5fb28-77aa-4594-b7dc-e22c2b626ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ff31db9a-9959-4e4f-badf-508cedd944ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_42e5fb28-77aa-4594-b7dc-e22c2b626ecd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ff31db9a-9959-4e4f-badf-508cedd944ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cf41d5aa-01f2-4d34-89ee-a5b4fdc4e3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_42e5fb28-77aa-4594-b7dc-e22c2b626ecd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cf41d5aa-01f2-4d34-89ee-a5b4fdc4e3db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_197e5897-d588-479f-bf55-c9e64d2e5d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_42e5fb28-77aa-4594-b7dc-e22c2b626ecd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_197e5897-d588-479f-bf55-c9e64d2e5d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1ac1d15a-5314-4f82-93c3-a7118ac05dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_42e5fb28-77aa-4594-b7dc-e22c2b626ecd" xlink:to="loc_us-gaap_CommonStockValue_1ac1d15a-5314-4f82-93c3-a7118ac05dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_0ae136d8-0eaa-4e11-bbcf-36fd9e33d032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_42e5fb28-77aa-4594-b7dc-e22c2b626ecd" xlink:to="loc_us-gaap_TreasuryStockValue_0ae136d8-0eaa-4e11-bbcf-36fd9e33d032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b23310c7-b5c9-446c-9369-e7c5a2e25613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fc28eae8-477f-4d66-a1f5-6317433afe85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b23310c7-b5c9-446c-9369-e7c5a2e25613" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fc28eae8-477f-4d66-a1f5-6317433afe85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_687fecac-a8e4-4ba0-a40e-beefb2c6c787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b23310c7-b5c9-446c-9369-e7c5a2e25613" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_687fecac-a8e4-4ba0-a40e-beefb2c6c787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5555abc9-6d33-43b6-a384-842e5e403dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b23310c7-b5c9-446c-9369-e7c5a2e25613" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5555abc9-6d33-43b6-a384-842e5e403dbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f240e91d-27cd-4f51-b957-c8326c306f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b23310c7-b5c9-446c-9369-e7c5a2e25613" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f240e91d-27cd-4f51-b957-c8326c306f7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_86651080-0c87-4583-91e6-78118443c303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_91d976c4-44be-4389-a381-6b14fead300a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_86651080-0c87-4583-91e6-78118443c303" xlink:to="loc_us-gaap_Liabilities_91d976c4-44be-4389-a381-6b14fead300a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0241f5b6-797c-48fd-9b8b-705613044a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_86651080-0c87-4583-91e6-78118443c303" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0241f5b6-797c-48fd-9b8b-705613044a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff8b1661-29d5-4dc0-8b4e-ea2957d38ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_86651080-0c87-4583-91e6-78118443c303" xlink:to="loc_us-gaap_StockholdersEquity_ff8b1661-29d5-4dc0-8b4e-ea2957d38ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0c4e07b9-6a9f-4c4d-ab3a-7b1b26860859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_95d94a5e-66b2-48da-9771-341358afda31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c4e07b9-6a9f-4c4d-ab3a-7b1b26860859" xlink:to="loc_us-gaap_LiabilitiesCurrent_95d94a5e-66b2-48da-9771-341358afda31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_112da525-57d1-4ea7-9f12-58394539cd56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c4e07b9-6a9f-4c4d-ab3a-7b1b26860859" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_112da525-57d1-4ea7-9f12-58394539cd56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d8ffd55e-6b1f-49da-aeab-b3454ebec545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c4e07b9-6a9f-4c4d-ab3a-7b1b26860859" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d8ffd55e-6b1f-49da-aeab-b3454ebec545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14f8123b-00bb-4c02-b70c-eca430803ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c4e07b9-6a9f-4c4d-ab3a-7b1b26860859" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14f8123b-00bb-4c02-b70c-eca430803ba8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a7d992a4-5f9f-4ce6-84ca-ce9cc951a7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c4e07b9-6a9f-4c4d-ab3a-7b1b26860859" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a7d992a4-5f9f-4ce6-84ca-ce9cc951a7d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_09dedb20-520e-4629-a506-a6b1eee198ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_59e08aaf-1d9a-4516-b700-9010ef533d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09dedb20-520e-4629-a506-a6b1eee198ed" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_59e08aaf-1d9a-4516-b700-9010ef533d44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7bc97a6c-85a2-499e-aaab-3d5387c502ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09dedb20-520e-4629-a506-a6b1eee198ed" xlink:to="loc_us-gaap_AssetsCurrent_7bc97a6c-85a2-499e-aaab-3d5387c502ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b3c3f630-698e-47d1-af70-4c8e7f67d725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09dedb20-520e-4629-a506-a6b1eee198ed" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b3c3f630-698e-47d1-af70-4c8e7f67d725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1c34b75e-18a6-45ec-9596-f6cb38bf01a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09dedb20-520e-4629-a506-a6b1eee198ed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1c34b75e-18a6-45ec-9596-f6cb38bf01a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_90d1b687-7bfc-49df-9cf8-b71baf966af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09dedb20-520e-4629-a506-a6b1eee198ed" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_90d1b687-7bfc-49df-9cf8-b71baf966af8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_50bf5733-4505-4952-8545-667189e0be57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09dedb20-520e-4629-a506-a6b1eee198ed" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_50bf5733-4505-4952-8545-667189e0be57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_8a517841-eb20-48ff-b31e-5fd1ab260e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09dedb20-520e-4629-a506-a6b1eee198ed" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_8a517841-eb20-48ff-b31e-5fd1ab260e21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d15c1b71-86e3-4351-9602-9b98d2bdada9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09dedb20-520e-4629-a506-a6b1eee198ed" xlink:to="loc_us-gaap_Goodwill_d15c1b71-86e3-4351-9602-9b98d2bdada9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_444a2eb1-6352-4238-bdb8-eefd7d2c08bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09dedb20-520e-4629-a506-a6b1eee198ed" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_444a2eb1-6352-4238-bdb8-eefd7d2c08bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e6589a5c-be7a-4632-96a6-30e3c693963b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e64c4239-167a-48c7-bce9-650521ccd4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_e6589a5c-be7a-4632-96a6-30e3c693963b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e64c4239-167a-48c7-bce9-650521ccd4a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b93e75b3-fbd5-4c35-9d8d-d1c075c63b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_e6589a5c-be7a-4632-96a6-30e3c693963b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b93e75b3-fbd5-4c35-9d8d-d1c075c63b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_76c3b33c-7c66-4248-8538-f8d0e013ab9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_67493bd9-c007-44a4-a73b-e19ac1fe73ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76c3b33c-7c66-4248-8538-f8d0e013ab9f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_67493bd9-c007-44a4-a73b-e19ac1fe73ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_bd37c71a-6fe8-4f12-9330-cba7757b37f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76c3b33c-7c66-4248-8538-f8d0e013ab9f" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_bd37c71a-6fe8-4f12-9330-cba7757b37f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_42feeef9-7b2b-4992-9370-a0a2400d6a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76c3b33c-7c66-4248-8538-f8d0e013ab9f" xlink:to="loc_us-gaap_DepreciationAndAmortization_42feeef9-7b2b-4992-9370-a0a2400d6a0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_32d7a696-d65d-47dc-8cf8-f0d91d97c3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76c3b33c-7c66-4248-8538-f8d0e013ab9f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_32d7a696-d65d-47dc-8cf8-f0d91d97c3f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_753d220f-4be2-4f60-a04b-843a9a2028c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5006b932-2ab8-4964-88c3-8c7aafdf6208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_753d220f-4be2-4f60-a04b-843a9a2028c4" xlink:to="loc_us-gaap_NetIncomeLoss_5006b932-2ab8-4964-88c3-8c7aafdf6208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9b7d112c-82c9-44ab-9461-54e1e0a95879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_753d220f-4be2-4f60-a04b-843a9a2028c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9b7d112c-82c9-44ab-9461-54e1e0a95879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f1a26d14-3b88-46b7-8d57-128c98771a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_20306844-ac32-4d1e-8a8c-5fbb3a97f5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f1a26d14-3b88-46b7-8d57-128c98771a69" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_20306844-ac32-4d1e-8a8c-5fbb3a97f5f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0d985fd1-ea70-4625-a4f9-10fbadcf05ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f1a26d14-3b88-46b7-8d57-128c98771a69" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0d985fd1-ea70-4625-a4f9-10fbadcf05ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_460bcdc2-e680-4466-b7a5-4d62c4038582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b381260f-d2af-4f23-8bba-4c60bbe9baca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_460bcdc2-e680-4466-b7a5-4d62c4038582" xlink:to="loc_us-gaap_CostsAndExpenses_b381260f-d2af-4f23-8bba-4c60bbe9baca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e036560b-f75f-4357-aa78-59dd88bee22b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_460bcdc2-e680-4466-b7a5-4d62c4038582" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e036560b-f75f-4357-aa78-59dd88bee22b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7586bff1-abb1-45b3-a510-69141821b242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_af9ffb2c-2caf-41c5-a4db-7af2ed055a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7586bff1-abb1-45b3-a510-69141821b242" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_af9ffb2c-2caf-41c5-a4db-7af2ed055a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2de99028-e43d-475e-996a-548e55bcb14a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7586bff1-abb1-45b3-a510-69141821b242" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2de99028-e43d-475e-996a-548e55bcb14a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6efe4930-1eb3-40be-b368-eb978f86ccf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_78bcf507-b222-4698-bf58-98d01d9507e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6efe4930-1eb3-40be-b368-eb978f86ccf7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_78bcf507-b222-4698-bf58-98d01d9507e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_47299efe-dfeb-4769-98a3-33fc04df68f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6efe4930-1eb3-40be-b368-eb978f86ccf7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_47299efe-dfeb-4769-98a3-33fc04df68f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_76303eba-8421-4809-89b6-39f9d4f204ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6efe4930-1eb3-40be-b368-eb978f86ccf7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_76303eba-8421-4809-89b6-39f9d4f204ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b695a73f-69cf-48f0-ab2f-cd4922d4c3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6efe4930-1eb3-40be-b368-eb978f86ccf7" xlink:to="loc_us-gaap_OperatingIncomeLoss_b695a73f-69cf-48f0-ab2f-cd4922d4c3c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8c63fc1d-8030-4c04-bee9-bf91999e743c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6efe4930-1eb3-40be-b368-eb978f86ccf7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8c63fc1d-8030-4c04-bee9-bf91999e743c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fad79070-b3db-4f68-8828-e95fbde8bf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6efe4930-1eb3-40be-b368-eb978f86ccf7" xlink:to="loc_us-gaap_InterestExpense_fad79070-b3db-4f68-8828-e95fbde8bf1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_7c1ae2af-98d5-4b26-aefa-7272400897ab" xlink:href="evh-20220630.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6efe4930-1eb3-40be-b368-eb978f86ccf7" xlink:to="loc_evh_GainOnTransferOfMembership_7c1ae2af-98d5-4b26-aefa-7272400897ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_075a6b4e-275a-443a-9ff2-386d0f3a09b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7ccbd7c0-e18a-496a-92cd-bf331c76f95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_075a6b4e-275a-443a-9ff2-386d0f3a09b9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7ccbd7c0-e18a-496a-92cd-bf331c76f95c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_eb0ce935-fe6f-44e8-b5dc-71c08cf72031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_075a6b4e-275a-443a-9ff2-386d0f3a09b9" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_eb0ce935-fe6f-44e8-b5dc-71c08cf72031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_2279f325-84b5-49f4-ba66-3fe236457b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e7f1f430-681d-40d5-a152-37e14fccce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_2279f325-84b5-49f4-ba66-3fe236457b75" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e7f1f430-681d-40d5-a152-37e14fccce9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_aa89d8fb-4bf2-4496-975d-d5498185de36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_2279f325-84b5-49f4-ba66-3fe236457b75" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_aa89d8fb-4bf2-4496-975d-d5498185de36" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75685910-178c-433f-9eaa-80c25f981a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_7e66acc9-6cfa-470d-b61a-5cf36f50b3c0" xlink:href="evh-20220630.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75685910-178c-433f-9eaa-80c25f981a6a" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_7e66acc9-6cfa-470d-b61a-5cf36f50b3c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_e042327f-5d62-4406-bdb2-f7dbd657add0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75685910-178c-433f-9eaa-80c25f981a6a" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_e042327f-5d62-4406-bdb2-f7dbd657add0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_8dc9ab8e-df19-47bd-87df-05d62a9a88bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75685910-178c-433f-9eaa-80c25f981a6a" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_8dc9ab8e-df19-47bd-87df-05d62a9a88bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_00ce4019-9bc4-44d5-b968-f96dd7f4eba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75685910-178c-433f-9eaa-80c25f981a6a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_00ce4019-9bc4-44d5-b968-f96dd7f4eba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6defd94d-7912-4695-bbbe-8388959fda82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75685910-178c-433f-9eaa-80c25f981a6a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6defd94d-7912-4695-bbbe-8388959fda82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_190ec336-c434-4cac-b994-f5ae4c2af34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_661a0a64-4f47-4439-a4a8-10c41da2d94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_190ec336-c434-4cac-b994-f5ae4c2af34b" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_661a0a64-4f47-4439-a4a8-10c41da2d94a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_637900a0-a5ff-49d0-be66-18437cc077a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_190ec336-c434-4cac-b994-f5ae4c2af34b" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_637900a0-a5ff-49d0-be66-18437cc077a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_2f738c2a-4651-4dfb-8767-5a9b7e6e7a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_190ec336-c434-4cac-b994-f5ae4c2af34b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_2f738c2a-4651-4dfb-8767-5a9b7e6e7a64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_194d31b2-e8eb-4b57-a713-0c607696487a" xlink:href="evh-20220630.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_190ec336-c434-4cac-b994-f5ae4c2af34b" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_194d31b2-e8eb-4b57-a713-0c607696487a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_3a5d7355-ade6-48b7-9015-17d5d7f8f992" xlink:href="evh-20220630.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_190ec336-c434-4cac-b994-f5ae4c2af34b" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_3a5d7355-ade6-48b7-9015-17d5d7f8f992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_fb8afd73-1946-4537-ae76-08e5e035a46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_190ec336-c434-4cac-b994-f5ae4c2af34b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_fb8afd73-1946-4537-ae76-08e5e035a46d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_c300dab1-5d16-4c76-b692-dea028dfaf23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_190ec336-c434-4cac-b994-f5ae4c2af34b" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_c300dab1-5d16-4c76-b692-dea028dfaf23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1dcd49f-aed6-47bd-bbc9-4801fbe516c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6ec4fa8-6558-4ae7-b376-7241c92b4024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1dcd49f-aed6-47bd-bbc9-4801fbe516c6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6ec4fa8-6558-4ae7-b376-7241c92b4024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f19cf45b-cc52-45b8-b0e2-e0edaedbaf92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1dcd49f-aed6-47bd-bbc9-4801fbe516c6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f19cf45b-cc52-45b8-b0e2-e0edaedbaf92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0653e86e-710a-42fc-8da5-69b10bc671f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1dcd49f-aed6-47bd-bbc9-4801fbe516c6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0653e86e-710a-42fc-8da5-69b10bc671f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e97c1032-3c24-4571-955a-7a23139815fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f1dcd49f-aed6-47bd-bbc9-4801fbe516c6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e97c1032-3c24-4571-955a-7a23139815fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_479fbc73-1ac3-4232-b44a-afbc1de5bdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_479fbc73-1ac3-4232-b44a-afbc1de5bdb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f2a737aa-eae8-4463-ab87-f47594dfc5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f2a737aa-eae8-4463-ab87-f47594dfc5c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c067fc2-3048-4c56-818e-92387f068e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_NetIncomeLoss_2c067fc2-3048-4c56-818e-92387f068e71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ea147c61-3026-4738-9dcd-fb47a7764018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ea147c61-3026-4738-9dcd-fb47a7764018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1335f81d-1036-403f-bdb7-02e08720e724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1335f81d-1036-403f-bdb7-02e08720e724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_9288c761-ff61-49b4-b61e-47f1da20d6de" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_9288c761-ff61-49b4-b61e-47f1da20d6de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_0d474197-1d8a-44eb-a913-98a9ba2d3258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_0d474197-1d8a-44eb-a913-98a9ba2d3258" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3b3af802-1b22-4fc5-a357-880db131a0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3b3af802-1b22-4fc5-a357-880db131a0cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c367d3cd-bc70-4a7b-bf5c-7c5abd28eb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c367d3cd-bc70-4a7b-bf5c-7c5abd28eb0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_b0a5b951-76d9-4c98-806b-4de860f874bc" xlink:href="evh-20220630.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_b0a5b951-76d9-4c98-806b-4de860f874bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_41b96144-4f56-4c63-a0b1-5cf8baa678a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_41b96144-4f56-4c63-a0b1-5cf8baa678a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5faa1d09-4da7-4fcf-96f8-58113d493e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5faa1d09-4da7-4fcf-96f8-58113d493e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_dbcc312f-38a0-4bef-9913-c70a19494089" xlink:href="evh-20220630.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_evh_GainOnTransferOfMembership_dbcc312f-38a0-4bef-9913-c70a19494089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_e59dd703-b4aa-40c5-9a8c-3c469f362581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_e59dd703-b4aa-40c5-9a8c-3c469f362581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1114bcb5-37d7-41b7-a3ce-3d15d7dcd41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1114bcb5-37d7-41b7-a3ce-3d15d7dcd41e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c646fa65-0c04-4429-94fd-17ca213360f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c646fa65-0c04-4429-94fd-17ca213360f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_b28f25a9-87b9-4265-b033-6ca12da735b2" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_b28f25a9-87b9-4265-b033-6ca12da735b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a24fddce-88f3-4799-af02-68d75f5d1bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_ShareBasedCompensation_a24fddce-88f3-4799-af02-68d75f5d1bce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_496f6cbe-1f3a-4866-b3ff-804be6d45ad1" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_496f6cbe-1f3a-4866-b3ff-804be6d45ad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_68c65fe0-c925-446b-a2e8-48b6b25740b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_68c65fe0-c925-446b-a2e8-48b6b25740b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_853c9d6e-6465-4d9c-a0de-c6eeefc92840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_853c9d6e-6465-4d9c-a0de-c6eeefc92840" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f489dded-2b79-4244-b812-61392d3aa46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f489dded-2b79-4244-b812-61392d3aa46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_6c28c095-bd25-4692-b4c0-8c1b9961c941" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce978383-d7cc-4227-bb25-228bdc4af1b7" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_6c28c095-bd25-4692-b4c0-8c1b9961c941" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb9306d5-c768-4024-b9b6-cc7d8b6ca0af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_5f372f7d-b6db-4d89-837c-8f71298da3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb9306d5-c768-4024-b9b6-cc7d8b6ca0af" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_5f372f7d-b6db-4d89-837c-8f71298da3ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_5296a4d1-1bc6-4446-b525-4eb17621a6cf" xlink:href="evh-20220630.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb9306d5-c768-4024-b9b6-cc7d8b6ca0af" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_5296a4d1-1bc6-4446-b525-4eb17621a6cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_726cdcff-4675-4f28-b8c2-84b0a58a9f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ad13eebc-9c02-4a1b-a389-78fcf6295bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_726cdcff-4675-4f28-b8c2-84b0a58a9f68" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ad13eebc-9c02-4a1b-a389-78fcf6295bb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f8ed7ff1-2be7-428f-a54c-3ef73d12399d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_71573743-34e5-4aff-88f4-d838f42e44a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f8ed7ff1-2be7-428f-a54c-3ef73d12399d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_71573743-34e5-4aff-88f4-d838f42e44a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#TransactionsVitalDecisionsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b64525b9-80cc-4ed2-8065-ae1416f84193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_d0e42305-f1da-4911-b479-e802c698af8b" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b64525b9-80cc-4ed2-8065-ae1416f84193" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_d0e42305-f1da-4911-b479-e802c698af8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_f9f584fe-7dee-4e3d-a557-5ee4ff96fdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b64525b9-80cc-4ed2-8065-ae1416f84193" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_f9f584fe-7dee-4e3d-a557-5ee4ff96fdf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_4a2b19a8-99a3-406a-9519-1c0677e1c7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b64525b9-80cc-4ed2-8065-ae1416f84193" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_4a2b19a8-99a3-406a-9519-1c0677e1c7ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_78788bf8-aca9-4a49-a34b-0dcda5379711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b64525b9-80cc-4ed2-8065-ae1416f84193" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_78788bf8-aca9-4a49-a34b-0dcda5379711" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_76631e31-46a7-4335-b381-41018db789b6" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b64525b9-80cc-4ed2-8065-ae1416f84193" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_76631e31-46a7-4335-b381-41018db789b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_de4ac275-633f-451b-a7cc-4132d2ad0c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b64525b9-80cc-4ed2-8065-ae1416f84193" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_de4ac275-633f-451b-a7cc-4132d2ad0c9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7673e57a-c79b-42f3-97cb-4fca0ecc8708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4f554dc5-bcf8-47b6-a7e3-713468303827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7673e57a-c79b-42f3-97cb-4fca0ecc8708" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4f554dc5-bcf8-47b6-a7e3-713468303827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f6462012-8048-4781-a165-73f19627178d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7673e57a-c79b-42f3-97cb-4fca0ecc8708" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f6462012-8048-4781-a165-73f19627178d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_789379bf-1f05-456d-b4fe-4384d7d4b5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7673e57a-c79b-42f3-97cb-4fca0ecc8708" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_789379bf-1f05-456d-b4fe-4384d7d4b5cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_82cdf89e-77a9-4038-aa3b-8d85462a3ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6300c258-367b-4120-8e52-c227ae86c4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_82cdf89e-77a9-4038-aa3b-8d85462a3ca3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6300c258-367b-4120-8e52-c227ae86c4d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_a9f8fd43-02c0-4fd5-8ff6-05a6b31fda83" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_82cdf89e-77a9-4038-aa3b-8d85462a3ca3" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_a9f8fd43-02c0-4fd5-8ff6-05a6b31fda83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9cd321d3-fa8f-46ce-8ec5-5e8c10335e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_82cdf89e-77a9-4038-aa3b-8d85462a3ca3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9cd321d3-fa8f-46ce-8ec5-5e8c10335e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7062ff5b-f9fe-4e41-8f85-82a95b120acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_82cdf89e-77a9-4038-aa3b-8d85462a3ca3" xlink:to="loc_us-gaap_Goodwill_7062ff5b-f9fe-4e41-8f85-82a95b120acf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_7ab3f34d-7005-45ae-ab0f-1588f2b6dc45" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_90b0ecc2-5188-4dbe-b84d-b8119623f677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_7ab3f34d-7005-45ae-ab0f-1588f2b6dc45" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_90b0ecc2-5188-4dbe-b84d-b8119623f677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_708d657e-568c-4ce0-9353-33c5ee0d42c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_7ab3f34d-7005-45ae-ab0f-1588f2b6dc45" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_708d657e-568c-4ce0-9353-33c5ee0d42c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_18683006-1422-40f3-8ac7-41a2e7a65870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_7ab3f34d-7005-45ae-ab0f-1588f2b6dc45" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_18683006-1422-40f3-8ac7-41a2e7a65870" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_487245fe-bf6a-4246-9652-6c884f72dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_7ab3f34d-7005-45ae-ab0f-1588f2b6dc45" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_487245fe-bf6a-4246-9652-6c884f72dfc7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_56e01cf7-c426-4fd9-a135-2842c09070f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_d2f9a6a1-c5ce-4133-8d95-54357282b427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_56e01cf7-c426-4fd9-a135-2842c09070f8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_d2f9a6a1-c5ce-4133-8d95-54357282b427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_8ef48b03-fe4e-4e07-bf25-7aabd4e2b453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_56e01cf7-c426-4fd9-a135-2842c09070f8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_8ef48b03-fe4e-4e07-bf25-7aabd4e2b453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_44c31a3f-cc98-4600-bc65-dd49430fe5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_56e01cf7-c426-4fd9-a135-2842c09070f8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_44c31a3f-cc98-4600-bc65-dd49430fe5f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_05b8b925-460e-47de-a7bf-a20a34b94680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_56e01cf7-c426-4fd9-a135-2842c09070f8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_05b8b925-460e-47de-a7bf-a20a34b94680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3412409a-75cf-4b28-a498-d7024435e94b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_cef84846-3c85-49b4-b917-5c987e2e36d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3412409a-75cf-4b28-a498-d7024435e94b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_cef84846-3c85-49b4-b917-5c987e2e36d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_a390239f-e079-48be-8e44-782d86a54e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3412409a-75cf-4b28-a498-d7024435e94b" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_a390239f-e079-48be-8e44-782d86a54e94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_a4e906a9-b016-43ff-81d0-39dd4f8f816b" xlink:href="evh-20220630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3412409a-75cf-4b28-a498-d7024435e94b" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_a4e906a9-b016-43ff-81d0-39dd4f8f816b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_23d31e84-a563-4a31-bebc-1b8eec37568d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3412409a-75cf-4b28-a498-d7024435e94b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_23d31e84-a563-4a31-bebc-1b8eec37568d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7e4276f0-a9cb-42c6-9233-2306d02d19ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00c711ee-9a3b-42f9-addd-ae8bd3178098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7e4276f0-a9cb-42c6-9233-2306d02d19ad" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00c711ee-9a3b-42f9-addd-ae8bd3178098" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_f4b3233f-64ef-45f6-88ab-c8cd7030e7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7e4276f0-a9cb-42c6-9233-2306d02d19ad" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_f4b3233f-64ef-45f6-88ab-c8cd7030e7d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_50fbbcb3-5939-4ba8-8800-9497ec6e33a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f1a0ad3a-61c5-4154-82bd-f67f9ebf4c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_50fbbcb3-5939-4ba8-8800-9497ec6e33a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f1a0ad3a-61c5-4154-82bd-f67f9ebf4c73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f559293d-544c-4a20-9c6e-c5a9a8d36bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_50fbbcb3-5939-4ba8-8800-9497ec6e33a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f559293d-544c-4a20-9c6e-c5a9a8d36bd5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d5e116c6-c185-4b1f-a4d7-34f5a369f231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fb445b8b-2b42-4574-ad46-7e52a49f7929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d5e116c6-c185-4b1f-a4d7-34f5a369f231" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fb445b8b-2b42-4574-ad46-7e52a49f7929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d904855e-2909-4a32-bbb1-d0ddd1bbdb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d5e116c6-c185-4b1f-a4d7-34f5a369f231" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d904855e-2909-4a32-bbb1-d0ddd1bbdb09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_effe31a9-3870-432a-88a4-a42d293e0eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad5cd78b-9b6e-405d-965b-22316af94852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_effe31a9-3870-432a-88a4-a42d293e0eea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad5cd78b-9b6e-405d-965b-22316af94852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_014d4b20-830b-405f-8dce-a2bc7e5720b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_effe31a9-3870-432a-88a4-a42d293e0eea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_014d4b20-830b-405f-8dce-a2bc7e5720b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa3e3f9a-a490-4277-95a7-a2f559a19387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d30642a7-9458-47c6-b656-7919bca15ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa3e3f9a-a490-4277-95a7-a2f559a19387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d30642a7-9458-47c6-b656-7919bca15ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_62b3a8df-bc60-4075-a445-0dacfc233723" xlink:href="evh-20220630.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa3e3f9a-a490-4277-95a7-a2f559a19387" xlink:to="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_62b3a8df-bc60-4075-a445-0dacfc233723" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_33ff551d-1f66-4792-a428-a5e6f1a94c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa3e3f9a-a490-4277-95a7-a2f559a19387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_33ff551d-1f66-4792-a428-a5e6f1a94c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_669ce8a7-c141-4fbd-ace5-d24da0d7072d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa3e3f9a-a490-4277-95a7-a2f559a19387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_669ce8a7-c141-4fbd-ace5-d24da0d7072d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e09b5147-35a2-4a23-b382-7459c45cc98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa3e3f9a-a490-4277-95a7-a2f559a19387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e09b5147-35a2-4a23-b382-7459c45cc98a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_498751c8-5f3e-42d4-87d2-9bf55f052b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa3e3f9a-a490-4277-95a7-a2f559a19387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_498751c8-5f3e-42d4-87d2-9bf55f052b31" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_a9ab0c9f-e5d4-4a7e-a09d-750539439fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_70247487-e082-4774-a260-43c4c30b6db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_a9ab0c9f-e5d4-4a7e-a09d-750539439fb5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_70247487-e082-4774-a260-43c4c30b6db2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d207524a-0f7d-4980-b277-53c2afade5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_a9ab0c9f-e5d4-4a7e-a09d-750539439fb5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d207524a-0f7d-4980-b277-53c2afade5c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b9becfe0-0ad3-464f-8ebf-7ca5c4278813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_794ec64d-f526-435b-ab20-98c42ef997ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b9becfe0-0ad3-464f-8ebf-7ca5c4278813" xlink:to="loc_us-gaap_OperatingLeaseCost_794ec64d-f526-435b-ab20-98c42ef997ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_7368767b-1d9f-4a2d-a750-14e47745cdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b9becfe0-0ad3-464f-8ebf-7ca5c4278813" xlink:to="loc_us-gaap_VariableLeaseCost_7368767b-1d9f-4a2d-a750-14e47745cdf5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f52db8dc-823e-464f-b4fa-56766274049e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9b9863df-206e-45d7-bd51-3da43f0f8cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f52db8dc-823e-464f-b4fa-56766274049e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9b9863df-206e-45d7-bd51-3da43f0f8cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_27e1baa3-bcb4-4f0b-868e-5439cab641d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f52db8dc-823e-464f-b4fa-56766274049e" xlink:to="loc_us-gaap_OperatingLeaseLiability_27e1baa3-bcb4-4f0b-868e-5439cab641d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812e3ab8-8201-4e69-9143-66c8a8dc47c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_df5e2720-eebd-4ebe-ab40-2ae28d3ddd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812e3ab8-8201-4e69-9143-66c8a8dc47c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_df5e2720-eebd-4ebe-ab40-2ae28d3ddd15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1f14378f-64f9-4dbb-9870-560499e39f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812e3ab8-8201-4e69-9143-66c8a8dc47c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1f14378f-64f9-4dbb-9870-560499e39f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_40aa9c15-1922-423b-9c91-096029bd6e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812e3ab8-8201-4e69-9143-66c8a8dc47c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_40aa9c15-1922-423b-9c91-096029bd6e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_eaeba147-8f2b-4499-be21-cae0a19cb25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812e3ab8-8201-4e69-9143-66c8a8dc47c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_eaeba147-8f2b-4499-be21-cae0a19cb25e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8f44b05e-4a30-4c28-b0cf-7789212bd76c" xlink:href="evh-20220630.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812e3ab8-8201-4e69-9143-66c8a8dc47c8" xlink:to="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8f44b05e-4a30-4c28-b0cf-7789212bd76c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cd37a7c6-e26d-4f5e-a648-422c90de5d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812e3ab8-8201-4e69-9143-66c8a8dc47c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cd37a7c6-e26d-4f5e-a648-422c90de5d77" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_da0f7c98-53ea-4879-b285-499ba4ee2038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_04f639fe-3ad2-440e-a36b-948f09cef3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_da0f7c98-53ea-4879-b285-499ba4ee2038" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_04f639fe-3ad2-440e-a36b-948f09cef3a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="evh-20220630.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_afecdbac-7623-48fa-a223-feef332260a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_us-gaap_InvestmentIncomeInterest_afecdbac-7623-48fa-a223-feef332260a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_ca6deeb6-f000-4537-bfe2-787cf813c2bb" xlink:href="evh-20220630.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_ca6deeb6-f000-4537-bfe2-787cf813c2bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_3dd40348-bdfc-4e77-8d54-c09b1b782bca" xlink:href="evh-20220630.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_3dd40348-bdfc-4e77-8d54-c09b1b782bca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices_0fd0099a-f2fb-4aae-927c-f36f790519a8" xlink:href="evh-20220630.xsd#evh_ShareholderAdvisoryServices"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_evh_ShareholderAdvisoryServices_0fd0099a-f2fb-4aae-927c-f36f790519a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts_cf56bdec-bcd4-4364-8823-b2773f48ea03" xlink:href="evh-20220630.xsd#evh_TransactionCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_evh_TransactionCosts_cf56bdec-bcd4-4364-8823-b2773f48ea03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3413b7f8-b9b6-45ed-be64-dd11271ffc33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3413b7f8-b9b6-45ed-be64-dd11271ffc33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d2e52234-6c9d-4ab1-a7a2-b02b89b7b02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d2e52234-6c9d-4ab1-a7a2-b02b89b7b02e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b0e2a148-dd05-4813-9ee4-927f19e3b6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_us-gaap_RestructuringCharges_b0e2a148-dd05-4813-9ee4-927f19e3b6bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fb3634ee-7df1-4bc1-92eb-7d7a6008f733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fb3634ee-7df1-4bc1-92eb-7d7a6008f733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_26db83a3-50b7-410c-970a-c3dbcf0f03a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_us-gaap_DepreciationAndAmortization_26db83a3-50b7-410c-970a-c3dbcf0f03a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ac3e07ba-bc84-4240-b69b-761c9f9ce22b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ac3e07ba-bc84-4240-b69b-761c9f9ce22b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f43530e4-5c33-48d3-ad14-636cf3b209d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f43530e4-5c33-48d3-ad14-636cf3b209d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_59dc1e13-29c4-4920-a068-02e2784e099e" xlink:href="evh-20220630.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_evh_GainOnTransferOfMembership_59dc1e13-29c4-4920-a068-02e2784e099e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dc295c2b-e73d-4ffd-8e53-4d7c689b9c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_us-gaap_InterestExpense_dc295c2b-e73d-4ffd-8e53-4d7c689b9c89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f6950a9f-9bb0-4621-b9af-587f52a5ca97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f6950a9f-9bb0-4621-b9af-587f52a5ca97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_6bab9f00-53a9-48ea-a9d9-a5f5aec75238" xlink:href="evh-20220630.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_6bab9f00-53a9-48ea-a9d9-a5f5aec75238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_afea8d6b-2419-40cd-b762-8e1348786b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5de3d66-130b-4011-99fd-136ab0b9f940" xlink:to="loc_us-gaap_SeveranceCosts1_afea8d6b-2419-40cd-b762-8e1348786b04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_ede8d851-1302-4d4c-8070-858cfa1fa73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_adf19db8-7f18-4dd4-a464-66220dd0fdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_ede8d851-1302-4d4c-8070-858cfa1fa73b" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_adf19db8-7f18-4dd4-a464-66220dd0fdb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_708acdbf-7941-43e7-905a-d9a103573c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_ede8d851-1302-4d4c-8070-858cfa1fa73b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_708acdbf-7941-43e7-905a-d9a103573c6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_701aea5f-775c-425c-b022-a02a1d3d7aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_ede8d851-1302-4d4c-8070-858cfa1fa73b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_701aea5f-775c-425c-b022-a02a1d3d7aae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_1ea151a1-261a-4854-9952-e8a6052b3a1b" xlink:href="evh-20220630.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_ede8d851-1302-4d4c-8070-858cfa1fa73b" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_1ea151a1-261a-4854-9952-e8a6052b3a1b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>evh-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a212dad2-7296-44b7-8af9-e12f408b43ae,g:23ff20ea-0869-45df-9d88-aeb2d6e74df5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended" id="iab7e0a1fd75f408b9def3740c7428cab_CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_25735e0b-144f-4387-8b68-5588962de5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_25735e0b-144f-4387-8b68-5588962de5e3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_be696e11-68fa-4f06-8320-6636917426c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_SharesIssued_be696e11-68fa-4f06-8320-6636917426c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_816b7918-fd9b-4526-a025-fda3ea13f884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockholdersEquity_816b7918-fd9b-4526-a025-fda3ea13f884" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_52ff467b-4dbf-4f72-80e7-8bc78952d94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_52ff467b-4dbf-4f72-80e7-8bc78952d94f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_983c9d1d-2e72-4d7a-8d4c-70709a40da23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_983c9d1d-2e72-4d7a-8d4c-70709a40da23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1ee6bd2e-2c5e-4d99-b05d-50fdf52abb48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1ee6bd2e-2c5e-4d99-b05d-50fdf52abb48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_222fe194-90cc-4cac-a269-9851bba86011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_222fe194-90cc-4cac-a269-9851bba86011" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_8a1fbe63-4ef0-4341-837b-b4a291e8ed3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_8a1fbe63-4ef0-4341-837b-b4a291e8ed3d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a19cff7a-19d3-46cb-b380-5dae8226ef3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a19cff7a-19d3-46cb-b380-5dae8226ef3d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_da19976d-3750-4ca5-9ed0-d00ba33fe726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_da19976d-3750-4ca5-9ed0-d00ba33fe726" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_607f1672-aa87-4d16-8b21-adf05058edfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_607f1672-aa87-4d16-8b21-adf05058edfc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_31281467-d970-443e-b4a7-9524b2293e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_NetIncomeLoss_31281467-d970-443e-b4a7-9524b2293e04" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_b3eeec3b-47cf-4da9-a096-3b7ee447a77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_23f35a92-d333-4ae4-87ad-ad16f6de62ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_68924e67-295a-4c97-84a6-3dceb2101151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_25735e0b-144f-4387-8b68-5588962de5e3" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_68924e67-295a-4c97-84a6-3dceb2101151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c545f0bc-7b5b-472f-8f2d-241c32e9ed49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_25735e0b-144f-4387-8b68-5588962de5e3" xlink:to="loc_us-gaap_StatementTable_c545f0bc-7b5b-472f-8f2d-241c32e9ed49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bbe76c47-dd09-4b5a-ae72-dc730077a434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c545f0bc-7b5b-472f-8f2d-241c32e9ed49" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bbe76c47-dd09-4b5a-ae72-dc730077a434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bbe76c47-dd09-4b5a-ae72-dc730077a434_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbe76c47-dd09-4b5a-ae72-dc730077a434" xlink:to="loc_us-gaap_EquityComponentDomain_bbe76c47-dd09-4b5a-ae72-dc730077a434_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbe76c47-dd09-4b5a-ae72-dc730077a434" xlink:to="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c91d17d3-4715-4f42-8969-b51f7dabcf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:to="loc_us-gaap_CommonStockMember_c91d17d3-4715-4f42-8969-b51f7dabcf7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2e3ea172-c0d2-4f14-8426-2faf217c407b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2e3ea172-c0d2-4f14-8426-2faf217c407b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_798ad5b5-dcf5-45fe-bc16-f79549b362fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_798ad5b5-dcf5-45fe-bc16-f79549b362fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bfa9f259-f6c4-4980-87a5-61a2d99e7d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:to="loc_us-gaap_RetainedEarningsMember_bfa9f259-f6c4-4980-87a5-61a2d99e7d24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_53020125-941c-47c3-8909-b4d2ca4f77a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:to="loc_us-gaap_TreasuryStockMember_53020125-941c-47c3-8909-b4d2ca4f77a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b76b490e-8511-4449-9d1e-33573ca5c34a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c545f0bc-7b5b-472f-8f2d-241c32e9ed49" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b76b490e-8511-4449-9d1e-33573ca5c34a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b76b490e-8511-4449-9d1e-33573ca5c34a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b76b490e-8511-4449-9d1e-33573ca5c34a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b76b490e-8511-4449-9d1e-33573ca5c34a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27bf4173-9745-44d3-a9c9-380932aa6d85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b76b490e-8511-4449-9d1e-33573ca5c34a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27bf4173-9745-44d3-a9c9-380932aa6d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_51892b85-c386-49e0-aa1b-77d8ed524bbd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27bf4173-9745-44d3-a9c9-380932aa6d85" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_51892b85-c386-49e0-aa1b-77d8ed524bbd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended" id="i4d22d4ad88374f95b8a7c589c6b5e111_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_45cfda6d-8d1d-4f72-a069-2a14aa954e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_45cfda6d-8d1d-4f72-a069-2a14aa954e11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_03981b69-eef1-4c4d-8fd8-eba15a649777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_03981b69-eef1-4c4d-8fd8-eba15a649777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_d903d8b5-8008-49df-b750-a5cf6a5f4e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_d903d8b5-8008-49df-b750-a5cf6a5f4e4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2efad5f4-06ef-43f7-b19b-bf303dbd78fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2efad5f4-06ef-43f7-b19b-bf303dbd78fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_8dacc754-013b-4469-91f2-4d1c445d1113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_8dacc754-013b-4469-91f2-4d1c445d1113" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_6e945d89-f595-4183-8da5-50962756b273" xlink:href="evh-20220630.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_6e945d89-f595-4183-8da5-50962756b273" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_e1e657c9-0127-4377-a8de-2a12e7578293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_e1e657c9-0127-4377-a8de-2a12e7578293" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2798dafc-6fce-4fd4-bb2d-4586b10ee1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2798dafc-6fce-4fd4-bb2d-4586b10ee1c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_46112a92-a57b-4ca2-96ec-56867d8f03e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_46112a92-a57b-4ca2-96ec-56867d8f03e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_07c7363e-29a2-458e-927a-a2d4b934c5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_46112a92-a57b-4ca2-96ec-56867d8f03e2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_07c7363e-29a2-458e-927a-a2d4b934c5e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_07c7363e-29a2-458e-927a-a2d4b934c5e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_07c7363e-29a2-458e-927a-a2d4b934c5e3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_07c7363e-29a2-458e-927a-a2d4b934c5e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_07c7363e-29a2-458e-927a-a2d4b934c5e3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_6ebdff18-444f-404a-81dd-685ffad1c91b" xlink:href="evh-20220630.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_6ebdff18-444f-404a-81dd-685ffad1c91b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_ef21a8a9-9578-43d6-aeca-ad9382c165b4" xlink:href="evh-20220630.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_ef21a8a9-9578-43d6-aeca-ad9382c165b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_91e879aa-640f-433e-a550-28df38a634d1" xlink:href="evh-20220630.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_91e879aa-640f-433e-a550-28df38a634d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_930f99ae-d2aa-4a03-acf0-e19b1a16720a" xlink:href="evh-20220630.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_930f99ae-d2aa-4a03-acf0-e19b1a16720a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_487f8445-640d-4097-971b-38053a11f012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:to="loc_us-gaap_BankTimeDepositsMember_487f8445-640d-4097-971b-38053a11f012" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended" id="idf2b93b5698742558f3e8e40df138d9c_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b9bce448-d660-40f5-a10b-6dc41aa21ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3195c8bd-63a9-4d58-99a7-21c16709244f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b9bce448-d660-40f5-a10b-6dc41aa21ab0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3195c8bd-63a9-4d58-99a7-21c16709244f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11c0ac3f-9dfb-4186-ae94-d57425605cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b9bce448-d660-40f5-a10b-6dc41aa21ab0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11c0ac3f-9dfb-4186-ae94-d57425605cfa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1cd57a6-2a33-4204-b631-f8b31953b6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11c0ac3f-9dfb-4186-ae94-d57425605cfa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1cd57a6-2a33-4204-b631-f8b31953b6a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1cd57a6-2a33-4204-b631-f8b31953b6a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1cd57a6-2a33-4204-b631-f8b31953b6a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1cd57a6-2a33-4204-b631-f8b31953b6a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1cd57a6-2a33-4204-b631-f8b31953b6a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_c247ef4f-a3a3-46e5-80bc-0eca0934a91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:to="loc_us-gaap_TradeNamesMember_c247ef4f-a3a3-46e5-80bc-0eca0934a91a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_903fc9e1-96c3-42de-819a-8611171690bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:to="loc_us-gaap_CustomerRelationshipsMember_903fc9e1-96c3-42de-819a-8611171690bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1eaeddb0-a3f5-4f9d-ad50-a35d7e665308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1eaeddb0-a3f5-4f9d-ad50-a35d7e665308" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_5c9a1994-99f0-4b9d-8da0-fece47e46049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_5c9a1994-99f0-4b9d-8da0-fece47e46049" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_11ea468c-7d39-46a5-8f22-32f0f20c7de8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11c0ac3f-9dfb-4186-ae94-d57425605cfa" xlink:to="loc_srt_RangeAxis_11ea468c-7d39-46a5-8f22-32f0f20c7de8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11ea468c-7d39-46a5-8f22-32f0f20c7de8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_11ea468c-7d39-46a5-8f22-32f0f20c7de8" xlink:to="loc_srt_RangeMember_11ea468c-7d39-46a5-8f22-32f0f20c7de8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d80ad52-e644-4ffc-b07d-f068aa2f2a45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_11ea468c-7d39-46a5-8f22-32f0f20c7de8" xlink:to="loc_srt_RangeMember_2d80ad52-e644-4ffc-b07d-f068aa2f2a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c9742b6-c1ff-4c16-a49a-76487acc0d2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2d80ad52-e644-4ffc-b07d-f068aa2f2a45" xlink:to="loc_srt_MinimumMember_5c9742b6-c1ff-4c16-a49a-76487acc0d2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b650ba92-4674-4797-bb11-05c7306de658" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2d80ad52-e644-4ffc-b07d-f068aa2f2a45" xlink:to="loc_srt_MaximumMember_b650ba92-4674-4797-bb11-05c7306de658" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended" id="i06996609f36246a8ae3fd9effbe66dca_RecentlyIssuedAccountingStandardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_23c3f36a-585f-4dd1-96e6-24e7fc452dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e759376-c676-4fb1-92da-3249d687e68e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_23c3f36a-585f-4dd1-96e6-24e7fc452dea" xlink:to="loc_us-gaap_StockholdersEquity_9e759376-c676-4fb1-92da-3249d687e68e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2b46b7dd-6b1e-43ff-93f4-d781703ba36d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_23c3f36a-585f-4dd1-96e6-24e7fc452dea" xlink:to="loc_us-gaap_LongTermDebt_2b46b7dd-6b1e-43ff-93f4-d781703ba36d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_23c3f36a-585f-4dd1-96e6-24e7fc452dea" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4a4aecf1-f31e-4d73-b54a-0d4bd097f810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4a4aecf1-f31e-4d73-b54a-0d4bd097f810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4a4aecf1-f31e-4d73-b54a-0d4bd097f810_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a4aecf1-f31e-4d73-b54a-0d4bd097f810" xlink:to="loc_us-gaap_EquityComponentDomain_4a4aecf1-f31e-4d73-b54a-0d4bd097f810_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7177956c-4d3d-4b4f-8ac0-7cb6b6ab0f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a4aecf1-f31e-4d73-b54a-0d4bd097f810" xlink:to="loc_us-gaap_EquityComponentDomain_7177956c-4d3d-4b4f-8ac0-7cb6b6ab0f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9d78d707-da98-4752-9771-d256fd2a9563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7177956c-4d3d-4b4f-8ac0-7cb6b6ab0f7c" xlink:to="loc_us-gaap_RetainedEarningsMember_9d78d707-da98-4752-9771-d256fd2a9563" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7663cdb3-7cf2-44d6-9095-cefd269802b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7177956c-4d3d-4b4f-8ac0-7cb6b6ab0f7c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7663cdb3-7cf2-44d6-9095-cefd269802b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d749a7d-b5cd-4a7a-9710-a68a9bdd8c40" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d749a7d-b5cd-4a7a-9710-a68a9bdd8c40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8d749a7d-b5cd-4a7a-9710-a68a9bdd8c40_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d749a7d-b5cd-4a7a-9710-a68a9bdd8c40" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8d749a7d-b5cd-4a7a-9710-a68a9bdd8c40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_606a3c2c-a294-455e-b585-a0cce0ddb277" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d749a7d-b5cd-4a7a-9710-a68a9bdd8c40" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_606a3c2c-a294-455e-b585-a0cce0ddb277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ac15e38f-44ea-4e96-a3f2-835f1713fdca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_606a3c2c-a294-455e-b585-a0cce0ddb277" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ac15e38f-44ea-4e96-a3f2-835f1713fdca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3a84a739-550e-4576-ac4e-5d9971f74d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:to="loc_us-gaap_DebtInstrumentAxis_3a84a739-550e-4576-ac4e-5d9971f74d14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3a84a739-550e-4576-ac4e-5d9971f74d14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a84a739-550e-4576-ac4e-5d9971f74d14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3a84a739-550e-4576-ac4e-5d9971f74d14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2e08e263-6193-438b-b97d-57d9577b6f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a84a739-550e-4576-ac4e-5d9971f74d14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2e08e263-6193-438b-b97d-57d9577b6f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_0e09d885-da9a-458e-bdc6-6c13597d3f75" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e08e263-6193-438b-b97d-57d9577b6f43" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_0e09d885-da9a-458e-bdc6-6c13597d3f75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_3bc0660e-89fe-427f-84fb-c52455dbc65a" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e08e263-6193-438b-b97d-57d9577b6f43" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_3bc0660e-89fe-427f-84fb-c52455dbc65a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_174157a7-8349-4218-aa18-b3a68f1234ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_174157a7-8349-4218-aa18-b3a68f1234ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_174157a7-8349-4218-aa18-b3a68f1234ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_174157a7-8349-4218-aa18-b3a68f1234ed" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_174157a7-8349-4218-aa18-b3a68f1234ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_983b3d32-2979-4a7f-ac0b-effde57279fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_174157a7-8349-4218-aa18-b3a68f1234ed" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_983b3d32-2979-4a7f-ac0b-effde57279fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7d4e0956-7322-4622-847a-bd60daa78ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_983b3d32-2979-4a7f-ac0b-effde57279fa" xlink:to="loc_us-gaap_SeniorNotesMember_7d4e0956-7322-4622-847a-bd60daa78ea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_63281121-a8e4-44dc-91a6-1b41fe53b222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_63281121-a8e4-44dc-91a6-1b41fe53b222" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_63281121-a8e4-44dc-91a6-1b41fe53b222_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_63281121-a8e4-44dc-91a6-1b41fe53b222" xlink:to="loc_us-gaap_TypeOfAdoptionMember_63281121-a8e4-44dc-91a6-1b41fe53b222_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_077c42e5-38f8-4266-9c89-63afec910fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_63281121-a8e4-44dc-91a6-1b41fe53b222" xlink:to="loc_us-gaap_TypeOfAdoptionMember_077c42e5-38f8-4266-9c89-63afec910fad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_4355ea45-b4a3-4443-aa39-83c53daefb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_077c42e5-38f8-4266-9c89-63afec910fad" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_4355ea45-b4a3-4443-aa39-83c53daefb5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#TransactionsVitalDecisionsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="extended" id="i1f2b2f50ee734af6833d97ff7337c074_TransactionsVitalDecisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_afae07c0-2d73-4425-890f-83114117d739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_afae07c0-2d73-4425-890f-83114117d739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_f71e3e00-6de3-459a-af67-4f8c304c629a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_f71e3e00-6de3-459a-af67-4f8c304c629a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4b42a9a5-b331-4af6-ac61-41b03b870a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4b42a9a5-b331-4af6-ac61-41b03b870a00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6aaf9ff6-7882-45db-b105-ad6ada4012b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6aaf9ff6-7882-45db-b105-ad6ada4012b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_37054db3-fe3c-4246-bc50-b624d506c0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_37054db3-fe3c-4246-bc50-b624d506c0c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7ff3dffc-af23-4254-ae74-7e7084d478c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7ff3dffc-af23-4254-ae74-7e7084d478c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_2e41938d-3bd2-43ed-9f31-8f0a37d67492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_2e41938d-3bd2-43ed-9f31-8f0a37d67492" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_90300b04-a4e2-40ac-aeb7-e0a2fa82ed7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_90300b04-a4e2-40ac-aeb7-e0a2fa82ed7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4b31af68-9f55-43ac-8339-84c08f646de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4b31af68-9f55-43ac-8339-84c08f646de4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3292a05f-76cf-4506-94fb-869aa23f49f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3292a05f-76cf-4506-94fb-869aa23f49f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e2be72bf-a092-4065-ab5e-4e55404ee51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e2be72bf-a092-4065-ab5e-4e55404ee51e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_93e7feac-7aea-4117-b15b-06ae17f5d3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_93e7feac-7aea-4117-b15b-06ae17f5d3cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_93c5d5a2-e698-433f-b765-4c8271184486" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_93c5d5a2-e698-433f-b765-4c8271184486" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_a56a6ba6-24c1-4aa3-8322-42dd6309f201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_a56a6ba6-24c1-4aa3-8322-42dd6309f201" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_94e0e9fc-962a-44c8-b5bf-674d114457f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_a56a6ba6-24c1-4aa3-8322-42dd6309f201" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_94e0e9fc-962a-44c8-b5bf-674d114457f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5b6a60e9-8b7c-4263-a9b4-d5e5e6439ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5b6a60e9-8b7c-4263-a9b4-d5e5e6439ab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_2eb018e6-608e-4a91-92fe-98f22f6a43c3" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_2eb018e6-608e-4a91-92fe-98f22f6a43c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_a2d78bda-238f-4d1e-9c4b-424f5b2cc650" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_a2d78bda-238f-4d1e-9c4b-424f5b2cc650" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ce90a731-131d-43a6-9413-79b1d83f8aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ce90a731-131d-43a6-9413-79b1d83f8aad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_a82565ab-cc08-42f6-b828-852da683d4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_a82565ab-cc08-42f6-b828-852da683d4be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_74f67bc8-52a8-403e-b303-d348e5dba74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_74f67bc8-52a8-403e-b303-d348e5dba74a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ff111327-499c-44ef-bbbb-92792c1e66c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ff111327-499c-44ef-bbbb-92792c1e66c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c4ead30f-e624-46f0-89ca-1d00fd7d26a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_Goodwill_c4ead30f-e624-46f0-89ca-1d00fd7d26a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_22920902-b1f3-4746-a837-7338b46fb2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_22920902-b1f3-4746-a837-7338b46fb2c2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_df321ecc-07ac-48fd-b737-d52e1490614c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_df321ecc-07ac-48fd-b737-d52e1490614c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_aa81cc5b-2808-4174-803f-21329818b79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_aa81cc5b-2808-4174-803f-21329818b79c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13fac8b1-286c-4fac-8a41-e11b46f341a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13fac8b1-286c-4fac-8a41-e11b46f341a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_534a22af-8087-4f54-a893-b269d6a1d106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13fac8b1-286c-4fac-8a41-e11b46f341a5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_534a22af-8087-4f54-a893-b269d6a1d106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_534a22af-8087-4f54-a893-b269d6a1d106_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_534a22af-8087-4f54-a893-b269d6a1d106" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_534a22af-8087-4f54-a893-b269d6a1d106_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5563f8a-7ee5-4531-b443-53edbb72e611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_534a22af-8087-4f54-a893-b269d6a1d106" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5563f8a-7ee5-4531-b443-53edbb72e611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_60649871-c7f5-4d39-9ab5-04196f92bf64" xlink:href="evh-20220630.xsd#evh_VitalDecisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5563f8a-7ee5-4531-b443-53edbb72e611" xlink:to="loc_evh_VitalDecisionsMember_60649871-c7f5-4d39-9ab5-04196f92bf64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f89605e-79d7-4042-877d-4090d7769832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13fac8b1-286c-4fac-8a41-e11b46f341a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f89605e-79d7-4042-877d-4090d7769832" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2f89605e-79d7-4042-877d-4090d7769832_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f89605e-79d7-4042-877d-4090d7769832" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2f89605e-79d7-4042-877d-4090d7769832_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fcf898bc-5d69-4041-8c12-e29253fac30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f89605e-79d7-4042-877d-4090d7769832" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fcf898bc-5d69-4041-8c12-e29253fac30d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2ff5f494-cb75-4047-bade-547bd601ae86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fcf898bc-5d69-4041-8c12-e29253fac30d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2ff5f494-cb75-4047-bade-547bd601ae86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_48eede5e-e108-49f7-a894-b90f49b01580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fcf898bc-5d69-4041-8c12-e29253fac30d" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_48eede5e-e108-49f7-a894-b90f49b01580" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_0d799276-a95b-4aef-b6fa-ae207d6f2887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fcf898bc-5d69-4041-8c12-e29253fac30d" xlink:to="loc_us-gaap_TradeNamesMember_0d799276-a95b-4aef-b6fa-ae207d6f2887" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended" id="i44164a0964d840a883f68eba10bebfd6_DiscontinuedOperationsSummaryofResultsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0656c8c8-a7fe-4299-acbe-d9ca90d2ad0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_RevenuesAbstract_0656c8c8-a7fe-4299-acbe-d9ca90d2ad0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9ac6384a-8c92-4202-9b18-073999db4477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0656c8c8-a7fe-4299-acbe-d9ca90d2ad0a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9ac6384a-8c92-4202-9b18-073999db4477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_09fae78b-ce2f-45ae-985a-814349971dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_09fae78b-ce2f-45ae-985a-814349971dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_94394323-0aef-4bde-b03e-6fad32b74e50" xlink:href="evh-20220630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_94394323-0aef-4bde-b03e-6fad32b74e50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e241b361-96ea-4172-9bc3-1072142dbf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e241b361-96ea-4172-9bc3-1072142dbf5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_56a66e22-11be-4a3b-aa78-3a894e17255c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_56a66e22-11be-4a3b-aa78-3a894e17255c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2e8f5270-148f-4d0d-8248-257f301b2d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2e8f5270-148f-4d0d-8248-257f301b2d67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a52b85c0-9a3a-4474-a506-ffe7456eae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a52b85c0-9a3a-4474-a506-ffe7456eae6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_a51d6aac-b106-49c1-a5b0-79c543eb96bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_a51d6aac-b106-49c1-a5b0-79c543eb96bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_76616d9f-7776-4b71-b5cd-64e91dcd40e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_76616d9f-7776-4b71-b5cd-64e91dcd40e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_3f67b276-4320-4fe6-85e6-d9ac13c502e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_3f67b276-4320-4fe6-85e6-d9ac13c502e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9b26e1d7-0ea5-451b-8772-981191ecf05d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9b26e1d7-0ea5-451b-8772-981191ecf05d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_8308e3df-d695-4f36-b7f1-331afac437e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_8308e3df-d695-4f36-b7f1-331afac437e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1f27b7a6-cefb-48f1-9275-916246298296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1f27b7a6-cefb-48f1-9275-916246298296" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dac28e11-a01d-4795-af1c-40ad56156517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dac28e11-a01d-4795-af1c-40ad56156517" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b8e4f172-fceb-4f8b-a02c-bd4686fbd31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dac28e11-a01d-4795-af1c-40ad56156517" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b8e4f172-fceb-4f8b-a02c-bd4686fbd31b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b8e4f172-fceb-4f8b-a02c-bd4686fbd31b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b8e4f172-fceb-4f8b-a02c-bd4686fbd31b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b8e4f172-fceb-4f8b-a02c-bd4686fbd31b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0a24c202-8697-4145-8a88-df1c5a8f7940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b8e4f172-fceb-4f8b-a02c-bd4686fbd31b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0a24c202-8697-4145-8a88-df1c5a8f7940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4d75095b-bad2-4064-83a8-0ca26d823da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0a24c202-8697-4145-8a88-df1c5a8f7940" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4d75095b-bad2-4064-83a8-0ca26d823da6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbc7097e-ce07-4895-b99d-e4936a5437fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dac28e11-a01d-4795-af1c-40ad56156517" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbc7097e-ce07-4895-b99d-e4936a5437fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fbc7097e-ce07-4895-b99d-e4936a5437fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbc7097e-ce07-4895-b99d-e4936a5437fe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fbc7097e-ce07-4895-b99d-e4936a5437fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9695d69-a3f7-4a13-85fe-16faf7f1132b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbc7097e-ce07-4895-b99d-e4936a5437fe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9695d69-a3f7-4a13-85fe-16faf7f1132b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_be21e396-fd18-4214-b566-7f418e60865a" xlink:href="evh-20220630.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9695d69-a3f7-4a13-85fe-16faf7f1132b" xlink:to="loc_evh_TrueHealthMember_be21e396-fd18-4214-b566-7f418e60865a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e164ff70-fe7c-4e2a-89fa-afb75a657d58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dac28e11-a01d-4795-af1c-40ad56156517" xlink:to="loc_srt_ProductOrServiceAxis_e164ff70-fe7c-4e2a-89fa-afb75a657d58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e164ff70-fe7c-4e2a-89fa-afb75a657d58_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e164ff70-fe7c-4e2a-89fa-afb75a657d58" xlink:to="loc_srt_ProductsAndServicesDomain_e164ff70-fe7c-4e2a-89fa-afb75a657d58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e0889690-a0ee-419a-b8b1-0bf54e3dfac9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e164ff70-fe7c-4e2a-89fa-afb75a657d58" xlink:to="loc_srt_ProductsAndServicesDomain_e0889690-a0ee-419a-b8b1-0bf54e3dfac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_f28a958d-2072-4bb8-b723-4b5f48f6add0" xlink:href="evh-20220630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e0889690-a0ee-419a-b8b1-0bf54e3dfac9" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_f28a958d-2072-4bb8-b723-4b5f48f6add0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_2647545f-a89c-475c-8da4-36c144472a5a" xlink:href="evh-20220630.xsd#evh_PremiumsRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e0889690-a0ee-419a-b8b1-0bf54e3dfac9" xlink:to="loc_evh_PremiumsRevenueMember_2647545f-a89c-475c-8da4-36c144472a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_1a4651ee-5145-41ca-a20e-946dd5f961a7" xlink:href="evh-20220630.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e0889690-a0ee-419a-b8b1-0bf54e3dfac9" xlink:to="loc_evh_ServicesAgreementsMember_1a4651ee-5145-41ca-a20e-946dd5f961a7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended" id="i6813de705666431c84a4f3cbdb349e4f_DiscontinuedOperationsSummaryofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6d9a9c8c-f132-4de8-b956-0ab8a4e8430c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_d929e3e9-3025-4bec-95df-762adfcb9eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6d9a9c8c-f132-4de8-b956-0ab8a4e8430c" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_d929e3e9-3025-4bec-95df-762adfcb9eb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_23db4e50-d91f-4af8-9a85-835b47f34e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6d9a9c8c-f132-4de8-b956-0ab8a4e8430c" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_23db4e50-d91f-4af8-9a85-835b47f34e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9d3d4da6-7863-47fb-b4eb-187a386b7019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6d9a9c8c-f132-4de8-b956-0ab8a4e8430c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9d3d4da6-7863-47fb-b4eb-187a386b7019" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce3d8a27-2055-4f25-ad81-e03119c29014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9d3d4da6-7863-47fb-b4eb-187a386b7019" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce3d8a27-2055-4f25-ad81-e03119c29014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ce3d8a27-2055-4f25-ad81-e03119c29014_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce3d8a27-2055-4f25-ad81-e03119c29014" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ce3d8a27-2055-4f25-ad81-e03119c29014_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1ab12ac0-e6a4-440f-a191-d231735416d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce3d8a27-2055-4f25-ad81-e03119c29014" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1ab12ac0-e6a4-440f-a191-d231735416d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_2b313e8d-dda5-482e-b682-3d851f2db48d" xlink:href="evh-20220630.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1ab12ac0-e6a4-440f-a191-d231735416d1" xlink:to="loc_evh_TrueHealthMember_2b313e8d-dda5-482e-b682-3d851f2db48d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_79892460-39ac-4bcf-b16d-6f535e9624c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9d3d4da6-7863-47fb-b4eb-187a386b7019" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_79892460-39ac-4bcf-b16d-6f535e9624c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_79892460-39ac-4bcf-b16d-6f535e9624c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_79892460-39ac-4bcf-b16d-6f535e9624c3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_79892460-39ac-4bcf-b16d-6f535e9624c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6f9ee5e2-9afe-428f-a31d-4306f3f51717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_79892460-39ac-4bcf-b16d-6f535e9624c3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6f9ee5e2-9afe-428f-a31d-4306f3f51717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_cda1112b-0f58-4f53-a06a-144cd5cc73fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6f9ee5e2-9afe-428f-a31d-4306f3f51717" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_cda1112b-0f58-4f53-a06a-144cd5cc73fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="ia3f0e04936cb4e3eb18a02bb31255ea6_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6da6c49a-d0e4-4d27-ba69-f01b9c18f6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93eefd98-b7b8-454b-acfe-1f4a44170433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6da6c49a-d0e4-4d27-ba69-f01b9c18f6fa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93eefd98-b7b8-454b-acfe-1f4a44170433" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f7af251c-e204-4312-8de6-d37d8a4ce82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6da6c49a-d0e4-4d27-ba69-f01b9c18f6fa" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f7af251c-e204-4312-8de6-d37d8a4ce82a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f9572da8-ecf7-4a4d-8599-4aeb03afd42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7af251c-e204-4312-8de6-d37d8a4ce82a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f9572da8-ecf7-4a4d-8599-4aeb03afd42e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f9572da8-ecf7-4a4d-8599-4aeb03afd42e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f9572da8-ecf7-4a4d-8599-4aeb03afd42e" xlink:to="loc_us-gaap_SegmentDomain_f9572da8-ecf7-4a4d-8599-4aeb03afd42e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bb164483-56b2-4790-a93c-35c4e61e5831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f9572da8-ecf7-4a4d-8599-4aeb03afd42e" xlink:to="loc_us-gaap_SegmentDomain_bb164483-56b2-4790-a93c-35c4e61e5831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_e25a6fc2-840b-4e34-b1a0-0ba2523d699f" xlink:href="evh-20220630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bb164483-56b2-4790-a93c-35c4e61e5831" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_e25a6fc2-840b-4e34-b1a0-0ba2523d699f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_63eccda8-c6e2-4aa7-b115-7443a71282e2" xlink:href="evh-20220630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bb164483-56b2-4790-a93c-35c4e61e5831" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_63eccda8-c6e2-4aa7-b115-7443a71282e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_96d14062-9ab8-4542-b097-e8ae9fbca12e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7af251c-e204-4312-8de6-d37d8a4ce82a" xlink:to="loc_srt_MajorCustomersAxis_96d14062-9ab8-4542-b097-e8ae9fbca12e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_96d14062-9ab8-4542-b097-e8ae9fbca12e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_96d14062-9ab8-4542-b097-e8ae9fbca12e" xlink:to="loc_srt_NameOfMajorCustomerDomain_96d14062-9ab8-4542-b097-e8ae9fbca12e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b051981c-2684-410a-b3bd-24bc24bae35e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_96d14062-9ab8-4542-b097-e8ae9fbca12e" xlink:to="loc_srt_NameOfMajorCustomerDomain_b051981c-2684-410a-b3bd-24bc24bae35e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_a39d92c9-6bc4-408e-a19c-6bd274c722ca" xlink:href="evh-20220630.xsd#evh_MedicaidCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b051981c-2684-410a-b3bd-24bc24bae35e" xlink:to="loc_evh_MedicaidCustomersMember_a39d92c9-6bc4-408e-a19c-6bd274c722ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_7292cad3-71a4-4433-bb72-3bcd1a7e681d" xlink:href="evh-20220630.xsd#evh_MedicareCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b051981c-2684-410a-b3bd-24bc24bae35e" xlink:to="loc_evh_MedicareCustomersMember_7292cad3-71a4-4433-bb72-3bcd1a7e681d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_2060404e-14a9-4cc9-af27-51b7a960f896" xlink:href="evh-20220630.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b051981c-2684-410a-b3bd-24bc24bae35e" xlink:to="loc_evh_CommercialAndOtherCustomersMember_2060404e-14a9-4cc9-af27-51b7a960f896" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended" id="i0c6437a5b31a4bd2ab8c5fa690b4e7eb_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_86bb9de4-26d6-49b5-9a1d-4b69ccbe6890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_86bb9de4-26d6-49b5-9a1d-4b69ccbe6890" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_21e0c598-3492-49b0-9d35-ab36926c9006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_21e0c598-3492-49b0-9d35-ab36926c9006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_760aef2e-8a63-40e7-a212-1d0cfe1b025c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_760aef2e-8a63-40e7-a212-1d0cfe1b025c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_53614445-a94d-4875-a12d-1ce58f49df52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_760aef2e-8a63-40e7-a212-1d0cfe1b025c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_53614445-a94d-4875-a12d-1ce58f49df52" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20220630.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended" id="if7495c0844a54b2fa4043bf42cc4b44e_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_86bb9de4-26d6-49b5-9a1d-4b69ccbe6890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_86bb9de4-26d6-49b5-9a1d-4b69ccbe6890" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_21e0c598-3492-49b0-9d35-ab36926c9006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_21e0c598-3492-49b0-9d35-ab36926c9006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_760aef2e-8a63-40e7-a212-1d0cfe1b025c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_760aef2e-8a63-40e7-a212-1d0cfe1b025c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended" id="ibb9dbe70cb3d476d85567157452fc988_RevenueRecognitionContractCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_2091b3e2-4aff-4d26-9967-4b96edcbd03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_f81fb0a4-356c-4a8a-b2f4-2acc94522b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_2091b3e2-4aff-4d26-9967-4b96edcbd03f" xlink:to="loc_us-gaap_CapitalizedContractCostNet_f81fb0a4-356c-4a8a-b2f4-2acc94522b57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_adf09a5f-424c-4911-a102-5a0442e94e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_2091b3e2-4aff-4d26-9967-4b96edcbd03f" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_adf09a5f-424c-4911-a102-5a0442e94e6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_470508ee-3bc4-436b-b466-a02c3a8310ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_2091b3e2-4aff-4d26-9967-4b96edcbd03f" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_470508ee-3bc4-436b-b466-a02c3a8310ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_1a94dd7a-242d-409e-93e2-48ed95f9bb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_2091b3e2-4aff-4d26-9967-4b96edcbd03f" xlink:to="loc_us-gaap_CapitalizedContractCostTable_1a94dd7a-242d-409e-93e2-48ed95f9bb36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_41cca131-b0f8-4d64-b9e8-f4d9b868a3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_1a94dd7a-242d-409e-93e2-48ed95f9bb36" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_41cca131-b0f8-4d64-b9e8-f4d9b868a3e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_41cca131-b0f8-4d64-b9e8-f4d9b868a3e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_41cca131-b0f8-4d64-b9e8-f4d9b868a3e7" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_41cca131-b0f8-4d64-b9e8-f4d9b868a3e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_bcc6915e-6f78-4ba6-848f-9b3b47a21dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_41cca131-b0f8-4d64-b9e8-f4d9b868a3e7" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_bcc6915e-6f78-4ba6-848f-9b3b47a21dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_98cc779b-2bc2-447f-a68c-4416d576c883" xlink:href="evh-20220630.xsd#evh_BonusesAndCommissionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_bcc6915e-6f78-4ba6-848f-9b3b47a21dd8" xlink:to="loc_evh_BonusesAndCommissionsMember_98cc779b-2bc2-447f-a68c-4416d576c883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_b9767217-dcec-48f1-ab83-8407ae2b408b" xlink:href="evh-20220630.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_bcc6915e-6f78-4ba6-848f-9b3b47a21dd8" xlink:to="loc_evh_ContractFulfillmentCostsMember_b9767217-dcec-48f1-ab83-8407ae2b408b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended" id="i6474d395ef30447a8252dbd18edd888f_CreditLossesAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_e1ce8ebe-18de-4457-87f7-95ea1a763d4d" xlink:href="evh-20220630.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_e1ce8ebe-18de-4457-87f7-95ea1a763d4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_36a13a79-278b-4c8b-b65e-0f8553c26c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_36a13a79-278b-4c8b-b65e-0f8553c26c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_64895ece-41e2-40d5-989b-69be41d730a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:to="loc_us-gaap_AccountsReceivableNet_64895ece-41e2-40d5-989b-69be41d730a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cb2c2939-6288-4907-8ac7-3bfef87149ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cb2c2939-6288-4907-8ac7-3bfef87149ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_ce633310-2f6f-4200-b2d4-5ebb1276bd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_ce633310-2f6f-4200-b2d4-5ebb1276bd6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ce610d34-34cb-4784-916a-6173bf64e8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_ce633310-2f6f-4200-b2d4-5ebb1276bd6b" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ce610d34-34cb-4784-916a-6173bf64e8ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_ce610d34-34cb-4784-916a-6173bf64e8ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ce610d34-34cb-4784-916a-6173bf64e8ed" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_ce610d34-34cb-4784-916a-6173bf64e8ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_5fab5b6c-f48a-4187-9c5f-c98c4970388b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ce610d34-34cb-4784-916a-6173bf64e8ed" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_5fab5b6c-f48a-4187-9c5f-c98c4970388b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_a46ef42b-d312-4c7e-91b0-4554cbab7710" xlink:href="evh-20220630.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_5fab5b6c-f48a-4187-9c5f-c98c4970388b" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_a46ef42b-d312-4c7e-91b0-4554cbab7710" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_411c09a8-729e-4509-b472-8eecc8626627" xlink:href="evh-20220630.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_5fab5b6c-f48a-4187-9c5f-c98c4970388b" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_411c09a8-729e-4509-b472-8eecc8626627" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="ibf1b224dde604ac3b7a203685853ce99_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1670e8d7-549b-486c-b10a-c32fcd176918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1670e8d7-549b-486c-b10a-c32fcd176918" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_330de10e-2e29-429f-ba5b-cd444376d254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_330de10e-2e29-429f-ba5b-cd444376d254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3548c7b7-2efa-4ae8-a298-42864c3c5a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3548c7b7-2efa-4ae8-a298-42864c3c5a0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_108fac4f-17be-46e6-ae86-42d38638098c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_108fac4f-17be-46e6-ae86-42d38638098c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_11109e0d-5b31-4a19-ad71-639e04a361c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_Depreciation_11109e0d-5b31-4a19-ad71-639e04a361c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_b5b119a4-fe3f-4dd9-9357-3d81b55d4d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_b5b119a4-fe3f-4dd9-9357-3d81b55d4d5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ceb1820f-9794-4587-ae24-36f1542dde71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ceb1820f-9794-4587-ae24-36f1542dde71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75d9147e-27a6-47c4-9746-284d99e2e1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ceb1820f-9794-4587-ae24-36f1542dde71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75d9147e-27a6-47c4-9746-284d99e2e1f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75d9147e-27a6-47c4-9746-284d99e2e1f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75d9147e-27a6-47c4-9746-284d99e2e1f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75d9147e-27a6-47c4-9746-284d99e2e1f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75d9147e-27a6-47c4-9746-284d99e2e1f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_af842c15-b405-4862-bd7e-5f04b67863e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:to="loc_us-gaap_ComputerEquipmentMember_af842c15-b405-4862-bd7e-5f04b67863e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2ff3bd89-f94e-4011-9ffe-1f29ec5317d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2ff3bd89-f94e-4011-9ffe-1f29ec5317d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_c4d9e232-7d6f-427a-87e9-5229d4ed6d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_c4d9e232-7d6f-427a-87e9-5229d4ed6d16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_95b78d60-56e2-49f5-bf8c-53c0cae89903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_95b78d60-56e2-49f5-bf8c-53c0cae89903" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended" id="ie5885e5a8942439dbff1ae6b313c4a66_GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_257a6ec1-7fe8-40d8-9431-d5e7668da0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_99bd2c81-6dae-4afc-809c-d8e7e149a601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_257a6ec1-7fe8-40d8-9431-d5e7668da0c9" xlink:to="loc_us-gaap_GoodwillRollForward_99bd2c81-6dae-4afc-809c-d8e7e149a601" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0d769519-7160-4789-967d-bf192e165505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_99bd2c81-6dae-4afc-809c-d8e7e149a601" xlink:to="loc_us-gaap_Goodwill_0d769519-7160-4789-967d-bf192e165505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_2af196cd-2796-48a0-82aa-0e2135d0b3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_99bd2c81-6dae-4afc-809c-d8e7e149a601" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_2af196cd-2796-48a0-82aa-0e2135d0b3f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_89f9cbf3-0775-4a47-a669-c576be5ecf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f813259-2a21-4d58-8fb1-6be716a01aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_257a6ec1-7fe8-40d8-9431-d5e7668da0c9" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f813259-2a21-4d58-8fb1-6be716a01aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_f580fded-8b2c-4894-904d-9448c6229c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_257a6ec1-7fe8-40d8-9431-d5e7668da0c9" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_f580fded-8b2c-4894-904d-9448c6229c5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e0616a44-d6c5-443a-85d1-b6fb2041cf03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_f580fded-8b2c-4894-904d-9448c6229c5c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e0616a44-d6c5-443a-85d1-b6fb2041cf03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e0616a44-d6c5-443a-85d1-b6fb2041cf03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e0616a44-d6c5-443a-85d1-b6fb2041cf03" xlink:to="loc_us-gaap_SegmentDomain_e0616a44-d6c5-443a-85d1-b6fb2041cf03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ed13ae38-3075-4793-ae87-c58f581c87b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e0616a44-d6c5-443a-85d1-b6fb2041cf03" xlink:to="loc_us-gaap_SegmentDomain_ed13ae38-3075-4793-ae87-c58f581c87b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_bd410f16-d936-4121-a21e-ec55d42a8f54" xlink:href="evh-20220630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ed13ae38-3075-4793-ae87-c58f581c87b1" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_bd410f16-d936-4121-a21e-ec55d42a8f54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_b5d17c18-cbca-4341-911c-3d556ea03b8e" xlink:href="evh-20220630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ed13ae38-3075-4793-ae87-c58f581c87b1" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_b5d17c18-cbca-4341-911c-3d556ea03b8e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended" id="i52af4b3c6243470e972da8036b1d1826_GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_7d04e6b5-8935-4e32-9742-b962c690d829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_7d04e6b5-8935-4e32-9742-b962c690d829" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_456dbaab-e516-468a-b2d7-aa833a6b23a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_456dbaab-e516-468a-b2d7-aa833a6b23a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6e8aefa6-f41c-4c32-91c3-d992e6cd4dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6e8aefa6-f41c-4c32-91c3-d992e6cd4dec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_327cdf04-0900-46ed-bd06-936b649572c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_327cdf04-0900-46ed-bd06-936b649572c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_13328861-9471-4ff7-b8f2-b2a751f816cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_13328861-9471-4ff7-b8f2-b2a751f816cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5ba0d613-3626-4d6e-9cf7-07492f17a1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5ba0d613-3626-4d6e-9cf7-07492f17a1bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0007f5d-bb3b-4b62-9232-def087032383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5ba0d613-3626-4d6e-9cf7-07492f17a1bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0007f5d-bb3b-4b62-9232-def087032383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0007f5d-bb3b-4b62-9232-def087032383_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0007f5d-bb3b-4b62-9232-def087032383" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0007f5d-bb3b-4b62-9232-def087032383_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0007f5d-bb3b-4b62-9232-def087032383" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_8fe2fbde-b3f3-4633-ab58-0f4dee5a15f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:to="loc_us-gaap_TradeNamesMember_8fe2fbde-b3f3-4633-ab58-0f4dee5a15f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_fc23bca9-e2e9-4e39-a655-1a1f50e1fb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:to="loc_us-gaap_CustomerRelationshipsMember_fc23bca9-e2e9-4e39-a655-1a1f50e1fb3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2b556e62-ba74-4697-bfb7-3a981fcf3170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2b556e62-ba74-4697-bfb7-3a981fcf3170" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_7c79458e-9536-4dfd-ba3d-2e18abb40549" xlink:href="evh-20220630.xsd#evh_BelowMarketLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:to="loc_evh_BelowMarketLeasesMember_7c79458e-9536-4dfd-ba3d-2e18abb40549" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_dca76164-d26f-45e2-bb5f-1206474a56cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_dca76164-d26f-45e2-bb5f-1206474a56cd" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebt2024NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended" id="i471d0d06d8f2436bacad2dc03f49f050_LongtermDebt2024NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2d36c600-4d60-448d-98b9-0e8ede9b36fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2d36c600-4d60-448d-98b9-0e8ede9b36fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ba87b5d-90f1-483a-a236-d352b611e9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ba87b5d-90f1-483a-a236-d352b611e9c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0b52a4c9-e624-43b0-a2d9-36d869c7eb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0b52a4c9-e624-43b0-a2d9-36d869c7eb6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_82246f52-89a0-4897-9f68-d6e79365cb02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_82246f52-89a0-4897-9f68-d6e79365cb02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2a041bd4-2393-419c-93b7-c8d217d2e844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2a041bd4-2393-419c-93b7-c8d217d2e844" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_91bbb9f8-e470-4ffc-a2a2-0d3ea943548c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_91bbb9f8-e470-4ffc-a2a2-0d3ea943548c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_37f8834d-94b6-4b3a-9873-eed6e6a955b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_InterestExpenseDebt_37f8834d-94b6-4b3a-9873-eed6e6a955b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ea389c9f-7be9-48a8-8643-69a5689e76da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ea389c9f-7be9-48a8-8643-69a5689e76da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c84599cc-d507-4ae4-b8fb-18b051f0ac41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c84599cc-d507-4ae4-b8fb-18b051f0ac41" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_992a593e-4448-45c5-96ac-fb3ced54b6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_992a593e-4448-45c5-96ac-fb3ced54b6d8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_915fb932-b69f-45d7-9ebc-344a92e173d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_LongTermDebt_915fb932-b69f-45d7-9ebc-344a92e173d1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_879ed211-d51a-4e76-8450-3fad4a942d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_879ed211-d51a-4e76-8450-3fad4a942d92" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_72df3d50-61e1-4ea2-9705-4940675c9cbd" xlink:href="evh-20220630.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_72df3d50-61e1-4ea2-9705-4940675c9cbd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d3f9a983-aaed-4d66-a0ac-0c24bcbcd68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_StockholdersEquity_d3f9a983-aaed-4d66-a0ac-0c24bcbcd68b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f2150643-18d9-4ab5-aeab-b5bb46d2f2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f2150643-18d9-4ab5-aeab-b5bb46d2f2ed" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_a6a01ae9-afdb-491a-87c0-27c3335f93ec" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_a6a01ae9-afdb-491a-87c0-27c3335f93ec" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_ec11a302-3db6-4b9d-974d-b730b63e95b0" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_ec11a302-3db6-4b9d-974d-b730b63e95b0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_307c2f1b-4512-43da-a833-59c98beedffa" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_307c2f1b-4512-43da-a833-59c98beedffa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_b1ac7035-c3be-4bd5-a064-20ba47a7f667" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_b1ac7035-c3be-4bd5-a064-20ba47a7f667" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_8af633e9-9645-4ae0-a3c6-633738b3a431" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_8af633e9-9645-4ae0-a3c6-633738b3a431" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2dfedd90-f0f4-48a4-b416-588c66afa779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_DebtInstrumentAxis_2dfedd90-f0f4-48a4-b416-588c66afa779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2dfedd90-f0f4-48a4-b416-588c66afa779_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2dfedd90-f0f4-48a4-b416-588c66afa779" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2dfedd90-f0f4-48a4-b416-588c66afa779_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2ba768ff-365d-4dca-9e75-8ee363168de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2dfedd90-f0f4-48a4-b416-588c66afa779" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2ba768ff-365d-4dca-9e75-8ee363168de6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_0c1997a2-6b58-41d2-a9f2-6ac4e71ab69b" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ba768ff-365d-4dca-9e75-8ee363168de6" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_0c1997a2-6b58-41d2-a9f2-6ac4e71ab69b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_8afc4750-8662-456c-be27-f59dc6ea0b17" xlink:href="evh-20220630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ba768ff-365d-4dca-9e75-8ee363168de6" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_8afc4750-8662-456c-be27-f59dc6ea0b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_9e0666fd-0471-4a33-9abe-d4871dbc5a3a" xlink:href="evh-20220630.xsd#evh_NewNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ba768ff-365d-4dca-9e75-8ee363168de6" xlink:to="loc_evh_NewNotesMember_9e0666fd-0471-4a33-9abe-d4871dbc5a3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_892d823f-93b3-4e26-bd1f-b625412c293e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_892d823f-93b3-4e26-bd1f-b625412c293e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_892d823f-93b3-4e26-bd1f-b625412c293e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_892d823f-93b3-4e26-bd1f-b625412c293e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_892d823f-93b3-4e26-bd1f-b625412c293e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_67e474be-ee11-45ad-8dbc-726d2710325a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_892d823f-93b3-4e26-bd1f-b625412c293e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_67e474be-ee11-45ad-8dbc-726d2710325a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1f042ddb-5589-467d-a7af-3c651fc701b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_67e474be-ee11-45ad-8dbc-726d2710325a" xlink:to="loc_us-gaap_SeniorNotesMember_1f042ddb-5589-467d-a7af-3c651fc701b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d92e6375-0041-4f5c-b325-b7a9fe1f70f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d92e6375-0041-4f5c-b325-b7a9fe1f70f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d92e6375-0041-4f5c-b325-b7a9fe1f70f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d92e6375-0041-4f5c-b325-b7a9fe1f70f8" xlink:to="loc_us-gaap_EquityComponentDomain_d92e6375-0041-4f5c-b325-b7a9fe1f70f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c42c1fc4-52b5-4065-8840-29bac64e1e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d92e6375-0041-4f5c-b325-b7a9fe1f70f8" xlink:to="loc_us-gaap_EquityComponentDomain_c42c1fc4-52b5-4065-8840-29bac64e1e5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_25d95d14-17c8-43a2-a6ff-72425cd8cb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c42c1fc4-52b5-4065-8840-29bac64e1e5f" xlink:to="loc_us-gaap_CommonStockMember_25d95d14-17c8-43a2-a6ff-72425cd8cb3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_030dfe0e-f2ba-4f3c-9c13-2bcbde0bc168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c42c1fc4-52b5-4065-8840-29bac64e1e5f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_030dfe0e-f2ba-4f3c-9c13-2bcbde0bc168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_02c5ae87-1199-4a24-9791-0239f5cc61d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c42c1fc4-52b5-4065-8840-29bac64e1e5f" xlink:to="loc_us-gaap_RetainedEarningsMember_02c5ae87-1199-4a24-9791-0239f5cc61d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a25e2f2c-abfa-4e98-aa8f-9b3fc7facaff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a25e2f2c-abfa-4e98-aa8f-9b3fc7facaff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a25e2f2c-abfa-4e98-aa8f-9b3fc7facaff_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a25e2f2c-abfa-4e98-aa8f-9b3fc7facaff" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a25e2f2c-abfa-4e98-aa8f-9b3fc7facaff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1f31d6de-7774-4242-b066-cb5a5b4a066b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a25e2f2c-abfa-4e98-aa8f-9b3fc7facaff" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1f31d6de-7774-4242-b066-cb5a5b4a066b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2e67aa76-968a-4079-baae-e0a8e0318c91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1f31d6de-7774-4242-b066-cb5a5b4a066b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2e67aa76-968a-4079-baae-e0a8e0318c91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5535b645-0343-4b61-88a3-704c601641b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5535b645-0343-4b61-88a3-704c601641b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_5535b645-0343-4b61-88a3-704c601641b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5535b645-0343-4b61-88a3-704c601641b1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_5535b645-0343-4b61-88a3-704c601641b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d61870ba-cbf9-4ddb-8bb8-b80094d4bcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5535b645-0343-4b61-88a3-704c601641b1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d61870ba-cbf9-4ddb-8bb8-b80094d4bcf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_004b9599-c879-4bfe-afaf-66f64b78a954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d61870ba-cbf9-4ddb-8bb8-b80094d4bcf7" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_004b9599-c879-4bfe-afaf-66f64b78a954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7a0dbc22-a45e-42cd-90a4-78ff36d7cc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7a0dbc22-a45e-42cd-90a4-78ff36d7cc07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7a0dbc22-a45e-42cd-90a4-78ff36d7cc07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a0dbc22-a45e-42cd-90a4-78ff36d7cc07" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7a0dbc22-a45e-42cd-90a4-78ff36d7cc07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_55946b2b-ab21-4002-b29c-81c54b0a912a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a0dbc22-a45e-42cd-90a4-78ff36d7cc07" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_55946b2b-ab21-4002-b29c-81c54b0a912a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_b2de4d71-7ac1-4153-972b-8a8a4594756f" xlink:href="evh-20220630.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_55946b2b-ab21-4002-b29c-81c54b0a912a" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_b2de4d71-7ac1-4153-972b-8a8a4594756f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_9a7e5453-76a2-4fd4-9c1e-95c3062c1f1a" xlink:href="evh-20220630.xsd#evh_DeferredFinancingFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_55946b2b-ab21-4002-b29c-81c54b0a912a" xlink:to="loc_evh_DeferredFinancingFeesMember_9a7e5453-76a2-4fd4-9c1e-95c3062c1f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3afb2679-a1c4-4e4e-b846-c1a51f7326ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3afb2679-a1c4-4e4e-b846-c1a51f7326ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3afb2679-a1c4-4e4e-b846-c1a51f7326ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3afb2679-a1c4-4e4e-b846-c1a51f7326ee" xlink:to="loc_us-gaap_ClassOfStockDomain_3afb2679-a1c4-4e4e-b846-c1a51f7326ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e0f97df9-2df4-46d3-a198-60e1aa789fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3afb2679-a1c4-4e4e-b846-c1a51f7326ee" xlink:to="loc_us-gaap_ClassOfStockDomain_e0f97df9-2df4-46d3-a198-60e1aa789fc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d06ffd0e-ae4b-446d-b638-69341f32b593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e0f97df9-2df4-46d3-a198-60e1aa789fc8" xlink:to="loc_us-gaap_CommonClassAMember_d06ffd0e-ae4b-446d-b638-69341f32b593" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebtCreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="extended" id="if32823695042455b8e3decb1156ef4f8_LongtermDebtCreditAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1d8cd5be-e527-4100-8c37-c96e0735146f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1d8cd5be-e527-4100-8c37-c96e0735146f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d2acc428-c69a-49b4-baf3-a4edef466c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d2acc428-c69a-49b4-baf3-a4edef466c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_95854b2b-6efb-4fea-9b10-54082bbe5ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_95854b2b-6efb-4fea-9b10-54082bbe5ee3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_514e5029-3e02-4935-9de4-0c68137b4d91" xlink:href="evh-20220630.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_evh_PaymentsOfMakeWholePremium_514e5029-3e02-4935-9de4-0c68137b4d91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3787a967-9573-45dc-bbfa-6e38c75dbd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_InterestPaidNet_3787a967-9573-45dc-bbfa-6e38c75dbd4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_44c33b0e-554b-4caa-9b46-cd8c6e2c4448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_44c33b0e-554b-4caa-9b46-cd8c6e2c4448" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_982faa23-d487-4e80-8bef-41656b08a8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_982faa23-d487-4e80-8bef-41656b08a8b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_28349e92-4f9b-4a8b-8313-21c4fa16f386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_LegalFees_28349e92-4f9b-4a8b-8313-21c4fa16f386" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_26895d10-9775-41da-a2a8-7d00148a83c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_DebtInstrumentTable_26895d10-9775-41da-a2a8-7d00148a83c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4f466d2a-468e-4724-82ac-6ea57de1051a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_26895d10-9775-41da-a2a8-7d00148a83c5" xlink:to="loc_us-gaap_DebtInstrumentAxis_4f466d2a-468e-4724-82ac-6ea57de1051a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4f466d2a-468e-4724-82ac-6ea57de1051a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4f466d2a-468e-4724-82ac-6ea57de1051a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4f466d2a-468e-4724-82ac-6ea57de1051a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0d2ac4a0-deb5-44d1-ba54-461329ef49b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4f466d2a-468e-4724-82ac-6ea57de1051a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0d2ac4a0-deb5-44d1-ba54-461329ef49b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_b955a39e-ae1d-46db-b769-1aa970901728" xlink:href="evh-20220630.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0d2ac4a0-deb5-44d1-ba54-461329ef49b5" xlink:to="loc_evh_InitialTermLoanFacilityMember_b955a39e-ae1d-46db-b769-1aa970901728" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_f8fc8f15-1edf-4e6e-9c0d-02e01d0102fd" xlink:href="evh-20220630.xsd#evh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0d2ac4a0-deb5-44d1-ba54-461329ef49b5" xlink:to="loc_evh_CreditAgreementMember_f8fc8f15-1edf-4e6e-9c0d-02e01d0102fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_09e5f0a0-07e6-46de-976f-b2165ba40e46" xlink:href="evh-20220630.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0d2ac4a0-deb5-44d1-ba54-461329ef49b5" xlink:to="loc_evh_SeniorCreditFacilitiesMember_09e5f0a0-07e6-46de-976f-b2165ba40e46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0842c19b-497f-4cd6-a651-ed7e25e29a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_26895d10-9775-41da-a2a8-7d00148a83c5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0842c19b-497f-4cd6-a651-ed7e25e29a79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0842c19b-497f-4cd6-a651-ed7e25e29a79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0842c19b-497f-4cd6-a651-ed7e25e29a79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0842c19b-497f-4cd6-a651-ed7e25e29a79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_71e3a41b-7319-402f-b5b3-5b7f3901289f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0842c19b-497f-4cd6-a651-ed7e25e29a79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_71e3a41b-7319-402f-b5b3-5b7f3901289f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_689dbdd8-38da-46f1-87e0-0bff72361c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_71e3a41b-7319-402f-b5b3-5b7f3901289f" xlink:to="loc_us-gaap_SecuredDebtMember_689dbdd8-38da-46f1-87e0-0bff72361c9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_13c85375-9f94-4fe3-b8c6-12183162ff66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_71e3a41b-7319-402f-b5b3-5b7f3901289f" xlink:to="loc_us-gaap_LineOfCreditMember_13c85375-9f94-4fe3-b8c6-12183162ff66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2a710df4-bf93-4289-b86c-fee6585d2801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_26895d10-9775-41da-a2a8-7d00148a83c5" xlink:to="loc_us-gaap_CreditFacilityAxis_2a710df4-bf93-4289-b86c-fee6585d2801" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a710df4-bf93-4289-b86c-fee6585d2801_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2a710df4-bf93-4289-b86c-fee6585d2801" xlink:to="loc_us-gaap_CreditFacilityDomain_2a710df4-bf93-4289-b86c-fee6585d2801_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8a0ad599-fec1-4e59-b94a-da969a981ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2a710df4-bf93-4289-b86c-fee6585d2801" xlink:to="loc_us-gaap_CreditFacilityDomain_8a0ad599-fec1-4e59-b94a-da969a981ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_9f88dd01-74c9-4574-81f9-5d12cab6ddfe" xlink:href="evh-20220630.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8a0ad599-fec1-4e59-b94a-da969a981ee4" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_9f88dd01-74c9-4574-81f9-5d12cab6ddfe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended" id="i0c6688a6b66d4c81a1884e4da03c54c0_LongtermDebtWarrantAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_291f8756-b9b6-418a-aabc-0d02ce5246da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_291f8756-b9b6-418a-aabc-0d02ce5246da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ff13b387-6e62-44a8-9533-ac83976647c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ff13b387-6e62-44a8-9533-ac83976647c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_fd37fdae-ce4c-46b2-a90f-e33a2f2a3fbe" xlink:href="evh-20220630.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_fd37fdae-ce4c-46b2-a90f-e33a2f2a3fbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_0c8c5a08-4062-4ab7-b239-94f454b223b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_0c8c5a08-4062-4ab7-b239-94f454b223b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_c7192734-ea3b-4778-afce-8a47ebff46a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_c7192734-ea3b-4778-afce-8a47ebff46a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_af76b6b4-84f9-4716-b368-2ddcf272a354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_c7192734-ea3b-4778-afce-8a47ebff46a3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_af76b6b4-84f9-4716-b368-2ddcf272a354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_af76b6b4-84f9-4716-b368-2ddcf272a354_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_af76b6b4-84f9-4716-b368-2ddcf272a354" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_af76b6b4-84f9-4716-b368-2ddcf272a354_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a77cbc3e-ac8c-442e-b344-2f4540bac03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_af76b6b4-84f9-4716-b368-2ddcf272a354" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a77cbc3e-ac8c-442e-b344-2f4540bac03f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c4d1fcd1-0a67-42a2-ac9e-b267737f487b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a77cbc3e-ac8c-442e-b344-2f4540bac03f" xlink:to="loc_us-gaap_CommonClassAMember_c4d1fcd1-0a67-42a2-ac9e-b267737f487b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebt2025NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended" id="i86b2e2ffb5fc46e0b4a5c31603fe020e_LongtermDebt2025NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7d925942-bdf6-445e-a141-0aca6d6f80d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7d925942-bdf6-445e-a141-0aca6d6f80d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62e6a30e-cd6e-4220-a2e7-f28fb5f165b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62e6a30e-cd6e-4220-a2e7-f28fb5f165b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f996a4a5-3360-4c22-a6c2-af61e685d9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_InterestExpenseDebt_f996a4a5-3360-4c22-a6c2-af61e685d9f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d2e79c28-a1bc-482e-a976-61465d2b245c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d2e79c28-a1bc-482e-a976-61465d2b245c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_2b2ab767-feb2-43e1-af09-a116c483b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_2b2ab767-feb2-43e1-af09-a116c483b7fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_f1bdc093-98e2-45a7-8dc8-b47ae3e7982e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_f1bdc093-98e2-45a7-8dc8-b47ae3e7982e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9d6d2ce3-793a-49c9-9c81-fc409fe9a9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_LongTermDebt_9d6d2ce3-793a-49c9-9c81-fc409fe9a9a8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_b7260be3-a617-4853-894a-7754d2c967a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_b7260be3-a617-4853-894a-7754d2c967a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c3546f48-9d25-4147-b9be-1a14dce4682b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c3546f48-9d25-4147-b9be-1a14dce4682b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ad93dcd-756f-44de-ad3e-2fbd95cdae32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_StockholdersEquity_5ad93dcd-756f-44de-ad3e-2fbd95cdae32" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_e498f895-7fad-410e-bacc-47ebc31dd243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_e498f895-7fad-410e-bacc-47ebc31dd243" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_57896716-d350-4a20-8024-2fd039b230bd" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_57896716-d350-4a20-8024-2fd039b230bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_89c9cb7b-3648-42df-add7-e644d4701fa9" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_89c9cb7b-3648-42df-add7-e644d4701fa9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_2b13cea6-6783-4e9b-b662-3badff29e8fe" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_2b13cea6-6783-4e9b-b662-3badff29e8fe" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_0c7e1c8b-a59f-4797-a51b-542638de6033" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_0c7e1c8b-a59f-4797-a51b-542638de6033" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_8bfdf9f5-8c1e-4df3-8fc8-6fc9f0a96294" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_8bfdf9f5-8c1e-4df3-8fc8-6fc9f0a96294" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_85e24a8d-3c10-4c7f-9bed-1931b41aa8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_85e24a8d-3c10-4c7f-9bed-1931b41aa8f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_85e24a8d-3c10-4c7f-9bed-1931b41aa8f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85e24a8d-3c10-4c7f-9bed-1931b41aa8f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_85e24a8d-3c10-4c7f-9bed-1931b41aa8f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_058aade8-72a4-459d-868b-ba5fdc0ed737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85e24a8d-3c10-4c7f-9bed-1931b41aa8f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_058aade8-72a4-459d-868b-ba5fdc0ed737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_497d0fe2-f2c4-4fdd-9c08-1e59da91cf09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_058aade8-72a4-459d-868b-ba5fdc0ed737" xlink:to="loc_us-gaap_SeniorNotesMember_497d0fe2-f2c4-4fdd-9c08-1e59da91cf09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39a22598-41b8-4377-a361-b145d3822e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_DebtInstrumentAxis_39a22598-41b8-4377-a361-b145d3822e60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_39a22598-41b8-4377-a361-b145d3822e60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_39a22598-41b8-4377-a361-b145d3822e60" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_39a22598-41b8-4377-a361-b145d3822e60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_06b1c280-0d7e-41a6-bb1b-ab111ce81491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_39a22598-41b8-4377-a361-b145d3822e60" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_06b1c280-0d7e-41a6-bb1b-ab111ce81491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_2db2d3f8-00d2-45a1-8e2b-2fbfe951d464" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06b1c280-0d7e-41a6-bb1b-ab111ce81491" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_2db2d3f8-00d2-45a1-8e2b-2fbfe951d464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_840089b0-057f-403e-9e81-d12f07d551a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_840089b0-057f-403e-9e81-d12f07d551a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_840089b0-057f-403e-9e81-d12f07d551a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_840089b0-057f-403e-9e81-d12f07d551a6" xlink:to="loc_us-gaap_EquityComponentDomain_840089b0-057f-403e-9e81-d12f07d551a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b0dee3e-b910-475a-8902-206926c8f0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_840089b0-057f-403e-9e81-d12f07d551a6" xlink:to="loc_us-gaap_EquityComponentDomain_6b0dee3e-b910-475a-8902-206926c8f0b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3703b9e8-64e9-4fdb-a8f3-f84df14c793b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b0dee3e-b910-475a-8902-206926c8f0b2" xlink:to="loc_us-gaap_CommonStockMember_3703b9e8-64e9-4fdb-a8f3-f84df14c793b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_015bbe75-65ed-47b1-98fc-84ed9353ca30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b0dee3e-b910-475a-8902-206926c8f0b2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_015bbe75-65ed-47b1-98fc-84ed9353ca30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3ea08394-913b-413a-8ca0-9aa714c2111e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b0dee3e-b910-475a-8902-206926c8f0b2" xlink:to="loc_us-gaap_RetainedEarningsMember_3ea08394-913b-413a-8ca0-9aa714c2111e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d9774df7-ff0e-4db0-bdd3-0926998b7491" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d9774df7-ff0e-4db0-bdd3-0926998b7491" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d9774df7-ff0e-4db0-bdd3-0926998b7491_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d9774df7-ff0e-4db0-bdd3-0926998b7491" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d9774df7-ff0e-4db0-bdd3-0926998b7491_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d5a82e1-ea24-4f3b-a6e6-f0f63769e12e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d9774df7-ff0e-4db0-bdd3-0926998b7491" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d5a82e1-ea24-4f3b-a6e6-f0f63769e12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b44d5f7c-0c30-4266-97b1-b74ac58d9752" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d5a82e1-ea24-4f3b-a6e6-f0f63769e12e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b44d5f7c-0c30-4266-97b1-b74ac58d9752" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a7edcb66-519d-4c3d-b486-9f4071e8a874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a7edcb66-519d-4c3d-b486-9f4071e8a874" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a7edcb66-519d-4c3d-b486-9f4071e8a874_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a7edcb66-519d-4c3d-b486-9f4071e8a874" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a7edcb66-519d-4c3d-b486-9f4071e8a874_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a6939c28-af5a-4d7a-82ce-7ba4344e23c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a7edcb66-519d-4c3d-b486-9f4071e8a874" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a6939c28-af5a-4d7a-82ce-7ba4344e23c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_bd1d3838-2518-4df9-97a3-861d0a694fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a6939c28-af5a-4d7a-82ce-7ba4344e23c9" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_bd1d3838-2518-4df9-97a3-861d0a694fb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_16d9e0b0-01a6-4305-91a5-9cb582f8ab21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_16d9e0b0-01a6-4305-91a5-9cb582f8ab21" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_16d9e0b0-01a6-4305-91a5-9cb582f8ab21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_16d9e0b0-01a6-4305-91a5-9cb582f8ab21" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_16d9e0b0-01a6-4305-91a5-9cb582f8ab21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2ab16b92-eddb-4a79-885f-a70d436c4a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_16d9e0b0-01a6-4305-91a5-9cb582f8ab21" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2ab16b92-eddb-4a79-885f-a70d436c4a6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_729eec61-42f7-4342-a4fd-3b2f3395ebb2" xlink:href="evh-20220630.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2ab16b92-eddb-4a79-885f-a70d436c4a6f" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_729eec61-42f7-4342-a4fd-3b2f3395ebb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_d74c268e-826f-4644-92ae-9582f1d89d67" xlink:href="evh-20220630.xsd#evh_DeferredFinancingFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2ab16b92-eddb-4a79-885f-a70d436c4a6f" xlink:to="loc_evh_DeferredFinancingFeesMember_d74c268e-826f-4644-92ae-9582f1d89d67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dd653d3e-cb5f-4bac-8a7c-1235bad36e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dd653d3e-cb5f-4bac-8a7c-1235bad36e58" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dd653d3e-cb5f-4bac-8a7c-1235bad36e58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dd653d3e-cb5f-4bac-8a7c-1235bad36e58" xlink:to="loc_us-gaap_ClassOfStockDomain_dd653d3e-cb5f-4bac-8a7c-1235bad36e58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2dc3d7ab-caa7-4385-8403-6d3b899de712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dd653d3e-cb5f-4bac-8a7c-1235bad36e58" xlink:to="loc_us-gaap_ClassOfStockDomain_2dc3d7ab-caa7-4385-8403-6d3b899de712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_dc50760c-0c49-40a0-8529-c3b65dc43829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2dc3d7ab-caa7-4385-8403-6d3b899de712" xlink:to="loc_us-gaap_CommonClassAMember_dc50760c-0c49-40a0-8529-c3b65dc43829" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebt2021NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended" id="i53c12d9de9044af48b3ba2807aaf8ee8_LongtermDebt2021NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0a2d8239-259f-4e11-9af0-4c3958a96f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0a2d8239-259f-4e11-9af0-4c3958a96f9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c25a2587-5fa7-4a40-b8f6-4038fdab08c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c25a2587-5fa7-4a40-b8f6-4038fdab08c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_88797f55-ec1a-44c0-aebf-26b817a5e9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_88797f55-ec1a-44c0-aebf-26b817a5e9bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_77dad62b-dab2-4024-b93b-f19c3f4fa854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_77dad62b-dab2-4024-b93b-f19c3f4fa854" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_02df9cdc-3218-4588-ba61-97890acbaebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_02df9cdc-3218-4588-ba61-97890acbaebd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_17af69be-3b81-4690-b07f-731e64486ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_17af69be-3b81-4690-b07f-731e64486ba2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8609feea-c904-4230-a98d-de136f8c593d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8609feea-c904-4230-a98d-de136f8c593d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_d8a2e5d8-0e0a-44dd-88a0-e4d89fee0507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_d8a2e5d8-0e0a-44dd-88a0-e4d89fee0507" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_1d04e40a-64a2-43b0-b148-43f5daa82fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_1d04e40a-64a2-43b0-b148-43f5daa82fef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_31e25438-645e-4591-a962-c309f208c517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_31e25438-645e-4591-a962-c309f208c517" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtConversionOriginalDebtFairValue_933c9b59-4919-47f5-bec8-41fc2e018cdb" xlink:href="evh-20220630.xsd#evh_DebtConversionOriginalDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_evh_DebtConversionOriginalDebtFairValue_933c9b59-4919-47f5-bec8-41fc2e018cdb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5bd28017-e949-4db4-930f-fe668a4d532e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_DebtInstrumentTable_5bd28017-e949-4db4-930f-fe668a4d532e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bd4afbf1-106f-45a1-99db-9901fb0ac4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5bd28017-e949-4db4-930f-fe668a4d532e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bd4afbf1-106f-45a1-99db-9901fb0ac4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bd4afbf1-106f-45a1-99db-9901fb0ac4e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd4afbf1-106f-45a1-99db-9901fb0ac4e5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bd4afbf1-106f-45a1-99db-9901fb0ac4e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ccf76324-57b2-4d76-9011-9fac51e847c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd4afbf1-106f-45a1-99db-9901fb0ac4e5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ccf76324-57b2-4d76-9011-9fac51e847c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_29a2afed-b4ea-4be6-803e-5d446e796dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ccf76324-57b2-4d76-9011-9fac51e847c7" xlink:to="loc_us-gaap_SeniorNotesMember_29a2afed-b4ea-4be6-803e-5d446e796dd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e4564d3d-4763-46ab-81ec-ea630d3e83f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5bd28017-e949-4db4-930f-fe668a4d532e" xlink:to="loc_us-gaap_DebtInstrumentAxis_e4564d3d-4763-46ab-81ec-ea630d3e83f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e4564d3d-4763-46ab-81ec-ea630d3e83f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e4564d3d-4763-46ab-81ec-ea630d3e83f3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e4564d3d-4763-46ab-81ec-ea630d3e83f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d804968-5389-40d5-9cff-0f4f9721818e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e4564d3d-4763-46ab-81ec-ea630d3e83f3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d804968-5389-40d5-9cff-0f4f9721818e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_a589e778-41e4-4716-822b-44d05215473b" xlink:href="evh-20220630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d804968-5389-40d5-9cff-0f4f9721818e" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_a589e778-41e4-4716-822b-44d05215473b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_1416ef16-9d88-4138-8a21-98f23bdae67a" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d804968-5389-40d5-9cff-0f4f9721818e" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_1416ef16-9d88-4138-8a21-98f23bdae67a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended" id="if0afee203f5e461885285cca14ff9397_LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_67d01e9a-6cbf-48b5-abf1-6ceaea971b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:to="loc_us-gaap_ConvertibleDebt_67d01e9a-6cbf-48b5-abf1-6ceaea971b06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f7c02ff5-49ad-45e0-92c8-44743fdcbd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f7c02ff5-49ad-45e0-92c8-44743fdcbd51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4a57241f-8a99-418b-a758-d7d5f2d5e747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4a57241f-8a99-418b-a758-d7d5f2d5e747" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_19ac86ab-c8f1-40b7-bbe3-7f368ac3edbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_19ac86ab-c8f1-40b7-bbe3-7f368ac3edbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_a9ded386-8b3f-4614-9775-429b60264b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:to="loc_us-gaap_LongTermDebtFairValue_a9ded386-8b3f-4614-9775-429b60264b79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c2756323-15e2-4b71-961e-4905c4737d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:to="loc_us-gaap_DebtInstrumentTable_c2756323-15e2-4b71-961e-4905c4737d72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e71d5cc9-140f-405e-9bcf-a8b1ca0c6f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2756323-15e2-4b71-961e-4905c4737d72" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e71d5cc9-140f-405e-9bcf-a8b1ca0c6f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e71d5cc9-140f-405e-9bcf-a8b1ca0c6f77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e71d5cc9-140f-405e-9bcf-a8b1ca0c6f77" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e71d5cc9-140f-405e-9bcf-a8b1ca0c6f77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3bec7c22-af94-4bb0-ab12-f26e4aa3bfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e71d5cc9-140f-405e-9bcf-a8b1ca0c6f77" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3bec7c22-af94-4bb0-ab12-f26e4aa3bfe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5cda04b2-3528-43a5-92fc-c02e785e584e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3bec7c22-af94-4bb0-ab12-f26e4aa3bfe1" xlink:to="loc_us-gaap_SeniorNotesMember_5cda04b2-3528-43a5-92fc-c02e785e584e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1972007e-0acf-42ea-b73c-9144c2fa093b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2756323-15e2-4b71-961e-4905c4737d72" xlink:to="loc_us-gaap_DebtInstrumentAxis_1972007e-0acf-42ea-b73c-9144c2fa093b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1972007e-0acf-42ea-b73c-9144c2fa093b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1972007e-0acf-42ea-b73c-9144c2fa093b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1972007e-0acf-42ea-b73c-9144c2fa093b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e5762dce-c101-4204-9536-cb6cf469a6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1972007e-0acf-42ea-b73c-9144c2fa093b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e5762dce-c101-4204-9536-cb6cf469a6c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_2c4cc51d-b653-40d9-a371-d0fff29500d2" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5762dce-c101-4204-9536-cb6cf469a6c2" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_2c4cc51d-b653-40d9-a371-d0fff29500d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_cc3f5754-840c-464b-8283-f6b4a9bc1468" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5762dce-c101-4204-9536-cb6cf469a6c2" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_cc3f5754-840c-464b-8283-f6b4a9bc1468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2de854cb-50e6-40d8-94a1-116dc4cbe23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2756323-15e2-4b71-961e-4905c4737d72" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2de854cb-50e6-40d8-94a1-116dc4cbe23a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2de854cb-50e6-40d8-94a1-116dc4cbe23a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2de854cb-50e6-40d8-94a1-116dc4cbe23a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2de854cb-50e6-40d8-94a1-116dc4cbe23a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a25556f0-b6ef-4bde-bc8a-9ed669be8963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2de854cb-50e6-40d8-94a1-116dc4cbe23a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a25556f0-b6ef-4bde-bc8a-9ed669be8963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e866ff22-4b63-456e-a139-5c05f85c569d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a25556f0-b6ef-4bde-bc8a-9ed669be8963" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e866ff22-4b63-456e-a139-5c05f85c569d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i8411cd895efc44f19fa7e4fa64810ebf_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a16275c1-b90d-48c4-8812-25b741bab3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a16275c1-b90d-48c4-8812-25b741bab3fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_40d7e6e4-b17d-4aef-bb69-6f483335bd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_40d7e6e4-b17d-4aef-bb69-6f483335bd4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_e57c9d1b-faaf-4abc-b2c3-97d844709325" xlink:href="evh-20220630.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:to="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_e57c9d1b-faaf-4abc-b2c3-97d844709325" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_939d9988-f003-40a9-8815-eb80bb739c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_939d9988-f003-40a9-8815-eb80bb739c5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f2f68ac3-fdb4-4ee1-b51c-6db447e6f08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:to="loc_us-gaap_CreditFacilityAxis_f2f68ac3-fdb4-4ee1-b51c-6db447e6f08e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f2f68ac3-fdb4-4ee1-b51c-6db447e6f08e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f2f68ac3-fdb4-4ee1-b51c-6db447e6f08e" xlink:to="loc_us-gaap_CreditFacilityDomain_f2f68ac3-fdb4-4ee1-b51c-6db447e6f08e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d8b93480-2633-4edc-8b50-ad30f41f8f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f2f68ac3-fdb4-4ee1-b51c-6db447e6f08e" xlink:to="loc_us-gaap_CreditFacilityDomain_d8b93480-2633-4edc-8b50-ad30f41f8f61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_643e599c-43f6-4acf-869f-39605ba3e060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d8b93480-2633-4edc-8b50-ad30f41f8f61" xlink:to="loc_us-gaap_LetterOfCreditMember_643e599c-43f6-4acf-869f-39605ba3e060" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_38b16c09-0dec-4a3f-8f78-056040ce5b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_38b16c09-0dec-4a3f-8f78-056040ce5b18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_38b16c09-0dec-4a3f-8f78-056040ce5b18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38b16c09-0dec-4a3f-8f78-056040ce5b18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_38b16c09-0dec-4a3f-8f78-056040ce5b18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8c511a84-ef8d-4b5e-a023-231e24c88883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38b16c09-0dec-4a3f-8f78-056040ce5b18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8c511a84-ef8d-4b5e-a023-231e24c88883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_58c10f6b-3b3f-42b9-92f5-f413e0b31cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8c511a84-ef8d-4b5e-a023-231e24c88883" xlink:to="loc_us-gaap_LineOfCreditMember_58c10f6b-3b3f-42b9-92f5-f413e0b31cdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_433a8dd5-6693-43b8-879c-4e4258024e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_433a8dd5-6693-43b8-879c-4e4258024e9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_433a8dd5-6693-43b8-879c-4e4258024e9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_433a8dd5-6693-43b8-879c-4e4258024e9f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_433a8dd5-6693-43b8-879c-4e4258024e9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee536f4b-61d5-4ba3-b80d-50709047dbea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_433a8dd5-6693-43b8-879c-4e4258024e9f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee536f4b-61d5-4ba3-b80d-50709047dbea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_8285d0a2-b84a-4adb-86df-4ec6f925b0a0" xlink:href="evh-20220630.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee536f4b-61d5-4ba3-b80d-50709047dbea" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_8285d0a2-b84a-4adb-86df-4ec6f925b0a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_85773e24-b451-4034-999e-da514e427d27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:to="loc_srt_StatementScenarioAxis_85773e24-b451-4034-999e-da514e427d27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_85773e24-b451-4034-999e-da514e427d27_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_85773e24-b451-4034-999e-da514e427d27" xlink:to="loc_srt_ScenarioUnspecifiedDomain_85773e24-b451-4034-999e-da514e427d27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_48faabe8-a577-4bfd-b04c-fe576e837bb5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_85773e24-b451-4034-999e-da514e427d27" xlink:to="loc_srt_ScenarioUnspecifiedDomain_48faabe8-a577-4bfd-b04c-fe576e837bb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ba167a0a-d33a-48ee-aa4f-ae87c4d59c3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_48faabe8-a577-4bfd-b04c-fe576e837bb5" xlink:to="loc_srt_ScenarioForecastMember_ba167a0a-d33a-48ee-aa4f-ae87c4d59c3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d7205bc2-032f-45f7-9174-0fe3a1deb027" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:to="loc_srt_LitigationCaseAxis_d7205bc2-032f-45f7-9174-0fe3a1deb027" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d7205bc2-032f-45f7-9174-0fe3a1deb027_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_d7205bc2-032f-45f7-9174-0fe3a1deb027" xlink:to="loc_srt_LitigationCaseTypeDomain_d7205bc2-032f-45f7-9174-0fe3a1deb027_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ca517324-8cd8-4a74-9105-b52bb40d595f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_d7205bc2-032f-45f7-9174-0fe3a1deb027" xlink:to="loc_srt_LitigationCaseTypeDomain_ca517324-8cd8-4a74-9105-b52bb40d595f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderClassActionComplaintMember_ab06a73b-d3df-4aca-a083-83146a04cd16" xlink:href="evh-20220630.xsd#evh_ShareholderClassActionComplaintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ca517324-8cd8-4a74-9105-b52bb40d595f" xlink:to="loc_evh_ShareholderClassActionComplaintMember_ab06a73b-d3df-4aca-a083-83146a04cd16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended" id="i36e9051af8b24ff78d48986783497143_CommitmentsandContingenciesConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_52dd001b-c0f9-49f0-aec2-e0f50154439b" xlink:href="evh-20220630.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_52dd001b-c0f9-49f0-aec2-e0f50154439b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94cf7e6f-5169-4357-a7bf-3c2d32242084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94cf7e6f-5169-4357-a7bf-3c2d32242084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_1de32eb0-7995-47ca-bc86-7917f2029e53" xlink:href="evh-20220630.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_1de32eb0-7995-47ca-bc86-7917f2029e53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_88464195-9960-4425-b90c-72b979e3aa45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_88464195-9960-4425-b90c-72b979e3aa45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:to="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_26b570f9-962f-47d2-b71b-91dc8631e12d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:to="loc_srt_MajorCustomersAxis_26b570f9-962f-47d2-b71b-91dc8631e12d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_26b570f9-962f-47d2-b71b-91dc8631e12d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_26b570f9-962f-47d2-b71b-91dc8631e12d" xlink:to="loc_srt_NameOfMajorCustomerDomain_26b570f9-962f-47d2-b71b-91dc8631e12d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_26b570f9-962f-47d2-b71b-91dc8631e12d" xlink:to="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_142b3bea-ba36-468d-b806-a7992132d2a9" xlink:href="evh-20220630.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_142b3bea-ba36-468d-b806-a7992132d2a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_d3c9c729-0417-4ff8-a606-fccd22e3fa43" xlink:href="evh-20220630.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_FloridaBlueMedicareIncMember_d3c9c729-0417-4ff8-a606-fccd22e3fa43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_d346a590-8395-4d3d-820b-f75dbec82b49" xlink:href="evh-20220630.xsd#evh_MolinaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_MolinaHealthcareMember_d346a590-8395-4d3d-820b-f75dbec82b49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CenterForMedicareAndMedicaidServicesMember_80644ceb-f91c-4056-9a47-bc9c6cb5d117" xlink:href="evh-20220630.xsd#evh_CenterForMedicareAndMedicaidServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_CenterForMedicareAndMedicaidServicesMember_80644ceb-f91c-4056-9a47-bc9c6cb5d117" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember_ef081660-43c5-4037-9c50-538d09db9b97" xlink:href="evh-20220630.xsd#evh_BrightHealthManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_BrightHealthManagementIncMember_ef081660-43c5-4037-9c50-538d09db9b97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember_e5572a58-6e0f-4fdb-b34a-aefae82fc3fa" xlink:href="evh-20220630.xsd#evh_BlueCrossAndBlueShieldOfNorthCarolinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember_e5572a58-6e0f-4fdb-b34a-aefae82fc3fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2aa6d6b9-1b40-4104-bf58-3220076be93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2aa6d6b9-1b40-4104-bf58-3220076be93a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2aa6d6b9-1b40-4104-bf58-3220076be93a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2aa6d6b9-1b40-4104-bf58-3220076be93a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2aa6d6b9-1b40-4104-bf58-3220076be93a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_74f67a76-f736-411e-9a2c-a7305336f23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2aa6d6b9-1b40-4104-bf58-3220076be93a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_74f67a76-f736-411e-9a2c-a7305336f23d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_9510d77a-2865-4229-8070-33b384e180c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_74f67a76-f736-411e-9a2c-a7305336f23d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_9510d77a-2865-4229-8070-33b384e180c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_596907d2-079b-4a74-bf07-d848d94540ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_596907d2-079b-4a74-bf07-d848d94540ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_596907d2-079b-4a74-bf07-d848d94540ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_596907d2-079b-4a74-bf07-d848d94540ed" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_596907d2-079b-4a74-bf07-d848d94540ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5a1d105-758e-4d31-8635-c25e905ad7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_596907d2-079b-4a74-bf07-d848d94540ed" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5a1d105-758e-4d31-8635-c25e905ad7a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_ca117569-5aac-47cc-956d-51884fa35978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5a1d105-758e-4d31-8635-c25e905ad7a6" xlink:to="loc_us-gaap_AccountsReceivableMember_ca117569-5aac-47cc-956d-51884fa35978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_798f21c3-cbcc-4c8c-9bc0-4ff2033fae78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5a1d105-758e-4d31-8635-c25e905ad7a6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_798f21c3-cbcc-4c8c-9bc0-4ff2033fae78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0b4c9e8f-b314-4e34-8362-26353047d3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0b4c9e8f-b314-4e34-8362-26353047d3ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_0b4c9e8f-b314-4e34-8362-26353047d3ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0b4c9e8f-b314-4e34-8362-26353047d3ee" xlink:to="loc_us-gaap_ReceivableTypeDomain_0b4c9e8f-b314-4e34-8362-26353047d3ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_d47de7e4-36f0-4997-82d5-a720303c3fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0b4c9e8f-b314-4e34-8362-26353047d3ee" xlink:to="loc_us-gaap_ReceivableTypeDomain_d47de7e4-36f0-4997-82d5-a720303c3fcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_8eab4927-f6c6-4510-b503-8ed1a830bc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_d47de7e4-36f0-4997-82d5-a720303c3fcb" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_8eab4927-f6c6-4510-b503-8ed1a830bc80" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i28e98336153d41079b7ac8b521d051b8_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b958ce95-d0c4-4a8b-8038-acee430094a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b8f978b4-1c50-4425-b8c1-314c9055491a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b958ce95-d0c4-4a8b-8038-acee430094a1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b8f978b4-1c50-4425-b8c1-314c9055491a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_e699eca0-9283-4a5a-aee0-dff4a24c9802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b958ce95-d0c4-4a8b-8038-acee430094a1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_e699eca0-9283-4a5a-aee0-dff4a24c9802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_279a70ca-b9da-44d4-993e-7c87101fab37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b958ce95-d0c4-4a8b-8038-acee430094a1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_279a70ca-b9da-44d4-993e-7c87101fab37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_ac3d3847-5a87-497e-be96-2a4e16efb2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_279a70ca-b9da-44d4-993e-7c87101fab37" xlink:to="loc_us-gaap_OtherCommitmentsAxis_ac3d3847-5a87-497e-be96-2a4e16efb2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_ac3d3847-5a87-497e-be96-2a4e16efb2c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_ac3d3847-5a87-497e-be96-2a4e16efb2c5" xlink:to="loc_us-gaap_OtherCommitmentsDomain_ac3d3847-5a87-497e-be96-2a4e16efb2c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_a4abdf45-b2a6-463c-b73a-8944d9ef89b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_ac3d3847-5a87-497e-be96-2a4e16efb2c5" xlink:to="loc_us-gaap_OtherCommitmentsDomain_a4abdf45-b2a6-463c-b73a-8944d9ef89b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_e545c0ca-bdfb-439d-97d2-72c5db81ab0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_a4abdf45-b2a6-463c-b73a-8944d9ef89b0" xlink:to="loc_us-gaap_LeaseAgreementsMember_e545c0ca-bdfb-439d-97d2-72c5db81ab0a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended" id="i042e3cf932c74c6681351784aab94dcc_LeasesPrimaryOfficeLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9fbe2-8f69-47fc-92e5-0711e38f3be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c0667554-6ade-4fb0-bcc7-ebf302164643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9fbe2-8f69-47fc-92e5-0711e38f3be1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c0667554-6ade-4fb0-bcc7-ebf302164643" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_428c3cc9-7958-415d-983f-76a64dc151ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9fbe2-8f69-47fc-92e5-0711e38f3be1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_428c3cc9-7958-415d-983f-76a64dc151ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_65b422d8-dd22-4347-889d-946bc34fbf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9fbe2-8f69-47fc-92e5-0711e38f3be1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_65b422d8-dd22-4347-889d-946bc34fbf3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c5c47cbd-de5e-4975-a632-d343e2eb707e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9fbe2-8f69-47fc-92e5-0711e38f3be1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c5c47cbd-de5e-4975-a632-d343e2eb707e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e56c75ab-e9f1-4cea-b49e-b5834750144f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c5c47cbd-de5e-4975-a632-d343e2eb707e" xlink:to="loc_srt_StatementGeographicalAxis_e56c75ab-e9f1-4cea-b49e-b5834750144f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e56c75ab-e9f1-4cea-b49e-b5834750144f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e56c75ab-e9f1-4cea-b49e-b5834750144f" xlink:to="loc_srt_SegmentGeographicalDomain_e56c75ab-e9f1-4cea-b49e-b5834750144f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e56c75ab-e9f1-4cea-b49e-b5834750144f" xlink:to="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_d9f03ad9-a218-4f60-9b15-9135a0ed978d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:to="loc_stpr_VA_d9f03ad9-a218-4f60-9b15-9135a0ed978d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_22324526-1825-41c7-a596-062f23c0b7ec" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:to="loc_stpr_IL_22324526-1825-41c7-a596-062f23c0b7ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_18a0fa14-eafa-4c33-9a45-592bb3d2c8f0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:to="loc_stpr_NJ_18a0fa14-eafa-4c33-9a45-592bb3d2c8f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_3817fc2a-8052-49d0-95d5-4427c2be4722" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:to="loc_country_IN_3817fc2a-8052-49d0-95d5-4427c2be4722" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_95a6e4f6-91c3-405a-b417-c0c7c1c1b8cc" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:to="loc_stpr_CA_95a6e4f6-91c3-405a-b417-c0c7c1c1b8cc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="ied71ed6e47fe46e5b2b9b8bce7522afa_LossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c333e9d1-d317-45ce-81bd-58db0b3d9200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e42efb6d-6747-4317-a60d-39ba9423c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c333e9d1-d317-45ce-81bd-58db0b3d9200" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e42efb6d-6747-4317-a60d-39ba9423c16b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ce117f49-03e4-4c14-a78e-ce96f32c3c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c333e9d1-d317-45ce-81bd-58db0b3d9200" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ce117f49-03e4-4c14-a78e-ce96f32c3c92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab9e93f1-b178-4265-b073-38356171d269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ce117f49-03e4-4c14-a78e-ce96f32c3c92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab9e93f1-b178-4265-b073-38356171d269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ab9e93f1-b178-4265-b073-38356171d269_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab9e93f1-b178-4265-b073-38356171d269" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ab9e93f1-b178-4265-b073-38356171d269_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5efbd765-d045-4374-92f9-66f562394a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab9e93f1-b178-4265-b073-38356171d269" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5efbd765-d045-4374-92f9-66f562394a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_9f14b65a-858b-4173-8c9f-4544c293c7fe" xlink:href="evh-20220630.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5efbd765-d045-4374-92f9-66f562394a23" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_9f14b65a-858b-4173-8c9f-4544c293c7fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4fe90c73-a353-4a85-88d2-c54107c1979a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5efbd765-d045-4374-92f9-66f562394a23" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4fe90c73-a353-4a85-88d2-c54107c1979a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1e466b5d-b292-47c1-9800-47b31633c197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5efbd765-d045-4374-92f9-66f562394a23" xlink:to="loc_us-gaap_ConvertibleDebtMember_1e466b5d-b292-47c1-9800-47b31633c197" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended" id="i7d691c5af17e47f8aa409a74418c5774_StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9c544a24-f4e9-4ab4-9498-483d93628ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_77e4c622-1c15-48ac-8b99-50c40ec6cd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9c544a24-f4e9-4ab4-9498-483d93628ccd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_77e4c622-1c15-48ac-8b99-50c40ec6cd31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_992a8c90-6d67-44ba-9fc4-be0d323d4c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9c544a24-f4e9-4ab4-9498-483d93628ccd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_992a8c90-6d67-44ba-9fc4-be0d323d4c45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9073db8c-38ce-4cdc-b022-4f3b28ff70fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_992a8c90-6d67-44ba-9fc4-be0d323d4c45" xlink:to="loc_us-gaap_AwardTypeAxis_9073db8c-38ce-4cdc-b022-4f3b28ff70fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9073db8c-38ce-4cdc-b022-4f3b28ff70fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9073db8c-38ce-4cdc-b022-4f3b28ff70fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9073db8c-38ce-4cdc-b022-4f3b28ff70fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9073db8c-38ce-4cdc-b022-4f3b28ff70fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35fa86c7-6276-4fd2-aef0-49be8f054e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35fa86c7-6276-4fd2-aef0-49be8f054e5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9cba4154-5bbd-49ea-9658-f671dd7a36e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9cba4154-5bbd-49ea-9658-f671dd7a36e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_c0d145c5-acdf-4a10-af10-d86768c01671" xlink:href="evh-20220630.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_c0d145c5-acdf-4a10-af10-d86768c01671" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_49c45db3-e06c-467c-addc-c692a11c8f13" xlink:href="evh-20220630.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_49c45db3-e06c-467c-addc-c692a11c8f13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b8047cb4-ff8a-4816-8c4c-0e8d1aa5f72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_992a8c90-6d67-44ba-9fc4-be0d323d4c45" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b8047cb4-ff8a-4816-8c4c-0e8d1aa5f72d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b8047cb4-ff8a-4816-8c4c-0e8d1aa5f72d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b8047cb4-ff8a-4816-8c4c-0e8d1aa5f72d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b8047cb4-ff8a-4816-8c4c-0e8d1aa5f72d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_98b12124-5f87-4d08-9210-f1d2f3a516a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b8047cb4-ff8a-4816-8c4c-0e8d1aa5f72d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_98b12124-5f87-4d08-9210-f1d2f3a516a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_1829f3d0-3bcf-439a-b3bc-a422b029a06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98b12124-5f87-4d08-9210-f1d2f3a516a8" xlink:to="loc_us-gaap_CostOfSalesMember_1829f3d0-3bcf-439a-b3bc-a422b029a06e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5c9a801a-95a9-4a1e-9743-3deb4d0e2bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98b12124-5f87-4d08-9210-f1d2f3a516a8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5c9a801a-95a9-4a1e-9743-3deb4d0e2bd3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="extended" id="i3987f9b232d24548b45d4c6e8c61b547_StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20c0413f-785b-4d20-aa87-b2b2c1fd07d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_74637fdb-0412-4167-a9a5-5c13f6489506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20c0413f-785b-4d20-aa87-b2b2c1fd07d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_74637fdb-0412-4167-a9a5-5c13f6489506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86ab9cf1-827c-4701-ad64-e29ada7aed41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20c0413f-785b-4d20-aa87-b2b2c1fd07d2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86ab9cf1-827c-4701-ad64-e29ada7aed41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_652a2614-d18e-4ff7-b056-33146c221ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86ab9cf1-827c-4701-ad64-e29ada7aed41" xlink:to="loc_us-gaap_AwardTypeAxis_652a2614-d18e-4ff7-b056-33146c221ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_652a2614-d18e-4ff7-b056-33146c221ebd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_652a2614-d18e-4ff7-b056-33146c221ebd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_652a2614-d18e-4ff7-b056-33146c221ebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_166c78a6-43ef-4f15-8b84-ef0a858b7434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_652a2614-d18e-4ff7-b056-33146c221ebd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_166c78a6-43ef-4f15-8b84-ef0a858b7434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1f93e7e7-c02b-4eec-aba4-2e99d484f16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_166c78a6-43ef-4f15-8b84-ef0a858b7434" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1f93e7e7-c02b-4eec-aba4-2e99d484f16a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_d47d8f12-0734-4073-a3b7-533c2a2b5e38" xlink:href="evh-20220630.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_166c78a6-43ef-4f15-8b84-ef0a858b7434" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_d47d8f12-0734-4073-a3b7-533c2a2b5e38" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended" id="i5335d4c9555043b78d3fe423e89534a9_InvestmentsinEquityMethodInvesteesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_f3b06b9c-9a68-466d-b29a-c43cd06bed24" xlink:href="evh-20220630.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_f3b06b9c-9a68-466d-b29a-c43cd06bed24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_305efc8b-696e-46b2-bc4b-0dcfeb401cf5" xlink:href="evh-20220630.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_305efc8b-696e-46b2-bc4b-0dcfeb401cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_14f1ba94-5124-46cb-b46d-e6a181ba7478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_14f1ba94-5124-46cb-b46d-e6a181ba7478" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_eb7ac3b6-675a-42c9-85fb-a1826cb0e112" xlink:href="evh-20220630.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:to="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_eb7ac3b6-675a-42c9-85fb-a1826cb0e112" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4d155de4-f775-436d-85b4-393d1cc3fea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4d155de4-f775-436d-85b4-393d1cc3fea0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2d492201-21c8-415e-ad82-472ff5e38ad3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4d155de4-f775-436d-85b4-393d1cc3fea0" xlink:to="loc_srt_RangeAxis_2d492201-21c8-415e-ad82-472ff5e38ad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d492201-21c8-415e-ad82-472ff5e38ad3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2d492201-21c8-415e-ad82-472ff5e38ad3" xlink:to="loc_srt_RangeMember_2d492201-21c8-415e-ad82-472ff5e38ad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18c37ad5-2a83-4c74-bebc-5118a13cdee2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2d492201-21c8-415e-ad82-472ff5e38ad3" xlink:to="loc_srt_RangeMember_18c37ad5-2a83-4c74-bebc-5118a13cdee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_21b1dec4-5549-4674-91a6-b124d37cb43e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18c37ad5-2a83-4c74-bebc-5118a13cdee2" xlink:to="loc_srt_MinimumMember_21b1dec4-5549-4674-91a6-b124d37cb43e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74200fea-9bad-43ba-b0c2-b852416c01a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18c37ad5-2a83-4c74-bebc-5118a13cdee2" xlink:to="loc_srt_MaximumMember_74200fea-9bad-43ba-b0c2-b852416c01a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc06164-706f-4412-bef6-ac3156f199c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4d155de4-f775-436d-85b4-393d1cc3fea0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc06164-706f-4412-bef6-ac3156f199c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0fc06164-706f-4412-bef6-ac3156f199c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc06164-706f-4412-bef6-ac3156f199c2" xlink:to="loc_us-gaap_RelatedPartyDomain_0fc06164-706f-4412-bef6-ac3156f199c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bc81654b-4707-46d1-b830-1e94628db4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc06164-706f-4412-bef6-ac3156f199c2" xlink:to="loc_us-gaap_RelatedPartyDomain_bc81654b-4707-46d1-b830-1e94628db4c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_05ea329a-f559-4090-8cce-2699566f17f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_bc81654b-4707-46d1-b830-1e94628db4c7" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_05ea329a-f559-4090-8cce-2699566f17f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_540039ab-6c60-47b5-a203-2bd2a089086d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4d155de4-f775-436d-85b4-393d1cc3fea0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_540039ab-6c60-47b5-a203-2bd2a089086d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_540039ab-6c60-47b5-a203-2bd2a089086d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_540039ab-6c60-47b5-a203-2bd2a089086d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_540039ab-6c60-47b5-a203-2bd2a089086d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b083e449-82dd-4beb-ac8d-f00f21f5c6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_540039ab-6c60-47b5-a203-2bd2a089086d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b083e449-82dd-4beb-ac8d-f00f21f5c6bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_4d60fd89-e1a3-4b35-a130-d41cae393ec0" xlink:href="evh-20220630.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_b083e449-82dd-4beb-ac8d-f00f21f5c6bd" xlink:to="loc_evh_ServicesAgreementsMember_4d60fd89-e1a3-4b35-a130-d41cae393ec0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="i7d61ba4d5a734df2be99c4b643219717_FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5959b466-f4f5-4413-95d7-18cc317d1327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7bb11690-d945-4bd4-8cca-2f57e341641f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5959b466-f4f5-4413-95d7-18cc317d1327" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7bb11690-d945-4bd4-8cca-2f57e341641f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3e0a0d58-5f75-41e5-9720-d634e48b7b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7bb11690-d945-4bd4-8cca-2f57e341641f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3e0a0d58-5f75-41e5-9720-d634e48b7b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_be3d55f9-9dc3-44e7-958e-9e895fba7e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7bb11690-d945-4bd4-8cca-2f57e341641f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_be3d55f9-9dc3-44e7-958e-9e895fba7e47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_25229e23-6b6b-4dfb-9e7e-f36c9ff50b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5959b466-f4f5-4413-95d7-18cc317d1327" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_25229e23-6b6b-4dfb-9e7e-f36c9ff50b9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b0b3b7b-569e-4ab9-b3e4-3f8f6f0738c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_25229e23-6b6b-4dfb-9e7e-f36c9ff50b9d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b0b3b7b-569e-4ab9-b3e4-3f8f6f0738c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b0b3b7b-569e-4ab9-b3e4-3f8f6f0738c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b0b3b7b-569e-4ab9-b3e4-3f8f6f0738c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b0b3b7b-569e-4ab9-b3e4-3f8f6f0738c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa7baba-3fa5-45a4-8621-da3d076cb7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b0b3b7b-569e-4ab9-b3e4-3f8f6f0738c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa7baba-3fa5-45a4-8621-da3d076cb7e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ab63f52f-f598-4977-baf5-9fadfffcb140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa7baba-3fa5-45a4-8621-da3d076cb7e0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ab63f52f-f598-4977-baf5-9fadfffcb140" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_412deb2f-bb72-4363-934a-cc828a816732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa7baba-3fa5-45a4-8621-da3d076cb7e0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_412deb2f-bb72-4363-934a-cc828a816732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c1c4593f-ad80-4f42-a0de-726a1f5c6e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa7baba-3fa5-45a4-8621-da3d076cb7e0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c1c4593f-ad80-4f42-a0de-726a1f5c6e4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e077484d-2eca-4c6e-bdda-21ff9b515c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_25229e23-6b6b-4dfb-9e7e-f36c9ff50b9d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e077484d-2eca-4c6e-bdda-21ff9b515c2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e077484d-2eca-4c6e-bdda-21ff9b515c2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e077484d-2eca-4c6e-bdda-21ff9b515c2e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e077484d-2eca-4c6e-bdda-21ff9b515c2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7bd4159c-b6c1-4bbf-ad29-fa16ca6b8bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e077484d-2eca-4c6e-bdda-21ff9b515c2e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7bd4159c-b6c1-4bbf-ad29-fa16ca6b8bc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_40462330-6c64-4d49-9346-70c7472f8458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7bd4159c-b6c1-4bbf-ad29-fa16ca6b8bc0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_40462330-6c64-4d49-9346-70c7472f8458" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended" id="i02379f6e4b8744229acaf3a543b15f8d_FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2d852efe-49dd-4569-8b5f-e9539cd011b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_66808a98-3472-4333-8710-d374c9f5a461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2d852efe-49dd-4569-8b5f-e9539cd011b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_66808a98-3472-4333-8710-d374c9f5a461" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b3a00b8b-8578-4aaa-9c3b-4ca83cc74cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2d852efe-49dd-4569-8b5f-e9539cd011b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b3a00b8b-8578-4aaa-9c3b-4ca83cc74cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_01d65873-185d-4914-85b1-b2d2886b9494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2d852efe-49dd-4569-8b5f-e9539cd011b8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_01d65873-185d-4914-85b1-b2d2886b9494" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f8c0871-3d58-423e-b5b8-fba59ac020ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_01d65873-185d-4914-85b1-b2d2886b9494" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f8c0871-3d58-423e-b5b8-fba59ac020ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6f8c0871-3d58-423e-b5b8-fba59ac020ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f8c0871-3d58-423e-b5b8-fba59ac020ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6f8c0871-3d58-423e-b5b8-fba59ac020ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c7c5439f-a71a-4e2c-97dc-4c87801b6dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f8c0871-3d58-423e-b5b8-fba59ac020ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c7c5439f-a71a-4e2c-97dc-4c87801b6dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fbb9f93a-1098-4a50-953b-4bb6907f5996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c7c5439f-a71a-4e2c-97dc-4c87801b6dc9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fbb9f93a-1098-4a50-953b-4bb6907f5996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bb630c2-6a78-4ee5-adc0-9e194e873cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_01d65873-185d-4914-85b1-b2d2886b9494" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bb630c2-6a78-4ee5-adc0-9e194e873cf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bb630c2-6a78-4ee5-adc0-9e194e873cf7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bb630c2-6a78-4ee5-adc0-9e194e873cf7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bb630c2-6a78-4ee5-adc0-9e194e873cf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9769c117-f98b-4312-ac07-d80bd9befb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bb630c2-6a78-4ee5-adc0-9e194e873cf7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9769c117-f98b-4312-ac07-d80bd9befb1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8d830f53-7b95-44d1-83e6-a5c25f97f22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9769c117-f98b-4312-ac07-d80bd9befb1b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8d830f53-7b95-44d1-83e6-a5c25f97f22d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4f0d8998-e87f-490d-a643-56d3eb5ba357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_01d65873-185d-4914-85b1-b2d2886b9494" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4f0d8998-e87f-490d-a643-56d3eb5ba357" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4f0d8998-e87f-490d-a643-56d3eb5ba357_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4f0d8998-e87f-490d-a643-56d3eb5ba357" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4f0d8998-e87f-490d-a643-56d3eb5ba357_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3cd4d013-90f6-40c7-baf4-20fe57e651d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4f0d8998-e87f-490d-a643-56d3eb5ba357" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3cd4d013-90f6-40c7-baf4-20fe57e651d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_39b1596a-83fb-4b69-90c9-3c1901ed699d" xlink:href="evh-20220630.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3cd4d013-90f6-40c7-baf4-20fe57e651d7" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_39b1596a-83fb-4b69-90c9-3c1901ed699d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a4e81473-e1c1-4a5d-a887-bf46a90eea1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3cd4d013-90f6-40c7-baf4-20fe57e651d7" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a4e81473-e1c1-4a5d-a887-bf46a90eea1f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended" id="icf8cefbe83294dacb6aa0e149a4f8753_RelatedPartiesAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_116f0a42-001a-4d11-a9ee-4839483c29ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a6f5846e-e198-4454-9613-139f2f8d1bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_116f0a42-001a-4d11-a9ee-4839483c29ce" xlink:to="loc_us-gaap_AssetsAbstract_a6f5846e-e198-4454-9613-139f2f8d1bbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_af4fe029-ac1d-44d6-8349-aa731cd1b49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a6f5846e-e198-4454-9613-139f2f8d1bbe" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_af4fe029-ac1d-44d6-8349-aa731cd1b49b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf5f1b4a-5511-4110-a163-0b73451cc5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a6f5846e-e198-4454-9613-139f2f8d1bbe" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf5f1b4a-5511-4110-a163-0b73451cc5e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_c22d110d-804d-40a1-9c00-1bd738563f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a6f5846e-e198-4454-9613-139f2f8d1bbe" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_c22d110d-804d-40a1-9c00-1bd738563f8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_e14be179-dc0b-42ca-a1a9-5365e29f563f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_116f0a42-001a-4d11-a9ee-4839483c29ce" xlink:to="loc_us-gaap_LiabilitiesAbstract_e14be179-dc0b-42ca-a1a9-5365e29f563f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8755cf7d-f76c-4518-90ce-249a7cb240ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_e14be179-dc0b-42ca-a1a9-5365e29f563f" xlink:to="loc_us-gaap_AccountsPayableCurrent_8755cf7d-f76c-4518-90ce-249a7cb240ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5e6a1ba5-0fa8-4171-b978-6aeb442f3c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_e14be179-dc0b-42ca-a1a9-5365e29f563f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5e6a1ba5-0fa8-4171-b978-6aeb442f3c8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_5e01882b-d469-4330-bbab-ffdb7c20b92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_e14be179-dc0b-42ca-a1a9-5365e29f563f" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_5e01882b-d469-4330-bbab-ffdb7c20b92f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76e60788-95e0-4604-ba5d-3cb817370fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_116f0a42-001a-4d11-a9ee-4839483c29ce" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76e60788-95e0-4604-ba5d-3cb817370fc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0e744c8d-8c86-40b5-b084-c2275375a675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76e60788-95e0-4604-ba5d-3cb817370fc4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0e744c8d-8c86-40b5-b084-c2275375a675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0e744c8d-8c86-40b5-b084-c2275375a675_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0e744c8d-8c86-40b5-b084-c2275375a675" xlink:to="loc_us-gaap_RelatedPartyDomain_0e744c8d-8c86-40b5-b084-c2275375a675_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_34b955b2-67ef-4412-8b05-04744862a064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0e744c8d-8c86-40b5-b084-c2275375a675" xlink:to="loc_us-gaap_RelatedPartyDomain_34b955b2-67ef-4412-8b05-04744862a064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_8f08b0cb-9c0b-4512-b855-3d858d5dba09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_34b955b2-67ef-4412-8b05-04744862a064" xlink:to="loc_srt_AffiliatedEntityMember_8f08b0cb-9c0b-4512-b855-3d858d5dba09" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended" id="i2ee31c7cf7174bbea27899d1f0a66db4_RelatedPartiesRevenuesandExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b7e7f39c-a87c-4eb7-b8a4-179afff973fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_0fe76648-6955-4f2d-9575-4ada5e9cfa8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b7e7f39c-a87c-4eb7-b8a4-179afff973fc" xlink:to="loc_us-gaap_RevenueFromRelatedParties_0fe76648-6955-4f2d-9575-4ada5e9cfa8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c2695b10-ec8b-4b79-8c35-7a6c5a2b7dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b7e7f39c-a87c-4eb7-b8a4-179afff973fc" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c2695b10-ec8b-4b79-8c35-7a6c5a2b7dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_66d03421-3f9c-4f5a-b6ab-1f968dc42655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b7e7f39c-a87c-4eb7-b8a4-179afff973fc" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_66d03421-3f9c-4f5a-b6ab-1f968dc42655" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_160d9d2e-c488-4701-a576-10179ada703a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_66d03421-3f9c-4f5a-b6ab-1f968dc42655" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_160d9d2e-c488-4701-a576-10179ada703a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_160d9d2e-c488-4701-a576-10179ada703a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_160d9d2e-c488-4701-a576-10179ada703a" xlink:to="loc_us-gaap_RelatedPartyDomain_160d9d2e-c488-4701-a576-10179ada703a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cd32cbc7-f8f2-47e7-80f5-f0dd50b5641a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_160d9d2e-c488-4701-a576-10179ada703a" xlink:to="loc_us-gaap_RelatedPartyDomain_cd32cbc7-f8f2-47e7-80f5-f0dd50b5641a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_ce471057-b051-45bf-ba72-d29cfe5b1fd4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cd32cbc7-f8f2-47e7-80f5-f0dd50b5641a" xlink:to="loc_srt_AffiliatedEntityMember_ce471057-b051-45bf-ba72-d29cfe5b1fd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9f43b158-60e6-4ff0-a7bb-31900c33fc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_66d03421-3f9c-4f5a-b6ab-1f968dc42655" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9f43b158-60e6-4ff0-a7bb-31900c33fc3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9f43b158-60e6-4ff0-a7bb-31900c33fc3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9f43b158-60e6-4ff0-a7bb-31900c33fc3d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9f43b158-60e6-4ff0-a7bb-31900c33fc3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1a9d28ca-344b-432c-996f-f3a59a9f6893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9f43b158-60e6-4ff0-a7bb-31900c33fc3d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1a9d28ca-344b-432c-996f-f3a59a9f6893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_946b1821-7d50-4882-8f05-2da5916f3027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1a9d28ca-344b-432c-996f-f3a59a9f6893" xlink:to="loc_us-gaap_CostOfSalesMember_946b1821-7d50-4882-8f05-2da5916f3027" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_296987c2-4c22-423f-9735-00a192ad3e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1a9d28ca-344b-432c-996f-f3a59a9f6893" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_296987c2-4c22-423f-9735-00a192ad3e51" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RepositioningandOtherChangesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended" id="ifdaf1f00bd194ee0a08d330c3c7e9236_RepositioningandOtherChangesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c0266310-5b74-4707-9b82-d3e2e30ac06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9d43ad9a-fb5b-42a9-8c91-4551a2ace65a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c0266310-5b74-4707-9b82-d3e2e30ac06c" xlink:to="loc_us-gaap_RestructuringCharges_9d43ad9a-fb5b-42a9-8c91-4551a2ace65a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_5f51762f-0b32-469e-91c9-667d1b126e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c0266310-5b74-4707-9b82-d3e2e30ac06c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_5f51762f-0b32-469e-91c9-667d1b126e82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d0d92134-cf3a-41df-b48f-ae1f85f8a622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c0266310-5b74-4707-9b82-d3e2e30ac06c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d0d92134-cf3a-41df-b48f-ae1f85f8a622" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_bcda5499-16ce-442d-9204-1212f120d776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d0d92134-cf3a-41df-b48f-ae1f85f8a622" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_bcda5499-16ce-442d-9204-1212f120d776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_bcda5499-16ce-442d-9204-1212f120d776_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_bcda5499-16ce-442d-9204-1212f120d776" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_bcda5499-16ce-442d-9204-1212f120d776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_45838153-5374-4465-8089-3c697f9b1961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_bcda5499-16ce-442d-9204-1212f120d776" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_45838153-5374-4465-8089-3c697f9b1961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_b5988bf7-1062-4c0d-8c34-c262f4c1eb88" xlink:href="evh-20220630.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_45838153-5374-4465-8089-3c697f9b1961" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_b5988bf7-1062-4c0d-8c34-c262f4c1eb88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_a8f93299-20c6-44ab-85eb-3bae69556a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_45838153-5374-4465-8089-3c697f9b1961" xlink:to="loc_us-gaap_FacilityClosingMember_a8f93299-20c6-44ab-85eb-3bae69556a0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_37e3e436-bebb-4c25-bf81-dbdbdf7f553a" xlink:href="evh-20220630.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_45838153-5374-4465-8089-3c697f9b1961" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_37e3e436-bebb-4c25-bf81-dbdbdf7f553a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended" id="ic1d369a530394b3ca48882a00516afc9_SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_b50c6fdc-c776-4440-b636-a2051c7d8ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_994a422a-4916-4f4e-9635-5c8d9134dd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_b50c6fdc-c776-4440-b636-a2051c7d8ce2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_994a422a-4916-4f4e-9635-5c8d9134dd23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_aa6ceeb8-58ff-4731-b6ac-62c8a4eb4387" xlink:href="evh-20220630.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_b50c6fdc-c776-4440-b636-a2051c7d8ce2" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_aa6ceeb8-58ff-4731-b6ac-62c8a4eb4387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_bbcb2d87-34c6-4f1f-b033-2cad59c26a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_b50c6fdc-c776-4440-b636-a2051c7d8ce2" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_bbcb2d87-34c6-4f1f-b033-2cad59c26a95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9d2877ee-b6c2-40e8-8466-d5873cefacd2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_bbcb2d87-34c6-4f1f-b033-2cad59c26a95" xlink:to="loc_srt_ConsolidationItemsAxis_9d2877ee-b6c2-40e8-8466-d5873cefacd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9d2877ee-b6c2-40e8-8466-d5873cefacd2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_9d2877ee-b6c2-40e8-8466-d5873cefacd2" xlink:to="loc_srt_ConsolidationItemsDomain_9d2877ee-b6c2-40e8-8466-d5873cefacd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_46a6b61b-60b3-4066-9d2f-eb7027df7508" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_9d2877ee-b6c2-40e8-8466-d5873cefacd2" xlink:to="loc_srt_ConsolidationItemsDomain_46a6b61b-60b3-4066-9d2f-eb7027df7508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_4488405c-ce90-493d-8d41-d79d99b02a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_46a6b61b-60b3-4066-9d2f-eb7027df7508" xlink:to="loc_us-gaap_IntersegmentEliminationMember_4488405c-ce90-493d-8d41-d79d99b02a0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e51de345-69c0-4ff6-add3-4fdd39bf6e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_46a6b61b-60b3-4066-9d2f-eb7027df7508" xlink:to="loc_us-gaap_OperatingSegmentsMember_e51de345-69c0-4ff6-add3-4fdd39bf6e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3cc2435d-a941-45e7-b7c4-ff71206f64fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_46a6b61b-60b3-4066-9d2f-eb7027df7508" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3cc2435d-a941-45e7-b7c4-ff71206f64fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6a436050-4fa3-41b0-b3d0-2470bc67328b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_bbcb2d87-34c6-4f1f-b033-2cad59c26a95" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6a436050-4fa3-41b0-b3d0-2470bc67328b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6a436050-4fa3-41b0-b3d0-2470bc67328b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6a436050-4fa3-41b0-b3d0-2470bc67328b" xlink:to="loc_us-gaap_SegmentDomain_6a436050-4fa3-41b0-b3d0-2470bc67328b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_45ba4e69-023f-4bac-aea0-6c2888db01a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6a436050-4fa3-41b0-b3d0-2470bc67328b" xlink:to="loc_us-gaap_SegmentDomain_45ba4e69-023f-4bac-aea0-6c2888db01a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_6c9cbf5e-a48f-4ae4-a580-efa7ceb96ce3" xlink:href="evh-20220630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_45ba4e69-023f-4bac-aea0-6c2888db01a5" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_6c9cbf5e-a48f-4ae4-a580-efa7ceb96ce3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_ddc11be9-316a-48ee-b4d7-91ee6c6ae1dd" xlink:href="evh-20220630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_45ba4e69-023f-4bac-aea0-6c2888db01a5" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_ddc11be9-316a-48ee-b4d7-91ee6c6ae1dd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended" id="id94f18460a2044c98af781fdcd8ccd55_ReservesforClaimsandPerformanceBasedArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_7084f058-9f5e-4201-8c1b-9750af8205c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_7084f058-9f5e-4201-8c1b-9750af8205c0" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f4c1c903-099a-451a-9f14-dfab51b5242a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f4c1c903-099a-451a-9f14-dfab51b5242a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_3df8b998-3fac-45b9-9bd2-5db2b4d418f5" xlink:href="evh-20220630.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_3df8b998-3fac-45b9-9bd2-5db2b4d418f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_20db82f1-bb94-40d4-82a0-4999792e74b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_20db82f1-bb94-40d4-82a0-4999792e74b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_c29af084-6f3d-47d2-8d56-f5414a08a943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_c29af084-6f3d-47d2-8d56-f5414a08a943" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_5d472dc3-8562-45f3-8cac-3e5f1ee9e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_5d472dc3-8562-45f3-8cac-3e5f1ee9e74b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_408c5eb7-2b04-4da7-8a3b-7dfdfbf0ae77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_408c5eb7-2b04-4da7-8a3b-7dfdfbf0ae77" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_490c14ed-184e-43bf-a6ea-e66312105e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_490c14ed-184e-43bf-a6ea-e66312105e97" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_4cb11c95-3223-409d-83a4-d0a1e48059a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_4cb11c95-3223-409d-83a4-d0a1e48059a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7449df95-fd15-4d98-9c8f-86e8bd425612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_4a3c27f6-c8fb-4cf1-bc9f-1d8969ea79dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_7084f058-9f5e-4201-8c1b-9750af8205c0" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_4a3c27f6-c8fb-4cf1-bc9f-1d8969ea79dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4a57eb69-ed6c-441f-9ca9-67921e0053ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_4a3c27f6-c8fb-4cf1-bc9f-1d8969ea79dc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4a57eb69-ed6c-441f-9ca9-67921e0053ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4a57eb69-ed6c-441f-9ca9-67921e0053ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4a57eb69-ed6c-441f-9ca9-67921e0053ca" xlink:to="loc_us-gaap_SegmentDomain_4a57eb69-ed6c-441f-9ca9-67921e0053ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_540c7238-d571-4715-b2a6-702a89e4d377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4a57eb69-ed6c-441f-9ca9-67921e0053ca" xlink:to="loc_us-gaap_SegmentDomain_540c7238-d571-4715-b2a6-702a89e4d377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_72c66672-43e6-4392-a84d-192811f74b92" xlink:href="evh-20220630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_540c7238-d571-4715-b2a6-702a89e4d377" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_72c66672-43e6-4392-a84d-192811f74b92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_3fc96baf-723e-4e16-8e81-8203accea62c" xlink:href="evh-20220630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_540c7238-d571-4715-b2a6-702a89e4d377" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_3fc96baf-723e-4e16-8e81-8203accea62c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="extended" id="i4f5a0b0daa7f4ffdb2dec8e3c3346ec5_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_e829d5ac-39f5-4f46-8815-3e06b5e27e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_e829d5ac-39f5-4f46-8815-3e06b5e27e7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a345ee06-5545-4d83-b060-7c38e754f7af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a345ee06-5545-4d83-b060-7c38e754f7af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_20fb91e9-cc79-4fe4-8fb2-1c576ab95db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_20fb91e9-cc79-4fe4-8fb2-1c576ab95db4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_959a9357-9f9d-45b6-b646-332e238281e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_959a9357-9f9d-45b6-b646-332e238281e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8a07c346-d6b4-4a24-9f88-028c46708b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8a07c346-d6b4-4a24-9f88-028c46708b92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0088be81-8f74-4201-947d-dec169141557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0088be81-8f74-4201-947d-dec169141557" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_3cc027ec-de54-40b4-b529-7214e58388db" xlink:href="evh-20220630.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_3cc027ec-de54-40b4-b529-7214e58388db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_329f6d6e-d220-4db7-9a9a-3cb312cc071c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_329f6d6e-d220-4db7-9a9a-3cb312cc071c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c264823e-7c15-4152-82af-3beb71c2b0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c264823e-7c15-4152-82af-3beb71c2b0ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_f52f2987-8dee-4d48-ae95-cb7f72ff01a5" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_f52f2987-8dee-4d48-ae95-cb7f72ff01a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_fe75b318-32bd-43b1-8069-0c767cdf7ea6" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_fe75b318-32bd-43b1-8069-0c767cdf7ea6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_85129477-da6a-45b5-8d9a-f545b4f45136" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_85129477-da6a-45b5-8d9a-f545b4f45136" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_1afa2997-a1be-4ac2-aed5-c7e2a294afc6" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_1afa2997-a1be-4ac2-aed5-c7e2a294afc6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7cc97a55-e576-4647-86c9-501c3d6530f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7cc97a55-e576-4647-86c9-501c3d6530f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7cc97a55-e576-4647-86c9-501c3d6530f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7cc97a55-e576-4647-86c9-501c3d6530f8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7cc97a55-e576-4647-86c9-501c3d6530f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07cf48f5-dfb5-4e69-a440-08e94d7a80b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7cc97a55-e576-4647-86c9-501c3d6530f8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07cf48f5-dfb5-4e69-a440-08e94d7a80b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIncMember_496b1687-c96b-4d45-91a2-5259ed581c23" xlink:href="evh-20220630.xsd#evh_ImplantableProviderGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07cf48f5-dfb5-4e69-a440-08e94d7a80b1" xlink:to="loc_evh_ImplantableProviderGroupIncMember_496b1687-c96b-4d45-91a2-5259ed581c23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_05477eaf-ca69-4d45-827b-eca13bad44ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_VariableRateAxis_05477eaf-ca69-4d45-827b-eca13bad44ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_05477eaf-ca69-4d45-827b-eca13bad44ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_05477eaf-ca69-4d45-827b-eca13bad44ea" xlink:to="loc_us-gaap_VariableRateDomain_05477eaf-ca69-4d45-827b-eca13bad44ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_abd51673-60d6-49aa-8b4d-f9c4c8f44331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_05477eaf-ca69-4d45-827b-eca13bad44ea" xlink:to="loc_us-gaap_VariableRateDomain_abd51673-60d6-49aa-8b4d-f9c4c8f44331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_c5c9d3b6-2dfa-4b83-b7ff-65a86ac8d9fd" xlink:href="evh-20220630.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_abd51673-60d6-49aa-8b4d-f9c4c8f44331" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_c5c9d3b6-2dfa-4b83-b7ff-65a86ac8d9fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_d12b438f-541f-446a-9a12-136288def6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_abd51673-60d6-49aa-8b4d-f9c4c8f44331" xlink:to="loc_us-gaap_BaseRateMember_d12b438f-541f-446a-9a12-136288def6e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e818f32d-f458-4f0f-9a1f-7b8949c6d8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e818f32d-f458-4f0f-9a1f-7b8949c6d8c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e818f32d-f458-4f0f-9a1f-7b8949c6d8c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e818f32d-f458-4f0f-9a1f-7b8949c6d8c1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e818f32d-f458-4f0f-9a1f-7b8949c6d8c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b7c6d4dc-db9d-4a1a-9b90-08965c447301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e818f32d-f458-4f0f-9a1f-7b8949c6d8c1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b7c6d4dc-db9d-4a1a-9b90-08965c447301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_af11dceb-71e4-4ea0-97e6-b73b024dd5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b7c6d4dc-db9d-4a1a-9b90-08965c447301" xlink:to="loc_us-gaap_LineOfCreditMember_af11dceb-71e4-4ea0-97e6-b73b024dd5d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_25fe5d36-02a7-4e44-ab09-87348f8329b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_CreditFacilityAxis_25fe5d36-02a7-4e44-ab09-87348f8329b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_25fe5d36-02a7-4e44-ab09-87348f8329b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_25fe5d36-02a7-4e44-ab09-87348f8329b3" xlink:to="loc_us-gaap_CreditFacilityDomain_25fe5d36-02a7-4e44-ab09-87348f8329b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_08d9783a-908a-4c53-803a-b936ac416c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_25fe5d36-02a7-4e44-ab09-87348f8329b3" xlink:to="loc_us-gaap_CreditFacilityDomain_08d9783a-908a-4c53-803a-b936ac416c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_fd0c77ae-b806-423f-95a3-6ef17473ce4e" xlink:href="evh-20220630.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_08d9783a-908a-4c53-803a-b936ac416c30" xlink:to="loc_evh_A2022CreditFacilitiesMember_fd0c77ae-b806-423f-95a3-6ef17473ce4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_5182fad7-5a6d-41ad-a303-b0e15f66c07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_A2022CreditFacilitiesMember_fd0c77ae-b806-423f-95a3-6ef17473ce4e" xlink:to="loc_us-gaap_SecuredDebtMember_5182fad7-5a6d-41ad-a303-b0e15f66c07a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_75795bdc-82e5-436c-af00-1bc20e84b573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_A2022CreditFacilitiesMember_fd0c77ae-b806-423f-95a3-6ef17473ce4e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_75795bdc-82e5-436c-af00-1bc20e84b573" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a858324d-dd02-459b-9ad6-aab8ac36fada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a858324d-dd02-459b-9ad6-aab8ac36fada" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a858324d-dd02-459b-9ad6-aab8ac36fada_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a858324d-dd02-459b-9ad6-aab8ac36fada" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a858324d-dd02-459b-9ad6-aab8ac36fada_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_805cfc86-6c62-4ffb-8f89-b2f7bd91fba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a858324d-dd02-459b-9ad6-aab8ac36fada" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_805cfc86-6c62-4ffb-8f89-b2f7bd91fba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cdbf5ffc-980b-4fd0-8a3f-13d2e469c554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_805cfc86-6c62-4ffb-8f89-b2f7bd91fba8" xlink:to="loc_us-gaap_SubsequentEventMember_cdbf5ffc-980b-4fd0-8a3f-13d2e469c554" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6d50e0aa-4f81-42f4-a0bf-1befb2bd5d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6d50e0aa-4f81-42f4-a0bf-1befb2bd5d10" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6d50e0aa-4f81-42f4-a0bf-1befb2bd5d10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d50e0aa-4f81-42f4-a0bf-1befb2bd5d10" xlink:to="loc_us-gaap_EquityComponentDomain_6d50e0aa-4f81-42f4-a0bf-1befb2bd5d10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f955f4a7-8447-497f-a010-912e81527ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d50e0aa-4f81-42f4-a0bf-1befb2bd5d10" xlink:to="loc_us-gaap_EquityComponentDomain_f955f4a7-8447-497f-a010-912e81527ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2ebfd6b6-d8bb-4fa5-a0b8-707680b53313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f955f4a7-8447-497f-a010-912e81527ba0" xlink:to="loc_us-gaap_CommonStockMember_2ebfd6b6-d8bb-4fa5-a0b8-707680b53313" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>evh-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a212dad2-7296-44b7-8af9-e12f408b43ae,g:23ff20ea-0869-45df-9d88-aeb2d6e74df5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_6fb00269-86b0-4244-999d-251202788303_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_30fa16b0-b5a4-4265-8fa5-5eb06a1790f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d91557ed-6c11-4bc4-8a52-1018e58ad16b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_78d7cab0-322e-4d65-a548-5eb7a68f50c1_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5dd8676d-1df0-4269-8ea5-17004d19c123_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_8accb318-7b21-4550-8146-aac2b2eceb53_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_10fef3f1-e9e8-4e6c-aa7f-b13d42e8d843_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_be85da63-cb1e-4d5f-b66a-7fc8c0c63def_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0a96f718-6802-4356-a9ff-8959122c16a5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_9529da81-c000-442d-8cea-06638b3f17d6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_eccb0dea-b884-49cc-8230-4a58ef739c62_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_98350184-3f32-44c5-ab97-bbcfd97d289d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity in claims reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_9a97395a-007d-4934-aa8d-cc0087f7766a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a694f83c-280b-477e-acc6-c4904755ace5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0fd9f103-8a77-4d30-b227-cce727bda864_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c124bb21-e474-40b0-a104-5919c4000432_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_b5dab9ae-cc73-41f6-baf4-d5d7e8aa04cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_39f281e6-ae22-4bee-a4e8-677739514910_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e8b3b43b-519b-4b90-8537-facde82b27b6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_decc5024-16bb-4918-aaef-a230f8cca2bf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_71b54499-f834-4c77-8362-0f95d0afa801_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1aa5f7c5-2e87-4e09-b842-ee5a45ceb482_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_93a9f19b-4833-4978-a3dd-d458ecfe703a_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_699adc12-e281-4c4e-a4d1-c33171469d30_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f0a076a9-929d-477a-9e38-7b9747905cfa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from performed obligations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_cb819df7-4ea1-4a87-95dd-7e4eaadf7991_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_89dc780c-3201-4b67-ad58-b682b2646b47_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from transfer of membership and release of Passport escrow</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_d2f9e1ad-6459-4f56-afb4-a0e9f8c5129c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_15bfb3f8-d584-4850-8cad-815c7933c0bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_028f2461-729a-46b4-ab0c-aa58cff3e507_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3f20f641-3c93-4c60-a076-a024f2644d57_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f4423848-bbf6-4283-97dd-08322f5cc637_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_1ecdac2f-3227-4c51-9d36-7f1703d64855_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ae01d870-0cd9-48aa-bdfd-cf49a8ef0464_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_99f8fe2e-1097-4184-8fe7-851778741efd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b5b1588f-17fe-492e-a868-df4c534702cd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_a77273c5-a4e5-431f-87dc-3b0d9001dca3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f27b9ec3-a616-4c24-9698-203d5ae723f5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ee8de1ae-0973-4d84-a6f3-972eb3086639_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8381412c-702a-4cd2-bc85-7c187a32a475_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of allocation of purchase price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_78f975dc-ea86-4013-a0d7-84363b55db30_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current operating cash inflows (outflows), net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_1e269a3d-413f-4a2d-8b25-e379c9388212_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:to="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d7d406bb-bcdd-425d-bbc4-b4ebca5211ff_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1e7ffee6-2031-488e-b221-949b63925d37_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_44ab1075-ae6b-4503-b387-d9e17a63c4eb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_6d6f27f8-7ad1-42fc-9fc9-2f2319e8fb30_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_acbd418b-5fd0-460c-bccf-d94ede5e9917_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_d1d7f36c-26d2-4012-aef4-0fbccbf4cf77_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7927a6be-2c2d-4a64-bbec-35c7d37ddb68_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_804b4120-4898-47b7-8999-0fa2cc5e7c17_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_ba37184b-c7a7-4405-bb3f-bcb4ed6fa04c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_37aac021-defe-42e9-b411-86f0262c8ad0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_87cb7456-3cb5-4ed9-a9e9-9e4ce87eaafe_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9beb893e-43c8-4bb1-bc04-3a6ba91b304c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e46213af-00a8-4474-b447-8a95d26e985c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9f7f2852-1ef5-4b82-b3a7-059dfa4d011e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_941a8dbb-632c-4013-b083-9d5479bed687_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_01f6ed07-b9df-4932-87c6-2e99660795a0_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_3a8c9d46-56fd-4db2-a814-079d36aedafb_terseLabel_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of tax savings to be paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_label_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings to be Paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_documentation_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:href="evh-20220630.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:to="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_cd0fa1cd-5c04-49fc-adc7-bc0f21c77a71_terseLabel_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_label_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</link:label>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:href="evh-20220630.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:to="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_37aa3cdb-153d-475b-93b9-c13c74a83a56_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_acffbf2b-02ba-4a0c-95e2-076bd485bd31_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_68ca2f13-13b3-4a3d-835f-fa092fb22445_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_458065d5-cc34-4a28-abd3-01e78f54124e_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:href="evh-20220630.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_c337dcaa-669d-4bcd-859c-7795269cf075_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, consecutive trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_f7ed5b84-de30-4e69-983b-c611cea49b7a_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_2125367c-aa44-4ce8-a84f-67d38256716c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_155c17ae-43d7-40c7-8a0b-499b0af0915c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_5586fab7-81a1-4f64-91b7-2fbdd759c8af_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b9ecd8bb-25fe-459e-963c-453232daec88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_ce30337e-bd59-459b-a198-f33d9b735d12_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4ca4c8bf-bd1c-4e65-85ff-bb2c81614911_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9759db51-763d-4e10-b83c-9cbe5027adc1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_46e67bab-b26d-434e-a6f0-cf319d62a136_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_86f65077-9abf-4a9b-b318-0cccdb17dd52_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3a3b2846-b90c-4cc7-85d1-566721e1d572_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_76f2eb41-06cb-4eee-99d8-12222c787f13_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_bf57ba9f-2762-48a7-b46b-818eb514b42b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_43b7e7c2-f191-4abc-bcf6-91c425b37eae_terseLabel_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and other</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_label_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers [Member]</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_documentation_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember" xlink:href="evh-20220630.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CommercialAndOtherCustomersMember" xlink:to="lab_evh_CommercialAndOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b5bd0c24-eaaa-4c99-8600-de673975c6b3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6c572eb6-310e-4a8e-9f4e-7400363c12a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_2dd33a33-2f74-4492-8ae1-d92bc66cd824_negatedLabel_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_label_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:href="evh-20220630.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:to="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_97a02aeb-14ce-41c7-b412-b63f8fb6641f_terseLabel_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="evh-20220630.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bdaae0ea-7ff5-4a3e-a73b-9caca744a128_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of taxes, related to:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PremiumsRevenueMember_cb23e827-26ea-4375-b97d-15a842444f68_terseLabel_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_label_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_documentation_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember" xlink:href="evh-20220630.xsd#evh_PremiumsRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PremiumsRevenueMember" xlink:to="lab_evh_PremiumsRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6fd4159b-14b4-4f85-9db4-0671a962e963_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NewNotesMember_e29d32f4-459a-42cf-94c9-899808fc84f8_terseLabel_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:label id="lab_evh_NewNotesMember_label_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes [Member]</link:label>
    <link:label id="lab_evh_NewNotesMember_documentation_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember" xlink:href="evh-20220630.xsd#evh_NewNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NewNotesMember" xlink:to="lab_evh_NewNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_43850dac-2b17-4e30-bf74-98bc8000f239_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f051af1c-1db2-4857-9cdc-6556d8fd56b0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_108a2c10-46e8-4cba-8b03-23e446d31fc6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_cab73094-6878-49c9-9d77-d9d0417e9a1d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_82840c26-464e-4649-b8b6-c8d6af8493d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_76a609d6-58f9-48a0-8891-5e7282197cfc_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_8ba1a053-f433-4946-aec2-2bcb91bb74bf_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_4b368960-0544-4590-98e6-51a6288ca0c4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e6349fca-e81d-44e5-b4d7-5fd382312814_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_1d0c92dd-1bf2-4281-ab00-ed9178374b0a_terseLabel_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, current</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_label_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_documentation_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue" xlink:href="evh-20220630.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FinancingReceivablePercentNotPastDue" xlink:to="lab_evh_FinancingReceivablePercentNotPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_2c332e25-c412-462a-a302-83a67e0dd3ff_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Two, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Two, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_9357cadb-8ee5-421a-8621-ddbb5de6fee8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4fef1db2-4cfb-4670-afe4-19b9f70894eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_297da445-9e6c-489d-b706-a8b293f6840b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_da65235f-de75-44cf-ba13-4c3e4ca1f91e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4b200cbf-e2d9-491f-8b28-f35c3714ae3a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFlowLesseeAbstract_3109db46-e4b3-4e1e-b614-93063db9169b_terseLabel_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Leases</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract" xlink:href="evh-20220630.xsd#evh_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFlowLesseeAbstract" xlink:to="lab_evh_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_c9ae87d3-f7a6-4016-b49d-118f7ff58eb9_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_label_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy [Policy Text Block]</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:href="evh-20220630.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:to="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_91d855fe-9166-4d68-ad6b-a11b16bdc30e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_b67ebf29-35c2-4ff1-aa6a-1a92d8ebf03d_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f9a9589a-cf76-4d60-88c5-46c45d13e846_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9611b7c-07ea-4617-8ce4-b30911bf9d3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_b2c623bf-1ba3-4331-ac30-433397f05d22_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ecc83d1-b3af-4d87-aced-f3a5a96a9646_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_08fee879-a2e4-497c-916b-5309600013bd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_24627ed7-4086-4026-977e-914f78be4247_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_a8adbdd8-3d56-4a12-94bf-ab857524b492_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid costs related to prior period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareholderClassActionComplaintMember_d3a50c2a-393e-42a3-a95f-f6ca4d82bbe1_terseLabel_en-US" xlink:label="lab_evh_ShareholderClassActionComplaintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Class Action Complaint</link:label>
    <link:label id="lab_evh_ShareholderClassActionComplaintMember_label_en-US" xlink:label="lab_evh_ShareholderClassActionComplaintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Class Action Complaint [Member]</link:label>
    <link:label id="lab_evh_ShareholderClassActionComplaintMember_documentation_en-US" xlink:label="lab_evh_ShareholderClassActionComplaintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Class Action Complaint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderClassActionComplaintMember" xlink:href="evh-20220630.xsd#evh_ShareholderClassActionComplaintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareholderClassActionComplaintMember" xlink:to="lab_evh_ShareholderClassActionComplaintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_92f2f76c-b4ce-40eb-a003-f0d5f82eb457_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fabe41cf-df47-4e5c-a69f-303d49d6a6a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_e2ae91d6-06e9-483c-aeaf-9978227a168a_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e9ea0bb3-c9c7-4a00-ab51-926a9cb6a4d8_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward_ad31cdf3-02cf-4ba4-b76f-191190472e09_terseLabel_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward_label_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward_documentation_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability for Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward" xlink:href="evh-20220630.xsd#evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward" xlink:to="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a6cbe23b-1e27-4bf8-90ce-ed49691484cd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6041f61f-5047-4e6b-96f2-ec9e31d4a3ed_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_efa4a750-7df4-48aa-ad4b-789a1a4bd88e_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:to="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_2a4ddf6f-0e7b-42f9-9b15-69d4141f4d2b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0e63da70-e071-46f3-a376-e8aec8df3782_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ImplantableProviderGroupIncMember_55c0efa6-fde4-4291-97fe-397f31701d89_terseLabel_en-US" xlink:label="lab_evh_ImplantableProviderGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implantable Provider Group, Inc.</link:label>
    <link:label id="lab_evh_ImplantableProviderGroupIncMember_label_en-US" xlink:label="lab_evh_ImplantableProviderGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implantable Provider Group, Inc. [Member]</link:label>
    <link:label id="lab_evh_ImplantableProviderGroupIncMember_documentation_en-US" xlink:label="lab_evh_ImplantableProviderGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implantable Provider Group, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIncMember" xlink:href="evh-20220630.xsd#evh_ImplantableProviderGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ImplantableProviderGroupIncMember" xlink:to="lab_evh_ImplantableProviderGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_1ac6947d-3037-45d9-b7d4-dfde3fffaa02_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_64fd16eb-594b-4067-b584-094d80fdb023_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_c624c212-d123-4a1d-a71b-4ba2079d44c8_negatedLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_33592e2f-da7d-4ac0-9815-fcfaa955f387_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_17e14b58-57b7-4f18-9a16-207866f75897_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_0357cd74-a777-4865-8e4c-f8fddc79f842_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9fc1c9d1-3b7d-4c33-9b47-eb879ed54774_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cf25b1ca-cfe3-443c-b89e-f4ac710f4ab5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_211973ca-11ea-4e77-bc02-309d8f8e4053_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_e88f771f-ee33-4f02-bd15-3bce7a4a67c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in internal-use software and purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_661260f9-132c-4396-8ed2-69dae0763893_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_aab05091-6dea-4063-9143-79b60e8321d0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8c27d17c-77e3-4471-898d-10c7bffa345f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest issued or issuable, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_ad8abf57-8e38-4569-9861-664f1dce2341_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_c9da5839-ebf5-4961-9d98-bbf53f2a7b14_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_681893c7-4ac7-4ed8-b639-3cf2e3bf1571_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty prior to first anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period One, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period One, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_b4854b54-6f85-4ec6-a7c7-5bd8a24048d9_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_e2c1a8e9-4ef7-490f-8e6f-d5720f2adffe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_f5627381-28ed-45fb-aab5-adca56c09047_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_a2dca299-67da-4ecd-af94-8fbd8a08e9b3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, asset and liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ccade0e2-76dd-4055-8681-d4ae2094c1c6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_8d260e1b-ccec-46c5-9ca1-ad77f89160ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_10c77194-a679-43cd-b9ce-8a73dda266ff_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_9c5db0ec-b138-40bb-a57b-cbc19244079a_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_06933a33-64ef-44cf-a290-3c1fc0b5dfe4_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price (at least)</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_41e60f83-fd43-49e1-aa2f-deccfb357369_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b38a4bf7-b95d-4dfd-84fb-e8347398d439_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8ce5c702-f922-468d-9485-616141ea585b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_39b6a3f5-42e2-4a44-ace5-e6abb4f99883_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_037b2dd3-b933-4867-9789-e42fcee31c2b_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NumberOfSourcesOfRevenue_4b93a94f-efd3-4e3e-89d6-71f3817ad961_terseLabel_en-US" xlink:label="lab_evh_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sources of revenue</link:label>
    <link:label id="lab_evh_NumberOfSourcesOfRevenue_label_en-US" xlink:label="lab_evh_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sources Of Revenue</link:label>
    <link:label id="lab_evh_NumberOfSourcesOfRevenue_documentation_en-US" xlink:label="lab_evh_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sources Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfSourcesOfRevenue" xlink:href="evh-20220630.xsd#evh_NumberOfSourcesOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NumberOfSourcesOfRevenue" xlink:to="lab_evh_NumberOfSourcesOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_c1f4831d-e755-4f59-ab1a-55b87863ef7f_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_77ce11d6-b506-44d0-9bba-2f3a64d596a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_fdc4ce2a-0d78-4b10-a71e-642b4e5b2742_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c4b93066-95a4-44fd-99eb-bf118b6bf36e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8d982d8e-fcd9-456b-9e70-8866ed5b729d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb465dcd-e9fe-4b6a-83be-bf27b4bc5968_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_ab69a7dc-be49-4bc7-9143-dfc6df61eced_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_99cad40f-8c8f-44e8-84a9-58923358696e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_805cb024-6d57-4832-a1f0-6d106a1dcce1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_882cdcee-391f-4341-932f-fc83f4e7f53f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_630d22af-a78e-47fd-9072-8feb84e6a657_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_74b39618-ab07-47b8-a57a-ca8f1f9f0c04_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_06da2bdd-1caa-4c2c-8669-8a7135d60a32_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_4951da51-a9aa-4eea-8a61-0664a2fd845a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d5f5e578-5f44-4486-a728-f3f02cf76ebe_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bedf2d74-1592-49d0-9751-73c1b0b0e8ec_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a0702159-f1a5-4c77-832a-9d889504e9d3_netLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_b853b37a-2e54-4221-b21d-157dd23e91da_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_9dee5f8c-6a1f-43bd-b306-b7cbb9a3bf36_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_ad7745fe-ed43-46eb-93f5-22395d3b9d38_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_aa555123-4ef4-4880-99fa-885d4050ef1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_31d7411b-5f56-4c25-b99a-cac3bb84fd81_terseLabel_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember" xlink:href="evh-20220630.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_InitialTermLoanFacilityMember" xlink:to="lab_evh_InitialTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6a85c97a-f763-46e3-ad96-7f5ad77faf65_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_15653719-ceeb-430a-8b9f-0097d7d738f3_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_77d0512f-da3f-46d2-9601-86e84d21467b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-based Arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_85387e04-bdb6-4e80-a281-c13dbb2323c1_terseLabel_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net, debt component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_label_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_documentation_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:href="evh-20220630.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:to="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_6cd6a07d-3c87-4c8c-abc9-5cb04c65f855_terseLabel_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt</link:label>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_label_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt [Member]</link:label>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_documentation_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember" xlink:href="evh-20220630.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityComponentOfLongTermDebtMember" xlink:to="lab_evh_EquityComponentOfLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_62e2fcb2-a5de-4315-a607-ac4b59ead3ae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2339ef9a-8a83-4cb5-aede-9719e5d90d5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_30d146d7-5ad4-4d64-8ed5-5833014c3470_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_465dff7b-bbfc-407b-bc0d-9940022d3bab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_c9db3673-0edb-43b4-9c98-b61fa65e9bf8_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_62f68e51-9c6c-43aa-a23f-50e0506e46c0_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0b41066b-9d29-40ed-aae3-fb0171a83860_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_73554c76-fdbd-4339-99b9-3c95f9d4d84f_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_df918b27-333d-4d45-9ff7-18922b1a24d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_53dfd3a0-8c7e-460c-96a2-c2f43a46c189_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_c8c9d30b-48be-4ce0-bff6-6c3209b05ea6_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_34305cdd-b258-40d4-bc40-58cbc930e188_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for asset acquisitions and business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_dd1cba26-b34e-4787-9e20-664dfdcdc46f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_7edc8d9a-4d15-4a8a-92d8-2cb6e14b861f_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_b7b7ca1c-12fb-4f4c-a0ff-4bc526f7d3c5_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on extinguishment of debt, including fees paid to lenders</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c2e7c73b-4836-479f-aacb-6e1d22812566_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_29f2c03f-d73b-465d-ad62-a9dc36378840_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f5331aa1-d2b6-45d3-83e5-3fe7b8a99c01_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_dfc8a236-e3d0-456e-8584-9eaac2cdc881_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_530a1449-4e41-4b52-8119-2794cb59b4e1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestments" xlink:to="lab_us-gaap_RestrictedCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_47ebddd8-8c49-425b-8121-d647edc824bf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_53d6a3a1-fb3f-48b3-8bc9-e63bf3502055_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_d4eb4234-abdc-4e9c-933a-e42181bfd98a_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software development costs</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_ecb58276-6c64-4aa0-8d9a-b468d17181bc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_a1616a00-5831-4651-9d59-33ec3c542bf5_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b1839de8-fb57-46f9-889b-e4f56fb7e908_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_e4f8ed02-43a1-4a9c-8844-e537b86f1aca_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a7cf09e2-7bff-4432-b974-6d0b0fcb7ea8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_0902416b-8dd5-4a65-aa57-82ca79d803d3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_de588384-212a-42d5-a6ca-41b27546d9d1_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_68b56dab-5270-4eef-af1a-fddaa9551ac1_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_57513f96-1146-4fa8-b9f3-070c35e2aecb_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_dcbee25b-e12a-458c-9d85-bf61263dd1a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate per $ 1000 principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_13102cba-81d8-4d90-85c3-f00fca8c549c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_d8dbcab2-0f3e-47c8-bb9b-85eef4e04660_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2b6a6826-9244-4e02-8f82-a132e1782645_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_59332400-c86c-4c14-9d4b-612b8235d0a8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d8f8143-acaa-44e9-b0c0-654a36efd58b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_8b395396-92eb-4be6-bcc8-a51975ee8da5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_922026fc-dfeb-4d1d-8be9-7981031d543e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_875d74d0-896c-4abe-a9df-a34de827cded_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_156c50b4-eb29-406d-b371-31bc185fd837_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3b3c0a96-d15c-4797-a40f-ed39313ea2cc_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_61004e6e-a9a3-4c75-9db6-367b742ca824_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_09d8eb6e-17ce-4690-88fe-a0cf581643ff_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicareCustomersMember_c7a6f26b-cf78-4767-bb73-7535dce03567_terseLabel_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_label_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers [Member]</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember" xlink:href="evh-20220630.xsd#evh_MedicareCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicareCustomersMember" xlink:to="lab_evh_MedicareCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8de25fee-1601-4b6c-bac7-95b0bc3bca2d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_a2ed64c6-1913-4358-9569-c8700bcea647_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c8d90bc9-3ad3-4a25-82bc-051c7ff0dd44_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_804b50d9-699b-4813-9604-403653f722a5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_3d73475e-cd2c-4f84-8ee7-a8e163421d8a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted funds</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6e2753d-3056-4e83-b0b7-bc24daea0b25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_48c757fd-b10c-4cad-ba3e-f55b243f3f82_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9e15186d-8df9-4f6a-aefa-792f689b0ec3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_26eaa8a6-e054-4703-b719-fc8cb6268749_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9d79a24e-0cf0-4196-9773-6c456cf75df7_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_53b3cc01-964f-48ea-804d-467a15f403da_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4f51af74-3924-4e30-aadc-27b01042b727_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_76c0fc1e-ceb2-40ca-b58f-4e1905db3d36_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5caac61d-4882-4d3b-ab9e-9034d4397a10_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e6ec7294-4f32-4260-9bbd-c99271e4cd9e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b0bc3f46-24fd-4ddd-a352-c5196f706afe_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_1c38e7de-684f-4f29-9bbc-2b22d5832c90_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_1fb316c3-1e59-4770-a76e-5add47652a1a_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (in percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_a7165184-4200-4547-b75e-d11740f14f69_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, amortization period</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:to="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_971988b8-a8ad-4b48-a394-8a00856451c9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6598e022-b985-499d-98b3-bd252579e9e5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_b10717bb-c7f3-418e-9589-4c33aec2a6a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_311f48cc-8657-4d89-bab0-87a2a83d21ba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_394a7cc0-09a0-4ef9-a01f-38488e7c6cde_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_e3514b5c-7163-46df-950f-919c9ed57d57_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_f5f7fc66-ce40-462f-9387-a8e7bd95b5ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_29390d62-bfbe-47e3-9a0f-f3044bbf8a2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Credit Agreement including settlement of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_75359655-9363-400d-a636-681837e6ec76_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_28df4e7c-18d2-4c26-adc4-b77b8f6779b0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_35c08a3a-8ca8-47e2-affe-ec13e5456b26_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_78eae7b2-2b04-4287-9e54-34c7f355e024_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0b7bddc4-536c-439f-94a4-e4622394b47a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_028187f3-061c-4ec8-b1c6-a750a911ba5c_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_a4dbf683-cd37-41c6-9dcb-fcdc0df02a30_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty on or after third anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Four, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Four, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_8a19f324-774f-407c-9112-84e7dd8ad60d_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Three, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Three, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_97be7eea-1076-4133-bbeb-d987279f1b4e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c313abd2-1f96-4f7c-af33-ef45044592ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtConversionOriginalDebtFairValue_5021b840-a9c1-4947-98ef-8a83dc6b2b5b_terseLabel_en-US" xlink:label="lab_evh_DebtConversionOriginalDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, original debt, fair value</link:label>
    <link:label id="lab_evh_DebtConversionOriginalDebtFairValue_label_en-US" xlink:label="lab_evh_DebtConversionOriginalDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Fair Value</link:label>
    <link:label id="lab_evh_DebtConversionOriginalDebtFairValue_documentation_en-US" xlink:label="lab_evh_DebtConversionOriginalDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtConversionOriginalDebtFairValue" xlink:href="evh-20220630.xsd#evh_DebtConversionOriginalDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtConversionOriginalDebtFairValue" xlink:to="lab_evh_DebtConversionOriginalDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e1b135d8-d1b0-472d-936c-acc97f3d58ef_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_e5724aa7-8b97-407d-b4d2-bb2647a490c9_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-Based Arrangements</link:label>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:to="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_5309441a-1706-4a45-be0a-2890eb08c178_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_340ba16f-fd02-43e9-be15-1bc2cf1a522a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_9a4f9e7e-20b8-4f18-b579-ea2b9dfd841e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to Sponsors</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_ef7fdefc-000c-4b09-b0d6-f3b5437cbebb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_f9d91202-14e6-4b51-a74c-53e244c7faf9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_99cb652e-1572-4b23-b1a7-4637c5cb8897_terseLabel_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_label_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_documentation_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:href="evh-20220630.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:to="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_bf1eb04e-e56d-4b06-ae5c-cf049d0ae857_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6d112dca-eec4-49b3-8732-e358d34f42de_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c0371383-d9b6-4df9-93f5-ecd1a190626d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4d21aa8d-d5e0-4a8c-8982-dddf13f47d33_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_cd60341a-1971-4cdf-b9e5-63da4082335f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_84162f18-1b34-41f8-8309-ba6d60dc5095_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_d44a9c33-5c9c-4201-b6b7-f706a8c43ecb_terseLabel_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with financial institutions</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_label_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_documentation_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:href="evh-20220630.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:to="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_ff7cf8b1-19bc-4ce0-8f11-9b3c329392a5_terseLabel_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding</link:label>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_label_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Common Shares Outstanding [Abstract]</link:label>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_documentation_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Common Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:href="evh-20220630.xsd#evh_WeightedAverageCommonSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:to="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e61dc662-8d1e-4a87-a6c7-86c6e05963b8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_b880409d-9d39-46d9-8c3b-01b6cab944ec_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_afb08820-076d-4cd0-acd3-fab3a16ca2e5_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_f450f1b9-bb01-47c5-937e-9626f7b97974_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 120 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:href="evh-20220630.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:to="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_47a55b94-d2bd-43d8-b8e4-eaa6bf7a2a75_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_label_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:href="evh-20220630.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:to="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_28c3d38f-40a2-4005-8366-233c88f8b87f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0a3039d2-d1b4-4319-9739-06bb8c7ceecc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5867bfab-c1b2-4dd8-aca6-6cb11b0c9b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b94c3617-b505-40cc-9b5a-e700fcaf7bfe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_41687d50-080f-4be1-b779-0e4f9581466b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in contingent consideration measured at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IN_65abc65a-731e-41d9-80b9-19b5672635b2_terseLabel_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pune, India</link:label>
    <link:label id="lab_country_IN_label_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_03a4307d-17cc-4150-a1b1-d51a4f06f156_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_VitalDecisionsMember_3a4dbd2c-8b60-4006-be8f-7a94c1df07ba_terseLabel_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions</link:label>
    <link:label id="lab_evh_VitalDecisionsMember_label_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions [Member]</link:label>
    <link:label id="lab_evh_VitalDecisionsMember_documentation_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember" xlink:href="evh-20220630.xsd#evh_VitalDecisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_VitalDecisionsMember" xlink:to="lab_evh_VitalDecisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_cc5c82d2-3a43-498d-b58a-a55f497c8969_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_30037ec8-ff13-4e86-9532-f26fc90d5e6f_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_748509bf-95b0-4889-90fd-9247cb628a3a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_165e6a16-82a6-4b14-8d90-09494b5ddc29_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_98c59fe9-e897-49c7-b0b4-1505ce69892c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_8a8f7180-4e8b-44bd-aad0-c71b148cbf47_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_dc4bc190-c6a5-436d-b447-7b785d76b12a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5130b0a2-c27f-4e37-837b-4607ca236307_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ffde86bf-52ea-4a84-b866-b42790d2a308_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8bc2cb27-6472-4dc8-b14f-5a8a4368db46_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainOnTransferOfMembership_38010585-ec72-4b71-b394-b62e8295c025_terseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_1ba69a74-034c-4a0e-9222-691ee8afce81_negatedTerseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_label_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_documentation_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership" xlink:href="evh-20220630.xsd#evh_GainOnTransferOfMembership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainOnTransferOfMembership" xlink:to="lab_evh_GainOnTransferOfMembership" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_b49d1443-7198-4ba5-a295-5846feacc8cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of discontinued operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_ccd2b74b-891b-4b94-b471-4020e897e707_verboseLabel_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs related to current period</link:label>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_label_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</link:label>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_documentation_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:href="evh-20220630.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:to="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e2f68750-6eca-4a32-93e9-b824c1f4c053_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_f79f5285-7dea-406e-ada8-227fe6fb4008_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6ceebe44-7640-4dec-bd01-1f94003ece7d_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_76ed71fa-13ba-468a-a1f4-0aada861e8ce_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_57097506-8949-4ddb-bba4-4c539de41dd8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_6ee2961e-d0e4-40cc-b48f-e67d04b5781c_terseLabel_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of make-whole premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_label_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_documentation_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium" xlink:href="evh-20220630.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsOfMakeWholePremium" xlink:to="lab_evh_PaymentsOfMakeWholePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_a483d2cd-ac6c-4b45-8e3c-01e05379584d_terseLabel_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_label_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_documentation_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember" xlink:href="evh-20220630.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractFulfillmentCostsMember" xlink:to="lab_evh_ContractFulfillmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a5f58d8b-3d7d-475a-bfbc-266f6b2037b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation techniques and significant unobservable inputs of Level 3 fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6a84de60-8aea-4a68-b808-8c5022684698_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_cfdfd0f0-8053-4a4a-a8a4-6dd27b429603_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_09489e2b-dba0-41cc-987d-f2f8270ec199_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_340674ff-3c3a-4dfa-a122-c00f9e527ad7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_078c347b-ac8b-4ace-a947-2535f20ecf76_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_be839420-f1e6-4621-93c8-c2d01df216ed_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e6734764-2b89-4a41-8a6d-d01f7f257647_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3882f0fc-3dda-4163-88a0-661c27f36938_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3822307a-2ada-4ffe-aa73-0bc710c77182_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0ae39cd8-00fb-47ad-84d4-60033faa3181_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_207706fe-cc06-4fac-a892-01e43d87281a_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_75df0d03-8a3d-498a-ad30-4cea982adcb7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_f931e028-5343-4b4a-bb64-4bdc50691716_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6c871d7f-78a0-4cb3-8c3c-5c227deb211e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_b43d2b24-f4ca-4723-b713-9946c2f44bac_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a71e48c1-f7ba-40d0-83bf-9c707479c1bd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_b9e459ae-280d-4fa5-8356-8a2b13b3c7f5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_c21c6cb1-c1a3-487c-b897-7956a9503b70_terseLabel_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received in advance of satisfaction of performance obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_label_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_documentation_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:href="evh-20220630.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:to="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2a3cbef-21ad-4363-9467-a3dbd8ade43e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Used In Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_08ac734a-bb5b-4035-bf09-0afc38453731_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_fbd64b11-68df-469d-9d9a-d0fbc5b7e7ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_4579747e-5d01-4420-aadd-c13de217ff83_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fd81d9ba-bb13-4f3f-8f5f-5e87dcf41767_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_899b4622-c377-4580-9070-454e70ebc25b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1f5b801e-8bae-4cd8-b1e1-ceb2ecc60093_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_65b27334-08b7-47eb-a8d5-164b2bdf978e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_094f395b-fb49-4891-8232-a63684ed18b7_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_f5a68d1f-c26a-4858-83eb-ee5589b3b2a0_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brea, CA</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedPremiumsWritten_8a227800-8667-4575-a120-a6f6061a9789_terseLabel_en-US" xlink:label="lab_us-gaap_AssumedPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance premiums assumed</link:label>
    <link:label id="lab_us-gaap_AssumedPremiumsWritten_label_en-US" xlink:label="lab_us-gaap_AssumedPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Premiums Written</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsWritten" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedPremiumsWritten"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedPremiumsWritten" xlink:to="lab_us-gaap_AssumedPremiumsWritten" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_82eb6023-c672-4989-b574-296ffd0290f6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_38764bac-7e7a-41f0-9d86-2535459ef52e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7848a9af-078a-4dfd-b620-a9bb853b5bff_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ed360425-c3d8-4ce9-a58f-9eb2fe7bdac1_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_aaf63d1f-dc72-4ef9-b594-ca5545c6aeeb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets - operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_2a30d99b-c07d-4a12-bb7d-6dba291ed26a_terseLabel_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:href="evh-20220630.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:to="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_616fabc2-9185-411e-8a4c-5d163f8637a1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember" xlink:to="lab_us-gaap_LeaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_328bd78a-71ab-4234-859c-90852f893d15_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_8eb5b811-b13d-47ed-81c7-0425b9a72f4b_terseLabel_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which warrants or rights exercisable, after maturity of credit agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_label_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_documentation_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:href="evh-20220630.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:to="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c48ce934-c6f3-4bc9-93f5-af09bfb23032_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_a544bf03-8e64-48de-a6d2-2ae0ae4205a3_totalLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tangible assets acquired</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4176bbd6-ae82-4b41-ad2b-9f560bf70fd9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_9ee0b37d-2073-49e2-b023-866d6f1e4665_terseLabel_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="evh-20220630.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_750c6b44-0649-4ddf-b53a-3242e087cf9b_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_9f26178f-35b4-4cc4-838e-b8e408c430ba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6e0f3815-9503-4b29-bc33-00087ee8f8fe_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_c3e9c732-d1db-4d93-b69c-e6562fb0375a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based awards granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_c98049a2-a77e-4b27-9984-6fdbe1e660e8_terseLabel_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_label_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring [Member]</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_documentation_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember" xlink:href="evh-20220630.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProfessionalServicesRestructuringMember" xlink:to="lab_evh_ProfessionalServicesRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1b961f38-cb1e-4821-996c-295b5c08229a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e71ed8f2-afc4-450f-b48d-816aee472bcc_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ba3a0799-f0dd-4987-805c-0669dfa6c0b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_b3a060aa-456d-4716-9ad0-7a9ac6b0b64a_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_aeec672f-9b3b-4295-a91e-55f827ea54bf_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_06ac6c0d-370e-467c-a475-a8e087277c6c_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_21917fd6-ea19-4e02-ada8-44d792941bbd_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_819e0e78-dbf7-4e21-a1ba-739b97f37cce_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_2a251a6a-d710-4398-84b9-82b353556932_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_1f209531-e9e1-46e1-a5d2-9c2eb597fe9d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of liabilities measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_57d8ea66-4c24-440d-8547-deb93497e173_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_5d158e9a-8d65-459a-8f81-93dd2deddfea_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember" xlink:to="lab_us-gaap_EquityMethodInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96a405e1-238b-44b9-ad26-f922d368eeaa_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1237d719-7bc0-4fb6-b28e-96fec6585545_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_70dfc701-97ad-4ae9-935c-c9c62e9ce11a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0af02b6e-fe54-490d-a808-f86dc29364da_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from (provision for) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_151a9f59-a080-485a-87c4-0ec94c642fe3_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_fe9611a7-91c8-4e08-8273-88f98df8b281_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9fd0bb7f-2be4-4f84-872c-7e6469a6f4b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_83b73994-0156-4d69-b7b1-f4e47e8f3ef1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossAbstract_253e96fa-5e86-4afb-9ae5-88f01071b3f0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_CreditLossAbstract_label_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossAbstract" xlink:to="lab_us-gaap_CreditLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredFinancingFeesMember_06abd1b2-a1a8-4adf-abe6-67c68418657d_terseLabel_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees</link:label>
    <link:label id="lab_evh_DeferredFinancingFeesMember_label_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees [Member]</link:label>
    <link:label id="lab_evh_DeferredFinancingFeesMember_documentation_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember" xlink:href="evh-20220630.xsd#evh_DeferredFinancingFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredFinancingFeesMember" xlink:to="lab_evh_DeferredFinancingFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6406c2a2-db3c-4c0f-9c78-b9847069ec77_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d712cfaa-ca31-410f-aa8b-240cdd48918f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_be2c9fff-1115-4248-a408-a935a266c7a4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_c7580a56-ca1e-45b6-b654-3c20bd6bf2bb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_a2e5cbfa-daac-4203-b02b-960ecb78a5ce_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims expenses</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:href="evh-20220630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_e3f8a8af-0504-4337-94d9-77097840510b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2ff87493-4481-41c0-a3f5-3e420601c8dc_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93437ca3-e52c-488f-9964-6b839a912314_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9d09ac90-4803-4d3b-b810-28c0fd5c7296_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IL_3fe4a30b-686b-4395-8e6c-9c9b0cc52ef3_terseLabel_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riverside, IL</link:label>
    <link:label id="lab_stpr_IL_label_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILLINOIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IL" xlink:to="lab_stpr_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_0da8231a-26ad-4da1-b323-44acf849ce88_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, past due</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:to="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MolinaHealthcareMember_5676ee71-7f7b-4b90-a44e-a5dd0350e25f_terseLabel_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_label_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare [Member]</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_documentation_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember" xlink:href="evh-20220630.xsd#evh_MolinaHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MolinaHealthcareMember" xlink:to="lab_evh_MolinaHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_c1af9840-92cf-4210-b408-a9a97548cc90_terseLabel_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_label_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_documentation_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember" xlink:href="evh-20220630.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorCreditFacilitiesMember" xlink:to="lab_evh_SeniorCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_674a01bd-7a29-471e-a69b-3261413aa1b7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider network contracts</link:label>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_f3393ca6-2105-46e1-bb2b-b42f9cc4dd4c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BelowMarketLeasesMember_4faeed4f-811f-4913-9768-54e78861e368_terseLabel_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below market lease, net</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_label_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_documentation_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember" xlink:href="evh-20220630.xsd#evh_BelowMarketLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BelowMarketLeasesMember" xlink:to="lab_evh_BelowMarketLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d6b9a5be-ac54-4fed-b15c-6798cb8dc38d_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_5b168dbc-1f52-476b-81bf-d98a3bbcacb5_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_10128035-8937-4fe5-93b2-e63cc5c0f927_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 91,657,480 and 90,758,318 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_279911ee-b726-48fa-bedf-1e41763dafe9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, original debt, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_c04e2c6c-c629-443d-8061-7e8ce51b074b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4cfedbae-8de5-4825-b1b2-1803b52c45d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e7aff1fd-d629-4645-a212-c5ca0ef49024_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_2a573cdc-a269-4b9b-9dfb-5d5fcc72f82f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_614ac570-b91e-4405-853c-e1f59f6a61e7_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_65e91d2b-aa20-4d83-aa8f-1107a36d4953_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_394f8ebb-071c-45e9-b8a6-429e6369f7da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6443d1c3-1b5e-4cd2-a13d-85b00ddc552f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_780ab8af-bdc9-4b55-ac65-ece650722d6e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_2b60d6b7-406f-47bc-98ad-49a49df1bcba_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_2fbbcf85-a745-4f09-8f9b-9a7a00ba7e54_terseLabel_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash held in international banks (less than)</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_label_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_documentation_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage" xlink:href="evh-20220630.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashHeldInInternationalBanksPercentage" xlink:to="lab_evh_CashHeldInInternationalBanksPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_fe1c4107-4930-414f-9d7d-407d62053fe7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostDomain" xlink:to="lab_us-gaap_CapitalizedContractCostDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_5eb34008-e5fb-4824-b9d4-2b2c44093db1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_12a6466c-3cdd-4096-9e4f-0c986495114c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a511a94c-8fb3-4b9b-a728-a1a7ec6805b8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of end-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_777c6d5b-bd8c-4f74-b625-89a2e9932ce4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3a86281d-1460-4456-a128-7de61ec6b887_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (including restricted cash)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_21009343-c042-47a7-b606-0393514cbb01_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of premiums and claims assumed</link:label>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_label_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:to="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_26affa1b-5fc4-4599-94a4-52d1f35e4a0a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_13611844-b3b7-4bc8-820a-d8c0249e3eff_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative inception to date impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e5db12f9-3331-4438-be60-948282a4c9ca_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_66f8b485-1a43-4374-8e6e-01b65c992fd6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_b79d9819-47f5-4055-8dc5-f33b775ed18e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_687c4add-3691-4556-a6b5-91d2fc1cf714_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f057b38c-4e87-4b1f-b92c-5ca55a8e89d8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_09122376-5e98-4009-b4b8-a87f779f1386_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_1b2d4171-cbaa-43a2-865e-bb2e1fab04b9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_e92a9909-727f-4468-8656-4945fd7e692c_terseLabel_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities</link:label>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_label_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities [Member]</link:label>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_documentation_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember" xlink:href="evh-20220630.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_A2022CreditFacilitiesMember" xlink:to="lab_evh_A2022CreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_59169b55-eb52-469c-b567-79faf6e6bb9f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7e04c954-ca52-4ce6-acea-a1bcbd9842b4_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_731fad09-2d04-4b6c-87ad-fd8bee3dfa62_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment purchases</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f474aa9a-6aca-4ad2-adc2-a8769d7274aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_9d35b6db-4825-4d04-b9ad-16704e9b5d95_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space consolidation</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_e4f59c39-9af1-4d9f-b7d8-189a9ebda21d_terseLabel_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_label_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc. [Member]</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_documentation_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember" xlink:href="evh-20220630.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FloridaBlueMedicareIncMember" xlink:to="lab_evh_FloridaBlueMedicareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_25b7d979-7531-45c6-a708-2758a0e120d0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9ae8ae96-6315-4b74-9160-b30c1bf329a3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd0a47f2-0ca9-4c67-93fa-a41d9208659e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a985567c-27d8-4ba5-83a2-5e7a914ce9c2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_426f3543-4a02-4d46-b672-289f9fe9d02c_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0e9c6c9f-99d2-4197-9dd4-986c3217c0f0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_dbef6caf-1629-4b50-a822-64d5c0f7b31c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_52ddeb6d-6015-4d3b-9f6b-6fe1af996267_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_6a21b551-ac2e-48b9-b4e3-644f36b5555f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of liabilities at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_1a3d5bc3-0df0-4d11-8842-c87c113a2bce_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_590da74e-e08d-4d40-b5f7-661dbd0cc7f0_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7c33b064-da93-4b28-a018-c50684d8cda5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6c3b1015-5c54-4d13-a1d0-28808fac8e65_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_125272f3-f8c0-462d-96c1-4d9d03ec9b46_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_2d854caf-bcb7-448c-8228-3fc17135fcf9_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Total</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bda6ea42-4a35-4128-9b57-c4001dd39413_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_712d636c-b2da-431f-81b0-ba9e59843bb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4c3b0ce8-f034-4e0b-9b4e-5af4ee6cf52f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_21e8e823-137a-483d-bfcb-130b277ba41f_terseLabel_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Notes</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_label_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_documentation_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:href="evh-20220630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:to="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_6b1de67a-7f51-49ed-9005-5c0f0969423f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_137d8bee-e18b-431e-bd94-57b540d55eff_terseLabel_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash and cash equivalents held with FDIC participating bank</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_label_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_documentation_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage" xlink:href="evh-20220630.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFDICInsuredAmountPercentage" xlink:to="lab_evh_CashFDICInsuredAmountPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TrueHealthMember_9b6b8788-4091-4c79-b9de-45a3a4e21370_terseLabel_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:label id="lab_evh_TrueHealthMember_label_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health [Member]</link:label>
    <link:label id="lab_evh_TrueHealthMember_documentation_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember" xlink:href="evh-20220630.xsd#evh_TrueHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TrueHealthMember" xlink:to="lab_evh_TrueHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_30eb16fb-e126-4370-ab78-e9e3417dced5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_7355bf88-b37f-4bda-92e5-8feeec3e2db9_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and contract assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:to="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_8a537f79-9d88-4aed-9268-5622c1a93f1a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change during the year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_221388ce-828a-4d8b-a995-722f9fc7e098_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_2ac5e9e2-5353-4532-aad0-3e0dc82edceb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of consolidation on reserves for claims and performance-based arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_da3f7c9d-8b79-4a87-b145-46f6bab1b3a6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Termination Term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransactionCosts_8dea68c8-e550-443e-a3d5-54f201a9cb9f_negatedLabel_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_evh_TransactionCosts_label_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:label id="lab_evh_TransactionCosts_documentation_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts" xlink:href="evh-20220630.xsd#evh_TransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransactionCosts" xlink:to="lab_evh_TransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_8b54dadf-8b12-438e-bde7-ad2e904838f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of related parties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_a5f054ba-0576-48d1-b3b1-b2207cc23ee6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net assets acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_e6d29ba1-d14f-4f69-aae2-89dc1b3da492_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of non-strategic assets and divestiture of discontinued operations, net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:href="evh-20220630.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:to="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_0b395c87-8e8c-4442-a5b4-c4cdb7feb522_verboseLabel_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LSUs</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember" xlink:href="evh-20220630.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LeveragedStockUnitsLSUsMember" xlink:to="lab_evh_LeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8fed23d8-b44f-47e5-9b8c-3ee9bd238e05_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c0f42421-b82d-43ce-a507-5d73286029d3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_51f20cfe-d5ba-41ed-b4da-1e678c5dbc3e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b7760900-36ae-4389-a16e-ec049a2acd0b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_871fabd1-e20d-470a-984d-0b5373935810_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_326ebf0e-bf8b-4644-8f2c-a478307d7e57_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9a51442a-df34-4dae-8c71-0566906995c3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_166101bb-b90d-4a43-a014-394ee11bbae3_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_b0505b85-e306-47af-88f6-082e72fcb69d_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_15c9019a-ebe3-4d8b-9d1c-9a072c4cb281_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5b1bcb1d-35ea-4949-98e6-9063ce125086_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future estimated amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ae66ae98-c811-4a64-af65-f91bf52305e2_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_98d49ac0-0145-4ec5-9982-f1eb212500e4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_cf88dac5-0cf4-425a-b194-a957f67a5400_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 1,537,582 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ec35deda-5488-40af-8c8e-cd328bd5d3a8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration arrangements (up to)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CreditAgreementMember_84ce66cb-1349-4793-b434-95d580074012_terseLabel_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_evh_CreditAgreementMember_label_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_evh_CreditAgreementMember_documentation_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember" xlink:href="evh-20220630.xsd#evh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CreditAgreementMember" xlink:to="lab_evh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_055abc7d-fd35-4b9a-be8c-6d1e320a16c4_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2b63840a-e858-4f67-b741-2da55efb4b41_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2dbffe25-0010-499e-ac25-6206ce0242f1_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_efd0f553-4619-49f5-9d17-8fc4b13655d8_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_75d882e6-43b2-44aa-92af-46f46664b1ca_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_d6c2a016-fc28-4b4e-a883-b2da143900e0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_b78b5a7f-2aa6-4610-be97-23275b8fce07_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a19db5eb-d42a-4594-a987-f89043c0670a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_7f966ddf-4820-43c2-9cd7-eb81a15bc705_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f5c3db7e-6c94-4737-b20d-31c57eb92d7b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_233d2a2b-5b2e-497b-8243-169b5fcf4025_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days prior to any junior debt maturity</link:label>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_label_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</link:label>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_documentation_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:href="evh-20220630.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:to="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_63a6953c-afea-446b-b5ae-0a0b4f1cb158_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning and Other Changes</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4e4e93ef-9a10-48f5-8b4e-70e642e49865_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_edffad03-0fd8-4921-b5ee-11dea67b6d40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_3f80028c-5094-4e2e-a5a5-e3983358527f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_149f4ffb-1229-47a4-b46c-65962aea070d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a98ee59a-ce56-4696-bc70-e3517d735044_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_34be1d04-93c1-4ec9-a047-e96e6998b6f8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8a8e9cc4-2f20-4cf8-9676-e14c897340ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_4c56a645-6246-4933-bd0f-1cbcced8a2c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_bfc86fa9-0644-49e0-aebc-820a8f7300bd_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_0c1d8546-b9c1-42a2-985a-eab7c4d75023_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19af9cd0-a986-48bd-8aaa-8668610a7ee7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3a5228e4-82f6-4722-9285-6eb8cb71fc3f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_90144cdc-5fa3-44e2-bf3e-ec10e086f4bf_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c4f5406d-d771-4219-8be4-d7f2ab440bd3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2a829bf4-3d0c-4bb6-9131-95682258e0e7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_de03289c-9d0a-4276-b7a7-c2747cd46d65_terseLabel_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-neutral expected earnout consideration</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_label_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration [Member]</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_documentation_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:href="evh-20220630.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:to="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_da15b5c4-f6e2-4c4b-adbd-c50ab01cfa4a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to revenue, as a result of performance obligations satisfied</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_1599c8d9-d8e4-4e14-88e9-772669f4de09_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4c6379d1-fcfe-4b8d-aa2e-daceb478b650_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_11f513fb-9f90-47b7-a754-dbb9702dc2cc_terseLabel_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from long-term services agreement</link:label>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_label_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Services Agreement</link:label>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_documentation_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:href="evh-20220630.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:to="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BonusesAndCommissionsMember_f7b8aa5a-2727-4ce1-b56f-37bf0b72b36f_terseLabel_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses and Commissions</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_label_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_documentation_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember" xlink:href="evh-20220630.xsd#evh_BonusesAndCommissionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BonusesAndCommissionsMember" xlink:to="lab_evh_BonusesAndCommissionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c46e7caa-acd0-4652-a82e-62386f18eb79_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_72955638-7d2e-4886-95c4-393fa5041f65_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_bbe02971-dfff-4bca-9ad2-db7a2d7838c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_f5b75008-a74d-4d6f-8cd4-76b710eabc58_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units for goodwill testing</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_68416723-b907-48d9-8ea2-79fcbd93297f_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Edison, NJ</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_e542ff7a-afd0-490d-a0b6-e671a4e5158d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_729843e0-6235-49de-84d8-8839422abe73_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Gross Difference [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_6f03233c-9f6e-4d52-ba7e-0968528295da_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_55dcaa98-e3e1-40be-8e4e-0fb624c21224_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_27723c68-bcf8-406f-bb53-f1c084da5b72_negatedLabel_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on discontinued operations</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_label_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_documentation_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:href="evh-20220630.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:to="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a61b3607-63d6-43ac-bdf1-8aee168752bf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_6b23538d-bb10-427f-89dd-7e98116a56d1_terseLabel_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</link:label>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_label_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Written And Policyholder Benefits And Claims Incurred, Net</link:label>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_documentation_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Written And Policyholder Benefits And Claims Incurred, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:href="evh-20220630.xsd#evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:to="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_7d2b5f35-c26e-4a75-8d93-bc4137e494b8_terseLabel_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_label_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment [Member]</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_documentation_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember" xlink:href="evh-20220630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClinicalSolutionsSegmentMember" xlink:to="lab_evh_ClinicalSolutionsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_39f8d117-2c51-45df-91c8-daa47743bddb_terseLabel_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_label_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment [Member]</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_documentation_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember" xlink:href="evh-20220630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EvolentHealthServicesSegmentMember" xlink:to="lab_evh_EvolentHealthServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d719560e-cce6-4c65-acdc-d90d7072da4d_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of major customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2a74c358-374f-4f43-923b-8501df003ad3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_58284085-5504-4e2a-9151-433e54664d80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash flow, supplemental disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_e5027000-f8d7-463e-8824-08dbf654d768_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes and non-controlling interests</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_02d197de-061b-48ed-837f-ea301628a3c0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a6bae9fd-f427-4624-a480-9ec04f3d482b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9a5bd130-1224-44cf-9cdb-a910dea96463_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicaidCustomersMember_a9f23c5a-d607-4982-a296-f8c68db6b307_terseLabel_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_label_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers [Member]</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember" xlink:href="evh-20220630.xsd#evh_MedicaidCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicaidCustomersMember" xlink:to="lab_evh_MedicaidCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsRepaymentsForReinsurance_a5ca8580-9484-4ae5-978b-f6aee77e68a7_negatedLabel_en-US" xlink:label="lab_evh_ProceedsRepaymentsForReinsurance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance payments paid (received)</link:label>
    <link:label id="lab_evh_ProceedsRepaymentsForReinsurance_label_en-US" xlink:label="lab_evh_ProceedsRepaymentsForReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Repayments) For Reinsurance</link:label>
    <link:label id="lab_evh_ProceedsRepaymentsForReinsurance_documentation_en-US" xlink:label="lab_evh_ProceedsRepaymentsForReinsurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Repayments) For Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsRepaymentsForReinsurance" xlink:href="evh-20220630.xsd#evh_ProceedsRepaymentsForReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsRepaymentsForReinsurance" xlink:to="lab_evh_ProceedsRepaymentsForReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_9d19a9f9-c3a7-40d0-a4c6-19266f8c3311_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_093ccd85-f8a4-4c48-9d50-4778ba757ec9_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_8227edc2-1384-4be8-8be6-c811b2b05549_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2adb25a5-8d9e-4cb1-a3a7-48271ad82505_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_6f04e772-86f1-4384-8c4c-a91bdf6d0d92_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_9cbec308-9621-4095-9087-f76083ca6c9f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants agreed to be sold (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Unissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_22e0da9f-2c0f-4dc3-b855-ca7488d7e47d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d7a1b404-d5fc-4813-a96f-2d30653ef10c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_11072a99-38b1-4962-9d38-b888a26448e8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2d9e307e-d911-41fb-bc0a-e7872ed51eee_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_ca234d38-a307-4e70-899b-9460da4c771b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_80136ebc-bc0e-41e9-8e9d-bc3f47b1ef05_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_b01cda89-6cd6-490d-b803-839da593b536_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to settle outstanding warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_561b2913-2f19-4a94-b49f-979a73d0a1a9_terseLabel_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember" xlink:href="evh-20220630.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_590f76c3-c0ff-4384-9eac-57aa420da410_terseLabel_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities and sales of investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_label_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_documentation_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments" xlink:href="evh-20220630.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromMaturityOfInvestments" xlink:to="lab_evh_ProceedsFromMaturityOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f34db7f4-42ae-424c-9fe1-ac0586523fd6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8b433d68-7f99-4619-a387-cc2ca5b2a4ca_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_49083991-7e26-4db5-83fd-4897d78113a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_d396d641-1fdd-46cb-9979-36014b7ec8ef_terseLabel_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and termination benefits</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_label_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits [Member]</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_documentation_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:href="evh-20220630.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:to="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_a1ba7aee-f827-4b47-b546-16c849545540_terseLabel_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DDTL Facility</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:href="evh-20220630.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:to="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_968be743-40ce-442a-89f7-0d1b07015cb5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_326424f1-b6f2-4d75-a01e-50eff6b9e0a7_negatedTerseLabel_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</link:label>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_label_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</link:label>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_documentation_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:href="evh-20220630.xsd#evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:to="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_433600ae-f9f3-4409-b88b-3b5697837036_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b293f95a-5dd2-4545-a4b3-075ed6cd3e2a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_070de7d7-2472-4581-9f29-d91f0b483f81_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_512f5eb3-66cb-478b-bee6-c348dbf626b4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_ea36a1b4-fa3c-4649-aadc-106c92dfe497_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_5ae353fa-e697-45c7-8252-c3de0c07c03c_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_b61c06a2-18a1-4530-8b5d-9d20468b53c7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase consideration:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_fec1dfa1-43b9-4040-93d9-86195866225d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_77d74b8c-4a3c-42ff-9891-77d1216611f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_4ce78b6b-991a-4297-8eaf-2089b7ad3fb9_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ab434867-9ca1-475e-a83a-e91f0c744ccb_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9a1877b0-4fd1-479e-ad0a-fd0025e3a297_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20313ccb-db1f-4b53-b63d-c9b8c90d33d9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bb68e44f-4486-45a1-9860-bb5999e18e65_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1e8e3406-dcd8-41b6-b405-f9ed562e1255_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_616d5088-32b5-4a0e-81df-b067714862b6_verboseLabel_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platform and operations</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_label_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_documentation_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember" xlink:href="evh-20220630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PlatformsAndOperationsServicesMember" xlink:to="lab_evh_PlatformsAndOperationsServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_039f0f3e-8c4c-4457-96f4-6d7f96ebc215_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_3094f8b6-e682-40c4-bcd0-4a22683bdc13_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_59febfd2-5a96-4005-a1da-95cb672585a0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs related to prior period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_322805f6-2677-42df-b32a-0284689c8341_verboseLabel_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral for letters of credit for facility leases</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:href="evh-20220630.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:to="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_3f0ecf6c-5724-4b43-9b85-776b7e548302_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_be30db91-1a8a-4114-86d0-0b5f2873f0a1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_fb1477df-b38d-49d3-9302-f892f7a10c65_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (See Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ccbf93c0-bafd-4049-b790-0b59bfaf96af_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_1515c975-630e-4525-bfd5-6a408fa7118d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_c273c553-1a9c-4eb1-9435-b0000e696d62_verboseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_40bf12f4-9560-4f9a-aabd-b4dd874b8905_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareholderAdvisoryServices_f10e89d2-9487-4a17-8383-0d17d8577e77_negatedLabel_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategy and shareholder advisory expenses</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_label_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_documentation_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices" xlink:href="evh-20220630.xsd#evh_ShareholderAdvisoryServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareholderAdvisoryServices" xlink:to="lab_evh_ShareholderAdvisoryServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_49a2a6ce-8ce2-4838-aff3-dc86fcf813cf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_413d8ebd-3707-4237-926e-4eaf29e60515_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_39e7bca2-068f-4cdc-9c92-09212ce45013_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement, percent of cash savings paid to shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:href="evh-20220630.xsd#evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:to="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_8d2fdf2a-feaf-4d28-89c9-173bb77bd4d7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of revenue from segments to consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_60e6e73e-16aa-4150-aa00-0bec9c61ff81_verboseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding, amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_4ae95264-87dd-49d8-9688-9e06456b15c6_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Amount Required</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_a63f0c22-dc9a-43c1-aa73-bded7bb5e048_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_88eaebf2-5c8c-4c88-a9fe-a1bc01114436_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9127eeee-acb6-4b37-ad51-0bd8013d9b2a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_61952f09-1ca5-4e78-8bdb-4cbea366839f_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_f518209c-89bd-4fa9-aa10-09bcaf0729a1_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_97b6a275-b864-4de8-b926-6017fff13fc9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Class A common stock issued</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_91175507-a403-420f-a867-ecc97258deaf_terseLabel_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims-related administrative expenses</link:label>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_label_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</link:label>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_documentation_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:href="evh-20220630.xsd#evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:to="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0d3b1b2f-0a9f-4f7e-be17-0a1527d024bc_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_56609834-0d81-4df1-b410-d7c5a8b9e53f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_86a44636-547c-428e-9b79-c0146ca935a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9e6cfdf1-d161-4c28-b5bf-1a7a8620d3b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_8651f641-ded5-4074-8055-9354bb96c6d2_terseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:to="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_4ecf68c7-1407-4cc3-ac35-6475341a7e0d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_0daf3439-66e3-443b-8154-36d7a31c0ac3_negatedLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ce0b5c14-7a49-4fec-af6b-24ff6324d401_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1e263a3a-5024-4c09-98c7-34c717aeb6c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3f5a39ce-3472-4472-a9ef-fed783a28e42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1a60b3db-009e-4624-a4ab-157de8059ed7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_5f80f1df-e2a1-4abb-bc64-68ee68512a29_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_77047623-f494-4da9-832f-c28b39c1007c_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_2694eb07-7425-4ea2-a3dd-e4d9d0738c5b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6bb3f923-2a16-4fa9-84a2-8f4687b52ebc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes withheld and paid for vesting of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a0461fc4-2b8d-4ad1-ada8-4f7286018202_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_58180d0d-7c8d-4e0e-9e74-c326d90f8fa8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid costs related to current period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_40e03fef-11d1-420c-91ac-66b89bfd2562_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2626b41f-5b78-491e-aa92-5f0700e41b1b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_a63e7aaa-07e8-40da-87de-520cc405136c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b4c34149-187c-4e5c-a355-20f9e63ea311_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_454d2255-95cd-4c39-97d7-90a780d479da_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt repaid</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_c9a38f90-f260-4465-981a-b3ac838e6387_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_32995941-5000-4898-87b0-559f6b6da860_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_90c5f6a8-8623-4390-8658-3c8246864f0b_negatedLabel_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:href="evh-20220630.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:to="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_add69368-384c-4986-a9f9-d9ec84a677be_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9ecdd780-c22c-48df-9f58-3cc552a280f9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_74d94f0b-6616-466b-9001-0d7da1b043de_terseLabel_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_label_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:href="evh-20220630.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_e92ae9e2-0b28-41eb-91e8-1e87181211c9_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Adjusted EBITDA to net loss</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fcbeda19-0198-4249-b29f-6a7d2b024e7b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_192b8ec3-d8ad-4ec8-834e-15aae802d75e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_f1a1ed9d-4e21-4ce8-87a8-51efdf1e7c1f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, expected tax deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BrightHealthManagementIncMember_fb773268-8c62-46e2-8594-1066b8bbc6d4_terseLabel_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc.</link:label>
    <link:label id="lab_evh_BrightHealthManagementIncMember_label_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc [Member]</link:label>
    <link:label id="lab_evh_BrightHealthManagementIncMember_documentation_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember" xlink:href="evh-20220630.xsd#evh_BrightHealthManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BrightHealthManagementIncMember" xlink:to="lab_evh_BrightHealthManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c3acf616-1ee0-4aaf-932d-839c9970ca84_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_413b160e-2178-4d2d-af10-c50bc66cc93b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_44cf6af2-4950-4304-9021-c3cfb44a486b_terseLabel_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="evh-20220630.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_55c9242a-3143-4284-9a93-81588b27f108_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Economic interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:href="evh-20220630.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_7ec3942d-45a2-4342-ac47-0774be0a1a02_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ac61cf47-c27b-4272-b343-a8eef0779092_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0fa1c42c-1810-4889-9cef-ca924b56f0f5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5f0be075-ab3c-49af-8482-f7bfc5586b89_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2d6a95f4-d9b6-4a99-a10d-f7c7c460f067_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CenterForMedicareAndMedicaidServicesMember_2edc969d-edf5-494b-8480-f59e832ff93f_terseLabel_en-US" xlink:label="lab_evh_CenterForMedicareAndMedicaidServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Centers for Medicare and Medicaid Services</link:label>
    <link:label id="lab_evh_CenterForMedicareAndMedicaidServicesMember_label_en-US" xlink:label="lab_evh_CenterForMedicareAndMedicaidServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Center For Medicare And Medicaid Services [Member]</link:label>
    <link:label id="lab_evh_CenterForMedicareAndMedicaidServicesMember_documentation_en-US" xlink:label="lab_evh_CenterForMedicareAndMedicaidServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Center For Medicare And Medicaid Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CenterForMedicareAndMedicaidServicesMember" xlink:href="evh-20220630.xsd#evh_CenterForMedicareAndMedicaidServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CenterForMedicareAndMedicaidServicesMember" xlink:to="lab_evh_CenterForMedicareAndMedicaidServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e3d65229-fc80-496a-a26f-e476b87673be_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion amount (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_db6f3aaf-757f-4656-9822-ea0b69caff9c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_a9a9b955-ad57-4edb-bec7-90eee598a70f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_aac51c03-d1c5-4c40-a5d4-574b78224d29_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_fdc5d65c-9871-4ad7-9fdb-3f9e5f5e5c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_430a130e-5b6a-4851-bc9a-74fb5bfd90bf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_8084cd3b-4300-4254-98cd-7cc6fa3cc2bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2b117dd6-17a1-49da-b182-26e10566abcd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_2e6c3b99-148a-4832-860c-64b6a3682afb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_3fd022c6-6b92-4357-bcaf-d835b60709d0_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BasicAndDilutedEarningsPerShareAbstract_bb1c21e8-14de-4dda-8cea-0acaf571f759_verboseLabel_en-US" xlink:label="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share, Basic and diluted</link:label>
    <link:label id="lab_evh_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_evh_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:href="evh-20220630.xsd#evh_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_b01f672b-2f69-4bd4-aa47-b6277a9f81f1_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_df2d82c3-a93f-4a34-b3c7-72cb4dfed988_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_9fc1d1c3-c7db-4dd3-9bc7-a5e9c06ed222_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_a79ac58f-7b3b-49ba-951a-3a98c070839b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term receivables</link:label>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_c0ad8c73-9471-49f5-9021-591efd331c75_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software additions</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_43bd94f4-c5bb-4d16-8709-faba323f9e6c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_60d448cf-0547-4c61-b0ed-e5bb1e65bde1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5b228201-7002-4a03-b47c-f52042ca41c9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3decbc0d-de26-4cfb-b65c-28a20621bced_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_f408837f-c5b8-4a83-91ed-fad10a6d4796_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6a70f746-1255-43a7-a9a7-63abb2e54300_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_943f1fb0-8089-414c-804e-afb9d0f31554_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_3630a88f-08fe-4f9c-8389-be0aa27c8ca0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4384d9b2-68c6-4a71-b86d-d6c4c8f016b7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of primary office leases and maturity of lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_7d0c58e9-c4d3-445c-a66f-d4596d5dd77d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1fe70890-5a22-443b-ac02-4844e749900b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_977606a7-8882-4e6d-8dd5-67fef1c8e5de_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized as software development costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_305d2420-2de6-4007-91c8-e597c72f9f72_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_aa18c0db-2184-45c8-a7a8-06cb750e2454_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b5067ccf-f3ff-4a64-ae8b-8eb038a01006_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_39e12aea-d41c-4565-a6f7-866760f1bcf6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_eba1b448-a175-4eb1-973a-f0db2b626ab8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_aa5514ea-71e0-4fd8-85e9-3a67e6e7bfb0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_VA_f5f0e8f9-f1b8-481e-871f-c6f2d06d243f_terseLabel_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arlington, VA</link:label>
    <link:label id="lab_stpr_VA_label_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_VA" xlink:to="lab_stpr_VA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f5ef67e5-0355-4a27-aaed-8e4b5caf12b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_f54fc597-4184-46ff-ac8d-e7560cb8cf77_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_e88980de-5c02-4629-8245-eb9b5821269b_negatedTerseLabel_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets disposed of (obtained in) exchange for operating lease liabilities</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_label_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_documentation_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:href="evh-20220630.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:to="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_44b5852e-65e7-4f08-ba0f-d745d77cf3b4_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ServicesAgreementsMember_de6ee77f-c05d-41c6-8f83-cc97c7d99091_terseLabel_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_label_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_documentation_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember" xlink:href="evh-20220630.xsd#evh_ServicesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ServicesAgreementsMember" xlink:to="lab_evh_ServicesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_8aaa7422-b513-40ae-b3b2-d9b1afd08a6a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAxis" xlink:to="lab_us-gaap_CapitalizedContractCostAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_26e3703e-5e90-4391-aa11-a9b3dea19c11_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_5dacecb2-6a46-4d72-86a2-6e6d5500c2eb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_d244e95d-051f-41d2-baae-bfed139efbb0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d535f3e9-47a0-4ed7-a6cc-280b7b6dbe81_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_7ff3b10f-308f-4c3a-8885-942b526862a2_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims assumed</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_80b9e501-8b6b-4a69-909c-61b10fa0b1a4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostTable" xlink:to="lab_us-gaap_CapitalizedContractCostTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_b1bd6e25-c5c5-412b-a744-00ddeb020db0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_cdb4cb3c-c8f2-48a4-a7e5-663103a7167e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d7dc18ec-3e26-4a72-a94a-0f39bb3d004e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_3d9981e3-f873-475d-883b-8ed5f56c6dc8_terseLabel_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_label_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_documentation_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:href="evh-20220630.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:to="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0ba70862-094c-4b4f-85b7-34a5166a0d9c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3360960f-a27a-42c8-b378-dc254283382c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_8a700667-f5c8-440a-a92a-3c5d583e90f9_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims processing services</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:href="evh-20220630.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:to="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_8f27bff4-35ab-4a40-932c-fb70a8632faf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs associated with the Repositioning Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e936c131-3022-405c-a3bd-23e78d16c128_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumption or Input Ranges</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_b15ca3bb-7fd7-4812-8263-602b1d04132b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period (years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9569f81c-6cc0-47b1-a21b-4d273b453c9d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2a0865e9-a1b2-4353-adbf-f68507a7b5ea_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_1fdf01c3-597b-4762-abb8-c60873d65382_terseLabel_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health and Hospitals System</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_label_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_documentation_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:href="evh-20220630.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:to="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_8d960ad3-7d44-43e9-8f1d-6bdf1ad3512c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ecc7dab1-abeb-47c5-a55d-747cad04d628_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_3cf9d383-0862-40fc-8008-ce231f3193cf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9395695-6bd4-484f-b4b6-87b02ce8e388_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df137afa-0285-45c6-a146-3f69d121bc97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_0bbf780e-6c42-4155-aa5c-0fedc523186e_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_0ccbb2ce-266b-44f2-a3c2-0cbdb157f900_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_cdfcb654-77a6-4b76-a696-a69654094554_periodStartLabel_en-US" xlink:label="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_cb9ff5e3-3e1b-48d2-aae7-b75ca30de259_periodEndLabel_en-US" xlink:label="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable (receivable) for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</link:label>
    <link:label id="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability for Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_5def819b-e2c2-4e28-8f08-9f9531fdc37c_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7b8b4f2c-099a-415f-8e8c-150ff31ecc2b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d612d327-2158-4992-b629-69c4948ea7c3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_a8c9a66c-cd9f-4f89-a247-3875594f4d7f_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal expenses</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e8d7cc68-a622-460f-90eb-e2a5677e2baf_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ad8bf299-a3f6-493d-8085-3beda4b8d820_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_92bb6cdf-41b0-4478-a547-2b12a08864b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_2236e528-0454-42e3-9424-93a906a91262_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d02f781-31e2-46c1-88d1-8829518b8dd4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Used In Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_421825b3-c1f4-4e2c-8153-ed6d6097981f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems" xlink:to="lab_us-gaap_CapitalizedContractCostLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_b9369b69-1429-4ee0-bc10-83b0f64d5217_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in working capital balances related to claims processing on behalf of partners</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:href="evh-20220630.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:to="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39cb7a0e-b76f-47ce-a87c-8c5cf9cdda46_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Non-cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9d7525ba-c06d-4355-92f5-36fc6a13f76b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember_ca96c156-c5a3-48eb-8a30-730beaf2ab8c_terseLabel_en-US" xlink:label="lab_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Cross and Blue Shield of North Carolina</link:label>
    <link:label id="lab_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember_label_en-US" xlink:label="lab_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Cross And Blue Shield Of North Carolina [Member]</link:label>
    <link:label id="lab_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember_documentation_en-US" xlink:label="lab_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Cross And Blue Shield Of North Carolina</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember" xlink:href="evh-20220630.xsd#evh_BlueCrossAndBlueShieldOfNorthCarolinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember" xlink:to="lab_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_e14be6e4-cf25-4795-bd37-6c3aae12b1d7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_d6e71dc6-8560-42a0-b439-da978cf0c9c9_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of senior debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_066c6121-61e6-45cf-9b8d-3d00d7115a6a_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 60 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember" xlink:href="evh-20220630.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan60DaysMember" xlink:to="lab_evh_FInancialAssetLessThan60DaysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2171aed9-6147-4f53-8edb-c0af5c23edc3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_ddfb14c6-23dd-464a-9ec1-0b4ee15c83eb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Equity Method Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_abcabc49-c8c7-4477-a8a8-325c0240ef42_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_7fb41d54-f158-40f5-bc30-928816d2933a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_0e17afa8-20ed-473b-9207-4ea704bef911_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_731e3200-306f-42d5-928f-35dc74e0cfd3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term receivables</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_2c5cbbb8-4c72-466a-a2b2-a3b4298382f7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9a05e2ef-c79a-44ce-8eca-527c93e746a8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_673233c8-6348-4e54-bf31-15728bbcaf60_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of offset, percentage of accounts receivable netted against claims payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:href="evh-20220630.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1f00d50a-9c3a-45d4-86c5-d6b6916b07c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_4f9e04f1-413b-454d-92ee-832d60cafb71_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_2f634522-8b00-478a-9af7-c97258e589c7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_392cd269-316b-4aec-9c1d-ea9e663b21a8_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_eb480ed4-4c35-4c5f-8de1-7af16f11a291_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of offset, percentage of accounts receivable, net eligible for net basis settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:href="evh-20220630.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_d75857a6-6252-48d9-b004-e4398f38fd54_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>evh-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a212dad2-7296-44b7-8af9-e12f408b43ae,g:23ff20ea-0869-45df-9d88-aeb2d6e74df5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPage" xlink:type="simple" xlink:href="evh-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_434777ab-1431-4987-8083-dc5177225962" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_DocumentType_434777ab-1431-4987-8083-dc5177225962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_f62ec989-9399-4689-99e3-a55517ec7913" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_DocumentQuarterlyReport_f62ec989-9399-4689-99e3-a55517ec7913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_04e8247f-bdea-4669-a5d9-2992b9f65317" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_DocumentPeriodEndDate_04e8247f-bdea-4669-a5d9-2992b9f65317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_177f5c01-6e50-4f0b-9e22-16c520ecf135" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_DocumentTransitionReport_177f5c01-6e50-4f0b-9e22-16c520ecf135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9b2cce49-c203-4156-9617-161550b16f68" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityFileNumber_9b2cce49-c203-4156-9617-161550b16f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c8613f9c-e518-4b21-97d0-ec0c87ee8e54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityRegistrantName_c8613f9c-e518-4b21-97d0-ec0c87ee8e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c2d52c61-6c8f-4760-8555-074b3426aa08" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c2d52c61-6c8f-4760-8555-074b3426aa08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d354f7c6-411b-42f7-8232-9712b1cdb29c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityTaxIdentificationNumber_d354f7c6-411b-42f7-8232-9712b1cdb29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_48247aa3-a46a-420c-8166-db201caa87c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityAddressAddressLine1_48247aa3-a46a-420c-8166-db201caa87c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_4345be32-8cae-4b0c-8d16-b1673aef4a9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityAddressAddressLine2_4345be32-8cae-4b0c-8d16-b1673aef4a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3f79da08-1461-4d66-a6a5-5a93550f1604" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityAddressCityOrTown_3f79da08-1461-4d66-a6a5-5a93550f1604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_67f3e5f9-dc52-4642-bc87-8b96cc5132c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityAddressStateOrProvince_67f3e5f9-dc52-4642-bc87-8b96cc5132c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a3503012-e221-410c-aeda-3019ef510df0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityAddressPostalZipCode_a3503012-e221-410c-aeda-3019ef510df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2c5d83c7-fe49-4aba-a48d-caafd04a8ca9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_CityAreaCode_2c5d83c7-fe49-4aba-a48d-caafd04a8ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_79ef1055-7580-4019-8298-4de724a110f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_LocalPhoneNumber_79ef1055-7580-4019-8298-4de724a110f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1a5a6cae-e118-4b14-a6f0-407ed128916d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_Security12bTitle_1a5a6cae-e118-4b14-a6f0-407ed128916d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9b1882ad-18b7-4af6-b6ce-67a0e395c8a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_TradingSymbol_9b1882ad-18b7-4af6-b6ce-67a0e395c8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_13ae1d62-ac5a-4c07-bdb7-0526b9f71179" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_SecurityExchangeName_13ae1d62-ac5a-4c07-bdb7-0526b9f71179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0f57f2eb-e800-4c5c-b518-e6a54f58d32a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityCurrentReportingStatus_0f57f2eb-e800-4c5c-b518-e6a54f58d32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0d90260c-1346-4288-9c37-f43ec6daac74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityInteractiveDataCurrent_0d90260c-1346-4288-9c37-f43ec6daac74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f7ae1ba5-ebd9-4c93-bf32-4eae2313fd1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityFilerCategory_f7ae1ba5-ebd9-4c93-bf32-4eae2313fd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_0c966002-c6ad-4d11-a0ec-7de7a93f23a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntitySmallBusiness_0c966002-c6ad-4d11-a0ec-7de7a93f23a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e5730755-124d-4047-810e-c40e45bf76eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityEmergingGrowthCompany_e5730755-124d-4047-810e-c40e45bf76eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bd7c4ff8-3144-4f09-a7ec-c3b655f5dba4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityShellCompany_bd7c4ff8-3144-4f09-a7ec-c3b655f5dba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_03a9b0be-d34b-4d98-9354-0134da73a855" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_03a9b0be-d34b-4d98-9354-0134da73a855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e8fd7c5c-77ba-4843-8c4b-ac9ec0ebba6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_EntityCentralIndexKey_e8fd7c5c-77ba-4843-8c4b-ac9ec0ebba6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f45e0e26-1eab-4353-8085-2b8716fe221f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_AmendmentFlag_f45e0e26-1eab-4353-8085-2b8716fe221f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_eb246aa5-7ba9-4d0b-a27e-41ddc40150eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_DocumentFiscalYearFocus_eb246aa5-7ba9-4d0b-a27e-41ddc40150eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ef06d7a1-4f92-4013-ad6f-c7d15fdbd3de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ef06d7a1-4f92-4013-ad6f-c7d15fdbd3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7dd3a0df-bc33-4d58-9f77-8cf4e9c73cd0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3f289eb2-3e32-400f-b3e4-43634930168a" xlink:to="loc_dei_CurrentFiscalYearEndDate_7dd3a0df-bc33-4d58-9f77-8cf4e9c73cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_90db462d-0564-4f20-8cd7-fc9dc1122418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_90db462d-0564-4f20-8cd7-fc9dc1122418" xlink:to="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5a6febee-0c0c-4e3c-8bf6-74ec6b3a4725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5a6febee-0c0c-4e3c-8bf6-74ec6b3a4725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fc7bdf1-4d43-4ee4-a1cb-19b458df5e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5a6febee-0c0c-4e3c-8bf6-74ec6b3a4725" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fc7bdf1-4d43-4ee4-a1cb-19b458df5e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_7689078d-def9-4cdc-9f83-0a8aed2cc00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5a6febee-0c0c-4e3c-8bf6-74ec6b3a4725" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_7689078d-def9-4cdc-9f83-0a8aed2cc00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2450bfc6-5e22-42ba-a5eb-08898873fb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5a6febee-0c0c-4e3c-8bf6-74ec6b3a4725" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2450bfc6-5e22-42ba-a5eb-08898873fb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c54c3b93-5910-468a-87cf-87d20c5f9a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5a6febee-0c0c-4e3c-8bf6-74ec6b3a4725" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c54c3b93-5910-468a-87cf-87d20c5f9a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2a43f1ce-e73c-4f5b-a8e7-4fb888d473d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5a6febee-0c0c-4e3c-8bf6-74ec6b3a4725" xlink:to="loc_us-gaap_AssetsCurrent_2a43f1ce-e73c-4f5b-a8e7-4fb888d473d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_411e4e21-81cd-4c88-a05f-98d26939249b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_411e4e21-81cd-4c88-a05f-98d26939249b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0bab2044-862a-4bce-8fc7-b937a54bb7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0bab2044-862a-4bce-8fc7-b937a54bb7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_46e89917-087f-4186-a5b0-676535202734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_46e89917-087f-4186-a5b0-676535202734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d9516f98-c5a1-4425-b9bd-efa99a7e5ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d9516f98-c5a1-4425-b9bd-efa99a7e5ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_d91a2f4a-447d-4fa0-a7ac-352b54ba3d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_d91a2f4a-447d-4fa0-a7ac-352b54ba3d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_16426e38-3a71-48e6-aaae-48c9ff21e421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_16426e38-3a71-48e6-aaae-48c9ff21e421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b6e95617-330a-4400-b97f-e2850b2f39b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b6e95617-330a-4400-b97f-e2850b2f39b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_51884c26-9928-4772-afb3-df7a36657eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:to="loc_us-gaap_Goodwill_51884c26-9928-4772-afb3-df7a36657eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c2bc7e4b-ae02-4ae9-9292-9c7d63799e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af9606be-3929-452a-be66-a71a00b7272b" xlink:to="loc_us-gaap_Assets_c2bc7e4b-ae02-4ae9-9292-9c7d63799e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ac951d75-8e86-48a4-83f3-0cac7af0873f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_90db462d-0564-4f20-8cd7-fc9dc1122418" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ac951d75-8e86-48a4-83f3-0cac7af0873f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_6d5bf84b-953a-4c82-96c8-d901f90021da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ac951d75-8e86-48a4-83f3-0cac7af0873f" xlink:to="loc_us-gaap_LiabilitiesAbstract_6d5bf84b-953a-4c82-96c8-d901f90021da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a5426b67-97ab-424b-b593-78034a37b7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_6d5bf84b-953a-4c82-96c8-d901f90021da" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a5426b67-97ab-424b-b593-78034a37b7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a7fed0b-26f4-4a4a-b04c-8ae22e51b5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5426b67-97ab-424b-b593-78034a37b7be" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a7fed0b-26f4-4a4a-b04c-8ae22e51b5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7d086e70-c896-40be-8d10-b1bed096ce3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5426b67-97ab-424b-b593-78034a37b7be" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7d086e70-c896-40be-8d10-b1bed096ce3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ea95d78a-3313-4fdc-b049-fae4725ca57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5426b67-97ab-424b-b593-78034a37b7be" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ea95d78a-3313-4fdc-b049-fae4725ca57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bdb2d6b5-cf53-4767-ac6e-064ca253d770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5426b67-97ab-424b-b593-78034a37b7be" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bdb2d6b5-cf53-4767-ac6e-064ca253d770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4e8579bc-981d-455c-9379-891480d536d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5426b67-97ab-424b-b593-78034a37b7be" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4e8579bc-981d-455c-9379-891480d536d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_2180896c-0be7-4e9c-a8cf-023a5089f588" xlink:href="evh-20220630.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5426b67-97ab-424b-b593-78034a37b7be" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_2180896c-0be7-4e9c-a8cf-023a5089f588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8519946a-1cbc-41bd-850d-625bbf99822a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5426b67-97ab-424b-b593-78034a37b7be" xlink:to="loc_us-gaap_LiabilitiesCurrent_8519946a-1cbc-41bd-850d-625bbf99822a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_bc7f9620-aa9c-470b-ab12-3ae27c7ac353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_6d5bf84b-953a-4c82-96c8-d901f90021da" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_bc7f9620-aa9c-470b-ab12-3ae27c7ac353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b82d6720-0d1d-42f3-ab2e-8a25b24db41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_6d5bf84b-953a-4c82-96c8-d901f90021da" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b82d6720-0d1d-42f3-ab2e-8a25b24db41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f6c0afb2-4984-4ce7-a7eb-0c8497789677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_6d5bf84b-953a-4c82-96c8-d901f90021da" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f6c0afb2-4984-4ce7-a7eb-0c8497789677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9a22bec6-4c2d-4b59-82c7-77fe230103da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_6d5bf84b-953a-4c82-96c8-d901f90021da" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9a22bec6-4c2d-4b59-82c7-77fe230103da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3dde46e4-4b26-44a8-903e-f96d646f8b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_6d5bf84b-953a-4c82-96c8-d901f90021da" xlink:to="loc_us-gaap_Liabilities_3dde46e4-4b26-44a8-903e-f96d646f8b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_09c02358-eeda-4086-b62a-ae12dc3c0c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ac951d75-8e86-48a4-83f3-0cac7af0873f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_09c02358-eeda-4086-b62a-ae12dc3c0c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e959b6bd-7f6e-4e81-8d49-d9c402dbab5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ac951d75-8e86-48a4-83f3-0cac7af0873f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e959b6bd-7f6e-4e81-8d49-d9c402dbab5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_996d5f9a-9692-4e38-b2b5-c055bae98149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e959b6bd-7f6e-4e81-8d49-d9c402dbab5c" xlink:to="loc_us-gaap_CommonStockValue_996d5f9a-9692-4e38-b2b5-c055bae98149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_89fdad1a-f0c6-462c-8773-036d28d66a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e959b6bd-7f6e-4e81-8d49-d9c402dbab5c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_89fdad1a-f0c6-462c-8773-036d28d66a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ff3fda91-58ce-4f13-8302-5193fad0abe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e959b6bd-7f6e-4e81-8d49-d9c402dbab5c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ff3fda91-58ce-4f13-8302-5193fad0abe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_af177b0f-f9b1-467c-8f80-778322df03dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e959b6bd-7f6e-4e81-8d49-d9c402dbab5c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_af177b0f-f9b1-467c-8f80-778322df03dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_5d92e313-4761-4c83-9ee2-09bdcdbd2eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e959b6bd-7f6e-4e81-8d49-d9c402dbab5c" xlink:to="loc_us-gaap_TreasuryStockValue_5d92e313-4761-4c83-9ee2-09bdcdbd2eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cdd45c12-9e0f-4376-a2e8-319099da13ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e959b6bd-7f6e-4e81-8d49-d9c402dbab5c" xlink:to="loc_us-gaap_StockholdersEquity_cdd45c12-9e0f-4376-a2e8-319099da13ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_92af64a2-5836-4c0b-a566-0f121f91cc16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ac951d75-8e86-48a4-83f3-0cac7af0873f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_92af64a2-5836-4c0b-a566-0f121f91cc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="evh-20220630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e10c2691-348a-4c76-8f8c-c0c7144573d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9bb246d3-6227-4359-ab95-f09ee0c02676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e10c2691-348a-4c76-8f8c-c0c7144573d9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9bb246d3-6227-4359-ab95-f09ee0c02676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c8b7490b-8687-41c4-90f4-4614b9859ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e10c2691-348a-4c76-8f8c-c0c7144573d9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c8b7490b-8687-41c4-90f4-4614b9859ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3c2f6391-ca9b-4677-aba3-d85e8859f42a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e10c2691-348a-4c76-8f8c-c0c7144573d9" xlink:to="loc_us-gaap_CommonStockSharesIssued_3c2f6391-ca9b-4677-aba3-d85e8859f42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_d1cc427f-a1d1-4ade-883d-18d8752235bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e10c2691-348a-4c76-8f8c-c0c7144573d9" xlink:to="loc_us-gaap_TreasuryStockShares_d1cc427f-a1d1-4ade-883d-18d8752235bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6e34379f-8baa-4bdb-b99a-ba3dff8b78d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6e34379f-8baa-4bdb-b99a-ba3dff8b78d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_570c7219-cb97-4007-bc42-43448ee8889f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_570c7219-cb97-4007-bc42-43448ee8889f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_72843bd2-1b77-4e78-b51a-2d91e6996612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_570c7219-cb97-4007-bc42-43448ee8889f" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_72843bd2-1b77-4e78-b51a-2d91e6996612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0904cebc-7cf9-4890-ad1f-6c750ef59f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_570c7219-cb97-4007-bc42-43448ee8889f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0904cebc-7cf9-4890-ad1f-6c750ef59f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9988651e-d2e0-4cf5-8dc0-fffc2af935c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_570c7219-cb97-4007-bc42-43448ee8889f" xlink:to="loc_us-gaap_DepreciationAndAmortization_9988651e-d2e0-4cf5-8dc0-fffc2af935c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e3485427-1582-46f9-ba57-d9d38678b1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_570c7219-cb97-4007-bc42-43448ee8889f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e3485427-1582-46f9-ba57-d9d38678b1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e59cc919-4f83-4d9e-aeb0-91c2266c7e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_570c7219-cb97-4007-bc42-43448ee8889f" xlink:to="loc_us-gaap_CostsAndExpenses_e59cc919-4f83-4d9e-aeb0-91c2266c7e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f9ddb552-0870-453c-90d7-d8459a98e27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_OperatingIncomeLoss_f9ddb552-0870-453c-90d7-d8459a98e27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c4e8a981-4949-4d66-8a9e-fc1a91673af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c4e8a981-4949-4d66-8a9e-fc1a91673af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_541b43d2-179d-41e0-b062-05f5e3b02152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_InterestExpense_541b43d2-179d-41e0-b062-05f5e3b02152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2ac5d61e-669d-41d5-9453-31023a9a4b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2ac5d61e-669d-41d5-9453-31023a9a4b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_16c8ff37-bce6-46e0-88b7-1469124fcbdd" xlink:href="evh-20220630.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_evh_GainOnTransferOfMembership_16c8ff37-bce6-46e0-88b7-1469124fcbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e39dbd52-7e09-43c5-b628-9c46f2a5a731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e39dbd52-7e09-43c5-b628-9c46f2a5a731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1395edfb-d29b-4f83-a93a-0fe31d94cfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1395edfb-d29b-4f83-a93a-0fe31d94cfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_655a9ff8-377c-4a2c-ba79-a400ed451b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_655a9ff8-377c-4a2c-ba79-a400ed451b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b5218f78-67cf-4dcd-b280-ac3c7cde49ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b5218f78-67cf-4dcd-b280-ac3c7cde49ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_755ac7e2-ea2f-4a91-a244-ee762d06f486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_755ac7e2-ea2f-4a91-a244-ee762d06f486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8b564693-139c-4a77-8234-5fd9ddc3f395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8b564693-139c-4a77-8234-5fd9ddc3f395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3e0464ed-66dc-4876-b9ee-2cbfe19c3be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3e0464ed-66dc-4876-b9ee-2cbfe19c3be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_bf1ee035-41ee-4a04-9861-edcbeac6d06b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_bf1ee035-41ee-4a04-9861-edcbeac6d06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_49f452b3-d82f-4c04-9c82-95b4242e45e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_EarningsPerShareAbstract_49f452b3-d82f-4c04-9c82-95b4242e45e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_305891c4-4892-4c67-8994-d2ed19d9d2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_49f452b3-d82f-4c04-9c82-95b4242e45e4" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_305891c4-4892-4c67-8994-d2ed19d9d2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9365d66c-d56b-4848-822f-d25ad6cadb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_305891c4-4892-4c67-8994-d2ed19d9d2f6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9365d66c-d56b-4848-822f-d25ad6cadb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f231b161-ccb8-4200-9058-bef408014af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_305891c4-4892-4c67-8994-d2ed19d9d2f6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f231b161-ccb8-4200-9058-bef408014af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f4d572ab-fc92-4d7d-a050-19ec7aa25eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_305891c4-4892-4c67-8994-d2ed19d9d2f6" xlink:to="loc_us-gaap_EarningsPerShareBasic_f4d572ab-fc92-4d7d-a050-19ec7aa25eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_d75c9393-75b7-4ce0-9207-30949c14912b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_49f452b3-d82f-4c04-9c82-95b4242e45e4" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_d75c9393-75b7-4ce0-9207-30949c14912b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3d5fe65e-03ba-44d7-906d-41aafaa27001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d75c9393-75b7-4ce0-9207-30949c14912b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3d5fe65e-03ba-44d7-906d-41aafaa27001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_94c9704b-3d40-4b4f-bc24-1d47f81eb0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d75c9393-75b7-4ce0-9207-30949c14912b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_94c9704b-3d40-4b4f-bc24-1d47f81eb0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_87828233-222d-4f5a-bb24-3227973cf3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d75c9393-75b7-4ce0-9207-30949c14912b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_87828233-222d-4f5a-bb24-3227973cf3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_d2d30353-3ae0-49b3-96f6-99a866855f69" xlink:href="evh-20220630.xsd#evh_WeightedAverageCommonSharesOutstandingAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_d2d30353-3ae0-49b3-96f6-99a866855f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_395169ef-b77d-4bce-92ec-f3ca746eb697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_d2d30353-3ae0-49b3-96f6-99a866855f69" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_395169ef-b77d-4bce-92ec-f3ca746eb697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_04e3d87a-3cf8-456e-9f66-9c0a67c944a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_d2d30353-3ae0-49b3-96f6-99a866855f69" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_04e3d87a-3cf8-456e-9f66-9c0a67c944a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_015e6c16-e26c-47a8-a2a9-bc4ac1fcbecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f140b480-27c9-4456-8905-fe45c03faaf4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_015e6c16-e26c-47a8-a2a9-bc4ac1fcbecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d21b6e77-9feb-4dce-aa5f-7907799fb2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_015e6c16-e26c-47a8-a2a9-bc4ac1fcbecf" xlink:to="loc_us-gaap_NetIncomeLoss_d21b6e77-9feb-4dce-aa5f-7907799fb2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2047dcbe-674d-4a09-b749-c7357e3bc030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_015e6c16-e26c-47a8-a2a9-bc4ac1fcbecf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2047dcbe-674d-4a09-b749-c7357e3bc030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9a233831-23a0-4734-bae0-b9bdeacc6691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2047dcbe-674d-4a09-b749-c7357e3bc030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9a233831-23a0-4734-bae0-b9bdeacc6691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_193adc38-9ea0-4239-b881-bf3c7c3d8dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_015e6c16-e26c-47a8-a2a9-bc4ac1fcbecf" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_193adc38-9ea0-4239-b881-bf3c7c3d8dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="evh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_db63361f-0ea3-4784-b75c-e0d4a3677b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_ecdb1909-0437-45c6-9453-0b9f5a4bed0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db63361f-0ea3-4784-b75c-e0d4a3677b3c" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_ecdb1909-0437-45c6-9453-0b9f5a4bed0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7fdebcef-0630-4424-aeca-1aeaa10f36eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c545f0bc-7b5b-472f-8f2d-241c32e9ed49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7fdebcef-0630-4424-aeca-1aeaa10f36eb" xlink:to="loc_us-gaap_StatementTable_c545f0bc-7b5b-472f-8f2d-241c32e9ed49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bbe76c47-dd09-4b5a-ae72-dc730077a434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c545f0bc-7b5b-472f-8f2d-241c32e9ed49" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bbe76c47-dd09-4b5a-ae72-dc730077a434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbe76c47-dd09-4b5a-ae72-dc730077a434" xlink:to="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c91d17d3-4715-4f42-8969-b51f7dabcf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:to="loc_us-gaap_CommonStockMember_c91d17d3-4715-4f42-8969-b51f7dabcf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2e3ea172-c0d2-4f14-8426-2faf217c407b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2e3ea172-c0d2-4f14-8426-2faf217c407b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_798ad5b5-dcf5-45fe-bc16-f79549b362fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_798ad5b5-dcf5-45fe-bc16-f79549b362fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bfa9f259-f6c4-4980-87a5-61a2d99e7d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:to="loc_us-gaap_RetainedEarningsMember_bfa9f259-f6c4-4980-87a5-61a2d99e7d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_53020125-941c-47c3-8909-b4d2ca4f77a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f5745dc-29da-40ac-a396-9825caa823f5" xlink:to="loc_us-gaap_TreasuryStockMember_53020125-941c-47c3-8909-b4d2ca4f77a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b76b490e-8511-4449-9d1e-33573ca5c34a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c545f0bc-7b5b-472f-8f2d-241c32e9ed49" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b76b490e-8511-4449-9d1e-33573ca5c34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27bf4173-9745-44d3-a9c9-380932aa6d85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b76b490e-8511-4449-9d1e-33573ca5c34a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27bf4173-9745-44d3-a9c9-380932aa6d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_51892b85-c386-49e0-aa1b-77d8ed524bbd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_27bf4173-9745-44d3-a9c9-380932aa6d85" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_51892b85-c386-49e0-aa1b-77d8ed524bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_25735e0b-144f-4387-8b68-5588962de5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c545f0bc-7b5b-472f-8f2d-241c32e9ed49" xlink:to="loc_us-gaap_StatementLineItems_25735e0b-144f-4387-8b68-5588962de5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_25735e0b-144f-4387-8b68-5588962de5e3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_be696e11-68fa-4f06-8320-6636917426c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_SharesIssued_be696e11-68fa-4f06-8320-6636917426c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_816b7918-fd9b-4526-a025-fda3ea13f884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockholdersEquity_816b7918-fd9b-4526-a025-fda3ea13f884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_52ff467b-4dbf-4f72-80e7-8bc78952d94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_52ff467b-4dbf-4f72-80e7-8bc78952d94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_983c9d1d-2e72-4d7a-8d4c-70709a40da23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_983c9d1d-2e72-4d7a-8d4c-70709a40da23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1ee6bd2e-2c5e-4d99-b05d-50fdf52abb48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1ee6bd2e-2c5e-4d99-b05d-50fdf52abb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_222fe194-90cc-4cac-a269-9851bba86011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_222fe194-90cc-4cac-a269-9851bba86011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_8a1fbe63-4ef0-4341-837b-b4a291e8ed3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_8a1fbe63-4ef0-4341-837b-b4a291e8ed3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a19cff7a-19d3-46cb-b380-5dae8226ef3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a19cff7a-19d3-46cb-b380-5dae8226ef3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_da19976d-3750-4ca5-9ed0-d00ba33fe726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_da19976d-3750-4ca5-9ed0-d00ba33fe726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_607f1672-aa87-4d16-8b21-adf05058edfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_607f1672-aa87-4d16-8b21-adf05058edfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_31281467-d970-443e-b4a7-9524b2293e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_NetIncomeLoss_31281467-d970-443e-b4a7-9524b2293e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_b3eeec3b-47cf-4da9-a096-3b7ee447a77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_SharesIssued_b3eeec3b-47cf-4da9-a096-3b7ee447a77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_23f35a92-d333-4ae4-87ad-ad16f6de62ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1f389c9e-89e3-4335-ba43-4c8499d4079b" xlink:to="loc_us-gaap_StockholdersEquity_23f35a92-d333-4ae4-87ad-ad16f6de62ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_68924e67-295a-4c97-84a6-3dceb2101151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_25735e0b-144f-4387-8b68-5588962de5e3" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_68924e67-295a-4c97-84a6-3dceb2101151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8a4c04c0-5c83-4c8d-aad4-77a17bb6460c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_03cc5186-bd94-421d-8eda-0ce7d985bcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a4c04c0-5c83-4c8d-aad4-77a17bb6460c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_03cc5186-bd94-421d-8eda-0ce7d985bcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_95797cac-e612-4894-9f7a-6fa75d55549d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_03cc5186-bd94-421d-8eda-0ce7d985bcc0" xlink:to="loc_us-gaap_NetIncomeLoss_95797cac-e612-4894-9f7a-6fa75d55549d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_03cc5186-bd94-421d-8eda-0ce7d985bcc0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7125327d-dbcc-40ba-bc80-0a30f823ab95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7125327d-dbcc-40ba-bc80-0a30f823ab95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_8737460e-42c1-4da7-9663-50f7ae936dc4" xlink:href="evh-20220630.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_8737460e-42c1-4da7-9663-50f7ae936dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5c07442b-cde7-4461-b62b-a586be059efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5c07442b-cde7-4461-b62b-a586be059efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dc7abb75-720e-405d-908d-f553cd82d578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dc7abb75-720e-405d-908d-f553cd82d578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_22d1b283-560b-4982-9a8e-f914b478c8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_us-gaap_ShareBasedCompensation_22d1b283-560b-4982-9a8e-f914b478c8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_214d23e4-b577-4cd1-ae05-617913e54017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_214d23e4-b577-4cd1-ae05-617913e54017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_e8b58ce4-415d-4073-99f6-5c4b966e699f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_e8b58ce4-415d-4073-99f6-5c4b966e699f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_54fb7a08-1a7b-4535-b630-0def56e15c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_54fb7a08-1a7b-4535-b630-0def56e15c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_0fd91529-3799-4695-b5c5-607408b5f87d" xlink:href="evh-20220630.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_evh_GainOnTransferOfMembership_0fd91529-3799-4695-b5c5-607408b5f87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7a00a4f8-30c4-4337-aeb0-e8a06414fd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7a00a4f8-30c4-4337-aeb0-e8a06414fd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a78311df-3fec-499b-bf6f-fd15374230e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a78311df-3fec-499b-bf6f-fd15374230e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_ecb0f5c9-be5c-4047-888b-95eeb0b46e7d" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_ecb0f5c9-be5c-4047-888b-95eeb0b46e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e64ab6fc-f0ef-4fdf-a581-543bc4fb177e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e64ab6fc-f0ef-4fdf-a581-543bc4fb177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_84e1db7d-d0eb-4268-8934-8b45d4a830f9" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_84e1db7d-d0eb-4268-8934-8b45d4a830f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a96c3564-9d25-491e-8507-bdb1b3b06c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a96c3564-9d25-491e-8507-bdb1b3b06c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_24086634-6afb-4463-9a95-04022906d27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_24086634-6afb-4463-9a95-04022906d27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0e0e5256-0dc6-4b62-96d2-5c88b9c3bea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0e0e5256-0dc6-4b62-96d2-5c88b9c3bea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_59c8b6d8-eaca-4176-bf27-d29621d924c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_59c8b6d8-eaca-4176-bf27-d29621d924c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_686a8189-a3e7-4b28-858c-59078968ca69" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_686a8189-a3e7-4b28-858c-59078968ca69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_ae447d89-a34b-4a2a-a7a3-421bbb39ab45" xlink:href="evh-20220630.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_ae447d89-a34b-4a2a-a7a3-421bbb39ab45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8286b1f9-44e3-477d-8b62-9d8126674197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8286b1f9-44e3-477d-8b62-9d8126674197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_b43a7125-f715-439d-9a1d-953c7cfa0aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59733c91-7a99-48a0-a832-f95f9a2f9c32" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_b43a7125-f715-439d-9a1d-953c7cfa0aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2efe72bc-379c-40b0-9f05-9f2eea02bf09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78d0a887-52f1-4086-922a-8e73403e42ac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2efe72bc-379c-40b0-9f05-9f2eea02bf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f58848aa-b3e9-47fc-8a3b-6d67674fad50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a4c04c0-5c83-4c8d-aad4-77a17bb6460c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f58848aa-b3e9-47fc-8a3b-6d67674fad50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3cafe5dc-6e3c-4cf6-82f1-751a93732201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f58848aa-b3e9-47fc-8a3b-6d67674fad50" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3cafe5dc-6e3c-4cf6-82f1-751a93732201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_27687158-f0e1-44b5-a5be-dcf7ad870606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f58848aa-b3e9-47fc-8a3b-6d67674fad50" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_27687158-f0e1-44b5-a5be-dcf7ad870606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_45849432-17e2-4487-8b33-f3a348ef2425" xlink:href="evh-20220630.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f58848aa-b3e9-47fc-8a3b-6d67674fad50" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_45849432-17e2-4487-8b33-f3a348ef2425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_55903fac-c081-421d-aa9e-956b5eb7601c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f58848aa-b3e9-47fc-8a3b-6d67674fad50" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_55903fac-c081-421d-aa9e-956b5eb7601c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_3814c8ca-1f98-40e6-9c15-4ec865a8bdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f58848aa-b3e9-47fc-8a3b-6d67674fad50" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_3814c8ca-1f98-40e6-9c15-4ec865a8bdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_025553d5-8d6b-4a26-9b55-3e51f2ed40c5" xlink:href="evh-20220630.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f58848aa-b3e9-47fc-8a3b-6d67674fad50" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_025553d5-8d6b-4a26-9b55-3e51f2ed40c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_7461c5f0-2b80-4b0c-9fc9-9453dde47be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f58848aa-b3e9-47fc-8a3b-6d67674fad50" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_7461c5f0-2b80-4b0c-9fc9-9453dde47be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43444923-a6e6-4380-82c3-07049e68cdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f58848aa-b3e9-47fc-8a3b-6d67674fad50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43444923-a6e6-4380-82c3-07049e68cdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a9efdd3-cc71-427e-9aa5-eadf18d0fbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a4c04c0-5c83-4c8d-aad4-77a17bb6460c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a9efdd3-cc71-427e-9aa5-eadf18d0fbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_b5485611-7aae-4d92-9252-399b2e6498f7" xlink:href="evh-20220630.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a9efdd3-cc71-427e-9aa5-eadf18d0fbe7" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_b5485611-7aae-4d92-9252-399b2e6498f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_788a9eb4-587e-4a17-9035-ff7ab4092a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a9efdd3-cc71-427e-9aa5-eadf18d0fbe7" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_788a9eb4-587e-4a17-9035-ff7ab4092a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3954e2c2-63a0-4284-b66d-80f6bd02d95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a9efdd3-cc71-427e-9aa5-eadf18d0fbe7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3954e2c2-63a0-4284-b66d-80f6bd02d95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_6ccef153-a384-4e27-a1c6-fad0796399db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a9efdd3-cc71-427e-9aa5-eadf18d0fbe7" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_6ccef153-a384-4e27-a1c6-fad0796399db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_343510c2-74ae-43f5-9763-1e4c564c1443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a9efdd3-cc71-427e-9aa5-eadf18d0fbe7" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_343510c2-74ae-43f5-9763-1e4c564c1443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c9dbac95-60eb-4c0f-b459-e9b45bab2040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a9efdd3-cc71-427e-9aa5-eadf18d0fbe7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c9dbac95-60eb-4c0f-b459-e9b45bab2040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ebd140b-eb0b-484f-bbc7-a932f0941657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a4c04c0-5c83-4c8d-aad4-77a17bb6460c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ebd140b-eb0b-484f-bbc7-a932f0941657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_09bad119-2887-45ee-bf90-fb0d7cb73c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a4c04c0-5c83-4c8d-aad4-77a17bb6460c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_09bad119-2887-45ee-bf90-fb0d7cb73c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa8ff6d3-6e84-4320-b046-94138f61d110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a4c04c0-5c83-4c8d-aad4-77a17bb6460c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa8ff6d3-6e84-4320-b046-94138f61d110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37e2577a-968b-4380-a7c5-b5e8a3fc059a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8a4c04c0-5c83-4c8d-aad4-77a17bb6460c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37e2577a-968b-4380-a7c5-b5e8a3fc059a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Organization" xlink:type="simple" xlink:href="evh-20220630.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c57d7503-7c0f-4478-90db-11f2e3e8ae9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_483acd88-2f85-4aaf-aa5d-37e6035deae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c57d7503-7c0f-4478-90db-11f2e3e8ae9a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_483acd88-2f85-4aaf-aa5d-37e6035deae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8d7f95b-2f3e-47d5-bc9c-b10f6aab867e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9782b410-9fe5-49ed-a5ed-30d9069a8270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8d7f95b-2f3e-47d5-bc9c-b10f6aab867e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9782b410-9fe5-49ed-a5ed-30d9069a8270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="simple" xlink:href="evh-20220630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2e2e95e3-e5f2-4df4-9840-e480177ae1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_712cdc51-c7d4-451a-8b43-305a2a76557c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e2e95e3-e5f2-4df4-9840-e480177ae1cb" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_712cdc51-c7d4-451a-8b43-305a2a76557c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="simple" xlink:href="evh-20220630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6472b8bc-8acd-4914-b2c5-9377a07d6c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6472b8bc-8acd-4914-b2c5-9377a07d6c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_70cb4d8c-fbba-45b7-8a0f-43b7c369131d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_UseOfEstimates_70cb4d8c-fbba-45b7-8a0f-43b7c369131d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_16cdc20b-232d-4b47-ac48-d3edddd66187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_16cdc20b-232d-4b47-ac48-d3edddd66187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_76d613f2-5ef1-4d5f-81d8-427219f47a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_76d613f2-5ef1-4d5f-81d8-427219f47a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_8ef0772d-146a-41c0-bf1c-1b862d0a0f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_8ef0772d-146a-41c0-bf1c-1b862d0a0f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_34c6a265-479c-433f-85ab-9e33b0a5f77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_34c6a265-479c-433f-85ab-9e33b0a5f77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_de3781f9-ccb9-4da4-a7f4-0f1dd5bb0d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_de3781f9-ccb9-4da4-a7f4-0f1dd5bb0d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_000b3fd4-bdc7-4658-be27-bb8d85f587a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_000b3fd4-bdc7-4658-be27-bb8d85f587a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy_c028c70b-cac1-407e-b7dd-793a928b39a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_LiabilityReserveEstimatePolicy_c028c70b-cac1-407e-b7dd-793a928b39a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock_9f3724dc-5c91-4c7d-949d-0a0f0c4521b9" xlink:href="evh-20220630.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_evh_RightOfOffsetPolicyPolicyTextBlock_9f3724dc-5c91-4c7d-949d-0a0f0c4521b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_6bb683d4-1834-49d3-b24e-1979ee9755a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_6bb683d4-1834-49d3-b24e-1979ee9755a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_157e5147-5eef-4b83-8143-9e696d9b5e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_157e5147-5eef-4b83-8143-9e696d9b5e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bcb77a98-c27f-450a-92ab-c4afac95436a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bcb77a98-c27f-450a-92ab-c4afac95436a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a4aaa102-5077-4309-a7e0-42ade21212d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aab0be7-e16d-49ca-a101-065218d4f529" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a4aaa102-5077-4309-a7e0-42ade21212d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="simple" xlink:href="evh-20220630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8e88cdaa-acbb-4c51-a7d1-1f686c1df01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_ed5f0b8a-63e9-4515-9023-e4c7d0b5d885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e88cdaa-acbb-4c51-a7d1-1f686c1df01e" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_ed5f0b8a-63e9-4515-9023-e4c7d0b5d885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0adf9c2e-4911-4155-ab9b-d8a8ad920ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e88cdaa-acbb-4c51-a7d1-1f686c1df01e" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0adf9c2e-4911-4155-ab9b-d8a8ad920ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2b41aff8-bb69-4fd2-a56e-d7e6df264903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e88cdaa-acbb-4c51-a7d1-1f686c1df01e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2b41aff8-bb69-4fd2-a56e-d7e6df264903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5904a9f3-1e3c-4ff2-a59b-806f9a356cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_46112a92-a57b-4ca2-96ec-56867d8f03e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5904a9f3-1e3c-4ff2-a59b-806f9a356cf9" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_46112a92-a57b-4ca2-96ec-56867d8f03e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_07c7363e-29a2-458e-927a-a2d4b934c5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_46112a92-a57b-4ca2-96ec-56867d8f03e2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_07c7363e-29a2-458e-927a-a2d4b934c5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_07c7363e-29a2-458e-927a-a2d4b934c5e3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_6ebdff18-444f-404a-81dd-685ffad1c91b" xlink:href="evh-20220630.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_6ebdff18-444f-404a-81dd-685ffad1c91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_ef21a8a9-9578-43d6-aeca-ad9382c165b4" xlink:href="evh-20220630.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_ef21a8a9-9578-43d6-aeca-ad9382c165b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_91e879aa-640f-433e-a550-28df38a634d1" xlink:href="evh-20220630.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_91e879aa-640f-433e-a550-28df38a634d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_930f99ae-d2aa-4a03-acf0-e19b1a16720a" xlink:href="evh-20220630.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_930f99ae-d2aa-4a03-acf0-e19b1a16720a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_487f8445-640d-4097-971b-38053a11f012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e109a5a-17b4-444b-b288-5ecd1f69085e" xlink:to="loc_us-gaap_BankTimeDepositsMember_487f8445-640d-4097-971b-38053a11f012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_46112a92-a57b-4ca2-96ec-56867d8f03e2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_45cfda6d-8d1d-4f72-a069-2a14aa954e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_45cfda6d-8d1d-4f72-a069-2a14aa954e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_03981b69-eef1-4c4d-8fd8-eba15a649777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_03981b69-eef1-4c4d-8fd8-eba15a649777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_d903d8b5-8008-49df-b750-a5cf6a5f4e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_d903d8b5-8008-49df-b750-a5cf6a5f4e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2efad5f4-06ef-43f7-b19b-bf303dbd78fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2efad5f4-06ef-43f7-b19b-bf303dbd78fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_8dacc754-013b-4469-91f2-4d1c445d1113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_8dacc754-013b-4469-91f2-4d1c445d1113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_6e945d89-f595-4183-8da5-50962756b273" xlink:href="evh-20220630.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_6e945d89-f595-4183-8da5-50962756b273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_e1e657c9-0127-4377-a8de-2a12e7578293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_e1e657c9-0127-4377-a8de-2a12e7578293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2798dafc-6fce-4fd4-bb2d-4586b10ee1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_38b0a911-94e3-4ba0-8f32-e5892df962d4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2798dafc-6fce-4fd4-bb2d-4586b10ee1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_626c9f3f-1df4-4467-b62d-18d4927d50fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_f7935014-0db0-407c-8f7c-9ba5384d8ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_626c9f3f-1df4-4467-b62d-18d4927d50fa" xlink:to="loc_us-gaap_NumberOfReportingUnits_f7935014-0db0-407c-8f7c-9ba5384d8ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f0f60472-3a2e-4edb-8766-4b99f7fdd10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11c0ac3f-9dfb-4186-ae94-d57425605cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0f60472-3a2e-4edb-8766-4b99f7fdd10c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11c0ac3f-9dfb-4186-ae94-d57425605cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1cd57a6-2a33-4204-b631-f8b31953b6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11c0ac3f-9dfb-4186-ae94-d57425605cfa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1cd57a6-2a33-4204-b631-f8b31953b6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1cd57a6-2a33-4204-b631-f8b31953b6a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_c247ef4f-a3a3-46e5-80bc-0eca0934a91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:to="loc_us-gaap_TradeNamesMember_c247ef4f-a3a3-46e5-80bc-0eca0934a91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_903fc9e1-96c3-42de-819a-8611171690bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:to="loc_us-gaap_CustomerRelationshipsMember_903fc9e1-96c3-42de-819a-8611171690bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1eaeddb0-a3f5-4f9d-ad50-a35d7e665308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1eaeddb0-a3f5-4f9d-ad50-a35d7e665308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_5c9a1994-99f0-4b9d-8da0-fece47e46049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ff77853-fc0e-4a1d-8df0-14dafd47d585" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_5c9a1994-99f0-4b9d-8da0-fece47e46049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_11ea468c-7d39-46a5-8f22-32f0f20c7de8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11c0ac3f-9dfb-4186-ae94-d57425605cfa" xlink:to="loc_srt_RangeAxis_11ea468c-7d39-46a5-8f22-32f0f20c7de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d80ad52-e644-4ffc-b07d-f068aa2f2a45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_11ea468c-7d39-46a5-8f22-32f0f20c7de8" xlink:to="loc_srt_RangeMember_2d80ad52-e644-4ffc-b07d-f068aa2f2a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c9742b6-c1ff-4c16-a49a-76487acc0d2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2d80ad52-e644-4ffc-b07d-f068aa2f2a45" xlink:to="loc_srt_MinimumMember_5c9742b6-c1ff-4c16-a49a-76487acc0d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b650ba92-4674-4797-bb11-05c7306de658" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2d80ad52-e644-4ffc-b07d-f068aa2f2a45" xlink:to="loc_srt_MaximumMember_b650ba92-4674-4797-bb11-05c7306de658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b9bce448-d660-40f5-a10b-6dc41aa21ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11c0ac3f-9dfb-4186-ae94-d57425605cfa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b9bce448-d660-40f5-a10b-6dc41aa21ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3195c8bd-63a9-4d58-99a7-21c16709244f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b9bce448-d660-40f5-a10b-6dc41aa21ab0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3195c8bd-63a9-4d58-99a7-21c16709244f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_18de9847-665f-4639-b361-0fd2ad9a7dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_800e2378-3b55-4e97-92f0-79bbb1922be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18de9847-665f-4639-b361-0fd2ad9a7dd4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_800e2378-3b55-4e97-92f0-79bbb1922be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_de614fd3-d92a-4815-ae60-4c67b77c8d51" xlink:href="evh-20220630.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18de9847-665f-4639-b361-0fd2ad9a7dd4" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_de614fd3-d92a-4815-ae60-4c67b77c8d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_35c635cd-2742-4224-bc82-d0067f51478a" xlink:href="evh-20220630.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18de9847-665f-4639-b361-0fd2ad9a7dd4" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_35c635cd-2742-4224-bc82-d0067f51478a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfSourcesOfRevenue_38d9ac87-5ac3-434c-b066-45b330703952" xlink:href="evh-20220630.xsd#evh_NumberOfSourcesOfRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18de9847-665f-4639-b361-0fd2ad9a7dd4" xlink:to="loc_evh_NumberOfSourcesOfRevenue_38d9ac87-5ac3-434c-b066-45b330703952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="evh-20220630.xsd#RecentlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7aa1853f-e1da-4748-b00b-39ba472db608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_0061e8c6-b4b6-4e7a-ac58-11f17cc4aff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7aa1853f-e1da-4748-b00b-39ba472db608" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_0061e8c6-b4b6-4e7a-ac58-11f17cc4aff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_974a8165-c3b9-4d77-91e8-28de1f6ee115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_974a8165-c3b9-4d77-91e8-28de1f6ee115" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4a4aecf1-f31e-4d73-b54a-0d4bd097f810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4a4aecf1-f31e-4d73-b54a-0d4bd097f810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7177956c-4d3d-4b4f-8ac0-7cb6b6ab0f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a4aecf1-f31e-4d73-b54a-0d4bd097f810" xlink:to="loc_us-gaap_EquityComponentDomain_7177956c-4d3d-4b4f-8ac0-7cb6b6ab0f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9d78d707-da98-4752-9771-d256fd2a9563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7177956c-4d3d-4b4f-8ac0-7cb6b6ab0f7c" xlink:to="loc_us-gaap_RetainedEarningsMember_9d78d707-da98-4752-9771-d256fd2a9563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7663cdb3-7cf2-44d6-9095-cefd269802b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7177956c-4d3d-4b4f-8ac0-7cb6b6ab0f7c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7663cdb3-7cf2-44d6-9095-cefd269802b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d749a7d-b5cd-4a7a-9710-a68a9bdd8c40" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d749a7d-b5cd-4a7a-9710-a68a9bdd8c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_606a3c2c-a294-455e-b585-a0cce0ddb277" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8d749a7d-b5cd-4a7a-9710-a68a9bdd8c40" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_606a3c2c-a294-455e-b585-a0cce0ddb277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ac15e38f-44ea-4e96-a3f2-835f1713fdca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_606a3c2c-a294-455e-b585-a0cce0ddb277" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ac15e38f-44ea-4e96-a3f2-835f1713fdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3a84a739-550e-4576-ac4e-5d9971f74d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:to="loc_us-gaap_DebtInstrumentAxis_3a84a739-550e-4576-ac4e-5d9971f74d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2e08e263-6193-438b-b97d-57d9577b6f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a84a739-550e-4576-ac4e-5d9971f74d14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2e08e263-6193-438b-b97d-57d9577b6f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_0e09d885-da9a-458e-bdc6-6c13597d3f75" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e08e263-6193-438b-b97d-57d9577b6f43" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_0e09d885-da9a-458e-bdc6-6c13597d3f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_3bc0660e-89fe-427f-84fb-c52455dbc65a" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e08e263-6193-438b-b97d-57d9577b6f43" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_3bc0660e-89fe-427f-84fb-c52455dbc65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_174157a7-8349-4218-aa18-b3a68f1234ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_174157a7-8349-4218-aa18-b3a68f1234ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_983b3d32-2979-4a7f-ac0b-effde57279fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_174157a7-8349-4218-aa18-b3a68f1234ed" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_983b3d32-2979-4a7f-ac0b-effde57279fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7d4e0956-7322-4622-847a-bd60daa78ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_983b3d32-2979-4a7f-ac0b-effde57279fa" xlink:to="loc_us-gaap_SeniorNotesMember_7d4e0956-7322-4622-847a-bd60daa78ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_63281121-a8e4-44dc-91a6-1b41fe53b222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_63281121-a8e4-44dc-91a6-1b41fe53b222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_077c42e5-38f8-4266-9c89-63afec910fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_63281121-a8e4-44dc-91a6-1b41fe53b222" xlink:to="loc_us-gaap_TypeOfAdoptionMember_077c42e5-38f8-4266-9c89-63afec910fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_4355ea45-b4a3-4443-aa39-83c53daefb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_077c42e5-38f8-4266-9c89-63afec910fad" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_4355ea45-b4a3-4443-aa39-83c53daefb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_23c3f36a-585f-4dd1-96e6-24e7fc452dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_aaf83af9-bbc1-4ee6-90c0-01db99b352a2" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_23c3f36a-585f-4dd1-96e6-24e7fc452dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e759376-c676-4fb1-92da-3249d687e68e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_23c3f36a-585f-4dd1-96e6-24e7fc452dea" xlink:to="loc_us-gaap_StockholdersEquity_9e759376-c676-4fb1-92da-3249d687e68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2b46b7dd-6b1e-43ff-93f4-d781703ba36d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_23c3f36a-585f-4dd1-96e6-24e7fc452dea" xlink:to="loc_us-gaap_LongTermDebt_2b46b7dd-6b1e-43ff-93f4-d781703ba36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Transactions" xlink:type="simple" xlink:href="evh-20220630.xsd#Transactions"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Transactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b5922180-4bbb-42e1-bcda-481e1a119ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_84274586-12d9-4df6-9475-35663986b754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b5922180-4bbb-42e1-bcda-481e1a119ab6" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_84274586-12d9-4df6-9475-35663986b754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="simple" xlink:href="evh-20220630.xsd#TransactionsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b4a6a03e-a1d3-4bcc-b4c2-526ed2892521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_47317cfe-cc8d-4f8c-9fa8-0fdec9b42644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b4a6a03e-a1d3-4bcc-b4c2-526ed2892521" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_47317cfe-cc8d-4f8c-9fa8-0fdec9b42644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_07942837-3cb4-4c7f-b5c0-50b41f45d7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b4a6a03e-a1d3-4bcc-b4c2-526ed2892521" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_07942837-3cb4-4c7f-b5c0-50b41f45d7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#TransactionsVitalDecisionsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_93edf4a7-9143-44f8-9038-da22eb594791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13fac8b1-286c-4fac-8a41-e11b46f341a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_93edf4a7-9143-44f8-9038-da22eb594791" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13fac8b1-286c-4fac-8a41-e11b46f341a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_534a22af-8087-4f54-a893-b269d6a1d106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13fac8b1-286c-4fac-8a41-e11b46f341a5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_534a22af-8087-4f54-a893-b269d6a1d106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5563f8a-7ee5-4531-b443-53edbb72e611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_534a22af-8087-4f54-a893-b269d6a1d106" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5563f8a-7ee5-4531-b443-53edbb72e611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_60649871-c7f5-4d39-9ab5-04196f92bf64" xlink:href="evh-20220630.xsd#evh_VitalDecisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5563f8a-7ee5-4531-b443-53edbb72e611" xlink:to="loc_evh_VitalDecisionsMember_60649871-c7f5-4d39-9ab5-04196f92bf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f89605e-79d7-4042-877d-4090d7769832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13fac8b1-286c-4fac-8a41-e11b46f341a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f89605e-79d7-4042-877d-4090d7769832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fcf898bc-5d69-4041-8c12-e29253fac30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f89605e-79d7-4042-877d-4090d7769832" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fcf898bc-5d69-4041-8c12-e29253fac30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2ff5f494-cb75-4047-bade-547bd601ae86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fcf898bc-5d69-4041-8c12-e29253fac30d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2ff5f494-cb75-4047-bade-547bd601ae86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_48eede5e-e108-49f7-a894-b90f49b01580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fcf898bc-5d69-4041-8c12-e29253fac30d" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_48eede5e-e108-49f7-a894-b90f49b01580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_0d799276-a95b-4aef-b6fa-ae207d6f2887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fcf898bc-5d69-4041-8c12-e29253fac30d" xlink:to="loc_us-gaap_TradeNamesMember_0d799276-a95b-4aef-b6fa-ae207d6f2887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_13fac8b1-286c-4fac-8a41-e11b46f341a5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_afae07c0-2d73-4425-890f-83114117d739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_afae07c0-2d73-4425-890f-83114117d739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_f71e3e00-6de3-459a-af67-4f8c304c629a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_f71e3e00-6de3-459a-af67-4f8c304c629a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4b42a9a5-b331-4af6-ac61-41b03b870a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4b42a9a5-b331-4af6-ac61-41b03b870a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6aaf9ff6-7882-45db-b105-ad6ada4012b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6aaf9ff6-7882-45db-b105-ad6ada4012b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_37054db3-fe3c-4246-bc50-b624d506c0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_37054db3-fe3c-4246-bc50-b624d506c0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7ff3dffc-af23-4254-ae74-7e7084d478c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7ff3dffc-af23-4254-ae74-7e7084d478c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_2e41938d-3bd2-43ed-9f31-8f0a37d67492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_2e41938d-3bd2-43ed-9f31-8f0a37d67492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_90300b04-a4e2-40ac-aeb7-e0a2fa82ed7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_aa2e6072-45b0-47ad-9e22-37ff5d6cb475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_90300b04-a4e2-40ac-aeb7-e0a2fa82ed7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4b31af68-9f55-43ac-8339-84c08f646de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4b31af68-9f55-43ac-8339-84c08f646de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3292a05f-76cf-4506-94fb-869aa23f49f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3292a05f-76cf-4506-94fb-869aa23f49f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e2be72bf-a092-4065-ab5e-4e55404ee51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e2be72bf-a092-4065-ab5e-4e55404ee51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_93e7feac-7aea-4117-b15b-06ae17f5d3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_93e7feac-7aea-4117-b15b-06ae17f5d3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_93c5d5a2-e698-433f-b765-4c8271184486" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_9dae790b-d0b2-45bd-b253-ff6066a5cc86" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_93c5d5a2-e698-433f-b765-4c8271184486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_a56a6ba6-24c1-4aa3-8322-42dd6309f201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_a56a6ba6-24c1-4aa3-8322-42dd6309f201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_94e0e9fc-962a-44c8-b5bf-674d114457f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_a56a6ba6-24c1-4aa3-8322-42dd6309f201" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_94e0e9fc-962a-44c8-b5bf-674d114457f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5b6a60e9-8b7c-4263-a9b4-d5e5e6439ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5b6a60e9-8b7c-4263-a9b4-d5e5e6439ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_2eb018e6-608e-4a91-92fe-98f22f6a43c3" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_2eb018e6-608e-4a91-92fe-98f22f6a43c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_a2d78bda-238f-4d1e-9c4b-424f5b2cc650" xlink:href="evh-20220630.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_a2d78bda-238f-4d1e-9c4b-424f5b2cc650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ce90a731-131d-43a6-9413-79b1d83f8aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ce90a731-131d-43a6-9413-79b1d83f8aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_a82565ab-cc08-42f6-b828-852da683d4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_a82565ab-cc08-42f6-b828-852da683d4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_74f67bc8-52a8-403e-b303-d348e5dba74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_74f67bc8-52a8-403e-b303-d348e5dba74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ff111327-499c-44ef-bbbb-92792c1e66c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_74c9ec68-2add-44a4-a2a5-34484c086abf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ff111327-499c-44ef-bbbb-92792c1e66c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c4ead30f-e624-46f0-89ca-1d00fd7d26a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_Goodwill_c4ead30f-e624-46f0-89ca-1d00fd7d26a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_22920902-b1f3-4746-a837-7338b46fb2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_22920902-b1f3-4746-a837-7338b46fb2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_df321ecc-07ac-48fd-b737-d52e1490614c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_df321ecc-07ac-48fd-b737-d52e1490614c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_aa81cc5b-2808-4174-803f-21329818b79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2b76abb-3a21-4762-9770-2a36c20aaea0" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_aa81cc5b-2808-4174-803f-21329818b79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="evh-20220630.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9357bee0-a2e6-4551-876b-302de6b72b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_970292a0-be03-4836-885b-10bc4b0472cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9357bee0-a2e6-4551-876b-302de6b72b04" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_970292a0-be03-4836-885b-10bc4b0472cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="evh-20220630.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6c364af8-d7ee-4595-9c70-91d8e4a527af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_423a299e-7116-4c3a-a462-f9510bce8a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6c364af8-d7ee-4595-9c70-91d8e4a527af" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_423a299e-7116-4c3a-a462-f9510bce8a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5fc35198-9511-4f53-96d8-ff0996b014e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dac28e11-a01d-4795-af1c-40ad56156517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5fc35198-9511-4f53-96d8-ff0996b014e1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dac28e11-a01d-4795-af1c-40ad56156517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b8e4f172-fceb-4f8b-a02c-bd4686fbd31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dac28e11-a01d-4795-af1c-40ad56156517" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b8e4f172-fceb-4f8b-a02c-bd4686fbd31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0a24c202-8697-4145-8a88-df1c5a8f7940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b8e4f172-fceb-4f8b-a02c-bd4686fbd31b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0a24c202-8697-4145-8a88-df1c5a8f7940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4d75095b-bad2-4064-83a8-0ca26d823da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0a24c202-8697-4145-8a88-df1c5a8f7940" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4d75095b-bad2-4064-83a8-0ca26d823da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbc7097e-ce07-4895-b99d-e4936a5437fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dac28e11-a01d-4795-af1c-40ad56156517" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbc7097e-ce07-4895-b99d-e4936a5437fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9695d69-a3f7-4a13-85fe-16faf7f1132b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbc7097e-ce07-4895-b99d-e4936a5437fe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9695d69-a3f7-4a13-85fe-16faf7f1132b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_be21e396-fd18-4214-b566-7f418e60865a" xlink:href="evh-20220630.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9695d69-a3f7-4a13-85fe-16faf7f1132b" xlink:to="loc_evh_TrueHealthMember_be21e396-fd18-4214-b566-7f418e60865a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e164ff70-fe7c-4e2a-89fa-afb75a657d58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dac28e11-a01d-4795-af1c-40ad56156517" xlink:to="loc_srt_ProductOrServiceAxis_e164ff70-fe7c-4e2a-89fa-afb75a657d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e0889690-a0ee-419a-b8b1-0bf54e3dfac9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e164ff70-fe7c-4e2a-89fa-afb75a657d58" xlink:to="loc_srt_ProductsAndServicesDomain_e0889690-a0ee-419a-b8b1-0bf54e3dfac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_f28a958d-2072-4bb8-b723-4b5f48f6add0" xlink:href="evh-20220630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e0889690-a0ee-419a-b8b1-0bf54e3dfac9" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_f28a958d-2072-4bb8-b723-4b5f48f6add0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_2647545f-a89c-475c-8da4-36c144472a5a" xlink:href="evh-20220630.xsd#evh_PremiumsRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e0889690-a0ee-419a-b8b1-0bf54e3dfac9" xlink:to="loc_evh_PremiumsRevenueMember_2647545f-a89c-475c-8da4-36c144472a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_1a4651ee-5145-41ca-a20e-946dd5f961a7" xlink:href="evh-20220630.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e0889690-a0ee-419a-b8b1-0bf54e3dfac9" xlink:to="loc_evh_ServicesAgreementsMember_1a4651ee-5145-41ca-a20e-946dd5f961a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dac28e11-a01d-4795-af1c-40ad56156517" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0656c8c8-a7fe-4299-acbe-d9ca90d2ad0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_RevenuesAbstract_0656c8c8-a7fe-4299-acbe-d9ca90d2ad0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9ac6384a-8c92-4202-9b18-073999db4477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0656c8c8-a7fe-4299-acbe-d9ca90d2ad0a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9ac6384a-8c92-4202-9b18-073999db4477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_09fae78b-ce2f-45ae-985a-814349971dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_09fae78b-ce2f-45ae-985a-814349971dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_94394323-0aef-4bde-b03e-6fad32b74e50" xlink:href="evh-20220630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_94394323-0aef-4bde-b03e-6fad32b74e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e241b361-96ea-4172-9bc3-1072142dbf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e241b361-96ea-4172-9bc3-1072142dbf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_56a66e22-11be-4a3b-aa78-3a894e17255c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_56a66e22-11be-4a3b-aa78-3a894e17255c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2e8f5270-148f-4d0d-8248-257f301b2d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_08a75350-13ed-4644-8035-2f51b4586d94" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2e8f5270-148f-4d0d-8248-257f301b2d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a52b85c0-9a3a-4474-a506-ffe7456eae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a52b85c0-9a3a-4474-a506-ffe7456eae6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_a51d6aac-b106-49c1-a5b0-79c543eb96bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_a51d6aac-b106-49c1-a5b0-79c543eb96bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_76616d9f-7776-4b71-b5cd-64e91dcd40e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_76616d9f-7776-4b71-b5cd-64e91dcd40e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_3f67b276-4320-4fe6-85e6-d9ac13c502e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_3f67b276-4320-4fe6-85e6-d9ac13c502e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9b26e1d7-0ea5-451b-8772-981191ecf05d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9b26e1d7-0ea5-451b-8772-981191ecf05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_8308e3df-d695-4f36-b7f1-331afac437e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_8308e3df-d695-4f36-b7f1-331afac437e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1f27b7a6-cefb-48f1-9275-916246298296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_733eb9c6-cc9b-4c42-8597-779720c8a0a2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1f27b7a6-cefb-48f1-9275-916246298296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7805234a-8008-4085-974f-7e45c3edb5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9d3d4da6-7863-47fb-b4eb-187a386b7019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7805234a-8008-4085-974f-7e45c3edb5a1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9d3d4da6-7863-47fb-b4eb-187a386b7019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce3d8a27-2055-4f25-ad81-e03119c29014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9d3d4da6-7863-47fb-b4eb-187a386b7019" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce3d8a27-2055-4f25-ad81-e03119c29014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1ab12ac0-e6a4-440f-a191-d231735416d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce3d8a27-2055-4f25-ad81-e03119c29014" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1ab12ac0-e6a4-440f-a191-d231735416d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_2b313e8d-dda5-482e-b682-3d851f2db48d" xlink:href="evh-20220630.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1ab12ac0-e6a4-440f-a191-d231735416d1" xlink:to="loc_evh_TrueHealthMember_2b313e8d-dda5-482e-b682-3d851f2db48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_79892460-39ac-4bcf-b16d-6f535e9624c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9d3d4da6-7863-47fb-b4eb-187a386b7019" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_79892460-39ac-4bcf-b16d-6f535e9624c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6f9ee5e2-9afe-428f-a31d-4306f3f51717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_79892460-39ac-4bcf-b16d-6f535e9624c3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6f9ee5e2-9afe-428f-a31d-4306f3f51717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_cda1112b-0f58-4f53-a06a-144cd5cc73fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6f9ee5e2-9afe-428f-a31d-4306f3f51717" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_cda1112b-0f58-4f53-a06a-144cd5cc73fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6d9a9c8c-f132-4de8-b956-0ab8a4e8430c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9d3d4da6-7863-47fb-b4eb-187a386b7019" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6d9a9c8c-f132-4de8-b956-0ab8a4e8430c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_d929e3e9-3025-4bec-95df-762adfcb9eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6d9a9c8c-f132-4de8-b956-0ab8a4e8430c" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_d929e3e9-3025-4bec-95df-762adfcb9eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_23db4e50-d91f-4af8-9a85-835b47f34e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6d9a9c8c-f132-4de8-b956-0ab8a4e8430c" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_23db4e50-d91f-4af8-9a85-835b47f34e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="simple" xlink:href="evh-20220630.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_901f1e11-3ae0-4d45-bc9c-dee83d505ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_8c2cf22c-47a5-4ee8-a6a3-92776bdd3fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_901f1e11-3ae0-4d45-bc9c-dee83d505ea9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_8c2cf22c-47a5-4ee8-a6a3-92776bdd3fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="evh-20220630.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_703e7303-6260-43b6-9af8-13a2d4b40746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f8fac86a-44c5-43b8-9029-d40f3f87da90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_703e7303-6260-43b6-9af8-13a2d4b40746" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f8fac86a-44c5-43b8-9029-d40f3f87da90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5f2e0543-f809-4476-afea-9c17e2b4fe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_703e7303-6260-43b6-9af8-13a2d4b40746" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5f2e0543-f809-4476-afea-9c17e2b4fe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c5fa86c2-5885-4785-bd2a-0e2d55a8749b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f7af251c-e204-4312-8de6-d37d8a4ce82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c5fa86c2-5885-4785-bd2a-0e2d55a8749b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f7af251c-e204-4312-8de6-d37d8a4ce82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f9572da8-ecf7-4a4d-8599-4aeb03afd42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7af251c-e204-4312-8de6-d37d8a4ce82a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f9572da8-ecf7-4a4d-8599-4aeb03afd42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bb164483-56b2-4790-a93c-35c4e61e5831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f9572da8-ecf7-4a4d-8599-4aeb03afd42e" xlink:to="loc_us-gaap_SegmentDomain_bb164483-56b2-4790-a93c-35c4e61e5831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_e25a6fc2-840b-4e34-b1a0-0ba2523d699f" xlink:href="evh-20220630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bb164483-56b2-4790-a93c-35c4e61e5831" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_e25a6fc2-840b-4e34-b1a0-0ba2523d699f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_63eccda8-c6e2-4aa7-b115-7443a71282e2" xlink:href="evh-20220630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bb164483-56b2-4790-a93c-35c4e61e5831" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_63eccda8-c6e2-4aa7-b115-7443a71282e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_96d14062-9ab8-4542-b097-e8ae9fbca12e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7af251c-e204-4312-8de6-d37d8a4ce82a" xlink:to="loc_srt_MajorCustomersAxis_96d14062-9ab8-4542-b097-e8ae9fbca12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b051981c-2684-410a-b3bd-24bc24bae35e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_96d14062-9ab8-4542-b097-e8ae9fbca12e" xlink:to="loc_srt_NameOfMajorCustomerDomain_b051981c-2684-410a-b3bd-24bc24bae35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_a39d92c9-6bc4-408e-a19c-6bd274c722ca" xlink:href="evh-20220630.xsd#evh_MedicaidCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b051981c-2684-410a-b3bd-24bc24bae35e" xlink:to="loc_evh_MedicaidCustomersMember_a39d92c9-6bc4-408e-a19c-6bd274c722ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_7292cad3-71a4-4433-bb72-3bcd1a7e681d" xlink:href="evh-20220630.xsd#evh_MedicareCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b051981c-2684-410a-b3bd-24bc24bae35e" xlink:to="loc_evh_MedicareCustomersMember_7292cad3-71a4-4433-bb72-3bcd1a7e681d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_2060404e-14a9-4cc9-af27-51b7a960f896" xlink:href="evh-20220630.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b051981c-2684-410a-b3bd-24bc24bae35e" xlink:to="loc_evh_CommercialAndOtherCustomersMember_2060404e-14a9-4cc9-af27-51b7a960f896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6da6c49a-d0e4-4d27-ba69-f01b9c18f6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7af251c-e204-4312-8de6-d37d8a4ce82a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6da6c49a-d0e4-4d27-ba69-f01b9c18f6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93eefd98-b7b8-454b-acfe-1f4a44170433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6da6c49a-d0e4-4d27-ba69-f01b9c18f6fa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93eefd98-b7b8-454b-acfe-1f4a44170433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_84afa419-9942-429a-8598-962ba90bdfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_11e6834a-a31a-4c83-af83-067e667cd192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_84afa419-9942-429a-8598-962ba90bdfd1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_11e6834a-a31a-4c83-af83-067e667cd192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_760aef2e-8a63-40e7-a212-1d0cfe1b025c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_84afa419-9942-429a-8598-962ba90bdfd1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_760aef2e-8a63-40e7-a212-1d0cfe1b025c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_53614445-a94d-4875-a12d-1ce58f49df52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_760aef2e-8a63-40e7-a212-1d0cfe1b025c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_53614445-a94d-4875-a12d-1ce58f49df52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_760aef2e-8a63-40e7-a212-1d0cfe1b025c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_86bb9de4-26d6-49b5-9a1d-4b69ccbe6890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_86bb9de4-26d6-49b5-9a1d-4b69ccbe6890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_21e0c598-3492-49b0-9d35-ab36926c9006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_8aa898eb-19c6-4bd3-ae36-bdb2524a7882" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_21e0c598-3492-49b0-9d35-ab36926c9006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20220630.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_660bf79a-53e7-4efa-943b-3014ff44772e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_bfd20229-4614-4ce8-af52-6db469413473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_660bf79a-53e7-4efa-943b-3014ff44772e" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_bfd20229-4614-4ce8-af52-6db469413473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_95014bf4-e5e9-4703-be69-95476aaf1eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_660bf79a-53e7-4efa-943b-3014ff44772e" xlink:to="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_95014bf4-e5e9-4703-be69-95476aaf1eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_88814525-5cf1-4581-9447-ae3b2ef92b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_660bf79a-53e7-4efa-943b-3014ff44772e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_88814525-5cf1-4581-9447-ae3b2ef92b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_81f0b930-08af-4c5d-ab4b-db6dbcfb42f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_660bf79a-53e7-4efa-943b-3014ff44772e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_81f0b930-08af-4c5d-ab4b-db6dbcfb42f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_15458346-1605-44c2-b9bd-6274b035c910" xlink:href="evh-20220630.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_660bf79a-53e7-4efa-943b-3014ff44772e" xlink:to="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_15458346-1605-44c2-b9bd-6274b035c910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_165fbcb7-5fce-40c0-bf58-b6157132a4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_15458346-1605-44c2-b9bd-6274b035c910" xlink:to="loc_us-gaap_ContractWithCustomerLiability_165fbcb7-5fce-40c0-bf58-b6157132a4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ef6d027d-1615-48da-ae8c-7648c8010aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_15458346-1605-44c2-b9bd-6274b035c910" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ef6d027d-1615-48da-ae8c-7648c8010aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_e69003c5-d5cf-49d5-b364-ce1474d17e7a" xlink:href="evh-20220630.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_15458346-1605-44c2-b9bd-6274b035c910" xlink:to="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_e69003c5-d5cf-49d5-b364-ce1474d17e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_13613a17-5677-4d3d-8161-7b3c1f038dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_15458346-1605-44c2-b9bd-6274b035c910" xlink:to="loc_us-gaap_ContractWithCustomerLiability_13613a17-5677-4d3d-8161-7b3c1f038dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_fd9115fe-da9e-475d-adcd-463e7ed89d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_660bf79a-53e7-4efa-943b-3014ff44772e" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_fd9115fe-da9e-475d-adcd-463e7ed89d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f5f248df-d011-4388-9f6d-e13ea638d0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_1a94dd7a-242d-409e-93e2-48ed95f9bb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f5f248df-d011-4388-9f6d-e13ea638d0bb" xlink:to="loc_us-gaap_CapitalizedContractCostTable_1a94dd7a-242d-409e-93e2-48ed95f9bb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_41cca131-b0f8-4d64-b9e8-f4d9b868a3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_1a94dd7a-242d-409e-93e2-48ed95f9bb36" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_41cca131-b0f8-4d64-b9e8-f4d9b868a3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_bcc6915e-6f78-4ba6-848f-9b3b47a21dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_41cca131-b0f8-4d64-b9e8-f4d9b868a3e7" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_bcc6915e-6f78-4ba6-848f-9b3b47a21dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_98cc779b-2bc2-447f-a68c-4416d576c883" xlink:href="evh-20220630.xsd#evh_BonusesAndCommissionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_bcc6915e-6f78-4ba6-848f-9b3b47a21dd8" xlink:to="loc_evh_BonusesAndCommissionsMember_98cc779b-2bc2-447f-a68c-4416d576c883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_b9767217-dcec-48f1-ab83-8407ae2b408b" xlink:href="evh-20220630.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_bcc6915e-6f78-4ba6-848f-9b3b47a21dd8" xlink:to="loc_evh_ContractFulfillmentCostsMember_b9767217-dcec-48f1-ab83-8407ae2b408b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_2091b3e2-4aff-4d26-9967-4b96edcbd03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_1a94dd7a-242d-409e-93e2-48ed95f9bb36" xlink:to="loc_us-gaap_CapitalizedContractCostLineItems_2091b3e2-4aff-4d26-9967-4b96edcbd03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_f81fb0a4-356c-4a8a-b2f4-2acc94522b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_2091b3e2-4aff-4d26-9967-4b96edcbd03f" xlink:to="loc_us-gaap_CapitalizedContractCostNet_f81fb0a4-356c-4a8a-b2f4-2acc94522b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_adf09a5f-424c-4911-a102-5a0442e94e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_2091b3e2-4aff-4d26-9967-4b96edcbd03f" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_adf09a5f-424c-4911-a102-5a0442e94e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_470508ee-3bc4-436b-b466-a02c3a8310ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_2091b3e2-4aff-4d26-9967-4b96edcbd03f" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_470508ee-3bc4-436b-b466-a02c3a8310ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLosses" xlink:type="simple" xlink:href="evh-20220630.xsd#CreditLosses"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLosses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_380e1309-0851-4a7a-9860-1eb65aa0de57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_10d4e7d4-be05-47d3-b8d5-474c12337912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_380e1309-0851-4a7a-9860-1eb65aa0de57" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_10d4e7d4-be05-47d3-b8d5-474c12337912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="simple" xlink:href="evh-20220630.xsd#CreditLossesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_f54c2410-a31c-46a6-89f3-6b683544ec00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_407a8e2b-eb18-4114-910f-e268327750fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_f54c2410-a31c-46a6-89f3-6b683544ec00" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_407a8e2b-eb18-4114-910f-e268327750fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_20976257-84c5-437e-8da4-46f8f6d373a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_ce633310-2f6f-4200-b2d4-5ebb1276bd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_20976257-84c5-437e-8da4-46f8f6d373a2" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_ce633310-2f6f-4200-b2d4-5ebb1276bd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ce610d34-34cb-4784-916a-6173bf64e8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_ce633310-2f6f-4200-b2d4-5ebb1276bd6b" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ce610d34-34cb-4784-916a-6173bf64e8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_5fab5b6c-f48a-4187-9c5f-c98c4970388b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ce610d34-34cb-4784-916a-6173bf64e8ed" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_5fab5b6c-f48a-4187-9c5f-c98c4970388b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_a46ef42b-d312-4c7e-91b0-4554cbab7710" xlink:href="evh-20220630.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_5fab5b6c-f48a-4187-9c5f-c98c4970388b" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_a46ef42b-d312-4c7e-91b0-4554cbab7710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_411c09a8-729e-4509-b472-8eecc8626627" xlink:href="evh-20220630.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_5fab5b6c-f48a-4187-9c5f-c98c4970388b" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_411c09a8-729e-4509-b472-8eecc8626627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_ce633310-2f6f-4200-b2d4-5ebb1276bd6b" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_e1ce8ebe-18de-4457-87f7-95ea1a763d4d" xlink:href="evh-20220630.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_e1ce8ebe-18de-4457-87f7-95ea1a763d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_36a13a79-278b-4c8b-b65e-0f8553c26c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_36a13a79-278b-4c8b-b65e-0f8553c26c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_64895ece-41e2-40d5-989b-69be41d730a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:to="loc_us-gaap_AccountsReceivableNet_64895ece-41e2-40d5-989b-69be41d730a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cb2c2939-6288-4907-8ac7-3bfef87149ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6cb6362a-d9f3-4506-bfbf-47e1da2d739e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cb2c2939-6288-4907-8ac7-3bfef87149ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_0a48ca3f-a7b3-4359-95d2-3a59dfd357d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9ad40833-bf72-4e9b-a182-d838acbe5169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_0a48ca3f-a7b3-4359-95d2-3a59dfd357d0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9ad40833-bf72-4e9b-a182-d838acbe5169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a91495b5-0cbb-4db7-9a91-8517602a30a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9ad40833-bf72-4e9b-a182-d838acbe5169" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a91495b5-0cbb-4db7-9a91-8517602a30a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_0bcfa811-cf92-47a0-9086-6b615674de51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9ad40833-bf72-4e9b-a182-d838acbe5169" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_0bcfa811-cf92-47a0-9086-6b615674de51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f119a6d4-67d7-425a-9404-7607025d175d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9ad40833-bf72-4e9b-a182-d838acbe5169" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f119a6d4-67d7-425a-9404-7607025d175d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="evh-20220630.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d38215e0-84a6-475c-94ae-7eeb800f767f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_50bdb7f7-f879-446f-9128-28622f2d66bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d38215e0-84a6-475c-94ae-7eeb800f767f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_50bdb7f7-f879-446f-9128-28622f2d66bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="evh-20220630.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f7feafaf-a505-423e-a7f4-572485cc469e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d24b7b70-309f-4727-ae4d-6e84d951093a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f7feafaf-a505-423e-a7f4-572485cc469e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d24b7b70-309f-4727-ae4d-6e84d951093a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b7550cd3-745d-434c-b1b0-3418ff500c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ceb1820f-9794-4587-ae24-36f1542dde71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b7550cd3-745d-434c-b1b0-3418ff500c0a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ceb1820f-9794-4587-ae24-36f1542dde71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75d9147e-27a6-47c4-9746-284d99e2e1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ceb1820f-9794-4587-ae24-36f1542dde71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75d9147e-27a6-47c4-9746-284d99e2e1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75d9147e-27a6-47c4-9746-284d99e2e1f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_af842c15-b405-4862-bd7e-5f04b67863e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:to="loc_us-gaap_ComputerEquipmentMember_af842c15-b405-4862-bd7e-5f04b67863e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2ff3bd89-f94e-4011-9ffe-1f29ec5317d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2ff3bd89-f94e-4011-9ffe-1f29ec5317d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_c4d9e232-7d6f-427a-87e9-5229d4ed6d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_c4d9e232-7d6f-427a-87e9-5229d4ed6d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_95b78d60-56e2-49f5-bf8c-53c0cae89903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_156c6b20-4836-4a32-92c6-ff1e3090fec1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_95b78d60-56e2-49f5-bf8c-53c0cae89903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ceb1820f-9794-4587-ae24-36f1542dde71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1670e8d7-549b-486c-b10a-c32fcd176918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1670e8d7-549b-486c-b10a-c32fcd176918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_330de10e-2e29-429f-ba5b-cd444376d254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_330de10e-2e29-429f-ba5b-cd444376d254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3548c7b7-2efa-4ae8-a298-42864c3c5a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3548c7b7-2efa-4ae8-a298-42864c3c5a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_108fac4f-17be-46e6-ae86-42d38638098c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_108fac4f-17be-46e6-ae86-42d38638098c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_11109e0d-5b31-4a19-ad71-639e04a361c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_Depreciation_11109e0d-5b31-4a19-ad71-639e04a361c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_b5b119a4-fe3f-4dd9-9357-3d81b55d4d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_203dadcd-ea7a-4f50-b88a-c41c1eb62745" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_b5b119a4-fe3f-4dd9-9357-3d81b55d4d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="evh-20220630.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c8745d91-ae81-4632-ae66-19e8d79a7ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5e549be0-80c7-4516-825f-85fad2102ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c8745d91-ae81-4632-ae66-19e8d79a7ece" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5e549be0-80c7-4516-825f-85fad2102ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="evh-20220630.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fdf6db5e-0a02-438b-b36a-a3910898539d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_a6dd7e16-bbe4-4eee-a387-eff80bce25d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fdf6db5e-0a02-438b-b36a-a3910898539d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_a6dd7e16-bbe4-4eee-a387-eff80bce25d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0bf3d5c6-c457-4bd7-ba3a-7f10864c37af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fdf6db5e-0a02-438b-b36a-a3910898539d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0bf3d5c6-c457-4bd7-ba3a-7f10864c37af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c3a6fc0f-42d9-42be-8976-b12fd6c809fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fdf6db5e-0a02-438b-b36a-a3910898539d" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c3a6fc0f-42d9-42be-8976-b12fd6c809fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#GoodwillandIntangibleAssetsNetImpairmentTestingDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97418b16-14cd-472c-8f17-763b726d5271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_656502eb-57c3-43f6-885a-27d6a261bf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97418b16-14cd-472c-8f17-763b726d5271" xlink:to="loc_us-gaap_NumberOfReportingUnits_656502eb-57c3-43f6-885a-27d6a261bf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aa4cd4e1-3117-40fa-8e4b-7c1eca275215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_8ecc084c-ba9e-4ae3-a3e3-c89a33bf7ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aa4cd4e1-3117-40fa-8e4b-7c1eca275215" xlink:to="loc_us-gaap_NumberOfReportingUnits_8ecc084c-ba9e-4ae3-a3e3-c89a33bf7ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_f580fded-8b2c-4894-904d-9448c6229c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aa4cd4e1-3117-40fa-8e4b-7c1eca275215" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_f580fded-8b2c-4894-904d-9448c6229c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e0616a44-d6c5-443a-85d1-b6fb2041cf03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_f580fded-8b2c-4894-904d-9448c6229c5c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e0616a44-d6c5-443a-85d1-b6fb2041cf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ed13ae38-3075-4793-ae87-c58f581c87b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e0616a44-d6c5-443a-85d1-b6fb2041cf03" xlink:to="loc_us-gaap_SegmentDomain_ed13ae38-3075-4793-ae87-c58f581c87b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_bd410f16-d936-4121-a21e-ec55d42a8f54" xlink:href="evh-20220630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ed13ae38-3075-4793-ae87-c58f581c87b1" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_bd410f16-d936-4121-a21e-ec55d42a8f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_b5d17c18-cbca-4341-911c-3d556ea03b8e" xlink:href="evh-20220630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ed13ae38-3075-4793-ae87-c58f581c87b1" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_b5d17c18-cbca-4341-911c-3d556ea03b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_257a6ec1-7fe8-40d8-9431-d5e7668da0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_f580fded-8b2c-4894-904d-9448c6229c5c" xlink:to="loc_us-gaap_GoodwillLineItems_257a6ec1-7fe8-40d8-9431-d5e7668da0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_99bd2c81-6dae-4afc-809c-d8e7e149a601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_257a6ec1-7fe8-40d8-9431-d5e7668da0c9" xlink:to="loc_us-gaap_GoodwillRollForward_99bd2c81-6dae-4afc-809c-d8e7e149a601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0d769519-7160-4789-967d-bf192e165505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_99bd2c81-6dae-4afc-809c-d8e7e149a601" xlink:to="loc_us-gaap_Goodwill_0d769519-7160-4789-967d-bf192e165505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_2af196cd-2796-48a0-82aa-0e2135d0b3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_99bd2c81-6dae-4afc-809c-d8e7e149a601" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_2af196cd-2796-48a0-82aa-0e2135d0b3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_89f9cbf3-0775-4a47-a669-c576be5ecf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_99bd2c81-6dae-4afc-809c-d8e7e149a601" xlink:to="loc_us-gaap_Goodwill_89f9cbf3-0775-4a47-a669-c576be5ecf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f813259-2a21-4d58-8fb1-6be716a01aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_257a6ec1-7fe8-40d8-9431-d5e7668da0c9" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f813259-2a21-4d58-8fb1-6be716a01aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_02a22ad0-150e-418c-a9de-4aa7a8513c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5ba0d613-3626-4d6e-9cf7-07492f17a1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_02a22ad0-150e-418c-a9de-4aa7a8513c85" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5ba0d613-3626-4d6e-9cf7-07492f17a1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0007f5d-bb3b-4b62-9232-def087032383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5ba0d613-3626-4d6e-9cf7-07492f17a1bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0007f5d-bb3b-4b62-9232-def087032383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0007f5d-bb3b-4b62-9232-def087032383" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_8fe2fbde-b3f3-4633-ab58-0f4dee5a15f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:to="loc_us-gaap_TradeNamesMember_8fe2fbde-b3f3-4633-ab58-0f4dee5a15f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_fc23bca9-e2e9-4e39-a655-1a1f50e1fb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:to="loc_us-gaap_CustomerRelationshipsMember_fc23bca9-e2e9-4e39-a655-1a1f50e1fb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2b556e62-ba74-4697-bfb7-3a981fcf3170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2b556e62-ba74-4697-bfb7-3a981fcf3170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_7c79458e-9536-4dfd-ba3d-2e18abb40549" xlink:href="evh-20220630.xsd#evh_BelowMarketLeasesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:to="loc_evh_BelowMarketLeasesMember_7c79458e-9536-4dfd-ba3d-2e18abb40549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_dca76164-d26f-45e2-bb5f-1206474a56cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77c56f5b-1894-471e-b97f-59475cf7b035" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_dca76164-d26f-45e2-bb5f-1206474a56cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5ba0d613-3626-4d6e-9cf7-07492f17a1bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_7d04e6b5-8935-4e32-9742-b962c690d829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_7d04e6b5-8935-4e32-9742-b962c690d829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_456dbaab-e516-468a-b2d7-aa833a6b23a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_456dbaab-e516-468a-b2d7-aa833a6b23a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6e8aefa6-f41c-4c32-91c3-d992e6cd4dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6e8aefa6-f41c-4c32-91c3-d992e6cd4dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_327cdf04-0900-46ed-bd06-936b649572c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_327cdf04-0900-46ed-bd06-936b649572c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_13328861-9471-4ff7-b8f2-b2a751f816cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d87d5370-d688-4ae7-b887-ebf178b76ccc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_13328861-9471-4ff7-b8f2-b2a751f816cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05e6dec6-0344-436a-b3e2-0432cba3a9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b1c4af78-424b-4950-ab3d-1e6c4a8352be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05e6dec6-0344-436a-b3e2-0432cba3a9ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b1c4af78-424b-4950-ab3d-1e6c4a8352be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d70e93fe-79db-42d7-b26e-9affaca7cdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05e6dec6-0344-436a-b3e2-0432cba3a9ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d70e93fe-79db-42d7-b26e-9affaca7cdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a75d3fcf-5111-4cb5-8058-c952198d17c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05e6dec6-0344-436a-b3e2-0432cba3a9ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a75d3fcf-5111-4cb5-8058-c952198d17c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_59fa0e02-a3aa-4e32-81e9-d449e7e7f946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05e6dec6-0344-436a-b3e2-0432cba3a9ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_59fa0e02-a3aa-4e32-81e9-d449e7e7f946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_664ef6d2-28aa-4617-9fa7-89a29e6d676c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05e6dec6-0344-436a-b3e2-0432cba3a9ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_664ef6d2-28aa-4617-9fa7-89a29e6d676c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_6afd5d95-7cd8-4682-9cca-1f18101d456d" xlink:href="evh-20220630.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05e6dec6-0344-436a-b3e2-0432cba3a9ef" xlink:to="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_6afd5d95-7cd8-4682-9cca-1f18101d456d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b4102f70-c6aa-47f4-9a98-43349853a210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05e6dec6-0344-436a-b3e2-0432cba3a9ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b4102f70-c6aa-47f4-9a98-43349853a210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1f1a6883-5610-46b5-88da-94e7a51c67fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_cda8b82d-c3ac-47a1-b2bd-dccbec269b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1f1a6883-5610-46b5-88da-94e7a51c67fe" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_cda8b82d-c3ac-47a1-b2bd-dccbec269b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_887b94c8-bd69-4cb9-a2c2-c606a865f695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_4599761b-7479-4d51-b855-fe31f6168aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_887b94c8-bd69-4cb9-a2c2-c606a865f695" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_4599761b-7479-4d51-b855-fe31f6168aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebt2024NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e89183c3-0273-4d35-9a59-bb5bd6ed9646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e89183c3-0273-4d35-9a59-bb5bd6ed9646" xlink:to="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2dfedd90-f0f4-48a4-b416-588c66afa779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_DebtInstrumentAxis_2dfedd90-f0f4-48a4-b416-588c66afa779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2ba768ff-365d-4dca-9e75-8ee363168de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2dfedd90-f0f4-48a4-b416-588c66afa779" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2ba768ff-365d-4dca-9e75-8ee363168de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_0c1997a2-6b58-41d2-a9f2-6ac4e71ab69b" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ba768ff-365d-4dca-9e75-8ee363168de6" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_0c1997a2-6b58-41d2-a9f2-6ac4e71ab69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_8afc4750-8662-456c-be27-f59dc6ea0b17" xlink:href="evh-20220630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ba768ff-365d-4dca-9e75-8ee363168de6" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_8afc4750-8662-456c-be27-f59dc6ea0b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_9e0666fd-0471-4a33-9abe-d4871dbc5a3a" xlink:href="evh-20220630.xsd#evh_NewNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ba768ff-365d-4dca-9e75-8ee363168de6" xlink:to="loc_evh_NewNotesMember_9e0666fd-0471-4a33-9abe-d4871dbc5a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_892d823f-93b3-4e26-bd1f-b625412c293e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_892d823f-93b3-4e26-bd1f-b625412c293e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_67e474be-ee11-45ad-8dbc-726d2710325a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_892d823f-93b3-4e26-bd1f-b625412c293e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_67e474be-ee11-45ad-8dbc-726d2710325a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1f042ddb-5589-467d-a7af-3c651fc701b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_67e474be-ee11-45ad-8dbc-726d2710325a" xlink:to="loc_us-gaap_SeniorNotesMember_1f042ddb-5589-467d-a7af-3c651fc701b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d92e6375-0041-4f5c-b325-b7a9fe1f70f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d92e6375-0041-4f5c-b325-b7a9fe1f70f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c42c1fc4-52b5-4065-8840-29bac64e1e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d92e6375-0041-4f5c-b325-b7a9fe1f70f8" xlink:to="loc_us-gaap_EquityComponentDomain_c42c1fc4-52b5-4065-8840-29bac64e1e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_25d95d14-17c8-43a2-a6ff-72425cd8cb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c42c1fc4-52b5-4065-8840-29bac64e1e5f" xlink:to="loc_us-gaap_CommonStockMember_25d95d14-17c8-43a2-a6ff-72425cd8cb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_030dfe0e-f2ba-4f3c-9c13-2bcbde0bc168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c42c1fc4-52b5-4065-8840-29bac64e1e5f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_030dfe0e-f2ba-4f3c-9c13-2bcbde0bc168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_02c5ae87-1199-4a24-9791-0239f5cc61d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c42c1fc4-52b5-4065-8840-29bac64e1e5f" xlink:to="loc_us-gaap_RetainedEarningsMember_02c5ae87-1199-4a24-9791-0239f5cc61d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a25e2f2c-abfa-4e98-aa8f-9b3fc7facaff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a25e2f2c-abfa-4e98-aa8f-9b3fc7facaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1f31d6de-7774-4242-b066-cb5a5b4a066b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a25e2f2c-abfa-4e98-aa8f-9b3fc7facaff" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1f31d6de-7774-4242-b066-cb5a5b4a066b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2e67aa76-968a-4079-baae-e0a8e0318c91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1f31d6de-7774-4242-b066-cb5a5b4a066b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2e67aa76-968a-4079-baae-e0a8e0318c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5535b645-0343-4b61-88a3-704c601641b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5535b645-0343-4b61-88a3-704c601641b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d61870ba-cbf9-4ddb-8bb8-b80094d4bcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5535b645-0343-4b61-88a3-704c601641b1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d61870ba-cbf9-4ddb-8bb8-b80094d4bcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_004b9599-c879-4bfe-afaf-66f64b78a954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d61870ba-cbf9-4ddb-8bb8-b80094d4bcf7" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_004b9599-c879-4bfe-afaf-66f64b78a954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7a0dbc22-a45e-42cd-90a4-78ff36d7cc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7a0dbc22-a45e-42cd-90a4-78ff36d7cc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_55946b2b-ab21-4002-b29c-81c54b0a912a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a0dbc22-a45e-42cd-90a4-78ff36d7cc07" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_55946b2b-ab21-4002-b29c-81c54b0a912a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_b2de4d71-7ac1-4153-972b-8a8a4594756f" xlink:href="evh-20220630.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_55946b2b-ab21-4002-b29c-81c54b0a912a" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_b2de4d71-7ac1-4153-972b-8a8a4594756f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_9a7e5453-76a2-4fd4-9c1e-95c3062c1f1a" xlink:href="evh-20220630.xsd#evh_DeferredFinancingFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_55946b2b-ab21-4002-b29c-81c54b0a912a" xlink:to="loc_evh_DeferredFinancingFeesMember_9a7e5453-76a2-4fd4-9c1e-95c3062c1f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3afb2679-a1c4-4e4e-b846-c1a51f7326ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3afb2679-a1c4-4e4e-b846-c1a51f7326ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e0f97df9-2df4-46d3-a198-60e1aa789fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3afb2679-a1c4-4e4e-b846-c1a51f7326ee" xlink:to="loc_us-gaap_ClassOfStockDomain_e0f97df9-2df4-46d3-a198-60e1aa789fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d06ffd0e-ae4b-446d-b638-69341f32b593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e0f97df9-2df4-46d3-a198-60e1aa789fc8" xlink:to="loc_us-gaap_CommonClassAMember_d06ffd0e-ae4b-446d-b638-69341f32b593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1bd6efb-8378-4e5a-aa56-bde81f17bf49" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2d36c600-4d60-448d-98b9-0e8ede9b36fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2d36c600-4d60-448d-98b9-0e8ede9b36fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ba87b5d-90f1-483a-a236-d352b611e9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ba87b5d-90f1-483a-a236-d352b611e9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0b52a4c9-e624-43b0-a2d9-36d869c7eb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0b52a4c9-e624-43b0-a2d9-36d869c7eb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_82246f52-89a0-4897-9f68-d6e79365cb02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_82246f52-89a0-4897-9f68-d6e79365cb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2a041bd4-2393-419c-93b7-c8d217d2e844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2a041bd4-2393-419c-93b7-c8d217d2e844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_91bbb9f8-e470-4ffc-a2a2-0d3ea943548c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_91bbb9f8-e470-4ffc-a2a2-0d3ea943548c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_37f8834d-94b6-4b3a-9873-eed6e6a955b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_InterestExpenseDebt_37f8834d-94b6-4b3a-9873-eed6e6a955b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ea389c9f-7be9-48a8-8643-69a5689e76da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ea389c9f-7be9-48a8-8643-69a5689e76da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c84599cc-d507-4ae4-b8fb-18b051f0ac41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c84599cc-d507-4ae4-b8fb-18b051f0ac41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_992a593e-4448-45c5-96ac-fb3ced54b6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_992a593e-4448-45c5-96ac-fb3ced54b6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_915fb932-b69f-45d7-9ebc-344a92e173d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_LongTermDebt_915fb932-b69f-45d7-9ebc-344a92e173d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_879ed211-d51a-4e76-8450-3fad4a942d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_879ed211-d51a-4e76-8450-3fad4a942d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_72df3d50-61e1-4ea2-9705-4940675c9cbd" xlink:href="evh-20220630.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_72df3d50-61e1-4ea2-9705-4940675c9cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d3f9a983-aaed-4d66-a0ac-0c24bcbcd68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_StockholdersEquity_d3f9a983-aaed-4d66-a0ac-0c24bcbcd68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f2150643-18d9-4ab5-aeab-b5bb46d2f2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f2150643-18d9-4ab5-aeab-b5bb46d2f2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_a6a01ae9-afdb-491a-87c0-27c3335f93ec" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_a6a01ae9-afdb-491a-87c0-27c3335f93ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_ec11a302-3db6-4b9d-974d-b730b63e95b0" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_ec11a302-3db6-4b9d-974d-b730b63e95b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_307c2f1b-4512-43da-a833-59c98beedffa" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_307c2f1b-4512-43da-a833-59c98beedffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_b1ac7035-c3be-4bd5-a064-20ba47a7f667" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_b1ac7035-c3be-4bd5-a064-20ba47a7f667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_8af633e9-9645-4ae0-a3c6-633738b3a431" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2fec3d3b-933c-4588-b61f-2da53b7a4429" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_8af633e9-9645-4ae0-a3c6-633738b3a431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebtCreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9120c3ef-e4ae-4f3d-909e-92cbfe850504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_26895d10-9775-41da-a2a8-7d00148a83c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9120c3ef-e4ae-4f3d-909e-92cbfe850504" xlink:to="loc_us-gaap_DebtInstrumentTable_26895d10-9775-41da-a2a8-7d00148a83c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4f466d2a-468e-4724-82ac-6ea57de1051a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_26895d10-9775-41da-a2a8-7d00148a83c5" xlink:to="loc_us-gaap_DebtInstrumentAxis_4f466d2a-468e-4724-82ac-6ea57de1051a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0d2ac4a0-deb5-44d1-ba54-461329ef49b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4f466d2a-468e-4724-82ac-6ea57de1051a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0d2ac4a0-deb5-44d1-ba54-461329ef49b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_b955a39e-ae1d-46db-b769-1aa970901728" xlink:href="evh-20220630.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0d2ac4a0-deb5-44d1-ba54-461329ef49b5" xlink:to="loc_evh_InitialTermLoanFacilityMember_b955a39e-ae1d-46db-b769-1aa970901728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_f8fc8f15-1edf-4e6e-9c0d-02e01d0102fd" xlink:href="evh-20220630.xsd#evh_CreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0d2ac4a0-deb5-44d1-ba54-461329ef49b5" xlink:to="loc_evh_CreditAgreementMember_f8fc8f15-1edf-4e6e-9c0d-02e01d0102fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_09e5f0a0-07e6-46de-976f-b2165ba40e46" xlink:href="evh-20220630.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0d2ac4a0-deb5-44d1-ba54-461329ef49b5" xlink:to="loc_evh_SeniorCreditFacilitiesMember_09e5f0a0-07e6-46de-976f-b2165ba40e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0842c19b-497f-4cd6-a651-ed7e25e29a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_26895d10-9775-41da-a2a8-7d00148a83c5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0842c19b-497f-4cd6-a651-ed7e25e29a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_71e3a41b-7319-402f-b5b3-5b7f3901289f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0842c19b-497f-4cd6-a651-ed7e25e29a79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_71e3a41b-7319-402f-b5b3-5b7f3901289f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_689dbdd8-38da-46f1-87e0-0bff72361c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_71e3a41b-7319-402f-b5b3-5b7f3901289f" xlink:to="loc_us-gaap_SecuredDebtMember_689dbdd8-38da-46f1-87e0-0bff72361c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_13c85375-9f94-4fe3-b8c6-12183162ff66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_71e3a41b-7319-402f-b5b3-5b7f3901289f" xlink:to="loc_us-gaap_LineOfCreditMember_13c85375-9f94-4fe3-b8c6-12183162ff66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2a710df4-bf93-4289-b86c-fee6585d2801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_26895d10-9775-41da-a2a8-7d00148a83c5" xlink:to="loc_us-gaap_CreditFacilityAxis_2a710df4-bf93-4289-b86c-fee6585d2801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8a0ad599-fec1-4e59-b94a-da969a981ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2a710df4-bf93-4289-b86c-fee6585d2801" xlink:to="loc_us-gaap_CreditFacilityDomain_8a0ad599-fec1-4e59-b94a-da969a981ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_9f88dd01-74c9-4574-81f9-5d12cab6ddfe" xlink:href="evh-20220630.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8a0ad599-fec1-4e59-b94a-da969a981ee4" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_9f88dd01-74c9-4574-81f9-5d12cab6ddfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_26895d10-9775-41da-a2a8-7d00148a83c5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1d8cd5be-e527-4100-8c37-c96e0735146f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1d8cd5be-e527-4100-8c37-c96e0735146f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d2acc428-c69a-49b4-baf3-a4edef466c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d2acc428-c69a-49b4-baf3-a4edef466c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_95854b2b-6efb-4fea-9b10-54082bbe5ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_95854b2b-6efb-4fea-9b10-54082bbe5ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_514e5029-3e02-4935-9de4-0c68137b4d91" xlink:href="evh-20220630.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_evh_PaymentsOfMakeWholePremium_514e5029-3e02-4935-9de4-0c68137b4d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3787a967-9573-45dc-bbfa-6e38c75dbd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_InterestPaidNet_3787a967-9573-45dc-bbfa-6e38c75dbd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_44c33b0e-554b-4caa-9b46-cd8c6e2c4448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_44c33b0e-554b-4caa-9b46-cd8c6e2c4448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_982faa23-d487-4e80-8bef-41656b08a8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_982faa23-d487-4e80-8bef-41656b08a8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_28349e92-4f9b-4a8b-8313-21c4fa16f386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace58ac6-4e34-4980-a263-39f1b8f68130" xlink:to="loc_us-gaap_LegalFees_28349e92-4f9b-4a8b-8313-21c4fa16f386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4ed15018-9340-4043-b66a-178bfbf97ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_c7192734-ea3b-4778-afce-8a47ebff46a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4ed15018-9340-4043-b66a-178bfbf97ce1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_c7192734-ea3b-4778-afce-8a47ebff46a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_af76b6b4-84f9-4716-b368-2ddcf272a354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_c7192734-ea3b-4778-afce-8a47ebff46a3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_af76b6b4-84f9-4716-b368-2ddcf272a354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a77cbc3e-ac8c-442e-b344-2f4540bac03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_af76b6b4-84f9-4716-b368-2ddcf272a354" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a77cbc3e-ac8c-442e-b344-2f4540bac03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c4d1fcd1-0a67-42a2-ac9e-b267737f487b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a77cbc3e-ac8c-442e-b344-2f4540bac03f" xlink:to="loc_us-gaap_CommonClassAMember_c4d1fcd1-0a67-42a2-ac9e-b267737f487b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_c7192734-ea3b-4778-afce-8a47ebff46a3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_291f8756-b9b6-418a-aabc-0d02ce5246da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_291f8756-b9b6-418a-aabc-0d02ce5246da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ff13b387-6e62-44a8-9533-ac83976647c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ff13b387-6e62-44a8-9533-ac83976647c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_fd37fdae-ce4c-46b2-a90f-e33a2f2a3fbe" xlink:href="evh-20220630.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_fd37fdae-ce4c-46b2-a90f-e33a2f2a3fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_0c8c5a08-4062-4ab7-b239-94f454b223b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be086207-4163-44bc-8801-e5cd626552a0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_0c8c5a08-4062-4ab7-b239-94f454b223b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebt2025NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_afe334f3-5c8c-4f46-a628-b2606b1992db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_afe334f3-5c8c-4f46-a628-b2606b1992db" xlink:to="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_85e24a8d-3c10-4c7f-9bed-1931b41aa8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_85e24a8d-3c10-4c7f-9bed-1931b41aa8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_058aade8-72a4-459d-868b-ba5fdc0ed737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85e24a8d-3c10-4c7f-9bed-1931b41aa8f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_058aade8-72a4-459d-868b-ba5fdc0ed737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_497d0fe2-f2c4-4fdd-9c08-1e59da91cf09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_058aade8-72a4-459d-868b-ba5fdc0ed737" xlink:to="loc_us-gaap_SeniorNotesMember_497d0fe2-f2c4-4fdd-9c08-1e59da91cf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39a22598-41b8-4377-a361-b145d3822e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_DebtInstrumentAxis_39a22598-41b8-4377-a361-b145d3822e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_06b1c280-0d7e-41a6-bb1b-ab111ce81491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_39a22598-41b8-4377-a361-b145d3822e60" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_06b1c280-0d7e-41a6-bb1b-ab111ce81491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_2db2d3f8-00d2-45a1-8e2b-2fbfe951d464" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06b1c280-0d7e-41a6-bb1b-ab111ce81491" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_2db2d3f8-00d2-45a1-8e2b-2fbfe951d464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_840089b0-057f-403e-9e81-d12f07d551a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_840089b0-057f-403e-9e81-d12f07d551a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b0dee3e-b910-475a-8902-206926c8f0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_840089b0-057f-403e-9e81-d12f07d551a6" xlink:to="loc_us-gaap_EquityComponentDomain_6b0dee3e-b910-475a-8902-206926c8f0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3703b9e8-64e9-4fdb-a8f3-f84df14c793b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b0dee3e-b910-475a-8902-206926c8f0b2" xlink:to="loc_us-gaap_CommonStockMember_3703b9e8-64e9-4fdb-a8f3-f84df14c793b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_015bbe75-65ed-47b1-98fc-84ed9353ca30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b0dee3e-b910-475a-8902-206926c8f0b2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_015bbe75-65ed-47b1-98fc-84ed9353ca30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3ea08394-913b-413a-8ca0-9aa714c2111e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b0dee3e-b910-475a-8902-206926c8f0b2" xlink:to="loc_us-gaap_RetainedEarningsMember_3ea08394-913b-413a-8ca0-9aa714c2111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d9774df7-ff0e-4db0-bdd3-0926998b7491" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d9774df7-ff0e-4db0-bdd3-0926998b7491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d5a82e1-ea24-4f3b-a6e6-f0f63769e12e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d9774df7-ff0e-4db0-bdd3-0926998b7491" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d5a82e1-ea24-4f3b-a6e6-f0f63769e12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b44d5f7c-0c30-4266-97b1-b74ac58d9752" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d5a82e1-ea24-4f3b-a6e6-f0f63769e12e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b44d5f7c-0c30-4266-97b1-b74ac58d9752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a7edcb66-519d-4c3d-b486-9f4071e8a874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a7edcb66-519d-4c3d-b486-9f4071e8a874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a6939c28-af5a-4d7a-82ce-7ba4344e23c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a7edcb66-519d-4c3d-b486-9f4071e8a874" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a6939c28-af5a-4d7a-82ce-7ba4344e23c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_bd1d3838-2518-4df9-97a3-861d0a694fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a6939c28-af5a-4d7a-82ce-7ba4344e23c9" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_bd1d3838-2518-4df9-97a3-861d0a694fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_16d9e0b0-01a6-4305-91a5-9cb582f8ab21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_16d9e0b0-01a6-4305-91a5-9cb582f8ab21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2ab16b92-eddb-4a79-885f-a70d436c4a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_16d9e0b0-01a6-4305-91a5-9cb582f8ab21" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2ab16b92-eddb-4a79-885f-a70d436c4a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_729eec61-42f7-4342-a4fd-3b2f3395ebb2" xlink:href="evh-20220630.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2ab16b92-eddb-4a79-885f-a70d436c4a6f" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_729eec61-42f7-4342-a4fd-3b2f3395ebb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_d74c268e-826f-4644-92ae-9582f1d89d67" xlink:href="evh-20220630.xsd#evh_DeferredFinancingFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2ab16b92-eddb-4a79-885f-a70d436c4a6f" xlink:to="loc_evh_DeferredFinancingFeesMember_d74c268e-826f-4644-92ae-9582f1d89d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dd653d3e-cb5f-4bac-8a7c-1235bad36e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dd653d3e-cb5f-4bac-8a7c-1235bad36e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2dc3d7ab-caa7-4385-8403-6d3b899de712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dd653d3e-cb5f-4bac-8a7c-1235bad36e58" xlink:to="loc_us-gaap_ClassOfStockDomain_2dc3d7ab-caa7-4385-8403-6d3b899de712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_dc50760c-0c49-40a0-8529-c3b65dc43829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2dc3d7ab-caa7-4385-8403-6d3b899de712" xlink:to="loc_us-gaap_CommonClassAMember_dc50760c-0c49-40a0-8529-c3b65dc43829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf724301-f96b-4a2a-af0a-d6b6bde618fa" xlink:to="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7d925942-bdf6-445e-a141-0aca6d6f80d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7d925942-bdf6-445e-a141-0aca6d6f80d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62e6a30e-cd6e-4220-a2e7-f28fb5f165b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62e6a30e-cd6e-4220-a2e7-f28fb5f165b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f996a4a5-3360-4c22-a6c2-af61e685d9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_InterestExpenseDebt_f996a4a5-3360-4c22-a6c2-af61e685d9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d2e79c28-a1bc-482e-a976-61465d2b245c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d2e79c28-a1bc-482e-a976-61465d2b245c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_2b2ab767-feb2-43e1-af09-a116c483b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_2b2ab767-feb2-43e1-af09-a116c483b7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_f1bdc093-98e2-45a7-8dc8-b47ae3e7982e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_f1bdc093-98e2-45a7-8dc8-b47ae3e7982e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9d6d2ce3-793a-49c9-9c81-fc409fe9a9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_LongTermDebt_9d6d2ce3-793a-49c9-9c81-fc409fe9a9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_b7260be3-a617-4853-894a-7754d2c967a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_b7260be3-a617-4853-894a-7754d2c967a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c3546f48-9d25-4147-b9be-1a14dce4682b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c3546f48-9d25-4147-b9be-1a14dce4682b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ad93dcd-756f-44de-ad3e-2fbd95cdae32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_StockholdersEquity_5ad93dcd-756f-44de-ad3e-2fbd95cdae32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_e498f895-7fad-410e-bacc-47ebc31dd243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_e498f895-7fad-410e-bacc-47ebc31dd243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_57896716-d350-4a20-8024-2fd039b230bd" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_57896716-d350-4a20-8024-2fd039b230bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_89c9cb7b-3648-42df-add7-e644d4701fa9" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_89c9cb7b-3648-42df-add7-e644d4701fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_2b13cea6-6783-4e9b-b662-3badff29e8fe" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_2b13cea6-6783-4e9b-b662-3badff29e8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_0c7e1c8b-a59f-4797-a51b-542638de6033" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_0c7e1c8b-a59f-4797-a51b-542638de6033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_8bfdf9f5-8c1e-4df3-8fc8-6fc9f0a96294" xlink:href="evh-20220630.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_074e2d4c-8c1a-4c07-97b2-aafce587bf5e" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_8bfdf9f5-8c1e-4df3-8fc8-6fc9f0a96294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebt2021NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5ddc473f-be15-4b7b-b130-61d5d4e79791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5bd28017-e949-4db4-930f-fe668a4d532e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5ddc473f-be15-4b7b-b130-61d5d4e79791" xlink:to="loc_us-gaap_DebtInstrumentTable_5bd28017-e949-4db4-930f-fe668a4d532e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bd4afbf1-106f-45a1-99db-9901fb0ac4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5bd28017-e949-4db4-930f-fe668a4d532e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bd4afbf1-106f-45a1-99db-9901fb0ac4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ccf76324-57b2-4d76-9011-9fac51e847c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd4afbf1-106f-45a1-99db-9901fb0ac4e5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ccf76324-57b2-4d76-9011-9fac51e847c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_29a2afed-b4ea-4be6-803e-5d446e796dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ccf76324-57b2-4d76-9011-9fac51e847c7" xlink:to="loc_us-gaap_SeniorNotesMember_29a2afed-b4ea-4be6-803e-5d446e796dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e4564d3d-4763-46ab-81ec-ea630d3e83f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5bd28017-e949-4db4-930f-fe668a4d532e" xlink:to="loc_us-gaap_DebtInstrumentAxis_e4564d3d-4763-46ab-81ec-ea630d3e83f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d804968-5389-40d5-9cff-0f4f9721818e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e4564d3d-4763-46ab-81ec-ea630d3e83f3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d804968-5389-40d5-9cff-0f4f9721818e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_a589e778-41e4-4716-822b-44d05215473b" xlink:href="evh-20220630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d804968-5389-40d5-9cff-0f4f9721818e" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_a589e778-41e4-4716-822b-44d05215473b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_1416ef16-9d88-4138-8a21-98f23bdae67a" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d804968-5389-40d5-9cff-0f4f9721818e" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_1416ef16-9d88-4138-8a21-98f23bdae67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5bd28017-e949-4db4-930f-fe668a4d532e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0a2d8239-259f-4e11-9af0-4c3958a96f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0a2d8239-259f-4e11-9af0-4c3958a96f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c25a2587-5fa7-4a40-b8f6-4038fdab08c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c25a2587-5fa7-4a40-b8f6-4038fdab08c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_88797f55-ec1a-44c0-aebf-26b817a5e9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_88797f55-ec1a-44c0-aebf-26b817a5e9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_77dad62b-dab2-4024-b93b-f19c3f4fa854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_77dad62b-dab2-4024-b93b-f19c3f4fa854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_02df9cdc-3218-4588-ba61-97890acbaebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_02df9cdc-3218-4588-ba61-97890acbaebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_17af69be-3b81-4690-b07f-731e64486ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_17af69be-3b81-4690-b07f-731e64486ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8609feea-c904-4230-a98d-de136f8c593d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8609feea-c904-4230-a98d-de136f8c593d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_d8a2e5d8-0e0a-44dd-88a0-e4d89fee0507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_d8a2e5d8-0e0a-44dd-88a0-e4d89fee0507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_1d04e40a-64a2-43b0-b148-43f5daa82fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_1d04e40a-64a2-43b0-b148-43f5daa82fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_31e25438-645e-4591-a962-c309f208c517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_31e25438-645e-4591-a962-c309f208c517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtConversionOriginalDebtFairValue_933c9b59-4919-47f5-bec8-41fc2e018cdb" xlink:href="evh-20220630.xsd#evh_DebtConversionOriginalDebtFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_79b019ba-bc55-4c4a-8988-5c0e9c5de06a" xlink:to="loc_evh_DebtConversionOriginalDebtFairValue_933c9b59-4919-47f5-bec8-41fc2e018cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fcfe3fad-a504-4bae-823b-57ca272ac315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c2756323-15e2-4b71-961e-4905c4737d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fcfe3fad-a504-4bae-823b-57ca272ac315" xlink:to="loc_us-gaap_DebtInstrumentTable_c2756323-15e2-4b71-961e-4905c4737d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e71d5cc9-140f-405e-9bcf-a8b1ca0c6f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2756323-15e2-4b71-961e-4905c4737d72" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e71d5cc9-140f-405e-9bcf-a8b1ca0c6f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3bec7c22-af94-4bb0-ab12-f26e4aa3bfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e71d5cc9-140f-405e-9bcf-a8b1ca0c6f77" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3bec7c22-af94-4bb0-ab12-f26e4aa3bfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5cda04b2-3528-43a5-92fc-c02e785e584e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3bec7c22-af94-4bb0-ab12-f26e4aa3bfe1" xlink:to="loc_us-gaap_SeniorNotesMember_5cda04b2-3528-43a5-92fc-c02e785e584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1972007e-0acf-42ea-b73c-9144c2fa093b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2756323-15e2-4b71-961e-4905c4737d72" xlink:to="loc_us-gaap_DebtInstrumentAxis_1972007e-0acf-42ea-b73c-9144c2fa093b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e5762dce-c101-4204-9536-cb6cf469a6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1972007e-0acf-42ea-b73c-9144c2fa093b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e5762dce-c101-4204-9536-cb6cf469a6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_2c4cc51d-b653-40d9-a371-d0fff29500d2" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5762dce-c101-4204-9536-cb6cf469a6c2" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_2c4cc51d-b653-40d9-a371-d0fff29500d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_cc3f5754-840c-464b-8283-f6b4a9bc1468" xlink:href="evh-20220630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5762dce-c101-4204-9536-cb6cf469a6c2" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_cc3f5754-840c-464b-8283-f6b4a9bc1468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2de854cb-50e6-40d8-94a1-116dc4cbe23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2756323-15e2-4b71-961e-4905c4737d72" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2de854cb-50e6-40d8-94a1-116dc4cbe23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a25556f0-b6ef-4bde-bc8a-9ed669be8963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2de854cb-50e6-40d8-94a1-116dc4cbe23a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a25556f0-b6ef-4bde-bc8a-9ed669be8963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e866ff22-4b63-456e-a139-5c05f85c569d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a25556f0-b6ef-4bde-bc8a-9ed669be8963" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e866ff22-4b63-456e-a139-5c05f85c569d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2756323-15e2-4b71-961e-4905c4737d72" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_67d01e9a-6cbf-48b5-abf1-6ceaea971b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:to="loc_us-gaap_ConvertibleDebt_67d01e9a-6cbf-48b5-abf1-6ceaea971b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f7c02ff5-49ad-45e0-92c8-44743fdcbd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f7c02ff5-49ad-45e0-92c8-44743fdcbd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4a57241f-8a99-418b-a758-d7d5f2d5e747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4a57241f-8a99-418b-a758-d7d5f2d5e747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_19ac86ab-c8f1-40b7-bbe3-7f368ac3edbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_19ac86ab-c8f1-40b7-bbe3-7f368ac3edbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_a9ded386-8b3f-4614-9775-429b60264b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3069731b-cf0c-42a9-ab8b-c12ac99ab3a9" xlink:to="loc_us-gaap_LongTermDebtFairValue_a9ded386-8b3f-4614-9775-429b60264b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="evh-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c06b0964-0a27-4b79-a516-3b4c963898dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_20e53f6c-c9b3-46de-ba68-a43479d7c447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c06b0964-0a27-4b79-a516-3b4c963898dd" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_20e53f6c-c9b3-46de-ba68-a43479d7c447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="evh-20220630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65120b05-5357-4e62-bfc5-30a425db0311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_4f386406-1d41-436f-a168-467e9364c6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65120b05-5357-4e62-bfc5-30a425db0311" xlink:to="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_4f386406-1d41-436f-a168-467e9364c6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c624adea-ed9c-4102-9acd-480ccc70b864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65120b05-5357-4e62-bfc5-30a425db0311" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c624adea-ed9c-4102-9acd-480ccc70b864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_82a6f141-2fd5-41e0-a369-d0e77a2ff58a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_82a6f141-2fd5-41e0-a369-d0e77a2ff58a" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f2f68ac3-fdb4-4ee1-b51c-6db447e6f08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:to="loc_us-gaap_CreditFacilityAxis_f2f68ac3-fdb4-4ee1-b51c-6db447e6f08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d8b93480-2633-4edc-8b50-ad30f41f8f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f2f68ac3-fdb4-4ee1-b51c-6db447e6f08e" xlink:to="loc_us-gaap_CreditFacilityDomain_d8b93480-2633-4edc-8b50-ad30f41f8f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_643e599c-43f6-4acf-869f-39605ba3e060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d8b93480-2633-4edc-8b50-ad30f41f8f61" xlink:to="loc_us-gaap_LetterOfCreditMember_643e599c-43f6-4acf-869f-39605ba3e060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_38b16c09-0dec-4a3f-8f78-056040ce5b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_38b16c09-0dec-4a3f-8f78-056040ce5b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8c511a84-ef8d-4b5e-a023-231e24c88883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38b16c09-0dec-4a3f-8f78-056040ce5b18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8c511a84-ef8d-4b5e-a023-231e24c88883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_58c10f6b-3b3f-42b9-92f5-f413e0b31cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8c511a84-ef8d-4b5e-a023-231e24c88883" xlink:to="loc_us-gaap_LineOfCreditMember_58c10f6b-3b3f-42b9-92f5-f413e0b31cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_433a8dd5-6693-43b8-879c-4e4258024e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_433a8dd5-6693-43b8-879c-4e4258024e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee536f4b-61d5-4ba3-b80d-50709047dbea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_433a8dd5-6693-43b8-879c-4e4258024e9f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee536f4b-61d5-4ba3-b80d-50709047dbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_8285d0a2-b84a-4adb-86df-4ec6f925b0a0" xlink:href="evh-20220630.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee536f4b-61d5-4ba3-b80d-50709047dbea" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_8285d0a2-b84a-4adb-86df-4ec6f925b0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_85773e24-b451-4034-999e-da514e427d27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:to="loc_srt_StatementScenarioAxis_85773e24-b451-4034-999e-da514e427d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_48faabe8-a577-4bfd-b04c-fe576e837bb5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_85773e24-b451-4034-999e-da514e427d27" xlink:to="loc_srt_ScenarioUnspecifiedDomain_48faabe8-a577-4bfd-b04c-fe576e837bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ba167a0a-d33a-48ee-aa4f-ae87c4d59c3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_48faabe8-a577-4bfd-b04c-fe576e837bb5" xlink:to="loc_srt_ScenarioForecastMember_ba167a0a-d33a-48ee-aa4f-ae87c4d59c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d7205bc2-032f-45f7-9174-0fe3a1deb027" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:to="loc_srt_LitigationCaseAxis_d7205bc2-032f-45f7-9174-0fe3a1deb027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ca517324-8cd8-4a74-9105-b52bb40d595f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_d7205bc2-032f-45f7-9174-0fe3a1deb027" xlink:to="loc_srt_LitigationCaseTypeDomain_ca517324-8cd8-4a74-9105-b52bb40d595f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderClassActionComplaintMember_ab06a73b-d3df-4aca-a083-83146a04cd16" xlink:href="evh-20220630.xsd#evh_ShareholderClassActionComplaintMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ca517324-8cd8-4a74-9105-b52bb40d595f" xlink:to="loc_evh_ShareholderClassActionComplaintMember_ab06a73b-d3df-4aca-a083-83146a04cd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_e942b978-e562-4a63-8611-6eac4b099250" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a16275c1-b90d-48c4-8812-25b741bab3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a16275c1-b90d-48c4-8812-25b741bab3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_40d7e6e4-b17d-4aef-bb69-6f483335bd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_40d7e6e4-b17d-4aef-bb69-6f483335bd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_e57c9d1b-faaf-4abc-b2c3-97d844709325" xlink:href="evh-20220630.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:to="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_e57c9d1b-faaf-4abc-b2c3-97d844709325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_939d9988-f003-40a9-8815-eb80bb739c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dec73a1a-70eb-401a-8939-03c96f0f454a" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_939d9988-f003-40a9-8815-eb80bb739c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#CommitmentsandContingenciesReinsuranceAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1df98cda-6d32-4662-b195-9c003f51e0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsWritten_cebd43b9-5346-4065-8eec-66fddb757bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedPremiumsWritten"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1df98cda-6d32-4662-b195-9c003f51e0d1" xlink:to="loc_us-gaap_AssumedPremiumsWritten_cebd43b9-5346-4065-8eec-66fddb757bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_189063a0-9583-484c-8528-aa296c428e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1df98cda-6d32-4662-b195-9c003f51e0d1" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_189063a0-9583-484c-8528-aa296c428e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_deed9fbd-1106-4958-95a5-4e7ac1cdb059" xlink:href="evh-20220630.xsd#evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1df98cda-6d32-4662-b195-9c003f51e0d1" xlink:to="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_deed9fbd-1106-4958-95a5-4e7ac1cdb059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_11c53fa3-eaef-409d-8e37-5f79d0662df3" xlink:href="evh-20220630.xsd#evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1df98cda-6d32-4662-b195-9c003f51e0d1" xlink:to="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_11c53fa3-eaef-409d-8e37-5f79d0662df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward_f0d2563f-65d3-480e-974d-574e11473916" xlink:href="evh-20220630.xsd#evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1df98cda-6d32-4662-b195-9c003f51e0d1" xlink:to="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward_f0d2563f-65d3-480e-974d-574e11473916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_e6abfd5b-bf6d-4b8b-b188-0b6ee1e502a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward_f0d2563f-65d3-480e-974d-574e11473916" xlink:to="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_e6abfd5b-bf6d-4b8b-b188-0b6ee1e502a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_69b56ab6-ebe1-46a1-b2b6-1d6a52768d4e" xlink:href="evh-20220630.xsd#evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward_f0d2563f-65d3-480e-974d-574e11473916" xlink:to="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_69b56ab6-ebe1-46a1-b2b6-1d6a52768d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsRepaymentsForReinsurance_7c7cc3fe-0730-4bec-a84a-289aeb0c1be0" xlink:href="evh-20220630.xsd#evh_ProceedsRepaymentsForReinsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward_f0d2563f-65d3-480e-974d-574e11473916" xlink:to="loc_evh_ProceedsRepaymentsForReinsurance_7c7cc3fe-0730-4bec-a84a-289aeb0c1be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_17309115-45bc-48e8-a948-f1a8f81a1642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward_f0d2563f-65d3-480e-974d-574e11473916" xlink:to="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_17309115-45bc-48e8-a948-f1a8f81a1642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4869f53-2cc0-453c-854d-2956ff73eea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4869f53-2cc0-453c-854d-2956ff73eea6" xlink:to="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_26b570f9-962f-47d2-b71b-91dc8631e12d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:to="loc_srt_MajorCustomersAxis_26b570f9-962f-47d2-b71b-91dc8631e12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_26b570f9-962f-47d2-b71b-91dc8631e12d" xlink:to="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_142b3bea-ba36-468d-b806-a7992132d2a9" xlink:href="evh-20220630.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_142b3bea-ba36-468d-b806-a7992132d2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_d3c9c729-0417-4ff8-a606-fccd22e3fa43" xlink:href="evh-20220630.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_FloridaBlueMedicareIncMember_d3c9c729-0417-4ff8-a606-fccd22e3fa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_d346a590-8395-4d3d-820b-f75dbec82b49" xlink:href="evh-20220630.xsd#evh_MolinaHealthcareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_MolinaHealthcareMember_d346a590-8395-4d3d-820b-f75dbec82b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CenterForMedicareAndMedicaidServicesMember_80644ceb-f91c-4056-9a47-bc9c6cb5d117" xlink:href="evh-20220630.xsd#evh_CenterForMedicareAndMedicaidServicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_CenterForMedicareAndMedicaidServicesMember_80644ceb-f91c-4056-9a47-bc9c6cb5d117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember_ef081660-43c5-4037-9c50-538d09db9b97" xlink:href="evh-20220630.xsd#evh_BrightHealthManagementIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_BrightHealthManagementIncMember_ef081660-43c5-4037-9c50-538d09db9b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember_e5572a58-6e0f-4fdb-b34a-aefae82fc3fa" xlink:href="evh-20220630.xsd#evh_BlueCrossAndBlueShieldOfNorthCarolinaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9dbc7858-5350-47b0-b91e-a30edd0edc9c" xlink:to="loc_evh_BlueCrossAndBlueShieldOfNorthCarolinaMember_e5572a58-6e0f-4fdb-b34a-aefae82fc3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2aa6d6b9-1b40-4104-bf58-3220076be93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2aa6d6b9-1b40-4104-bf58-3220076be93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_74f67a76-f736-411e-9a2c-a7305336f23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2aa6d6b9-1b40-4104-bf58-3220076be93a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_74f67a76-f736-411e-9a2c-a7305336f23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_9510d77a-2865-4229-8070-33b384e180c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_74f67a76-f736-411e-9a2c-a7305336f23d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_9510d77a-2865-4229-8070-33b384e180c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_596907d2-079b-4a74-bf07-d848d94540ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_596907d2-079b-4a74-bf07-d848d94540ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5a1d105-758e-4d31-8635-c25e905ad7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_596907d2-079b-4a74-bf07-d848d94540ed" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5a1d105-758e-4d31-8635-c25e905ad7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_ca117569-5aac-47cc-956d-51884fa35978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5a1d105-758e-4d31-8635-c25e905ad7a6" xlink:to="loc_us-gaap_AccountsReceivableMember_ca117569-5aac-47cc-956d-51884fa35978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_798f21c3-cbcc-4c8c-9bc0-4ff2033fae78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5a1d105-758e-4d31-8635-c25e905ad7a6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_798f21c3-cbcc-4c8c-9bc0-4ff2033fae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0b4c9e8f-b314-4e34-8362-26353047d3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0b4c9e8f-b314-4e34-8362-26353047d3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_d47de7e4-36f0-4997-82d5-a720303c3fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0b4c9e8f-b314-4e34-8362-26353047d3ee" xlink:to="loc_us-gaap_ReceivableTypeDomain_d47de7e4-36f0-4997-82d5-a720303c3fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_8eab4927-f6c6-4510-b503-8ed1a830bc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_d47de7e4-36f0-4997-82d5-a720303c3fcb" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_8eab4927-f6c6-4510-b503-8ed1a830bc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7942a7c1-4af0-4a5f-b5b6-aa0820db1f79" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_52dd001b-c0f9-49f0-aec2-e0f50154439b" xlink:href="evh-20220630.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_52dd001b-c0f9-49f0-aec2-e0f50154439b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94cf7e6f-5169-4357-a7bf-3c2d32242084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94cf7e6f-5169-4357-a7bf-3c2d32242084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_1de32eb0-7995-47ca-bc86-7917f2029e53" xlink:href="evh-20220630.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_1de32eb0-7995-47ca-bc86-7917f2029e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_88464195-9960-4425-b90c-72b979e3aa45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_048a0f7d-f2c5-476a-9884-c4c4bf28cf65" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_88464195-9960-4425-b90c-72b979e3aa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Leases" xlink:type="simple" xlink:href="evh-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c89da5b6-6355-44c5-ab1a-c8aa150a2be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ac2a8572-fd57-4f4d-9e3d-3ca70479a0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c89da5b6-6355-44c5-ab1a-c8aa150a2be9" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ac2a8572-fd57-4f4d-9e3d-3ca70479a0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c54b4f60-ce19-481e-89fe-9781eb6f856c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6a4cfc31-790d-49fb-bf51-7aa17d23fb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c54b4f60-ce19-481e-89fe-9781eb6f856c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6a4cfc31-790d-49fb-bf51-7aa17d23fb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1a327435-8281-48ee-8821-fef3bbfa1e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c54b4f60-ce19-481e-89fe-9781eb6f856c" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_1a327435-8281-48ee-8821-fef3bbfa1e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_715c88e6-58f0-452e-a69c-29227940c978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_279a70ca-b9da-44d4-993e-7c87101fab37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_715c88e6-58f0-452e-a69c-29227940c978" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_279a70ca-b9da-44d4-993e-7c87101fab37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_ac3d3847-5a87-497e-be96-2a4e16efb2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_279a70ca-b9da-44d4-993e-7c87101fab37" xlink:to="loc_us-gaap_OtherCommitmentsAxis_ac3d3847-5a87-497e-be96-2a4e16efb2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_a4abdf45-b2a6-463c-b73a-8944d9ef89b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_ac3d3847-5a87-497e-be96-2a4e16efb2c5" xlink:to="loc_us-gaap_OtherCommitmentsDomain_a4abdf45-b2a6-463c-b73a-8944d9ef89b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_e545c0ca-bdfb-439d-97d2-72c5db81ab0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_a4abdf45-b2a6-463c-b73a-8944d9ef89b0" xlink:to="loc_us-gaap_LeaseAgreementsMember_e545c0ca-bdfb-439d-97d2-72c5db81ab0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b958ce95-d0c4-4a8b-8038-acee430094a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_279a70ca-b9da-44d4-993e-7c87101fab37" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_b958ce95-d0c4-4a8b-8038-acee430094a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b8f978b4-1c50-4425-b8c1-314c9055491a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b958ce95-d0c4-4a8b-8038-acee430094a1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b8f978b4-1c50-4425-b8c1-314c9055491a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_e699eca0-9283-4a5a-aee0-dff4a24c9802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b958ce95-d0c4-4a8b-8038-acee430094a1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_e699eca0-9283-4a5a-aee0-dff4a24c9802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a2bf9069-154d-4610-87e3-f8779d5fb704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c5c47cbd-de5e-4975-a632-d343e2eb707e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2bf9069-154d-4610-87e3-f8779d5fb704" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c5c47cbd-de5e-4975-a632-d343e2eb707e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e56c75ab-e9f1-4cea-b49e-b5834750144f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c5c47cbd-de5e-4975-a632-d343e2eb707e" xlink:to="loc_srt_StatementGeographicalAxis_e56c75ab-e9f1-4cea-b49e-b5834750144f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e56c75ab-e9f1-4cea-b49e-b5834750144f" xlink:to="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_d9f03ad9-a218-4f60-9b15-9135a0ed978d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:to="loc_stpr_VA_d9f03ad9-a218-4f60-9b15-9135a0ed978d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_22324526-1825-41c7-a596-062f23c0b7ec" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:to="loc_stpr_IL_22324526-1825-41c7-a596-062f23c0b7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_18a0fa14-eafa-4c33-9a45-592bb3d2c8f0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:to="loc_stpr_NJ_18a0fa14-eafa-4c33-9a45-592bb3d2c8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_3817fc2a-8052-49d0-95d5-4427c2be4722" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:to="loc_country_IN_3817fc2a-8052-49d0-95d5-4427c2be4722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_95a6e4f6-91c3-405a-b417-c0c7c1c1b8cc" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b13acb3e-28c5-4ced-9f80-dba76669872b" xlink:to="loc_stpr_CA_95a6e4f6-91c3-405a-b417-c0c7c1c1b8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9fbe2-8f69-47fc-92e5-0711e38f3be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c5c47cbd-de5e-4975-a632-d343e2eb707e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9fbe2-8f69-47fc-92e5-0711e38f3be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c0667554-6ade-4fb0-bcc7-ebf302164643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9fbe2-8f69-47fc-92e5-0711e38f3be1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c0667554-6ade-4fb0-bcc7-ebf302164643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_428c3cc9-7958-415d-983f-76a64dc151ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9fbe2-8f69-47fc-92e5-0711e38f3be1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_428c3cc9-7958-415d-983f-76a64dc151ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_65b422d8-dd22-4347-889d-946bc34fbf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7ef9fbe2-8f69-47fc-92e5-0711e38f3be1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_65b422d8-dd22-4347-889d-946bc34fbf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_94290f19-7ea5-46f5-8c8a-64cf498da9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a2246862-654b-492a-8f63-3e6fe2f54278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_94290f19-7ea5-46f5-8c8a-64cf498da9a3" xlink:to="loc_us-gaap_OperatingLeaseCost_a2246862-654b-492a-8f63-3e6fe2f54278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_b0f98f46-7257-4a06-a589-21ca7dff2535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_94290f19-7ea5-46f5-8c8a-64cf498da9a3" xlink:to="loc_us-gaap_VariableLeaseCost_b0f98f46-7257-4a06-a589-21ca7dff2535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_049e8a4c-508b-49a4-8d1a-ac8465dad581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_94290f19-7ea5-46f5-8c8a-64cf498da9a3" xlink:to="loc_us-gaap_LeaseCost_049e8a4c-508b-49a4-8d1a-ac8465dad581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7db030ac-4876-4290-a9bd-9da484983056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d72d7712-48b2-42ce-9ae6-9512b60a2a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db030ac-4876-4290-a9bd-9da484983056" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d72d7712-48b2-42ce-9ae6-9512b60a2a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2472d935-9442-478b-b039-a95318e1f3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db030ac-4876-4290-a9bd-9da484983056" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2472d935-9442-478b-b039-a95318e1f3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_543c2721-b40b-45ca-af42-e130c99e6bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db030ac-4876-4290-a9bd-9da484983056" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_543c2721-b40b-45ca-af42-e130c99e6bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6d5eaa4a-12ce-4f9c-8c9b-14270e044f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db030ac-4876-4290-a9bd-9da484983056" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6d5eaa4a-12ce-4f9c-8c9b-14270e044f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_80316357-5160-43fc-bb26-52bfc6e55e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db030ac-4876-4290-a9bd-9da484983056" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_80316357-5160-43fc-bb26-52bfc6e55e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_a97c5d1b-59fd-45ce-9fe8-4257e732806c" xlink:href="evh-20220630.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db030ac-4876-4290-a9bd-9da484983056" xlink:to="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_a97c5d1b-59fd-45ce-9fe8-4257e732806c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6cc8ef88-a6e3-47c0-add0-a744c3e7cd86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db030ac-4876-4290-a9bd-9da484983056" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6cc8ef88-a6e3-47c0-add0-a744c3e7cd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_2cc92113-918a-4ed3-8ad8-f825acb17a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db030ac-4876-4290-a9bd-9da484983056" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_2cc92113-918a-4ed3-8ad8-f825acb17a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_70d82273-5f52-4b19-9537-1424f167fca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_2cc92113-918a-4ed3-8ad8-f825acb17a78" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_70d82273-5f52-4b19-9537-1424f167fca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f694ac63-2db3-4b59-8e03-a504de1218a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db030ac-4876-4290-a9bd-9da484983056" xlink:to="loc_us-gaap_OperatingLeaseLiability_f694ac63-2db3-4b59-8e03-a504de1218a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_914b46ea-2254-4350-8208-5c025307e4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8ceed281-60d1-49c7-bce0-87a6defa553a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_914b46ea-2254-4350-8208-5c025307e4a0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8ceed281-60d1-49c7-bce0-87a6defa553a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_44e0b1f0-ecd5-4496-ae68-7796e383451a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_914b46ea-2254-4350-8208-5c025307e4a0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_44e0b1f0-ecd5-4496-ae68-7796e383451a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="evh-20220630.xsd#LossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_108383a8-2e12-4002-8eab-adb52cb63e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_6db5739d-d537-4365-a944-a8799b81b011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_108383a8-2e12-4002-8eab-adb52cb63e41" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_6db5739d-d537-4365-a944-a8799b81b011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareTables" xlink:type="simple" xlink:href="evh-20220630.xsd#LossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7d7f3a68-a449-4d87-8719-02986256098a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6263002d-bc59-4548-8264-7222d1b5048e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7d7f3a68-a449-4d87-8719-02986256098a" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6263002d-bc59-4548-8264-7222d1b5048e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d14cac5e-a214-4fd0-9d48-a7854ed63f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7d7f3a68-a449-4d87-8719-02986256098a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d14cac5e-a214-4fd0-9d48-a7854ed63f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LossPerCommonShareComputationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b6a7daab-e08a-4aa8-942a-e2099e1ed972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_305c36b6-5960-4fec-944a-c58815d8b791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b6a7daab-e08a-4aa8-942a-e2099e1ed972" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_305c36b6-5960-4fec-944a-c58815d8b791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2487f57d-9e73-448d-92c9-989a0804b387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b6a7daab-e08a-4aa8-942a-e2099e1ed972" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2487f57d-9e73-448d-92c9-989a0804b387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5ab4915f-038a-43ae-9a94-937854f5289b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b6a7daab-e08a-4aa8-942a-e2099e1ed972" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5ab4915f-038a-43ae-9a94-937854f5289b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9692e4e4-967c-48f0-a372-ab3b3a2c9a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b6a7daab-e08a-4aa8-942a-e2099e1ed972" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9692e4e4-967c-48f0-a372-ab3b3a2c9a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_02c904ff-ed8b-42d5-abc6-ab613df320b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b6a7daab-e08a-4aa8-942a-e2099e1ed972" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_02c904ff-ed8b-42d5-abc6-ab613df320b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_883bd866-0db4-4193-8207-dd0d3cc03476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b6a7daab-e08a-4aa8-942a-e2099e1ed972" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_883bd866-0db4-4193-8207-dd0d3cc03476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BasicAndDilutedEarningsPerShareAbstract_438e1308-7e2e-4597-9582-8a98209d632f" xlink:href="evh-20220630.xsd#evh_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b6a7daab-e08a-4aa8-942a-e2099e1ed972" xlink:to="loc_evh_BasicAndDilutedEarningsPerShareAbstract_438e1308-7e2e-4597-9582-8a98209d632f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_6c93bde8-42a3-4083-afce-39c7eb5ed7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract_438e1308-7e2e-4597-9582-8a98209d632f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_6c93bde8-42a3-4083-afce-39c7eb5ed7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_16ce7840-f4d4-4cc0-9189-a2edc6437351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract_438e1308-7e2e-4597-9582-8a98209d632f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_16ce7840-f4d4-4cc0-9189-a2edc6437351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f51cb837-f858-485f-ba8f-f22c4ebfc0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract_438e1308-7e2e-4597-9582-8a98209d632f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f51cb837-f858-485f-ba8f-f22c4ebfc0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_0357d278-5f17-4d71-8a7a-800b1c4c3467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract_438e1308-7e2e-4597-9582-8a98209d632f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_0357d278-5f17-4d71-8a7a-800b1c4c3467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d21c29c3-2cd7-4157-9f74-26a6e60ed287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract_438e1308-7e2e-4597-9582-8a98209d632f" xlink:to="loc_us-gaap_EarningsPerShareBasic_d21c29c3-2cd7-4157-9f74-26a6e60ed287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ce5c8e38-5b99-4d4e-9093-b4a074cbd492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract_438e1308-7e2e-4597-9582-8a98209d632f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ce5c8e38-5b99-4d4e-9093-b4a074cbd492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b93f4b89-1aad-456c-b2f8-948d79f1372f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ce117f49-03e4-4c14-a78e-ce96f32c3c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b93f4b89-1aad-456c-b2f8-948d79f1372f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ce117f49-03e4-4c14-a78e-ce96f32c3c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab9e93f1-b178-4265-b073-38356171d269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ce117f49-03e4-4c14-a78e-ce96f32c3c92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab9e93f1-b178-4265-b073-38356171d269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5efbd765-d045-4374-92f9-66f562394a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab9e93f1-b178-4265-b073-38356171d269" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5efbd765-d045-4374-92f9-66f562394a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_9f14b65a-858b-4173-8c9f-4544c293c7fe" xlink:href="evh-20220630.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5efbd765-d045-4374-92f9-66f562394a23" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_9f14b65a-858b-4173-8c9f-4544c293c7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4fe90c73-a353-4a85-88d2-c54107c1979a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5efbd765-d045-4374-92f9-66f562394a23" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4fe90c73-a353-4a85-88d2-c54107c1979a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1e466b5d-b292-47c1-9800-47b31633c197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5efbd765-d045-4374-92f9-66f562394a23" xlink:to="loc_us-gaap_ConvertibleDebtMember_1e466b5d-b292-47c1-9800-47b31633c197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c333e9d1-d317-45ce-81bd-58db0b3d9200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ce117f49-03e4-4c14-a78e-ce96f32c3c92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c333e9d1-d317-45ce-81bd-58db0b3d9200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e42efb6d-6747-4317-a60d-39ba9423c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c333e9d1-d317-45ce-81bd-58db0b3d9200" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e42efb6d-6747-4317-a60d-39ba9423c16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="evh-20220630.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71e9f828-fafd-41e2-81e2-38c3d59e92bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2edb2215-68e2-4d0a-8758-044c4e230e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71e9f828-fafd-41e2-81e2-38c3d59e92bb" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2edb2215-68e2-4d0a-8758-044c4e230e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="evh-20220630.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09d376c5-27d5-4967-b214-204e450f2b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_c51bcc2b-0c3f-4c07-aad0-a74d1c736528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09d376c5-27d5-4967-b214-204e450f2b7f" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_c51bcc2b-0c3f-4c07-aad0-a74d1c736528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_f5ea73c9-a7b0-4189-af01-1dd2189077bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09d376c5-27d5-4967-b214-204e450f2b7f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_f5ea73c9-a7b0-4189-af01-1dd2189077bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef2617f5-009e-4556-953b-db39e3165907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_992a8c90-6d67-44ba-9fc4-be0d323d4c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef2617f5-009e-4556-953b-db39e3165907" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_992a8c90-6d67-44ba-9fc4-be0d323d4c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9073db8c-38ce-4cdc-b022-4f3b28ff70fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_992a8c90-6d67-44ba-9fc4-be0d323d4c45" xlink:to="loc_us-gaap_AwardTypeAxis_9073db8c-38ce-4cdc-b022-4f3b28ff70fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9073db8c-38ce-4cdc-b022-4f3b28ff70fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35fa86c7-6276-4fd2-aef0-49be8f054e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35fa86c7-6276-4fd2-aef0-49be8f054e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9cba4154-5bbd-49ea-9658-f671dd7a36e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9cba4154-5bbd-49ea-9658-f671dd7a36e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_c0d145c5-acdf-4a10-af10-d86768c01671" xlink:href="evh-20220630.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_c0d145c5-acdf-4a10-af10-d86768c01671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_49c45db3-e06c-467c-addc-c692a11c8f13" xlink:href="evh-20220630.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dfc82fd-171c-45fd-af6c-6bded0635cc1" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_49c45db3-e06c-467c-addc-c692a11c8f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b8047cb4-ff8a-4816-8c4c-0e8d1aa5f72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_992a8c90-6d67-44ba-9fc4-be0d323d4c45" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b8047cb4-ff8a-4816-8c4c-0e8d1aa5f72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_98b12124-5f87-4d08-9210-f1d2f3a516a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b8047cb4-ff8a-4816-8c4c-0e8d1aa5f72d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_98b12124-5f87-4d08-9210-f1d2f3a516a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_1829f3d0-3bcf-439a-b3bc-a422b029a06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98b12124-5f87-4d08-9210-f1d2f3a516a8" xlink:to="loc_us-gaap_CostOfSalesMember_1829f3d0-3bcf-439a-b3bc-a422b029a06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5c9a801a-95a9-4a1e-9743-3deb4d0e2bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98b12124-5f87-4d08-9210-f1d2f3a516a8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5c9a801a-95a9-4a1e-9743-3deb4d0e2bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9c544a24-f4e9-4ab4-9498-483d93628ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_992a8c90-6d67-44ba-9fc4-be0d323d4c45" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9c544a24-f4e9-4ab4-9498-483d93628ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_77e4c622-1c15-48ac-8b99-50c40ec6cd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9c544a24-f4e9-4ab4-9498-483d93628ccd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_77e4c622-1c15-48ac-8b99-50c40ec6cd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#StockbasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5dcdada-29f3-4715-bb75-91e2f3f8fd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_eaee6567-cde4-4b29-b49f-a060abcedbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5dcdada-29f3-4715-bb75-91e2f3f8fd37" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_eaee6567-cde4-4b29-b49f-a060abcedbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e27c0898-07a1-40f9-894a-eab6fee451f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86ab9cf1-827c-4701-ad64-e29ada7aed41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e27c0898-07a1-40f9-894a-eab6fee451f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86ab9cf1-827c-4701-ad64-e29ada7aed41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_652a2614-d18e-4ff7-b056-33146c221ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86ab9cf1-827c-4701-ad64-e29ada7aed41" xlink:to="loc_us-gaap_AwardTypeAxis_652a2614-d18e-4ff7-b056-33146c221ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_166c78a6-43ef-4f15-8b84-ef0a858b7434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_652a2614-d18e-4ff7-b056-33146c221ebd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_166c78a6-43ef-4f15-8b84-ef0a858b7434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1f93e7e7-c02b-4eec-aba4-2e99d484f16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_166c78a6-43ef-4f15-8b84-ef0a858b7434" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1f93e7e7-c02b-4eec-aba4-2e99d484f16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_d47d8f12-0734-4073-a3b7-533c2a2b5e38" xlink:href="evh-20220630.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_166c78a6-43ef-4f15-8b84-ef0a858b7434" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_d47d8f12-0734-4073-a3b7-533c2a2b5e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20c0413f-785b-4d20-aa87-b2b2c1fd07d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86ab9cf1-827c-4701-ad64-e29ada7aed41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20c0413f-785b-4d20-aa87-b2b2c1fd07d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_74637fdb-0412-4167-a9a5-5c13f6489506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20c0413f-785b-4d20-aa87-b2b2c1fd07d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_74637fdb-0412-4167-a9a5-5c13f6489506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="evh-20220630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6cd1e668-3427-4d54-addf-bb4dbadd8cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d917955f-dfce-4db5-b479-7c0d38b23651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cd1e668-3427-4d54-addf-bb4dbadd8cb0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d917955f-dfce-4db5-b479-7c0d38b23651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4882d6f5-5228-45ab-a732-530763f4efa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_47314af4-9d8b-4466-896b-ee3a85128364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4882d6f5-5228-45ab-a732-530763f4efa3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_47314af4-9d8b-4466-896b-ee3a85128364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d4202e56-acdd-48f6-84fb-16823d98adfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4882d6f5-5228-45ab-a732-530763f4efa3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d4202e56-acdd-48f6-84fb-16823d98adfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_85b4e8e5-4073-4f89-9b94-2d374833d491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4882d6f5-5228-45ab-a732-530763f4efa3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_85b4e8e5-4073-4f89-9b94-2d374833d491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_0d75eff1-b3aa-4f48-9901-8341159885d0" xlink:href="evh-20220630.xsd#evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4882d6f5-5228-45ab-a732-530763f4efa3" xlink:to="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_0d75eff1-b3aa-4f48-9901-8341159885d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="simple" xlink:href="evh-20220630.xsd#InvestmentsinEquityMethodInvestees"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_efd7cc15-80e8-4415-9edc-7a53d42d80c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_0e6f785a-92d7-49f1-bf4c-7b43dad2f4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_efd7cc15-80e8-4415-9edc-7a53d42d80c1" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_0e6f785a-92d7-49f1-bf4c-7b43dad2f4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_92d537b6-28d0-43f2-8076-03a1af8704ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4d155de4-f775-436d-85b4-393d1cc3fea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_92d537b6-28d0-43f2-8076-03a1af8704ea" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4d155de4-f775-436d-85b4-393d1cc3fea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2d492201-21c8-415e-ad82-472ff5e38ad3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4d155de4-f775-436d-85b4-393d1cc3fea0" xlink:to="loc_srt_RangeAxis_2d492201-21c8-415e-ad82-472ff5e38ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18c37ad5-2a83-4c74-bebc-5118a13cdee2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2d492201-21c8-415e-ad82-472ff5e38ad3" xlink:to="loc_srt_RangeMember_18c37ad5-2a83-4c74-bebc-5118a13cdee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_21b1dec4-5549-4674-91a6-b124d37cb43e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_18c37ad5-2a83-4c74-bebc-5118a13cdee2" xlink:to="loc_srt_MinimumMember_21b1dec4-5549-4674-91a6-b124d37cb43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74200fea-9bad-43ba-b0c2-b852416c01a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_18c37ad5-2a83-4c74-bebc-5118a13cdee2" xlink:to="loc_srt_MaximumMember_74200fea-9bad-43ba-b0c2-b852416c01a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc06164-706f-4412-bef6-ac3156f199c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4d155de4-f775-436d-85b4-393d1cc3fea0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc06164-706f-4412-bef6-ac3156f199c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bc81654b-4707-46d1-b830-1e94628db4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc06164-706f-4412-bef6-ac3156f199c2" xlink:to="loc_us-gaap_RelatedPartyDomain_bc81654b-4707-46d1-b830-1e94628db4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_05ea329a-f559-4090-8cce-2699566f17f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_bc81654b-4707-46d1-b830-1e94628db4c7" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_05ea329a-f559-4090-8cce-2699566f17f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_540039ab-6c60-47b5-a203-2bd2a089086d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4d155de4-f775-436d-85b4-393d1cc3fea0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_540039ab-6c60-47b5-a203-2bd2a089086d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b083e449-82dd-4beb-ac8d-f00f21f5c6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_540039ab-6c60-47b5-a203-2bd2a089086d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b083e449-82dd-4beb-ac8d-f00f21f5c6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_4d60fd89-e1a3-4b35-a130-d41cae393ec0" xlink:href="evh-20220630.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_b083e449-82dd-4beb-ac8d-f00f21f5c6bd" xlink:to="loc_evh_ServicesAgreementsMember_4d60fd89-e1a3-4b35-a130-d41cae393ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4d155de4-f775-436d-85b4-393d1cc3fea0" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_f3b06b9c-9a68-466d-b29a-c43cd06bed24" xlink:href="evh-20220630.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_f3b06b9c-9a68-466d-b29a-c43cd06bed24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_305efc8b-696e-46b2-bc4b-0dcfeb401cf5" xlink:href="evh-20220630.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_305efc8b-696e-46b2-bc4b-0dcfeb401cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_14f1ba94-5124-46cb-b46d-e6a181ba7478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_14f1ba94-5124-46cb-b46d-e6a181ba7478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_eb7ac3b6-675a-42c9-85fb-a1826cb0e112" xlink:href="evh-20220630.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731cdff3-ae37-4650-a417-05a10af824bf" xlink:to="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_eb7ac3b6-675a-42c9-85fb-a1826cb0e112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="evh-20220630.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_202c066e-d416-4663-837a-ce23746f0c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_01189b72-945f-43d1-a52d-08b4b776794d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_202c066e-d416-4663-837a-ce23746f0c48" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_01189b72-945f-43d1-a52d-08b4b776794d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="evh-20220630.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23d1be6c-c751-439d-89f2-c81d49981315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_73c11750-494b-4d99-a727-97e90b41848c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23d1be6c-c751-439d-89f2-c81d49981315" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_73c11750-494b-4d99-a727-97e90b41848c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b732cea7-3c15-43b7-8a1f-677f9f7e991b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23d1be6c-c751-439d-89f2-c81d49981315" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b732cea7-3c15-43b7-8a1f-677f9f7e991b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1b5d0acc-75a0-4a86-a84e-dc00b71b53ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23d1be6c-c751-439d-89f2-c81d49981315" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1b5d0acc-75a0-4a86-a84e-dc00b71b53ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_52801313-7cd4-429c-bd6d-0e4f01933de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_25229e23-6b6b-4dfb-9e7e-f36c9ff50b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52801313-7cd4-429c-bd6d-0e4f01933de4" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_25229e23-6b6b-4dfb-9e7e-f36c9ff50b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b0b3b7b-569e-4ab9-b3e4-3f8f6f0738c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_25229e23-6b6b-4dfb-9e7e-f36c9ff50b9d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b0b3b7b-569e-4ab9-b3e4-3f8f6f0738c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa7baba-3fa5-45a4-8621-da3d076cb7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b0b3b7b-569e-4ab9-b3e4-3f8f6f0738c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa7baba-3fa5-45a4-8621-da3d076cb7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ab63f52f-f598-4977-baf5-9fadfffcb140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa7baba-3fa5-45a4-8621-da3d076cb7e0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ab63f52f-f598-4977-baf5-9fadfffcb140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_412deb2f-bb72-4363-934a-cc828a816732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa7baba-3fa5-45a4-8621-da3d076cb7e0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_412deb2f-bb72-4363-934a-cc828a816732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c1c4593f-ad80-4f42-a0de-726a1f5c6e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa7baba-3fa5-45a4-8621-da3d076cb7e0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c1c4593f-ad80-4f42-a0de-726a1f5c6e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e077484d-2eca-4c6e-bdda-21ff9b515c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_25229e23-6b6b-4dfb-9e7e-f36c9ff50b9d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e077484d-2eca-4c6e-bdda-21ff9b515c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7bd4159c-b6c1-4bbf-ad29-fa16ca6b8bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e077484d-2eca-4c6e-bdda-21ff9b515c2e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7bd4159c-b6c1-4bbf-ad29-fa16ca6b8bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_40462330-6c64-4d49-9346-70c7472f8458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7bd4159c-b6c1-4bbf-ad29-fa16ca6b8bc0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_40462330-6c64-4d49-9346-70c7472f8458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5959b466-f4f5-4413-95d7-18cc317d1327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_25229e23-6b6b-4dfb-9e7e-f36c9ff50b9d" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5959b466-f4f5-4413-95d7-18cc317d1327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7bb11690-d945-4bd4-8cca-2f57e341641f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5959b466-f4f5-4413-95d7-18cc317d1327" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7bb11690-d945-4bd4-8cca-2f57e341641f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3e0a0d58-5f75-41e5-9720-d634e48b7b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7bb11690-d945-4bd4-8cca-2f57e341641f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3e0a0d58-5f75-41e5-9720-d634e48b7b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_be3d55f9-9dc3-44e7-958e-9e895fba7e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7bb11690-d945-4bd4-8cca-2f57e341641f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_be3d55f9-9dc3-44e7-958e-9e895fba7e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#FairValueMeasurementChangesinContingentConsiderationandOtherDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f800c45e-5dc8-4bcb-91b0-e69191455a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_96858b68-f78f-4584-ac06-dbc93f25a792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f800c45e-5dc8-4bcb-91b0-e69191455a06" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_96858b68-f78f-4584-ac06-dbc93f25a792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_04b32105-cba3-4ef4-9331-befad1f7eb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_96858b68-f78f-4584-ac06-dbc93f25a792" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_04b32105-cba3-4ef4-9331-befad1f7eb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0abce887-f231-44e7-8bb7-6758dbb1424f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_96858b68-f78f-4584-ac06-dbc93f25a792" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0abce887-f231-44e7-8bb7-6758dbb1424f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1d2c2dec-3be9-4c8a-aff8-2fbcd478830c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_96858b68-f78f-4584-ac06-dbc93f25a792" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1d2c2dec-3be9-4c8a-aff8-2fbcd478830c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_009e430e-f24b-4a76-87fe-462e2cd68353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_96858b68-f78f-4584-ac06-dbc93f25a792" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_009e430e-f24b-4a76-87fe-462e2cd68353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a6492f43-188f-45a6-9e28-a4b1483cd6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_01d65873-185d-4914-85b1-b2d2886b9494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a6492f43-188f-45a6-9e28-a4b1483cd6ec" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_01d65873-185d-4914-85b1-b2d2886b9494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f8c0871-3d58-423e-b5b8-fba59ac020ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_01d65873-185d-4914-85b1-b2d2886b9494" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f8c0871-3d58-423e-b5b8-fba59ac020ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c7c5439f-a71a-4e2c-97dc-4c87801b6dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f8c0871-3d58-423e-b5b8-fba59ac020ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c7c5439f-a71a-4e2c-97dc-4c87801b6dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fbb9f93a-1098-4a50-953b-4bb6907f5996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c7c5439f-a71a-4e2c-97dc-4c87801b6dc9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fbb9f93a-1098-4a50-953b-4bb6907f5996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bb630c2-6a78-4ee5-adc0-9e194e873cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_01d65873-185d-4914-85b1-b2d2886b9494" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bb630c2-6a78-4ee5-adc0-9e194e873cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9769c117-f98b-4312-ac07-d80bd9befb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bb630c2-6a78-4ee5-adc0-9e194e873cf7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9769c117-f98b-4312-ac07-d80bd9befb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8d830f53-7b95-44d1-83e6-a5c25f97f22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9769c117-f98b-4312-ac07-d80bd9befb1b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8d830f53-7b95-44d1-83e6-a5c25f97f22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4f0d8998-e87f-490d-a643-56d3eb5ba357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_01d65873-185d-4914-85b1-b2d2886b9494" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4f0d8998-e87f-490d-a643-56d3eb5ba357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3cd4d013-90f6-40c7-baf4-20fe57e651d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4f0d8998-e87f-490d-a643-56d3eb5ba357" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3cd4d013-90f6-40c7-baf4-20fe57e651d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_39b1596a-83fb-4b69-90c9-3c1901ed699d" xlink:href="evh-20220630.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3cd4d013-90f6-40c7-baf4-20fe57e651d7" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_39b1596a-83fb-4b69-90c9-3c1901ed699d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a4e81473-e1c1-4a5d-a887-bf46a90eea1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3cd4d013-90f6-40c7-baf4-20fe57e651d7" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a4e81473-e1c1-4a5d-a887-bf46a90eea1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2d852efe-49dd-4569-8b5f-e9539cd011b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_01d65873-185d-4914-85b1-b2d2886b9494" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2d852efe-49dd-4569-8b5f-e9539cd011b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_66808a98-3472-4333-8710-d374c9f5a461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2d852efe-49dd-4569-8b5f-e9539cd011b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_66808a98-3472-4333-8710-d374c9f5a461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b3a00b8b-8578-4aaa-9c3b-4ca83cc74cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2d852efe-49dd-4569-8b5f-e9539cd011b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b3a00b8b-8578-4aaa-9c3b-4ca83cc74cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedParties" xlink:type="simple" xlink:href="evh-20220630.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b3273586-3b80-45e4-93bf-3526f9785922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d516157c-009f-44fe-a8c7-52c1ebb3edcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b3273586-3b80-45e4-93bf-3526f9785922" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d516157c-009f-44fe-a8c7-52c1ebb3edcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="simple" xlink:href="evh-20220630.xsd#RelatedPartiesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_057db78a-0fdf-446a-aec5-308edab7d75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_7846b9ff-cd7a-4027-9495-8e887e6bd037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_057db78a-0fdf-446a-aec5-308edab7d75e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_7846b9ff-cd7a-4027-9495-8e887e6bd037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6052a260-8486-428c-b01b-2ac30bc5e866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76e60788-95e0-4604-ba5d-3cb817370fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6052a260-8486-428c-b01b-2ac30bc5e866" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76e60788-95e0-4604-ba5d-3cb817370fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0e744c8d-8c86-40b5-b084-c2275375a675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76e60788-95e0-4604-ba5d-3cb817370fc4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0e744c8d-8c86-40b5-b084-c2275375a675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_34b955b2-67ef-4412-8b05-04744862a064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0e744c8d-8c86-40b5-b084-c2275375a675" xlink:to="loc_us-gaap_RelatedPartyDomain_34b955b2-67ef-4412-8b05-04744862a064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_8f08b0cb-9c0b-4512-b855-3d858d5dba09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_34b955b2-67ef-4412-8b05-04744862a064" xlink:to="loc_srt_AffiliatedEntityMember_8f08b0cb-9c0b-4512-b855-3d858d5dba09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_116f0a42-001a-4d11-a9ee-4839483c29ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76e60788-95e0-4604-ba5d-3cb817370fc4" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_116f0a42-001a-4d11-a9ee-4839483c29ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a6f5846e-e198-4454-9613-139f2f8d1bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_116f0a42-001a-4d11-a9ee-4839483c29ce" xlink:to="loc_us-gaap_AssetsAbstract_a6f5846e-e198-4454-9613-139f2f8d1bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_af4fe029-ac1d-44d6-8349-aa731cd1b49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a6f5846e-e198-4454-9613-139f2f8d1bbe" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_af4fe029-ac1d-44d6-8349-aa731cd1b49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf5f1b4a-5511-4110-a163-0b73451cc5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a6f5846e-e198-4454-9613-139f2f8d1bbe" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf5f1b4a-5511-4110-a163-0b73451cc5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_c22d110d-804d-40a1-9c00-1bd738563f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a6f5846e-e198-4454-9613-139f2f8d1bbe" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_c22d110d-804d-40a1-9c00-1bd738563f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_e14be179-dc0b-42ca-a1a9-5365e29f563f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_116f0a42-001a-4d11-a9ee-4839483c29ce" xlink:to="loc_us-gaap_LiabilitiesAbstract_e14be179-dc0b-42ca-a1a9-5365e29f563f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8755cf7d-f76c-4518-90ce-249a7cb240ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_e14be179-dc0b-42ca-a1a9-5365e29f563f" xlink:to="loc_us-gaap_AccountsPayableCurrent_8755cf7d-f76c-4518-90ce-249a7cb240ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5e6a1ba5-0fa8-4171-b978-6aeb442f3c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_e14be179-dc0b-42ca-a1a9-5365e29f563f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5e6a1ba5-0fa8-4171-b978-6aeb442f3c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_5e01882b-d469-4330-bbab-ffdb7c20b92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_e14be179-dc0b-42ca-a1a9-5365e29f563f" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_5e01882b-d469-4330-bbab-ffdb7c20b92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_95f97c1c-71ab-4a36-b795-c9b5940ec6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_66d03421-3f9c-4f5a-b6ab-1f968dc42655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_95f97c1c-71ab-4a36-b795-c9b5940ec6b5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_66d03421-3f9c-4f5a-b6ab-1f968dc42655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_160d9d2e-c488-4701-a576-10179ada703a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_66d03421-3f9c-4f5a-b6ab-1f968dc42655" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_160d9d2e-c488-4701-a576-10179ada703a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cd32cbc7-f8f2-47e7-80f5-f0dd50b5641a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_160d9d2e-c488-4701-a576-10179ada703a" xlink:to="loc_us-gaap_RelatedPartyDomain_cd32cbc7-f8f2-47e7-80f5-f0dd50b5641a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_ce471057-b051-45bf-ba72-d29cfe5b1fd4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cd32cbc7-f8f2-47e7-80f5-f0dd50b5641a" xlink:to="loc_srt_AffiliatedEntityMember_ce471057-b051-45bf-ba72-d29cfe5b1fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9f43b158-60e6-4ff0-a7bb-31900c33fc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_66d03421-3f9c-4f5a-b6ab-1f968dc42655" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9f43b158-60e6-4ff0-a7bb-31900c33fc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1a9d28ca-344b-432c-996f-f3a59a9f6893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9f43b158-60e6-4ff0-a7bb-31900c33fc3d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1a9d28ca-344b-432c-996f-f3a59a9f6893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_946b1821-7d50-4882-8f05-2da5916f3027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1a9d28ca-344b-432c-996f-f3a59a9f6893" xlink:to="loc_us-gaap_CostOfSalesMember_946b1821-7d50-4882-8f05-2da5916f3027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_296987c2-4c22-423f-9735-00a192ad3e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1a9d28ca-344b-432c-996f-f3a59a9f6893" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_296987c2-4c22-423f-9735-00a192ad3e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b7e7f39c-a87c-4eb7-b8a4-179afff973fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_66d03421-3f9c-4f5a-b6ab-1f968dc42655" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_b7e7f39c-a87c-4eb7-b8a4-179afff973fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_0fe76648-6955-4f2d-9575-4ada5e9cfa8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b7e7f39c-a87c-4eb7-b8a4-179afff973fc" xlink:to="loc_us-gaap_RevenueFromRelatedParties_0fe76648-6955-4f2d-9575-4ada5e9cfa8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c2695b10-ec8b-4b79-8c35-7a6c5a2b7dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b7e7f39c-a87c-4eb7-b8a4-179afff973fc" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c2695b10-ec8b-4b79-8c35-7a6c5a2b7dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="simple" xlink:href="evh-20220630.xsd#RepositioningandOtherChanges"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bff2b853-0557-4f51-aa2c-5e0235c23e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_40d73460-bb30-442e-b366-a73762ee3313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bff2b853-0557-4f51-aa2c-5e0235c23e2d" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_40d73460-bb30-442e-b366-a73762ee3313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="simple" xlink:href="evh-20220630.xsd#RepositioningandOtherChangesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4e82fb7b-7b35-4bfa-b215-61888206ffb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fc5bc72b-6ca2-4b2d-bbe5-f30fe2fe3fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4e82fb7b-7b35-4bfa-b215-61888206ffb3" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fc5bc72b-6ca2-4b2d-bbe5-f30fe2fe3fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#RepositioningandOtherChangesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d8152bac-efa9-4908-ad8a-bcec0bdfae40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d0d92134-cf3a-41df-b48f-ae1f85f8a622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d8152bac-efa9-4908-ad8a-bcec0bdfae40" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d0d92134-cf3a-41df-b48f-ae1f85f8a622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_bcda5499-16ce-442d-9204-1212f120d776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d0d92134-cf3a-41df-b48f-ae1f85f8a622" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_bcda5499-16ce-442d-9204-1212f120d776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_45838153-5374-4465-8089-3c697f9b1961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_bcda5499-16ce-442d-9204-1212f120d776" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_45838153-5374-4465-8089-3c697f9b1961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_b5988bf7-1062-4c0d-8c34-c262f4c1eb88" xlink:href="evh-20220630.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_45838153-5374-4465-8089-3c697f9b1961" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_b5988bf7-1062-4c0d-8c34-c262f4c1eb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_a8f93299-20c6-44ab-85eb-3bae69556a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_45838153-5374-4465-8089-3c697f9b1961" xlink:to="loc_us-gaap_FacilityClosingMember_a8f93299-20c6-44ab-85eb-3bae69556a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_37e3e436-bebb-4c25-bf81-dbdbdf7f553a" xlink:href="evh-20220630.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_45838153-5374-4465-8089-3c697f9b1961" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_37e3e436-bebb-4c25-bf81-dbdbdf7f553a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c0266310-5b74-4707-9b82-d3e2e30ac06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d0d92134-cf3a-41df-b48f-ae1f85f8a622" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c0266310-5b74-4707-9b82-d3e2e30ac06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9d43ad9a-fb5b-42a9-8c91-4551a2ace65a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c0266310-5b74-4707-9b82-d3e2e30ac06c" xlink:to="loc_us-gaap_RestructuringCharges_9d43ad9a-fb5b-42a9-8c91-4551a2ace65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_5f51762f-0b32-469e-91c9-667d1b126e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c0266310-5b74-4707-9b82-d3e2e30ac06c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_5f51762f-0b32-469e-91c9-667d1b126e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="evh-20220630.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4139809a-03c7-4528-bde4-3b5762a86dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_289a417d-9e09-46ad-aa2c-ccd7cbe5b0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4139809a-03c7-4528-bde4-3b5762a86dd0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_289a417d-9e09-46ad-aa2c-ccd7cbe5b0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="evh-20220630.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_43f6d272-37e4-4c28-beb8-5b1129588611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_c4be0466-2de0-4842-b629-a4a9e2d1ac2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_43f6d272-37e4-4c28-beb8-5b1129588611" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_c4be0466-2de0-4842-b629-a4a9e2d1ac2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_64606ab9-81b3-40db-a5c9-23cbae49a306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_43f6d272-37e4-4c28-beb8-5b1129588611" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_64606ab9-81b3-40db-a5c9-23cbae49a306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_07b7aa39-4ca3-46a9-a701-1b3da35141cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_05890073-930b-4ac7-978b-a9f31c8956c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_07b7aa39-4ca3-46a9-a701-1b3da35141cc" xlink:to="loc_us-gaap_NumberOfOperatingSegments_05890073-930b-4ac7-978b-a9f31c8956c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_513a8ba1-5a44-47aa-a9c7-9473429affa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_bbcb2d87-34c6-4f1f-b033-2cad59c26a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_513a8ba1-5a44-47aa-a9c7-9473429affa3" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_bbcb2d87-34c6-4f1f-b033-2cad59c26a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9d2877ee-b6c2-40e8-8466-d5873cefacd2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_bbcb2d87-34c6-4f1f-b033-2cad59c26a95" xlink:to="loc_srt_ConsolidationItemsAxis_9d2877ee-b6c2-40e8-8466-d5873cefacd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_46a6b61b-60b3-4066-9d2f-eb7027df7508" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_9d2877ee-b6c2-40e8-8466-d5873cefacd2" xlink:to="loc_srt_ConsolidationItemsDomain_46a6b61b-60b3-4066-9d2f-eb7027df7508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_4488405c-ce90-493d-8d41-d79d99b02a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_46a6b61b-60b3-4066-9d2f-eb7027df7508" xlink:to="loc_us-gaap_IntersegmentEliminationMember_4488405c-ce90-493d-8d41-d79d99b02a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e51de345-69c0-4ff6-add3-4fdd39bf6e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_46a6b61b-60b3-4066-9d2f-eb7027df7508" xlink:to="loc_us-gaap_OperatingSegmentsMember_e51de345-69c0-4ff6-add3-4fdd39bf6e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3cc2435d-a941-45e7-b7c4-ff71206f64fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_46a6b61b-60b3-4066-9d2f-eb7027df7508" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3cc2435d-a941-45e7-b7c4-ff71206f64fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6a436050-4fa3-41b0-b3d0-2470bc67328b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_bbcb2d87-34c6-4f1f-b033-2cad59c26a95" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6a436050-4fa3-41b0-b3d0-2470bc67328b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_45ba4e69-023f-4bac-aea0-6c2888db01a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6a436050-4fa3-41b0-b3d0-2470bc67328b" xlink:to="loc_us-gaap_SegmentDomain_45ba4e69-023f-4bac-aea0-6c2888db01a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_6c9cbf5e-a48f-4ae4-a580-efa7ceb96ce3" xlink:href="evh-20220630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_45ba4e69-023f-4bac-aea0-6c2888db01a5" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_6c9cbf5e-a48f-4ae4-a580-efa7ceb96ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_ddc11be9-316a-48ee-b4d7-91ee6c6ae1dd" xlink:href="evh-20220630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_45ba4e69-023f-4bac-aea0-6c2888db01a5" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_ddc11be9-316a-48ee-b4d7-91ee6c6ae1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_b50c6fdc-c776-4440-b636-a2051c7d8ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_bbcb2d87-34c6-4f1f-b033-2cad59c26a95" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_b50c6fdc-c776-4440-b636-a2051c7d8ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_994a422a-4916-4f4e-9635-5c8d9134dd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_b50c6fdc-c776-4440-b636-a2051c7d8ce2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_994a422a-4916-4f4e-9635-5c8d9134dd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_aa6ceeb8-58ff-4731-b6ac-62c8a4eb4387" xlink:href="evh-20220630.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_b50c6fdc-c776-4440-b636-a2051c7d8ce2" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_aa6ceeb8-58ff-4731-b6ac-62c8a4eb4387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="evh-20220630.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6392fe5f-6ab1-49cc-be3a-a5ffd2a0a882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_NetIncomeLoss_6392fe5f-6ab1-49cc-be3a-a5ffd2a0a882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8e479bd1-031b-4943-9e1b-3e534ace0d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8e479bd1-031b-4943-9e1b-3e534ace0d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7c21a35d-b251-4e29-9997-c6407708bff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_InterestExpense_7c21a35d-b251-4e29-9997-c6407708bff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_75708df2-cacf-45a7-a5d2-b30e17f2916b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_75708df2-cacf-45a7-a5d2-b30e17f2916b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a7bd6946-8cec-458d-b1e6-2cd42170a7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_DepreciationAndAmortization_a7bd6946-8cec-458d-b1e6-2cd42170a7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_051fe503-1a80-4864-8ce0-0f3272d06281" xlink:href="evh-20220630.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_evh_GainOnTransferOfMembership_051fe503-1a80-4864-8ce0-0f3272d06281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_af090a09-e56f-4d31-858a-e5d08dc88e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_af090a09-e56f-4d31-858a-e5d08dc88e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f86d6efc-bc7a-4132-91b3-402fba3d9b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f86d6efc-bc7a-4132-91b3-402fba3d9b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_09c5c6ef-7660-41f9-81d5-a3b1d90fdd93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_09c5c6ef-7660-41f9-81d5-a3b1d90fdd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_59f3d190-626e-4fe4-9af1-fe6e00645fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_59f3d190-626e-4fe4-9af1-fe6e00645fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1c09cf5d-3a89-4d1c-9799-5ff8d9a326f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_RestructuringCharges_1c09cf5d-3a89-4d1c-9799-5ff8d9a326f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_28ab91a5-df74-4232-8999-655b67621e39" xlink:href="evh-20220630.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_28ab91a5-df74-4232-8999-655b67621e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_ff59043b-efe0-4a17-a10a-a2030874e8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_SeveranceCosts1_ff59043b-efe0-4a17-a10a-a2030874e8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_2ac6aac0-fb2e-4bd6-bb60-1f595e3de9cc" xlink:href="evh-20220630.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_2ac6aac0-fb2e-4bd6-bb60-1f595e3de9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices_e6590af8-cd84-4df7-88f6-4753ddb3c12a" xlink:href="evh-20220630.xsd#evh_ShareholderAdvisoryServices"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_evh_ShareholderAdvisoryServices_e6590af8-cd84-4df7-88f6-4753ddb3c12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts_a16980bf-682e-4136-a10b-20e629dce1e7" xlink:href="evh-20220630.xsd#evh_TransactionCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_evh_TransactionCosts_a16980bf-682e-4136-a10b-20e629dce1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9068a6e3-39aa-449e-8c0f-9ec4029edcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9068a6e3-39aa-449e-8c0f-9ec4029edcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_97e9259f-7b3e-46ca-b191-a277d1da08e6" xlink:href="evh-20220630.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_97e9259f-7b3e-46ca-b191-a277d1da08e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_9cd559e3-d02d-4705-a0d2-d4230906323a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f40d9146-d67d-43c4-b973-5e10d1c55d08" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_9cd559e3-d02d-4705-a0d2-d4230906323a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="simple" xlink:href="evh-20220630.xsd#ReservesforClaimsandPerformanceBasedArrangements"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_fdea8cfc-19c7-4cdc-8c8f-5eb1b170bb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock_e0f019ed-5cdc-461b-887d-0374575f08f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_fdea8cfc-19c7-4cdc-8c8f-5eb1b170bb64" xlink:to="loc_us-gaap_InsuranceDisclosureTextBlock_e0f019ed-5cdc-461b-887d-0374575f08f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="simple" xlink:href="evh-20220630.xsd#ReservesforClaimsandPerformanceBasedArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_24421a87-cfea-4990-bc9f-3d27faa536c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_2b7b6602-a3c4-480e-9e13-f7e55b92816f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_24421a87-cfea-4990-bc9f-3d27faa536c1" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_2b7b6602-a3c4-480e-9e13-f7e55b92816f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_50268689-6bff-497b-879d-000e1983f63a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_4a3c27f6-c8fb-4cf1-bc9f-1d8969ea79dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_50268689-6bff-497b-879d-000e1983f63a" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_4a3c27f6-c8fb-4cf1-bc9f-1d8969ea79dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4a57eb69-ed6c-441f-9ca9-67921e0053ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_4a3c27f6-c8fb-4cf1-bc9f-1d8969ea79dc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4a57eb69-ed6c-441f-9ca9-67921e0053ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_540c7238-d571-4715-b2a6-702a89e4d377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4a57eb69-ed6c-441f-9ca9-67921e0053ca" xlink:to="loc_us-gaap_SegmentDomain_540c7238-d571-4715-b2a6-702a89e4d377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_72c66672-43e6-4392-a84d-192811f74b92" xlink:href="evh-20220630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_540c7238-d571-4715-b2a6-702a89e4d377" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_72c66672-43e6-4392-a84d-192811f74b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_3fc96baf-723e-4e16-8e81-8203accea62c" xlink:href="evh-20220630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_540c7238-d571-4715-b2a6-702a89e4d377" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_3fc96baf-723e-4e16-8e81-8203accea62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_7084f058-9f5e-4201-8c1b-9750af8205c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_4a3c27f6-c8fb-4cf1-bc9f-1d8969ea79dc" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_7084f058-9f5e-4201-8c1b-9750af8205c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_7084f058-9f5e-4201-8c1b-9750af8205c0" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f4c1c903-099a-451a-9f14-dfab51b5242a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f4c1c903-099a-451a-9f14-dfab51b5242a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_3df8b998-3fac-45b9-9bd2-5db2b4d418f5" xlink:href="evh-20220630.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_3df8b998-3fac-45b9-9bd2-5db2b4d418f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_20db82f1-bb94-40d4-82a0-4999792e74b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_20db82f1-bb94-40d4-82a0-4999792e74b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_c29af084-6f3d-47d2-8d56-f5414a08a943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_c29af084-6f3d-47d2-8d56-f5414a08a943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_5d472dc3-8562-45f3-8cac-3e5f1ee9e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_5d472dc3-8562-45f3-8cac-3e5f1ee9e74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_408c5eb7-2b04-4da7-8a3b-7dfdfbf0ae77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_408c5eb7-2b04-4da7-8a3b-7dfdfbf0ae77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_490c14ed-184e-43bf-a6ea-e66312105e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_490c14ed-184e-43bf-a6ea-e66312105e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_4cb11c95-3223-409d-83a4-d0a1e48059a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_4cb11c95-3223-409d-83a4-d0a1e48059a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7449df95-fd15-4d98-9c8f-86e8bd425612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_1506a5e4-4e45-4a46-8fb1-8b1bc23a6a08" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7449df95-fd15-4d98-9c8f-86e8bd425612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="evh-20220630.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_b8c77cae-0d2d-4310-9ac3-f2be027cee57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_2a31d4ec-b56d-4f10-938c-b3383eb8efed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_b8c77cae-0d2d-4310-9ac3-f2be027cee57" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_2a31d4ec-b56d-4f10-938c-b3383eb8efed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="evh-20220630.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_2154a3ba-467a-436a-9135-7c7c1d98d77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_370c9824-f5ba-48b1-a2e9-b1b13ffb3807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_2154a3ba-467a-436a-9135-7c7c1d98d77e" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_370c9824-f5ba-48b1-a2e9-b1b13ffb3807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_14a3d8fc-81a9-45a6-802f-44479d6bfe5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6e641f6e-dd6f-4333-929e-f3599d2e5974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14a3d8fc-81a9-45a6-802f-44479d6bfe5a" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6e641f6e-dd6f-4333-929e-f3599d2e5974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_da265eee-54de-49b9-8f87-3d58a6fea934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6e641f6e-dd6f-4333-929e-f3599d2e5974" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_da265eee-54de-49b9-8f87-3d58a6fea934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract_8ef93dbf-7159-4242-b1c3-673220a0cfd5" xlink:href="evh-20220630.xsd#evh_CashFlowLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14a3d8fc-81a9-45a6-802f-44479d6bfe5a" xlink:to="loc_evh_CashFlowLesseeAbstract_8ef93dbf-7159-4242-b1c3-673220a0cfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_95709ca0-1102-4628-bf5f-8bf507333b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_8ef93dbf-7159-4242-b1c3-673220a0cfd5" xlink:to="loc_us-gaap_OperatingLeasePayments_95709ca0-1102-4628-bf5f-8bf507333b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_cf55b3ea-e20a-49ca-af4f-f05c2fdbc8d5" xlink:href="evh-20220630.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_8ef93dbf-7159-4242-b1c3-673220a0cfd5" xlink:to="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_cf55b3ea-e20a-49ca-af4f-f05c2fdbc8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEvents" xlink:type="simple" xlink:href="evh-20220630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_6ae5ff38-6351-4858-8821-3d603e359456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_7eab1e97-086d-4607-ba13-d4237479c1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_6ae5ff38-6351-4858-8821-3d603e359456" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_7eab1e97-086d-4607-ba13-d4237479c1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="evh-20220630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8089a068-7512-4657-95c2-4207a8c032f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8089a068-7512-4657-95c2-4207a8c032f1" xlink:to="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7cc97a55-e576-4647-86c9-501c3d6530f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7cc97a55-e576-4647-86c9-501c3d6530f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07cf48f5-dfb5-4e69-a440-08e94d7a80b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7cc97a55-e576-4647-86c9-501c3d6530f8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07cf48f5-dfb5-4e69-a440-08e94d7a80b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIncMember_496b1687-c96b-4d45-91a2-5259ed581c23" xlink:href="evh-20220630.xsd#evh_ImplantableProviderGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07cf48f5-dfb5-4e69-a440-08e94d7a80b1" xlink:to="loc_evh_ImplantableProviderGroupIncMember_496b1687-c96b-4d45-91a2-5259ed581c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_05477eaf-ca69-4d45-827b-eca13bad44ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_VariableRateAxis_05477eaf-ca69-4d45-827b-eca13bad44ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_abd51673-60d6-49aa-8b4d-f9c4c8f44331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_05477eaf-ca69-4d45-827b-eca13bad44ea" xlink:to="loc_us-gaap_VariableRateDomain_abd51673-60d6-49aa-8b4d-f9c4c8f44331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_c5c9d3b6-2dfa-4b83-b7ff-65a86ac8d9fd" xlink:href="evh-20220630.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_abd51673-60d6-49aa-8b4d-f9c4c8f44331" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_c5c9d3b6-2dfa-4b83-b7ff-65a86ac8d9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_d12b438f-541f-446a-9a12-136288def6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_abd51673-60d6-49aa-8b4d-f9c4c8f44331" xlink:to="loc_us-gaap_BaseRateMember_d12b438f-541f-446a-9a12-136288def6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e818f32d-f458-4f0f-9a1f-7b8949c6d8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e818f32d-f458-4f0f-9a1f-7b8949c6d8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b7c6d4dc-db9d-4a1a-9b90-08965c447301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e818f32d-f458-4f0f-9a1f-7b8949c6d8c1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b7c6d4dc-db9d-4a1a-9b90-08965c447301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_af11dceb-71e4-4ea0-97e6-b73b024dd5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b7c6d4dc-db9d-4a1a-9b90-08965c447301" xlink:to="loc_us-gaap_LineOfCreditMember_af11dceb-71e4-4ea0-97e6-b73b024dd5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_25fe5d36-02a7-4e44-ab09-87348f8329b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_CreditFacilityAxis_25fe5d36-02a7-4e44-ab09-87348f8329b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_08d9783a-908a-4c53-803a-b936ac416c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_25fe5d36-02a7-4e44-ab09-87348f8329b3" xlink:to="loc_us-gaap_CreditFacilityDomain_08d9783a-908a-4c53-803a-b936ac416c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_fd0c77ae-b806-423f-95a3-6ef17473ce4e" xlink:href="evh-20220630.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_08d9783a-908a-4c53-803a-b936ac416c30" xlink:to="loc_evh_A2022CreditFacilitiesMember_fd0c77ae-b806-423f-95a3-6ef17473ce4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_5182fad7-5a6d-41ad-a303-b0e15f66c07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_A2022CreditFacilitiesMember_fd0c77ae-b806-423f-95a3-6ef17473ce4e" xlink:to="loc_us-gaap_SecuredDebtMember_5182fad7-5a6d-41ad-a303-b0e15f66c07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_75795bdc-82e5-436c-af00-1bc20e84b573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_A2022CreditFacilitiesMember_fd0c77ae-b806-423f-95a3-6ef17473ce4e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_75795bdc-82e5-436c-af00-1bc20e84b573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a858324d-dd02-459b-9ad6-aab8ac36fada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a858324d-dd02-459b-9ad6-aab8ac36fada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_805cfc86-6c62-4ffb-8f89-b2f7bd91fba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a858324d-dd02-459b-9ad6-aab8ac36fada" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_805cfc86-6c62-4ffb-8f89-b2f7bd91fba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cdbf5ffc-980b-4fd0-8a3f-13d2e469c554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_805cfc86-6c62-4ffb-8f89-b2f7bd91fba8" xlink:to="loc_us-gaap_SubsequentEventMember_cdbf5ffc-980b-4fd0-8a3f-13d2e469c554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6d50e0aa-4f81-42f4-a0bf-1befb2bd5d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6d50e0aa-4f81-42f4-a0bf-1befb2bd5d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f955f4a7-8447-497f-a010-912e81527ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d50e0aa-4f81-42f4-a0bf-1befb2bd5d10" xlink:to="loc_us-gaap_EquityComponentDomain_f955f4a7-8447-497f-a010-912e81527ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2ebfd6b6-d8bb-4fa5-a0b8-707680b53313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f955f4a7-8447-497f-a010-912e81527ba0" xlink:to="loc_us-gaap_CommonStockMember_2ebfd6b6-d8bb-4fa5-a0b8-707680b53313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2dd67898-c06e-4641-980b-53deaa59cc2a" xlink:to="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_e829d5ac-39f5-4f46-8815-3e06b5e27e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_e829d5ac-39f5-4f46-8815-3e06b5e27e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a345ee06-5545-4d83-b060-7c38e754f7af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a345ee06-5545-4d83-b060-7c38e754f7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_20fb91e9-cc79-4fe4-8fb2-1c576ab95db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_20fb91e9-cc79-4fe4-8fb2-1c576ab95db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_959a9357-9f9d-45b6-b646-332e238281e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_959a9357-9f9d-45b6-b646-332e238281e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8a07c346-d6b4-4a24-9f88-028c46708b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8a07c346-d6b4-4a24-9f88-028c46708b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0088be81-8f74-4201-947d-dec169141557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0088be81-8f74-4201-947d-dec169141557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_3cc027ec-de54-40b4-b529-7214e58388db" xlink:href="evh-20220630.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_3cc027ec-de54-40b4-b529-7214e58388db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_329f6d6e-d220-4db7-9a9a-3cb312cc071c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_329f6d6e-d220-4db7-9a9a-3cb312cc071c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c264823e-7c15-4152-82af-3beb71c2b0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c264823e-7c15-4152-82af-3beb71c2b0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_f52f2987-8dee-4d48-ae95-cb7f72ff01a5" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_f52f2987-8dee-4d48-ae95-cb7f72ff01a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_fe75b318-32bd-43b1-8069-0c767cdf7ea6" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_fe75b318-32bd-43b1-8069-0c767cdf7ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_85129477-da6a-45b5-8d9a-f545b4f45136" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_85129477-da6a-45b5-8d9a-f545b4f45136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_1afa2997-a1be-4ac2-aed5-c7e2a294afc6" xlink:href="evh-20220630.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f851072-3c6d-4dab-8d4f-75e1891a6e02" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_1afa2997-a1be-4ac2-aed5-c7e2a294afc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481021728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 N. Glebe Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,669,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434478871136">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 193,070<span></span>
</td>
<td class="nump">$ 266,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74,377<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">118,525<span></span>
</td>
<td class="nump">130,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">37,173<span></span>
</td>
<td class="nump">51,391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">423,145<span></span>
</td>
<td class="nump">523,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,986<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,831<span></span>
</td>
<td class="nump">5,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92,627<span></span>
</td>
<td class="nump">81,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,873<span></span>
</td>
<td class="nump">50,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,655<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,721<span></span>
</td>
<td class="nump">32,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">264,846<span></span>
</td>
<td class="nump">279,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">426,228<span></span>
</td>
<td class="nump">426,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,303,912<span></span>
</td>
<td class="nump">1,419,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">96,565<span></span>
</td>
<td class="nump">96,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">75,846<span></span>
</td>
<td class="nump">107,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,389<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,371<span></span>
</td>
<td class="nump">51,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,711<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">125,960<span></span>
</td>
<td class="nump">171,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">342,842<span></span>
</td>
<td class="nump">445,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">283,138<span></span>
</td>
<td class="nump">215,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,619<span></span>
</td>
<td class="nump">5,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,581<span></span>
</td>
<td class="nump">57,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,644<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">690,824<span></span>
</td>
<td class="nump">725,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (See Note 11)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 91,657,480 and 90,758,318 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">916<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,231,005<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(782)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(596,928)<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 1,537,582 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,123)<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">613,088<span></span>
</td>
<td class="nump">693,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,303,912<span></span>
</td>
<td class="nump">$ 1,419,458<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434480751904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">91,657,480<span></span>
</td>
<td class="nump">90,758,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, at cost (in shares)</a></td>
<td class="nump">1,537,582<span></span>
</td>
<td class="nump">1,537,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475753856">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 319,939<span></span>
</td>
<td class="nump">$ 222,057<span></span>
</td>
<td class="nump">$ 616,996<span></span>
</td>
<td class="nump">$ 437,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">249,705<span></span>
</td>
<td class="nump">172,113<span></span>
</td>
<td class="nump">469,444<span></span>
</td>
<td class="nump">329,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">58,955<span></span>
</td>
<td class="nump">42,699<span></span>
</td>
<td class="nump">117,887<span></span>
</td>
<td class="nump">101,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,112<span></span>
</td>
<td class="nump">14,916<span></span>
</td>
<td class="nump">30,218<span></span>
</td>
<td class="nump">30,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,878<span></span>
</td>
<td class="num">(594)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">324,572<span></span>
</td>
<td class="nump">229,728<span></span>
</td>
<td class="nump">624,427<span></span>
</td>
<td class="nump">460,744<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,633)<span></span>
</td>
<td class="num">(7,671)<span></span>
</td>
<td class="num">(7,431)<span></span>
</td>
<td class="num">(23,616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">223<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,148)<span></span>
</td>
<td class="num">(6,274)<span></span>
</td>
<td class="num">(4,389)<span></span>
</td>
<td class="num">(12,611)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
<td class="nump">12,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">297<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,309)<span></span>
</td>
<td class="num">(9,016)<span></span>
</td>
<td class="num">(8,457)<span></span>
</td>
<td class="num">(19,595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(184)<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,125)<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(9,475)<span></span>
</td>
<td class="num">(20,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(463)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,588)<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(9,938)<span></span>
</td>
<td class="num">(18,914)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,588)<span></span>
</td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (9,938)<span></span>
</td>
<td class="num">$ (18,914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.05)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.05)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_WeightedAverageCommonSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,071<span></span>
</td>
<td class="nump">85,448<span></span>
</td>
<td class="nump">89,792<span></span>
</td>
<td class="nump">85,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,071<span></span>
</td>
<td class="nump">85,448<span></span>
</td>
<td class="nump">89,792<span></span>
</td>
<td class="nump">85,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income (loss)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,588)<span></span>
</td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (9,938)<span></span>
</td>
<td class="num">$ (18,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of taxes, related to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(288)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="num">(420)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,876)<span></span>
</td>
<td class="num">$ (9,165)<span></span>
</td>
<td class="num">$ (10,358)<span></span>
</td>
<td class="num">$ (19,003)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes $(0.5)&#160;million loss on disposal for the three and six months ended June 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021, respectively</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_WeightedAverageCommonSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Common Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_WeightedAverageCommonSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434485805744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on disposal of discontinued operations</a></td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475010224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th">
<div>Retained Earnings (Accumulated Deficit) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 1,229,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (278)<span></span>
</td>
<td class="num">$ (589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">9,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">9,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(3,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(3,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">614,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">1,242,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(608,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">1,229,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 693,633<span></span>
</td>
<td class="num">$ (66,383)<span></span>
</td>
<td class="nump">$ 908<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
<td class="nump">$ 39,789<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">$ 617,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">1,236,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="num">(598,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">614,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">1,242,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(608,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">693,633<span></span>
</td>
<td class="num">$ (66,383)<span></span>
</td>
<td class="nump">$ 908<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
<td class="nump">$ 39,789<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">12,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(5,239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(5,243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Leveraged stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Leveraged stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(11,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(11,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">613,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">1,231,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(782)<span></span>
</td>
<td class="num">(596,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">611,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">1,224,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(494)<span></span>
</td>
<td class="num">(592,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 613,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">$ 1,231,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (782)<span></span>
</td>
<td class="num">$ (596,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475604688">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows Used In Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,938)<span></span>
</td>
<td class="num">$ (18,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,878<span></span>
</td>
<td class="num">(594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainLossOnDispositionOfAssetsOperatingActivities', window );">Loss (gain) on discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">463<span></span>
</td>
<td class="num">(1,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,548)<span></span>
</td>
<td class="num">(12,662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,218<span></span>
</td>
<td class="nump">30,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,358<span></span>
</td>
<td class="nump">7,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax provision (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">472<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,186<span></span>
</td>
<td class="nump">8,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">8,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other current operating cash inflows (outflows), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">692<span></span>
</td>
<td class="num">(729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of acquisitions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset', window );">Accounts receivable, net and contract assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,042<span></span>
</td>
<td class="num">(120,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,453)<span></span>
</td>
<td class="num">(3,439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInCapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,284)<span></span>
</td>
<td class="num">(3,991)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(823)<span></span>
</td>
<td class="nump">9,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,826)<span></span>
</td>
<td class="num">(17,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22,379)<span></span>
</td>
<td class="num">(21,505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,233)<span></span>
</td>
<td class="nump">2,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(45,334)<span></span>
</td>
<td class="nump">62,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset', window );">Right-of-use operating assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(669)<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">179<span></span>
</td>
<td class="num">(2,719)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(858)<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and restricted cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43,778)<span></span>
</td>
<td class="num">(72,410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Provided by Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for asset acquisitions and business combinations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,070)<span></span>
</td>
<td class="num">(1,472)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates', window );">Proceeds from transfer of membership and release of Passport escrow</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,969<span></span>
</td>
<td class="nump">42,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet', window );">Disposal of non-strategic assets and divestiture of discontinued operations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Return of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,175<span></span>
</td>
<td class="nump">9,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,994)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ProceedsFromMaturityOfInvestments', window );">Maturities and sales of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Investments in internal-use software and purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17,744)<span></span>
</td>
<td class="num">(11,512)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and restricted cash provided by investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">330<span></span>
</td>
<td class="nump">40,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows Used In Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities', window );">Changes in working capital balances related to claims processing on behalf of partners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">360<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Repayment of Credit Agreement including settlement of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(98,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">309<span></span>
</td>
<td class="nump">9,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to Sponsors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,884)<span></span>
</td>
<td class="num">(1,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes withheld and paid for vesting of equity awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,471)<span></span>
</td>
<td class="num">(3,142)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and restricted cash used in financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(30,686)<span></span>
</td>
<td class="num">(91,087)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(375)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(74,509)<span></span>
</td>
<td class="num">(123,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of beginning-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">354,942<span></span>
</td>
<td class="nump">361,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of end-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 280,433<span></span>
</td>
<td class="nump">$ 238,410<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossOnDispositionOfAssetsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition Of Assets, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossOnDispositionOfAssetsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInCapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Capitalized Contract Cost, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInCapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Claims Processing, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromMaturityOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Maturity Of Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromMaturityOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434486874592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred losses from operations. As of June&#160;30, 2022, the Company had unrestricted cash and cash equivalents of $193.1 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div>Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434487816640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</a></td>
<td class="text">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2021 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of June&#160;30, 2022 and December 31, 2021, approximately $11.5&#160;million and $11.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and was $3.8&#160;million and $7.9&#160;million for the three and six months ended June 30, 2022, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 21 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right of Offset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of June&#160;30, 2022 and December&#160;31, 2021, approximately 64% and 42% of gross accounts receivable was netted against claims payable in lieu of cash receipt. Furthermore, as of June&#160;30, 2022, approximately 13% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div>See Note 6 for further discussion of our policies related to revenue recognition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482108992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text">Recently Issued Accounting Standards<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482044608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Transactions</a></td>
<td class="text">Transactions<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vital Decisions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company completed its acquisition of Vital Decisions, including 100% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total merger consideration, net of cash on hand and certain closing adjustments, was $117.7 million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $46.5 million of cash consideration, 1.8&#160;million shares of Class A common stock, fair valued at $56.6 million as of October 1, 2021, and an earn-out of up to $45.0&#160;million, fair valued at $14.6 million as of October 1, 2021. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of 13 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $69.6&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments will be finalized by the end of the third quarter of 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481979040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued OperationsOn January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six <br/>Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the six months ended June 30, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the six months ended June 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the six months ended June 30, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"/><td style="width:89.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482018048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:114.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,967&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,603&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $139.6 million of transaction price to performance obligations that are unsatisfied as of June&#160;30, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 28%, 60% and 82% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June&#160;30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the six months ended June 30, 2022 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $19.5&#160;million and $46.1&#160;million for the three and six months ended June 30, 2022, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of June&#160;30, 2022 and December 31, 2021, the Company had $3.8 million and $5.2 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of $0.3 million and $1.7 million for the three and six months ended June 30, 2022, respectively, and $0.6 million and $1.0 million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our platform and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of June&#160;30, 2022 and December 31, 2021, the Company had $18.9 million and $27.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for certain customers of $1.2 million and $11.5 million for the three and six months ended June 30, 2022, respectively, and $4.6 million and $7.3 million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482009760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentTextBlock', window );">Credit Losses</a></td>
<td class="text">Credit Losses <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic and current inflationary pressures on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the three and six months ended June 30, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three and six months ended June 30, 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;June&#160;30, 2022,&#160;90% were current, 6%&#160;were past due less than 60 days, with 8% past due less than 120 days and at December 31, 2021, 90% was current, 2% was past due less than 60 days, with 3% past due less than 120 days. As of&#160;June&#160;30, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$127.7 million&#160;and $171.5&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$3.1 million and $3.4 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,052)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,667)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919236-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919269-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481980272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $7.1 million and $13.5 million for the three and six months ended June 30, 2022, respectively, and $5.6 million and $11.1 million for the three and six months ended June 30, 2021, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $71.5 million and $71.2 million as of June&#160;30, 2022 and December 31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $7.8 million and $15.4 million for the three and six months ended June 30, 2022, respectively, and $7.6 million and $15.4 million for the three and six months ended June 30, 2021, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.5 million and $13.2 million for the three and six months ended June 30, 2022, respectively, and $6.6 million and $13.3 million for the three and six months ended June 30, 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482006032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">Goodwill and Intangible Assets, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three and six months ended June 30, 2022</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will perform our annual impairment test on October 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2022 and December&#160;31, 2021  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,195&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,349&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,846&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was $7.3 million and $14.8 million for the three and six months ended June 30, 2022, respectively, and $7.2 million and $14.7 million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of June&#160;30, 2022, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,846&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the three and six months ended June 30, 2022, that would require an impairment test for our intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482012192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $1.0 million and $2.0 million for both the three and six months ended June 30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7&#160;million and $1.3&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1&#160;million decrease in additional paid-in capital and a $1.3&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.2 million and $0.4 million for the three and six months ended June 30, 2022, respectively, and $2.0 million and $3.9 million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;2019 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#8220;DDTL Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's 2019 Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the 2019 Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the 2019 Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the 2019 Credit Agreement for $13.7&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $0.7 million and $1.3 million for both the three and six months ended June 30, 2022 and 2021 respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8&#160;million </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease in additional paid-in capital and a $2.5&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.3 million and $0.6 million for the three and six months ended June 30, 2022, respectively, and $2.4 million and $4.8 million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $28.5&#160;million resulting in a loss on debt extinguishment of $2.2&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of June&#160;30, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of June&#160;30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482015616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $13.8&#160;million and&#160;$15.4 million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $13.8&#160;million and $15.4 million, respectively, in restricted cash and restricted investments as collateral as of June&#160;30, 2022 and December&#160;31, 2021. The letters of credit have current expiration dates between June 2022 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three and six months ended June 30, 2022, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of June&#160;30, 2022, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable (receivable) for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,336)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#8217;s customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#8217;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, was filed on December 2, 2021. On July 13, 2022, the parties to the class action executed a term sheet for settlement of the litigation, subject to documentation of the settlement and approval of the court after notice to class members. On August 2, 2022, the lead plaintiff in the case filed an unopposed motion seeking preliminary approval of the settlement and related exhibits, including draft notice to class members and a proposed final order. The settlement stipulation is subject to preliminary and final approval by the court. If the settlement is approved, we expect that the agreed-upon settlement payment of $23.5&#160;million will be funded entirely by applicable directors&#8217; and officers&#8217; liability insurance. As such, we do not expect to incur a significant net loss or cash outflow as a result of the settlement of this matter.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lincolnshire Police Pension Fund, derivatively on behalf o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. (&#8220;Derivative Action&#8221;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs have not yet responded to the motion to dismiss and there is not currently a briefing schedule on file with the Delaware Chancery Court. Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of June&#160;30, 2022, approximately 98.6% of our $280.4 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 0.9% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable, as of June&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Centers for Medicare and Medicaid Services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and six months ended June 30, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross and Blue Shield of North Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div>We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481998672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $2.3 million and $3.8 million in letters of credit as of June&#160;30, 2022 and December&#160;31, 2021. As of June&#160;30, 2022 and December&#160;31, 2021, the Company held $2.3 million and $3.8 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of June&#160;30, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,402&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of June&#160;30, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481953376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
<td class="text">Loss Per Common Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,475)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,297)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,549&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,322&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481938896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,012&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock-based compensation was capitalized as software development costs for the three and six months ended June 30, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481953376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax expense (benefit) of $(0.2)&#160;million and $1.0&#160;million and was recognized for the three and six months ended June 30, 2022, respectively, which resulted in effective tax rates of 3.9% and (11.4)%, respectively. An income tax expense (benefit) of $0.1&#160;million and $0.7&#160;million was recognized for the three and six months ended June 30, 2021, respectively, which resulted in effective tax rates of (1.0)% and (3.6)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax expense recorded during the three and six months ended June 30, 2022 and 2021 primarily relates to foreign taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, the Company had unrecognized tax benefits of $0.6 million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of June&#160;30, 2022, there are no changes to the unrecognized tax benefits. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above for discussion of our TRA.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482063824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments in Equity Method Investees</a></td>
<td class="text">Investments in Equity Method Investees<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;June&#160;30, 2022 and December&#160;31, 2021, the Company&#8217;s economic interests in its equity method investments ranged between 4% and 38% and 4% and 39%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $2.0 million and $2.5 million for the three and six months ended June 30, 2022, respectively, and $4.9 million and $12.7 million for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $3.9 million and $7.5 million for the three and six months ended June 30, 2022, respectively, and $2.3 million and $8.6 million for the three and six months ended June 30, 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482044608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three and six months ended June 30, 2022 and 2021, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the acquisition of Vital Decisions includes a provision for additional equity consideration contingent upon the Company obtaining certain annualized performance metrics during the three months ending December 31, 2022. The fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Vital Decisions contingent consideration are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482100864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related Parties  <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:319.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482059104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Repositioning and Other Changes</a></td>
<td class="text">Repositioning and Other Changes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Costs Incurred through December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482099200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment ReportingWe define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:<div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, provision for income taxes, depreciation and amortization expenses, adjusted to exclude gain on transfer of membership, loss on repayment of debt, net, gain from equity method investees, changes in fair value of contingent consideration, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain from discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,492&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,782)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,609&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,417&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,688&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,473&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,793)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,253&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,070)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,253&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $(0.5)&#160;million loss on disposal of discontinued operations for the three and six months ended June 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482059104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceDisclosureTextBlock', window );">Reserves for Claims and Performance-Based Arrangements</a></td>
<td class="text">Reserve for Claims and Performance-Based Arrangements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,486)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,774)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,260)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,512)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on reserves for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,828&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,960&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,504&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,601&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,105&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI https://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481980272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">Supplemental Cash Flow Information <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482051904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of  IPG</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company, Evolent Health LLC, and Endzone Merger Sub, Inc, entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with TPG Growth Iceman Parent, Inc., and TPG Growth V Iceman, L.P. to acquire Implantable Provider Group, Inc. (&#8220;IPG&#8221;) for $250.0 million in cash and $125.0&#160;million in Class A Common Stock of the Company, together with a potential earnout of up to $87.0&#160;million  payable in in cash and shares of Class A Common Stock of the Company in 2023. On August 1, 2022, the transactions contemplated by the Merger Agreement were consummated and the Company issued 3.7&#160;million shares of Class A Common Stock in connection therewith. IPG will report into Evolent&#8217;s specialty care management offering, New Century Health, and will be consolidated into the Company&#8217;s Clinical Solutions segment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ares Secured Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022 (the &#8220;Closing Date&#8221;), the Company entered into a Credit Agreement, by and among the Company, Evolent Health LLC (&#8220;Evolent&#8221;), Endzone Merger Sub, Inc. (&#8220;Endzone&#8221; or &#8220;Initial Borrower&#8221;), which upon consummation of the transactions contemplated by the Merger Agreement will be merged with and into TPG Growth Iceman Parent, Inc., Implantable Provider Group, Inc. (&#8220;Implantable&#8221;, collectively with Evolent, Endzone and TPG Growth Iceman Parent, the &#8220;Borrowers&#8221; and each a &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, Ares Capital Corporation, as administrative agent, and ACF Finco I LP, as collateral agent and as revolver agent (the &#8220;2022 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrowers in the form of (i) an initial term loan in the aggregate principal amount of $175.0&#160;million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million and a borrowing base (the &#8220;Revolving Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;2022 Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the Initial Term Loan Facility on August 1, 2022 (the &#8220;Initial Term Loan&#8221;), and also borrowed $50.0&#160;million under the Revolving Facility on the Closing Date. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2022 Credit Agreement, on August 1, 2022, the Company entered into a Security Agreement, by and among the Company, the Borrowers, the other guarantors and the collateral agent for the benefit of the secured parties and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The proceeds of the Initial Term Loan may be used to fund ongoing working capital needs and other growth capital expenditure investments, and to finance the transactions contemplated by the Merger Agreement and fund fees and expenses incurred in connection therewith. The proceeds of the Revolving Facility may be used to finance the transactions contemplated by the Merger Agreement and to pay fees and expenses incurred in connection therewith on the Closing Date and thereafter to fund acquisitions, ongoing working capital needs and other growth capital investments and to pay fees and expenses in connection therewith.  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Initial Term Loan and loans under the Revolving Facility will mature on the date that is the earliest of (a) August 1, 2027, (b) the date on which all amounts outstanding under the 2022 Credit Agreement have been declared or have automatically become due and payable under the terms of the 2022 Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the 2022 Credit Agreement) unless certain liquidity conditions are satisfied.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest and Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The interest rate for each loan under the 2022 Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the 2022 Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">base rate plus 2.50%. A commitment fee of (a) 2.00% per annum of the aggregate amount of the commitments in respect of the Term Loan Facility as of the Closing Date and (b) 2.00% of the aggregate amount of the commitments in respect of the Revolving Facility as of the Closing Date is payable by the Borrowers quarterly in arrears.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepayment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts outstanding under the Credit Facility may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 3.00% of the principal amount so prepaid after the Closing Date but prior to the first anniversary of the Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the Closing Date but prior to the third anniversary of the Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees and Collateral.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The 2022 Credit Facilities are guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain exceptions. The 2022 Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain exceptions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenants and Other Provisions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The 2022 Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum liquidity test commencing upon closing of the 2022 Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending September 30, 2022. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the 2022 Credit Facilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434480951952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationIn our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates and Assumptions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div>Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">Research and Development CostsResearch and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and was $3.8&#160;million and $7.9&#160;million for the three and six months ended June 30, 2022, respectively.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityReserveEstimatePolicy', window );">Reserves for Claims and Performance-based Arrangements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company </span></div>uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfOffsetPolicyPolicyTextBlock', window );">Right of Offset</a></td>
<td class="text">Right of OffsetCertain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434483442640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of restricted cash and cash equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of June&#160;30, 2022 and December 31, 2021, approximately $11.5&#160;million and $11.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash and cash equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2022 and December&#160;31, 2021  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,195&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,349&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,846&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481996144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of allocation of purchase price</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of net assets acquired</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482038496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of discontinued operations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six <br/>Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the six months ended June 30, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the six months ended June 30, 2021.</span></div>Cash flows related to the True Health business during the six months ended June 30, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"/><td style="width:89.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434479027808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of revenue</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:114.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,967&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,603&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with customer, asset and liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June&#160;30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the six months ended June 30, 2022 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482150256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Accounts receivable, allowance for credit loss</a></td>
<td class="text">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,052)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,667)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482137344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434478973680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets details</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2022 and December&#160;31, 2021  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,195&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,349&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,846&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future estimated amortization of intangible assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of June&#160;30, 2022, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,846&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482177520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible debt</a></td>
<td class="text">The following table summarizes the carrying value of the long-term convertible debt as of June&#160;30, 2022 and December 31, 2021 (in thousands):<div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434483633744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectsOfReinsuranceTableTextBlock', window );">Summary of premiums and claims assumed</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable (receivable) for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,336)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of major customers</a></td>
<td class="text">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable, as of June&#160;30, 2022 and December&#160;31, 2021:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Centers for Medicare and Medicaid Services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and six months ended June 30, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross and Blue Shield of North Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectsOfReinsuranceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectsOfReinsuranceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482145936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of primary office leases and maturity of lease liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of June&#160;30, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of June&#160;30, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,402&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434478969024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of basic and diluted earnings per share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,475)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,297)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,549&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,322&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434483582432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-based compensation expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,012&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of share-based awards granted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481992496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of liabilities at fair value on recurring basis</a></td>
<td class="text">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands): <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in contingent consideration measured at fair value</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Valuation techniques and significant unobservable inputs of Level 3 fair value measurements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482103744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related parties</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:319.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482116832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Costs associated with the Repositioning Plan</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Costs Incurred through December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434483569904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of revenue from segments to consolidated</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,492&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,782)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,609&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,417&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,688&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,473&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,793)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,253&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Adjusted EBITDA to net loss</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,070)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,253&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $(0.5)&#160;million loss on disposal of discontinued operations for the three and six months ended June 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482167296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Activity in claims reserves</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,486)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,774)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,260)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,512)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on reserves for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,828&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,960&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,504&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,601&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,105&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482084992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of cash flow, supplemental disclosures</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434483564336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 193,070<span></span>
</td>
<td class="nump">$ 266,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481180096">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 74,377<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Total current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74,377<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,986<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Total non-current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,986<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">193,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">280,433<span></span>
</td>
<td class="nump">354,942<span></span>
</td>
<td class="nump">$ 238,410<span></span>
</td>
<td class="nump">$ 361,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember', window );">Collateral for letters of credit for facility leases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,504<span></span>
</td>
<td class="nump">11,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember', window );">Claims processing services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73,585<span></span>
</td>
<td class="nump">73,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Bank time deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434483564336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details) - reportingUnit<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units for goodwill testing</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475374224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474236064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>source</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs | $</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable', window );">Right of offset, percentage of accounts receivable netted against claims payable</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement', window );">Right of offset, percentage of accounts receivable, net eligible for net basis settlement</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_NumberOfSourcesOfRevenue', window );">Number of sources of revenue | source</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfSourcesOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Sources Of Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfSourcesOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434479916400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recently Issued Accounting Standards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">$ 613,088<span></span>
</td>
<td class="nump">$ 611,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,633<span></span>
</td>
<td class="nump">$ 614,190<span></span>
</td>
<td class="nump">$ 617,298<span></span>
</td>
<td class="nump">$ 619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member', window );">2025 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | 2024 Notes | Senior Notes | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | 2025 Notes | Senior Notes | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="num">(596,928)<span></span>
</td>
<td class="num">(592,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
<td class="num">(608,092)<span></span>
</td>
<td class="num">(598,985)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | 2024 Notes | Senior Notes | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | 2025 Notes | Senior Notes | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">$ 1,231,005<span></span>
</td>
<td class="nump">$ 1,224,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
<td class="nump">$ 1,242,900<span></span>
</td>
<td class="nump">$ 1,236,847<span></span>
</td>
<td class="nump">$ 1,229,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474816304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions - Vital Decisions (Details) - USD ($)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,070<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,228<span></span>
</td>
<td class="nump">$ 349,009<span></span>
</td>
<td class="nump">$ 426,297<span></span>
</td>
<td class="nump">$ 349,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
<td class="text">14 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
<td class="text">11 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interests acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares)</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration arrangements (up to)</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="nump">56,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="nump">14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">117,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Tangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">3,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">2,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Total tangible assets acquired</a></td>
<td class="nump">7,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Operating lease liabilities</a></td>
<td class="nump">2,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">6,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">77,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">117,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="nump">69,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474806400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Results of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="num">$ (463)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (463)<span></span>
</td>
<td class="nump">$ 1,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense', window );">Claims expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation and amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,763<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss before income taxes and non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(326)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Platform and operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Claims Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1063-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PremiumsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481929248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Cash Flows (Details) - True Health - Discontinued Operations, Disposed of by Sale<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash flows provided by operating activities</a></td>
<td class="nump">$ 5,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Cash flows used in investing activities</a></td>
<td class="num">$ (2,494)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474254768">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 319,939<span></span>
</td>
<td class="nump">$ 222,057<span></span>
</td>
<td class="nump">$ 616,996<span></span>
</td>
<td class="nump">$ 437,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92,336<span></span>
</td>
<td class="nump">74,863<span></span>
</td>
<td class="nump">199,194<span></span>
</td>
<td class="nump">159,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicaid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,422<span></span>
</td>
<td class="nump">52,064<span></span>
</td>
<td class="nump">122,336<span></span>
</td>
<td class="nump">112,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicare</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,863<span></span>
</td>
<td class="nump">6,346<span></span>
</td>
<td class="nump">14,696<span></span>
</td>
<td class="nump">14,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Commercial and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,051<span></span>
</td>
<td class="nump">16,453<span></span>
</td>
<td class="nump">62,162<span></span>
</td>
<td class="nump">32,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,603<span></span>
</td>
<td class="nump">147,194<span></span>
</td>
<td class="nump">417,802<span></span>
</td>
<td class="nump">277,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicaid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,080<span></span>
</td>
<td class="nump">53,648<span></span>
</td>
<td class="nump">156,967<span></span>
</td>
<td class="nump">96,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicare</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">101,529<span></span>
</td>
<td class="nump">90,761<span></span>
</td>
<td class="nump">193,796<span></span>
</td>
<td class="nump">176,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Commercial and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 39,994<span></span>
</td>
<td class="nump">$ 2,785<span></span>
</td>
<td class="nump">$ 67,039<span></span>
</td>
<td class="nump">$ 3,897<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicaidCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicaidCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicareCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicareCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475011280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 139.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">82.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434478896960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Short-term receivables</a></td>
<td class="nump">$ 116,580<span></span>
</td>
<td class="nump">$ 116,580<span></span>
</td>
<td class="nump">$ 129,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent', window );">Long-term receivables</a></td>
<td class="nump">5,038<span></span>
</td>
<td class="nump">5,038<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="nump">8,711<span></span>
</td>
<td class="nump">8,711<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">3,605<span></span>
</td>
<td class="nump">3,605<span></span>
</td>
<td class="nump">$ 4,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of beginning-of-period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Reclassification to revenue, as a result of performance obligations satisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations', window );">Cash received in advance of satisfaction of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of end of period</a></td>
<td class="nump">12,316<span></span>
</td>
<td class="nump">12,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized from performed obligations</a></td>
<td class="nump">$ 19,500<span></span>
</td>
<td class="nump">$ 46,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475734512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,186<span></span>
</td>
<td class="nump">$ 8,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationPeriod', window );">Capitalized contract cost, amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember', window );">Bonuses and Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember', window );">Contract Fulfillment Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">18,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131251-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474072448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Losses - Accounts Receivable (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_FinancingReceivablePercentNotPastDue', window );">Percentage of receivables, current</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 127,700<span></span>
</td>
<td class="nump">$ 171,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts, current</a></td>
<td class="nump">$ 3,052<span></span>
</td>
<td class="nump">$ 3,374<span></span>
</td>
<td class="nump">$ 7,667<span></span>
</td>
<td class="nump">$ 7,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember', window );">Past due less than 60 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember', window );">Past due less than 120 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FinancingReceivablePercentNotPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Percent Not Past Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FinancingReceivablePercentNotPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNoncurrentPastDueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePercentPastDue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of financing receivable balance that is past due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePercentPastDue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434479034752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of beginning of period</a></td>
<td class="num">$ (3,374)<span></span>
</td>
<td class="num">$ (7,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="nump">322<span></span>
</td>
<td class="num">(611)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of end of period</a></td>
<td class="num">$ (3,052)<span></span>
</td>
<td class="num">$ (7,667)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474721248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 226,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization expenses</a></td>
<td class="num">(134,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,098)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">92,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">7,800<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Capitalized computer software, amortization</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="nump">13,200<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">26,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">173,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,587<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">71,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software additions</a></td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 23,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434486793808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Impairment Testing (Details) - reportingUnit<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units for goodwill testing</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474744144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units for goodwill testing | reportingUnit</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,297<span></span>
</td>
<td class="nump">$ 349,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426,228<span></span>
</td>
<td class="nump">349,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative inception to date impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,500<span></span>
</td>
<td class="nump">$ 575,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,334<span></span>
</td>
<td class="nump">214,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,265<span></span>
</td>
<td class="nump">214,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,963<span></span>
</td>
<td class="nump">134,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,963<span></span>
</td>
<td class="nump">$ 134,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475853536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 442,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">177,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,592<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">264,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="nump">$ 14,800<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">8,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">17,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">311,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">81,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,697<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">229,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">87,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">77,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,378<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">10,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember', window );">Below market lease, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">16,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">9,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,874<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 6,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474720288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 14,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">26,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">20,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">19,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">19,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">164,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 264,846<span></span>
</td>
<td class="nump">$ 279,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434471347392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2024 Notes (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (613,088,000)<span></span>
</td>
<td class="num">$ (614,190,000)<span></span>
</td>
<td class="num">$ (613,088,000)<span></span>
</td>
<td class="num">$ (614,190,000)<span></span>
</td>
<td class="num">$ (611,209,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (693,633,000)<span></span>
</td>
<td class="num">$ (617,298,000)<span></span>
</td>
<td class="num">$ (619,600,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,000<span></span>
</td>
<td class="nump">8,837,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(916,000)<span></span>
</td>
<td class="num">(872,000)<span></span>
</td>
<td class="num">(916,000)<span></span>
</td>
<td class="num">(872,000)<span></span>
</td>
<td class="num">(916,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(908,000)<span></span>
</td>
<td class="num">(868,000)<span></span>
</td>
<td class="num">(859,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,231,005,000)<span></span>
</td>
<td class="num">(1,242,900,000)<span></span>
</td>
<td class="num">(1,231,005,000)<span></span>
</td>
<td class="num">(1,242,900,000)<span></span>
</td>
<td class="num">(1,224,250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,340,989,000)<span></span>
</td>
<td class="num">(1,236,847,000)<span></span>
</td>
<td class="num">(1,229,320,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,928,000<span></span>
</td>
<td class="nump">608,092,000<span></span>
</td>
<td class="nump">596,928,000<span></span>
</td>
<td class="nump">608,092,000<span></span>
</td>
<td class="nump">$ 592,340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626,779,000<span></span>
</td>
<td class="nump">$ 598,985,000<span></span>
</td>
<td class="nump">$ 589,178,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,789,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtIssuanceCostsNetDebtComponent', window );">Debt issuance costs, net, debt component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Repurchase covenant, consecutive trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0548667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Deferred Financing Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member', window );">2021 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="nump">26,300,000<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember', window );">New Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtIssuanceCostsNetDebtComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Net, Debt Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtIssuanceCostsNetDebtComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_NewNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474756800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Credit Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (19,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember', window );">Initial Term Loan Facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="nump">$ 19,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Unamortized debt issuance cost</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal expenses</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit | DDTL Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of long-term lines of credit</a></td>
<td class="nump">98,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsOfMakeWholePremium', window );">Payments of make-whole premium</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid, Excluding Capitalized Interest, Operating Activities</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsOfMakeWholePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Make-Whole Premium</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsOfMakeWholePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474063984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Warrant Agreement (Details) - Class A Common Stock - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants agreed to be sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,513,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement', window );">Period during which warrants or rights exercisable, after maturity of credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments to settle outstanding warrants</a></td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434470119968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2025 Notes (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 22, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (613,088,000)<span></span>
</td>
<td class="num">$ (614,190,000)<span></span>
</td>
<td class="num">$ (613,088,000)<span></span>
</td>
<td class="num">$ (614,190,000)<span></span>
</td>
<td class="num">$ (611,209,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (693,633,000)<span></span>
</td>
<td class="num">$ (617,298,000)<span></span>
</td>
<td class="num">$ (619,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,000<span></span>
</td>
<td class="nump">8,837,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(916,000)<span></span>
</td>
<td class="num">(872,000)<span></span>
</td>
<td class="num">(916,000)<span></span>
</td>
<td class="num">(872,000)<span></span>
</td>
<td class="num">(916,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(908,000)<span></span>
</td>
<td class="num">(868,000)<span></span>
</td>
<td class="num">(859,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,231,005,000)<span></span>
</td>
<td class="num">(1,242,900,000)<span></span>
</td>
<td class="num">(1,231,005,000)<span></span>
</td>
<td class="num">(1,242,900,000)<span></span>
</td>
<td class="num">(1,224,250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,340,989,000)<span></span>
</td>
<td class="num">(1,236,847,000)<span></span>
</td>
<td class="num">(1,229,320,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,928,000<span></span>
</td>
<td class="nump">608,092,000<span></span>
</td>
<td class="nump">596,928,000<span></span>
</td>
<td class="nump">608,092,000<span></span>
</td>
<td class="nump">$ 592,340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626,779,000<span></span>
</td>
<td class="nump">$ 598,985,000<span></span>
</td>
<td class="nump">$ 589,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,789,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="nump">$ 100,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">166,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price (at least)</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Repurchase covenant, consecutive trading days, minimum</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 71,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="nump">0.0299135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Deferred Financing Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434471315408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2021 Notes (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 01, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Net loss on extinguishment of debt, including fees paid to lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="nump">26,300,000<span></span>
</td>
<td class="nump">84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Net loss on extinguishment of debt, including fees paid to lenders</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Face amount of debt repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of senior debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtConversionOriginalDebtFairValue', window );">Debt conversion, original debt, fair value</a></td>
<td class="nump">$ 28,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtConversionOriginalDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Original Debt, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtConversionOriginalDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474709104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Oct. 24, 2018</div></th>
<th class="th"><div>Oct. 22, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt, Total</a></td>
<td class="nump">$ 114,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">2,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,051,000<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 197,477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt, Total</a></td>
<td class="nump">168,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">4,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 195,434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475008864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid', window );">Percent of tax savings to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Shareholder Class Action Complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,504<span></span>
</td>
<td class="nump">11,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit | Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivables Agreement, Percent of Tax Savings to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=evh_ShareholderClassActionComplaintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=evh_ShareholderClassActionComplaintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474721824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Reinsurance Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumedPremiumsWritten', window );">Reinsurance premiums assumed</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 17,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed', window );">Claims assumed</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">16,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims', window );">Claims-related administrative expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet', window );">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</a></td>
<td class="num">(151)<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward', window );"><strong>Assumed Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">4,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables', window );">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ProceedsRepaymentsForReinsurance', window );">Reinsurance payments paid (received)</a></td>
<td class="num">(328)<span></span>
</td>
<td class="nump">7,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Payable (receivable) for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</a></td>
<td class="nump">$ 267<span></span>
</td>
<td class="num">$ (3,336)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed Liability for Unpaid Claims and Claims Adjustment Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premiums Written And Policyholder Benefits And Claims Incurred, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsRepaymentsForReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Repayments) For Reinsurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsRepaymentsForReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability as of the balance sheet date for the estimated ultimate cost of settling claims and claim adjustment expense relating to insured events that have occurred on or before the balance sheet date for those liabilities owed to another party as a result of assuming another insurer's primary obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedPremiumsWritten">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of written premiums assumed from other entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedPremiumsWritten</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of policy benefits and costs incurred for policies assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434480887824">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Concentration Risk (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashFDICInsuredAmountPercentage', window );">Percentage of cash and cash equivalents held with FDIC participating bank</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">98.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents (including restricted cash)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 280,433<span></span>
</td>
<td class="nump">$ 238,410<span></span>
</td>
<td class="nump">$ 280,433<span></span>
</td>
<td class="nump">$ 238,410<span></span>
</td>
<td class="nump">$ 354,942<span></span>
</td>
<td class="nump">$ 361,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashHeldInInternationalBanksPercentage', window );">Percentage of cash held in international banks (less than)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24.10%<span></span>
</td>
<td class="nump">29.60%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">29.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
<td class="nump">11.80%<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember', window );">Molina Healthcare | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CenterForMedicareAndMedicaidServicesMember', window );">The Centers for Medicare and Medicaid Services | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember', window );">Bright Health Management, Inc. | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_BlueCrossAndBlueShieldOfNorthCarolinaMember', window );">Blue Cross and Blue Shield of North Carolina | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFDICInsuredAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, FDIC Insured Amount, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFDICInsuredAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashHeldInInternationalBanksPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Held In International Banks, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashHeldInInternationalBanksPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MolinaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CenterForMedicareAndMedicaidServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CenterForMedicareAndMedicaidServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_BlueCrossAndBlueShieldOfNorthCarolinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_BlueCrossAndBlueShieldOfNorthCarolinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434478958432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475755056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Primary Office Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 84,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_VA', window );">Arlington, VA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 34,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Riverside, IL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 39,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">Edison, NJ</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 1,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">Pune, India</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Brea, CA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 4,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_VA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_VA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475423200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,231<span></span>
</td>
<td class="nump">$ 2,437<span></span>
</td>
<td class="nump">$ 4,505<span></span>
</td>
<td class="nump">$ 7,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">2,513<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 3,402<span></span>
</td>
<td class="nump">$ 3,629<span></span>
</td>
<td class="nump">$ 7,002<span></span>
</td>
<td class="nump">$ 9,768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434483298448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 5,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">10,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">10,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">9,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">8,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">40,377<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">84,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="nump">19,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 64,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481820432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475768416">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Computation of Earnings per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,125)<span></span>
</td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (9,475)<span></span>
</td>
<td class="num">$ (20,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(463)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,588)<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(9,938)<span></span>
</td>
<td class="num">(18,914)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,588)<span></span>
</td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (9,938)<span></span>
</td>
<td class="num">$ (18,914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,071<span></span>
</td>
<td class="nump">85,448<span></span>
</td>
<td class="nump">89,792<span></span>
</td>
<td class="nump">85,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,071<span></span>
</td>
<td class="nump">85,448<span></span>
</td>
<td class="nump">89,792<span></span>
</td>
<td class="nump">85,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_BasicAndDilutedEarningsPerShareAbstract', window );"><strong>Loss per common share, Basic and diluted</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.05)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.05)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $(0.5)&#160;million loss on disposal for the three and six months ended June 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021, respectively</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BasicAndDilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic and Diluted Earnings Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BasicAndDilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434470001664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">15,076<span></span>
</td>
<td class="nump">16,549<span></span>
</td>
<td class="nump">15,206<span></span>
</td>
<td class="nump">16,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember', window );">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">1,642<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
<td class="nump">1,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">11,582<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
<td class="nump">11,582<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475732192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 7,012<span></span>
</td>
<td class="nump">$ 3,653<span></span>
</td>
<td class="nump">$ 12,358<span></span>
</td>
<td class="nump">$ 7,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="nump">892<span></span>
</td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">5,850<span></span>
</td>
<td class="nump">2,761<span></span>
</td>
<td class="nump">10,396<span></span>
</td>
<td class="nump">5,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4,647<span></span>
</td>
<td class="nump">2,427<span></span>
</td>
<td class="nump">7,948<span></span>
</td>
<td class="nump">4,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,892<span></span>
</td>
<td class="nump">$ 737<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434483606032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized as software development costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474964656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Share-based Awards Granted (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">980<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475397696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="num">$ (184)<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 1,018<span></span>
</td>
<td class="nump">$ 702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(11.40%)<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders', window );">Tax receivable agreement, percent of cash savings paid to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475775216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="nump">$ 1,952<span></span>
</td>
<td class="nump">$ 4,879<span></span>
</td>
<td class="nump">$ 2,548<span></span>
</td>
<td class="nump">$ 12,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember', window );">Equity Method Investee | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement', window );">Income from long-term services agreement</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentEconomicInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Economic Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentEconomicInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentVotingInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Voting Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentVotingInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Services Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475533696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 33,400<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">33,400<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">33,400<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">$ 33,400<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434481013184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Changes in Contingent Consideration and Other (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 28,700<span></span>
</td>
<td class="nump">$ 13,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,730)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized losses</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of end of period</a></td>
<td class="nump">$ 33,400<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475766176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) - Fair Value, Recurring<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value</a></td>
<td class="nump">$ 33,400<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value</a></td>
<td class="nump">$ 33,400<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Risk-neutral expected earnout consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or Input Ranges</a></td>
<td class="nump">36,277<span></span>
</td>
<td class="nump">30,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or Input Ranges</a></td>
<td class="nump">0.1083<span></span>
</td>
<td class="nump">0.0604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475757536">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Related Parties - Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 118,525<span></span>
</td>
<td class="nump">$ 130,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">37,173<span></span>
</td>
<td class="nump">51,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,655<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">96,565<span></span>
</td>
<td class="nump">96,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">75,846<span></span>
</td>
<td class="nump">107,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,191<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,038<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">323<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">972<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 734<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475294016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Revenues and Expenses (Details) - Affiliated Entity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue</a></td>
<td class="nump">$ 42,810<span></span>
</td>
<td class="nump">$ 10,368<span></span>
</td>
<td class="nump">$ 74,874<span></span>
</td>
<td class="nump">$ 25,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses</a></td>
<td class="nump">36,684<span></span>
</td>
<td class="nump">606<span></span>
</td>
<td class="nump">63,145<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434471333472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and Related Cost, Cost Incurred to Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember', window );">Severance and termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and Related Cost, Cost Incurred to Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Office space consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and Related Cost, Cost Incurred to Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember', window );">Professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and Related Cost, Cost Incurred to Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434482170736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434475822832">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenue from Segments to Consolidated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 319,939<span></span>
</td>
<td class="nump">$ 222,057<span></span>
</td>
<td class="nump">$ 616,996<span></span>
</td>
<td class="nump">$ 437,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,739<span></span>
</td>
<td class="nump">13,346<span></span>
</td>
<td class="nump">45,994<span></span>
</td>
<td class="nump">28,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92,336<span></span>
</td>
<td class="nump">74,863<span></span>
</td>
<td class="nump">199,194<span></span>
</td>
<td class="nump">159,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,603<span></span>
</td>
<td class="nump">147,194<span></span>
</td>
<td class="nump">417,802<span></span>
</td>
<td class="nump">277,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(460)<span></span>
</td>
<td class="num">(460)<span></span>
</td>
<td class="num">(920)<span></span>
</td>
<td class="num">(898)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">319,939<span></span>
</td>
<td class="nump">222,057<span></span>
</td>
<td class="nump">616,996<span></span>
</td>
<td class="nump">437,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,621<span></span>
</td>
<td class="nump">20,128<span></span>
</td>
<td class="nump">59,034<span></span>
</td>
<td class="nump">42,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92,796<span></span>
</td>
<td class="nump">75,323<span></span>
</td>
<td class="nump">200,114<span></span>
</td>
<td class="nump">160,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,129<span></span>
</td>
<td class="nump">6,531<span></span>
</td>
<td class="nump">23,346<span></span>
</td>
<td class="nump">12,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,603<span></span>
</td>
<td class="nump">147,194<span></span>
</td>
<td class="nump">417,802<span></span>
</td>
<td class="nump">277,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,492<span></span>
</td>
<td class="nump">13,597<span></span>
</td>
<td class="nump">35,688<span></span>
</td>
<td class="nump">29,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (6,882)<span></span>
</td>
<td class="num">$ (6,782)<span></span>
</td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (13,793)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434479815632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,588)<span></span>
</td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (9,938)<span></span>
</td>
<td class="num">$ (18,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,148)<span></span>
</td>
<td class="num">(6,274)<span></span>
</td>
<td class="num">(4,389)<span></span>
</td>
<td class="num">(12,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from (provision for) income taxes</a></td>
<td class="nump">184<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="num">(1,018)<span></span>
</td>
<td class="num">(702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="num">(15,112)<span></span>
</td>
<td class="num">(14,916)<span></span>
</td>
<td class="num">(30,218)<span></span>
</td>
<td class="num">(30,103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
<td class="nump">12,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,878)<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">297<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(663)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,043)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationIncludingOnetimeAdjustment', window );">Stock-based compensation expense</a></td>
<td class="num">(7,012)<span></span>
</td>
<td class="num">(3,653)<span></span>
</td>
<td class="num">(12,358)<span></span>
</td>
<td class="num">(7,359)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments', window );">Amortization of contract cost assets</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ShareholderAdvisoryServices', window );">Strategy and shareholder advisory expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,513)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TransactionCosts', window );">Acquisition costs</a></td>
<td class="num">(3,421)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(3,878)<span></span>
</td>
<td class="num">(2,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Gain from discontinued operations</a></td>
<td class="num">(463)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="nump">21,739<span></span>
</td>
<td class="nump">$ 13,346<span></span>
</td>
<td class="nump">45,994<span></span>
</td>
<td class="nump">28,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on disposal of discontinued operations</a></td>
<td class="num">$ (500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500)<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationIncludingOnetimeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Including One-time Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationIncludingOnetimeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareholderAdvisoryServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholder Advisory Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareholderAdvisoryServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434480015936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">$ 171,294<span></span>
</td>
<td class="nump">$ 178,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current period</a></td>
<td class="nump">246,955<span></span>
</td>
<td class="nump">228,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior period</a></td>
<td class="nump">22,438<span></span>
</td>
<td class="nump">6,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current period</a></td>
<td class="nump">201,508<span></span>
</td>
<td class="nump">94,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior period</a></td>
<td class="nump">101,145<span></span>
</td>
<td class="nump">92,065<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="num">(33,260)<span></span>
</td>
<td class="nump">48,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Impact of consolidation on reserves for claims and performance-based arrangements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="num">(12,074)<span></span>
</td>
<td class="nump">11,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">125,960<span></span>
</td>
<td class="nump">238,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">25,618<span></span>
</td>
<td class="nump">56,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior period</a></td>
<td class="num">(10,289)<span></span>
</td>
<td class="nump">6,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current period</a></td>
<td class="num">(1,239)<span></span>
</td>
<td class="nump">20,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior period</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">20,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="num">(9,486)<span></span>
</td>
<td class="num">(26,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Impact of consolidation on reserves for claims and performance-based arrangements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">16,132<span></span>
</td>
<td class="nump">33,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">145,676<span></span>
</td>
<td class="nump">122,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current period</a></td>
<td class="nump">246,955<span></span>
</td>
<td class="nump">219,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior period</a></td>
<td class="nump">32,727<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current period</a></td>
<td class="nump">202,747<span></span>
</td>
<td class="nump">73,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior period</a></td>
<td class="nump">100,709<span></span>
</td>
<td class="nump">71,392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="num">(23,774)<span></span>
</td>
<td class="nump">74,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Impact of consolidation on reserves for claims and performance-based arrangements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="num">(12,074)<span></span>
</td>
<td class="nump">7,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">$ 109,828<span></span>
</td>
<td class="nump">$ 204,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of adjustments to the estimated reserve for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474803184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued property and equipment purchases</a></td>
<td class="nump">$ 1,118<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashFlowLesseeAbstract', window );"><strong>Effects of Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">7,010<span></span>
</td>
<td class="nump">6,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfUseAssetAcquiredAndDisposedOf', window );">Leased assets disposed of (obtained in) exchange for operating lease liabilities</a></td>
<td class="nump">$ 4,153<span></span>
</td>
<td class="num">$ (2,157)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfUseAssetAcquiredAndDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Acquired And Disposed Of</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfUseAssetAcquiredAndDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140434474948304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($) </div>
<div>day </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,070<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | 2022 Credit Facilities | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity', window );">Number of days prior to any junior debt maturity | day</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent', window );">Prepayment penalty prior to first anniversary of closing date (in percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent', window );">Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent', window );">Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent', window );">Prepayment penalty on or after third anniversary of closing date (in percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Secured Debt | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember', window );">Secured Overnight Financing Rate (SOFR) | Line of Credit | Secured Debt | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember', window );">Secured Overnight Financing Rate (SOFR) | Line of Credit | Revolving Credit Facility | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate | Line of Credit | Secured Debt | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate | Line of Credit | Revolving Credit Facility | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIncMember', window );">Implantable Provider Group, Inc. | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIncMember', window );">Implantable Provider Group, Inc. | Subsequent event | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued for acquisition (in shares) | shares</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Four, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period One, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Three, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Two, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=evh_A2022CreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=evh_A2022CreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>evh-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:evh="http://www.evolenthealth.com/20220630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="evh-20220630.xsd" xlink:type="simple"/>
    <context id="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7e86b1305605495eb71612e57efef826_I20220729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="ibdd1ae63ddb547ab8ce350f06563934d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6ea08b719de041fc860ca2321a09f2b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8946244240e648d0a726ae8260273c82_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib26e65edf5734cb5a6a97189f7553074_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icedd565fde88475e9cb04f61cf5d0594_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia57e8ce997404651a93ef7beb639c1fc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i12f3a63417094173a2013d8e4651e2e0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id4eecfcec6264b2fb00d016b793a019b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibd40945fb1484885837f7eecfa567b33_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i857e987b97514fad8244212f054173d6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i84e5e1239271498cbccbaa25d09f5b81_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia37f68ad663840209db72f32dcc9dfdc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i351ea9834113446b96f0ad47bfeced58_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i516e6c58c8cb48b1b164c617bc7de6db_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7370f70d6fa74976a5e9c877a75a03a4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i958225ec182147f59a33c03bebe13eef_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9600a3d7bfdd4cf2815bf9a7f3593ec9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iab17026c20264a4c8395c9212169b9ba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3e70344e764b4b3eadeaeb6935ee38ec_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5ed22694590747a1bd2bf4c01a9a662d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i942e52ba18744355b76f7bfdb9cc3cea_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib1386eedb115480fa7ca578380d21b98_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if8f5739ceffa4cb4899666cc1243c638_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i53b61856fe974331a02b815438214cb5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3116ce9873b14871adcc379848660cb6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9c7070523c2a4ac0a2bfd9ae3b7d3917_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7acd46ba77bf4a96a952527d6ff359fd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib89434c9149543b4bf183e45ab6d2cf8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0f315c260fa84b9f8d0fc3b0633fcce4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iae9ab04f40cb4c6bad7fa0fa0fad903f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i23bc8d4fc78f4724b0d9d7084e7cf0a8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3102f93190494ddfbe3bef856a36e4ee_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8df42535fdba44a8a1627241486db72e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i89706c80b2d7431b8baf438482e6530c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ef1ba80206c47a796768e04faddc954_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d886f333c9c4fd6a9e342ad9244c5cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2007122f7a6c433aaea325edfea7445c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia13c29e1eae04177baea5d09b310b513_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4911134f45a64c4ca8b04e812b37c8e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id32760879e474657bbcb44bcfd8b4cbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7e24955768747af87552990e9881d89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94fd6d6b927d418abe899d5a671e0e19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i782b0724932e45c1b2ed8ea424d579e1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id74b0636d9fe405398d1c373024c9a01_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idf10f4217fba4210b4c5f9862e155922_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i64151525a8774f5e8e11c91ec179e8ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e2ac7d92b6447f2848e96bc058402a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6081395d9faa4fdcab6aed9df74e298b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7edb2b3056d4a5688f8e8aaafb90eef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie633b270dd0c4bbc8043c2a1e40d609c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic30a5e30d65042cc8f8a3f395110a09a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5d6c1e91bd04b9d96ff15934542fb4a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8cd9533bbf4643e5aeaa123dabd40c39_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9bdd7eadd3304d3a9a793b4224c5ecee_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i159494a380f0403f9294af2487029a51_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i843b60b3c07d4c0f966b1c7efd11f445_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5e9c59f6393b4a8faa1337db8d4243fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f49366fb4ea4c75a9085b9b029857ac_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4458c03c2b504669b6dc29624dbd3320_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d346c5c8ea64d16b5d1df5450434600_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id592466e76c249e8b646509e71afaf92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4de7d7c7a1b34a538212057e51b487b2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic0fd83c25925422897d5d200f710ee27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e843b7962284872a802350d9f9601e8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i07da018892914858a3261ae1eb51a8be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i422269ae7dc54ddf975203be2bc9ec3f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icd4ee5d15f6c48e98699e31b2e8899a7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6b656d6a747c43c0807ef9a72b117fe5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic18f73ba368e43578c5dc017d9986091_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8920304c21f34d2e8d814f99e02bb672_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie2f2470a268e4d5593d8214f2752ddb2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id10401febbb0459b90ba3a22611bb8d1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1576668fe0314dd3b3b3ec454798b582_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="if8072fe070714d70b4c7d5054c1d19bd_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ib3ecfc57dd454ea480838c4fc5252936_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ie80fd38d9d5b4ab2bc9f658f6aadf4a0_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="id53f2482994740c4afac4ded4824ffa5_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i477230494f1041fd9804ec69666a9459_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ica9021ecacd5411b9522695f0968fd6e_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i569f17d92bfa4d41a92b3f6f73066652_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="iff1070f5f0bf442684f5ebf0e562d035_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i9b5a5d27c5cd45318130592162ae2979_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i5cfda0e9098c4c609e2cc6cf7786ab7f_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i155bf891da8c4ffd8ff2e7f58e3b77cb_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i75dc927515b3477cb3c9aeebb4a7a7d0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i30adaf2d743e41079b7a12ac72d1fc61_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0ef29e9326024b2192d9ecc9a670b854_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e64363b84144ffdac3dc9bb780e39a8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ide9111e594364928b4f284bff447dc08_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id3e532127d5f44dcaa0a6d0b870251c4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic18910942b2e485ea30def8e9cefca28_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i908235d4f83442cfa2a22b2a90120a12_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id190777694a14c8296979c0037b1333a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i20b23e58105b4c5f9f250d293d1bbf58_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i92b903bf1e5f4a638b29eeb71fe6c6b4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i26d5d6d44adc4e43990ce92c4c44933a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic1702427992f426b85f07248e2895331_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib280f91a402940c69f0c3e5cc12d4d56_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id0b2ccb4486a4651913ac8302c5c0ec4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i18dabb68c8274ea0a5201f8219bce96d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9cb66e4294e54785b37e073174f3db3c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i60f215dd151c4adb9f5d581b6725305d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i53d31d53daf04bb8b14968d7533e3c30_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaa385ea46e294eeabd2ab99940f8e291_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i66dd2b3d936841cea2ea68298ff824f5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1d1117684efa42b1a391ffcc826e14e1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieaf1aec104e64ca9ab855423a51a4a6c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if40f448b1aee435882087e7f40e19f83_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i861b85e9482e4845a118116261fe251b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i031024ab0cda4f04a32cb998ae9efc29_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie94a3b4a3c854650a274a22df3bb7e4b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic519d1466dfe43928dcfe5d77bdee3ae_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i404e9ab7124f42c99765abd6b37736c1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia36ffca71bef413bab9a1cae99ccecfa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie208d4a1cb3e4377a6d2ee9c2549f37c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia71fe81096cc402e8ae97e15131a0756_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3b091472e7f14e738060f39d3bb11f9e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id7def236e69944f2bfd7976a1f32c4f4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i84587f740e7e43fb93a344871522bc54_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i313903f297d04e91ba3039b43d058117_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ice247f5d11034730aa4a605431fb5369_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6f80fd138cee4ef2abfdef7ff9b68ef6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9a64da34af914c9daa54dedee5a5cd92_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i132fb5a493164122bbdcd92d3b2833eb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i55fd2849c11d40aa8dac15390f64e184_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i91e9cc56ffee4613adb9a6ab56554271_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3532becac70546b4bcc03b106edda27c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia3ce003447674e2abab64b23eeba11a1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i84c9dc97776a4d2ab2a8a979cad50e02_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iff2de2ac36d149c7b524f3b5582f9909_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4bcd88cb096e4aeab56740f6386ffe14_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieeb135f182f34812b3000c1ef3bc7bba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b532269dce647ae8ba0e135b9f58fd9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i872c6081b968491a9d538c7086489d91_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i26704ded411543a5924bf706b6248305_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4f98d9fd601a4df297a857523d498b81_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i98a3c0b9b3254cfc9d6d4301e6079769_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icfd3ac7207dd485b866d1ecf9d8370e4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idb1b05b4923144d994dffe62ce8c0056_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia32e4243b72b414dbf63a7b58e4444cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i461ebb8b4b4143dfb77186edf095976d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id8ccca889cbf4b0c9a6c45d4e2792d4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaade151a67ae47c98d6ef7473bc42db4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic3a47a1bfe944f4bbffaee6cdd3b92ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief715b13c4fc48beb1cac256135e9d7f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifb1738f7f0924690b9cc702596588af5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8ff1f6df23841edbf927ca013625866_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7055b6f3699b4fc89fec4593a36e0cf2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5282067d6cfa41b8b9bc8d0fd65c75a1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic460399d0bce4695b06b3c4950e6867b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic7732b8c39c44818a62b633ed2eec750_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7c7ba00b2dca4b97bd4add7fef4ab781_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9098a44763454939966aead2b01058a5_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i5aa8d21a22a84ccabb1b42d66a503b1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i744902b106114f94aaf10f93f79da793_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31ec6c709d854ece8b361ce8b9f623c6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icf7021225a1d4ebe992272c6b7a424f3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9ab714214aec4c62895368e7b5d77d47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb91a25096ac488099c2f68651d8104a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id929ac4578254f3a8ac5a00ef4adae72_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i47bf34c04d3d4427a895561238e93dfb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id7ca912d3a02465795eea96c1e250e26_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8e4ef4f58a5044038cbe7d46e8dfea60_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i960826d299ae4c44bc47f074ce02ed28_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4cb0816a5da441f6960846569f93e09e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c75751fbbd54a6eae8d08e6b4ab94a2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie2d81d730eae4c75b3cb95f6789994b0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2706c4da523140c79cd5bc0fc5dd4e18_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i13f3c31fcc184de09194d8a0f21020a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i525fe873d3c2406f95c7b1e8fe7f01a1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if49cfadd37a2439693bcaef2ca7aea4e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i96994f66670d402b9792042ce4aa991c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90169973e5d44809bbd3c5d4c63ea01d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i41a84937692640da928c5aff561db4f2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id7f5959c88534df58f8cc98840f9d9c6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i50f6763c502f4844b08ec38b15b78eb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40c2436f586643c299cf6643b5e47526_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic284e67a71b64b93b2d5099b8216ad4f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i59a87beef6454e0cacb2bf3bac49aa68_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c1e999ffea0466ea3a2914cd626dbde_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d41b951fcf5438d958a6230f14dd8c2_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="iaedce6468a3e4e8ca15a5333813a91c5_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i79aed8a5f7344a37b2a701ae05c1b842_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i8c24e626673740bfbc5c482a85f9be03_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i51f45a85ad1d44d3b1bba8c3ef692bb0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id96a059c175048b68ce735b693389c60_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide775581b0c2448ba46085d3508e93e6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if5bfcb0c398a4d1ba18c1a7084e71a4d_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="id342da7701a44166b2290441fd002835_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ic42188622755410b90efa5d41026374a_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i7530c57faa32498ca2794192fcf4a689_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ice3c432af1ef4dc0a423e7d7b0e84b24_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="idffc7ad1a4654adf98f1038cfa6da4be_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i6be98831456946c8b796aa596a41a463_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i2420da3a7fa34500b18bdcbdb21aba50_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i00e82484500e428e8076ddebadf195b8_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i5631b43e9caf49eeb64e4768bdfb4735_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="ib6ca31f441294fd2bd58db5233a8cc5f_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i5870d3d480b24bfb8fce0c75a91af736_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="id0f03be090e54e69ab5736238c33be28_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i93205c45ea8547a98bc7ff1c11408e54_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i4e280a759a5741be8b52ce88da866568_I20181022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-22</instant>
        </period>
    </context>
    <context id="i3b03deaf81e94b908e898c240f288f46_I20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-24</instant>
        </period>
    </context>
    <context id="i0b019d63dd4e49a68deed79176b07e2d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2bc2482dd4334134b1fadb0256b066b3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i62205ea298424eb981ea4ca7c04b1743_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5aa4d8786f5243df8cf17673c36d708d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i56b4489e137445769dd2d5c0552d9a73_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i6d77309eeff741329a3b33008063d50d_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="id5ae38a0018f4e7a9d7dcd73631d6bd7_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="if0901a44b29f424c9815549f850adf16_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ie4df19daedef45a6b93e44ce65f0f0e7_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i3584d11db2f3491898d24a547ffcbb7a_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i7648a33bd59947509a7713b0d44e5483_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i9c63bf821d6e48e2ab3a8136ab3612ae_D20211201-20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="i427a803b22b943cbb1135ad1eb47ec78_I20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-01</instant>
        </period>
    </context>
    <context id="if6ccdc5191c44efea9d1d9edc7499e87_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ica61ba8f679544528ab9c464177763cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44077d7155334c2a88271bade68c730c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib9d50749331f4a3db9bce7b2180496cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idcf121a6589f44c98a0e5e8344398edb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i33bdb53de4cf4bf4acf5c9415254f853_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i199532edebf94240832d93a367225b5e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i287a359f1cb24979b1d38fe6e75caa46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f5f7300b0d042e0a3bd9a21c41816ba_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i804fa23f02a940218c7286e946780122_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="iddc1d80def48423e86b4d3005ffe55ed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iff1d7b85971f4121968757b59f6d1b6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6ed29b7f1b44cf89f0a291dd12cf6d2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0198a0ff5cce4a9b91c42f736cd3a452_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2dde99085614be3a48c4e542d462eac_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">evh:ShareholderClassActionComplaintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="ice2334023a474418a26edc96b4914f57_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i74f5855d88434c3285d8d998872119e6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b48f947d8c0471a835cbc7da3f1cf01_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i97331e99ea5547e0b35d6859a1d13dd0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i858366f085d4485eb18d0f7cc216d020_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CenterForMedicareAndMedicaidServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idea8512b30824967af5d24f3c9c780b0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:BrightHealthManagementIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1f081253ccd6415999b9700a0d052cc4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4369d3b9e5314c63bacd3f01a5ccb6b1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5f3674d843144031a1c5d85f7415f252_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iffcd008fc3494897b3c4b55545b1ecf2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id09252d541af4f6480d509935a97ae1c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie59876efdc3d43669106ec8d543d109a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id3f5b407f5d74c80b132051dcf12fe42_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4697f31a51524c06a29c429847fa3a82_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7549a5bc04b3412f8b50fb05b19fe749_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:BlueCrossAndBlueShieldOfNorthCarolinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia8618f6dc2f0455a9e812da51a84fc9f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iafda5615eab24ad0adebb2033f75ea7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38cfdd80181d48dc95c448a5bd762e1c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i92f67640b93b448585be7724489ed0b2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i31cae587563b4dfaba6a55698e21f99a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib0fe093ce52b4d0081c2f7e51b68a9fa_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i11a4e8a319824f4b96b6989839081ca3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6d54b939218e47729004114229359446_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie5f918cd7826430298dbf550d4b035ad_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if231d8338180440882ba220f0ce751c6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide8b1a427528491e95fa193e43b94d38_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifcfcf1b04d4841ccbb92d2a7320961fe_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id2901a75f3a247c5ac744dd557ba51f0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i24857afd029946ad953d32e472b7bcbc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iabd7310dc91f4778877cc439a686f2ce_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie134ed611c47418485ab07b86a56f78d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2447e2f271ab4cd5b596bc7f50ab65ce_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i964b6c8302364f4fa39a31e5fe8af1a4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7a6bfcf39da045688459cbd536822b1d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0bfb82287c064822b44c47e618455986_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia74da95131c94444b02cb9706d3d7af2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i34f9d2b1aa2e48d89223c9302b8b413b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ida2bfbe459a7424eb6baf496ceffcbc0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic9002002234e467d88e03554eac894c8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3b58614dca7f4fbeb927b1354f4e9b79_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibfa8508ca389418f81bf326a680bd658_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7783015b2ae54c6e9b2422c563ab6deb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic1b51644e7c048c88aea7ed7a62c9f77_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idc87bed7f2074590b61ec2fb0cc0f0f8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3f97a58aa80547029649a0cf3a2a5dd7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic329299275fa4a088f919d8e59845bff_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i76cc4f8c28014238a98362c8d2ef9224_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i92729353701e4160afc71576b5f23a25_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib699196b28014c31a00d19bb66ee014a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i10c9925c2945438f916183ef76ede0c0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i84dbc81371174a2aaee8be24c4769d0e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i527e4616505d460da52a06d5e9031339_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id03a4fc06028452a8a6a2c80df8c07cf_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7deec1f9d05a4e7b8276434ce19b2f18_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6f9702c58070468c9b2a1580cb0175db_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6ea4f0986d4c4a1e9f1370d4957fd642_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6ee8a89e489b4af9ac0113c9d93ce86e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibb490ebfa4014df7bbc4f1b2f06baaaa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i54dd4caef2f344379688eaef3449c98e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i94ebbd62d39b4c6e878b3190d03982a1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if8f2eb0ac1624558acdb53e52c269e19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bd208a32416460385f7876f38b23d85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if038fb24676c4fbe8fcd625e0c03f2e4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if35ad6a7d0874e9989f37adcab1d604c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic72c81faddfb4d16898248ad47a599c1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic59c227acd8640a480a066d3194993ca_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1f1f46b4a5da4b88ab1161c697899756_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i901fed8a465841a2a7d4e3c79e3b289f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i60e8394722604655b91f21d472ddc55f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i37f4d51ef9aa4ab4a4f13f3a70a0afb2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9a0e0359a3b54f88ac3fba23ecf413ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67639f87145d4008acf2702010dc086c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c9af5aa7ede47a29b2eff96c883a5f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idad3e10b3ea8472d88039d89be09d82a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d10e11febe742e388c4185b0dfb5f67_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i20f895ec0c394fb7a1b6962e0c4d6c9c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia1d611e598104338b6853034734ea3e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65efdf8b544f497a9ccb4054da27c745_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i117805e609ff46d0921c81fc5e9621b3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2ddb18e6282b4f94a145adbb9bf20767_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieea3e0212f024a4cb925e63dc3d63669_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie9f2571b77c148eba97976fcd4e2bcf2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id6a6977963ca49b586c2fcf93713da7b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7607171276ef40a8b48df3ab23ab716e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7b8255e04a5a48e69c16aa566c4151bc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0fac99680e9547b89140b689b06a4952_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i47e7ef4ce9c44edb84ead5d40559f606_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib07e032acadb4ab4aeff1fa0375c42f0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4e2e5a89677e4a3694479947d5a435a8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7295fdf6eb154c00992c57534af23daa_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5adf3c79b7f64f2aa0af3af80b0553b1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib0464c31a82d4d04b71913910715453f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0d215ef7e89344058608e5d4f9363124_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f163348ee8540d09c2f6ee2944703fc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4e3a1495b5e04e5b850b1f4ce62855aa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1caf080cfaca42c29144aff3c13b93b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc4a298cd056483f927ffa2a3469d4ee_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2548e4d1f3694bce8967d2081c947aac_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7b3b51310ab149b399238bbc8da2f487_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f99af9f1bbe4f909c3d4ea820bf365b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i67189557a7ea47dfa0d97556d16c7c5a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i29d5e516649a4eb1bd68a4ae83bd5e16_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i420c2960b8964c268e95e8eda2a47790_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1f83964678a340d8a8a7893bffb76713_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2ad7b61e97de4695ab5cc762df1bab8d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9c4cc0b519ac4301afbf3a86f9d1a16f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia5fd05553c104209a219f91c15de897b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7e90bde16c38406cb0456caf29ecea2a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib1fd13e0887f4184bc87321d513724b5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i43ace05961a24c8aad395abf32e9e34e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia437c1047b404319a8f7f650e06e4e90_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8546f2bf902a41be9774135aea47d11d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i09d7524a42e2444db7f04130d8c7e586_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4c79847ac9a6406dbd571e7e8285c8ab_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie88d244c079c44a6a96afafc4dd811c7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idc490f2a102c40368f57f3b421851b0d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if5fb402086e24b79a85a9f5d622bf485_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i34d9d012a2bb4aea8bee56c1bbb1747d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iea87c5d05fc147deb58c839bf401c1ee_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i371114cbc06e4f95811ba2a6fec0c8b1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7734adf1b5e6413988815cac05b34700_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i748aee67f29648e5bcea7fa5140a470e_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="ie583be11220d441c9171d7d8b813691e_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i26ac2d191e26480fa87349b7a8290bde_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i0b9cc6fdb0d444239ea5b97cef38f068_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i244a3a3fba544622b797356979f8025f_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i47af930ce9a049169a33fecd6da9992c_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i2065d4ade06445edb3d844c8ae917420_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i151d150fd9d24075af69e985884cae3a_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="id5ea489e80dc4ac28fa3620d03b1c6d0_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i0379117a2c6c4cab9b19860640687c97_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="reportingunit">
        <measure>evh:reportingUnit</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="source">
        <measure>evh:source</measure>
    </unit>
    <unit id="segment">
        <measure>evh:segment</measure>
    </unit>
    <unit id="day">
        <measure>evh:day</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80L2ZyYWc6YWRjYTJhMjY0NmE2NGVjZDg4MThiMDQ1ZDMzNDRiNDcvdGFibGU6YjU5ZDIzYjgxMjBmNDA4N2JhNmU3NGIyOTY0NWIyMTMvdGFibGVyYW5nZTpiNTlkMjNiODEyMGY0MDg3YmE2ZTc0YjI5NjQ1YjIxM18xLTEtMS0xLTUwMjk5_8862be39-4299-49d5-a5b9-cd6ca84dbcdf">0001628908</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80L2ZyYWc6YWRjYTJhMjY0NmE2NGVjZDg4MThiMDQ1ZDMzNDRiNDcvdGFibGU6YjU5ZDIzYjgxMjBmNDA4N2JhNmU3NGIyOTY0NWIyMTMvdGFibGVyYW5nZTpiNTlkMjNiODEyMGY0MDg3YmE2ZTc0YjI5NjQ1YjIxM18yLTEtMS0xLTUwMjk5_fa52cf5a-b2f6-4bd8-88e5-12141ff3563e">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80L2ZyYWc6YWRjYTJhMjY0NmE2NGVjZDg4MThiMDQ1ZDMzNDRiNDcvdGFibGU6YjU5ZDIzYjgxMjBmNDA4N2JhNmU3NGIyOTY0NWIyMTMvdGFibGVyYW5nZTpiNTlkMjNiODEyMGY0MDg3YmE2ZTc0YjI5NjQ1YjIxM18zLTEtMS0xLTUwMjk5_e3ae108f-2608-4747-8c39-9d9051c3e7e3">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80L2ZyYWc6YWRjYTJhMjY0NmE2NGVjZDg4MThiMDQ1ZDMzNDRiNDcvdGFibGU6YjU5ZDIzYjgxMjBmNDA4N2JhNmU3NGIyOTY0NWIyMTMvdGFibGVyYW5nZTpiNTlkMjNiODEyMGY0MDg3YmE2ZTc0YjI5NjQ1YjIxM180LTEtMS0xLTUwMjk5_656aab5e-f79a-42bb-a8f3-aaa20592db5b">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80L2ZyYWc6YWRjYTJhMjY0NmE2NGVjZDg4MThiMDQ1ZDMzNDRiNDcvdGFibGU6YjU5ZDIzYjgxMjBmNDA4N2JhNmU3NGIyOTY0NWIyMTMvdGFibGVyYW5nZTpiNTlkMjNiODEyMGY0MDg3YmE2ZTc0YjI5NjQ1YjIxM181LTEtMS0xLTUwMjk5_22ff95c8-fd35-4e22-a4b2-5d6d2ecaab10">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i4911134f45a64c4ca8b04e812b37c8e9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNS0wLTEtMS01MDI5OQ_25776320-c78c-4049-999b-e8ec8d6418cf">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i6f80fd138cee4ef2abfdef7ff9b68ef6_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81OC9mcmFnOjE3N2FlZmY5YjYwZjQwNTM4NzQyZTdmMmY1YzFjMTIxL3RhYmxlOjJhMWRlMTEwNGE4YzQyOTBhMTc1ZDNmYmZkNzRmNDJmL3RhYmxlcmFuZ2U6MmExZGUxMTA0YThjNDI5MGExNzVkM2ZiZmQ3NGY0MmZfMi0xLTEtMS01MDI5OQ_4cfafc32-eab8-470e-9c70-7450adc9de99">P6M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i9a64da34af914c9daa54dedee5a5cd92_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81OC9mcmFnOjE3N2FlZmY5YjYwZjQwNTM4NzQyZTdmMmY1YzFjMTIxL3RhYmxlOjJhMWRlMTEwNGE4YzQyOTBhMTc1ZDNmYmZkNzRmNDJmL3RhYmxlcmFuZ2U6MmExZGUxMTA0YThjNDI5MGExNzVkM2ZiZmQ3NGY0MmZfMy0xLTEtMS01MDI5OQ_a7edf994-3a40-4ae2-b13c-550584869711">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i132fb5a493164122bbdcd92d3b2833eb_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81OC9mcmFnOjE3N2FlZmY5YjYwZjQwNTM4NzQyZTdmMmY1YzFjMTIxL3RhYmxlOjJhMWRlMTEwNGE4YzQyOTBhMTc1ZDNmYmZkNzRmNDJmL3RhYmxlcmFuZ2U6MmExZGUxMTA0YThjNDI5MGExNzVkM2ZiZmQ3NGY0MmZfNC0xLTEtMS01MDI5OQ_e1510c02-654e-4289-829d-12be02938b71">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i0f5f7300b0d042e0a3bd9a21c41816ba_D20200801-20200831"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83My9mcmFnOjE4ZGQwNWFhZDlkZjQzOTdiYjYyMzlmZDczMzQ3OWM4L3RleHRyZWdpb246MThkZDA1YWFkOWRmNDM5N2JiNjIzOWZkNzMzNDc5YzhfNQ_af625767-125e-4889-a364-a1dfd2456d6a"
      unitRef="number">0.0548667</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i804fa23f02a940218c7286e946780122_D20181001-20181031"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83My9mcmFnOjE4ZGQwNWFhZDlkZjQzOTdiYjYyMzlmZDczMzQ3OWM4L3RleHRyZWdpb246MThkZDA1YWFkOWRmNDM5N2JiNjIzOWZkNzMzNDc5YzhfMjE1_38cf07d4-bd06-4f2a-975b-caf47a954acb"
      unitRef="number">0.0299135</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMzA5_797818c7-6ca6-446d-9018-a9553ed9c6ea">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMzEw_f544d7ae-7519-4fc2-8cf4-d8e6bb67b02a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMDY_1811a45f-1a9c-4a75-ae0e-16c4ec66f0d8">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMTU_6151c599-0ff9-417d-ad64-30b80f1523ed">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18zOTc_1569134e-f370-45fb-9b04-c2545cb095ce">001-37415</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y180Mjc_cdde3680-387f-4017-9420-8b142886b71e">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8wLTEtMS0xLTUwMjk5_4481b247-0cf9-4661-ac60-21d55a3f1d8a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8wLTktMS0xLTUwMjk5_92182389-7f59-4ae3-90f4-c770a10500bc">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8zLTEtMS0xLTUwMjk5_70c0c14d-03e2-4622-84ca-da8f45549347">800 N. Glebe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8zLTMtMS0xLTUwMjk5_3fe698fd-6220-42a2-9f19-656dd18505e2">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8zLTUtMS0xLTUwMjk5_98864a75-fc6f-4a21-938a-daba404ee64c">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8zLTctMS0xLTUwMjk5_47ee2ad7-170a-42d7-8c19-d9b93e6b33ae">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6NzFjNjFmMjA3OTIwNDYyYTlkNWQ5MmQ3MzUxNzhlZTkvdGFibGVyYW5nZTo3MWM2MWYyMDc5MjA0NjJhOWQ1ZDkyZDczNTE3OGVlOV8zLTktMS0xLTUwMjk5_a291f1d1-0765-4439-93ac-d0e571f40423">22203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y181MzU_368ebc49-e508-4f7f-8342-77097fb0241a">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y181Mzk_6a4b5a0c-5bc0-4b77-ba4d-e24dfbf8b0a6">389-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6ODUxNmU5YWYzMTE4NGQyZTk1MTY1NGJlODlhZjRjMTkvdGFibGVyYW5nZTo4NTE2ZTlhZjMxMTg0ZDJlOTUxNjU0YmU4OWFmNGMxOV8xLTAtMS0xLTUwMjk5_9fabd2d6-edca-4b1b-9b1a-b0f5948ea5c6">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6ODUxNmU5YWYzMTE4NGQyZTk1MTY1NGJlODlhZjRjMTkvdGFibGVyYW5nZTo4NTE2ZTlhZjMxMTg0ZDJlOTUxNjU0YmU4OWFmNGMxOV8xLTEtMS0xLTUwMjk5_b0b27f08-de16-40de-b1c8-e559e56241d5">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGFibGU6ODUxNmU5YWYzMTE4NGQyZTk1MTY1NGJlODlhZjRjMTkvdGFibGVyYW5nZTo4NTE2ZTlhZjMxMTg0ZDJlOTUxNjU0YmU4OWFmNGMxOV8xLTItMS0xLTUwMjk5_776a0372-f41b-4227-96c3-a5ff3642b9cf">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18xMDQw_ee2c4cd5-4362-4ce2-ae06-9eef995a6b4d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18xMzYy_1077a9a7-9fde-49d6-acee-2cded992f891">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18xNzI5_6192de5d-13f0-4664-a06c-a2be672071b3">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18xODEw_8443a7e0-b608-4a11-b32c-91f283cd825e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMzEx_1555c6f6-8be2-4fa2-8263-6e90d9a94319">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMjE1_dd300a93-2951-4038-b866-bd8816017fa0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7e86b1305605495eb71612e57efef826_I20220729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xL2ZyYWc6MmFmYTdlYjI2ODI1NGE3NDk5ZTQzZTg1ZDFiZWQzOGMvdGV4dHJlZ2lvbjoyYWZhN2ViMjY4MjU0YTc0OTllNDNlODVkMWJlZDM4Y18yMjQ2_e2c84f0b-f41d-4d50-97a3-ec8da7f13222"
      unitRef="shares">91669520</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMy0xLTEtMS01MDI5OQ_257cf865-391e-4043-9b36-f068243da4c1"
      unitRef="usd">193070000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMy0zLTEtMS01MDI5OQ_8a209f91-566b-4e45-8cbc-b961da12592f"
      unitRef="usd">266280000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNC0xLTEtMS01MDI5OQ_4db3b800-b304-4ebf-9e78-35845657e03a"
      unitRef="usd">74377000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNC0zLTEtMS01MDI5OQ_1e026770-9260-43b6-88c1-61419cd06108"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0xLTEtMS01MDI5OQ_97a656e4-10e5-42a1-b495-b5cdd1969fea"
      unitRef="usd">118525000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0zLTEtMS01MDI5OQ_e9cfb95b-d053-4a12-b35e-ceeda4fe4188"
      unitRef="usd">130604000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0xLTEtMS01MDI5OQ_6ff647ab-fc7f-4b9f-8ba2-6da66d240d2d"
      unitRef="usd">37173000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0zLTEtMS01MDI5OQ_70fe2f65-5e3f-42d1-9054-6bf2243f19a2"
      unitRef="usd">51391000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNy0xLTEtMS01MDI5OQ_2df252fd-6d6a-496a-ab4b-17fe160bd0a9"
      unitRef="usd">423145000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNy0zLTEtMS01MDI5OQ_a8da48fd-60f4-43e7-afb2-624b2abc24a7"
      unitRef="usd">523960000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfOC0xLTEtMS01MDI5OQ_0dbf653c-ddb1-4f8d-be6b-f565e1031919"
      unitRef="usd">12986000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfOC0zLTEtMS01MDI5OQ_54c99049-77b0-4c3b-b4b1-0ba9de2569a0"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfOS0xLTEtMS01MDI5OQ_8f11685d-70d2-4d05-a50f-2137a504b1ee"
      unitRef="usd">3831000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfOS0zLTEtMS01MDI5OQ_ba235c1b-37bf-43f9-9d3e-bf71a01972a3"
      unitRef="usd">5458000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTAtMS0xLTEtNTAyOTk_a765f80b-00a8-450e-bbbc-b595f1463daf"
      unitRef="usd">92627000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTAtMy0xLTEtNTAyOTk_3d0858b5-cc42-440b-9e73-ab8e6ddeed33"
      unitRef="usd">81365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTEtMS0xLTEtNTAyOTk_f467cc1f-ae9a-4b9e-9bee-606b5991864a"
      unitRef="usd">50873000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTEtMy0xLTEtNTAyOTk_a20213be-0873-4e6a-98f8-49bf5162620d"
      unitRef="usd">50203000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMS0xLTEtNTAyOTk_c73fb9ae-1251-4539-9157-05f9e988f6bd"
      unitRef="usd">6655000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMy0xLTEtNTAyOTk_21824ee8-66f2-4feb-81be-27e21a353033"
      unitRef="usd">6790000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTMtMS0xLTEtNTAyOTk_864734d8-96c1-4015-98f8-01f18c513317"
      unitRef="usd">22721000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTMtMy0xLTEtNTAyOTk_0c55e7bb-a19c-4173-a7e0-75a8c8eeaced"
      unitRef="usd">32624000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTQtMS0xLTEtNTAyOTk_40297c6d-5e6a-4f0d-a399-36f35ea609d2"
      unitRef="usd">264846000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTQtMy0xLTEtNTAyOTk_d8a093e6-504c-4664-91b0-59fb78ef52cd"
      unitRef="usd">279784000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTUtMS0xLTEtNTAyOTk_e7c9085d-d297-4f99-9863-c329e4aff7cc"
      unitRef="usd">426228000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTUtMy0xLTEtNTAyOTk_b554a331-d7de-4ad1-bb95-9a634fa31504"
      unitRef="usd">426297000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTYtMS0xLTEtNTAyOTk_5308bfb9-dd25-40a8-9ad2-e06cdb0edc9c"
      unitRef="usd">1303912000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTYtMy0xLTEtNTAyOTk_a0ab5e04-06e2-4e5d-aeee-f83b3d271071"
      unitRef="usd">1419458000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMS0xLTEtNTAyOTk_6e579c51-776c-481d-b0d7-7151719b7e28"
      unitRef="usd">96565000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMy0xLTEtNTAyOTk_78b7293f-57e3-44f6-9cd6-cab6a1c2b4dc"
      unitRef="usd">96084000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMS0xLTEtNTAyOTk_e7fa3d27-9397-4ab1-bd1a-cfa9c7e74f93"
      unitRef="usd">75846000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMy0xLTEtNTAyOTk_9d97e8d6-10c5-497f-8469-fdd1ffdcf538"
      unitRef="usd">107241000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjItMS0xLTEtNTAyOTk_d234d571-8f12-4cae-a841-abb837fb13f7"
      unitRef="usd">6389000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjItMy0xLTEtNTAyOTk_6a798a83-167b-43b8-8065-e0927f754963"
      unitRef="usd">7069000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjMtMS0xLTEtNTAyOTk_98876eb6-3a81-4f5d-8cc2-f86a5fe9641f"
      unitRef="usd">29371000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjMtMy0xLTEtNTAyOTk_60ba112c-8583-4256-bc94-8db5a619a9ab"
      unitRef="usd">51861000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjQtMS0xLTEtNTAyOTk_c0e9cb99-7f79-4b40-a1a7-ab858e8928b6"
      unitRef="usd">8711000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjQtMy0xLTEtNTAyOTk_587e8b9c-8af0-4760-883e-6f6420e7d883"
      unitRef="usd">11944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMS0xLTEtNTAyOTk_c3daba8c-5415-4626-a6f0-894377885a08"
      unitRef="usd">125960000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMy0xLTEtNTAyOTk_e331c0b9-e116-4212-87f0-3fbd284d7232"
      unitRef="usd">171294000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjYtMS0xLTEtNTAyOTk_ba35d818-669b-42ee-baf6-a56d2eb0a7ad"
      unitRef="usd">342842000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjYtMy0xLTEtNTAyOTk_59b6d178-b4ae-47f4-a664-33234139759f"
      unitRef="usd">445493000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjctMS0xLTEtNTAyOTk_7f40fb0e-3277-4f28-bf9b-f226c6e5aa96"
      unitRef="usd">283138000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjctMy0xLTEtNTAyOTk_f2428e19-1a4d-48e6-a144-670ccc60a640"
      unitRef="usd">215676000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjgtMS0xLTEtNTAyOTk_6ba11d65-60de-4a56-9d12-549b78449b6d"
      unitRef="usd">4619000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjgtMy0xLTEtNTAyOTk_d6b52c54-dede-4053-bb92-b298ed773f1a"
      unitRef="usd">5531000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjktMS0xLTEtNTAyOTk_1d42115f-e8e7-4cf3-a15c-25b86fb1455e"
      unitRef="usd">58581000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjktMy0xLTEtNTAyOTk_3e47d3da-29cf-4a09-81ef-ce0a5e566a4c"
      unitRef="usd">57722000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzAtMS0xLTEtNTAyOTk_28ca91a0-5a86-4239-9639-ce1cc1e44479"
      unitRef="usd">1644000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzAtMy0xLTEtNTAyOTk_1e656525-1a00-493e-9129-5525612684e7"
      unitRef="usd">1403000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzEtMS0xLTEtNTAyOTk_8908cf92-2372-4f4a-89e6-bda02f7702b5"
      unitRef="usd">690824000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzEtMy0xLTEtNTAyOTk_06d54094-dd6e-4eff-8fbc-a42ba0e2e0cb"
      unitRef="usd">725825000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzItMS0xLTEtNTAyOTk_b921ca0c-8fe7-4068-b178-28563263a24a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzItMy0xLTEtNTAyOTk_fb0adae7-b96a-4c42-9163-677bbd636ec4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl8yNw_2810b51b-d34e-498c-b8ad-72b43ad32ab7"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl8yNw_9594887c-ea6d-46eb-b3b9-818cd4874d3f"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl80MQ_755ba1ab-9569-45cc-90ed-6f0e8af068c6"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl80MQ_ccf1aa20-88c1-4c83-a323-e8962676730a"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl82Mw_dba124ee-ce63-4ca4-bfb1-50762df3e78d"
      unitRef="shares">91657480</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjpmMDE5MWRlMjM5NTY0NTJmOGU5NmY3Y2RjZDlmOWM3Zl83MA_cb352c43-a751-477f-a142-3943215b1ebb"
      unitRef="shares">90758318</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMS0xLTEtNTAyOTk_00edb1a8-ca9e-4584-aa54-df0bcf806c82"
      unitRef="usd">916000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzQtMy0xLTEtNTAyOTk_8581b91a-a573-49d3-aa71-afd1b9884084"
      unitRef="usd">908000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzUtMS0xLTEtNTAyOTk_8ba1e87c-1633-4e84-b93f-b046a2914d60"
      unitRef="usd">1231005000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzUtMy0xLTEtNTAyOTk_13cc6e8f-df8b-48cc-a014-a2504e8afc0d"
      unitRef="usd">1340989000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzYtMS0xLTEtNTAyOTk_d42c4fdf-ba18-4586-a6a6-a6bb2eb2e9fe"
      unitRef="usd">-782000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzYtMy0xLTEtNTAyOTk_b3f5d975-aa7e-4bc8-90c9-30e4bebb546a"
      unitRef="usd">-362000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzctMS0xLTEtNTAyOTk_2c23e8ee-c169-4229-9b18-30070666b1c7"
      unitRef="usd">-596928000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzctMy0xLTEtNTAyOTk_46f7f167-56e7-4afa-bddd-ac3d983958d0"
      unitRef="usd">-626779000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzgtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjo5YTExMDA2ZTVmMTU0MWU0OWJmMzc3ODVhOTZhOGQyZV8yOQ_4e491049-c092-4e35-8ce9-96d37fd89348"
      unitRef="shares">1537582</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzgtMC0xLTEtNTAyOTkvdGV4dHJlZ2lvbjo5YTExMDA2ZTVmMTU0MWU0OWJmMzc3ODVhOTZhOGQyZV8yOQ_a3688d61-5f89-421a-b979-de276187d549"
      unitRef="shares">1537582</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzgtMS0xLTEtNTAyOTk_88ae886e-1ee3-46e9-ad75-f834b5095457"
      unitRef="usd">21123000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzgtMy0xLTEtNTAyOTk_06a5319c-e3b5-4b89-a748-ce30e0463644"
      unitRef="usd">21123000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzktMS0xLTEtNTAyOTk_fead2357-c9d3-456b-84c8-8d17bd9c9df5"
      unitRef="usd">613088000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMzktMy0xLTEtNTAyOTk_7600c7ef-8ae7-452a-94b3-bd9a0fb01bf2"
      unitRef="usd">693633000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNDAtMS0xLTEtNTAyOTk_54034b4c-44ea-42af-9ea8-21ee794de2a7"
      unitRef="usd">1303912000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNDAtMy0xLTEtNTAyOTk_5c07109a-96b6-465d-b375-3066e0029256"
      unitRef="usd">1419458000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDU4OA_1a89fd1b-74de-463e-a1e5-2355d32025e7"
      unitRef="usd">319939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDU4OA_55975170-d5a0-4043-94f4-be240ba735b5"
      unitRef="usd">222057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDI5OQ_69277f2f-30d6-41c3-bcac-5fb7817d7d63"
      unitRef="usd">616996000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDI5OQ_5c9aeeb5-648f-4616-8c31-69a18c6f0408"
      unitRef="usd">437128000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDU5Ng_911a2c47-3850-4275-81ec-10373623a70c"
      unitRef="usd">249705000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDU5Ng_ac682693-add5-4a42-9252-82d4e320ee74"
      unitRef="usd">172113000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDI5OQ_93cc4c54-276c-44e8-94c1-f48e1cb760c6"
      unitRef="usd">469444000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDI5OQ_17b92439-90b9-43f1-91f1-6f1c765fb21a"
      unitRef="usd">329945000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDYwNA_1988702f-171f-41b1-85e9-cb63feec4a20"
      unitRef="usd">58955000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDYwNA_d025d75a-23ed-4fd9-803c-6e9eda31fa44"
      unitRef="usd">42699000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDI5OQ_85fe62ba-44a3-4785-b828-b469eeda2fdb"
      unitRef="usd">117887000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDI5OQ_3d2a993f-44b2-4115-aa5e-34b7dcf52020"
      unitRef="usd">101290000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNy0xLTEtMS01MDYxMg_5c713e1a-c784-452b-acab-e5b0f704c2c5"
      unitRef="usd">15112000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNy0zLTEtMS01MDYxMg_3101ed74-ad8d-4d16-ac51-76e7408e6c2f"
      unitRef="usd">14916000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNy0xLTEtMS01MDI5OQ_52e315e2-656c-42d1-aacc-94e8d380fd2c"
      unitRef="usd">30218000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNy0zLTEtMS01MDI5OQ_9c6ffd64-b875-4f41-90ee-55d30d9b84c4"
      unitRef="usd">30103000</us-gaap:DepreciationAndAmortization>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOC0xLTEtMS01MDYyNg_dfd1b9dd-c74b-4997-9d87-4bd9351cb536"
      unitRef="usd">800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOC0zLTEtMS01MDYyNg_3b632233-5b57-4064-bfc4-f1ce1d4d477d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOC0xLTEtMS01MDI5OQ_c1463bce-a319-4ea3-b3ec-13369b701ccf"
      unitRef="usd">6878000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOC0zLTEtMS01MDI5OQ_105ec464-12e2-4b3c-9646-ec8a7b0713e9"
      unitRef="usd">-594000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:CostsAndExpenses
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOS0xLTEtMS01MDYyNg_5919e52d-5a7d-445f-861e-c80e40312873"
      unitRef="usd">324572000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOS0zLTEtMS01MDYyNg_404677b9-f539-45b7-8906-878e86103fa2"
      unitRef="usd">229728000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOS0xLTEtMS01MDI5OQ_6b436524-dded-49eb-9d71-ea1ae728f88b"
      unitRef="usd">624427000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfOS0zLTEtMS01MDI5OQ_dc3f9ff3-cff0-4733-bde4-2dc4acb9bab1"
      unitRef="usd">460744000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTAtMS0xLTEtNTA2MjY_3737c224-db1e-40e8-88d8-afc201a1f116"
      unitRef="usd">-4633000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTAtMy0xLTEtNTA2MjY_9aa88232-b0c8-487b-8eae-8766e5a09721"
      unitRef="usd">-7671000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTAtMS0xLTEtNTAyOTk_5476f0a7-c612-47b9-8e50-e6c6394ac08e"
      unitRef="usd">-7431000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTAtMy0xLTEtNTAyOTk_8377b28b-0d80-4412-9c67-544a4620b045"
      unitRef="usd">-23616000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTEtMS0xLTEtNTA2MjY_2c7fd4da-bb62-4abb-9676-bf6e03061de5"
      unitRef="usd">223000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTEtMy0xLTEtNTA2MjY_23ee9933-4c04-496e-a5d9-6cd6b251c3c7"
      unitRef="usd">68000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTEtMS0xLTEtNTAyOTk_9ed4b197-f83e-4d92-815e-3fddd284bbf2"
      unitRef="usd">340000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTEtMy0xLTEtNTAyOTk_ba8765c7-73f2-4c51-80d6-973e9450a72d"
      unitRef="usd">191000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTItMS0xLTEtNTA2MjY_980c785f-3c41-445c-9809-39e58c413668"
      unitRef="usd">2148000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTItMy0xLTEtNTA2MjY_fcf6ddc2-3420-41b6-b3e7-a6f62801ae05"
      unitRef="usd">6274000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTItMS0xLTEtNTAyOTk_0c3d52c5-b7b9-45e7-ae6c-7dd6f31caff6"
      unitRef="usd">4389000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTItMy0xLTEtNTAyOTk_cf922404-940b-48da-a63c-5d9cdb64ecdb"
      unitRef="usd">12611000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTMtMS0xLTEtNTA2NDI_532371ed-7292-4af5-ae85-9c28fe14e188"
      unitRef="usd">1952000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTMtMy0xLTEtNTA2NDI_5ec83cf9-83bd-4f28-987d-d201d39bb46a"
      unitRef="usd">4879000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTMtMS0xLTEtNTAyOTk_772b0223-f248-4dc7-bec8-9ab864cb5e86"
      unitRef="usd">2548000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTMtMy0xLTEtNTAyOTk_b90eeedf-4ce1-4b9e-8ffc-18b86469d786"
      unitRef="usd">12662000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:GainOnTransferOfMembership
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTQtMS0xLTEtNTA2NDU_03c07e02-43c6-4193-8b95-3e190d93b902"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTQtMy0xLTEtNTA2NDU_77370f4d-6558-4f84-b464-c5f346fbe0d6"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTQtMS0xLTEtNTAyOTk_782732ca-5fd7-4949-9e86-9e7784ddf433"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTQtMy0xLTEtNTAyOTk_03542c00-12a9-4f83-9e99-6be2e2961e88"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTUtMS0xLTEtNTA2NTI_16e509cc-2957-4694-a8e5-64279889b5da"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTUtMy0xLTEtNTA2NTI_91b002f7-d609-4d25-81e3-f9e412ba0c97"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTUtMS0xLTEtNTAyOTk_01c84cac-8963-423d-9e0c-1ceab438eceb"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTUtMy0xLTEtNTAyOTk_e389997c-a3ea-4761-919c-6ba84a13025d"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTYtMS0xLTEtNTA2NTk_fa5a6863-e9bb-4760-9beb-d8a33fa683d8"
      unitRef="usd">297000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTYtMy0xLTEtNTA2NTk_67a69309-78e4-4be9-841f-71d42cc87f2b"
      unitRef="usd">-18000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTYtMS0xLTEtNTAyOTk_8826c335-8f5b-4d7b-b309-49e5690f89a8"
      unitRef="usd">475000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTYtMy0xLTEtNTAyOTk_36af74ce-94bc-4b9d-bd08-b0ff72a9482c"
      unitRef="usd">-32000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTctMS0xLTEtNTA2NTk_e1f3b69f-8226-4286-99a1-4dc4058edce9"
      unitRef="usd">-4309000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTctMy0xLTEtNTA2NTk_56a93eea-e83b-4c7b-bf54-116344c83827"
      unitRef="usd">-9016000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTctMS0xLTEtNTAyOTk_9ab025a3-64f7-4c6c-be6d-e2cce74bdf9e"
      unitRef="usd">-8457000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTctMy0xLTEtNTAyOTk_3e27395a-19ec-4acc-88c6-46d08052012e"
      unitRef="usd">-19595000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTgtMS0xLTEtNTA2NTk_8d340b63-743d-434e-8e93-8df1799945e3"
      unitRef="usd">-184000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTgtMy0xLTEtNTA2NTk_5dbe7074-7c67-4b7e-9c9b-b65ba52940e0"
      unitRef="usd">91000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTgtMS0xLTEtNTAyOTk_b72a5cad-2452-4dd8-abe8-65aa57c75350"
      unitRef="usd">1018000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTgtMy0xLTEtNTAyOTk_61d67c4d-693e-451e-9f70-9d4c0bff4545"
      unitRef="usd">702000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTktMS0xLTEtNTA2NTk_a18efcc0-26c1-40a8-b285-2b77595deb95"
      unitRef="usd">-4125000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTktMy0xLTEtNTA2NTk_05e6ff98-613b-42b7-8fdf-21017a50b82a"
      unitRef="usd">-9107000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTktMS0xLTEtNTAyOTk_cf7ba85f-9d70-4564-b248-3c5ab3abd91b"
      unitRef="usd">-9475000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMTktMy0xLTEtNTAyOTk_745240e1-c2fb-40f2-945e-f63634659172"
      unitRef="usd">-20297000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTA2NTk_d0078107-c79a-4908-a96b-fcb12333a564"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTA2NTk_49497634-fa51-4fa0-8ab4-f53f91f2fa50"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTAyOTk_6dccf1fb-174b-4581-aaea-f9ea25f1d932"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTAyOTk_cc81acb2-9163-4391-91dc-f0317c70e013"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMS0xLTEtNTA2NTk_10ac028c-89f7-4af7-80f9-34ab4e32e9e2"
      unitRef="usd">-4588000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMS0xLTEtNTA2NTk_7948e45f-8d96-4ea4-b9c6-3b20feeee5b6"
      unitRef="usd">-4588000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMy0xLTEtNTA2NTk_1acd41b6-42ce-45ae-a4a1-03d19643a650"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMy0xLTEtNTA2NTk_c3862b2a-4d72-496d-b7e0-f334b76efc7c"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMS0xLTEtNTAyOTk_9de7c05c-8ff5-49a7-a0fa-6adbc9eca954"
      unitRef="usd">-9938000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMS0xLTEtNTAyOTk_a1e5913a-80c9-4d4e-98e9-37b9a429f74c"
      unitRef="usd">-9938000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMy0xLTEtNTAyOTk_8901d8b4-bc5c-47d0-9431-64b6adc94066"
      unitRef="usd">-18914000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjEtMy0xLTEtNTAyOTk_bb195bd1-d582-459e-9876-c28c963d1c05"
      unitRef="usd">-18914000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMS0xLTEtNTA2ODI_485f8172-519d-4db8-9aed-4799287e8186"
      unitRef="usdPerShare">-0.05</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMS0xLTEtNTA2ODI_8355fdd5-4e49-42e8-b447-5bc60b22d565"
      unitRef="usdPerShare">-0.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMy0xLTEtNTA2ODI_22b63fdb-447c-4f0e-b062-dbd3ef19cd8c"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMy0xLTEtNTA2ODI_8ae57cde-39cb-45ea-ad89-116a1790131c"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMS0xLTEtNTAyOTk_9b9629f2-0d83-4975-9977-6ff59dfc6aef"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMS0xLTEtNTAyOTk_b6000604-7750-4e79-8f0f-7b737cda8fa1"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMy0xLTEtNTAyOTk_51986ab2-8998-4136-9236-ccd91dd19900"
      unitRef="usdPerShare">-0.24</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjUtMy0xLTEtNTAyOTk_f8c42eff-43de-49fb-b7c3-b43d543b531c"
      unitRef="usdPerShare">-0.24</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMS0xLTEtNTA2ODI_e3b9ea4d-4e41-4467-a709-f0c6a630b4b6"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMS0xLTEtNTA2ODI_fd21a903-cf8b-49f1-b98d-4603eda45280"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMy0xLTEtNTA2ODI_3398dcf7-71be-4a2d-b3cb-f96294615a1e"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMy0xLTEtNTA2ODI_d1ce6784-6ad2-4ace-9d6f-deae258379e5"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMS0xLTEtNTAyOTk_5dc7a43d-578a-4be3-9269-b52f17c8b3a6"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMS0xLTEtNTAyOTk_85c081d6-9eaf-4668-84ea-a67c89dc82b2"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMy0xLTEtNTAyOTk_0ca56ccf-fb13-4418-9dec-67e6074c8574"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjYtMy0xLTEtNTAyOTk_798eff45-60b2-455d-9c7a-9af99196bae1"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMS0xLTEtNTA2ODU_7a65e334-57d7-4878-bdfd-5c1b9c4f9bd2"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMS0xLTEtNTA2ODU_9453d8a9-eec7-4306-8c88-ff964bce8b6d"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMy0xLTEtNTA2ODU_688690ff-b6c4-4da6-aba8-506911ebf495"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMy0xLTEtNTA2ODU_7343f8c5-ee6a-465a-a801-3e37c33ac703"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMS0xLTEtNTAyOTk_12962f70-5c62-4b02-b9f2-da79d80cb9af"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMS0xLTEtNTAyOTk_5ecc3bd6-602a-47da-86bc-b7111a531ad5"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMy0xLTEtNTAyOTk_bb9b3f1b-30af-4b1e-83c8-4a8ea9925c0e"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjctMy0xLTEtNTAyOTk_e7620d26-5d56-482b-8cb1-d67e65ce2e29"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMS0xLTEtNTA2OTA_197cea3b-b8e6-4dc6-bb04-e2517ebc3bf5"
      unitRef="shares">90071000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMS0xLTEtNTA2OTA_f73b6be8-0559-4edc-a4ec-525d36a2cf68"
      unitRef="shares">90071000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMy0xLTEtNTA2OTA_04b21dc9-bcb1-47cb-9b38-2bccddcc1c8a"
      unitRef="shares">85448000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMy0xLTEtNTA2OTA_20a29989-6086-40ab-a7c3-24bd2e418e4f"
      unitRef="shares">85448000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMS0xLTEtNTAyOTk_53b5f9ce-d970-4657-94a1-c315b1e69321"
      unitRef="shares">89792000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMS0xLTEtNTAyOTk_5e57e7cf-9f3a-4611-9f09-ef7b143f6d62"
      unitRef="shares">89792000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMy0xLTEtNTAyOTk_0f412b0b-9466-4a0f-942d-631e68f121a5"
      unitRef="shares">85056000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzAtMy0xLTEtNTAyOTk_c8a5bad9-5fe3-4e34-be45-f8eb414f8265"
      unitRef="shares">85056000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzMtMS0xLTEtNTA2OTk_1e5e317d-316e-41b7-b3a7-6efde24349f6"
      unitRef="usd">-4588000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzMtMy0xLTEtNTA2OTk_ab4fd6df-8d30-4850-8d5c-14c389ce453b"
      unitRef="usd">-9107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzMtMS0xLTEtNTAyOTk_c17de08c-762f-4592-b2b8-5d2de5745318"
      unitRef="usd">-9938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzMtMy0xLTEtNTAyOTk_c91f547c-35fa-457f-ad85-65633176dcc5"
      unitRef="usd">-18914000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzUtMS0xLTEtNTA2OTk_4beb9a28-a99f-4ec1-a7a6-5904f2bc4cf9"
      unitRef="usd">-288000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzUtMy0xLTEtNTA2OTk_23dd3e26-269e-4af8-a6cd-3caa786676c6"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzUtMS0xLTEtNTAyOTk_a4a6b480-ab86-47b3-9202-0a749293f228"
      unitRef="usd">-420000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzUtMy0xLTEtNTAyOTk_30ae1654-9676-4ed8-95f3-028b3000ff0f"
      unitRef="usd">-89000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzYtMS0xLTEtNTA2OTk_d9f4e596-20f1-42f7-b07e-21339b9b4185"
      unitRef="usd">-4876000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzYtMy0xLTEtNTA2OTk_79593568-552a-4ac3-9f91-76fac1c36488"
      unitRef="usd">-9165000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzYtMS0xLTEtNTAyOTk_e1844cdd-bc33-46d8-bba2-2d56f72b56d1"
      unitRef="usd">-10358000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMzYtMy0xLTEtNTAyOTk_d05752be-3de3-4168-9886-0fc16fb9c090"
      unitRef="usd">-19003000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfNDk0NzgwMjMyNTQ4Mg_26b2f69f-de74-4a2c-889b-a19ac36d8193"
      unitRef="usd">-500000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfNDk0NzgwMjMyNTQ4Mg_4aca174c-29b5-4e14-b905-9f48320d20fd"
      unitRef="usd">-500000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMjY5_ac040d59-83f7-4884-9009-ebda27bd6d7b"
      unitRef="usd">1900000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ib26e65edf5734cb5a6a97189f7553074_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy0xLTEtMS01MDg4Mg_d4470500-8caa-4638-aed1-a4a554bff758"
      unitRef="shares">91588000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib26e65edf5734cb5a6a97189f7553074_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy0zLTEtMS01MDg4Mg_fe3c7532-30d0-4874-92d8-127b228d8355"
      unitRef="usd">916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icedd565fde88475e9cb04f61cf5d0594_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy01LTEtMS01MDg4Mg_80c2c396-3af2-4d17-a09f-fe9df61f7257"
      unitRef="usd">1224250000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia57e8ce997404651a93ef7beb639c1fc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy03LTEtMS01MDg4Mg_c5a9d5da-5160-4015-a5e3-3fea8631201d"
      unitRef="usd">-494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i12f3a63417094173a2013d8e4651e2e0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy05LTEtMS01MDg4Mg_a4e9f891-daf8-4e09-86ad-5663f1d64c04"
      unitRef="usd">-592340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4eecfcec6264b2fb00d016b793a019b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy0xMS0xLTEtNTA4ODI_630eac24-bced-4a99-ac58-427248325c78"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd40945fb1484885837f7eecfa567b33_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMy0xMy0xLTEtNTA4ODI_1d22d74c-e595-4355-a393-2a7c0ac9e1de"
      unitRef="usd">611209000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i857e987b97514fad8244212f054173d6_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfNS01LTEtMS01MDg0Mg_b3a86978-748e-4c16-ba27-6948e3907a13"
      unitRef="usd">7011000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfNS0xMy0xLTEtNTA4NDI_ade69419-b3c3-4f16-95eb-c4b998ebf5a4"
      unitRef="usd">7011000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i84e5e1239271498cbccbaa25d09f5b81_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfNy0xLTEtMS01MDg1NA_df1f6faa-8339-4c7d-bfdf-923fb85e755c"
      unitRef="shares">69000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i857e987b97514fad8244212f054173d6_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfNy01LTEtMS01MDg1NA_61ba373b-57b4-4b96-8424-6de1b0ff4cca"
      unitRef="usd">-256000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfNy0xMy0xLTEtNTA4NTQ_bfd6ffa0-0f76-415f-8252-bd676ae46e80"
      unitRef="usd">-256000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia37f68ad663840209db72f32dcc9dfdc_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfOC03LTEtMS01MDg1NA_7693d2f0-06ed-4f1b-b60b-9b9aad03655c"
      unitRef="usd">-288000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfOC0xMy0xLTEtNTA4NTQ_14fe8306-fa39-4488-8050-621ac77e8d5f"
      unitRef="usd">-288000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i351ea9834113446b96f0ad47bfeced58_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfOS05LTEtMS01MDg1NA_d67c3fac-2af5-4a82-adf6-87ffda4365ea"
      unitRef="usd">-4588000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfOS0xMy0xLTEtNTA4NTQ_62daf232-9ed0-4130-928c-72dfc58e1d3d"
      unitRef="usd">-4588000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i516e6c58c8cb48b1b164c617bc7de6db_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtMS0xLTEtNTA4NjE_1f9a6017-4a15-4304-9f50-a66c4f17139d"
      unitRef="shares">91657000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i516e6c58c8cb48b1b164c617bc7de6db_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtMy0xLTEtNTA4NjE_1c92f17a-ae86-476a-9709-aa9116137ea4"
      unitRef="usd">916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7370f70d6fa74976a5e9c877a75a03a4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtNS0xLTEtNTA4NjE_697772f0-cf66-4459-8315-a9d57d5f5bee"
      unitRef="usd">1231005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i958225ec182147f59a33c03bebe13eef_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtNy0xLTEtNTA4NjE_6c30d472-7d6a-491e-b166-848506134441"
      unitRef="usd">-782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9600a3d7bfdd4cf2815bf9a7f3593ec9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtOS0xLTEtNTA4NjE_82bfa22d-0a6b-4f10-963f-3d302e444fad"
      unitRef="usd">-596928000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab17026c20264a4c8395c9212169b9ba_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtMTEtMS0xLTUwODYx_ac906651-c90e-4e1c-8e41-6227a8b7cd28"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTEtMTMtMS0xLTUwODYx_38b1fa55-aa86-4029-ad3c-0bfd3c845a37"
      unitRef="usd">613088000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i3e70344e764b4b3eadeaeb6935ee38ec_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctMS0xLTEtNTUwMzQ_1e87b200-4303-42d9-b362-9359db812d5a"
      unitRef="shares">86779000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i3e70344e764b4b3eadeaeb6935ee38ec_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctMy0xLTEtNTUwMzQ_58f94fe6-8272-4156-898f-db14cbb7eaaa"
      unitRef="usd">868000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5ed22694590747a1bd2bf4c01a9a662d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctNS0xLTEtNTUwMzQ_7ac4f26b-1d7d-4c08-a362-2bd5c6bc1bf7"
      unitRef="usd">1236847000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i942e52ba18744355b76f7bfdb9cc3cea_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctNy0xLTEtNTUwMzQ_d7984057-d67c-4253-bfe9-932c23e3dd8f"
      unitRef="usd">-309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1386eedb115480fa7ca578380d21b98_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctOS0xLTEtNTUwMzQ_0f029346-861e-4274-95c1-416bbcdffb96"
      unitRef="usd">-598985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if8f5739ceffa4cb4899666cc1243c638_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctMTEtMS0xLTU1MDM0_005c91c4-d967-4c2e-ab10-f625aa14d77a"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53b61856fe974331a02b815438214cb5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTctMTMtMS0xLTU1MDM0_23437b80-e91a-4efe-b7d2-fa2876eaf892"
      unitRef="usd">617298000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3116ce9873b14871adcc379848660cb6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTktNS0xLTEtNTUwMzA_c58e7d79-f5b5-4d93-9ea9-2aa9e2baef9e"
      unitRef="usd">3653000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMTktMTMtMS0xLTU1MDMw_0b5f4252-660d-4935-9b4f-64870e24fccd"
      unitRef="usd">3653000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9c7070523c2a4ac0a2bfd9ae3b7d3917_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjAtMS0xLTEtNTUwMzA_49c5763e-c2ef-41a3-90f0-cacb3bafdec7"
      unitRef="shares">306000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9c7070523c2a4ac0a2bfd9ae3b7d3917_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjAtMy0xLTEtNTUwMzA_ecc5425c-0dde-4c00-a6bc-87dbbde0fc3c"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3116ce9873b14871adcc379848660cb6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjAtNS0xLTEtNTUwMzA_cceffc6d-c46c-48b0-b812-2c330d07d42a"
      unitRef="usd">2855000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjAtMTMtMS0xLTU1MDMw_65d578bc-eb86-4277-807c-e216d05294ce"
      unitRef="usd">2858000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i9c7070523c2a4ac0a2bfd9ae3b7d3917_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjEtMS0xLTEtNTUwMzA_d1031a0a-ea13-4f99-9847-934974d7b57c"
      unitRef="shares">110000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i9c7070523c2a4ac0a2bfd9ae3b7d3917_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjEtMy0xLTEtNTUwMzA_ba204dd2-fcf4-42ed-9ad3-93b9b2dc3398"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i3116ce9873b14871adcc379848660cb6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjEtNS0xLTEtNTUwMzA_1f1e5195-512c-4fe4-8cec-3f886a252fad"
      unitRef="usd">-455000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjEtMTMtMS0xLTU1MDMw_03832aa6-a353-4eee-9c9f-b429451f81d3"
      unitRef="usd">-454000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7acd46ba77bf4a96a952527d6ff359fd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjItNy0xLTEtNTUwMzA_220e3718-413f-428b-b5cb-be0ccbd21a2e"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjItMTMtMS0xLTU1MDMw_8343dfca-ee96-49e9-b03c-4892808b74c5"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ib89434c9149543b4bf183e45ab6d2cf8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjMtOS0xLTEtNTUwMzA_d9acc697-68af-4f90-ae3f-0f4fa0fe589e"
      unitRef="usd">-9107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjMtMTMtMS0xLTU1MDMw_dcde5fa3-a587-46fc-9a28-b5358798db88"
      unitRef="usd">-9107000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i0f315c260fa84b9f8d0fc3b0633fcce4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtMS0xLTEtNTUwMzI_5f6632f6-ccf1-4e12-a262-1e13cdb071a0"
      unitRef="shares">87195000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0f315c260fa84b9f8d0fc3b0633fcce4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtMy0xLTEtNTUwMzI_c4b66098-7357-4d63-ac03-2fcf8a590a5d"
      unitRef="usd">872000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae9ab04f40cb4c6bad7fa0fa0fad903f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtNS0xLTEtNTUwMzI_5753a1d2-04fd-4a7b-b542-75ef3dcfe0b7"
      unitRef="usd">1242900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23bc8d4fc78f4724b0d9d7084e7cf0a8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtNy0xLTEtNTUwMzI_3d45729d-da13-49bf-9217-ab5046194c56"
      unitRef="usd">-367000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3102f93190494ddfbe3bef856a36e4ee_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtOS0xLTEtNTUwMzI_1017b131-d9e3-4e22-8232-86086a99eb57"
      unitRef="usd">-608092000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8df42535fdba44a8a1627241486db72e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtMTEtMS0xLTU1MDMy_29324f5e-094f-4a44-a614-5073ee776260"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjhlNzhhNTA1ODY3ZjQ0OTBhYzA3NzlkMDAwYWNlZjA0L3RhYmxlcmFuZ2U6OGU3OGE1MDU4NjdmNDQ5MGFjMDc3OWQwMDBhY2VmMDRfMjUtMTMtMS0xLTU1MDMy_e76a9785-a819-4794-9ed1-7119814a1d26"
      unitRef="usd">614190000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i89706c80b2d7431b8baf438482e6530c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy0xLTEtMS01MDI5OQ_33009161-3f1e-4269-84ca-f54fef065bba"
      unitRef="shares">90759000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i89706c80b2d7431b8baf438482e6530c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy0zLTEtMS01MDI5OQ_446005f6-8d32-4756-a417-ee0ee34d3ca4"
      unitRef="usd">908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0ef1ba80206c47a796768e04faddc954_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy01LTEtMS01MDI5OQ_749870e5-d06a-4c63-a346-a4103594a361"
      unitRef="usd">1340989000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d886f333c9c4fd6a9e342ad9244c5cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy03LTEtMS01MDI5OQ_ef5d9100-c1c1-426f-8d87-32b75fb76e30"
      unitRef="usd">-362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2007122f7a6c433aaea325edfea7445c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy05LTEtMS01MDI5OQ_80e48c15-8dc7-4b3b-9cdb-8408ca09bb2e"
      unitRef="usd">-626779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia13c29e1eae04177baea5d09b310b513_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy0xMS0xLTEtNTAyOTk_f857e4e6-bbca-4f6b-b472-c184e39d7b4d"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMy0xMy0xLTEtNTAyOTk_a61850a2-02dd-4df8-adff-57dbf3c9ddb6"
      unitRef="usd">693633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id32760879e474657bbcb44bcfd8b4cbe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNS01LTEtMS01MDI5OQ_ace91666-b82e-4d2e-80ed-3dfab68fe016"
      unitRef="usd">-106172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic7e24955768747af87552990e9881d89_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNS05LTEtMS01MDI5OQ_84cb9a5f-1f4a-4815-8c15-cd9605e95f33"
      unitRef="usd">39789000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i94fd6d6b927d418abe899d5a671e0e19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNS0xMy0xLTEtNTAyOTk_803f98d0-90c0-43fa-931e-43971dad1ca2"
      unitRef="usd">-66383000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i782b0724932e45c1b2ed8ea424d579e1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNi01LTEtMS01MDI5OQ_4c94ab64-7faa-4100-af5c-7fe24598e545"
      unitRef="usd">12358000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNi0xMy0xLTEtNTAyOTk_8378ca5c-283b-4529-bd01-313f886e53de"
      unitRef="usd">12358000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNy0xLTEtMS01MDI5OQ_4df3d447-aaa0-4a12-876a-1475d1c4ba76"
      unitRef="shares">37000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i782b0724932e45c1b2ed8ea424d579e1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNy01LTEtMS01MDI5OQ_3b5d389f-bef0-4259-b3ff-005504e8ff4c"
      unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfNy0xMy0xLTEtNTAyOTk_97b8ef29-f0b1-4573-98b8-0949870e46f4"
      unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOC0xLTEtMS01MDI5OQ_91b7f838-b64c-42d8-a78a-813ea4666c68"
      unitRef="shares">403000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOC0zLTEtMS01MDI5OQ_e5c19012-8070-4db6-9758-7888f1ed6412"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i782b0724932e45c1b2ed8ea424d579e1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOC01LTEtMS01MDI5OQ_4d79283a-a02d-48f0-8a89-10734dc5f474"
      unitRef="usd">-5243000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOC0xMy0xLTEtNTAyOTk_587ef4cc-8b8c-4f12-b7c3-97552f4125c0"
      unitRef="usd">-5239000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOS0xLTEtMS01MDI5OQ_2a353431-5ac3-467d-bafb-c193ad60379d"
      unitRef="shares">458000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie36df8966cbe4f8ab7f90853c7d0439e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOS0zLTEtMS01MDI5OQ_31c9a787-82fb-46d6-9091-aedc2fa58e07"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i782b0724932e45c1b2ed8ea424d579e1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOS01LTEtMS01MDI5OQ_90fc2a4b-8489-4457-8c35-ddd5b7b45a18"
      unitRef="usd">-11236000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfOS0xMy0xLTEtNTAyOTk_1a59470a-2310-42c2-850b-99f4604fcde2"
      unitRef="usd">-11232000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id74b0636d9fe405398d1c373024c9a01_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTAtNy0xLTEtNTAyOTk_287636c3-9ba4-4e82-9e9c-9e763425f2d2"
      unitRef="usd">-420000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTAtMTMtMS0xLTUwMjk5_fab28264-dd3d-4905-ad52-f6da5de4c6ae"
      unitRef="usd">-420000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="idf10f4217fba4210b4c5f9862e155922_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTEtOS0xLTEtNTAyOTk_153fac5e-f5c6-4a4e-8b3c-c715a3d7fa40"
      unitRef="usd">-9938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTEtMTMtMS0xLTUwMjk5_7c58e681-0d84-4998-8296-1ab87130fa77"
      unitRef="usd">-9938000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i516e6c58c8cb48b1b164c617bc7de6db_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtMS0xLTEtNTAyOTk_5fe751ae-4f26-4e73-826d-c9367bf0dc9d"
      unitRef="shares">91657000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i516e6c58c8cb48b1b164c617bc7de6db_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtMy0xLTEtNTAyOTk_72d633fb-a622-4e99-9973-1ca4cfe2afa3"
      unitRef="usd">916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7370f70d6fa74976a5e9c877a75a03a4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtNS0xLTEtNTAyOTk_5c933256-160b-442b-a6e6-755a2f61bd52"
      unitRef="usd">1231005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i958225ec182147f59a33c03bebe13eef_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtNy0xLTEtNTAyOTk_97c18b7d-14e5-4a30-8b6d-7986e14745c7"
      unitRef="usd">-782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9600a3d7bfdd4cf2815bf9a7f3593ec9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtOS0xLTEtNTAyOTk_7652d852-ca6a-46e4-b58d-a1e8c471eb58"
      unitRef="usd">-596928000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab17026c20264a4c8395c9212169b9ba_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtMTEtMS0xLTUwMjk5_12d56e05-615e-48b1-ba10-b0a46a2d4d19"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTMtMTMtMS0xLTUwMjk5_963a57bd-e735-44bb-845f-9aa71d3c8e2f"
      unitRef="usd">613088000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i64151525a8774f5e8e11c91ec179e8ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktMS0xLTEtNTAyOTk_53cb7d8f-09d5-439c-b1f7-96fa3ffc2844"
      unitRef="shares">85895000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i64151525a8774f5e8e11c91ec179e8ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktMy0xLTEtNTAyOTk_de1f82bc-95a1-40e2-bd1a-162813b1ff88"
      unitRef="usd">859000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e2ac7d92b6447f2848e96bc058402a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktNS0xLTEtNTAyOTk_d1199f6f-89bc-4e13-abcd-13721c620138"
      unitRef="usd">1229320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6081395d9faa4fdcab6aed9df74e298b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktNy0xLTEtNTAyOTk_bfe5c215-d940-4dc8-be19-6cf1ec45475b"
      unitRef="usd">-278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic7edb2b3056d4a5688f8e8aaafb90eef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktOS0xLTEtNTAyOTk_0d95d286-c8ae-4948-82d4-c6d879b9361b"
      unitRef="usd">-589178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie633b270dd0c4bbc8043c2a1e40d609c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktMTEtMS0xLTUwMjk5_5866dddf-7ba9-4749-87c5-467339a0e2b5"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMTktMTMtMS0xLTUwMjk5_65722719-ca30-487c-8399-553571eedc47"
      unitRef="usd">619600000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id5d6c1e91bd04b9d96ff15934542fb4a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjEtNS0xLTEtNTAyOTk_bd77061f-ad55-480b-a85c-6ffd7dac4d02"
      unitRef="usd">7359000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjEtMTMtMS0xLTUwMjk5_eefaf38d-a8d1-457f-b404-7b3bdff7f4ed"
      unitRef="usd">7359000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8cd9533bbf4643e5aeaa123dabd40c39_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjItMS0xLTEtNTAyOTk_89fcc068-b88d-4c21-8143-840aed8dc94e"
      unitRef="shares">900000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8cd9533bbf4643e5aeaa123dabd40c39_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjItMy0xLTEtNTAyOTk_2e4d052b-cdcc-4e56-a72a-bdf410a98fdc"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id5d6c1e91bd04b9d96ff15934542fb4a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjItNS0xLTEtNTAyOTk_3f79ea8b-3861-48c6-833b-909c9e7d9363"
      unitRef="usd">9367000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjItMTMtMS0xLTUwMjk5_09e04f82-e784-4976-b02f-f9fa827fe5f8"
      unitRef="usd">9376000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8cd9533bbf4643e5aeaa123dabd40c39_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjMtMS0xLTEtNTAyOTk_cb5a29c1-e9ef-4ebe-9bc6-f5a8520fea5c"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8cd9533bbf4643e5aeaa123dabd40c39_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjMtMy0xLTEtNTAyOTk_efb47f51-6a77-4d8a-bf22-37ead165a8f2"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="id5d6c1e91bd04b9d96ff15934542fb4a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjMtNS0xLTEtNTAyOTk_6c65ba99-5361-4f97-acf6-6323f5f7e3f6"
      unitRef="usd">-3146000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjMtMTMtMS0xLTUwMjk5_ad67c719-2017-4b67-91bd-65d33ddf4c04"
      unitRef="usd">-3142000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9bdd7eadd3304d3a9a793b4224c5ecee_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjQtNy0xLTEtNTAyOTk_c7076e28-9465-4da9-a392-70dc19e28175"
      unitRef="usd">-89000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjQtMTMtMS0xLTUwMjk5_732e8477-45ed-4565-ac7c-2102a7b2d1da"
      unitRef="usd">-89000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i159494a380f0403f9294af2487029a51_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjUtOS0xLTEtNTAyOTk_acc6c3e8-25fb-455f-ad6a-75576ae59d8c"
      unitRef="usd">-18914000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjUtMTMtMS0xLTUwMjk5_b0b0f058-26f3-4766-90ec-e6fdfe052737"
      unitRef="usd">-18914000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i0f315c260fa84b9f8d0fc3b0633fcce4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctMS0xLTEtNTAyOTk_cd570ee4-fca5-43e2-976b-4bd4573f7116"
      unitRef="shares">87195000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0f315c260fa84b9f8d0fc3b0633fcce4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctMy0xLTEtNTAyOTk_50d92437-06d9-49f5-a292-e68d43b4b317"
      unitRef="usd">872000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae9ab04f40cb4c6bad7fa0fa0fad903f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctNS0xLTEtNTAyOTk_e4f9bdc4-46cc-4ab5-b35b-c484a3c3d212"
      unitRef="usd">1242900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23bc8d4fc78f4724b0d9d7084e7cf0a8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctNy0xLTEtNTAyOTk_bf9bb97d-1bca-4b33-8ef9-d78bc4205cb3"
      unitRef="usd">-367000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3102f93190494ddfbe3bef856a36e4ee_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctOS0xLTEtNTAyOTk_10f2bd9e-d439-4291-9298-fb478a1c4895"
      unitRef="usd">-608092000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8df42535fdba44a8a1627241486db72e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctMTEtMS0xLTUwMjk5_79b1eb54-5a17-4f50-9c90-a38e10b082fe"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zMS9mcmFnOjYzNTBmMjdiNmQwMjQ5YzVhNDU2MzE3YzY3NmYxMDY0L3RhYmxlOjI2MDNkM2ZkMjkyNDQ5ZjBiOTk0MWYyZjgwOTA5Y2EyL3RhYmxlcmFuZ2U6MjYwM2QzZmQyOTI0NDlmMGI5OTQxZjJmODA5MDljYTJfMjctMTMtMS0xLTUwMjk5_5180b351-3a26-4b6c-9a1d-ff7388ab01d2"
      unitRef="usd">614190000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMy0xLTEtMS01MDI5OQ_0d31846e-6838-491c-b5ee-deefcfdc5dde"
      unitRef="usd">-9938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMy0zLTEtMS01MDI5OQ_49bb9004-d9bb-407e-a332-62c2031e850f"
      unitRef="usd">-18914000</us-gaap:NetIncomeLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNS0xLTEtMS01MDI5OQ_0616ad72-cf9a-42aa-bcff-ed8020f47d77"
      unitRef="usd">6878000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNS0zLTEtMS01MDI5OQ_c4d5ffbd-719f-4d7d-a377-408aa735677d"
      unitRef="usd">-594000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNi0xLTEtMS01MDI5OQ_b7ffd419-e5d4-4eca-b205-a227008167c3"
      unitRef="usd">-463000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNi0zLTEtMS01MDI5OQ_6fbc6da1-eacf-46b6-adcb-d491afe48288"
      unitRef="usd">1904000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNy0xLTEtMS01MDI5OQ_e6b7bdf5-e75f-43ba-8827-22ab5920b89e"
      unitRef="usd">2548000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNy0zLTEtMS01MDI5OQ_ea90a76c-b6d0-4e8b-9756-4bf912169c4f"
      unitRef="usd">12662000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfOS0xLTEtMS01MDI5OQ_f865967d-9294-43ad-81e3-fb6a57cbc4a3"
      unitRef="usd">30218000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfOS0zLTEtMS01MDI5OQ_5e822b09-b2cc-4c2b-8c0a-70ccded79044"
      unitRef="usd">30263000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTAtMS0xLTEtNTAyOTk_275ae5b5-75ed-408d-960d-c67bc5b2652a"
      unitRef="usd">12358000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTAtMy0xLTEtNTAyOTk_9ba09b01-16f7-4e79-b9c7-51ebf63474fe"
      unitRef="usd">7359000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTEtMS0xLTEtNTAyOTk_b5a5916d-0331-4306-8290-8d54109aab6a"
      unitRef="usd">472000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTEtMy0xLTEtNTAyOTk_1c220b03-9430-4089-adf2-dd5e21be4e36"
      unitRef="usd">-268000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTItMS0xLTEtNTAyOTk_63f56c4b-3674-4218-81e5-9b8f82bb57ec"
      unitRef="usd">13186000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTItMy0xLTEtNTAyOTk_5e1f7bc8-564a-4098-be37-87a269af8f9b"
      unitRef="usd">8311000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTMtMS0xLTEtNTAyOTk_fe3575cb-4e2c-4685-8c80-f63a4140fffd"
      unitRef="usd">1079000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTMtMy0xLTEtNTAyOTk_4eb8a794-1970-4575-a050-66286c1db34f"
      unitRef="usd">8837000</us-gaap:AmortizationOfFinancingCosts>
    <evh:GainOnTransferOfMembership
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTQtMS0xLTEtNTAyOTk_a86b68b3-b3db-4fa4-a113-6a4e3f20d7b2"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTQtMy0xLTEtNTAyOTk_dcd119a1-4363-4c96-98aa-11d845918781"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTUtMS0xLTEtNTAyOTk_05ee1a85-43bd-49ca-a72e-6e9810dbf97d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTUtMy0xLTEtNTAyOTk_85d67e64-508e-4fcc-a99e-35b7914db2a8"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTYtMS0xLTEtNTAyOTk_7def0408-5205-4c25-919c-dbd91ae87d7b"
      unitRef="usd">-692000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTYtMy0xLTEtNTAyOTk_d862cfe6-73d3-4afd-a1a8-94a0c2e15ab2"
      unitRef="usd">729000</us-gaap:OtherNoncashIncomeExpense>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTgtMS0xLTEtNTAyOTk_eb479991-c102-4ed5-9c01-f40aa8d10dd0"
      unitRef="usd">-13042000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTgtMy0xLTEtNTAyOTk_7aa3b9c8-b443-4abb-b789-03c2fbc8255f"
      unitRef="usd">120066000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTktMS0xLTEtNTAyOTk_7508d309-c250-4b0b-ac92-ddb367068b47"
      unitRef="usd">8453000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMTktMy0xLTEtNTAyOTk_b5e4538a-e8ce-4a40-980e-14a852ebd2f6"
      unitRef="usd">3439000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjAtMS0xLTEtNTAyOTk_ed0fdbcc-0def-448f-ace4-4dcd02b0b1a3"
      unitRef="usd">3284000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjAtMy0xLTEtNTAyOTk_44315dd7-586a-4596-9b04-47fcf0bdb212"
      unitRef="usd">3991000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjEtMS0xLTEtNTAyOTk_bacd4f9a-792a-4787-b28d-c2e19f3d048c"
      unitRef="usd">-823000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjEtMy0xLTEtNTAyOTk_da8466f4-3924-4523-9058-cd7aa96607f6"
      unitRef="usd">9904000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjItMS0xLTEtNTAyOTk_de91b2d0-3d3e-4582-9c28-3d4a1cfe6540"
      unitRef="usd">-24826000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjItMy0xLTEtNTAyOTk_078b65f6-9148-4e32-8d1f-5391fd891755"
      unitRef="usd">-17725000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjMtMS0xLTEtNTAyOTk_43d305f7-bc5d-4a87-a8f7-1234f31cd0d4"
      unitRef="usd">-22379000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjMtMy0xLTEtNTAyOTk_8c8ae354-0113-4058-b71c-dc71dba20654"
      unitRef="usd">-21505000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjQtMS0xLTEtNTAyOTk_44b0ffa1-d054-4cbe-acad-652595b9f46d"
      unitRef="usd">-3233000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjQtMy0xLTEtNTAyOTk_92a31164-ae85-4b54-86b0-03d463354dde"
      unitRef="usd">2490000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjUtMS0xLTEtNTAyOTk_c94bf264-c8af-4276-8723-abaf0ad41651"
      unitRef="usd">-45334000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjUtMy0xLTEtNTAyOTk_ad1ee920-f9b9-4dab-bf21-bbe9989abff6"
      unitRef="usd">62614000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjYtMS0xLTEtNTAyOTk_1f922677-8cb5-4753-92f4-fb7c48066fd2"
      unitRef="usd">669000</evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset>
    <evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjYtMy0xLTEtNTAyOTk_5b357ea9-df58-4942-8545-56fcde6f543f"
      unitRef="usd">-4621000</evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjctMS0xLTEtNTAyOTk_e5d79869-abd9-4f37-90cc-0ef96fcb81cf"
      unitRef="usd">179000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjctMy0xLTEtNTAyOTk_7fbcc143-2df5-4100-8116-4123c3639435"
      unitRef="usd">-2719000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjgtMS0xLTEtNTAyOTk_c25b822e-2704-4f15-ab5d-84904b4d9843"
      unitRef="usd">-858000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjgtMy0xLTEtNTAyOTk_32f48674-37bc-4f12-a1dd-442675f18883"
      unitRef="usd">1518000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjktMS0xLTEtNTAyOTk_c8b02452-ca62-431d-ae25-6298ac7c7752"
      unitRef="usd">-43778000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMjktMy0xLTEtNTAyOTk_a2f1c233-c806-4532-a4ae-2ba5fce52053"
      unitRef="usd">-72410000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzEtMS0xLTEtNTAyOTk_211f04d9-55f4-45dc-9f5f-d2189157fb7b"
      unitRef="usd">9070000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzEtMy0xLTEtNTAyOTk_69f4a28a-3692-43a6-b343-9661fca600a8"
      unitRef="usd">1472000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzItMS0xLTEtNTAyOTk_00514beb-09f2-479a-930c-f6a19cf29aee"
      unitRef="usd">22969000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzItMy0xLTEtNTAyOTk_0f9858f8-68a4-4788-abd0-710a6ba63d5d"
      unitRef="usd">42996000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzMtMS0xLTEtNTAyOTk_e4707b95-c1d1-4457-9eeb-4b907da53c79"
      unitRef="usd">0</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzMtMy0xLTEtNTAyOTk_df7a5d79-a824-46d7-babb-e27d96c060dd"
      unitRef="usd">-3490000</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzQtMS0xLTEtNTAyOTk_934c134a-a520-499d-9511-6b2e972bd059"
      unitRef="usd">4175000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzQtMy0xLTEtNTAyOTk_384ce7b6-494b-4b7d-9007-60ccaa03da0c"
      unitRef="usd">9372000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzUtMS0xLTEtNTAyOTk_b38d640c-3d6d-406e-b193-1b8e7a132dc7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzUtMy0xLTEtNTAyOTk_1edd232b-7aaa-47e3-98b1-51558a975a7d"
      unitRef="usd">2994000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzYtMS0xLTEtNTAyOTk_e86c0d10-d726-4d5e-86c8-0b010ef38f00"
      unitRef="usd">0</evh:ProceedsFromMaturityOfInvestments>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzYtMy0xLTEtNTAyOTk_e48402eb-d8e9-4900-af35-bad48e32d69e"
      unitRef="usd">500000</evh:ProceedsFromMaturityOfInvestments>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzctMS0xLTEtNTAyOTk_8e106202-eae2-4640-b611-620f83111afe"
      unitRef="usd">17744000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzctMy0xLTEtNTAyOTk_c13ad71f-3ded-40b8-b7e8-a13c48857e40"
      unitRef="usd">11512000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzgtMS0xLTEtNTAyOTk_224185a6-bcda-45f2-8bf8-0da809a37f63"
      unitRef="usd">330000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfMzgtMy0xLTEtNTAyOTk_f058e148-8fad-4686-b484-ad900bcb93d2"
      unitRef="usd">40380000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDAtMS0xLTEtNTAyOTk_45e31173-8f56-40e0-bc59-2fadfafe1311"
      unitRef="usd">-360000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDAtMy0xLTEtNTAyOTk_078d936a-93f8-4968-9e43-ccb804cb0e2c"
      unitRef="usd">-2399000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDEtMS0xLTEtNTAyOTk_d43ee110-b3af-4631-bb4c-e553ec94a4b1"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDEtMy0xLTEtNTAyOTk_f8f1c253-985c-4c1b-8ea7-d22292e4218b"
      unitRef="usd">98420000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDItMS0xLTEtNTAyOTk_019f93a7-f89e-4987-8573-52e021468440"
      unitRef="usd">309000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDItMy0xLTEtNTAyOTk_8c72e293-7f81-4156-9e86-908f3597da0b"
      unitRef="usd">9376000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDMtMS0xLTEtNTAyOTk_b7121078-3e30-46c4-983a-fc0518405e54"
      unitRef="usd">14884000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDMtMy0xLTEtNTAyOTk_c007d16a-5d01-4801-af2e-194d0964233c"
      unitRef="usd">1300000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDQtMS0xLTEtNTAyOTk_53d8d912-554e-4287-aa32-c8f5d08f4d74"
      unitRef="usd">16471000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDQtMy0xLTEtNTAyOTk_7573b2f8-a373-4bb4-81d7-41266e04671b"
      unitRef="usd">3142000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDUtMS0xLTEtNTAyOTk_7cb6acf4-e9ea-4f5a-a3b3-dddbaaa2ae9b"
      unitRef="usd">-30686000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDUtMy0xLTEtNTAyOTk_714f23d6-869b-4281-abc6-066ba8eceb49"
      unitRef="usd">-91087000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDYtMS0xLTEtNTAyOTk_23f6e388-9a5e-4e3e-854e-bca4988a30a4"
      unitRef="usd">-375000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDYtMy0xLTEtNTAyOTk_b0de145a-d570-4631-87a9-471128009776"
      unitRef="usd">-54000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDctMS0xLTEtNTAyOTk_f722eaba-86fa-4b5e-af96-ce6d3256facd"
      unitRef="usd">-74509000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDctMy0xLTEtNTAyOTk_d176db04-af64-4471-a447-cf0554f43eb5"
      unitRef="usd">-123171000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMS0xLTEtNTAyOTk_4c1972bb-dfd5-4f56-9c73-e15c8c00e245"
      unitRef="usd">354942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMy0xLTEtNTAyOTk_c7a5e83c-5f21-49c0-b45f-eebb0c4d690d"
      unitRef="usd">361581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMS0xLTEtNTAyOTk_ee292a9f-87ae-4203-bf77-93525b8dfbc2"
      unitRef="usd">280433000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMy0xLTEtNTAyOTk_5c760221-6054-44a2-b77c-2d92546fb78d"
      unitRef="usd">238410000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80MC9mcmFnOmE4MDQzZDEyYWIyOTQzZWM4ZmJjYzI0ZDI2ZjUzNjg2L3RleHRyZWdpb246YTgwNDNkMTJhYjI5NDNlYzhmYmNjMjRkMjZmNTM2ODZfMTA3Mg_6e261e55-a548-483a-9c82-24deaae23f92">Organization &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its inception, the Company has incurred losses from operations. As of June&#160;30, 2022, the Company had unrestricted cash and cash equivalents of $193.1 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s headquarters is located in Arlington, Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evolent Health LLC Governance&lt;/span&gt;&lt;/div&gt;Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#x2019;s business and affairs and is responsible for the management of its business.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80MC9mcmFnOmE4MDQzZDEyYWIyOTQzZWM4ZmJjYzI0ZDI2ZjUzNjg2L3RleHRyZWdpb246YTgwNDNkMTJhYjI5NDNlYzhmYmNjMjRkMjZmNTM2ODZfNTMw_76ef3a60-9910-43b3-8573-9880acb864d3"
      unitRef="usd">193100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NjU_8727b1fd-75ee-4ee9-b596-ccbd337fd770">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#x201c;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#x201d; in our 2021 Form 10-K for a complete summary of our significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash and Restricted Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements. As of June&#160;30, 2022 and December 31, 2021, approximately $11.5&#160;million and $11.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and was $3.8&#160;million and $7.9&#160;million for the three and six months ended June 30, 2022, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 21 for additional discussion regarding our reserves for claims and performance-based arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right of Offset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of June&#160;30, 2022 and December&#160;31, 2021, approximately 64% and 42% of gross accounts receivable was netted against claims payable in lieu of cash receipt. Furthermore, as of June&#160;30, 2022, approximately 13% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 12 for additional lease disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;See Note 6 for further discussion of our policies related to revenue recognition.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU2MDU_8bc88c1f-7b16-40ea-9e6c-20d4cd3cb51b">Basis of PresentationIn our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NzQ_b8fb7432-c46e-43e4-ad0a-151c370d1034">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1ODE_e5f74ecc-0585-45f0-abdf-6f6c0227ee72">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NDg_d72d5c70-c496-45ba-ace0-35a44b90af9b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NTU_9a4145a4-6ba9-4956-a746-2c252dbeccd3">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements. As of June&#160;30, 2022 and December 31, 2021, approximately $11.5&#160;million and $11.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i843b60b3c07d4c0f966b1c7efd11f445_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMS0xLTEtMS01MDI5OQ_77a2d1d3-a162-4b63-9351-487e055ef7ab"
      unitRef="usd">2269000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i5e9c59f6393b4a8faa1337db8d4243fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMS0zLTEtMS01MDI5OQ_6ef6817c-f3df-4104-b903-358db4bc152f"
      unitRef="usd">3769000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i8f49366fb4ea4c75a9085b9b029857ac_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMi0xLTEtMS01MDI5OQ_d847e3b0-a6c6-4af0-a4b8-2977430a444e"
      unitRef="usd">11504000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i4458c03c2b504669b6dc29624dbd3320_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMi0zLTEtMS01MDI5OQ_ed6e910a-d895-460a-8108-168195bb1465"
      unitRef="usd">11662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i3d346c5c8ea64d16b5d1df5450434600_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMy0xLTEtMS01MDI5OQ_2569057c-ef4f-43db-aafb-20a32e62681c"
      unitRef="usd">73585000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="id592466e76c249e8b646509e71afaf92_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMy0zLTEtMS01MDI5OQ_aa553893-7da2-4b4d-a917-d3cb46da6d26"
      unitRef="usd">73226000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i4de7d7c7a1b34a538212057e51b487b2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNC0xLTEtMS01MDI5OQ_c5c6637c-841e-417d-ab2a-a5870c51d8a7"
      unitRef="usd">5000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ic0fd83c25925422897d5d200f710ee27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNC0zLTEtMS01MDI5OQ_54dc06d6-98c8-4b98-a8a5-047563ef311c"
      unitRef="usd">5000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNS0xLTEtMS01MDI5OQ_cd54b2e6-ff8d-45ff-9cde-21b329dec269"
      unitRef="usd">87363000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNS0zLTEtMS01MDI5OQ_b85b6a67-1442-466a-85cf-045c00dd1943"
      unitRef="usd">88662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNy0xLTEtMS01MDI5OQ_94296386-06ac-4467-a120-5f898a50e98d"
      unitRef="usd">74377000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfNy0zLTEtMS01MDI5OQ_70137a8e-1bf5-4214-b6f5-9d3141a2c99a"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfOC0xLTEtMS01MDI5OQ_81e012ef-2fc9-4281-99d2-d8df316b3875"
      unitRef="usd">74377000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfOC0zLTEtMS01MDI5OQ_7710e9ab-7327-4995-b9ff-a96ee7f71865"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMTAtMS0xLTEtNTAyOTk_0a5884dc-4bac-4dbe-9c78-225e402b2ee5"
      unitRef="usd">12986000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMTAtMy0xLTEtNTAyOTk_e9c55d68-7982-4a9d-81bc-4607bd2185ea"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMTEtMS0xLTEtNTAyOTk_9536aaed-f635-4609-8448-bf3dd646891b"
      unitRef="usd">12986000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjQxMzE4OTJkZjYwZjRhNGRhOTk0YjU1MmIyMmVkM2FiL3RhYmxlcmFuZ2U6NDEzMTg5MmRmNjBmNGE0ZGE5OTRiNTUyYjIyZWQzYWJfMTEtMy0xLTEtNTAyOTk_5740ea09-aca2-40c7-8df4-835386667688"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i2e843b7962284872a802350d9f9601e8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMzcyNw_b359c421-2bdb-4a8f-8e42-0998fa3cf35b"
      unitRef="usd">11500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i07da018892914858a3261ae1eb51a8be_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMzczNA_0f0cfb57-9875-4891-bd3b-ddc236cebc15"
      unitRef="usd">11700000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NTY_1496d3e2-189f-4268-ab36-e247333897f4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfMi0xLTEtMS01MDI5OQ_26e2c71d-fbad-4c1c-a25a-86093ea074da"
      unitRef="usd">193070000</evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations>
    <evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfMi0zLTEtMS01MDI5OQ_5e53758b-986d-4dfb-8129-6b92e9eaa053"
      unitRef="usd">207273000</evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfMy0xLTEtMS01MDI5OQ_ebfd92d1-a1db-4bd7-bcb3-62e9d663eeaa"
      unitRef="usd">87363000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfMy0zLTEtMS01MDI5OQ_1af4146b-7d16-4452-b119-c1db5f544552"
      unitRef="usd">31137000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfNS0xLTEtMS01MDI5OQ_b2397693-30ea-4514-a416-094de6f8d868"
      unitRef="usd">280433000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOmM1MGI2NzI3ODAyOTQyYzBhODE0MTU0NWFlMWIwYmVmL3RhYmxlcmFuZ2U6YzUwYjY3Mjc4MDI5NDJjMGE4MTQxNTQ1YWUxYjBiZWZfNS0zLTEtMS01MDI5OQ_102b2586-8ec2-4fd7-83ae-57c963e153bd"
      unitRef="usd">238410000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1ODM_fa78ed75-da12-4230-aa63-bad14a44b730">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1ODk_1235490d-85b4-48ce-a51e-06ecca5294ab">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfNzU0NQ_2a083814-e743-4acb-b535-3b7579c233f0"
      unitRef="reportingunit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NDY_b4b9f2b0-c340-4df2-97ca-2a1c0a294a1d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NjQ_14ebba4c-3c5b-44ec-b798-5a51f222b8ce">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2022 and December&#160;31, 2021  are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i422269ae7dc54ddf975203be2bc9ec3f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMC0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOmQwZDU2YmE0ZjMwODQ2NzI4ZTM3OTA3ZmQwNDBiNjg5XzQ_ca7c7ffd-f726-444b-b521-550a721c3fb6">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icd4ee5d15f6c48e98699e31b2e8899a7_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMC0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOmQwZDU2YmE0ZjMwODQ2NzI4ZTM3OTA3ZmQwNDBiNjg5Xzk_92ab8efa-bd0f-48bc-a98f-27c24edd71eb">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6b656d6a747c43c0807ef9a72b117fe5_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMS0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOmZjYjc5ZGNiMmJkYjQ5OWViOTk4MDIzMDc1ZDk5ZTFmXzQ_032e8976-bafb-4681-8cc8-9073759ea27b">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic18f73ba368e43578c5dc017d9986091_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMS0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOmZjYjc5ZGNiMmJkYjQ5OWViOTk4MDIzMDc1ZDk5ZTFmXzk_b20a1180-0743-4914-bf76-7b981943aa4e">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8920304c21f34d2e8d814f99e02bb672_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMi0xLTEtMS01MDI5OQ_42ba26b0-c360-4f43-80d9-434691a31802">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie2f2470a268e4d5593d8214f2752ddb2_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMy0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOjAxYTJmMmYzZDEyMzQ1OTM4MmNiODM3NWEyNzI2ZTgzXzQ_d9b5be9e-5758-429f-93fa-5f85ca6ea9ad">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id10401febbb0459b90ba3a22611bb8d1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RhYmxlOjU1ZTcyNTdkOTNlMzQ5YTA5MjEwM2E5MDdlNGMxNjc0L3RhYmxlcmFuZ2U6NTVlNzI1N2Q5M2UzNDlhMDkyMTAzYTkwN2U0YzE2NzRfMy0xLTEtMS01MDI5OS90ZXh0cmVnaW9uOjAxYTJmMmYzZDEyMzQ1OTM4MmNiODM3NWEyNzI2ZTgzXzk_fe29e43d-2086-4ecf-95ac-4873ba249102">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1Nzg_96c66de8-c6f7-403c-a82e-dca35a00cb17">Research and Development CostsResearch and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and was $3.8&#160;million and $7.9&#160;million for the three and six months ended June 30, 2022, respectively.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTA5OTUxMTY0MzYzNg_16d656a0-f376-4eb8-82ce-bb22546904cb"
      unitRef="usd">3800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTA5OTUxMTY0MzY0NA_26e88782-14b3-480c-a09e-992b6d8ee566"
      unitRef="usd">7900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LiabilityReserveEstimatePolicy
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1ODU_01703d8c-47a1-4745-935c-62935dd0f952">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company &lt;/span&gt;&lt;/div&gt;uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.</us-gaap:LiabilityReserveEstimatePolicy>
    <evh:RightOfOffsetPolicyPolicyTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1NzI_92e7e424-7114-4d85-a87b-77d554b2a22c">Right of OffsetCertain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.</evh:RightOfOffsetPolicyPolicyTextBlock>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTIyNDc_4da2515f-80cc-4095-89a5-ad28d33c2aee"
      unitRef="number">0.64</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTIyNTQ_d9f05bf9-0112-4a0a-b6ae-6cc2b790af46"
      unitRef="number">0.42</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTIzODI_e8d0afeb-b0c7-4222-adcd-b27269740aca"
      unitRef="number">0.13</evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU2MDg_72f8b4ae-cf8e-4ac7-afb7-4f77833b1851">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMTU1OTI_57cc079f-66d3-47bd-a229-bd281427d409">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue primarily from platform and operations services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#x201c;TPA&#x201d;) services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal vs. Agent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <evh:NumberOfSourcesOfRevenue
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80My9mcmFnOmFhMjljODJiN2RkZTQ0YzFiMWI2MzZiMzkzYTcwYWRlL3RleHRyZWdpb246YWEyOWM4MmI3ZGRlNDRjMWIxYjYzNmIzOTNhNzBhZGVfMzI5ODUzNDg5OTMwNA_7a9f0e95-2321-4c10-b4ee-6caaca6f5a69"
      unitRef="source">2</evh:NumberOfSourcesOfRevenue>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMzE3Mw_a8fd881e-fae7-4f89-b9be-6d4758e80bc0">Recently Issued Accounting Standards&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMzE3OA_6c04e994-1919-4d22-9a0a-75dc3afad4d5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i1576668fe0314dd3b3b3ec454798b582_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMjIxMQ_7bed4fb8-e0bb-4b46-8e09-51d1ceeea1c8"
      unitRef="usd">39800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if8072fe070714d70b4c7d5054c1d19bd_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMjI1Mw_3c286d43-2065-4374-9241-ff42973f66e7"
      unitRef="usd">106200000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="ib3ecfc57dd454ea480838c4fc5252936_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMjMyNA_80f043f1-6fc7-4320-8c8d-a5e14cc166d8"
      unitRef="usd">25100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie80fd38d9d5b4ab2bc9f658f6aadf4a0_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80Ni9mcmFnOmE1OWY1OWE1NTlhMDRkY2ZiYTZkNzA4ZGU0MmUyMGI3L3RleHRyZWdpb246YTU5ZjU5YTU1OWEwNGRjZmJhNmQ3MDhkZTQyZTIwYjdfMjMzMQ_2b4ee06c-37a1-4730-a8c7-0497bd2c3f9b"
      unitRef="usd">41300000</us-gaap:LongTermDebt>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMzQ2MA_2a3abdb2-5ee6-4981-8939-b14a6811d08a">Transactions&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vital Decisions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, the Company completed its acquisition of Vital Decisions, including 100% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total merger consideration, net of cash on hand and certain closing adjustments, was $117.7 million, based on the closing price of the Company&#x2019;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $46.5 million of cash consideration, 1.8&#160;million shares of Class A common stock, fair valued at $56.6 million as of October 1, 2021, and an earn-out of up to $45.0&#160;million, fair valued at $14.6 million as of October 1, 2021. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of 13 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $69.6&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts above reflect management&#x2019;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments will be finalized by the end of the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMTU2_14184e4f-ab50-4f5b-8851-a85a7de28e1b"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfNzE3_2adda0b2-56b5-4a2e-af21-2a551296d0df"
      unitRef="usd">117700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfODU2_f033ee28-ec60-4bc2-8792-54735126a34a"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfODgy_885bc26a-ac3a-4e4d-8cdb-b9b0e658b975"
      unitRef="shares">1800000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfOTMy_ee7ddb2e-7392-4680-b6e7-8961e74ec672"
      unitRef="usd">56600000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfOTgz_1c0a89d7-8f74-4665-b938-ade9e297b74f"
      unitRef="usd">45000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMTAwMg_97a6e55d-d452-4ade-990b-6611a6011b25"
      unitRef="usd">14600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMzQ2Nw_e1e848f5-a8aa-4747-ba01-65dc1c2bbc5c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMzQ2OA_b57e9d84-d12c-47ab-b565-5dcb19027045">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMS0xLTEtMS01MDI5OQ_034b296c-c424-4197-839f-0900b947e239"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMi0xLTEtMS01MDI5OQ_fc52d11a-a708-4167-b82f-728d8d949290"
      unitRef="usd">56626000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMy0xLTEtMS01MDI5OQ_f73e4d72-4155-46fd-8203-e6ba6e259d81"
      unitRef="usd">14600000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i477230494f1041fd9804ec69666a9459_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfNC0xLTEtMS01MDI5OQ_a1fa3b4f-4bec-4a63-a995-b751ae92b79f"
      unitRef="usd">117726000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfNy0xLTEtMS01MDI5OQ_c8f5a5a6-f53b-4b72-afe8-dfadabad4357"
      unitRef="usd">1430000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfOC0xLTEtMS01MDI5OQ_16aad94d-8782-413d-8fc6-905ac1c5f836"
      unitRef="usd">3301000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfOS0xLTEtMS01MDI5OQ_023f912b-55bd-4d3b-a669-558bc0e2678d"
      unitRef="usd">78000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTAtMS0xLTEtNTAyOTk_3cf22b80-8b16-47a0-b304-585f8577ace1"
      unitRef="usd">2564000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTEtMS0xLTEtNTAyOTk_4e1339cd-e544-4a39-a2a0-5bf09346981d"
      unitRef="usd">7373000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ica9021ecacd5411b9522695f0968fd6e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTQtMS0xLTEtNTAyOTk_c5089e4f-4d79-488b-9d8d-98d56b53a510"
      unitRef="usd">32500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i569f17d92bfa4d41a92b3f6f73066652_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTUtMS0xLTEtNTAyOTk_2b2a5f04-8f66-40de-8dde-f0e2540de9ae"
      unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iff1070f5f0bf442684f5ebf0e562d035_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTYtMS0xLTEtNTAyOTk_b6e98dc3-90bb-4df5-a915-5de97d997863"
      unitRef="usd">2500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMTctMS0xLTEtNTAyOTk_31067b81-35f3-4eb1-a801-9121f23882f4"
      unitRef="usd">40000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjAtMS0xLTEtNTAyOTk_8911ee7a-bafa-49a2-acb1-df3a1a2bafa9"
      unitRef="usd">93000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjEtMS0xLTEtNTAyOTk_216944c4-b66a-4ebc-9532-47c208f4f391"
      unitRef="usd">661000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjItMS0xLTEtNTAyOTk_c9cf79ab-4941-4fb8-a1c5-48aa59e4d947"
      unitRef="usd">970000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjMtMS0xLTEtNTAyOTk_c2736c5d-4e07-4787-b97f-d9bf7d54df98"
      unitRef="usd">499000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjQtMS0xLTEtNTAyOTk_285fb174-ae40-4de8-907a-a63c05aacdea"
      unitRef="usd">2000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjUtMS0xLTEtNTAyOTk_e5e71da6-bab1-4a57-9257-f8b56c6ecb9c"
      unitRef="usd">2712000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjYtMS0xLTEtNTAyOTk_bc128300-ed3c-4828-b029-ec7639d951bc"
      unitRef="usd">6935000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:Goodwill
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjgtMS0xLTEtNTAyOTk_bee281f9-237f-47c1-8321-881a2659049f"
      unitRef="usd">77288000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RhYmxlOjZhZTAyY2IyN2ZjOTRhNDI5ZWVlNjY0ZDY0ODRkYzFjL3RhYmxlcmFuZ2U6NmFlMDJjYjI3ZmM5NGE0MjllZWU2NjRkNjQ4NGRjMWNfMjktMS0xLTEtNTAyOTk_330e6fa2-0126-463a-bac3-668bfafcb848"
      unitRef="usd">117726000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i9b5a5d27c5cd45318130592162ae2979_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMTY2OA_5c039e61-ce9e-4cfc-8994-ba671b0ad782">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i5cfda0e9098c4c609e2cc6cf7786ab7f_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMTY3Mg_99c5579e-1fed-4aac-bea1-d25ec6522c06">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i155bf891da8c4ffd8ff2e7f58e3b77cb_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMTY4MA_6026ddf1-09fa-4017-9fa1-87fce823eb66">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="id53f2482994740c4afac4ded4824ffa5_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl80OS9mcmFnOjU2NzhkZjg3YmI2ZTQxNzk5YWM1YWMyZGM1YjllNzdkL3RleHRyZWdpb246NTY3OGRmODdiYjZlNDE3OTlhYzVhYzJkYzViOWU3N2RfMzE0Ng_1d59b020-7033-4bc5-95ef-ef671632a5c9"
      unitRef="usd">69600000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RleHRyZWdpb246ZDFkNGE3OWIxMjQ2NDAxYWFhZDg4MDViYzRhM2Y2MzNfMjI5NA_a0acbb99-e0dc-4dcb-95b4-f8327d1ea319">Discontinued OperationsOn January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#x201c;True Health SPA&#x201d;) with Bright Health Management, Inc. (&#x201c;Bright HealthCare&#x201d;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#x201c;True Health Closing&#x201d;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six &lt;br/&gt;Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the six months ended June 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RleHRyZWdpb246ZDFkNGE3OWIxMjQ2NDAxYWFhZDg4MDViYzRhM2Y2MzNfMjI5NQ_3c0d069a-7e32-4822-a83f-87cd576123f2">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six &lt;br/&gt;Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;Cash flows related to the True Health business during the six months ended June 30, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i75dc927515b3477cb3c9aeebb4a7a7d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMi0xLTEtMS01OTQ3MQ_45cd1822-d5d4-491c-9df1-f1892d58b7b5"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i30adaf2d743e41079b7a12ac72d1fc61_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMS0xLTEtMS01MDI5OQ_b65253c0-d4a0-4789-bb20-f0c5c3b48e95"
      unitRef="usd">38000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i0ef29e9326024b2192d9ecc9a670b854_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMy0xLTEtMS01OTQ3MQ_828fa1df-4a59-4a40-b621-7962e89057f8"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i3e64363b84144ffdac3dc9bb780e39a8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMi0xLTEtMS01MDI5OQ_298ad10c-dfb7-41b4-bd4d-94829902f1d7"
      unitRef="usd">44795000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfNC0xLTEtMS01OTQ3MQ_c6abd930-0021-48a8-be66-7e5f30a43e5f"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMy0xLTEtMS01MDI5OQ_9c2cdedd-5be7-4f7f-8496-875ee66840ee"
      unitRef="usd">44833000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfNy0xLTEtMS01OTQ3MQ_39c44844-6d0e-4fed-8b6c-e5d91a5e6503"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfNi0xLTEtMS01MDI5OQ_8fce3ef5-2369-42b7-8b8e-f2dc5738e7a3"
      unitRef="usd">5885000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfOC0xLTEtMS01OTQ3MQ_ab86c846-4e7d-46bd-9e54-f420675fa4aa"
      unitRef="usd">0</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfNy0xLTEtMS01MDI5OQ_5be3e68e-b75b-467c-abb6-903646658095"
      unitRef="usd">33954000</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfOS0xLTEtMS01OTQ3MQ_12898778-fbbd-4750-879c-6379bb47f744"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfOC0xLTEtMS01MDI5OQ_7e4278ff-8177-44dd-98a1-1f604b88e7e7"
      unitRef="usd">5764000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTAtMS0xLTEtNTk0NzE_fc281a29-3490-4166-b31c-25df1c23830e"
      unitRef="usd">0</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfOS0xLTEtMS01MDI5OQ_ca66b475-1fe2-4a8d-9eed-7e3132620a75"
      unitRef="usd">160000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTEtMS0xLTEtNTk0NzE_81324f3a-17f7-4c38-afe2-116997dd16d1"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTAtMS0xLTEtNTAyOTk_dc96dbfd-dad4-4835-b16d-1647fd13c7de"
      unitRef="usd">45763000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTItMS0xLTEtNTk0NzE_4bce9602-4fbd-44c2-8f30-7ca077f1bb35"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTEtMS0xLTEtNTAyOTk_45cd59be-5e1f-4109-92a3-9f9f3351efdd"
      unitRef="usd">-930000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTMtMS0xLTEtNTk0NzE_c02f5d56-1415-4284-8271-d57245395aed"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTItMS0xLTEtNTAyOTk_820ac5c3-5da5-4b9a-96f1-647439848343"
      unitRef="usd">112000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTQtMS0xLTEtNTk0NzE_670ac8fc-dbf9-4f99-b38a-7ebabeb0b558"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTMtMS0xLTEtNTAyOTk_c7d8ebdf-8a6e-4ace-8dbe-07a621faa222"
      unitRef="usd">4000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTUtMS0xLTEtNTk0NzE_314520a2-20a2-454b-8990-9d5026463da2"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTQtMS0xLTEtNTAyOTk_f9d9845d-d21a-4ef6-b01e-a4155fe404ed"
      unitRef="usd">25000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTYtMS0xLTEtNTk0NzE_c4208258-9498-4f38-b6da-f963b556da5b"
      unitRef="usd">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTUtMS0xLTEtNTAyOTk_0ef73340-c99a-4203-88c9-ac8792cc7673"
      unitRef="usd">-847000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTctMS0xLTEtNTk0NzE_3e9c5c38-5e60-4635-924a-57652f36847e"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTYtMS0xLTEtNTAyOTk_4abb07f7-a4bb-4e56-8112-1ce6fa0ffef1"
      unitRef="usd">-326000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ide9111e594364928b4f284bff447dc08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTgtMS0xLTEtNTk0NzE_91868229-3f1d-4087-892c-fe33e51dd37f"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjNjMDI4ZmQ4Mzc3MTQ0OGJiZjc1OTQ5MzQ4YmQ4NzNhL3RhYmxlcmFuZ2U6M2MwMjhmZDgzNzcxNDQ4YmJmNzU5NDkzNDhiZDg3M2FfMTctMS0xLTEtNTAyOTk_13f06d27-a927-415b-bbbb-ed700447d17a"
      unitRef="usd">-521000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="id3e532127d5f44dcaa0a6d0b870251c4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RleHRyZWdpb246ZDFkNGE3OWIxMjQ2NDAxYWFhZDg4MDViYzRhM2Y2MzNfMTY4OQ_3bfb2ab0-bc46-4fb4-8afb-057547abd3ef"
      unitRef="usd">2800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="id3e532127d5f44dcaa0a6d0b870251c4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RleHRyZWdpb246ZDFkNGE3OWIxMjQ2NDAxYWFhZDg4MDViYzRhM2Y2MzNfMjA2Mg_efadc642-ffc5-4235-9a37-f566d4969cc1"
      unitRef="usd">1100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjJhZDAzMDk5NGZmZDQ0MGQ5OTdmMDc2N2U5ZGVjZmMzL3RhYmxlcmFuZ2U6MmFkMDMwOTk0ZmZkNDQwZDk5N2YwNzY3ZTlkZWNmYzNfMC0xLTEtMS01MDI5OQ_4f57e49d-145d-42dc-a49c-afbedaecc547"
      unitRef="usd">5002000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81Mi9mcmFnOmQxZDRhNzliMTI0NjQwMWFhYWQ4ODA1YmM0YTNmNjMzL3RhYmxlOjJhZDAzMDk5NGZmZDQ0MGQ5OTdmMDc2N2U5ZGVjZmMzL3RhYmxlcmFuZ2U6MmFkMDMwOTk0ZmZkNDQwZDk5N2YwNzY3ZTlkZWNmYzNfMS0xLTEtMS01MDI5OQ_66088199-3083-41de-9474-27ceaed8192c"
      unitRef="usd">-2494000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTAyNzk_56794889-a5d3-4da3-80a6-73770508a18e">Revenue Recognition&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue primarily from platform and operations services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#x201c;TPA&#x201d;) services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal vs. Agent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:114.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction Price Allocated to the Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts with a term greater than one year, we have allocated approximately $139.6 million of transaction price to performance obligations that are unsatisfied as of June&#160;30, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 28%, 60% and 82% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June&#160;30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the six months ended June 30, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $19.5&#160;million and $46.1&#160;million for the three and six months ended June 30, 2022, due primarily to net gain share as well as changes in other estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Cost Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of June&#160;30, 2022 and December 31, 2021, the Company had $3.8 million and $5.2 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amortiza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tion expense of $0.3 million and $1.7 million for the three and six months ended June 30, 2022, respectively, and $0.6 million and $1.0 million for the three and six months ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our platform and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of June&#160;30, 2022 and December 31, 2021, the Company had $18.9 million and $27.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for certain customers of $1.2 million and $11.5 million for the three and six months ended June 30, 2022, respectively, and $4.6 million and $7.3 million for the three and six months ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTAyODE_b2f774d3-1da7-4725-be41-7da251675e7a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:114.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic18910942b2e485ea30def8e9cefca28_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy0xLTEtMS01MTMzOA_0e921b07-533c-4a03-90e9-fde26b5f5eda"
      unitRef="usd">55422000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i908235d4f83442cfa2a22b2a90120a12_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy0zLTEtMS01MTMzMQ_860639ee-b80b-4b54-a360-4c8c452205c5"
      unitRef="usd">52064000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id190777694a14c8296979c0037b1333a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy01LTEtMS01MTM0NQ_415a8d29-55aa-4996-9557-490e4801073b"
      unitRef="usd">86080000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20b23e58105b4c5f9f250d293d1bbf58_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy03LTEtMS01MTM0NQ_3b586dc8-3e70-4a76-a684-92b7f8e1eeb7"
      unitRef="usd">53648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92b903bf1e5f4a638b29eeb71fe6c6b4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy0xLTEtMS01MDI5OQ_8a463f7e-3261-4cae-a422-7406391740ed"
      unitRef="usd">122336000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26d5d6d44adc4e43990ce92c4c44933a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy0zLTEtMS01MDI5OQ_704cdb7e-95d9-48ac-aec0-e4c312e59655"
      unitRef="usd">112993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1702427992f426b85f07248e2895331_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy01LTEtMS01MDI5OQ_e8450e27-c7f5-4434-84d1-df5ac77c56cb"
      unitRef="usd">156967000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib280f91a402940c69f0c3e5cc12d4d56_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfMy03LTEtMS01MDI5OQ_94276e72-9b09-46ed-8479-ee9b839a4972"
      unitRef="usd">96987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0b2ccb4486a4651913ac8302c5c0ec4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC0xLTEtMS01MTMzOA_5c4e6ffb-837a-4c67-88a0-ec8424ea581c"
      unitRef="usd">9863000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18dabb68c8274ea0a5201f8219bce96d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC0zLTEtMS01MTMzMQ_e5c47f33-0cd8-4ce7-9889-d5f87a591ecd"
      unitRef="usd">6346000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cb66e4294e54785b37e073174f3db3c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC01LTEtMS01MTM0NQ_215c7c39-7e43-4911-9554-84c7ba2b51ac"
      unitRef="usd">101529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60f215dd151c4adb9f5d581b6725305d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC03LTEtMS01MTM0NQ_da42413a-0a3b-4e79-91ba-62eb41e6f1e0"
      unitRef="usd">90761000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53d31d53daf04bb8b14968d7533e3c30_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC0xLTEtMS01MDI5OQ_7447d135-1fcb-4004-81ee-1914fc1afec7"
      unitRef="usd">14696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa385ea46e294eeabd2ab99940f8e291_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC0zLTEtMS01MDI5OQ_2e45e240-6dd0-44c1-85be-b3920e91c2a0"
      unitRef="usd">14684000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66dd2b3d936841cea2ea68298ff824f5_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC01LTEtMS01MDI5OQ_b44648a2-9afa-4b7d-bc25-8c671e1f0f7d"
      unitRef="usd">193796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d1117684efa42b1a391ffcc826e14e1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNC03LTEtMS01MDI5OQ_355af165-06bd-4428-9f75-e50181d58298"
      unitRef="usd">176544000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaf1aec104e64ca9ab855423a51a4a6c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS0xLTEtMS01MTMzOA_1cbe6eb6-cc90-4ce5-91e2-1c3e1188449c"
      unitRef="usd">27051000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if40f448b1aee435882087e7f40e19f83_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS0zLTEtMS01MTMzMQ_a738b3e0-82a6-4ca5-81de-a90bd616153d"
      unitRef="usd">16453000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i861b85e9482e4845a118116261fe251b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS01LTEtMS01MTM0NQ_d0ac8eda-976f-44cd-a2fc-f87f73fe4183"
      unitRef="usd">39994000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i031024ab0cda4f04a32cb998ae9efc29_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS03LTEtMS01MTM0NQ_d7a5f9b2-d1d2-4ad9-a911-aea5331e505a"
      unitRef="usd">2785000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie94a3b4a3c854650a274a22df3bb7e4b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS0xLTEtMS01MDI5OQ_96821df7-cc48-40fa-8071-fbb690b76e85"
      unitRef="usd">62162000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic519d1466dfe43928dcfe5d77bdee3ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS0zLTEtMS01MDI5OQ_0a2c6ff3-c77b-471f-8019-5c858dcd9ebd"
      unitRef="usd">32023000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i404e9ab7124f42c99765abd6b37736c1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS01LTEtMS01MDI5OQ_c07ac4f0-27a8-4e09-8610-89f80101f97b"
      unitRef="usd">67039000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia36ffca71bef413bab9a1cae99ccecfa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNS03LTEtMS01MDI5OQ_6f2286a7-5ef5-4198-bd90-ee6b6f33af62"
      unitRef="usd">3897000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie208d4a1cb3e4377a6d2ee9c2549f37c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi0xLTEtMS01MTMzOA_03023f56-2e99-41bc-8ed8-095a724311d8"
      unitRef="usd">92336000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia71fe81096cc402e8ae97e15131a0756_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi0zLTEtMS01MTMzMQ_99223873-0817-4ff9-9b0b-4535792a32a6"
      unitRef="usd">74863000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b091472e7f14e738060f39d3bb11f9e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi01LTEtMS01MTM0NQ_2b86e47f-8803-46ae-bd74-bf41f9c297f9"
      unitRef="usd">227603000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7def236e69944f2bfd7976a1f32c4f4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi03LTEtMS01MTM0NQ_029232f2-a7d3-40b9-b9db-7a309be66c76"
      unitRef="usd">147194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi0xLTEtMS01MDI5OQ_e5e93daa-ad93-4b97-80b2-94387e20c544"
      unitRef="usd">199194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi0zLTEtMS01MDI5OQ_ef94aa82-5484-4dbf-baa9-0daef1815784"
      unitRef="usd">159700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi01LTEtMS01MDI5OQ_1e589af3-a07d-4a6f-9add-616efc2c058d"
      unitRef="usd">417802000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjI0YThiZjI3ZTkyNDQ2NzJhODY1MmQ0YmIwNTEwOGY3L3RhYmxlcmFuZ2U6MjRhOGJmMjdlOTI0NDY3MmE4NjUyZDRiYjA1MTA4ZjdfNi03LTEtMS01MDI5OQ_53f20758-badb-4e97-bd26-5e1c61524d4f"
      unitRef="usd">277428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfNTE2Ng_397ea223-c91d-4e0e-9946-964c100aca88"
      unitRef="usd">139600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i6f80fd138cee4ef2abfdef7ff9b68ef6_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfNTc4NQ_81be2e03-8453-4818-b773-4ed399ee07ae"
      unitRef="number">0.28</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i9a64da34af914c9daa54dedee5a5cd92_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfNTc4OQ_a686bc87-c6cf-438e-802a-186b871770d0"
      unitRef="number">0.60</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i132fb5a493164122bbdcd92d3b2833eb_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfNTc5Ng_31cd4351-cc1b-4331-a06f-91ac3f4c0d77"
      unitRef="number">0.82</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTAyODQ_c30d3308-fac6-4423-a3d5-bb30e2d5ee46">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June&#160;30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the six months ended June 30, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMS0xLTEtMS01MDI5OQ_fd1a2446-daa3-4519-bd3f-307c72555e95"
      unitRef="usd">116580000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMS0zLTEtMS01MDI5OQ_43c30ee0-d591-44b5-90ff-4b935a0286d8"
      unitRef="usd">129012000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMi0xLTEtMS01MDI5OQ_a9d6705d-ad6a-41c6-aa17-49ab02280913"
      unitRef="usd">5038000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMi0zLTEtMS01MDI5OQ_b5efa413-914a-4fd5-bd86-406d465f9618"
      unitRef="usd">4877000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMy0xLTEtMS01MDI5OQ_de9a68ad-7f7d-4a7e-951b-4a02b9aed844"
      unitRef="usd">8711000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfMy0zLTEtMS01MDI5OQ_de2668d7-5741-472d-abe1-48c5f2757566"
      unitRef="usd">11944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfNC0xLTEtMS01MDI5OQ_a81a2bd4-04bd-404d-ad56-5c28d4fc7c25"
      unitRef="usd">3605000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjQ5NDQ5MDkwMzJjMjRhOTk4NjY2YTEzYzlkODZmMGQ3L3RhYmxlcmFuZ2U6NDk0NDkwOTAzMmMyNGE5OTg2NjZhMTNjOWQ4NmYwZDdfNC0zLTEtMS01MDI5OQ_ce80376d-c832-49d9-b574-6bb08a592228"
      unitRef="usd">4437000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjBlYWRkYzYxOGU0ZjQ0ZTBhMzE2ODhkNGZmN2E5N2M4L3RhYmxlcmFuZ2U6MGVhZGRjNjE4ZTRmNDRlMGEzMTY4OGQ0ZmY3YTk3YzhfMS0xLTEtMS01MDI5OQ_e21c7b6b-7e91-4ad0-be9e-037a9b3da67d"
      unitRef="usd">16381000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjBlYWRkYzYxOGU0ZjQ0ZTBhMzE2ODhkNGZmN2E5N2M4L3RhYmxlcmFuZ2U6MGVhZGRjNjE4ZTRmNDRlMGEzMTY4OGQ0ZmY3YTk3YzhfMi0xLTEtMS01MDI5OQ_6f6ab731-53c7-465d-a91a-5622e9873e0c"
      unitRef="usd">10796000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjBlYWRkYzYxOGU0ZjQ0ZTBhMzE2ODhkNGZmN2E5N2M4L3RhYmxlcmFuZ2U6MGVhZGRjNjE4ZTRmNDRlMGEzMTY4OGQ0ZmY3YTk3YzhfMy0xLTEtMS01MDI5OQ_8e9d46a3-127e-4974-807c-70db5a7ba9fa"
      unitRef="usd">6731000</evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RhYmxlOjBlYWRkYzYxOGU0ZjQ0ZTBhMzE2ODhkNGZmN2E5N2M4L3RhYmxlcmFuZ2U6MGVhZGRjNjE4ZTRmNDRlMGEzMTY4OGQ0ZmY3YTk3YzhfNC0xLTEtMS01MDI5OQ_d3e6fed3-7339-4202-a062-4d9101445ada"
      unitRef="usd">12316000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTA5OTUxMTYzODM4Mw_8e12d0dc-3917-4d01-ba11-fb69120a5ef7"
      unitRef="usd">19500000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfNzk5OA_3b0969d3-0799-4e35-a368-ac91f03c938f"
      unitRef="usd">46100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i55fd2849c11d40aa8dac15390f64e184_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfODY1MQ_c8cfb0fb-cfb3-49e5-aec9-05bfcece158e"
      unitRef="usd">3800000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i91e9cc56ffee4613adb9a6ab56554271_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfODY1OA_dc989eea-1c6e-4683-90c4-669328fe6591"
      unitRef="usd">5200000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i3532becac70546b4bcc03b106edda27c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTA5OTUxMTYzODE2Ng_a124930f-90eb-4cd0-a0fb-7579d30c06af"
      unitRef="usd">300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ia3ce003447674e2abab64b23eeba11a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfODg3Mw_32529eb1-77ff-43fc-a175-aabca36f095d"
      unitRef="usd">1700000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i84c9dc97776a4d2ab2a8a979cad50e02_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTA5OTUxMTYzODIyNQ_5e8aea5a-155c-44b5-921a-035d45259ff8"
      unitRef="usd">600000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="iff2de2ac36d149c7b524f3b5582f9909_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfODg4MA_c365f00c-7779-49f4-9627-7d90588041c6"
      unitRef="usd">1000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i4bcd88cb096e4aeab56740f6386ffe14_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfOTYzNg_1ff77e3f-763e-4dc0-ade2-6ca25666f6e4"
      unitRef="usd">18900000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="ieeb135f182f34812b3000c1ef3bc7bba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfOTY0Mw_d8cc4f48-7cea-4dcf-874b-9c2f164c42f4"
      unitRef="usd">27400000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i4b532269dce647ae8ba0e135b9f58fd9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTA5OTUxMTYzODM1MA_11b9502b-9caa-40ef-a67a-634f231b2f12"
      unitRef="usd">1200000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i872c6081b968491a9d538c7086489d91_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfOTk0MQ_88b829e6-6e9a-4983-9e58-400b9a689735"
      unitRef="usd">11500000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i26704ded411543a5924bf706b6248305_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTA5OTUxMTYzODM2MA_af64872e-8034-4d35-a3f2-b6055f75404c"
      unitRef="usd">4600000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i4f98d9fd601a4df297a857523d498b81_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfOTk0OA_44a1b43d-3e97-4e25-b270-859433342089"
      unitRef="usd">7300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortizationPeriod
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl81NS9mcmFnOjM1M2JmYmNlNzZjYjQxMTg4ZDI2MGVjNzViYThiMWE4L3RleHRyZWdpb246MzUzYmZiY2U3NmNiNDExODhkMjYwZWM3NWJhOGIxYThfMTAxNjY_6729c73e-8e0c-4908-8ce1-c20c93f9b269">P5Y</us-gaap:CapitalizedContractCostAmortizationPeriod>
    <us-gaap:CreditLossFinancialInstrumentTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjk0Nw_c05e8764-ae89-4bae-bd29-02b3b1f31ed0">Credit Losses &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic and current inflationary pressures on our customers&#x2019; and other third parties&#x2019; ability to pay. We did not observe notable increases in delinquencies during the three and six months ended June 30, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three and six months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable from Revenue Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#x2019;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#x2019;s consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;June&#160;30, 2022,&#160;90% were current, 6%&#160;were past due less than 60 days, with 8% past due less than 120 days and at December 31, 2021, 90% was current, 2% was past due less than 60 days, with 3% past due less than 120 days. As of&#160;June&#160;30, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$127.7 million&#160;and $171.5&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$3.1 million and $3.4 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentTextBlock>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjMwMA_acef2ccc-0c22-4507-a6a5-2e24fbed4246"
      unitRef="number">0.90</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i98a3c0b9b3254cfc9d6d4301e6079769_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjMxNw_16ef6d0a-0653-454d-a482-e16e16f61ac2"
      unitRef="number">0.06</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="icfd3ac7207dd485b866d1ecf9d8370e4_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjM1OA_9a0d165a-ee26-401d-9701-ea88953a588d"
      unitRef="number">0.08</us-gaap:FinancingReceivablePercentPastDue1>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjQxNQ_946ff4eb-103e-4f79-bac1-a719ee72f71e"
      unitRef="number">0.90</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="idb1b05b4923144d994dffe62ce8c0056_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjQzMQ_c4ff14c5-6748-4d19-9e83-c2af5a2b67a0"
      unitRef="number">0.02</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="ia32e4243b72b414dbf63a7b58e4444cc_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjQ3MQ_acf1ba1a-1dcc-43a8-adf4-d35f3b65be0e"
      unitRef="number">0.03</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:AccountsReceivableNet
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjU5MA_befa5ef9-9c40-47ad-a04c-237b7656f344"
      unitRef="usd">127700000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjU5Nw_843cbfbb-b1c3-410e-b869-891ccff7cb1a"
      unitRef="usd">171500000</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjczMA_68b74b2c-ccac-4981-8304-0bdcdb81235d"
      unitRef="usd">3100000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjczNw_9a5a0504-220c-4f40-9a26-be136583bbfa"
      unitRef="usd">3400000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RleHRyZWdpb246MGYzZGYyMzBmNjg1NDg0NmEzZDEwN2Q1Y2JhMDU0OWFfMjk0OA_26fc3e3c-54f7-4514-bcb4-26f5b21b0b55">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfMi0xLTEtMS01MDI5OQ_002097b5-999b-497b-a668-8bf7bcc94a68"
      unitRef="usd">3374000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfMi0zLTEtMS01MDI5OQ_6187b9e6-9f88-4fa4-8d79-a7733f366531"
      unitRef="usd">7056000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfMy0xLTEtMS01MDI5OQ_ed9c7809-0b5e-484a-89ca-6547a1a1d06c"
      unitRef="usd">-322000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfMy0zLTEtMS01MDI5OQ_6677f52c-6f0a-4cb3-8d4c-b4cd875e4cbb"
      unitRef="usd">611000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfNC0xLTEtMS01MDI5OQ_451eb4ea-ef4f-486f-9879-c6b5233404e1"
      unitRef="usd">3052000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82MS9mcmFnOjBmM2RmMjMwZjY4NTQ4NDZhM2QxMDdkNWNiYTA1NDlhL3RhYmxlOmRiNDExYWRkZWQyODQ4NTc4MDY4NzAzNmYwODcwYmVjL3RhYmxlcmFuZ2U6ZGI0MTFhZGRlZDI4NDg1NzgwNjg3MDM2ZjA4NzBiZWNfNC0zLTEtMS01MDI5OQ_c090c5af-8a1b-4c55-91f6-7ea253986a13"
      unitRef="usd">7667000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNTc0_c45577e0-e6bb-4803-9673-c5b7bd47460f">Property and Equipment, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalized $7.1 million and $13.5 million for the three and six months ended June 30, 2022, respectively, and $5.6 million and $11.1 million for the three and six months ended June 30, 2021, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $71.5 million and $71.2 million as of June&#160;30, 2022 and December 31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $7.8 million and $15.4 million for the three and six months ended June 30, 2022, respectively, and $7.6 million and $15.4 million for the three and six months ended June 30, 2021, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.5 million and $13.2 million for the three and six months ended June 30, 2022, respectively, and $6.6 million and $13.3 million for the three and six months ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNTgx_475703d0-9424-4775-8777-e771b4f7dd75">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i461ebb8b4b4143dfb77186edf095976d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMS0xLTEtMS01MDI5OQ_0add18d9-6d56-4ab1-ae4e-838b670affad"
      unitRef="usd">26452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id8ccca889cbf4b0c9a6c45d4e2792d4d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMS0zLTEtMS01MDI5OQ_0cf3697c-ff2b-451b-90ef-5dd8a8fe6731"
      unitRef="usd">21970000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaade151a67ae47c98d6ef7473bc42db4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMi0xLTEtMS01MDI5OQ_b02033a7-39dc-4d63-8968-8b3cf2d02a47"
      unitRef="usd">4021000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic3a47a1bfe944f4bbffaee6cdd3b92ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMi0zLTEtMS01MDI5OQ_9efdebd0-0231-4454-b561-f4a472b004fb"
      unitRef="usd">3581000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ief715b13c4fc48beb1cac256135e9d7f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMy0xLTEtMS01MDI5OQ_3ae89587-a20c-42b5-a775-da731381b7ac"
      unitRef="usd">173099000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifb1738f7f0924690b9cc702596588af5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfMy0zLTEtMS01MDI5OQ_4db770b2-167c-4013-92fa-a997bfc7d15f"
      unitRef="usd">159587000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic8ff1f6df23841edbf927ca013625866_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNC0xLTEtMS01MDI5OQ_6418dca6-b067-495e-8efa-936c490f7296"
      unitRef="usd">23112000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7055b6f3699b4fc89fec4593a36e0cf2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNC0zLTEtMS01MDI5OQ_f733d4a0-beab-48c6-bb48-92a178c14a40"
      unitRef="usd">15325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNS0xLTEtMS01MDI5OQ_1627a6d8-d5d3-48ab-9914-94ba74f6c9d5"
      unitRef="usd">226684000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNS0zLTEtMS01MDI5OQ_6f2c0cdd-ae1c-448b-a1ee-ab73f5b2503f"
      unitRef="usd">200463000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNi0xLTEtMS01MDI5OQ_9f4aa87e-406a-4b11-b59d-bbcf486240c2"
      unitRef="usd">134057000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNi0zLTEtMS01MDI5OQ_beb930d2-c2b0-4fdf-8526-a97ece7983dc"
      unitRef="usd">119098000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNy0xLTEtMS01MDI5OQ_79571184-464e-4c66-a364-5c63d472ff1f"
      unitRef="usd">92627000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RhYmxlOmQ1NTE3YWNjYTAwYzRkMDY4ZDA4ZDExZTYzN2EwYzI0L3RhYmxlcmFuZ2U6ZDU1MTdhY2NhMDBjNGQwNjhkMDhkMTFlNjM3YTBjMjRfNy0zLTEtMS01MDI5OQ_3e46c095-adfe-49a2-94ab-b2ad0d449950"
      unitRef="usd">81365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i5282067d6cfa41b8b9bc8d0fd65c75a1_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODM2MQ_0a5e3eb2-519d-4a6d-ab06-315a383fe436"
      unitRef="usd">7100000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="ic460399d0bce4695b06b3c4950e6867b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTM5_25fa1f09-3e2d-4f0f-b01b-6c5682496a73"
      unitRef="usd">13500000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="ic7732b8c39c44818a62b633ed2eec750_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODQwMg_8399c8d2-2a5f-4ac6-8818-c1f81a198fb6"
      unitRef="usd">5600000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i7c7ba00b2dca4b97bd4add7fef4ab781_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTQ2_eec1545b-3047-4f86-a3d6-0cde0004077a"
      unitRef="usd">11100000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ief715b13c4fc48beb1cac256135e9d7f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMjk5_7d7833e4-da31-46a0-865a-f171df0b65e7"
      unitRef="usd">71500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifb1738f7f0924690b9cc702596588af5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMzA2_01ede2f6-6d06-408c-adea-ef51a80ffe18"
      unitRef="usd">71200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODQ2Mw_716a5824-93b0-4651-9a36-92ec9f42a391"
      unitRef="usd">7800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNDE2_2949bb7f-c4be-422e-867b-37dee559c4e4"
      unitRef="usd">15400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODUxMA_10684483-f722-4557-808b-243a8e2eaff1"
      unitRef="usd">7600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNDIz_ea6612db-fd2d-46d8-bae7-98cf5396b2b7"
      unitRef="usd">15400000</us-gaap:Depreciation>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODUzNA_00deeb75-7204-4a3a-b123-2f580808bf27"
      unitRef="usd">6500000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNTUy_16af232b-9744-432c-9d78-e791d766976a"
      unitRef="usd">13200000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfMTA5OTUxMTYyODU3OA_775fb0ec-13a0-45b5-aead-dce9f3632964"
      unitRef="usd">6600000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82NC9mcmFnOjMwNDY5NzM4NDZlMDQyODQ5YzU1YTk0NGZkY2Q5NDJmL3RleHRyZWdpb246MzA0Njk3Mzg0NmUwNDI4NDljNTVhOTQ0ZmRjZDk0MmZfNTU2_cded9389-f491-450f-aa08-91bfe06b3566"
      unitRef="usd">13300000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMzAwNA_960caf2e-fb52-45a8-a2b9-83fedb06975c">Goodwill and Intangible Assets, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three reporting units, each with &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our annual goodwill impairment review occurs on October 31 of each fiscal &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the three and six months ended June 30, 2022&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We will perform our annual impairment test on October 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Change in Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2022 and December&#160;31, 2021  are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to intangible assets was $7.3 million and $14.8 million for the three and six months ended June 30, 2022, respectively, and $7.2 million and $14.7 million for the three and six months ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of June&#160;30, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#x2019; carrying value. We did not identify any circumstances during&#160;the three and six months ended June 30, 2022, that would require an impairment test for our intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMzE3_73a82c91-b976-4797-bd22-47bf61112e93"
      unitRef="reportingunit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfReportingUnits
      contextRef="i9098a44763454939966aead2b01058a5_D20211001-20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMTg4NA_a55a5939-59a7-4028-95f9-1eafc940bb3f"
      unitRef="reportingunit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMjk4Ng_a2288e06-4c4c-40ab-b2f6-99ae3ca86e60">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i5aa8d21a22a84ccabb1b42d66a503b1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMS0xLTEtMS01MDI5OQ_8376e427-b452-4977-8f70-1a2e76c7f16c"
      unitRef="usd">214334000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i744902b106114f94aaf10f93f79da793_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMS0zLTEtMS01MDI5OQ_151d4233-fb2b-420a-9526-94c08fcfe3ad"
      unitRef="usd">211963000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMS01LTEtMS01MDI5OQ_c27bf560-4a53-41af-ad83-882ec2e55437"
      unitRef="usd">426297000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMi0xLTEtMS01MDI5OQ_c2a1358d-51c7-497b-91ad-b7ab7f41038f"
      unitRef="usd">-69000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMi0zLTEtMS01MDI5OQ_a05e2574-e9e1-435f-b3b4-5bcb7120697d"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMi01LTEtMS01MDI5OQ_206f07a3-8dae-4f6c-a29e-f86f3bb64585"
      unitRef="usd">-69000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i31ec6c709d854ece8b361ce8b9f623c6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMy0xLTEtMS01MDI5OQ_6ca244e3-5b5a-42ef-88d0-41a95750e8d3"
      unitRef="usd">214265000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icf7021225a1d4ebe992272c6b7a424f3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMy0zLTEtMS01MDI5OQ_a913f906-a404-415f-bd39-e2a1acab9792"
      unitRef="usd">211963000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfMy01LTEtMS01MDI5OQ_743aa318-d362-47d0-8810-6cef5b4b34e4"
      unitRef="usd">426228000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9ab714214aec4c62895368e7b5d77d47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNS0xLTEtMS01MDI5OQ_ea550e1d-64f2-4c8a-affb-6ed5cba45eeb"
      unitRef="usd">214354000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idb91a25096ac488099c2f68651d8104a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNS0zLTEtMS01MDI5OQ_086adbee-54b5-4691-93b8-962e4607e417"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNS01LTEtMS01MDI5OQ_bb557bda-6d9c-44f1-82b4-db0e366aa68e"
      unitRef="usd">349029000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNi0xLTEtMS01MDI5OQ_7ac98e2e-1b0a-4fdd-aec2-919a17446c43"
      unitRef="usd">-20000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNi0zLTEtMS01MDI5OQ_772e9866-945a-4e17-96aa-53035a14f81b"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNi01LTEtMS01MDI5OQ_bed1e879-769b-430b-82ca-1838299fee10"
      unitRef="usd">-20000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="id929ac4578254f3a8ac5a00ef4adae72_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNy0xLTEtMS01MDI5OQ_d653955e-c589-4012-907b-8311749befdf"
      unitRef="usd">214334000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i47bf34c04d3d4427a895561238e93dfb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNy0zLTEtMS01MDI5OQ_dd3cf781-91fa-4120-b1cd-a0cc8ff1cff3"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjdiOWFmNzQ1M2EwODQ2NTY4ZWY4YjkwNjFmNzNmYjE3L3RhYmxlcmFuZ2U6N2I5YWY3NDUzYTA4NDY1NjhlZjhiOTA2MWY3M2ZiMTdfNy01LTEtMS01MDI5OQ_a7ac74f3-c084-4080-86ce-35da79ff4bf2"
      unitRef="usd">349009000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMjI0OQ_4d2aaafc-374f-4370-b046-9c89ca11d624"
      unitRef="usd">575500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMjI0OQ_c721de2a-3ca4-4382-8277-1546b3944ec4"
      unitRef="usd">575500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id7ca912d3a02465795eea96c1e250e26_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi0xLTEtMS01MDI5OQ_066ac9bf-5fcf-46ec-8ed9-5d11fc88ef7d">P11Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8e4ef4f58a5044038cbe7d46e8dfea60_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi0zLTEtMS01MDI5OQ_812c8057-a008-45e6-971c-755bd3b229b7"
      unitRef="usd">25800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8e4ef4f58a5044038cbe7d46e8dfea60_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi01LTEtMS01MDI5OQ_c34d5961-579a-414f-aa90-dfdcf412adb7"
      unitRef="usd">8466000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8e4ef4f58a5044038cbe7d46e8dfea60_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi03LTEtMS01MDI5OQ_e13ab8cc-d183-49b8-a9ee-e6ff442f2246"
      unitRef="usd">17334000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i960826d299ae4c44bc47f074ce02ed28_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi05LTEtMS01MDI5OQ_4a33b541-f6b6-411b-8327-606bc6fde5ea">P12Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4cb0816a5da441f6960846569f93e09e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi0xMS0xLTEtNTAyOTk_4c7d6533-f921-464a-a469-6a66a60e4564"
      unitRef="usd">25800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4cb0816a5da441f6960846569f93e09e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi0xMy0xLTEtNTAyOTk_7bb095f7-3c0e-4039-b205-3299154bcda6"
      unitRef="usd">7693000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4cb0816a5da441f6960846569f93e09e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMi0xNS0xLTEtNTAyOTk_83bede3a-094c-4225-af2b-6e4b96888645"
      unitRef="usd">18107000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i2c75751fbbd54a6eae8d08e6b4ab94a2_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy0xLTEtMS01MDI5OQ_aed8b8f7-9b9f-4758-887a-383a814011df">P14Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie2d81d730eae4c75b3cb95f6789994b0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy0zLTEtMS01MDI5OQ_6c9cc81e-a672-4f6f-ae1d-4f8f058d8b74"
      unitRef="usd">311019000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie2d81d730eae4c75b3cb95f6789994b0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy01LTEtMS01MDI5OQ_363f26b2-8094-48fe-be9f-f8d38e379c8f"
      unitRef="usd">81125000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie2d81d730eae4c75b3cb95f6789994b0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy03LTEtMS01MDI5OQ_ed3a827c-c9ae-4017-944c-652c44f6d1e3"
      unitRef="usd">229894000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i2706c4da523140c79cd5bc0fc5dd4e18_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy05LTEtMS01MDI5OQ_6184d7d9-bdc2-451b-8d73-c5258f583bd2">P14Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i13f3c31fcc184de09194d8a0f21020a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy0xMS0xLTEtNTAyOTk_49f06dc7-005e-4a85-bd85-8e5434b9c2fb"
      unitRef="usd">311019000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i13f3c31fcc184de09194d8a0f21020a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy0xMy0xLTEtNTAyOTk_79bef51f-948a-41f2-93fb-2508a6aa0e25"
      unitRef="usd">72697000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i13f3c31fcc184de09194d8a0f21020a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfMy0xNS0xLTEtNTAyOTk_e7bbda43-4031-4997-9e47-50e8139d98d9"
      unitRef="usd">238322000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8920304c21f34d2e8d814f99e02bb672_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC0xLTEtMS01MDI5OQ_e113dc43-9fce-41fe-af29-07253f0a3d14">P1Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i525fe873d3c2406f95c7b1e8fe7f01a1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC0zLTEtMS01MDI5OQ_ee5de95a-7942-438a-81b2-c67365d9dc34"
      unitRef="usd">87922000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i525fe873d3c2406f95c7b1e8fe7f01a1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC01LTEtMS01MDI5OQ_573250c8-27ac-4e47-8fe5-1be9dfa7c0ec"
      unitRef="usd">77041000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i525fe873d3c2406f95c7b1e8fe7f01a1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC03LTEtMS01MDI5OQ_5228d8bd-33fe-48d3-a7b6-b6a4efaa2388"
      unitRef="usd">10881000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if49cfadd37a2439693bcaef2ca7aea4e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC05LTEtMS01MDI5OQ_6b2c2679-f831-4a0f-97eb-e8ff65cf92cd">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i96994f66670d402b9792042ce4aa991c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC0xMS0xLTEtNTAyOTk_4f454de8-6f73-473a-86f9-c31e28760830"
      unitRef="usd">87922000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i96994f66670d402b9792042ce4aa991c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC0xMy0xLTEtNTAyOTk_ade27291-9297-419d-9613-311004febfba"
      unitRef="usd">73378000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i96994f66670d402b9792042ce4aa991c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNC0xNS0xLTEtNTAyOTk_2f32924a-1c9b-442f-ad19-ad31ca07fa2d"
      unitRef="usd">14544000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i90169973e5d44809bbd3c5d4c63ea01d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS0xLTEtMS01MDI5OQ_54d6dabf-f264-40f3-9566-23a2650a5521">P0Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i41a84937692640da928c5aff561db4f2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS0zLTEtMS01MDI5OQ_903d840b-3d8d-45e6-ac5a-e5d6a0573c78"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i41a84937692640da928c5aff561db4f2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS01LTEtMS01MDI5OQ_d297f94b-a3cb-46a5-9462-ccce6ad8d28a"
      unitRef="usd">1050000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i41a84937692640da928c5aff561db4f2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS03LTEtMS01MDI5OQ_73b334ff-e5eb-4c54-812c-5bd3dbdf4e48"
      unitRef="usd">168000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id7f5959c88534df58f8cc98840f9d9c6_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS05LTEtMS01MDI5OQ_1c3cc5f2-3d4e-4443-b860-f489a25c8f8f">P1Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i50f6763c502f4844b08ec38b15b78eb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS0xMS0xLTEtNTAyOTk_c9b997fa-3d9b-4465-9a57-bba2ddff5fad"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i50f6763c502f4844b08ec38b15b78eb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS0xMy0xLTEtNTAyOTk_ae072d4f-4537-4a9b-b0fe-46e81394b1f2"
      unitRef="usd">950000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i50f6763c502f4844b08ec38b15b78eb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNS0xNS0xLTEtNTAyOTk_3c66c71e-b3a2-4bcf-9ee3-d22bb82337bc"
      unitRef="usd">268000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i40c2436f586643c299cf6643b5e47526_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi0xLTEtMS01MDI5OQ_044881f8-111b-4001-973a-15a7e532565a">P1Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic284e67a71b64b93b2d5099b8216ad4f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi0zLTEtMS01MDI5OQ_167afee1-3819-43a9-8ff4-82add9957b54"
      unitRef="usd">16236000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic284e67a71b64b93b2d5099b8216ad4f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi01LTEtMS01MDI5OQ_01a37912-438e-42a4-a9e9-f1dece8f527b"
      unitRef="usd">9667000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic284e67a71b64b93b2d5099b8216ad4f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi03LTEtMS01MDI5OQ_499448ca-e950-4a08-8304-c2faff4014c2"
      unitRef="usd">6569000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i59a87beef6454e0cacb2bf3bac49aa68_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi05LTEtMS01MDI5OQ_3657fcb7-1451-43c0-93c7-d658ddd2dba7">P2Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7c1e999ffea0466ea3a2914cd626dbde_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi0xMS0xLTEtNTAyOTk_80902006-23d8-442d-a95d-797ffb9a0f58"
      unitRef="usd">16417000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7c1e999ffea0466ea3a2914cd626dbde_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi0xMy0xLTEtNTAyOTk_a63c4432-f99d-4e4b-8451-fef96ecf078c"
      unitRef="usd">7874000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7c1e999ffea0466ea3a2914cd626dbde_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNi0xNS0xLTEtNTAyOTk_d2468bc6-183c-4db3-937c-9ad001fc75d5"
      unitRef="usd">8543000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy0zLTEtMS01MDI5OQ_c0aaf03c-18ed-458f-b0d1-2689cca6d87b"
      unitRef="usd">442195000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy01LTEtMS01MDI5OQ_0b4f3bb3-84bc-4b42-a12f-004cd8b77123"
      unitRef="usd">177349000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy03LTEtMS01MDI5OQ_676d63d5-7f48-47e4-b8f1-4501e7264831"
      unitRef="usd">264846000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy0xMS0xLTEtNTAyOTk_6dcaf487-7303-4c52-b8d6-2d093b1a3e33"
      unitRef="usd">442376000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy0xMy0xLTEtNTAyOTk_122a8bba-db3e-4983-ae0c-c332c93a88ed"
      unitRef="usd">162592000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOmU3MzA4YjYwODNjNTRlMjA5OTE4ZTZmMzZhMWNiMGM3L3RhYmxlcmFuZ2U6ZTczMDhiNjA4M2M1NGUyMDk5MThlNmYzNmExY2IwYzdfNy0xNS0xLTEtNTAyOTk_a4c38de4-4212-4e13-97cf-5018bf9fa851"
      unitRef="usd">279784000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMTA5OTUxMTYzMDc5NA_27900192-f584-424f-8aee-f33b01df72de"
      unitRef="usd">7300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMjUxOQ_42b53ade-84ea-4836-9533-c8d030578d1c"
      unitRef="usd">14800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMTA5OTUxMTYzMDk2Nw_9cd63e23-fac8-4e89-9cea-107fc8a52d86"
      unitRef="usd">7200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMTA5OTUxMTYzMDk3NQ_18a9cec4-8743-49e5-bbb6-e6b9b0577944"
      unitRef="usd">14700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RleHRyZWdpb246NjBkMGUwNzBiYWQ1NDY2ZGI5MjNhMTVjMWIwN2NlOWJfMzAwMQ_19249b87-a362-4e1d-998f-0ea3dd9d95a7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of June&#160;30, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfMC0xLTEtMS01MDI5OQ_ff0acb31-895d-4bf5-8baa-cb2fa422244c"
      unitRef="usd">14375000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfMS0xLTEtMS01MDI5OQ_c6fc689d-49ae-4e5a-8fa7-168366f7fb02"
      unitRef="usd">26760000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfMi0xLTEtMS01MDI5OQ_6de46033-6de9-4568-830e-d6960700cf2e"
      unitRef="usd">20875000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfMy0xLTEtMS01MDI5OQ_8ea47b8b-7834-4cad-8f7c-e10fc265fdd3"
      unitRef="usd">19330000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfNC0xLTEtMS01MDI5OQ_4426e164-e54e-4477-86c7-9fb257896cc9"
      unitRef="usd">19153000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfNS0xLTEtMS01MDI5OQ_27cf4bb6-a768-4f47-8b3a-04ceec4a6ce2"
      unitRef="usd">164353000</evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl82Ny9mcmFnOjYwZDBlMDcwYmFkNTQ2NmRiOTIzYTE1YzFiMDdjZTliL3RhYmxlOjI5Y2YyNDk3OWU3YjRjMWJiY2RkZjMzYWQzNGIwZTJkL3RhYmxlcmFuZ2U6MjljZjI0OTc5ZTdiNGMxYmJjZGRmMzNhZDM0YjBlMmRfNi0xLTEtMS01MDI5OQ_ed9e89dc-1975-4cdf-ae2f-a0d1e12575a9"
      unitRef="usd">264846000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTc2Njg_aa991f5c-fe30-4d36-931e-804bd1ec9d46">Long-term Debt&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#x201c;2024 Notes&#x201d;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#x2019;s Class A common stock. We recorded interest expense of $1.0 million and $2.0 million for both the three and six months ended June 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2024 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7&#160;million and $1.3&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1&#160;million decrease in additional paid-in capital and a $1.3&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.2 million and $0.4 million for the three and six months ended June 30, 2022, respectively, and $2.0 million and $3.9 million for the three and six months ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#x201c;Borrower&#x201d;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#x201c;2019 Credit Agreement&#x201d;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the &#x201c;Initial Term Loan Facility&#x201d;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#x201c;DDTL Facility&#x201d; and, together with the Initial Term Loan Facility, the &#x201c;Senior Credit Facilities&#x201d;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2020, an amendment to the Company's 2019 Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Company&#x2019;s entry into the 2019 Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the 2019 Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company settled the outstanding warrants associated with the 2019 Credit Agreement for $13.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#x201c;2025 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#x2019; exercise in full of their option to purchase additional notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $0.7 million and $1.3 million for both the three and six months ended June 30, 2022 and 2021 respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2025 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8&#160;million &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;decrease in additional paid-in capital and a $2.5&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.3 million and $0.6 million for the three and six months ended June 30, 2022, respectively, and $2.4 million and $4.8 million for the three and six months ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#x201c;2021 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $28.5&#160;million resulting in a loss on debt extinguishment of $2.2&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Convertible Senior Notes Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of June&#160;30, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of June&#160;30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzg_16704000-60c2-4891-8793-8527b08afc7e"
      unitRef="usd">117100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTE1_9c9b83ad-16fc-45be-9a42-a65bf711f032"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzMz_ce818c93-24da-4c33-93bb-4ff4ad4906c1"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="iaedce6468a3e4e8ca15a5333813a91c5_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDAx_1990d906-8007-4551-9fbf-84fe27d4163b"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDkw_57fe795c-7b56-4c56-acbf-386373688dbb"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i79aed8a5f7344a37b2a701ae05c1b842_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTA1_f35b09b0-bf97-40d4-8ea9-b336f658e315"
      unitRef="usd">32800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTg1_1bc71ee6-6ba5-4a04-861f-589bb78d99b4"
      unitRef="usd">3000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA1Nw_9784383e-27b6-46a7-9574-c035b153e9c7"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i8c24e626673740bfbc5c482a85f9be03_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM2NQ_ade12412-d368-45e4-ad16-dc8998f0e03a"
      unitRef="usd">1000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i51f45a85ad1d44d3b1bba8c3ef692bb0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM2NQ_b37b0fba-60f1-443d-bdc8-341b466c4982"
      unitRef="usd">1000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="id96a059c175048b68ce735b693389c60_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM3Mg_c24c455f-9363-49cd-b0ee-df197a540d32"
      unitRef="usd">2000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ide775581b0c2448ba46085d3508e93e6_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM3Mg_fea75f84-caf5-4c29-b8a4-4f827bb990c0"
      unitRef="usd">2000000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTc5MA_3373af80-56b4-4853-b56e-982fd22d5604"
      unitRef="usdPerShare">18.23</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTkwNg_93e3c5cc-0b75-4ab7-b40f-bc00c6bd99b8"
      unitRef="shares">6400000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMjgyMQ_a0186a97-6ff3-409b-a4b7-5713ca293145"
      unitRef="usd">78900000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="if5bfcb0c398a4d1ba18c1a7084e71a4d_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMjk3MA_539611f4-0ec7-4eab-9bb4-1503e4c3f9a6"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzA2NQ_eba92773-d41b-46a9-be95-cbe4c38d2e92"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="id342da7701a44166b2290441fd002835_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzA3Mg_132d5956-e760-4e71-a4e3-eccd533582cb"
      unitRef="usd">1300000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="if5bfcb0c398a4d1ba18c1a7084e71a4d_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzIwNA_3d11818a-8e07-4b0f-802b-5df119a4aab4"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="i3d41b951fcf5438d958a6230f14dd8c2_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzIwOA_eda95e84-9533-440d-be68-4d830464e76f"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:StockholdersEquity
      contextRef="ic42188622755410b90efa5d41026374a_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzg4Nw_6617a960-10e3-4492-bfdc-f299052e78e9"
      unitRef="usd">-38100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7530c57faa32498ca2794192fcf4a689_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMzkzNQ_ec454c8b-a8d3-42ea-ba32-9a870f43a697"
      unitRef="usd">1300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice3c432af1ef4dc0a423e7d7b0e84b24_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDA3Ng_217fbaca-fb9b-47d9-952d-115f0d5641e5"
      unitRef="usd">-11700000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="ib3ecfc57dd454ea480838c4fc5252936_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDM1OA_80f043f1-6fc7-4320-8c8d-a5e14cc166d8"
      unitRef="usd">25100000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i8c24e626673740bfbc5c482a85f9be03_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NTYzMQ_b7af28cf-3c45-485f-bfcd-e76711318156"
      unitRef="usd">200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id96a059c175048b68ce735b693389c60_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDc2MQ_d4528e87-3a31-495e-9f31-063c5054a5fb"
      unitRef="usd">400000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i51f45a85ad1d44d3b1bba8c3ef692bb0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NTc4NQ_cb6a6355-656c-463f-82e7-0847534ae2e5"
      unitRef="usd">2000000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ide775581b0c2448ba46085d3508e93e6_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNDc2OA_658cceef-121b-47d1-8f91-8a8eba46aad4"
      unitRef="usd">3900000</us-gaap:AmortizationOfFinancingCosts>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTAyOA_b9cd3517-fe3d-436b-9f4e-2e01da1b86df"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTQ0OQ_fcfff1f9-cbf0-4a31-8772-12a743cdba66"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTUwNA_2100a368-0c5a-47db-915a-920a63c7d426">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTU2MA_ccb7841c-5ffe-4e81-8940-68aaa86a0661">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNTc5OA_4467319f-2708-41ea-b124-12b1244db431"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idffc7ad1a4654adf98f1038cfa6da4be_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNjQ3Mw_a96b0b8a-b606-47be-b132-f8b05c36a8d7"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6be98831456946c8b796aa596a41a463_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNjYwNQ_97c89d65-3ebc-448c-bfd7-d334714dca20"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i2420da3a7fa34500b18bdcbdb21aba50_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzY4OA_40129228-b4ea-4180-b4eb-e54c70937177"
      unitRef="usd">98600000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <evh:PaymentsOfMakeWholePremium
      contextRef="i2420da3a7fa34500b18bdcbdb21aba50_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzcwNw_7f92d10a-8c2a-4d40-8751-d1b94478aa7b"
      unitRef="usd">9700000</evh:PaymentsOfMakeWholePremium>
    <us-gaap:InterestPaidNet
      contextRef="i2420da3a7fa34500b18bdcbdb21aba50_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzc0OA_103456b2-de29-4c81-96c2-6dfdc1962078"
      unitRef="usd">200000</us-gaap:InterestPaidNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i00e82484500e428e8076ddebadf195b8_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzg2MQ_051327d6-2321-428f-9383-4bb6c24285e2"
      unitRef="usd">19200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="i00e82484500e428e8076ddebadf195b8_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzkyNw_1ecf1c69-2426-4054-93f4-4ee073cdc50a"
      unitRef="usd">9500000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:LegalFees
      contextRef="i00e82484500e428e8076ddebadf195b8_D20210108-20210108"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfNzk1OA_59126934-8ab1-444e-90f3-afb72f25ec15"
      unitRef="usd">35000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="i5631b43e9caf49eeb64e4768bdfb4735_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODE4NA_2ec8e5e7-632f-47c8-a33f-7540a81b3020"
      unitRef="shares">1513786</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i5631b43e9caf49eeb64e4768bdfb4735_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODI1Nw_c62dd7a7-ed8a-4304-a56f-9804455fe872"
      unitRef="usdPerShare">8.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement
      contextRef="ib6ca31f441294fd2bd58db5233a8cc5f_D20191230-20191230"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODMxOQ_fec09ea3-ab88-4047-9a51-c8991dfe366d">P30D</evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i5870d3d480b24bfb8fce0c75a91af736_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODc0NQ_5746c03b-33aa-435d-a3c0-948253b31b4e"
      unitRef="usd">13700000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id0f03be090e54e69ab5736238c33be28_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODc5OA_541a0a16-7974-4222-9deb-28a43e1140c3"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id0f03be090e54e69ab5736238c33be28_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfODgzNQ_adef235c-e468-4703-8a36-69b11a7ba575"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTEwMw_62c8130d-356b-4227-8485-c014607ac587"
      unitRef="usd">166600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i93205c45ea8547a98bc7ff1c11408e54_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTExOQ_cd1e0663-59f9-47fe-b66e-fbdc14cc3fbe"
      unitRef="usd">5900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4e280a759a5741be8b52ce88da866568_I20181022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTIyMA_3030b8d3-d631-451d-b7bb-1da630adfe16"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3b03deaf81e94b908e898c240f288f46_I20181024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTM0OA_2e43ea8c-a1e8-4c1d-8c65-5ec9d7fd2056"
      unitRef="usd">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id0f03be090e54e69ab5736238c33be28_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTY4OA_adef235c-e468-4703-8a36-69b11a7ba575"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i0b019d63dd4e49a68deed79176b07e2d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NTgxNQ_7b60c468-16ba-44d8-92ce-ed4d6db7f21f"
      unitRef="usd">700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i2bc2482dd4334134b1fadb0256b066b3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NTgxNQ_d5a6b2da-33a1-4b4e-8ddd-73b9d873a8c7"
      unitRef="usd">700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i62205ea298424eb981ea4ca7c04b1743_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTc0Mw_429b1c1f-9641-431b-9a6f-8d21eb5d1be6"
      unitRef="usd">1300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i5aa4d8786f5243df8cf17673c36d708d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfOTc0Mw_4681c4a6-0405-4e79-b69d-be383ae96d8f"
      unitRef="usd">1300000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="id0f03be090e54e69ab5736238c33be28_I20181031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA2NzE_8ec59867-ec30-4daa-b02b-bf5689cd2836"
      unitRef="usdPerShare">33.43</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA3ODc_301fffb0-2af1-4b3c-8a42-a51e0ee7fb6c"
      unitRef="shares">5200000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="id0f03be090e54e69ab5736238c33be28_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTE2OTU_e24a7644-d1f1-48b6-8d2e-d4989ac95837"
      unitRef="usd">100700000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i56b4489e137445769dd2d5c0552d9a73_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTE4NDQ_96715669-1e6e-4264-8bb1-06e2ea73c5ee"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="id0f03be090e54e69ab5736238c33be28_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTIwNTU_f1e9c7c1-6751-43f2-8e07-9fdca6bc46fb"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i6d77309eeff741329a3b33008063d50d_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTIwNjI_1ca6b55c-ad33-4c92-ac0f-79a86117d1bc"
      unitRef="usd">2500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i56b4489e137445769dd2d5c0552d9a73_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTIxOTM_96715669-1e6e-4264-8bb1-06e2ea73c5ee"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="id0f03be090e54e69ab5736238c33be28_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTIxOTc_f1e9c7c1-6751-43f2-8e07-9fdca6bc46fb"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockholdersEquity
      contextRef="id5ae38a0018f4e7a9d7dcd73631d6bd7_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTI5MjM_57e8d822-eced-40a8-98fc-58fd4017a049"
      unitRef="usd">-71800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0901a44b29f424c9815549f850adf16_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTI5NzE_cd68ca0c-92b3-409b-92ca-d80c761b05a5"
      unitRef="usd">2500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie4df19daedef45a6b93e44ce65f0f0e7_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTMxMTE_d5215c07-c661-4c27-9c1b-9dd7e55bfd26"
      unitRef="usd">-28100000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="ie80fd38d9d5b4ab2bc9f658f6aadf4a0_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTMzOTM_2b4ee06c-37a1-4730-a8c7-0497bd2c3f9b"
      unitRef="usd">41300000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i2bc2482dd4334134b1fadb0256b066b3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NjAwNw_cad3bf85-51ad-4288-950c-8e2658c5e95c"
      unitRef="usd">300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i0b019d63dd4e49a68deed79176b07e2d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM3OTY_96972f50-bb95-4d14-a4dd-370583a7db9f"
      unitRef="usd">600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i5aa4d8786f5243df8cf17673c36d708d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTA5OTUxMTY0NjE1Ng_3bf8f6f9-56dc-4769-a002-7d8067fa96e7"
      unitRef="usd">2400000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i62205ea298424eb981ea4ca7c04b1743_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTM4MDM_078704ec-c93a-4ba2-8e93-418b2777e020"
      unitRef="usd">4800000</us-gaap:AmortizationOfFinancingCosts>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTQwOTg_6aeef0c0-928f-4fb1-aa8e-25d486085f6d"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTQ0OTc_dbebc0d3-4153-483a-9447-82cdf9d98329"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTQ1NTI_643d9447-2b8d-4031-9671-c558b4700c73">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTQ2MDg_0060c7af-f6f1-486d-9fad-f51a24709d49">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="i9aac380994ab4b39a45f987d6f712462_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTQ4NDY_1e4dca08-e74d-409e-b218-86312a3901f7"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3584d11db2f3491898d24a547ffcbb7a_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTUwMTQ_a0bc8a9e-445c-4d7e-9543-79232bfa750f"
      unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3584d11db2f3491898d24a547ffcbb7a_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTUwNTE_00e62cdd-1646-484e-b4fb-be0b2a3a09d2"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i7648a33bd59947509a7713b0d44e5483_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTUyNzQ_84069fb8-64d5-4165-9e4f-036c2ca0fbe3"
      unitRef="usd">120400000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i3584d11db2f3491898d24a547ffcbb7a_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTUyOTA_af8eb51b-4840-42be-91b6-1184e0832395"
      unitRef="usd">4600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i77eee5e0c0c74f33a67c9ce10e81611a_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTU3MDg_7ac3d723-f3ec-47c5-ab53-30910d27aa3d"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="iaedce6468a3e4e8ca15a5333813a91c5_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTU3NzI_4e36100d-818c-415b-ba73-37f05e3fb417"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTU5MDU_d1a47f63-7c87-4c18-9693-2bc1574d2a51"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTYwNDk_25a5411f-6193-4b24-8ce1-304178c18258"
      unitRef="usd">-4800000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTYwOTI_fa8eee6b-6bc8-4827-8f0c-8e5213193f94"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="iaedce6468a3e4e8ca15a5333813a91c5_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTYxNjU_b033f28f-a1ba-4be6-bca8-3b4284424b21"
      unitRef="usd">14000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="iaedce6468a3e4e8ca15a5333813a91c5_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTYxOTE_c12c9dfa-8e22-48a9-b3a5-258191617cc0"
      unitRef="usd">13900000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i9c63bf821d6e48e2ab3a8136ab3612ae_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTYzNjU_68b90b77-cf89-463e-9d00-777a29b3d040"
      unitRef="usd">26700000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i9c63bf821d6e48e2ab3a8136ab3612ae_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTY0MjY_f42156e4-c1a7-4b6e-9ca5-34321191a6af"
      unitRef="usd">26300000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i9c63bf821d6e48e2ab3a8136ab3612ae_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTY1MDk_e32b792b-3b5b-441d-a08e-6a122fab8f24"
      unitRef="usd">400000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <evh:DebtConversionOriginalDebtFairValue
      contextRef="i427a803b22b943cbb1135ad1eb47ec78_I20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTY2NjQ_6a7430b7-3750-42d6-90d4-7ecad25a5549"
      unitRef="usd">28500000</evh:DebtConversionOriginalDebtFairValue>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i9c63bf821d6e48e2ab3a8136ab3612ae_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTY3MTM_9d774b74-032c-47a2-8054-8a518fdde09a"
      unitRef="usd">-2200000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RleHRyZWdpb246ZjlhYThhZDRiMWRjNDA2YTllYjllYjE0Y2VmMGVlN2FfMTc2NjY_73d9c39b-7c6f-4bc3-a19c-226eb1d129b7">The following table summarizes the carrying value of the long-term convertible debt as of June&#160;30, 2022 and December 31, 2021 (in thousands):&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="if6ccdc5191c44efea9d1d9edc7499e87_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMi0xLTEtMS01MDI5OQ_db048660-f9c1-4f46-ac2f-616194aa3284"
      unitRef="usd">114893000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="ica61ba8f679544528ab9c464177763cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMi0zLTEtMS01MDI5OQ_2f411648-5180-4ffc-9c92-a50401234393"
      unitRef="usd">89361000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="if6ccdc5191c44efea9d1d9edc7499e87_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMy0xLTEtMS01MDI5OQ_da88eb53-a71f-4839-a905-a7062e8402c2"
      unitRef="usd">2158000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ica61ba8f679544528ab9c464177763cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMy0zLTEtMS01MDI5OQ_93b88cd4-d005-4f06-afda-d6167aeead51"
      unitRef="usd">27690000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if6ccdc5191c44efea9d1d9edc7499e87_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNC0xLTEtMS01MDI5OQ_6a2bcf97-e622-46d6-b9b5-4f2196e874ec"
      unitRef="usd">117051000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ica61ba8f679544528ab9c464177763cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNC0zLTEtMS01MDI5OQ_d820ab63-a406-4220-9218-5a3984d0911c"
      unitRef="usd">117051000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="id96a059c175048b68ce735b693389c60_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNS0xLTEtMS01MDI5OQ_97542fe5-a272-41cb-8f7e-e78e18a54832">P2Y4M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="ide775581b0c2448ba46085d3508e93e6_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNS0zLTEtMS01MDI5OQ_00de7656-205e-40c4-8bfc-ea901ec1ac4d">P2Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i44077d7155334c2a88271bade68c730c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNi0xLTEtMS01MDI5OQ_2f964849-47ee-42b6-8adc-6f72a75a6948"
      unitRef="usd">197477000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib9d50749331f4a3db9bce7b2180496cb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfNi0zLTEtMS01MDI5OQ_b5996abb-a2ea-4d51-8df3-e3a811560410"
      unitRef="usd">195445000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ConvertibleDebt
      contextRef="idcf121a6589f44c98a0e5e8344398edb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfOS0xLTEtMS01MDI5OQ_7091a7bf-0f57-4566-857e-5e94d8620a9a"
      unitRef="usd">168245000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i33bdb53de4cf4bf4acf5c9415254f853_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfOS0zLTEtMS01MDI5OQ_2bbfb471-3570-4751-a2d1-1621a60da062"
      unitRef="usd">126315000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="idcf121a6589f44c98a0e5e8344398edb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTAtMS0xLTEtNTAyOTk_bd02cdf2-e625-4743-84dd-f49e438415ee"
      unitRef="usd">4255000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i33bdb53de4cf4bf4acf5c9415254f853_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTAtMy0xLTEtNTAyOTk_5c2457ef-dff2-4078-aa9b-826d4694aac5"
      unitRef="usd">46185000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idcf121a6589f44c98a0e5e8344398edb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTEtMS0xLTEtNTAyOTk_6a676b11-1420-46d1-a4b8-dad21119f394"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i33bdb53de4cf4bf4acf5c9415254f853_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTEtMy0xLTEtNTAyOTk_3500a043-e2e2-42c6-9a1c-e1c06885af57"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i0b019d63dd4e49a68deed79176b07e2d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTItMS0xLTEtNTAyOTk_a7c176f5-a999-4228-b71c-a0809569fabd">P3Y3M18D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i62205ea298424eb981ea4ca7c04b1743_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTItMy0xLTEtNTAyOTk_0c723f4e-a499-4706-90c6-1c640e1ce6bb">P3Y9M18D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i199532edebf94240832d93a367225b5e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTMtMS0xLTEtNTAyOTk_7d616610-05b0-42ec-8157-ed5bd72746c0"
      unitRef="usd">195434000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i287a359f1cb24979b1d38fe6e75caa46_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83MC9mcmFnOmY5YWE4YWQ0YjFkYzQwNmE5ZWI5ZWIxNGNlZjBlZTdhL3RhYmxlOjAzMzJlNDk0MjRkMTRjNGQ4NTQyODJiMGZjYzA0NThlL3RhYmxlcmFuZ2U6MDMzMmU0OTQyNGQxNGM0ZDg1NDI4MmIwZmNjMDQ1OGVfMTMtMy0xLTEtNTAyOTk_5d96b6d1-0e24-4185-96dd-de0516b8473f"
      unitRef="usd">177251000</us-gaap:LongTermDebtFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTI0ODE_aa8eceb1-f6a0-499a-a6d0-12264a5b5b77">Commitments and Contingencies &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $13.8&#160;million and&#160;$15.4 million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $13.8&#160;million and $15.4 million, respectively, in restricted cash and restricted investments as collateral as of June&#160;30, 2022 and December&#160;31, 2021. The letters of credit have current expiration dates between June 2022 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-IPO Investor Registration Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three and six months ended June 30, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#x201c;Molina&#x201d;) entered into an Asset Purchase Agreement (the &#x201c;Molina APA&#x201d;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#x2019;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#x201c;Molina Closing&#x201d;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#x201c;KY DOI&#x201d;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of June&#160;30, 2022, no amounts have been funded under this guarantee.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reinsurance Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#x201c;Passport Closing&#x201d;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#x2019;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims-related administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance payments paid (received)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payable (receivable) for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UPMC Reseller Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#x201c;UPMC Reseller Agreement&#x201d;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#x2019;s obligations under &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#x2019;s customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#x201c;TRA&#x201d;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#x2019;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, was filed on December 2, 2021. On July 13, 2022, the parties to the class action executed a term sheet for settlement of the litigation, subject to documentation of the settlement and approval of the court after notice to class members. On August 2, 2022, the lead plaintiff in the case filed an unopposed motion seeking preliminary approval of the settlement and related exhibits, including draft notice to class members and a proposed final order. The settlement stipulation is subject to preliminary and final approval by the court. If the settlement is approved, we expect that the agreed-upon settlement payment of $23.5&#160;million will be funded entirely by applicable directors&#x2019; and officers&#x2019; liability insurance. As such, we do not expect to incur a significant net loss or cash outflow as a result of the settlement of this matter.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#x2019;s Board was negligent in its oversight of the Company&#x2019;s relationship with Passport Health Plan. The case is &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Lincolnshire Police Pension Fund, derivatively on behalf o&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;f &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#x2019;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. (&#x201c;Derivative Action&#x201d;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs have not yet responded to the motion to dismiss and there is not currently a briefing schedule on file with the Delaware Chancery Court. Based on the Company&#x2019;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit and Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of June&#160;30, 2022, approximately 98.6% of our $280.4 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 0.9% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable, as of June&#160;30, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Centers for Medicare and Medicaid Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bright Health Management, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and six months ended June 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Cross and Blue Shield of North Carolina&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.&lt;/span&gt;&lt;/div&gt;We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iddc1d80def48423e86b4d3005ffe55ed_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTc1_40241eed-0fed-4a3f-a48e-96df1c2b3d06"
      unitRef="usd">13800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iff1d7b85971f4121968757b59f6d1b6a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTgy_16d93401-f6c1-4b4a-a163-8ae253584d3c"
      unitRef="usd">15400000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="id6ed29b7f1b44cf89f0a291dd12cf6d2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMzAx_e5e18fee-bf81-4bf0-9b35-06afaa91fad6"
      unitRef="usd">13800000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i0198a0ff5cce4a9b91c42f736cd3a452_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMzA4_746ac397-c627-453c-8361-fe3e37b7871a"
      unitRef="usd">15400000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:EffectsOfReinsuranceTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTI0ODM_e9239ee3-6679-4ed8-834b-72de5eb96fa0">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims-related administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance payments paid (received)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payable (receivable) for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EffectsOfReinsuranceTableTextBlock>
    <us-gaap:AssumedPremiumsWritten
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfMi0xLTEtMS01MDI5OQ_92075583-2a87-408e-b229-dc2ad7c9360b"
      unitRef="usd">-2000</us-gaap:AssumedPremiumsWritten>
    <us-gaap:AssumedPremiumsWritten
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfMi0zLTEtMS01MDI5OQ_1c35aae5-8a8a-465f-b39b-d2ffdf7b79d4"
      unitRef="usd">17576000</us-gaap:AssumedPremiumsWritten>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfMy0xLTEtMS01MDI5OQ_262dea3f-90cb-4565-b31c-2313b8fd51de"
      unitRef="usd">149000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfMy0zLTEtMS01MDI5OQ_70cfc2bc-c093-4702-818e-b639f52ec868"
      unitRef="usd">16863000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNC0xLTEtMS01MDI5OQ_db626a08-7e1f-4a1c-b390-ab1f34c1c8a6"
      unitRef="usd">0</evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims>
    <evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNC0zLTEtMS01MDI5OQ_19475a01-45d8-4435-a0ee-4508e5c1cf39"
      unitRef="usd">545000</evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims>
    <evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNS0xLTEtMS01MDI5OQ_550ea1c3-f43d-4e79-8d43-dd33bf3e79cb"
      unitRef="usd">-151000</evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet>
    <evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNS0zLTEtMS01MDI5OQ_493acc7c-88c4-42db-9227-fddaf6193044"
      unitRef="usd">168000</evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNi0xLTEtMS01MDI5OQ_4910fa69-712b-4d4c-acd8-4ab1bfebb9c7"
      unitRef="usd">90000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNi0zLTEtMS01MDI5OQ_1128b5bf-fd67-4a4a-bd18-b4dab82781ae"
      unitRef="usd">4002000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNy0xLTEtMS01MDI5OQ_6d5f4f42-a0e5-4573-b530-484bc7c6edc6"
      unitRef="usd">0</evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables>
    <evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfNy0zLTEtMS01MDI5OQ_3e3896a5-fad3-4273-9a73-cda48b5c6733"
      unitRef="usd">0</evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables>
    <evh:ProceedsRepaymentsForReinsurance
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfOC0xLTEtMS01MDI5OQ_a0c41602-9428-4e5e-b8fd-4ba3e7bc4e4d"
      unitRef="usd">328000</evh:ProceedsRepaymentsForReinsurance>
    <evh:ProceedsRepaymentsForReinsurance
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfOC0zLTEtMS01MDI5OQ_a34acd02-3d62-41bb-8664-ee7028ab87e4"
      unitRef="usd">-7506000</evh:ProceedsRepaymentsForReinsurance>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfOS0xLTEtMS01MDI5OQ_0f8a5226-5654-478f-8e45-f3ba54799252"
      unitRef="usd">267000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjdkZTYyNGUwMDRlYjRhNzA5NGFlMGRlMmUzN2NlZmMyL3RhYmxlcmFuZ2U6N2RlNjI0ZTAwNGViNGE3MDk0YWUwZGUyZTM3Y2VmYzJfOS0zLTEtMS01MDI5OQ_d6d4ee4e-cef1-4776-993a-a3f9568c7340"
      unitRef="usd">-3336000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfNjcyMA_f4349757-d744-494d-82a7-d01d19e96f5b"
      unitRef="number">0.85</evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ic2dde99085614be3a48c4e542d462eac_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMzI5ODUzNDg5OTM0MA_8e95190a-aca9-4745-8ade-564173f13c5c"
      unitRef="usd">23500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <evh:CashFDICInsuredAmountPercentage
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTA4MTg_8d9c57f8-3487-422b-80ba-f1219bd01111"
      unitRef="number">0.986</evh:CashFDICInsuredAmountPercentage>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTA4Mjg_fbcbf0b8-388f-4a22-9b53-604dff6c3844"
      unitRef="usd">280400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <evh:CashHeldInInternationalBanksPercentage
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTA5Nzk_e483c861-838c-4a71-bfd7-85f3572f63fc"
      unitRef="number">0.009</evh:CashHeldInInternationalBanksPercentage>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RleHRyZWdpb246ZjM2ZmRkMjM4N2YzNGQ2N2E2YWJjNTQ4NmFlZWIyMGVfMTI0ODg_699549ea-e4a7-4b1a-a89d-35d88a8aadda">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable, as of June&#160;30, 2022 and December&#160;31, 2021:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Centers for Medicare and Medicaid Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bright Health Management, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and six months ended June 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Cross and Blue Shield of North Carolina&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ice2334023a474418a26edc96b4914f57_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfMS0xLTEtMS02MDYwMQ_3256cb43-1558-4212-84ab-6edaa74621dd"
      unitRef="number">0.245</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i74f5855d88434c3285d8d998872119e6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfMS0zLTEtMS01MDI5OQ_a1fa8971-653f-44ce-9a9b-c29755b81e4a"
      unitRef="number">0.464</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8b48f947d8c0471a835cbc7da3f1cf01_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfMy0xLTEtMS01MDI5OQ_3024de64-892d-4426-805d-0277cc460ed2"
      unitRef="number">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i97331e99ea5547e0b35d6859a1d13dd0_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfMy0zLTEtMS01MDI5OQ_8f865b28-5adc-4a77-bd45-e154e9619d25"
      unitRef="number">0.104</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i858366f085d4485eb18d0f7cc216d020_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfNC0xLTEtMS02MDYzMQ_6dfb8f4b-08c5-49da-a334-83017bd9beaf"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idea8512b30824967af5d24f3c9c780b0_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjI4MDI1ZGMyZWVlNzRiMDRhZjM5NjIwMzllMDFkNGQ0L3RhYmxlcmFuZ2U6MjgwMjVkYzJlZWU3NGIwNGFmMzk2MjAzOWUwMWQ0ZDRfNS0xLTEtMS02MDY0NQ_1b7836e3-d271-477a-8f96-a56b62b9142c"
      unitRef="number">0.114</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1f081253ccd6415999b9700a0d052cc4_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMi0xLTEtMS01MjIxMQ_7ddb623b-0312-46b7-a160-1d6e48df17f8"
      unitRef="number">0.241</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4369d3b9e5314c63bacd3f01a5ccb6b1_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMi0zLTEtMS01MjIyMw_1c02afdc-9354-422b-8044-16f52161a9db"
      unitRef="number">0.296</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5f3674d843144031a1c5d85f7415f252_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMi0xLTEtMS01MDI5OQ_45ea8a89-a4cb-4334-8b62-89fe59e41a38"
      unitRef="number">0.240</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iffcd008fc3494897b3c4b55545b1ecf2_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMi0zLTEtMS01MDI5OQ_2bdc5e27-6c73-4170-82e6-b48cff6886b6"
      unitRef="number">0.292</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id09252d541af4f6480d509935a97ae1c_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMy0xLTEtMS01MjIwNA_461137ae-e35a-4d59-be04-bafceb0bb465"
      unitRef="number">0.117</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie59876efdc3d43669106ec8d543d109a_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMy0zLTEtMS01MjIzMA_b1f60908-82af-4fa2-a77b-5f26b5990f13"
      unitRef="number">0.142</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id3f5b407f5d74c80b132051dcf12fe42_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMy0xLTEtMS01MDI5OQ_6cbcce7f-ac90-4382-9eb1-19e9fd14d4db"
      unitRef="number">0.118</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4697f31a51524c06a29c429847fa3a82_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfMy0zLTEtMS01MDI5OQ_455c6a74-b3f9-458c-836c-b235b1344c4c"
      unitRef="number">0.145</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7549a5bc04b3412f8b50fb05b19fe749_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83Ni9mcmFnOmYzNmZkZDIzODdmMzRkNjdhNmFiYzU0ODZhZWViMjBlL3RhYmxlOjExMDFkMmIxYjNkNjQ5ZGNiODU4MGQ3MTljMDAyNGI5L3RhYmxlcmFuZ2U6MTEwMWQyYjFiM2Q2NDlkY2I4NTgwZDcxOWMwMDI0YjlfNC0xLTEtMS02MDY4Ng_7170b7fc-1225-4b81-8667-9fbdf9b4dc37"
      unitRef="number">0.102</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMzI1OA_5506dc9b-b4de-4be4-94c5-cc4ecb8a1123">Leases&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#x2019;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with various lease agreements, the Company is required to maintain $2.3 million and $3.8 million in letters of credit as of June&#160;30, 2022 and December&#160;31, 2021. As of June&#160;30, 2022 and December&#160;31, 2021, the Company held $2.3 million and $3.8 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of June&#160;30, 2022 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of June&#160;30, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ia8618f6dc2f0455a9e812da51a84fc9f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMjY2Mw_6815632c-b998-4229-bd61-6902ec032434"
      unitRef="usd">2300000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="iafda5615eab24ad0adebb2033f75ea7e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMjY3MA_a4571d37-f353-4828-80cc-5f884b1098d2"
      unitRef="usd">3800000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ia8618f6dc2f0455a9e812da51a84fc9f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMjc0NQ_24d6efa5-09b4-4817-8ac5-66014951f11f"
      unitRef="usd">2300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="iafda5615eab24ad0adebb2033f75ea7e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMjc1Mg_881862de-53fe-415a-a33b-181331d17ccb"
      unitRef="usd">3800000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMzI1OQ_15c9a326-8123-4b3a-9db9-38955aecda14">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of June&#160;30, 2022 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of June&#160;30, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i38cfdd80181d48dc95c448a5bd762e1c_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMS0yLTEtMS01MDI5OQ_7b93de75-cccd-4f0c-9888-f2cf4be522f8">P9Y7M6D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i38cfdd80181d48dc95c448a5bd762e1c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMS00LTEtMS01MDI5OQ_c4b5c2db-f73f-45f5-bef5-92416f19b55f"
      unitRef="usd">34014000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i38cfdd80181d48dc95c448a5bd762e1c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMS02LTEtMS01MDI5OQ_d9ac58e1-f1ed-47e6-bd4d-06f8f7a2f20a"
      unitRef="usd">1579000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i92f67640b93b448585be7724489ed0b2_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMi0yLTEtMS01MDI5OQ_8f881b82-8a80-474d-903d-bd941e9d8725">P8Y9M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i92f67640b93b448585be7724489ed0b2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMi00LTEtMS01MDI5OQ_20c5fe85-5a42-4d41-8576-ca331d662b82"
      unitRef="usd">39712000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i92f67640b93b448585be7724489ed0b2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMi02LTEtMS01MDI5OQ_79ebc47a-b2b5-41d1-97d6-c250891be0d3"
      unitRef="usd">232000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i31cae587563b4dfaba6a55698e21f99a_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMy0yLTEtMS01MDI5OQ_d34fa53b-f9e0-4a06-931b-e1856f39f651">P3Y9M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i31cae587563b4dfaba6a55698e21f99a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMy00LTEtMS01MDI5OQ_36e32c5a-a95d-42fe-b16d-c8be9d9b4bce"
      unitRef="usd">1981000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i31cae587563b4dfaba6a55698e21f99a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfMy02LTEtMS01MDI5OQ_7c9f5c1c-5b72-4860-a6e3-63fe7af65d3e"
      unitRef="usd">222000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ib0fe093ce52b4d0081c2f7e51b68a9fa_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNC0yLTEtMS01MDI5OQ_78e81237-99be-4cca-b017-455a95f3d373">P1Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib0fe093ce52b4d0081c2f7e51b68a9fa_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNC00LTEtMS01MDI5OQ_af3a1963-190f-42e8-b6ea-8b7abfc807d9"
      unitRef="usd">864000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ib0fe093ce52b4d0081c2f7e51b68a9fa_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNC02LTEtMS01MDI5OQ_042e6105-a2a5-409d-bec3-d147ff6dd5f5"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i11a4e8a319824f4b96b6989839081ca3_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNS0yLTEtMS01MDI5OQ_c06a4e24-3c58-44ec-90db-65941b6381e1">P4Y10M24D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i11a4e8a319824f4b96b6989839081ca3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNS00LTEtMS01MDI5OQ_708d0655-8b48-46c6-9a7d-a8b8ccb450da"
      unitRef="usd">4304000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i11a4e8a319824f4b96b6989839081ca3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjVjMjdjOGQ2MTU2OTRiMzI5MjY1MjY0OTM3YWZlZTEzL3RhYmxlcmFuZ2U6NWMyN2M4ZDYxNTY5NGIzMjkyNjUyNjQ5MzdhZmVlMTNfNS02LTEtMS01MDI5OQ_eee84acc-b007-436d-89e3-3ae1daf8b653"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RleHRyZWdpb246NGZmNjEyZmUxMWNjNDYwZjhhMzMxNDhiYTMzZDM0NzdfMzI2MA_cb0eece2-2a1d-415b-b667-ea10c59330b6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMi0xLTEtMS01NTA2Mw_6da37c2f-e4a0-4fe7-8283-3f236209e0a1"
      unitRef="usd">2231000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMi0zLTEtMS01NTA2Mw_20ea69a1-a709-4c97-8315-5b8c7f650016"
      unitRef="usd">2437000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMi0xLTEtMS01MDI5OQ_74a94c39-ef4f-4778-8d62-3668f3004b45"
      unitRef="usd">4505000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMi0zLTEtMS01MDI5OQ_1a667879-61b4-4d8b-8b5d-ac9f3dfff4cf"
      unitRef="usd">7255000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMy0xLTEtMS01MjMxOA_b4390cef-198c-4414-8fd9-8e9412c4ebe2"
      unitRef="usd">1171000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMy0zLTEtMS01MjMxOA_f35dfb6b-0be2-4ec6-afa5-9f70dfc172db"
      unitRef="usd">1192000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMy0xLTEtMS01MDI5OQ_48d0aad1-b33a-4131-9dbb-ac6a7200af61"
      unitRef="usd">2497000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfMy0zLTEtMS01MDI5OQ_c809d175-af1b-4d83-b177-bc902b56e6e2"
      unitRef="usd">2513000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfNC0xLTEtMS01MjMyNQ_fa1bc73a-6c1d-41f1-a2e7-6ecf8df6a94a"
      unitRef="usd">3402000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfNC0zLTEtMS01MjMyNQ_7c617870-4d85-4984-970a-bee1b221ca74"
      unitRef="usd">3629000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfNC0xLTEtMS01MDI5OQ_28e642c2-7b35-4327-8b37-303987eaea64"
      unitRef="usd">7002000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjliMGUwMjBjZWZiMjRiMGY5ZDBmZWQ5NGJhNjhkYTNmL3RhYmxlcmFuZ2U6OWIwZTAyMGNlZmIyNGIwZjlkMGZlZDk0YmE2OGRhM2ZfNC0zLTEtMS01MDI5OQ_06635693-2214-4961-960c-6cd98c2525b9"
      unitRef="usd">9768000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfMS0xLTEtMS01MDI5OQ_c9df44b3-e885-44a4-99ec-2d40680532fe"
      unitRef="usd">5196000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfMi0xLTEtMS01MDI5OQ_5628c277-396b-4cac-a0de-cbe536925524"
      unitRef="usd">10271000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfMy0xLTEtMS01MDI5OQ_f3fdc0a2-b1d8-4204-85d1-95a08506d450"
      unitRef="usd">10025000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfNC0xLTEtMS01MDI5OQ_53425112-f930-4769-8c19-3652edaf2d9e"
      unitRef="usd">9651000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfNS0xLTEtMS01MDI5OQ_54576b71-b8b6-4de5-bfb5-e0e2c2a4190f"
      unitRef="usd">8987000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfNi0xLTEtMS01MDI5OQ_0219e976-de22-4df1-8aad-364c4845bf97"
      unitRef="usd">40377000</evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfNy0xLTEtMS01MDI5OQ_f5e82dc2-9f85-4fa0-9f1d-63bd2fc29aa4"
      unitRef="usd">84507000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfOS0xLTEtMS01MDI5OQ_8546f344-8389-4ae5-989a-d8e3b6c878a0"
      unitRef="usd">19537000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjRhYjA4OTIwNmEwNTQwNjg4NWZiNjBkNWNjODkxMGI0L3RhYmxlcmFuZ2U6NGFiMDg5MjA2YTA1NDA2ODg1ZmI2MGQ1Y2M4OTEwYjRfMTAtMS0xLTEtNTAyOTk_d6ebe903-de48-4bde-be6b-340ba4f4a2ac"
      unitRef="usd">64970000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjFmZGQ4YWFmZDM3YjRkYTk5MTdlNzc1MzAyNTdlNmM0L3RhYmxlcmFuZ2U6MWZkZDhhYWZkMzdiNGRhOTkxN2U3NzUzMDI1N2U2YzRfMS0xLTEtMS01MDI5OQ_b0ab76f7-baf7-4a73-a7e0-d555c7d6c2c1"
      unitRef="number">0.0630</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl83OS9mcmFnOjRmZjYxMmZlMTFjYzQ2MGY4YTMzMTQ4YmEzM2QzNDc3L3RhYmxlOjFmZGQ4YWFmZDM3YjRkYTk5MTdlNzc1MzAyNTdlNmM0L3RhYmxlcmFuZ2U6MWZkZDhhYWZkMzdiNGRhOTkxN2U3NzUzMDI1N2U2YzRfMi0xLTEtMS01MDI5OQ_88f87696-d450-4c9e-ab62-a77165572c6e">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RleHRyZWdpb246NmQ3M2M4YjhlNWRhNDk2YWI2YjA5NGRlYTIwNThjNDZfMzUz_b8f464c1-f2c1-4110-8ca1-6e7484c3d4a6">Loss Per Common Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RleHRyZWdpb246NmQ3M2M4YjhlNWRhNDk2YWI2YjA5NGRlYTIwNThjNDZfMzQx_784d649a-9313-4ef4-b4ed-9bd49dec4dfe">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMi0xLTEtMS01MjM2MA_a18efcc0-26c1-40a8-b285-2b77595deb95"
      unitRef="usd">-4125000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMi0zLTEtMS01MjM2MA_05e6ff98-613b-42b7-8fdf-21017a50b82a"
      unitRef="usd">-9107000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMi0xLTEtMS01MDI5OQ_cf7ba85f-9d70-4564-b248-3c5ab3abd91b"
      unitRef="usd">-9475000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMi0zLTEtMS01MDI5OQ_745240e1-c2fb-40f2-945e-f63634659172"
      unitRef="usd">-20297000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MjM2NA_d0078107-c79a-4908-a96b-fcb12333a564"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MjM2NA_49497634-fa51-4fa0-8ab4-f53f91f2fa50"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MDI5OQ_6dccf1fb-174b-4581-aaea-f9ea25f1d932"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MDI5OQ_cc81acb2-9163-4391-91dc-f0317c70e013"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0xLTEtMS01NTUwMA_62c30aa7-8701-44e4-83c9-125ef9fa625c"
      unitRef="usd">-4588000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0xLTEtMS01NTUwMA_789cea32-0a2c-4472-9d4b-1e221a42e408"
      unitRef="usd">-4588000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0zLTEtMS01NTUxMA_b528ba5c-0d8d-46fd-9353-9a6c4e1285ae"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0zLTEtMS01NTUxMA_c5cc5564-fc76-4665-9de2-9bc53d8b19a2"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0xLTEtMS01MDI5OQ_071b4d2e-7213-4176-9794-ad2849a45adb"
      unitRef="usd">-9938000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0xLTEtMS01MDI5OQ_277edb41-089a-4d99-955a-9992f6a848f4"
      unitRef="usd">-9938000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0zLTEtMS01MDI5OQ_464827c9-5ea2-4be7-93f2-215a05027e61"
      unitRef="usd">-18914000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNC0zLTEtMS01MDI5OQ_694cb801-830b-4ea4-9bd5-c6e422cf548d"
      unitRef="usd">-18914000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0xLTEtMS01MjM2OQ_41f5d268-1f8d-4c2d-a385-c9e08c0f72c8"
      unitRef="shares">90071000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0xLTEtMS01MjM2OQ_6ad0f78d-e413-4159-b6f8-0aaf7e5ff8a7"
      unitRef="shares">90071000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0zLTEtMS01MjM2OQ_5ead25c1-071b-4036-a56f-97db9ea68cae"
      unitRef="shares">85448000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0zLTEtMS01MjM2OQ_85e6bbd0-5212-4a6e-9468-303c4f000d65"
      unitRef="shares">85448000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0xLTEtMS01MDI5OQ_53b5f9ce-d970-4657-94a1-c315b1e69321"
      unitRef="shares">89792000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0xLTEtMS01MDI5OQ_5e57e7cf-9f3a-4611-9f09-ef7b143f6d62"
      unitRef="shares">89792000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0zLTEtMS01MDI5OQ_0f412b0b-9466-4a0f-942d-631e68f121a5"
      unitRef="shares">85056000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfNi0zLTEtMS01MDI5OQ_c8a5bad9-5fe3-4e34-be45-f8eb414f8265"
      unitRef="shares">85056000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMS0xLTEtNTIzNzI_485f8172-519d-4db8-9aed-4799287e8186"
      unitRef="usdPerShare">-0.05</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMS0xLTEtNTIzNzI_8355fdd5-4e49-42e8-b447-5bc60b22d565"
      unitRef="usdPerShare">-0.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMy0xLTEtNTIzNzI_22b63fdb-447c-4f0e-b062-dbd3ef19cd8c"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMy0xLTEtNTIzNzI_8ae57cde-39cb-45ea-ad89-116a1790131c"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMS0xLTEtNTAyOTk_9b9629f2-0d83-4975-9977-6ff59dfc6aef"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMS0xLTEtNTAyOTk_b6000604-7750-4e79-8f0f-7b737cda8fa1"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMy0xLTEtNTAyOTk_51986ab2-8998-4136-9236-ccd91dd19900"
      unitRef="usdPerShare">-0.24</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTAtMy0xLTEtNTAyOTk_f8c42eff-43de-49fb-b7c3-b43d543b531c"
      unitRef="usdPerShare">-0.24</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMS0xLTEtNTIzNzI_e3b9ea4d-4e41-4467-a709-f0c6a630b4b6"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMS0xLTEtNTIzNzI_fd21a903-cf8b-49f1-b98d-4603eda45280"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMy0xLTEtNTIzNzI_3398dcf7-71be-4a2d-b3cb-f96294615a1e"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMy0xLTEtNTIzNzI_d1ce6784-6ad2-4ace-9d6f-deae258379e5"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMS0xLTEtNTAyOTk_5dc7a43d-578a-4be3-9269-b52f17c8b3a6"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMS0xLTEtNTAyOTk_85c081d6-9eaf-4668-84ea-a67c89dc82b2"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMy0xLTEtNTAyOTk_0ca56ccf-fb13-4418-9dec-67e6074c8574"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTEtMy0xLTEtNTAyOTk_798eff45-60b2-455d-9c7a-9af99196bae1"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMS0xLTEtNTIzNzU_7a65e334-57d7-4878-bdfd-5c1b9c4f9bd2"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMS0xLTEtNTIzNzU_9453d8a9-eec7-4306-8c88-ff964bce8b6d"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMy0xLTEtNTIzNzU_688690ff-b6c4-4da6-aba8-506911ebf495"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMy0xLTEtNTIzNzU_7343f8c5-ee6a-465a-a801-3e37c33ac703"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMS0xLTEtNTAyOTk_12962f70-5c62-4b02-b9f2-da79d80cb9af"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMS0xLTEtNTAyOTk_5ecc3bd6-602a-47da-86bc-b7111a531ad5"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMy0xLTEtNTAyOTk_bb9b3f1b-30af-4b1e-83c8-4a8ea9925c0e"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMTItMy0xLTEtNTAyOTk_e7620d26-5d56-482b-8cb1-d67e65ce2e29"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RleHRyZWdpb246NmQ3M2M4YjhlNWRhNDk2YWI2YjA5NGRlYTIwNThjNDZfMzUy_5faf268a-7c68-4f00-966f-cea95e11a670">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6d54b939218e47729004114229359446_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMi0xLTEtMS01MjQxMA_2dabee9c-e0f5-4b26-a6de-83747cfb607e"
      unitRef="shares">1642000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie5f918cd7826430298dbf550d4b035ad_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMi0zLTEtMS01MjQxMA_0e9acac9-c4b2-4cab-b850-5e4282bd65fd"
      unitRef="shares">2052000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if231d8338180440882ba220f0ce751c6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMi0xLTEtMS01MDI5OQ_9b85dbe4-2154-472a-ab7c-32c22ce24876"
      unitRef="shares">1817000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide8b1a427528491e95fa193e43b94d38_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMi0zLTEtMS01MDI5OQ_6fb0a5a9-184c-45a5-9fd0-828d894fc5a0"
      unitRef="shares">1793000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifcfcf1b04d4841ccbb92d2a7320961fe_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMy0xLTEtMS01MjQxMA_bb1ab702-3514-439b-8f45-d355d7bdd023"
      unitRef="shares">1852000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id2901a75f3a247c5ac744dd557ba51f0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMy0zLTEtMS01MjQxMA_d3e3c5ae-f2e5-4cfa-9f5c-443782fa2af7"
      unitRef="shares">1801000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i24857afd029946ad953d32e472b7bcbc_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMy0xLTEtMS01MDI5OQ_0f661c6f-cf5c-4565-b9b1-08ddd19de9aa"
      unitRef="shares">1807000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iabd7310dc91f4778877cc439a686f2ce_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfMy0zLTEtMS01MDI5OQ_32883b3a-6010-4ac7-b3c0-271eff82f5b1"
      unitRef="shares">1833000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie134ed611c47418485ab07b86a56f78d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNC0xLTEtMS01MjQxMA_c9926779-1afc-44de-87e2-b3a56307315d"
      unitRef="shares">11582000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2447e2f271ab4cd5b596bc7f50ab65ce_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNC0zLTEtMS01MjQxMA_7713cd86-2bfb-41c2-8b70-5c930753c53b"
      unitRef="shares">12696000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i964b6c8302364f4fa39a31e5fe8af1a4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNC0xLTEtMS01MDI5OQ_ee17b5ef-488d-43a0-995f-c04d74b0f4ca"
      unitRef="shares">11582000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7a6bfcf39da045688459cbd536822b1d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNC0zLTEtMS01MDI5OQ_5b65f08e-305c-4482-a812-73a9c6eaba1b"
      unitRef="shares">12696000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNS0xLTEtMS01MjQxMA_69f5208a-daaf-4367-9f54-cb1747655511"
      unitRef="shares">15076000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNS0zLTEtMS01MjQxMA_0617110b-3c7f-4ff4-8085-3ac2c8a00f78"
      unitRef="shares">16549000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNS0xLTEtMS01MDI5OQ_8a68eb72-48e6-4c4e-9e46-bc8cbb9365fc"
      unitRef="shares">15206000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjQ3NjQwY2E2YzVmOTQzZDBiMmEyZWU1NmIxMjFjOTNiL3RhYmxlcmFuZ2U6NDc2NDBjYTZjNWY5NDNkMGIyYTJlZTU2YjEyMWM5M2JfNS0zLTEtMS01MDI5OQ_bf367c17-777f-4cfa-9806-d7f733980085"
      unitRef="shares">16322000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMzI3_4c87cdd0-264b-4853-9eb0-6cc02bee7dd4">Stock-based Compensation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No stock-based compensation was capitalized as software development costs for the three and six months ended June 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards were granted as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMzI4_3a1c1299-9fd6-4528-9f75-feb0ab9a3a65">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0bfb82287c064822b44c47e618455986_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMy0xLTEtMS01MjQ4MA_4714b577-8837-4932-8906-94d79f06a7cb"
      unitRef="usd">91000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia74da95131c94444b02cb9706d3d7af2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMy0zLTEtMS01MjQ4MA_226885c0-6daf-4e8a-b830-ce27d0608e33"
      unitRef="usd">267000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34f9d2b1aa2e48d89223c9302b8b413b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMy0xLTEtMS01MDI5OQ_774de994-7d8c-4371-bda8-3889f62be397"
      unitRef="usd">253000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ida2bfbe459a7424eb6baf496ceffcbc0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMy0zLTEtMS01MDI5OQ_bd9dbc31-987c-4dc1-a79f-15c896db84b6"
      unitRef="usd">671000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9002002234e467d88e03554eac894c8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNC0xLTEtMS01MjQ4Nw_9c101c09-9c50-45cf-9ba1-ba69c80dd47d"
      unitRef="usd">4647000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b58614dca7f4fbeb927b1354f4e9b79_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNC0zLTEtMS01MjQ4Nw_94ba84f7-49f5-45d5-b7aa-e5b5f8e72e6d"
      unitRef="usd">2427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibfa8508ca389418f81bf326a680bd658_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNC0xLTEtMS01MDI5OQ_27f0cfd9-c9c1-4d9b-bd59-af6ea5854cce"
      unitRef="usd">7948000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7783015b2ae54c6e9b2422c563ab6deb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNC0zLTEtMS01MDI5OQ_10c552da-b74f-47aa-b0d0-b64a3f61ee70"
      unitRef="usd">4401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1b51644e7c048c88aea7ed7a62c9f77_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNS0xLTEtMS01MjQ5NA_efde0a3c-3c5d-41d0-b3c0-9c38ad5c07c0"
      unitRef="usd">382000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idc87bed7f2074590b61ec2fb0cc0f0f8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNS0zLTEtMS01MjQ5NA_907a7bc5-075b-409e-9bda-c6406174028f"
      unitRef="usd">222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f97a58aa80547029649a0cf3a2a5dd7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNS0xLTEtMS01MDI5OQ_30f52eec-0517-4dd9-9fc4-e968d1000e64"
      unitRef="usd">1157000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic329299275fa4a088f919d8e59845bff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNS0zLTEtMS01MDI5OQ_920dd2b3-115e-4666-be2c-1f41367f7e85"
      unitRef="usd">1307000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i76cc4f8c28014238a98362c8d2ef9224_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNi0xLTEtMS01MjQ5NA_d6f1afb5-76ba-4b40-b42f-cb2fd2ce8689"
      unitRef="usd">1892000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i92729353701e4160afc71576b5f23a25_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNi0zLTEtMS01MjQ5NA_ea814209-f17a-4978-8ff8-1f3b95085087"
      unitRef="usd">737000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib699196b28014c31a00d19bb66ee014a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNi0xLTEtMS01MDI5OQ_2951ae6a-81bf-4f69-88df-64d0942571c9"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i10c9925c2945438f916183ef76ede0c0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNi0zLTEtMS01MDI5OQ_091528b3-4284-4208-ba62-016e68c13844"
      unitRef="usd">980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNy0xLTEtMS01MjQ5NA_d1a21991-36b6-429b-861c-6fec5f569261"
      unitRef="usd">7012000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNy0zLTEtMS01MjQ5NA_292aaed7-87dc-4f12-a9ce-206d6bb74350"
      unitRef="usd">3653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNy0xLTEtMS01MDI5OQ_a2fcc096-ea70-4bd3-9d03-5f95ba401bc2"
      unitRef="usd">12358000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfNy0zLTEtMS01MDI5OQ_53a0913e-3ac3-4413-8e55-988a9f4e7984"
      unitRef="usd">7359000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84dbc81371174a2aaee8be24c4769d0e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTAtMS0xLTEtNTI1MTQ_8c15fb8d-e542-4053-8033-0f072b9fa238"
      unitRef="usd">1162000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i527e4616505d460da52a06d5e9031339_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTAtMy0xLTEtNTI1MTQ_0c85a7b2-7cdf-406b-80c5-a7ba7261f359"
      unitRef="usd">892000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id03a4fc06028452a8a6a2c80df8c07cf_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTAtMS0xLTEtNTAyOTk_924b242b-1eeb-4c0e-94a3-dd00b7da141d"
      unitRef="usd">1962000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7deec1f9d05a4e7b8276434ce19b2f18_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTAtMy0xLTEtNTAyOTk_9e47a40a-7381-490b-898a-f46830463490"
      unitRef="usd">1487000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6f9702c58070468c9b2a1580cb0175db_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTEtMS0xLTEtNTI1MTQ_ad87f13c-b325-4b77-8a86-f125e5184453"
      unitRef="usd">5850000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6ea4f0986d4c4a1e9f1370d4957fd642_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTEtMy0xLTEtNTI1MTQ_90327d2e-9409-4d0a-93ab-2ebed5bb58ef"
      unitRef="usd">2761000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6ee8a89e489b4af9ac0113c9d93ce86e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTEtMS0xLTEtNTAyOTk_f4b8741a-089b-4eba-9ae8-13ae894e9164"
      unitRef="usd">10396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibb490ebfa4014df7bbc4f1b2f06baaaa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTEtMy0xLTEtNTAyOTk_71faaa18-108a-4787-8ed0-9148e0ad7ea0"
      unitRef="usd">5872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTItMS0xLTEtNTI1MTQ_58a044a2-cd9c-4390-882d-38e9607fd7de"
      unitRef="usd">7012000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTItMy0xLTEtNTI1MTQ_7faee790-5976-4ac4-b561-d696d8bcc933"
      unitRef="usd">3653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTItMS0xLTEtNTAyOTk_e3f2d5a7-be51-4fd9-969d-600bc53576e0"
      unitRef="usd">12358000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOmNlMzVkNWE1NWFhZDRkNDI5MmUxNmYxMTE4MGU5YzRiL3RhYmxlcmFuZ2U6Y2UzNWQ1YTU1YWFkNGQ0MjkyZTE2ZjExMTgwZTljNGJfMTItMy0xLTEtNTAyOTk_53a0913e-3ac3-4413-8e55-988a9f4e7984"
      unitRef="usd">7359000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMTcx_5653bfdb-6f08-4975-a34b-03a72cb473ce"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMTcx_76340ec6-1181-43b5-a948-697f22fc4731"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMTcx_aefb7822-eedc-4be1-8a77-ac11d1578026"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMTcx_e711f07f-8d1d-43da-b64a-f0d9dce6277c"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RleHRyZWdpb246NTExNWEyOWFkNDQ4NGFlZTk1NjFlYjc3M2RmYTI1ZThfMzI5_9d037c75-101b-44c6-86e3-148ae4479810">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards were granted as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic9002002234e467d88e03554eac894c8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMi0xLTEtMS01MjU1Mw_d861ffb4-c8da-4cf3-92f3-d608194ad069"
      unitRef="shares">63000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3b58614dca7f4fbeb927b1354f4e9b79_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMi0zLTEtMS01MjU1Mw_c7157cf8-60e6-41d7-9c25-e67e8a685a38"
      unitRef="shares">89000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibfa8508ca389418f81bf326a680bd658_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMi0xLTEtMS01MDI5OQ_1fbe8668-8b65-49b8-9c1d-6bfe89962b58"
      unitRef="shares">980000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7783015b2ae54c6e9b2422c563ab6deb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMi0zLTEtMS01MDI5OQ_5102f2c3-979e-48a0-b53e-a0dd6387f277"
      unitRef="shares">1028000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i76cc4f8c28014238a98362c8d2ef9224_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMy0xLTEtMS01MjU1Mw_709965ea-b926-4391-bde7-860c1b8633c2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i92729353701e4160afc71576b5f23a25_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMy0zLTEtMS01MjU1Mw_83330cca-2052-4add-ab59-a4a24930e0a1"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib699196b28014c31a00d19bb66ee014a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMy0xLTEtMS01MDI5OQ_0a53b2fb-80dd-4726-b183-afa459bd8ae2"
      unitRef="shares">479000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i10c9925c2945438f916183ef76ede0c0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84NS9mcmFnOjUxMTVhMjlhZDQ0ODRhZWU5NTYxZWI3NzNkZmEyNWU4L3RhYmxlOjMzODI5YzdjZWEzNDRkMjk4MzE5MDBmOTA0NjNmMDgyL3RhYmxlcmFuZ2U6MzM4MjljN2NlYTM0NGQyOTgzMTkwMGY5MDQ2M2YwODJfMy0zLTEtMS01MDI5OQ_4a9e56ea-90e1-4fee-901e-b60af2747abc"
      unitRef="shares">319000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMTQ1MQ_d64a17fc-a73c-4116-a7e1-d6912752cdf4">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An income tax expense (benefit) of $(0.2)&#160;million and $1.0&#160;million and was recognized for the three and six months ended June 30, 2022, respectively, which resulted in effective tax rates of 3.9% and (11.4)%, respectively. An income tax expense (benefit) of $0.1&#160;million and $0.7&#160;million was recognized for the three and six months ended June 30, 2021, respectively, which resulted in effective tax rates of (1.0)% and (3.6)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax expense recorded during the three and six months ended June 30, 2022 and 2021 primarily relates to foreign taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2021, the Company had unrecognized tax benefits of $0.6 million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of June&#160;30, 2022, there are no changes to the unrecognized tax benefits. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above for discussion of our TRA.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzI5ODUzNDg4NTA4MA_4568e746-c951-4938-8a61-e01299b2a366"
      unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzI5ODUzNDg4NTExMg_7a9d8baa-88fe-4510-9f09-c9be265aa90f"
      unitRef="usd">1000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMTA5OTUxMTYyOTMwNg_47eef0b7-3356-4dfc-9574-70d4392b0251"
      unitRef="number">0.039</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzAx_6017eedd-00b8-4c35-a318-153e2d9e8fad"
      unitRef="number">-0.114</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzI5ODUzNDg4NTE0NA_0ebe6251-27ee-48e8-9d69-92357cab867c"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzI5ODUzNDg4NTE3OA_14491221-2384-4460-a539-b15ced70fe11"
      unitRef="usd">700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMTA5OTUxMTYyOTM1OQ_93e7dea4-deea-4324-981f-8e87f39e8878"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMzA4_a92066bf-e04b-474d-b3ed-39b63bc582b7"
      unitRef="number">-0.036</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfNjMx_d8071612-9320-478e-b1d8-3ca36da01af3"
      unitRef="usd">600000</us-gaap:UnrecognizedTaxBenefits>
    <evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84OC9mcmFnOjMxODhkMWM1NTUzMTRkNGY5ODA4NGYzMjZjMWNkNjY1L3RleHRyZWdpb246MzE4OGQxYzU1NTMxNGQ0Zjk4MDg0ZjMyNmMxY2Q2NjVfMTE1Ng_97de1f39-c86d-413c-b7b0-c77d3ffb1cc7"
      unitRef="number">0.85</evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMjE3NQ_10e9a463-2628-4a3f-8e72-5ed64d1c5b5c">Investments in Equity Method Investees&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;June&#160;30, 2022 and December&#160;31, 2021, the Company&#x2019;s economic interests in its equity method investments ranged between 4% and 38% and 4% and 39%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#x2019; earnings and losses for each reporting period. The Company&#x2019;s proportional share of the gain from these investments was approximately $2.0 million and $2.5 million for the three and six months ended June 30, 2022, respectively, and $4.9 million and $12.7 million for the three and six months ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $3.9 million and $7.5 million for the three and six months ended June 30, 2022, respectively, and $2.3 million and $8.6 million for the three and six months ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i54dd4caef2f344379688eaef3449c98e_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTI0NA_25c5796d-684c-4de5-a056-2f403036f96f"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i94ebbd62d39b4c6e878b3190d03982a1_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTI1MQ_68db7c2c-d175-4473-aaf8-800cf5fdd325"
      unitRef="number">0.38</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="if8f2eb0ac1624558acdb53e52c269e19_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTI1OA_0ffbc92e-0565-4456-8103-0ce7eadccb08"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i5bd208a32416460385f7876f38b23d85_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTI2NQ_7e849bfd-c3d4-4027-bc9e-7439148f76bf"
      unitRef="number">0.39</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="if8f2eb0ac1624558acdb53e52c269e19_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTM1Mg_029f661c-0d6a-499b-a676-26f559fd89c9"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i54dd4caef2f344379688eaef3449c98e_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTM1Mg_6cffbb82-4b12-481b-9029-6f72164f0086"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i5bd208a32416460385f7876f38b23d85_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTM1OQ_7382521e-9a0c-48f8-b81d-c84a1bcd4e5f"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i94ebbd62d39b4c6e878b3190d03982a1_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTM1OQ_e61b7dcc-10b5-4e0c-a587-1e8fd0b6074d"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTA5OTUxMTYyOTk1Nw_a537e0a3-ad58-4f40-98b8-d2ccb911534c"
      unitRef="usd">2000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTgwMQ_0d6c8305-759d-482d-942c-7f5f5b12303c"
      unitRef="usd">2500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTA5OTUxMTYzMDAzOQ_84ea3918-a85b-4449-8464-99047c804e99"
      unitRef="usd">4900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTgwOA_0503f1e6-2ffe-40b6-a4cd-1527e7c3ab80"
      unitRef="usd">12700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="if038fb24676c4fbe8fcd625e0c03f2e4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTA5OTUxMTYzMDA3Mg_89905dbc-5578-4ce6-a6b7-5dca3b90f1ab"
      unitRef="usd">3900000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="if35ad6a7d0874e9989f37adcab1d604c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMjExMw_8fb500da-aee2-4f56-98a7-67b3d7c03bb8"
      unitRef="usd">7500000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="ic72c81faddfb4d16898248ad47a599c1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMTA5OTUxMTYzMDE1Ng_d78e8b26-20e9-4c05-b7de-a10c77983e4a"
      unitRef="usd">2300000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="ic59c227acd8640a480a066d3194993ca_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85MS9mcmFnOjQyODMwNjk0Mjg2MTRiYjc5OTExNzYzY2FiMzM1MDkzL3RleHRyZWdpb246NDI4MzA2OTQyODYxNGJiNzk5MTE3NjNjYWIzMzUwOTNfMjEyMA_c029466d-4414-406d-8675-0c3a4fd6c7e9"
      unitRef="usd">8600000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RleHRyZWdpb246YmI5ZmRiYjk5OWQ2NDk4MWJiMzAxYjNhMDYxOWE2MzFfNDk2MQ_529b6c45-0e97-4aa2-b154-a0186d35001f">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three and six months ended June 30, 2022 and 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, the acquisition of Vital Decisions includes a provision for additional equity consideration contingent upon the Company obtaining certain annualized performance metrics during the three months ending December 31, 2022. The fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Vital Decisions contingent consideration are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RleHRyZWdpb246YmI5ZmRiYjk5OWQ2NDk4MWJiMzAxYjNhMDYxOWE2MzFfNDk4Nw_d6890209-3dbe-4024-94c5-dc9ec1cadeeb">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RleHRyZWdpb246YmI5ZmRiYjk5OWQ2NDk4MWJiMzAxYjNhMDYxOWE2MzFfNDk3NA_abf65e9c-26d2-4f4d-ae98-3cb454d359f5">The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands): &lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1f1f46b4a5da4b88ab1161c697899756_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfMy0xLTEtMS01MDI5OQ_25073793-9804-41e0-a663-e7499909f162"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i901fed8a465841a2a7d4e3c79e3b289f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfMy0zLTEtMS01MDI5OQ_0f0cae6a-256d-42b6-ac14-153922f7f594"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i60e8394722604655b91f21d472ddc55f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfMy01LTEtMS01MDI5OQ_7749cf44-6dda-4bd7-8963-cab7e3f4dea1"
      unitRef="usd">33400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i37f4d51ef9aa4ab4a4f13f3a70a0afb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfMy03LTEtMS01MDI5OQ_70b7ab7a-c2dd-4506-9206-888f8c0716c2"
      unitRef="usd">33400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1f1f46b4a5da4b88ab1161c697899756_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfNC0xLTEtMS01MDI5OQ_1d099d8b-2a48-4ded-bef0-70f150ac6c82"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i901fed8a465841a2a7d4e3c79e3b289f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfNC0zLTEtMS01MDI5OQ_bf9bb33f-1989-41c6-b3e0-945d735f0da2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i60e8394722604655b91f21d472ddc55f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfNC01LTEtMS01MDI5OQ_cced9446-14e2-452c-835b-5ce3596b43cb"
      unitRef="usd">33400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i37f4d51ef9aa4ab4a4f13f3a70a0afb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjg1ZmMzZjBkYzBiNTQ1YjBhNmU4Mzg4ZTIyNGQyODg0L3RhYmxlcmFuZ2U6ODVmYzNmMGRjMGI1NDViMGE2ZTgzODhlMjI0ZDI4ODRfNC03LTEtMS01MDI5OQ_387a17af-c3ba-4e87-9add-de4b0d30f2df"
      unitRef="usd">33400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9a0e0359a3b54f88ac3fba23ecf413ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfMy0xLTEtMS01MDI5OQ_779d7751-3b68-4694-9c32-176bdbf500e3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i67639f87145d4008acf2702010dc086c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfMy0zLTEtMS01MDI5OQ_70d99907-7619-4233-afbb-ba4e2b037b6a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2c9af5aa7ede47a29b2eff96c883a5f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfMy01LTEtMS01MDI5OQ_dcea9835-f054-438e-962e-0591892e66fb"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idad3e10b3ea8472d88039d89be09d82a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfMy03LTEtMS01MDI5OQ_d63cd124-23c3-44fd-a5ff-15f8a4a1bb29"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9a0e0359a3b54f88ac3fba23ecf413ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfNC0xLTEtMS01MDI5OQ_3cf5023c-643b-43d0-af8d-0af43bb4a6f9"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i67639f87145d4008acf2702010dc086c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfNC0zLTEtMS01MDI5OQ_d141cd69-2232-47ad-800c-750bfe68f015"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2c9af5aa7ede47a29b2eff96c883a5f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfNC01LTEtMS01MDI5OQ_47c91c1a-7384-4cd0-bb8d-15f7b6e3dcce"
      unitRef="usd">28700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idad3e10b3ea8472d88039d89be09d82a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjRiZDhkZDcxNzdjZjQwYzBhOGZjMzhkNDY3MTIyYzFlL3RhYmxlcmFuZ2U6NGJkOGRkNzE3N2NmNDBjMGE4ZmMzOGQ0NjcxMjJjMWVfNC03LTEtMS01MDI5OQ_5a8c2133-028f-496a-a8fd-aa87dadfd278"
      unitRef="usd">28700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RleHRyZWdpb246YmI5ZmRiYjk5OWQ2NDk4MWJiMzAxYjNhMDYxOWE2MzFfNDk2Mw_f559e370-0b55-4016-a69a-f810bd0bc658">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfMi0xLTEtMS01MDI5OQ_fc0124fc-050b-431a-80e6-b0a1f962536d"
      unitRef="usd">28700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfMi0zLTEtMS01MDI5OQ_a831a988-2b85-49b2-b2fe-fe5bdb7dbac4"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfMy0xLTEtMS01MDI5OQ_efaebbb6-927c-48d5-86dc-9d3cc33a0a9a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfMy0zLTEtMS01MDI5OQ_6e9bfd71-8219-4e10-8cda-e514eadc5c6e"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfNC0xLTEtMS01MDI5OQ_53ded41a-27a9-468e-82c2-12b24916e377"
      unitRef="usd">-4700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfNC0zLTEtMS01MDI5OQ_a74de3a3-f418-4114-a87a-4229074d2401"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfNS0xLTEtMS01MDI5OQ_2b76242f-9b63-4d59-9910-a5e2443418cf"
      unitRef="usd">33400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjU2YTgyMGIwMzRjODQ0YmJiNWQyMzQ0ZTY1M2Y4Mjc0L3RhYmxlcmFuZ2U6NTZhODIwYjAzNGM4NDRiYmI1ZDIzNDRlNjUzZjgyNzRfNS0zLTEtMS01MDI5OQ_41d35dec-753f-4ae8-af39-4f76eef32a06"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RleHRyZWdpb246YmI5ZmRiYjk5OWQ2NDk4MWJiMzAxYjNhMDYxOWE2MzFfNDk3MA_9a23fd91-1839-47ef-b07f-2eb7ef072afc">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i60e8394722604655b91f21d472ddc55f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjk1M2I5Y2ZkMzg2ZDQyODVhZmY2MWEwMWIyZmU2MzU3L3RhYmxlcmFuZ2U6OTUzYjljZmQzODZkNDI4NWFmZjYxYTAxYjJmZTYzNTdfMy0xLTEtMS01MDI5OQ_38291e34-9a98-4879-9fff-692c52910dae"
      unitRef="usd">33400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6d10e11febe742e388c4185b0dfb5f67_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjk1M2I5Y2ZkMzg2ZDQyODVhZmY2MWEwMWIyZmU2MzU3L3RhYmxlcmFuZ2U6OTUzYjljZmQzODZkNDI4NWFmZjYxYTAxYjJmZTYzNTdfMy03LTEtMS01MDI5OQ_45bc3e15-ca8b-4519-86c3-18973f143cc3"
      unitRef="usd">36277000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i20f895ec0c394fb7a1b6962e0c4d6c9c_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOjk1M2I5Y2ZkMzg2ZDQyODVhZmY2MWEwMWIyZmU2MzU3L3RhYmxlcmFuZ2U6OTUzYjljZmQzODZkNDI4NWFmZjYxYTAxYjJmZTYzNTdfNC03LTEtMS01MDI5OQ_53512e12-c743-4cdf-97f8-73eb868684c5"
      unitRef="number">0.1083</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2c9af5aa7ede47a29b2eff96c883a5f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOmJiODdmYTM1OTAwZTQxZTdiMWIzNDFjMWZkMGNhYWVkL3RhYmxlcmFuZ2U6YmI4N2ZhMzU5MDBlNDFlN2IxYjM0MWMxZmQwY2FhZWRfMy0xLTEtMS01MDI5OQ_e46701f9-1504-44dc-86be-232fef0b55bb"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia1d611e598104338b6853034734ea3e6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOmJiODdmYTM1OTAwZTQxZTdiMWIzNDFjMWZkMGNhYWVkL3RhYmxlcmFuZ2U6YmI4N2ZhMzU5MDBlNDFlN2IxYjM0MWMxZmQwY2FhZWRfMy03LTEtMS01MDI5OQ_26cf04b7-466e-4569-b35d-a556a1b48dae"
      unitRef="usd">30935000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i65efdf8b544f497a9ccb4054da27c745_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85NC9mcmFnOmJiOWZkYmI5OTlkNjQ5ODFiYjMwMWIzYTA2MTlhNjMxL3RhYmxlOmJiODdmYTM1OTAwZTQxZTdiMWIzNDFjMWZkMGNhYWVkL3RhYmxlcmFuZ2U6YmI4N2ZhMzU5MDBlNDFlN2IxYjM0MWMxZmQwY2FhZWRfNC03LTEtMS01MDI5OQ_81512f05-803f-4b69-bdc0-12f130caad4e"
      unitRef="number">0.0604</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RleHRyZWdpb246MmRhMTlmZDhmZDg1NDYwYTgwZThjMTY0NjNjNjFiYjJfMTIwMw_ff1075c3-d07e-4acd-99d9-6f612c2b3962">Related Parties  &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#x2019; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also works with UPMC, one of its founding investors. The Company&#x2019;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:319.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RleHRyZWdpb246MmRhMTlmZDhmZDg1NDYwYTgwZThjMTY0NjNjNjFiYjJfMTIwNQ_d3682534-9100-47fb-81f0-468c699fdff3">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:319.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfMi0xLTEtMS01MDI5OQ_664d0093-0a87-4535-966c-cf6d60f7bd81"
      unitRef="usd">4191000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfMi0zLTEtMS01MDI5OQ_345136cd-f81e-41d9-a580-d1b694e83a59"
      unitRef="usd">2719000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfMy0xLTEtMS01MDI5OQ_573143f3-6e82-49ae-954a-123bc836d4ec"
      unitRef="usd">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfMy0zLTEtMS01MDI5OQ_95f42056-2655-4c6d-b1c3-906fb4022a78"
      unitRef="usd">15000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfNC0xLTEtMS01MDI5OQ_7d530405-4540-4c8a-821b-741c8dbc262d"
      unitRef="usd">5038000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfNC0zLTEtMS01MDI5OQ_b6f3c1cc-3efd-4b5d-8e4e-6edf61b6a462"
      unitRef="usd">4877000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfNy0xLTEtMS01MDI5OQ_afb286bc-e5c3-4366-ab1e-fda062fc1fa4"
      unitRef="usd">323000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfNy0zLTEtMS01MDI5OQ_fb28f054-3be8-441b-a610-4076aa5dccda"
      unitRef="usd">1967000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfOC0xLTEtMS01MDI5OQ_3ddb5718-97f2-4704-aa6d-418fddc0a59b"
      unitRef="usd">972000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfOC0zLTEtMS01MDI5OQ_712fb992-0695-421d-a69e-a9a597f3a53a"
      unitRef="usd">1120000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i117805e609ff46d0921c81fc5e9621b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfOS0xLTEtMS01MDI5OQ_28ddabf6-01e1-4643-b5ee-ca1f3e8775a9"
      unitRef="usd">0</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i2ddb18e6282b4f94a145adbb9bf20767_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjU2YTY3NDgyZDYxNzQ4ZDRiMGI3MzAyMDliY2Q4YTYwL3RhYmxlcmFuZ2U6NTZhNjc0ODJkNjE3NDhkNGIwYjczMDIwOWJjZDhhNjBfOS0zLTEtMS01MDI5OQ_90f8d58c-4a42-47ea-b10c-a0e9d8f6ceb4"
      unitRef="usd">734000</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ieea3e0212f024a4cb925e63dc3d63669_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfMi0xLTEtMS01MjkwNA_bfc2ead3-63f5-49aa-94ce-2770de7f59ee"
      unitRef="usd">42810000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ie9f2571b77c148eba97976fcd4e2bcf2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfMi0zLTEtMS01MjkwNA_e1f62b24-9e74-4645-a216-b5f32bf720b7"
      unitRef="usd">10368000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="id6a6977963ca49b586c2fcf93713da7b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfMi0xLTEtMS01MDI5OQ_2b223fed-000a-4e52-b23a-21b1af07bb2f"
      unitRef="usd">74874000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i7607171276ef40a8b48df3ab23ab716e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfMi0zLTEtMS01MDI5OQ_9deb5958-e36f-43e9-a334-7e1a2e6e32c9"
      unitRef="usd">25943000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i7b8255e04a5a48e69c16aa566c4151bc_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNS0xLTEtMS01MjkxMg_1a6f2eba-f6fb-414e-b1ed-41e64411cd2c"
      unitRef="usd">36684000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i0fac99680e9547b89140b689b06a4952_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNS0zLTEtMS01MjkxMg_52a9d51a-fff3-4723-89b1-530e520e8af9"
      unitRef="usd">606000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i47e7ef4ce9c44edb84ead5d40559f606_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNS0xLTEtMS01MDI5OQ_7ae79548-897e-4cd2-839b-8b9d8f7735c0"
      unitRef="usd">63145000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ib07e032acadb4ab4aeff1fa0375c42f0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNS0zLTEtMS01MDI5OQ_31e04fe2-be59-413f-947b-2c75708ceb4f"
      unitRef="usd">1099000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i4e2e5a89677e4a3694479947d5a435a8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNi0xLTEtMS01MjkxMg_2560f4e2-d5bc-4695-8eb0-51a69294d256"
      unitRef="usd">236000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i7295fdf6eb154c00992c57534af23daa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNi0zLTEtMS01MjkxMg_e9a8c4ee-30bd-49c5-9f8d-82067b026d39"
      unitRef="usd">81000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i5adf3c79b7f64f2aa0af3af80b0553b1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNi0xLTEtMS01MDI5OQ_5939fc19-75c3-4aa1-bbe0-44703288b3a7"
      unitRef="usd">302000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ib0464c31a82d4d04b71913910715453f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl85Ny9mcmFnOjJkYTE5ZmQ4ZmQ4NTQ2MGE4MGU4YzE2NDYzYzYxYmIyL3RhYmxlOjNiMWFjOGQ5ZGFkYTQyN2I5ZmU1ZTlhODNlMDlkZGMyL3RhYmxlcmFuZ2U6M2IxYWM4ZDlkYWRhNDI3YjlmZTVlOWE4M2UwOWRkYzJfNi0zLTEtMS01MDI5OQ_9dc25e64-bd19-4973-afcb-3160acc5c159"
      unitRef="usd">112000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90ZXh0cmVnaW9uOjRhNTE4YzAxMzY0NDQwNDlhZTc2OTQxNjZjYWM2M2ZjXzE0NjQ_7ac306aa-b076-491d-9185-4d8d79dd4b56">Repositioning and Other Changes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#x201c;Repositioning Plan&#x201d;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Costs Incurred through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90ZXh0cmVnaW9uOjRhNTE4YzAxMzY0NDQwNDlhZTc2OTQxNjZjYWM2M2ZjXzE0NjU_c38c5884-d9d7-4322-8df3-adb38c61219c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Costs Incurred through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i0d215ef7e89344058608e5d4f9363124_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzEtMS0xLTEtNTAyOTk_d707bd56-0b90-4555-bb92-c1025b9937bd"
      unitRef="usd">185000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i5f163348ee8540d09c2f6ee2944703fc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzEtMy0xLTEtNTI5NDQ_1f3c159d-a688-4e53-8d85-49f884bf44e4"
      unitRef="usd">76000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4e3a1495b5e04e5b850b1f4ce62855aa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzEtMy0xLTEtNTAyOTk_b3eede6e-7766-4e14-883b-11103e61d846"
      unitRef="usd">185000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i1caf080cfaca42c29144aff3c13b93b6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzItMS0xLTEtNTAyOTk_d6dc5ef1-9b01-4f91-b7c3-c2e1052063b2"
      unitRef="usd">2742000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="icc4a298cd056483f927ffa2a3469d4ee_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzItMy0xLTEtNTI5NDQ_92169361-78fa-44d6-a6e3-ae46e396c7d3"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2548e4d1f3694bce8967d2081c947aac_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzItMy0xLTEtNTAyOTk_5eb32a9e-e04f-4bba-a507-892ffb897ab2"
      unitRef="usd">2071000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i7b3b51310ab149b399238bbc8da2f487_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzMtMS0xLTEtNTAyOTk_eac7494c-9891-4d41-a747-c6888ddb1ed9"
      unitRef="usd">5666000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i1f99af9f1bbe4f909c3d4ea820bf365b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzMtMy0xLTEtNTI5NDQ_34d15161-cde9-4cdb-a999-72ad47b3330f"
      unitRef="usd">587000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i67189557a7ea47dfa0d97556d16c7c5a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzMtMy0xLTEtNTAyOTk_fe9e0a82-3b3b-416d-9cfe-76ade5f9a6ee"
      unitRef="usd">3787000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzQtMS0xLTEtNTAyOTk_8a6e2576-67c1-4565-b216-8102a27ec6ca"
      unitRef="usd">8593000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzQtMy0xLTEtNTI5NDQ_c3cc0a60-1b5a-4d5d-878e-0bb32b2b2919"
      unitRef="usd">663000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDAvZnJhZzo0YTUxOGMwMTM2NDQ0MDQ5YWU3Njk0MTY2Y2FjNjNmYy90YWJsZTo2MGU2YzgyMjJmZmU0NDRhYTVmODNkN2QzMjFjYzRiOS90YWJsZXJhbmdlOjYwZTZjODIyMmZmZTQ0NGFhNWY4M2Q3ZDMyMWNjNGI5XzQtMy0xLTEtNTAyOTk_28520f8d-afea-4bc1-af91-2dc020bbb843"
      unitRef="usd">6043000</us-gaap:RestructuringCharges>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzI5NjY_074b5994-ac19-47b0-a870-f95c6087fe63">Segment ReportingWe define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, provision for income taxes, depreciation and amortization expenses, adjusted to exclude gain on transfer of membership, loss on repayment of debt, net, gain from equity method investees, changes in fair value of contingent consideration, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain from discontinued operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from (provision for) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $(0.5)&#160;million loss on disposal of discontinued operations for the three and six months ended June 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzI0Mg_ea8ff5c0-1fc6-4886-888a-affa345b570f"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzI5NjI_d1066ebf-bd41-4171-8142-7d501c5f9a2d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29d5e516649a4eb1bd68a4ae83bd5e16_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtMS0xLTEtNTI5NTE_9efc4d84-5498-4996-bf75-3d69ad8dab7a"
      unitRef="usd">92796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i420c2960b8964c268e95e8eda2a47790_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtMy0xLTEtNTI5NTE_088bcd24-1b06-4b94-981d-d000541ff06d"
      unitRef="usd">227603000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f83964678a340d8a8a7893bffb76713_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtNS0xLTEtNTI5NTE_55863b14-3a78-4916-8158-bec29bb63965"
      unitRef="usd">-460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ad7b61e97de4695ab5cc762df1bab8d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtNy0xLTEtNTI5NTE_ad764486-a775-46ee-b618-4cc237f33dc0"
      unitRef="usd">319939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c4cc0b519ac4301afbf3a86f9d1a16f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtOS0xLTEtNTI5NTE_1fc23232-56bb-4863-9893-018b8551029b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzMtMTEtMS0xLTUyOTUx_99a26b99-75b4-46d1-af72-214a7ed3ceb0"
      unitRef="usd">319939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5fd05553c104209a219f91c15de897b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtMS0xLTEtNTI5NTE_0c50224a-da2b-4115-be42-209104d4986f"
      unitRef="usd">75323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e90bde16c38406cb0456caf29ecea2a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtMy0xLTEtNTI5NTE_b809e6dc-a227-4fb5-8ecb-bf810b7d39d0"
      unitRef="usd">147194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1fd13e0887f4184bc87321d513724b5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtNS0xLTEtNTI5NTE_d5558f61-051b-47d6-bffc-b8c821cefe9b"
      unitRef="usd">-460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43ace05961a24c8aad395abf32e9e34e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtNy0xLTEtNTI5NTE_29a24886-298a-4731-89ea-37a0852041d0"
      unitRef="usd">222057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia437c1047b404319a8f7f650e06e4e90_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtOS0xLTEtNTI5NTE_952135f7-eeef-43df-8857-d14e0b6afd3c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzYtMTEtMS0xLTUyOTUx_3e2ca088-e538-46e3-b59e-ab3b69044f08"
      unitRef="usd">222057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i29d5e516649a4eb1bd68a4ae83bd5e16_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEwLTEtMS0xLTUyOTUx_8febdcbf-ca08-45fe-afbf-e15d0ad865ff"
      unitRef="usd">15129000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i420c2960b8964c268e95e8eda2a47790_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEwLTMtMS0xLTUyOTUx_a48400dc-2f00-43ee-aff9-aac720bfa4a8"
      unitRef="usd">13492000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i2ad7b61e97de4695ab5cc762df1bab8d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEwLTUtMS0xLTUyOTUx_2d987c30-98c5-44f2-b47f-ee4bda19675f"
      unitRef="usd">28621000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i9c4cc0b519ac4301afbf3a86f9d1a16f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEwLTctMS0xLTUyOTUx_9fd9c01e-3e6b-492f-8769-edf45abdb44a"
      unitRef="usd">-6882000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEwLTktMS0xLTUyOTUx_a4096d23-a26a-4399-898e-12323b9c9d9c"
      unitRef="usd">21739000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ia5fd05553c104209a219f91c15de897b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEzLTEtMS0xLTUyOTUx_eda7b58a-8688-4de4-a41a-34682781e957"
      unitRef="usd">6531000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i7e90bde16c38406cb0456caf29ecea2a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEzLTMtMS0xLTUyOTUx_5ba4a561-8507-464b-b383-58df7ef8aa66"
      unitRef="usd">13597000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i43ace05961a24c8aad395abf32e9e34e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEzLTUtMS0xLTUyOTUx_05b678f6-e645-43b8-9e5f-66be286923ee"
      unitRef="usd">20128000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ia437c1047b404319a8f7f650e06e4e90_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEzLTctMS0xLTUyOTUx_2b4c03a4-e3fc-4097-b896-1ca9b2ba3bdd"
      unitRef="usd">-6782000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTozM2MxODExMDU1YzQ0NThlOTMxZjMxZGFjOTNkNDdhMC90YWJsZXJhbmdlOjMzYzE4MTEwNTVjNDQ1OGU5MzFmMzFkYWM5M2Q0N2EwXzEzLTktMS0xLTUyOTUx_be0e5b47-b08d-4a29-8870-7153f4d941e1"
      unitRef="usd">13346000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8546f2bf902a41be9774135aea47d11d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtMS0xLTEtNTAyOTk_3d96b1da-420f-461d-8384-779e76e9f484"
      unitRef="usd">200114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09d7524a42e2444db7f04130d8c7e586_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtMy0xLTEtNTAyOTk_c7d435ea-fab1-4a2d-b9ab-b7d874845804"
      unitRef="usd">417802000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c79847ac9a6406dbd571e7e8285c8ab_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtNS0xLTEtNTAyOTk_5691460b-bc2c-439e-993c-98c0a5310b0c"
      unitRef="usd">-920000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie88d244c079c44a6a96afafc4dd811c7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtNy0xLTEtNTAyOTk_0897a6e7-9ba3-448b-993f-abd496eb9e96"
      unitRef="usd">616996000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc490f2a102c40368f57f3b421851b0d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtOS0xLTEtNTAyOTk_bd0e378b-7846-423e-a0d3-d411bb8bad27"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzMtMTEtMS0xLTUwMjk5_2fbfe452-05ee-4c08-82b9-41febb8afe13"
      unitRef="usd">616996000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5fb402086e24b79a85a9f5d622bf485_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtMS0xLTEtNTAyOTk_2604bcb6-c17d-4a54-9e1c-86c363b4408b"
      unitRef="usd">160609000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34d9d012a2bb4aea8bee56c1bbb1747d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtMy0xLTEtNTAyOTk_cc0cf26c-c9fe-4012-9e87-c3104f2dc382"
      unitRef="usd">277417000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea87c5d05fc147deb58c839bf401c1ee_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtNS0xLTEtNTAyOTk_be621d1e-9ba5-4e31-b91a-0c243425899e"
      unitRef="usd">-898000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i371114cbc06e4f95811ba2a6fec0c8b1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtNy0xLTEtNTAyOTk_6a332264-9e1e-4a28-91f4-65444268be42"
      unitRef="usd">437128000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7734adf1b5e6413988815cac05b34700_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtOS0xLTEtNTAyOTk_7f8889b6-0f51-4d90-a754-40e4f3d3eab9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzYtMTEtMS0xLTUwMjk5_a0d9bd8c-8222-4ab2-982b-d629dbc8043b"
      unitRef="usd">437128000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i8546f2bf902a41be9774135aea47d11d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEwLTEtMS0xLTUwMjk5_16c5d46e-428b-4e73-9a94-8267f771bd6e"
      unitRef="usd">23346000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i09d7524a42e2444db7f04130d8c7e586_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEwLTMtMS0xLTUwMjk5_3c02fed6-8f01-4110-95ed-b47ed9099e01"
      unitRef="usd">35688000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ie88d244c079c44a6a96afafc4dd811c7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEwLTUtMS0xLTUwMjk5_50c8ca54-5495-4642-b18b-95dd668c4b2d"
      unitRef="usd">59034000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="idc490f2a102c40368f57f3b421851b0d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEwLTctMS0xLTUwMjk5_680393ed-3445-4f00-b98a-fcbbc8830688"
      unitRef="usd">-13040000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEwLTktMS0xLTUwMjk5_4320ab89-85af-4a1e-8e1a-4712d03cfb84"
      unitRef="usd">45994000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="if5fb402086e24b79a85a9f5d622bf485_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEzLTEtMS0xLTUwMjk5_06aedd4c-052f-460c-8be4-44e2d96f17ed"
      unitRef="usd">12473000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i34d9d012a2bb4aea8bee56c1bbb1747d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEzLTMtMS0xLTUwMjk5_436a96b1-5290-4a2a-b465-c6a4c7967954"
      unitRef="usd">29573000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i371114cbc06e4f95811ba2a6fec0c8b1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEzLTUtMS0xLTUwMjk5_522e913b-e882-4089-926b-3d3044d9fe79"
      unitRef="usd">42046000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i7734adf1b5e6413988815cac05b34700_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEzLTctMS0xLTUwMjk5_f7fff6e6-e223-4522-ab11-e4a1eb31d701"
      unitRef="usd">-13793000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZTowMWNjMWFmNmViMGE0MzYzOTMwNzFmMDc2OTZlZGQ4NS90YWJsZXJhbmdlOjAxY2MxYWY2ZWIwYTQzNjM5MzA3MWYwNzY5NmVkZDg1XzEzLTktMS0xLTUwMjk5_2fdca9bf-61a5-4147-af25-4b89f22f52c5"
      unitRef="usd">28253000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzI5NjQ_bb5b32d9-3412-459a-a73a-fc09e9a59c4a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from (provision for) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $(0.5)&#160;million loss on disposal of discontinued operations for the three and six months ended June 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzItMS0xLTEtNTMyMzk_cc213c14-3485-4229-9627-772858bfc410"
      unitRef="usd">-4588000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzItMy0xLTEtNTMyMzk_2e5a2638-28b7-4be9-bc89-849549bbd62f"
      unitRef="usd">-9107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzItMS0xLTEtNTAyOTk_35c29167-bfc8-431f-bc19-c021b9e5b3af"
      unitRef="usd">-9938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzItMy0xLTEtNTAyOTk_67c6aeb8-8768-492a-9be9-1099e3470074"
      unitRef="usd">-18914000</us-gaap:NetIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzQtMS0xLTEtNTMyMzE_2c7fd4da-bb62-4abb-9676-bf6e03061de5"
      unitRef="usd">223000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzQtMy0xLTEtNTMyMzE_7b510061-fa90-4fb2-820a-c4476c72997d"
      unitRef="usd">68000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzQtMS0xLTEtNTAyOTk_9ed4b197-f83e-4d92-815e-3fddd284bbf2"
      unitRef="usd">340000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzQtMy0xLTEtNTAyOTk_998de72e-3c0e-4f7d-b16e-3de00f34c7f5"
      unitRef="usd">191000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzUtMS0xLTEtNTMyMzQ_980c785f-3c41-445c-9809-39e58c413668"
      unitRef="usd">2148000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzUtMy0xLTEtNTMyMzQ_5026a581-73b2-4241-855f-42be1cae8d0f"
      unitRef="usd">6274000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzUtMS0xLTEtNTAyOTk_0c3d52c5-b7b9-45e7-ae6c-7dd6f31caff6"
      unitRef="usd">4389000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzUtMy0xLTEtNTAyOTk_401ee9f4-268f-4d3a-8c26-8fe27b390a55"
      unitRef="usd">12611000</us-gaap:InterestExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzYtMS0xLTEtNTMyMzk_66dd00e9-c04f-453c-95bc-22432f9a75f8"
      unitRef="usd">-184000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzYtMy0xLTEtNTMyMzk_7dd863b1-f5ca-44ce-bd61-52ed55a927b0"
      unitRef="usd">91000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzYtMS0xLTEtNTAyOTk_11c29d80-a1c8-45ea-b0cb-1a5b678a0b27"
      unitRef="usd">1018000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzYtMy0xLTEtNTAyOTk_63bb37ef-d4f8-488b-bbc7-7507776a72e0"
      unitRef="usd">702000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DepreciationAndAmortization
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzctMS0xLTEtNTMyMzk_0715d8c0-e7ba-4997-aa52-09573ea189ee"
      unitRef="usd">15112000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzctMy0xLTEtNTMyMzk_5a3fe96e-b7eb-4ef7-aec6-04003ac98363"
      unitRef="usd">14916000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzctMS0xLTEtNTAyOTk_7057ea20-56d8-4bf0-a52b-5caac8aae476"
      unitRef="usd">30218000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzctMy0xLTEtNTAyOTk_af4b36cb-861c-4abf-87ff-4f03ba71f03f"
      unitRef="usd">30103000</us-gaap:DepreciationAndAmortization>
    <evh:GainOnTransferOfMembership
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzgtMS0xLTEtNTMyMzk_3ecc4a78-5768-4e5e-816b-21e3be1e78db"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzgtMy0xLTEtNTMyMzk_427f193e-ecb5-4d44-9892-db3a842c6a53"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzgtMS0xLTEtNTAyOTk_1cd5fd02-bbbe-41c4-8831-3e3f4bdea02d"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzgtMy0xLTEtNTAyOTk_88fb5ad4-66d9-4259-b11e-0dfcfe101bcd"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzktMS0xLTEtNTMzMDA_fc041e4c-30b9-4996-8a3d-b8358cc94cfa"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzktMy0xLTEtNTMzMDA_9d0bd75b-408f-4b3c-8ccb-9216f002ceeb"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzktMS0xLTEtNTAyOTk_a54e5c91-07b7-409d-8b3e-9f16475d7d64"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzktMy0xLTEtNTAyOTk_35fcb3b2-7cba-43c6-bb2a-efcb8d3fe9c5"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEwLTEtMS0xLTUzMzM3_2902be53-35ef-48e4-8bc9-4f8875ecb8cb"
      unitRef="usd">1952000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEwLTMtMS0xLTUzMzM3_29a0ffc1-0f7a-4e23-a4fe-2883bb139a85"
      unitRef="usd">4879000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEwLTEtMS0xLTUwMjk5_01ffc85d-0b83-496b-8982-45c609240fed"
      unitRef="usd">2548000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEwLTMtMS0xLTUwMjk5_d6e4c085-c84a-45a2-8a48-8eafcfc03ffc"
      unitRef="usd">12662000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzExLTEtMS0xLTUzMzQw_9eb1296c-520e-41ee-9edf-9ee7b6a5522b"
      unitRef="usd">800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzExLTMtMS0xLTUzMzQw_5fe0f31e-f718-482e-90bf-f91947e14334"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzExLTEtMS0xLTUwMjk5_502c4160-241f-488e-b645-70172553b590"
      unitRef="usd">6878000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzExLTMtMS0xLTUwMjk5_b1609b05-9078-461b-be8e-b672e74b7a15"
      unitRef="usd">-594000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEyLTEtMS0xLTUzMzQw_e3ff43bc-1cb8-4632-a14f-a6870cb0bb5d"
      unitRef="usd">297000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEyLTMtMS0xLTUzMzQw_3835ff58-94e7-4018-ad0c-6e0b96383133"
      unitRef="usd">-18000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEyLTEtMS0xLTUwMjk5_d6d08bd6-be7b-4906-8d40-43287dba1e9b"
      unitRef="usd">475000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEyLTMtMS0xLTUwMjk5_dc7f8f85-3401-43eb-91de-d20545bf982a"
      unitRef="usd">-32000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEzLTEtMS0xLTUzMzQ3_8c581b50-ecaa-4d94-b788-93b791dcb713"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEzLTMtMS0xLTUzMzQ3_f0282e9f-1bbc-4acc-8953-f1e44371f63a"
      unitRef="usd">663000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEzLTEtMS0xLTUwMjk5_e32898b3-c64b-4a9e-ae87-10c5f3035c60"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzEzLTMtMS0xLTUwMjk5_7a4bcc22-d1b0-41e7-b778-afbea9073451"
      unitRef="usd">6043000</us-gaap:RestructuringCharges>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE0LTEtMS0xLTUzMzQ3_da1826a5-e533-41fb-b401-abbfcd67ab15"
      unitRef="usd">7012000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE0LTMtMS0xLTUzMzQ3_fe18f363-5800-4f31-b309-c2c6c0242af6"
      unitRef="usd">3653000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE0LTEtMS0xLTUwMjk5_e81e5e6b-e627-4104-9676-cda3cb4c03e8"
      unitRef="usd">12358000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE0LTMtMS0xLTUwMjk5_21f7146b-4e8d-4498-b5b8-08532aa6188f"
      unitRef="usd">7359000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <us-gaap:SeveranceCosts1
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE1LTEtMS0xLTUzMzQ3_e76ab99e-8f94-4f80-b333-2d962bb09b88"
      unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE1LTMtMS0xLTUzMzQ3_a9bd5e72-837d-4ad9-9a34-39311353b147"
      unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE1LTEtMS0xLTUwMjk5_67407af9-1b7d-4f9f-9ef6-1a3bf7f00e02"
      unitRef="usd">39000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE1LTMtMS0xLTUwMjk5_0a88f02e-ec2f-4013-bf18-aee079b2059c"
      unitRef="usd">52000</us-gaap:SeveranceCosts1>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE2LTEtMS0xLTUzMzUy_5bc923af-9d8b-40bc-a814-ae91c917d4ba"
      unitRef="usd">27000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE2LTMtMS0xLTUzMzUy_44cd82d5-8167-4538-b3d1-683eec37010a"
      unitRef="usd">196000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE2LTEtMS0xLTUwMjk5_132f0ca6-60dd-4acc-8dc2-0490e6bb611c"
      unitRef="usd">54000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE2LTMtMS0xLTUwMjk5_c15810be-18a4-4169-aa96-543654d3e20d"
      unitRef="usd">323000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:ShareholderAdvisoryServices
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE3LTEtMS0xLTUzMzUy_ba597674-1e3d-4581-b90f-a8daa7480398"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE3LTMtMS0xLTUzMzUy_037092ba-2735-4dd6-b99b-5a5cd1a7a697"
      unitRef="usd">1513000</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE3LTEtMS0xLTUwMjk5_a5c15502-8868-4b1b-886a-4e4386ebf414"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE3LTMtMS0xLTUwMjk5_aa55592e-b88d-41a6-8b82-4ba6f56ed09b"
      unitRef="usd">6513000</evh:ShareholderAdvisoryServices>
    <evh:TransactionCosts
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE4LTEtMS0xLTUzMzUy_ca6205d2-bd99-4248-b6ae-887ad513bc39"
      unitRef="usd">3421000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE4LTMtMS0xLTUzMzUy_20d106e9-8abd-4782-854e-20acafb9a5b5"
      unitRef="usd">76000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE4LTEtMS0xLTUwMjk5_c65e4f87-13cd-4898-85aa-48c652da2084"
      unitRef="usd">3878000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE4LTMtMS0xLTUwMjk5_dc73c194-1265-4cf5-8a65-41a4059c5068"
      unitRef="usd">2070000</evh:TransactionCosts>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE5LTEtMS0xLTUzMzUy_1c1e0b3c-dbce-4509-964c-393e4c99508b"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE5LTMtMS0xLTUzMzUy_679384c5-e3b3-404a-9eec-e971bd848e0e"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE5LTEtMS0xLTUwMjk5_23c4e756-3cd3-4239-a254-98f322b773e7"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzE5LTMtMS0xLTUwMjk5_31efc605-826b-4d74-9af9-2247336a237d"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzIwLTEtMS0xLTUzMjU5_bef75670-3ca8-4436-a25e-df532532d044"
      unitRef="usd">21739000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i45c832aa997d4d04a77ea03dbaa46436_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzIwLTMtMS0xLTUzMjU5_d5376237-36de-465d-a314-3ccb414cce00"
      unitRef="usd">13346000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzIwLTEtMS0xLTUwMjk5_d57d8e3f-d3bb-48e3-a135-80add91acf9f"
      unitRef="usd">45994000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90YWJsZToxOWY5YzQ1NjZhZDY0YjA0YjM2YTk2NDZkNTFjODYxYy90YWJsZXJhbmdlOjE5ZjljNDU2NmFkNjRiMDRiMzZhOTY0NmQ1MWM4NjFjXzIwLTMtMS0xLTUwMjk5_291b3509-71a1-45d1-93e1-c30a7ae4b1a8"
      unitRef="usd">28253000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i8946244240e648d0a726ae8260273c82_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzQ5NDc4MDIzMjc5OTE_26b2f69f-de74-4a2c-889b-a19ac36d8193"
      unitRef="usd">-500000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzQ5NDc4MDIzMjc5OTE_4aca174c-29b5-4e14-b905-9f48320d20fd"
      unitRef="usd">-500000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDMvZnJhZzozOTFmY2FiMzRlMzY0NjY4YTA3MGJlODRiMzIwNmM3MC90ZXh0cmVnaW9uOjM5MWZjYWIzNGUzNjQ2NjhhMDcwYmU4NGIzMjA2YzcwXzI3NTQ_ac040d59-83f7-4884-9009-ebda27bd6d7b"
      unitRef="usd">1900000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:InsuranceDisclosureTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90ZXh0cmVnaW9uOjc5ZTg5ZjZhYzYxYzRjZWZiNjJmNGRmMGNjYjgxNGNlXzQ2MjU_a1d698b3-cd50-4547-bb6c-63c7440d341a">Reserve for Claims and Performance-Based Arrangements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on reserves for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.&lt;/span&gt;&lt;/div&gt;</us-gaap:InsuranceDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90ZXh0cmVnaW9uOjc5ZTg5ZjZhYzYxYzRjZWZiNjJmNGRmMGNjYjgxNGNlXzQ2Mjc_5c403cf5-27af-4bb8-b813-93f880fc6e82">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to prior period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on reserves for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i5aa8d21a22a84ccabb1b42d66a503b1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtMS0xLTEtNTAyOTk_90a62be0-8b88-4706-9d3d-022fb6866e32"
      unitRef="usd">25618000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i744902b106114f94aaf10f93f79da793_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtMy0xLTEtNTAyOTk_572cb2e2-e9b5-4695-87a4-b2dad2e0af96"
      unitRef="usd">145676000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6ea08b719de041fc860ca2321a09f2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtNS0xLTEtNTAyOTk_800cafb5-cb7f-4887-abbe-1f6996b244ea"
      unitRef="usd">171294000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9ab714214aec4c62895368e7b5d77d47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtNy0xLTEtNTAyOTk_32ef35ac-4a75-46c9-b789-60c98c6a6af9"
      unitRef="usd">56295000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="idb91a25096ac488099c2f68651d8104a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtOS0xLTEtNTAyOTk_5d63823e-1fdd-4956-aa3a-cd2222024782"
      unitRef="usd">122532000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ic30a5e30d65042cc8f8a3f395110a09a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzMtMTEtMS0xLTUwMjk5_3211d48d-8a34-4f3e-8890-403dcc29ad66"
      unitRef="usd">178827000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtMS0xLTEtNTAyOTk_02aa8c8e-5a2b-491b-99b1-c83e8ce41144"
      unitRef="usd">0</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtMy0xLTEtNTAyOTk_6317709c-ff6a-495c-bd70-692819b787a6"
      unitRef="usd">246955000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtNS0xLTEtNTAyOTk_d92ea550-cec2-4f10-a24e-7c8275a46677"
      unitRef="usd">246955000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtNy0xLTEtNTAyOTk_ce67632c-208f-446a-9ee9-bdaa4dfd3b32"
      unitRef="usd">8669000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtOS0xLTEtNTAyOTk_ca043789-fe0e-4819-a447-f9500547d70f"
      unitRef="usd">219343000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzUtMTEtMS0xLTUwMjk5_5e50ef38-4949-4f8d-8168-2a4324b2a38c"
      unitRef="usd">228012000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtMS0xLTEtNTAyOTk_7eb1c7c5-7ffc-4f1f-9f05-636991190612"
      unitRef="usd">-10289000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtMy0xLTEtNTAyOTk_fc788ab4-8f46-4007-9d24-1f9aa938c631"
      unitRef="usd">32727000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtNS0xLTEtNTAyOTk_e325d42d-0e0e-44ae-9c5a-f318791324bb"
      unitRef="usd">22438000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtNy0xLTEtNTAyOTk_8cf6749c-991d-40ab-8177-554f94ea1af2"
      unitRef="usd">6293000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtOS0xLTEtNTAyOTk_3d4a8ec0-eadf-4fc8-b1b2-0328619b89e7"
      unitRef="usd">215000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzYtMTEtMS0xLTUwMjk5_bd1c2178-59a9-44cb-9f71-5e7161f7b63d"
      unitRef="usd">6508000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtMS0xLTEtNTAyOTk_3a5741e3-e1bc-428b-a076-5b412be5d071"
      unitRef="usd">-1239000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtMy0xLTEtNTAyOTk_815da677-4de7-4ef5-852c-6a3a07444646"
      unitRef="usd">202747000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtNS0xLTEtNTAyOTk_51a93bfc-3b9b-47e9-a5a6-c13efbe24211"
      unitRef="usd">201508000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtNy0xLTEtNTAyOTk_b2bc7a08-f80f-4cc2-ae50-002e4ce3ada8"
      unitRef="usd">20801000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtOS0xLTEtNTAyOTk_08d3f6a3-c569-4c48-8343-61fb9eb7ff68"
      unitRef="usd">73379000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzgtMTEtMS0xLTUwMjk5_68d662e4-0e61-4cf3-af36-275d217cc483"
      unitRef="usd">94180000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktMS0xLTEtNTAyOTk_d516ee40-4e7b-445b-a86d-3bde0caabd24"
      unitRef="usd">436000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktMy0xLTEtNTAyOTk_37839752-a333-484f-9106-8947df78c23b"
      unitRef="usd">100709000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktNS0xLTEtNTAyOTk_90b850a0-91b4-46d4-97f7-7ea1ca868132"
      unitRef="usd">101145000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktNy0xLTEtNTAyOTk_87acf920-bace-4ec5-86f1-62cf80b84b8e"
      unitRef="usd">20673000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktOS0xLTEtNTAyOTk_e415d08d-252e-4b84-870e-f35ba87fbdca"
      unitRef="usd">71392000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzktMTEtMS0xLTUwMjk5_27dad9ba-f824-449d-945c-741d9210d9d0"
      unitRef="usd">92065000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTEtMS0xLTUwMjk5_7a4719f1-f208-488f-9f40-d823a4908f8b"
      unitRef="usd">-9486000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTMtMS0xLTUwMjk5_c6f21202-d92d-47e2-9e5a-aff20dcb065b"
      unitRef="usd">-23774000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTUtMS0xLTUwMjk5_8293c40d-319d-4d07-99f6-3984b07538b7"
      unitRef="usd">-33260000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTctMS0xLTUwMjk5_7bcc252e-4b16-474f-87be-fddbc4449c32"
      unitRef="usd">-26512000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTktMS0xLTUwMjk5_c8086e80-189e-4af5-96b9-5d5a53a612c2"
      unitRef="usd">74787000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEwLTExLTEtMS01MDI5OQ_1b1482e3-e163-4071-ad1b-28b0b82085a2"
      unitRef="usd">48275000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i84587f740e7e43fb93a344871522bc54_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTEtMS0xLTUwMjk5_e7a2e5b4-f444-4462-93ae-d9aa1e9f8195"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i368910b9b5d242b085d5b039c87d2461_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTMtMS0xLTUwMjk5_13fb9760-bde2-4bbc-b9ba-949157a6e101"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTUtMS0xLTUwMjk5_341730e4-f96f-4188-86ed-127b62a54014"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i313903f297d04e91ba3039b43d058117_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTctMS0xLTUwMjk5_83c008fd-e9dc-4394-92e7-be2421c6d8e9"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="ice247f5d11034730aa4a605431fb5369_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTktMS0xLTUwMjk5_de14749c-c2f5-4c13-addd-c06135efcae3"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEyLTExLTEtMS01MDI5OQ_374b6177-2427-4b02-a011-45e4726d7950"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i31ec6c709d854ece8b361ce8b9f623c6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTEtMS0xLTUwMjk5_55bf0af2-6556-41d3-8ee6-0a737a62679b"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="icf7021225a1d4ebe992272c6b7a424f3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTMtMS0xLTUwMjk5_32cf63d5-d633-4616-a018-d91fa9c2713c"
      unitRef="usd">12074000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTUtMS0xLTUwMjk5_025cb042-2489-4f33-ac44-f4ebc4ecda37"
      unitRef="usd">12074000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="id929ac4578254f3a8ac5a00ef4adae72_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTctMS0xLTUwMjk5_25bc5c02-6267-4911-ae4d-b932beec99dd"
      unitRef="usd">-3721000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i47bf34c04d3d4427a895561238e93dfb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTktMS0xLTUwMjk5_bd581c09-08c0-488e-89b8-693b486ae594"
      unitRef="usd">-7282000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzEzLTExLTEtMS01MDI5OQ_c8a58054-36a9-40d2-bd41-9ed4da22acf4"
      unitRef="usd">-11003000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i31ec6c709d854ece8b361ce8b9f623c6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTEtMS0xLTUwMjk5_94583ad5-b329-49e2-a215-c86f9ff8c40c"
      unitRef="usd">16132000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="icf7021225a1d4ebe992272c6b7a424f3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTMtMS0xLTUwMjk5_4f440c04-4cba-4f8e-bc30-115d6b6aef1e"
      unitRef="usd">109828000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ibdd1ae63ddb547ab8ce350f06563934d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTUtMS0xLTUwMjk5_9e1997c5-8d51-4faa-89c2-2ae1d2217893"
      unitRef="usd">125960000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="id929ac4578254f3a8ac5a00ef4adae72_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTctMS0xLTUwMjk5_e2eb7c74-e189-4531-ae60-71b43b9dcf6b"
      unitRef="usd">33504000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i47bf34c04d3d4427a895561238e93dfb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTktMS0xLTUwMjk5_5b4d5c61-cb4a-4c2d-8ec0-11ffc90f0f04"
      unitRef="usd">204601000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iee92b0aa2a5443b780d4e4afe53d9d25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDYvZnJhZzo3OWU4OWY2YWM2MWM0Y2VmYjYyZjRkZjBjY2I4MTRjZS90YWJsZTpiNDBjMzkyYzk2ZTY0MTQ3YThiNDc4OTA2YjM2MGJkNy90YWJsZXJhbmdlOmI0MGMzOTJjOTZlNjQxNDdhOGI0Nzg5MDZiMzYwYmQ3XzE0LTExLTEtMS01MDI5OQ_74a5e3b0-1d9f-421f-baa7-28c01285cd5f"
      unitRef="usd">238105000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90ZXh0cmVnaW9uOmQyMDViODgzZjRkYTQxYTE4ZDM3Y2JhNjVhN2I4YTdjXzEyOQ_51cf746e-bcdc-49be-aa48-0d830f8af7d0">Supplemental Cash Flow Information &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90ZXh0cmVnaW9uOmQyMDViODgzZjRkYTQxYTE4ZDM3Y2JhNjVhN2I4YTdjXzEzNA_ba53b09b-e755-45fc-bcfd-21e3b7fd8d57">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzMtMS0xLTEtNTAyOTk_0d463669-6025-47ca-b28c-6b59dcc736b1"
      unitRef="usd">1118000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzMtMy0xLTEtNTAyOTk_08a99189-6f4a-4b95-a39d-fc91164baabb"
      unitRef="usd">668000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OperatingLeasePayments
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzUtMS0xLTEtNTAyOTk_c0e86b98-ccc2-4774-b784-b9884afdd742"
      unitRef="usd">7010000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzUtMy0xLTEtNTAyOTk_91a8818d-5931-4119-8c42-fcecae50e1b8"
      unitRef="usd">6622000</us-gaap:OperatingLeasePayments>
    <evh:RightOfUseAssetAcquiredAndDisposedOf
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzYtMS0xLTEtNTAyOTk_5567e95a-17a8-4c51-b75e-90d8286adb1a"
      unitRef="usd">-4153000</evh:RightOfUseAssetAcquiredAndDisposedOf>
    <evh:RightOfUseAssetAcquiredAndDisposedOf
      contextRef="if87d2c789e34470eb537d3a37ac29705_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8xMDkvZnJhZzpkMjA1Yjg4M2Y0ZGE0MWExOGQzN2NiYTY1YTdiOGE3Yy90YWJsZTo4YTRmYzFiM2EyM2U0MmIxYmRjN2ZlNGJjMzFkYTM0YS90YWJsZXJhbmdlOjhhNGZjMWIzYTIzZTQyYjFiZGM3ZmU0YmMzMWRhMzRhXzYtMy0xLTEtNTAyOTk_f8f888d7-9198-4389-805f-1695db18fa87"
      unitRef="usd">2157000</evh:RightOfUseAssetAcquiredAndDisposedOf>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzUz_b8ab9334-4198-44aa-8e62-13b31dba9cd2">Subsequent Events&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of  IPG&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 24, 2022, the Company, Evolent Health LLC, and Endzone Merger Sub, Inc, entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) with TPG Growth Iceman Parent, Inc., and TPG Growth V Iceman, L.P. to acquire Implantable Provider Group, Inc. (&#x201c;IPG&#x201d;) for $250.0 million in cash and $125.0&#160;million in Class A Common Stock of the Company, together with a potential earnout of up to $87.0&#160;million  payable in in cash and shares of Class A Common Stock of the Company in 2023. On August 1, 2022, the transactions contemplated by the Merger Agreement were consummated and the Company issued 3.7&#160;million shares of Class A Common Stock in connection therewith. IPG will report into Evolent&#x2019;s specialty care management offering, New Century Health, and will be consolidated into the Company&#x2019;s Clinical Solutions segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ares Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2022 (the &#x201c;Closing Date&#x201d;), the Company entered into a Credit Agreement, by and among the Company, Evolent Health LLC (&#x201c;Evolent&#x201d;), Endzone Merger Sub, Inc. (&#x201c;Endzone&#x201d; or &#x201c;Initial Borrower&#x201d;), which upon consummation of the transactions contemplated by the Merger Agreement will be merged with and into TPG Growth Iceman Parent, Inc., Implantable Provider Group, Inc. (&#x201c;Implantable&#x201d;, collectively with Evolent, Endzone and TPG Growth Iceman Parent, the &#x201c;Borrowers&#x201d; and each a &#x201c;Borrower&#x201d;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, Ares Capital Corporation, as administrative agent, and ACF Finco I LP, as collateral agent and as revolver agent (the &#x201c;2022 Credit Agreement&#x201d;), pursuant to which the lenders agreed to extend credit to the Borrowers in the form of (i) an initial term loan in the aggregate principal amount of $175.0&#160;million (the &#x201c;Initial Term Loan Facility&#x201d;) and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million and a borrowing base (the &#x201c;Revolving Facility&#x201d; and, together with the Initial Term Loan Facility, the &#x201c;2022 Credit Facilities&#x201d;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the Initial Term Loan Facility on August 1, 2022 (the &#x201c;Initial Term Loan&#x201d;), and also borrowed $50.0&#160;million under the Revolving Facility on the Closing Date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2022 Credit Agreement, on August 1, 2022, the Company entered into a Security Agreement, by and among the Company, the Borrowers, the other guarantors and the collateral agent for the benefit of the secured parties and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Proceeds.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The proceeds of the Initial Term Loan may be used to fund ongoing working capital needs and other growth capital expenditure investments, and to finance the transactions contemplated by the Merger Agreement and fund fees and expenses incurred in connection therewith. The proceeds of the Revolving Facility may be used to finance the transactions contemplated by the Merger Agreement and to pay fees and expenses incurred in connection therewith on the Closing Date and thereafter to fund acquisitions, ongoing working capital needs and other growth capital investments and to pay fees and expenses in connection therewith.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturity.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Initial Term Loan and loans under the Revolving Facility will mature on the date that is the earliest of (a) August 1, 2027, (b) the date on which all amounts outstanding under the 2022 Credit Agreement have been declared or have automatically become due and payable under the terms of the 2022 Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the 2022 Credit Agreement) unless certain liquidity conditions are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest and Fees.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The interest rate for each loan under the 2022 Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the 2022 Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;base rate plus 2.50%. A commitment fee of (a) 2.00% per annum of the aggregate amount of the commitments in respect of the Term Loan Facility as of the Closing Date and (b) 2.00% of the aggregate amount of the commitments in respect of the Revolving Facility as of the Closing Date is payable by the Borrowers quarterly in arrears.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepayment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Amounts outstanding under the Credit Facility may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 3.00% of the principal amount so prepaid after the Closing Date but prior to the first anniversary of the Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the Closing Date but prior to the third anniversary of the Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Guarantees and Collateral.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The 2022 Credit Facilities are guaranteed by the Company and the Company&#x2019;s domestic subsidiaries, subject to certain exceptions. The 2022 Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Covenants and Other Provisions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The 2022 Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum liquidity test commencing upon closing of the 2022 Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending September 30, 2022. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the 2022 Credit Facilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i748aee67f29648e5bcea7fa5140a470e_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQ5NDc4MDIzMzYwOTY_47aad6d6-eb26-453f-8827-6c3e333eab88"
      unitRef="usd">250000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i748aee67f29648e5bcea7fa5140a470e_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQ5NDc4MDIzMzYxMTg_087413c0-2fae-4444-a8cf-56c49a786153"
      unitRef="usd">125000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i748aee67f29648e5bcea7fa5140a470e_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ4OTIxMjQ_b157682f-c1f6-42d8-87fd-834c3dae9eb0"
      unitRef="usd">87000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ie583be11220d441c9171d7d8b813691e_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ4OTQ0Nzg_5a9a0f6f-ae9e-4391-b109-5f695d5b1bfa"
      unitRef="shares">3700000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i26ac2d191e26480fa87349b7a8290bde_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ4OTIxMzk_ba610eab-06b3-4d8d-bb7d-5d224fe56aef"
      unitRef="usd">175000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0b9cc6fdb0d444239ea5b97cef38f068_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDc3OTQ_ac346b14-8db5-44e8-9494-920a3c78b7b4"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0b9cc6fdb0d444239ea5b97cef38f068_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDc4MjM_ac346b14-8db5-44e8-9494-920a3c78b7b4"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0b9cc6fdb0d444239ea5b97cef38f068_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ5MjEyMzY_534a2546-dcb4-49f7-a074-a201236f7ac8"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i244a3a3fba544622b797356979f8025f_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ5MjEyNTE_c01588a2-46d3-42e1-b80d-677c1e2be780"
      unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity
      contextRef="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ5MjE0ODE_10328e97-ed3e-4a65-928c-ed23f66685ea"
      unitRef="day">91</evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i47af930ce9a049169a33fecd6da9992c_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDc4Mzg_49cbac04-b86d-4492-b13a-7b64cfab70a5"
      unitRef="number">0.0550</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2065d4ade06445edb3d844c8ae917420_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3MDU_8d9c3259-5a62-4955-ae88-2e7a923cf760"
      unitRef="number">0.0450</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i151d150fd9d24075af69e985884cae3a_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDc5MTE_c9039cfc-e6ce-4d1b-af98-11ed44802559"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id5ea489e80dc4ac28fa3620d03b1c6d0_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzMyOTg1MzQ5MjE0NzQ_b7174475-b5c7-484b-8d5c-0052442c94a3"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i0379117a2c6c4cab9b19860640687c97_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3MTI_7270dbb6-6732-4be0-845c-8ecc6d0112e1"
      unitRef="number">0.0200</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i244a3a3fba544622b797356979f8025f_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3MjM_49af092f-1e9c-461a-bf4a-855a21e5b1b2"
      unitRef="number">0.0200</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent
      contextRef="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3MzE_3679774c-631f-491f-b05c-db8aa48f52c7"
      unitRef="number">0.0300</evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent
      contextRef="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3Mzk_e441107d-1b1d-4beb-af36-777c66d378b4"
      unitRef="number">0.0200</evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent
      contextRef="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3NDc_2787fc96-f919-4cb0-8ffb-bf2037ce4912"
      unitRef="number">0.0100</evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent
      contextRef="if20ec831579b44b7aef9c74422893d4f_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNTYvZnJhZzphMWQwZTU3Y2Y5MDg0MWVlYmU1MDVjMTYzOGQxZTkwYi90ZXh0cmVnaW9uOmExZDBlNTdjZjkwODQxZWViZTUwNWMxNjM4ZDFlOTBiXzQzOTgwNDY1NDg3NTU_d7f0219a-36a3-4e62-84d6-2ee496c3074d"
      unitRef="number">0.0000</evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMS0xLTEtNTAyOTk_c3daba8c-5415-4626-a6f0-894377885a08"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMS0xLTEtNTAyOTk_c3daba8c-5415-4626-a6f0-894377885a08"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0xLTEtMS01MDI5OQ_97a656e4-10e5-42a1-b495-b5cdd1969fea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0xLTEtMS01MDI5OQ_97a656e4-10e5-42a1-b495-b5cdd1969fea"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMS0xLTEtNTAyOTk_c73fb9ae-1251-4539-9157-05f9e988f6bd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMS0xLTEtNTAyOTk_c73fb9ae-1251-4539-9157-05f9e988f6bd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMy0xLTEtNTAyOTk_21824ee8-66f2-4feb-81be-27e21a353033"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMy0xLTEtNTAyOTk_21824ee8-66f2-4feb-81be-27e21a353033"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0xLTEtMS01MDI5OQ_6ff647ab-fc7f-4b9f-8ba2-6da66d240d2d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0xLTEtMS01MDI5OQ_6ff647ab-fc7f-4b9f-8ba2-6da66d240d2d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMS0xLTEtNTAyOTk_6e579c51-776c-481d-b0d7-7151719b7e28"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMS0xLTEtNTAyOTk_6e579c51-776c-481d-b0d7-7151719b7e28"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMy0xLTEtNTAyOTk_78b7293f-57e3-44f6-9cd6-cab6a1c2b4dc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMy0xLTEtNTAyOTk_78b7293f-57e3-44f6-9cd6-cab6a1c2b4dc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0zLTEtMS01MDI5OQ_e9cfb95b-d053-4a12-b35e-ceeda4fe4188"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0zLTEtMS01MDI5OQ_e9cfb95b-d053-4a12-b35e-ceeda4fe4188"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMy0xLTEtNTAyOTk_e331c0b9-e116-4212-87f0-3fbd284d7232"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMy0xLTEtNTAyOTk_e331c0b9-e116-4212-87f0-3fbd284d7232"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMy0xLTEtNTAyOTk_9d97e8d6-10c5-497f-8469-fdd1ffdcf538"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMy0xLTEtNTAyOTk_9d97e8d6-10c5-497f-8469-fdd1ffdcf538"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMS0xLTEtNTAyOTk_e7fa3d27-9397-4ab1-bd1a-cfa9c7e74f93"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMS0xLTEtNTAyOTk_e7fa3d27-9397-4ab1-bd1a-cfa9c7e74f93"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0zLTEtMS01MDI5OQ_70fe2f65-5e3f-42d1-9054-6bf2243f19a2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0zLTEtMS01MDI5OQ_70fe2f65-5e3f-42d1-9054-6bf2243f19a2"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 18 for amounts attributable to related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMS0xLTEtNTAyOTk_c3daba8c-5415-4626-a6f0-894377885a08"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0xLTEtMS01MDI5OQ_97a656e4-10e5-42a1-b495-b5cdd1969fea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMS0xLTEtNTAyOTk_c73fb9ae-1251-4539-9157-05f9e988f6bd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMTItMy0xLTEtNTAyOTk_21824ee8-66f2-4feb-81be-27e21a353033"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0xLTEtMS01MDI5OQ_6ff647ab-fc7f-4b9f-8ba2-6da66d240d2d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMS0xLTEtNTAyOTk_6e579c51-776c-481d-b0d7-7151719b7e28"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjAtMy0xLTEtNTAyOTk_78b7293f-57e3-44f6-9cd6-cab6a1c2b4dc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNS0zLTEtMS01MDI5OQ_e9cfb95b-d053-4a12-b35e-ceeda4fe4188"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjUtMy0xLTEtNTAyOTk_e331c0b9-e116-4212-87f0-3fbd284d7232"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMy0xLTEtNTAyOTk_9d97e8d6-10c5-497f-8469-fdd1ffdcf538"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfMjEtMS0xLTEtNTAyOTk_e7fa3d27-9397-4ab1-bd1a-cfa9c7e74f93"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RhYmxlOmVhYzQ0OTY5ZGI2NzQzNTZiYmJiNjE4YWRiZmE1MGZhL3RhYmxlcmFuZ2U6ZWFjNDQ5NjlkYjY3NDM1NmJiYmI2MThhZGJmYTUwZmFfNi0zLTEtMS01MDI5OQ_70fe2f65-5e3f-42d1-9054-6bf2243f19a2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yNS9mcmFnOjU0YjI2YWE1ZjkzZjRjMzg4MGEwYjFlODQzMTM3NjY4L3RleHRyZWdpb246NTRiMjZhYTVmOTNmNGMzODgwYTBiMWU4NDMxMzc2NjhfMTkw_20a01a91-693f-4ee5-9d77-7b843c276087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTAyOTk_cc81acb2-9163-4391-91dc-f0317c70e013"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTAyOTk_cc81acb2-9163-4391-91dc-f0317c70e013"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MDI5OQ_cc81acb2-9163-4391-91dc-f0317c70e013"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MDI5OQ_cc81acb2-9163-4391-91dc-f0317c70e013"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MjM2NA_49497634-fa51-4fa0-8ab4-f53f91f2fa50"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MjM2NA_49497634-fa51-4fa0-8ab4-f53f91f2fa50"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MDI5OQ_6dccf1fb-174b-4581-aaea-f9ea25f1d932"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MDI5OQ_6dccf1fb-174b-4581-aaea-f9ea25f1d932"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTA2NTk_49497634-fa51-4fa0-8ab4-f53f91f2fa50"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTA2NTk_49497634-fa51-4fa0-8ab4-f53f91f2fa50"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MjM2NA_d0078107-c79a-4908-a96b-fcb12333a564"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MjM2NA_d0078107-c79a-4908-a96b-fcb12333a564"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTAyOTk_6dccf1fb-174b-4581-aaea-f9ea25f1d932"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTAyOTk_6dccf1fb-174b-4581-aaea-f9ea25f1d932"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTA2NTk_d0078107-c79a-4908-a96b-fcb12333a564"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTA2NTk_d0078107-c79a-4908-a96b-fcb12333a564"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes $(0.5)&#160;million loss on disposal for the three and six months ended June 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021, respectively</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTAyOTk_cc81acb2-9163-4391-91dc-f0317c70e013"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MDI5OQ_cc81acb2-9163-4391-91dc-f0317c70e013"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0zLTEtMS01MjM2NA_49497634-fa51-4fa0-8ab4-f53f91f2fa50"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MDI5OQ_6dccf1fb-174b-4581-aaea-f9ea25f1d932"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMy0xLTEtNTA2NTk_49497634-fa51-4fa0-8ab4-f53f91f2fa50"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl84Mi9mcmFnOjZkNzNjOGI4ZTVkYTQ5NmFiNmIwOTRkZWEyMDU4YzQ2L3RhYmxlOjA1ZGUyNjcwMzQ0ZjRmNDU4MGQ4ZDMxMTU4YmY1OTM3L3RhYmxlcmFuZ2U6MDVkZTI2NzAzNDRmNGY0NTgwZDhkMzExNThiZjU5MzdfMy0xLTEtMS01MjM2NA_d0078107-c79a-4908-a96b-fcb12333a564"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTAyOTk_6dccf1fb-174b-4581-aaea-f9ea25f1d932"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMjAtMS0xLTEtNTA2NTk_d0078107-c79a-4908-a96b-fcb12333a564"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzIy_adcdf782-7871-4aaa-9d7d-15e0d6127b2f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMy0xLTEtNTAyOTk_c7a5e83c-5f21-49c0-b45f-eebb0c4d690d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMy0xLTEtNTAyOTk_c7a5e83c-5f21-49c0-b45f-eebb0c4d690d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMy0xLTEtNTAyOTk_5c760221-6054-44a2-b77c-2d92546fb78d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMy0xLTEtNTAyOTk_5c760221-6054-44a2-b77c-2d92546fb78d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMS0xLTEtNTAyOTk_4c1972bb-dfd5-4f56-9c73-e15c8c00e245"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMS0xLTEtNTAyOTk_4c1972bb-dfd5-4f56-9c73-e15c8c00e245"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMS0xLTEtNTAyOTk_ee292a9f-87ae-4203-bf77-93525b8dfbc2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMS0xLTEtNTAyOTk_ee292a9f-87ae-4203-bf77-93525b8dfbc2"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RleHRyZWdpb246MzJlOTdlODQ4YmVmNDkzMjg4ZWRlY2QzODFiMGE4ZWRfNTcx_567b7399-c20a-4925-8240-cbdd77cce4ce" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RleHRyZWdpb246MzJlOTdlODQ4YmVmNDkzMjg4ZWRlY2QzODFiMGE4ZWRfNTcx_567b7399-c20a-4925-8240-cbdd77cce4ce" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the six months ended June 30, 2021. See Note 5.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMy0xLTEtNTAyOTk_c7a5e83c-5f21-49c0-b45f-eebb0c4d690d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RleHRyZWdpb246MzJlOTdlODQ4YmVmNDkzMjg4ZWRlY2QzODFiMGE4ZWRfNTcx_567b7399-c20a-4925-8240-cbdd77cce4ce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMy0xLTEtNTAyOTk_5c760221-6054-44a2-b77c-2d92546fb78d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RleHRyZWdpb246MzJlOTdlODQ4YmVmNDkzMjg4ZWRlY2QzODFiMGE4ZWRfNTcx_567b7399-c20a-4925-8240-cbdd77cce4ce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDgtMS0xLTEtNTAyOTk_4c1972bb-dfd5-4f56-9c73-e15c8c00e245"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RleHRyZWdpb246MzJlOTdlODQ4YmVmNDkzMjg4ZWRlY2QzODFiMGE4ZWRfNTcx_567b7399-c20a-4925-8240-cbdd77cce4ce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RhYmxlOjExMzQ0NTkxYmRiNDQ3MDk4Mjc5YzFmZmU3OTU2OTBhL3RhYmxlcmFuZ2U6MTEzNDQ1OTFiZGI0NDcwOTgyNzljMWZmZTc5NTY5MGFfNDktMS0xLTEtNTAyOTk_ee292a9f-87ae-4203-bf77-93525b8dfbc2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8zNC9mcmFnOjMyZTk3ZTg0OGJlZjQ5MzI4OGVkZWNkMzgxYjBhOGVkL3RleHRyZWdpb246MzJlOTdlODQ4YmVmNDkzMjg4ZWRlY2QzODFiMGE4ZWRfNTcx_567b7399-c20a-4925-8240-cbdd77cce4ce"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDU4OA_55975170-d5a0-4043-94f4-be240ba735b5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDU4OA_55975170-d5a0-4043-94f4-be240ba735b5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDI5OQ_3d2a993f-44b2-4115-aa5e-34b7dcf52020"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDI5OQ_3d2a993f-44b2-4115-aa5e-34b7dcf52020"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDYwNA_1988702f-171f-41b1-85e9-cb63feec4a20"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDYwNA_1988702f-171f-41b1-85e9-cb63feec4a20"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDI5OQ_85fe62ba-44a3-4785-b828-b469eeda2fdb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDI5OQ_85fe62ba-44a3-4785-b828-b469eeda2fdb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDU4OA_1a89fd1b-74de-463e-a1e5-2355d32025e7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDU4OA_1a89fd1b-74de-463e-a1e5-2355d32025e7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDI5OQ_17b92439-90b9-43f1-91f1-6f1c765fb21a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDI5OQ_17b92439-90b9-43f1-91f1-6f1c765fb21a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDI5OQ_93cc4c54-276c-44e8-94c1-f48e1cb760c6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDI5OQ_93cc4c54-276c-44e8-94c1-f48e1cb760c6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDI5OQ_5c9aeeb5-648f-4616-8c31-69a18c6f0408"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDI5OQ_5c9aeeb5-648f-4616-8c31-69a18c6f0408"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDU5Ng_ac682693-add5-4a42-9252-82d4e320ee74"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDU5Ng_ac682693-add5-4a42-9252-82d4e320ee74"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDI5OQ_69277f2f-30d6-41c3-bcac-5fb7817d7d63"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDI5OQ_69277f2f-30d6-41c3-bcac-5fb7817d7d63"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDU5Ng_911a2c47-3850-4275-81ec-10373623a70c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDU5Ng_911a2c47-3850-4275-81ec-10373623a70c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDYwNA_d025d75a-23ed-4fd9-803c-6e9eda31fa44"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDYwNA_d025d75a-23ed-4fd9-803c-6e9eda31fa44"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDU4OA_55975170-d5a0-4043-94f4-be240ba735b5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDI5OQ_3d2a993f-44b2-4115-aa5e-34b7dcf52020"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDYwNA_1988702f-171f-41b1-85e9-cb63feec4a20"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0xLTEtMS01MDI5OQ_85fe62ba-44a3-4785-b828-b469eeda2fdb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDU4OA_1a89fd1b-74de-463e-a1e5-2355d32025e7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDI5OQ_17b92439-90b9-43f1-91f1-6f1c765fb21a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDI5OQ_93cc4c54-276c-44e8-94c1-f48e1cb760c6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0zLTEtMS01MDI5OQ_5c9aeeb5-648f-4616-8c31-69a18c6f0408"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0zLTEtMS01MDU5Ng_ac682693-add5-4a42-9252-82d4e320ee74"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfMi0xLTEtMS01MDI5OQ_69277f2f-30d6-41c3-bcac-5fb7817d7d63"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNS0xLTEtMS01MDU5Ng_911a2c47-3850-4275-81ec-10373623a70c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RhYmxlOjNiZGVjM2Q4YTIwMzQzNTRiYjNmYWUzMWNjZDk4MjcxL3RhYmxlcmFuZ2U6M2JkZWMzZDhhMjAzNDM1NGJiM2ZhZTMxY2NkOTgyNzFfNi0zLTEtMS01MDYwNA_d025d75a-23ed-4fd9-803c-6e9eda31fa44"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFlYzRkOWI1MjMzZjRhYTVhN2Y1MzUzYzQwOGZhZGQyL3NlYzoxZWM0ZDliNTIzM2Y0YWE1YTdmNTM1M2M0MDhmYWRkMl8yOC9mcmFnOmYwMTVmOTA2Yjc5MDQ5MDA4NDQ2NGQ4YzY3NzhmNWI0L3RleHRyZWdpb246ZjAxNWY5MDZiNzkwNDkwMDg0NDY0ZDhjNjc3OGY1YjRfMzI1_8d97a609-720d-4226-b055-8a1ad75f6b9a"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>119
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M -]O!?12?Z$></AOA]7_ %!+ P04    " !G@ -50J-^DKH"  !;!P  &
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M=-8OO]$US5<4Z-8G?</O&!RRII%3-Q)+U?K2Q+YO^N?C]?9@J#!"B&&[N[!
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M /CWCP4/GO9"/&#SRY++_P%02P,$%     @ 9X #5=*(.]FQ @  #P<  !@
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M-G>TZN?"\$4B4<4O;*I<QX(H5UJD%1@K2!DO1_)<Z; #0)[] +<"N*\%M"I
MZR6@?0#0K@"%U';92J&#3S3Q.E)L0)IL9#.30LP"C>TS;HX]U!*_,L1IKS\>
MA>/[@=^;!3Z$,QR&P6@6PO@6QI-@VIL-, %Z(Q_ZX^%D&MP%HW#P&,!@A'$
MI_?C,#R#TPF1E.L5U2PBR1F<PT/HP^G)&9P XS!D28*'K#JVQI+-QG94E7=3
MEN<>**\%0X&\"@(>TW@/OG\<?WD$;Z-4M5[N5J\;]RCAUYPWH.5\ -=QW7WU
M_!_<?SV\>:2;5GWZK8*O=8!OP".14@@UT13OLH;OO;G2$B_CCWUG59*U]Y,9
M@[I6&8EHUT('4E2NJ>6]?]>\=#[O$^HMR?PW(OM+Q'8M8OL8N_<%S170PF*F
M,J%( F)AYA'^\1C/:0SHT9+H0Q>@)+\JR(U)K[USIW'1L=>[8KTFR?\WJ=FX
MJG/*WNP=JTBI7!:6JR 2.=?E+:A7:U?O%6;V8KV/;E^:\Q^:\JD8$KED7$%"
M%TCI-#ZB]<G2?LM BZPPI+G0:&_%=(4O%I4F ;\OA-#;P&Q0OX'>;U!+ P04
M    " !G@ -51X*[HJ$-  #XG@  &    'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;,6=;W.;.A;&OPKCO;-[.]/4(/[8W$TRD\8@8'K;;M+NSLZ=?4%M$K.U
M(1=PTW[[%8X;@G0BF_1)]TUB)^AW#O@YLLPCR<>W9?6Y7F998WQ=KXKZ9+1L
MFIO?QN-ZOLS6:?VJO,D*\9^KLEJGC7A:78_KFRI+%]M&Z]68F:8W7J=Y,3H]
MWO[M?75Z7&Z:55YD[RNCWJS7:?7M=;8J;T]&UNC['R[RZV73_F%\>GR37F>7
M6?/QYGTEGHWO*8M\G15U7A9&E5V=C,ZLWQ+7;1MLC_AGGMW6#QX;[:E\*LO/
M[9-X<3(RVXRR539O6D0J?GW)SK/5JB6)//[<04?W,=N&#Q]_IX?;DQ<G\RFM
ML_-R]:]\T2Q/1M.1L<BNTLVJN2AOHVQW0ML$Y^6JWOXT;G?'FB-COJF;<KUK
M+#)8Y\7=[_3K[D(\:&![CS1@NP9,:N ^%L'>-;"E!I;]2 -GU\"1&K#)(PW<
M70-7:C!YK(&W:^!)#9S'3GJR:S"1&SQVTM-=@ZG4X-'7P=\U\.6KY#[VPIG?
M7SESJZ"[EWRKEUG:I*?'57EK5.WQ@M<^V(INVU[()"_:^KAL*O'?7+1K3L_?
MO;U\]R:>G7T(9L;E!_'K]^#MATOC76B<1V=O>7!IQ&^-R^CL(HC>O9D%%Y=_
M,X)_?(P__-LX,CY>SHQ??WEAU,NTRFHC+XP/RW)3I\6B?FG\TGM^/&Y$MFW,
M\7R7V>N[S-@CF7THFW1%-#O7-SO?K#>KM"TZ([BZ$E7XTGB?57FY,,HKXVQ1
MWK1E^5(\^J^XO*+0&R+$;$^(<KT6I7W9E///1.M W_ILL<C;'-*5\3[-%T=Q
M89RG-SE]LN%360;B.O ]T>?SNR#9PGC7++/*$%=&]-++MOL4<>-B7JXSX]<W
M95V_(/"1'G^1-:)_%^P@K8J\N*Z-7Q]&G&57^3QO*' , 4,N8;)'Y.(]K=Y4
MWR@QC44IW]<SNZ]GM@4ZCP!?9]=YT9Z4>-=8I<5<7'Y1AG<%^L)(&W%V\U>&
M;;TTF,E,JBJU_/;M^K?Z)IUG)R/Q2M=9]24;G?[U+Y9G_IVJ521L=@=SM[#V
M??_+Z=2=^N[Q^,O#ZD.&#)$PCH1%2%B,A"4@6$_^]KW\[8'R/T3R=TSO@; \
MR_=,LZ^L<VWHH6)68TY=7Y*R>HS%F&\S*;$0F1A7@QZQR;0?,2(.$J5HR<?%
MR,P2*C/+8O9]S)YDG'O).-MV]B.2$>]2;2<L.DJAD^VC%^W(9=LA+\O5(JMJ
M,>3Y<Y,WWXP_+LK5RA #\]NT6OR'DI*#[#V1L!D2%B!A(1+&D; ("8N1L 0$
MZU6,>U\QKK:3W9;&4?NI=&&($9[XJ%ZGVP^[V=?V<4;5A:N\=T]LN;\[UX8=
MJG<D+#@D_1 9D2-A$1(6(V$)"-;3L7>O8T^KX^!K5LUST?.+X7S=:MJX&]+7
M#\?,E)BUV*&=/!(V\Q2=^O(P)D &#)$PCH1%2%B,A"4@6$_SDWO-3YZF>4KG
M$U5-]L23.FUMO*'ZG2A#/'E,3.7D3:2>&)D31\(B)"Q&PA(0K*?*Z;TJIUI5
M7F1U4^7S]N[+G2@W1=[4QA?QYVSQTBBR9JO7N]N,MWFS7&:KA7%55D:3?LWV
M]M?:X$/[:R1L-E74["C]-3)@B(1Q)"Q"PF(D+ '!>I7AWU>&_YR5056#KVCN
MR+8<)G7KVK2&RMQ7NG5'$CF=E/1>$R*3XDA8A(3%2%@"@O74:YF=O61J]1N6
M599?%\9\4U59,?]F-%5:U*N[SXNI[L[YZQVYIXFI_)%1'WZH3J&T $H+H31^
MR,6-H"%C*"U!T?JZ?F";6EI=OQ4=[ZJL:5_34J^M-?4M1]:N-L1@[2)I 906
M0FD<2HL.?+5B:-0$1>O+MW,)+;U-&!0+C4>8;(I7AFUN#1.+5#C4)(329A9A
M$TXLQ2:$!@VA- ZE15!:#*4E*%J_##JWT-+;A5(9'"1]6Y&79SF6+YN%^LB#
M14W8A1,F2UI-S6(.4^X AM#<.!'V2+DE$U%'>>;4])G<ST(]0RJLQC2T.M?0
MTEHL@(D6^@"#.U&H6;BC[9MK 0T:0FD<2HN@M!A*2U"T?B5T;J"EMP.?-N?"
M4BTU<M*%/OA@7;L'3+L@4J/G74!SXT188N8%=10Y]0*:7$(FI^E'.P_.VF/"
M:4>B#V5$OQU#O3@H;691;MQ$E1O4D(/2.)0606DQE):@:/TRZ&PY:X\OIXQ$
M]TM?-<L\W_9L6^Y!U>../,^>2L?-B.-\<RJ+5?7?+-LQ??G>44A%M4S/DD>M
MG""*X2.3NSWB*(]YDXDO=WMJ7-N?R.DE%$_7GW5.EG5G!_R<Z606U+J"TF90
M6@"EA5 :A](B*"V&TA(4K5\\G=EEZ=VNL_F\W!1-VQ->-FFQ$&51&Q]O%FF3
M&7\$7YMV8<&G568$Q6:=55L3@2Z;IX=IQZM'ID>6#]03@]("*"V$TCB4%D%I
M,926H&C]I1^=V<;T9MO>>Q*_IY5^3*$/,'CU!]2<8ZIE-54'  $T: BE<2@M
M@M)B*"U!T?J5T-ES3&_/D?<D]JO?4D?48L#J2X/@<WWPP;I6HTX]>=S-5)=*
M#%:]J2-/?8/FQHFP1[8I^\344:[X2#"5[A?&T.02*JQF#,\Z=XRQGSB&9]@5
M==@E=4A: *6%4!J'TB(H+8;2$A2M7SR=I\;TGMI35H<PU:6Q/5>^D:$//%CZ
M2%IPT!F$T)@<2HN@M!A*2U"TOJ0[KX_IO;XG+Q31<P=W_5"+CZD6GVUZ\K #
M:O!!:1Q*BZ"T&$I+4+2^_#N#C^D-OD%K1IAJ%+&IJXR@H:X>4UT]6Q8RF98K
M]\]00P]*BZ"T&$I+4+2^0#L/D>D]Q&=>/J*//K@7AWJ,3/48+4M>00(-&4)I
M'$J+H+082DM0M'Z1= XCTSN,S["2A!$FFN/*TYSU>0T6O.KO6;+<R;24OAZZ
M2!!*BZ"T&$I+4+2^C#M_E>F7"O[ @A*FKK8[4D<F4(\42@N@M!!*XX=<W @:
M,H;2$A2MK^O.^F1Z3U*WH(01J^-\RYS(TH7ZDU!: *6%4!J'TJ+#7JP8&C1!
MT?J;;G7&HZTW'G]P.8F>/G2 #:7-;,)U)):30(.&4!J'TB(H+8;2$A2M7P:=
MZVCK7<<G+">Q50^+7$ZBCSQ8U(3EJ"PG(5*CEY- <^-$6&(Y"744N9P$FEQ"
MA=58CG9G.=K ?3MI)4%M1BAM9JMK\JB9T-"@(93&H;0(2HNAM 1%ZU?"@QT\
M?W +3UK]Q+(\:C*T36PB24V&)HY3)T,30>G)T%14<C(T020F0U-'D9.AB;C4
M9&B*I^O5.N/,=G[B1 H;ZJ9!:3,H+8#20BB-0VD1E!9#:0F*UB^>SG:S\=ML
MVM32-5NYR:6//%C[T*TV#SN%$!J40VD1E!9#:0F*UA=U9]79S[3GIIX[N/.'
MFG"V:L+9$WFL /7@H#0.I4506@RE)2A:7_V=!V<#=]^T51M+F7I[K@\X6,A(
M6G#("830D!Q*BZ"T&$I+4+2^DCL;SOZ_[MBICSZXMX=Z>C:U::<\WP@:,H32
M.)0606DQE):@:/TBZ3P]^Z=OWFD3[I++;.5M 6H%VOOW[Z3S<N0)T-"\.)06
M06DQE):@:/UO2.G\/4?O[[W)OF15>OU,G;T^^-#.'DJ;.:K]Y\B?10-HR!!*
MXU!:!*7%4%J"HO5KI#/_'+WY]V,U0M8%M3.EQ6QYJV9]8H,5KWJ#<F?_6&+R
M=LW0Q#B4%D%I,926H&A])7=>I*/W(G]@BIVC&GU'CKQOUKD^_F#!0M<P0FDA
ME,8/NKH1-&8,I24H6E_9G;?HZ+U%W20[AS#!?-^6;YWK(PS6+G01(I060FD<
M2HL.>[%B:- $1>N+]\'W%&K]I@&3[!BI;ZA["J7-=K3>_!#+<^5[Z-"@(93&
MH;0(2HNAM 1%ZY=!9XLZ>U8C:B?9T=*G]AJUS:G2MT-M44==E2A$+4N:=#LM
MTY27JT!SXT38H\E4GF="'>7ZGL^4?A9J45)A=5_TVIF/CMY\'+0_$JTDJ L)
MI<T<8KM1RY5%'D"#AE :A](B*"V&TA(4K5\)G1'IZ(W(O?LCT>I7#3U/U*5B
M2NJ##]8UL2^IVH\2^Y(RYC!7GJP,S8T388\<WY'[4>(HUV>V8\K]*-0BI,+J
M^M'._'-^YAZG#M3K@])F4%H I850&H?2(B@MAM(2%*U?/)TIZ.A-P:=,ZW-4
M=VUB6I;<[4)-/R@M..@,0FA,#J5%4%H,I24H6O_KX#M[T-7;@\\\&40??>@;
M!)0V<U5_T).7M4 CAE :A](B*"V&TA(4K5\CG3WHZNW!9Y@+XE*+T5SY^[GU
M>0W6._1;!@\Z@Q :DT-I$9060VD)BM97?&<CNL]F([J$T<64VW7Z^(.5#;41
MH;002N,'7=T(&C.&TA(4K:_LSD9TGVXCNH0SY2AWX<[U$09K%VHC0FDAE,:A
MM.BP%RN&!DU0M+YX.QO1?58;44\?/!B'VHCN838B-&@(I7$H+8+28B@M0='Z
M9=#9B"[<1G150X^T$?61!XOZ$!N1.(BV$:&Y<2(L82-21Y$V(C2YA I+W?X>
MU\LL:V9IDYX>WZ37V>]I=9T7M;'*KD1#\]5$<*K\>GG_I"EO3D9B;/VI;)IR
MO7VXS-)%5K4'B/]?E67S_<E8\&_+ZO,VQNG_ %!+ P04    " !G@ -50\8\
MTXH*  "U*P  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*U:VW+;.!+]
M%91F:BJIBBSB0I'TV*YRY&22J21VQ<[.P]8^0"1D<8<B%1+R9;]^&Z!,2L1%
M]I1?;))J@ >-1I_3($[NJ_KO9BF$1 ^KHFQ.1TLIU\>329,NQ8HW1]5:E/#+
MHJI77,)M?3MIUK7@F6ZT*B8D"*:3%<_+T=F)?G95GYU4&UGDI;BJ4;-9K7C]
M^%X4U?WI"(^>'GS/;Y=2/9B<G:SYK;@6\L?ZJH:[2==+EJ]$V>15B6JQ.!V=
MX^.+4#?0%O_*Q7VS<XW44.95];>Z^9R=C@*%2!0BE:H+#O_NQ$P4A>H)</S<
M=CKJWJD:[EX_]?Y1#QX&,^>-F%7%7WDFEZ>C>(0RL>";0GZO[C^)[8!"U5]:
M%8W^B^ZWML$(I9M&5JMM8T"PRLOV/W_8.F*G ::.!F3;@ P;A(X&=-N #ALP
M1P.V;<"T9]JA:#]<<,G/3NKJ'M7*&GI3%]J9NC4,/R_5O%_+&G[-H9T\FUU^
MN[[\\OGB_.;#!;J^@7]?/WR[N4:7']'L_/H3^OCE\J]K-$8_KB_0FU_?HE]1
M7J*;9;5I>)DU)Q,)&%1/DW3[OEG[/N)XWQ1]K4JY;-"',A/9?OL)8.\&0)X&
M,"/>#O_<E$>(!N\0"0BQX+EX?G/L@4,[?U+='W7YDS=+]!%64X-^-")#GTMT
MN18UEWEYB\Y5D.<R%U;'M1TS>\=J_1\W:YZ*TQ$L\$;4=V)T]MLO>!K\;AOU
M*W6VYP/6^8#Y>C_[!NFJJ!KK(-N64]U2Y:2[LW&2T/AD<K>+WF*%XP2SSFP/
M5]CA"KUS<Y[]%Q84)"W9(%E!UDJK,LT+@<HM8/547:=J$B&^P:21=9Y*F$C]
M;*.F%!9 U4TI[Z;TV#;<\#7G])4ZV_/=M//=U#NGLR4O;X4:^X+G-;KCQ4:@
M:H' A<H/X%-UV>29=DQ5VIS1OB'<F=5I' VGWC0:AXECXJ,.?.0%_T7-[9M;
M8,&W"+@FRYL6]@9F<SN5@-T&.3+0L"D=(#9MQC@)')#C#G+LA?P'5ZZNJQ42
M/S>Y?$0K(9>5"KX[B$EASR"QB82$;.AABQ4FTRFQ TXZP(D7\(6 J$MSWK(Y
MK!V^JFJ9_Z]](!Y J#1VU(F!AT(N'J*V6NW,Q1YH'/3T%WAA7\LJ_7NLE ,L
M\6JE4.XAMC)<8&#!A(9#Q!:SB(:) _$.8>,#CEZ(N@:XDC^@=5W=Y5J#O9F+
M4BQR^=:*&)MQ')$A7M-H3*:Q R_I\1(OWO/=.-AFC!K2)EPT$O&F$=*N(XCI
M98KCZ1"U:193C!VH>QK'7H8T4&=/7E_D)0?6@-2O\-N14Q-Y$"5#X*95'-/(
M ;SG7NPG7YTX #/XN&P LP*_$JNYJ)MEOK;"90:08(C5-!D3DDQ=P=PS,O:2
M5IN9=06QYH^*F5M?SZ45:'@8J&F"$QRZ@KAG/^RGOTNY!%>F&P@!A;&C?ZT*
M\G*A!=\;J*OTU=MW2D98AV#AP,18B!8.C(C+UST)XL@O336%-XK#VU6GTW21
M\WE>: 6C4:L)X"EP3I-K5K3*&NSEVY?JFM?J;=\O/=-B/]6>IVFU49H0^$OD
M=WQ>B-83RCU=MO(D*I-0,0V8,:M6WH7R?.J8V)YYL9]ZK]3JR;..9#7P:B]B
MU9.R*L?=O7LT)M&.8Q8.18_-C#+J"%+2\S'Q\_'LF>Q 3'(=4Q*S 4RK69(X
MZ('T)$S\)-S%#*0M%3!6B!8^C<G0D1:KQ*D>2<^ZY #KIFFMY.W.\K9B--ES
M3%A,ABQKL\-11$('SIYGR0&>W>+<TUXJ6L5J752/0J"MKK'#-SD4>(D:7&NU
MPV'@@M^S+?&S;2?&:G$GH)ZP@K20)R74" 33C+ D<"#L&9;X&?9[FS'1HH)L
M4/!\U:8'8#"]:5BF8JM^>5TK?M#EL748)K6.(2]08\F9=E,R==7NI*=@XJ=@
MO24YKA9C*,)W"W!WBK#0Z'1JA(9IQ:;$E2!ZLB7^DK/?]"D$N/?@.C2+2&Q&
ML:72)!%VY=R> (F? %MQ4U3E[5B*>G40JX7(8J/ZL5CA$#N$&.FYCOBY[ML_
MW9ZQCL1"8HQ&QIZ$S2XB##L6)^W9C@;/W2V\4I5<!OCGC^BS+O*?L6/HY=(7
M;QF^4F_[ON@IE?HI5?M"ZQB5JO2RWA.B>L;GFP::0<T ?#&'2LRY<4,MY)L$
MT;!>L)GAW=)X?S ]_5(__<)LID)D3;N%8Z_%MB'<Y@?XY0K&O(:J$XDFA1=:
M1V72\'X9MAV5:<9(DCB$)MW9V_:3]44. !M>*+1*3<+JXU+<YNEN09'E.GCE
MIM:C<FRV.2LD:E*U,6FF"74R)>VYG/JY_+L S+K8MVVY.7F1FKS-<!0.,9M6
M"77&6<_NU,_N5YLZ77*E^0'V(:"'RV>+R1@"Q\'=M.=NZN?NKQQ<J].8#A$(
MH><A-KG90&R:A($K%'KVIG[V_MSC4GR2E\"+)2^T]&BJA;SG$-Q:1NWZ?UVK
M^(; T?H58FBM>K .S+9G'$5LJ*6L=D"CKKCI*9_Z*=]+H^L=*LH[*O)3*37I
MGE)CLDPC%M#8-5V]**#)2S^Z?>RVZ0Y0J%=NO)A"7ZFW_<]NO9Q@!XKG?H='
M?6UO-ZC6N82,/>>%TOIJDZ/@:J9E]50.K!57-8VRAMIK+I:\6.APYK4L@:JL
MG_',NII.A]-M,2)0?-MGF_5"@?F%PO?=O<(9%%^Y1.>WM="E"XP]+3:9&@PP
MDBS$D^&]KF_L>8:9*L 8BTU/Q(PX8I?U2H&]1"DTZG,$T.3V$X2HT]SQU829
M'$^#H1"P& 'K.'0 ZW4 .Z@#(&',-ZTN@TBZ7L-%Y0@52^V-66QLU5CMJ"N7
MLYV/T7Y:O^$/$/;WN5PN19&U6?M)93[EMI[S.<2)_5P#LY3Q>,HB/!R'K=S'
MS)&R64_US$_USZI\^J\3_G3-+$1/@ZGQ=<5FE^ @=GRF8+TB8'Y%\&&Q$*E>
MF.(A;;\M*RVI,E W2'VAYN4.]$*YE9>#D5L'9RG\J:'(;%:A0^FP7CDPOW)0
MLY2)M-:B/G^-P5@D0,1"<ZG;I *A.')L9;!>*S"_5IB]9 A0":A)G4-54)80
MAVK#!D117F66P;T_\.9_X_]876+1&B%+C!UWF]T4A['+([W>8/Y-B'_B$5%F
M!WSA?Z?+%VVKW:,R) Z8L;MHLZ.Q<PLC5)IC_TG/SZ&?GP'I.7A"^6%3Z"4N
MEP+$1M5L4ZVZ526 NKZI-P)]$KR02Y1!C0 6ZN=%7C<2_=R !&G+9G4\ZUW;
MD:*:(L^TBFDD_'NB^+ZZ?"JMM<TV)X((RLOVH.3VS*(Z>ZB[G%6K-2\??_LE
M)CCZO1EV9/]:-D0/T^RH=8^0#ICV(V'[46D%^F^I3D_>J2P!]P(M.5R7E82U
M(TK$]5DET?*5JC9:7=-F>;<;-*IT^#:WI0W(&W44ZJWF1SU3^0-:M6?VA#JS
MA_[<E*([,G>$KH5 WRI(W>&13<1.=LXFKD1]J\]XJOV;32G;(V7=T^X<Z7M]
M>G+P?(:/+[#E^7D8',\@7FV_8/BE/4':O[H]T/J5UY"A&E2(!< (CB+($G5[
M1K2]D=5:GYJ<5U)6*WVY%#P3M3* WQ<5C'E[HU[0G=0]^S]02P,$%     @
M9X #5;9-Q.>B P  P0<  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6R-
M55%SVS8,_BLX==>GS+)E-VU3VW>.TZ[MM==<LW4/NSU0$F3Q2I$*05GQ?OT
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M_BLHK;-G5U$CS<B2'+]5R8JSJ]M-XK*<\X>K^\ A,3.(.01#D)*UO_[ZZ09
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MPE4&X/"*&(+ V"%E,^TMX8[NH$CJ>#C<6PLN<-:'<6RS(=%GKPOM0[&+7\)
MKTN7:F>5> ^"Q=4E">0YOJDDP_=I]G@8Q=F1D7/]\I[= EC'G;L56RU>4([L
M()(6OA4O@'G7M89B[Q#/!K".8YIM&#*4$6\7^M+!NXP4YZN%^#W>P<!AZ61L
M$@H(7<EK4-@BK[V\3UY[^8C0HP7@\%*,E(=NB0J200H"G_-L&K^I,(A93 M
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MB<F#8 %]C]?TPR\X(/[=F-?_"U!+ P04    " !G@ -5A!SQ\@D'  !2$0
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RM6&MO&[<2_2L#M2@20-;+
MC[BI;<!V6]P4MZT1);>X*/J!VIV5V'#)#<FUK/[Z>X9<K65;=HO>?DB\#\[,
MF=>969VMG?\45LR1[FICP_E@%6/S=CP.Q8IK%4:N88LWE?.UBKCURW%H/*LR
M"=5F/)M,3L:UTG9P<9:>W?B+,]=&HRW?> IM72N_N6+CUN>#Z6#[X+U>KJ(\
M&%^<-6K)<XX?FQN/NW&OI=0UVZ"=)<_5^>!R^O;J2,ZG __1O X[UR2>+)S[
M)#?ORO/!1 "QX2**!H4_MWS-QH@BP/C<Z1ST)D5P]WJK_?OD.WQ9J,#7SORB
MR[@Z'YP.J.1*M2:^=^M_<>?/L>@KG GI?UKGLX=O!E2T(;JZ$P:"6MO\5]UU
M<=@1.)T\(S#K!&8)=S:44'ZKHKHX\VY-7DY#FUPD5Y,TP&DK29E'C[<:<O'B
M/1=LH]G0NQ!:+NFR*%QKH[9+FD=E2^7+<#:.L"3GQT6G]2IKG3VC]81^=#:N
M GUG2RX?RH^!L(<YV\*\FKVH\(?6CNAP,J399#9[0=]A[_9ATG?XC+X=-V^<
MT87F0+]>+D+T*)/?]CF<]1WMUR>M\S8TJN#S 7HCL+_EP<577TQ/)M^\@/:H
M1WOTDO:_G:3_7RM=EJY)[>,J^@D]MO?0.TO?0EF]8(\$3;\>4EPQ?7\YOR+=
MZ9Y_I)_<*+T]F,Z&--=U8W2U$45R>$<OF 8:"U<S?5!W'$;T 0<4F*#$OQA(
MVRP"G9YK=\M4L(\@(.*[@A/<0-&E0]HBI0U[[4J*ZHZ4,:Y06X^,"P&9AQ^T
MA'R@RKN:2EU5[&&**FV5+;0R%***+.8)P!IG$Q"1Z^S4'%<P 9V>"[>T^@]Q
M16<WHKA!, DT@%)3!VC'O.CH)+?@P"WL/6?<1JN%-GB'\Q(@\&O0)0LCZ= C
M+B1:R(8JRZ0F)\(B;\M6EW"%*>3 BQX5&G!C$%MR3#U,0>5Q?J7#%KZ@+(SR
M67:/  )M@RJZ\*]4A$,!Y"CY4@@@-P=MLTV>^)2QP_K2N7*MC<F9OD: E=W
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ML(Q;P2K%M28ABH?,!$P!F=26EGS!?3 C[(0RJ7,)S357#A7H"Q*2IL;Q2@7
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MZ<].TZ?,^=KL9*)>7B UC*IOU<6KK[Z(Y^/G]T@_"]+/[J/^6!]]-A'QJT(
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M#N#WC=:-_T ,P@OTK_X#4$L#!!0    ( &>  U5B2B$QZP8  &$1   9
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*58;6\3.1#^*U8.$)72O+9I@;92
M6^#@= A4./APN@_.KI/UX;47VYLT]^OOF?%N7B M!R<ANMZU9YYY>V:<LZ7S
MGT.A5!2WI;'AO%/$6#WM]T-6J%*&GJN4Q9>9\Z6,6/IY/U1>R9P/E:8_&@PF
M_5)JV[DXXW?O_,69JZ/15KWS(M1E*?WJ2AFW/.\,.^V+&STO(KWH7YQ5<J[>
MJ_A']<YCU5]+R76I;-#."J]FYYW+X=.K(]K/&SYJM0Q;SX(LF3KWF1:O\_/.
M@  IH[)($B3^+-2U,H8$ <:71F9GK9(.;C^WTE^R[;!E*H.Z=N:3SF-QWCGM
MB%S-9&WBC5N^4HT]QR0O<R;P_V*9]H[&'9'5(;JR.0P$I;;IK[QM_+!UX'1P
MQX%1<V#$N),B1OE<1GEQYMU2>-H-:?3 IO)I@-.6@O(^>GS5.!<OKKW*=12_
MNQ!4..M'B*0/_:PY?I6.C^XX/A%OG(U%$"]LKO+=\WU 6>,9M7BN1O<*_*VV
M/3$>=,5H,!K=(V^\MF_,\L;?MT_\>3D-T2,/_MIG:))SM%\.U<;34,E,G7>0
M_$'YA>I<//IE.!D\NP?ET1KET7W2OQ^%'S@N/BDAO1+JMG)!Y2(ZD:7O)GVO
MO$;]:;,2L?"NGA?"U1[ED;G:QH!*RY1>R*E18N9=B?5"V5H)>,X&R;44ND+;
MA0H1U8D3A3*YD%'(TOFH_X'.S 4L;=YDL(+X?"%M!NW@$8B<UT9&YU<BDY6.
MTO!F%POLM"ZJ;10],@BZ #JR5:AG4K%C$Q4F!%A126@FQ!$@L]I[/ &.Q5X"
MSGI 7L%9MI"6H:XJ $\6.RB&B- 3+_9K(M>6$%![4K@ 8*"&2") ;>>DBW.L
MAE%&SY1P,]H1H OG2? E0B!]I _D>!P(.E=>,DOA98N:L '/4OK\T(#62+K"
M;E?J;,NDKEBJM1"*-^#H$JD:&]7B^NW'U\\/AT^@%E5*IU-HDAIM9X9U@Y,%
MY3:9%LB7C*X)8'CTR^EH>/)L*U"QT#YG4[3:?)YJH^.*LJZ2*XY=KG,*JG!3
M+AMZ9E]KFU$DH$M;$"F2^DNM; 9A(J\]64O@D:.JB9.^%65B&T5L(\ 5:LT5
M/?$KZ-WR&2LC;&@=/*T#ZB7 4;3B! %KMFV!$LIKZ%6M5DJ]$!J'D&(XY7#G
M)9UP>4HFDMEF#3!]S_.-6S>8EAL'08B#1RG/O4;Z9(6T\^0>KE"##IJ***=Z
M='>H^"GG7;;E?_-5^=\TY?]AJ_PWN[?(PBLF1F04:087\ :W3!3$4!V<8U=,
M 7-'#L0#Y83.F);<0N<-8;591SMV\JPGKMOR^!9#JL[,H-+T3$/44N.PW;>U
M*RPF'F>W@34Y'+B:G-&YI(A.I2&G"^ZQ%+!"&TIB>YC].!*XJ)((-V6=93K9
MXCV[%LA,\1/HN-X09@UNY9QQ=NZ8E1*'<4^@TFB9/PU%Q/$T0!'YD"7*D[=7
MK7"@G(/=N&X2N0EL*>$+RD/"D>QHDUI0EXUJCO)_RYT%.C0%CTK>U#G48ZY#
M_VD<QXF/PC>:>0AB=:CJ2+!@:)VF-ZI#N2H;.I]IFLCP(5DL5T*5E7$K8=2<
M*@=B,?DQ"]4^U(I5@*Q79&,SM*E\.V ]\1I:\D2JW9U\76ICJ -AGP[PF9@K
M"[XVHAD$-MUGPV(K02Z U%<:J>QU1NV AA"?W(48Y(J\"(\QS0LELV)'P+3.
M/BOB9Y3I80X3B;H.R>6:0K20)KD=4(&\JHS>E%H&Z"[HMJ6D%D5=CI*!(K9.
MG'W8>^(#E7#+-T1J+)P)@35E<EMTL==&'1IH^=\U<6,7>8VJ(QX%B7;9Z/_5
MH:]:Z!+_YF29M-*L A0WU(\\1+;M+W\4\)V?4X-LD[TI1\EB=WBS*YX,'H+"
MJ=:3)5TQ:5YPHZ%H&2J)""X7DP%\OR(. 1N(TX?[]@Q':1-#P%#U'*#**?AA
M/&2=PT8GT*Q5CM+ZNQK']VKDR>1K"QG&'@S(RNAH<%NVF95"D9+O+H(2#X:C
MD]X)+C+&M%7]8'@R[!VO7P' WGAE"@D K??'K2&87-S/M2FB30^8;7=6K!Z,
M>\-=A./>4?NB2T5/@R%HTS2%,G-TGGLN@T@77 S"(;ECT\8W)<7)OS-8-I/!
MOF;R7ZW?E[6/*5*%JP,^AH.GXJ5+$^M[# 3;=[>OPDY11H&EV*7,GRK4&,^X
M6*012#P0C\?=\<G1 3V== ?'DP/QCAHY7]J_-7(,T8\GP^'!5[(5A697ZN!X
MU$B=3$X.]EVR^EO77@P+<[[<A]3"T@UX_7;]^\%ENC9OMJ<?']Y(#^,"JF*&
MHX/>R7%'^'2A3XOH*KY$3UW$9,*/A4(</&W ]YG#M:59D(+UKRH7_P)02P,$
M%     @ 9X #52+V6YRT P  10H  !D   !X;"]W;W)K<VAE971S+W-H965T
M,34N>&ULK59M;]LV$/XK!RT8&D#3NV0[LPTD:8MU6(>@[;8/PSXPTMDB2I$J
M2=E)?_V.DJ/:>?':+A]LD:>[YUX>'G7SK=(?38UHX:81TBR\VMKV+ Q-66/#
M3*!:E/1FI73#+&WU.C2M1E;U1HT(DR@JPH9QZ2WGO>Q*+^>JLX)+O-)@NJ9A
M^O8"A=HNO-B[$[SCZ]HZ0;B<MVR-[]'^T5YIVH4C2L4;E(8K"1I7"^\\/KO(
MG'ZO\"?'K=E;@\OD6JF/;O.F6GB1"P@%EM8A,'IL\!*%<$ 4QJ<=IC>Z=(;[
MZSOTUWWNE,LU,WBIQ%^\LO7"FWI0X8IUPKY3VU]PET_N\$HE3/\/VT$W(X]E
M9ZQJ=L:T;[@<GNQF5X<]@VGTA$&R,TCZN ='?90OF67+N59;T$Z;T-RB3[6W
MIN"X=*2\MYK><K*SRRM-_&I["TQ6\.I3QUNJN/7A=[3ST)(#IQ:6.["+ 2QY
M JR MTK:VL K66%U:!]28&-TR5UT%\E1P%\[&4 :^9!$27($+QVS37N\]#^R
M]>%*,&D/DX:_SZ^-U71._GDL]0$Y>QS9]<Z9:5F)"X^:PZ#>H+?\\8>XB'X^
M$G<VQIT=0_]6EKX;##[4""LEJ%6Y7.\ZE7]& ZK3T.X;XEBV%UR"K55G2&Q.
MSX!(PY$T>(DE-M>H(8U[20R7JFD[2Y*:Z6K+-,())(6?Y8E;Q/YL$L'K3DMN
M.WIWZ"OS'4+JY],8WD@"D4S\U!D$HU:VQZIP0S?-H%TJ8PW$D]2/9C.(\QG9
M3> WI"ZNE:B -Y32!IVN@23UXS@A+3]-<OB@+!-/99Q0N,4THW0B/RM2."_+
MKND$LUB1?^*_Y&RX<\B,-4I;_GD0X W=IH;J^2).*9=\<DJK>$;Q34^/^O1!
M$CTG,$O\(IG08AK[:9'WA+F",GD+)6LY(1!?%9Q,@ICN"R'NPCB)TR ?)72;
M$V=(/XU#C0V_@6;H7G3=>TBC3Q>P:;&_0@6U3X^8!\4]%_&>TV]T$=]WH5;
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M 1)*5(XX</Q[$/="*6($&)\ZGH.]2"+LKW?<?_*Z0Y<9M^)>JP^R=LOKP63
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MS(0/CN'!Z;7_R(?^B%KHETN!^FKH -[/M7:[!Q*P_^I[\S]02P,$%     @
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ME0$Y#I:ATA&H2[5F&>  !HBM99%SI1V.8(1T!0!$N4)D8HL;//$[2K ; NX
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M /T@+ [4O1&*ANH.<:R,(QY. ]$A[XM:NZAT.'L\0I[$OM\<AD4E])O#(#'
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M"VPLP+@7WDH,V*^I0E\><.85<>:WNNRP9J^N#8GJG0E4#K+YGN!F9P]NQB.
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MMQ;[ZI>7;K&P-;A<>Z7+7%VZLK;ES)29-?[YDQI'T,(G60#W2L"-=X [4Q\
M8.[5ZS(W>7__$Z"6\!M'_%Z-OPKPEZ8<JN.C@1H?C<=?@7><Z#UF>,?_&WK5
ME?59X7Q3&?7?%Q-?5U":_]G&!3GD9/LA9$@_^J7.S(L]6(HWU:W9>_GWOXW.
MCG[Z"@DGB823KT'_?I']!^!4]^U[4]>F\LI-U65E<ENK"_X"&9DD(X9Q93*S
MF)A*'8_X*?ZOYX: +76Y5BOMU5)7]5K53MFJ,K<NTY/"*%]C]V2MBO:D3$Y:
MV7JN- RP_*+@BM2CT?'P' 91%&S;.//1Z'1X$I\,X##\TK#)%^L!;R$,)J8T
M4X #X,K,FD+7KEHKW=1S5]D:!--&72@#3&K#<"OKOQSZN:[ %*5GE3',C2$1
M[YML/E KH^:FR+\7)TM>#3IFL]KD*M-^+N>USVQYBR]!-%[!UH&PJ8"??BCC
MA^HSR+[/S[F^-? OX'U9*W.WM)5F+YGC  \VU2MC2CD@ ?^@JVR.K\?R=06R
MB'4.OM%FNBC6 %0;?@-^-K720#TG])G_&CS)<3:. 06N-(=KHRNU-)5U>0LQ
M8_UK#.G&5NAZ"EJ4T< E <&3A9I6;L%29GK63(MJRL)X+\(GY>%XX%7I:CH@
M@)R8M<,?6F1+8$CX$<+Q3,BB W.HWN'1HK13($;D>&9RT.Z__^U\/'KZDP_>
M&ZBV2J-@5B0_$&/+K&ARJ)A:5N[6<I"#YJ_F%G1UC85W>T(6P8:0M;583TD2
MU3,$7@]:YK;*#\6HLD+;A5?[^H#YGAM=0TLG+K=\[I]-!>VC%WJ!N$N0(0//
M4@$N^$PP=.-!-3"*>)1F5EAR"X;VDJBF30'=]A!8WF3U0.U/#F@#90J@&HNB
M?D409K$LW)JH@35YLB<6&5D18EH)9')%WM+BC)9I )P));:L$;XAOZ:+JBVG
M9)N\&.+.<3:9&:1#9@7DK,B(-&P_%T@1HUOK"E%\F(9>+@LKCJC0*YQ+.\A#
M!6FO22Z+Q'+:+RP4V)GS9*<K7>5LNW1V&9(/=E],IP@'9NE8E_J.<:Y%,Z$<
MQ+J<SUB0S9-*A@/PCYP$T@Y"FH$&#,F!,2H1CLZRJ@E@"JLGMI UE2%'PL3Q
M?C>!:(,J W%""5L%*1(3*/&NL#EOFMI2(S@ (7:2P1M>5^;PW?5'F ;Y++#X
MDYE9BJ!,/R=[7EU$H:H_8*609L6<(DLG?]RNKV1]4@)A(%G910YC(:?]RH'1
M _7;]8?+@?I\_3,3KD'UW%3!<Y+3=P$P'I+@O2Y,4!*B\L: T<*3BZQ6Y.8-
MNTG70$D*#<]Q >H7"^ $>-F703!<X@J<G#<PKP(.70B!E\CF&KHH2L;[7_7V
M2XCMOV@@.7#PIIG\"74AE#,HMA8-ZFIO81&+14RD-[;+(/8BN6%/YTUB@!?.
M18!0$P :J*6=S=83'?!!^EA,MPE HL<VR<PJ79(RM*S\EOS@VLE+0WG(*R^=
MJ!G[:/HP=T4>0E200CW7T."*7:0D"Y"L 7=*IPH')E>\B96;M7AS'\ZU=2%J
MOI6XZZ;R#>B@!21P"CV4\I%[Z9I$)+++< [[4TO@-W0W607"DZ+20=T<'HL8
M6.5>7]*+7QHXX_$Y1>G1V2#X?4J,<@,70>IDIE-)%FCY13-#.%&CL6P8D@$Q
M3Y<:(0)_$9]0*D7;9O5TXJ+NB9S,X)[$$1'8<L"]4@A>D6$ 3DXNOHGI(>FL
M]3[I)!T!$*6?TF9]1RF4;S5YIR?NZ/)N+6OU)X3+&%51/R:W'()P&T=]UT@W
M5T&_2 JD43:S2V'5?>6C''>+^4M(F!N+Z&DKT @+ ^>F ,_1&&_;((=8V/B0
M^L#_.N^).1( !BETX'77-4M6N&3VD;Y37"KS5KS@J>@*JWQ$? $MF!A@:A+S
M=SFY@2@HA3@ZFZ6^LMZP2N4V;P-02("Z>A5BAB%AD@Q N:'@ZQ,H]K!=3H(+
M9%O)(S,?(]YY4XDG)2< 68L[LG=J(66DY%Z]/+>?1@_5SXUF7X2C/@:S(H/"
M4FQX_?M;=0TQ+ET%PE_?NH*4Z2U2?%CC^_>7DM<BM)4Z/,V ] !1+!NJ?4KE
MQD<_R7O^,OKI8"-NP30AUYI\"5P_/&\;X_:)K!X,=7%]$>%$FR>G0SHCS,4.
M#E'@6A=WXGH 03E\\.::3NYI>WRS/5,*5@4(/=C$@^Z#E,&&]:TFI2T?4$1D
MVDJU2"YS2,R_,<M:RH_1-@%TF4T9!?6!(M'L0G0F_J''D@D[?M4R<!M?+V%=
MH#_)*)CI5Q!F7UNZVZC3 HA2^WMY6^?X<$X_:XL5"\,)<1BE#D)=<&BW9)5+
MQB.DMWTW_0U,6]G#1EPS$XRH%( DB<U#A)FB<*MH2IO(]H0P,3,H+?7*:#D3
MN+T4[F4Z1OT#*MUD7]:H,<EY2H";@E^^@>R0L4=S^<=_J:N/[Y(H !R)6H0"
M''.5NQ4[8JID2#5#F W44>4HI>N%%#KBLW7=V0PN@XF^)X<!I<;!MP?D^N:_
MD7#.HN/8UAU@BID0=GC T"/_)VGWF!D]]YK]7TH98A)M;@F1W@X;,G.J,@!Y
M08U7XD-+6S<:]*!*SV&S[A]0/J07$J&YK)]0Z3YMV'5V4I=$[Q"YN4UBNVBK
M4YAPVT!@\*-GR+#?(L&^?GNCWO75?M-M?+]-IYV;5IU>;-CUADIT(&S7=4(1
MZ-]SV6U>P7H5;#9/BM UWM#* <AFL>RF$&T=1"TB?\]EAV57AS>_7JM7#="C
M1@3$9 L)WK5%N(;.;IAGIO&8'+GD35SOB5.HN/R!#*EL_UC!CNV_6@RW'(:\
MK:#N1LK0*G%2W1/9<W]$)M/SVUN D</LPN':G;A[#^!%O=4-A>_W].:[I?,0
M4;31\F%":(,\A[[D[>:2*T!QRY!A^?\CX5B_*988@SY_P\K::!,5-<3GK63^
MHLN&<K74BB5/*FTFHCTP*N@=Y58P5TONB5LNE(7WK4&@[E 03H4M=[BV$M>I
M:C:SA="KG*90)H,B^R]P?%F9A6T6H021_A:K0:\$W>'6]MD;N\9CLS_XD6HR
MR8N19W;'%1O]5$*I![)%(IS\2.V/#_#_Z.G@].D9%0Q=O$8GSR@3/3\[#F\.
M8PJ]D1ND%)NU;_R3.CTYI0RT,I1/[J,@Y$\'H3:@<8*4%9$1X FB*$_H@.<A
M3:EP2%7IT!7#DKJN[*2I8]C9R2VU/SH='0#O<[S_BX_2=8BZ,UN6)/!8FTE'
M^-F1.AD<'8W5.UA"QOZT[4.Q\9=4_>JHJG\%BE$B\6]/'?1:P"TI6]M'-6@@
MS?Q [1^/SP\4=.+H#&8K"(;7]/G@KV9HR P[K'RDQF=/25V/!\?'9P?<-&/Y
MHD:H.@ V'0^O(\_&Y;)4G]Q\Y(V#-INEQ:4K#ZEG:&HK;J]ME4CC,/0P9#0Q
M&G6;'CPI,'D:@'2SA'BVB_.(I[S_6.UW-G8S8^XI2>TL@2QD%3NH;I.+WY(G
MH4Z5CTS<L4]ZC]QKU4CN;1GSGL1!"@[$%7.'1-J3J4?6=:NXR,1>W^3;'<!.
M:R5DFSOPC#6-1Q -+CQ&TLV1Q;:FUTZX4JM_%>7<^ RZ*WRIH+-=GA&</ YB
M"'B"@(A/$P4A.>F8-%R*M2AACDR]-,017TL=%,6U:PZ#]+D_V_RL[T!6-,MN
M=WI'$?@Q=#NPRW4"?#\M[F4S]&+W,=V4]_.GU!GHMVQ#G90:NM%L4L,W"C/X
MHV@V$1_!HM<2!LCST\>17U([Q&\UL UU$'46J/NT'D@BUH5J2;AF$9NKND"8
MWAQ-V!#"N*E%/2"&K;WM-9-BR[S3<^MWQ@GLBM2#\L\.=EL=X[2I:7K?($6)
MZ1? +L-PXM>/[Z$%5TU:;I&!<$%&OF?B;LT@96M3+KV)[G[;*#2'+%.E<2 P
MN]5%$W(]2EXD/"#KE7XPIYF1@33$DY0(I$@#I\N-;0J,X@UBHR%H(D2:B8)K
M8FKD=ZIC.4-O^<O%(=D;%XA!:/GV"11,S?$<2W=JW&6G7\Z:_>EBJ-Z#RE#U
M?M R9O[#A/[[C$=Z,I>E7)/VT5_R$D&]"S,#7;GURZ;N# :#2W/4.:#D%95,
M!<H@RTE(-[MM+^FYLO;'^=H?<R,@"OO%%';N' =%S:P+230Y@G7*ZF%0$U:E
MJ %]PY!]7 40[VA>.J&AM =%)#T>",C K<>T:)Z;YW*_M3OLKLPMW6)B$+H(
MW?7\SX:GNV8A2Z;4U$,HG#FBNS0S5]LX$8(NU46<F59-07U9Z'/.\U10(:RF
M7CZ\K2BZM&RA?X8J%QJE\E4GP.,)I0S3:^)K"=0ZKTG_W80D2)0S*!@X$<"!
MFOU1Y*=K:N$P!;W0_?8-^Q<R .\#RN*@4@"BQCACS,T>DW.;671YH*).!\\2
M!YW=WLDJ%K])EX-2A:0(WSJ=]-S$Z52@;J%SP[5Q2%O.8S]$2V=;6M@;02=-
MA#)V9-+\(&^&^M%2R$SC^E[;RE-!2>U;20HE]-Z$\#,ZHL$ZL7A\1#/]<&*G
MJ_\Z3ATO)$T>/3L^&:2L #X4*-W4?+/CRLKM$IS><$M<4_%8ML^Q_7=;(2.W
M>J N"G.'@RNKL4"&*ZCNRY1UM811$B>T4YH6*\ZCV$[086;PS9V4X)VG7;1!
MKC;<WTA]KY4*$[[K8@UC1=2\))-=(][6R!;8(=RL0>%"W0ZW^O&!>E/1M9 _
MZ(Z.)LW\%2KA"NH(9#_C%73MQ@#PJT)G7PJS5H,^QJEA-HY%;)I"',<&73>+
M#:ZSIQ_F#K+D$"076>0Z)H^KDTDG-Y3<;2]?S%W6T++>D*NSFUFYI)R!9IOR
MFGQJ':[3P.>3EZ TCC%;,%&^:P#C+CF%T;D20=CI-.I:1M$GF !%;X>\F.J9
MA9-(: PWG1'%*)%EQ[Z)U ;.,32:N[F=V/ZP(Z^ ^R[,@_+0[(-1H!81W>J!
M94F?H7,0G,ZR*9+E=]C:P[2,4!+.(=5B1B+-OD>!]6%M" ]4Z<>L@B,,Y\"'
M/ WO;(N9'%CR:'P\/$UWRGCB.S&QN4L#;B"X)CPZEU?29#)D$.*>PXPR/FL#
M5*HD^U?:<L>)0$39Q9F@\G8F\U2."K4$-JIHZ08;C'"*#&@S%=S@"S]A'TL)
M0S"99/FC!_I8O$).S2V48$A!#:^@-"O*0"[G1%>U%F^7O*^G.6F\G,1BE2M+
M?*6DKT#W_74LZQ:L"G(G2Y,[0NI'G8S9O60Y)7("GP=/X3(5A5P9@]SB2!JW
M[:IB9%Z$N#BW2RD04D<PC#.O"UV*:K,9@KWO(3)7T!;PXMH59"?7X4+UFX8N
M!;0LA!;1#30SU\54.37=X2WA1J,G''2<YDWF:K#@+<L+/E57)?V]"NA?0- .
M7YOI%-O>F )K;^#1><M$4R B;E_KM2>_QCW/^\>K=B1[U8K^@D7?%O&;/0Q6
MB& 1AU=17#YI4?!-Y$.MIZL-P:1C?&HO7TCC@=63D(W.SX>F:2XM"\#EFZ+;
MHJ1K.^WCLQ@O'HS35G@I_HR>1H =S%+*OS9U!\T0A.X?$QA6F3BG"E8"[=!J
M4EDJNF>*?AJ0-P5?3"&4VPIYA^5!:;BO%3+#3=WN)7[L?"9PN^;6M$&%ZA)X
MJYKNYG%2"(<S#5=U8+H61[QU*VRI)#Z%G)-3?K[\EHH42_E5J#Z&\2)SN/B<
MF;*]L>:_]'2I'QBZ3C#K;NQ>LJ5A1+>X2W=\^8/Y9P,=+M+%:[IQQT.\ME6X
M8^#',>6.RPX(YMGY\.QQO+/V:'Q^U%XY9EQV'3KXGNO'*]()ON4,A\47:7/#
M%6ZX8/;FZMWEQJ4:6N7;Q"/A>S1\]K@/CUIGE63>%%1I'Q5PI%E=QTN_,2&I
M>?:8NYG)"+4C(7+@MFY$./QN#D>;9,3(4EY!KA>E3N<8Z9LD0H'IU.3I_B[]
M3"#?=8[<!:2I"$1P?Q?W\7S?6<72FR(N+ TZ);>K8J$>BWXJ*';27KMP17E#
M=5%0N@?I+UO,?4T47>;0!RAT3Y]O25/\"9NXP5/IW&S=SOVBBOKCT@X F 5=
M6RL;=EYA?[S6O#D)DA9/9QX4,VJ^ [V:4V7,O[3@'BRB+])3NBUW-#Q*EM&[
MP^KG0/R0D^V=. \4]VTYU5PB&UGH+-VM[E#&'?PX&>KN?O =_1\W%MU; $&Z
M+[&T"=&>(+UU?FEKZA6$(F=\,CQ]K'Y0;PI7@5*$ZL:D\61H7/V@3LZ&)X_O
MWWHB=AT_IO_QEM6'6YG28$PS3K[#$Z^HW,3>[&A,G/Y!O>(K0Q''#WRG6WKE
M?/9H1+!_B..4[_Z#K9^BH!$/Y&*_+EM!UW/3N1X&5U)(8ONN_>U!O]_U0*\N
M/QBY-=2J>9 EQ,7?UOONI=-NDA=\%0$+=V1(#Q]N('0W^3\QD4A![%\]]'Y>
MZ%206L=!ZV?>NGW4^CW#V/;3 PW"DT6,'JOQ,PJ1^'S$G\>/OVHAT-*GL(,3
M6H?/Y_P9=L5K+RL7\B3^>C.W%,3 P%^A '-UJ2NQ*S!V3*K^P_^#NF_[D=F3
MSF\$D3#-^)>0?$.DK.7G@NEI^K'EA?S&L%TNO]3\H*D_1 A-L?5H^/1T3ZX*
MQB^U6_(O#B<H"MR"/\X-O&Q%"_!^ZEP=O] !Z2>H+_\-4$L#!!0    ( &>
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M%E0Y"C%&CL]G$\'ZD+P1MSA$1.+N1DR&%V(2I>/]JW^!.N2W.V/TSV6=V!T
M##S?-FG^O$;1'/RUW6>FG?-)/WYC!N>.2-R[^_.H_U)/ VQ)E*0Q7R?I'-=)
M-!U/<9U'R70*(<&1@\+JK8FC>![3[T5"JR[F^)W&J?ALZ%AR8#R-)N.$K[/D
M@HV.^1DIF9V+>PE"<.=ISX!M,]) [Q"94^R,^-^1:U+@7C\+L06903@34[@\
MHX=4Q.,HF3,Z$[H?)U.ZG\*QV92'9^(<[)A3BI'_)?%R,H[2^?P@S*Z3G1-L
M<S#8P8UW=.!3A-1%- 6H#Z</O/U@S\1L$EW,Q^)/,&3'7W!4_DK2Z6)%G=9E
M7 G<6OB(U9N&^B?MW(<=.E^O\NBDT,?ID"=?6SNGMYL-T['X\?FL4[NBX-)3
M7R1&O>]"I;(K_OI%\H9=PB>B;K3[P'83OBOMIX>O<_>2&B;UEB66CH?SZ4#8
M\,4K/'BSX:],"^.]*?F6FK&R- 'OE\;X]H$VZ#X[7O\?4$L#!!0    ( &>
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MCV+#?86P4H):E(($EBT%@D%K:%+;"BPM%ZK>-);Y7E(KUPJ\ "9+*+EH+):
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M![4H-D"-7BW)J6T@R3:L0SL$<;I]&/:!ELXV$8G42#I.]NMW1]FN SCN]F6
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M1P7-=]?T#P(-&]#Z4FNW'W" PW^2V3]02P,$%     @ 9X #5=HJ8S;5!
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M">+V6\1Z+>T#+:FIA$EW:II-;-O]75_L5NPIUVM3Q2E1[-Q!$>9NJI4M5H+
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ML<(4398-L+\R^+;U+WS ;BZ?_P=02P,$%     @ 9X #562J+!<T!0  O L
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MM5=WXAXN;MDG42O=RNK^XJR%6+IYEO8B;JP(_PD1,_9!56W>L'=5)K+]_6>
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M)CM[NQ'8KM=UAC--Z"]SX[A;A6G%OP>TWH'W2V/<H^$#]#^<V2]02P,$%
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M+EG#R.>C''!L69VY-?5H^!GSF0!93V,[)2 OL(B1'#8E&+;I$SIT4$W@JWJ
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M5H[L=IB<-K1ODYD$G5DA%B%L'Z-[A07N<(W %(+#:G<-T8N>;?7;T@'OR/Z
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M7!"#4? :.31>%\0)A%.\'\KG%B?KW5YS)2@6_IY#@I-,_;M&<$50A;/.">_
MC4^=*L2RS!KQ?!Z'J%'SX3%',A4=P<I1DS)N:-5&<K!*SI,:(93I+4X7V/W=
M$-M/2_A#7DR.R2 0 \;CK$-G&QBAU0KY<=8%:A4*?DYL*:%!D0"$34@KDA^3
MU.24HU32 )AIZ9T/@ 5=3=9Q4-"&BC!7Q%'O/.!)HQ;JKKD I9MTVI'60#$/
MPQ\XVI[+BKT'=/2)V3X3U'O3<SJ%C4DTH9 #.84Z"B<VKG+0N-E_@D*JY"A<
MBAT!>'J27>9&<U6TL\X@0X ?\IUHE#Q+ MJMI!?B$XV<\6AU?1A73+(FOG8^
MRR2^I/ELNL+VWDE(C\=O4Z;L&)6(0G+I%@V#PJ1FL.:0FW,P(E)RUL?[_AA[
M[F.%V'(?_';OAPB9YYER/H?N\MJ%O>4<Z:W%Y7ZJW:74]F/XR;J7><4'RS76
MX&@$/<3: +/H&9<-CZ2U@3P]H4U;6$F=S1"Z&GLI,J7M2=@:0M-TG7@K[&G$
M^=(T:72;VTJ<?[#REEXO1#;8@R.".Y9PL;I6"G-#M$-8UQE:QJ-C+ZHP62LX
MJN9:1E@6GUR!9LM^E)##GNP@QM%S#8)J"XY/U.?R%]NF6NPVI _N(==!(4QN
MRFSO*5&X-!;[8X(.&!14$E>00IR]/';?)$JN'Y<'>@O#]AST7['6X@?*1 \"
MZ/*I* .27]I9,NC.2+IA>\B!W;KZ"RF+Z5U**U]#S0RIX#R4B4_9CE#8N3A=
M@_E12]$^AE*T24/RNT<!S]!)8+VNW$WR'W=$'&)M0BDOL\>+,RGZ"=SK(0PH
M]?CR+&O)Q^-(,8.2H O<@W2^1T9P'J3$ZRN1H_21.V3U$97B" $>9J%V:(!D
MI<K'NM@X^]4VK181.QA$K**?:*&U<Z0D/.UG]4KU_LV\J_W#1<Z)]V,$*O):
MV-D9#5_[V?=-85DC24G1V 6'<.6')Q$Z)TR,6NVZ/"^;N\2-%*!NI3!ITZBS
M:@<)V+ "I[&"(>\BVLRS#_?L,ZH =ZOGJL1SSCHG($S2*QY$D6PYS>GPR<&A
MS)(C"=//,L@0B2%YY Q?HYK@&)P)Y.8H@ELONX3T[W4CI5#$*[/$V<<A">,3
M*;JQ/D?FWK^.:+S? MD00V26\DU%Y3]_N(J8P,E3:D-9V6K6S*D%/X/5-6AE
M))+X<)/=I(D.#W&O9^?]8%JR4J6IB&6E%:O<Z\ZY&8@X>5>BEJGT42]? 7]U
MXRO@LY^;UA;9\XOG,[\'EOKKM +UVM,B&@2ON8%F*8Z;*ICE<344$(_MM_PR
MX]&>OW*1T%V"\AX37A#['^1]\H43A;4):G0OO_'+9B4>:AJUSM0]=Z4E54<>
M Z,?F=F-\-$G8QV!F$4>PRK2[J3 BVM?$/OJ5QR@.C+JA+X.W,FTOE]WW2OU
MD+EAU\)[18G!%TN\CUM-1(H(CHWJ46B3T;5[^L;]1"M:2XR+=:/_&NLK3:@
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MI.:B&5U=V+$[=74A.U.)!NX4TUU=<[6^@4JN+D?!:#-P+Y:EH8')U47+E_
MYM?V3N'79*!2B!H:+63#%"PN1]?!^4U"Z^V"WP2L]-8[(TWF4C[1QT_%Y<@G
M@:""W! %CH]GN(6J(D(HQJ>>YFA@21NWWS?4O[>ZHRYSKN%65K^+PI27HVS$
M"ECPKC+W<O4C]/I,B5XN*VU_V:I?ZX]8WFDCZWXS2E"+QCWY2V^'+]D0]AM"
M*[=C9*7\R V_NE!RQ12M1FKT8E6UNU$XT9!3'HS"68'[S-4-UT(SN6!W"C0T
MAI.M//;@?$03#V+9B(7(>6/8=9[+KC&B6;([68E<@&:\*=AMR9LE,-'LK%"B
MR45;X9KO'OD<GZ<7$X,R$^=)WLMWX^0+#\B7L)]E8TK-_M844.SNGZ"N@\+A
M1N&;\"C!OW?-F$6^QT(_#(_0BP8#1I9>=(#>/I/\ZWJNC<* ^_<^A1V]>#\]
M2L)SW?(<+D<MN40]P^CJVV^"Q/]P1-IXD#8^1OWJ 9.ZZ"H@QR)UHT1NH& Y
MUZ5UI'V!3YUXYA5&@]XG_W$.]WNH;G$2S3-^U$0;W_.J*^#SNNW)3N-J(QD&
M>,4-*%Z)/X$]<R5DIW&TL0;N>,7DO!)+&[<8:!B"IL052$Z?,J[9 O?+E3YG
MZ'@8',\^0@[U'!2+ CL2L-N!$>Y1K *#'S8U<@6%,'9TP7-1";/&:80"Y!><
MLA,6>F$RPV?DI?C<(K02IF0+T7!,!/P4C3;"=+VHX2D+ F_JQ_1(DI#=5ES4
MFK5*YJ U112Y7^3$)SIE:>1-LRD]PC!A_S0E2C_%OT=ID/8^;QZP^PG+4B]*
M(GK)'.=.*9QZ0R2-O2A-63KUDFS#*#^P]BC#GM#)AM0OLCD[1"@(O5F6V =N
M<4R;(^N/,NZ)G6S(??M-%@;AAW<_K*?OH74HJ=\(H8!\_BIB#P22H@135E0*
MY#^ZQE4H&RTVL!A?*@"KPY@] *"]#* *+@8[97U?"(T%PE9'I"T[U>_-95T+
MTV^F*-L2>TNV$JKB:( 2+R7TTYDN,>LP&LG0TK+F2A'@]SRNK7*[^45KW^28
MQWB+T?TBL)I"M68G03">8E6K*EN@<0N-I)L1CZS<@JW;U=HC)LA]6P=>$_9J
MM@(%3B$T*6???_SIEK5<&83CEEMLGO/F"5L B]7;)DVMFKNF7'"A$&FJ#EB-
M%NV45=3*YS8%>S:1_7>MM6,C2N!M/U#,6('G:ZO4K:Q;WJQWXN@P'"#+.92\
M6A!G4K3!"!NSQQ(H=M 6+=?ZS)1*=LMRL)(#^(8MJHZ0$S4A/RAT//IBH63-
M6OR2EGG_5@!V?P7QEHV5TXC:?BW8J@0WU,MIV3I9H;"R]-A+ZPW5?YI^%@7U
M#*@G1CYAJ05NFQR':M#K!._SK96*OBB"12\(1BV6X,(:<,XK#&I@MC72.,\-
M=9ZDF]7#PDH?49K7,%A)EW+5L'TD-79'SI^#O NJ+:^JSNM2XZK+0>T0FF:1
MYZ<^%1(_]<(T8N\HHCV48XH%T08MWV?*_T5A5_8RWXLC*B-AE'EQX/\U=+UV
M<:&QGQY2O9*Z#S?G)]>Y/"I,S1^!5PA>16>SC:870FG#/G68#P@ZN,YASF&U
M;-YBI/?-@S..R[]M3'1'G_X40L>)[8RU&J0?]&M"F(#0&QR#?$Y= [6&KZ3'
M!H5@1%(#V2';ST3&+F2<O:TOD9^"DLY#S]1JXS=B'L?W1AJ$ \Q&7OR!)P8D
M8P50L.FPBO=YUW$[O'*?(-^AI[#A(ERTGA(OK':-.U#COI,2P18 3\='NMKI
MT-5.O[BK?5<K>YSL5PC["F%?(>PKA/T5"$L&"$N^&,)$8[!S% 0WS@7[H.LH
MN?VW"+MXYJ[A\%"MK;J84;8M+^CDO>@J=#EF*+6G5@;J\K )I7L@\NTYQHY"
M^*(F$@_B>(AO"( P?\[0/&P-'$\\M_;Z"N/81B1%1"E:W2^:]HL>(2\;6<GE
MFFV&[AS&*M: H3N]X;2O681;-\L^@N&BTIOF^XW5=C'-8_"20VOPK$ 7=5"<
M8=PIOH0=?>V5P9<=9OJ&US;T!-9TO_G?;QE^WW!GUSW[>Z"[4_+(KTZ0?X@%
ML!\4!B/FCU)KFKJVR$ZW:UW=N?3&(3S@_.FR^A?TT+#X-WMT^?]QVA\*P9BN
M1,*IE_E4%Q!=$WL.1["/8CS+CN/MZ=1+9@3#0>8%?GHP=&+<%06!YP<SEF&]
MP# *PYF7S6*:FPUS:8CT4@OJ$?IA*\CH?(D%9X:C:>KY<8#QZ&59P,*Q/TQ$
M7I1F2-&;QC&S-]=X5%)/J+H]8GL4F<P?XQ(O#.C7G_HL2/!M'/5C,QP)<>1(
M,%/%('&"Q NCA,V\)$E9XDV3&0H3TG",Y]/4R](8S3>-H[XVOHET)\\)B^/0
M"V93:V4T<VP=D,1>%B?];)1:'R2A-YV%-)O.O#2+V3X$FVS=*J,KEO;NG*X0
M,#[<!?,P.ES/7[M;Z<_+W=W^SUPM!5:5"A:XU1^GV'@I=U_N/HQL[1WU7!KT
MNWTM 6-)T0*<7TA$VOZ#& S_M+CZ#U!+ P04    " !G@ -5,V)QJP$$   B
M#0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6SM5U%OVS80_BL'K1A6
M0(MDR983SS;@N.O6H6V"QML>ACW0TMDB0I$J2<7)O]^1DA4W<8R^+R^V>+S[
M[KM/QP,UW2E]:TI$"_>5D&86E-;6DR@R>8D5,V>J1DD[&Z4K9FFIMY&I-;+"
M!U4B2N(XBRK&93"?>MNUGD]58P67>*W!-%7%],,E"K6;!8-@;_C"MZ5UAF@^
MK=D6;]#^65]K6D4]2L$KE(8K"1HWLV QF%R.G+]W^(OCSAP\@ZMDK=2M6WPH
M9D'L"*' W#H$1G]WN$0A'!#1^-IA!GU*%WCXO$=_[VNG6M;,X%*)OWEARUEP
M'D"!&]8(^T7M?L>N'D\P5\+X7]BUOJ-A 'ECK*JZ8&)0<=G^L_M.AX. \_B%
M@*0+2#SO-I%G^8Y9-I]JM0/MO G-/?A2?321X]*]E!NK:9=3G)VO-).&>84,
M_+1B:X'F[32R!.T<HKR#N6QADA=@,OBDI"T-_"H+++Z-CXA2SRO9\[I,3@+^
MT<@S2.,0DCA)3N"E?9VIQTM?P+ML#%F,@:6JUERRMB5D 0MCJ/47^=>&&^ZM
M_RS6QFK2Y-]C.K1IAL?3N",T,37+<1;0&3&H[S"8__C#((M_.5'$L"]B> I]
M?D-'LF@$@MH $T+E;1FTJAN=E]2<4&N>XS'>)Y&/\UZ5^ 08=LSL,V,!5H$E
M'^8D)+O34)/9R2HX6W-!@J)Q^TU%=G=Z"B#"%,0UH+&\\C@;1LL[)AKO[.JY
MRJU:HX:!;P#Z)?-&4>(==2EW"*HQE,>\G<#UGF)./<P+U%Z5"2R9*>$-#+-P
M%,?POL_A\)>"2,&"0JJ*"-$QRV^!$T]B,\K"+,F>!!"VY7*+TGZ;!@;#,"/X
ME;),/-EZ X/!.!P3UHK)+:>C]52JCJ03+'</2&9*25F,BPZ':4RMF:O&&33F
M2+L.)@W3> #7&FO&"\![&M'&:4<XBL35-#FT=ER[?.-SN/)VJ>3/3_:2<)0-
M._[V!9XP#M-Q"A\*BN,;[CEP^9(W5>4'%^73*+P6IN2U@33QKV*%>2F54-L'
M&(4Q&99*UXI$0Z!S5R!(5B%TOIX7_[[$,(P]WL?GS3=YU+%F#Q[G(G4V[5[Y
M8;=FV:"W4WLX:1^G!5:U4 ^(L$:)&TYH%^,8WN$&M<MOV?TA5@B29LOPXN+1
M0^,=RL95YXA>U;Y7Y!8$N@X^Y)&$XT'2U7_L-&7A13J"WY0J=EP(&(_#Y/P<
M/J-]ILIC'YZ80:-^!HV^>P;)Y\F.C9Z3@*^CYW7TO(Z>_^?HB0[NK?3*MOYV
M;L"+U5YA>VO_ ;!H[[V/[NW7PR>FMYRNL (W%!J?C6GHZ/9&WBZLJOTM>*TL
M]8=_+.DC!K5SH/V-4G:_< GZSZ+Y?U!+ P04    " !G@ -5)Y9)DX8$  !H
M#   &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6S55]MNVT80_94!$P02
MH(H22=FR+0FPY:1)T32&[;8/11]6Y$A<9,EE=Y>2G*_O[/(BVK&%^J$H^F+N
M9>;,[<QH/=M)]56GB ;VF<CUW$N-*<Y]7\<I9DP/98$YW:RERIBAK=KXNE#(
M$J>4"3\8C4[\C/'<6\S<V8U:S&1I!,_Q1H$NLXRIARL4<C?WQEYS<,LWJ;$'
M_F)6L W>H?FUN%&T\UN4A&>8:RYS4+B>>Y?C\ZO(RCN!WSCN=&<--I*5E%_M
MYE,R]T;6(108&XO Z+/%)0IA@<B-OVI,KS5I%;OK!OV#BYUB63&-2RE^YXE)
MY][4@P37K!3F5NX^8AW/Q.+%4FCW%W:5[&3B05QJ([-:F3S(>%Y]V;[.0T=A
M.GI!(:@5 N=W9<AY><T,6\R4W(&RTH1F%RY4ITW.\=P6Y<XHNN6D9Q;77,<R
M-SPO,8$O!2IFDZ6A=\]6 G5_YANR8F7]N$:\JA"#%Q!/X#,!IAK>YPDFC_5]
M\JYU,6A<O J. OY4YD,(1P,(1D%P!"]L0PX=7OC*D%F> -T54C,!/RI9%AK^
MN%QIHX@Z?SZ7B,I.]+P=VT[GNF QSCWJ%XUJB][BW9OQR>CB2!11&T5T#'UQ
M1^V9E )!KB'I1B3;B)YS^3CH?8JPEH(ZE><;,)8"=;OR;ZC!T#5%0H37UNS!
MDMW9RZ7,"I8_O'LS#<:G%QKN58GP$9DP*:Q*3=:T'L NY7$*3"'P/!8EL806
M=BTS,J]D]E) 5LR:H3LM!4^8H6MMZ$-CXCN?;#T)DG*?VB&RQ<9$3TBM^Q2H
M<F@F58A.6O,]9!5YT9(7B'K84&]\#A]JC7NGT:7Y8\E6\(X ;W&+% ?<"&;L
M$'66.FZ^!9>NX()6X11N%&:\S'1[&D6#T[,)W$M#M%0U6.=R&H;P?D]#6E.%
MEE(;FX9&KH=[RK +WO($*1DQ9]4\)#=8)I7AWZH#;$ <6W.76RP8^8GB 59V
M?O>A-^ZWQB>#Z70"2\$XN=MJ-[=A.#B;1'!' Y?(-( -YA2SJ.PF-,JX[2P[
MDP^ZO:"+?GH2P?4_<[E1HN:J,U5GF&C\G5!DH<.F]4G"\J&][9V%HSY\HO@I
M#:;A3&M@'!SN:N2#:M2'+U1W]00QF/3A9WNR0F) RT/#]EC1-)?Y#Y;P2KID
MD4!EH8,QC4[[1 ZYY>[WT)+W$4PK& 8G??B%?LZ=#UUV]2;!H7JO_KC2/^57
MW<"Z\CBNVO^0\16:'6+>G0TNWNY<,"DS;AA0G:5Z9AC4D\#FY=\:!0J% S"2
M1,E]HJ8U9V<VCVV--M3P%MCE/:X87RA)=]H*NI9VA4^KH I!.$]8OB[SN)V6
M;X/AE'[/J=QU,6TPQ^?/T+7'J_KIORN/_)^79SP<O[H\2Z936-.8=,:WW(JL
M'CJ3R#U!N>%H^W(R&(V"KDZIF^1N43^5[P6#Z"SJ/_=P\#NOOPS5QKUQ-26T
MS$WU$&Q/VV?T9?5Z/(A7;_#/3&TX94#@FE1'PU-ZM:KJ75MMC"S<6W(E#;U,
MW9)2FJ"R G2_EM(T&VN@_>=B\3=02P,$%     @ 9X #5;G0]&+!!   0PL
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MIM^4])MN>+EJE%3+.]B2KK2Z%17R-=RZ;@HEEF]7] Q$R+K==MDYQWE.M7K
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M!N,,NX[N7AC=Q*JUO]5CIT2\^N$*'V5<NPVXOE#*;B=.P>Z9-_L74$L#!!0
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MOFWN%$I1AU*R&H1F4A %JUEPE5Q<#ZV^4_B=P5;OK8FU9"GEHQ4^E[,@MH2
M0V$L L6?)[@!SBT0TOBKQ0RZ)^W%_?4._:.S'6U94@TWDG]GI:EF01Z0$E:T
MX>9>;C]!:X\C6$BNW9=L6]TX($6CC:S;R\B@9L+_TN?6#S]S(6TOI(ZW?\BQ
M_$ -G4^5W!)EM1'-+IRI[C:28\(&96$4GC*\9^9?I-;D#A2YD76-7EI45 $Y
M>Z!+#KHWC0R^836CHL6[]GCI&W@C\E4*4VER*THH#^]'R*TCF.X(7J<G 7]M
M1)]D<4C2.$U/X&6=P9G#R][ NZ5*,+'V1GMK_[A::J,P/_X\9J^'&QR'LS5S
MH3>T@%F 1:%!/4$P?_\N&<67)\@..K*#4^AS#,JF,=3EKUS9]&,%H:(D)>.-
M@9+ SIH-6J.M-<=,./W(0P5D)3F6)R(18R-/-!B-F\I4Q.!Q\>]Y$/I$&7=@
MB&,1;'IA/A>/E>0E*$W.F$!TV6A$TB&!YP(V9@^AQ(3N71"L/D?BH5( !^E%
M,#G )<=.9\&>W]"PZ6,_R=[*)?]*R1KI"<-$8QV _4XY2S7YA9P-PB0=]NQJ
M$B;QN%T-QGXOC<-T@IN?!=J'9<,1L.<12Z9;4&3Q@AD2@9T6?6CH,Z*/LAYY
M_RY/D_2RE9(PRS/R&RI9,$*-46S9^*@8V?G1.FCG1T2[?9(<A"&?@')3A990
MW],?YOD/]">9WTOR<)(,>N2[ZUU0GM,GY+F&@U<0OS':8(RL=\Z/!'\2A_$X
M(?DP' QRDD_"\22U4CP<>1?;D.Y#DNL?,&[>"D#<C[VOXWZ2O%ZD2/[#<4=W
M;GW]BX#I$0)\1[3-WO_F]].LT]Z)WC#L>L/P9-DN\/^Y;) =TJ!HOS,$_^&P
M=HM&,<,P<EA2O+%ET";Y017_7.\X2>)X^[M"-N<O='P2'5)Q387RHN$=G>WI
M)'3PPD:*+B7"VB"]["WM=''84/[7SG$/^(_!"ONT:VFD$0P[YEEPO_BF@UYH
M?>HF)E' N9T:2F)/R)G-PC2^O$/!+9/+GDM##M[JUWA?'!YVA=$ G\:22G&=
M)V/\CB<963AEN?$ICR?^/$[<UVKE66:+"]$-\YU=,#192(-.31+L#W@C#4>3
MT2OI01K*28)E/,:C43@<3*R4QD[*T!/'DCC:&T5J4&LW<&F,92.,GTJZW6ZF
MN_*CS(NZ'PB_4K5F:!6'%5Z-^V-,1>6'+"\8N7&#S5(:')/<LL*Y%)15P/.5
M1"-;P3[03;KS?P!02P,$%     @ 9X #57#1OY>2 P  P@@  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&ULQ59M;]LV$/XK![4H6D"-)$J6Y-0VX&0K
MUJ$%C#C=/@S[0%MGBXA$>B05)_]^1\K6G,%Q]VV 0?'E[KGGCG<\3_9*/Y@:
MT<)3VT@S#6IK=]=19-8UMMQ<J1U*.MDHW7)+2[V-S$XCK[Q2VT0LCO.HY4(&
MLXG?6^C91'6V$1(7&DS7MEP_WV"C]M,@"8X;=V);6[<1S28[OL4EVN^[A:95
M-*!4HD5IA)*@<3,-YLGUS<C)>X'?!.[-R1R<)RNE'MSB2S4-8D<(&UQ;A\#I
M\XBWV#0.B&C\=< ,!I-.\71^1/_L?2=?5MS@K6I^%Y6MIT$90(4;WC7V3NU_
MP8,_GN!:-<:/L.]ELS2 =6>L:@_*Q* 5LO_RIT,<3A3*^!4%=E!@GG=OR+/\
MB5L^FVBU!^VD"<U-O*M>F\@)Z2YE:36="M*SLZ55ZX>/SJ\*;E5+=VVX#]?[
M>[YJT'R81);,..%H?8"\Z2'9*Y Y?%/2U@9^EA56+_4CHC=P9$>.-^PBX*^=
MO((T#H'%C%W 2P>?4X^7ON9SS35^O/$^+_@SI9B%N=9<;M'/_YBOC-64+W^>
M<[['SLYCNQJZ-CN^QFE 16)0/V(P>_<FR>-/%YAG _/L$OJ+VUJ?WA8^N3F>
MXWL1\3S?>V5Y<]8 K)Z![[FNP#[O$+BLP"&"L-B"D* Z37K2J$94W!++C9!<
MK@7!&4L;+KX&]MP _3:JH3?!P'M2M+7J#,&9#]= Y49KA/M:([Y()J!40)\*
M1YFE>'I%PB6+&Y*3V=Q3OW?4?2A![9QW!M[".*&!Y84;1RF->9' W?*[@2S,
MLP)8F+$"BG"<E;23Q0E\=8=I2= $GX3)J* QC0M8N(,D+,<,BK2 -(SC&,9E
M#/\YKF_)4)PP^J9A[MDD+$Q'I3](1V/XZH+^Q07]5AD+:D,/Y"/*SJD2E=RI
M.OMN-<[[;U86L*3G3\AM"%N4J(F,NT%>T<,B7,J[%_)(R< H+$<Q.5[D"21Q
MF(YSMU6P'_AQYLI/DN2'KETHD]%0)J/+94*MJ^H:='$QOMC[DO$1-K"E4K?_
M?IGZ8KF(>[Y83FOR8&"/&H]6_I]$]XF;IY0#/O&2,&9EGY?OWI0L89^&;U:,
M(4W.ASTZZ2LMZJWOGH8NOI.V;S'#[M"@YWU?^D>\[^[?N-X**K0&-Z0:7Q44
M:=UWS'YAU<YWJ96RU//\M*8_&:B= )UOE++'A3,P_&V9_0U02P,$%     @
M9X #54 QK8UH!   $0T  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL
MQ5=M;]LV$/XKA+H6">!:LN3866(;B),5Z] 4@9UF'X9]H*6S180B59**T_WZ
M'BE9D1U%#885^V+Q[9Y['O+N2$^V4MWK%,"0QXP+/?528_(SW]=Q"AG5?9F#
MP)FU5!DUV%4;7^<*:.*,,NZ'03#R,\J$-YNXL1LUF\C"<";@1A%=9!E5W^;
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MC<H:T/E:2G-8V N.77_V'5!+ P04    " !G@ -5S[!MC@L#  "H!@  &0
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M4*LU:&=-;&[A0_5H$L>ENY0GJ^DK)YP=S[!2AKL$<;D$)C-XM 5JF!1,+M'
MV9PM!)KS86C)F\.$Z8;YIF&./V!.X$%)6QCX(C/,WN-#4KF3&F^EWL1'";_5
M\@(Z40OB*(Z/\'5VH7<\7^?#T(W5=6IKO0U]AH)9S.#:E0HEA>+_=;T@*ZJ=
MWX<RT#CH'G;@WM.EJ5B*HX >C$&]PF!\^JF=1%='Y'=W\KO'V,<39:P!9HQ*
MN5>]YK8 NCQX?Z=3P>0A[4?9#VN?$WFN!#UD1VQ=94"EU8IGE"FV?=B@<E"U
M!JLL$Y#^ATQ8O%)M_U&$?:W0\3@TG'%) %4;NB-S?@F3NJSIHN@U0Y.$>YG6
M6A.W+;2JEP7<8HKE@LJXT_;ETGXSN7/LY'U>:,1W)0I48+@ML .()_YRS/X)
M5ZB93-&7DD5-KY7YSK- B3DGG2?0'O1H[">;Y6.><P+X1%.LTBC!LP84M_K=
M&$X_#>)V?$6[J-^&J58Y&M</*;'N3@ALH-=*D@1Z@SYT6GT:YS[O)S!H]3YW
M:$X2/[:B;@<.U5VXUSU*U$O?(PW)J:5M&LGN=->&KYON\V;>]/ 'II=<&A"8
M$S2ZZ/<"T$U?;#965;X7+92ESN:7!?U*4#L#^IXK9;<;YV#W<QK_ U!+ P04
M    " !G@ -5@LQY>XD&  "L$0  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6S%6&MOXS86_2N$.RAL@!N+U#M- B29Z786[>X@SK8?%ON!EFE;.Y+H
MBE0>_?4]EY(?F63<!&BQ7RR*(N_CW'/O)7UV;]K/=JVU8P]UU=CST=JYS>ET
M:HNUKI4],1O=X,O2M+5R>&U74[MIM5KX374UE4&03&M5-J.+,S_WJ;TX,YVK
MRD9_:IGMZEJUCU>Z,O?G(S':3MR4J[6CB>G%V4:M]$R[?V\^M7B;[J0LREHW
MMC0-:_7R?'0I3J]B6N\7_%SJ>WLP9N3)W)C/]/)Q<3X*R"!=Z<*1!(7'G;[6
M546"8,:O@\S13B5M/!QOI7_O?8<O<V7UM:E^*1=N?3[*1FRAEZJKW(VY_T$/
M_G@#"U-9_\ON^[5Q,F)%9YVIA\VPH"Z;_JD>!AP.-F3!5S;(88/T=O>*O)7O
ME5,79ZVY9RVMAC0:>%?];AA7-A24F6OQM<0^=S'3*T#LV(W>F-:5S8J-;]6\
MTG9R-G603ZNFQ2#KJI<EOR(K83^9QJTM^] L].+I_BGLVADGM\9=R:,"_]$U
M)RP,.).!E$?DA3MG0R\O?+6S_[F<6]>"&O]]R=U>6O2R-$J74[M1A3X?(1^L
M;N_TZ.+;;T02?'?$UFAG:W1,^L6-+DQ3E%6I/'O-$BEPIYM.LV5K:F9[5RQS
MAF&A-56Y4.Y+U'LWCBNZ74.DJ9"=!(CSP6?>(2!ENG:KBI5-7P/(G''9,+<V
MG57-PDY.V8<[4]&:'[2JW)K- $990,XUM)6%JMC,5!WMM.QCXW2[E3GKYLXX
M?+\V+6("#]A83/"V]XC=^@4W@_?(16C6[';=:OV$< QTT3NZ#-NVH+UCN>1I
MGF @9<J3(,1H'"7!!,]0Y#P/<XR^_2:30GYW,/=*?>*9OC3FH20M(DJYR*,#
M?5)*'L3I$WW;N3<@^7KP7@W:Y>)_J#F8_G#U\?;])5D?<R$)&A'R*)=D:<83
M^ MW$IYETCLD>/H6K)ZK27@<BEY+G!,R,H#>K->2]EKP+8R2_P/79N7#6YB&
MALB%H(!'(N590*"-<^E#GXB$YYZ&^]!OYUZE[CG14'# 9PJ13%,.E:0NRS-2
M%X7I .->W7;N+V7:'T#VG "R#RX2+^9)1A;'.0]"GS8(?!!Y^*(82$6O1>H%
M-DL>I924,N>Q'T1(.Z^7M*1Y..D9+N-P"]F;'P,V6Z3*IJBZ!8"]4VV)DLF6
M9:.:0G.V[FI%1QN+,@OD.:OT2E6<Z0==='1:82BOS,#3%D5^+V_9*G2MKG!=
MJ[$8!S2K[<F1IA/OFD[\QJ;S)81H-PV.BI6Q]J56<US\"ZUFVVFL;S7M,_V'
MO>VPZ1'7CMC&E'-M.>]Z';Y'UC4DVK5J]=I4"Y0%$O\T!S@*1G'RK+F]IJR]
MDO>>EOO1/_\,<ZFO\#CS^3[.N0C2892'_9S(>"ZB"?M16WO:UT1MJ9]#BT;C
M"5F2L3 *F,C%_O/ *S:67$00A#HL4TB!LC#+\40N)0),O]*-7I:N/Y>,-ZVY
M*_V1':>%R5:)4P]( )%%L$O07AX(DID&J.SO-4A0##$GQJN:CF>_]1-;?F,3
M6I&0M#N"0PD&P%5Z.1B( +G[=UQ#&#;A3-?8)=(&H-6ZG@._=;G9%<$OG^B]
M>9*S'RD4_K*Q48^^9V#[0L\=]\3ZVNXQC@HBS@;M'@;]:U>Z1Z@&CQ8 X0Z(
M:D* Y[%D$<_2G$D>1QE5I"21['JMFA7E-ENJLD6IJ%#;>_[3095LH50HP83A
M!)8%J(@[$]"*4U@0HSC^R]>+ ?CQ -^D=T&BMXX)L2B-@1K I+.P+4DDY61A
M+-)K+S4)G^@((KS/G"D^_XVN0@OB*8E_$BE$%=&E.(4\B<.>*6'LPXTGJ#-#
M[VJI!'ZA;Z<I)'[%$'%YR(0!#CJN^XU,6:NQ?2Q34I(3(V)B*,Y=9"95R]6C
M9]1!(C&U $%-^[AGUCZ0/!9//?;OEP7"V8,T6 S7(DE$3CT->_"1*4$:##08
M4UY/>C8L2MO'L0-DN$_W(;2^3^!,>*C1OPED6/A2C^R/6;N3T*X?_CDMZ^.V
M4;T;!R?Q!-?-JB*7JR$MX :X@L)+6?$5EY9#'72^5GKH41'KOB+J%RHB+7DG
M3O*=MM60PF_1=E2'X-1B-]K?_ZO'%_OD]. &7>MVY?\GL AVU[C^,KV;W?T5
M<=G?P/?+^_\Q?E+MJH1ME5YB:W"2HB>V_7\#_8LS&W\?GQN'V[T?KK4",VD!
MOB^-<=L74K#[@^;B=U!+ P04    " !G@ -5:6-7B'8$   7"@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T."YX;6R=5MMN&S<0_97!M@AD@+5([MVQ!=AN
MBKAH4"-.TX>B#]0N);'9);<DUXK_OD.NI,BH[:9YV1U>YO#,S.'E?&OL)[>1
MTL/GOM/N(MEX/YS-YZ[9R%ZX4S-(C2,K8WOAL6G7<S=8*=KHU'=S3FDQ[X72
MR>(\]MW:Q;D9?:>TO+7@QKX7]N%*=F9[D;!DW_%>K3<^=,P7YX-8RSOI?QMN
M+;;F!Y16]5([9318N;I(+MG951;FQPD?E=RZ(QM")$MC/H7&37N1T$!(=K+Q
M 4'@[UY>RZX+0$CC[QUF<E@R.![;>_2?8NP8RU(X>6VZWU7K-Q=)E4 K5V+L
M_'NS?2MW\>0!KS&=BU_83G.++(%F=-[T.V=DT"L]_<7G71Z.'"KZC /?.?#(
M>UHHLOQ1>+$XMV8+-LQ&M&#$4*,WDE,Z%.7.6QQ5Z.<7[Z63]EXZP/K"=2=4
M[T#H%FZEC177C?SA"J-NX=):H=<2"^(=S#Z(92?=R?G<(XD -6]V"UY-"_)G
M%BS@G=%^X^"-;F7[V'^.Y \1\'T$5_Q%P)]'?0HI)< IYR_@I8>,I!$O?0;O
M1KO1AKCAC\NE\Q9U\^=384XHV=,H82^=N4$T\B+!S1)SG"Q>?<<*^OH%CMF!
M8_82^N(R:%GY!U :FJEHNT7<4U2_'LP>RZ'Y(H?A2 [+* =Q+(>MP&G!J<--
MCNI )+\QHT-7=W(&N'^P+>%.?7Y4?<#:R4/MPH?!F[=W,&,GJ$6E52,ZN#/=
M&#:PB]T?C,>^KYIT)==*:Z77N&V[6-#O@>>D8!4:+$.K+()5,L+K#*V\0",/
M79R3/.5QL"(5+^%&-Z.UR+@QSH=D=\)CRQN(_=J'#"G3PJOO*L[X:^!90>H\
M/_PK4A0U<%:3-$N!\XI0QE^ '1#-[D%GC!)>U2>0<E(B&Z27I14$NHC%<K1R
M6L$OTKDSN!7JOVG.,.84 3'EI,P0D;((P2FI*(,R)6E90YT15M%G$!\QS-("
M&*6DI#7^&<'T!JRB3 '3F]8<:DYHD</U)J@&VM&&P@11/$AA85:3K"I.8,93
M4I89&FE*>$%##P;'^ F4&2FK$K**\#*'FQXWEP>S0F+:F4ZU(I[RYILUO*_<
MU_Y_1?(61/L7'M*[0Q%9[D=G#..-@>P-# SE76(A.3!&*$W#)G@L3U80-NF.
MUJB[*%24;%U0M# C.0TZY30C!58)K;0BC.;[5?_W;]I$L;)J+\586G.O6@EN
MD(T2'1X-C; 2KQTMIFS%?+[Y^!:EX=Q@+';@N)6-L6%;;Y7?A),)@4.%K+R7
M>I3A?#$C/@@\2BBBX!B^+FRLG#N-^?MW5I'/-U84[_=P^4,3-1="Q$= 8T<\
M&P*0Z,T8I@WB(5QF8:&5:%2GO)(3_GZ&V4YY">QQM@Q?Z[6TCQ@-89N8*<:E
MW(AN=?K443\_NJQ[:=?Q2>(P6;C4=&\?>@^OGLOILO\R?7HRO1,6CS@'G5RA
M*STM\P3L] R9&MX,\>I?&H\/B6AN\.4F;9B XRMC_+X1%CB\!1?_ %!+ P04
M    " !G@ -5WN/X)?$"  !O!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6R556UOVC 0_BNG;)I:B34O4(H8($%?M$[K5I5N^S#M@TDNQ*IC9[93
MZ+_?V8$,)HJT+['/OGON>6S?9;12^LD4B!;6I9!F'!365L,P-&F!)3-GJD))
M.[G2);-DZF5H*HTL\T&E"),HZH<EXS*8C/S:O9Z,5&T%EWBOP=1ER?3+#(5:
MC8,XV"X\\&5AW4(X&55LB7.TWZI[35;8HF2\1&FXDJ Q'P?3>#CK.7_O\)WC
MRNS,P2E9*/7DC-ML'$2.$ I,K4-@-#SC)0KA@(C&[PUFT*9T@;OS+?J-UTY:
M%LS@I1(_>&:+<3 ((,.<U<(^J-5'W.@Y=WBI$L9_8=7X]L@YK8U5Y2:8&)1<
M-B-;;\YA)V 0O1*0; (2S[M)Y%E>,<LF(ZU6H)TWH;F)E^JCB1R7[E+F5M,N
MIS@[F==5)9!.V3(!E\P4<$/W!+>RN6]W<">/;"'0G(Y"2PE=6)ANP&<->/(*
M>!_NE+2%@6N98;8?'Q+1EFVR93M+C@)^JN49=*,.)%&2','KMNJ['J_[?^JO
MFS4#/Z<+8S6]G%^'Q#?8O</8KIJ&IF(IC@,J%X/Z&8/)NS=Q/_IPA'FO9=X[
MACZ94W5FM4!0.:2.>$[$.U1;.X(R;E*A3$W9#]$_GN"Q0,B5(%0NEU1^7H,[
MD[T4;6K@NR^&2["%J@V3F3D= M4/V0ASOMY[$4#WB>U]ND\,>U=RU2IP.K\H
M^=XGO)7/:*SC10G@ADLF4V=-78ESR]'0--4U9:@T]2]M7[PG_JYYY:"AJG5:
M4#$;> MQ)XX'-/;[ [C.<VH7QF7[C'[_*X4SGZO5:B#7J@35[HC&]:(3Q1'T
M.WW2XJ,S8,8@P=%-5,K9A'NB%I::)1E<G@*NB8=<NK/6_R*"X&S!12.HUXG/
MNW"2T'!Q>N@!A3M-H$2]]*W.0*IJ:9M^T*ZVW73:-)&_[DTKOF-ZR:4A%CF%
M1F<7YP'HIKTUAE65;RD+9:E!^6E!?P34SH'V<Z7LUG )VG_,Y ]02P,$%
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MEP:[$/=88F,)R@;@>BZE>1K8%_2M:OPO4$L#!!0    ( &>  U7->HF4H0D
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MAVH^J@6H%E*:G$[-L@!#V3'M7+.A_7U4LVMM_T]C \,ZKMG0WCVJ>:CFHUJ
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MHG+Z5P>4/[]/T^+KDW[I/Z;9Q^T8UW\"4$L#!!0    ( &>  U4)($]K.@L
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M<'VOVTM +2J41J$T!J5Q%$UO=651;:-X.]IZ+)*PWK6574::R@%&6>71]W:
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M1I=,F KZ]Q7GZNG&$-2GCV?_ 5!+ P04    " !G@ -5]$@VT+$"   &!@
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MF>(C$;1;@/,SI>RFX]XMY;-S^!M02P,$%     @ 9X #5:M'SE'_ P  0Q
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MS:RQA1)(R397SWS_,]2"1B5?S'-I_J)]%1OJX'@K%2]JL)Y!05GU2[[41IP
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M&ZTK1@^_52_>9=,S&3GM#JHCS ]P.RSJG^UKW;!/3EVZEUZ;TZM$,=\R51W
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M+!G[ICNODYF%=4:002PU!5%_6[B!+--,*H_O-:G5C*F!^^T']I?EY-5DED3
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M9>7/+24QY=I G5\S)A\/] 6JK2WS_P%02P,$%     @ 9X #5877+$@P"
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M+^GY(96L]94XL3FALW9!0_/&AC;B=H2!1L:AT-K%T\B$6*\3CN_Y^^(@Q=C
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MK8 A@:9]P 7BPDU/&FM.7&RG'?QZ;"<+79NEJ.(FL9WSOG[.26)[M&'\0>0
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MP>G,V?D&&L]$-1?5/%3S42U M1#5!*I%J!:C6H)J*:7)'<$8SW3TJRV>/-]
M8YFHYJ*:AVH^J@6H%J*:0+7(.;[DM:6\HD^,MIN@6DII<G&/D4M''[GL1O:6
M<KZAK' T6(EJ+JIYJ.:C6H!J(:H)5(M0+4:U!-522I-Z@?D8O9R;Z%A_CB8<
M4<U%-0_5?%0+4"U$-8%J$:K%J):@6DII<D<P)ASG^JLO^UF_B/.+OZS0[WUV
MW:.!QD&3AH/V3'6U- ]MV$>U -5"5!.H%J%:C&H)JJ64)A?UF%:<Z].*HFSS
MSFUW/Z92EC4:4T0U=]"DY=S-=Z;]O*31_"&J!:@6HII M0C58E1+4"VE-+FD
MQXSB_(3+*H\_DWPS_-U_#5@<AO%O=)_DQU=#MAW5R9-K_9&<7<YH!!#5?%0+
M4"U$-8%J$:K%J):@6DII<M6/$<"Y-EET7/557=P6?1AYOT"RIMRG1]D,VU%E
M,ZZ'+9]V#(NIZN+$KOY@SRYE4O-1+4"U$-4$JD6H%J-:@FHII<FE/(;XYOH0
MW^?L6_\1W3PN?';":H?SX_4)5=?XOM:W?/8'-IK40S4?U0)4"U%-H%J$:C&J
M):B64II<Y6.:;ZY/\YVXCJE>.7O^C6;HYL?K)4X=Y4DU-!Z':@&JA:@F4"U"
MM1C5$E1+*4TN[3$>-]<O<'C^.J9Z\.PJ1P-R@R:?/#=5PPL/;=A'M0#50E03
MJ!:A6HQJ":JEE";7^9A^F^O3;W_-OYZ<C]%39U<XFH!#-0_5?%0+4"U$-8%J
M$:K%J):@6DII<B<PIN3F2S8?@P;E4,U%-0_5?%0+4"U$-8%J$:K%J):@6DII
M4D>P&(-R"_T:A?_G[]WT_KD]PZ!)%S.P%ZJ3]6B['JKYJ!:@6HAJ M4B5(M1
M+4&UE-+V57_9W.5YZV9M=O5AF]>W^76^V33&[N>O?2-/[C7J_*;K%:SWG^R+
MRZ/[KZWWKJ6XW[/>^ZK[ ^M]N+O_<FSVZL-]=ING67W;=2#&)K_I#L%\UY^W
MK(O;N\.-MKK_>&%=&+]6;5MM=W_>Y=DZK_L-NG^_J;I)R7"C;^!K5?^V>YA7
M_PM02P,$%     @ 9X #5>,Q#'N(!0  %2P  !D   !X;"]W;W)K<VAE971S
M+W-H965T-S$N>&ULK9IK3^,X%(;_BM4=K68DH$EZ9TLE:"[+"K2(R^Z'U7XP
MJ6DM$KMC.Q16\^/73M*TH:FAFO.%)H[/<Y*<5[;SXO&*BV>Y($2AUS1A\JRU
M4&IYVF[+>$%2+$_XDC!]Y8F+%"M]*N9MN10$S_*@-&E[CM-OIYBRUF2<M]V(
MR9AG*J&,W @DLS3%XNV")'QUUG);ZX9;.E\HT]">C)=X3NZ(>EC>"'W6KB@S
MFA(F*6=(D*>SUKE[&GF."<A[_$7)2FX=(_,HCYP_FY/+V5G+,7=$$A(K@\#Z
MYX5,29(8DKZ/[R6T5>4T@=O':WJ8/[Q^F$<LR90G?].96IRUABTT(T\X2]0M
M7_U.R@?J&5[,$YG_1:NB;W_40G$F%4_+8'T'*67%+WXM7\16@-O=$^"5 =[[
M@-Z>@$X9T/ELAFX9T/ULAEX9T/MLAGX9T/]LP* ,&.3%*MYN7AH?*SP9"[Y"
MPO36-'.0US>/UA6AS$CQ3@E]E>HX-;GB;'ZLB$B13QX5.D930694H?.Y($1+
M3J&O/E&8)O*;OOAPYZ.O7[ZA+X@R=+_@F<1L)L=MI>_$\-IQF75:9/7V9.V@
M:\[40J* S<BL(3ZPQ_<M\6W]!JK7X*U?PX5G!?Z!V0ERAD?(<SRWZ7D^",]T
M>,?)P[V&</_SX4W9@Y_+'OY<]L@>[I-X'>Z.+*7H5(KLY+S.7I[6X2632F2Y
M_OZYTAW0I2*I_+?A[BX*6K>99D;R4[G$,3EKZ:%:$O%"6I-??W'[SF]-98:$
M^9"P !(60L(B(%A-+-U*+%T;70]?4J)\4ESBMUPN_$G/1(_J"#&BFN1BY1TJ
MEP+6SV%FTG^9../VR[8&/NP1?-@CW.UQ[([<WK#>+0)ZLEH=>E4=>M8Z7#*J
M*$[0O9E)KCAF*,0Q3:AZ0S_0'8DS/:OD,TQ32:SH0TL""?,A80$D+(2$14"P
MFG+ZE7+ZH,-]'U(LD# ?$A9 PD)(6 0$JXEE4(EE8!UF]*!"$$YYQAH'$FOP
MH=J A/F0L  2%D+"HL'.3#7H.<YF/JL5?5@5?6@M^LX7R0^4CQ%ZIB\N-4G!
MBCQ4"I P'Q(60,)"2%@$!*LI9E0I9@0ZIXP@Q0()\R%A 20LA(1%0+":6%QG
M8X$XP!\1)7![H'-'GO-NX3ZUYSU4"Z"T )06@M(B*%I=#UN6F&O5PP/32PRA
MZ'_ZF\7( %$I,\STTB/FLED/!;"WI8=1;U<.UK0'RP&2%H#20E!:!$6KR\';
MR,&S#P]DKK]LR>N2,$F:S,Z+$K!=_D[O??&M20XN/B0M *6%H+0(BE8O_L:,
M=*WVU<>+3]W@^_=7E=_1J ]0CQ*4YH/2 E!:"$J+H&AU)6V<2K<+NBAU09U*
M4)H/2@M :2$H+8*BU46SL55=NZ]ZC5]IFJ7HD0L=2]D<Q5BGVS?.@#JIH#0?
ME!: TD)06E32MC\.C FRQP5Q-T:I:[76)G>$42[6TTXYWU B/^&PV\D'"P/4
M-@6E!:"T$)060='J^MEXI^X =@("M5-!:3XH+0"EA:"T"(I6%\W&>W7MYNOM
MVA.19LF;5+M%3+^\*=YKP9;DVD?QL+_[50SJKH+2 E!:"$J+H&AU86PL5M=J
MRDUNMF21XF=RO%KPA""=*Z59VJB'T:X>!KMR /5/06D!*"T$I450M/KVJ8V'
MZMD]U$NFAP4B%;K!=':$@M<XR69FO3K%2ZIPDIMIZTY'Z,\E$5B9Z^=F+V*^
MCFG2C+=KM.[:K/9;.U0RH+0 E!:"TB(H6B&9]M8FQ)2(>;Z_5*+8_+.VV/U5
MM59[6,_SG9OOVJ?NJ>\VM ?N:5CL4-W@BPVSUUC,*9,H(4\ZE7,RT&.,*/:@
M%B>*+_,MD(]<*9[FAPN"9T28#OKZ$^=J?6(25#N!)_\#4$L#!!0    ( &>
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MM"]5VU:;W8^W>=;U*OT&W;]?5]T\Y_!+OX-O5?W3[G0N_PM02P,$%     @
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MN:@^N$;?G@/TX>>/XZ[28\A)W7G5;U;V(V?Z8?2%9VHM49@MV,*L[^JQUQM
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M3C3:(GK+=-]V-='CPEQML%^.0_03A4/0PM'Y5QQKFMK:EHD.VC0\:-J_C?N
M&YL3[O\<;K[ G;29Y.0IDL33D^GFF:C9RZC C!J\G(&D1:"T&)260-'Z+MPG
M[/B%!+M[A#.'G&;,X)4T)"T I86@M B4%H/2$BA:WWK[>!W/8!_F0(-V4%H
M2@M!:1$H+0:E)5"T_O;+?=QN&[/4%[+.5MS/.EUGXAPOHLQUAKI)5]A7BQG-
MGYA!"T>@M!B4ED#1&JN,#_8D%Y2OZOWI M5/9,T&WNYLMP?^7;WS^]GY:WRQ
M:':R[S'-QOJ/A*^R4J"<WBND]=97BV+>[%5O#B3;U#N?[YB4K*C?KBE)*:\:
MJ,_OF9J7VX.J0/<? _-_ 5!+ P04    " !G@ -5#,I:'2L$  "A%@  &0
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M]?BS>W(=J"]OWU&Q1:<C&6S0SAM<(5Y1WX?6%<5WU0WAFBO%\ZJ8 L6T6#?
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M<:Y3ROJ1E?KCXVU'LP:T#IEH&H7=T*(:6O0*:$,)*=60$)I@A6 F=DQM)/"
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M.Y_@0<FR2R\G6N2VT=T(C6VS'>[QRP:D$<#W6R'TT\1L4'\K+?\%4$L#!!0
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MGT-XIIC([-V>IO9"U'V5,BF)6M*LK6]FX[8KQ'$F)_5_C;/>V<)#+](7-2%
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MJM3X;V781[<QYF;K$Q4;%DL4PEK'.%<3G3(BNRS*.HKOT@N:9ZX4C]+F%F@
MPKR@GZ\Y5X>.N?,IKNS\?P%02P,$%     @ 9X #5;E[")+M @  E D  !D
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MOY+8SC[XS3[XA]2C[R5P(C.Z0+GY1\Z8D%U;4:F$1D5?#:L(8T\=A-5VB3M
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M;W)K<VAE971S+W-H965T.#,N>&ULE51=;],P%/TKEI$02*Q.DZY4(XFTKD*
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M&-O#8]7"I.H/*[Y\@PI2<KQW=A2Z5X;N-8;^+EVQ!':L&!#<Y R"2!08:'!
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M()@BI@+D\Q65_E@UU #UJ?/L;U!+ P04    " !G@ -5MFD,4N@$  #P(0
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MP65MC_K/3S1&A/0?H&B,,';]OHQHK&SKR",4TK9V9+BUNSTB(\-NI]8>*"T
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MJ,H[N\!N*YM9TVRTJ&PS70F-K=DN<QS/((T WJ^%T/N-4= -_/@/4$L#!!0
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M%E@1.>);9/I+SD5%E)Z*C2NW DEF057I!IX7N16AS(GG=NU&Q'.^4R5E>"-
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M[._7Z'K(F:E8AN. FH2[&(/TV9/>('JU+X'_B>Q>.OM=.ON'V-,)$TQF",R
M6L("5UQ*ES@R*M1<Y?NB;R@'GM(UO'4:GPZC:!2NM\/:]>HEP^3.ZY[>DT[O
MR4&]U""M\%_;WF^C 9]LW?E0U:['RP.R!IVLP4%9<TG#0/!?]/X)90SN%3?8
MN;J_F[5=IT>D#3MIPW^H,%+S.5C;X4[5DJ2_HW+7ZZ'*<*N[EJA7?N@8R%0M
M;=-\NMUNKKWV[?S!_H3F73.>[FB:87G)-+VN!@0NB3(Z'E+6=#. &L.JRO?P
MA;(T$?RRH)F-VCG0^5(I>VNX"[I_ >EO4$L#!!0    ( &>  U56L>'#1@,
M +X-   9    >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;,5774_;,!3]*U:&
M)B9!XR3]@K65@ J-"234#O8P[<%-;UN+Q ZVTS)I/WZV$T(*(6JU2+PT_KCW
M^-[CX_IZL.'B0:X %'J*(R:'SDJIY-1U9;B"F,@63X#IF047,5&Z*Y:N3 20
MN76*(]?'N.O&A#)G-+!CMV(TX*F**(-;@60:QT3\.8>(;X:.YSP/3.ARI<R
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M%@ACH.<7G*OGCBGABR?;Z!]02P,$%     @ 9X #57S_:D14!   V1$  !D
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MVZCDI 0J"*.(PVKN7/F7F>]I@D%\(7 0)VVD3;EG[+ON?,CGCJ=7! 4LI9;
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M@6N ^KYB3!X[>H*F_$_^ U!+ P04    " !G@ -5@2FLVH4$  !R(   &0
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M3 E<96NJ_WJZAP)6J>S-E(/,<]7#A 68L! 3%B'!6BK[C<K^2Z8W'U-N3%B
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MJC AP3"R]5UYD,;VN-_6]E$!Y1SL?2FE.1DNP/A,97\ 4$L#!!0    ( &>
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MQEBM($^+^C]]:@)Q9*#\P :D,2"F@==AX#8&[J4S>(V!=^D,?F-041_5W*O
M+:BDTTG)'U&IT<J;?JBB7UFK>*6%WBCWLE2?ILI.3N_96J5=H@]LRTN9%FLT
M5,\Q+^(T2VF52[Y"L^0OM126H.7=VX^+&;I:,$G33%PK]*?[!;IZ=8U>H;1
M'S=\)VB1B,E(JM7I.49QLY*[>B6D8R4N>L<+N1%H620L >P7_?9!C_U(1>40
M&O(2FCO2Z_"G7?$&N<YK1!Q"@/7,+S?'$)W_-_OR/\]^$@SWL$_<RI][\3[Y
M8_8@9*D.^I]0KFMO'NQ-5[\;L:4QNQVH\B98N6>#Z;??X,#Y#@KTUW2V^)K.
MEE_)V4E*O$-*O#[OTU]4&\FX (]:;1E4EKI7[*=#SP_#R6A_'%< %6%G?(I:
M0*C(-7PM 10.(^P=8"<<_0-'OY?CVT(R%3FI:DO,<P91K1WX1Q,3XAI$;4Q@
MK']A0US/,3C:&!QAF&!P(!A<1I ]J=XO0(:!->V08,],)H *R-@S: (HSPTC
M@RB PB3 '5S'!Z[C7JYWK&"K5*)5R7-TM2WY/JWTAI([UTV"D:1/#-S18SOV
MH4%N;F.&1_FI P!@L(/-W0R@Q@Z!Z8<'^F$O_05312!NFJKJD8CFNI3^70\T
M^0>YA\":?8R)01^">1$.C @ ,%<U"3,$( P[+AR$Z!"$J#<(/RCMBA1=U3D*
ML6*E5A<YRQ]8*3;I%B(?6>LPCN7\+&)Q%K&T$81$0023Q4ZKKIQ>NC^K^HPJ
M2;VESU4#57P3]B!?HX))4"0Y9_F>ARS.0Y8 9*C*F1]V<#Y2E/A\BJLSSK[L
M4OFL\BLW/%$G?*\*'8.W>./SM+;ZY@X'4%XXCDSR-HKX9KU<0C.2(.@XY)BT
M]$DO_?F&%FNFQ?"*IB7:TVS'=-:5IM:Z2>\!]2C2A)75R0>C0>S<A(ZU#VR4
MM0\ 1T$XMF)AP_RHHW7C5C+B7ODS_55NU %O"OM54^"NNW>^:Z<M&IN<;=#0
M+%T+ .2-?9,SX,GMRGZKR7"_*-/Z6*0ZKUHCQUQ(>+M[YT^Y#1D&@6M2/>MH
M"3IRO(Y"CEMIAONUV;WD\>>A_I:>***YSNY)*P-YVQ)*-5:KDT$P-_ M\@ ,
M$]>WMC<TJ^MW5?=6N^%^\7;/]NH0%S'K2;0MI:Q$GX4L ,C0-44;!/*[-G2K
MV7"_:)L=BY2FC.EO?15E1(5@'<0!"46LTPRIL<@4+!#*]TSV ,@E79N\U6RX
M7[2I9RK9^KD2;&)#2[;AF2K=B"9*O?+RN5>X85M$6=F'Q9VUU<]Z6D*>@F-/
MIR%H%1ONEVRS6+7QNJ;U['-;0 U=CV"3+0 ;6_F&? %-"X 19^S ?$FKV4B_
M9FOU2Y**NFOO5(GCVZ9A@_P)H*8\LUK/ 91YU"]RM 10V T[4DU:Z4;ZI9MQ
MSP<2!<05'IO%:-[ @I,%NIZ9:L";YT>1>;BA24/B=_%MM1KIUVHOWT94HE7;
MIEFESO]%THE]Z>%;,JU_#?_V^NJB.9< "D>.>31&1_?&.2O7U86]4(=\5\CZ
M:O P>OA18%9=A1OC=_AFCH'Q!;Y9UE?^K?OZ%XAWM%RGA4 96ZFIG#=CE=NR
MOM2O7R3?5K?6#UQ*GE>/&T95Y=4 ]?F*<_GRHB<X_+0R_0=02P,$%     @
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M\OIRR5G"966@?W\40CW?5 ]H#A:G_P-02P,$%     @ 9X #50<UWP@/ P
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M[^FV;SN GSIPA;V"E\6RBX+P/<(!QNCC-$9OW[Q#<_)8-[>IB7[%WXJ\BZ+
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MSE,=*+XN-[C,N%(\*S^N]'*="G.!_G[!N7HZ,!5L-U6-_P=02P,$%     @
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" !G@ -5;(3(WF$'  #<0@  #P   'AL+W=O<FMB;V]K+GAM;,6<WV_:.A2
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M<'#,$&)BP@F(A8-C1A 3$TY +AQD4[&^]8[NO1-[IQ:\MMFC=./16"06Q)5
M3,P[ ;%W3H6Q[4.[0TQ,/@&Q?%#,>J-C\@F(Y=,4;;>9A>>;C19P-3+ Y!.0
M[\LW8?ZY8V%B"&:AD-A"S9@N)-,6$W:A$+-02&PA%+-V;X:8A4+JY*_:*DO[
M.&X:QRWD$\3$+!2><_O>]6][S72?"2<F.V>'F)B%PLMMZ+OI',3$+!1><E._
MMM(;HCE@Q!;",>%\,\0L%%YTC0W.-T/,0B&QA7!,.-\,,0N%Y D M:7 -O.Z
MGL]FJG2K"+4N%&$6BJC7VMYBOHY00VMT&V="3,Q"$?G:VQO,[UQ;H1\Y(29F
MH8C80DV-'C0W.F:AB-A"39B]9DS,0A&QA=[?FZIX<AG_KKLO:YB8A2+J#1YT
M5;T-,3$+1=2IR!AF;2(7H;G(E\PUJSD]PBP4G27;S-Z3,S<0N4=(&M>Y(DQ!
M$;6"CHP++:N\Z7GU2?9:#C 'F((&Y]GN:5?;%:JH6MY.AZMB-OD%,3$%#:@5
M=,2\X^5>N^2O/Y!3R5<0$U/0@%I!1\SO0FZVI4C;W(Z9?"-8M<H ,3$%#<@5
MU+29=K@']B4,A :8@@;D"FK&'-I!*949Q,04-"!6T,E-/QMAVD,0$U/0@'H;
MZ#3F,$WARLP 4]" 6$%8;=K+0TST&1EB!<$LV08104S,0@-B"Z&)L[5Y1XQ9
M*":VT(D-Z?;K$P(0$[-03&RADYB'7%6(B5DH)K;024Q75DNUC#$+Q<06>KN]
M?VSM:N8YA5THQBP4GSD+H<U>5V4/H! 3LU!\T60$.'6/,0O%9T]&..C'G<BS
M6FUB%HJI+=2 >5R,7VLXD8LQ"\74&0F-F(FR\5HFZST=?5:3?%,(R^^ ]V:O
MBS^M2?UL#IKA40=%'^'L$IOH79IZ8P#<ZZ(/<G8K#W6JT\WG3ZE8RT*D,_L%
MQI8G/$L6FKF7ZEJ>'[B'NM;[+!O9LGDQ53P]_G.&XS^6^/PO4$L#!!0    (
M &>  U7M2,2UY (  /$[   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'/-V\UNVD 81N%;0;Z V/,_4X6LNLFVR@T@8B *8(1=-;G[(K* =]1%-Y'/
M"HT1'T>R] B9F<=?_7XUO0W'<?=V&A<?A_UQ7#:[:3K]:-MQO>L/J_%A./7'
MRSN;X7Q839?E>=N>5NOWU;9O;=?%]GP_HWEZO)^Y>/D\]?\S<=ALWM;]SV']
M^] ?IW\,;O\,Y_=QU_=3LWA9G;?]M&S:C_WM\MA>7\S#97*S>'Y=-N?G5].T
M<P=9";+S!SD)<O,'>0GR\P<%"0KS!T4)BO,')0E*\P=E"<KS!Q4)*O,'F4YE
M[ !)%=8 K8UR;0!>&P7; ,0V2K8!F&T4;0-0VRC;!N"V4;@-0&ZC=!N W4;Q
M-@"]K>IM 7I;U=L"]+;5CVV WE;UM@"]K>IM 7I;U=L"]+:JMP7H;55O"]#;
MJMX6H+=5O2U ;Z=Z.X#>3O5V +V=ZNT >KOJ80E ;Z=Z.X#>3O5V +V=ZNT
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &>  U6BP!AS^ 4  .,?   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !G@ -5X<WGVO('  #Y(   &               @($[#@  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 9X #54*C?I*Z @  6P<
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M965T-RYX;6Q02P$"% ,4    " !G@ -5MDW$YZ(#  #!!P  &
M    @('D/@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M9X #5=ZB5EI.%P  0T8  !@              ("!O$(  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &>  U6$'/'R"0<  %(1   9
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M970Q-"YX;6Q02P$"% ,4    " !G@ -5(O9;G+0#  !%"@  &0
M    @($*B   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M &>  U5.MG>(K0@   $6   9              " @?6+  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ 9X #51]CM N)$P  (5$  !D
M             ("!V90  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !G@ -57=J/#*(4  "..@  &0              @(&9J   >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &>  U6@_./>9@@
M ((4   9              " @7*]  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ 9X #53 %!DTG!   '0H  !D              ("!
M#\8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !G@ -5
MK3NL#:0#  "?"   &0              @(%MR@  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &>  U7:*F,VU00  ),+   9
M      " @4C.  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ 9X #5<-4H>E2!0  <@X  !D              ("!5-,  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !G@ -5<,2E400*  !N'
M&0              @('=V   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( &>  U5<49[.)P4  *,+   9              " @1CC  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 9X #562J+!<T
M!0  O L  !D              ("!=N@  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !G@ -5ID:*RIX)  "3&@  &0
M@('A[0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &>
M U6I'AK,UPD  %T:   9              " @;;W  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ 9X #50RN>$#: @  ? 8  !D
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M=#,S+GAM;%!+ 0(4 Q0    ( &>  U4GEDF3A@0  &@,   9
M  " @;PZ 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M9X #5;G0]&+!!   0PL  !D              ("!>3\! 'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " !G@ -5S5K4+[,"   0!@  &0
M            @(%Q1 $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( &>  U5>%E"6 0,  ($&   9              " @5M' 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 9X #57:WR<-U!0
M\@T  !D              ("!DTH! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " !G@ -5S0CBNF #  "N!P  &0              @($_
M4 $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &>  U6.
M.87/V 0  "X-   9              " @=93 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ 9X #58_"+'D]!   )0H  !D
M     ("!Y5@! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &>  U7/L&V."P,  *@&   9              "
M@0IN 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 9X #
M58+,>7N)!@  K!$  !D              ("!3'$! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " !G@ -5:6-7B'8$   7"@  &0
M        @($,> $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( &>  U7>X_@E\0(  &\&   9              " @;E\ 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ 9X #55!<OTE$ @  ,@4
M !D              ("!X7\! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " !G@ -5U29:&MD&  #5*@  &0              @(%<@@$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( &>  U7[/R\0
M@0(  #,&   9              " @6R) 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ 9X #50,1>N:* P  C!$  !D
M ("!)(P! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !G
M@ -5Y\_W46<#  "V"@  &0              @('ECP$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( &>  U7->HF4H0D   *'   9
M          " @8.3 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#
M%     @ 9X #50D@3VLZ"P  SG\  !D              ("!6YT! 'AL+W=O
M<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !G@ -5DR6HA10&  ")
M+   &0              @(',J $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM
M;%!+ 0(4 Q0    ( &>  U7T2#;0L0(   8&   9              " @1>O
M 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ 9X #52I%
M"0@(!@  7RH  !D              ("!_[$! 'AL+W=O<FMS:&5E=',O<VAE
M970U.2YX;6Q02P$"% ,4    " !G@ -5AZ(J($L#  ""#@  &0
M    @($^N $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M &>  U6K1\Y1_P,  $,0   9              " @<"[ 0!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ 9X #59WI5?\+!   ZQ<  !D
M             ("!]K\! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    " !G@ -5^DV.;Y4#  "Y$@  &0              @($XQ $ >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( &>  U7^"[&&R0(
M %<'   9              " @03( 0!X;"]W;W)K<VAE971S+W-H965T-C0N
M>&UL4$L! A0#%     @ 9X #5:0Z)<QZ!0  9"8  !D              ("!
M!,L! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " !G@ -5
M_OD\)7 "   1!@  &0              @(&UT $ >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;%!+ 0(4 Q0    ( &>  U4A!/';,04  .8B   9
M      " @5S3 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%
M  @ 9X #5877+$@P"   UDH  !D              ("!Q-@! 'AL+W=O<FMS
M:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " !G@ -5+!QN'-P"  #*"0
M&0              @($KX0$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+
M 0(4 Q0    ( &>  U4-.PEE"Q0  .D\ 0 9              " @3[D 0!X
M;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ 9X #5>,Q#'N(
M!0  %2P  !D              ("!@/@! 'AL+W=O<FMS:&5E=',O<VAE970W
M,2YX;6Q02P$"% ,4    " !G@ -5?R#":@@#  !V"   &0
M@($__@$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( &>
M U469XKP2A$  %L) 0 9              " @7X! @!X;"]W;W)K<VAE971S
M+W-H965T-S,N>&UL4$L! A0#%     @ 9X #59U125JH!0  12P  !D
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M=#<X+GAM;%!+ 0(4 Q0    ( &>  U63E_.UG0(  &P(   9
M  " @>,O @!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @
M9X #5;/>K"3; P  OA,  !D              ("!MS(" 'AL+W=O<FMS:&5E
M=',O<VAE970X,"YX;6Q02P$"% ,4    " !G@ -5N7L(DNT"  "4"0  &0
M            @(')-@( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4
M Q0    ( &>  U5@3R8!Q@(  $X(   9              " @>TY @!X;"]W
M;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ 9X #59SG7D(P @
M[ 0  !D              ("!ZCP" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX
M;6Q02P$"% ,4    " !G@ -5%DV[?%8%  #6%P  &0              @(%1
M/P( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( &>  U69
ML.@W*P0  ($6   9              " @=Y$ @!X;"]W;W)K<VAE971S+W-H
M965T.#4N>&UL4$L! A0#%     @ 9X #5;9I#%+H!   \"$  !D
M     ("!0$D" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &>  U4FH-(Y3@,  /</   9              "
M@>)< @!X;"]W;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ 9X #
M5:69"UP% P  $0@  !D              ("!9V " 'AL+W=O<FMS:&5E=',O
M<VAE970Y,BYX;6Q02P$"% ,4    " !G@ -55K'APT8#  "^#0  &0
M        @(&C8P( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0
M   ( &>  U5\_VI$5 0  -D1   9              " @2!G @!X;"]W;W)K
M<VAE971S+W-H965T.30N>&UL4$L! A0#%     @ 9X #5;YS"16  P  "A
M !D              ("!JVL" 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q0
M2P$"% ,4    " !G@ -5@2FLVH4$  !R(   &0              @(%B;P(
M>&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( &>  U6C%LL2
M)@(  +($   9              " @1YT @!X;"]W;W)K<VAE971S+W-H965T
M.3<N>&UL4$L! A0#%     @ 9X #5:$-VV%K!@  4"L  !D
M ("!>W8" 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q02P$"% ,4    " !G
M@ -5B36DK?X%  !F&0  &0              @($=?0( >&PO=V]R:W-H965T
M<R]S:&5E=#DY+GAM;%!+ 0(4 Q0    ( &>  U7=-<BQM@4  &0<   :
M          " @5*# @!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4
M Q0    ( &>  U4'-=\(#P,  ' (   :              " @4") @!X;"]W
M;W)K<VAE971S+W-H965T,3 Q+GAM;%!+ 0(4 Q0    ( &>  U7(>_X-&0<
M & U   :              " @8>, @!X;"]W;W)K<VAE971S+W-H965T,3 R
M+GAM;%!+ 0(4 Q0    ( &>  U65-F;*4P,  )85   -              "
M =B3 @!X;"]S='EL97,N>&UL4$L! A0#%     @ 9X #59>*NQS     $P(
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9>&UL4$L%!@    !N &X /!X  'FE @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>374</ContextCount>
  <ElementCount>405</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>104</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</Role>
      <ShortName>Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Transactions</Role>
      <ShortName>Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Credit Losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLosses</Role>
      <ShortName>Credit Losses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2146111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2151112 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2158113 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2162114 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2167115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2169116 - Disclosure - Investments in Equity Method Investees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</Role>
      <ShortName>Investments in Equity Method Investees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2171117 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2176118 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2180119 - Disclosure - Repositioning and Other Changes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChanges</Role>
      <ShortName>Repositioning and Other Changes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2183120 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2188121 - Disclosure - Reserves for Claims and Performance-Based Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2191122 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2194123 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsTables</Role>
      <ShortName>Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Transactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/DiscontinuedOperations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RevenueRecognition</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Credit Losses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesTables</Role>
      <ShortName>Credit Losses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CreditLosses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2339308 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/LongtermDebt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2347309 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CommitmentsandContingencies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2352310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2359311 - Disclosure - Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShareTables</Role>
      <ShortName>Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/LossPerCommonShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2363312 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/StockbasedCompensation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2372313 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/FairValueMeasurement</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2377314 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RelatedParties</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2381315 - Disclosure - Repositioning and Other Changes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</Role>
      <ShortName>Repositioning and Other Changes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChanges</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2384316 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SegmentReporting</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2389317 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2392318 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Organization</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Recently Issued Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails</Role>
      <ShortName>Recently Issued Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Transactions - Vital Decisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails</Role>
      <ShortName>Transactions - Vital Decisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Results of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails</Role>
      <ShortName>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Revenue Recognition - Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails</Role>
      <ShortName>Revenue Recognition - Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Revenue Recognition - Contract Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails</Role>
      <ShortName>Revenue Recognition - Contract Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails</Role>
      <ShortName>Credit Losses - Accounts Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails</Role>
      <ShortName>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Impairment Testing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Long-term Debt - 2024 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails</Role>
      <ShortName>Long-term Debt - 2024 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Long-term Debt - Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails</Role>
      <ShortName>Long-term Debt - Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Long-term Debt - Warrant Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails</Role>
      <ShortName>Long-term Debt - Warrant Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Long-term Debt - 2025 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails</Role>
      <ShortName>Long-term Debt - 2025 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Long-term Debt - 2021 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails</Role>
      <ShortName>Long-term Debt - 2021 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails</Role>
      <ShortName>Long-term Debt - Convertible Senior Notes Carrying Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Reinsurance Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails</Role>
      <ShortName>Commitments and Contingencies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2453430 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Leases - Primary Office Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails</Role>
      <ShortName>Leases - Primary Office Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2455432 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2456433 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2457434 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails</Role>
      <ShortName>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2460435 - Disclosure - Loss Per Common Share - Computation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails</Role>
      <ShortName>Loss Per Common Share - Computation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2461436 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2464437 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2465438 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2466439 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2468440 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2470441 - Disclosure - Investments in Equity Method Investees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails</Role>
      <ShortName>Investments in Equity Method Investees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2473442 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2474443 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails</Role>
      <ShortName>Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2475444 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2478445 - Disclosure - Related Parties - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails</Role>
      <ShortName>Related Parties - Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2479446 - Disclosure - Related Parties - Revenues and Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails</Role>
      <ShortName>Related Parties - Revenues and Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2482447 - Disclosure - Repositioning and Other Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails</Role>
      <ShortName>Repositioning and Other Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2485448 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2486449 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Reporting - Revenue from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2487450 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2490451 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2493452 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="evh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2495453 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SubsequentEvents</ParentRole>
      <Position>102</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="evh-20220630.htm">evh-20220630.htm</File>
    <File>a2022q2form10qex101.htm</File>
    <File>a2022q2form10qex102.htm</File>
    <File>a2022q2form10qex103.htm</File>
    <File>a2022q2form10qex24.htm</File>
    <File>a2022q2form10qex41.htm</File>
    <File>a63022exhibit311.htm</File>
    <File>a63022exhibit312.htm</File>
    <File>a63022exhibit321.htm</File>
    <File>a63022exhibit322.htm</File>
    <File>evh-20220630.xsd</File>
    <File>evh-20220630_cal.xml</File>
    <File>evh-20220630_def.xml</File>
    <File>evh-20220630_lab.xml</File>
    <File>evh-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1225">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>125
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evh-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 41,
   "contextCount": 374,
   "dts": {
    "calculationLink": {
     "local": [
      "evh-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "evh-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "evh-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "evh-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 700,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 6,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 11
   },
   "keyCustom": 55,
   "keyStandard": 350,
   "memberCustom": 45,
   "memberStandard": 55,
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.evolenthealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Recently Issued Accounting Standards",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards",
     "shortName": "Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2490451 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2493452 - Disclosure - Supplemental Cash Flow Information (Details)",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2495453 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.evolenthealth.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "if20ec831579b44b7aef9c74422893d4f_D20220801-20220801",
      "decimals": "INF",
      "lang": "en-US",
      "name": "evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "day",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Transactions",
     "role": "http://www.evolenthealth.com/role/Transactions",
     "shortName": "Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Discontinued Operations",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Revenue Recognition",
     "role": "http://www.evolenthealth.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Credit Losses",
     "role": "http://www.evolenthealth.com/role/CreditLosses",
     "shortName": "Credit Losses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Property and Equipment, Net",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Goodwill and Intangible Assets, Net",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - Long-term Debt",
     "role": "http://www.evolenthealth.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151112 - Disclosure - Leases",
     "role": "http://www.evolenthealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158113 - Disclosure - Loss Per Common Share",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShare",
     "shortName": "Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162114 - Disclosure - Stock-based Compensation",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167115 - Disclosure - Income Taxes",
     "role": "http://www.evolenthealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169116 - Disclosure - Investments in Equity Method Investees",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees",
     "shortName": "Investments in Equity Method Investees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171117 - Disclosure - Fair Value Measurement",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2176118 - Disclosure - Related Parties",
     "role": "http://www.evolenthealth.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2180119 - Disclosure - Repositioning and Other Changes",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChanges",
     "shortName": "Repositioning and Other Changes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2183120 - Disclosure - Segment Reporting",
     "role": "http://www.evolenthealth.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2188121 - Disclosure - Reserves for Claims and Performance-Based Arrangements",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements",
     "shortName": "Reserves for Claims and Performance-Based Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2191122 - Disclosure - Supplemental Cash Flow Information",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2194123 - Disclosure - Subsequent Events",
     "role": "http://www.evolenthealth.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Transactions (Tables)",
     "role": "http://www.evolenthealth.com/role/TransactionsTables",
     "shortName": "Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Credit Losses (Tables)",
     "role": "http://www.evolenthealth.com/role/CreditLossesTables",
     "shortName": "Credit Losses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339308 - Disclosure - Long-term Debt (Tables)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectsOfReinsuranceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347309 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectsOfReinsuranceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352310 - Disclosure - Leases (Tables)",
     "role": "http://www.evolenthealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359311 - Disclosure - Loss Per Common Share (Tables)",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShareTables",
     "shortName": "Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2363312 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2372313 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2377314 - Disclosure - Related Parties (Tables)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesTables",
     "shortName": "Related Parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2381315 - Disclosure - Repositioning and Other Changes (Tables)",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables",
     "shortName": "Repositioning and Other Changes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2384316 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2389317 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2392318 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization (Details)",
     "role": "http://www.evolenthealth.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i9098a44763454939966aead2b01058a5_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i422269ae7dc54ddf975203be2bc9ec3f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i422269ae7dc54ddf975203be2bc9ec3f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Recently Issued Accounting Standards (Details)",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
     "shortName": "Recently Issued Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Transactions - Vital Decisions (Details)",
     "role": "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails",
     "shortName": "Transactions - Vital Decisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "id53f2482994740c4afac4ded4824ffa5_I20211001",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
     "shortName": "Discontinued Operations - Summary of Results of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ide9111e594364928b4f284bff447dc08_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
     "shortName": "Discontinued Operations - Summary of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i107db0c7db6e4100a90aee518df9dfc4_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ic18910942b2e485ea30def8e9cefca28_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i64151525a8774f5e8e11c91ec179e8ba_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "if87d2c789e34470eb537d3a37ac29705_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails",
     "shortName": "Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Revenue Recognition - Contract Balances (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails",
     "shortName": "Revenue Recognition - Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Revenue Recognition - Contract Costs (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails",
     "shortName": "Revenue Recognition - Contract Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i91e9cc56ffee4613adb9a6ab56554271_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)",
     "role": "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
     "shortName": "Credit Losses - Accounts Receivable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "role": "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
     "shortName": "Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i9098a44763454939966aead2b01058a5_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i9098a44763454939966aead2b01058a5_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:GainLossOnDispositionOfAssetsOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Long-term Debt - 2024 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
     "shortName": "Long-term Debt - 2024 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8c24e626673740bfbc5c482a85f9be03_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Long-term Debt - Credit Agreement (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
     "shortName": "Long-term Debt - Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "idffc7ad1a4654adf98f1038cfa6da4be_I20191230",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i5631b43e9caf49eeb64e4768bdfb4735_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Long-term Debt - Warrant Agreement (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails",
     "shortName": "Long-term Debt - Warrant Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i5631b43e9caf49eeb64e4768bdfb4735_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Long-term Debt - 2025 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
     "shortName": "Long-term Debt - 2025 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i93205c45ea8547a98bc7ff1c11408e54_I20181031",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Long-term Debt - 2021 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
     "shortName": "Long-term Debt - 2021 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i0a5fe91fca294dc59c8c83d983098472_D20200801-20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "if6ccdc5191c44efea9d1d9edc7499e87_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
     "shortName": "Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "if6ccdc5191c44efea9d1d9edc7499e87_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EffectsOfReinsuranceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssumedPremiumsWritten",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails",
     "shortName": "Commitments and Contingencies - Reinsurance Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EffectsOfReinsuranceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssumedPremiumsWritten",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "evh:CashFDICInsuredAmountPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
     "shortName": "Commitments and Contingencies - Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ice2334023a474418a26edc96b4914f57_D20220101-20220630",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453430 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ia8618f6dc2f0455a9e812da51a84fc9f_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.evolenthealth.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Leases - Primary Office Leases (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails",
     "shortName": "Leases - Primary Office Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i38cfdd80181d48dc95c448a5bd762e1c_I20220630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455432 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456433 - Disclosure - Leases - Maturity of Lease Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturity of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457434 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails",
     "shortName": "Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460435 - Disclosure - Loss Per Common Share - Computation of Earnings per Share (Details)",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails",
     "shortName": "Loss Per Common Share - Computation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461436 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)",
     "role": "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Loss Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464437 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
       "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
       "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465438 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
       "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
       "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ic9002002234e467d88e03554eac894c8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466439 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
     "shortName": "Stock-based Compensation - Schedule of Share-based Awards Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ic9002002234e467d88e03554eac894c8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468440 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470441 - Disclosure - Investments in Equity Method Investees (Details)",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
     "shortName": "Investments in Equity Method Investees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "if038fb24676c4fbe8fcd625e0c03f2e4_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i37f4d51ef9aa4ab4a4f13f3a70a0afb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473442 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i37f4d51ef9aa4ab4a4f13f3a70a0afb2_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474443 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails",
     "shortName": "Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i37f4d51ef9aa4ab4a4f13f3a70a0afb2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475444 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
     "shortName": "Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6d10e11febe742e388c4185b0dfb5f67_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ibdd1ae63ddb547ab8ce350f06563934d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478445 - Disclosure - Related Parties - Assets and Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
     "shortName": "Related Parties - Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i117805e609ff46d0921c81fc5e9621b3_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ieea3e0212f024a4cb925e63dc3d63669_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2479446 - Disclosure - Related Parties - Revenues and Expenses (Details)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
     "shortName": "Related Parties - Revenues and Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "ieea3e0212f024a4cb925e63dc3d63669_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2482447 - Disclosure - Repositioning and Other Changes (Details)",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
     "shortName": "Repositioning and Other Changes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i6ea08b719de041fc860ca2321a09f2b7_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485448 - Disclosure - Segment Reporting - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i2b77fd02e94b4093957a73b0207402ee_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2486449 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails",
     "shortName": "Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i1f83964678a340d8a8a7893bffb76713_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2487450 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
     "shortName": "Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220630.htm",
      "contextRef": "i8946244240e648d0a726ae8260273c82_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:SharebasedCompensationIncludingOnetimeAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 104,
   "tag": {
    "country_IN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INDIA",
        "terseLabel": "Pune, India"
       }
      }
     },
     "localname": "IN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "evh_A2022CreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Credit Facilities",
        "label": "2022 Credit Facilities [Member]",
        "terseLabel": "2022 Credit Facilities"
       }
      }
     },
     "localname": "A2022CreditFacilitiesMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "label": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "terseLabel": "Adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables",
        "label": "Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables",
        "negatedTerseLabel": "Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement"
       }
      }
     },
     "localname": "AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed Liability for Unpaid Claims and Claims Adjustment Expense",
        "label": "Assumed Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Assumed Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]"
       }
      }
     },
     "localname": "AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRollForward",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and Diluted Earnings Per Share",
        "label": "Basic and Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Loss per common share, Basic and diluted"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_BelowMarketLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Below Market Leases [Member]",
        "label": "Below Market Leases [Member]",
        "terseLabel": "Below market lease, net"
       }
      }
     },
     "localname": "BelowMarketLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BlueCrossAndBlueShieldOfNorthCarolinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blue Cross And Blue Shield Of North Carolina",
        "label": "Blue Cross And Blue Shield Of North Carolina [Member]",
        "terseLabel": "Blue Cross and Blue Shield of North Carolina"
       }
      }
     },
     "localname": "BlueCrossAndBlueShieldOfNorthCarolinaMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BonusesAndCommissionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonuses And Commissions [Member]",
        "label": "Bonuses And Commissions [Member]",
        "terseLabel": "Bonuses and Commissions"
       }
      }
     },
     "localname": "BonusesAndCommissionsMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BrightHealthManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bright Health Management, Inc",
        "label": "Bright Health Management, Inc [Member]",
        "terseLabel": "Bright Health Management, Inc."
       }
      }
     },
     "localname": "BrightHealthManagementIncMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "totalLabel": "Total tangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "label": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "negatedLabel": "Amortization of contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPurchaseAccountingAdjustments",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations",
        "label": "Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CashFDICInsuredAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, FDIC Insured Amount, Percentage",
        "label": "Cash, FDIC Insured Amount, Percentage",
        "terseLabel": "Percentage of cash and cash equivalents held with FDIC participating bank"
       }
      }
     },
     "localname": "CashFDICInsuredAmountPercentage",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee [Abstract]",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Effects of Leases"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_CashHeldInInternationalBanksPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Held In International Banks, Percentage",
        "label": "Cash, Held In International Banks, Percentage",
        "terseLabel": "Percentage of cash held in international banks (less than)"
       }
      }
     },
     "localname": "CashHeldInInternationalBanksPercentage",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_CenterForMedicareAndMedicaidServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Center For Medicare And Medicaid Services",
        "label": "Center For Medicare And Medicaid Services [Member]",
        "terseLabel": "The Centers for Medicare and Medicaid Services"
       }
      }
     },
     "localname": "CenterForMedicareAndMedicaidServicesMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability [Roll Forward]",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "label": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "terseLabel": "Period during which warrants or rights exercisable, after maturity of credit agreement"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_ClinicalSolutionsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Solutions Segment",
        "label": "Clinical Solutions Segment [Member]",
        "terseLabel": "Clinical Solutions"
       }
      }
     },
     "localname": "ClinicalSolutionsSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CollateralwithFinancialInstitutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateral with Financial Institutions [Member]",
        "label": "Collateral with Financial Institutions [Member]",
        "terseLabel": "Collateral with financial institutions"
       }
      }
     },
     "localname": "CollateralwithFinancialInstitutionsMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CommercialAndOtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial And Other Customers",
        "label": "Commercial And Other Customers [Member]",
        "terseLabel": "Commercial and other"
       }
      }
     },
     "localname": "CommercialAndOtherCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractFulfillmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Fulfillment Costs [Member]",
        "label": "Contract Fulfillment Costs [Member]",
        "terseLabel": "Contract Fulfillment Costs"
       }
      }
     },
     "localname": "ContractFulfillmentCostsMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "label": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "terseLabel": "Cash received in advance of satisfaction of performance obligations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ConvertibleSeniorNotesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes due 2021 [Member]",
        "label": "Convertible Senior Notes due 2021 [Member]",
        "terseLabel": "2021 Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesdue2021Member",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CookCountyHealthAndHospitalsSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cook County Health And Hospitals System [Member]",
        "label": "Cook County Health And Hospitals System [Member]",
        "terseLabel": "Cook County Health and Hospitals System"
       }
      }
     },
     "localname": "CookCountyHealthAndHospitalsSystemMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization",
        "label": "Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization",
        "verboseLabel": "Incurred costs related to current period"
       }
      }
     },
     "localname": "CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DebtConversionOriginalDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion, Original Debt, Fair Value",
        "label": "Debt Conversion, Original Debt, Fair Value",
        "terseLabel": "Debt conversion, original debt, fair value"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtFairValue",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity",
        "label": "Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity",
        "terseLabel": "Number of days prior to any junior debt maturity"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Four, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Four, Percent",
        "terseLabel": "Prepayment penalty on or after third anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodFourPercent",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period One, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period One, Percent",
        "terseLabel": "Prepayment penalty prior to first anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodOnePercent",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Three, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Three, Percent",
        "terseLabel": "Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodThreePercent",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Two, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Two, Percent",
        "terseLabel": "Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodTwoPercent",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "terseLabel": "Repurchase covenant, consecutive trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, sale price as a percentage of conversion price",
        "verboseLabel": "Repurchase covenant, sale price as a percentage of conversion price (at least)"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "terseLabel": "Repurchase covenant, trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "label": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "verboseLabel": "Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtIssuanceCostsNetDebtComponent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Issuance Costs, Net, Debt Component",
        "label": "Debt Issuance Costs, Net, Debt Component",
        "terseLabel": "Debt issuance costs, net, debt component"
       }
      }
     },
     "localname": "DebtIssuanceCostsNetDebtComponent",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DeferredFinancingFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Financing Fees",
        "label": "Deferred Financing Fees [Member]",
        "terseLabel": "Deferred Financing Fees"
       }
      }
     },
     "localname": "DeferredFinancingFeesMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DelayedDrawTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Delayed Draw Term Loan Facility [Member]",
        "label": "Delayed Draw Term Loan Facility [Member]",
        "terseLabel": "DDTL Facility"
       }
      }
     },
     "localname": "DelayedDrawTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "label": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "terseLabel": "Claims expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationClaimsExpense",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_EmployeeSeveranceAndTerminationBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Severance And Termination Benefits",
        "label": "Employee Severance And Termination Benefits [Member]",
        "terseLabel": "Severance and termination benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceAndTerminationBenefitsMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityComponentOfLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Component of Long Term Debt",
        "label": "Equity Component of Long Term Debt [Member]",
        "terseLabel": "Equity Component of Long Term Debt"
       }
      }
     },
     "localname": "EquityComponentOfLongTermDebtMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityMethodInvestmentEconomicInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Economic Interest Percentage",
        "label": "Equity Method Investment, Economic Interest Percentage",
        "terseLabel": "Economic interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentEconomicInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EquityMethodInvestmentVotingInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Voting Interest Percentage",
        "label": "Equity Method Investment, Voting Interest Percentage",
        "terseLabel": "Voting interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentVotingInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EvolentHealthServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolent Health Services Segment",
        "label": "Evolent Health Services Segment [Member]",
        "terseLabel": "Evolent Health Services"
       }
      }
     },
     "localname": "EvolentHealthServicesSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan120DaysPastDueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "label": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "terseLabel": "Past due less than 120 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan120DaysPastDueMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan60DaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 60 Days [Member]",
        "label": "FInancial Asset, Less Than 60 Days [Member]",
        "terseLabel": "Past due less than 60 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan60DaysMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FinancingReceivablePercentNotPastDue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Percent Not Past Due",
        "label": "Financing Receivable, Percent Not Past Due",
        "terseLabel": "Percentage of receivables, current"
       }
      }
     },
     "localname": "FinancingReceivablePercentNotPastDue",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_FloridaBlueMedicareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Florida Blue Medicare, Inc.",
        "label": "Florida Blue Medicare, Inc. [Member]",
        "terseLabel": "Florida Blue Medicare, Inc."
       }
      }
     },
     "localname": "FloridaBlueMedicareIncMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_GainLossOnDispositionOfAssetsOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "label": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "negatedLabel": "Loss (gain) on discontinued operations"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsOperatingActivities",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_GainOnTransferOfMembership": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 13.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain On Transfer Of Membership",
        "label": "Gain On Transfer Of Membership",
        "negatedTerseLabel": "Gain on transfer of membership",
        "terseLabel": "Gain on transfer of membership"
       }
      }
     },
     "localname": "GainOnTransferOfMembership",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ImplantableProviderGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implantable Provider Group, Inc.",
        "label": "Implantable Provider Group, Inc. [Member]",
        "terseLabel": "Implantable Provider Group, Inc."
       }
      }
     },
     "localname": "ImplantableProviderGroupIncMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Services Agreement",
        "label": "Income (Loss) from Equity Method Investments, Services Agreement",
        "terseLabel": "Income from long-term services agreement"
       }
      }
     },
     "localname": "IncomeLossfromEquityMethodInvestmentsServicesAgreement",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "label": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "negatedTerseLabel": "Accounts receivable, net and contract assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInCapitalizedContractCostNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "label": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "negatedTerseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInCapitalizedContractCostNet",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "label": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-of-Use Asset",
        "negatedTerseLabel": "Right-of-use operating assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightofUseAsset",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_InitialTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Term Loan Facility [Member]",
        "label": "Initial Term Loan Facility [Member]",
        "terseLabel": "Initial Term Loan Facility"
       }
      }
     },
     "localname": "InitialTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_LeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leveraged Stock Units (LSUs) [Member]",
        "label": "Leveraged Stock Units (LSUs) [Member]",
        "verboseLabel": "LSUs"
       }
      }
     },
     "localname": "LeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "label": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Risk-neutral Expected Earnout Consideration",
        "label": "Measurement Input, Risk-neutral Expected Earnout Consideration [Member]",
        "terseLabel": "Risk-neutral expected earnout consideration"
       }
      }
     },
     "localname": "MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicaidCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid Customers",
        "label": "Medicaid Customers [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicareCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Customers",
        "label": "Medicare Customers [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MolinaHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molina Healthcare",
        "label": "Molina Healthcare [Member]",
        "terseLabel": "Molina Healthcare"
       }
      }
     },
     "localname": "MolinaHealthcareMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NewNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Notes",
        "label": "New Notes [Member]",
        "terseLabel": "New Notes"
       }
      }
     },
     "localname": "NewNotesMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NumberOfSourcesOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Sources Of Revenue",
        "label": "Number Of Sources Of Revenue",
        "terseLabel": "Number of sources of revenue"
       }
      }
     },
     "localname": "NumberOfSourcesOfRevenue",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "label": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "negatedTerseLabel": "Changes in working capital balances related to claims processing on behalf of partners"
       }
      }
     },
     "localname": "PaymentsForProceedsFromClaimsProcessingFinancingActivities",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "label": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "negatedTerseLabel": "Disposal of non-strategic assets and divestiture of discontinued operations, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsOfMakeWholePremium": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Make-Whole Premium",
        "label": "Payments Of Make-Whole Premium",
        "terseLabel": "Payments of make-whole premium"
       }
      }
     },
     "localname": "PaymentsOfMakeWholePremium",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PerformanceBasedRestrictedStockUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "label": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsPSUsMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PlatformsAndOperationsServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Platforms And Operations Services [Member]",
        "label": "Platforms And Operations Services [Member]",
        "verboseLabel": "Platform and operations"
       }
      }
     },
     "localname": "PlatformsAndOperationsServicesMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims",
        "label": "Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims",
        "terseLabel": "Claims-related administrative expenses"
       }
      }
     },
     "localname": "PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PremiumsRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums Revenue [Member]",
        "label": "Premiums Revenue [Member]",
        "terseLabel": "Premiums"
       }
      }
     },
     "localname": "PremiumsRevenueMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums Written And Policyholder Benefits And Claims Incurred, Net",
        "label": "Premiums Written And Policyholder Benefits And Claims Incurred, Net",
        "terseLabel": "Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement"
       }
      }
     },
     "localname": "PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProceedsFromMaturityOfInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Maturity Of Investments",
        "label": "Proceeds From Maturity Of Investments",
        "terseLabel": "Maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturityOfInvestments",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProceedsRepaymentsForReinsurance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Repayments) For Reinsurance",
        "label": "Proceeds (Repayments) For Reinsurance",
        "negatedLabel": "Reinsurance payments paid (received)"
       }
      }
     },
     "localname": "ProceedsRepaymentsForReinsurance",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProfessionalServicesRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional Services, Restructuring",
        "label": "Professional Services, Restructuring [Member]",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalServicesRestructuringMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforBenefitManagementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Benefit Management Services [Member]",
        "label": "Restricted Cash for Benefit Management Services [Member]",
        "terseLabel": "Claims processing services"
       }
      }
     },
     "localname": "RestrictedCashforBenefitManagementServicesMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforLettersofCreditforFacilityLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "label": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "verboseLabel": "Collateral for letters of credit for facility leases"
       }
      }
     },
     "localname": "RestrictedCashforLettersofCreditforFacilityLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforOtherContractualCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Other Contractual Commitments [Member]",
        "label": "Restricted Cash for Other Contractual Commitments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "RestrictedCashforOtherContractualCommitmentsMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock and Restricted Stock Units [Member]",
        "label": "Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]",
        "terseLabel": "Restricted stock units (\"RSUs\"), performance-based RSUs (\u201cPSUs\u201d) and leveraged stock units (\"LSUs\")"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "label": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "terseLabel": "Right of offset, percentage of accounts receivable, net eligible for net basis settlement"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "label": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "terseLabel": "Right of offset, percentage of accounts receivable netted against claims payable"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Policy",
        "label": "Right of Offset, Policy [Policy Text Block]",
        "terseLabel": "Right of Offset"
       }
      }
     },
     "localname": "RightOfOffsetPolicyPolicyTextBlock",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evh_RightOfUseAssetAcquiredAndDisposedOf": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset Acquired And Disposed Of",
        "label": "Right-Of-Use Asset Acquired And Disposed Of",
        "negatedTerseLabel": "Leased assets disposed of (obtained in) exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetAcquiredAndDisposedOf",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_SecuredOvernightFinancingRateSOFRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2024",
        "label": "Senior Convertible Notes Due 2024 [Member]",
        "terseLabel": "2024 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2024Member",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorConvertibleNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2025 [Member]",
        "label": "Senior Convertible Notes Due 2025 [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2025Member",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Credit Facilities [Member]",
        "label": "Senior Credit Facilities [Member]",
        "terseLabel": "Senior Credit Facilities"
       }
      }
     },
     "localname": "SeniorCreditFacilitiesMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ServicesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services Agreements [Member]",
        "label": "Services Agreements [Member]",
        "terseLabel": "Services Agreements"
       }
      }
     },
     "localname": "ServicesAgreementsMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SharebasedCompensationIncludingOnetimeAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 16.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation, Including One-time Adjustment",
        "label": "Share-based Compensation, Including One-time Adjustment",
        "negatedLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "SharebasedCompensationIncludingOnetimeAdjustment",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ShareholderAdvisoryServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Advisory Services",
        "label": "Shareholder Advisory Services",
        "negatedLabel": "Strategy and shareholder advisory expenses"
       }
      }
     },
     "localname": "ShareholderAdvisoryServices",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ShareholderClassActionComplaintMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Class Action Complaint",
        "label": "Shareholder Class Action Complaint [Member]",
        "terseLabel": "Shareholder Class Action Complaint"
       }
      }
     },
     "localname": "ShareholderClassActionComplaintMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders",
        "label": "Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders",
        "terseLabel": "Tax receivable agreement, percent of cash savings paid to shareholders"
       }
      }
     },
     "localname": "TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivables Agreement, Percent of Tax Savings to be Paid",
        "label": "Tax Receivables Agreement, Percent of Tax Savings to be Paid",
        "terseLabel": "Percent of tax savings to be paid"
       }
      }
     },
     "localname": "TaxReceivablesAgreementPercentofTaxSavingstobePaid",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs",
        "label": "Transaction Costs",
        "negatedLabel": "Acquisition costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TrueHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "True Health",
        "label": "True Health [Member]",
        "terseLabel": "True Health"
       }
      }
     },
     "localname": "TrueHealthMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_VitalDecisionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vital Decisions",
        "label": "Vital Decisions [Member]",
        "terseLabel": "Vital Decisions"
       }
      }
     },
     "localname": "VitalDecisionsMember",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_WeightedAverageCommonSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Common Shares Outstanding",
        "label": "Weighted Average Common Shares Outstanding [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageCommonSharesOutstandingAbstract",
     "nsuri": "http://www.evolenthealth.com/20220630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r451",
      "r668",
      "r669",
      "r671",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r140",
      "r207",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r229",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r348",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r140",
      "r207",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r229",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r348",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r145",
      "r156",
      "r162",
      "r256",
      "r499",
      "r500",
      "r501",
      "r518",
      "r519",
      "r580",
      "r583",
      "r586",
      "r587",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r145",
      "r156",
      "r162",
      "r256",
      "r499",
      "r500",
      "r501",
      "r518",
      "r519",
      "r580",
      "r583",
      "r586",
      "r587",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r145",
      "r156",
      "r162",
      "r256",
      "r499",
      "r500",
      "r501",
      "r518",
      "r519",
      "r580",
      "r583",
      "r586",
      "r587",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r236",
      "r431",
      "r437",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r357",
      "r396",
      "r454",
      "r457",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r767",
      "r771",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r357",
      "r396",
      "r454",
      "r457",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r767",
      "r771",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r236",
      "r431",
      "r437",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r232",
      "r333",
      "r334",
      "r431",
      "r435",
      "r696",
      "r766",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r232",
      "r333",
      "r334",
      "r431",
      "r435",
      "r696",
      "r766",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r311",
      "r332",
      "r333",
      "r334",
      "r335",
      "r357",
      "r396",
      "r443",
      "r454",
      "r457",
      "r488",
      "r489",
      "r490",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r767",
      "r771",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r311",
      "r332",
      "r333",
      "r334",
      "r335",
      "r357",
      "r396",
      "r443",
      "r454",
      "r457",
      "r488",
      "r489",
      "r490",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r767",
      "r771",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r157",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r157",
      "r162",
      "r331",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r233",
      "r234",
      "r431",
      "r436",
      "r769",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r233",
      "r234",
      "r431",
      "r436",
      "r769",
      "r790",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r157",
      "r162",
      "r331",
      "r455",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "Brea, CA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Riverside, IL"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "Edison, NJ"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_VA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VIRGINIA",
        "terseLabel": "Arlington, VA"
       }
      }
     },
     "localname": "VA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r148",
      "r149",
      "r150",
      "r152",
      "r243",
      "r244",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r499",
      "r500",
      "r501",
      "r518",
      "r519",
      "r546",
      "r547",
      "r548",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r619",
      "r620",
      "r629",
      "r630",
      "r637",
      "r638",
      "r639",
      "r658",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r238",
      "r239",
      "r740"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Short-term receivables"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r59",
      "r676"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Accounts receivable, allowance for credit loss"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r740",
      "r794"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "netLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Line Items]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueTable": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about aging analysis for accounts receivable, classified as noncurrent.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Table]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Table]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r304"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization expenses"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r52",
      "r73",
      "r74",
      "r75",
      "r746",
      "r779",
      "r783"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted- Average Remaining Useful Life",
        "verboseLabel": "Useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r50",
      "r676"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r499",
      "r500",
      "r501",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r148",
      "r149",
      "r150",
      "r152",
      "r162",
      "r243",
      "r244",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r499",
      "r500",
      "r501",
      "r516",
      "r517",
      "r518",
      "r519",
      "r546",
      "r547",
      "r548",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r619",
      "r620",
      "r629",
      "r630",
      "r637",
      "r638",
      "r639",
      "r640",
      "r658",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r698",
      "r699",
      "r700",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r459",
      "r503",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r56",
      "r240",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedPeriodEndLabel": "Balance as of end of period",
        "negatedPeriodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Allowance for doubtful accounts, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r95",
      "r121",
      "r377",
      "r634"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r121",
      "r291",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Number of antidilutive securities excluded from the calculation of earning per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r72",
      "r75",
      "r81",
      "r82",
      "r83",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r43",
      "r137",
      "r215",
      "r221",
      "r227",
      "r251",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r349",
      "r351",
      "r352",
      "r566",
      "r571",
      "r609",
      "r674",
      "r676",
      "r721",
      "r742"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r36",
      "r57",
      "r137",
      "r251",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r349",
      "r351",
      "r352",
      "r566",
      "r571",
      "r609",
      "r674",
      "r676"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r760",
      "r763"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability as of the balance sheet date for the estimated ultimate cost of settling claims and claim adjustment expense relating to insured events that have occurred on or before the balance sheet date for those liabilities owed to another party as a result of assuming another insurer's primary obligation.",
        "label": "Assumed Liability for Unpaid Claims and Claims Adjustment Expense",
        "periodEndLabel": "Payable (receivable) for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period",
        "periodStartLabel": "Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period"
       }
      }
     },
     "localname": "AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssumedPremiumsWritten": {
     "auth_ref": [
      "r785"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of written premiums assumed from other entities.",
        "label": "Assumed Premiums Written",
        "terseLabel": "Reinsurance premiums assumed"
       }
      }
     },
     "localname": "AssumedPremiumsWritten",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Bank time deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r453",
      "r456",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r453",
      "r456",
      "r534",
      "r535",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Equity interest issued or issuable, number of shares (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r560"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill, expected tax deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r551",
      "r552",
      "r554"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]",
        "terseLabel": "Purchase consideration:"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r551",
      "r552"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Fair value of Class A common stock issued"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r549",
      "r551",
      "r552",
      "r556"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r120",
      "r561"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedLabel": "Change in fair value of contingent consideration",
        "terseLabel": "Change in fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent consideration arrangements (up to)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r550",
      "r553",
      "r558"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of contingent consideration",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "verboseLabel": "Assumption or Input Ranges"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r540",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Transactions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Transactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Tangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 4.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 1.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 2.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "Identifiable intangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r536",
      "r537"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Liabilities assumed:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 3.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r126",
      "r127",
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued property and equipment purchases"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAdditions": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions made to capitalized computer software costs during the period.",
        "label": "Capitalized Computer Software, Additions",
        "terseLabel": "Capitalized computer software additions"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r812",
      "r814"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Capitalized computer software, amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract cost assets",
        "verboseLabel": "Contract cost amortization"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortizationPeriod": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Contract Cost, Amortization Period",
        "terseLabel": "Capitalized contract cost, amortization period"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_CapitalizedContractCostAxis": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Axis]",
        "terseLabel": "Capitalized Contract Cost [Axis]"
       }
      }
     },
     "localname": "CapitalizedContractCostAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostDomain": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Domain]",
        "terseLabel": "Capitalized Contract Cost [Domain]"
       }
      }
     },
     "localname": "CapitalizedContractCostDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Contract Cost [Line Items]"
       }
      }
     },
     "localname": "CapitalizedContractCostLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "auth_ref": [
      "r274"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostTable": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Table]",
        "terseLabel": "Capitalized Contract Cost [Table]"
       }
      }
     },
     "localname": "CapitalizedContractCostTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r35",
      "r38",
      "r123"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r117",
      "r123",
      "r129"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash as of end-of-period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash as of beginning-of-period",
        "totalLabel": "Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows",
        "verboseLabel": "Cash and cash equivalents (including restricted cash)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r117",
      "r621"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-cash Investing and Financing Activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r24",
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Cash flows used in investing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r24",
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Cash flows provided by operating activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r135",
      "r137",
      "r168",
      "r169",
      "r174",
      "r177",
      "r179",
      "r187",
      "r188",
      "r189",
      "r251",
      "r338",
      "r343",
      "r344",
      "r345",
      "r351",
      "r352",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r609",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r408",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r408",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.",
        "label": "Class of Warrant or Right, Unissued",
        "terseLabel": "Warrants agreed to be sold (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightUnissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r68",
      "r725",
      "r750"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (See Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r336",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r49",
      "r676"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Class A common stock - $0.01 par value; 750,000,000 shares authorized; 91,657,480 and 90,758,318 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r77",
      "r79",
      "r80",
      "r92",
      "r731",
      "r756"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss attributable to common shareholders of Evolent Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r196",
      "r197",
      "r236",
      "r606",
      "r607",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r196",
      "r197",
      "r236",
      "r606",
      "r607",
      "r787",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r196",
      "r197",
      "r236",
      "r606",
      "r607",
      "r787",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r196",
      "r197",
      "r236",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Concentration risk (in percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r194",
      "r196",
      "r197",
      "r198",
      "r606",
      "r608",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r196",
      "r197",
      "r236",
      "r606",
      "r607",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r131",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Provider network contracts"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Contract with customer, asset and liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r409",
      "r410",
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning-of-period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r409",
      "r410",
      "r432"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Short-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r409",
      "r410",
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Reclassification to revenue, as a result of performance obligations satisfied"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized from performed obligations"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r46",
      "r723",
      "r744"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Convertible Debt, Total"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r357",
      "r367",
      "r368",
      "r369",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r387",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r229",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Loss [Abstract]",
        "terseLabel": "Credit Loss [Abstract]"
       }
      }
     },
     "localname": "CreditLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentTextBlock": {
     "auth_ref": [
      "r262",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.",
        "label": "Credit Loss, Financial Instrument [Text Block]",
        "terseLabel": "Credit Losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLosses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r195",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r126",
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r126",
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Debt conversion, original debt, amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r134",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r371",
      "r378",
      "r379",
      "r381",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r136",
      "r140",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r387",
      "r388",
      "r389",
      "r390",
      "r635",
      "r722",
      "r723",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r356",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r65",
      "r356",
      "r400",
      "r401",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate per $ 1000 principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r65",
      "r356",
      "r400",
      "r401",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Initial conversion amount (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining amortization period (years)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r354",
      "r387",
      "r388",
      "r633",
      "r635",
      "r636"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r64",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r66",
      "r136",
      "r140",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r387",
      "r388",
      "r389",
      "r390",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r66",
      "r136",
      "r140",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r387",
      "r388",
      "r389",
      "r390",
      "r400",
      "r402",
      "r403",
      "r404",
      "r632",
      "r633",
      "r635",
      "r636",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r367",
      "r382",
      "r387",
      "r388",
      "r634"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "verboseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r367",
      "r634"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r508",
      "r509"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred tax provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r121",
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r121",
      "r302"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "negatedLabel": "Depreciation and amortization expenses",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "auth_ref": [
      "r25",
      "r121"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.",
        "label": "Depreciation and Amortization, Discontinued Operations",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r121",
      "r210"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Technology",
        "verboseLabel": "Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r431",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r462",
      "r463",
      "r495",
      "r496",
      "r497",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "auth_ref": [
      "r8",
      "r10",
      "r14",
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "terseLabel": "Gain on disposal of discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r22",
      "r88",
      "r753"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Loss before income taxes and non-controlling interests"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r14",
      "r22",
      "r28",
      "r510",
      "r524",
      "r527"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r23",
      "r31"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "auth_ref": [
      "r12",
      "r13",
      "r23",
      "r32"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "negatedTerseLabel": "Other loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r23",
      "r31"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r33",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r453",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r93",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r165",
      "r168",
      "r177",
      "r178",
      "r179",
      "r183",
      "r184",
      "r587",
      "r588",
      "r732",
      "r757"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r93",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r168",
      "r177",
      "r178",
      "r179",
      "r183",
      "r184",
      "r587",
      "r588",
      "r732",
      "r757"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r621"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate on cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectsOfReinsuranceTableTextBlock": {
     "auth_ref": [
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.",
        "label": "Effects of Reinsurance [Table Text Block]",
        "terseLabel": "Summary of premiums and claims assumed"
       }
      }
     },
     "localname": "EffectsOfReinsuranceTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock-based compensation capitalized as software development costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r81",
      "r82",
      "r83",
      "r142",
      "r143",
      "r144",
      "r149",
      "r159",
      "r161",
      "r186",
      "r256",
      "r399",
      "r405",
      "r499",
      "r500",
      "r501",
      "r518",
      "r519",
      "r586",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r664",
      "r774",
      "r775",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvesteeMember": {
     "auth_ref": [
      "r248",
      "r706",
      "r708",
      "r710",
      "r712",
      "r714",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.",
        "label": "Equity Method Investee [Member]",
        "terseLabel": "Equity Method Investee"
       }
      }
     },
     "localname": "EquityMethodInvesteeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investments in Equity Method Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Face amount of debt repaid"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Office space consolidation"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Valuation techniques and significant unobservable inputs of Level 3 fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r593",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r369",
      "r387",
      "r388",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r594",
      "r681",
      "r682",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r593",
      "r594",
      "r596",
      "r597",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r369",
      "r444",
      "r445",
      "r450",
      "r452",
      "r594",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r369",
      "r387",
      "r388",
      "r444",
      "r445",
      "r450",
      "r452",
      "r594",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r369",
      "r387",
      "r388",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r594",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of liabilities at fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r598",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in contingent consideration measured at fair value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r599"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Unrealized losses"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r600"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r598"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r369",
      "r387",
      "r388",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r681",
      "r682",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r601",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancingReceivablePercentPastDue1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of financing receivable balance that is past due.",
        "label": "Financing Receivable, Percent Past Due",
        "terseLabel": "Percentage of receivables, past due"
       }
      }
     },
     "localname": "FinancingReceivablePercentPastDue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueAxis": {
     "auth_ref": [
      "r241",
      "r265",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by period in which financial asset is past due or not past due.",
        "label": "Financial Asset, Aging [Axis]",
        "terseLabel": "Financial Asset, Period Past Due [Axis]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueDomain": {
     "auth_ref": [
      "r241",
      "r265",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats.",
        "label": "Financial Asset, Aging [Domain]",
        "terseLabel": "Financial Asset, Period Past Due [Domain]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r42",
      "r297"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r292",
      "r294",
      "r297",
      "r300",
      "r697",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r297",
      "r704"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r292",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r297",
      "r697"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total future amortization of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r121",
      "r391",
      "r392"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 11.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on repayment of debt",
        "terseLabel": "Loss on repayment of debt, net",
        "verboseLabel": "Loss on repayment of debt, net"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r391",
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.",
        "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost",
        "negatedLabel": "Net loss on extinguishment of debt, including fees paid to lenders"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r41",
      "r276",
      "r277",
      "r284",
      "r288",
      "r676",
      "r719"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r277",
      "r284",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Cumulative inception to date impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r98",
      "r122",
      "r154",
      "r155",
      "r156",
      "r157",
      "r175",
      "r179",
      "r563"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Loss from continuing operations",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r86",
      "r215",
      "r220",
      "r223",
      "r226",
      "r229",
      "r717",
      "r728",
      "r735",
      "r758"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r84",
      "r93",
      "r148",
      "r154",
      "r155",
      "r156",
      "r157",
      "r168",
      "r177",
      "r178",
      "r588",
      "r726",
      "r729",
      "r732",
      "r752"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r84",
      "r93",
      "r148",
      "r154",
      "r155",
      "r156",
      "r157",
      "r168",
      "r177",
      "r178",
      "r179",
      "r588",
      "r732",
      "r752",
      "r755",
      "r757"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations, diluted (in dollars per share)",
        "verboseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r28",
      "r31",
      "r528",
      "r753"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 15.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss",
        "verboseLabel": "Gain from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r22",
      "r28",
      "r564"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income (loss) from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r88",
      "r93",
      "r169",
      "r177",
      "r178",
      "r732",
      "r753",
      "r755",
      "r757"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations, basic (in dollars per share)",
        "verboseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r169",
      "r177",
      "r178",
      "r573"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations, diluted (in dollars per share)",
        "verboseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r87",
      "r121",
      "r212",
      "r249",
      "r727",
      "r751"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 9.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Gain from equity method investees",
        "terseLabel": "Gain from equity method investees"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r453",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r6",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r26",
      "r29",
      "r30",
      "r31",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r306",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r138",
      "r512",
      "r514",
      "r515",
      "r523",
      "r525",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r139",
      "r160",
      "r161",
      "r213",
      "r510",
      "r524",
      "r526",
      "r759"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 7.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit from (provision for) income taxes",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r120",
      "r691"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r120",
      "r651"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]",
        "terseLabel": "Insurance [Abstract]"
       }
      }
     },
     "localname": "InsuranceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceDisclosureTextBlock": {
     "auth_ref": [
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.",
        "label": "Insurance Disclosure [Text Block]",
        "terseLabel": "Reserves for Claims and Performance-Based Arrangements"
       }
      }
     },
     "localname": "InsuranceDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r132",
      "r296",
      "r693",
      "r694",
      "r695",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r290",
      "r295"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r85",
      "r209",
      "r631",
      "r634",
      "r733"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 14.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r102",
      "r375",
      "r386",
      "r389",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r115",
      "r118",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r207",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "terseLabel": "Intersegment Eliminations"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r101",
      "r208"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "verboseLabel": "Investments in equity method investees"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r654",
      "r656"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal expenses"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of primary office leases and maturity of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Future Minimum Lease Commitments",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease Termination Term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of Credit Amount Required",
        "verboseLabel": "Letters of credit outstanding, amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r61",
      "r137",
      "r222",
      "r251",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r347",
      "r349",
      "r351",
      "r352",
      "r567",
      "r571",
      "r572",
      "r609",
      "r674",
      "r675"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r55",
      "r137",
      "r251",
      "r609",
      "r676",
      "r724",
      "r748"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r63",
      "r137",
      "r251",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r347",
      "r349",
      "r351",
      "r352",
      "r567",
      "r571",
      "r572",
      "r609",
      "r674",
      "r675",
      "r676"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r593"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total fair value of liabilities measured on a recurring basis"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r760",
      "r763"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r743",
      "r760",
      "r763"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions",
        "terseLabel": "Impact of consolidation on reserves for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "terseLabel": "Paid costs related to current period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "terseLabel": "Paid costs related to prior period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments": {
     "auth_ref": [
      "r764"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of adjustments to the estimated reserve for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments",
        "negatedTerseLabel": "Other adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "auth_ref": [
      "r764"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "totalLabel": "Change during the year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).",
        "label": "Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Reserves for Claims and Performance-based Arrangements"
       }
      }
     },
     "localname": "LiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation Settlement, Amount Awarded to Other Party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term receivables"
       }
      }
     },
     "localname": "LongTermAccountsNotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r46",
      "r368",
      "r383",
      "r387",
      "r388",
      "r723",
      "r744"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r66",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash and restricted cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows Used In Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash and restricted cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r117",
      "r119",
      "r122"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash and restricted cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows Used In Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r76",
      "r78",
      "r83",
      "r91",
      "r122",
      "r137",
      "r148",
      "r154",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r175",
      "r215",
      "r220",
      "r223",
      "r226",
      "r229",
      "r251",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r347",
      "r349",
      "r351",
      "r352",
      "r588",
      "r609",
      "r730",
      "r754"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r165",
      "r166",
      "r176",
      "r179",
      "r215",
      "r220",
      "r223",
      "r226",
      "r229"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r167",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r179"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r5",
      "r146",
      "r147",
      "r150",
      "r151",
      "r162",
      "r163",
      "r164",
      "r245",
      "r246",
      "r257",
      "r258",
      "r520",
      "r521",
      "r522",
      "r584",
      "r590",
      "r591",
      "r592",
      "r616",
      "r617",
      "r618",
      "r641",
      "r642",
      "r659",
      "r665",
      "r701",
      "r702",
      "r703",
      "r778",
      "r779",
      "r780",
      "r781",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r145",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r156",
      "r162",
      "r183",
      "r243",
      "r244",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r499",
      "r500",
      "r501",
      "r516",
      "r517",
      "r518",
      "r519",
      "r546",
      "r547",
      "r548",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r619",
      "r620",
      "r629",
      "r630",
      "r637",
      "r638",
      "r639",
      "r640",
      "r658",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r698",
      "r699",
      "r700",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units for goodwill testing"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r215",
      "r220",
      "r223",
      "r226",
      "r229"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r649",
      "r656"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Gross Difference [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r644"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r644"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r644"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r645",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets - operating"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r653",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r652",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r34",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r564",
      "r565",
      "r569"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss, net of taxes, related to:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other current operating cash inflows (outflows), net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 12.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Payments to settle outstanding warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Repayment of Credit Agreement including settlement of warrants"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes withheld and paid for vesting of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r106",
      "r555"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for asset acquisitions and business combinations",
        "terseLabel": "Cash",
        "verboseLabel": "Payments to acquire businesses"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "auth_ref": [
      "r105",
      "r247"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.",
        "label": "Payments to Acquire Held-to-Maturity Securities",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Investments in internal-use software and purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distributions to Sponsors"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "netLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r43",
      "r720",
      "r741"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "verboseLabel": "Prepaid expenses and other noncurrent assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.",
        "label": "Proceeds from Divestiture of Interest in Subsidiaries and Affiliates",
        "terseLabel": "Proceeds from transfer of membership and release of Passport escrow"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r104",
      "r116"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Return of equity method investments"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r108",
      "r498"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r310",
      "r797",
      "r798",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r39",
      "r303"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r305",
      "r676",
      "r736",
      "r749"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Summary of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r94",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "negatedTerseLabel": "Provision for credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r220",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Adjusted EBITDA to net loss"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r219",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r219",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of revenue from segments to consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed": {
     "auth_ref": [
      "r738"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of policy benefits and costs incurred for policies assumed.",
        "label": "Policyholder Benefits and Claims Incurred, Assumed",
        "terseLabel": "Claims assumed"
       }
      }
     },
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r451",
      "r668",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r451",
      "r668",
      "r669",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r668"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r451",
      "r668",
      "r671",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r666",
      "r667",
      "r669",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-Term Lines of Credit",
        "terseLabel": "Repayments of long-term lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayments of senior debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r506",
      "r692",
      "r813"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r38",
      "r123",
      "r129",
      "r718",
      "r745"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted funds"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r38",
      "r123",
      "r129"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "verboseLabel": "Current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r123",
      "r129",
      "r792"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "verboseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestments": {
     "auth_ref": [
      "r791",
      "r793"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Cash and Investments",
        "terseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsCurrent": {
     "auth_ref": [
      "r57",
      "r791",
      "r793"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Current",
        "terseLabel": "Restricted cash and restricted investments",
        "totalLabel": "Total current restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "auth_ref": [
      "r791",
      "r793"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Noncurrent",
        "totalLabel": "Total non-current restricted cash and restricted investments",
        "verboseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r313",
      "r315",
      "r318",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Repositioning and Other Changes"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChanges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r314",
      "r317",
      "r323",
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring and Related Cost, Cost Incurred to Date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r121",
      "r312",
      "r321",
      "r323"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 8.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Repositioning costs",
        "terseLabel": "Repositioning costs incurred"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r314",
      "r315",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r51",
      "r405",
      "r676",
      "r747",
      "r778",
      "r783"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r142",
      "r143",
      "r144",
      "r149",
      "r159",
      "r161",
      "r256",
      "r499",
      "r500",
      "r501",
      "r518",
      "r519",
      "r586",
      "r774",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r206",
      "r207",
      "r219",
      "r224",
      "r225",
      "r232",
      "r233",
      "r236",
      "r430",
      "r431",
      "r696"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r196",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r420",
      "r421",
      "r434",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r97",
      "r341",
      "r343",
      "r344",
      "r350",
      "r351",
      "r352",
      "r789"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Revenue, remaining performance obligation, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r534",
      "r535",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of allocation of purchase price"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of cash flow, supplemental disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r6",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r26",
      "r29",
      "r30",
      "r31",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of discontinued operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r492",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r31",
      "r137",
      "r250",
      "r251",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r292",
      "r296",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r292",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets",
        "verboseLabel": "Schedule of intangible assets details"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Activity in claims reserves"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of net assets acquired"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r129",
      "r718",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r129",
      "r718",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of restricted cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r319",
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Costs associated with the Repositioning Plan"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r474",
      "r481",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of share-based awards granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r458",
      "r460",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of future estimated amortization of intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r194",
      "r196",
      "r197",
      "r198",
      "r606",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of major customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r202",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r236",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r317",
      "r325",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r202",
      "r204",
      "r205",
      "r215",
      "r218",
      "r223",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r235",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 17.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "negatedLabel": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": {
     "auth_ref": [
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "verboseLabel": "Internal-use software development costs"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r15",
      "r202",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r236",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r307",
      "r317",
      "r325",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r135",
      "r137",
      "r168",
      "r169",
      "r174",
      "r177",
      "r179",
      "r187",
      "r188",
      "r189",
      "r251",
      "r338",
      "r343",
      "r344",
      "r345",
      "r351",
      "r352",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r609",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r70",
      "r81",
      "r82",
      "r83",
      "r142",
      "r143",
      "r144",
      "r149",
      "r159",
      "r161",
      "r186",
      "r256",
      "r399",
      "r405",
      "r499",
      "r500",
      "r501",
      "r518",
      "r519",
      "r586",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r664",
      "r774",
      "r775",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r186",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r48",
      "r49",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Shares issued for acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r48",
      "r49",
      "r399",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r48",
      "r49",
      "r399",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Leveraged stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r49",
      "r399",
      "r405",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r399",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r48",
      "r49",
      "r405",
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Leveraged stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r70",
      "r399",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r49",
      "r53",
      "r54",
      "r137",
      "r242",
      "r251",
      "r609",
      "r676"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "negatedTerseLabel": "Stockholders' equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Stockholders' equity",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r628",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r628",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r628",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r628",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r677",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r761"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Incurred costs related to prior period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r69",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r69",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, at cost (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r69",
      "r406",
      "r407"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 1,537,582 shares issued, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r148",
      "r149",
      "r150",
      "r152",
      "r162",
      "r243",
      "r244",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r499",
      "r500",
      "r501",
      "r516",
      "r517",
      "r518",
      "r519",
      "r546",
      "r547",
      "r548",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r619",
      "r620",
      "r629",
      "r630",
      "r637",
      "r638",
      "r639",
      "r640",
      "r658",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r698",
      "r699",
      "r700",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r314",
      "r315",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r507",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r199",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Accounting Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r650",
      "r656"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r167",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r165",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126960272&loc=d3e32014-111567"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919269-210447"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919236-210447"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131251-203054"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL108322424-203045"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/subtopic&trid=2560295"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "https://asc.fasb.org/topic&trid=2303980"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756"
  },
  "r815": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r816": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r817": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r818": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r819": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r820": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r821": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>126
<FILENAME>0001628908-22-000098-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-22-000098-xbrl.zip
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ME,%49F,X%F]4,:&-J)(B]7Z=\67>7WSZ'3;<Z=')A\''X'QP ;OP+ISZNWJ
M7'PI6('>RFO8"^!7^'E>9M?J.LWP'YE,1_2%6")Q5D&Z+S-S^N'\;/#Q:O#V
M["0XO_CTV^DQR"18_%_/]6H'WK]";34>6"#Y\H[U<_ E+<VYR$BQ?\1SPBN-
MY4AFA5!)<%D.<Q4ID2F9UR3'^U*  5:D6;ZJ)/7J_:Y (I[))))9'@2X2*,L
MG0;XB*!(^7]AR8O;X!=XY2)]D>\(Y\1+'#8<TI?!T>#\]&IP%AQ]NCC_=#%
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M0.U<W%*")/XILU&:P?-#V67T'7B$OKVM#J/OH U%1VDVP\F09$VH!(8V[K+
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M?G.49EDYHZ>=HT6LPDY[ '>]<CUW&;BM 8YS460J+;I=:'&XZY6KN5.$[7-
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MY.+CZ<?WP=G@]RZCS2_2V-TNAS?:<_PNR^%4Y;G.,OU/L%/S2.D<9[0=NI^
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M':?XZYLT^TS"5<QPQP0)30C^.B7U>0Q;NIC8K^D-0 J78'BJY%KJADVPO?E
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ML'P";L@)C=W^ ;'Q'+W&RM3]-S_S?X/^X=X^C0#^>&,Y@:V]2MP]ES($:Y.
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M$0N+O@,J3[#QF#O/P^6^ZI;>WW/J,3?ZQC2N:UG/*S9GVL)38-0U&[/J;5B
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M1A[:01AJQF.WU9CV\AM=[1<I8O*C9=<*6PQ8VN=+.>9R1"H3WWB[Z<PRD17
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MYQR.;$"-W<KF^AJ%!_T8I$FA8K>S$\H<%I$+PZ)U7VO.=VK.?L[-J,QP63W
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M_Y9GGOOVR2]2#&M$2)86*DX^EPSF;YNW!^H@\KSS=GW'M(',S J3L_\@T_9
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M130(J:K@PC4&<:Y)N<G)EC:-.E U$4-X]TIKA5> PS;'IZ+V/52L@H$HP2$
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M[B,J9]]'.7!8FW<(CW'(^#?=!WK#>KQAW6.XYIT'Q8WW-LDZ!K?V6^N^D[A
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MO*YHK#D[UD5CQ)<$/RY3!C]%U+S"$% 7EB\:.3T:#*V^J/Y:R.RUJYY379\
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M9@G+)'R4!%!J_4E.L<^"^WA6S3P'GHR$WX37QSJ]B2J65S!L)> 99@9_+!%
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M89]UEELC(!,A9ERBW6&0!FO;MIF/>?3UY6R>)L7HR\9:UB1Z&R /016SOW"
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M#"0TO*=PZYLD&\Y,J8N5X/BA0QFW)#M-3\'F3M-,\Z_.3%O#8VT$19558D(
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M$%@TD25W\#76-6A)._%#PGXTR:SRD]E'Y@<<(@*/:(:M>[''+2QG!,[S])F
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M7SVCZDOGCVG^):,TQ'5%,'-IV@N,Y4RFQZERO=+5$[AQ/A0VP09+ORSEDKQ
M'1)<N9J&TO">%FZVET@1X+8CYGW<5??.,VHI.H/PH,!3J=_!R1KM<.'^\%^]
M^6QD/D0@V\&IVKKQ/'*J>G/:V)Q@5QQ#%/A=6E5O0Y]K0W!<P*QIN'V1N2X;
MT*K><0U6@B@TOG43]=GD*W6UMS^VK<N'?0NV?6[!_=ZO$^]C7&Y=9[.3-O[(
M:>MM:Q/;NL'42.)=!7/U?6Z]?4#WY8W*2BU]Q';+\R2(9[UQ]<;U)>;H0A%Z
MQNL/H;U9?4FSTBP8'9RKWIZ>GSV]^:.*Y[U!]0;UI>;H)Y62T/ME6@;I%!5P
M>\OJ+>N+6%:6145O3+TQ?8DY^ED%27FS=Q[D:N\R+:J< $L?5*CBVZ!W6KV=
M?:$YNC2L*+U%]1;U92P*.7.S?-$;5&]07\J@F)0?.4+G*B][T^I-ZXO,T3N"
MQ>W].MD3<.H'?+.WKMZZOL0<_8H]#M\I$J<WIR\^1UH%HH-3M7-<3E$G.](<
M5'%JU7GV1@>'@Q?'0P='O6W,3H^T^/*3] &[ :+OTJ?V@.O/M!WP!1EVS"Z\
M?FONM^8O:U@5MJ<2S5IO5+U1?1&CRB8EBB=W<*J^-W-:.R,("N_@,^J<.5=S
MD?'DW;=.<=^AB?L,DNSC#7CWGTM#\.C@>34$7\3"$,0L1-=P?;7CMN"WV%"?
M),CG.,\*53AJ:DW>-=^+)[Y0#:=R9&56PI2Y%PMAV)@G@2B1RVO+;?2D( '1
MB":-7?Q_]MZUN6TC6Q?^*ZPS<Z;(*L0ER98O.U6G2I&5&>WCV#ZV,YGY"!*@
MA)@$N %0LMY?__:Z]0T-$B*9 /3H0V8L$@0:W:M7K^OS4$^\NA$]_VVZB.%@
M&:G_TUBV5MM\BJ2'S-*J'C3'%OMZ]/NZS*HDP\%I,G4 #I@0<@"\:R%4F/-1
M7%5I3=A/HPI7 S]M']X?LEBO!^$];7SX'[4JA!"('!BP%!'Q[T8>9(M9!@9K
M812&J=IE\)*(]]GY]]; Z#[8_LY<9W6I9HG!2#5;IE)_]1J0*C1U 5PU-PQ$
M$-TQK?5VLSP\D7]D4:+*[WSH:HM4M5!ODN4$;5P5&A;4@B^4P0N8&4Q,KI:;
M?T!3D^7 ^/T-X;YG:40O:5W5AI$\35.8.L1J)# U>#J#?2 \A]HWE]20/_H,
MT!^C(K>Z^07;!B[3C]\=QN+\0,PAPSBV3H_KV/H$7#,]HU=\:6.W3XJ48%B4
M8BIC E"*9X@T#R<.0-WSWI\79>216Z"HP[XQ&L(_JT _,04SD.;*T:'N9(V&
M/T+T_JJ2/RVD?]@*#G0-X=0P3[U&=OI8 H+:)\W[ C! H\\??OXTTK"P_.U%
M N*M?FE=@ENN-)]$(TM%$_ZQI9BX*12N 1B>!G:]I\?X<GW/> &0;[@2$:%0
M556!K-($<DCP'@CPPSB1-JXK8DFKU[E56_BK>CG]BTED"&$T'Q$,I3^ 5OG)
M8!!0WSPAH#Y*?:#X,Q<Y -+<QH 4K.ZE!C739 4$5-I=JCM)LU(G=+P*M0+
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M>049)* M6L$?968E7+V?F< D\./6X**]-36#IB8R0D6J5#%U<C&%K';9*;#
M*H[.:%UH]W.6+I+1U;=X6=GU=C:?+!6ZXFM(M1]WCEEM<]!GG^E^.KBS4KAJ
MHM5A<%E(#1T;/]9/'B; N2M#Q6E27TJIL!?V&$_Y6V,;0<TF\5'#+.HJ#IE/
M[P9V$=^$F@$Q6'-79(F08R?%>EJW;R6NX@PO"'@]H1^Z)9,VT3:Q\<ZR<K9>
M@AY$SN&)MK0BF0VLB5VD&#=2/Y#Y0B/S'OE)T[NL6%?*R[,#-"*J@]6=ZEP%
M U0=$OW64NU^0'?(L'8XH(=1@W=V7#5X9G<C$)<R65.R!3^G=4V5]OV6Z.TJ
M5<]/NN:1!VSWM1?H#5.:M QAO-O(UH#J4M19B8ZC&1P&?MT1&D]((H[QZ+Z$
MPRI79\C_K,'3PH+RT04QT4/#ZP=BN7<<&FIXD9_F19W-M*$"->CP\&$NY=6W
MVVRJ+(SW/_1JD&-A/D9?T-G%.4.C[ZXU6T/VPC@>9HG6>Y(!M>Y: @=AD9L<
MF!);W_B" Z%$E'Z:=?][:&*)J71%[0EH5CY__>/)R2A^MGR&/M)/$$B%P/O;
M^,%T@:G%ZZ_QH&=XA)_7Y+!3@0]E(1ZPIBV;>(6C*/]&7XTILD+-AW21E0_
M] 8N T9L(/9H%P68VU!YP"0R,4]R;5"[J66V!ZB?*6HQ=E9T\A3*[A3*#CA#
MD7A#5>%TLT4CZHB# GQJ30>O6(UI\2!K)!V'&'K@O;EI%Y)4K59*3V'@S5Y!
M6D",@<I\1:/YN@2ERX/OKX2DGT*1;9978QX&4^%RVE[A,J1:E<$T>^O4$*DW
MM0&6*RP6QVI,/A@?M";V#<%9D<^S<MD:>,+-N=(]B7!^KFXY<"CWXGL0>MAH
M])N'*('Y;GD>]D5:BMP-H \V3&&%>,^48].O.DXW]1&TZ6I0U6V+W%#?$,<*
MQ[#XH.80%AI<D94D-B>P66*ULG:OR315-YH'4D-<"@'U2*//\$MX=V4?8WQO
M#U?Z0"7#PZP@&N9V^27^RL[IH)SGW67H,"""IR?]E2MN:)FXF!,T#VEZC"AT
M4=?#%+U!:>J&*VI7[Q!V1Z[A1#B)0'HV4>=FAE$#5I3S8K' -=BO@^+Y:8>2
M\Y>[-*CT&,'>T%'QF%-/4DG-SL>68\V47,)]()D':*I%K@Y&98$--8C3.%L'
M$<*!Y*5S7KB+5=SGRJ7+DZJ+"9%YC76\F$YC'?[43 4&3M]!\C3BX@^1!ATV
M@-@&.Z).>(&+, T:HH:?"83+W&"$@1XT$2PW' 6F]OATXL:@,I/V; BH/;2)
M"8_D;:46/.;04+TJ#&RCD]I@9>>'#42T!;DH%+E1X)X-D5,V'H$E+5)O(S5=
M?6>R(6K*8)18GY0MEVF2T88SMR1)<7NH]'CXM=ZFE5)E:,->S&8@()")5F\0
M&"P&T@>?2W6.ONE$R:M2C+W&O_7>L6K33&XN5$Y\!#.;]#NGTU39 13RRL 7
M@UV 0ZWJHDA,^?DJ?B#@JR(WX$$!V=9K)#5M<"XN'D*1=/X&C$(T8^YI_=8(
M@EMG"WMM)6!@*;IB1NT(:I]MJKR(PWO0*OVC,DEXP)K:]V RU!UW-XHZ@!\=
MD5%TNJ4)$E)Y<[]U1PY/T+#J ,,H3S1*ETJG1@93#@.[99%G,YT"1'W,.*#1
M!HN)EHD >0MN7V+H,] 0(#3JV3KPN[("O\[IAQ*>5>&CT4[/M)R*2ORN&X:&
MDM"*A\6V07-F;,_(,07W&Z6;3*D!FCD<X?$.6"_'\HBFUC:3UCF3_0D"3Z7]
ML(T"/]$CX/.5@"WL*/])*,H?G,:-RTD.[+80)K^X;9?X$X=Z14-2-R2@Z="U
MV3RB_?JS<NR,)XVUU>[I-0%V.N@$V*E)@#4*[*VNI_X*(;9,GV.XS";@"O0[
MDWG1IM<8F]JNCM084/F#MTNQ>%^I5<'\,(7,O,NMG66U/ZQ@5R2X<>U*T6&N
MW46I7#(U_G_^20"'X24C1%\.^U=JD!6>D+J8.)AQGXMY9R5L]2G#78RHKO3:
MX/F+GO!]#&J+\'//)J:C.G1@W1?K16([]!<6!"^,$1_BG!9/8 (ZU7IV"#"!
MYZ>F07L@"=K!]L.<;L/2^96VAF]E\%E>20T>6BAQ4Y%JL_(-VE7/][*K1B+[
M9+H$[44,IE! ZY#V- XN:-0:;40'@[:%XDI >2FWG97<"+V63M80J 'J*/9@
MG1;Z1@S82:IV,K#UZS2M1FS)J2I ,\<[A\U]F$$,/!7\VB;-*NABMG79Q4H/
MQB]AWD(CQ&X&)^M;%7IND;< 1"1#[QU!*VAH\%Y.=[(]2*L:#&'4U+E'K!44
ME%QR&.YZ'FT^82+?)K M"<UT4:;<HX$)E/5"]R62].,&T,*BC8W=G2#*Z(1]
M2US)-G? 7M0M[UUKZI[OTC_<PSTD(A[G:P-)UE8:F$FO)Z'!PZ6-=E01;6_>
M.-D3*'(4U>*F"23.1F@J&V=B0C&*+3*.XOWGR7:;AIT^'$+N6;*#FM;,G5UW
MXHR6YL+>1\TW;.\[KMDSGL?<OL[/_23&+&KH)'[@.&>S5=A^<E:1IB3E@_UM
M?' C84Y=A^N0&3\_<.1Y;'+X% B_ZM!OKUF);BXH&3@#\4.-0"D'9+90*@/(
M Y3E3F=?GLU!+!"[GW:BI4\IP-Y<)F^_D4!FH0W0%$NMTSEH'PR^^PWPF[4Z
M)C3G/MMAJ(O_>NY++]E76X8=U,>Z2B$0V:1?B0$G >B&BT@E#SBBN7HZ]..H
MAX,.HA)?-#62= DZI[F+(L_$X*I(0<QHU0U=M'*K_F"0 E=3*.MY!6VW:G:X
MID XXMS3 J&<8NI?I<[@?+UT@</T@_ B:\8,4A.K, VZ%8"58*Z9_,8;@#EK
MC&&&D]UZ^*PP!RTO[S_--:\17@BY$^T#4[Z9P"MG11+NM_5*6OF\\ZW(@*VC
M!X<8$M,'[Q=SZ<NAA^]>6WAZ(!S]?M)$)UO AWK2T"=;V_1J0K.VB@F4O'Y
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M'$]OP.>%Z47:#_H]=O++X]_)[35<%PZ%U%.Y8H=R1:](K9ESSNS&RPU(@X$
M86<7;%XJ/Y><*\*H)+?8S@VC>M-\$;X3A>6TX"JG<1*%GZ+YOW6SGM^O-@0
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M?FS=<J(D][?9(@T'A\B%T25S)\].3B%[5_B?W4XH@@24(V[N.=!EQNY<2+W
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M)LI^-(R*6^0K<G(5^7HYE=KNU;JDEMYRM*[B&VTN\K54-AX[+K)[!24: IM
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MM>0@!BUK+Y"%CM.M!47<;A(8S8.%PI6R:T9\SJZ 1M3TIU/MC!*@HP]MN]E
M*CSU]NED[]G@D[U#@:-%^:Z8^1NUF5,4-X4#%.)]I;K]G)I5+B[_H:O=E/0W
MU V&K59<34O=Y[A#B!^K^0S>059M$_QI\<X=H\HZZ5MG[6&'=@5P&Z0ANJW+
MM"&NI#\9 6R[+!+_"1S(6D>'+$C8!%34U?@*#"S]6]WQ(WDYKGTH(9*_8 @Q
M=%WNXFQ!($^!/0=49"X@Q0,5$KK7Z68NJSC-#A)GWI];7I+J.:: ^:)<WM'J
MV?(90BHY^SL2=B4]0F?W9\NEFGEU6V6KS]4#J(+TCQ@M)23:APD6W:/?/\:I
M%OQA[#)P;@NESOA5L'7/N#1:P2)O @HC.^HD$$1PM\$,@'A0#>!&ZQ5*\7WA
M8GSLH0\.0TC3ISIH;S:Z"@?&N":)@-;6E&-"F@W\.$6J)H[08?RJO@URNS5;
MPT24=?\?>[TS)0V5QSY&M$0B<W3IS,3W1V., N=0$0X9^PIJKC/6$+%^!3@\
MJ2^:O:>)1_C:L#FE_L*9EK%Q9%@[FFI\D<&WZ;0NE*]%[O/"M,JZ(27U]#(%
MYE@"#%*[B+7O#+R=*EX J!H')1L^#N\TR['>'+D<%]) 7<R^3HMO?EZ4MI?1
MM01BA;NMM!;<O%/'@6T84PB&H^M>/ RG3Y][L;V;[7WA"@J=S-IGASH.9!R6
M*@X(=7]>3ZM,G1]E1AU=3NHD(M?Z2GE:=]#8X: OFH0JWL]?SYVCTQ)14%>H
MW0)D;>KCDCS#*2N'B8[!8$[6LD,P%:YWXF;1#G 5.E&2G:7LU6$8=?J4LG8*
MLJ;&9PL0]3S.XD=U4D/S#JCEJF+(0=&\7 ]NJRRM$(O2Z')1]HCOAUJ.VM0#
MT7&6W21=9'=2,Q&\IW2:$[,86!LH1'.L\T/4 I37AH\5'4J=[B%3AP'.ZU.F
MVMG( "K:!G'"D]L6,=[1IL89:#_1$T@D>,F$63C??/@;62J=@Y^("97)"/%.
M'94^ B:(WI)B7"I).TMFE6;<3"OI 7"EI@ ZL2"(K7)M]>LXBSI'YR=/YYGV
M%'T7@5F#N3X(T5[RFX4@]O YUKBS05&QRN$12%NL$3ZT_*8=^R;1R**UM6U7
MT@6U0U?A^EO6&9>D\8+3OQ**Y$&IDY7;^)HS0Q5,.AM@ZH^;\].THP,6M&<U
M[Z&%.I3V#UL+6<5*YP,K5MJB!AH]FWU59YSM%Q][?9@JW3Y!V-HKE(8I.@2@
MC_90SWT@K06Y/D,S_"-&0LY&J2ZV9E@5M0:VKK%%A*5*:>.,N6<1-"?F4GZ#
M)@EZM,AOP+$)WL9Q>LF/8KWLPC#MQVWQND,U:(>]T1-N_-D6:HMA;H[?8O :
MF"96<WWWO$^^@'0VY-!$=.%J]#96D%9E2*=*_G)HRZ/1/;ZAS3/N=T!YM? Z
M)PJ@Z&5&0?3*[:@6J_3T[-G)Z1,PJDF>/C\(,.IK4\<[Z)3K@/3.L2F>3\HW
M6!2FYH\IVOM6/1<MF#*&)B$:S5/+%P]&P'5@K@I!)-1!]68P395?I:X$.P"[
ME/,$V^6P&D007*(@. QGCC'/;@.YZ* !I=-<; (9/\%]V(E"Q$.YT45DP4&'
MA@%*\<TD,HI4JH<D38E6",P++EY<B<MG$9&[DQA7G-ZKT,(8:*@"<S@]MW,6
MOE_N&6\<'/H,B5*XP>@".C!GS$IT]4W9GSKTK+\BR%@E_3IIXS]$PRKC53;6
M!_0B0;P1O\@+*'T"$@5>WX"Q.=#%K:"7M>]FW4:!@<_7 I"FS$S1LF&;=95<
M6""(P4/NF5:66MGS&G"OW28*$D'B&5?D5HV0NH,K9+%Z'A=%;4EU TCG\)I
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MRI,NL&*^94RMF/%3SHOZ7=T M!#PS8SR02]MO8)K_WIZ8KOD;N[:2CEC\Z#
M-YEV9TG!$JH$!'&PU;II56M,:FL^_5A"(Q2T_?F"ONK&H^ O@SGQU_/7T7-^
M13ME?*&;JB[H<;-X,8-N0.)GYO%2?GINJG3-.T4T\TE:JQN9()?<!I1)DBX
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MJ6B82%Q?FB+GH8VC\&&ZG(5(RL,"HNS*)])J5YP@*>#89J"5N%SJ1IM%FM^
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MYU_Q)+4#T7H.&F\>F5^>GORP2LL9QR_*%*825L<JKUBF2D.I<=BWQ&D=/Y\
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MDR:BF=6&;%<K-I)&M*"3K?UKG1+$Z=HX#J76*4P N2?>;'H.K<I2J8RR%[[
M_'?L>.3'<#(,()1D&S"P!UB/V;M1UE8'*&W3BTU!9YTI/&/?&H+AIZ]^=$A\
M?E\G-TMMZ8EA!S$D>@P7O2DK:<E]*&0@@KI=0L%SQGTDJ;H3M@#"IH?QC\13
MT4$M[BK<71L?!@JX3VV<;.PVVC%#;W?>2_!='>3CTY,)5'8+T87T'*M[LG%=
MIG-H@9%2#B(^UXV.+34.ZF([4X[E-%OR^&YY1J BQ%16VLK;KFK7%:!6O0E:
M([I!:U-_EE5UN?V-L(P2X_]JK&JAN6T$U1OUD8A]L:'&CPWFB88DUL40=JF$
M%"R0X:8.3KC:VIV,- >U/\K8HM"O6C0^B]WYDJ:F^UO*5!4E=YN%ZZ6\EU83
M!C0_)01S%SC7HH1"T\'KO:4\0AF0%TY&(S8]16X[K2YB4(_-XFFV@'B<";QM
M.9F!6$7DOR@W"V.N:YDDLNW7%;LFZQ3)C]3,57 3)!\$Q:<V)8;<U0CV46C'
MW#Y)"BUM56C8.RX+BT8#\F"*GL)3!!I23#UX:^1>B:@60[6Z/U]\N;R ](M]
M;*( JYM 09 ^+Q],WY[=#)(B%@G6B*$GHA/)=&=+6RA)KHC^BAJUE6K5#ON+
M5Z?L':M_GN$_[:RMXR%/HD"0XA#1\PZF)IC@J(58&;C7[F!V;@J>ABP1=SC6
M0L#(; !.?^3>5$,*^W*"(1H[BZU#2E:QISN 0[]CK#OX356U'*+=(E@!"<U*
MI]N8SA(2R#AG7YE*PM*FT0@19[R?S2?[%'I^]6+PH>=!%5BC+(8\AC;)I/"T
M+9CZ;,?/(5B@6VE G5,@P3[TGXT^%PMHQ/-+8M".$LIUT*!<YH-/EL(>W3(!
MM@TW7JBA6[U#:AR\B^8U!R4$QL4KP=[Y'']S_"VS\XWGN*G#W:06M1B@C1O"
MN-$T=WB2WA1% N=U?2L!TAH5F:[6AE@"M$V37096 ,B(Q(UL?2]V!OS<=-%N
MY')OA+KM.#=$X\^;(H)%.HY/O3F1&/)U2&(U=K0W0MWOSKMH#&RZ16X:O[FH
M"5#4&)7ZP6V6H\A9N.\AVECTX$P&;%IW-GSW#.X#:W*3(9!!F56F%I_63>W9
M/#48\&L A/AA5<R^IK5Q;80+KDL7D@O6[;EK.?LDU#,@K@6/Q.GGTR4S8ZOM
MCNK:^0O;J]U6!.[/B_W88XA_#2 SXI7KZ_076VN/D)&(:NVYJ4+@B7DSX:H6
MELEMML%XH&ND',]>PY,MH0O3>,(]IK9_UF'3;,9O\[8]Y\TH(]WY1RZJ(<F"
MM37U3FV-77QQLT]."DMYA.KQ:[DW/J=K*PN0H0/%ND%>@9,2HC_JD%R7RL*2
MRB::X2R'Q)A5=<OP(?PK;#N"$S&K$4\"'(%\#HT_=18O)DU1=VY.>>T]3)_#
M,+[T:?K<M)H^%V;1="TBFIBATY5"@)LM#)(A,&BSV@G#IW,HOU0K#X*EQ$=
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MHQN\.NU0J3QT0(YVT,"!2K[K!O;M,'QI+<DP%?XZM>9*J^X$CIJMN7$N45$
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M-$P1$NGI4W H,K>[\+PZZD+6DRU@*L.4&R[JU#Z>E2COFT3]42$TEY<+/.A
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M>-(-4@[I7D'-=&&8=/(UR&11+HNQ)&3G2SZ:/<$K9K%AES@Y'M6 =$R\[7M
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MI]$L&#&F+\L=VG[->.0GEQ6"TAQL:?67<H;T(S)2UEG74_%9"R(DD8?4C7O
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MP+;Q5X.7<\V ^#,,8K 6]/<"40/8'$BZE# R/-K,!08$\"0F;24RPF-VA$@
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MUFT.!XQ\@R,Q0TDBI!KDWX7%SM3WW-G0@3K%$0UM)$7\10;4K)O!WH=IDQ-
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M?X(AT(EF7Y_L"#PG]$NFGJNPVQ5FVQ"*0 KK-Z?MV1.A$_M!OFV/I1([_>Q
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M@RMFF$$(.$F8#V->THHQL21X0-=5.G/(&&-0QED-L\QK#3$P9?A-=D56+(;
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MCA$3SQ190=X]-WZZ#F;FD4@Y+B-JW4;;<:*=RBA*I!=A<J*N'F3^AF4\,@1
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MQV)Q(E^P@%/O[U=7'TTTF=58P,CK&\814%6O++]TF)=0C]CEAD(#@QH]:#S
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M>#%GE#\^)T<\WIH#>?WR=$O&O?/SHZY=GZYA5PKCE0U<&10.S*O%,M.*%48
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MXM(V5&J12IZ?"^JRGFOME6*2K4(U,KT^KS!RN/<I LWJO**K45J7>ZGP K#
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MIW'CG1>[BCOO<'G_F-<C6/+_FZ6=4HJ'+>VU)O+<=T7QA"J*AQF5HPG=[[S
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M%?5YBRZGT&-LR)GMB.=]?=)XWDT$IN@T<SPGN4()^2NJ(/C*/*JDQS,HFX.
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MP*<W_WCWP_LO;Z^4.@<%MIX1:BI[/.0HIBKH(&EHYR_1$8DMBEQ0#()L'W=
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M$,#.OP+!BR6\:3?UU_D+<X2"43"/\<W;(Z["ZN.N\*6M$%_02B>22]=N>\!
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M,XD[=,*]O/@>J.6Z;6*@5F]G&XT*50&F9D+-JF 01Q*E3]HAVW9QTH#F38*
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M_KIEDF&19F#,G^ +_,>3BZ<7E\=(_/_^N)G_OW0LEATF<$^0^&/($IT?GP#
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M!@B"7]=5TP16"3JDS8@JZX3\ND"SJTV:500PXU8'HKFJINU&S6\+<,7X"?!
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MK7T>W:D^?2UFM_%.OH1XDYA.M\%.K7O8[L0^EVTBE7'&!,>XJKYRI@9Z9:(
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M9?:]>3K,K%%=QV8Y R*5+Q7T-_%5W@&N:44-02+]2V=WAF:@%"%1?\8@Q=D
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MO<8K\QA@4MEON3R-V;LY\'I7RCQ*5"0!"#JF SG$$(T2X+;D 7YQ&@,\/?
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MYJA@N'6 3^V=X&*;YX<+I$U5$NZ@=+2Q$"&LED^JZ9-%-?F: T5DPRF,G*<
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M#0 8Z&WE800#H.38>U]]FW?F08=BT01 F%I&(SC>7Z _!E2Y+EFB_$INAZ=
MKH <%-22[/O "QI/DIQ<*(B8FUMH+_?K:CWW]G)+=EAK]BP!;V?H5]$LP@M@
M9&EMW-]T<8.9?-DVWBB,!I%*G.,"Z/220U=4UE(/M-#5*RVU-P(:\FN*):!B
MMT0_UD/5(3TYQD 683A><_X\&JJ9684I;Y9I*8E'FF9^27BG&FI3@H,&I(3*
M+MA)=@,/19!9GEUC+N :@$M0A!*]72N.7%!+A=!BFSW/X21N"L?(I*5LW.)5
M@@W&O4:_$\$>>'\7:I@9[Q'Y=,VC'EDF"^5(R**5=6DY8J$'WXB"\D#_0KU
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M=D0,N]N8D)L1GYG+5R )4E:A1$W'%9P[8'4S* VK@R<T(:ZEQID!$C#1?UG
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MSY% A#"Y22%$8'93&^V8:RW\-@24F!G[OTP<?@JZK_.RH19MRYO@X!+354F
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MQN&8@/AEU)9&%7D0EE!/"H1,.J9S #=4BQSQ/#;'TVMP;:F/NN]9"M6W:EO
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M:C8""#P/671,44-AF4ZBH=BD(E2+L"S^YZ5RJZSV\?1W:JC00J ]),N[#F(
MJ5Y@ZZCO?#0?D:[_H$9\R5?#J44;!PS;*8,_D@89R^5[HS:/X^](2:_C*/"
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M!Z*X]:"B1/C6*E2D.5D4XA+SUD=+/F6,/E.E!62\8:7P0CY%U1KT[0=O1B7
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M-'FJ+Z)(.7H#0B8I<T%&J964IX2U-1-M1UNH!VNUUI^5(->Z.Y,U?R$KA#+
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MSSRJIL>U/Z*C.Z4D@1QOHJ$JXA.H-\:;4+T"F/\6^<V:-V1/\L"SZ9@L:N?
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MB<U[YGC=ID--43,;\83&(/'1>CF0GK/G<S@,JBB5T0-A2 DCE=M&.C 1G*X
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M%[;=V2_X;474F.<@EG32$KDF ?V7_<,#+P9[H7[8CCNR_;O<%G1-G19CZN4
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M?^W@.588$A=N#W<,QW*7>74><C@\;63#AD\EE0E)('Y"^EK0;B07"MTTF;L
MW6#?D=B4YN+3MD@(3)XR%XHDJ:IB>\$?CQD 9"1KEN&_V?E<B IY!-:KDM1
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M[J._4[>X7OU<D1K8IVIM6)[]!UBY>.YPUXG#Z0)(?"D2^CZ91K"TL>./E_.
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MWPENX''A"_</8/-X\AZ/"E6.YRY)YL?K1M%Y$J8FJ0%0MI/E&(W&QWN/P'/
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M2V4RLET0_&'BEC= &1@#$)_JITUZ"@X[D*))J)'1BA(ZH1,N0ZR4C*9?<?\
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MZV?FZ>:SVJ\#:K9!#P+M#/!79C/O,:AFM^\:DXY,NOK33+J=4 7.7@)5X'G
M6$^C]SA@Q^E9]0N)):I'B"B!L&,I.+<([+_)O_PZ<8+%S%K]S7'I#.A'&5BR
M"9!+6BC_6KSNYWKUM/X5WSB$I883^6"Q&57:C+^&D_1W]5KUZW$]]^NC:BWW
MNW6W!:/\[/3K5K?]*RV9+QLV)EA8[O_\<OI+8G__5E_\P6IQJ81;GMH;;_'+
M)L$6.[+C:DW[B)QX_IG!Z"+<;Z#]W2&O](--"-&ZX(^UAWW$^ 'D$\AQ'H$P
M_+->3V%'YA/+&^_K\3'A7ZD-$_RQYLV>LANQWV1?*J02@ND>54\4H+5\^:Q]
M_5SR;55P4['=?;DM>ZXPBDN>LSS1$[-S/QT7!P(5@3UMS=^UDQ1_/VNKY:4O
MN(M9QH!ZH;^2$MYH(=<_YR,+&8/!& QO9S!L*B4NTGQ(6 \9-?G&7C#V@K$7
MC+WP$>P%8QX8\^#M8]5KV_6,<6", V,<&..@',;!2^G2??GNS?)++YZO.:D;
M%.A70H$>[AT*='T[%.AA"_[L], "Z6;!0.>_8T$%,6^"$%WR^H?WC/1<DCXM
M _5LH)Z+A'I6 [??#.99/?'#X3SCFQN,9[4<@_'\<3">MS)P]@GVF:28@7PV
MD,\&\ME@;*[9CG(VK1O(9P/Y;%C)0#X;R&?#0V7@(0/YO&F+#.1SF=C(0#X;
MR.<RTF4I19>!?#:0SP;RV4 ^;V^$&<CG?1%K!O*Y6$HTD,]/W[4RB#H#^6P@
MGPWDLX%\?E.F-Y#/!O+YO7%[TT ^[\U9E1'R>8\QGZ-2)(/WO*]XST>I;KBL
MHO\"V[?*@?@<D;I!>RX4&G!HT)X-VO,:Q?ITM&?%X@;IV2 ][\4VYW0WO![2
M,[52=@W*\^M6/<1WVB \EZ().=?3S//O#.CSDRR[-P!]/CDQH,\&I,F -!G0
M9X/39'":#$[3A\-I,NK4J-.WA40N5*T65<//]\2@/1HKPE@1QHHP5H2Q(HP5
ML87&-,C)1I<:76ITZ5[JTOV!'?[KR)NLX(_[<#[[^_\'4$L#!!0    ( &>
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MLH;C1R@@V*P,<N!>Y>TW^@U94'2D'#^9W(U:N 7:!_[HK&B^UK^PW!(LU<4
MF2*-1%ER1F[>3)Q[/_K4#M^(Q\O\-DSC_PY%/OJ-8IOBEK:P*0_VH*\><6?
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MK%<=$$3[<YB[*9A&FM.E49M6'-CMJ@^UR&RM#,>XC3(2&R@3:0I;!<0;9IW
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M:1SU"952 >*^N?RI7NLL80>&3PI1:,;9@W.)?C]ZPZ"S_OZWP^.?'??OO1D
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M+73;GBU4:Y>:,@&8M/K\J+,;3+8UIC(RM"6ES@QE+,OPP!/Y/3?\FUN9WFL
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M+6DK@9$LKWG!5-P AHOM63\?%*V_=0PAJR:+9!9?*XKH?' ="&T$>NWZ(V:
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M<R*.#1R>'%LFZ=F40]&^J-69"\6 S,"8,*-D?DU.[;!!U1&I]Y;92N?<W]0
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M+*A&H7])LM%'E0<H\[J#W&F#+@?YU7.01WLO3_8[/=#I@39,Z,W[M\';/'L
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MG@]*TW%WWO#C\Y:#(YH[115T75SEE6R^1B%K1-?JNC+EZ *$=WYL_F<%KT"
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M:--=-.(TT7&BWCG[U79,QZ)_=*T?J:;]V1O\=2 R*%=&!KLAZH;WJ?$BZG)
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M8#?$PUV0VP;YF)UQOB5-D<Z^K:>["(,)0&_J&G\P]%*B1"7G3DTN2<12P +
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M!(4JJWU;V<E%%\G%JG]NJ#ML4;.4M")MR==741>-S95G!T>UU24Y,HUMZK;
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M:L[]"9S[,R.*-><NX=R#ZG)ND4)L79S37^V+3Y>M\S^L_M5%^S\V_V-=7%(
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MG0\7O8ZMIMTP>)28A3F>N)&R(<B7E\0)F%0P5WP<=4!AV$]TX0CE-.F+-T'
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M8'GPN7/<N>1!'*VX0DL] <8)4\^3LE+XYBQ9-7)!G(EPKE+ $W=&WB\/+9L
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MA>K>DB>+3%6XGRPV/&XV,5MR?AK*6S=(,.B"21Z;ST]'7#H<CT,IR8^I0Y%
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M'YBQ;E3Z#$'4F5];:"V8G_6?1L%(0+QL[U@;<Z"/A)GB9+5Q<_=1U2?>><3
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M15H-5=33 A_LQD'(J4IIMBW'4QQWZ@48*QTJ1PA(4BSZH/@VO8R&D1LLUDW
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M>G8/7HP C,X4+[ Z^=T_E49+UFLLK7P3DI>8L(9EM6(KAK%T1B-,6KR5%KZ
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MAN4%8 58,6YO:B>+).Y@UOL$9DI&D74"[QV!P [N\ ET!<QK-&*BL(+0NA-
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M62C)@M%FO N,JA5'S>[?E6(-ZPM(*\P>]=P)"Q4\=2-]&0)MQ3-],>Q7\B:
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M'X 7?&##2CE,Z#CZZ>)7EU>'A9[8U:4-ZB\I_?J\CKNOHW=F^NOI_?F\KML
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M2,2H#I=-X4P1PX!P5Q3+NZS,B0.FBG"99K>]"D!!X@JK%OO?=.D$"BVR<))
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M5:SYL-I.XX'9K\,]66J7J!3^[AJL*Z95,O@ZEL;18<#8VQ2IT-6T'IGV1#@
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M:#N^+AY<'A-9TT@MTCC\)HDK[K%/UZ^^P+JDM=/=X7U6I-)++/<Q76%TW#
MD!:5I8 '?7H TU(FPX'+V<XD/D@6"V3YP9.U+-LAAC]! C0:.$!G6J6N'J5F
M7+]P>DU7K.6^2-) 4 ?=;*5F#2\/CUOC34#NCH3GGW6&PX3WL32$FV[*3V0!
M,1?P(9DNKUE5.BVYP9XQ+!HP"@4OW8>4F('UX:>BBLR2^Z[MVVF-Z%<Q'+,Z
M@+-A)<4-&HA'GDX<:,60 '_M =E)WL#TXBQ<1.Q;6V:@'O.!BDI/D>TS76CC
MT-KNYM*$W;RD7; E-3X:4K*Q)Q:^2@0\SFWU8)Z8&^E#;X- H4K!X\X<W/;
MDN*"I<(S2(2#2:H=%OQY6I:?JQ9/._S@DOA),U=IT3?**T^9 6;2<37T (F!
M#WHC3S:0-.R&\"0C)75">(1JEM5F+#=:@S0A@1%[.& (>]:/P88R'4N&Y23%
M#AI[@TMQ3,6  P:5W_V(>F8V&CV#-IBP9AU_,L!)V87GX:'I4'!TTNU->>X>
MVIC>N#K2>NN!ULM2AVT5STE$10NF\C 4XIKFUAA7<#^3W8VK3"2G.J@>KBO
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M9%Z/.R,SMA3S/L'S\T.G%W7\0PWB32W9(T(/64>'XKBV,7D+R0CJ=%^PM9L
M'!#^Q%'1HC:F,< UUUCP85'=(#.644E$.2)7/GS%<P3E37JF%R]&WXD85@\'
MT@96)I&^!RTP.1'L^+([5,[!T;NV2:$,7+5A(>\R.ICAV>A/1W^LA*J_&S'X
MAT<'#WRKF,+_>8MHO54B[DP!$3C.S:[9_YECXR%E!G*55'INQOM,(0Q0G! $
M2/)OI/)BS7MMF[NY%M7YI*X%1.6*_36<OVU=/R&)(D+3DD<*Q^;A:YQ7[+O
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M?(C\YI/6(?6)):7'K?_!IFD.K]SA\Q[1O&L8WL NZZ%_/ZTQ!?EP2-'W+TX
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M.H19<5?F9%I 9RL^D__KV9 109ARVV!;[/8(GL4EUE8/F8)B#I?+JB*X8>V
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M-_ :Q C.4R'0_9\QB-9]FR@&%]<_7T^Z108CY[6K(-S,ZTQ+J#U6IV*%CC3
M'E]0C6Y6V[BI(! 6T$<X=X[9S*C1=UTW:FGK#E2%<&/4DAU*C/MB-PB,D1QU
M:2H.B%-*<?;5'=@M6S(AEPFN7,[:)<_ZI5$.N:V--.7)2.ZQBBZ)P!@$%]R;
M(UBID;F9_;1K'!6JD<JV<Z855MT@'LMF6,*'(XB^G)24J7V,8 SSA*B"_;+(
MO9I"//3_L_>FS6TC6=KH7T'4O#$C1L *R99ENSMN1ZB\='M>V^617-UQ/]T
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MHN8+-,!E8)J-&6 T@ZMAZDHW'G2XE:0:*N\!K=#-TK?9W!][MV:HPB'<V2:
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MLE8/V&?PQ-[J*<@O<M^\L?8HE=K#B4'4&R@H@T4;\:8%)(+H-#CS(%R?&;M
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M>"[;2.*IA2X<2+P[0E6W-J@Q+A+:S'0,$]EQQ9HUNG/'"J+2SD\74Y@X")6
MW@""4HJ1 6-$_Z($QP8W<9OOUVMX6$N(2:R9@9-@Z^I/$;V,)1K!+0/KTT:K
MI7L1$B2RE$=\(TGV9.M&;H^0F7A%'WU2MNR/ZO2&R^(&R5M>-=X:_GZ;L^1G
M=8-I.5>)HK]0"XH6""=8:@R.';ZP=,10J,JWA2^;]0#R9^A6PE"49J/660)Z
MF(>RY\:G+*;;7/S5G+L**IA+VC;8>%  IV\"/RF:#7W0],=#ZH*:;0:I>JC=
M2N6T=-*JV55%^\DEJ.)D&A&%"VH#Q=1XDM"/N%X14P7_P$/'Z5V1$D0[).&-
MPL9 ;1. 51)&T3$*X+ZYN >.WL^NF^ ]/XK9BB6"NS]!4IN_P;;EU^.KX^!=
M L\CR22^,QBTO]5FUH,K)O?ADSOX!2> ^-4QC0<G+4'6Z1;F+_;>'XW%,SO0
M')<5QFWO\Q4BS>T;X>A1_PVF+ZZ *@*-RCOWZR]XRE*D\W-6S&Z36((9CE#<
M0QFS:99='EQ G9V:Z0L+(>QXWV\E2G&NE5VXLRDL1^O$A!TPT126L@J4Q)O&
M\F&DF:7,%!^MHFE4#29J&;OQ&*'04J_U"/=C/D(\>/I/?(RHP7.8DQP%TO_<
MLOX,=D(S_Z'$#J$DO"T_4AA<IW.S^*9 7 K9EBG*19A#VUP4>?2S&DCVY1@/
M@]MT=@MTV/PP]2RQ\H(^P5@+)R$I%)=G4 UD(1=T,A::)KY!W8GK=R6WFE[[
M@Q*FHB#"5,IM,$?2/+HK2NJ] TLLG7G4,6(,J>7U-K]LW;!9.3J0??DDK?/[
M\=N.KL)^A Q(6ZOLX0/+[-A!J'P+"2&@OET"71*>R-Q3^#.V;'.O'&PJ_OVO
M.2N9@K.RHC.3]YIJ?0OEB[ J('G("'5HN4WF1-.P"LY>!F^//QQ?'@> >C"^
MQNGYV?'9R7/M+1![+)3V)-1@D7MB9$0' TVO0.O $RAFJ/EPU']W<TD<C@DL
M56I<Y?!N"V4P^H25I4&H'!<7L85BES5T-6T<'V KD.>-[/.Z^A9C$9"B0^'\
MF^A^? 4;C4I[P8;2K&4MZFVQ<^T$W,F# RB+HC7&=I[-O?E#5_74G9<=TV*_
MX@CUO*[6<-QMK1WKS#:.CZ*O57;/W61X=K*O7#PPHX=E)"EO^/>PFE&%K<Y0
M^TN:6?;G!=N>@7!0Z65'""PW!&WY"N=J.A(73^4,*6><GSS6<L:>G#%UGB)"
M><"&DSIRD^V&]@%3Z/#ZYA@7K/E;K%(S)6P34D/$ &I=<UY\PWX8TA*'>SHN
MEI0_?! A'H,7+(-4%WN2^G0?PU3'KL5W'L@+83E%0D]C!H[HC;:<CE48\!V?
M/]3D)<+[O-D=F!-ID?#)5)V$,H0I])H(26])W2;NS%\.1**?'41C_-E8(J1M
M2/3W^5U:%G+J?B;^@WUW8VWOE&4A-%)P6^']8PK(?W]4L#]$!)(9 J%BEP">
M;MO#=?*9L;G6*-9U'PJ6<T\=8%B<:\KJM%ZD4W382=XADQ&H28(]A *%4R;K
M,>B#U#U1QH]>]6_1/\V[ :7M9TM"O#&%TYX+;N)V.AF$6B$,->A,T[FV&5&-
MGP-.LE;WC0PDO+2VW)V+XN%&[_P0C-[+1V/T) W[U'-SB#TW%SL<"\D0[TUX
M2G=O(6FA.:D"((6@+)H6GM;1E,002$"';%/K,N!F$7J4TO,W41D1?QADA  3
MJ[@3NM@AW#.$R)MD7MW$QU7E(,^*!1H'#H^!YH?,E>C;%7.96+6J3;H:>&Y#
MNXMYBA7S/^3/Z)\3\SP1HA)O (;BL3\T'QSH)Y=2HP,>5>XIO2'']JBW9>6Z
M3HEJ:EDK0O@- ,T&&//M+W__^.[9Z1NSG,S;+M+9!)5I[^A4-)$V*0Y+J<?Q
MSR+5E/T74L*XQ;"$\8*2IUX-<+N/BT5ZS4KFET ?N @L8W>1 0[5$=!B(C6_
M1D!0L\FGSN=16M**LW?K:7T??>;<-JB]W*OYP09XVZ/\+^YT;S5\NS*CK3UB
MD<VJDQP1V"LMK;BPI,8GPDRY81N836RNGG,S'%+;JO7;-$HMSPW<36W%]%Z&
MOUL-UNX/D3;,E#N[7'5<&-L&V5G=H[=Q+M1T4KL>6C&O7T]UZK6\1]76SP1_
M6TZAE95'%A)D9E,=E/6D;V,LC@$'+B7;*_YK3FCTZRA/_\F)?^JU8;<>1M 8
MWXH. [.#BN62K#"(Y-RBXG8QNRUJ^,@RG8GV6I45]S$I<R^35<HL?PFV)0&8
M_#I/[0((IL:G80:^,F%0&"ML8!+6B?.B@;* \F!: ,;$-OCW)8D[S9M/"7U=
MILD=:238RTG!F;YG>Y!DL<&R7M90%2&J PG"-J'LJ60TI+$'NW@:BH , @E=
MZYD4)?00>MU*#0UC&DF:=D6PA#$1?\3F<?+DV@29PK^[]=6( ^$.W\Z>;Z*!
MLN%M-QD>' GW9;=B.V+3M-3[NIO&.'BW<:OIEJNGM+M-NY\^I=UW.O?[14:!
MEW"!B%=<RW:;9(B7 5N900H!$J5"]N*<7'NLB":L*H9_-LZW.47A*K8B7LH?
MO^)%W])%Y<^P@QC?O4BBG)D1X9__N+C\ @?4H<2@(VQE=GXUD=A3148U[HMC
M_LFFZOS37HSN1A#&H/ 5UL%-DA$)=+0H:J<?1X:?$5!3W09+\&W[5=NXP %:
M%9EC4^HDS+U#^*^FR**"J4,R+4L8<@U-$25Z/Q!(TE7AO!;UUS#X%GU/T+DP
M(9XX*WQL&S\,+V,._0PXU(F"?)FMG2/!PP%N[75AYL>+=?8^)\LHM5R3FZ&"
MG. 43&M_H&VNU)@<'-!%6E64S9T6>6U9%VD@]8 ;)]7-C9779,[_GJ+.H[06
MXVOX^E;626 5<1)L2U4X'4N=C\KP*J:SM-N<DA&A>!'!^ZV8*JI3P :;'_(Z
M:N@L2^5/ON;6'B1=ABQGO_,!9$/J<F;^D)3'P[K@[:U)A0 PK;>).C[1?\>H
M=^X_WC;?$YX. C1;3Y$,_R9PA\ Y/&E-U@"DR> SVP1M4(RZ836SIHMJC=&F
MNZEC>G6?9,;3/SI]/@&&A=6-+]@P+T"16KQ;1;;'^JX[N>3H>O-78MM%#LFX
ME%).\/P0$-ZE5>1,+_Y*Q%)8)88E>R5IF8(I*5UC-%'<;UL%&_;D?/X'FX0]
MIKM^^DM_PSN8X>^P6W6*EW]E_AV9@XN0W/0K/P=#61IV*SG_  HCYO.(8$]R
M.#BC54<0]8>,QJOCUX/L8RO>6A7+/ST[.X;!O(-BY"S*^& !@T:)P4,YFD;8
MHQA<I9 M_^_(G!OE.C@-@^<GST^W4I<09M:%,<@@ TVGN![3G)G1,=."D9'*
ML4#U^^CT9&*9OKD%0GF5B,6-MW\2<MEUCMX6)NFQCEV7&5!#AH3TMRV%^'RL
M=HX%"-2;3I);T,J)R*/<=K^'*T*<GQY"#?A\+.MW: TX^#G)DWFZ"B"$?BH(
M'V!!>*>"TOF>"TH!,O52&2[BSC[QP24ZM4L7ENRAK)I1IW >8VGT?*]#:E9R
M<$0@U6544OBB-**D*:9@FJ"*GWZRU:_@_,3[RX]7%\'%?)YF")EU[<T$UA62
M$6AB1(4J/.RYD:>O#*<N$O-%F*.2<V6DO\=7U1?%"J=-&K5J%Q!MP4<X6[NH
M(9]%N[C$A+"D;*%;2+4'7274K?#BZ,6K"38YPVM/1JZ%_=E[/3!28VA)X4IL
M<QJ6F12+&U,1)Q!-3?V).#M]X99EG$BU#RX*W]7D--\P[_+Q[W;:0JJ==7T6
M4_1IGB[JA?%."3=@M<_@ N[^S_7]8?G9-7+R7-T*PNZ[+6][GV3SJ/1$&E7+
M7.<R/#MQR_ X"/YAUCGPRV+D;\O]7MIU8*#@M&2W837QLXT-1]F+UHAW,G_:
M+,F4'3^<#*="O\6RA%UV):WZ; 3;AX9ET1>)Y2*;38T')^ZW8< ZR=USXVYA
M:PSS""P$%LFTPFL(C92TR6RC).2ZH#A_G5 VK#O!]U19MI7EYT^5Y9T68Z/2
M1(6J*=,/D.=D2\)0[%4&?7/=UQXA)R>GQC4\.G66'%;XV>F9^6T(FASF?Q:8
MX3@J)OJT,;;E4/)LXRL!N6##'@&<D_<0Q:'HO6\Z4O,>)]EVB7>[K>TC!ZZA
M@TT^)D5YU6K)/OB)'/!)'L<QW,$3\)VZG[=QNH<@];=ZYF&&2_I=F:RX99WQ
MP:%Q6>9PCE9U27+FMK[!3A%[!UCMD>(4\94M@)1G"[L+T[!L+MF&7#"JE@75
M9>VG*O('X EF*9=R"R:>,;/ &&?[B-IIF":N#D<+"!U%N_O?O#[Y6;/5$L$_
M5 !I;F'N9DQLP'Q'2V.*R:D#1<NE&<C4^*FSHF)A ?-A8[^'UX??C-LVC# '
M_TTC4A\,+!9D\I%:2F9WKLPS",_@W*Z[537I=)]]>\#;>E6:.:S$B2X3QR<1
M*_EU[ZLL:?X0,"YQ\^W:TN6!<KGOP!(N>8]&+!UL?84@M-4NC>#\G)7:+Y.[
M)*\3(2XC8A6?].L3 DJMG5%FO1/3:O;\5J+V/JN*!!S";= **^ OCF?CX^45
MD(=#7\'K-\]?4]H#WAPHEXTM-+9S6904>[#=P8#) KSUM*N05JN7PRP@F*=]
MI*&MJGP:5(BK'P[5+IK**H.6BZ_+MEU51<.G;#0N@VN7FQW6H5G:D9O&\=$Y
M_J-AHC!3[MLH@2=8MYF )&HQ#W.<7YJW<XZS6ZI; 3),?FY.^L9&K8@V5-PR
M;J./8D@%542-AA?'M82[KK<!K8.? ![DJ]FB8'^X\3]E*G;S!&:3XP9$<K(+
M0AP\/SD]"3'"6"!S9"B/#DW(M6SWM*IJJI*6B>TNCG=IE(,K*AM %D;M*H(1
MDJW@T:^"\Y.7+_%&YH=S/0/$?C'45J#.$L 1 0YE5D6]+'3VYP&I9V54;+2F
M3<NT7]O/@S;:WT8H6$WF43"5WF X+T[_XF_^LAS2/^*\[CFO^HUOW[.(O>YU
M5,0Q'BT8*V'WD7/&'7[7YH]I8A70K9(-K70[*K V<6307L?U8&K+D=O1$3);
M/O9BUSZ']*>_=)T[%M=E_,:(6TU#9>Q#3/5W&?U-5CZ:@4R'L_(8HMI&WXX6
M9"'4\!^.L(S60/VO"5.I,M<P-">GH/"K2P[8N H71*??NQ!=9=VXQLOV-6!H
MB&PSB7T3$2G&S3C1L3S -YWX>Q0;M[$HL><767[!MBQ3[!S*$N@)U)8=B-0A
MV$%F-X+3PKBYM\9S+OK.?<A0>UG5$"@1S'O;Y\1Z1C!_F'0PQVVQ6B^Q#K((
M]', Z-*MA\E01Y?=VZ9W*\?9(!_7C)D)Z*$2&PEMF7XW]S+6?VT%>SCG3_(K
M+KW]XK&FMT=S%HZ03=:$W=)7Q1IU9GM\ U)-8@\,!V;:W[QZV5.MK8QE/<>T
M^\DKEX:GK,1*9479SC2-\FM5Z45;.N/ZZ?:,C6<I).8=V/AR(-[7S?A6W&/W
MOO8YI,)CS*TC@D$P!ZWET;-Q+#*1+!8>5&'E-C:QK$,>7WJB&]<YBC+,&I8=
M)6 *;2 1N*+C/B0,!S$FF*^%JNUL"D)^D%\SMT^OK[&G#7I-<FS7D=9NX^PE
M&=-Q03K6>'?P92@!\2=5N5KVN^5AQX0E(##BM%)T[IC,! [A*I&T@>T$4NE?
M-CI%N=VH,+3&F2UY)^SR4^]@/*JY/!;Z24ZGU-ZV*%N/9"\\<2(J?L)NBDS1
M\-<6+UJ<S*%1PB-"\P"4!U*V2,=CU<Z.S]^@51N0C,N+W+F@5A?76P$Z1:<R
M*>XX?'/1BBXP\"(J.W;;59:M(UG6>[&N#!C\SM$(V:XWFQ#K#> &$@=Z54Y8
M_WY--%I[4DGX>>Z5+9QVI)=;2E%IH0+H"DP )U0L[$HSVS7*A6_>P/?]7YHQ
M.A!7X+?Q;9IO:DW :D )C^@N2C.2H4!PG?0!QH4)!:7IVO9<MBSV!OPXIGMM
MQH#UA4XGHFSM=Z7.3(CMV!^E+(Z9:?<DFGH+&\Z3/.9GA!V"!TC,@;&)-5%#
M2/&PNVTT@0"\6[Z[SBTA+M42 SS62Y?)E)>EW,B*^B0G]#K\W);8"Q,9[@5\
MZC"'$9#2O6I$%["F@E!R(J;UUN:0?#XAEXF>$.KGD#J%=<</3R.)P-,E;W?M
M95"#(+]GR3_RA-@77A2QS9.HFZ<8UIN'>#%IW;ZOC#ERG/''RZL1P 8G?IXJ
ME#14Z&6L.,G'22O*4!E[#;A-]$%OS/KWYH3[M*DV8C85EA*O$ISNER]/3FRZ
M3Z#SM.Z<<@ZD<V1!KE81?$I6 R"\7D[\4@1U1P/7DSR;66'0#6P1 GYB?XOZ
MN4?(U9%+LDD_%(AH<2@<G=.XH.PE'Z$T$/C:-#8YL!IZ+:\K=BW).70J%#2\
ML/35$&=K:]ABVGEX<T6F_JHQ1E#QR*^1$V'%3$R(F4)+"7@#B2)6T6W29C!J
M!^/D+6Q"$MA<X-^+K#9#7 )3&MW/O*_2]^X!'-COOX-.V?^MX6\?4N./>Q>T
MOE#C@NXS']*X!BA2U^T'"<HC]/H[,']5Q$JQ$IH1DC/IQV8C#;&5,7>&ED6;
MT-Y!6A<LKN;323I\_0.!+]Z.QVU1.;,M4)4A:>Z.^BIEN$A2%,X_(291]*/6
M!:> O8R?(;6:(SPC,K>J!C\G(6+1!>B_EVL-VN/#COFI[1\&)OM.SX[R23/=
MYT"  ),IJ-YO']>^RP;^5$UMO2.2!4DBTHK#*\?:V@GC0FN+A6>Q'UNJU(SK
M62&N9[NI^Q'$E,NN]$*EGDH2MB1QUE^2V*$=_<VKGQYA(6._S>^OQF*5MS6_
M?XN^CT+KX4".X[%UO#_V>L*KO;,Z#R*]@E8\8&5R!+8,;"N+98G0L)[8",(V
MV(*7R:HN\Q9^GRZ(%8+CX$+D[_07 !>U*FMPF*#RAUY2@SZL!T%"2#VG50X'
M;BLCNCO-/5Q694B/ WQNPOP.X1"+F?]L&:WQHD?W-Y3WP"!T!>+K]YBJD@\4
MN:0]>5 FZK5X8I#U!9AFH&V!?<\!LR,^'OE<#9Y$[J]L+X9FFDZGXUS:#,9N
MGL0H7)WF9L@3;U[54FJHLO@WQ+@V^DX003-'15P%TA5 H'PXG8T[-:,Q?X&L
M/:<O0YLU2+Y'-FKFT)K^J-(&YGEC[$!AL!ZYAXJA'&X$B3M:N%L)A%LO1KJ8
M_GL<RIGPQ&?QNQ\*^^6SP-3X[[@X]^BJ'J6<B&[_[X!F?:BA$\$Q2&9C\WL#
MWVS>,LDK*;%SP[K#6(/%XPJ4-2E8]46J<\=%;BP#YM8=RSM=PUT^Q?B813@C
M6YA0S(B8S3N46?NA:8.#+*E6JBD(.1ZQ.MJ8,<B8PJPAPR[F/!N'+4XT#3.4
M4+B7#._+O-;O;'<G_<U,8@&PBYF[E:1).T"M2&P@+/Z'-87]<TC]"4B5S(GD
MT&RL%&JVC8U PI0)=P%RCUI>W*-(->1*(<D*\ KV"=1YO=VWZ$KEP,R;+[L%
M,+A!2[0''O!"::6:%P]J$=S]R#XFG0]/,L$E2V.A=]5;SS'GNA9?N2X1@MZS
M1"D$ _EJ8DL@!S+@#QYO)]/!9]VTJ'-[/L%V@+=;Y!C420D;B<O!R2ZD]*?5
M.N!OU4U4>C(>H>[(5K]-R&,331NPG-PCXZX)<X?Y1@SCD" '/UV :"1DN&<%
MHD0 8V7EWAEH:@(AJ"!GGL@51FV'XH:/C^AAD$:F.JJ]N179"(>7"$E2#$YB
M:GLH:RQ20HUC=I,#6R[6G6?8W64<[3R..E<;&@+^LE>]]4J@C#,"KPMB^IF)
M;QE3A.A$C,&A?)'F-7Q=7+/YBNN<[!\<RO(:(5? @/5%2%ENV%L6]WR.F!$O
M\Z3%JR&VSJ.@P&]5WM>(-9U:L;,BOR8<'-+\'LITCZ__V6.&^)0:SYKZGE13
M)\18M+NUG.]VBG@UVQE>>$['5T)B'NMDU4S;$;P1J21HG=TE'&H\E>=L>>YE
M?WENW(6V/6TZ3*QN5NC$&OEO=9E6<4K5^'O:%IMSS@6O9.1LT&E8UXJ\Q3ET
MO<F:S#'ZKDA"S)7TDPV3-[<-]9[".3-Y5,BC*KL1L+MF%Q#K*>#G9Z#O0T!(
MR#"72TZN"7N1@Z.Q*H]6#]4D@QQHV!LRU%Z$8^@NHA>CGJ2EO:H@.P+(BNX*
MAD]#DKFH,67.XS;9CI).+8,5/J1FW42?G#O1>2"<':,6$#<^!/;L&R,S?W=I
MN:KQ(8UG@R\43 $,>@.R1.9S.6J62#\G.>U(34_,2*31BJLDCQQJ:9Y^)\C9
MS'?+T[QCP1S(T3G"EO<!GE*+MQ,I=U@HE;ZU$#PQ5ISDX[!64@0F,ZKH4UHU
MN@@'X8HH3#U_=?+JPL0R37C1-X !U68Q7]K:F__%T^/SD]/39T3M9Y^%"CY4
MIVH_C^)^]?L.S5.<PU,T&%#0@'0\266_Z#V%I8RR-^8:&^+9TPI"G-KQ+RG<
M*6>')'*QU$'P,%BV0J'2*.-=;.;?>"[1_:'LH'$VR@[!?6:VF47LOZT,J_8U
M+V>5L[QO_]4G_NJ4]7[Z\N3Y,\L/T[DLCW@)[KJ0)D2^B2MWGI2D2F7<A)FQ
MW0!OG"K$H>Y:.Y0%.,*^V2T+$',2T\0#6)!S@B4IJL"C24J^TV\Q)[I*%E3\
M9KT:1*MC6@]M)A?NE>NC"MBXNI#/")6QN.U$$O'-/ C527!9,6Z3]X0MT<UN
MP'F"IX4+UQ6K>X'0*$9S$S, Q@^.\=<S=&[@NOAPS4?S( )+\RO'$*0?1W>#
M67CKZQ:)AVRCI1G8A/: VTJ3X"&;#+RWC$A.TXF<5JV<UR:&=AJT5Z?/3SN?
M]<<.$WZ\"=.^T[VPM6[&R\[K)>9[0A+7.'?F+2J9(?_1.XU4EW%[>?+\#WZK
M._M2YM-9A@YK%67$C[H$:(TZMD$<F^-O@K]L65B6E1YA1VFLM$B90(I5Z-N%
MQ'H%0<BVO/:A&-H1MO)^T\5) G]1;R[;E.WM0)C2AH]"X$2:I-:$DI&SVAS-
M>B)_ZJJ>FE4 32CV+\KBD1FL6G'QH2R*$;:J#G#_M)1UDA+YFQAV1TM@ID]%
MX4K>VGZ68^D,>\-;G\0$D&8Y('M7S&YI&91<2^DBJT)H2I%QNP:&<+*&GLW!
MR4/F=;2$/B,A6<H7+U_"-U^<>P?.X$7W<MR+;H2-1EO39QX1)6H0@87(O%,%
M'4-2C)YTHEI!.C/S^2AU38R*Y<RSX?@KX68HF5UD,<?Q%.FHE%CGWSM<+EY?
MIV=GIV%@_O<Y_B]18)H?SINY@-:9;]EVP0O;$-5@@U6HTQ!/V7J;K3\??[:^
MVX3LR6)@YI@4RS6*&OH^V>$U43*Z^!1=,3F'KS./66/V#=%1!._S7I6CI3<O
M1";15=C3/1=";VF<XD]7<!K ODL4"3<V"Q+ (^1"%MSM+K'^*P59P;7V:B+7
M=X8N>%KQQ[)U(#M[7C"CC\6BH[&8,"6"^+T>[K\JW#CX#\,;>9N)"A5U@:#,
M+:8[^&CQYE#!_\!__VCI#=X6N3L_+V9F5#\GP,Y:)N[3O^9*W1J\+/R<L0#)
M792O^$8<'R-1I/]I;?LR%!Z0XH/72X%2]NJC7NN#M#FD#BE/T)42<,3Q;9(L
MFU3"H54X%[#\ZJ8$!5A>J3)FS;CC4$[Q;#RG^ ZN8SMS2&=E5*8X0V@J)#_Q
MYOSE(?I?B]',W.GKX3-'O3!@IS.>'F/@D-M)",K E?<D ?!"%Y?OKXB+O R^
M(!\%:$V?/#M_>2CSF8]F/MF?'M*"$6#WQ3X?_:>_H!0N@521^6X-,).J\OK:
MMW:9@0WY]?CJN-F"M=J<+AC6,?WJI>N8?JQ(63/1K\>R0+?U,/]<%K<H/+37
M#N8@<%U57+R$5,.CZ:K:XW0S;Z>#KVD-(IE<XHK!;"&X<;!%'*?-/"%."@E]
M/=9 ;&DUP0<#@J0]=Q>VSVG$D]F$L10*-QMH@-(&Z^/$-#IJ5("]0>QLY$F@
M=1-KD!01/V%^*\-"(J(X<(, MP/-VOG)(9BU-X_%K#E=$045V2]+@[5QL#.A
M"AC%=RRM5'BB=ZR$APO=*N3AMX"@)B>0&E-.#NA2@-PQH&:@R<%VA<W,TL(4
M06P;Q,+@:#H)(-Z#,+Y8"I)+!9\*Y6XK%2Z)P _.HN%0AHUR6XG=N*4!DX/\
MLSYI;A=#;CSAS6MVYC.I%ZKGJHH,J?D7A42B\AFG<,"H([B1+8:DS/QVE !E
M&N#OWA;"4_@83Z0][E0XD<PYQ,LAM&LXI%J"RQXI 4M_6?@-0U[GA*2E0DU_
MAI(*KJ+:(R?<$N*1\-A>7/A=K8"9Y6XBR/>:"+2VGU(_<$Z\.(!SXOG)8SDG
M;-YNST?#X[ J^YQ7$[QB P81+D2.I(52F42S"^&MC6$=Y>RRR-(9VI)A$F7.
M_@#<,X\6>-("GC+V(&GX52<PN]9"KL$1_''<S*]V@+[" )DC< Q$L,QZ Z5G
MR/RW'Q(#'4S;A\&=L8!Q&$Q31H9!LCS'9BE,[G,)!:EK\+?T"6RG:\N7RB+(
MG8_0A:/P? ;B3K 'A6/0%\+\9NB!Y/PJ-"%7I^=5B2>'8SL'D,Z5,"B'>\TF
M=?T^&UP>)SHJ:L7.]>H:>1PQC],0[\H/X;B#S!F$0D]E0[6/MY$+/LW().6=
M33Z5L" JXFMBB>2J16O4U7W?\;"*H"E*XP;E$,+2+><\7<-1#0D?5!]O-W:3
M:'[LGK&"=S5>P[3(X^JI'NSJP:_&7P\>5?>6 C[XBU#XVQU1>D@$K5*RNX_2
M.VXQI;V%ZY)AX9KC?/(#/NOY(?BLIX_%9_TU=P&I"%SL^>SNY7/#=EK[B)86
M!S3]% UO UL^373(7?(9H1C3HF :96AMJYLD67D$?$T2G+]>7'SU>JXA]4(1
MON/OXC3*)Q!B704_\\6OX.*4%J$O--,N)A@%]$6G$VE/.)N(,?\W2WKO0SQ
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MW;>_4,#VEDY+.FDOE*8F?/]B1NRA"4 5H?1@3.[_((EYD>=16GK3,Z O1">
MK^",+FV>=]/)!HX!L3T\E4UMV?3-Z,NFW0?>GLXW74<@4/4]TEE!"H6--R($
MJ) 90I4SHW8I$'I%8IT!RN&RZ; \0?45_\:5NK.TPP.6>[I61T@LYUNLD57H
MW'&=M?]MT!LJ,!&44C'0'),@+K!B&E$2(!=.42AII"M,!9%>"NEWU4BC37R
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MF]:,"$9;B=OT^,%YE&88S9&JAWE_-Z $B_9'CZ CL/7NTKA&E A]##..U]?
MPPA[C1K+G=RO2UY&,<C=)*SQ!7-.)MS2PYCKV5U@?RF'%*&>JWH!U]MB;NB@
M>7C2\_3TT7>:GQ^/1F!AFSO)U'SD3XY 7('\'6;70G=G+50C>.9!O8-I@;>Y
MC*U,0CC<3;*2B+1+0A]NYFZ"K:4NY1]JB59;II>=HZA>MVT?YW%-UUH^KF8=
M!W%H%;?]=-WK>#*=,JO4T0!X?^5RTRQ)8F:J0@-I7@/=L6UC0";2=R0[Y!Z
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M:OUR;AYO9K:)_AV2[^K;Z1C18_JJ5F4MH(]!NT7O#IP@_EJ*.?EI4>>8IJ;
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MA2(\!-!!@,]<V/?[: Y21&/ +=]R.Z9/7H,Y#SRY14O($N#T-?O[[@V60,%
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MX*Y(K>0X2*WBIZ8H3*QD14JMGPT?I$8(3K9!&"H=H5[8KT_51Q?E[]5W))J
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M#@]JMYW8\J@:5&9"?R<X%/RE5]>2MO70+_Q@OAGSQY(KX' DI!0WPF020%+
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M-A20 .;2690N$K^9ID.H?=B.WFC0V9(3[# 4/*CN;NG>7>X;D$A=)<M*84F
MZL L LHMB W,'9O'6-T@VLVOC\_WZNG^"#?]JP&,/P."C+WV_KP:39"QI??G
M'1['!6,X?C&;8P9A^<>\JDL(H*D=\CUS9 :?\>3;;S?DP#CTQ;CCT/%U!%VL
M^EO$M;EE:58VQS;GHA3VE-S?_4T!P6V1-_L3$!0)?Y7*7=>-F<H51*EH98;L
M/Q981S##$%V3![#-;SQ*;%\\/1F4X48=T;[#^/N7X&<<5T3:C"&<#64JK)M
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MQ/HDA@[6=Z>2_B8D41ULSF(C?]$9]%6_L7H==V42&YA;UHV!+5UDF@/GA C
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M$^.:,\+&;H00JM9ASON*>3H/$B<_OL :'"+\4E:MKC!D1[&;SI)ZVW:]).T
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M_8'I.+L9HP2YXTP!PG$S.7G(+2E(:?&<,[\;ISL9]N"LAV^M!E;PWD9)@'$
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M0P^L5B6J=H/!$T3_.^V/,>^J^TI@1,VJ454RQ>T@8= @=;5W3OLAITE"*=Z
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M437HBG5+QB?<'!<PP@,X/7!JR(R"CND !:X6#Y^,H)/B3"6NTI^PTD]?4UH
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MWGX G>73.-++]G\YCD3/WS7/>9E9ZS.;%X$*(H'&:=%A@X<P/K%_?B#>8KP
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MBJR-57"&?5?W0V^@UA<\RX3D8QRPIHFZ0YSW,X\8('&=60)''C@_G-A!G*.
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M<J" <,$ 03Y0THZH!XEEF+DI>].SD#91VI;8CW*ZT2H KS Z 8&O+3M$G E
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MK-48J-;G?%A]]S%5UH:L4'H*V#H9Z9"G^4HH('2_" 5J/IX$5S.>\_O4JGV
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MB709.FA+K!4T.NDMT30MT,TQ=A,LF2Y/PPYP[AW]0^#<>SQP!C:4!0*&L+<
M2!.QC.+8;);:93'$Y!9XA2Q250G4B2!<0D,3 2PI(9:((8(_A852"WS7T++W
MAL80$I[7-TFB4BB H-:(/#^<]?:DW&9LJ/3$SA!O8"2M,\1O.+T,=J.5S27@
MVIDQ:]9^Q>XZ=OM[A]V;E85^^N1%-SX^M34Z:]Y$J4L/D?6".;#//0JN&3?@
M\8;XD8D"P@4#!'FBI,VH!XGEF+DI>].SD#95VE;8CW*ZT2H KS0Z!8&O+3M
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MA9<B9(:]J38W1?[ERF_];&X?W3WHP3]02P,$%     @ 9X #5<Y,KX#.!
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M?WN[L_] '>P?'NT*>W9^?OQV]]WOC;5#89^X)W$YQR_KSE"]_8AE4"K68LV
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M,M?&-N[,-HJ.2:L$)AN&Z!BM(JZ14^%:T,3+]4[0\?5.%[WDEV-K'W!XATD
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ML/KN&/%TP:K$7*LD_-8DM-G:MD9+9+Y3U/WNF UK5[?F98D]3^20;42A2*S
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M;9LLI;(B!8852EA-:'0!';7/F]T7_^S(ZV6MB<5\S;]<8J*[AMF%2:NKWUY
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MVUC!<I)0:0Z>/IE,K^2O//?%RR$]Y^G9L"QO#+;#5KB2N$>M<KXVV:IH(/F
MU9&!:DLJ(:K<!RO\(VH]G+9]5B[BW@Z.\=6B+V^)Z=7&]#>F]Q=-3TOLT\;9
M4LB#=BFEG()2J$@Y4PKTJ'1U=SM7[JZ#\^OI_8S/>'S*3Z:38SE)SBCS%\/Y
MX=73WS[7[[["-EB?R.;$SFIH]0ZPD*U*HRLE^ZQ[5!QYP_7^<'TU-9RK]0$H
M@E =E-6HBZ/H6D5<5XTS/9!4&Z[WC^LKT3"U%E(JUF(A04PAVP+9.0<N:R[5
M]&CGA W7^\/UE6SP0"J)]R8'&BM4#U&14RE9ARD@Z[+1ZYT?#.T+OU>BT=FE
M&#Q7*I9$K_LD[II+%,);TBKA1J-O^-UG72X)I\N@0G44H$25==L\5"^*.E2&
MC2[?\+O76AQ\"E723:>=@:(\FE2@[6D6*EJ,&RV^X7>O]7=PD-#EMBF?!7'9
M,3M5LY),,U4.D'J@O_]PJ$HH]6@ZF;6AF_;Z^>&01[17=R=3P16GBQD<ZS5L
MU1>ZKT2.8_0Z5D_%5 5.DDR.VI!X=XQ02ZK=7Z"V-S]LY#D^'EY4T?]X'4U;
MX?!JRA=%])</X:TLP\(J$'CM&+,!)(7$.1ME;0WR6>#N+\/J#BK+6VQD8ZE$
ML=4Y((A4DBL 48(%!6]:UTQG;>7&&J.?>?)JBB>'(BLNZ[O,YB?3'W]_T'FS
M2*;ZX$'E9-L&EBZZS"&8Q5Z6I'*'5]-^#0#;3SL/@-4%V<7@O ! %3-Z=,ZG
MR$;7E+#? .S^J_, 9%59)5O8&0% J:@E< =V.ON(J?87@,54G.GYC]N[G<=
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M?K<8)RG!"3*)5+ AXA0I&7O]6!/*&%,BYD_',LUWY:1V]L_J86%NTOUC(^K
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M%+YONRAM<QW<%EY!'?C.(_\Q9-4%NG"JCUSWM8%]:_\[20E1/C*(*&D05XE
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M"5KU0^7M< 3OU5M?QZ<2[C*%.Y_=,/#% 6RD.CZJUY81N2',H=@D0[KY,"R
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MO+Z 8X;7?*Q'WE'MP?^N(8!$5W6<OR,Z5.KTK5])FUWK_]F^6D:;PW>JW[^
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MQW#1./QN?<4Q:6&Q)UPC#B8FDC9-$-=6,D$,[&3QVD:*5\DQ6IUZK+J#X='
M/ZT*9?FYL^C2]7L5*=R/%"YG2('IF%'*&!): !5@KP]EAJ.,&$=@A? DL6M
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M"@JM!H4*W55*54I52D]'2G/0(*F"%<7(.1-EI!*,0: B>@"II:@TZ''3H*E
MZ9=WU*LDN>(DL^!(I!.*."\3T9DC4^0RA1#;QX,>U6BLRW7ZQ5<<AMX(2ZG;
MJ 10.H-/9=6OK@-]E+,WYRMF<\%00Q47@8.$0('[%!V@\"8*Q\S<Z-:$KB9%
M;5M'P[QT$Y":%+LU;^Y.I'(JKE@A:1Y(^K Q5=ZV\4ZZH(P62 +'1"2#[)G1
M,G0!@A<>4A:7*2F&RQHCTZ(NE4]4E2])!;XG/6X81E7CI:CQ\44UQA!4)A:!
MT!BQ5#^4>78^$&NB]Q%I"B)D-:Y*_&B5>.D1UULH<?4=EJ?A,R'4DOP7=-[3
M4@<BK:>D5)\3'H2@D6;_DI<$LJY5RQJ%5+6\U6&?*J4JI2JE*J55E-)#AE K
MKWE8SV4Z)JI55,9F7P5]:3'/C2&6FOPC9SIFK]3)@!-BLZP&\P\2$UV]1++7
M.!H/>Z$TO9R$1(N6CCJ?\\L8NYT^CIMH:1.<ZWSIC??W\2 67>F,X>LU'?2>
MUJ%0"R*G9X)L/K;Q!89Q!\>[Z>5@F+ W/FINL.+8'#CV8B:0&ADM%0M $)@@
M,CE'LO-MB!/2&1F-5R:LK3-&6W2P4X][5SB06K7Z+K1Z*J[J@5,92RE+2#*3
M$XS$0119J[WS/ 8AG,U:775ZM71ZGMK;)016KRO"K=I]?]H]'5-EB:%B3A'%
M>,@V&R6Q 0,1R5H-7/%F4*F\)*(Z=T5N5>U6!X"JE*J4JI2JE%912O.0F25$
M4RN9:0>9F4TN%8UH-0&A!)&(2%QPB7C)G50L619%83.R'6SF"625YNV=?^QW
MPM%PB/UPW!D/\\4.)N6X\#V5^VGEF-83NBJE*J4JI:<CI7D(FH$0I?:9E_DD
MP6EPBBMNHDY)*)?B[0E:,S/PPLC R<3 $R.U>6*C]HJ)FMSG1C_NG1FLL]*C
MAKKMP=<_!\/FC7$F=_YH#/X ]P9_0K[,N+*YN=C<JZG6OQOO.*<H#+-$,I&(
MY-83KT+^@C0$'SD#CFOKEQR)WYS+51BH8%VE5*6TBE)J1\RCFM0VF]29 (D5
M4L04@" Z3:1#1SP5)9G><4NM-S*H]MC4)Y!AEG=]YV P>F*I8C6J7J54I52E
M5*54I=0F*<TU=,4Z*61P3#HEA9<^,2M0*O Z\I#L[3EUY@03$OU')@:U]&)Y
MA'A[:O#*QKOH( 3M#-$64DE9I@10)$*33$ 3*ENZ\KDNH[/C\FH"5%O5N(+M
M*DBI'0&,"K9W!K8ST8<8(JH$@H"RADB= G' +?%*Y!><C=[:5J%M'8!0KU&O
M\<BN\:BBBN92T_HK'$ _8 =&I3[UWT=][ C:[133N$B@\63@S.3)GHL,JG%P
MY _P^]"9Q>95M8ZAS%?12I-@*G!-$UCI7;*Q])SRF8N(E!=0GLQN^G'%6W/Q
M21YI)23+(R1_3Q6LOGJGDM:")TU"2(Q(9)P UYPP9")$3PT#NK9N39>YA3L*
M+5V%'M@W>6"L>"RS[9:Q/JN)H;-.WM( M(YA7Q@ICR\B99!>:^HL,4)ESRWJ
M[,,%*@A/(5E0CH**!2EYA<D*DQ4F[Q0F 1UX*I.DP<N@/4138M7EO^BH2(O
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M8"32#&8R>"00(!*MN'+*NR1U;!)/Q"*'0#7:\J0/@:I^WY]^3\]^Y" 8TY(
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MN@/W7WZZ^/=BVN_WZ?K#)2@<\<&Y8IAA<;C[]_G!7WOLX/CMM\/CM]&GCQ]
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MM37VVBE+S N<;++T%/6[VZ^'&J]'?V8]1&L]1A4T)XJ7]<65_W;812_$#8_
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M-#(9[F!&-[:3="M=S)1\.? 9Q='C+!<TY,J=8"'"/@++NY#5C^F"MZ4F5%-
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M7G3=NKB;_ICTT"2PB"Z$'T1WO5]NZ_S7XUH'6Z&O=S HX3_=O+G^>LM]]=M
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MS]\RC-<^^'AH#]Z'W_XYWAO O]$!//_H[4D8,TGS5!&%74-9E(.2'>>6A(!
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M$]LO3/7LI /=N=+AW*3"[S+;+'P1^I1Y;K99@.)W2H^R.0RVWWQ3X9:EM^X
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M[8W6G[3&, ^Y?\,*E:$/H>SM^O%.Z^]Y90^PFSO0LD4KE<V%%/,&PW#BQQ,
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M,Y8].+AI,CX%-M&+XY,!O.K7?,9B>7)FKP]YP4-'S^LG5QN^Q9YM90DOC J
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MMGMFST=;_[IJ-H+-.#^ BWV_?@:JGPL36J&6Q9Q@(#^,L, ]C]9R98#A8ZI
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M;VF%#3T8G]%X6.*'+G/0UJE,<Q;;'BR*\SH#_64K1F/XJ\JPFL?YLAA+/7]
M0D[@4?FA,#,PSJT?NH/1Z)^E%,T=4B!6.>I_J5K1.K%WTTI"I$ U-YZ0P+&U
M.EA/!#,X21Z)YK>MZ?3+Y>1/I3,+9SO>,KKRI2F94M;N[0>O?7(X.01_,<1-
M!"43O4%8N.1AIHG0<6N7[2R?_&[=EX<8$HWW0J:44Y(29H,S5EHGI!"<*G+-
M5G@SXVN8<: 5P1MM8K2(>!D1EYHA@SU'4AI&=8I2&+*U*W:6DZ],9WRQF@9@
MQ;5P6\-DG:B[))>?]'+-JXR\\[ XP\(;@+;4S+H):-_D+8XJ%_I55)H]?55<
MY;7NUN^E8*<#\4V"/F_9ABNZ"2;J+A+-!*.Y(HI76'#IN/,>,T>PC"%8JOS=
MS='5HCVO1QL9_[J]64KU64*Y83B!E$>'N \8V0SX2B@P+K#'TH(9@7?8^A#>
M,A\Q9IPKJ7BDUEDGN:,LQFSIVJ]6!&_6P_HP_Y@=G'U@5% 3'4%*Y51;+'ED
MB0)5;YT'FS)A(W+LTL[R"8C6_8W(JTKBKFM(YUILWBBEI.4!UA"UVII<=R8(
M'#&MBQ[SZXH>-VOHVV#*F_/VVP\B:ANM  XAA*^3N%%B$68B<$&%24EG3+FA
M^.==UT-*- "4>"8# 6M!.4%Y8DX(39,Q^*M%L)OUL$9,X0=['V F1,+8 Z8H
M Y9#XLA(JI *!@NM<<XCE3%E.7'I?3&%7,649^%?6DW&WO1OK*9JA\/L="NV
M?:FPW,DG"5N^]M-4;HYRXNBR%'6G=]JMG"_3B)\K;W 1_HKY625*/=]5;5I4
M3IUKZMW6SY[Z:6HW3'[]M-+K4FF54CYOP3%4-1B^D";=E&O27KJ"%NH8U5_(
M_:CONG133JO\EII\T-O!.2RJKG6E8O6H]NF,3SK#@/+.S'GK,RRQZ<4;/$C+
M[_R*!^DQ7$?EN7,[5L_$.P2F1-#:9T]XY*!RG !&B9-D.KL/2.,=^E88#[H>
M; >2DE*1):0DBX@'#[8#:&$DO:5"2IE@5@#C]8Y9GZ('(X$PD0CH=<8UH8X!
MUGH20=F#UG>V<0]]LRG'8"H$[3U/7"/EH\U3GI!6W"'C:2*2>TX33#E5.\OI
M6F[C'UH$TTWS#]F5>#LKUUIC:NQ.:_[E)L_?,M_72EG<H63JRRM]*C:\].G&
MES)=/:Z96,_8X*RRU1V]>F#5,4HE6.%1<F6C=A9'@&9GDM IF,:K]TA1) 2L
M+T*<$9AF7+8 TS@F9*6R2#*>0#4Z &N:K:_KO?AW]\@HZB76\&*IN2'6!,&T
M5UA+KDTPC5?O.ZKJ3_C@[0>MG:8F2B2C@35@\DY.%!I6 \X[:MHH5LJ'K(@D
M>C2W'I4*<W@J)T1PEM.O<)<4EDY2KAD6C5OOD4"% JC8!**L:$0:,P[<KT0<
M)8J<Q$(D)3CF?FN7K].MQY/1P:0 .M;RD*A15@LE* NPGITFC5OO>X+*X=X'
MSBUQG 7$HE&(1RJ0HPHC+0P0(,8IUF9K5]VT7=2X]:X/+A[%.1_2+&=,Y9F*
M_:DM454JMJT<]9/O1_E9N81Q!UC<YSC,(<15Y'!)*]&/J3.>!4F=V,_YT3F+
M8Z=?.0!=K%+1Y-32<'>NE%Z92I6A4A(^PJ3=5,OW+L<7[BR1*Z)!88S]CV$R
M/ .[;!3[+TP8 9R_M#^^^R 5-5XQ0.2(/:AXK!$,/$&>8F]8,@[X.=#][*4[
MCW8X6HS-K]R:RVLE!YS/*F)G)^0X^I,^B,'Q>648]^UX,HQ3-_$L$&_>\SQ7
M!3V?0AP,%R,^;[1U[RS,9?Y)]#P8!_J!)6ZML"H))ICG6">P[.D'2;;F;GJ<
MZ-!<\*"E=FX4IW64Q@;DZ(S_,QB-?NWT;=]W;/=-'Q!CDF=G0ZIATX.9X/S<
M.Z!_]. =9R VO'WTEK?WWY\<4!"@_?"I_7<;!&>/M/>[)TN"\_K=Q?O7[\X/
M+G[NM3\>PW>.<;OWZN+]_JNS-GU+WM'?3@[V_\*'?_^:#CY^PNVS#QZ+J)7D
M",Q6@[BS$;E #0*+B3F2&(D!5TP$%F<,>QES G%!)TR-%H0;9S2AAB0>L3 Q
M!;54/+L:_U:>@%+R:.%4S.("OK&"^@K/P]=:LYDJ[N]8-%O\<CH85;K'5\/4
MK89I+JK\9#B8')\4?+%UJ9#Y;'+EH,UT.P.T1G]4\8S1=JO3_QQ'XPJ$3F(7
M].=X3G-63L&\BS%#K>K(]*@PDV$\SO[%P?!\NMTS!V3]7*MD/G=="SHTC6BO
M=[+R*Z[T:0:DIQ;>G%N<'9K3[2"8VLKC. TJMJ-!?Y8O;S0Y/86&5ST>P(MM
MV8QZM?I->6A[\(!))@V%"&2L'L9>'4(]U>@3Z%2WDV*MZ4>Q=I*6S9N\^34#
M]GH3[M)Y.;>)!>TYL\. NH/!I_ST"-\>]"HDJ[M4=A_G=O+JG<9,*FJ2\<OA
M?]_L(V+@M<#\\MW5U%2OZ?13M[S;PG2< @W,7;O<&9NZKDI.2/73W$25?;SJ
MA%6\O%P=@LRK[M2>E[D+G9 GM35PL*!!2\+O9:Q+++H=37/WP4+^WTD$#(4/
M@'1,7;VWM8IW6J]!!?=7:$XW&8&,C&"@RC9J7B Y\U[T,P?SL!.SB[I^:UYZ
M):P^#TB=4!%=^;!2YK7VA6=.5TUVC7]EY.MAO6S3V>4 51[P5E[GPTX.T)\[
MUY$E-*<GK(0H'PZI-WZ77W&?P;L#5"YG0*R]WZOS@'X[$"Q/_+'P6G\+6)S6
M0FK]L0!P=1:;UM$<P&UHEV_7P3D$'\8LT5G,Q[-3E2#;9Y=!"=/MEXS+QX.\
MJN&7+*@=7W3%X',GU%KDTHN](/P[K5^FF+7<AJ6]^GJ[?,57ZRVH_GS#:F 9
MW;2K5"(=NO%J",#M6P)#=&I!!F?G.N:547_A5,K=6[?3VGRS&& :T*$#*KE
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M+<GEEH1 AB2)5+14,*.E)2Q[W8!-/VTLO5H8?"G5U]U2@%W)0OW #&!\0S*
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M+8?-$$F5E4&C( )#.6<N,H9P9+BSBB?I31! 3:C<EGHY<]F&;B,_@IOD!:/
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MSJ,=[K3^AE69EVZ6A?^%'@&ER;94*P$:#*#Y14_ZP:2;5TUV&T]&>9FXV.V
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MM*V= )=-!WK@6/338 C_/&E2<>)%YVP(=^M7R2SM$*#-);Y265.,I-ED*4K
MX:U26L,4YR$J>54U)U(3O##\M FSFH-YU9S+P>Q8?O:]DW]7H]!:X+H^<*W.
M]HG<,Z%L(HI%',=L G',)Q*,#Z9(1H4M+UYJ]S"&?+1C?6Y9R1#:.D:#"RIQ
MR0.U*JE A8M82RDUNP8+WYQSY_61TON<$_F2AX.6H[?CZ&7KRE.5N3*29)<9
MD4(5$D201(4(VB3'&C*PKO[/_[*<\1\?T%CFEK=O6SY_;;>%5CY_>VY>-BS@
M5 HU'BR)Y#/!(<3$<Y=)L;J($#2H8.KAR.=O'3F\_Z#AVCSHUI_3^G-652V6
MHXZ&NF25S#';(#3#OUS17$1]W<E8K3_GUF%W=0J6CIY+F05H3<H3R7,AUB:*
MGAV0HHIFFT0==>.W/;2E=5$_%.9N(>VJ403%4+ BN/(LR1RR<YP;'G4P7G)9
M1 MI]PAI*W:A8Z(XJHF7V.Z-H5V8A".9>^:C#\XXWD;=6DA[WI!V6_-+6TB[
M TA;-HZ-%-X+9DD2&AM9@()F+:-$QUQ4D$%4G9FKJ!M?;<3]$"%MPQ1KM=44
MZ^MZR*YQC[FW79HB>"NW;Y>X]O9M G;E3Z'/* '[&:@23U-A<#X8)CF3/D<9
M-;=."6VS"2H9DV2=ID/;-)UOKS#LKR939Z\4S2P1+0LH#-%ZXDL)1.>D8O!2
MY1R:9&IU6\G4C\C2:4'H(;W;%B"4@F.>*^JTC]):ZESD15NM6 )]6/H6A.X1
MA)8=,=1JGT+.1,F@B-2.X1 A2YSF66IJLF0X*D+(KC:WY5MN0:@%H3OW!HMJ
MHC)-6E')8[3%>E&$4XQ13UT+0O<)0LNNDQ"4,B%YHI.+1,K"B.5!DA1H%EI[
M#SKLBY="NB[EJ\D%]P=";5IRFY9\9:!=."H*=R91F1T+7E#A@A2)*LN8N6H.
M1)OV]*WA:34MV?CH<$(:88%Z(DM*!.QK3AQSGADI=908?Z</(^VI35V\;54B
M<VF*2MAA3AK0*[STFBHI6 E*:'<-%F[3DN^7HY>M'F-X=E9CE2=FU&1FP.#Q
MGB@ 9^69+):%-BWYL?+V-O+Y:^<TM?+YVW/SBOF0$\O6.&*T"T0*&L!\B)XP
M*RQWKN3,Z,.1S\\[+9G=,,3==-E;CEBVZ3!?NS4/&\JW<3L[[GR4REBN9!'>
M^J@\I;E(GWPVO"Y1;Y-E[@&R5U.:DU;"*95)5-8121E84]0 ;@NPB:4+N:1R
M1XV$OHI='KB[N@7+%BRO-[/6A")DI#*))"4WW@(W:L:%S4ZD$EJPO$>P7+96
M4Q*Q&,N(8P6L5<8I"2PFXBG&-0J+I8C;CM&U8-F"90N6-5CF['B@WG.OI!3!
M6)IDEKYD)9)+7+5@>8]@N>P,\,9' _H_B=1*T"PM)5;'3(3"WGNER%!X$TND
MMQ5+O$^PK-P)_Z@ZTB\TMK^/=O^-PW3KOS8.J6@VB""B_L#L!&9Q8NO)V0\$
M?W/;\*%V^#7>=5-&+M^QU\S(O=5%VVLM>6$SV8Z3N'O[N1JR$,?'X_I%<.9:
M/JTP\6S0P8;<\W-6X-+_NOLT#+4).NLI43GMQF;!.<T&1ZU&3#9AJWZ<V/H5
M<T7>4L!&F;CWOD0B "&)% 8422HU<=&ZZ!E+FLMOT1:P/=X[.=YH.$N9>R*B
M!]$G+">6&T.8DCH()V6.<+S*J)U5*V%U>A/@3Q^/O_;A@M#YL-J4OAK'AQR\
M-&5I96+[TK3U!9!O,$IH +%56)T.3OG?BS-N&F%+9U_Q881S%#9_964:Q#U-
MQ6%F:;?F_OPPG,F^HTS",/M/Q!=8[ ^^?^XO1B_^L?!.Q[T3,K^!R^^^>:;3
MDJZP8>S3_*DU3/549MZ_/3GS)T<]U--VFSG$( QO;6#6ZL[I$*QF1LEDBN0@
M&8N*(4NF=$8KGCW0(4ZO\YGO]:<C8GNS;6NF62],6>IV\F?4'SKU/7,B'N?1
M'N%@WES&_4X?N'KT_5QHJ-:Y)VUK*DB9 $WST01M.O48V<ETIVJ6W.I0IQL=
MV%7?^[9SHI3$.5%UG>7Z.5'K/!WUAX;O<+7YXTN_>^F'2M[1C=F.N9/[2OO(
M%JS%(UNPU'=TX[M:<$O#+0TO[["Z_H(W5,3S2RKBK\[!8H]T?-FEW>:>U4YL
M'-9U"=%(>0VB>0S!A5I'6^\X71?&V>0-7>,0?>#'_N=$P^WL-BKN;_G8]TYP
M?.D?M;+[[U[)M[4IUVGZ\'0V]^?A8#3JO)J,@]VMQL&V6WF3K9SSIN$^PL*^
M7%ZVT^[F);N)#O,I6?X'QY7?[M3.)[15+4"V /D8MK(%R&\(D.O587Z9.OPD
M<N)?#8:G@R&&4\^&/N4J G8= MNZ]]M#IIA+<W&:<-%26K>)WC&>A*=<:F6<
MRMD['5GFBF:NU\X-6(PN[L;_&6-4\2>0/&?YW[V_<YKY_FO7_T12-7*J%DXH
MFQ8"CO!^\8<T'EYD/WR<(<8Z.^?X#['W95>^A^^^>[W_<?_@M_[>QUWU[N"-
M_.O@KV-8[8>]/_=[>S_OK63G_'40O\ Z>OL?=R6LB>W__,?%WNM/:N_@0W__
M^/V7_>,WG]_SM^?OOZR=\$.U]M&%0E2)A4B=([$Y.8+5E25:FPO. \'DA-48
MXLU9Y=:;K2ZSV--. [S&^S^97#^;92ZR*.L5E9(*&T,V"0C5II*]IM=MN7H)
MUE2*VS/( ?QV*+.<,&T9CY8J0SREEDB5-7&&16*4"DD$SETP+UYRU;5TM2CP
MECNQKI'&CR INH6\%O)N$?+F#*QY^ZH%P5L$P94IL$(FY30CH#-CU8@LQ'M'
M22HI%LFX3PB"MBNU;C&PQ< 6 ^\8 _?S68MWMXAW8KF=+A,X(2&2Q*P@T@5+
MO,N99%V*E+QP+C7F7MY^1?&#![S6K;3B5G*:6JX3=\YG&:4,49I"C8R9\IRX
M778K"4QA;]U*#X3WU1+O2R]$4)*1HH,&78=A)P%NB*8Z1%U25MD#[_,=V;J5
M6OWB/NKM8Z"6::^2EY(5C? CM=*N.)&IRQL*95JWTKTZK_>:IOW[![L7[PX^
M'<IHL'&)(,5Q1J26GGBI'=%>P_]IEDK+UJ_48EZ+>=\(\UJ_TK= P8M%%#0A
M4*>*(2+23,!8=B1PJH@ 99HIT*23!T/+=+6[\\F-+0BV(/CL0;!U+-TRX.TO
MJ7U6A)RR\(0Z&8GD7!%?. YJDL%I:ZV6"JQ+VV74/!;$NT$6UJ-*MAJ/X.%Y
MV*GKR <GHP^]T]$6B;J/W\/%HU%&L1)"4M+K[+--U&8=I ].>MXF3CU<$%IM
MF.ESLL&"TN6"*T0:98FUQA-AA;=,4L:P82:3-_)P;=$G_!&V ]^FTQ=/EB4C
M:$:OL%%!Q "JKC;6.2=#F_WS$%EE.?M'1Q>C99EX;3B111?B<<RB++9098&/
MC'SQ4C#6I6S+#F!W9VNT+/CM6+#U&MP]4RYGHP@M"M>!$PM*-)&V9!(R2+)B
MD[!9&!<MR"_+NHQOV<*TY<FGP).M$7N[_+>2'9% 3^0FDN@\.NUPXHT$:U8K
M'B7(R,0RSK#BKFO=END1]\B 3])N,U1'F;SB O3Z",B85(BT1)62S*S-3'C0
M?+><F:"9E<DD1T**H(PJS$P )"51<66+LB(D7MEM-REX:054PS-,%!$%*S'B
M=F?JF)/)>EHXHYSZ37TH6[OM7ET<*^%U5ZA.T1!*%<@H;Q5P#?QALY)"!APC
M'EK#[1GS8&NX?0NN7 [WXC0>Q0KHBQ;K" HG3I1 N*+6:^]IYNK%2\.[VFT9
M_6B9\BDP96NYW3(#+H<?LPDA>2DPU8(1Z1R8;ED:HFBV3+CD;')@N@G;%=B'
M[5MSX(:>>.JI]W,XR/'#"3SKZ.(V<H@?O]UJ'=BB5$;.BI")9YLLD\6Y3'D(
MVK3QQH>+.ONO5N*-F3&1(H".*S&CU,^8\^ (-5R)0KU(3(+=NF.^14+]&K%]
M+89Z>O)<<56R-2*)R"75Q:EH LNV9%,H\ZP-4#Y WEH.4.:L4G;*$^,DQSD-
MGE@6.(G:"*V22U$ ;UG3==O*\^N*F0=1C-8R\]TS<VLQWSU[+X<ZE1%@&T=+
MN/&12%35X4@582&[5+R)-$<PF$V72M:R=\O>;=3TP;#R<M14<8[Y0HD( 0JP
MM$D0;X(F07N9B_=@=%O0@FG7VJ?,RL_*CBW2Q0)O(XSG4CCM1(@^%QZ]\1F.
MO8V_/F0.7HF_!AZY-HX4B\XS3PMQ)@<",%RTBL7QF%Z\Y#NTM6._I6P$MG*R
M:*T-39+RX(SC." R2^^=8[$-V#Y WEH-V!:I9,J6Z&($D4: (0MZ#HF"96Z-
MIA9TF]:0;;FY#?T^#OY>"OWZE+GACA''G2&2N42<9H((!B0B2PXE>+!D15<8
MV_)WR]]M%/GA\/)R%)D7P1V7GK#H L&&:,0GYN /P:*GIGB.G;=E5\G;:H_6
MUJE>R83_Q!&FG6,__)3/.OWL1[G;.<G7&>/Q= QN1QG@BQ%9)2DM=2$D$>'G
MJ$7VE*4V</QP@>;WE< Q& 0Z^5!(X5H228L@3FE-N/!<*^J5XNS%2[ICVWSG
MK^@JP;R53ACM8)-I\H[;J'PI2K,49.%M&/@!<LIR&-A1D:RD@<!?J>Y2[^$4
M">"@]E09$0TZE[N<;:E<MWF53X$!6XOW[EER.72;P,XM3@;B100E67M%G-2<
M1-!HM0<VY1;[B':IVK*_7\N23X$E*R.UY;!M.&PYHFI$$$*6 E(N X=%)0E.
M:R$XF"6%5&26*/3TXQ%Y3]$D2Z8HIURT5@F9BK+%QN@L:"O%)1=7AJZU,="'
MQ'/+,5 618RJ<% T92922D&"U904:9WG*L+I8N^@'=&:9%^1[4.+-EI$13GL
MJY2!VAR%#4P%8W-P;43S 7+*2D0SNN! !?3 *I675(,"Z)4A(7B>$B@3Q:?6
M)GNV'+C1)FO9;CNV6PXT9FIXDH5()0R1'G@O4,RXTU6)FPRL\!<O76MU/4>F
M:ZVN[1EL.?HGHM;1L$R"\)S($ MQ.0N2. _!<B%,B"]>\OLPN]9'^,0WK1]-
MO;_OA]-^&0[^[J4\Q*#?^6#XJ6(NW/I19[+EM[HLO:.NL:X?3P>C'I[^#W7[
MW+_SC]B)F(CJV\N;Z$<9;_#BY7?L^RF=5#OZO!.))8U<"@W6L]921.Y<+/A3
M4%D:U4XN?\@0NF9RN936LF()P^E20 V,.$QX9,J;K 176OFV(/:;ZQ^16YFU
M\88%+8,3@2=%G0.9QK0'C;*-A#Y WEJ.A#(XP)(S(\(R1Z3PCMA2)+$<:-<Y
M98+"8G/=Y>*V9M6V>8;/DYG;J.K=L_=R5)4R+XQC5:D[V/3<2YS,ZDAAL,'9
M%L5- .N^J_5MC<]HN?MY<G>;17R[G+P<O97.@1H</<E.4:RFL\0**DGDQ8/
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M%<6MJ8 "&(*CP7^-3V9U&NOF]-PW"?TY[)WE=Z4@O=3E@<L=&5H:6D]#GRY
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MH;<VUR<NYY\&PUE:[DQDM;;Z>@R*=/_70V6DCE0$ D("Q9A*H/]$2IRT7(F
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M2%B3D%=]16LP/F!8J3*4O\9@K,_XM$JQAP.];DO;;=._ I 8R-R49);.:YO
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M[%MHW@#-"M[C4)ELD^6<8/R78"<;XFR)1-F2)&7&4^DV".+%OI%;-!!_=HW
M<3S?@VX$?F5C[Z5&X,$IH!FIX?68#(7;Z'U65BKI'99(/=!&X,#TL+UU#<%F
METGM4=X*Q@KHE<Q+&;@KDH,999E2TA6KL)J'Z<TPUJ+73=$+P]PQ:2 ]&HGC
M <Q7Z@+F$'N2+(U&LT"55^O-U^6FM]<BC'HN5MU6_>_>8#SJ7TP#&7E5(-?7
MI\9BF.@H(&9Q),CB@//N#8@N2^Q*F7R&)TA,MW4B2QFS5@6,G=S*SKNCOKW/
M>P=O#I/B3$6P8Z+68-9$#A9-Q!S7E$Q6*I14S6:U.^P*\IOB4J,Z+JG.J(".
MC\?UJ!DX[%[LG:WIFMM<@[HS/(HLEOM,["%4^8Y.*G.IDK@SETUC1ZWJFJA!
M5[[?=8U^+B/_58,'==_1)*1=6V +NN,<)V[IV<F6EB1L<DD%Z0,/T14-2HSV
M ,#2T^LB<!MSNP;U?T$7#@_8I5='(@QF^!M!"2;U$U 834@\BN+ J)?K<H$7
MJ7_>97@I\>Q.D;G?#*):=!LNC-2IG03-O5=(LT+;?G_Y\B666,I=JN?;7^YO
MN&47P2QC;SJO86(9SKA]QDZ3A0]@,;B.B;&&H<I5#+ENE=4U@.+KVG+?>N7.
M[MP2WY6?)H*W\M:U7'UE"<_'71PT$7T2 518HIA/V. =3$,%NI;-') UJNQ4
MQ!*>-1F$-XT%W7J!7DL(-X!W\>[@_:'3SO"B* E@[!&9F"1>I@1H3Y45WJ3@
M"I[^YE8GTQ:-UZWI6*<2;Q7=N>WJH)9ZO@Y&WK#]HT/$D**+(TJG"'J"=L13
MRHD!(TV;XIW.!FVTVPPIWW;A7TL(-X 1N?=Z[Y ::ZC,D40G/)'!8^C'"1Q@
M%;@Q)E==L^4E<;YM880MPL@3#K)L;OV ^;Q#5'J'>2$1&#2X65W;I&('9WLO
ME^I,:Z6:QC$3)7)=_G/=N'RQ2_EVW1J^,I=_KFT#=J=>3.2?]7FM2D->C_/!
MX*?92[RJWF%W-.OC\*[\,DEZFO22>:Z-'?8.8+T'1X?:YUPH]GK%*3^R!$:\
MMYEPE:35U*J"[:<QO7)=+\!9SZJUJ60UP=6VU4+1Y6E_/*J2^"?SJ)#UQR?5
MJ,2IC8)C7<,8;94F[;\V#->0Z1SA5[68"\8/,@Q&!NM"SV5VFL;U%DO]&K5E
M]4[-71"XZISJ3:5Q<P^9]MB>U-/-U_NM?6ZWTZMOTO>CLUG<LNK.-*W=NG;A
M!&P,'$(^P67T,][Q(?+P*["=0?B>_>[[-3_OCG;G67>I$.Q9LR[%U(L4<H@T
MH<!5\ =H[@2G!!++8RHN.2NXPZ[-E[+N2E$@_/)D+NZ-A+Y,-FOG#MR(2*Y/
M%0=#CQ#PVE^,]NIAQVM'"21_\?RH@<&Z#C681=7Q\V QVBMP2*!A)"IE@S24
M1B/J<.72^("S>F>KV0*=[\X_U /C!Y6Z4.4'Y#A&?>O[3AH/)\57]T@)KV9+
M:HEB,U'PO=='AY1J.'=?"%AI6#RA$W'%)U(4\QR(PB5, 1"K1#%W[O,$,LG)
M^:YV64[\H964FK\,P*7JC%!?_CVJ\G5WL-KRGWZ[ENCSW]Q<N9ZJJNF3QFTZ
MK_J>#@=_]Q((\W65>I.V8[/2O4>ES]9*[-N3.:G8"L7U%"_W7[\_9%FFZ*DE
MV4B$09=)X,P2JP7C7CC*BOE*?7:23%;W#9DHL]LKLG,D^?@[B&P_/($]@^$)
MKP' CIOI"?JKIR<(965B+ 5>A'3,.INX]$J:4F((QE>)SIKQ=GK"+4/+'^<
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MPGN0[=.;[0O+9Y8E:)Z]$SO;G\]:V]_$SB[T9>NK"EH0C0TRSFC$"YYJW_N
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MAS_30:>..?VCW<T0EA_Z$Q;^&T!_907%\<*=NOS"\N/** @.RX_+:AK]Z;N
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M_FF^QE5#XG60N+AGK514A=02I9/$B<8M(&,E!5PLB!2BH$Z&%R_5)ENXH+X
M!M=%7A?&8C=R_2LQ9!+D]+@W:*>G_^B'#C3S(YS[YO^:#;<JSQZ?/V(L(/!H
M>/DC"Y[L(P5H4V?YRLF<^F_J;I9T$ASWV@K*& 3T1I@B"B:8XUA%P!7Z5=$7
MXX<.^N?.^[> ;#^8[RB?T/G#=$[,Z>#%OV?OPD-D-#WK\Q-V^;+=/-[[A8%
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M'&-Q894T0L9"^3J9L=ZHUGJUD,QP6E-9%!H1$U,4DPZ5%($"M,&:,PQ&3GA
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ME;# 84"<()+SJ#SFVFMMHU4Q*"NI-TFI.J)D!2!HMB*6:&U^B2E$;)E'S(N
M.,GHDWL=&,^T#<)CV,ZUU^S^94%7[_"DYMV+TP:OE0->33DE51CL0/1XFASV
M'B><=!V#L1*\>S['NP8KJYP7""OA$,<F(N- F_"2YZ)3'%.=P.A?6KF%FG=7
MD'=9,@K,0&LU%EQA:B0W%@Q&9JD5(:C:Y%]]QIXW^1E.@L;H$19$@<D?<CZZ
MYR@:J0-02"Y8FAL0$?$"PZMJUKY0J1DUU!BJ1++<8JV3(2;H*(SFPJ54F_RK
MS]KS)K^A. 3J&")$1,2EE,A%ZA%)G#"IDHIEE:1UME*-!7_6&(&_ZQB![[DD
MI?<\:4\U)IR"O6@T VM?!QJ3H937,0*KCD_%%7] D(G8Y 12TEF4"Q8AQVE"
MWM$4J(]::E/V/C1UHY 7S-J@=%##!%.81 Z[:I-7H&U*)Q(%RT+4'H&5X-YY
MCT"T&I 8&Y2( NXU2B.=D@;M@CDC<#X;5FNO%:N# %XP[SIIP$Z0KA3+GA&+
M<2#&.2ECA$]L[1%8?<:^$@1@!+%16I0C.A!/TB"M0T*2!VPX%8IX$,ML'8BP
M9NV7R]H$YRZNPE/#!6?9'R")9C$I&4/$=5K BG#OO-&/#1%4@]'/J>;P ^L<
M<TL1)C)*[0G3G*^]-GJ5>/<!3_F?5?>M&]30O&/9ZJO%27Z&?*T;3O[%0/;R
MNXS5VMCCXOG952<)L92 DHV8=!+PW#BD)?%(INA%$M)027)()B9+KG3_ ZY9
M\6S4&O=^(MQ;?J>S&O<>&_?FW4O4P(;&H)!6P8,52BBRQD?80!FD<XHSD8/%
MUN72<NUKW*MQ;P5F?0O<6WZWM1KWGD[?J^QW2Y/WV$@4K<*(N\"0"9@AD8QP
M%D28\[1LH,W$O7-P:N"K@6]U9GT+X%M^R[<:^)Y.X:N 3S"+#6$Q-ZMEB'/"
MD(Y"(*.U-8E'933/ABX32VY=^T"X=XU3D]XGCFE)98KGNM=-SWB%BBG7HWS\
M42ZE\/O=\NU@F$]4]?W?N275]C!V[E3T_:8AQO4S5N<93QAC^AADOEB_RLWW
M&KW4Z,>OL3NZ^4G234^[G[$:O6B*+T99UCPXKPE3A"ANLU<M:A=I+L(NP;2,
M]:G0BBO+S=W-K"B7G@*8$VGNOO^B/1')Z8"BX!1Q+$!;QHPAG+"BSB1+F2[3
M=N0+C)VMH>J%0I6@*G))I, B<(F#%=1B&40TF!'&'JY<6(U&MT.CLUDTPEX+
MJQQ%RH<$:"0=H)$7"#[+,0@D@=&^]OI%QO'76/1"L2A@9GGR6&*J.>"0MM+2
M7+HRZ5RI(M6'*\\!J"[4ILVSG=WC+X;R7,O*(1*C0]SCB RW#(6 L5/!$DY"
M5IM,K3;54/5LH$J%&#U)8,P)RZ-RFBK)&?>1&$<3T?5QR'. JK,YJ(I<68XM
M4DP3Q T&G<IHBQ*7FF$N&7R4H8KK5<JP>L*";4_G6?L8V_#AP7KC('9CW[8;
MMAL:-G2*;C$8]H%EOL9)-'==U>U:%)/)*$R]T%@!>6L/V&4)_.4=)DH$5_NI
M5A[%WESQ4]F@52+,(\>H0-SE?H)62Y0(%5$0S;E@:Z_%NA;W3DBIR\NL,&]'
ML*6PT3)PSRV)!FA"X<"-4"E(_G"=]VK>7B)OSWE]#&94!9I-*&P0#Z"K&&8=
MHM'%()P3.N::<.M*KE(/FIJWE\[;$2 =U%5M'+?)6(\)(+X)AN4:'G44ZK/@
M[3E'2>).*TXLPK"KB$<'O&VC1H3!3\.C(659.+S.C*R9^^4RMW-@9D:7<N0Q
M#TDYYWDBCB8LG87_JUT+SX&YYUP+BB38.@+<C+5%7&E0RF/ R!"N([8A9T^5
M2KE:I7*N#QBT4[$MW: W2!-_.C?#]W/$4]&U75_ %8,A\%<G=H>-_(Q&L2"R
M[8:A@]4&+(H>_#G#[9>\.B]&2M2)Y\]>2FQ?<=T(;3'GEB(?3.YU;##2F@;$
M=#02@]VN0EQ2YOER^>J1CME^.-J[GL/5X%N#;YW]_I.![YQO324;HP+(%49)
MQ*WGR E)4)!&!NV\-XPM*?W]68+O@V#K]5.LL?56J_-BL+7.L'\)V#KGVXPL
MT2"L0BX*@GCN=VFD"4AB[+Q@0LF(EY5BOUS&>L[@6BNNM>):9_&_/'"=\RT_
M8AK_:BBNI5OZMZ&%-\*_H?CZ>C*OUJ@#/.2KOS/E%]U128BO_QLNF\QKZFU'
MH\&P2&=CSGW]WZ[_V^N+U2B?/'7?F.N8!+8\Z0V*_.!7_=@NP\U^/RW"\'#"
MDE-WC5<)7]YB'2S(:'C]+5,#]!'8M__XR$+SF'([^>FUF/YY>'$L<&(/(G+]
M:(^133#85[9]:L\&:[_-S*E3=-'T L[/_?H=J'[.;6@%%5Q@'PDCF#'!G73&
M"[#2M,7YZ,P1?NVRSN[[8Z_KXR'V=NOM/&2_Z9RT>V<Q?HS]KX6/BX%[C.OP
MVT[Z$'WOH O3"W_#='LA9S4/_K0GQ1#6$C[=[ !$#&<Q/A7?8D#GL=^[@'?\
M/.&]'?_GP]G^YW#B*)>MW3?? .+/=C),;[WGK7=OV_N[QZ25QW[D69-^Z.SM
M;I/]W4. :O_MBY""N10<D@GKW+)!(,NX0YA91;WCBN7V[H_G>JKIX6GI04G&
M<?02$9)#S)D#>C!<(VE4HC1Y( CRF.9R30]/2P\V)J<TI2C&7'/318(TL#2R
MGI! A-*8RL<\%ZSIX6GI(2I"$E8)Z4 "X$.PR$EN4<+!!!\E5<JOO6[UKBCR
M=_@ M)Z>/T8N[^5LC,.I'33\Y88UX,]!+PU/8>>!5K[&=N^D#';P>6?S/C:&
MAQ'^Z\=8)F(,BF^-#E#EX: 1NP$>\->H&QL,KS<RS9679.&T<:VF?2L-?4;U
M7P(ZSI+_1W\8PZ@==](UE ^+^;48GNUF<V07WOP'<,+QST:[Y]OB2RZ:J3QH
M.+"<#NQ0D'):1H8(US:"\FHT@=6-P-XG>8O[HSBM^3^V#OYQBOC+9@^#QFD$
M^C[H6R"@DN93#U#M=-#XI>@"<?=&\+HP^/75M53;L?T#L'*RU3L.D<HT<6D'
MEC8QS*]M3P;QU>27WT,Q.&G;LU=%MQQE>=/OXV>-C<<<)#4?%)59I/IZ;$L)
MCC<PKE[<G[;CQZ;6!E[D6JR^9%25H5C7??_=F[_[)=</]& RF6P]X <;L'IR
MDE@<@DB_5Q[OAR'&YLJE"[S?E>/EB1R]BZOFO1T+VMU2T#8K ?MF1L#>H)[>
MBU^>CZ!]_'AQ[E L]#;%\6YQOK3BRYH5HYN4:;S)C'^ZE2/+8,B7NC@U62V'
MK!ZB[O%S. _^<,_^[?<X&W]&I\"#;+8.YMQ$WF P@H$%&8]<JJ!UQ$P('JW7
MAGM]Z_#Q:XSC/EA3!V5FQ!]GEY?\;<_R1YO9['KSGQ%8S]O= 1B$^</!#LCP
M_NZA[>Z<Y$<,WF6#;+#=K9Q)+^.T&,:SL[4M]L[#T?[G-^>M+7CFT3%OGK\1
MS:T_.CN[F[AUU.HTMP[.YD^+F^=-#N\Z:E$8\VX3MV#\.[L'Y\W=X]/FNSVX
M_SV%L9_N;/V5FC,=X#^1YNF7H"5)R7'D=;"(^\20H? C2*R)X39@:=9>RR6'
M.*YV!&.-&3?"#.8$$ \/WJK$DXO.4.4($SSQ:)RZ?:G(&C-6$S/.YS##*R*4
M3QI)'"7B)"AD/!4H2A6UE5K87/E6+SFZI,:,%X 9+EDML/9 (883G7*#<T8E
M$ UV00I]ZVC>&C-6$S/FFVH1$!!:2HVTDP)QXS1@!@E(NA2U,9*",%EF4^P:
M-%X.:"BE&2;"41L%]Q*4"\HI]4(RZV2([M91JH\'&B\^SO4IM)!QMRJ"::(>
M[!5E(N+:8N0$B\CB$"33*E&E<G5&3)><0K#*W:KN5K?Q2;'@[[MZ;5Y@]9?%
M\">]YTE[JC'AE&EK-),4['4:DZ&4K[!OY@<A/37RW0#YSJ[X;!0&A4E$B\#B
MEKDL $$N1(6TQ)XX+1G+#4K_[__1E-#?5ZA\3%T::OG@8*BBA@FF,(D<-M:F
MTCJ73B3*+!4K[(2IP6$9X##OG-&,,>R]A>T6%'&@?V2=,,AR2[EA.&)+:G#X
M.<#!26.(D:[4'#PC%N- C'-2Q@B?V-K;\D) 8-[;@JU@CJ;< PCXGRM0$QS1
M#-EDN3 N:!M!0^!J67U\:P!830 @V!M#A:>&"\YT,D0"&<2D9 P1>[S"GI,:
M .ZF!50 P*V)0H*)8'#,!19BA-](1"YKB%1Q99U?>\W(*@' 7=-XOY^K6U(/
MB9X'XP1E+'%KA55)@-+L.=8)1DZ_:+UVF[2#1PSQ*8/36[UA;!"QT6A,)C@]
MBFMWY;&&]\ I%]M=W^O$7?MMJQCX=F\PZJ],8L7.GQ-X:'[;V3H\;GYNDM;N
M)V#3#\<M8-.=K4T._YXWC_:/FI];QZVC/3*?6 %PP'?>O?^V=_X)[FU^R_G^
M^QDFM@[@W^89 ,2W/?J>MH[^2<W=]Z3Y_DN0W!*5/(*E](@3(N&W6-:F(E0)
MZD/BE2@ 3HEA,UM9R20E+"'.!\YM3)9F/0!'> 1VP?KY5(QJU1NP[+EERCPC
M+BE1YVH*]P^'^=0<NCA]) <;%SDTL.@T3DH1-EAOG,9&?Y+\UH Q%=62#NVW
MQDF_][48Y%G_XF(WIF+X:Z-*/H&/>J,^;,80I'"9>=*%!6HW8DK1EXUL\OU]
M^*JL/>OS)9.4JS1JMQMGT?:7E$JUBBN].;..D_*[EZO82XW_^N41*Z<*T%5@
M5>"W:W%K7/;DCVJ(%[J-_-G ZQQTDZU/H <=\-;N)F]N?N%"ZJBX1-[D0E"&
M::2M) C,4VIR^R$FY=IKO'&UONFOE:("!-;.&YQS"/_K$<N*B1MO]DV. ']N
M2GCSK7GP15D3M+,6:9TBXH)@9!(V0!@N4BFL-3BMO28;UP4(3!-"SE>] -YP
MZX34=;AY<%*!;?L,8/RP\(?YLU$[@VW178#%@XP[U](?[+N+_>4"SQ7;[,UD
M4!>D^ $&]F<E84$YWP&Y5 K:P07=(?JS$=[NIMC9S:;<'IA3S=/6P1>N8DS8
M*<28D(@'T*H ##C*S9&8H0 )@H"IM''55/I724O7RYJ%NWY/X&'72IMZ^V^"
M.YO?ODA,8,M#0!@[C;AGN09+;L4@6*3!Q&P2 M*0#7Y5Z/QK%ALV&C?11AZQ
MDG MEI8HEG!K\PN.+DI  $2!9A#742,#5A8RE GEK=,R%V# &]?UU[JK?G+?
MRGPU(2R1$-C.YA?".=C6%):;:8XXEQA9P0QR1/@8%$Z1D$P(U[6"G1#"_703
M<F?=Y)9BZIY 5(NI)6HI9.?]%\.B"M%R8,UH$6>4(Z-)0@!(*C$06EKIQ>KQ
MKW=24^Z)/_7^WU--X5^L >5/N@2V,'>(*QZ08S$@9IQDS@L-FF362Z\V?[NJ
MI>P"PN0#&]L]*XFA& X:GS8^;C0&(S<H0F'[!:#$Q%_8&/9*B.J'AFU\M>VQ
M>\[FZB>VZP&F#FS1'0S+QW3C$/8]Q7X?X"<CCAT,XC [OXKA80EM\9N/Y1E/
MAJ$"("T50'JQT8;!586&>MU\(E0-<X$V58T%K@VC/E#(W8H+-4[Z0)O]HGW6
M*$MTPGQAF@"_$>@TORX.7J;3C(CL-"MEP%;T,?-Z)9$8F8B4X11Y'-H T# E
MH?).C-79P6W560DR0SM%3  B)LGG"#5+&246FP3T^V4[#X!01KZOO'R:&A @
MQEAW&=3*RR+T:,%[O@2-%9&$(L,HS@WF(F@J02/F+9/!8F(3R^K*5?1H3#25
MX:$=KC>*-*6N %?W1NW0Z/:&#5L"><7A5UW3H8*1_.W=$ 1,JY+<,C>/Z?7"
M/9./CN$9\%^WU_"'^>QY,'G;M;0[BX+%H)R$'\%;NT, !4#"HW(^O6D(LJ.0
MAUAD!?ZLA,SU1MG<;;T!BML$/8X EP:A*->OJG^6K\[W/W]??/G$5V7I-W\#
M[SQP9^,#P$SQ-9_C#AJ;!X#3^<#_62_"=Z>\W<V@UXT5&EZ(O1U@BE)<?8B]
M_H$%@BR98!9MRVH2I=X^)M_=#YO5(WSL#X%'2IE94N#7.!CV^H.)RE\>((5X
M66[OI(JVR(T(I]]0/7<0+Y]P>T_E\HJ*QJ^'K[+*=T$A%_3Q=^SGVAJ]]*<=
M''ZT7V'E!G_;(@Q[94#)8:\=8O]GU@EWWY#6P1<PQR(!A1^!+ V($^:14PXC
MKT ]3\D1[T$KU&*!LQ*V/1.&+<MM3OZ:1L@2[(%FUDOHGZ$B@,N0]RE4NF%9
M!S*7Q+-CT[-2[3Q\,X@E7.8CS/+9=E ,QAI7>3-H@V/ AEO^; /6-_[(2F!G
M3(6#_-C3V&[G?V=T#SL<]@LWJHKHC=DEC88C$ .C8=$>\U=^[$D_HNV_=QJM
MG7\#['\$1;$*H" -ZWH@I3++A&+@1X/!^(X\7&"].:A^L' 30YY!N(G,X28/
M&]E1184UX_"P%[9+?"ICPU8NSD,T+\+ WI_M;#5/6T?'N'ET0(';B[TC#];Z
MFV\M>,L>?5LTS^'^K>/S*P4TM[8Y6'9T9S<_8P^X_:^B=7XL@+-9ZPCPX3.,
MX_S3Z<YN*S6/X+/W7PB.QG+)$)54(VY9-O@512(&R0/QP@E_)<[#$Y9PY"%*
MS5T0#FYP\!O)E^>VPE?B/"[6/3-NM26-:D\:U9?Q<2- ?C2!IV:::S2?:2,*
MI!4 W&D71-9A<5)%AL1!M<)'/?BS\146' A\4!JHO:S19F6@&&9#O)+P6;^U
MWF>T'CL*1V#?5L(^5KO4*7=I5K.-E;Z=8;A\W]2;*T7@XC6 H2'"UYW<H_CT
M,):#@!_YN;'"_[&Q/D9)V_AG^TUUPGIY];2,Z.=Q]2N@AXTM,R2S-3#[8E#M
MRP<5@^F+0M9<\I K0_UL#/R^@-\G2@_<4:DZ_>%9):0.04HX6+[&+\6OU7>]
MTSPNF!H,9&R?V*HF;SGG?%.G!Z9']D\5\'Q;JO\%S&%BS<"@>AU NY/8+^W+
M;+",Q>5D_K\4\+KL'.D7I3B:+'/U?%\:22> HC!C,'KR7*;?-Y%>\#38NT6[
M )M=VE@+WS!/9[=XW:SVF5>_R&I5M83_&0$?#<ON)>4DX>^\8]4'"98G*X_]
M>&#[8>*&Z=I,Q& 351%.)9EV)HLU?LW_*[777OMKU1'[0D&N9C_C>AA<+D6H
MEO)'-'PMI5Y9N'58K=/X-?;7YZDVKW1).E<)#R:6=[_('6UB=>6A_1H74MHE
ME8TMU&P>SKXL%)7M/,<;>2D6>)^>EQE4FNN5I7[59B]IXP;NIS(O2?T^N&3"
MF<W/U# #?6.KII)>91 ZP$@<GL;8O:6-(W@(W-N8:&*<,V6DUA'^A#^,-SJ6
MKJHKI@V=-FP6:S-OQC/9'D]D;.C8@[@RQLSCJS>[V_EPE0HO8*$# D'O$0A\
M@2P6$M'$,<-,)B/3VNNKQ_#5B<;M]M?PZ%R0-##C<A$)K;1CQ." F='4DGI_
ME[N_.4Q9ZN"4IQX%H@3B7#%D;=)(8^R32"$P*M9>LZOU&>ZRP4DG&AVVGDC*
MA=#6AUP/0E!/I8G$+/8UUQM\YPW>V?R"4W+>T(B :_,& ^]J@AG"/JIH@_<.
MZV4QL'"!8FT9Y41RB9D626DE$]..LJ!%O;_+W5\*]J>*FAN7 O(L< 16O4*P
MWQ&I7'2 ZZ2D X!F"T+CYN,4\GY_[0VSWOA8$OW! .&?<AXUN4R3"SSCX NF
M)DE)/,)!6L2-<<A*!?)<)B%,"AHTJ>^D,#ZN7E;OXC6[*#V@NM,4<4?@AR8.
M&=A9)).B +T)8RW77M.K+N;5AOEZOQ?M]PZ /--44!*1L1BT< T*FM,$,%]S
M6Z9A19%NR[4/IFW7NWC-+D9)G *-"Q'L0!6+L)56:(5(U"E@)['B 52QJ_%A
M/Y+=LSZ:J_Z9TFTS[6TJNJD]BJ73[&OE(IQVV+C1\.+.69]*)J!^KUW=E=\U
M=B--N0U]#@2"_6^?55Z#:5WAQN[2TC]479C5D0Q1<PXA.^EB/?9']DYZ_;PT
MMMTHT^SG1S;V6C2B[7?SN67YS'9O,!@?ST9;QFB63X$W5OF!,^MZX?>X_F4Y
M8J*1^KW.S'EN-?<<5&I/X-YO9<Y@^^Q643I+R(!;%&O\;UB MS#>:PYYGD7P
MSA-P\W3HYS%IG7ZQ@JF(+=C.06C$$\?(:*=1H&!?&4($XQ[D\8+0S\:*9<?5
M%'$GBC@X;;[_ BJUUPP+I(0)(*5I0(93CU0228"BQC KJ>"J6G9!!??-@[LM
M%3U0,DM-1??#E?/FUN8Y: R:1PMFO$96B]R?D1ND85^0,9@KKS&/!JPUOB#Q
M[<ZX\D!9+35%W!%7L@M/8)9(S$[WG'<+FB*RW =$!%51>6:=QFNO"5V0V')7
M8)E+8GG>\9$WC@G(*C(LQ*!JFPSZVB3R;7 EX*\\L\ZGA_EK6&"X;?K0?ASZ
M=W$'#--6U9?6&[U)^@2HC^5&C$ZR/GGY6KC_,+9/QC<U8GL\ANJU17]R)7Q0
MQ2^"WOTA?HTY+V JC*O201=.)L?FW@H4P,A/F7J5]+F/B$X>+$>1ZU.Q1.,/
MZ]N*::OQ$A#2]8 P;ET]N @^K!'B!C*#-0^^:! .(CB/A% Y=Q9PPTJGD C>
M,F=P(M8M3I:^N\Q@P@9I5<!:99&D30)Y >]S)$C,_8UUT9H\EAZC]BT7'$U.
M8!PLLC%2,$^$!//$*B258T$!#SNGUUZK55),O:)>DQR*F1P/1&JC*=<V<&6%
M,9[<6#&M2>HA$:<,> Y*1^THZ"<X&D <L("<"A%9@KU21K/(;;9[KG8HNS/B
M>&$\I:"3!BTYMEQCBZ4,C!AN#//VQEIJ31Y+1YRSYN87CZGA,H>_<Y)/)>$W
M+95 &+15GL!.5A$,%_V]W*:E:JP+P\3OJ\..]4@F0=$\Z0W*R+97I0(&0QAW
M>!^7!)VZ:]P?'E_>8MV@UQX-K[_E2G/3)]*5<YN.F56=^GF+R'I^$5E_>-%+
MXP0T7>3ZT1XCFV"&KVS[U)X-UGZ;68A.T473JSZ_8-=OVRH8(-^+Y%<;#QW(
M_]86_7]L>Q0O0_<'JQ*[WYIDZG3^*G8^[Q_O=;8!F=K'K:/W8F?K+2!5\[0)
M*+.WNPG(U3[,^9/S*)7OV>]D5#L6.Y_?T];6,6]^_JO(!67VCEJ'34"NG<]O
M://\;8+O://]%T&- X,&8"D:A8!8::X5P9'%1(,P 9V)I/G8?4G %/<JR*0Y
M-]3H!#H5]L0FV!IO]7SL_F/M:C/:O*5EGE:O7?BSZN=/O,.\=?HE@.((RVD0
M"RZ[3G)-!NX%"MY$3[P-,;KY'09KB6A,9&*1P+7)Z)"PBDH'2X,@9GZ'\Q8T
MRCUH3&W"PL*XCY.=\6,2G9TPJ-,B$L*)\)XK'YTW :2WY@K[Y 5?N^8]/UZH
MV?<$J8ARN9M@DEP[XY07DGOBI%%6NU7-&GFWN?EW%;N>SPKS9G\M-]L.)B'I
M/E;GI57FM2O+(<2R=,+D,+ Q &VP/-7L5KG3.7W@Q!:5HZ8/HTOY1+71+JPK
MVOD@]!>X,GXKAM7S?\UWC3K586BC;'+5/JMN'"O+5=Q]E3=APU=;'KGW1H-&
MQ_:/X7WC;,'.)84V<FS[1J.<'FC%O5S/U+IV,3C,WJ+&81'[MN\/<S'H,A6O
MDADP)0"@TU[_^"++M>CU09$Y'R?*P)B.JY5I1]#$RM0]E[U0DYF5>8@GH^&@
M,1I4]7"J0>7)72YO>?8Z@(4M<O)#T?7M48BOENZ''%?%1KGGUBO!9VO+CY]4
M?93+8G2'KQ#193'[IZ#$? 1-Y>^+"DP_SA!^GUDNPC=$7HM_E_M,&FBRKU>J
M"E2G^C#$@[,R". _HUYV4I:D#53SU1;M<2)(E:(1QU1;G<T7>>%+,BPNB]-G
M]AO[82^/[3-%_U[O]8/O-;W%7O?&66@P_MEMO[+9ZU-9=;$H;ZOR=@#JRMK-
MEW^- :4=KR6#BZ"1*<3V, 879P-D^KW1097L!&B4']7IA=@>Y!=6(U\TLR(.
M?J\"YVI:>VA:8[>@M5%WBC+&-P&9@9U=W9#S-O/91U6=I!B O!T.LV#.N7P7
MDK)*$CN[\$!<".P+Z?R"S\-RJ8SQH97/E0(F45R7 AMV8:Q%3/-6Q\*"V7:[
MJI,1BGPTE96,4@FXX-&I&R;ZQ=E& ]XY& 'C3[VPTAWRJ=M8L5ET9][!BXKL
MY5V]TYQ_>:%XE,,>Q[(-%N5;3D_@4C/::.R,^N6V#P:EIC0>_>4#JG136Z:Y
M%G[4MOW)N[[WW(MH>A!G_3@\FR3C#AI'HW!07I%!Y3+G<Y+1F?U:^<63QT^]
M]BIQ L1E$!R_-VPT'L$5MC+>E \QUPO*\U]LE@U>-.?:,OJR),_RP#KK]NL7
M_%R5?:LB'\?$DH^K,W!.9X6[J7)NP#A3I)P=]?F[\0J7A4,>SV_U[\LQCS<T
M['0O]ON//)B?V-O!6IM?K$M21.,1E2&?\_& ;#2YHICC@@<F3!)7O1U*"6,)
M,<+R@+7F7%+##9.6X:##O+<CQTND7JX25B:8EY(6+--<M^\\#A8F"E]#=Q.
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M.4E>2^PM9918;!+8 C<]2;S0^9N7#H7/Q?#PBGX_F%7P![/FP$4^2OFLG^$
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M8)"T"M0K;2+C7.'H!%.!6::LIT9A48(!F8 !61TPJ+6@>R'"O!8DHW$I*(*
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MVGSWAC???>)[YV]H:VL/WK7W#8RKL_ERC\W.AT,PX#K[\-S]K0,"UY[N[1Z
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M&A<EYX3X0/W::R;7I;ZW]5QGQZTNT^-DO3%2XV@$!P0PA&,GM7%86F[$74X
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M[:);^4O&BNZ5@)X[I][^U$GZ+S1#'P=*1$PJ:L,XQT)+K*,(/!DF&:'\ICT
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M*W6^QX!.XZ!?P.I&8/5YSBW HO=@!VHDJL(X442DB72(DLA<)%'IX,[Z<97
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M>_WC"IEZGVM/\%E#F@).-P&GDSFG1F0I<>8\(MYE<&(46<(3LE(K[!UV3N2
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MI7*F972)D])89&U9^6'/ 12A?*]"><+05@AA:$1.YY1_8B72+O=%=58F(6/
MN>RG;(Y0+MD$6\_]?\>=NG3@'9+^GX8S<ZE^@+T!S+I^9I7*5+!IB=C$YSP
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M<;<J"6F[;\Z;$O[1'_PUR"6T1R<O['"<2^2?=<1[GQNT?!MT1G$P_"OOWW6
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M#\@91EV,WI@0-K986]$[-V4J"-!<!.#*)<8]YH$%SJFRVH#]1RC3T;"07$&
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M[L$BKFS]ZY!?:06UU%-W:] *ZGEV%8$L.AYDE^'HI"*?^-]QY[AR)1Z/!_[
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M_37H,]\)] %&!B@3S\>?09]ID8O:Q"AO>_W\84V!60B/0$MP)]4%L[*_]0U
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M'OK<(JQJ]->F(YB*CTX5FB:<U77E8FR ,M293FF0]S>KJ)62.V-]+S;^,V@
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M>&.++Z2$6M=Q"U#G7"V\"?3<@HR((($(G'(O,(Z5L$F::+30FGL;F2UDM')
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M-\=?)F[%_\?>FS:WC62)HG\%4;=JGGP?Q"*XB*0]TQ%JN5RMF7+9;;FZ/DY
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MOH-N6?&S%KNR_RKC:!059Y:7&DROV(MRZGN@8!%^ZV>D?<5*O6G5J5P@RGM
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M9_'\;1^.6KN,/(\*.*'WZ)P*ON>I>*M^>(?=54+WX6T0$7SH2^_D\C)*A6\
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MH,;D@3SW^G9N\B 3QUYNR36SJ\LM$?6HW#IZT"67(?"VU * SX'/P?W.\!H
ML?!.^?*+BP6@TFWB#Y\_?OYHC85(UT;JXOMGOZF7?E8O?4HA9U.0>5B%@\U>
M#[D@<Z%PI+96Z< *1Q88TK.4V!P#I"YA,Z 0,O__(,1&%3:[J$HZ,'C5UOHV
MT&F*I ^W./488+9.$?1I0J;!IF<N93Z*++E-*Y/72!MY@K=Y_URK';L]VO7
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MJKZ45_$D(JQ\JK+/5,V$Q@)0C,?\,>T4"^X)S[NM$<?FSQRGU7OSTT(Z0^F
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MJM$=;EBE48^XVU=;' W#64(T[-58WJRNL]EY:REF_]"JU[,'HRV'@KT*:JU
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M2\#BQ:E2"K#9-IW%F(U"S1$3H:9684MLN?6 9@7,40VX$\;">2K&>6B% 0Y
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M0K8396_/,9+T2K=!VO3%<]M.*[;PK@2N;J?51UB ?,\IKCK)W03P $M""EF
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M^Z3;CBF0']-(8)X(B&>O)#@!;P4O2RJVT\#K8WR-<MJMMMGJF$<&"0+.'L*
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MG=<)6,*04C""?M_:;[@?S4!3'G>C1)NY;WSZ-N(A8XZ2,R,YA>M64KANN&5
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MRRMMFHS]*'OK_8BJIZ.:-]/Y&1G95/WP=]B567=27RUK\US?SKJ^OQ"E+])
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M!DL(-*[&P_D>Q9"VX[>3]&V]L.-,-[,-?X=N6<;P&@QEO:OM;$0FE4=Q7V9
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MNO,/V'T9)YR/>,F<AP"LR$*S ( L2)=84;:XP(T(MRL2W\F3!QZQX5;E4Z!
MJPEM(MV/'4SG1,+Q18N%42K&QHR)Q523TY75S/MZ5T\ZIXKV"'R=^@:WOW?#
M/<.G(,>=IJ[//O7WA$W/.P+\:;DY,3_Z7']\,UUE5QV7QR(M4?M\J.@*Z9U
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MM0<3%DM0M61&PWI!]>13?]*+$9U-FG:=S /3D;@*]<0_)Z<X=X[VLO;WUO<
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MV9:#\C():Z+>@D%;O_ 'X4PW"NAZU?D=AZ20Z1\PA(NY;[(L>KS"6JO:N0#
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M0O/R,(<DP0.FX*$XL(N4.]#]8C>;;V&K"YJLR5HQECDE:SPW_>.U S)8+,\
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M!_U1%CTID"<3/%,ZR#H.SD)6AD%4-DB; N>MRV&WPOZ3JX=4?@<7.WN/8W'
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MO-AX7PYO+)3WKI.QY!**J2)$IG,AO[\DSVQ)H7 (5@;=Q%K:#=?Y<NP@FMI
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MH$9*/"\%T[*:X)OR)(^NY]*MNUP.SM&2Y%@IO%Y=TWX7<U:,TX!#\-%M>29
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MF%A6E[\^ JO,VZ\HJ:N;JXTB,<]B"NB$*NG*_1])' --//JD490:;]&IO/D
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MOV_2-*SJHA(U1EH9"4\!2.FT2GR,0#C+V7G%5."U6V!W@/4CA%15*&FI-;L
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M&AQ-":JWP3F,ZMEK3B,"1ISE>:_I&GIQNSI>'5]^V?VS:U56'ODT6T63(=N
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M[6F]BTY68?1_+3:/.Z[=GR?_9F"H7= YBY7,L,A@1*,$XB0EAOTR"@7)D>%
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M<88>B8&)J#K*/N@^:Q]K-^K/F@(6P%IPO37I[8#+E:@NK;9A7PWX(RW^F0;
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M'$DM<F36WSF3$#-E^[6E @HJLEA1H:+(RV&^(&=JS'4<4?$3K[4$=JA_OB'
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M;MPYE,LL1FFB_4)F.J5-C<1;RH*=ML"JVS,<KQMJ1T<O%("#4W1O['KT.W7
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MXDP::3_*. ^I&U7<#-3(%-':!QH#1VB_T M!($8X/\:D3-#KYDL&Z/^P_P'
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M*WFJ(,8JAQ%.9)$HSG(B_(02W0:>&W=W[:V78L8+\'%EY<3\-R:=)\"-9L:
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M:5)D3,?!,BK\Y+F'8C>-IO9;NMD\&QZBC^:%? -R;O0]%(V1F=E^B8Q=MM-
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MP'G9?N92_S9Y7R7?;<KM<YRP;^5V*1<T9U02):!"ILM)KJ-$BG $B>014JE
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MK-[MI(80-2]^(F*B0TL">4IU6!F)"%+$<QB3),]U;)FFL7-=O,-X<PLQC67
MFNG.#2ZP7N?6P&"-3*^UM:!C;HT:T 8#"Z)_+.J"HSO-!L9S(J:]BFL8EO4
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M4!5YA%-.<TZ\--][1YL;;3165H :$5[1]%RMUDL!?BE7H/I!]6B.I\MN<-]
M'T- ?"T&N0.MM2-SR$M0QJ21_5BOSR0OW78BDY.+!NX ;M?\/S_:.[W;;6K-
M\W(MOMJ'Q?[YQJA@ZV#(;#C69U1)(B-!B8()CQ1$@J>0X2R#G!8(8U%(5/@)
M6/G;,#?N^21_R@W]KEFG,LZ W<K('?^4U=8H'*_TJL#TBK .@3_+[8\?4K.2
MD1ZO*W('\].0Z7/<?QQW4L;>FJRAKNV_ _5?F_]":SCX7.<B@/N#OOL=H$I_
M6TP:B)*EZ1@<<!=S.)ZA-C@'6##MWN=PB$ZV16^XU< FW+3<_!M=[MH>=$>]
MYWZ5U"1/BP?3MVZW,0;I#_RV7FW:OVISRLI<;VWY)OF/5?E?.UD==@A%06.&
M(@1%ICA$.$[U4C#7)"S2*,]2J>*(^[#NV ;/C:*-O\ Z#!KO[./_<?6T:\XL
M]]Z @SLW;/6._HUP(_(YS?/(K#_F%/MW,)\(]U ]T,<V=]HNZA.!?]*'?:IQ
M!PHT-/F7#\J>$^CWH\F_M$D%BSB.BH02 E/,8HA(GD B4JQ#>XQIDB.$I5-K
M!8>QYO9J:$TU0;HP!UAE8RW@:V])G#Z,W1@[$'(CDVT7M/K4KP7M;2]H_H(+
MU^$();30,]*T @O773X15G"X9&#%=IOF]LETSVKY['F1""+3J)!0D%@31JP8
M9#RB4!:X2*3(8BFE5^'U^7%F1Q9UL23X:>,,_>5?VO9B2X<NYU[PNG%% -!&
MYHE#*UMKXMV^'WP *09'%$(5&E\89=IZX7Y73\I^KWQ\X*YA+:'_13ZM-^;F
MYXK[.4U29 ((FIIJ7EE$$!/"($%Y)"CB11$[2:]XC#DWJFC;9.QM]MS<<T#9
M<3,O+'9C;]Z]A&U\B0,/@$+MQCF,..WNFSL$)[MM'I<.)1PK4_EWN=)TMC3Y
M&.*Q7)65E;+_*=MTZ*:D!D=QFDO&33PB=60B"<22"/W75*&"Q5+Y92EZC3X_
M$K+&WX'OM?EV'X0>.3"P?L%O4ER9:B2H1^>L!N6_=U ^MGU?$W&]D&P ?PV
M+1B3^8P],:<-@.64W8;<Y+8-&EL@^Z2_G#]TU+8_^JT6+(JYH)C G(L<(A)I
M4L-1"G%*!,U(RK(T'[))<V&\N7'9?L]ANP:5W%J!M]VVVNJ'S80)?S9F#]NP
MN82YWZ9- "2GVKA1MMJ]M;63^3'"YLT56 )OX%P:[54V<:ZX?FDCY]IE0XKE
MN=U^_BDW*Y-"T@@]K;Y_H5OY]>'#E^9-G>4Q2TB<PD3%!")*$&2(*$@*0HM4
M1#2F3L5?'F/.C6@:L\'>;K W'!C+P2_&=@^I$E?L^\EF)$1'CXV<P!Q47^^&
MJD^-?7!T)ZNSO^TKZUEM[P53;\6]VYTFK+KW<NVX\M[OTN$"4T;0_5>ZM<*L
M#^KCRF2:V;?&(B.1*G*>0AXI59<-$$DYS I*46)VWF(G?76GT>9&VXV19=/D
MHJ)-R\/R8+*_0-)EK*^3=5 $QXX+6TDD8RQHK04/"GP<!SY_@:D@,$ZM,#4(
MSD$*4U?A<9"8NGR/R36FKKIS3F3J^D4#\_OTDG\K;8^!C_J[4S<9:+(\'LVV
M9RVMVNP&_+NDFV]_KA<J18(5"D&44*G_0!P2)6-(>93A/$M2);S6ZX.LF!M+
M]XK^! 3?;>$^.J0CTW9M?]/]XN!!78QZ9S<=^5;_JNO,'3!^ .U(P'RW6W ,
ME<0VR(9I,]-N@>DDW>RFFPTCPDY"V_U*V$3K'^NEOKXRO3RVS_LJ<,Q0FHH<
MPT(1 E$>$TA37$#.$TXSEE#$J0_WN0X\-[K[]/'^S<=/'[]]?/\5W/_V#GS]
ME_LO[__EX=.[]U^^_N__A9.X^'_@_?_W^\=O_^Y'BLX3X<:#8\ [,O5U3-XW
M4=(AUAA%][[H!"(TYV$GY3!?,%[2EO?U Q/7MC_DQI1X;.0/S7^:)>M&9Q_6
M&UE^7[W=;39RQ9^_;>BJTJ/5A?[V;\NZ[%_\QZX.'G^3VP?UC?[UV7"J_L5V
MNRG9;FN;8ZX_4WV;[0*1"*>$Q+"020YUV)=!K,,[B# I1('C.*5>C<TFM7YN
MG-DX"7CC)=@>' -T[YEGIMVDWP<WUIWM+(],W=9O<.3X<=/+.]!^!UH,0 <$
M2_<=&, !ASOP6UUNJ;&X PT:H N'.3VL 0F8@?@:\Q@JKW%2VZ?-EGR-:3G)
MP7P5(_PWE]\_/BW7SU)^M<7,&E]CAMP\-BHX;^1*JG*[[Z>1DESD*(:Q$OHM
MEW,&"2D(3/,H1JR0'$LGK0GOD>?VKMH;;4EI>S ;L,9N]TU3ORFXOO\\&K C
MOQY:N\$!W'O#^!UP6]L''!MZ?M&=MZE'0WNB+6L/U,-L7 \"K&<3V^]^DVUH
M#W*SN[D][ ;^;X!W<DF?I7BWH7^:VW]:T]4'RFW%0-NC*V:TH%)"A4U#588*
MR#*4PSCG&)$,91ER/EZ\.MK<F/[=NV^?0&NB.]U<1_4ZD0?%:F3R;FP%QEA+
M'L"8NP=N &%?1]"=I(,B.1$QWXRH%RL[(]3#Q-?O,1G[.KO395SWB\)44'W1
MS+[:R2_2.*2'67TW]=Z?]EH/),=,%BB%*.(2(I10B(DJ8"1B%A51G''F6=+@
M-?[<F/BD1.@.-!Z C@M6T^$6"7?/27+;\AD1^I&)/3CJ-]=I.6(W4LW6M=%?
MM7[+$9IKM5RNM_$/-N^K2K\[]P(9SQ_6F]]7IA?@VR4M'\W)0//#?ONC.<?\
M^*B_G]L'==3&]F'UF3Z;C9!JD28Y2I"*(<M5 I$H,DBC6,(LDDKEC,CHT&3Q
MFUNH.I:M3@_W<8?&;Q/0:VVUV43E1SVI]?^>:LMM\0"W/MMMCR>YT?_R:-8F
MD%E]-7K05=,?>;']NOTANXWVP+V1['3?T1_UZW,]&'_5;\,T5-^X>"C6M[T1
M:R]![9W=&VA_W'O:5KG=@>9+]*!>-#9_6('6X1G,MOO"80ZS/M%ZXY5GWVNU
M,O:T]"QR1AMZLK71V.!UEU2CCS4TGVE;?K>W_&HK"LW ]X_KG?[S3ZKO([ZM
M[0'.9[K9/B]0FN911"541.G%&(J($<AB,&593@J<%I%? :;7Z'-;A1V,!P?K
M[T!M/V@<,*_[^K37^N";X^0S.:Z)3B-!/GJV4T"T!R1 #4 M6!:4S]@3IT(-
M@.4T'VK(38;1W3WGYL95PY[UX?-VP1*2*I)1F FAUTP9TFLFQ%(8%9D4.1>I
M3.CBI]RPM2NSG1_(YWGJ#C=BK-/8V:YL_ CJ IQ1$0E9B (FJ#!PXA@2E1 C
ME:8BAG"JL%//Z7!@3O$^& 5*-U*_':"Q%U0M-HV%=TU>4\ <I'X, G'QA4$F
M)=U^1U^RZY5/#Z/1+]+T6.-;*R[^]@?=?-=KR2Q.5"8U:^8F&P85.BYDTG1-
M31$63.5)SI#/4W]ND+D]\V:CL&Z)9;9^K5XJ*%<V;_-RNQ!W2"5-<Z-[#A5-
M.40Y(I!2P6$<Y9PD0DE$]GMY(X-ZO TW/:P!T'3CTEN_=B,SZ9%YH+$O'(OV
M>1^(0\\.,2F#]CGYDC][/SM$A>1R>_JL52"A,LU21:'4BVH=/O$"XB1+-)$*
M&?&HX%'JU.O <;RY<:JQ#%@S?:0PKL-Z?6<[,%BCGT<::T''W!HUH T&%L0A
MDB+7<?21$PF*YV12(C?CZJDFXHQ2KY+(];M,J"+B[-*Q@HC[9<%:^9I]U5)8
MG>#URN:=*VG"MWT!(<MC'N4T@3&FL:;C-(*890(2D40HUS^FO/"):P?8,#>*
M_MRJIO&NX?_7+T8;,A=N(=S("(_,Z^<:+-^!(P= QX.INBR[(CA>J^6K%KQV
MOV57B!R:+CO?:A@/UB4XIM3,*(;HP;;E:J<#W$8P70_^66Y,/Q9NVX4ME.2Q
M4(;^4D8@BE $22H(Q'E,,ISG29()OPU23POFMW-Z,!FL]S;;7H9BO5S2366R
M0NJ^AIYM#7TGIRA$@1CF$-E=@D0I2+ IQ2U$G,1Y'L?*ZP4UXM1,\7*REKW*
M1+B]G4:$=^0WTU&)*C"4"#I/P<'^.Z ] /4\6!_"O9@&@A?HI>0[^J0OI('0
MO'P9#;W-L!?1/S;E5CXH91KWU&^XEPU\%HC+ K/<%%C&5-,;*2"65.G9P805
M5*2*.0FRN@\Y-T;[7?_2ZMGH:.^T0Y<?ISD [D9C86$<F;FLL6"M5-VOJXF<
M3QMWA2,J=W@"<9/#@)/2D3L +QG(XTH_TA&R7+S7?+9]_E NY>8MW<KOZ\WS
M@C*4(IP7D' 3XA:9A!2G%$IS7LT+A#AW:M9SX?YSHY/:1&!M!*V1;BQR"<%^
MR@B R\C\X >),QE<<?S,DU])_D_?US__65]9/_3ZA\.S?NE^DSS85YQIG^)K
M'QL8)T@C*:S7OW6G^=]V9C/P0=4MK1\.71!L8+(@-,9%P2*(E# /--$/M(@H
M5"**DDRF5 <1?LM5K_'GMU@]K(GL.JCR7 CYH9]$:9QJRH2"Q0HBEJ60Y:F
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M=&-=+TO^7"?7O)$KJ<KM05Z\[8B@H_C=HS:CJ?C[4G=&^+:N/[4@<5QD651
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MCE0L%)0)C:'F(@89SQ',L90YSN*$)E[R*Y<&FAL#-7:"O:'>=8Q7H76,5@,
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M/?'$852N@)P&4CF/,(R6?MULQ-_+U>KWS6JE32WC\38=S&5!*06PD)I_H*
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M=>J*ZX)33TM<JV$FZX?KHE2W&:[3<P-OU5]4>:PB.Y ^4.$LD2#/I#;4%,2
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M8+EX0!,C:X1![P[0HD564F&&.*U%J=DR'IS0*<IGHJ]=GCNL^6\&R[VK;'M
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MW6"J86+6HX+:B690?!$@=1=J7X\[T96._2?Y[13!C3^^G7ZZ"(MQ&OOYN+O
M<Y0SNBE(!1I]HRTZ*+:<F)<QST$1KP*0%+/QR1JJ:>UFXOO0VV3?E][P>BC%
M#IS[N5R7O\SFMUDN_0S\Y"2CA_T)Q;F$+^.XJO1 7F])!-\;NU8<%Y#6OLUL
MNBA']E)9Z21Z^,P 1SETW16%(%EX(2UD+ODFB:(^:1RVQN) H&Y*T6T:[X>[
M(2#[J)=I6IS,D?E5W_/"\T= B4R+F]9%N".E'!791Q*I9:L.4]X[P(!3!P7!
M:,IJ=_:J1ORPM1X#FO7#J;Q%!_FO,$F?9[]YY JE\ EB^;>$HL(RC"ZB)RP[
MBZ$H8,0;2QH%HM7*VY#N%KK5]Y0?(V[8*I&A7>8J*AOT[D^W$=U8@I>\%+?J
MN@,-Y4HID12Q27<'&\A.4(H(4"QS2)+>/95_V&UX[D'#EGL<<N^O*O(6K5F7
M#$8VTT61&JQ+DHW4+*I,"0^6$AEH)"Y'1YQ$7A-($Z!VN=%FE U;U3&T'=M?
M6>WXD)O+<B2%E-)Q0;Q& RW+8#3+HR#44.E VYA"[6*CS:D;MJKCP(CL26GM
M)N:OVB(\($B.7FM.29 837%D#?JPWBL"/F5F$\T!:A^S;T_EL&'ZH1/SM=35
M9F[I>.+'9XONE<4"F7R VU%0TBK-RE&Q[^91<^*XXD0X%SAHZ6PVF[B .U/0
M9'*^&BZ>SPO55E([._8EPZN^";=[*:RZQAAK49A!$F51BA*7,<%87Y$RVC1(
MZCCN!3VYC8\2U63RO38>^U%10]"[L<"ZD50GYUUNZ<TWF,<QBG0DG)+ (R=:
M>'2"N94D:)V(I5F'1'ERJCKTGB.JR11Y;]"KJJ*F0N7?QM-9ES@J'2[7P]!&
M.D;(3*%_*Y 19,P0SZ(FZ#]3XS2:\A1ZLG4/4]1D.KIO0U=!.0U9N353Z^M$
MGV>?_;=RCZ-P53R)V?R1'JM""L4HKBPCBS\ALB+.:$$8R*BTC$S*VC=A=Z6U
MR41TWRCM5:'MX'=SZ8XB+D ?7>D!5^ZD1YI)D,H1</A/\(%3>:"BMEU#F$.G
MM_O":$]*:R"E\R9GB,N3_.9;[ :@?$2TGTP+L^7_Y1#SJY^LEF<YKHRX%LHO
MCJ;I]@LWWCF2$!*3-)#22X9(*U$$(>+NX@3/U$FF5>V<3P]L#.LJ])84&EKA
M#3BM>S'[H1NZ>__"0)Q<E.WJIEA7HAY1%WQBS!%>*KVE B A.TIRH,G$8$0T
MM9W@PW(XK+O2VTII&"8-;!S[68SL;<X:-V,-)?80G)) I29H*X3-FJ$@:KLV
M_6\&O7D[;4)\*R7N.>0<)3!?-H!;88 KE"QQVH;5@9TWL;1J!NM%CE2YVK.H
M^L=M;Z4 C>)V&R7NB=LWTYLE37V,33^9?_'3RU$2MXC>:$+ZK3^O-PS]<:HJ
MS3V_^8 RH'$V&2>_GN?TX0;M5TW[_>0*C=<8C,HDHZ@@IL1I4AI+'$V!L%*6
M)! -4'TY5R%\[^[8^Q!1"K4GL\7%'#ZC,E_AY_YC)*WP,5E+>+:*2.\S+F:5
M""XU385*X*'V99/:/ Q[)GMX/-_KO3TD)JI%A7V;V->P]./)8D]+>_DI_1C<
M!VELRNYZFTQV*B T!!!I$FZ^T442&,W:^V!U]3:!3=C=M6MRQR$Y6A[[^?P[
MAH5_\Y,+&#EC>9"L7-*&TA@2T#-2^$70Y*AVWG+31W#T+&$_@H7<!GD/>9UU
MM=>TV7OE%^/%+-^4[:>+LS,__S[+G\9?IN,\CGZZ7+<U1?X_H$KB&!8>9=1E
M-\;3&[^<CU$G:"9WL9V]D5+/ !]&6I6L^'TJKH])@(-3( BHS(E,61)G)24@
M+648- &+M;.5CU.SK[WME')R2RFX@)]4Q[7_8AB/*2I&HL&P5"KF2S=H@0M9
M>>Z-5LK4OG:W#[W#6N=*B+IK<@^FP'])2WSYMH8L\A5)[5OFAZ77OX56Z*;0
M (8 TPD=C.B)9Y01JA5G-LFL>.TKE+U;Z#L/^+[Z>KV4M30\V%!N8<3",Y,D
M\*B($VA J$DZVMHN\6:4-6MUMT')(U:WIE(:./;]?0$G^<UB.3[KVF@8&H-,
M-I(<@L?=(1CDHV1-1#!1:,<$J]UX[S8%PQ9=]P2=/83< $1NQ95WX<XT>A.<
M8N@H.(HE2$-\E)8D 0G_HS6SM<M:GJ)GV,+IGN!330$M@.G!=,'OT_G=DZJ[
MI0,=VR.CDV8"/68%I3=@4IE8EFRI7./,96F\JC^M?!^*ARV8Z@N0AU-B Y"]
M;)MV/#L+X^FJ \^:$PN9&H/KCDE=NN)'2D)FD;!@-4\4C3JM?;_X<6J&K3CJ
MR^NJ(_P&8/3K;);^&$\FN"S>HEZF7\9E(&%W$?_R5VO&A(S:<ZV([#J3"H'K
M0_E ' @1*"X.]"0KHVICXH:M^>D)9/VHI@',W>7FE_%TO(1WXZ^0U@PE$,:6
M+N(Q!H>VV$OB39:$9I:2"H$F5CMN?I:H8>MS>L)8754T@*V/J!8DH&SSK^$K
M3&;GY5!I/:ARS1*E-(B<, 1.T1"IE26A7*D*P2:KLK+&UZZ V("L81MO](2O
MVNIH &%7LPX*;_.O<!E!K[F)E-MH,/*)/I8^X09(,"D1XX1WW)9Q'+6=KZ<I
M&G9<2D^XJJB$@7MC=,-<3O))SFA_'T[>N2P,ERD2568FR&@2<=(ETCF34:*T
MPB9#GYY_TL##3"ICI0?IMF!^2JMLZ*:N+.YE>4/05J E959(E%(2)' )A#GC
M )Q1JOK&]@0Y \\CZ<OR5))_ U#ZB#OR] *Z+B\/C-F[E]-3!A23AB@H<[V#
M%<0R*3#*T$XG%Q3HVN4&VU&X&>!>6IJ^1RTU@,'W\,?- ]O9%+^-JT*PA\UU
MB &C66=)Y ;Y4]03QS'6C=+G<IE7"ET[#;$MC4./O^D'A[UJJ@$D_N+'\ZXL
M\#>T[1?SCK.'&?/2>Q0;)XH:#%@$=1@20VD!XQ-PAO]-M;N);DS<9MA[::G]
M?G3S+UE(]+D,M&^IC&A-4/M%1 ])KO\2(@O6QN1QL<10FE0HAH!.C+"LK8XL
M9<IJU]_W5T+T*9Y"NIC 2;YW!_#.H=SUBH:D,@W6$]WU=U5,$4>Y(%!"-1I4
MLK9V0F4',ILM+MH&/W?-;M_J:F#7OV;Q$<;*HK_FCOJ47>102J@8D4PIXH,+
M)%EO?7*<YES;^]R.PF8KE>K@L+J2FH+@C=.7NP<S=U@LUU9\SI:$H'&5Y<2)
M5QI(,J!3YEHZ6KM#V@YD-EOW5 >,_:CK7](KO;V_^)LM 6Y,I]C]1F<;=+?O
MX^ZAAP-4TSLJO<NE;6"9#)ES645HURW5V7FA=*P^D*@)5[C8DI'4C''O"LNF
MF"S/B=,0B4*+99+-5  ?S@TN)#;K F^#FSU<X*W5U(#O\1Q3C]RC_39>C*B)
M1J"33[A#)J6R0!PWN*7R)(,3N*E";1=D=VJ'Q6:O(+I?<7$(C;Y8[/X&9P'F
MZ $RZKSRA)D@B90RD,"M)0IB0B_045N]O_H^] Z+WT-AJ@J4=U#PT"4@M_C,
ML_D[6)9/GN5C)&2\Q%=^\;$K=UF=.Z]9U!!2SLP6[C*1N,F5BO5$M%48X286
M'0O/^,5[//XE0G(7;,P.JZB=L?@5YF%6 8W'LTGI[CWWDS_&R].K!AUOI]WX
MWZ[4?<T69,Z\]8XX99 WD33Q4(YUDA.61Z95D!O@;^,'#IO;&@1Q_2BC-7OW
M"J:0Q\O?_-1_Z<[V/L'\ZSA>K1_'P!KG/=&RNY"(VXE7BA)N4Q;6:R$3V\70
M/?/<8=-7;5BXFJII#7;=^,G+FIH+/SF>G9V-5QF.2^X$S<YY((DCB])307S,
ME !S@7FF#:=^%^ ]^^1A+^BU ;VZZFD@8'GEI__X/#Z#UW ^6XRON)#69"NE
M*DLHH7?@#'&&!2(L5<(SEBFKG=EYF))AK^H=''05U=( N)X3W]LEG"W>C:?0
M?3,2-E!?CL><!$%D\)38+#@!91U/V>GZ-4S;43BLL]=2QF8/S;T 7(ZDBCGY
M,C<M,5QGV: 0J7:$>R:]+S/6&#LP$ML.;??!PY;0VTHY+P!L=QM 4N$L*T>R
MT-WYCQ(9S<D2")XIKZ4SIG:?D"U);#OF/2 4]U'=H#F51QF\<:!Z?#$OZA@E
M1T6R01%+J2T72#()!J,IC\M0>Y4ER-ZSTO?):CL.[A.#>ZJH@=DOSTGO_6P:
MUYQQR#ZI<K5;EYLC(AL2,) B(0MD.21C\Z&/1*ZI:SL@/J =W%%AS9O &WS9
MY&,T"OEB IUIB4;>L:X?*8L8D"7&6.\GRP]2UG: ?"!#N*.B!K2%72)]$Z?B
MS;?US*\R(V%6BDDN()V<PWS5X6>DP2%7UI&LG"*2E;MUR2NB*$K3*!VXN0/,
MAP\\*M R;,>; T!Q$*6U&,+<6'HC8*"5B0X7'"^WFXPAWB8HX1@'HXSE[I"6
M<=B6.(W8PZV4T@# "@=W)'6/O=LOW$P(<.-P]>1(=(Y0*IDE":&T>%16!T8!
M6*R=K=F+X&&[ZAP0HH=3:[6=_"45J%]V7&NO!/TN9>T7F3\IR_[+R#77T661
M"2OS#=!KQ;!)EX:--DG'35*T^AVN_LK(WU^4PZIR3'$^FY<'_#X=EWF?Q@E%
M&7KF*=#2 "FB)<$O+G@EK$S65R_.?9B29HO"MT'!O58(^PO]7_*6S]U;4N]A
MV9X]?8+(]DWKIA+NW\IFFC65AA/ARTU,2(%8HS5Z-<YEDU-BUS-CF[>RF]_Y
M&S$6J8]H5US*H82;I0[/29*4D5QIJF*/-X2?HZY9:[P-6G:_D+F5<AH(U9[@
MY]7WW_Q_S>;'$[]8%=I[%I$+KS'L%!@[<(H>O!:,9!L$<TH$7;WWVQ;DM7+_
MIBY"[G:IZ4E=;2/QFK'W_@Q>S\[\>#K2.1MCE2 Y4ES/GI4*@DP)DQAEIC++
ML7K3CBU)'!:1O4%E<TCNK;<&8/EY[A,4\B^+]B*7!K+,Q N/LM)0SFE#)!2B
MITY([UCMW?<N#<T":W^%SRI*OP'T7+90_ B3U5G!Z?C\JK28BAP=,.)T+(LN
M ;',>6(U8\PP[6BH/7+J"7*&K0(Z)*9JZ:0!>*T;GD/Z#/%T.IO,OGSOVA%?
MLL/ 0RJ9 B^R(C*[1'PJE21"E;X@6@EJ*T/L&9*&+?0Y),QJZJ8!J%W>DGCE
M%P\(;\62BLXSAZXL1E2T!%9%7)Z2#!'0;$N,OVIWS]B K&'K>@YJV2KK:$#8
M+>;+T<>2A.K\4X:+16H;B4G"X:[O<=?/'$-YCE$]I]$DV,B.X:?> !7^= VH
M6P]LY69 +['D[J)M 0]K&/-D*9I+3D!+61JN1!*H2213;;WGF7NY4?2W"2*&
M=+KW4-9==>\@N8$5_AO"_^SB[-IR(:B#)I'E3&1DB'6)OIG1TAH?(TU\H^+1
M9U1^ZZ$#*WT7E<UJR&]HQ?MO-P@/6M%0;CY);6090%8&]S!&T+H9074"K6I8
M_UL/'68'J*;XG>771!'O$]O>NZM*EN ">BQEX*O6Y2@4G6C/:" Z1<E0.,R'
MVD/ -Z%KV !G^#3T;@IJ(,!YG*??%Y O)N_&&48E&QIM2$0+7T;5*8M^M#>$
M,S2GACHN9>TQO)O0U6Q"<$<T; RW'57S+UD:<932N'Q8Z>V29_.S[I/;*XYX
MDLSVRR,VEW+_!1+,)G!6&J*U0H]/8\P0A,:-/R?N$RZ.5/T&?G\%$A^?FO,X
MLI0"%\82$90B$DHK!0R*B'$!?1W'>=@L0[!=V?KC!#5;!K$-)K8:M;F5"H;N
MTW-K9A_,8U'.%_2:UH);?(0(XZ_%3WI?^J^EHR]^/%TLCR=^?+;XX+]W'A0Z
MSDSF)$ARW!-I&6YI4#:WJ$TP)MJD-NH958.89IOR[X*W853THC#Y9C+NO*!?
M9G/\J=O,/J$8)ET#K9%04>/_$^'HRQ/)N20A6DX2I=KD,KO-;M14JAY)S?;I
M/PP^ZZEK8)1>UB5_FET@RXM2H-S-#AP)B\**UA#ER\FID"554<KK5!""&BJ<
MXAM [K'/'_80IP?\5!%DTW%,60#3Y>3[V\7B LWSE0@_8027_#SM$G0\_YGU
M(H0MZ>_?G3?>,ZM$)L 2;F8&@^E ,806+GAI> JZ^FE^C[=*'I_U>'0982W>
M/CPE[7H,#]4,;-0DR( K!$K7YXB!/V.9F5BF0.;:?>UJT-UL<+ -PK88WMF/
M0E^V\=L]\;+Q1Q_0% Z4X'!&>LNT(E&$DO,S&'(B?DIK6&!9 S!6NP9X$(MX
M,E^MGP>7SRJ=[WVVPF?T/D)DN') $T<C)92EX%P0BOL#FL+G"6[6!FZ#J2UL
M8&45-G!@@HM_V?%6;GDOOQ_/SLYG4[B<RB"]]! S(UDP*&(4)"CI"4TR).I,
MMJSV\=R3! V+MP,"X^[5I6I::@!R=WA8E\P99HQ3.B+](A$99";6HWA,##IH
M'V@VM>\!/DC(P#>0ZBEZ5EOJ#4#G8_%0II#>^/D45]A5P7<R-AEJ2"ICY*51
MG#AC&$E<Z1+!(X?UV]T\1,FPX*F@XGMG!7O+NP'47)_F??#C]'9Z[,_'2S]9
M,V.T%C$%@0(I+<ED*G;9H>< R(IVEO)0^T+DDP0->PA0'T/UI#]P/=OQQ=E%
MN6SR%=[D#+'DB\>S=)*/TNR\4T\QT;@N9,D7HF&.*"F/L:\SC!*OK7<A)1OE
M1A[3,V5NF] R+) .[RSUHJ/&,7=YWX!J+R*/Q',GB50*D#>KB*<Q DTI\,WZ
M4^^)NB$]J'ZTOP6T=E!%X^ Z2O]UL6I>MS;6/C(%PF:TT^!+<8 N]YXXL4)E
M9IC(*6YT:W9?XW:'KG8!MPLFMK%F^RBH <?L-81E&5$VOR@\=*M3>(M+4CBB
M5+DYI0QR$"40E1RNTFQD8K6KG>Y3,>PY]W!IACWUT1RB;MS(XT M<"V(9JX<
MR-I @L--0)GDE#%!9UD[1'R,EF&#Q'UU_"1D=A3XP.40GV ZGI4)8E]AOBP%
M'N]G2UB\O@!4J5Q;5@K4)8LV&T->OYI/&U+41$<F%/(ELKES2/%@9<0&CVH)
M'KOJ<]:?<!O&BEJS(T*D6N-2LB[C>N(&HV69 XF*X]Z?0M1JD\*M#1XU;(AW
M4*SL(MP&-J1WL^D7_+2S(JO/^#>K&Z!&,F6\0;],.N2!65+.[$D0&(1DQH6$
MVDU#'J)CV'*LX=R<O772(*[6*\]9$402G'!G7 EN,V[E-!#(.8$RW+CJ704?
MIF3876Q_#3\#F1W$W0!H5O:U,ZJ7Z=<D<>]5FAC!R]52_&*E\;C]:IJ\-Q9\
M[3;M]XAH"RJ[:/;N:>U>8FX )]=YA457Z_QX35A95UIPRQAGQ%LH'9)3)(YY
M35B0+(,2@?/:12M;$3CL-)[AMKG^M-@ 1,M2O4Z$7<81QD3)01%ALT4+KU%:
MT;IRF31#=(QF7]NO>HB.@:NB^E/[W;Y^^^J@ 1P]4 ;Y^WGRRQ)R4*HO9SP+
MI<!+18(L#0NE%.@Z"(>>1%0B><CA;D17L43Q"<*&1=K^^K]KL:HKHP&$[;H!
MO+NZ=<]%%%EH3Y0MMU-2*IT-<2?@$DR.4O$$M=&W-]'#SAT;;M,]K+8;@/>G
MY2S^XW0V084N5L4C(P=&.6$TB1J_R!R0 YX\$5RZI*T!;6L/"+U/Q<LL%=T1
M!O?*1??220.H*E'9YW54-N)!ZF!2(CJ4LD>1,W$B2Y*,98:*X(7N(UUV^?R7
M64=3!TD[ZZ'I>SV?YWZZ\'$U(/,6P1O=W;GUY_7NYSQ.5:4[.*\N%@B*Q>)X
M=A;&TQ6"IZEKP7,4T4PLNCJ]JSL403G.F2W]14- 3PX8"3%U%_"!><:<KUX8
MN1V%^QJ9!YY69H-.9HN+.5Q?9[.2FS+?CC">REV2C.Z -.C@*JV%L[@D5.V2
MA,TH&W:+ZQ%-=ZU0#XIZ,?:I<TGWM5+K#^G'5CU$X4 62WKMJ0#B62IS,6/$
M&#%RHKB&Q*WCBM?.9A_68EUW!KQ\[HV'+%Y]O_'3];*01C 3,Y 8;4+7ST;B
MLK>EN0$&Y %#=%G;?NU"Y\NR9EL@[?$Y5#TIL0'__9K'CQ!G7Z;C?T)ZFU /
MXSR&E5A77"-I*.=W8Q_&$V09%OB[BS-(G5&Y<:7<.,FM,$3$((F,)I?R74H4
M+7E*J9+)M>\(5V9AV"AB$'@?7O4O9E?_6[D"\QHB"AY_VKV-P/.?V<^>OP']
MP[@ 3D#*TI?KWK(DA[,EC@I+DN<<T >5QOWKN "K%L$B^V@#(]R6"USX [%>
M,@*,83R?A62^/].Y&8TO:NO?!F'[;/U;*Z^!;?\!KKI31B4D2L=G8JDUR(:2
MQ%LG2.#:)8V;#*-]I1+ND-+*@,D^]/](U+R/,AK%U,I]N*S5R4IID:TG!D 1
MJ01#;P77IL*5&H+AH%E?-O]1HMHP:7NI?@,X[:Z'@<NX;_LOZX-E3;5TUC""
M/J8J5YT=<3XH0B5S.CL>LI;/^&./?79[<-A#=;.*<FS P&PS8Y5GZS150(Q+
MN("HY,0:@P$Y=309HYT5M6O=:D]//L#$JP-L;GTIK6T\/CAL+D?DSX9(5-*N
ML,>(C8P3X!BG%Q$+6OMX](>=H;P55/:<H;R-WAJ Y5,35WG.*DLG20Q&%58,
M"3X!4=*4$F?FP=;V[_>=@MO,9.6M8+#%%-QM=-( O)Z;M"HM0 )<F<"H)=)E
M4UQ728*CR&6@3-G:K>AJ3,%M9MCR/C"KJ9LF9I/=FTB.QMTY7BX^.Q6(])!)
MT-D3#YR:I#.W=J,&*MM4CN\R#[Z9H<K[P&DOZ3=@JAYP;]]=C\CBP6@? A&>
M,R*-[GJC4<*]T)%3[\'7ME-/T=/*)+MA\EV[J:5-B-T<3_&W6:GUPX4*J-#K
MX[21SQZHB<A6Z0TI)5?$H@TF5C F&3/X:NW9W;M1VEP^9$>D/ _!VFIK$YRK
M*N,KSE8MQD_FY=]N>,KEG(Q3U,_ZMZ-L& B@E.@$R+5R:/"S-EUQ@Z R:NYJ
M7VNH0WD;1_F' &_?:FT(S#=._XYG72DUZ@*_6XQ1G6OESDNU=5=ZW<WW/<DG
M%\N(\=?B;WYR 7]%EW@D@^3>>46"$*@ Y)SXJ/$[%J@(UE!/^]K^ZW PK,/0
M.[@'4/.+ OEE.<[WD?8^NXR,&6LYKN,42&!4$9^T3UY2AMH8#,E79 [;PZ0!
MN.ZFL&8Q><U85VZTHNRJ]L)[#IJ:PEV@*%*?B /.B3 Y8R :@[S;A:LG3#Y)
MYK -!PZ,R7H*:P"3'_SWSNY_GJU]\TN>8?'K?+98C(2A2I9VU1D$QJ=<:A*B
MHB1H+I.B.M)8.\!ZCJ8V0JG>0#'K44,-(&X+^3WHC!]-TZ4W/D+QB91S1'^;
MH^?-2W4'&$D,&&IEDL;& UQ4VI7\-J*J0^%X*+V_+,C?* Y_.XT7Y:41!\F<
ML(F(D%#T E#J&9UPFZD7)FDC7>T2C/TH;B.B:A#8^VKW96&9C1P5E :*JU,"
M\D8]KE@(A@#U/'O+(9G:A1K;T-=&*-4@3K?3W.ZHG"W]I"]4WK^+XZ\.^)Z\
MC;-^RU7U>\*MQ=% $@V=W!,)7*&WE375VJL8JU=Z],?-L$UJ#AFH#:'^-LWS
MSI(X]HM3_$7QQK[Z<C]J,9)!,)^UQ2U**=RLRFFE*)VH9*0V:ZD3',#AKLA1
M<['D(+CM<3GM":(?;4D5GV^Z7+VSC"=&H91> B/!'?=496)TS*@N6CHYY$"L
M=KCGBRQ=/L MONI\-1?B_G#+JP:@FJA0ZTTJ'^9P[L?IS;=SF"X WW^R/(7Y
MZG<CX $,#YEXZHJ?JQ7Q00&1H)2D$D"QVIW;!F&TN9#\AUZ(U2#W@VU_G1C>
MSU:ICTMAE?O%)@-Z <:7&5Z,&1*8"H1J#\Q@7"MB[4'(O3/57&KA1UMO^T-I
MT%VO7"6L*8[/MPJ840Y1)>4Y 5WF%0N1"4;7Z&Q'RPUC5LJ[28L'+W;V1V$;
M)\:-K(^&P/"#Y?+N5O9W5N/SJ9_^.INE/\:3R75F56FO@R]-0DL+9.\%!J5E
M= 5/"9>$RYRV'(!MS.A&"\_TO?":S@#V YH?S)6[%A(:& D47([$:8Z[+MH5
M$A0ZN+H,4F12*M-T\N(&*S]..K G$!]DV6V'J!\N>W'SE4LE&1D=1&W1&*:$
M O&2>.X5$;AYE[0IVLW<\!)[@*6-EIK]E]Z(]@7"#[;EK%,L-W^QZ@*_^."_
M=W5!*J I0\-!;#"E%$X+XEV0)"E0H*5P/MB&5\FS#/XXV]/>T.X_E5<)9P/W
M?=I1,'YCP<PO;FESQ"%09D$332V@.^'*W(T,Q-G,>=9>BBCZ2SWL3/>/<U)5
M:VDUCYY_A96%'U[.$"Y[=+XY.Y_,O@.\@BGD\7(Q\CP9&Y(G7-@RZH2AJ*(L
MXP9D5H''J!5M9;4]P\N/<T3UXE9@393]8$[GZS4+G_VWFW8J@J/>"$:88*G4
ML)3C=2:(<8$E6QH+5A^\V3]7/\ZA5<ON905$_6!K[+Y=NI311_@*TPL8><N5
M5CZ0&$N_)?0$2+#<$JMX\MJ*),,+*--XG,$?YSBLY957%V<_VB+TYZ6U[3OP
M"S@)D_&7[N-0=UF;$"U1W*-$RHB,(*@@24@+*@5O9%\]2_KCJHTR^!]^N>V/
MJ!]LC=W<[W-FC ENB'0NHI9*"[@R*,YQXWADH'5L.5>YK=O8^Y'RC[Z:=L5.
M Q4=ET>.HRC!)T$S <TED3I38EWTA"5*<S*):U_[+M7ELS<"J>L;I-6/FW82
M[<NUJE>'UP^MD/>P'''N.'64D\"R0%E*37P9I66$L*6?8N#Q '>E:["RV5D/
M?7&(;4'S#=C$2[Z>:$/[=R@MAW$[^ IS_P5^7T"^F+P;9QBE+#B#& DU'NV_
MS8D$@[PFQ8%)1S63M2NF]Z%W,RB_O.:7!]-A4R4N-UM]7LSC*7KW'^;C"$>3
M[C/PY<NU6NX_Q&67Z7H-Z2(N.[F<E:/4D?>6Q:@"X;9$VLQ(8JG(A*-?XRRS
MP;B^BOZK,+ 9IG^(GI@'TG+3HRS+].VN'5UI!WJ^[IBPR_S*1SZHWM#*32BM
M-*GRX4?A#HV_.)\M_.37^>SB_$9MO% F %!2NE@0J10CUFB$*>4)=# \T-JW
MQ[<D<>^9#K<^]>TT3B[2>/KE82H>FNCN#.TN;I( %+T8*S2Q%M</HR%*%(_A
MU>]"[4OSL$5)?6+PWE2(0VKW!9K#SZL[W[6,XN<;5\A[-(T/43V0@=11:.FS
M)<D E$[2BKB(&[=CR8+TBAM?N\KWP ;R>C["5HL)?ST[@T^H^:Y-\2L_\=,(
MGTX!EF5R;4J=H^(GUXMN<6.2/$<_R#D@AC%<\E%XXB7Z1-FILO# >EZ[K^\
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M8>>AKO9!SX[P5F/Y].!/[.+6:K6V<-_.,,PN9U??[VU1%Y&95A**8[Y6T1K
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MX#:)[%3KQ]4GR.DI!Z0-F%KQO@,8_1Q3W>RA]E_U/(3@BX.L+*MSK2*I613
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M;5CC@&?:"WH>"VN=QO2 B+Z@<HAD'U3='\/F#G"RHY6:]"B$]F2;\T!?I+6
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M[MD+C<G+%!-871^=52+/HKXSB1*2US'1#=OZU>TA%<.BF^R<$',DJ_<'B]^
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M)0Q1R'=C@O1TKP%#=Q[0KI#N*<H:%<(],C[[NNPH2F&E=@9DK,WE--9;/+&
MU,(4;YWVHO6-R.=H.M0H/O;\ZZJKZX$#67/#M4W F"^@%*VXX"@0T2)QC%%B
M3JUK 7<@K\O1Z_MAYZZ1&DI)74^%N+W@]YYX]N!CAC)+ TXY>Q9@3-L<K0O
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M%T_1,RZ(#M'S7<BT$OH!S7#:='7[N, ?89IKS>%LB2\V;5G7HKID*!5=B.H
M6M.Z4IPS"-Q(8-%*VKP3A<2M$RQ;D#7N#M<03*U5T#6FWL]GZ9(G(<A.,XHY
MF*)UP@*O_B #'K.53ILZ)?.(L+JF;-SK%$="UIZ*Z*)VYT;F^4I.R%5$;GT=
M>$\QA4B!5DCPH*71*'RI;#1&TP-DC&N4!G63#A5Z1[[2Q_"K[MF7QM59K5.Q
M&8HUJ8:CKE;3(PCE@TU1T(H8RDNZ34DWHRCV4_ C3M(!TNX#,XL+O'G8=<D(
M;;F!4X *K 2RS-QRB-XZ, &C4J+(Y)K'9(\1T\U B5;(:2#S#L!S527X9KYX
M<W%^L<"/\[-I^O429UBFJ^K'/V9UBWYU%J;?Z[>;#_G_7BS/:TWA9N\FQAEW
M3D3(ROA:7\L@QA"AE!QM$BQZ,=3V=C#QX_I3K<$YCDY/J.#A$_[$V;J+X8;3
M9O4.3SQZJ'*';;DY5K6#KW?D$T]@>:B=0J6!:+V&Y*/VBF$R\5@GJN-6.QB3
MF52"@RR>_(BB T1#(N'%&Y>3$D:W%L1?L=IA%SRUJ7;817$=[.$[G*)RP[+/
M B$I1]Z)911>:6N ,]IK0@Z6R? _U0Y#067_:H==]-89(B^[J64I4DP6BBN"
M.*C3#UC14%C.FD5M%!\2>2=6[;"3OI^O=MA%^'U6.R14EC-M(3+-*2:/!6*P
M K+PJ:".O.2MBF7^&M4..^GS^6J'783;@75Y.R-/&*^&X[ZK?U!U41>.+TI&
MKBG>9FC('A<&P<8(DGO&DI0ER=;=M)X@YQ1K' [9T5IIIE^0;18@A>)9. K*
MI:K3$&3M#>I-@2)K(UI?C/.MYV@\2="X%JJ9VK>#TQXZZ !0K^;+\P_E<SBK
MEXA79M<K$[FCE6;): -M] )<81I$)@:X*9*)UK=_[A'1)7#V4?"\I;0[@,MG
M/*,???T=9[@(9R]F^47^/IU-:TQ\/OV)EYF>#7/"&^]L(E\@"5$;8Q?P5FI@
M+' O0I:H6W>TV(G <3?"X6 VG)8Z@."SA[61',\BR4L(Q!4HC.1!NJ"@QBBE
M%.*M'.F"];N=JDH'R^1WDT/83T==8&Z5S'Y#HKV=Y9ZP@M8818Z$UYJD)#)X
M;>D3A<,:*5 )KO49^*/$]!,0'J[S>X!JH8 ND/2@E"Y-<F7PYL*L$])N_LDD
M">(S<@:8:G?A:#VX1,;:!I-T$-'FW+JEVH$D=U[:<Q@JCZ?,[EO>_)@OI_51
MY'B$3<7<JV]A]G7/?A-//*[ED>6V5#<[IB0G["*=7VQ:-&W@\(( \O/V47LL
M142G)3"M;=U^.81 3J!&)J1.0F+S!NQ;$W>X$7SF10^U9%$L6ZE,/>N7%"DI
M@1"E,12W2VL$HI2\=7)C'SK'WH2'P-=]NS>P_CJOVGC<:!S08.?9AQ['[ W:
M?&=;<"ITHD0;P4;:#E4L%'L(KL%PYQP)K91X]+4^1-7&@Z^L2:+E];HI2<=D
M1023 H7GD1S<&%%#D>3ZBH+DG[ !ZS6V(/%43-XNJ'JJ9*.UUD[6VAU2GO;\
M4X]C[X8M2ML6FMEQ+6)(@"7X.FO!0<B.\)DPL9A+0-5ZD?=F\%9)I\RR%UPJ
M2$4&4#P7B,H5",B+T\4%T[PWY [DG8JAVP5->QJZG;751>[E!D.5C153=43X
M>N!)3#EHY3UPD[!ZJ!F\8 JXX*)P0?ZK;=\0ZTF2^JD]:PJ%I\*) _72 <SJ
MO(D[(MN<Z2CM)"U-"5I:5=L":G#,U?$CQMOB(_?-.[P_2DQ'MNQ0E<^'D/_(
MHX=>DQ,U_X7X&7_B(LQ2O87Z!1??-]VU+R]-;([PHO;.Q6*!,U//\>J=U%07
MHS"BJ-JRUKEG/+*=7SHN@!HI>7X,B7=@D]Z$M+I[\^J,'.&K4;_!%2\%K3+!
MDB%1A=I\'2/(&+ >IYC 6E^.>I"0<8\(VD*IG<1'MD ?%_."RR4I(9Q])L,\
M3?52SPTA7<[4LBA1U>L/&&NW?J$A%L<A1_I?L47KN\7[#]J>+5\W[DEZ>ZLS
MA)0[L#=/[._71V^)"6,D9Z!CE9EE%GQT K)$@9*%Q$S[0HWGZ>JG/'8DIWL_
M#76'NF]A\167$Y^5#-D'*%'7.ZNA'K+Z6E"N>1 AH='MKWC<IZ-;?WM/;3\)
MISU$WQM\;B^X^O^WZ\8O^<O\-_IG/M%%<TO>'K HR04T'L'SY,$8FWGDPJ!K
M/\=D%PK'KKPX)N3:JJOKC/QG_%KK16M2>U%'+.V1?K_WB':Y]J>I:Y18O_N2
MZR,>+KUC9'&83);LC' 0,RKRKS7I/CB3<_/#LD=H.;S4^O9S'SI3%\X'Q6T&
MC\P3ID->'^*GE&V*J"-KW[G^>;)&SEJVP,;]BNJVRC@I [-W4<,C#QK.V Q8
MO/ XK&0Q65@!%**I&IFY&J,YVM$X%UX[9WC[2P[#F)Q/F.:SM+J+2?JH$<A5
MU>WFE<LO\SK.;WXVS76OO09_4A&9,@9$KCV(G1(03>WEJ8)'D7E(HGTKYWVI
M[=5 [8"D^\[04537A9=^F],//U:C)6=?:RIE>OYNOEQNP[51AID0*2+A48)B
M.4+0Y X*F6) Y8-D[0_[6E ^<GKB&. ]@DI/:@-^D?.J>B6<O9V5^>+[^I[8
MWL4W.SU^N,UZ>ZZ&WL*9C38$Z>NL65D]-S)^M;D%P2@'J;GBS4=R#K6%O[^H
MZ>(;2^ART4R8=IXQ*\'+VKLMD _LK:,EXHODR7EM4NMTQ:/$=+H![X*#NS:L
MC>!/RBQM?(QRPS2?WS+-[4S4UJ\:SESMQ^W0IDMS&5P,''10-8$6 N&J(DQ9
MJ42]PA1:5TKW$WVL#D%B3%%D9T&J>J1:>('(I 210M8^"5K%[1O[[4-IIT9O
M%P0='G7LK+*1&S]=$T\,KG+6Z_XA63AK$2E2JA?G&3IP-83*VEF9L(24M]I,
MGVG\]/#;QSY*&E[G\Z8*Z Y"ES4#)IAH> 3#5O$*D4]L%<!HF;"Y6,VVNLN[
M,XC&K !LI=,G(;*'@#O(;+R=K9ZU6D.OSZ:7E6>;"A"EG%-,)TCH&2@O,[BL
M.&3KL_>1B<!:GV,_25!/\-E'W_>Z.K42?@=(NA>$;-A S3-*I<'XQ&K;*P,A
M9Q)5H:\^%H/->SL]0LHX6:S!T--"X!W@YM5\0>XA;=KOY[,-)Y?U9RD))74F
MWU#5 @ZT$&U24(KE]>J<(8X:(^=18L:I 1P,.VV$W@%ZKEI9O;Q83F>X7%XN
MAM7N;H*2AM4F9Z4F5WAD$&5F()1E,1DK1?-..4\2-'9US-&\Z/;JZ0%K:]JO
MJF]C4&@\L-J]3-6K;P$# _(CG7,Y,AZ:][2_2<#(H7T[Q3Y<]K"'E,>^/K/.
MZ?W[*J=W65=]V[B:Y%,L&B'4DED54$'0CM4[DS9A]";AG<S9PW=FGGU3%WF?
M?50X'TR>(Z/C%?WC-(6SS_.SBU5GIMN<Y)PXC^A!<A- N1J1JFS!<T233$">
M\Q;(>/HM71SC'HB*AG+L9TNYF_"_VJEG7ZO']^ZZ<YAFR91,,:&U]2Z/(L-J
M)#GX@FF>;'8)F]]5WXW$<2_+C.'B#*C"#A!Z0X(DMU7ZOO:4>W6Q/)]_Q\7K
M/]/91:ZY_>62O( JT#\GWJN@A*#UYWD5IT+P1FK0R67/I<I9M&^ELS.97>R1
MP\#F\4Z6@^APM"G&=4-8SVK#_#HL:JN5Y4LL\P6N4FNX/"=6:K\5(BNM;4+M
M3/R]BOR_5M].0B G854TY KM0U;RVG(V@1')T085E71VBXWW,"JZV)@'A>*1
M-75B-0TW-ZUYN9+3R[=??GO1LJ!AF_<,6<VP,Y]#ES(4Q<B:*0/9V Q*)E5G
ME$K0R%GF2>N\W7%8!Z4,[_%\W=V]EBY.C/2BH"Y@0N1DPU."B#)0>%1*KB<'
MKOE%L5L$]+6Y[J7O>]56>PMX?VLT/P]GC<[Y?N)ZHNF:ATNK.W&HK(^9 Y,\
M$A]*@D?Z)%%+%1*RS%H#Y3%:^MH%FV"FB=@[B (NZ;X<AVN3X*&>$D11YV2A
M\."]MY",8M8R%TOQ0QP,7Y,P\GB#8<"ROY /<,&_KBO:VXZ+(F]NP\:FB<W$
M:B(Y%P$I)'+?=+!D*[. *!ER6P2%&:W/8AXA92OHJ!.#SN%"/Q1"3=#S9 !@
M8S:>!$0!1B)F'*T,C@9$RDIPRX)M?O/TT)A-GQ2*6@E_5"352//W,)U]F*WF
M()1:(+].#B^_37],*$0EMXU)X,'5FV=&58X8L"*%%9D9X>Y<G7PPWG_\#5OA
MPIP$+AJ*L@,?IG*RK+X[+C_,7O]9I7,Q77ZKXOI0?L-X/@F%>1:8!]2&K&66
M')QV@;XEX>3DR&EK'0T^2]16<+(G :=A%-%P2,FA3L_EI<'7_[Q8C90]_S;/
MUQ' <E*<R08+18K)UMY)4H!?7QL4)0:9?73#C&1]AK"M,.9."F/M%=*!!;NL
MM7@U_QXWM:(UGT\R(V[JJ=8TKTH"J]X6M=/XBLMUT_&W,]K.+^H*>^1/WDU#
M7'4/Y!/FDTXD%[#&D&'GI5YOS1J"C#Q[5G)N/M/U2*QMA71_4DCO$11=A!*K
MCOOOY[/Y99WLVB9<1M?:%YFY9V"$05 %%?A0.!0TR)A1NL36/32>IFB[E"D[
M*7 VU$$']O?!AG,\T<HH.H,,SI.OPA-XZSWH4ESV00I3VM\%W+?7WVEEW ^6
M]^B!Z&<B&F-8UA9QWROFUU7<L\V!^X<9GD^_X_H@K,IO(ER(G@<-N=3F=((\
M$N>).Z-U--8(CO).8O7!\'37]VZ'GM/(O0\N]RYVMZN6X:O>K'Q2BO9,R0A$
M$&W/@5L(G(5Z*"^9LPI=:MU;Y@X)VV'HM%+RATAY=./S*OR8GH>SZ7_55; N
M^UGUQ+R1UOMXL4C?:)F\2*GZ@:L.*9=K8CD1(9D0$H,2!6W/,1N(D9P_3E+0
M*#/ZNSU*'BY*/9".[8!U&@G[H^ME=!2N3/&W^1EIZ47^.5W.%[\NB[DG:&@Y
MA>(@94=6EVPO.%<,**MESE$F+K;IX_[$*[;#SFFDZ5M*<W18W!A2O+*MD\"-
M=RP6,*Z"FM>",LXB:1N-\#DAQVT*\>X^=SL G$X^_B"Y=>&YW$[-U:ZFJ]S#
M!>;-C=;Y;/D>SS^451DJ,RX8E"!]"*"41W")%?"8%!,>B;_6;;)VH6\[=)U6
M>GXP_8R:J6]0@.HM>J%]J;,\::69%"!RS\GYLS;S')A#LX6%.D*I,#^-9/V1
M==)!!NG!U53/P^IR^S"C'_^8+\/9A_+@+UZONI2U]K3J,A.YMK#7$%@6D"EP
M9;0DI;@[_^;P2H@FE&^'WM-*P(^@TZ[+VS<#%Y:TCE^=A>GW99CEC[A8M=ND
M2/IES<K</(K8H[)]YU>TG.M["'>-ZMG?SI87ZWEQ5P#.&%PJ"7CMHZ923K0/
MNT( CCQRRR@^;%T;=8^(PQW#S0,?ZG2/K#!._@3HRINJ?2^<H[7*I%7:ZL+<
M !6GC],S;GW[8?J_[_ UDOM?RBSM/8%@SQ>-9Z(&G&!P'ZA"*<&#LY *ULN%
MGD%,Y+_)+&P)04N36A^[-C=4U_/2KL['W\P7?\Q^A&E>2YS<U,V'J[3=Y9FG
MB#8:PP2$ZF4HQ[!6_DLH%K6.7CAN6@_ /(3>W@S=+OAY?,[XP'K[2QG"_2\@
M[ONF\4SAD)<0[V-9,V&<<1Y,K#=:O:6]U7K:6QE#[ITLIGD8U]X6?J-0*E\L
M-@>LFZ=?GFLL[S9D6&OA-_R)9_,?5>1?YE=K<=V+0='ZHJ5L@-R7.G6T\/4"
MY]EYXS&0@)HWQF_,0V\V<Q><W;.98^JW@XS-TXVN5- 6H_& V9!WK'@!GP()
MVGK!D3$M4^L5?'B#N>&*@$;%RDZMYW917 \HO-4[22N6K) .LK8<E.4:H@@&
M+!/!>519VM8M54^F]=Q.BGVR]=PN4NZ_]9P5R1AC!2B)AKYX<F2=RL"KY\J+
M5>3";G%X<5JMYW92X6ZMYW:19]^MYV1)WL10@"2%H) ;<.@X.,%D2 F#$5M5
M^3SYEB[N]A^(BH9R[&%+:;=9O[MJ#6294X5I![YV952"$?N)1_!6U\H4P71J
M/@MW #Y&1FM7;M38,.E@J>R>+7J/YU?1%]?,!%T'%*+2H$*]0UTB<1QY3$(&
M$YKW&#J(X+],#+$GWN9C*;\SI#^;$2TJ\>29!.9] *5Y(/ER!;F$J'G40MVM
MWFP*[+XSUT>$S1. ;:K#O?'Y Q?3>::X;7%XN\=7%XLJ_O_$\"QS5]<]:J'D
MA_+[?)[K;U_Y\_.S?-7Z\JD:(YF+B]X[D"74UA?1@X]9@,Y11)45=W=O>#WL
M(!^=\G'=F..O@!/ 1Q?="CY?_/AQMDJAW)J#2WKZN*@W-<]_O0K+"XI]?UUM
MP'_,""S_6DSK5O.15O-B&P%/!,O1B>IN1J_J=&1%T5"HPXR\MUX@1<G-Y]0?
MB;=Q^X^-M[MTB9W./*?M-++^YX_U-Z]M%I^D.O^2_%4P1=8Z0#(D+FL#12NN
M2#'!J];-%UK1/FYCM3X\KJ/I_L0Q?V4(EGRBL[(B)PE.&T$;:*%/B;92B;IP
M1%_7>D>0OT'ZN$W@3A/Q^VK^) '_<17ZD*>YP+#$WW#]WXEB+FF,%D1D]:I>
ML.""C&!SR246%K#Y"5XKVL?M;W=*D&^@^PXZ1^_.]^6Y[(OTSXOI<KHZ*IDH
MSQ)7F($[A:!D+! ,!D!C)!><:?3C(_XARL=MP'=*>#]8[R=IX3_0U^GLZ\MP
MMJJYNG%-7Z7(>?(:I!"UIYS/X&10D%G@J!S3/HP/^4?)'[<IX"GAO@T"^NG@
MO5,"V2KE<R$62^8DZNP=^'KQQ!ET,2NA#1<#@KQ)FF:P^X9]H+BI#@\\!'@]
MN]E$8)#I.C<25*_"\MN;L_F_;B2J]BAC?^Z)#2?F[$)[J]DX#[SS]?H?EE=0
MC"Y9FP("R_5RJN0,?*"PK8B(3-B$J)M7'&Y!U\&SQS?/O?FNZTMPR^M;<")(
MGA4FB-KD.B"0^)>.OI7228R.%D+S4>1;TC;R<7UK]-R;5#Z$BKJ^G_.,$=C[
M7N)VSSV:,1OPUN%6H!1<*PJ[ RA3>S]+$\!SJ<$FFSAM@=E:/$&3=GW'[;F5
M4^5_O7RD9<D[H:#H*A/R,2 (]%"O#\M2HG2LN87?C]03,'B[8.OQ2XK#*?"4
M[=\!\Q"W>_#1+."@$P^W@2DGD&97$C@>?)T.1 $&$Z6.]+0^FUA0-[^]=$2O
M[OU\ENCCNN%_[?8RRV^F,XK1Z^=T/OTY/9_B\GI%7<G%H%&\&(2<Z_@)*25X
MX1&*U-YG@=K;ULTT#J7Y!(SB+FA[S L\BDH[2$-N6H2N O0\/:_F_NTLU:/B
M_/+B_/W\_#_QO)ZE37(01B,B:)41E(\>7*F#S+-VP10,7K:'ZG:TC0O)XR+F
M'EP'4-_8MX@V GU71X1?BXGB*B]S+&"YIE4ME""/@V([8R5MO8&EDK<JCGSP
MZ2/?PQC*JC429P=VZL/E7(=W]6CS8_BUSGM[;9E/@0'G3) 3+!S$H@LX^LHL
M+:78_,K#PY2,8X-:Z??N,(W#A3VR#?DT_?KM_$/Y8XDO2"KGJX-"HH!L\KI+
M'N8/99**UE'6(T(22)VL'" 45: PG43),;FM+,HV[QK'OC2&QR"";7T:-4R@
M&)?XSXMZD/$3]VLD>.\1+8._IZAK%N;=?LFU]Q)0ER(=&%EG!SOMP#G!R;$P
M3"*Y,$HW'P?Q""V'5ZO??NYURL-BB!R]!>9JRM<P"S%PN6J9:6G[33RVSLH_
M2LS8 5@#'-PO]6XA^,YS3;=9/"2Y]/"3AC,HPZ:/'L&38\X'9AQ8S:NSH2UX
MVCWJG4H;7&)2E/8W.HYB5]97I05%>]9Y!XG5B604 D+MK@]:9@Q!^Y2:WVE\
MB(Y.K<DNVG_&FNPN[@["G0<JW%9-9VQ*W@:M ;4UE0T+SB0/FI'SEHV6K+2.
M=QXAI2O@[*'C1X9;'B+P3G&S=M%QTY.$V524*W7^6-2@T'@(2C':8-&K3(N+
M-;\I]RQ1XV*IB>JW@-/^>A@YF'Y+7DD@A= :^[B8_ZPS6W]?S"]^O)VE34<:
MY4WDIO9*I0^@LM+@>1"@A?:8M>-)R&?<FJU>U!]0#E#J?"@)=V"'_A$6T\K-
M)PK15XN):67)F2^0@O%K^IVP$3"1.Q]#5@I;NSMW:1@[Q]MXQSI(Q)U!9+-\
M0LR:&RO!L$P6MP[Z<5%E*#ZIY(I24K;>F^Y3,:Z-.4RK3T!D#Q&/O.U\QG1!
M;_SP$Q>SFG6\.DVK['S^\.;3QC0FG7R6T8#()8"*3D*TI8#1P9F07/8E;['Y
M;/FZ?N"QCT;GPXJW [-2.VU7#C;49RZBDG4^16W0J50MD H44G)IA',9B\'6
M?>)N4S#NKM,(+PV$VP$TWLUG7^EIWW_#>/Z%_F9E7]%Q5Z0@_I5VH$H=*1=X
M'?/EO/+)9-=\3,1#=(S;Y:.Y<W*PJ#N$RV;]1$N4JIP@1Y_K9&8"??35Q_=&
M)Z6L9$,#I@='Y7 -/P.9/<3= V@H0OQ07M&+IY?M6D/A/">,8/GJBE5@X"T:
MVD5E9$+EK'/K@5+WJ>@++/OH]MZ]LX,$W0%4UK2_"6EU?6ZU?H0NJ+,TP$2P
M]3:>@A"9!V>E<L5)X6/KECSWJ1BWN4[SK>A ,7<'E,M4$SG>UDE:,<R16YZT
M!,?HV^@E>>6*FR1;.[8/T3%R[>6!NGT2*GL(>N2(^455V2TFIKC<&,>26;(V
M($3'R.T7DK9F'2@*P,(M6=J$ZKF3YV=>T1,4]M'=O+T@.S >FS"_[KP;!C1W
MHH1L08=:4\%#AB 91?4,N2[&)&:;GSS?)6*\<LEFJKTWTN,0.7< E$^U&N1G
M;5)Z:R5=3J'0UNM8AWT*U/6B68)0&(/:(("A4U';UI[)DP2-5U Y%(#:R;\#
M,-WUXBX#Q. T;<$J0\ZUA%C[2 %B-A!"="%)0^MEZ*J771(N@S74:^[EMA!X
MG[C9;.6.Z522,V!2;>!72JP76#Q$46S,GI<86E>^/$I,7[4O>ZGZ>?CL(??^
M '1YAI'K1862UNM)D9FNG? *<)D%*N.3UJTOKSU(2'? V4?)3T-G#XGW )O+
M46^O_WE!F^ZK^?<?\QE>CGHS63-D@2*(XCAMZX5B2A:)F8@EBIAUYLV'#3U%
MT+B=,=OO7<V$WP&2[O"P66#%:UU4;<"IE*V#40LQ41O'<(&.:V%C:(V@!PGI
M9*#BX8J>MY9Z!] A\K_/9Y_/Y^G_;:RHP%BRB0:RB]6*!EU%XL R:VAU:2EY
M\WSP72+&A4P#Q=Y-\ATDY0Y@<L?^OKL:/B6+TYQ9 3+5A$,.M(MG5<!JY,[S
M8)"U[I#X&"WC]K(=.KK:3^0=0.?R*N^7^:9P];*D%9>_+^;+>H K?-:U+[HO
MFI9"[01)"PHD,A,U"HNV-(;0<S1UY3/OJ?GY@&KH8M#/)0-D7.-TMM+.J_EL
M60N9USW8%F&V7-.VMNAO9X1J7)XOWRZ7%ZO[P_7#:J$&J302HT A0FT26@O.
MF&%@DW1HM2HVM,9@0_*[JC)N ]>QE-N!P=R!]<M&N-/K%BP3P4KT'#VD9#VM
M8U2UL:X GK0U(7J=8^N\PV$4=U6&=G3T'JK"#@"[\FO7R^ZWB\5T]G4]&^+S
M-U+ [7[Y7OO@9;U866KQC2;_-QK::*04**03CF/S/HS;$M=5"4H;& ZCF X0
M]^Y&(=;5H57X<_K]XOO+^6(Q_U<]T@H_Z"?GOR8N,++TQ S%6PI4$(JX= Z8
M<$D9R]R-8?8#U,(]1U]7AT)M<#>8>CJ WL?%/"'FY1L2Y<K#F"7BM18;?MD4
M&TX8<RZBXV2TK5H/9/;*9LB8N/%<<=V\G_CS5'65OVT4TK15Q<B%5)7>M[/E
M^>*BQFE_#^=DL<]__19^K<=*4MPV^_6WBQE]7-5[;'X^D2DQBLT2L:3K)$E:
M0U$+#U9PA=I)Y_*=\7(/UECM]_:N4BZ'@>I(*NC @MWF\F583I>?B9:0/\QN
M7MWA$RE\,;DVB22PD!@CN0?!!Y)JE%P0TY:GQG9L6]K&G=\SB#4;1"T=P.TA
M9Z#FPZ>K*2UOL$Z22U5[7W&2A%%.2*30O,YJX5K4L;@%9,1(7(G(2NLTS [D
MC3MNYVB>6@OE=+67?ES@CW7V\R/.ZO#F=1CT87;)W:1H481WE@2'6"\\.PCH
M-:1HBQ6E,!ZVZ<JXXVNWRS*SDP#4T%(_!4!]^=?\BC6TFJRQ REB'0I3!ULQ
MXX$E:VS*Q6(PK0!U_=KM '4:YQ9#2_TD $70N%HM)$)!L8N%'$RH*1I-0J1M
MOVCZK(K27+:#U(T7;P>JTSA=&%[RIP"K-_.+Q25O/)0@O+<0>"0;')(@&YS)
M!EL4] ,52FJ&JAOOW0Y4IY'T'USNPS<9W?R@?HEAB?_G?_U_4$L! A0#%
M  @ 9X #5=Q ID_IT@( VH<8 !<              ( !     &$R,#(R<3)F
M;W)M,3!Q97@Q,#$N:'1M4$L! A0#%     @ 9X #583#3R'XBP  H_(% !<
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M              "  4-L!0!A-C,P,C)E>&AI8FET,S(Q+FAT;5!+ 0(4 Q0
M   ( &>  U7.3*^ S@0  !H5   4              "  55Q!0!A-C,P,C)E
M>&AI8FET,S(R+FAT;5!+ 0(4 Q0    ( &>  U4-/FR084@# +S4)  0
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M2P$"% ,4    " !G@ -5SLH]-+)0 0"GS0T %               @ &7EPD
M979H+3(P,C(P-C,P7VQA8BYX;6Q02P$"% ,4    " !G@ -5Q639B4K>  !#
M!0H %               @ %[Z H 979H+3(P,C(P-C,P7W!R92YX;6Q02P4&
2      \ #P#C P  ]\8+

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
